---
layout: null
---
# ESC Guidelines 2022

<!-- 2022_Cardio_Oncology.md -->

# ESC Guidelines: Cardio Oncology (2022)

**Source**: `2022_Cardio_Oncology.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 133

---

## Table of Contents

- [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](#2022-esc-guidelines-on-cardio-oncology-developed-i) *(p. 1)*
  - [Abbreviations and acronyms](#abbreviations-and-acronyms) *(p. 6)*
  - [1. Preamble](#1-preamble) *(p. 8)*
  - [2. Introduction](#2-introduction) *(p. 10)*
    - [2.1. Cancer and cardiovascular needs of patients with cancer](#21-cancer-and-cardiovascular-needs-of-patients-wit) *(p. 10)*
    - [2.2. Role of cardio-oncology services](#22-role-of-cardio-oncology-services) *(p. 10)*
    - [2.3. General principles of cardio-oncology](#23-general-principles-of-cardio-oncology) *(p. 11)*
  - [3. Cancer therapy-related cardiovascular toxicity definitions](#3-cancer-therapy-related-cardiovascular-toxicity-d) *(p. 14)*
  - [4. Cardiovascular toxicity risk stratification before anticancer therapy](#4-cardiovascular-toxicity-risk-stratification-befo) *(p. 16)*
    - [4.1. General approach to cardiovascular toxicity risk in patients with cancer](#41-general-approach-to-cardiovascular-toxicity-ris) *(p. 16)*
    - [4.2. History and clinical examination](#42-history-and-clinical-examination) *(p. 21)*
    - [4.3. Electrocardiogram](#43-electrocardiogram) *(p. 21)*
    - [4.4. Cardiac serum biomarkers](#44-cardiac-serum-biomarkers) *(p. 23)*
    - [4.5. Cardiovascular imaging](#45-cardiovascular-imaging) *(p. 24)*
    - [4.6. Cardiopulmonary fitness assessment](#46-cardiopulmonary-fitness-assessment) *(p. 25)*
    - [4.7. Cardiovascular risk evaluation before cancer surgery](#47-cardiovascular-risk-evaluation-before-cancer-su) *(p. 26)*
    - [4.8. Genetic testing](#48-genetic-testing) *(p. 26)*
  - [5. Prevention and monitoring of cardiovascular complications during cancer therapy](#5-prevention-and-monitoring-of-cardiovascular-comp) *(p. 26)*
    - [5.1. General principles](#51-general-principles) *(p. 26)*
    - [5.2. Primary prevention strategies](#52-primary-prevention-strategies) *(p. 28)*
      - [5.2.1. Primary prevention of cancer therapy-related cardiovascular toxicity during anthracycline chemotherapy](#521-primary-prevention-of-cancer-therapy-related-c) *(p. 28)*
      - [5.2.2. Primary prevention of radiation-induced cardiovascular toxicity](#522-primary-prevention-of-radiation-induced-cardio) *(p. 28)*
    - [5.3. Secondary prevention strategies](#53-secondary-prevention-strategies) *(p. 29)*
    - [5.4. Cardiovascular surveillance during cancer therapies](#54-cardiovascular-surveillance-during-cancer-thera) *(p. 29)*
      - [5.4.1. Cardiac serum biomarkers](#541-cardiac-serum-biomarkers) *(p. 29)*
      - [5.4.2. Cardiac imaging](#542-cardiac-imaging) *(p. 29)*
    - [5.5. Cancer therapy-related cardiovascular toxicity monitoring protocols](#55-cancer-therapy-related-cardiovascular-toxicity-) *(p. 31)*
      - [5.5.1. Anthracycline chemotherapy](#551-anthracycline-chemotherapy) *(p. 31)*
      - [5.5.2. HER2-targeted therapies](#552-her2-targeted-therapies) *(p. 31)*
      - [5.5.3. Fluoropyrimidines](#553-fluoropyrimidines) *(p. 33)*
      - [5.5.4. Vascular endothelial growth factor inhibitors](#554-vascular-endothelial-growth-factor-inhibitors) *(p. 33)*
      - [5.5.5. Multitargeted kinase inhibitors targeting BCR-ABL](#555-multitargeted-kinase-inhibitors-targeting-bcr-) *(p. 36)*
      - [5.5.6. Bruton tyrosine kinase inhibitors](#556-bruton-tyrosine-kinase-inhibitors) *(p. 39)*
      - [5.5.7. Multiple myeloma therapies](#557-multiple-myeloma-therapies) *(p. 40)*
      - [5.5.8. Rapidly accelerated fibrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor treatment](#558-rapidly-accelerated-fibrosarcoma-and-mitogen-a) *(p. 43)*
      - [5.5.9. Immune checkpoint inhibitors](#559-immune-checkpoint-inhibitors) *(p. 45)*
      - [5.5.10. Androgen deprivation therapies for prostate cancer](#5510-androgen-deprivation-therapies-for-prostate-c) *(p. 46)*
      - [5.5.11. Endocrine therapies for breast cancer](#5511-endocrine-therapies-for-breast-cancer) *(p. 48)*
      - [5.5.12. Cyclin-dependent kinase 4/6 inhibitors](#5512-cyclin-dependent-kinase-4/6-inhibitors) *(p. 48)*
      - [5.5.13. Anaplastic lymphoma kinase inhibitors](#5513-anaplastic-lymphoma-kinase-inhibitors) *(p. 49)*
      - [5.5.14. Epidermal growth factor receptor inhibitors](#5514-epidermal-growth-factor-receptor-inhibitors) *(p. 49)*
      - [5.5.15. Chimeric antigen receptor T cell and tumour-infiltrating lymphocytes therapies](#5515-chimeric-antigen-receptor-t-cell-and-tumour-) *(p. 50)*
      - [5.5.16. Radiotherapy](#5516-radiotherapy) *(p. 51)*
      - [5.5.17. Haematopoietic stem cell transplantation](#5517-haematopoietic-stem-cell-transplantation) *(p. 51)*
      - [5.5.18. Other cancer treatments](#5518-other-cancer-treatments) *(p. 54)*
  - [6. Diagnosis and management of acute and subacute cardiovascular toxicity in patients receiving anticancer treatment](#6-diagnosis-and-management-of-acute-and-subacute-c) *(p. 54)*
    - [6.1. Cancer therapy-related cardiac dysfunction](#61-cancer-therapy-related-cardiac-dysfunction) *(p. 54)*
      - [6.1.1. Anthracycline chemotherapy-related cardiac dysfunction](#611-anthracycline-chemotherapy-related-cardiac-dys) *(p. 54)*
      - [6.1.2. Human epidermal receptor 2-targeted therapy-related cardiac dysfunction](#612-human-epidermal-receptor-2-targeted-therapy-re) *(p. 56)*
      - [6.1.3. Immune checkpoint inhibitor-associated myocarditis and non-inflammatory heart failure](#613-immune-checkpoint-inhibitor-associated-myocard) *(p. 58)*
      - [6.1.4. Chimeric antigen receptor T cell and tumour-infiltrating lymphocytes therapies and heart dysfunction](#614-chimeric-antigen-receptor-t-cell-and-tumour-in) *(p. 62)*
      - [6.1.5. Heart failure during haematopoietic stem cell transplantation](#615-heart-failure-during-haematopoietic-stem-cell-) *(p. 63)*
      - [6.1.6. Takotsubo syndrome and cancer](#616-takotsubo-syndrome-and-cancer) *(p. 63)*
    - [6.2. Coronary artery disease](#62-coronary-artery-disease) *(p. 63)*
      - [6.2.1. Acute coronary syndromes](#621-acute-coronary-syndromes) *(p. 63)*
      - [6.2.2. Chronic coronary syndromes](#622-chronic-coronary-syndromes) *(p. 65)*
    - [6.3. Valvular heart disease](#63-valvular-heart-disease) *(p. 65)*
    - [6.4. Cardiac arrhythmias](#64-cardiac-arrhythmias) *(p. 66)*
      - [6.4.1. Atrial fibrillation](#641-atrial-fibrillation) *(p. 66)*
      - [6.4.2. Long corrected QT interval and ventricular arrhythmias](#642-long-corrected-qt-interval-and-ventricular-arr) *(p. 70)*
      - [6.4.3. Bradyarrhythmias](#643-bradyarrhythmias) *(p. 72)*
    - [6.5. Arterial hypertension](#65-arterial-hypertension) *(p. 72)*
    - [6.6. Thrombosis and thromboembolic events](#66-thrombosis-and-thromboembolic-events) *(p. 75)*
      - [6.6.1. Venous thromboembolism](#661-venous-thromboembolism) *(p. 75)*
      - [6.6.2. Arterial thromboembolism](#662-arterial-thromboembolism) *(p. 76)*
      - [6.6.3. Intracardiac thrombosis](#663-intracardiac-thrombosis) *(p. 76)*
      - [6.6.4. Anticoagulation therapy](#664-anticoagulation-therapy) *(p. 77)*
        - [6.6.4.1. Treatment and secondary prevention of venous thromboembolism](#6641-treatment-and-secondary-prevention-of-venous-) *(p. 77)*
        - [6.6.4.2. Primary prevention of venous thromboembolism](#6642-primary-prevention-of-venous-thromboembolism) *(p. 77)*
    - [6.7. Bleeding complications](#67-bleeding-complications) *(p. 78)*
      - [6.7.1. High-risk patients](#671-high-risk-patients) *(p. 78)*
      - [6.7.2. Antiplatelet therapy](#672-antiplatelet-therapy) *(p. 78)*
      - [6.7.3. Management of bleeding](#673-management-of-bleeding) *(p. 78)*
    - [6.8. Peripheral artery disease](#68-peripheral-artery-disease) *(p. 79)*
    - [6.9. Pulmonary hypertension](#69-pulmonary-hypertension) *(p. 79)*
    - [6.10. Pericardial diseases](#610-pericardial-diseases) *(p. 80)*
      - [6.10.1. Pericarditis](#6101-pericarditis) *(p. 80)*
      - [6.10.2. Pericardial effusion](#6102-pericardial-effusion) *(p. 80)*
  - [7. End-of-cancer therapy cardiovascular risk assessment](#7-end-of-cancer-therapy-cardiovascular-risk-assess) *(p. 81)*
    - [7.1. Cardiovascular evaluation during the first year after cardiotoxic anticancer therapy](#71-cardiovascular-evaluation-during-the-first-year) *(p. 81)*
    - [7.2. Which cancer survivors require cardiovascular surveillance in the first year after cancer treatment?](#72-which-cancer-survivors-require-cardiovascular-s) *(p. 81)*
    - [7.3. Management of cancer therapy-related cardiac dysfunction at the end-of-therapy assessment](#73-management-of-cancer-therapy-related-cardiac-dy) *(p. 82)*
    - [7.4. Cardiopulmonary exercise testing and fitness during the end-of-therapy assessment](#74-cardiopulmonary-exercise-testing-and-fitness-du) *(p. 82)*
    - [7.5. The role of cardiac rehabilitation](#75-the-role-of-cardiac-rehabilitation) *(p. 82)*
  - [8. Long-term follow-up and chronic cardiovascular complications in cancer survivors](#8-long-term-follow-up-and-chronic-cardiovascular-c) *(p. 84)*
    - [8.1. Cancer survivors](#81-cancer-survivors) *(p. 84)*
      - [8.1.1. Adult survivors of childhood and adolescent cancer](#811-adult-survivors-of-childhood-and-adolescent-c) *(p. 84)*
      - [8.1.2. Adult cancer survivors](#812-adult-cancer-survivors) *(p. 85)*
    - [8.2. Myocardial dysfunction and heart failure](#82-myocardial-dysfunction-and-heart-failure) *(p. 87)*
    - [8.3. Coronary artery disease](#83-coronary-artery-disease) *(p. 88)*
    - [8.4. Valvular heart disease](#84-valvular-heart-disease) *(p. 89)*
    - [8.5. Peripheral artery disease and stroke](#85-peripheral-artery-disease-and-stroke) *(p. 89)*
    - [8.6. Pericardial complications](#86-pericardial-complications) *(p. 89)*
    - [8.7. Arrhythmias and autonomic disease](#87-arrhythmias-and-autonomic-disease) *(p. 90)*
    - [8.8. Metabolic syndrome, lipid abnormalities, diabetes mellitus, and hypertension](#88-metabolic-syndrome,-lipid-abnormalities,-diabet) *(p. 90)*
    - [8.9. Pregnancy in cancer survivors](#89-pregnancy-in-cancer-survivors) *(p. 90)*
    - [8.10. Pulmonary hypertension](#810-pulmonary-hypertension) *(p. 91)*
  - [9. Special populations](#9-special-populations) *(p. 91)*
    - [9.1. Cardiac tumours](#91-cardiac-tumours) *(p. 91)*
    - [9.2. Pregnant patients with cancer](#92-pregnant-patients-with-cancer) *(p. 91)*
      - [9.2.1. Left ventricular dysfunction and heart failure](#921-left-ventricular-dysfunction-and-heart-failure) *(p. 92)*
      - [9.2.2. Venous thromboembolism and pulmonary embolism](#922-venous-thromboembolism-and-pulmonary-embolism) *(p. 92)*
    - [9.3. Carcinoid valvular heart disease](#93-carcinoid-valvular-heart-disease) *(p. 95)*
    - [9.4. Amyloid light-chain cardiac amyloidosis](#94-amyloid-light-chain-cardiac-amyloidosis) *(p. 96)*
    - [9.5. Cardiac implantable electronic devices](#95-cardiac-implantable-electronic-devices) *(p. 98)*
  - [10. Patient information, communication, and self-management](#10-patient-information,-communication,-and-self-ma) *(p. 102)*
  - [11. The role of scientific societies in the promotion and development of cardio-oncology in modern medicine](#11-the-role-of-scientific-societies-in-the-promoti) *(p. 103)*
  - [12. Key messages](#12-key-messages) *(p. 103)*
  - [13. Future needs](#13-future-needs) *(p. 104)*
  - [14. Gaps in evidence](#14-gaps-in-evidence) *(p. 105)*
  - [15. ‘What to do’ and ‘what not to do’ messages from the Guidelines](#15-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 105)*
  - [16. Quality indicators for cardio-oncology](#16-quality-indicators-for-cardio-oncology) *(p. 114)*
  - [17. Supplementary data](#17-supplementary-data) *(p. 114)*
  - [18. Data availability statement](#18-data-availability-statement) *(p. 114)*
  - [19. Author information](#19-author-information) *(p. 114)*
  - [Appendix](#appendix) *(p. 114)*
  - [References](#references) *(p. 115)*
  - [References](#references) *(p. 115)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European
Hematology Association (EHA), the European
Society for Therapeutic Radiology and
Oncology (ESTRO) and the International
Cardio-Oncology Society (IC-OS)
Developed by the task force on cardio-oncology of the European
Society of Cardiology (ESC)
Authors/Task Force Members: Alexander R. Lyon*† (Chairperson) (United
Kingdom), Teresa López-Fernández*† (Chairperson) (Spain), Liam S. Couch (Task
Force Coordinator) (United Kingdom), Riccardo Asteggiano (Italy),
Marianne C. Aznar1 (United Kingdom), Jutta Bergler-Klein (Austria),
Giuseppe Boriani (Italy), Daniela Cardinale (Italy), Raul Cordoba2 (Spain),
Bernard Cosyns (Belgium), David J. Cutter (United Kingdom),
Evandro de Azambuja (Belgium), Rudolf A. de Boer (Netherlands), Susan F. Dent3
(United States of America), Dimitrios Farmakis (Cyprus), Soﬁe A. Gevaert
(Belgium), Diana A. Gorog (United Kingdom), Joerg Herrmann3 (United States of
America), Daniel Lenihan3 (United States of America), Javid Moslehi (United
States of America), Brenda Moura (Portugal), Sonja S. Salinger (Serbia),
Richard Stephens (United Kingdom), Thomas M. Suter (Switzerland),
Sebastian Szmit (Poland), Juan Tamargo (Spain), Paaladinesh Thavendiranathan
(Canada), Carlo G. Tocchetti (Italy), Peter van der Meer (Netherlands),
Helena J.H. van der Pal (Netherlands), and ESC Scientiﬁc Document Group
*Corresponding authors: Alexander R. Lyon, National Heart and Lung Institute, Imperial College London and Cardio-Oncology Service, Royal Brompton Hospital, London, United
Kingdom. Tel: +44 207 352 8121, E-mail: a.lyon@imperial.ac.uk.
Teresa López-Fernández, Cardiology Department, La Paz University Hospital, IdiPAZ Research Institute, Madrid, Spain. Tel: +34 619 227 076, E-mail: tlfernandez8@gmail.com.
† The two chairpersons contributed equally to the document and are joint corresponding authors.
Author/Task Force Member afﬁliations are listed in Author information.
1Representing the European Society for Therapeutic Radiology and Oncology (ESTRO); 2representing the European Hematology Association (EHA); 3representing the International
Cardio-Oncology Society (IC-OS).
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC),
European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council of Cardio-Oncology, Council on Hypertension, Council on Valvular Heart Disease.
Working Groups: Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, e-Cardiology, Myocardial Function, Pulmonary Circulation and Right Ventricular Function,
Thrombosis.
Patient Forum
https://doi.org/10.1093/eurheartj/ehac244
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Patrizio Lancellotti (CPG Review Coordinator) (Belgium), Franck Thuny (CPG Review
Coordinator) (France), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Berthe Aleman1 (Netherlands),
Joachim Alexandre (France), Ana Barac3 (United States of America), Michael A. Borger (Germany),
Ruben Casado-Arroyo (Belgium), Jennifer Cautela (France), Jolanta Čelutkienė (Lithuania), Maja Cikes
(Croatia), Alain Cohen-Solal (France), Kreena Dhiman (United Kingdom), Stéphane Ederhy (France),
Thor Edvardsen (Norway), Laurent Fauchier (France), Michael Fradley3 (United States of America), Julia Grapsa
(United Kingdom), Sigrun Halvorsen (Norway), Michael Heuser2 (Germany), Marc Humbert (France),
Tiny Jaarsma (Sweden), Thomas Kahan (Sweden), Aleksandra Konradi (Russian Federation),
Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Bonnie Ky3 (United States of America), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip
(United Kingdom), Maja-Lisa Løchen (Norway), Katarzyna Malaczynska-Rajpold (United Kingdom),
Marco Metra (Italy), Richard Mindham (United Kingdom), Marie Moonen (Belgium), Tomas G. Neilan
(United States of America), Jens Cosedis Nielsen (Denmark), Anna-Sonia Petronio (Italy), Eva Prescott
(Denmark), Amina Rakisheva (Kazakhstan), Joe-Elie Salem (France), Gianluigi Savarese (Sweden), Marta Sitges
(Spain), Jurrien ten Berg (Netherlands), Rhian M. Touyz (Canada/United Kingdom), Agnieszka Tycinska
(Poland), Matthias Wilhelm (Switzerland), and Jose Luis Zamorano (Spain)
All experts involved in the development of these Guidelines have submitted declarations of interest. These have been compiled in a report and published in a supplementary document simultaneously to the Guidelines. The report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary data that includes background information and detailed discussion of the data that have provided the basis of the guidelines.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords
Guidelines • Androgen deprivation therapy • Anthracycline • Atrial ﬁbrillation • Arrhythmias • Biomarkers •
Cancer • Cancer survivors • Carcinoid syndrome • Amyloid light-chain cardiac amyloidosis • Cardiac magnetic resonance • Cardiac tumour • Cardio-oncology • Cardiotoxicity • Coronary artery disease • Chemotherapy •
Echocardiography • Fluoropyrimidine • Heart failure • Haematopoietic stem cell transplantation • Hormone therapy
• Hypertension • Immunotherapy • Ischaemic heart disease • Myocarditis • Pericardial disease • Pulmonary hypertension • Thrombosis • Risk stratiﬁcation • Trastuzumab • Valvular heart disease • Vascular endothelial growth factor inhibitors (VEGFi) • Venous thromboembolism • Pericardial disease • Proteasome inhibitors • QTc prolongation • Radiotherapy • Strain
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University
Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the
ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
This article has been co-published with permission in the European Heart Journal and the European Heart Journal – Cardiovascular Imaging. © The European Society of Cardiology 2022. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article. For permissions please e-mail: journals.permissions@oup.com.


<!-- PAGE 3 -->

### Page 3

Table of contents
1. Preamble ........................................................................................................
4236
2. Introduction .................................................................................................
4238
2.1. Cancer and cardiovascular needs of patients with cancer
4238
2.2. Role of cardio-oncology services ............................................... 4238
2.3. General principles of cardio-oncology ..................................... 4239
3. Cancer therapy-related cardiovascular toxicity deﬁnitions .....
4242
4. Cardiovascular toxicity risk stratiﬁcation before anticancer therapy .................................................................................................................
4244
4.1. General approach to cardiovascular toxicity risk in patients with cancer ................................................................................................... 4244
4.2. History and clinical examination ................................................. 4249
4.3. Electrocardiogram ............................................................................. 4249
4.4. Cardiac serum biomarkers ............................................................ 4251
4.5. Cardiovascular imaging ................................................................... 4252
4.6. Cardiopulmonary ﬁtness assessment ....................................... 4253
4.7. Cardiovascular risk evaluation before cancer surgery ...... 4254
4.8. Genetic testing ................................................................................... 4254
5. Prevention and monitoring of cardiovascular complications during cancer therapy ...................................................................................
4254
5.1. General principles ............................................................................. 4254
5.2. Primary prevention strategies ...................................................... 4256
5.2.1. Primary prevention of cancer therapy-related cardiovascular toxicity during anthracycline chemotherapy ..................................................................................
4256
5.2.2. Primary prevention of radiation-induced cardiovascular toxicity ..................................................................
4256
5.3. Secondary prevention strategies ................................................ 4257
5.4. Cardiovascular surveillance during cancer therapies ......... 4257
5.4.1. Cardiac serum biomarkers .............................................
4257
5.4.2. Cardiac imaging ....................................................................
4257
5.5. Cancer therapy-related cardiovascular toxicity monitoring protocols ....................................................................................................... 4259
5.5.1. Anthracycline chemotherapy .........................................
4259
5.5.2. HER2-targeted therapies .................................................
4259
5.5.3. Fluoropyrimidines ...............................................................
4261
5.5.4. Vascular endothelial growth factor inhibitors ........
4261
5.5.5. Multitargeted kinase inhibitors targeting BCR-ABL
4264
5.5.6. Bruton tyrosine kinase inhibitors .................................
4267
5.5.7. Multiple myeloma therapies ...........................................
4268
5.5.8. Rapidly accelerated ﬁbrosarcoma and mitogenactivated extracellular signal-regulated kinase inhibitor treatment ............................................................................................
4271
5.5.9. Immune checkpoint inhibitors ......................................
4273
5.5.10. Androgen deprivation therapies for prostate cancer ...................................................................................................
4274
5.5.11. Endocrine therapies for breast cancer ...................
4276
5.5.12. Cyclin-dependent kinase 4/6 inhibitors ..................
4276
5.5.13. Anaplastic lymphoma kinase inhibitors ...................
4277
5.5.14. Epidermal growth factor receptor inhibitors ......
4277
5.5.15. Chimeric antigen receptor
T cell and tumour-inﬁltrating lymphocytes therapies .....
4278
5.5.16. Radiotherapy ......................................................................
4279
5.5.17. Haematopoietic stem cell transplantation ............
4279
5.5.18. Other cancer treatments .............................................
4282
6. Diagnosis and management of acute and subacute cardiovascular toxicity in patients receiving anticancer treatment
4282
6.1. Cancer therapy-related cardiac dysfunction .......................... 4282
6.1.1. Anthracycline chemotherapy-related cardiac dysfunction .........................................................................................
4282
6.1.2. Human epidermal receptor 2-targeted therapyrelated cardiac dysfunction .........................................................
4284
6.1.3. Immune checkpoint inhibitor-associated myocarditis and non-inﬂammatory heart failure ...............
4286
6.1.4. Chimeric antigen receptor T cell and tumourinﬁltrating lymphocytes therapies and heart dysfunction
4290
6.1.5. Heart failure during haematopoietic stem cell transplantation .................................................................................
4291
6.1.6. Takotsubo syndrome and cancer ................................
4291
6.2. Coronary artery disease ................................................................. 4291
6.2.1. Acute coronary syndromes ............................................
4291
6.2.2. Chronic coronary syndromes .......................................
4293
6.3. Valvular heart disease ...................................................................... 4293
6.4. Cardiac arrhythmias ......................................................................... 4294
6.4.1. Atrial ﬁbrillation ...................................................................
4294
6.4.2. Long corrected QT interval and ventricular arrhythmias ........................................................................................
4298
6.4.3. Bradyarrhythmias ................................................................
4300
6.5. Arterial hypertension ....................................................................... 4300
6.6. Thrombosis and thromboembolic events .............................. 4303
6.6.1. Venous thromboembolism .............................................
4303
6.6.2. Arterial thromboembolism ............................................
4304
6.6.3. Intracardiac thrombosis ...................................................
4304
6.6.4. Anticoagulation therapy ...................................................
4305
6.7. Bleeding complications .................................................................... 4306
6.7.1. High-risk patients ................................................................
4306
6.7.2. Antiplatelet therapy ...........................................................
4306
6.7.3. Management of bleeding ..................................................
4306
6.8. Peripheral artery disease ................................................................ 4307
6.9. Pulmonary hypertension ................................................................ 4307
6.10. Pericardial diseases ......................................................................... 4308
6.10.1. Pericarditis ...........................................................................
4308
6.10.2. Pericardial effusion ...........................................................
4308
7. End-of-cancer therapy cardiovascular risk assessment .............
4309
7.1. Cardiovascular evaluation during the ﬁrst year after cardiotoxic anticancer therapy ............................................................ 4309
7.2. Which cancer survivors require cardiovascular surveillance in the ﬁrst year after cancer treatment? .......................................... 4309
7.3. Management of cancer therapy-related cardiac dysfunction at the end-of-therapy assessment ...................................................... 4310
7.4. Cardiopulmonary exercise testing and ﬁtness during the end-of-therapy assessment .................................................................... 4310
7.5. The role of cardiac rehabilitation ............................................... 4310
8. Long-term follow-up and chronic cardiovascular complications in cancer survivors ..........................................................................................
4312
8.1. Cancer survivors ................................................................................ 4312
8.1.1. Adult survivors of childhood and adolescent cancer ...................................................................................................
4312
8.1.2. Adult cancer survivors ......................................................
4313
8.2. Myocardial dysfunction and heart failure ................................ 4315
8.3. Coronary artery disease ................................................................. 4316
8.4. Valvular heart disease ...................................................................... 4317
8.5. Peripheral artery disease and stroke ........................................ 4317
8.6. Pericardial complications ................................................................ 4317
8.7. Arrhythmias and autonomic disease ......................................... 4318
ESC Guidelines
4231


<!-- PAGE 4 -->

### Page 4

8.8. Metabolic syndrome, lipid abnormalities, diabetes mellitus,
and hypertension ........................................................................................ 4318
8.9. Pregnancy in cancer survivors ..................................................... 4318
8.10. Pulmonary hypertension .............................................................. 4319
9. Special populations ....................................................................................
4319
9.1. Cardiac tumours ................................................................................ 4319
9.2. Pregnant patients with cancer ..................................................... 4319
9.2.1. Left ventricular dysfunction and heart failure ........
4320
9.2.2. Venous thromboembolism and pulmonary embolism ..................................................................................... 4320
9.3. Carcinoid valvular heart disease ................................................. 4323
9.4. Amyloid light-chain cardiac amyloidosis .................................. 4324
9.5. Cardiac implantable electronic devices .................................... 4326
10. Patient information, communication, and self-management
4330
11. The role of scientiﬁc societies in the promotion and development of cardio-oncology in modern medicine ..................
4331
12. Key messages ............................................................................................
4331
13. Future needs ..............................................................................................
4332
14. Gaps in evidence ......................................................................................
4333
15. ‘What to do’ and ‘what not to do’ messages from the
Guidelines ...........................................................................................................
4333
16. Quality indicators for cardio-oncology ..........................................
4342
17. Supplementary data ................................................................................
4342
18. Data availability statement ...................................................................
4342
19. Author information ................................................................................
4342
20. Appendix .....................................................................................................
4342
21. References ..................................................................................................
4343
Tables of Recommendations
Recommendation Table 1 — Recommendations for a general approach to cardiovascular toxicity risk categorization .................
4249
Recommendation Table 2 — Recommendations for electrocardiogram baseline assessment ................................................
4251
Recommendation Table 3 — Recommendation for cardiac biomarker assessment prior to potentially cardiotoxic therapies .
4252
Recommendation Table 4 — Recommendations for cardiac imaging modalities in patients with cancer ..........................................
4253
Recommendation Table 5 — Recommendations for primary prevention of cancer therapy-related cardiovascular toxicity ......................................................................................................... 4256
Recommendation Table 6 — Recommendation for secondary prevention of cancer therapy-related cardiovascular toxicity .....
4257
Recommendation Table 7 — Recommendations for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months after therapy ..............................................
4259
Recommendation Table 8 — Recommendations for baseline risk assessment and monitoring during human epidermal receptor
2-targeted therapies and in the ﬁrst 12 months after therapy ...
4260
Recommendation Table 9 — Recommendations for baseline risk assessment and monitoring during ﬂuoropyrimidine therapy .....
4261
Recommendation Table 10 — Recommendations for baseline risk assessment and monitoring during vascular endothelial growth factor inhibitors ...............................................................................
4264
Recommendation Table 11 — Recommendations for baseline risk assessment and monitoring during second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors .................................................................
4267
Recommendation Table 12 — Recommendations for baseline risk assessment and monitoring during Bruton tyrosine kinase inhibitor therapy ..............................................................................................
4267
Recommendation Table 13 — Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies ..................................................................................................... 4271
Recommendation Table 14 — Recommendations for baseline risk assessment and monitoring during combined rapidly accelerated ﬁbrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor therapy ...............................................
4272
Recommendation Table 15 — Recommendations for baseline risk assessment and monitoring during immunotherapy ...............
4274
Recommendation Table 16 — Recommendations for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer .......................................................................
4276
Recommendation Table 17 — Recommendations for baseline risk assessment and monitoring during endocrine therapy for breast cancer ....................................................................................................
4276
Recommendation Table 18 — Recommendations for baseline risk assessment and monitoring during cyclin-dependent kinase
4/6 inhibitor therapy ......................................................................................
4277
Recommendation Table 19 — Recommendations for baseline risk assessment and monitoring during anaplastic lymphoma kinase and epidermal growth factor receptor inhibitors ...............
4277
Recommendation Table 20 — Recommendations for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell and tumour-inﬁltrating lymphocytes therapies .............................................................................................................
4279
Recommendation Table 21 — Recommendations for baseline risk assessment of patients before radiotherapy to a volume including the heart ..........................................................................................
4279
Recommendation Table 22 — Recommendations for baseline risk assessment in haematopoietic stem cell transplantation patients ................................................................................................................
4281
Recommendation Table 23 — Recommendation for the management of cardiovascular disease and cancer therapy-related cardiovascular toxicity in patients receiving anticancer treatment .....................................................................................
4282
Recommendation Table 24 — Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy ........................................................
4284
Recommendation Table 25 — Recommendations for the management of cancer treatment-related cardiac dysfunction during human epidermal receptor 2-targeted therapies ...............
4286
Recommendation Table 26 — Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis ...............................................................
4289
Recommendation Table 27 — Recommendations for the diagnosis and management of Takotsubo syndrome in patients with cancer ........................................................................................................
4291
Recommendation Table 28 — Recommendations for the management of acute coronary syndromes in patients receiving anticancer treatment .....................................................................................
4292
Recommendation Table 29 — Recommendation for the management of chronic coronary syndromes in patients receiving anticancer treatment .....................................................................................
4293
Recommendation Table 30 — Recommendations for the management of valvular heart disease in patients receiving anticancer treatment .....................................................................................
4293


<!-- PAGE 5 -->

### Page 5

Recommendation Table 31 — Recommendations for the management of atrial ﬁbrillation in patients receiving anticancer treatment ............................................................................................................
4297
Recommendation Table 32 — Recommendations for the management of long corrected QT interval and ventricular arrhythmias in patients receiving anticancer treatment .................
4300
Recommendation Table 33 — Recommendations for the management of arterial hypertension in patients receiving anticancer treatment .....................................................................................
4302
Recommendation Table 34 — Recommendations for the management of venous thromboembolism in patients receiving anticancer treatment .....................................................................................
4305
Recommendation Table 35 — Recommendations for venous thromboembolism prophylaxis during anticancer treatment ......
4306
Recommendation Table 36 — Recommendation for management of peripheral artery disease during anticancer treatment ..................
4307
Recommendation Table 37 — Recommendations for the management of pulmonary hypertension during anticancer treatment ............................................................................................................
4308
Recommendation Table 38 — Recommendations for the management of pericardial diseases in patients receiving anticancer treatment .....................................................................................
4309
Recommendation Table 39 — Recommendations for end-of-cancer therapy cardiovascular risk assessment ...................
4312
Recommendation Table 40 — Recommendations for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer survivors .........................................
4313
Recommendation Table 41 — Recommendations for cardiovascular surveillance in asymptomatic adult cancer survivors
4314
Recommendation Table 42 — Recommendations for adult cancer survivors who develop cancer therapy-related cardiac dysfunction late after cardiotoxic cancer therapy ............................
4316
Recommendation Table 43 — Recommendations for adult cancer survivors with coronary artery disease ..................................
4316
Recommendation Table 44 — Recommendations for adult cancer survivors with valvular heart disease .......................................
4317
Recommendation Table 45 — Recommendation for adult cancer survivors with pericardial complications ...............................................
4318
Recommendation Table 46 — Recommendations for cardiovascular monitoring in cancer survivors during pregnancy
4319
Recommendation Table 47 — Recommendations for cardiovascular assessment and monitoring of pregnant women with cancer .............
4323
Recommendation Table 48 — Recommendations for carcinoid valvular heart diseases ...................................................................................
4323
Recommendation Table 49 — Recommendations for amyloid light-chain cardiac amyloidosis diagnosis and monitoring ..............
4326
Recommendation Table 50 — Recommendations for risk stratiﬁcation and monitoring for patients with cardiac implantable electronic devices undergoing radiotherapy ....................................................
4330
List of tables
Table 1 Classes of recommendations ....................................................
4237
Table 2 Levels of evidence ..........................................................................
4237
Table 3 Cancer therapy-related cardiovascular toxicity deﬁnitions
4243
Table 4 Heart Failure Association–International Cardio-Oncology
Society baseline cardiovascular toxicity risk stratiﬁcation ............... 4246
Table 5 Anthracycline equivalence dose ...............................................
4247
Table 6 Factors that could inﬂuence peri-operative risk during cancer surgery and preventive strategies .............................................
4254
Table 7 Cancer treatments that predispose to acute coronary syndromes ..........................................................................................................
4291
Table 8 Risk factors for drug-induced QT prolongation and torsade de pointes ..........................................................................................
4298
Table 9 Classiﬁcation of corrected QT interval prolongation induced by cancer drug therapy ...............................................................
4298
Table 10 Risk factors for future cardiovascular disease at the end-of-cancer therapy cardiovascular risk assessment ...................
4310
Table 11 Risk categories for asymptomatic adults who are childhood and adolescent cancer survivors .........................................
4313
Table 12 Risk categories for asymptomatic adult cancer survivors
4314
Table 13 Management strategies and surgery indications for symptomatic and asymptomatic patients with benign and malignant cardiac tumours ..........................................................................
4321
List of ﬁgures
Figure 1 Video 1 Central Illustration: Dynamics of cardiovascular toxicity risk of patients with cancer over their therapy continuum .................................................................................. 4239
Figure 2 Cardio-oncology care pathways .............................................
4240
Figure 3 Baseline cardiovascular toxicity risk assessment checklist
4241
Figure 4 Dimensions of cancer therapy-related cardiovascular toxicity risk and disease severity ..............................................................
4242
Figure 5 Baseline cardiovascular toxicity risk assessment before anticancer therapy ..........................................................................................
4245
Figure 6 General cardio-oncology approach after Heart Failure
Association–International Cardio-Oncology Society cardiovascular toxicity risk assessment ................................................ 4248
Figure 7 Baseline screening recommendations for patients with cancer treated with potentially cardiotoxic drugs ............................
4250
Figure 8 Recommended transthoracic echocardiography and cardiac magnetic resonance imaging parameters in the evaluation of patients with cancer ...............................................................................................
4252
Figure 9 Primary and secondary cancer therapy-related cardiovascular toxicity prevention ..................................................................
4255
Figure 10 Cardiovascular toxicity monitoring in patients receiving anthracycline chemotherapy ......................................................................
4258
Figure 11 Cardiovascular toxicity monitoring in patients receiving human epidermal receptor 2-targeted therapies ..............................
4260
Figure 12 Vascular endothelial growth factor inhibitors-related cardiovascular toxicities ...............................................................................
4262
Figure 13 Cardiovascular toxicity monitoring in patients receiving vascular endothelial growth factor inhibitors .....................................
4263
Figure 14 Breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitor-related cardiovascular toxicities ............
4265
Figure 15 Second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors surveillance protocol .....................................................................................
4266
Figure 16 Multiple myeloma drug-related cardiovascular toxicities
4268
Figure 17 Cardiovascular monitoring in patients with multiple myeloma receiving proteasome inhibitors ...........................................
4269
Figure 18 Risk factors for venous thromboembolic events in patients with multiple myeloma ...............................................................
4270
Figure 19 Rapidly accelerated ﬁbrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor-related cardiovascular toxicities ........................................................................................................................
4233


<!-- PAGE 6 -->

### Page 6

Figure 20 Cardiovascular surveillance in patients treated with immune checkpoint inhibitors ...................................................................
4273
Figure 21 Androgen deprivation therapy-related cardiovascular toxicities ..............................................................................................................
4275
Figure 22 Anaplastic lymphoma kinase and epidermal growth factor receptor inhibitor-related cardiovascular toxicities ...........
4278
Figure 23 Radiotherapy mean heart dose and associated cardiovascular toxicity risk ..........................................................................
4280
Figure 24 Risk factors and cardiovascular surveillance in patients referred for haematopoietic stem cell transplantation ..................
4281
Figure 25 Management of anthracycline chemotherapy-related cardiac dysfunction .........................................................................................
4283
Figure 26 Management of human epidermal receptor 2-targeted therapy-related cardiac dysfunction ........................................................
4285
Figure 27 Direct and indirect immune checkpoint inhibitor-related cardiovascular toxicity ................................................
4287
Figure 28 Diagnosis and management of immune checkpoint inhibitor-related myocarditis ......................................................................
4288
Figure 29 Diagnosis and management workup in cancer-related
Takotsubo syndrome ....................................................................................
4290
Figure 30 Pathophysiology of atrial ﬁbrillation associated with cancer ...................................................................................................................
4295
Figure 31 Structured approach to anticoagulation for atrial
ﬁbrillation in patients with cancer ............................................................
4296
Figure 32 Corrected QT interval monitoring before and during treatment with corrected QT interval-prolonging anticancer drugs
4299
Figure 33 Recommended threshold for asymptomatic hypertension treatment in different clinical scenarios ....................
4301
Figure 34 Treatment of arterial hypertension in patients with cancer ...................................................................................................................
4302
Figure 35 Risk factors for venous thromboembolism in patients with cancer ........................................................................................................
4303
Figure 36 Structured approach to anticoagulation for venous thromboembolism in patients with active cancer ............................
4304
Figure 37 Management of cancer therapy-related cardiac dysfunction after cancer therapy .............................................................
4311
Figure 38 Long-term follow-up in cancer survivors .........................
4315
Figure 39 Location of primary and secondary cardiac tumours .
4320
Figure 40 Diagnostic algorithm for cardiac masses ..........................
4321
Figure 41 Cardiac monitoring protocol for pregnant women receiving anthracycline-based chemotherapy .....................................
4322
Figure 42 Carcinoid heart disease: clinical features and diagnostic tests .......................................................................................................................
4324
Figure 43 Non-invasive diagnosis of amyloid light-chain cardiac amyloidosis .........................................................................................................
4325
Figure 44 Risk stratiﬁcation in patients with a cardiac implantable electronic device undergoing radiotherapy .........................................
4327
Figure 45 Management of patients with a cardiac implantable electronic device located in the radiotherapy treatment beam .
4328
Figure 46 Management of patients with a cardiac implantable electronic device located outside the radiotherapy treatment volume .................................................................................................................
4329
Figure 47 Patient information, communication, and self-management ..............................................................................................
4330
Figure 48 The role of scientiﬁc societies in the promotion and development of cardio-oncology .............................................................
4331
Abbreviations and acronyms
2D
Two-dimensional
3D
Three-dimensional
5-FU
5-ﬂuorouracil
5HIAA
5-hydroxyindoleacetic acid a′
Late diastolic velocity of mitral annulus obtained by tissue Doppler imaging
ABC
Atrial ﬁbrillation Better Care
ABI
Ankle–brachial index
AC
Anthracycline chemotherapy
ACE-I
Angiotensin-converting enzyme inhibitors
ACS
Acute coronary syndromes
ADT
Androgen deprivation therapy
ADVANCE
Action in Diabetes and Vascular Disease:
Preterax and Diamicron-MR Controlled
Evaluation
AF
Atrial ﬁbrillation
AI
Aromatase inhibitors
AL-CA
Amyloid light-chain cardiac amyloidosis
ALK
Anaplastic lymphoma kinase
ANS
Autonomic nervous system
ARB
Angiotensin receptor blockers
ARISTOTLE
Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation
ASCVD
AtheroSclerotic Cardiovascular Disease
ASPIRE
Carﬁlzomib, Lenalidomide, and
Dexamethasone vs. Lenalidomide and
Dexamethasone for the Treatment of
Patients with Relapsed Multiple Myeloma
ASTCT
American Society for Transplantation and
Cellular Therapy
ATAC
‘Arimidex’ and Tamoxifen Alone or in
Combination
ATE
Arterial thromboembolism
AV
Atrioventricular
BB
Beta-blockers
BC
Breast cancer
BCR-ABL
Breakpoint cluster region–Abelson oncogene locus
BIG
Breast International Group
BLEED
Increased bleeding risk
BMI
Body mass index
BNP
B-type natriuretic peptide
BP
Blood pressure
BTK
Bruton tyrosine kinase
C
Chemotherapy cycle
CABG
Coronary artery bypass graft
CAD
Coronary artery disease
CARDIOTOX
CARDIOvascular TOXicity induced by cancer-related therapies
CAR-T
Chimeric antigen receptor T cell
CCB
Calcium channel blockers
CCS
Chronic coronary syndromes
CCTA
Coronary computed tomography angiography


<!-- PAGE 7 -->

### Page 7

CCU
Coronary care unit
CDK
Cyclin-dependent kinase
CHA2DS2-VASc
Congestive heart failure, Hypertension, Age
≥75 years (2 points), Diabetes mellitus,
Stroke (2 points)—Vascular disease, Age
65–74 years, Sex category (female)
CIED
Cardiac implantable electronic device
CML
Chronic myeloid leukaemia
CMR
Cardiac magnetic resonance
COMPASS-CAT
Prospective COmparison of Methods for thromboembolic risk assessment with clinical
Perceptions and AwareneSS in real-life patients—Cancer Associated Thrombosis
CPET
Cardiopulmonary exercise testing
CrCl
Creatinine clearance
CRF
Cardiorespiratory ﬁtness
CRS
Cytokine release syndrome
CS
Cancer survivors
CT
Computed tomography
CTLA-4
Cytotoxic T lymphocyte-associated antigen-4
cTn
Cardiac troponin
CTRCD
Cancer therapy-related cardiac dysfunction
CTR-CVT
Cancer therapy-related cardiovascular toxicity
CV
Cardiovascular
CVD
Cardiovascular disease
CVRF
Cardiovascular risk factors
DAPT
Dual antiplatelet therapy
DASISION
DASatinib vs. Imatinib Study In treatment-Naïve chronic myeloid leukaemia patients
DL
Dyslipidaemia
DM
Diabetes mellitus
DNR
Do not resuscitate
DVT
Deep vein thrombosis
E
Mitral inﬂow early diastolic velocity obtained by pulsed wave e′
Early diastolic velocity of the mitral annulus obtained by tissue Doppler imaging
EACTS
European Association for Cardio-Thoracic
Surgery
EBC
Early breast cancer
ECG
Electrocardiogram
Echo
Echocardiography
ECV
Extracellular volume fraction eGFR
Estimated glomerular ﬁltration rate
EGFR
Epidermal growth factor receptor
EMA
European Medicines Agency
EMB
Endomyocardial biopsy
ENGAGE AF-TIMI 48
Effective Anticoagulation with Factor
Xa Next Generation in Atrial FibrillationThrombolysis in Myocardial Infarction 48
ENOXACAN
Enoxaparin and Cancer
EoL
End of life
ERS
European Respiratory Society
ESC
European Society of Cardiology
ESC-CCO
European Society of Cardiology Council of
Cardio-Oncology
ESH
European Society of Hypertension
EuroSCORE
European System for Cardiac Operative
Risk Evaluation
FAC
Fractional area change
FDA
Food and Drug Administration
FLT3
FMS-like tyrosine kinase 3
FWLS
Free wall longitudinal strain
GI
Gastrointestinal
GLS
Global longitudinal strain
GnRH
Gonadotropin-releasing hormone
GU
Genitourinary
GVHD
Graft vs. host disease
Gy
Gray
HAS-BLED
Hypertension, Abnormal renal and liver function, Stroke, Bleeding Labile international normalized ratio, Elderly,
Drugs or alcohol
HbA1c
Glycated haemoglobin
HDU
High-dependency unit
HER2
Human epidermal receptor 2
HF
Heart failure
HFA
Heart Failure Association
HFmrEF
Heart failure with mildly reduced ejection fraction
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HG
Hyperglycaemia
HIIT
High-intensity interval training
HSCT
Haematopoietic stem cell transplantation hs-cTn
High-sensitivity cardiac troponin
HTN
Hypertension
ICD
Implantable cardioverter deﬁbrillator
ICI
Immune checkpoint inhibitors
ICOS
International Cardio-Oncology Society
ICU
Intensive care unit
IHD
Ischaemic heart disease
IMiD
Immunomodulatory drugs i.v.
Intravenous
IVC
Inferior vena cava
IVS
Intraventricular septum
LA
Left atrial
LAA
Left atrial appendage
LGE
Late gadolinium enhancement
LIMA
Left internal mammary artery
LMWH
Low-molecular-weight heparins
LQTS
Long QT syndrome
LS
Longitudinal strain
LV
Left ventricular
LVD
Left ventricular dysfunction
LVEDD
Left ventricular end diastolic diameter
LVEF
Left ventricular ejection fraction
LVV
Left ventricular volume
M
Months
MACE
Major adverse cardiovascular events
MCS
Mechanical circulatory support
MDT
Multidisciplinary team
ESC Guidelines
4235


<!-- PAGE 8 -->

### Page 8

MedDRA
Medical dictionary for regulatory activities
MEK
Mitogen-activated extracellular signal-regulated kinase
MHD
Mean heart dose
MI
Myocardial infarction
MM
Multiple myeloma
MUGA
Multigated acquisition nuclear imaging
N
No
NOAC
Non-vitamin K antagonist oral anticoagulants
NP
Natriuretic peptides
NSTE-ACS
Non-ST-segment elevation acute coronary syndromes
NT-proBNP
N-terminal pro-B-type natriuretic peptide
PAD
Peripheral artery disease
PAH
Pulmonary arterial hypertension
PAP
Pulmonary arterial pressure
PCI
Percutaneous coronary intervention
PD-1
Programmed death-1
PD-L1
Programmed death-ligand 1
PE
Pulmonary embolism
Peric-E
Pericardial effusion
PET
Positron emission tomography
PH
Pulmonary hypertension
PI
Proteasome inhibitors
Pleu-E
Pleural effusion
PRECISE-DAPT
PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy
PRONOUNCE
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients
With Advanced Prostate Cancer and
Cardiovascular Disease
PW
Left ventricular posterior wall
QI
Quality indicator
↑QTc
Corrected QT interval prolongation
QTc
Corrected QT interval
QTcF
Corrected QT interval using Fridericia correction
RA
Right atrial
RAF
Rapidly accelerated ﬁbrosarcoma
RCT
Randomized controlled trial
RIMA
Right internal mammary artery
ROCKET AF
Rivaroxaban Once Daily Oral Direct Factor
Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation
RT
Radiotherapy
RV
Right ventricular
RVEF
Right ventricular ejection fraction
RVV
Right ventricular volume s′
Systolic velocity of tricuspid annulus obtained by doppler tissue imaging
SBr
Sinus bradycardia
SCORE2
Systematic Coronary Risk Estimation 2
SCORE2-OP
Systematic Coronary Risk Estimation 2—
Older Persons
SEER
Surveillance, Epidemiology, and End Results
SMART
Second manifestations of arterial disease sPAP
Systolic pulmonary artery pressure
SPEP
Serum protein electrophoresis
STEMI
ST-segment elevation myocardial infarction
STIR
Short tau inversion recovery
STS PROM
Society of Thoracic Surgeons – Predicted
Risk of Mortality
SVT
Supraventricular tachycardia
SYNTAX
SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery
TAPSE
Tricuspid annular plane systolic excursion
TAVI
Transcatheter aortic valve implantation
TBIP
Thromboembolic risk, Bleeding risk, drug–
drug Interactions, Patient preferences
TdP
Torsade de pointes
TIL
Tumour-inﬁltrating lymphocytes
TKI
Tyrosine kinase inhibitors
TRV
Tricuspid regurgitation velocity
TTE
Transthoracic echocardiography
TTS
Takotsubo syndrome tx
Treatment
ULN
Upper limit of normal
UPEP
Urine protein electrophoresis
VA
Ventricular arrhythmias
VascTox
Vascular toxicity
VEGF
Vascular endothelial growth factor
VEGFi
Vascular endothelial growth factor inhibitors
VH
Very high risk
VHD
Valvular heart disease
VKA
Vitamin K antagonists
VTE
Venous thromboembolism
Y
Yes
1. Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, guidelines are not a substitute for the patient’s relationship with their practitioner. The ﬁnal decisions concerning an individual patient must be made by the responsible health professional(s), based on what they consider to be the most appropriate in the circumstances. These decisions are made in consultation with the patient and caregiver as appropriate.
Guidelines are intended for use by health professionals. To ensure that all users have access to the most recent recommendations, the
ESC makes its Guidelines freely available. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
A great number of guidelines have been issued in recent years by the
ESC. Because of their impact on clinical practice, quality criteria for the development of guidelines have been established to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.
escardio.org/Guidelines). The ESC Guidelines represent the ofﬁcial position of the ESC on a given topic and are regularly updated.


<!-- PAGE 9 -->

### Page 9

In addition to the publication of Clinical Practice Guidelines, the ESC
carries out the EURObservational Research Programme of international registries of cardiovascular diseases and interventions, which are essential to assess diagnostic/therapeutic processes, use of resources and adherence to guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world,
based on high-quality data collected during routine clinical practice.
Furthermore, the ESC develops sets of quality indicators (QIs),
which are tools to evaluate the level of implementation of the guidelines and may be used by the ESC, hospitals, healthcare providers and professionals to measure clinical practice, and in educational programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes.
The Members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. The selection procedure aimed to ensure that there is a representative mix of members predominantly from across the whole of the ESC region and from relevant ESC Subspecialty Communities.
Consideration was given to diversity and inclusion, notably with respect to gender and country of origin. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk–beneﬁt ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and scored according to predeﬁned scales, as outlined below. The Task Force followed the ESC voting procedures. All recommendations subject to a vote achieved at least 75% among voting members.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conﬂicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/
Guidelines) and have been compiled in a report and published in a supplementary document simultaneously to the guidelines.
This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arise during the writing period were notiﬁed to the
Table 1
Classes of recommendations
©ESC 2022
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.
efficacy of the given treatment or procedure.
favour of usefulness/efficacy.
Usefulness/efficacy is less well useful/effective, and in some cases
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not may be harmful. 
Is not recommended
     Class IIb established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in
Should be considered
Class II 
Table 2
Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2022
ESC Guidelines
4237


<!-- PAGE 10 -->

### Page 10

ESC and updated. The Task Force received its entire ﬁnancial support from the ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the approval process of these guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts, including a mix of members from across the whole of the ESC region and from relevant
ESC Subspecialty Communities and National Cardiac Societies. After appropriate revisions, the guidelines are signed off by all the experts involved in the Task Force. The ﬁnalized document is signed off by the CPG for publication in the European Heart Journal. The guidelines were developed after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their writing.
The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommendations, including condensed pocket guideline versions, summary slides,
summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus,
for more detailed information, the user should always access the fulltext version of the guidelines, which is freely available via the ESC website and the European Heart Journal. The National Cardiac Societies of the ESC are encouraged to endorse, adopt, translate and implement all
ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably inﬂuenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC
Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession.
Off-label use of medication may be presented in this guideline if sufﬁcient level of evidence shows that it can be considered medically appropriate to a given condition and if patients could beneﬁt from the recommended therapy. However, the ﬁnal decisions concerning an individual patient must be made by the responsible health professional giving special consideration to:
(1) the speciﬁc situation of the patient. In this respect, it is speciﬁed that, unless otherwise provided for by national regulations, offlabel use of medication should be limited to situations where it is in the patient’s interest to do so, with regard to the quality,
safety and efﬁcacy of care, and only after the patient has been informed and has provided consent;
(2) country-speciﬁc health regulations, indications by governmental drug regulatory agencies and the ethical rules to which health professionals are subject, where applicable.
2. Introduction
This is the ﬁrst European Society of Cardiology (ESC) guideline on cardio-oncology. The aim of this guideline is to help all the healthcare professionals providing care to oncology patients before, during, and after their cancer treatments with respect to their cardiovascular (CV)
health and wellness. This guideline provides guidance on the deﬁnitions,
diagnosis, treatment, and prevention of cancer therapy-related CV
toxicity (CTR-CVT), and the management of CV disease (CVD)
caused directly or indirectly by cancer. This area of medicine has limited trials and evidence on which to base decision-making and,
where evidence is limited, this guideline provides the consensus of expert opinion to guide healthcare professionals.
This guideline includes the deﬁnitions of CTR-CVT (Section 3),1 and provides a personalized approach to care based upon the baseline
CV toxicity risk assessment (Section 4) and new protocols for CV surveillance during cancer treatment (Section 5). The management of acute
CTR-CVT is addressed in Section 6, where patients with activecancer are those receiving anticancer treatment. Throughout these sections,
decision-making depends upon the risk/beneﬁt balance of oncology treatment efﬁcacy and the severity and impact of CTR-CVT. Guidance is provided for the ﬁrst 12 months after completion of cardiotoxic treatments (Section 7), when subacute CVD can emerge, and when patients who developed CTR-CVT during cancer treatment are reviewed.
Diagnosis and management of the long-term CV complications of previous oncology treatments, beyond 12 months after completing the cardiotoxic treatments, and integration into the overall survivorship strategy for cancer survivors (CS) is presented in Section 8 with new long-term surveillance recommendations for high-risk patients.
In Section 9, we address special populations where CVDs are directly caused by the cancer, or where special considerations are required. Section 10 provides information for patients’ involvement in their own care. The ﬁnal section highlights the role of the ESC and the ESC Council of Cardio-Oncology (ESC-CCO).
CTR-CVT risk is a dynamic variable, and the risk changes throughout the pathway of care (Figure 1, Video 1). Absolute risk of
CTR-CVT is important to understand and balance against the absolute beneﬁt of the cancer treatment before and during treatment.
However, CTR-CVT risk can be inﬂuenced by several variables, including implementation of primary prevention treatments, optimization of pre-existing CVD, dose, frequency, and duration of oncology treatment, emergence of CV complications during treatment and their severity, and in CS, the overall cumulative treatment received,
the time since treatment, and the interaction with other CVDs.
2.1. Cancer and cardiovascular needs of patients with cancer
Since the 1990s, there has been a steady decline in cancer-related mortality mirrored by a steady increase in CS.2,3 In this context,
treatment-related side effects have gained more signiﬁcance.
Management of CTR-CVT has a tremendous impact on the type of anticancer therapies that patients can receive as well as the long-term morbidity and mortality outcomes of patients with cancer. Effective management of patients with both cancer and CVD requires the unique interest and expertise of healthcare providers, which has led to the formation of a new discipline: cardio-oncology.4,5 A recently published ESC-CCO document describes appropriate criteria for the organization and implementation of cardio-oncology services.5
2.2. Role of cardio-oncology services
The overarching goal of the cardio-oncology discipline is to allow patients with cancer to receive the best possible cancer treatments safely,


<!-- PAGE 11 -->

### Page 11

minimizing CTR-CVT across the entire continuum of cancer care.5
Before initiation of cancer therapies with a known CV toxicity proﬁle,
the cardio-oncology team should identify and treat CV risk factors
(CVRF) and pre-existing CVDs and deﬁne an appropriate prevention and surveillance plan for early identiﬁcation and appropriate management of potential CV complications (Figure 2). Another important aspect is the participation in interdisciplinary discussions regarding the beneﬁts and risks of certain cancer treatments and their continuation or interruption should side effects become apparent. After cancer treatment has been completed, the focus shifts to co-ordination of long-term follow-up and treatment. For patients on long-term cancer therapies with CV toxicity risk, surveillance should continue until the treatment is ﬁnished.6–8 There is also the need for re-assessment of
CV risks in patients requiring treatment for secondary malignancies.
2.3. General principles of cardio-oncology
A guiding principle of cardio-oncology is the integration of clinical disciplines. Cardio-oncology providers must have knowledge of the broad scope of cardiology, oncology, and haematology management.5
Recommendations are formed regarding the most permissible (from a
Time
Baseline risk
Du
D ring cardiotoxic cancer therapy p
Long-term foll f
ow-up after cancer treatment
Primary and secondary prevention strategies
Cancer treatment surveillance
Early CTR-CVT
management
Cancer survivorship programmes
Low risk
High risk
CTR-CVT
CTR-CVT
risk risk
Figure 1 Video 1 Central Illustration: Dynamics of cardiovascular toxicity risk of patients with cancer over their therapy continuum. CS, cancer survivors; CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; CTR-CVT risk is a dynamic variable that changes through the pathway of care, and is inﬂuenced by several conditions including age, cancer history, pre-existing CVRF or CVD, and previous cardiotoxic cancer therapy. The CTR-CVT risk changes during and after treatment according to type, dose, frequency, and duration of oncology treatment (blue solid line). Pre-existing CVRF, CVD, or previous cancer treatments may increase the magnitude of acute and long-term CV toxicity risk (purple solid line). CTR-CVT risk remains variable in extent during anticancer treatment and may or may not gradually increase over time (dotted lines). Cardio-oncology strategy may reduce the magnitude of CTR-CVT by: (1) optimizing CVD
and CVRF management (green arrows); (2) considering cardioprotective strategies in high-risk patients (green arrows); (3) organizing cancer treatment surveillance; and (4) introducing early cardioprotection after the detection of subclinical CTR-CVT (purple arrows). CV risk assessment within the ﬁrst year after completion of cardiotoxic cancer therapy identiﬁes CS who require long-term follow-up. Cancer survivorship programmes that include annual CV risk assessment and CVRF/CVD management are recommended to minimize long-term CV adverse events (brown arrows).
ESC Guidelines
4239


<!-- PAGE 12 -->

### Page 12

CVD perspective) and the most effective (from an oncological perspective) cancer treatment. Adjudication of CV events occurring in patients on active therapy is another important aspect of cardio-oncology practice.1,3 This is in addition to recommendations on best treatment and management practices. This includes the full scope of CV therapies, including healthy lifestyle promotion and pharmacological, device, and surgical treatments.4,9,10
The principle underlying the dynamic course of CTR-CVT development in patients with cancer is that the absolute risk depends on their baseline risk and changes with exposure to cardiotoxic therapies over
New cancer diagnosis
During cancer treatmenta
First year after cancer treatmentb
Long term follow-up
Cardio-Oncology Care Pathways
Class 1
Class 1Ia
Class 1Ib
Baseline CV
toxicity risk assessmentc
Informing, advising, and supporting patients to promote a healthy lifestyle
Management of CVRF and CVD according to ESC Guidelines
Low risk patients
Annual CVRF
assessmente
Reassessment if new CV
signs/symptoms 
Standard surveillance
Assessment at 1 year after completion of cancer therapy
Moderate risk
 patients
Annual CVRF assessmente
CV toxicity re-stratification at 5 years
TTE every 5 years
Cardiology referrald
Assessment at 1 year after completion of cancer therapy
High and very high risk patients
Annual CVRF
assessmente
TTE at years 1, 3, 5 and 
every 5 years
Cardiology referrald
CVD prevention
Assessment at 3
months and 1 year after completion of cancer therapy
Cardiology referrald if new CV signs/symptoms or CTR-CVT develop
Figure 2 Cardio-oncology care pathways. BP, blood pressure; CS, cancer survivors; CTR-CVT, cancer therapy-related cardiovascular toxicity;
CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; ECG, electrocardiogram; ESC, European Society of
Cardiology; HbA1c, glycated haemoglobin; HFA, Heart Failure Association; ICOS, International Cardio-Oncology Society; NP, natriuretic peptides; RT, radiotherapy; TTE, transthoracic echocardiography. aCV surveillance according to baseline CV toxicity risk, type of cancer, cancer stage, and cancer therapy. bCTR-CVT risk assessment is recommended during the ﬁrst year after cardiotoxic cancer treatment to establish a long-term follow-up care plan. cThe use of HFA-ICOS risk assessment tools should be considered to assess CTR-CVT risk in patients with cancer scheduled to receive cardiotoxic anticancer therapy. Clinical assessment and ECG are recommended at baseline in all patients with cancer and echocardiography, cardiac biomarkers, or other cardiac imaging tests in selected patients according to baseline CV toxicity risk and cancer treatment type (see Figure 7). dCardio-oncology referral is recommended when available, alternatively patients should be referred to a specialized cardiologist with expertise in managing CVD in patients with cancer. eAnnual CV risk assessment (including clinical review, BP, lipid proﬁle,
HbA1c, ECG, and NP) and CVRF management is recommended in CS who were treated with a potentially cardiotoxic cancer drug or RT to a volume exposing the heart.


<!-- PAGE 13 -->

### Page 13

time (Figure 3).11 This has been recognized in conceptual models, with risk stratiﬁcation tools designed to grade patients with cancer into low, moderate, high, and very high risk of CV complications prior to starting treatment. These have been published by the Heart Failure
Association (HFA) of the ESC in collaboration with the International
Cardio-Oncology Society (ICOS) (see Section 4).12,13 Severity, duration, and type of manifestation of CTR-CVT vary by type of malignancy and cancer treatment. The risk itself can be understood in two ways: (1) the likelihood of its occurrence and (2) the severity of the complication (Figure 4). For example, a patient could be very likely to experience a CTR-CVT, but if this event is mild, oncology treatment should continue. Conversely, a patient at low likelihood could still be at high risk according to the severity of the event, which would lead to interruption of cancer treatment, e.g. a signiﬁcant decline in left ventricular (LV) ejection fraction (LVEF) to , 40% with anthracycline chemotherapy. The timeline of these developments may also be rather different. After the cardiotoxic cancer treatment has been completed, a new risk assessment is recommended to establish different long-term trajectories of CV health. These trajectories are impacted by the permanent CV toxic effects and cardiac or vascular injury of some cancer therapies, patient-related CVRF, environmental factors, and stressors (e.g. acute viral infections). The aim should be to personalize approaches to minimize CTR-CVT and improve both cancer and CV outcomes.
Baseline CV toxicity risk assessment checklist
Cancer treatment history
CV history
CVRF
Physical examination
Vital signs measurementa
BNP or NT-p
T roBNPb cTnb
ECG
Fasting plasma glucose / HbA1c
Kidney function / eGFR
Lipid profile
TTEc
Clinical assessment
Complementary tests
CTR-CVT
risk factors
Medical
CVRF
Previous
CVD
Lifestyle risk factors
ECG, TTE, and cardiac biomarkers abnormalities
Previous cardiotoxic 
therapies
Age, sex,
genetics
Figure 3 Baseline cardiovascular toxicity risk assessment checklist. BNP, B-type natriuretic peptide; cTn, cardiac troponin; CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD, CV disease; CVRF, cardiovascular risk factors; ECG, electrocardiogram; eGFR, estimated glomerular ﬁltration rate; HbA1c, glycated haemoglobin; NT-proBNP, N-terminal pro-BNP; TTE, transthoracic echocardiography. aIncluding blood pressure, heart rate, height,
weight, and body mass index. bCardiac biomarkers (troponin and NP) should be measured in patients at risk of CTRCD where available and results should be interpreted according to the patient clinical status, type of cancer treatment, and kidney function. cConsider other CV complementary tests in selected patients: cardiac magnetic resonance, coronary computed tomography angiography, CPET (in selected patients for pre-operative [lung, colon, and rectal cancers] risk stratiﬁcation). See Section 4.6.
ESC Guidelines
4241


<!-- PAGE 14 -->

### Page 14

### 3 Cancer therapy-related cardiovascular toxicity deﬁnitions

Several terminologies and deﬁnitions have previously been proposed to describe the spectrum of CTR-CVT, leading to inconsistencies in diagnosis and management. The need to harmonize these deﬁnitions has frequently been stated and recognized, and resulted in the recent international deﬁnitions of CTR-CVT1 supported by this guideline
(Table 3; Supplementary data, Table S1). This document will focus on consensus deﬁnitions for cardiomyopathy and heart failure
(HF), myocarditis, vascular toxicities, hypertension, cardiac arrhythmias, and corrected QT interval (QTc) prolongation. The deﬁnitions of other CTR-CVT, including pericardial and valvular heart diseases
(VHDs), are the same as those used for the general cardiology population. For cardiac injury, cardiomyopathy, and HF, the descriptive term cancer therapy-related cardiac dysfunction (CTRCD) is recommended as it captures the broad spectrum of possible presentations and the aetiological link with the broad scope of various cancer therapies, including chemotherapy, targeted agents, immune therapies,
and radiation therapy.
High
Intermediate
Low
Severe and very severe
Moderate
Mild
Likelihood of
CTR-CVT
Clinical severity of CTR-CVT
Figure 4 Dimensions of cancer therapy-related cardiovascular toxicity risk and disease severity. CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular. The ultimate risk is the combination of the likelihood (based on reported incidence) and degree (severity or grade) of the adverse event. The most vulnerable patient groups are those at high likelihood of experiencing a severe adverse event. The level of attention that needs to be devoted to these patients varies accordingly. The risk and type of CTR-CVT, as well as the potential for reversibility, depends on different factors, listed in
Figure 3, that should be considered to deﬁne global CV and oncological prognosis and to individualize CTR-CVT surveillance. Additional factors that add to the complexity of CTR-CVT risk assessment are the cancer type and prognosis, and type, duration, and intensity of cancer treatment.


<!-- PAGE 15 -->

### Page 15

Table 3
Cancer therapy-related cardiovascular toxicity deﬁnitions
CTRCD
Symptomatic CTRCD (HF)a,b
Very severe
HF requiring inotropic support, mechanical circulatory support, or consideration of transplantation
Severe
HF hospitalization
Moderate
Need for outpatient intensiﬁcation of diuretic and HF therapy
Mild
Mild HF symptoms, no intensiﬁcation of therapy required
Asymptomatic CTRCD
Severe
New LVEF reduction to ,40%
Moderate
New LVEF reduction by ≥10 percentage points to an LVEF
of 40–49%
OR
New LVEF reduction by ,10 percentage points to an LVEF of 40–
49% AND either new relative decline in GLS by .15% from baseline
OR new rise in cardiac biomarkersc
Mild
LVEF ≥50%
AND new relative decline in GLS by .15% from baseline
AND/OR new rise in cardiac biomarkersc
ICI myocarditis (either pathohistological diagnosis or clinical diagnosis)
Pathohistological diagnosis (EMB)
Multifocal inﬂammatory cell inﬁltrates with overt cardiomyocyte loss by light microscopy
Clinical diagnosisd cTn elevation (new or signiﬁcant change from baseline)e with 1 major criterion or 2 minor criteria,
after exclusion of ACS and acute infectious myocarditis based on clinical suspicionf
Major criterion:
• CMR diagnostic for acute myocarditis (modiﬁed Lake Louise criteria)g
Minor criteria:
• Clinical syndrome (including any one of the following: fatigue, myalgias, chest pain, diplopia, ptosis,
shortness of breath, orthopnoea, lower-extremity oedema, palpitations, light-headedness/dizziness,
syncope, muscle weakness, cardiogenic shock)
• Ventricular arrhythmia (including cardiac arrest) and/or new conduction system disease
• Decline in LV systolic function, with or without regional wall motion abnormalities in a non-Takotsubo pattern
• Other immune-related adverse events, particularly myositis, myopathy, myasthenia gravis
• Suggestive CMRh
Severity of myocarditis
• Fulminant: Haemodynamic instability, HF requiring non-invasive or invasive ventilation, complete or high-grade heart block, and/or signiﬁcant ventricular arrhythmia
• Non-fulminant: including symptomatic but haemodynamically and electrically stable patients and incidental cases diagnosed at the same time as other immuno-related adverse events. Patients may have reduced LVEF but no features of severe disease
• Steroid refractory: non-resolving or worsening myocarditis (clinical worsening or persistent troponin elevation after exclusion of other aetiologies) despite high-dose methylprednisolone
Recovery from myocarditis
• Complete recovery: Patients with complete resolution of acute symptoms, normalization of biomarkers, and recovery of LVEF after discontinuation of immunosuppression. CMR may still show LGE
or elevated T1 due to ﬁbrosis, but any suggestion of acute oedema should be absent
• Recovering: Ongoing improvement in patient clinical symptoms, signs, biomarkers, and imaging parameters, but not yet normalized, while on tapering doses of immunosuppression
Vascular toxicity (for general cardiology deﬁnitions, see Supplementary data, Table S1)
Asymptomatic vascular toxicity
CAD
Symptomatic vascular toxicity
Stroke
PAD
Transient ischaemic attack
Carotid artery disease
MI
Venous thrombosis
ACS
Arterial thrombosis
CCS
Peripheral vasoreactivity
PAD
Continued
ESC Guidelines
4243


<!-- PAGE 16 -->

### Page 16

### 4 Cardiovascular toxicity risk stratiﬁcation before anticancer therapy

The optimal time to consider CVD prevention strategies in patients with cancer is at the time of cancer diagnosis and prior to the initiation of cancer treatment.4,5 This enables the oncology team to consider CV risk while making cancer treatment choices, educating patients regarding their CV risk, personalizing CV surveillance and follow-up strategies, and making appropriate referrals of high-risk patients to cardio-oncology services. These strategies are needed to mitigate CVD risk, and improve the adherence to effective cancer treatments and the overall survival.
CVD prevention strategies require a personalized approach. Risk assessment is a challenging task and it is vital that clinicians adopt a systematic approach without delaying oncological treatment.12,21,22
Figure 5 provides a comprehensive approach to risk assessment.
The choice of the cardiac tests (electrocardiogram [ECG], biomarkers, and imaging) should be individualized based on CV risk and the planned cancer treatments.
4.1. General approach to cardiovascular toxicity risk in patients with cancer
Pre-treatment CTR-CVT risk assessment should ideally be performed using a recognized risk stratiﬁcation method where multiple risk factors are incorporated to determine patient-speciﬁc risk.23
Coronary epicardial vasoreactivity
Vasospastic angina
Coronary microvascular vasoreactivity
Microvascular angina
Raynaud’s phenomenon
Arterial hypertension
Treatment threshold for hypertension before, during, and after therapy
In patients with high CV riski: ≥130 mmHg systolic and/or ≥80 mmHg diastolic
Otherwise: ≥140 mmHg systolic and/or ≥90 mmHg diastolic
Cancer therapy holding threshold
≥180 mmHg systolic and/or ≥110 mmHg diastolic
Hypertensive emergency
(Very high) BP elevation associated with acute hypertension-mediated organ damage (heart, retina, brain,
kidneys, and large arteries), requiring immediate BP reduction to limit extension or promote regression of target organ damage
Cardiac arrhythmias
QT prolongation
Prolonged: QTcF . 500 msj
Bradycardia
For general cardiology deﬁnitions, see Supplementary data, Table S1
Supraventricular tachycardia
Ventricular arrhythmias
AF
© ESC 2022
ACS, acute coronary syndromes; AF, atrial ﬁbrillation; BNP, B-type natriuretic peptide; BP, blood pressure; CAD, coronary artery disease; CCS, chronic coronary syndromes; CMR,
cardiac magnetic resonance; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; ECV, extracellular volume fraction; EMB,
endomyocardial biopsy; ESC, European Society of Cardiology; GLS, global longitudinal strain; HF, heart failure; HFmrEF, HF with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICI, immune checkpoint inhibitors; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAD, peripheral artery disease; QTcF,
corrected QT interval using Fridericia correction; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk Estimation 2—Older Persons.
See Supplementary data, Table S1 for expanded deﬁnitions.
aWith LVEF and supportive diagnostic biomarkers based on the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF.14
bSymptomatic CTRCD represents HF, which is a clinical syndrome consisting of cardinal symptoms (e.g. breathlessness, ankle swelling, and fatigue) that may be accompanied by signs (e.g.
elevated jugular venous pressure, pulmonary crackles, and peripheral oedema) and has traditionally been divided into distinct phenotypes based on the measurement of LVEF: ≤40% =
HFrEF; 41–49% = HFmrEF; ≥50% = HFpEF.
ccTnI/cTnT . 99th percentile, BNP ≥35 pg/mL, NT-proBNP ≥125 pg/mL or new signiﬁcant rise from baseline beyond the biological and analytical variation of the assay used.
dClinical diagnoses should be conﬁrmed with magnetic resonance imaging or EMB if possible and without causing treatment delays. Treatment with immunosuppression should be promptly initiated while awaiting further conﬁrmatory testing in symptomatic patients.
eBoth troponin I and troponin T can be used; however, clinical observations suggest that troponin T may be falsely elevated in patients with concomitant myositis and without myocarditis.15–17
fAccording to local protocols.
gDiagnostic CMR: Based on updated Lake Louise criteria18: T2-based criterion + T1-based criterion + supportive criteria (T2-based criteria: regional or global increase of native T2, or T2signal intensity; T1-based criteria: regional or global increase of native T1, or regional or global increase in the ECV, or presence of LGE; supportive criteria: pericarditis and/or regional or global LV
systolic dysfunction).
hSuggestive CMR: meeting some but not all of the modiﬁed Lake Louise criteria. The presence of T2- or T1-based criteria may support a diagnosis of acute myocardial inﬂammation in the appropriate clinical scenario.
iSCORE2 (,70 years), SCORE2-OP (≥70 years) or equivalent.19 CV risk stratiﬁcation: ,50 years: low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50–69 years: low risk ,5%;
moderate risk 5% to ,10%; high risk ≥10%; ≥70 years: low risk ,7.5%, moderate risk 7.5% to ,15%, high risk ≥15%.
jQTcF 480–500 ms: correct reversible causes, minimize other QT prolonging medications, close QTcF monitoring. Fridericia correction is recommended (QTcF = QT/3√RR).20


<!-- PAGE 17 -->

### Page 17

Only a limited number of retrospective risk scores have been published in patients with cancer. Most of these scores have been developed for speciﬁc cancer-patient groups and cannot be readily applied or extrapolated to other type of malignancies.24–29 While further validation is needed, HFA-ICOS risk assessment tools should be considered to determine pre-treatment risk of CTR-CVT as they are easy to use and implement in oncology and haematology services
(Table 4; Supplementary data, Tables S2–S7).12,13 Other CV risk
Physical and metabolic assessmentb
ECG
(Class I)
Pre-existing CVD or at risk of CTRCDc
New, untreated or uncontrolled medical, and lifestyle CVRF
Arrhythmias
Prolonged QTcF
Check and correct precipitant factorsf
(Class I)
Ref cardiologistg
(Class I)
Ref rdiologist g
(Class I)
Suspected
CVD
cTn and NP
increasedd
TTE
(LVEF and GLS)
reducede
Aggressive management of
CVRF and pre-existing CVD
according to ESC Guidelines
Healthy lifestyle promotion
(Class I)
Baseline cardiovascular toxicity risk assessment
Consider primary vs secondary preventive strategies according to CV toxicity risk,
pre-existing CVD, and cancer treatment type
HFA-ICOS risk assessment:
CVRFa
CVD history
Cancer history
Cancer treatment history
Figure 5 Baseline cardiovascular toxicity risk assessment before anticancer therapy. BNP, B-type natriuretic peptide; cTn, cardiac troponin; CTRCD,
cancer therapy-related cardiac dysfunction; CV, cardiovascular; CVD, CV disease; CVRF, CV risk factors; ECG, electrocardiogram; ESC, European
Society of Cardiology; GLS, global longitudinal strain; HFA, Heart Failure Association; ICOS, International Cardio-Oncology Society; LVEF, left ventricular ejection fraction; NP, natriuretic peptides (including BNP and NT-proBNP); NT-proBNP, N-terminal pro-BNP peptide; QTc, corrected QT
interval; QTcF, corrected QT interval using Fridericia correction; TTE, transthoracic echocardiography. aWhen assessing CVRF, include information about unhealthy lifestyle including sedentary behaviour, smoking, and alcohol intake. bSee Figure 3. cAccording to cancer treatment and HFA-ICOS
risk assessment. dcTnI/T . 99th percentile, BNP ≥35 pg/mL, NT-proBNP ≥125 pg/mL. ePatients with baseline LVEF , 50% or in the low normal range (LVEF 50–54%) should be referred to a specialized cardiologist or cardio-oncologist. When TTE is used, ideally three-dimensional-LVEF and GLS
should be measured. If GLS assessment is not available, other markers of longitudinal function (e.g. annular Doppler velocity) should be considered.
Cardiac magnetic resonance should be considered if echocardiography is of non-diagnostic quality. fAnaemia, infections, electrolyte abnormalities, metabolic problems, other QTc-prolonging drugs. gCardio-oncology referral is recommended when available; alternatively, patients should be referred to a specialized cardiologist with expertise in managing CVD in patients with cancer.
ESC Guidelines
4245


<!-- PAGE 18 -->

### Page 18

Table 4
Heart Failure Association–International Cardio-Oncology Society baseline cardiovascular toxicity risk stratiﬁcation
Baseline CV toxicity risk factors
Anthracycline chemotherapy
HER2-targeted therapies
VEGF
inhibitors
BCR-ABL
inhibitors
Multiple myeloma therapies
RAF and
MEK
inhibitors
Previous CVD
HF/cardiomyopathy/
CTRCD
VH
VH
VH
H
VH
VH
Severe VHD
H
H
–
–
–
H
MI or PCI or CABG
H
H
VH
–
–
H
Stable angina
H
H
VH
–
–
H
Arterial vascular disease
–
–
VH
VH
VH
–
Abnormal ankle-brachial pressure index
–
–
–
H
–
–
PH
–
–
–
H
–
–
Arterial thrombosis with TKI
–
–
–
VH
–
–
Venous thrombosis
(DVT/PE)
–
–
H
M2
VH
–
Arrhythmiaa
–
M2
M2
M2
M2
M1
QTc ≥480 ms
–
–
H
H
–
–
450 ≤QTc , 480 ms (men);
460 ≤QTc , 480 ms
(women)
–
–
M2
M2
–
–
Prior PI CV toxicity
–
–
–
–
VH
–
Prior IMiD CV toxicity
–
–
–
–
H
–
Cardiac imaging
LVEF , 50%
H
H
H
H
H
H
LVEF 50–54%
M2
M2
M2
–
M2
M2
LV hypertrophy
–
–
–
–
M1
–
Cardiac amyloidosis
–
–
–
–
VH
–
Cardiac biomarkers
Elevated baseline cTnb
M1
M2
M1
–
M2
M2
Elevated baseline NPb
M1
M2
M1
–
H
M2
Age and CVRF
Age ≥80 years
H
H
–
–
–
M1
Age 65–79 years
M2
M2
–
–
–
M1
Age ≥75 years
–
–
H
H
H
M1
Age 65–74 years
–
–
M1
M2
M1
M1
Age ≥60 years
–
–
–
M1
–
–
CVD 10-year risk score
. 20%
–
–
–
H
–
–
Hypertensionc
M1
M1
H
M2
M1
M2
Chronic kidney diseased
M1
M1
M1
M1
M1
M1
Proteinuria
–
–
M1
–
–
–
DMe
M1
M1
M1
M1
M1
M1
Hyperlipidaemiaf
–
–
M1
M1
M1
–
Family history of thrombophilia
–
–
–
M1
M1
–
Continued


<!-- PAGE 19 -->

### Page 19

calculators (e.g. SMART [Second manifestations of arterial disease]
risk score, ADVANCE [Action in Diabetes and Vascular Disease:
Preterax and Diamicron-MR Controlled Evaluation] risk score,
SCORE2 [Systematic Coronary Risk Estimation 2], SCORE2-OP
[Systematic Coronary Risk Estimation 2—Older Persons], ASCVD
[AtheroSclerotic Cardiovascular Disease] risk score, U-Prevent,
and lifetime risk calculators) may be considered at baseline for the assessment of CV risk, considering that cancer itself may increase the likelihood of CVD.19,23,30,31
Baseline risk assessment should be considered by the treating oncology or haematology team for all patients diagnosed with cancer who are scheduled to receive a cancer treatment identiﬁed to have a clinically signiﬁcant level of CRT-CVT, or by a cardiologist if appropriate.
In the case of patients scheduled to receive
Current cancer treatment
Dexamethasone . 160 mg/
month
–
–
–
–
M1
–
Includes anthracycline before HER2-targeted therapy
–
M1g
–
–
–
–
Previous exposure to
Anthracycline
H
M2h
H
–
H
H
Trastuzumab
–
VH
–
–
–
–
RT to left chest or mediastinum
H
M2
M1
–
M1
M2
Non-anthracycline chemotherapy
M1
–
–
–
–
–
Lifestyle risk factors
Current smoker or signiﬁcant smoking history
M1
M1
M1
H
M1
M1
Obesity (BMI . 30 kg/m2)
M1
M1
M1
M1
M1
M1
© ESC 2022
AF, atrial ﬁbrillation; BCR-ABL, breakpoint cluster region–Abelson oncogene locus; BMI, body mass index; BNP, B-type natriuretic peptide; BP, blood pressure; CABG, coronary artery bypass graft; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; DM, diabetes mellitus; DVT, deep vein thrombosis; eGFR, estimated glomerular ﬁltration rate; H, high risk; HbA1c, glycated haemoglobin; HER2, human epidermal receptor 2; HF, heart failure; IMiD,
immunomodulatory drugs; LV, left ventricular; LVEF, left ventricular ejection fraction; M, moderate risk; MEK, mitogen-activated extracellular signal-regulated kinase; MI, myocardial infarction; MM, multiple myeloma; NP, natriuretic peptides (including BNP and NT-proBNP); NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCI, percutaneous coronary intervention; PE, pulmonary embolism; PH, pulmonary hypertension; PI, proteasome inhibitors; QTc, corrected QT interval; RAF, rapidly accelerated ﬁbrosarcoma; RT,
radiotherapy; TKI, tyrosine kinase inhibitors; ULN, upper limit of normal; VEGFi, vascular endothelial growth factor inhibitors; VH, very high risk; VHD, valvular heart disease.
An expanded version of this table is provided in Supplementary data, Tables S2–S7.
Risk level: Low risk = no risk factors OR one moderate1 risk factor; moderate risk (M) = moderate risk factors with a total of 2–4 points (Moderate 1 [M1] = 1 point; Moderate
[M2] = 2 points); high risk (H) = moderate risk factors with a total of ≥5 points OR any high-risk factor; very-high risk (VH) = any very-high risk factor.
aAF, atrial ﬂutter, ventricular tachycardia, or ventricular ﬁbrillation.
bElevated above the ULN of the local laboratory reference range.
cSystolic BP . 140 mmHg or diastolic BP . 90 mmHg, or on treatment.
deGFR , 60 mL/min/1.73 m2.
eHbA1c . 7.0% or .53 mmol/mol, or on treatment.
fNon-high density lipoprotein cholesterol .3.8 mmol/L (.145 mg/dL) or on treatment.
gHigh risk if anthracycline chemotherapy and trastuzumab delivered concurrently.
hPrevious malignancy (not current treatment protocol).
Table 5
Anthracycline equivalence dose
Doxorubicin
Epirubicin
Daunorubicin
Mitoxantrone
Idarubicina
CV toxicity dose ratio
1
0.8
0.6
10.5
5
Isoequivalent dose
100 mg/m2
125 mg/m2
167 mg/m2
9.5 mg/m2
20 mg/m2
© ESC 2022
This table refers to anthracycline equivalence dose using doxorubicin as a reference. Note that these isoequivalent doses are derived from paediatric CS.
CS, cancer survivors; CV, cardiovascular.
aData for idarubicin are based upon an estimated anticancer efﬁcacy ratio, not derived from cardiotoxicity data. The CV toxicity dose ratio provides the value that should be used to multiply the dose of the anthracycline of interest to convert to isoequivalent doses of doxorubicin; e.g. to convert 125 mg/m2 of epirubicin to doxorubicin isoequivalent, multiply the dose by 0.8 (125 mg/m2 × 0.8 = 100 mg/m2 of doxorubicin).
ESC Guidelines
4247


<!-- PAGE 20 -->

### Page 20

anthracycline chemotherapy, the total planned cumulative anthracycline dose is also relevant, and ≥250 mg/m2 of doxorubicin or equivalent should be considered higher risk (Table 5).32
CV risk stratiﬁcation results should be discussed with the patient and documented in clinical notes. This process will also enable future validation of these tools.
Cardiology referral (cardio-oncology programme or cardiologist with expertise in managing CVD in patients with cancer) is recommended for patients identiﬁed to be at high or very high risk for CTR-CVT at baseline (Table 4) to institute strategies to mitigate risk.33 Patients at moderate risk can beneﬁt from closer cardiac monitoring, strict management of traditional CVRF, and selected moderate-risk patients may also beneﬁt from a cardio-oncology referral (Figure 6). Low-risk patients can be followed within the oncology programme with appropriate referral to cardio-oncology if a
CTR-CVT emerges or new or uncontrolled CVRF appear.
AND
AND
AND
AND
AND
CV risk stratification befof re anticancer therapy p
(Class I)
Communicate the CV toxicity risk assessment results (Class I)
Educate patients regarding risks and protective healthy lifestyle (Class I)
f
Management of CVRF and CVD according to ESC Guidelines (Class I)
HFA-ICOS baseline risk assessment
F
(Class IIa)
Low risk
Routine oncology foll f
ow-up
Moderate risk
Cardiologya refef rral if
CV toxicity develops
(Class I)
Closer oncology foll f
ow-up
Cardiologya refef rral if
CV toxicity develops
(Class I)
Cardiology refef rrala
(Class IIb)
Cardiologya refef rral
(Class I)
Cardioprotective strategies
(Class IIa)
Discussion of the risk/benefit balance of cardiotoxic anticancer treatment
(Class I)
HFA-ICOS
F
results
High/very high risk
Patient with cancer
Figure 6 General cardio-oncology approach after Heart Failure Association–International Cardio-Oncology Society cardiovascular toxicity risk assessment. CV, cardiovascular; CVD, CV disease; CVRF, CV risk factors; ESC, European Society of Cardiology; HFA, Heart Failure Association; ICOS,
International Cardio-Oncology Society. aCardio-oncology referral is recommended when available; alternatively, patients should be referred to a specialized cardiologist with expertise in managing CVD in patients with cancer.


<!-- PAGE 21 -->

### Page 21

4.2. History and clinical examination
A careful clinical history and physical examination is recommended as part of the baseline risk assessment. Oncology patients can be divided into two cohorts with respect to the presence or absence of pre-existing CVD. A primary prevention strategy can be considered in patients without previous CVD or CTR-CVT while secondary prevention includes interventions in patients with prior or active
CVD or previous CTR-CVT.12
Reviewing traditional risk factors for CVD is recommended.
Where present, the efﬁcacy of treatment and control of these modiﬁable risk factors should be determined to ensure optimal control during cancer therapy.4,34
Although recent
SCORE2
and
SCORE2-OP19 tables are not focused on patients with cancer, risk calculation is recommended for patients with cancer .40 years of age (unless they are automatically categorized as being at high risk or very high risk based on documented CVD, diabetes mellitus
[DM], kidney disease, or a highly elevated single risk factor) as a reference to optimize CVRF treatment goals.19,31,35 A family history of premature CVD should be considered because genetic abnormalities associated with CVD may predispose patients with cancer to a higher risk of CTR-CVT.36–38 Lifestyle factors such as smoking, alcohol consumption, sedentary lifestyle, exposure to pollution, and frailty are important shared risk factors for both cancer and CVD.
Information on prior history of cancer, cardiotoxic cancer therapies,
and their respective doses should be collected. Patients should be asked about typical cardiac symptoms (e.g. chest pain with activity,
dyspnoea on exertion, orthopnoea, palpitations, and peripheral oedema), which can guide clinical examination and investigations.
Physical examination should document vital signs and look for potential indicators of undiagnosed CVD such as HF, pericardial disease,
VHD, and arrhythmias.39–42
The second scenario is secondary prevention in patients with a prior history of CVD. These patients with cancer are potentially at high or very high risk of future CV events,12 and require a more comprehensive clinical evaluation of their CVD, its severity, and prior and current treatments. Depending on the type and severity of CVD, additional investigations—including resting or stress echocardiography, cardiac magnetic resonance (CMR), nuclear perfusion imaging, and coronary computed tomography angiography (CCTA)
—may be indicated to determine risk status. Identifying prior CVD
should not automatically be a reason to withhold cancer therapy but considered an opportunity to optimize CV risk prior to and during treatment. Risk/beneﬁt discussions should include the patient,
oncologist or haematologist, and—where available—a specialized cardio-oncology service.
Additional factors that add to the complexity of baseline CV risk assessment are the cancer type and prognosis, and type, duration,
and intensity of cancer treatment (Figure 1).4,12,43 Clinical history,
physical examination features, and treatment-related risk factors that contribute to CTR-CVT for various cancer therapies are summarized in Supplementary data, Table S8. These risk factors should be collected and considered along with baseline ECG, cardiac serum biomarkers, and cardiac imaging tests (summarized in Figure 7) to complete baseline CTR-CVT evaluation.
4.3. Electrocardiogram
A baseline 12-lead ECG is a readily available test that can provide important clues to underlying CVD. ECG evidence of chamber enlargement, conduction abnormalities, arrhythmias, ischaemia, or prior myocardial infarction (MI), and low voltages should be interpreted in the clinical context. A baseline ECG is recommended prior to starting a cancer treatment known to cause QTc prolongation.44–49
Measurement of QTc using the Fridericia correction (QTcF) is
Recommendation Table 1 — Recommendations for a general approach to cardiovascular toxicity risk categorization
Recommendations
Classa
Levelb
CV toxicity risk stratiﬁcationc before starting potentially cardiotoxic anticancer therapy is recommended in all patients with cancer.12,14,19,21,25,28,31
I
B
Communicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is recommended.
I
C
The use of HFA-ICOS risk assessment should be considered to stratify CV toxicity risk in patients with cancer scheduled to receive cardiotoxic anticancer therapy.12
IIa
C
It is recommended that patients categorized to be at low CV toxicity risk should proceed to anticancer therapy without delay.
I
C
In patients categorized at moderate CV toxicity risk, cardiology referrald may be considered.e
IIb
C
Cardiology referrald is recommended in high-risk and very high-risk patients before anticancer therapy.f
I
C
Discussion of the risk/beneﬁt balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary approach prior to starting treatment is recommended.
I
C
Cardiology referrald is recommended for patients with cancer and pre-existing CVD or abnormal
ﬁndings at baseline CV toxicity risk assessmentg who require potentially cardiotoxic anticancer therapy.
I
C
© ESC 2022
CV, cardiovascular; CVD, CV disease; ECG, electrocardiogram; GLS, global longitudinal strain; HbA1c, glycated haemoglobin; HFA, Heart Failure Association; ICOS,
International Cardio-Oncology Society; LVEF, left ventricular ejection fraction; TTE,
transthoracic echocardiography; ULN, upper limit of normal; VHD, valvular heart disease.
aClass of recommendation.
bLevel of evidence.
cIncluding clinical history and physical examination, ECG, general blood test, HbA1c,
lipid proﬁle, and cardiac serum biomarkers and/or TTE (according to cancer drug type and CV toxicity risk).
dCardio-oncology referral is recommended when available; alternatively, the patients should be referred to a specialized cardiologist with expertise in managing CVD in patients with cancer.
eWithout delaying cancer treatments.
fUnless there is an oncology emergency requiring immediate cancer treatment.
gModerate-to-severe pre-existing CVDs or new abnormal ﬁndings (baseline cardiac serum biomarkers . ULN, LVEF ≤50%, GLS under normal local values, previously undiagnosed moderate-to-severe myocardial, pericardial, or VHDs, abnormal baseline
ECG).
ESC Guidelines
4249


<!-- PAGE 22 -->

### Page 22

HER2-targeted therapiesc
Baseline clinical CV assessment, p
, hysical exam and ECG are recommended in all cancer patients scheduled for ca f
rdiotoxic therapiesa
Previous
CVD
Previous
CVD
All other patients
All patients
All patients
All other patients
Previous
CVD
All patients
High and very high risk
Moderate risk
Low risk
Other conditions
Class IIb
Class IIa
Class I
Anthracyclines
Fluoropyrymidines
VEGFi
Second- and third-generation BCR-ABL TKId
BTK inhibitors
PIe
RAF and MEK inhibitors
ICI
Osimertinib
CAR-T and TIL
RT to a
R
volume including the heart
HSCT
TTEb
Patient risk level
NP
cTn
Figure 7 Baseline screening recommendations for patients with cancer treated with potentially cardiotoxic drugs. 3D, three-dimensional; ADT, androgen deprivation therapy; AL-CA, amyloid light-chain cardiac amyloidosis; BC, breast cancer; BCR-ABL, breakpoint cluster region-Abelson oncogene locus;
BNP, B-type natriuretic peptide; BTK, Bruton tyrosine kinase; CAR-T, chimeric antigen receptor T cell; CDK, cyclin-dependent kinase; CMR, cardiac magnetic resonance; cTn, cardiac troponin; CV, cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; GLS, global longitudinal strain; HER2,
human epidermal receptor 2; HSCT, haematopoietic stem cell transplantation; ICI, immune checkpoint inhibitors; LVEF, left ventricular ejection fraction;
MEK, mitogen-activated extracellular signal-regulated kinase; NP, natriuretic peptides (including BNP and NT-proBNP); NT-proBNP, N-terminal pro-B-type natriuretic peptide; PI, proteasome inhibitors; RAF, rapidly accelerated ﬁbrosarcoma; RT, radiotherapy; TIL, tumour-inﬁltrating lymphocytes;
TKI, tyrosine kinase inhibitors; TTE, transthoracic echocardiography; VEGFi, vascular endothelial growth factor inhibitors. aIncluding patients scheduled to receive ADT for prostate cancer, CDK 4/6 inhibitors, endocrine hormone therapy for BC and anaplastic lymphoma kinase inhibitors. bTTE is recommended as the ﬁrst-line modality for the assessment of cardiac function. 3D echocardiography is recommended to measure LVEF. GLS is recommended in all patients with cancer having echocardiography, if available. CMR should be considered when echocardiography is unavailable or not diagnostic.
cBaseline cTn measurement should be considered (Class IIa, Level A) in low- and moderate-risk patients post-anthracycline chemotherapy but prior to starting HER2-targeted therapies. Baseline NP and cTn measurement may be considered (Class IIb, Level C) in low- and moderate-risk patients.
dBaseline echocardiography is recommended in patients scheduled to receive dasatinib (Class I, Level C). eNP and cTn measurements are recommended at baseline in patients with AL-CA (Class I, Level B).


<!-- PAGE 23 -->

### Page 23

recommended.44–48 When baseline QTcF prolongation is recognized, the correction of reversible causes and the identiﬁcation of genetic conditions that prolong QT is recommended (see Section
6.4.2).45
Left atrial enlargement on baseline ECG before ibrutinib has been shown to be a predictor for the development of atrial ﬁbrillation (AF) during chemotherapy.50,51 The presence of atrioventricular (AV) conduction delays and premature atrial complexes are associated with the development of atrial arrhythmias in patients undergoing autologous haematopoietic stem cell transplantation (HSCT).52
4.4. Cardiac serum biomarkers
The literature on the use of biomarkers for CTR-CVT risk stratiﬁcation before cancer therapy is limited, and recommendations are mostly based on expert opinion.12,43,53–55 Four recent position papers based on collaboration among the Cardio-Oncology Study
Group of the HFA of the ESC, the ESC-CCO, and ICOS have suggested that measurement of cardiac serum biomarkers—cardiac troponin (cTn) I or T and natriuretic peptides (NP) (e.g. B-type natriuretic peptide
[BNP]
or
N-terminal pro-BNP
[NT-proBNP])—help in baseline CV risk stratiﬁcation of patients scheduled for cancer therapies including anthracyclines, human epidermal receptor 2 (HER2)-targeted therapies, vascular endothelial growth factor (VEGF) inhibitors (VEGFi), proteasome inhibitors (PI), immune checkpoint inhibitors (ICI), chimeric antigen receptor T cell (CAR-T) and tumour-inﬁltrating lymphocytes
(TIL) therapies, allowing identiﬁcation of those who may beneﬁt from cardioprotective therapy.12,43,53,54 Baseline cardiac serum biomarker measurements are required if the degree of change in the biomarkers is to be used to identify subclinical cardiac injury during cancer treatment.
A few studies of paediatric and adult patients requiring anthracycline chemotherapy have reported that patients with cancer with an increased cTn before treatment were more likely to develop CTRCD.56–58 However, most published studies have not reported on the prognostic value of baseline cTn measurements, possibly due to the low prevalence of patients with previous CVD or CVRF in these studies.55,59,60 A study of 251
women receiving trastuzumab for early HER2-positive breast cancer (BC) reported that 19% of the patients who developed cardiac dysfunction during trastuzumab therapy had positive ultrasensitive troponin I at baseline (.80 ng/L).61 Furthermore,
baseline high cTnI level was a predictor of lack of recovery despite optimal HF therapy.61 These ﬁndings have been conﬁrmed in a subsequent study of 533 patients with BC who had serial high-sensitivity cTn (hs-cTn) I and T measurements during trastuzumab therapy.62
Increased baseline cTn
(.40 ng/L
and
.14 ng/L for hs-cTnI and hs-cTnT, respectively) was associated with a four-fold risk of developing LV dysfunction (LVD).62
However, given the high proportion of patients with previous anthracycline exposure in both studies, these elevated cTn levels are not a true baseline as they reﬂect pre-trastuzumab but postanthracycline chemotherapy.
It is unclear whether pretreatment cTn levels will be predictive of LVD in patients before any treatment, or for those BC patients treated with trastuzumab without prior anthracyclines.
NP are another potential biomarker for CV risk stratiﬁcation.
Several studies have shown the role of NP measurement at baseline or NP changes to predict future CTR-CVT.63–65 In patients with multiple myeloma (MM), pre-treatment NP may be a predictive marker for subsequent CV adverse events. In 109 patients with relapsed MM,
BNP . 100 pg/mL or NT-proBNP . 125 pg/mL levels before initiation of carﬁlzomib were associated with an odds ratio of 10.8 for subsequent CV adverse events.66 Therefore, baseline NP measurement is recommended in high- and very high-risk patients and should be considered in low- and moderate-risk patients before PI
treatment.
Baseline elevated values of CV functional peptides (including
NT-proBNP) and hs-cTnT were strongly related to all-cause mortality in 555 patients with different types of tumours, suggesting that the presence of a subclinical myocardial injury might be directly linked to disease progression.67 However, in the CARDIOTOX
(CARDIOvascular TOXicity induced by cancer-related therapies)
registry, in 855 patients treated with a range of oncological treatments, including radiotherapy (RT), both NT-proBNP and cTn elevation at baseline were not associated with the development of severe
CTRCD (LVEF , 40% or clinical HF).68
There has also been interest in other novel biomarkers for
CTR-CVT risk stratiﬁcation before cancer treatment; however,
the literature is limited. Candidates include myeloperoxidase,
C-reactive protein, galectin-3, arginine–nitric oxide metabolites,
growth differentiation factor-15,
placental growth factor,
fms-like tyrosine kinase-1, micro-ribonucleic acids, and immunoglobulin E.60,69–71 Currently, there is no evidence to support routine measurement of these novel biomarkers and more research is required.
Recommendation Table 2 — Recommendations for electrocardiogram baseline assessment
Recommendations
Classa
Levelb
An ECG is recommended in all patients starting cancer therapy as part of their baseline CV risk assessment.
I
C
In patients with an abnormal baseline ECG,c referral to a cardiologistd is recommended.
I
C
© ESC 2022
AF, atrial ﬁbrillation; CV, cardiovascular; ECG, electrocardiogram; LV, left ventricular;
QTc, corrected QT interval; QTcF, corrected QT interval using Fridericia correction.
aClass of recommendation.
bLevel of evidence.
cAdvanced conduction disease (left bundle branch block, right bundle branch block,
second degree heart block, severe ﬁrst degree heart block with a PR interval
.300 ms); Q waves in two or more contiguous leads; LV hypertrophy; AF/atrial
ﬂutter if previously undiagnosed; QTc prolongation using Fridericia correction formula (QTcF = QT/3√RR) .450 ms for men and .460 ms for women or other
ECG abnormality raising concern.
dCardio-oncology referral is recommended when available; alternatively, the patients should be referred to a specialized cardiologist with expertise in managing CVD in patients with cancer.
ESC Guidelines
4251


<!-- PAGE 24 -->

### Page 24

4.5. Cardiovascular imaging
CV imaging has an important role in identifying patients with subclinical CVD, determining the degree of pre-existing cardiac comorbidity prior to decisions regarding cancer therapy, and serves as a reference for identiﬁcation of changes during treatment and long-term followup.12,54,72–74 Transthoracic echocardiography (TTE) is the preferred imaging technique for baseline risk stratiﬁcation as it provides quantitative assessment of LV and right ventricular (RV) function, chamber dilation, LV hypertrophy, regional wall motion abnormalities,
diastolic function, VHD, pulmonary arterial pressure (PAP), and pericardial disease, which may inﬂuence the therapeutic decision.22,72
Suggestions for the components of a baseline echocardiography study are provided in Figure 8.
Current deﬁnitions of CTRCD are based on a reduction of LVEF
and/or relative changes in global longitudinal strain (GLS) (Table 3).
Three-dimensional (3D) echocardiography is the preferred echocardiography modality for the assessment of LVEF and cardiac
Recommendation Table 3 — Recommendation for cardiac biomarker assessment prior to potentially cardiotoxic therapies
Recommendation
Classa
Levelb
Baseline measurement of NPc and/or cTnd is recommended in all patients with cancer at risk of
CTRCD if these biomarkers are going to be measured during treatment to detect
CTRCD.e,53,55
I
C
© ESC 2022
cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; NP,
natriuretic peptides.
aClass of recommendation.
bLevel of evidence.
cNPs including B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide.
dcTn includes any of troponin I, troponin T, or hs-cTnT.
eSpeciﬁc recommendations for baseline cardiac biomarkers in patients with cancer at low, moderate, high, and very high risk of cancer therapy-related cardiovascular toxicity are included in Section 5.
TTE
Left ventricle-left atriuma
TTE
LVV and LV mass
3D-LVEF (2D-LVEF if 
3D not available)
Contrast echo if inadequate 
TTE image quality
GLS 
E/e´, LAV
RVV
RVEF
CMR
Right ventricle-right atriuma
RV dimensions
S´
TAPSE
FAC
RV-FWLS
RA area
Peak TRV
LVV and LV mass
LVEF 
LS and circumferential strain if available
Myocardial Characterization 
T2w (STIR), T1, T2 maps, LGE
CMR
Valvular and pericardial diseases
IVC diameter, and respiratory changes
Valvular and pericardial diseases
Other parameters
TTE
CMR
Figure 8 Recommended transthoracic echocardiography and cardiac magnetic resonance imaging parameters in the evaluation of patients with cancer.
2D, two-dimensional; 3D, three-dimensional; BP, blood pressure; CMR, cardiac magnetic resonance; E, mitral inﬂow early diastolic velocity obtained by pulsed wave; e′, early diastolic velocity of the mitral annulus obtained by tissue doppler imaging; echo, echocardiography; FAC, fractional area change; FWLS, free wall longitudinal strain; GLS, global longitudinal strain; IVC, inferior vena cava; LAV, left atrial volume; LGE, late gadolinium enhancement; LS, longitudinal strain; LV,
left ventricular; LVEF, left ventricular ejection fraction; LVV, left ventricular volume; RA, right atrial; RV, right ventricular; RVEF, right ventricular ejection fraction;
RVV, right ventricular volume; s′, systolic velocity of tricuspid annulus obtained by doppler tissue imaging; STIR, short tau inversion recovery; TAPSE, tricuspid annular plane systolic excursion; TTE, transthoracic echocardiography; TRV, tricuspid regurgitation velocity. aChanges in systemic arterial BP and loading conditions may inﬂuence cardiac function measurements.


<!-- PAGE 25 -->

### Page 25

volumes.54,75–79 If 3D echocardiography is not feasible (e.g. unavailable or poor tracking), the modiﬁed two-dimensional (2D)
Simpson’s biplane method is recommended.80,81 In patients with inadequate TTE image quality, ultrasound-enhancing contrast agents should be added to improve evaluation of LV function and volumes if two or more LV segments are not well visualized.82 Alternatively, in subjects with poor-quality echocardiography windows, when available, CMR should be considered (Figure 8).14,72,83,84 If TTE and
CMR are both unavailable for the assessment of LVEF, multigated acquisition nuclear imaging (MUGA) can be considered as a third-line modality. MUGA scans should be avoided whenever possible due to radiation exposure and the inability to obtain other important information (e.g. VHD, PAP, or GLS).
Baseline LVEF and GLS are recommended in all patients evaluated with TTE before cardiotoxic cancer treatment initiation to stratify
CTR-CVT risk and to identify signiﬁcant changes during treatment.8,64 Changes in loading conditions occur frequently during chemotherapy (e.g. volume increase due to intravenous [i.v.] ﬂuids,
volume loss due to vomiting or diarrhoea, blood pressure [BP] and heart rate changes with pain or stress) and may affect cardiac volumes, LVEF, and GLS quantiﬁcation. Systemic arterial BP measurement is recommended with all resting TTE as it can inﬂuence cardiac function measurements and should be recorded on the
TTE report. A baseline borderline (50–54%) or reduced (,50%)
LVEF is a risk factor for future CTR-CVT from most cardiotoxic cancer therapies, in particular with anthracyclines or trastuzumab.12,24,74
Increased baseline indexed LV end-diastolic volume can be a predictor of major CV events (symptomatic HF or cardiac death) during anthracycline chemotherapy in patients with preserved LVEF.85
A normal LVEF does not exclude CTRCD and deformation parameters can detect early systolic impairment with sufﬁcient test reliability.86–89 Determination of GLS using speckle tracking is recommended at baseline, using three apical views,90 particularly in moderate- and high-risk patients. Baseline GLS can predict
LVD89–94 in patients receiving anthracyclines and/or trastuzumab.
Strain measurements may be subject to inter-vendor variability95
and serial GLS measurement for each patient is recommended to be performed using the same machine/software. A median GLS
change of 13.6% predicted a future fall in LVEF with a 95% upper limit of GLS reduction of 15%.93 Using the 15% cut-off improves speciﬁcity and is therefore the threshold recommended when monitoring
GLS during cancer therapy. Global circumferential strain96 has been reported to identify patients at risk of CTRCD, but data are currently insufﬁcient to recommend its use routinely. Baseline LV diastolic function may be associated with a small risk of subsequent systolic dysfunction, especially with anthracyclines and trastuzumab, although the evidence is not consistent.97,98 Chest computed tomography (CT) or CMR may be helpful for identifying subclinical CVD
such as coronary calcium or intracardiac masses on readily available routine imaging performed for cancer staging.99
In the secondary prevention setting or patients with symptoms or signs of pre-existing CVD, a careful evaluation should begin with a comprehensive TTE.73 This is both to obtain baseline assessment as in the primary prevention setting and to determine the severity of the underlying CVD. In case of poor-quality or uninterpretable
TTE images, or if a speciﬁc CVD is identiﬁed (e.g. hypertrophic cardiomyopathy), CMR should be considered for further risk assessment.
Functional imaging tests for myocardial ischaemia—including stress echocardiography, perfusion CMR, or nuclear myocardial perfusion imaging—should be performed to assess for ischaemia in symptomatic patients (stable angina, limiting dyspnoea) if clinical suspicion of coronary artery disease (CAD) exists, especially prior to use of cancer therapies associated with vascular toxicity (e.g. ﬂuoropyrimidines, VEGFi, breakpoint cluster region–Abelson oncogene locus [BCR-ABL], tyrosine kinase inhibitors [TKI]). Alternatively, in patients with low to intermediate pre-test probability of CAD,
CCTA is a robust alternate modality with high sensitivity to rule out obstructive CAD.100,101
4.6. Cardiopulmonary ﬁtness assessment
Maximal cardiopulmonary exercise testing (CPET) assesses the integrative capacity of the CV system to transport oxygen and energy substrate to skeletal muscle during exercise,109 described as cardiorespiratory ﬁtness (CRF). CPET can therefore provide a more global assessment of CV health than organ-speciﬁc tools. CPET-derived
Recommendation Table 4 — Recommendations for cardiac imaging modalities in patients with cancer
General
Classa
Levelb
Echocardiography is recommended as the
ﬁrst-line modality for the assessment of cardiac function in patients with cancer.4,12,54,94
I
C
3D echocardiography is recommended as the preferred echocardiographic modality to measure
LVEF.77–79,89
I
B
GLS is recommended in all patients with cancer having echocardiography, if available.75,80,81,89,90,92,93,102,103
I
C
CMR should be considered for the assessment of cardiac function when echocardiography is unavailable or non-diagnostic.83,104,105
IIa
C
MUGA may be considered when TTE is not diagnostic and CMR is not available.106–108
IIb
C
Baseline cardiac imaging prior to potentially cardiotoxic therapiesc
Baseline comprehensive TTE is recommended in all patients with cancer at high risk and very high risk of CV toxicity before starting anticancer therapy.d,54
I
C
© ESC 2022
3D, three-dimensional;
CMR,
cardiac magnetic resonance;
CTR-CVT, cancer therapy-related CV toxicity; CV, cardiovascular; GLS, global longitudinal strain; LVEF,
left ventricular ejection fraction; MUGA, multigated acquisition nuclear imaging; TTE,
transthoracic echocardiography.
aClass of recommendation.
bLevel of evidence.
cSpeciﬁc recommendations for baseline CV imaging in patients with cancer at low or moderate risk of CTR-CVT are included in Section 5.
dExcept asymptomatic patients referred to breakpoint cluster region-Abelson oncogene locus therapy (BCR-ABL) where baseline TTE should be considered (see Figure 7
and Section 5.5.5).
ESC Guidelines
4253


<!-- PAGE 26 -->

### Page 26

CRF—typically measured as the peak rate of oxygen consumption110,111 or metabolic equivalents111,112 during exercise—is one of the most robust predictors of CV health and longevity,113,114
and improves risk classiﬁcation.115–121 Evidence for CPET pretreatment is limited to pre-operative risk stratiﬁcation particularly for patients with lung,122 colon,123 and rectal124 cancers. Whether
CPET performed prior to cardiotoxic cancer therapies is prognostic of future CV events is unknown.
4.7. Cardiovascular risk evaluation before cancer surgery
Cancer surgery remains the primary treatment modality for many cancers. Cardio-oncology teams should be involved in pre-operative
CV risk stratiﬁcation to identify and provide appropriate management and surveillance of the potential risk factors.5
In patients undergoing oncological surgery, peri-operative cardiac complications are determined by patient-related risk factors,
the tumour type, concomitant cancer therapies, and the expected surgical risk. To ensure safe cancer surgery, consultations should be directed at: (1) patients with previous signiﬁcant or symptomatic CVD; (2) patients at high and very high CV toxicity risk, according to baseline HFA-ICOS risk assessment tools,12 when adjuvant (post-surgery) cancer treatment is planned; and (3) patients who have received neoadjuvant (prior to surgery) cancer therapy that is potentially cardiotoxic. Pre-operative clinical evaluation should not delay surgery. Complementary tests required for the patients included in groups 1 and 2 should be guided by general
ESC Guidelines.125 However, in group 3 patients, the preoperative evaluation should be aimed at conﬁrming that no relevant events have occurred during CV monitoring (Section 5).
Table 6 summarizes factors that could inﬂuence peri-operative risk during cancer surgery.
4.8. Genetic testing
Candidate gene and genome-wide association studies have resulted in the identiﬁcation of 40 candidate genes and single nucleotide polymorphisms associated with anthracycline-related cardiac dysfunction.37,126–128 It should be noted that with the advent of immunotherapies, germline genes may not be the only genetic predispositions to CTR-CVT. A study of patients with ICI-associated myocarditis identiﬁed that the selective clonal T-cell populations inﬁltrating the myocardium were identical to those present in tumours and skeletal muscle, with ribonucleic acid sequencing studies revealing expression of cardiac-speciﬁc genes in the tumour,129
raising the intriguing possibility that somatic mutations in the tumour itself could contribute to CTR-CVT. A list of genetic variants associated with
CVD
during cancer therapy is provided
(Supplementary data, Table S9) and has recently been reviewed.38
Routine use of genetic testing for the assessment of CTR-CVT risk prior to initiation of cancer therapy is not currently recommended.
In the future, a personalized genetic approach may help deﬁne individual susceptibility to CVD in patients with cancer and more research is required.
5. Prevention and monitoring of cardiovascular complications during cancer therapy
5.1. General principles
CTR-CVT risk may vary according to cancer type and stage, anticancer drugs, doses, and underlying comorbidities. Certain therapy combinations (drug–drug or drug–radiation) may have a synergistically toxic effect on the heart, possibly depending on the timing of these therapies (sequential or concomitant) and previous comorbidities. The pathophysiology of CTR-CVT is out of the scope of this guideline and is extensively reviewed in the
ESC
CardioMed textbook.130
CVD and cancer share common modiﬁable and non-modiﬁable risk factors (Figure 3).4,131,132 The ﬁrst step is to optimize lifestyle
CVRF, smoking cessation, restricting alcohol consumption to a maximum of 100 g per week, and maintaining adequate physical activity.30 Exercise prescription seems to be a promising treatment to
Table 6
Factors that could inﬂuence peri-operative risk during cancer surgery and preventive strategies
Factors that could inﬂuence peri-operative risk during cancer surgery
Preventive strategies
Patient-related factors
• Lifestyle risk factors: smoking, obesity, sedentary lifestyle
• Poorly controlled CVRF: hypertension, DM
• Pre-existing CVD including CTR-CVT
• Cardiac medications that increase peri-operative bleeding risk (e.g. antiplatelets and anticoagulants)
• Historical primary malignancy
• Current cancer type, stage and location
• Optimal management of CVRF and
CVD (Section 5)
• Optimize VTE and ATE preventive strategies (Section 6)
Neoadjuvant cancer therapy
• Neoadjuvant cardiotoxic cancer treatments (see Section 5; especially anthracycline chemotherapy and/or trastuzumab, ICI, VEGFi, ﬂuoropyrimidine, and thoracic RT)
• Cancer treatments that increase peri-operative bleeding risk (e.g. VEGFi, BTK
inhibitors)
• Thrombocytopaenia caused by cancer treatment
• Ensure optimal CV monitoring of neoadjuvant therapy (Section 5)
• Optimize VTE and ATE preventive strategies (Section 6)
© ESC 2022
ATE, arterial thromboembolism; BTK, Bruton tyrosine kinase; CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF,
cardiovascular risk factors; DM, diabetes mellitus; ICI, immune checkpoint inhibitors; RT, radiotherapy; VEGFi, vascular endothelial growth factor inhibitors; VTE, venous thromboembolism.


<!-- PAGE 27 -->

### Page 27

counteract anticancer treatment side effects and different types of training can be prescribed during cancer therapy according to a patient’s individual characteristics.133 A healthy lifestyle decreases the risks of cancer, CVD, and transition from diagnosed cancer to subsequent CVD.134,135
Poor CRF is associated with a higher prevalence of acute and chronic CTR-CVT and exercise positively impacts CRF during chemotherapy, although in a recent meta-analysis, the ability of exercise to prevent CTRCD is unclear.136,137 CVRF must be corrected with intensive treatment of arterial hypertension,138 DM,139 and
Management of CVD and CVRF 
 according to ESC Guidelines
Primary vs secondary prevention
Minimize the use of cardiotoxic drugs
ACE-I/ARB and beta-blockers
Dexrazoxane/liposomal anthracyclines
(patients treated with anthracyclines)
Statins
Primary and secondary cancer-therapy related CV toxicity prevention strategies
In patients at high and very high risk of CTRCD
1°prevention
Baseline CV risk assessment
2°prevention
1st cancer requiring cardiotoxic cancer therapy
2nd cancer requiring cardiotoxic cancer therapy
CVD
CTR-CVT
Class IIa
Class I
Figure 9 Primary and secondary cancer therapy-related cardiovascular toxicity prevention. ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; CTR-CVT, cancer therapy-related cardiovascular toxicity; CTRCD, cancer therapy-related cardiac dysfunction; ESC, European Society of Cardiology.12 Left panel represents examples of ﬁve different primary or secondary prevention strategies deﬁnition based on the history of pre-existing CVD and/or prior CTR-CVT. Right panel describes general strategies to mitigate CTR-CVT risk in patients at high and very high risk of CTRCD.
ESC Guidelines
4255


<!-- PAGE 28 -->

### Page 28

dyslipidaemia,140 and underlying CVD and modiﬁable comorbidities should be managed according to appropriate 2021 ESC Guidelines on CVD prevention in clinical practice (Figure 9).19
Special attention should also be paid to the polypharmacy frequently seen in patients with cancer, reducing the use of drugs that may interfere with cancer therapies to the essential and actively monitoring their CV side effects and drug–drug interactions.141
Electrolyte imbalances such as hypokalaemia and hypomagnesaemia should be corrected. The CV risk management plan should be shared with the cancer specialist team, the primary care physician, and the patient to coordinate treatment strategies.
5.2. Primary prevention strategies
Primary prevention of CTR-CVT aims to avoid or minimize the development of CV damage due to therapy in patients without
CVD12,142 and requires a multidisciplinary team (MDT) discussion between oncologists and cardiologists for complex patients with cancer with multiple comorbidities.4,21,22,43,143,144
5.2.1. Primary prevention of cancer therapy-related cardiovascular toxicity during anthracycline chemotherapy
Neurohormonal therapies during anthracycline chemotherapy (with or without subsequent trastuzumab treatment) reduced the risk of signiﬁcant LVEF decline during follow-up in several small randomized controlled trials (RCTs) (Supplementary data, Table S10).145–154
Recent meta-analyses including patients with cancer treated with anthracycline chemotherapy and HER2-targeted therapies reported that renin–angiotensin–aldosterone system blockers, beta-blockers,
and mineralocorticoid receptor antagonists have a signiﬁcant beneﬁt in preventing LVEF reduction, but no statistical differences in the incidence of overt HF or other clinical outcomes were demonstrated
(Supplementary data, Table S11).155–160 This may be due, in part, to the fact that most trials included patients with a low baseline CTRCD
risk and therefore larger RCTs are needed in high-risk populations.
From the oncological perspective, some strategies that have been investigated include managing anthracycline-related toxicity by adjusting the infusion time and dose intensity.161 Dexrazoxane and liposomal anthracyclines are currently approved in patients with high and very high CTRCD risk or who have already received high cumulative anthracyclines doses.158,162–167 Dexrazoxane is protective against anthracycline-induced CTRCD. Currently, dexrazoxane is formally approved in adult patients with advanced or metastatic BC who have already received a minimum cumulative anthracycline dose of
300 mg/m2 of doxorubicin or equivalent (Table 5; Supplementary data, Table S12).163 In clinical practice, dexrazoxane infusion (dosage ratio dexrazoxane/doxorubicin is 10/1; e.g. 500 mg/m2 dexrazoxane per 50 mg/m2 doxorubicin) should be considered (at least 30 min prior to each anthracycline cycle) in adult patients with cancer scheduled to receive a high total cumulative anthracycline dose for curative treatment, and in patients with high and very high CTRCD risk (including those with pre-existing HF or low-normal or reduced
LVEF) where anthracycline chemotherapy is deemed essential.163
Pegylated and non-pegylated liposomal doxorubicin164,165,168
modify pharmacokinetics and tissue distribution without compromising antitumour efﬁcacy. Pegylated and non-pegylated liposomal doxorubicin are approved for metastatic BC and pegylated liposomal doxorubicin is also approved for advanced ovarian cancer, acquired immune deﬁciency syndrome-related Kaposi sarcoma, and MM. In a recent meta-analysis of 19 trials, in both the adjuvant and metastatic context, liposomal doxorubicin was reported to be less cardiotoxic than conventional doxorubicin.165
Liposomal daunorubicin is also available for acute leukaemia patients in place of daunorubicin when pre-existing
LVD
is present.164,165
5.2.2. Primary prevention of radiation-induced cardiovascular toxicity
Primary prevention of RT-induced damage to the CV system depends on technological advances that allow improved targeting of
RT delivery, thereby maintaining or increasing oncological efﬁcacy while reducing CTR-CVT.169,170 Modern techniques strive to minimize the mean heart dose (MHD), either by shaping the dose distribution (intensity-modulated RT) or by using respiratory management (gating or breath-hold).171,172 Proton therapy offers the potential to further decrease exposure to surrounding healthy organs.173 However, complete cardiac avoidance is not always possible due to the proximity of the tumour (e.g. central lung tumours, mediastinal lymphomas, irradiation of the internal mammary chain in BC). In patients where RT only has a consolidating role and the risk of RT-induced CV injury is very high (e.g.
due to baseline risk factors), a MDT is needed to consider the risk/beneﬁt of RT.171,174
There are no proven medical therapies to prevent RT-induced CV
toxicity. One component of RT-induced CV toxicity is accelerating pre-existing CAD, and therefore tight control of CVRFs is recommended.
Recommendation Table 5 — Recommendations for primary prevention of cancer therapy-related cardiovascular toxicity
Recommendations
Classa
Levelb
Management of CVRF according to the 2021 ESC
Guidelines on CVD prevention in clinical practice is recommended before,c during, and after cancer therapy.19
I
C
Dexrazoxane should be considered in adult patients with cancer at high and very high CV
toxicity risk when anthracycline chemotherapy is indicated.d,158
IIa
B
Liposomal anthracyclines should be considered in adult patients with cancer at high and very high CV
toxicity risk when anthracycline chemotherapy is indicated.e,164,165,168
IIa
B
Continued


<!-- PAGE 29 -->

### Page 29

5.3. Secondary prevention strategies
Secondary prevention refers to interventions in patients with preexisting CVD, including prior CTR-CVT, and new emerging
CTR-CVT during cancer therapy. CVD and comorbidities should receive the optimal therapy before and during cancer therapy as discussed in previous sections. Regular clinical assessments, physical examinations, and CV investigations (including 12-lead ECG, TTE,
and cardiac biomarkers) are recommended in patients receiving speciﬁc cardiotoxic cancer therapies, with the frequency of surveillance guided by baseline risk and the emergence of new
CTR-CVT.5,12,33,53,54,187–190
5.4. Cardiovascular surveillance during cancer therapies
A careful clinical evaluation and physical examination is recommended during cancer treatment to detect early signs and symptoms of CTR-CVT. ECG monitoring is required in patients at risk of cardiac arrhythmias according to speciﬁc drug protocols.
5.4.1. Cardiac serum biomarkers
During therapy, NP and cTn should be used for CTRCD screening and diagnosis and they may also serve to guide therapy.55,63,191–194
The release of cTn and NP differ for different cancer treatments.
Therefore, an increase in biomarker level should be interpreted in the patient clinical context
(cancer treatment timing and comorbidities).
It is important to consider that generally accepted cut-offs and reference values of CV biomarkers have not been established for patients with cancer or for those who receive cancer therapies. In addition, levels of NP and cTn may differ according to local laboratories and may be altered by many factors, including age, sex, renal function, obesity, infections, and comorbidities such as AF and pulmonary embolism (PE).53,63,195–197
5.4.2. Cardiac imaging
Cardiac imaging plays a critical role in clinical decision-making during the cancer process.72,198 Imaging techniques—particularly advanced echocardiography and CMR—facilitate early diagnosis and management of CTR-CVT.22,54,94 The frequency of cardiac imaging monitoring during therapy should be adapted according to the estimated baseline risk12 and the expected CTR-CVT manifestation.54 The cardiac imaging technique used should be based on local expertise and availability, and the same imaging modality (i.e. 3D-TTE, 2D-TTE,
CMR) is recommended throughout the entire treatment to decrease inter-technique variability.94,199,200 Cardiac imaging should be performed at any time if patients receiving cardiotoxic therapies present with new cardiac symptoms.
New deﬁnitions of CTRCD are presented in Section 3.1 Early recognition of asymptomatic CTRCD allows clinicians to incorporate cardioprotective therapy before there is a signiﬁcant decline in LVEF, which may or may not be reversible, and also decreases the risk of interruptions in cancer therapy, which could otherwise affect patients’ survival.22,43,72,94 For the diagnosis and management of asymptomatic CTRCD during cancer treatment, TTE—including 3D-LVEF and GLS assessment—is the preferred technique to detect and conﬁrm cardiac dysfunction.72,83,93,102 GLS evaluation is particularly important in patients with low-normal LVEF
to conﬁrm or not asymptomatic myocardial damage.201 It is recommended to use the same vendor to analyse GLS during cancer treatment to accurately compare values over time.73 Therefore, a relative change in GLS has been suggested as the ideal tool to identify asymptomatic mild CTRCD.1,4,94 Different thresholds have been considered in the literature in recent years.93,202,203
Currently, a relative GLS decrease of .15% compared with baseline is the recommended threshold as it reﬂects the 95% upper
Recommendation Table 6 — Recommendation for secondary prevention of cancer therapy-related cardiovascular toxicity
Recommendation
Classa
Levelb
Management of CVD according to applicable ESC
Guidelines is recommended before,c during, and after cancer therapy.
I
C
© ESC 2022
CVD, cardiovascular disease; ESC, European Society of Cardiology.
aClass of recommendation.
bLevel of evidence.
cWithout delaying cancer treatments.
ACE-I or ARB and beta-blockers recommended for HFf should be considered for primary prevention in high- and very high-risk patients receiving anthracyclines and/or anti-HER2
therapies.145,150,155–157,159,160,175
IIa
B
ACE-I or ARB and beta-blockers recommended for HFf should be considered for primary prevention in high- and very high-risk patients receiving targeted cancer therapies that may cause
HF.g
IIa
C
Statins should be considered for primary prevention in adult patients with cancer at high and very high CV toxicity risk.h,149,176–185
IIa
B
© ESC 2022
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
CV, cardiovascular; CVD, CV disease; CVRF, CV risk factors; ESC, European Society of Cardiology; HER2, human epidermal receptor 2; HF, heart failure; HFA, Heart
Failure
Association;
ICOS,
International
Cardio-Oncology
Society;
MEK,
mitogen-activated extracellular signal-regulated kinase; PI, proteasome inhibitors;
RAF, rapidly accelerated ﬁbrosarcoma; VEGFi, vascular endothelial growth factor inhibitors.
aClass of recommendation.
bLevel of evidence.
cWithout delaying cancer treatments.
dAs per the European Medicine Agency: ≥350 mg/m2 doxorubicin or equivalent; as per the
United States Food and Drug Administration: ≥300 mg/m2 doxorubicin or equivalent.
eSee Section 5.2.1 for speciﬁc liposomal doxorubicin type and malignancies.
fCarvedilol (preferred beta-blocker for CV protection if there is no contraindication),186
bisoprolol, controlled/extended-release metoprolol succinate and nebivolol.
gVEGFi and bevacizumab, RAF inhibitor, MEK inhibitor, PI, dasatinib, ponatinib, and osimertinib.
hAccording to HFA-ICOS risk assessment tools (Section 4.1; Table 4).
ESC Guidelines
4257


<!-- PAGE 30 -->

### Page 30

limit in the meta-analysis of GLS to predict future signiﬁcant LVEF
reduction.93 Using the 15% threshold will maximize speciﬁcity and minimize overdiagnosis of CTRCD and guide cardioprotective therapy.1,4,93
In patients with poor TTE image quality or when TTE is not diagnostic, CMR should be considered, including fast strain-encoded
CMR when available.105,204–206 MUGA can be considered as a thirdline modality.
Baseline
C4
C5
C6
3 M
post tx
12 M
post tx
C1
C2
C3
Anthracycline chemotherapy surveillance protocol
Class 1
Class 1Ia
Class 1Ib
ECG
cTnb / NPb
TTEa
ECG
cTnb / NPb
TTEa
ECG
cTn / NP
TTEa
High and 
very high 
risk
Moderate risk
Low risk
Figure 10 Cardiovascular toxicity monitoring in patients receiving anthracycline chemotherapy. cTn, cardiac troponin; C, chemotherapy cycle;
ECG, electrocardiogram; M, months; NP, natriuretic peptides; TTE, transthoracic echocardiography; tx, treatment. Biomarker and TTE assessment should ideally be performed before the corresponding anthracycline cycle (C1–C6). aCardiac magnetic resonance should be considered for the assessment of cardiac function when TTE is unavailable or not diagnostic. In moderate-risk patients, TTE should be considered after a cumulative dose of
≥250 mg/m2 of doxorubicin or equivalent. In low-risk patients, TTE may be considered after a cumulative dose of ≥250 mg/m2 of doxorubicin or equivalent. bMeasurement of NP and/or cTn is recommended in all patients with cancer if these biomarkers are going to be used during treatment monitoring.
cTn and NP monitoring every two cycles during anthracycline chemotherapy and within 3 months after therapy completion may be considered in low-risk patients (Class IIb, Level C). cTn and NP monitoring every two cycles during anthracycline chemotherapy and within 3 months after therapy completion should be considered in moderate-risk patients and in low-risk patients receiving a cumulative dose of ≥250 mg/m2 of doxorubicin or equivalent (Class IIa,
Level C).


<!-- PAGE 31 -->

### Page 31

5.5. Cancer therapy-related cardiovascular toxicity monitoring protocols
5.5.1. Anthracycline chemotherapy
Anthracycline-induced CTRCD is a dose-dependent and cumulative process of variable onset that may present with symptomatic or asymptomatic CTRCD.4
Figure 10 summarizes the recommended monitoring protocol during anthracycline therapy according to baseline CTRCD risk
(Table 4). Clinical assessment combined with cardiac biomarkers
(cTn and NP) and TTE (including 3D-LVEF and GLS when available) can identify both symptomatic and asymptomatic CTRCD
with a reasonably high negative predictive value. This topic has been extensively reviewed in two recent
HFA
position statements.53,54 Classifying patients based on their risk of anthracycline-induced CV toxicity has allowed the early implementation of personalized preventive strategies (Section 5.2.1).14
Patients with pre-existing CVD should be treated with guidelinebased medical therapy.14,19,207
5.5.2. HER2-targeted therapies
HER2-targeted therapies are a crucial part of the treatment of patients with HER2-positive invasive BC in both early and metastatic settings. In the neoadjuvant and/or adjuvant settings, drugs currently approved are trastuzumab, pertuzumab, trastuzumab emtansine, and neratinib. In the metastatic setting, trastuzumab,
pertuzumab, trastuzumab emtansine, tucatinib, and trastuzumab deruxtecan are currently approved.214–216 Trastuzumab can also be used in patients with HER2-overexpressing metastatic gastric adenocarcinomas in combination with platinum-based chemotherapy and either capecitabine or 5-ﬂuorouracil (5-FU).
It is recognized that anti-HER2 therapies may lead to LVD in up to 15–20% of patients and to overt HF if surveillance is missed, or in high- and very high-risk patients.217–220 LV function surveillance based on LVEF and GLS is recommended prior to and every 3 months during HER2-targeted therapies treatment surveillance (Figure 11).22 However, this single algorithm has not been tested in low- or high-risk patients and increased frequency of assessment (according to local availability) is recommended in high-risk patients.
The use of cardiac serum biomarkers to identify CTRCD is less well-deﬁned during anti-HER2 treatments.217 Measurement of cTn in BC patients after anthracycline-based chemotherapy but prior to trastuzumab should be considered, as an elevated cTn identiﬁes patients at higher risk of trastuzumab-induced
CTRCD. Serial NP measurement was more sensitive than cTn at predicting subsequent declines in LVEF during trastuzumab treatment.74
Recommendation Table 7 — Recommendations for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months after therapy
Recommendations
Classa
Levelb
TTE
Baseline echocardiographyc is recommended in all patients with cancer before anthracycline chemotherapy.12,24,208–210
I
B
In all adults receiving anthracycline chemotherapy,
an echocardiogram is recommended within 12
months after completing treatment.208
I
B
In high- and very high-risk patients,
echocardiography is recommended every two cycles and within 3 months after completing treatment.24,208–210
I
C
In moderate-risk patients, additional echocardiography should be considered after a cumulative dose of ≥250 mg/m2 of doxorubicin or equivalent.7
IIa
C
In low-risk patients, additional echocardiography may be considered after a cumulative dose of ≥250 mg/m2 of doxorubicin or equivalent.7
IIb
C
Cardiac serum biomarkers
Baseline measurement of NP and cTn is recommended in high- and very high-risk patients prior to anthracycline chemotherapy.55,65,211
I
B
Continued
Baseline measurement of NP and cTn should be considered in low- and moderate-risk patients prior to anthracycline chemotherapy.211
IIa
C
cTn and NP monitoring before every cycle during anthracycline chemotherapy and 3 and 12 months after therapy completion is recommended in highand very high-risk patients.55,175,211
I
B
cTn and NP monitoring every two cycles during anthracycline chemotherapy and within 3 months after therapy completion should be considered in moderate-risk patients and in low-risk patients receiving a cumulative dose of ≥250 mg/m2 of doxorubicin or equivalent.55,59,212,213
IIa
C
cTn and NP monitoring every two cycles during anthracycline chemotherapy and within 3 months after therapy completion may be considered in low-risk patients.55,59,212,213
IIb
C
© ESC 2022
cTn, cardiac troponin; NP, natriuretic peptides; TTE, transthoracic echocardiography.
aClass of recommendation.
bLevel of evidence.
cIf echocardiography is unavailable or non-diagnostic, follow general cardiac imaging modalities recommendations (see Section 4.5).
ESC Guidelines
4259


<!-- PAGE 32 -->

### Page 32

For patients requiring adjuvant chemotherapy and anti-HER2-targeted therapy, the use of non-anthracycline chemotherapy should be considered by the MDT according to risk of relapse, cardiac risks, and in discussion with the treating oncologist.217 When anthracycline chemotherapy in the
(neo)-adjuvant setting is necessary, sequential use (anthracyclines followed by taxanes and anti-HER2 agents) has been shown to signiﬁcantly decrease the incidence of CTRCD in several adjuvant trials, compared with concomitant use in earlier trials.220–224
Recommendation Table 8 — Recommendations for baseline risk assessment and monitoring during human epidermal receptor 2-targeted therapies and in the ﬁrst 12 months after therapy
Recommendations
Classa
Levelb
TTE
Baseline echocardiographyc is recommended before HER2-targeted therapies in all patients.225
I
B
Continued
9 M
12 M
3 M
6 M
HER2-targeted therapy surveillance protocol
High and 
very high 
riskb
Low and moderate riska
Baseline e
ECG
cTnd / NPd
TTEc
ECG
cTn / NP
TTEc
Class 1
Class 1Ia
Class 1Ib
3 M
post tx
12 M
post tx
Figure 11 Cardiovascular toxicity monitoring in patients receiving human epidermal receptor 2-targeted therapies. cTn, cardiac troponin; CV,
cardiovascular; EBC, early breast cancer; ECG, electrocardiogram; HER2, human epidermal receptor 2; M, months; NP, natriuretic peptides; TTE, transthoracic echocardiography; tx, treatment. This protocol refers to CV toxicity monitoring in patients receiving neoadjuvant or adjuvant anti-HER2 targeted therapies for non-metastatic disease or ﬁrst year in metastatic disease. Biomarker assessment should ideally be performed before the corresponding trastuzumab cycle. TTE should be performed in week 2 or 3 of a 3-weekly trastuzumab cycle. aIn low-risk HER2+ EBC patients who are asymptomatic and with a normal assessment after 3 months, reducing TTE monitoring to every 4 months may be considered (Class IIb, Level C).
In low- and moderate-risk metastatic HER2+ disease, TTE surveillance can be reduced to every 6 months after the ﬁrst year in asymptomatic patients with normal TTE assessment (Class I, Level C). bIn high- and very high-risk metastatic HER2+ disease, TTE monitoring every 2–3 cycles may be considered depending on the absolute risk and local availability. cCardiac magnetic resonance should be considered for the assessment of cardiac function when TTE
is unavailable or not diagnostic. dMeasurement of NP and/or cTn is recommended in all patients with cancer if these biomarkers are going to be used during treatment monitoring. eBaseline cTn measurement should be considered in low- and moderate-risk patients after anthracycline chemotherapy but prior to starting anti-HER2 targeted therapies for CV toxicity risk prediction.


<!-- PAGE 33 -->

### Page 33

5.5.3. Fluoropyrimidines
Fluoropyrimidines such as 5-FU and its oral prodrug capecitabine are mainly used for gastrointestinal (GI) malignancies and advanced
BC.
The most common
CTR-CVTs are angina pectoris,
ischaemia-related ECG abnormalities, hypertension, Takotsubo syndrome (TTS), and MI (even in patients with normal coronary arteries),1,4,10,43,229,230 with rarer CTR-CVT including myocarditis,
arrhythmias, and peripheral arterial toxicity (Raynaud’s phenomenon and ischaemic stroke).231 The incidence of myocardial ischaemia varies according to the dose, scheduling, and route of administration and is up to 10%.232 Among the several mechanisms responsible for
5-FU-induced myocardial ischaemia are coronary vasospasm and endothelial injury.233 Chest pain and ischaemic ECG changes usually occur at rest (less typically during exercise) within days of drug administration and sometimes persist even after treatment cessation.
CTR-CVT risk markedly increases in patients with cancer with preexisting CAD. Aggressive control of modiﬁable CVRFs, according to the 2021 ESC Guidelines on CVD prevention in clinical practice,19 is recommended during and after treatment. A baseline TTE is recommended in patients with a history of symptomatic CV to conﬁrm the presence of pre-existing regional wall motion abnormalities or LVD. Screening for CAD may be considered in selected high- and very high-risk patients before the administration of these drugs and according to local protocols and current recommendations.12,234,235
5.5.4. Vascular endothelial growth factor inhibitors
Aberrant activation of kinases plays a critical role in both the development of numerous cancer types and in CV and metabolic homeostasis. Inhibition of the VEGF signalling pathway is achieved with either monoclonal antibodies (administered i.v.) against circulating
VEGF or with small-molecule TKI (taken orally) targeting VEGF receptors.236 VEGFi are used for the treatment of numerous cancer types, including renal, thyroid, and hepatocellular carcinomas.
However, their use is associated with a wide array of CV complications including hypertension, HF, QTc prolongation, and acute vascular events (Figure 12).131,237–240 It can be challenging to assess the prognosis of patients experiencing severe CV side effects because
In patients receiving neoadjuvant or adjuvant
HER2-targeted therapies, echocardiography is recommended every 3 months and within 12
months after completing treatment.225,226
I
B
In low-risk HER2+ EBC patientsd who are asymptomatic and with a normal assessment after
3 months, reducing monitoring to every 4 months may be considered.
IIb
C
In high- and very high-risk HER2+ EBC patients,d more frequent echocardiography monitoringe should be considered during treatment.
IIa
C
In metastatic HER2+ disease, echocardiography is recommended every 3 months during the ﬁrst year; if the patient remains asymptomatic without
CV toxicity, then surveillance can be reduced to every 6 months during future treatment.f
I
C
In metastatic HER2+ disease patients at high- and very high-risk, more frequent echocardiography monitoringe may be considered.
IIb
C
Cardiac biomarkers
Baseline NP and cTn measurement are recommended in high- and very high-risk patients prior to anti-HER2-targeted therapies.227,228
I
C
NP and cTn monitoring every 2–3 cycles during therapy and 3 and 12 months after the end of therapy should be considered in high- and very high-risk HER2+ EBC patients.d,55
IIa
C
Baseline cTn measurement should be considered in low- and moderate-risk patients post-anthracycline chemotherapy but prior to starting anti-HER2-targeted therapies.55,62
IIa
A
NP and cTn monitoring at baseline, every 3
months, and 12 months after therapy may be considered in low- and moderate-risk HER2+
EBC patients.d,55
IIb
C
© ESC 2022
BC, breast cancer; cTn, cardiac troponin; CV, cardiovascular; EBC, early breast cancer;
HER2, human epidermal receptor 2; NP, natriuretic peptides; TTE, transthoracic echocardiography.
aClass of recommendation.
bLevel of evidence.
cIf echocardiography is unavailable or non-diagnostic, follow general cardiac imaging modalities recommendations (see Section 4.5).
dThese recommendations are also applicable for HER2+ non-BC patients.
eEvery 2–3 cycles depending on the absolute risk and local availability.
fPatients at low and moderate risk.
Recommendation Table 9 — Recommendations for baseline risk assessment and monitoring during ﬂuoropyrimidine therapy
Recommendations
Classa
Levelb
Baseline CV risk assessment and evaluation including BP measurement, ECG, lipid proﬁle,
HbA1c measurement, and SCORE2/
SCORE2-OPc or equivalent is recommended19
before starting ﬂuoropyrimidines.
I
C
A baseline echocardiogram is recommended in patients with a history of symptomatic CVD
before starting ﬂuoropyrimidines.
I
C
Screening for CADd may be considered in patients at high and very high risk of CADc before
ﬂuoropyrimidines.
IIb
C
© ESC 2022
BP, blood pressure; CAD, coronary artery disease; CV, cardiovascular; CVD,
cardiovascular disease; ECG, electrocardiogram; HbA1c, glycated haemoglobin;
SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary
Risk Estimation 2—Older Persons.
aClass of recommendation.
bLevel of evidence.
cSCORE2 (,70 years) or SCORE2-OP (≥70 years) CV risk stratiﬁcation: ,50 years:
low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50–69 years: low risk
,5%; moderate risk 5% to ,10%; high risk ≥10%; ≥70 years: low risk ,7.5%,
moderate risk 7.5% to ,15%, high risk ≥15%.
dAccording to pre-existing CVD and local protocols.234
ESC Guidelines
4261


<!-- PAGE 34 -->

### Page 34

these drugs are often used in patients with advanced cancer. The goal must be to continue VEGFi treatment for as long as possible with initiation or optimization of CV treatment if indicated.
Hypertension is a class effect and is the most reported adverse event under VEGFi treatment. It occurs within hours or days, is dosedependent,
and is usually reversed by
VEGFi discontinuation.131,239,241–243 The risk is higher in patients with pre-existing hypertension or CVD, previous anthracycline treatment, advanced age, history of smoking, hyperlipidaemia, and/or obesity (Table 4).4,244
LVD and HF occur in a minority of patients in RCTs,245 but are reported more frequently in routine practice246 and are often reversible.247 Acute arterial events (aortic dissection, stroke, arterial thrombosis,
acute coronary events, vasospasm)
and venous thromboembolism (VTE) can also complicate treatment with
VEGFi.248 QTc prolongation has been described with sunitinib, sorafenib, and vandetanib,249 but it is rarely related to severe arrhythmic events, except with vandetanib.250 Some small-molecule TKI (e.g.
sorafenib and sunitinib) can cause AF251 and HF.43,129,247
Aflibercept
Monoclonal antibodies
VEGF TKI
Bevacizumaba
Ramucirumaba
Axitinib
Cabozantinib
Lenvatinib
Pazopanib
Regorafenib
Sorafenib
Sunitinib
Vandetanib
HTN
HF
VTE
ATE
MI
VEGFi-related cardiovascular toxicities
Very common: ≥10% incidence
Common: 1% to <10% incidence
Uncommon: 0.1% to < 1% incidence
Rare: <0.1% incidence
QTc
Figure 12 Vascular endothelial growth factor inhibitors-related cardiovascular toxicities. ATE, arterial thromboembolism; EMA, European Medicines
Agency; FDA, Food and Drug Administration; HF, heart failure; HTN, hypertension; MedDRA, medical dictionary for regulatory activities; MI, myocardial infarction; ↑QTc, corrected QT interval prolongation; TKI, tyrosine kinase inhibitors; VEGF, vascular endothelial growth factor; VEGFi, vascular endothelial growth factor inhibitors; VTE, venous thromboembolism. Adverse reactions reported in multiple clinical trials or during post-marketing use are listed by system organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the available data, a blank space has been left.
aBevacizumab: hypertension frequency 5–42% (EMA); 60–77% of the patients who received bevacizumab in combination with erlotinib. Pre-existing hypertension should be adequately controlled before starting treatment. Ramucirumab: hypertension frequency 16–26% (EMA/FDA); in combination with erlotinib, the incidence of hypertension was 24–45%. Patients with uncontrolled hypertension were excluded from the trials. Figure developed from EMA prescribing information,252 FDA prescribing information.253


<!-- PAGE 35 -->

### Page 35

A baseline CV risk assessment includes clinical examination, BP
measurement, and an ECG with baseline QTcF measurement (see
Section 4).20 Especially in patients with known hypertension, BP
should be controlled before VEGFi therapy. A baseline TTE is recommended for high- and very high-risk patients.14 Patients with impaired LV function and/or patients at high or very high risk of developing HF should be referred to the cardiologist before starting
VEGFi therapy.14
ECGa
ECGa
TTEb
6 M
8 M
9 M
12 M
Every
6–12 M
3 M
4 M
NPc,d
ECGa
NPc
TTEb
VEGFi surveillance protocol
High and 
very high 
risk
Moderate risk
Low risk
TTEb,d
Baseline
Class 1
Class 1Ia
Class 1Ib
Figure 13 Cardiovascular toxicity monitoring in patients receiving vascular endothelial growth factor inhibitors. ECG, electrocardiogram; M, months;
NP, natriuretic peptides; QTc, corrected QT interval; TTE, transthoracic echocardiography; VEGFi, vascular endothelial growth factor inhibitors. aIn patients treated with VEGFi at moderate or high risk of QTc prolongation, ECG is recommended (Class I, Level C) monthly during the ﬁrst 3 months and every 3–6 months thereafter (Section 6.4). Consider an ECG 2 weeks after starting treatment in high-risk patients and new monitoring in the case of any dose increase (see Section 6.4.2). bCardiac magnetic resonance should be considered for the assessment of cardiac function when TTE is unavailable or not diagnostic. cMeasurement of NP is recommended in all patients with cancer if these biomarkers are going to be used during treatment monitoring. dTTE
and NP should be considered at 4 weeks after starting treatment in very high-risk patients.
ESC Guidelines
4263


<!-- PAGE 36 -->

### Page 36

Monitoring during and after treatment is indicated for all patients treated with a VEGFi and is based on close clinical follow-up using serial ECGs, biomarkers, and echocardiography. Early recognition and treatment of hypertension are essential to prevent other CV
complications, especially HF. Home BP monitoring is recommended daily during the ﬁrst cycle, after each increase of anticancer therapy dose, and every 2–3 weeks thereafter.138,254,255 When treatment with a VEGFi is stopped, a drop in BP must be anticipated and
BP-lowering therapy must be reduced and/or interrupted accordingly (Section 6).
In patients at risk of QTc prolongation, regular monitoring of the
QTc interval is recommended after a dose increase, whenever other
QT-prolonging agents are added, or if electrolyte imbalances occur
(Section 6).
Patients treated with a VEGFi must also be screened regularly for symptoms and clinical signs of HF. Regular NP measurement and echocardiography can be useful for the detection of
CTRCD,
although evidence is weak
(Figure 13).138,254,255
5.5.5. Multitargeted kinase inhibitors targeting
BCR-ABL
Chronic myeloid leukaemia (CML) results from aberrant activation of ABL1 kinase due to a chromosomal translocation.
Small-molecule TKIs targeting BCR-ABL—including imatinib,
bosutinib, dasatinib, nilotinib, and ponatinib—have proven effective in the treatment of CML. The toxicities associated with these TKIs are unique and due to ‘off-target’ effects of each drug. Dasatinib is associated with group 1 pulmonary hypertension (PH), HF, and pleural and pericardial effusion,
whereas nilotinib and ponatinib are generally associated with vascular events
(Figure
14).131,256–259
Secondgeneration BCR-ABL TKI may induce a QTc prolongation
(see Section 6.4.2). CV toxicity risk is higher in patients aged .65 years (relative risk 1.8) and in those with underlying DM (relative risk 2.5), hypertension (relative risk 3.2) or pre-existing
CAD
(relative risk
2.6).256–258,260
Before
BCR-ABL TKI therapy, it is critical to deﬁne baseline CV toxicity risk with special attention to BP, glucose, and lipids.
Recommendation Table 10 — Recommendations for baseline risk assessment and monitoring during vascular endothelial growth factor inhibitors
Recommendations
Classa
Levelb
BP monitoring
BP measurement is recommended for patients treated with VEGFi, bevacizumab, or ramucirumab at every clinical visit.
I
C
Daily home monitoring of BP for patients treated with VEGFi during the ﬁrst cycle, after each increase of VEGFi dose, and every 2–3 weeks thereafter is recommended.
I
C
ECG monitoring
In patients treated with VEGFi at moderate or high risk of QTc prolongation, QTcc monitoring is recommended monthly during the ﬁrst 3 months and every 3–6 months thereafter.d
I
C
Echocardiography
Baseline echocardiography is recommended in high- and very high-risk patients treated with
VEGFi or bevacizumab.
I
C
Baseline echocardiography should be considered in low- and moderate-risk patients treated with a
VEGFi or bevacizumab.
IIa
C
Continued
Echocardiography may be considered every 4
months during the ﬁrst year in moderate-risk patients receiving VEGFi or bevacizumab.
IIb
C
Echocardiography should be considered every 3
months during the ﬁrst year in high- and very high-risk patients receiving a VEGFi or bevacizumab.e
IIa
C
Echocardiography every 6–12 months should be considered in moderate- and high-risk patients with cancer who require long-term treatment with a VEGFi.
IIa
C
Cardiac biomarker
NP may be considered at baseline and then every
4 months during the ﬁrst year in moderate-risk patients receiving a VEGFi.
IIb
C
NP should be considered at baseline, 4 weeks after starting treatment, and them every 3 months during the ﬁrst year in high- and very high-risk patients receiving a VEGFi.
IIa
C
© ESC 2022
BP, blood pressure; ECG, electrocardiogram; NP, natriuretic peptides; QTc, corrected
QT interval; QTcF, corrected QT interval using Fridericia correction; VEGFi, vascular endothelial growth factor inhibitors.
aClass of recommendation.
bLevel of evidence.
cQTc interval using Fridericia correction (QTcF = QT/3√RR) is the preferred method.
dConsider an ECG 2 weeks after starting treatment in high-risk patients and new monitoring in the case of any dose increase (see Section 6.4.2).
eAn additional echocardiography 4 weeks after starting treatment should be considered in selected high- and very high-risk patients according to local availability, especially if cardiac biomarker surveillance is not available.


<!-- PAGE 37 -->

### Page 37

Imatinib
1st generation
BCR-ABL TKI
2nd generation
BCR-ABL TKI
3rd generation
BCR-ABL TKI
Nilotinib
Dasatinib
Bosutinib
Ponatinib
HTN
HF
HG
AF
DL
Peric-E
Pleu-E
PH
VascTox
BCR-ABL TKI-related cardiovascular toxicities
Very common: ≥10% incidence
Common: 1% to <10% incidence
Uncommon: 0.1% to < 1% incidence
Rare: <0.1% incidence
QTc
Figure 14 Breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitor-related cardiovascular toxicities. AF, atrial ﬁbrillation; BCR-ABL,
breakpoint cluster region–Abelson oncogene locus; DL, dyslipidaemia; EMA, European Medicines Agency; FDA, Food and Drug Administration; HF, heart failure; HG, hyperglycaemia; HTN, hypertension; MedDRA, medical dictionary for regulatory activities; MI, myocardial infarction; PAD, peripheral artery disease; Peric-E, pericardial effusion; PH, pulmonary hypertension; Pleu-E, pleural effusion; ↑QTc, corrected QT interval prolongation; TKI, tyrosine kinase inhibitors; VascTox, vascular toxicity (stroke, MI, PAD). Adverse reactions reported in multiple clinical trials or during post-marketing use are listed by system organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the available data, a blank space has been left.261
Figure developed from EMA prescribing information,252 FDA prescribing information.253
ESC Guidelines
4265


<!-- PAGE 38 -->

### Page 38

Baseline
3 M
6 M
9 M
12 M
Every
6–12 M
BP
HbA1c
ECG
ABI
TTE
Physical 
examinationa
Bosutinib
Dasatinib
Nilotinib
Ponatinib
Nilotinib
Ponatinib
Nilotinib
Ponatinib
Dasatinib
Nilotinib
Ponatinib
High and very high risk patients treated with dasatinib or ponatinib
Second and third generationBCR-ABL TKI surveillance protocol
Class 1
Class 1Ia
Class 1Ib
Bosutinib
Dasatinib
Nilotinib
Ponatinib
Nilotinib
Ponatinib
Dasatinib
Ponatinib
Bosutinib
Nilotinib
Ponatinib
Lipid profile/
Figure 15 Second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors surveillance protocol. ABI, ankle–
brachial index; BCR-ABL, breakpoint cluster region-Abelson oncogene locus; BP, blood pressure; CV, cardiovascular; ECG, electrocardiogram; HbA1c,
glycated haemoglobin; M, months; TKI, tyrosine kinase inhibitors; TTE, transthoracic echocardiography. aCoronary artery calcium scoring can reclassify
CV risk upwards and downwards in addition to conventional risk factors, and may be considered in men and women with calculated CV risk around decision thresholds.19


<!-- PAGE 39 -->

### Page 39

Baseline ECG is recommended in all patients and QTc monitoring in patients treated with second-generation BCR-ABL
TKI. Depending on the type of therapy used, speciﬁc CV assessments should be performed after drug initiation
(Figure 15).256
5.5.6. Bruton tyrosine kinase inhibitors
Bruton tyrosine kinase (BTK) inhibitors are increasingly used to treat lymphoid malignancies. Ibrutinib, a ﬁrst-in-class irreversible oral inhibitor of BTK, has proven highly effective in chronic lymphocytic leukaemia and related B-cell malignancies including mantle cell lymphoma, Waldenström macroglobulinemia, and marginal zone lymphomas.262 These disorders are usually diagnosed in elderly patients in whom frequent comorbidities coexist at diagnosis that increase the risk of CTR-CVT.263,264 Ibrutinib has been associated with bleeding diathesis, infections, and an increased risk of hypertension, AF, and HF.265–267 Ibrutinib may also cause ventricular arrhythmias without prolonging QT.267,268 Acalabrutinib is a secondgeneration BTK inhibitor with greater BTK selectivity. In a recent phase III, randomized, multicentre, open-label, non-inferiority study,
acalabrutinib demonstrated a non-inferior progression-free survival compared to ibrutinib in patients with previously treated chronic lymphocytic leukaemia with a lower incidence of symptomatic CV
events.269 However, grade ≥3 AF (symptomatic AF where urgent intervention is indicated)270 and AF in patients ≥75 years old or with previous AF history were comparable between groups, as was the risk of CV events in patients with pre-existing CVRFs or CVD.271
Therefore, we currently do not have enough data to establish different monitoring strategies in patients treated with these drugs.
Due to the lack of evidence-based recommendations, the management of these CV events is challenging.264 Antihypertensive initiation has been associated with a lower risk of a major adverse CV events
(MACE).264 Opportunistic screening for AF by pulse-taking or ECG
rhythm strip is recommended at every clinical visit during BTK inhibitor therapy.272
Due to a higher bleeding risk, ibrutinib should be temporarily interrupted in patients requiring dual antiplatelet therapy (DAPT)
and 3–7 days before invasive procedures. In case of emergency interventions, platelet transfusion should be considered to minimize bleeding risks.262
Recommendation Table 11 — Recommendations for baseline risk assessment and monitoring during second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors
Recommendations
Classa
Levelb
Baseline CV risk assessmentc is recommended in patients who require second- or third-generation
BCR-ABL TKI.256,261
I
C
In patients treated with nilotinib or ponatinib, CV
risk assessmentc is recommended every 3 months during the ﬁrst year and every 6–12 months thereafter.256,261
I
C
QTcd measurement should be considered at baseline, at 2 and 4 weeks after starting nilotinib,
and 2 weeks after any dose increase.259
IIa
C
Baseline echocardiography should be considered in all patients before starting second- and third-generation BCR-ABL TKI.
IIa
C
Baseline echocardiography is recommended in patients scheduled to receive dasatinib.
I
C
Echocardiography should be considered every 3
months during the ﬁrst year in high- and very high-risk patients receiving dasatinib or ponatinib.
IIa
C
Echocardiography may be considered every 6–12
months in patients who require long-term (.12
months) ponatinib or dasatinib.
IIb
C
Serial assessment of ankle brachial index may be considered to detect subclinical peripheral vascular disease.
IIb
C
© ESC 2022
BCR-ABL, breakpoint cluster region–Abelson oncogene locus; BP, blood pressure; CV,
cardiovascular; ECG, electrocardiogram; HbA1c, glycated haemoglobin; HFA, Heart
Failure Association; ICOS, International Cardio-Oncology Society; QTc, corrected
QT interval; QTcF, corrected QT interval using Fridericia correction; TKI, tyrosine kinase inhibitors.
aClass of recommendation.
bLevel of evidence.
cPhysical examination, BP measurement, ECG, lipid proﬁle, and HbA1c measurement.
Coronary artery calcium scoring can reclassify CV disease risk upwards and downwards in addition to conventional risk factors, and may be considered at baseline in low- and moderate-risk patients as per HFA-ICOS risk assessment tools.19
dQTc interval using Fridericia correction (QTcF = QT/3√RR) is the preferred method.
Recommendation Table 12 — Recommendations for baseline risk assessment and monitoring during
Bruton tyrosine kinase inhibitor therapy
Recommendations
Classa
Levelb
BP monitoring and management
BP measurement is recommended for patients treated with BTK inhibitors at every clinical visit.264
I
B
Weekly home monitoring of BP during the ﬁrst 3
months and every month thereafter should be considered for patients treated with BTK
inhibitors.
IIa
C
Echocardiography
Baseline echocardiography is recommended in high-risk patientsc scheduled to receive BTK
inhibitors.267,268
I
C
TTE is recommended in all patients who develop
AF during BTK inhibitor therapy.
I
C
Continued
ESC Guidelines
4267


<!-- PAGE 40 -->

### Page 40

5.5.7. Multiple myeloma therapies
There are many classes of pharmacotherapy that are approved for the treatment of MM using a range of combinations. These include immunomodulatory drugs (IMiD), dexamethasone, PI, and monoclonal antibodies (e.g. daratumumab). PI—including bortezomib, carﬁlzomib, and ixazomib—have become a mainstay of therapy for newly diagnosed MM as well as relapsed disease.276,277 Several large studies using combination therapy for MM have demonstrated an increased risk of serious CV adverse events.278–281 MM patients being treated with PI have a high incidence of coexistent CV comorbidities
AF
Opportunistic screening for AF by pulse-taking or
ECG rhythm strip is recommended at every clinical visit during BTK inhibitor therapy.273
I
C
© ESC 2022
AF, atrial ﬁbrillation; BP, blood pressure; BTK, Bruton tyrosine kinase; DM, diabetes mellitus; ECG, electrocardiogram; HF, heart failure; QTc, corrected QT interval; TTE,
transthoracic echocardiography; VHD, valvular heart disease.
aClass of recommendation.
bLevel of evidence.
cMale, age ≥65 years, previous history of hypertension, DM, QTc ≥480 ms, AF, HF,
cardiomyopathy, or severe VHD.263,274,275
Cyclophosphamide
Melphalan
Lenalidomide
Pomalidomide
Alkylating agents
Bortezomib
Carfilzomib
Proteasome inhibitorsa
Immunomodulatory drugs
Thalidomide
Daratumumab
Elotuzumab
Monoclonal antibodies
Isatuximab
HTN
HF
AF
HG/DM
MI
VTE
PH
ATE
Multiple myeloma drugs-related cardiovascular toxicities
Very common: ≥10% incidence
Common: 1% to <10% incidence
Uncommon: 0.1% to < 1% incidence
Rare: <0.1% incidence
Figure 16 Multiple myeloma drug-related cardiovascular toxicities. AF, atrial ﬁbrillation; ATE, arterial thromboembolism; DM, diabetes mellitus; EMA,
European Medicines Agency; FDA, Food and Drug Administration; HF, heart failure; HG, hyperglycaemia; HTN, hypertension; MedDRA, medical dictionary for regulatory activities; MI, myocardial infarction; PH, pulmonary hypertension; VTE, venous thromboembolism. Adverse reactions reported in multiple clinical trials or during post-marketing use are listed by system organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the available data, a blank space has been left. aIxazomib produces peripheral oedema in up to 18% of patients and hyperglycaemia in combination with lenalidomide or pomalidomide and dexamethasone. Figure developed from EMA prescribing information,252 FDA prescribing information.253


<!-- PAGE 41 -->

### Page 41

and increased baseline CV risk.282,283 PI have been associated with a variety of CV toxicities including hypertension, HF,284 acute coronary syndromes
(ACS),66
arrhythmias,285
PH,286
and
VTE
(Figure 16).287,288 During therapy, cardiac biomarkers and TTE are important diagnostic and prognostic tools that can inform clinical decision-making (Figure 17).66
HF—especially HF with preserved ejection fraction (HFpEF)—is a frequent manifestation of cardiac amyloidosis, but it is also an important adverse effect of PI therapy, especially under carﬁlzomib.
In a safety analysis of patients with MM being treated with carﬁlzomib, 7.2% of patients were found to have new HF.284 In another study, 23% of patients with MM treated with carﬁlzomib developed clinical HF and/or LVD.289 The mechanism is not well understood but is possibly related to PI-induced oxidative stress within myocytes,
inhibition of the proteasome, or transient endothelial dysfunction.281,283 Although no studies have yet addressed the optimal follow-up scheme in patients with MM treated with PI, a common scheme consists of 3–6-monthly visits with ECG, complete blood
Clinical assessment
Clinical assessment
BP and ECG
TTE
TTE every 3 cycles under carfilzomib
Baseline
During therapy
NP
Proteasome inhibitors surveillance protocol
Lowmoderate risk
High and 
very high 
risk
Cardiac amyloidosis
Clinical assessment
BP and ECG
TTE
TTE every 3 cycles under carfilzomib
NP
NP every cycle during the first 6 cycles under carfilzomib or bortezomiba
Clinical assessment
BP and ECG
TTE and CMR
TTE every 3 cycles
NP and cTn
NP and cTn every 3-6 months
BP at every clinical visit
BP home monitoring
Class 1
Class 1Ia
Class 1Ib
BP at every clinical visit
BP home monitoring
Clinical assessment
BP at every clinical visit
BP home monitoring
Clinical assessment
NP every cycle during the first 6 cycles under carfilzomib or bortezomiba
Figure 17 Cardiovascular monitoring in patients with multiple myeloma receiving proteasome inhibitors. BP, blood pressure; CMR, cardiac magnetic resonance; cTn, cardiac troponin; ECG, electrocardiogram; NP, natriuretic peptides; TTE, transthoracic echocardiography. aEvery 2 months for patients treated with ixazomib.
ESC Guidelines
4269


<!-- PAGE 42 -->

### Page 42

tests (including NP and cTn) and echocardiography surveillance during PI therapy.290 A recent prospective study of patients with relapsed MM conﬁrmed the utility of NP to assist in risk stratiﬁcation as well as management of CV morbidity during treatment.66
Hypertension, another adverse effect of PI, may also contribute to the development of HFpEF.
Patients with MM are at elevated risk of thrombosis due to both patient- and myeloma-related factors, particularly the combination of PI and IMiD (Figure 18).279,287,291–297 In the ASPIRE
(Carﬁlzomib,
Lenalidomide,
and
Dexamethasone vs.
Lenalidomide and
Dexamethasone for the
Treatment of
Patients with Relapsed Multiple Myeloma) study, patients treated with a combination of carﬁlzomib, lenalidomide, and dexamethasone had higher rates of VTE compared with those treated with lenalidomide and dexamethasone
(6.6%
vs.
3.9%).279
Oncological guidelines recommend the use of aspirin or prophylactic doses of low-molecular-weight heparins (LMWH) in lowrisk patients receiving thalidomide- or lenalidomide-based regimens.298 In patients at high risk of VTE, therapeutic doses of
LMWH are recommended.299 The role of non-vitamin K antagonist oral anticoagulants (NOAC) in MM patients needs further validation in larger trials, but recent small studies have conﬁrmed the efﬁcacy and safety of low doses of apixaban and rivaroxaban for
VTE prevention.300–302
Risk factors for venous thromboembolic events in patients with multiple myeloma
Patient-related risk factors
Previous VTE
Acute infections
Autoimmune disease
Central venous catheter
Chronic renal disease
Cigarette smoking
CVD
DM
General surgery
History of inherited thrombophilia
Immobilization, surgery, trauma
Obesity (BMI >30 kg/m2)
Myeloma-related risk factors
Advanced disease status
Erythropoietin-stimulating agents
High dexamethasone doses
Hyper-viscosity state
Thalidomide/lenalidomide/ponalidomide
Figure 18 Risk factors for venous thromboembolic events in patients with multiple myeloma. BMI, body mass index; CVD, cardiovascular disease; DM,
diabetes mellitus; VTE, venous thromboembolism.


<!-- PAGE 43 -->

### Page 43

5.5.8. Rapidly accelerated ﬁbrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor treatment
The rapidly accelerated ﬁbrosarcoma (RAF) inhibitors—vemurafenib,
dabrafenib, and encorafenib—are approved for the treatment of metastatic melanoma with a BRAF V600 mutation. The mitogenactivated extracellular signal-regulated kinase (MEK) inhibitors—
trametinib, cobimetinib, binimetinib, and selumetinib—have also shown signiﬁcant clinical activity in melanoma patients whose tumour contains a BRAF V600 mutation, and are now largely used in combination with RAF inhibitors. The main CV effects to be considered are hypertension, PE, and CTRCD, which are associated with all combinations of RAF and MEK inhibitors, and QTc prolongation, associated solely with the coadministration of cobimetinib and vemurafenib (Figure 19).12,308,309 RAF inhibitor treatment alone or in combination with a MEK inhibitor is associated with an increased risk of MI and AF.308
Patients with cancer with pre-existing CVD have an increased frequency of CV adverse events during treatment with MEK
and RAF inhibitors, and therefore baseline risk stratiﬁcation is recommended.12 Most cardiac complications induced by administration of MEK and RAF inhibitors seem to be attributable to the MEK inhibitor, with the RAF inhibitor enhancing the toxic effects of the MEK inhibitor.310–313 Hypertension and LVD
were twice as frequent when MEK and RAF inhibitors were coadministered compared with single therapy with RAF inhibitor alone.314
CTRCD can manifest any time from the ﬁrst month of therapy to 2 years after the end of the oncological treatment.315
Baseline TTE is recommended in patients at moderate to high risk of CTR-CVT. During treatment, it is necessary to monitor
BP at each visit and promote weekly outpatient monitoring during the ﬁrst 3 months and monthly thereafter. In patients treated with cobimetinib/vemurafenib, an ECG is recommended at 2
and 4 weeks after initiation of treatment and every 3 months thereafter. In high-risk patients, periodic monitoring of ventricular function with echocardiography should be considered every 6–12 months.
CV protective medications (such as angiotensin-converting enzyme inhibitors [ACE-I], angiotensin receptor blockers [ARB],
Recommendation Table 13 — Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies
Recommendations
Classa
Levelb
BP monitoring
BP measurement is recommended for patients treated with PI at every clinical visit.
I
C
Home monitoring of BP weekly during the ﬁrst 3
months and monthly thereafter should be considered for patients treated with PI.
IIa
C
Cardiac serum biomarkers
Measurement of NP is recommended prior to PI
in high- and very high-risk patients.66,303
I
C
Measurement of NP should be considered prior to PI in low- and moderate-risk patients.66
IIa
C
In patients receiving carﬁlzomib or bortezomib,
measurement of NP should be considered at baseline and every cycle during the ﬁrst 6
cycles.c,66
IIa
B
NP and cTn measurements are recommended at baseline and every 3–6 months in patients with
AL-CA.d,290
I
B
TTE
Baseline echocardiography, including assessment for AL-CA, is recommended in all patients with
MM scheduled to receive PI.
I
C
Echocardiography surveillance every 3 cycles should be considered in high- and very high-risk patients receiving carﬁlzomib.280
IIa
B
Echocardiography surveillance every 3 cycles may be considered in low- and moderate-risk patients receiving carﬁlzomib.
IIb
C
Echocardiography surveillance should be considered every 3–6 months in patients with
AL-CA treated with PI.d,290
IIa
C
VTE prophylaxis
Therapeutic doses of LMWH are recommended in patients with MM with previous
VTE.296,298,302,304,305
I
B
Prophylactic doses of LMWH are recommended in patients with MM with VTE-related risk factorse
(excluding previous VTE) at least during the ﬁrst 6
months of therapy.296,304,305
I
A
Aspirin should be considered as an alternative to
LMWH in patients with MM with no risk factors or one VTE-related risk factore (excluding previous VTE) at least during the ﬁrst 6 months of therapy.296,304–307
IIa
B
Continued
Low doses of apixaban or rivaroxabanf may be considered as an alternative to LMWH or aspirin in patients with MM with VTE-related risk factorse
(excluding previous VTE) at least during the ﬁrst 6
months of therapy.300–302
IIb
C
© ESC 2022
AL-CA, amyloid light-chain cardiac amyloidosis; BP, blood pressure; cTn, cardiac troponin; HF, heart failure; LMWH, low-molecular-weight heparins; MM, multiple myeloma; NP, natriuretic peptides; PI, proteasome inhibitors; TTE, transthoracic echocardiography; VTE, venous thromboembolism.
aClass of recommendation.
bLevel of evidence.
cEvery 2 months for patients treated with oral ixazomib.
dDepending on HF severity and treatment.
eSee Figure 18.295,296,299
fLow doses of apixaban (2.5 mg twice a day) or rivaroxaban (10 mg once a day).
ESC Guidelines
4271


<!-- PAGE 44 -->

### Page 44

and beta-blockers) have not been evaluated in patients treated with MEK and RAF inhibitors but, from a mechanistic perspective,
beta-blockers might prevent CTRCD induced by MEK inhibitors.
The MEK/ERK pathway has a cardiac protective effect, regulated by beta-adrenergic signalling, which also controls the p38 mitogen-activated protein kinases pathway, associated with cardiotoxic effects. Beta-blockers might exert their cardioprotective effects by reducing p38 signalling.315
Dabrafenib
Encorafenib
RAF inhibitors
Vemurafenibb
Binimetinib
Cobimetinib
MEK inhibitors
Trametinibb
HTN
SVT/SBra
HG/DM
HF
BLEED
VTE/PE
RAF inhibitor- and MEK inhibitor-related cardiovascular toxicities
Very common: ≥10% incidence
Common: 1% to <10% incidence
Uncommon: 0.1% to < 1% incidence
Rare: <0.1% incidence
QTc
Figure 19 Rapidly accelerated ﬁbrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor-related cardiovascular toxicities. AF, atrial
ﬁbrillation; BLEED, increased bleeding risk; DM, diabetes mellitus; EMA, European Medicines Agency; FDA, Food and Drug Administration; HF, heart failure;
HG, hyperglycaemia; HTN, hypertension; MedDRA, medical dictionary for regulatory activities; MEK, mitogen-activated extracellular signal-regulated kinase;
PE, pulmonary embolism; ↑QTc, corrected QT interval prolongation; RAF, rapidly accelerated ﬁbrosarcoma; SBr, sinus bradycardia; SVT, supraventricular tachycardia; VTE, venous thromboembolism. Adverse reactions reported in multiple clinical trials or during post-marketing use are listed by system organ class
(in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the available data, a blank space has been left. aDabrafenib is related with
SBr. Encorafenib is related with SVT. Vemurafenib rarely causes AF. Trametinib is related with bradycardia in some post-marketing reports. bPeripheral oedema is very common. Figure developed from EMA prescribing information,252 FDA prescribing information.253
Recommendation Table 14 — Recommendations for baseline risk assessment and monitoring during combined rapidly accelerated ﬁbrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor therapy
Recommendations
Classa
Levelb
BP monitoring at each clinical visit and weekly outpatient monitoring during the ﬁrst 3 months of treatment and monthly thereafter is recommended.
I
C
In patients treated with cobimetinib/vemurafenib, an ECG is recommended at 2 and 4 weeks after initiation of treatment and every 3
months thereafter.c
I
C
Baseline echocardiography is recommended in all high- and very high-risk patients scheduled to receive combined RAF and MEK
inhibitors.
I
C
Baseline echocardiography may be considered in low- and moderate-risk patients scheduled to receive combined RAF and MEK
inhibitors.
IIb
C
Echocardiography should be considered every 4 months during the ﬁrst year in high- and very high-risk patients receiving combined RAF
and MEK inhibitors.
IIa
C
© ESC 2022
BP, blood pressure; ECG, electrocardiogram; MEK, mitogen-activated extracellular signal-regulated kinase; RAF, rapidly accelerated ﬁbrosarcoma.
aClass of recommendation.
bLevel of evidence.
cConsider an ECG and new monitoring in the case of any dose increase (see Section 6.4.2).


<!-- PAGE 45 -->

### Page 45

5.5.9. Immune checkpoint inhibitors
Immunotherapies, which harness the immune system to destroy cancer cells, come in different forms but the most widely used are ICI.316 The immune checkpoints are proteins expressed in the T cells that inhibit their activation when they contact a body cell. ICI include monoclonal antibodies that block the immune brakes or regulators,
cytotoxic
T
lymphocyte-associated antigen-4
(CTLA-4)
(ipilimumab,
tremelimumab), programmed death-1 (PD-1) (nivolumab, cemiplimab, pembrolizumab), and programmed death-ligand 1
(PD-L1) (atezolizumab, avelumab, durvalumab) expressed in the cancer cells, with the consequent cytotoxic immune response. By blocking these checkpoints from binding with their partner proteins, ICI inhibit the ‘off’ signal, activating T cells and promoting killing of cancer cells. Although their pathophysiology is not clearly deﬁned, ICI may also trigger an
Low 
risk cTn
Class 1
Class 1Ia
Class 1Ib
ECG
TTE
CV assessmenta
NP
cTn
ECG
TTE
CV assessmenta
NP
High 
riskb
C4
Every
3Cc
Every
6 M–
12 Md
C2
C3
Baseline
Immune checkpoint inhibitors surveillance protocol
Figure 20 Cardiovascular surveillance in patients treated with immune checkpoint inhibitors. BNP, B-type natriuretic peptide; BP, blood pressure; C,
chemotherapy cycle; cTn, cardiac troponin; CV, cardiovascular; CVD, cardiovascular disease; CTRCD, cancer therapy-related cardiac dysfunction;
ECG, electrocardiogram; HbA1c, glycated haemoglobin; ICI, immune checkpoint inhibitors; M, months; NP, natriuretic peptides (including BNP and
NT-proBNP); NT-proBNP, N-terminal pro-B-type natriuretic peptide; TTE, transthoracic echocardiography. aIncluding physical examination, BP,
lipid proﬁle, and HbA1c. bDual ICI, combination ICI-cardiotoxic therapy, ICI-related non-CV events, prior CTRCD or CVD. cEvery three cycles until completion of therapy to detect subclinical ICI-related CV toxicity. dIn patients who require long-term (.12 months) ICI treatment.
ESC Guidelines
4273


<!-- PAGE 46 -->

### Page 46

overactivation of T cells against non-cancerous tissues, leading to immune-related adverse events.317 Immune-related CV side effects may lead to life-threatening CV complications such as fulminant myocarditis, myopericarditis, cardiac dysfunction, arrhythmias, or MI, which often results in the discontinuation of
ICI.318,319
The largest case series of 122 patients with ICI-associated myocarditis had early onset of symptoms (median of 30 days after initial exposure to ICI), and up to 50% died.320 Late CV
events (.90 days) are less well characterized but generally exhibit a higher risk of non-inﬂammatory HF, progressive atherosclerosis,
hypertension,
and mortality rates.321
Other
CV
toxicities described during ICI therapy are MI, AV block, supraventricular and ventricular arrhythmias,
sudden death,
Takotsubo-like syndrome, non-inﬂammatory HF, hypercholesterolaemia, pericarditis, pericardial effusion, ischaemic stroke,
and VTE.322 A meta-analysis including 32 518 patients receiving
ICI treatment reported an increased risk of myocarditis, pericardial diseases, HF, dyslipidaemia, MI, and cerebral arterial ischaemia.323 Conditions related with high baseline ICI-related
CV toxicity risk include dual ICI therapy (e.g. ipilimumab and nivolumab), combination ICI therapy with other cardiotoxic therapies, and patients with ICI-related non-CV events or prior
CTRCD or CVD (Figure 20).324,325 All patients on ICI treatment should have an ECG and troponin assay at baseline
(Figure 20).326–329 High-risk patients should additionally have a
TTE evaluation at baseline. Due to the lack of evidence-based recommendations, the monitoring of ICI therapy is challenging.
Once started on therapy, ECG, cTn, and NP should be checked.330–332 In the JAVELIN trial, which assessed avelumab plus axitinib vs. sunitinib, no clinical value was observed for ontreatment routine TTE monitoring in asymptomatic patients.333
However, in high-risk patients, and in those with high baseline cTn levels, TTE monitoring may be considered. In patients who develop ECG abnormalities, new biomarker changes, or new cardiac symptoms at any time, prompt cardio-oncology evaluation is strongly recommended, including TTE for the evaluation of LVEF and GLS, and CMR when myocarditis is suspected (Table 3).334
5.5.10. Androgen deprivation therapies for prostate cancer
Androgen deprivation therapy (ADT) is prescribed in 40% of men with prostate cancer as neoadjuvant and/or adjuvant therapy to
RT or for biochemical relapse following prostate cancer surgery.
Gonadotropin-releasing hormone (GnRH) agonists are the most frequently prescribed ADT. However, GnRH agonists are associated with an increased CV risk and mortality, particularly in patients with prostate cancer aged .60 years.337,338 Baseline risk stratiﬁcation in patients requiring GnRH agonists depends on vascular disease risk (Figure 21).339,340 No dedicated CV toxicity risk calculators have been developed for patients receiving ADT. It was the consensus of the authors to recommend SCORE2 or SCORE2-OP to stratify CV
risk in patients receiving ADT without previous CVD.19
The use of GnRH antagonists represents an alternative in the treatment of prostate cancer, and preclinical and clinical (HERO
trial)341 data suggest that GnRH antagonist use is associated with signiﬁcantly lower overall mortality and CV events compared with agonists.342 However, more research is needed in this ﬁeld. In the
PRONOUNCE trial, no difference in MACE at 1 year was observed between degarelix (a GnRH antagonist) and leuprolide (a GnRH
agonist), although the trial was stopped early.343 Lower CV event rates were detected compared with previous studies and all patients were reviewed by a cardiologist at enrolment (leading to optimal
CVRF management).343
The main CV effects to be considered are hypertension, DM, ischaemic heart disease (IHD) and CTRCD.339,344 ADT is uncommonly associated with QTc prolongation and rarely causes torsade de pointes
(TdP) through blockade of testosterone effects on ventricular repolarization.345,346 ECG monitoring and correction of QT prolongation precipitant factors (see Section 6.4.2; Table 9; Supplementary data,
Table S13) is recommended340,347,348 during prostate cancer treatment if the baseline QTc interval is prolonged.49,339,340,347,349,350
Recommendation Table 15 — Recommendations for baseline risk assessment and monitoring during immunotherapy
Recommendations
Classa
Levelb
ECG, NP, and cTn measurements are recommended in all patients before starting ICI
therapy.333
I
B
Baseline echocardiography is recommended in high-risk patientsc before starting ICI therapy.333
I
B
Baseline echocardiography may be considered in all patients before starting ICI therapy.
IIb
C
Continued
Serial ECG and cTn measurements should be considered before ICI doses 2, 3, and 4, and if normal, reduce to every three doses until completion of therapy to detect subclinical
ICI-related CV toxicity.333
IIa
B
CV assessmentd is recommended every 6–12
months in high-risk patientsc who require long-term (.12 months) ICI treatment.321–
323,335,336
I
C
CV assessmentd may be considered every 6–12
months in all patients who require long-term
(.12 months) ICI treatment.
IIb
C
© ESC 2022
BNP, B-type natriuretic peptide; BP, blood pressure; cTn, cardiac troponin; CTRCD,
cancer therapy-related cardiac dysfunction; CV, cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; HbA1c, glycated haemoglobin; ICI, immune checkpoint inhibitors; NP, natriuretic peptides; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
aClass of recommendation.
bLevel of evidence.
cDual ICI, combination ICI-cardiotoxic therapy; ICI-related non-CV events, prior
CTRCD, or CVD.
dPhysical examination, BP, NP (BNP or NT-proBNP), lipid proﬁle, HbA1c, and ECG.


<!-- PAGE 47 -->

### Page 47

Goserelin
GnRH agonist
GnRH antagonist
Histrelin
Degarelix
Relugolix
Leuprorelin
Bicalutamide
Flutamide
Nilutamide
Apalutamide
Abirateroneb
Darolutamide
Enzalutamide
Triptorelin
HTN
HG/DM
HF
IHD/MI
AF
Androgen deprivation therapy-related cardiovascular toxicities
1st generation antiandrogens
2nd generation androgen deprivation therapy
Androgen metabolism inhibitor
Very common: ≥10% incidence
Common: 1% to <10% incidence
Uncommon: 0.1% to < 1% incidence
Rare: <0.1% incidence
QTca
Figure 21 Androgen deprivation therapy-related cardiovascular toxicities. ADT, androgen deprivation therapy; AF, atrial ﬁbrillation; DM, diabetes mellitus; EMA, European Medicines Agency; FDA, Food and Drug Administration; GnRH, gonadotropin-releasing hormone; HF, heart failure; HG, hyperglycaemia; HTN, hypertension; IHD, ischaemic heart disease; MedDRA, medical dictionary for regulatory activities; MI, myocardial infarction; ↑QTc,
corrected QT interval prolongation; TdP, torsade de pointes. Adverse reactions reported in multiple clinical trials or during post-marketing use are listed by system organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the available data, a blank space has been left.
aADT may prolong the QTc interval. In patients with a history of risk factors for QT prolongation and in patients receiving concomitant medicinal products that might prolong the QT interval, physicians should assess the beneﬁt/risk ratio including the potential for TdP prior to initiating the treatment.
bIncreased risk of QTc prolongation in combination with ADT.49,339,340,349,350 Figure developed from EMA prescribing information,252 FDA prescribing information.253
ESC Guidelines
4275


<!-- PAGE 48 -->

### Page 48

5.5.11. Endocrine therapies for breast cancer
Endocrine therapy is a common treatment as 65–70% of all early and metastatic BC patients develop hormone receptor-positive disease.22 Selective oestrogen receptor modulators (tamoxifen,
toremifene) or aromatase inhibitors (AI) (letrozole, anastrozole,
or exemestane) are recommended in early BC (EBC) according to menopausal status, comorbidities, and the risk of disease relapse.
The use of AI in combination with cyclin-dependent kinase (CDK)
4/6 inhibitors is recommended as ﬁrst- or second-line therapy in patient with hormone receptor-positive/HER2-negative metastatic BC.
The use of AI increases the risk of dyslipidaemia, metabolic syndrome, hypertension, HF, and MI.339 In the ATAC (‘Arimidex’ and
Tamoxifen Alone or in Combination) trial, anastrozole-treated patients with pre-existing CAD experienced more CV events (17%
vs. 10%) and cholesterol level elevation (9% vs. 5%) than those treated with tamoxifen.351,352 Similarly, HF was signiﬁcantly more common with letrozole compared with tamoxifen in the BIG (Breast
International Group) 1–98 trial.353 Longer AI treatment duration was associated with increased odds of developing CVD in two large meta-analyses.354,355 Signiﬁcantly increased VTE risk has been consistently demonstrated with tamoxifen351,353 and it is not recommended in patients with thrombotic risks. Toremifene and high-dose tamoxifen were found to prolong QTc interval339,340;
however, no risk data have been published in patients treated with the standard tamoxifen dose used in BC (20 mg/day).
The risks of VTE, hypercholesterolaemia, and CVD should be discussed with patients, while recognizing that the absolute beneﬁts of preventing BC recurrence usually outweigh the CV risks.339 In patients ,70 years old without clinical manifestations of atherosclerotic disease, estimation of 10-year fatal and non-fatal CVD risk with
SCORE2
(if
≥70
years,
SCORE2-OP)
is recommended.19
Cholesterol levels and BP should be monitored regularly in patients receiving AI.356 Physical activity and healthy diet are also advised to reduce weight and cholesterol levels. Smoking cessation is strongly recommended to reduce CV risk (e.g. CAD during AI therapy and
VTE during tamoxifen therapy).
5.5.12. Cyclin-dependent kinase 4/6 inhibitors
The use of CDK 4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) in combination with endocrine therapy is approved for the treatment of patients with hormone receptor-positive/
HER2-negative metastatic BC. This combination has resulted in improvements in progression-free survival and, in some trials, overall survival.357–359 CDK 4/6 inhibitors have demonstrated a potential for QT prolongation,339,360 particularly with ribociclib. The phase
III trials of ribociclib incorporated routine ECG monitoring.361–368
Recommendation Table 16 — Recommendations for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer
Recommendations
Classa
Levelb
Baseline CV risk assessmentc and estimation of
10-year fatal and non-fatal CVD risk with
SCORE2 or SCORE2-OPd is recommended in patients treated with ADT without pre-existing
CVD.19,341,342
I
B
Baseline and serial ECGs are recommended in patients at risk of QTc prolongation during ADT
therapy.e,339–342
I
B
A GnRH antagonist should be considered in patients with pre-existing symptomatic CADf who require ADT.341,342
IIa
B
Annual CV risk assessmentc is recommended during ADT.19,339,341,342
I
B
© ESC 2022
ACS, acute coronary syndromes; ADT, androgen deprivation therapy; BP, blood pressure; CAD, coronary artery disease; CCS, chronic coronary syndromes; CV,
cardiovascular;
CVD,
cardiovascular disease;
ECG,
electrocardiogram;
GnRH,
gonadotropin-releasing hormone; HbA1c, glycated haemoglobin; QTc, corrected QT
interval; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic
Coronary Risk Estimation 2—Older Persons.
aClass of recommendation.
bLevel of evidence.
cBP, lipids, fasting glucose, HbA1c, ECG, and patient education on healthy lifestyle and lifestyle risk factor control is recommended.
dSCORE2 (,70 years) or SCORE2-OP (≥70 years) CV risk stratiﬁcation: ,50 years:
low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50–69 years: low risk ,5%; moderate risk 5% to ,10%; high risk ≥10%; ≥70 years: low risk ,7.5%,
moderate risk 7.5% to ,15%, high risk ≥15%.
eSee Table 9.
fCCS and ACS.
Recommendation Table 17 — Recommendations for baseline risk assessment and monitoring during endocrine therapy for breast cancer
Recommendations
Classa
Levelb
Baseline CV risk assessmentc and estimation of
10-year fatal and non-fatal CVD risk with
SCORE2 or SCORE2-OPd,e is recommended in
BC patients receiving endocrine therapies without pre-existing CVD.19
I
C
Annual CV risk assessmentc is recommended during endocrine therapy in BC patients with high
10-year risk of (fatal and non-fatal) CV events according to SCORE2/SCORE2-OP.d,e
I
C
CV risk assessmentc should be considered every 5
years in BC patients with low or moderate
10-year risk of (fatal and non-fatal) CV events according to SCORE2/SCORE2-OP.d,e
IIa
C
© ESC 2022
BC, breast cancer; BP, blood pressure; CV, cardiovascular; CVD, cardiovascular disease;
ECG,
electrocardiogram;
HbA1c,
glycated haemoglobin;
SCORE2,
Systematic
Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk Estimation 2—
Older persons.
aClass of recommendation.
bLevel of evidence.
cBP, lipids, fasting glucose, HbA1c, ECG and patient education on healthy lifestyle and lifestyle risk factor control.
dOr other validated CV risk scores.
eSCORE2 (,70 years) or SCORE2-OP (≥70 years) CV risk stratiﬁcation: ,50 years:
low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50–69 years: low risk ,5%; moderate risk 5% to ,10%; high risk ≥10%; ≥70 years: low risk ,7.5%,
moderate risk 7.5% to ,15%, high risk ≥15%.19


<!-- PAGE 49 -->

### Page 49

Baseline ECG is recommended and ECGs should be repeated at day
14 of the ﬁrst cycle, before the second cycle, with any dose increase and as clinically indicated.357
In patients who already have, or are at signiﬁcant risk of developing, QT prolongation (Section 6.4.2), the risks/beneﬁts for ribociclib should be discussed by a MDT. Importantly, the use of ribociclib should be avoided in combination with drugs known to prolong
QT interval and/or strong CYP3A inhibitors.357
The prescribing information does not recommend ribociclib in combination with tamoxifen due to a higher risk of QTc prolongation.252,367
5.5.13. Anaplastic lymphoma kinase inhibitors
Patients with cancer treated with anaplastic lymphoma kinase
(ALK) inhibitors may develop adverse CV events including sinus bradycardia, AV block, QTc prolongation, hypertension, hyperglycaemia, and dyslipidaemia.370,371 ACS and HF have rarely been described under crizotinib.372 A baseline ECG is recommended in patients prior to starting an ALK inhibitor, especially crizotinib,
and patients may have an ECG 4 weeks after the start of treatment and every 3–6 months thereafter, particularly if the baseline ECG is abnormal. Home BP monitoring should be considered in patients treated with brigatinib or lorlatinib. Patients receiving lorlatinib or crizotinib treatment should have cholesterol levels checked every
3–6 months and treated if elevated.
5.5.14. Epidermal growth factor receptor inhibitors
Osimertinib is an oral irreversible, epidermal growth factor receptor
(EGFR)-TKI approved for patients with non-small cell lung cancer expressing EGFR mutations. Recent data have shown that osimertinib is associated with an increased risk of QTc prolongation, AF, VTE, LVD,
and HF (Figure 22).373,374 A study of 123 patients with EGFR-mutant non-small cell lung cancer treated with osimertinib reported a 4.9%
incidence of HF or MI and a signiﬁcant decrease in LVEF ,53% in
11% of patients with TTE surveillance.375 Pre-existing hypertension and older age are risk factors for LVD and HF (3.9% and 2.6% incidence, respectively).376 LVD and HF were more common during the ﬁrst year of therapy.376
Baseline CV risk stratiﬁcation, ECG and TTE prior to starting osimertinib is recommended. Three-monthly echocardiographic surveillance for new LVD during osimertinib treatment should be considered. Close monitoring of magnesium levels is also recommended to minimize the risk of osimertinib-induced hypomagnesaemia and QTc prolongation.
Recommendation Table 18 — Recommendations for baseline risk assessment and monitoring during cyclindependent kinase 4/6 inhibitor therapy
Recommendations
Classa
Levelb
QTcc,d monitoring is recommended at baseline and 14 and 28 days in all patients with cancer receiving ribociclib.361,365,367,368
I
A
QTcc,d monitoring is recommended in patients treated with ribociclib with any dose increase.361,365,367,368
I
B
QTcc monitoring should be considered in patients treated with palbociclib or abemaciclib who have a baseline QTc above the normal rangec or other conditions that may prolong the QTc interval.e
IIa
C
© ESC 2022
QTc, corrected QT interval; QTcF, corrected QT interval using Fridericia correction.
aClass of recommendation.
bLevel of evidence.
cQT interval using Fridericia correction (QTcF = QT/3√RR) is the preferred method in patients with cancer. Upper 99% limit of normal for QTc values in the general population are 450 ms for men and 460 ms for women.369
dAccording to the European Medicines Agency: (1) ribociclib should be interrupted when QTcF . 480 ms; (2) if QTcF prolongation resolves to ,481 ms, resume treatment at the same dose level; (3) if QTcF ≥481 ms recurs, interrupt dose until
QTcF resolves to ,481 ms and then resume ribociclib at next lower dose level.
eSee Section 6.4.2 and Table 8.
Recommendation Table 19 — Recommendations for baseline risk assessment and monitoring during anaplastic lymphoma kinase and epidermal growth factor receptor inhibitors
Recommendations
Classa
Levelb
Baseline CV risk assessmentc is recommended in patients before ALK inhibitors and EGFR
inhibitors.
I
C
Baseline echocardiography is recommended in all patients with cancer before starting osimertinib.376
I
B
Home BP monitoring should be considered for patients treated with brigatinib, crizotinib, or lorlatinib.
IIa
C
Cholesterol proﬁle assessment every 3–6 months should be considered for patients on crizotinib and lorlatinib.
IIa
C
Echocardiography should be considered every 3
months in patients during osimertinib therapy.376
IIa
B
ECG should be considered 4 weeks after starting therapy and every 3–6 months in patients during
ALK inhibitor therapy.
IIa
C
© ESC 2022
ALK, anaplastic lymphoma kinase; BP, blood pressure; CV, cardiovascular; ECG,
electrocardiogram; EGFR, epidermal growth factor receptor; HbA1c, glycated haemoglobin.
aClass of recommendation.
bLevel of evidence.
cPhysical examination, BP measurement, ECG, lipid proﬁle, and HbA1c measurement.
ESC Guidelines
4277


<!-- PAGE 50 -->

### Page 50

5.5.15. Chimeric antigen receptor
T cell and tumour-inﬁltrating lymphocytes therapies
CAR-T therapy is used for the treatment of acute lymphocytic leukaemia and aggressive B-cell lymphomas.377 Although the reported incidence is variable, there is a growing recognition of the association between CAR-T therapy and CTR-CVT, including LVD, HF, cardiac arrhythmias, pericardial effusion, TTS, and cardiac arrest.378–383 The majority of the described CV toxicities have been shown to be associated with the occurrence of cytokine release syndrome
(CRS).377,384 Baseline CV evaluation including ECG, NP, and cTn is recommended in all patients. Baseline TTE should also be considered, especially in patients with pre-existing CVRF and CVD. After receiving CAR-T therapy, patients may develop systemic inﬂammatory syndromes.385 CRS should be suspected when a patient develops fever, with or without tachypnoea, tachycardia, hypotension,
hypoxia, and/or other end-organ dysfunction hours to days after treatment.385 A high index of suspicion is necessary to diagnose
CRS and to distinguish it from other conditions that occur in these settings (infections, HF, drug reactions, and PE).378,386 Among adults,
there was a relationship between CRS and CV events. An elevation in cTn is commonly seen in patients with CRS and is associated with an increased risk for subsequent CV events.378 In a recent retrospective pharmacovigilance study, CAR-T was associated with tachyarrhythmias (AF the most common, followed by ventricular arrhythmias),
cardiomyopathy, and pleural and pericardial diseases.379 Globally,
the fatality rate of CV and pulmonary adverse events was
30.9%.378,379,387 Early cardiac evaluation in patients with cTn increase should include NP, ECG, and echocardiography (see Section 6.1.4 for management).388
Adoptive cellular therapy with TIL has emerged as an effective treatment option for unresectable stage III/IV metastatic melanoma.
With TILs, the CV toxicity appears to be related to direct myocardial and vascular toxicity.380 Baseline assessment and CV surveillance in patients before TIL therapies is the same pathway recommended for CAR-T therapies.
Alectinib
Brigantinib
Ceritinib
Crizotinib
Lorlatinib
Osimertiniba
ALK inhibitors
EGFR inhibitors
HTN
HF
SBr
DL
HG/DM
AF
VTE
ALK inhibitor- and EGFR inhibitor-related cardiovascular toxicities
Very common: ≥10% incidence
Common: 1% to <10% incidence
Uncommon: 0.1% to <1% incidence
Rare: <0.1% incidence
QTc
Figure 22 Anaplastic lymphoma kinase and epidermal growth factor receptor inhibitor-related cardiovascular toxicities. AF, atrial ﬁbrillation; ALK, anaplastic lymphoma kinase; DL, dyslipidaemia; DM, diabetes mellitus; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; FDA,
Food and Drug Administration; HF, heart failure; HG, hyperglycaemia; HTN, hypertension; MedDRA, medical dictionary for regulatory activities;
↑QTc, corrected QT interval prolongation; SBr, sinus bradycardia; VTE, venous thromboembolism. Adverse reactions reported in multiple clinical trials or during post-marketing use are listed by system organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the available data, a blank space has been left. aOsimertinib increases the risk of hypomagnesaemia. Figure developed from EMA prescribing information,252
FDA prescribing information.253


<!-- PAGE 51 -->

### Page 51

5.5.16. Radiotherapy
RT increases the risk of developing subsequent CVD and peripheral artery disease (PAD).173,389–394 There is ongoing debate regarding the safest radiation dose, which cardiac substructures are most sensitive to RT-induced injury, and the most appropriate strategies to minimize RT-related CVD.395,396 The heart is considered a radiosensitive ‘organ at risk’ during RT and radiation exposure to the heart should be kept as low as reasonably achievable because there is no ‘safe’ dose (Figure 23).389,390 RT-induced CV
toxicity risk categorization based on MHD389,397 is recommended over categorization based on prescribed dose, which may not accurately reﬂect cardiac radiation exposure (e.g. 35 Gray [Gy] prescribed dose to approximately 70% of the heart is equivalent to approximately 25 Gy MHD, whereas 35 Gy prescribed dose to approximately 40% of the heart is equivalent to approximately 15 Gy
MHD). However, MHD is not a perfect metric, and in some patients, a very small portion of the heart might be irradiated to a very high dose, still conveying a substantial risk despite a low
MHD.398 Therefore, depending on dose distribution and exposure of speciﬁc cardiac substructures and CVRFs, the cancer treatment team may judge the patient to belong to a higher-risk category.397,399–401
Strategies to prevent and attenuate CV complications of RT
have focused on reducing radiation exposure of the heart and
CV substructures during cancer treatment and include the following.
(1) Modiﬁcation of cancer management to omit RT. This emphasizes the importance of integrating a personalized cardio-oncology evaluation.402–404
(2) Modiﬁcation of the dose and volume of RT treatments where possible. RT protocols should target the minimum volume required to the minimum dose needed to obtain the desired clinical beneﬁt.
(3) Modiﬁcation of delivery techniques to reduce cardiac radiation exposure should lead to a considerable reduction in risk.
Modern heart-sparing RT strategies include: the optimal use of modern intensity-modulated photon RT technologies; the use of deep inspiration breath-hold or respiratory-gated techniques in BC,405 lymphoma,406 and lung cancer407; or the use of imageguided RT to ensure accuracy of delivery and proton beam therapy.408
The incidence of cardiac events following RT may vary according to patient risk factors and synergistic effects of radiation with other cardiotoxic cancer treatments.12,173
There are no known RT-speciﬁc secondary preventative measures (e.g. drug treatments) to reduce the risk of CV events following
RT.
However,
given the known importance of conventional CVRF on the incidence of RT-related events, optimization of modiﬁable CVRF is recommended in all patients before and after RT.
5.5.17. Haematopoietic stem cell transplantation
HSCT constitutes a potentially curative therapeutic option for many haematological malignancies. Improvements in HSCT techniques and supportive strategies have markedly decreased treatment-related mortality (Supplementary data, Table S14).409,410 There is a growing recognition of HSCT-related CV toxicities and HSCT survivors constitute a population at high future CV risk. Several factors contribute to deﬁne the risk of HSCT-related CV toxicities, including the HSCT
Recommendation Table 20 — Recommendations for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell and tumourinﬁltrating lymphocytes therapies
Recommendations
Classa
Levelb
Baseline ECG, NP, and cTn are recommended in all patients with cancer before starting CAR-T and
TIL therapies.388
I
C
A baseline echocardiography is recommended in patients with pre-existing CVD before starting
CAR-T and TIL therapies.388
I
C
A baseline echocardiography should be considered before starting CAR-T and TIL
therapies.388
IIa
C
Measurement of NP, cTn, and echocardiography are recommended in patients who develop CRS
of ASTCT ≥2.c,378,388
I
C
© ESC 2022
ASTCT, American Society for Transplantation and Cellular Therapy; CAR-T, chimeric antigen receptor T cell; CRS, cytokine release syndrome; cTn, cardiac troponin; CVD,
cardiovascular disease; ECG, electrocardiogram; NP, natriuretic peptides; TIL,
tumour-inﬁltrating lymphocytes.
aClass of recommendation.
bLevel of evidence.
cDetermine CRS grade according to ASTCT grading: Grade 1: fever; Grade 2: fever
AND hypotension not requiring vasopressors AND/OR hypoxia requiring low-ﬂow nasal oxygen; Grade 3: fever AND hypotension requiring one vasopressor +
vasopressin AND/OR hypoxia requiring high-ﬂow nasal cannula or facemask or non-rebreather mask or Venturi mask; Grade 4: fever AND hypotension requiring multiple vasopressors, not including vasopressin AND/OR hypoxia requiring positive airway pressure.
Recommendation Table 21 — Recommendations for baseline risk assessment of patients before radiotherapy to a volume including the heart
Recommendations
Classa
Levelb
Baseline CV risk assessmentc and estimation of
10-year fatal and non-fatal CVD risk with
SCORE2 or SCORE2-OPd is recommended.19,389
I
B
Baseline echocardiography should be considered in patients with previous CVD before RT to a volume including the heart.
IIa
C
© ESC 2022
BP,
blood pressure;
CV,
cardiovascular;
CVD,
cardiovascular disease;
ECG,
electrocardiogram; HbA1c,
glycated haemoglobin; RT, radiotherapy; SCORE2,
Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk
Estimation 2—Older Persons.
aClass of recommendation.
bLevel of evidence.
cBP, lipids, fasting glucose, HbA1c, ECG and patient education on healthy lifestyle and lifestyle risk factor control.
dSCORE2 (,70 years) or SCORE2-OP (≥70 years) CV risk stratiﬁcation: ,50 years:
low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50–69 years: low risk ,5%; moderate risk 5% to ,10%; high risk ≥10%; ≥70 years: low risk ,7.5%,
moderate risk 7.5% to ,15%, high risk ≥15%.19
ESC Guidelines
4279


<!-- PAGE 52 -->

### Page 52

type (higher risk after allogeneic HSCT), multiple uncontrolled
CVRF, pre-existing CV conditions (AF or atrial ﬂutter, sick sinus syndrome, ventricular arrhythmias, CAD, MI, moderate-to-severe VHD,
and HF or LVEF ,50%),411 direct cardiotoxic effects of anticancer therapies received prior to and during HSCT (anthracyclinecombined induction regimen, mediastinal RT, total body irradiation,
or cyclophosphamide-based conditioning regimen) (Supplementary data, Table S14) and the development of graft vs. host disease
(GVHD), thrombotic microangiopathy, or sepsis.410,412 In the early phase following HSCT (,100 days), the most frequent CV event is AF, although some patients may experience HF, hypertension,
hypotension, pericardial effusion, or VTE.413,414 Late toxicities include DM, dyslipidaemia, metabolic syndrome, hypertension, HF,
CAD, conductions disorders, and pericardial effusion.410 Acute
>25 Gy MHDb
>15 Gy MHDb +
cumulative doxorubicinc
≥100 mg/m2
Very high risk
>15 to 25 Gy MHDb
5 to 15 Gy MHDd+
cumulative doxorubicinc 
≥100 mg/m2
5 to 15 Gy MHDd
<5 Gy MHDe +
cumulative doxorubicinc 
≥100 mg/m2
<5 Gy MHDe
High risk
Moderate risk
Low risk
RT doses CVa toxicity risk
Low risk
Figure 23 Radiotherapy mean heart dose and associated cardiovascular toxicity risk. CV, cardiovascular; Gy, Gray; MHD, mean heart dose; RT, radiotherapy. aRT risk categorization based on MHD is recommended over categorization based on prescribed dose, which may not accurately reﬂect cardiac radiation exposure. Depending on dose distribution and exposure of speciﬁc cardiac substructures (as well as clinical risk factors) the treatment team may judge the patient to belong to a higher risk category. In addition, a patient may be judged to belong to a lower risk category if only a small part of the heart was exposed to a relatively low prescribed dose.397,399–401 bOr prescribed RT ≥35 Gy to a volume exposing the heart if MHD is not available. Note that in this case, the limited information about cardiac exposure does not allow one to distinguish between high- and very high-risk categories. cOr equivalent.
dOr prescribed RT 15–34 Gy to a volume exposing the heart if MHD is not available. eOr prescribed RT , 15 Gy to a volume exposing the heart if MHD
is not available.


<!-- PAGE 53 -->

### Page 53

GVHD is associated with thrombosis and inﬂammatory myocardial damage (myocarditis, HF, conduction abnormalities, arrhythmias,
and pericardial effusions), and chronic GVHD has been linked with increasing risk of hypertension, DM, and dyslipidaemia.415,416
A comprehensive CV evaluation, including NP assessment, ECG,
and TTE, has become a core component of the pre-HSCT assessment409,410 to detect undiagnosed CVD, stratify CTR-CVT risk,
and optimize pre-existing CV conditions.411,417–420 In early surveillance, TTE monitoring is recommended in high-risk HSCT recipients at 3 and 12 months as LVEF and GLS can decrease after transplant
(see Section 7). Independent factors associated with long-term CVD
in HSCT survivors are allogenic HSCT, pre-existing CVD or multiple uncontrolled CVRF, cancer treatment history (mediastinal or mantle ﬁeld radiation, alkylating agents, .250 mg/m2 doxorubicin or equivalent), high-risk conditioning schemes (total body irradiation,
alkylating agents), and GVHD.410 Figure 24 summarizes strategies for the prevention and attenuation of CV complications in patients undergoing HSCT.
Cardiovascular surveillance in patients referred for haematopoietic stem cell transplantation
If new cardiac symptoms occur at any time
If new cardiac symptoms occur at any time
In selected patients
In selected patients
Low risk
Class 1
Class 1Ia
Class 1Ib
ECG
TTE
CV assessmenta
NP
NP
ECG
TTE
CV assessmenta
CPET
3 M
after
HSCT
12 M
after
HSCT
>12 M
(yearly)
Before
HSCT
High risk
Allogenic HSCT
Pre-existing CVD 
Multiple uncontrolled CVRF
Cancer treatment historyb
Conditioning schemesc
GVHD
Figure 24 Risk factors and cardiovascular surveillance in patients referred for haematopoietic stem cell transplantation. BNP, B-type natriuretic peptide; BP, blood pressure; CPET, cardiopulmonary exercise testing; CV, cardiovascular; CVD, CV disease; CVRF, cardiovascular risk factors; ECG, electrocardiogram; GVHD, graft vs. host disease; HbA1c, glycated haemoglobin; HSCT, haematopoietic stem cell transplantation; M, months; NP,
natriuretic peptides (including BNP or NT-proBNP); NT-proBNP, N-terminal pro-BNP; TTE, transthoracic echocardiography. aIncluding physical examination, BP, lipid proﬁle, and HbA1c. bMediastinal or mantle ﬁeld radiation, alkylating agents, .250 mg/m2 doxorubicin or equivalent. cTotal body irradiation, alkylating agents.
Recommendation Table 22 — Recommendations for baseline risk assessment in haematopoietic stem cell transplantation patients
Recommendations
Classa
Levelb
Baseline and serial CV risk assessment (3 and 12
months, then yearly) including BP measurement,
ECG, lipid measurement, and HbA1c is recommended in HSCT patients.
I
C
Echocardiography is recommended in all patients before HSCT.
I
C
Baseline NP measurement should be considered before HSCT.417,418
IIa
C
© ESC 2022
BP, blood pressure; CV, cardiovascular; ECG, electrocardiogram; HbA1c, glycated haemoglobin; HSCT, haematopoietic stem cell transplantation; NP, natriuretic peptides.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4281


<!-- PAGE 54 -->

### Page 54

5.5.18. Other cancer treatments
Several other cancer therapies may also induce clinically relevant CV
events. Cyclophosphamide, cisplatin, ifosfamide, and taxanes (paclitaxel and docetaxel) can induce myocardial dysfunction and HF.4
Cyclophosphamide CV toxicity is primarily seen in patients receiving high doses (.140 mg/kg) before HSCT and typically occurs within days of drug administration.410
Platinum-containing chemotherapy (cisplatin, carboplatin, oxaliplatin) may cause vascular disease (vasospasm, MI, and venous and arterial thrombosis). These may occur during treatment and also contribute to increased long-term risk of CAD in survivors.
Patients with testicular cancer treated with cisplatin have a higher risk for vascular disease at long-term follow-up.421 The risk of the individual patient is still hard to predict, but lifestyle interventions, a high degree of clinical suspicion in patients who experience chest pain, and close CVRF monitoring is recommended during and after therapy.422 Cisplatin422 infrequently causes HF; however, because it requires the administration of a high i.v. volume to avoid renal toxicity, patients with pre-existing CVD may develop symptomatic HF.
Arsenic trioxide is used to treat some leukaemias and myelomas.
Arsenic trioxide frequently prolongs the QT interval (26–93% of patients), and life-threatening ventricular tachyarrhythmias have been reported.45,259 QTc prolongation was observed 1–5 weeks after arsenic trioxide infusion and then returned towards baseline by the end of 8 weeks. Patients receiving treatment with arsenic trioxide should be monitored weekly with ECG during the ﬁrst 8 weeks of therapy.
Electrolyte monitoring is also required as arsenic trioxide may induce hypokalaemia, hypomagnesaemia, and renal dysfunction. Risk factors for QT prolongation should be controlled before, during, and after cancer treatment (Section 6.4.2).
Several FMS-like tyrosine kinase 3 (FLT3) inhibitors (ﬁrst-generation:
midostaurin; second-generation: gilteritinib) have been tested for the treatment of acute myeloid leukaemias. Gilterinib-induced differentiation syndrome (fever, dyspnoea, pleuropericardial effusion, pulmonary oedema, peripheral oedema, hypotension, renal dysfunction, and rash) requires early corticosteroid therapy and haemodynamic monitoring until resolution of symptoms. Midostaurin and gilterinib may prolong QTc interval and close electrolyte surveillance and minimizing drug–drug interactions are required (see Section 6.4.2; Table 9;
Supplementary data, Tables S15 and S16).423
6. Diagnosis and management of acute and subacute cardiovascular toxicity in patients receiving anticancer treatment
A coordinated MDT is recommended to discuss patients with cancer who develop acute CV complications of their cancer treatment.5
Referral to a specialized cardio-oncology service is recommended for patients with cancer who present with new CTR-CVT during and after cancer treatment.12 The prevention and management of
CVD in patients with cancer should generally follow published ESC
Guidelines for speciﬁc CVD. This chapter provides guidance on the management of CTR-CVT that occur during cancer treatment,
and highlights where management differs for patients with cancer compared with those without. The decision to initiate CV treatment
(medication, devices) needs to include consideration of a range of factors including both cancer and CV symptom burden, cancer prognosis, ongoing cancer treatment requirements including alternative options, possible adverse drug reactions, drug–drug interactions,
and patient preferences. An extensive list of drug–drug interactions is provided in Supplementary data, Tables S15–S17.
6.1. Cancer therapy-related cardiac dysfunction
6.1.1. Anthracycline chemotherapy-related cardiac dysfunction
CTRCD during anthracycline chemotherapy may present clinically or be detected in asymptomatic patients during surveillance (Figure 10;
Table 3).4 The diagnosis of anthracycline chemotherapy-related cardiac dysfunction includes new CV symptoms, new abnormalities in cardiac function on CV imaging, and/or new increases in cardiac biomarkers (Table 3). A MDT discussion is recommended to consider the risk/beneﬁt ratio of continuing anthracycline chemotherapy in patients who develop new CTRCD.
Discontinuation of anthracycline chemotherapy is recommended in patients with cancer who develop severe symptomatic CTRCD.22
There are rare exceptions where rechallenge with further anthracycline chemotherapy may be considered after a MDT discussion, using prevention strategies described below and under close monitoring with each cycle of anthracycline chemotherapy. Temporary interruption of anthracycline chemotherapy is recommended in patients who develop moderate symptomatic CTRCD, and in patients who develop moderate or severe asymptomatic CTRCD. A MDT approach regarding interruption vs. continuation of anthracycline chemotherapy is recommended in patients who develop mild symptomatic
CTRCD.
Guideline-based HF therapy is recommended in patients who develop symptomatic CTRCD or asymptomatic moderate or severe
CTRCD during anthracycline chemotherapy. The use of an ACE-I/
ARB or angiotensin receptor–neprilysin inhibitor, a beta-blocker, a sodium–glucose co-transporter 2 inhibitor, and a mineralocorticoid receptor antagonist is recommended unless the drugs are contraindicated or not tolerated. Up-titration to target doses as described in the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF is recommended.14 ACE-I, ARB, and/or beta-blockers
Recommendation Table 23 — Recommendation for the management of cardiovascular disease and cancer therapy-related cardiovascular toxicity in patients receiving anticancer treatment
Recommendation
Classa
Levelb
A specialist CV assessmentc is recommended for optimal diagnostic workup and management of patients with cancer who present with new CV
toxicity during and after cancer treatment.5
I
C
© ESC 2022
CV, cardiovascular; CVD, cardiovascular disease.
aClass of recommendation.
bLevel of evidence.
cCardio-oncology referral is recommended when available; alternatively, patients should be referred to a specialized cardiologist with expertise in managing CVD in patients with cancer.


<!-- PAGE 55 -->

### Page 55

should be considered in mild asymptomatic CTRCD while anthracycline chemotherapy continues uninterrupted (Figure 25).1,14,102,424
The beneﬁcial effects of aerobic exercise before and during anthracycline chemotherapy have been demonstrated and is recommended for patients with cancer who develop CTRCD.11
A MDT is recommended to discuss restarting anthracycline chemotherapy in patients who developed mild or moderate symptomatic CTRCD, or moderate or severe asymptomatic
CTRCD, after recovery of LV function under HF treatment. If there is a compelling reason to continue anthracycline chemotherapy,
three other strategies exist in addition to continuing ACE-I/ARB
and beta-blockers at target doses for HF.14 First, minimizing the dose of anthracycline chemotherapy administered. Second, switching to liposomal anthracycline preparations. Third, pre-treatment
Discontinue
AC
(Class I)
Interrupt
AC
(Class I)
MDT approach regarding interruption vs. conti
.
nuation of AC
(Class I)
Interrupt
AC
(Class I)
Continue
AC
with CV monitoring
(Class I)
Symptomatic CTRCDa
Ve
V ry severe/severe
Oncological strategy
CV
strategy
Moderate
MDTb
Mild
Severe/moderate
Mild
GLS decrease >15%
or cTn increase
ACE-I/ARB
and/or BB
(Class IIb)
ACE-I/ARB
and/or BB
(Class IIa)
HF therapy p
(Class I)
NP increase
Asymptomatic CTRCDa
Management of patients with AC-related cardiac dysfunction
AND
MDTc
AND
MDTc
AND
Figure 25 Management of anthracycline chemotherapy-related cardiac dysfunction. AC, anthracycline chemotherapy; ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BB, beta-blockers; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction;
CV, cardiovascular; GLS, global longitudinal strain; HF, heart failure; LV, left ventricular; LVEF, left ventricular ejection fraction; MDT, multidisciplinary team; NP, natriuretic peptides. aSee Table 3 (Section 3) for complete deﬁnition (symptomatic CTRCD: symptomatic conﬁrmed HF syndrome; asymptomatic severe CTRCD: LVEF , 40%; asymptomatic moderate CTRCD: LVEF 40–49%; asymptomatic mild CTRCD: LVEF . 50%). bIn rare exceptions, anthracycline chemotherapy may be restarted after recovery of LV function with optimal HF therapy. cA MDT discussion is recommended before restarting anthracycline chemotherapy after recovery of LV function.
ESC Guidelines
4283


<!-- PAGE 56 -->

### Page 56

with dexrazoxane before each further cycle of anthracycline chemotherapy (Section 5.2.1).
Close cardiac monitoring every 1–2 cycles is recommended in patients who restart anthracycline chemotherapy following an episode of CTRCD and in patients with mild asymptomatic CTRCD while they continue anthracycline chemotherapy.
6.1.2. Human epidermal receptor 2-targeted therapy-related cardiac dysfunction
The diagnosis of HER2-targeted therapy-related CTRCD can be made using the combination of new CV symptoms, imaging, and biomarkers. Patients may present with symptomatic CTRCD or may be asymptomatic.426 Early treatment of symptomatic and asymptomatic severe CTRCD (LVEF , 40%), according to the
particularly when targeted cancer therapy is continued.427 In patients who develop CTRCD, a MDT is recommended to guide clinical decisions.
Temporary interruption is recommended in patients who develop moderate or severe symptomatic
CTRCD or severe asymptomatic CTRCD (LVEF , 40%) during
HER2-targeted therapy. In patients with mild symptomatic
CTRCD, a MDT approach is recommended to continue vs. interrupt HER2-targeted therapy. In patients with asymptomatic moderate CTRCD (LVEF 40–49%), HER2-targeted treatment should be continued, and cardioprotective therapy (ACE-I/ARB and betablockers) is recommended with frequent cardiac monitoring.22,33,189 In patients with asymptomatic mild CTRCD (LVEF ≥
50% with a signiﬁcant new GLS reduction and/or cardiac biomarker increase), continuing HER2-targeted treatment is recommended and cardioprotective therapy
(ACE-I/ARB
and/or beta-blockers) should be considered.22,211,428,429
Frequent cardiac surveillance with cardiac imaging and cardiac serum biomarkers is recommended in all patients with CTRCD
Recommendation Table 24 — Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy
Recommendations
Classa
Levelb
Anthracycline chemotherapy-induced symptomatic CTRCD
HF therapy is recommended for patients who develop symptomatic CTRCD during anthracycline chemotherapy.c,208,425
I
B
Discontinuation of anthracycline chemotherapy is recommended in patients who develop symptomatic severe CTRCD.c
I
C
Temporary interruption of anthracycline chemotherapy is recommended in patients who develop symptomatic moderate CTRCDc and a multidisciplinary approach regarding the decision to restart is recommended.
I
C
A multidisciplinary approach regarding interruption vs. continuation of anthracycline chemotherapy is recommended in patients who develop mild symptomatic CTRCD.c
I
C
Anthracycline chemotherapy-induced asymptomatic
CTRCD
Temporary interruption of anthracycline chemotherapy and initiation of HF therapy is recommended in patients who develop asymptomatic moderate or severe CTRCD.c,22
I
C
A multidisciplinary approach regarding the decision when to restart is recommended in all patients with moderate or severe asymptomatic
CTRCD.c,22
I
C
Continuation of anthracycline chemotherapy is recommended in asymptomatic patients who have LVEF ≥50% and who have developed a signiﬁcant fall in GLSc or a troponin or a NP
elevation . ULN.
I
C
Asymptomatic patients who have LVEF ≥50%
and who have developed a signiﬁcant fall in GLSc should be considered for ACE-I/ARB and/or beta-blockers.d,75,93,102
IIa
B
Asymptomatic patients who have LVEF ≥50%
and who have developed a troponin elevation
.ULN should be considered for ACE-I/ARB and/
or beta-blockers.d,147,211
IIa
B
Continued
Asymptomatic patients who have LVEF ≥50%
and who have developed NP .ULN may be considered for ACE-I/ARB and/or beta-blockers.d,211
IIb
C
Strategies for restarting anthracycline chemotherapy in patients with CTRCD
Liposomal anthracyclinee may be considered in patients with moderate or severe symptomatic or asymptomatic CTRCDc who require further anthracycline chemotherapy to reduce the risk of further CV toxicity.
IIb
C
Dexrazoxanef may be considered in patients with moderate or severe symptomatic or asymptomatic CTRCDc who require further anthracycline chemotherapy to reduce the risk of further CV toxicity.
IIb
C
© ESC 2022
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; GLS, global longitudinal strain; HF, heart failure; LVEF, left ventricular ejection fraction; NP,
natriuretic peptides; ULN, upper limit of normal.
aClass of recommendation.
bLevel of evidence.
cSee Table 3. Signiﬁcant fall in GLS = relative reduction .15%.
dAvoid hypotension.
eSee text for speciﬁc liposomal doxorubicin type and malignancies (Section 5.2).
fAs per the European Medicines Agency: ≥350 mg/m2 doxorubicin or equivalent; as per the United States Food and Drug Administration: ≥300 mg/m2 doxorubicin or equivalent.


<!-- PAGE 57 -->

### Page 57

who continue HER2-targeted cancer therapies and in those who restart after an interruption following resolution of HF signs and symptoms and recovery of LVEF ≥40% (and ideally recovery to
LVEF ≥50%) (Figure 26).22,33,189 Echocardiography and cardiac serum biomarker measurement every two cycles for the ﬁrst four cycles after restarting HER2-targeted therapy is recommended, and then the frequency can be reduced if cardiac function and biomarker levels remain stable.
Anti-HER2
interruption
(Class I)
Anti-HER2
interruption
(Class I)
MDT approach regarding interruption vs. conti
.
nuation of anti-HER2
(Class I)c
Continue anti-HER2
under CV monitoring
(Class I)
Continue anti-HER2
under CV monitoring
(Class IIa)
Symptomatic CTRCDa
Moderata e to very severe
Oncological strategy
CV
strategy
Mild
MDTb,c
Severe
Moderate
Mild
ACE-I/ARB
and/or BB
(Class IIa)
HF therapy p
(Class I)
Asymptomatic CTRCDa
Management of patients with HER2-targeted therapies related cardiac dysfunction
AND
MDTb,c
AND
GLS decrease >15%
cTn and NP increase
Figure 26 Management of human epidermal receptor 2-targeted therapy-related cardiac dysfunction. ACE-I, angiotensin-converting enzyme inhibitors;
ARB, angiotensin receptor blockers; BB, beta-blockers; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular;
GLS, global longitudinal strain; HER2, human epidermal receptor 2; HF, heart failure; LVEF, left ventricular ejection fraction; MDT, multidisciplinary team;
NP, natriuretic peptides. aSee Table 3 (Section 3) (symptomatic CTRCD: symptomatic conﬁrmed HF syndrome; asymptomatic severe CTRCD: LVEF ,
40%; asymptomatic moderate CTRCD: LVEF 40–49%; asymptomatic mild CTRCD: LVEF . 50%). bFor patients in whom HER2-targeted therapy has been interrupted, whose signs and symptoms of HF do not resolve and/or LVEF remains ,40%, resumption of HER2-targeted therapy may be considered if no alternative therapeutic option exists. In advanced cancer that only responds well to trastuzumab, the risk/beneﬁt ratio may warrant continued therapy if other options remain limited.22 cFor patients where HER2-targeted therapy has been interrupted and who have recovered LVEF ≥40% and are now asymptomatic, resumption of HER2-targeted therapy should be considered, supported by HF therapy, and echocardiography and cardiac biomarker assessment every two cycles for the ﬁrst four cycles after restarting and then the frequency can be reduced.22
ESC Guidelines
4285


<!-- PAGE 58 -->

### Page 58

6.1.3. Immune checkpoint inhibitor-associated myocarditis and non-inﬂammatory heart failure
Myocarditis is a severe complication of ICI with a high fatality rate that most frequently develops during the ﬁrst 12 weeks of treatment, although late cases (after week 20) may occur.386
Other ICI-related CV toxicities include dyslipidaemia, ACS, vasculitis, AV block, supraventricular and ventricular arrhythmias, sudden death, TTS, non-inﬂammatory LVD, pericarditis, pericardial effusion, and ischaemic stroke, with higher risks for myocarditis
(odds ratio
4.42)
and dyslipidaemia
(odds ratio
3.68)
(Figure 27).323,325
The diagnosis of ICI-associated myocarditis is initially based on the presence of symptoms, a new increase in troponin (associated with either CV symptoms or non-CV immuno-related adverse events),
and new ECG abnormalities (AV or intraventricular conduction disorders,
bradycardia,
tachyarrhythmias)
(see
Section
3;
Table 3).17,434,435 Any abnormal ﬁnding should prompt urgent CV imaging and other causes of myocardial injury (e.g. ACS, acute infectious myocarditis) should be excluded. Treatment with high-dose methylprednisolone should be promptly initiated in haemodynamically unstable patients (including those with ventricular arrhythmias
[VA] or complete AV block) while awaiting further conﬁrmatory testing.436 TTE and CMR are recommended in all patients with suspected ICI-associated myocarditis. Currently, speciﬁc CMR features for ICI-induced myocarditis are not well described and modiﬁed Lake
Louise criteria are recommended (Table 3).18 Cardiac ﬂuorodeoxyglucose positron emission tomography (PET) may be considered437,438 if CMR is not available or contraindicated, although PET
sensitivity is low and requires a strict 18-h carbohydrate-free fast.439 Endomyocardial biopsy (EMB) should be considered in cases where the diagnosis is suspected but not conﬁrmed non-invasively
(e.g. conﬂicting results of cardiac imaging and biomarkers or clinically unstable patients).440 All cases of ICI-associated myocarditis should be classiﬁed according to the severity of the myocarditis (fulminant
Recommendation Table 25 — Recommendations for the management of cancer treatment-related cardiac dysfunction during human epidermal receptor 2-targeted therapies
Recommendations
Classa
Levelb
HER2-targeted therapy-induced symptomatic CTRCD
HF therapy is recommended for patients who develop symptomatic moderate-to-severe
CTRCD with LVEF , 50%c during HER2-targeted treatment.14,61,430,431
I
B
Temporary interruption of HER2-targeted treatment is recommended in patients who develop moderate or severe symptomatic
CTRCDc and the decision to restart should be based on a multidisciplinary approach after improvement of LV function and symptoms resolved.d
I
C
In patients who develop mild symptomatic
CTRCD,c HF therapy and a multidisciplinary approach regarding the decision to continue vs.
interrupt HER2-targeted therapy are recommended.d,431,432
I
C
HER2-targeted therapy-induced asymptomatic CTRCD
Temporary interruption of HER2-targeted therapy and initiation of HF therapy is recommended in patients who develop asymptomatic severe CTRCD.c
I
C
A multidisciplinary approach regarding the decision to restart HER2-targeted treatment is recommended in patients with severe asymptomatic CTRCD.c
I
C
Continuation of HER2-targeted therapy should be considered in patients who develop asymptomatic moderate (LVEF 40–49%) CTRCDc with more frequent cardiac monitoring.33,189,428,433
IIa
B
Continuation of HER2-targeted therapy is recommended in patients who develop asymptomatic mild (LVEF ≥50%) CTRCDc with more frequent cardiac monitoring.428
I
C
ACE-I/ARB and beta-blockers are recommended in patients who develop asymptomatic moderate
(LVEF 40–49%) CTRCDc during HER2-targeted treatment.e,189
I
C
ACE-I/ARB and/or beta-blockers should be considered in asymptomatic patients receiving
HER2-targeted therapies who have LVEF ≥50%
but develop a signiﬁcant fall in GLSc while continuing HER2-targeted therapy.e,22,428
IIa
B
Continued
ACE-I/ARB and/or beta-blockers should be considered in asymptomatic patients receiving
HER2-targeted therapies who have LVEF ≥50%
but develop a new troponin or NP rise while continuing HER2-targeted therapy.e,22,211,428
IIa
B
© ESC 2022
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
CTRCD, cancer therapy-related cardiac dysfunction; GLS, global longitudinal strain;
HER2, human epidermal receptor 2; HF, heart failure; LV, left ventricular; LVEF, LV
ejection fraction; NP, natriuretic peptides.
aClass of recommendation.
bLevel of evidence.
cSee Table 3.
dFor patients where HER2-targeted therapy has been interrupted and who have recovered LVEF ≥40% and are now asymptomatic, resumption of HER2-targeted therapy should be considered supported by HF therapy and echocardiography and cardiac biomarkers assessment every two cycles for the ﬁrst four cycles after restarting and then frequency can be reduced.
eAvoid hypotension.


<!-- PAGE 59 -->

### Page 59

or non-fulminant, including symptomatic but haemodynamically and electrically stable patients and incidental cases diagnosed at the same time as other immune-related adverse events) to guide the management pathway (Figure 28).331
Interruption of ICI treatment is recommended in all cases of suspected ICI-associated myocarditis (any patient developing new cardiac symptoms, new cardiac arrhythmias, new heart blocks, or new troponin increase who has received an ICI therapy in the past 12 weeks) while investigations are performed. Once the abnormal ﬁndings have resolved, a MDT discussion is recommended to determine the risk/beneﬁt to permanent stopping vs.
resuming ICI treatment in patients with suspected but not conﬁrmed myocarditis.
Cessation of ICI treatment is recommended in patients with cancer with fulminant or non-fulminant ICI-associated myocarditis and the patient should be admitted to hospital and a level 2 or 3 bed with continuous ECG monitoring is required. CV complications should be treated as per speciﬁc ESC Guidelines (HF,14 tachyarrhythmias,441,442 AV block,443 or pericardial effusion444).
Treatment of both non-fulminant and fulminant ICI-associated myocarditis with methylprednisolone 500–1000 mg i.v. bolus once daily for the ﬁrst 3–5 days should be started as soon as possible,
once the diagnosis is considered likely, to reduce MACE including mortality.386,436 If clinical improvement is observed (cTn reduced by .50% from peak level within 24–72 h and any LVD, AV block,
and arrhythmias resolved), switching to oral prednisolone is
Direct CV Toxicity
Arrhythmias
Arrhythmias
Myocarditis
Non-inflammatory HF
Takotsubo syndrome
Pericarditis
Vascular
Indirect CV Toxicity
Thyroid
Adrenal
Pituitary
Pancreas
Embolism
Figure 27 Direct and indirect immune checkpoint inhibitor-related cardiovascular toxicity. CV, cardiovascular; HF, heart failure.
ESC Guidelines
4287


<!-- PAGE 60 -->

### Page 60

recommended starting at 1 mg/kg up to 80 mg/day. Although the most appropriate weaning off protocol is not conﬁrmed, a weekly reduction of oral prednisolone (most commonly by 10 mg per week) under clinical, ECG, and cTn surveillance should be considered (Figure 28). A reassessment of LV function and cTn should be considered when the prednisolone dose is reduced to 20 mg/day and then continue weaning the prednisolone by 5 mg per week to
5 mg/day, and a ﬁnal reduction from 5 mg/day in 1-mg per week steps.
If the troponin does not reduce signiﬁcantly (.50% reduction from peak) and/or AV block, ventricular arrhythmias, or LVD persist despite 3 days of i.v. methylprednisolone plus cardiac treatments,
then steroid-resistant ICI-associated myocarditis is conﬁrmed and second-line immunosuppression should be considered.22,445,446
Complete recovery
Recoveringb
Steroid refractory
Haemodynamically unstable fulminant myocarditis
Switching to oral prednisolone (1 mg/kg/day)
a
(Class IIa)
Second-line immunosuppression
(Class IIa)
Methylprednisolone 500–1000 mg i.v.v bolus once dai
.
ly (minimum 3 days)
a
(Class I)
Discontinue ICI; hospital admission
;
; ECG monitoring
;
(Class I)
Severity (fulminant vs. non-fulminant)
.
a
Admission to ICU (level 3)
(Class I)
Optimal CV treatment including MCS
(Class I)
Weaning p
W
rotocol by 10 mg/week with troponin monitoring
(Class IIa)
Management of patients with a definitive diagnosis of ICI-related myocarditis
AND
AND
Second-line immunosuppression
(Class I)
AND
Figure 28 Diagnosis and management of immune checkpoint inhibitor-related myocarditis. CMR, cardiac magnetic resonance; CV, cardiovascular;
ECG, electrocardiogram; HF, heart failure; ICI, immune checkpoint inhibitor; ICU, intensive care unit; i.v., intravenous; LGE, late gadolinium enhancement;
LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support. aFulminant: haemodynamic instability, HF requiring non-invasive or invasive ventilation, complete or high-grade heart block, and/or signiﬁcant ventricular arrhythmia. Non-fulminant: including symptomatic but haemodynamically and electrically stable patients and incidental cases diagnosed at the same time as other immuno-related adverse events. Patients may have reduced LVEF but no features of severe disease. bRecovering: ongoing improvement in patient clinical symptoms, signs, biomarkers, and imaging parameters, but not yet normalized, while on tapering doses of immunosuppression. Complete recovery: patients with complete resolution of acute symptoms, normalization of biomarkers, and recovery of LVEF after discontinuation of immunosuppression. CMR may still show LGE or elevated T1 due to ﬁbrosis, but any suggestion of acute oedema should be absent.


<!-- PAGE 61 -->

### Page 61

There is a lack of data to recommend a speciﬁc second-line immunosuppression regimen and MDT discussion is recommended. Several agents are currently being investigated with promising results from case series including i.v. mycophenolate mofetil, anti-thymocyte globulin (anti-CD3
antibody), i.v. immunoglobulin, plasma exchange, tocilizumab, abatacept
(CTLA-4 agonist), alemtuzumab (anti-CD52 antibody), and tofacitinib.
Caution is advised against the use of inﬂiximab for steroid-refractory myocarditis and HF.447,448 Patients with fulminant ICI-associated myocarditis, complicated by haemodynamic and/or electrical instability, require admission to the intensive care unit (ICU) and cardiogenic shock should be managed according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF.14 A single dose of i.v. methylprednisolone should be considered in clinically unstable patients with cancer where ICI-induced myocarditis is suspected at presentation but before deﬁnitive diagnosis can be conﬁrmed.
Following recovery from ICI-associated myocarditis and weaning of oral steroid therapy, MDT discussion is recommended to review the decision on whether to restart ICI treatment. This depends on various factors including the severity of the ICI-associated myocarditis (fulminant vs. non-fulminant vs. asymptomatic), alternative oncology treatment options,
metastatic vs.
adjuvant/neoadjuvant indication, and reducing from dual ICI to single ICI treatment if triggered by combination ICI treatment.449
Non-inﬂammatory HF syndromes have also been observed in patients treated with ICI. These include TTS, non-inﬂammatory HF or
LVD,450 and post-MI HF.451,452 Non-inﬂammatory HF is generally a late event and the diagnostic workﬂow should be based on deﬁning the HF phenotype and excluding myocarditis, TTS, and ACS.14 There is also evidence that vasculitis and CAD can occur after ICI treatment.335 HF treatment as per the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF is indicated,14 but there is no indication for immunosuppression if myocarditis has been excluded.
Interruption vs. continuing ICI therapy depends on the severity of the HF syndrome and each case should be reviewed by a MDT.
Arrhythmias, such as AF, can be seen in patients with ICI therapy without myocarditis (e.g. ICI-associated thyroiditis with thyrotoxicosis,
ICI-associated pericarditis, or ICI-associated severe systemic inﬂammatory syndromes). ICI treatment can be continued after excluding myocarditis.
Recommendation Table 26 — Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis
Recommendations
Classa
Levelb cTn, ECG, and CV imaging (echocardiography and
CMR) are recommended to diagnose
ICI-associated myocarditis.320,434,435,453
I
B
In patients with suspected ICI-associated myocarditis, temporary interruption of ICI
treatment is recommended until the diagnosis is conﬁrmed or refuted.
I
C
Continued
EMB should be considered to conﬁrm the diagnosis of ICI-associated myocarditis if the diagnosis is suspected but not conﬁrmed after cardiac imaging and biomarkers.c
IIa
C
Interruption of ICI treatment is recommended in patients with conﬁrmed ICI-associated myocarditis.
I
C
Continuous ECG monitoring to assess for new
AV block and tachyarrhythmias during the acute phase is recommended for all patients with symptomatic ICI-associated myocarditis.
I
C
Early high-dose corticosteroidsd are recommended in patients with cancer and conﬁrmed ICI-associated myocarditis.22,436,454
I
C
Continuation of high-dose corticosteroids is recommended for the treatment of ICI-associated myocarditis until resolution of symptoms, LV
systolic dysfunction, conduction abnormalities,
and signiﬁcant cTn reduction.e
I
C
Switching from i.v. to oral prednisolone should be considered after clinical improvement (resolution of: symptoms, LV systolic dysfunction, conduction abnormalities, and signiﬁcant cTn reductione).f
IIa
C
Second-line immunosuppression treatment should be considered in patients with steroid-refractory ICI-associated myocarditis.g
IIa
C
Admission to ICU (level 3), treatment with i.v.
methylprednisolone, and optimal CV treatment including mechanical support (when indicated) is recommended for patients with ICI-associated fulminant myocarditis.14
I
C
A single dose of i.v. methylprednisoloned should be considered in unstableh patients with cancer where ICI-induced myocarditis is suspected.
IIa
C
A multidisciplinary discussion is recommended before restarting ICI treatment in selected patients with previous uncomplicated
ICI-associated myocarditis.
I
C
© ESC 2022
AV, atrioventricular; CMR, cardiac magnetic resonance; cTn, cardiac troponin;
CV, cardiovascular; ECG, electrocardiogram; EMB, endomyocardial biopsy; HF, heart failure; ICI, immune checkpoint inhibitors; ICU, intensive care unit; i.v., intravenous;
LGE, late gadolinium enhancement; LV, left ventricular; LVD, LV dysfunction; LVEF,
LV ejection fraction.
aClass of recommendation.
bLevel of evidence.
cSee Table 3 for ICI-related myocarditis deﬁnition. EMB should be considered in unstable patients or when CMR is contraindicated.
dEarly: ≤24 h; high-dose corticosteroids (methylprednisolone 500–1000 mg/day).
eReduction of cTn by .50% from peak level.
fComplete recovery: Patients with complete resolution of acute symptoms,
normalization of biomarkers, or reduction of cTn by .50% from peak level and recovery of LVEF after discontinuation of immunosuppression are considered to have achieved complete recovery. CMR may still show LGE or elevated T1 due to
ﬁbrosis but any suggestion of acute oedema should be absent. Incomplete recovery: (1) an increase in symptoms or biomarkers of myocarditis or an inability to taper immunosuppression without a clinical or biomarker ﬂare; (2) patients with persistent LVD despite resolution of acute symptoms with immunosuppression.
gSteroid refractory: non-resolving or worsening myocarditis (clinical worsening or persistent troponin elevation after exclusion of other aetiologies) despite high-dose methylprednisolone (Table 3; Supplementary data, Table S1).
hUnstable: patients with symptomatic HF, ventricular arrhythmias, new complete heart block.
ESC Guidelines
4289


<!-- PAGE 62 -->

### Page 62

6.1.4. Chimeric antigen receptor T cell and tumour-inﬁltrating lymphocytes therapies and heart dysfunction
Although no large-scale studies on the multiple CV complications among adults treated with CAR-T therapies exist, small studies and case reports have shown that CV complications represent around 20% of adverse events.378 CV complications are associated with high mortality rates, and are secondary to CRS and immune effector cell-associated neurotoxicity syndrome. The most common
CV complications in patients receiving CAR-T therapies are arrhythmias (77.6%), including QTc prolongation, ventricular arrhythmias,
and AF; HF (14.3%); and MI and VTE (0.5%).455 When suspected, a resting 12-lead ECG, continuous ECG monitoring, TTE, and cTn and NP are recommended. Admission to ICU (level 3) is recommended in severe cases due to the risk of malignant cardiac arrhythmias, circulatory collapse, and multiorgan system failure. In general,
the degree of elevation of cytokines correlates with the severity of
CRS. C-reactive protein is not speciﬁc for CRS and changes in
C-reactive protein may lag behind clinical changes by ≥12 h. A dramatic elevation of interleukin-6 is a supportive ﬁnding for the diagnosis of CRS. Management of the speciﬁc CV complication should follow ESC Guidelines, with additional management of the CRS
(e.g. the anti-interleukin-6 receptor antibody, tocilizumab, and dexamethasone).381
Recovery of function
MDT
(Class I)
N
Diagnosis and management workup in patients with cancer-r related Ta
T kotsubo synd k
rome
AND
Coronary angiography
(invasive or CCTA)
T
to exclude ACS
(Class I)
CMR
to exclude myocarditis and myocardial infarction
(Class I)
AND
Y
Clinical evaluation
ECG
TTE
Cardiac serum biomarkers k
AND
Interruption of the culprit cancer drug
(Class I)
Av
A oid QT-p
T rolonging drugs
(Class III)
Consider resuming cancer treatment under close monitoring
(Class I)
MDT approach regarding interruption vs resuming the culprit cancer drug
For ICI-related TTS:
methylprednisolone 
(1000 mg i.v.)
v
AND
CCU/HDU/ICU admission
ECG monitoring
Figure 29 Diagnosis and management workup in cancer-related Takotsubo syndrome. ACS, acute coronary syndromes; CCTA, coronary computed tomography angiography; CCU, coronary care unit; CMR, cardiac magnetic resonance; ECG, electrocardiogram; HDU, high-dependency unit; ICI, immune checkpoint inhibitor; ICU, intensive care unit; i.v., intravenous; MDT, multidisciplinary team; N, no TTE, transthoracic echocardiography; TTS,
Takotsubo syndrome; Y, yes.


<!-- PAGE 63 -->

### Page 63

Although CV complications are common with TIL therapies, survival does not appear to be signiﬁcantly affected. The most frequent
CV events are hypotension that may require treatment with i.v. ﬂuids and pressors, AF, and to a lesser extent, cTn elevation suggestive of myocardial damage.380 Further research is needed to deﬁne mechanisms and potential prevention strategies to help clinicians with the management of these CV events.
6.1.5. Heart failure during haematopoietic stem cell transplantation
CV complications during HSCT, including congestive HF,456 arterial events, tamponade, and rhythm disturbances (AF, atrial ﬂutter, and supraventricular tachycardia),457 are uncommon but clinically relevant, and should be treated as per speciﬁc ESC Guidelines (HF,14 tachyarrhythmias,273,441 pericardial effusion,444 or acute coronary syndrome458). Studies of treatments during HSCT to prevent both acute and late CV toxicity are limited.145 ACE-I and beta-blockers may be effective,
but this requires further conﬁrmation.
Outpatient and home-based exercise and education programmes instituted after HSCT can improve exercise capacity and quality of life,459 and the role of exercise pre-habilitation prior to HSCT is being investigated.460,461
6.1.6. Takotsubo syndrome and cancer
The prevalence of malignant diseases is high in patients with TTS
and is a risk factor for worse outcomes. Malignancy itself, some cancer treatments (5-FU, ICI, VEGFi), and the stress associated with the diagnosis, investigations, and treatment are recognized triggers or predisposing factors for TTS.462–466 Diagnosis using general TTS criteria is recommended.467,468 Investigations in a patient with cancer with suspected TTS should include clinical examination, ECG, TTE, cardiac biomarkers (cTn and NP), and CMR
(Figure 29).468,469 Most patients require invasive coronary angiography to exclude acute MI. In patients with advanced malignancy or signiﬁcant thrombocytopaenia where invasive coronary angiography is contraindicated, a CCTA is recommended. Cardiac imaging studies should be performed as early as possible when the diagnosis is suspected as LVD can be transient, and if signiﬁcant
LVD is detected then repeat imaging to conﬁrm recovery is recommended.
Interruption of the culprit cancer drug in patients with TTS is recommended. QT-prolonging drugs should be avoided.467 In cases of
ICI-associated TTS, the role of immunosuppression is unknown and if myocardial inﬂammation is present in a TTS pattern on CMR then i.v. methylprednisolone is recommended given the overlap between
ICI-induced TTS and ICI-induced myocarditis. Limited information exists regarding the feasibility of ICI rechallenge following TTS and after recovery of LV function.
A MDT discussion is recommended after recovery from the acute phase of TTS and, if restarting the culprit cancer drug is required from an oncology perspective, regular cardiac biomarker monitoring is recommended (e.g. cTn and NP measured before every ICI cycle, and TTE if a new rise in cardiac biomarkers occurs)
(Figure 29).
6.2. Coronary artery disease
6.2.1. Acute coronary syndromes
Patients with cancer are at increased risk of CAD because of shared
CVRFs34 and CV toxicity of cancer therapy12 compounded by a cancer-induced pro-inﬂammatory and prothrombotic state
(Table 7).467,468,470–473
Current knowledge on ACS in patients with cancer is based on observational data and registries demonstrating that, especially when diagnosed within 1 year, they are at increased risk for major
CV events, bleeding, and cardiac and non-cardiac mortality.474–480
The proportion of ACS patients with a diagnosis of cancer is rising and constitutes about 3% of large series.475
Diagnosis of ACS is based on the same principles as in patients without cancer, including symptoms, an early 12-lead ECG, and serial measurements of hs-cTn for patients presenting with possible non-ST-segment elevation ACS (NSTE-ACS).458 Clinical presentation can be atypical481 or masked by cancer or therapy-related side effects; therefore, diagnostic suspicion should be increased in patients at high CV risk or treated with vascular cardiotoxic therapies
Recommendation Table 27 — Recommendations for the diagnosis and management of Takotsubo syndrome in patients with cancer
Recommendations
Classa
Levelb
Coronary angiography (invasive or CCTA) is recommended to exclude ACS.
I
C
CMR is recommended to exclude myocarditis and
MI.458
I
B
QT-prolonging drugs are not recommended during the acute TTS phase.c
III
C
© ESC 2022
ACS, acute coronary syndromes; CMR, cardiac magnetic resonance; CCTA, coronary computed tomography angiography; LV, left ventricular; MI, myocardial infarction;
QTc, corrected QT interval; TTS, Takotsubo syndrome.
aClass of recommendation.
bLevel of evidence.
cUntil full recovery and normalization of LV function and QTc.
Table 7
Cancer treatments that predispose to acute coronary syndromes
Accelerated atherosclerosis and plaque rupture
ADT (GnRH agonists), ICI, nilotinib,
ponatinib, radiation therapy, VEGFi
Vasospasm
Bleomycin, ﬂuoropyrimidines, taxanes,
VEGFi, vinca alkaloids
Coronary thrombosis
Alkylating agents (cisplatin,
cyclophosphamide), erlotinib, ICI, IMiD
(lenalidomide, thalidomide), monoclonal antibodies (VEGFi, anti-CD20), nilotinib,
platinum chemotherapy, PI, ponatinib,
VEGFi.
© ESC 2022
ADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone; ICI,
immune checkpoint inhibitors; IMiD, immunomodulatory drugs; PI, proteasome inhibitors; VEGFi, vascular endothelial growth factor inhibitors.
ESC Guidelines
4291


<!-- PAGE 64 -->

### Page 64

(Table 7). Echocardiography improves the diagnostic precision in patients with atypical symptoms and assesses for other cardiac causes of chest pain.
Management of ACS in patients with cancer can be challenging because of frailty, increased bleeding risk, thrombocytopaenia, increased thrombotic risk, and the possible need for future surgery/interventions.482 Cancer treatment should be temporarily interrupted, and an urgent multidisciplinary approach5 is indicated to plan an individualized guideline-based management, taking into account cancer status,
prognosis, and the patient’s preferences regarding invasive management. As in patients without cancer, admission to a monitored unit and initiation of appropriate anti-ischaemic and antithrombotic treatment are indicated, in the absence of contraindications.
A large retrospective propensity score-matching analysis found that percutaneous coronary intervention (PCI), despite its lower use, was strongly associated with lower adjusted
MACE
and all-cause mortality in patients with cancer
(Hodgkin and non-Hodgkin lymphomas and breast, lung, colon,
and prostate cancers).483 Therefore, immediate coronary angiography and PCI are recommended in patients with cancer and ACS if cancer prognosis is ≥6 months or if they have acute complications of ACS (cardiogenic shock, pulmonary oedema,
ventricular tachyarrhythmias), where PCI offers palliation of symptoms.483
When stenting is indicated,
third-generation drug-eluting stents are preferred because of the lower risk of in-stent thrombosis. Balloon angioplasty is associated with worse outcome474 and should only be used in case of severe thrombocytopaenia or need for urgent surgery. Fractional
ﬂow reserve or instantaneous free wave ratio are advised by experts484 to avoid unnecessary interventions while intravascular ultrasound and optical coherence tomography can be used to ensure optimal stent apposition and expansion, to avoid thrombotic complications.485
Retrospective data have demonstrated a lower use of invasive management in patients with cancer with ST-segment elevation MI
(STEMI), with a better outcome for invasively treated patients.475,480,483 PCI has not demonstrated a mortality beneﬁt in patients with advanced cancer and NSTE-ACS compared with optimal medical therapy.479 Therefore, a non-invasive approach can be attempted in low-risk (without signs or symptoms of ongoing ischaemia or haemodynamic instability) NSTE-ACS patients with poor cancer prognosis (,6 months).
Due to a potentially higher bleeding risk (especially in patients with active GI cancer),477 the preferred antithrombotic strategy after drug-eluting stent consists of DAPT with aspirin and clopidogrel instead of newer P2Y12 antagonists. The duration of DAPT should be kept as short as possible (1–3 months).458 In patients with need for therapeutic anticoagulation and antiplatelet therapy, a NOAC and single oral antiplatelet (preferably clopidogrel) is the default strategy after a short period of triple antithrombotic therapy (up to 1 week in hospital).458 Coronary artery bypass graft (CABG) surgery can be considered in patients with extensive CAD who are not amenable with PCI, after MDT discussion and where cancer prognosis is
.12 months.
Thrombocytopaenia (platelet count , 100 000/µL) is present in about 10% of patients with cancer and may complicate ACS management. Based on a small series, coronary angiography can be safely performed in these patients when preventative measures to avoid bleeding are taken: platelet transfusion before catheterization (for platelets ,20 000/µL), radial access, careful haemostasis, and the use of a lower heparin dose (30–50 U/kg).486 Antiplatelets should not be withheld unless platelet count is ,10 000/µL for aspirin or
,30 000/µL for clopidogrel. For PCI and CABG, experts advise minimum platelet counts of 30 000/µL and 50 000/µL, respectively.484
In case of MI with non-obstructive coronary arteries, CMR may be considered to detect other causes of myocardial injury, especially myocarditis and TTS.
When acute ischaemia is provoked by cancer therapy, alternative cancer therapies should be considered after a MDT discussion. In the case of coronary vasospasm secondary to ﬂuoropyrimidines, and in the absence of an alternative therapy, a rechallenge, although controversial, can be considered in a monitored unit after exclusion of severe CAD (CT or coronary angiography) and after initiation of prophylactic therapy with long-acting nitrates and calcium channel blockers (CCB).487–489
Following ACS, a review of the cancer medications is recommended, and any cancer drug associated with thrombosis and MI
should be stopped. Restarting cancer drugs associated with acute thrombosis and MI after ACS (Table 7) should occur only after a
MDT to explore other cancer therapies, with appropriate patient education and consent. Cancer therapies not associated with MI
can be restarted once revascularization, where indicated, has been completed and the patient is stabilized on ACS medical therapy without complications.
Recommendation Table 28 — Recommendations for the management of acute coronary syndromes in patients receiving anticancer treatment
Recommendations
Classa
Levelb
An invasive strategy is recommended in patients with cancer presenting with STEMI or high-risk
NSTE-ACS with life expectancy ≥6
months.475,479,483
I
B
A conservative non-invasive strategy should be considered in patients with poor cancer prognosisc (with life expectancy ,6 months) and/
or very high bleeding risk presenting with STEMI
or NSTE-ACS.479
IIa
C
A temporary interruption of cancer therapy is recommended in patients where the cancer therapy is suspected as a contributing cause.d,10,490
I
C
A short DAPT strategy should be considered in patients with cancer with very high bleeding risk treated with PCI for an ACS.e
IIa
C
Continued


<!-- PAGE 65 -->

### Page 65

6.2.2. Chronic coronary syndromes
Several cancer treatments are associated with an increased risk of stable angina and chronic coronary syndromes (CCS).491 5-FU and capecitabine can precipitate effort angina in some cases.4,482,492
Platinum-containing chemotherapy-induced ischaemia usually occurs after one of the ﬁrst three cycles and in patients with underlying
CAD.493 The incidence of cardiac ischaemia is 1–5% with antimicrotubule agents, 2–3% with small-molecule VEGF-TKI, and 0.6–1.5%
with VEGFi monoclonal antibody therapies.492 Nilotinib, ponatinib,494 and ICI335 also accelerate atherosclerosis, which can lead to stable angina.
Patients receiving cancer therapy who present with new stable angina should have careful clinical evaluation, with aggressive CVRF
modiﬁcation and an initial medical management of their symptoms.484 The diagnosis and management of CAD should follow the
The management of CCS is similar in patients with and without cancer, in accordance with guideline recommendations.100
However, in the setting of CCS, decisions regarding coronary revascularization should be undertaken by a MDT that includes cardio-oncology, intervention, and oncology specialists.5 PCI in patients with cancer is associated with an increased risk of bleeding, 90-day readmissions for acute MI, in-hospital and longterm mortality, and the need for repeat revascularization, with the magnitude of risk depending on both cancer type and stage.495,496 The excess bleeding risk should be mitigated by keeping the duration of DAPT as short as possible.497,498 The risk is higher in patients with a cancer diagnosis within the preceding year.477
6.3. Valvular heart disease
New or worsening VHD in patients with cancer may be related to coexisting conditions, including CTRCD, ACS, PH, endocarditis,
cardiac tumours, and mechanical prosthetic valve thrombosis.499,500
Pre-existing severe VHD is associated with an increased risk of
CTRCD,12,501–503 and may also pose a risk for cancer surgery outcomes. In patients with mechanical prosthetic valves, the risk of thrombosis vs. bleeding should be carefully balanced during chemotherapy treatment. In patients with severe VHD diagnosed at baseline assessment, a MDT is required before cancer therapy to decide the best treatment option. Cardiac surgery is frequently challenging in patients with cancer because of comorbidities, frailty, mediastinal ﬁbrosis due to prior RT, impaired wound healing, and the need for urgent oncology treatment (surgery, chemotherapy, targeted cancer therapies that effect wound healing). Transcatheter aortic valve implantation (TAVI) may be a viable option for patients with cancer with severe aortic stenosis to limit recovery time and delays in starting cancer treatment.504–506
Patients with cancer suspected of new or worsening VHD, such as dyspnoea or a new cardiac murmur, or those with fever and positive blood cultures, should be screened for endocarditis and managed according to the recommendations from the 2021 ESC/European
Association for Cardio-Thoracic Surgery (EACTS) Guidelines for the management of VHD,507 while considering the cancer-related prognosis. If valve surgery or percutaneous valve treatment is indicated in a patient receiving cancer treatment, then a MDT is recommended regarding type of valve treatment and periprocedural management of cancer treatments.
In patients with cancer, thrombocytopaenia,
and ACS, aspirin is not recommended if platelets
,10 000/µL.
III
C
In patients with cancer, thrombocytopaenia, and
ACS, clopidogrel is not recommended if platelets
,30 000/µL and prasugrel or ticagrelor are not recommended if platelets ,50 000/µL.
III
C
Ticagrelor or prasugrel may be considered in patients with cancer with low bleeding risk and excessive thrombotic risk who are treated with
PCI for ACS.
IIb
C
© ESC 2022
ACS, acute coronary syndromes; CrCl, creatinine clearance; CV, cardiovascular; DAPT,
dual antiplatelet therapy;
GI,
gastrointestinal;
GU,
genitourinary;
NSTE-ACS,
non-ST-segment elevation acute coronary syndromes; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; ULN, upper limit of normal.
aClass of recommendation.
bLevel of evidence.
cRelated to advanced cancer stage and/or severe irreversible non-CV comorbidities.
dAnticancer therapies associated with high risk of ACS (very common [.10%]):
capecitabine, paclitaxel, cisplatin, carﬁlzomib, bevacizumab, ramucirumab, aﬂibercept,
axitinib, sorafenib, pazopanib, cabozantinib, lenvatinib, ponatinib, erlotinib.
eHigh risk of GI or GU bleeding, signiﬁcant drug–drug interactions, severe renal dysfunction (CrCl , 30 mL/min), signiﬁcant liver disease (alanine aminotransferase/
aspartate aminotransferase .2 × ULN), or signiﬁcant thrombocytopaenia (platelet count , 50 000/µL).
Recommendation Table 29 — Recommendation for the management of chronic coronary syndromes in patients receiving anticancer treatment
Recommendation
Classa
Levelb
Individualized duration of DAPT is recommended in patients with cancer with CCS, following revascularization, based upon thrombotic/
ischaemic and bleeding risk, type and stage of cancer, and current cancer treatment.100,498
I
C
© ESC 2022
CCS, chronic coronary syndromes; DAPT, dual antiplatelet therapy.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 30 — Recommendations for the management of valvular heart disease in patients receiving anticancer treatment
Recommendations
Classa
Levelb
In patients with cancer and pre-existing severe
VHD, management according to the 2021 ESC/
EACTS Guidelines for the management of VHD is recommended, taking into consideration cancer prognosis and patient preferences.507
I
C
Continued
ESC Guidelines
4293


<!-- PAGE 66 -->

### Page 66

6.4. Cardiac arrhythmias
6.4.1. Atrial ﬁbrillation
AF may occur in patients with cancer in different settings: it may be a marker of cancer type or occult cancer, or it may develop in patients undergoing surgery, chemotherapy, or RT.508,509 All types of cancer show an increased risk of AF compared with the control group, but the risk of AF depends on the cancer type and stage.510,511 AF during a cancer treatment may be caused by a speciﬁc therapy or interaction with a pre-existing substrate in older patients with cancer.
During cancer therapy AF may occur with a frequency ranging from 2% to 16%, according to a variety of factors,4,490,508,512–514
and may present either as ﬁrst-diagnosed AF or as recurrence of paroxysmal AF. The risk of developing AF is greater in patients older than 65 years and/or with pre-existing CVD.4,509,512,515 Cancer surgery is associated with a variable rate of AF occurrence, with the highest incidence reported for lung surgery, ranging from 6% to
32%, but with occurrence also in cases of non-thoracic surgery
(e.g. 4–5% after colectomy).509
Many anticancer drugs have been associated with an increased risk of AF both in terms of incident and recurrent AF (Supplementary data, Table S18).251 AF may occur shortly after treatment516 or weeks or months after starting treatment.517,518 The pathophysiology of AF associated with cancer is complex and has been extensively reviewed elsewhere (Figure 30).509
In patients with cancer, the occurrence of AF is associated with a two-fold higher risk of systemic thromboembolism/stroke and a sixfold increase in the risk of HF.4,509,512 The coexistence of cancer increases the risk of all-cause mortality, major bleeding, and intracranial haemorrhage in patients with AF. The association between cancer and ischaemic stroke differs between cancer types, and in some types, the risk of bleeding seems to exceed the thromboembolic risk.519 The management of AF in patients with cancer should follow the 2020 ESC Guidelines for the diagnosis and management of atrial
ﬁbrillation273 and the ‘ABC pathway’ (Atrial ﬁbrillation Better Care)
approach should be applied (A: Anticoagulation to avoid stroke/systemic embolism, B: Better symptom control with rate- and/or rhythm-control drugs and interventions, and C: Comorbidities and
CVRF management, including lifestyle changes).273,520
The acute management of AF in patients with cancer should consider electrical cardioversion in cases of haemodynamic instability,521
while in others, the alternative between rate and rhythm control has several important considerations speciﬁc to patients with cancer.
Drugs for rhythm control may lead to QT-interval prolongation,369
frequently have drug–drug interactions with cancer therapies, or may have a limited efﬁcacy if a cancer therapy is the speciﬁc cause of the AF.508 Among rate-control drugs, beta-blockers are preferred,
especially if the cancer therapies have potential CTRCD risk, whereas diltiazem and verapamil should be avoided where possible due to their drug–drug interactions and negative inotropic effects.508 The possibility of AF ablation should be discussed in selected patients with HF/LVD and/or uncontrolled symptoms, taking into consideration cancer status and prognosis in the context of a MDT
approach.522
A complex issue in patients with cancer with new AF is risk stratiﬁcation for stroke/systemic embolism, which according to guidelines,
should be based on the CHA2DS2-VASc score (Congestive heart failure, Hypertension, Age ≥75 years [2 points], Diabetes mellitus,
Stroke [2 points]—Vascular disease, Age 65–74 years, Sex category
[female]).273,523,524 The CHA2DS2-VASc score has not been extensively validated in patients with cancer.525 In a large cohort of patients with AF, the predictive value of the CHA2DS2-VASc score was lower in patients with cancer than in those without, but a progressive increase in the risk of ischaemic stroke according to the
CHA2DS2-VASc score was also found in AF patients with cancer
(from 0.9% per year to 8.9% per year).519 However, the scope of this score is not to identify high-risk patients, but rather to identify low-risk individuals in whom anticoagulation can be avoided. A study based on the Danish healthcare system data set found that
CHA2DS2-VASc scores of 0 and 1 in patients with recent cancer were linked with higher risk of stroke/thromboembolism at 2 years than in patients without recent cancer.526 This concept should be considered in deﬁning the risk/beneﬁt ratio of anticoagulation in individual patients with cancer. Therefore, the decision for anticoagulation in patients with an active malignancy should take into account the enhanced thrombotic and/or bleeding risk and other risk prediction scores used for general AF populations.509 For bleeding risk assessment, the HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, Bleeding Labile international normalized ratio,
Elderly, Drugs or alcohol) score may be considered. A proposed approach to anticoagulation therapy in cancer, based on the acronym T
(thrombotic risk), B (bleeding risk), I (interactions among drugs), P
(patient access and preferences), is outlined in Figure 31.519,527
Long-term anticoagulation is recommended in adult patients with
CHA2DS2-VASc score ≥2 in men or ≥3 in women and must be considered also when the score is 1 in men and 2 in women.273 The clinical pattern of AF (i.e. ﬁrst detected, paroxysmal, persistent,
long-standing persistent, permanent, post-operative) should not inﬂuence the indication of thromboprophylaxis.273 The same approach can be proposed for patients with cancer and AF, also considering that the CHA2DS2-VASc score likely underestimates their thromboembolic risk.530 In the speciﬁc setting of cancer, decision-making on long-term oral anticoagulation should also consider the cancerrelated type, stage, prognosis and the potentially changing thromboembolic or bleeding risk.508,509 The use of vitamin K antagonists
(VKA) in cancer is limited by their drawbacks in this setting; however,
they remain the only indicated anticoagulants in patients with moderate to severe mitral stenosis or a mechanical prosthetic valve.
LMWH constitute a viable short-term anticoagulation option, particularly in hospitalized patients with a recent cancer diagnosis, advanced cancer disease, or during some cancer treatments (e.g.
In patients with cancer developing new VHD
during cancer therapy, management according to the 2021 ESC/EACTS Guidelines for the management of VHD507 is recommended, taking into consideration cancer prognosis and patient comorbidities.
I
C
© ESC 2022
EACTS, European Association for Cardio-Thoracic Surgery; ESC, European Society of
Cardiology; VHD, valvular heart disease.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 67 -->

### Page 67

patients receiving myelosuppressive chemotherapy or with recent active bleeding). However, LMWH efﬁcacy for stroke or systemic embolism prevention in AF has not been established and their use is only based on their proven efﬁcacy and safety in VTE. The use of a NOAC for AF has not been evaluated in a dedicated
RCT in patients with cancer. However, secondary analyses of seminal NOAC trials using direct factor Xa inhibitors (ROCKET AF
[Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with
Vitamin
K
Antagonism for
Prevention of
Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE
[Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation], ENGAGE AF-TIMI 48 [Effective
Anticoagulation with Factor Xa Next Generation in Atrial
Fibrillation–Thrombolysis in Myocardial Infarction 48]) and observational data suggest better safety and at least similar effectiveness of the NOAC when compared with VKA in patients with AF and active cancer.531–538 NOAC use in cancer is limited by drug–drug interactions,508 severe renal dysfunction, increased risk of bleeding in patients with unoperated or residual GI or genitourinary (GU)
malignancies, or impaired GI absorption.
Left atrial appendage (LAA) occluder devices are used in very selected patients with cancer in clinical practice. The potential
Pathophysiology of AF associated with cancer
AF
in cancer
Ageing
CV and metabolic comorbiditiesb
Anticancer treatmentsa
Cancer invasion
Cancer surgery
Inflammation
Hypoxia
ANS imbalance
Paraneoplastic manifestations
Figure 30 Pathophysiology of atrial ﬁbrillation associated with cancer. AF, atrial ﬁbrillation; ANS, autonomic nervous system; CV, cardiovascular; DM,
diabetes mellitus; HF, heart failure; IHD, ischaemic heart disease; VHD, valvular heart disease. aSupplementary data, Table S18. bObesity, hypertension,
DM, CVDs (HF, VHD, IHD, cardiomyopathies, cardiac amyloidosis), thyroid diseases, obstructive sleep apnoea, chronic obstructive pulmonary disease,
chronic kidney disease, autonomic dysfunction, alcohol consumption, genetic predisposition.
ESC Guidelines
4295


<!-- PAGE 68 -->

### Page 68

Thrombocytopaenia
GI/GU cancer, GI comorbidities, or GI toxicity
Recent or evolving intracranial lesions
Active bleeding or recent major bleeding
Severe renal dysfunction (eGFR <30 mL/min/1.73 m 2)
Bleeding risk scores (e.g., HAS-BLED)
Assess Bleeding risk:
Cancer-related risk (cancer type and stage, cancer treatment)
CHA2DS2-VASc score for risk stratiﬁcation (Class IIa)
a
Assess Thromboembolic risk:
Anticancer agents
Supportive therapies
Assess drug-drug Interactions (P-glycoprotein, CYP3A4):
Assess Patient preferences and drug availability
T
B
I
P
Thromboembolic and bleeding risk reassessment
(Class I)
Very high bleeding riskb
Type of anticoagulant treatment
LAA oclusionc
(Class IIb)
LMWH
(Class IIa)
Moderate/severe mitral stenosis or mechanical prosthetic valve
Patients suitable for NOACd
N
N
Structured approach to anticoagulation for AF in patients with cancer
No anticoagulation
Y
VKA
(Class IIa)
Y
NOAC
(Class IIa)
Y
Long-term anticoagulation according to CHA2DS2-VASc score
≥2 (men) or ≥3 (women) (Class I)
1 (men) or 2 (women) (Class IIa)
 0 (men) or 1 (women) (Class IIb)
N
Figure 31 Structured approach to anticoagulation for atrial ﬁbrillation in patients with cancer. AF, atrial ﬁbrillation; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 years (2 points), Diabetes mellitus, Stroke (2 points)—Vascular disease, Age 65–74 years, Sex category (female); CrCl,
creatinine clearance; eGFR, estimated glomerular ﬁltration rate; GI, gastrointestinal; GU, genitourinary; HAS-BLED, Hypertension, Abnormal renal and liver function, Stroke, Bleeding Labile international normalized ratio, Elderly, Drugs or alcohol; LA, left atrial; LAA, left atrial appendage; LMWH,
low-molecular-weight heparins; N, no; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonists; Y, yes. aIn selected patients, cardiac imaging parameters related to increased thromboembolic risk should be considered (LAA thrombus, severely dilated left atrium, severely impaired
LA strain528). bVery high bleeding risk: active or recent major bleeding (,1 month previously); recent/evolving intracranial lesions; platelet count ,25
000/µL. According to the International Society on Thrombosis and Haemostasis,529 major bleeding is deﬁned as a fall in haemoglobin level ≥2 g/dL and/or transfusion of ≥2 units of red blood cells and/or fatal bleeding and/or bleeding in a critical area (intracranial, intraspinal, intraocular, pericardial,
intra-articular, intramuscular with compartment syndrome, or retroperitoneal). cPercutaneous left appendage closure may be considered in patients with a life expectancy of .1 year who are at high thromboembolic and bleeding risk and in whom anticoagulation is contraindicated. dConditions favouring LMWH: unoperated GI/GU cancer; GI comorbidities or toxicity; severe renal dysfunction (CrCl , 15 mL/min); NOAC major drug–drug interactions, platelet count ,50 000/µL.


<!-- PAGE 69 -->

### Page 69

complications related to the implant—including device-related thrombosis—and the lack of prospective data in the setting of patients with cancer have to be taken into consideration for this option. In a recent retrospective analysis of patients referred to LAA occlusion the risk of in-hospital ischaemic stroke/transient ischaemic attack was higher in patients with active cancer than in those with no cancer or prior history of cancer. The rate of in-hospital composite outcome (in-hospital death, ischaemic stroke/transient ischaemic attack, systemic embolism,
bleeding requiring blood transfusion, pericardial effusion/cardiac tamponade treated with pericardiocentesis or surgically, and removal of embolized device) and 30-day/180-day readmission outcomes were not signiﬁcantly different between the groups.539
The onset of AF may be related to transient factors, such as the peri-operative period or the effect of drugs known to facilitate AF
onset. The traditional assumption that in these cases, AF may occur as an isolated event without recurrence may not be valid as the occurrence of AF may often be related to a pre-existing atrial substrate with vulnerability to AF.540 Post-operative AF has been associated with a four- to ﬁve-fold risk of AF recurrence in the following 5 years,
along with a comparable long-term thromboembolic risk with AF not related to surgery.273,540,541 Anticoagulation therapy yielded a similarly lower risk of thromboembolic events and all-cause death in both groups.541 In the absence of direct evidence, anticoagulation to prevent thromboembolic events should be considered in patients at risk for stroke with AF after cancer surgery considering the anticipated net clinical beneﬁt and informed patient preferences.273
Similarly, in patients with AF apparently related to transient factors
—such as chemotherapy, other drugs, or electrolyte disturbances
—a careful clinical assessment of the propensity to further develop
AF is recommended, with need to revisit the risk/beneﬁt ratio of long-term prescription of anticoagulation after a period of 3 months.
In patients with cancer and newly detected or recurrence of AF, decision making on anticancer treatment requires a cardio-oncology MDT
management,5 taking into account that neither the presence nor the risk of AF constitutes contraindications to anticancer treatment.508,517
Recommendation Table 31 — Recommendations for the management of atrial ﬁbrillation in patients receiving anticancer treatment
Recommendations
Classa
Levelb
CHA2DS2-VASc score should be considered for risk stratiﬁcation for stroke/systemic thromboembolism taking into account that it may underestimate the actual thromboembolic risk.519,526
IIa
C
Long-term anticoagulation is recommended for stroke/systemic thromboembolism prevention in patients with cancer with AF and a
CHA2DS2-VASc score ≥2 (men) or ≥3 (women)
as per the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation.273
I
C
Continued
Long-term anticoagulation should be considered for stroke/systemic thromboembolism prevention in patients with cancer with AF and a
CHA2DS2-VASc score = 1 (men) or = 2
(women) as per the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation.273
IIa
C
Patients with cancer,c AF, and CHA2DS2-VASc score 0 (men) or 1 (women) may have a higher thrombotic risk than patients without cancer and may be considered for therapeutic anticoagulation after consideration of the bleeding risk.526
IIb
C
Thromboembolic and bleeding risk reassessment is recommended during follow-up in patients with cancer with AF.d,273
I
C
NOAC should be considered for stroke prevention in preference to LMWH and VKA
(excluding patients with mechanical heart valves or moderate-to-severe mitral stenosis) in patients without a high bleeding risk, signiﬁcant drug–drug interactions, or severe renal dysfunction.531–537
IIa
B
LMWH should be considered in patients with active cancere and AF who are not suitable for
NOACf.525
IIa
C
LAA occlusion may be considered for stroke prevention in patients with cancer with AF and contraindications for long-term anticoagulation with a life expectancy .12 months.273,539
IIb
C
Antiplatelet therapy or prophylactic LMWH are not recommended for stroke or systemic thromboembolism prevention in AF with cancer.273
III
C
Heart rate control strategy, preferably with beta-blockers, should be considered in patients who develop well-tolerated AF while they are receiving active cancer treatmentg.
IIa
C
© ESC 2022
5-FU, 5-ﬂuorouracil; AF, atrial ﬁbrillation; BMI, body mass index; CHA2DS2-VASc,
Congestive heart failure, Hypertension, Age .75 years (2 points), Diabetes mellitus,
Stroke (2 points)—Vascular disease, Age 65–74 years, Sex category (female); CrCl,
creatinine clearance; eGFR, estimated glomerular ﬁltration rate; EGFR, epidermal growth factor receptor; ESC, European Society of Cardiology; HF, heart failure; LAA,
left atrial appendage; LMWH, low-molecular-weight heparins; LV, left ventricular;
MM, multiple myeloma; NOAC, non-vitamin K antagonist oral anticoagulants; VKA,
vitamin K antagonists.
aClass of recommendation.
bLevel of evidence.
cFactors that may increase thromboembolic risk in patients with cancer including comorbidities (proteinuria . 150 mg/24 h, eGFR, 45 mL/min/1.73 m2, BMI ≥30 kg/m2,
thrombophilia), cancer type (pancreatic, gastric, ovarian, brain, lung, MM), cancer stage
(metastatic disease) anticancer therapies: alkylating agents, aﬂibercept, bevacizumab,
anthracyclines,
capecitabine,
5-FU,
gemcitabine,
methotrexate,
EGFR
inhibitors,
bleomycin, axitinib, lenvatinib, pazopanib, sorafenib, sunitinib, carﬁlzomib, irinotecan,
taxanes, tasonermin, tretinoin.
dStroke and bleeding risk may change during both cancer treatment and the course of the underlying disease; reassessment is important to inform treatment decisions and address potentially modiﬁable bleeding risk factors.
ePatients receiving cancer treatment, patients diagnosed with cancer in the past 6 months,
and patients with progressive or advanced disease.
fHigh bleeding risk, severe renal dysfunction (CrCl, 15 mL/min); NOAC major drug–drug interactions.
gAsymptomatic or mild symptomatic patients without HF signs or symptoms or deterioration of LV function. The optimal heart rate target in AF patients is unclear. A
resting heart rate ,110 bpm (i.e. lenient rate control) should be considered as the initial heart rate target for rate control therapy. A review of rate vs. rhythm strategy should be made at the end of cancer treatment.273
ESC Guidelines
4297


<!-- PAGE 70 -->

### Page 70

6.4.2. Long corrected QT interval and ventricular arrhythmias
VA are not common during cancer, although their incidence increases in patients with advanced cancer and CV comorbidities.49,259,516,542
Mechanisms proposed to explain cancer therapy-induced VA include: (1) direct effects of cancer drugs on the activity/expression of ionic channels that regulate the ventricular action potential,4,369,442,516,542,543 and (2) a permanent arrhythmogenic substrate created by cancer and systemic inﬂammation caused by cancer,
pre-existing
CV
comorbidities,
and/or a
new
CTR-CVT.4,9,259,369,442,516,542,543
Treatment of cancer therapy-induced VA should follow general clinical guidelines.22,442,544 In patients with asymptomatic selfterminating VA, drug discontinuation is not required unless they have additional
CVRF
or persistent
ECG
abnormalities.270
Symptomatic VA require cancer drug dose reduction or discontinuation and patients should be referred to the cardiologist for evaluation and treatment.4,442
Recurrent symptomatic life-threatening VA require urgent intervention.4,270,442,544 The administration of class IA, IC, and III antiarrhythmic drugs is limited by the risk of drug–drug interactions and QTc prolongation. Beta-blockers and class IB drugs are less likely to cause drug interactions or QTc prolongation. Beta-blockers are the preferred choice if the cancer drug is also associated with
CTRCD. Amiodarone is the antiarrhythmic drug of choice in patients with structural heart disease and haemodynamic instability.
Table 8
Risk factors for drug-induced QT prolongation and torsade de pointes
Correctable
Non-correctable
QT-prolonging drugsa
• Antiarrhythmics
• Antibiotics
• Antidepressants
• Antifungals
• Antiemetics
• Antihistamines
• Antipsychotics
• Loop diuretics
• Opioids (methadone)
Bradyarrhythmia
Electrolyte imbalance/
abnormalities
• Hypokalaemia (≤3.5 mEq/L)
• Hypomagnesaemia
(≤1.6 mEq/L)
• Hypocalcaemia (≤8.5 mEq/L)
Inadequate dose adjustment of renal or hepatic cleared
QT-prolonging drugs
Acute myocardial ischaemia
Age . 65 years
Baseline QTc interval prolongationb
Family history of sudden death
(congenital LQTS or genetic polymorphism)
Female sex
Impaired renal function (for renally excreted drugs)
Liver disease (for hepatically excreted drugs)
Personal history of syncope or drug-induced TdP
Pre-existing CVD (CAD, HF, LV
hypertrophy)
© ESC 2022
CAD, coronary artery disease; CVD, cardiovascular disease; HF, heart failure; LQTS,
long QT syndrome; LV, left ventricular; QTc, corrected QT interval; TdP, torsade de pointes.
aSee https://www.crediblemeds.org.
bQTc using Fridericia correction (QTcF = QT/3√RR) is recommended in patients with cancer.
Table 9
Classiﬁcation of corrected QT interval prolongation induced by cancer drug therapy
Classiﬁcation
Drugs
High risk: QTcF prolongation ≥10 ms and risk of TdP
• Aclarubicin
• Arsenic trioxide
• Glasdegib
• Nilotinib
• Oxaliplatin
• Pazopanib
• Ribociclib
• Sunitinib
• Toremifene
• Vandetanib
Moderate risk: QTcF prolongation ≥10 ms and low or no risk of TdP (or uncertain)
• Abarelix
• Belinostat
• Brigantinib
• Carbozantinib
• Ceritinib
• Crizotinib
• Dovitinib
• Entrectinib
• Eribulin
• Gilteritinib
• Ivosidenib
• Lapatinib
• Lenvatinib
• Osimertinib
• Panobinostat
• Rucaparib
• Selpercatinib
• Sorafenib
• Tipiracil/
triﬂuridine
• Vemurafenib
Low risk: QTcF prolongation , 10 msa
• ADT
• Afatinib
• Axitinib
• Binimetinib
• Bortezomib
• Bosutinib
• Carﬁlzomib
• Dabrafenib
• Dasatinib
• Encorafenib
• Midostaurin
• Pertuzumab
• Ponatinib
• Romidepsin
• Quizartinib
• Tamoxifen
• Vorinostat
© ESC 2022
ADT, androgen deprivation therapy; QTcF, corrected QT interval using Fridericia correction; TdP, torsade de pointes.
aADT may prolong the QTc interval (GnRH agonist, GnRH antagonist, bicalutamide,
ﬂutamide, apalutamide, darolutamide, enzalutamide, and abiraterone) (see Figure 21).
Developed from EMA prescribing information,252 FDA prescribing information,253
and AZCERT.547


<!-- PAGE 71 -->

### Page 71

Decisions on the use of antiarrhythmic drugs or device therapy (cardioverter deﬁbrillators, catheter ablation) should consider life expectancy, quality of life, and complication risks.349
Most cancer therapy-induced VA are related to a prolongation of
QTc leading to the development of TdP.259,516,542 Risk factors for
QTc prolongation and TdP are summarized in Table 8.4,22,45,48,516,543
The upper 99% limits of normal for QTc values in the general population are 450 ms for men and 460 ms for women.545
Although there is no threshold of QTc prolongation at which TdP
can occur, a QTc ≥500 ms is associated with a two- to three-fold higher risk for TdP, while TdP rarely occurs when QTc is
,500 ms.442
Although the incidence of
QTc prolongation
≥500 ms and TdP is low during cancer therapy, QTc prolongation to levels that require closer monitoring (QTc ≥480 ms) is more common (Table 9).4,9,22,45,48,49,259,369,516,543,546 Changes in the QT
interval of .60 ms from baseline should not routinely affect treatment decisions if the QTc remains ,500 ms.1 Cardiology consultation is advised in patients with an abnormal baseline QTc interval,
patients treated with drugs that prolong the QT interval, those who develop new cardiac symptoms (syncope or pre-syncope, rapid palpitations or QTc prolongation with new-onset bradycardia, high degree of heart block), and/or those with known inherited arrhythmia
QTcF value
QTcF value
QTcF value
QTcF monitoring according to drugspecific protocol
ECG after any dose increase of QTcprolonging drug
(class I)
If QTcF <500 ms
Continue treatment at same or reduced dose according to drug-specific protocol
(Class I)
Consider alternative treatment
Alternative treatment
(Class I)
(Class I)
(Class I)
QTcF value
Resume treatment at the same or reduced dose according to drug-specific protocol
Consider restarting treatment at reduced dose
(Class IIb)
MDT to discuss alternative cancer treatments
(Class I)
≤480 ms
≤480 ms
≤480 ms
>480 ms
>480 ms and
<500 ms
>480 ms and
<500 ms
>480 ms and
<500 ms
≥500 ms
≥500 ms
≥500 ms
TdP or sustainedVA
Correct baseline risk factors for QTc prolongationb
Avoid/stop concomitant QTc prolonging drugsb
Ensure K+ >4.0 mmol/L, Mg2+ >2.0 mg/dL (>1.10 mmol/L) and normal values of corrected Ca2+
Baseline 12-lead ECG: QTcF
Start therapy
ECG monitoringc
Cardio-oncology evaluation
Correct reversible causesb
Correct reversible causesb
Weekly ECG
monitoring
Drug interruption
Correct reversible causesb
Drug withhold
Correct reversible causesb
QTc monitoring before and duringtreatment withQTc prolonginganticancerdrugsa
Figure 32 Corrected QT interval monitoring before and during treatment with corrected QT interval-prolonging anticancer drugs. Ca2+ , calcium; ECG,
electrocardiogram; K+, potassium; MDT, multidisciplinary team; Mg2+, magnesium; QTc, corrected QT interval; QTcF, corrected QT interval using
Fridericia correction; TdP, Torsade de pointes; VA, ventricular arrhythmias. QT interval using Fridericia correction (QTcF = QT/3√RR) is recommended in patients with cancer. Upper 99% limits of normal for QTc values in the general population are 450 ms for men and 460 ms for women.369 aTable 9.
bTable 8 and https://www.crediblemeds.org. cECG monitoring at baseline, once steady-state anticancer drug levels have been achieved, after each dose modiﬁcation, or any treatment interruption .2 weeks; monthly for the ﬁrst 3 months, and then periodically during treatment depending on patient-speciﬁc risk factors and cancer treatment.
ESC Guidelines
4299


<!-- PAGE 72 -->

### Page 72

disorders.4,45,48,442,544 The challenges for the cardio-oncology teams are to identify patients more susceptible to developing VA, determine whether a VA is directly due to CTR-CVT, individualize the treatment strategy, and optimize clinical monitoring during treatment.
Figure 32 shows the algorithm for the management of QTc prolongation during cancer therapy. In patients with cancer, the
Fridericia formula is recommended and has demonstrated less error than other correction methods such as Bazzett at both high and low heart rates.44 In patients treated with QTc-prolonging drugs, serum electrolytes and other risk factors should be closely monitored and corrected, and concomitant QT-prolonging drugs avoided if possible.4,22,45,369,543 For selected cancer drugs, there are speciﬁc manufacturer recommendations for ECG monitoring during treatment,
dosage adjustments, or discontinuation of therapy in case of QTc prolongation.548
Although there are no recommendations, patients with cancer with QTc prolongation associated with severe bradycardia or sinus pauses may beneﬁt from isoprenaline infusion or temporary pacing. Despite present restrictions, the improved prognosis for many malignancies is increasing the number of patients with cancer who are candidates for an implantable cardioverter deﬁbrillator
(ICD), particularly when life expectancy is .1 year (including patients who experienced resuscitated sudden cardiac death or severe VA from a QTc-prolonging drug with no alternative treatment available).
6.4.3. Bradyarrhythmias
AV conduction disease can be caused by ICI in the presence or absence of myocarditis. If the PR interval increases (new ﬁrst-degree heart block) in patients treated with ICI, serial ECG monitoring is recommended, and if PR prolongation to .300 ms develops, the patient should be hospitalized under close ECG monitoring and i.v.
methylprednisolone is recommended.550
IMiD (thalidomide, pomalidomide)285 and ALK inhibitors (crizotinib, alectinib, brigatinib, or ceritinib)551 are associated with sinus bradycardia. Holter ECG monitoring is recommended to exclude signiﬁcant sinus pauses in symptomatic patients. In asymptomatic patients with normal LV function, sinus bradycardia is usually well tolerated and treatment can continue. If patients are symptomatic
(syncope, pre-syncope of reduced exercise tolerance from chronotropic incompetence) then a trial of cancer drug withdrawal to conﬁrm causation with the symptoms is recommended. A MDT
discussion is needed to analyse risks/beneﬁts of alternative cancer therapies vs. restarting the culprit cancer therapy at a lower dose with heart rate monitoring. In selected cases, when no cancer treatment alternative is available, pacing is indicated.
6.5. Arterial hypertension
Arterial hypertension in patients with cancer may be caused by their cancer treatments (e.g. VEGFi, second- and third-generation
BCR-ABL TKI, brigatinib, ibrutinib, ﬂuoropyrimidines, cisplatin, abiraterone, bicalutamide, enzalutamide), non-cancer drugs (e.g. corticosteroids, non-steroidal anti-inﬂammatory drugs), and other factors including stress, pain, excessive alcohol consumption, renal impairment, untreated sleep apnoea, obesity, and reduced exercise.552 In all patients with cancer with new hypertension assessment,
correction of these other factors is important before considering interruption of a cancer treatment.
Untreated hypertension344 is a conﬁrmed risk factor of HF during treatment with anthracyclines,553 ibrutinib,264 and VEGFi.554 Given that many of the cancer therapies that cause hypertension also cause
Recommendation Table 32 — Recommendations for the management of long corrected QT interval and ventricular arrhythmias in patients receiving anticancer treatment
Recommendations
Classa
Levelb
How to manage QTc prolongation in patients with cancer
Discontinuation of QTc-prolonging cancer therapy is recommended in patients who develop
TdP or sustained ventricular tachyarrhythmias during treatment.549
I
C
Temporary interruption of QTc-prolonging cancer therapy is recommended in patients who develop asymptomatic QTcF ≥500 ms and an
ECG should be repeated every 24 h until resolution of the QTcF prolongation.549
I
C
Immediate withdrawal of any offending drug and correction of electrolyte abnormalities and other risk factorsc is recommended in patients with cancer who develop QTcF ≥500 ms.349,442,546
I
C
Weekly ECG monitoring is recommended in asymptomatic patients with cancer with QTcF
480–500 ms who are treated with a
QTc-prolonging cancer therapy.349,442,546
I
C
A 12-lead ECG is recommended after any dose increase of QTc-prolonging cancer therapy.270,442,544
I
C
Continued
Restarting QTc-prolonging cancer therapy
A multidisciplinary discussion is recommended before restarting QTc-prolonging drugs in patients who have developed signiﬁcant QTcF
prolongation, to discuss alternative cancer treatments.4,22,259,349,442,546
I
C
In patients who experienced signiﬁcant QTcF
prolongation, restarting the culprit
QTc-prolonging cancer treatment may be considered, ideally at a reduced dose according to each drug recommendation.45,259,349,442,546,549
IIb
C
Weekly ECG monitoring during the ﬁrst 4–6
weeks and then monthly thereafter is recommended in patients with cancer after restarting QTc-prolonging cancer therapy.549
I
C
© ESC 2022
ECG, electrocardiogram; QTc, corrected QT interval; QTcF, corrected QT interval using Fridericia correction; TdP, torsade de pointes.
aClass of recommendation.
bLevel of evidence.
cSee https://www.crediblemeds.org and Table 8.


<!-- PAGE 73 -->

### Page 73

CTRCD, treatment of hypertension with ACE-I or ARB as ﬁrst-line therapy is recommended to reduce the risk of
CTRCD.
Combination therapy with an ACE-I or ARB and a dihydropyridine
CCB is recommended in patients with cancer with systolic BP ≥
160 mmHg and diastolic BP ≥100 mmHg due to the more rapid onset of BP control with the combination compared with ACE-I/ARB
monotherapy (Figures 33 and 34).
If severe hypertension is diagnosed (systolic BP ≥180 mmHg or diastolic BP ≥110 mmHg), the competing cancer and CV risks should be evaluated by a MDT, and any cancer therapy associated with hypertension should be deferred or temporarily withheld until the BP is controlled to values ,160 mmHg (systolic BP) and
,100 mmHg (diastolic BP). Culprit cancer therapy can be restarted once BP is controlled, with consideration for dose reduction.
In patients with resistant cancer therapy-related hypertension,
spironolactone, oral or transdermal nitrates, and/or hydralazine should be considered. In patients with cancer with evidence of high sympathetic tone, stress, and/or pain, beta-blockers including carvedilol or nebivolol should be considered. Diuretics, preferably spironolactone, may be considered in patients with cancer with hypertension and evidence of increased ﬂuid retention, with monitoring of BP, electrolytes, and renal function.
The decisions to initiate BP treatment and BP targets during the management of cancer-drug induced hypertension depend upon the context of the cancer and prognosis (Figure 34). CS should be treated according to the
2018
ESC/European
Society of
Hypertension (ESH) Guidelines for the management of arterial hypertension.138
Recommended threshold for asymptomatic hypertension treatment in differentclinicalscenarios
CS
Home
BP mmHg
Curable cancer during treatment
Metastatic cancer
Prognosis >3 years
Metastatic cancer
Prognosis 1–3 years
Metastatic cancer
Prognosis <1 year
160+
Treat
Treat
Treat
Treat
Treat
140–159
Treat
Treat
Treat
Consider treatment
May treat
135–139
Treat
May treat
Consider treatment
May treat
None
130–134
May treat
None
None
None
None
<130
None
None
None
None
None
Class 1
Class 1Ia
Class 1Ib
Figure 33 Recommended threshold for asymptomatic hypertension treatment in different clinical scenarios. BP, blood pressure; CS, cancer survivors.
ESC Guidelines
4301


<!-- PAGE 74 -->

### Page 74

BP target during cancer therapy p
Systolic BP ≥160 mmHg and diastolic BP ≥100 mmHg
Hypertension caused by cancer therapy p
ACE-I or ARB
(Class I)
ACE-I or ARB
(Class I)
Dihydropyridine CCB
p as second-line therapy p
in patients with uncontrolled BP
(Class I)
Dihydropyridine CCB
p
(Class I)
BP target <140 mmHg systolic and
<90 mmHg diastolic
(Class I)
BP target <130 mmHg systolic and <80 mmHg diastolic if well tolerated
(Class IIb)
Beta-blockers k
b
Spironolactone
Oral or transdermal nitrates and/or hydralazine
(Class IIa)
If resistant hypertensiona:
In selected asymptomatic patients with metastatic cancer systolic BP 140–160 mmHg,
and diastolic BP 90–100 mmHg 
(Class IIb)
N
Tr
T eatment of arterial hypertension in patients with cancer
Y
OR
AND
OR
Figure 34 Treatment of arterial hypertension in patients with cancer. AF, atrial ﬁbrillation; ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BP, blood pressure; CCB, calcium channel blockers; HF, heart failure; MI, myocardial infarction; N, no; VEGFi, vascular endothelial growth factor inhibitors; Y, yes. aResistant hypertension is deﬁned as BP being uncontrolled despite treatment with optimal or best-tolerated doses of three or more drugs including a diuretic, and conﬁrmed by ambulatory and home BP monitoring. bConsider beta-blockers (nebivolol or carvedilol are preferred in patients on VEGFi) at any treatment step, when there is a speciﬁc indication for their use, e.g. HF, angina, post-MI, or AF.
Recommendation Table 33 — Recommendations for the management of arterial hypertension in patients receiving anticancer treatment
Recommendations
Classa
Levelb
General
Effective treatment of cancer therapy-induced arterial hypertension to prevent cancer treatment interruption and CV complications is recommended.
I
C
A BP target ,140 mmHg systolic and ,90 mmHg diastolic is recommended during cancer therapy.
I
C
A BP target ,130 mmHg systolic and ,80 mmHg diastolic may be considered during cancer therapy provided that the treatment is well tolerated.
IIb
C
In selected asymptomatic patients with metastatic cancer, a systolic BP 140–160 mmHg and diastolic
BP 90–100 mmHg treatment threshold may be considered provided there is ongoing BP monitoring.
IIb
C
The competing cancer and CV risk evaluation is recommended if the systolic BP is ≥180 mmHg or diastolic BP ≥110 mmHg, and any cancer therapy associated with hypertension should be deferred or temporarily withheld until the BP is controlled to values ,160 mmHg (systolic) and
,100 mmHg (diastolic).
I
C
Continued
Cancer therapy-induced arterial hypertension treatment
ACE-I or ARB are the ﬁrst-line antihypertensive drugsc recommended for BP management in patients with cancer.555–557
I
B
Dihydropyridine CCB are recommended as second-line antihypertensive drugs for patients with cancer with uncontrolled BP.
I
C
Combination therapy with ACE-I or ARB and dihydropyridine CCB is recommended in patients with cancer with systolic BP ≥160 mmHg and diastolic BP ≥100 mmHg.
I
C
Diltiazem and verapamil are not recommended to treat arterial hypertension in patients with cancer due to their drug–drug interactions.d
III
C
© ESC 2022
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
BP, blood pressure; CCB, calcium channel blockers; CV, cardiovascular.
aClass of recommendation.
bLevel of evidence.
cUnless contraindicated.
dIn selected patients with cancer, who are intolerant to multiple other antihypertensive drugs, diltiazem and verapamil may be considered with close monitoring of drug–drug interactions.


<!-- PAGE 75 -->

### Page 75

6.6. Thrombosis and thromboembolic events
Thromboembolic events that develop during cancer and its treatment encompass both VTE and arterial thromboembolism (ATE)
and are collectively referred to as cancer-associated thrombosis.
Cancer-associated thrombosis is determined by the prothrombotic milieu induced by cancer, the prothrombotic properties of certain anticancer and adjunctive therapies, and patient-related risk factors,
including demographics,
genetic predisposition,
and comorbidities.513
6.6.1. Venous thromboembolism
VTE, including deep vein thrombosis (DVT) and PE, is the second-leading cause of death in patients with malignancies.558
Cancer confers a ﬁve-fold higher risk of VTE and cancer-associated
VTE represents 30% of all VTE cases.559,560 The risk of VTE varies in the course of cancer, with the highest risk occurring in the period following cancer diagnosis, during hospitalization and chemotherapy,
and upon development of metastatic disease.561,562 Unprovoked
VTE may be the ﬁrst clinical sign of a malignancy, followed by a 5%
incidence of cancer diagnosis during the subsequent 12 months.563
The risk factors for VTE in cancer are summarized in
Figure 35.564,565 Patients with symptoms or signs suggestive of
VTE, such as unilateral lower limb oedema or unexplained dyspnoea,
should be screened with lower-extremity venous ultrasonography or contrast-enhanced CT for DVT and CT pulmonary angiography for PE, according to the 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism recommendations566
Risk factors for VTE in patients with cancer
Patient-related factors
Ageing
Comorbiditiesa
Sex (female)
Hereditary coagulation defectsb 
Performance status 
Prior VTE history
Treatment-related factors
Cancer therapyc 
Central venous catheters
Hospitalization 
Major surgery
Cancer-related factors
Cancer type
Genetic characteristics (JAK2 or K-ras mutations)
Histology (adenocarcinoma)
Initial period after diagnosis 
Primary site (pancreas, stomach, ovaries,
brain, lung, myeloma)
Stage (advanced, metastatic)
Figure 35 Risk factors for venous thromboembolism in patients with cancer. ATE, arterial thromboembolism; BMI, body mass index; CrCl, creatinine clearance; IMiD, immunomodulatory drugs; PI, proteasome inhibitors; VTE, venous thromboembolism. aAcute infection, chronic kidney disease (CrCl ,
45 mL/min), pulmonary disease, obesity (BMI ≥30 kg/m2), ATE. bFactor V Leiden, prothrombin gene mutation. cChemotherapy (carboplatin, cyclophosphamide, anthracyclines, antimetabolites, irinotecan, taxanes, tasonermin), anti-angiogenic agents (bevacizumab, axitinib, lenvatinib, pazopanib, sorafenib,
sunitinib), IMiD (thalidomide, lenalidomide), PI (carﬁlzomib), hormonal therapy, erythropoiesis-stimulating agents.
ESC Guidelines
4303


<!-- PAGE 76 -->

### Page 76

and the second consensus document on diagnosis and management of acute deep vein thrombosis.567
6.6.2. Arterial thromboembolism
Cancer carries a two-fold higher risk of ATE, including MI and ischaemic stroke.568 ATE risk is higher in men, with advanced age, and in patients with lung or kidney cancer. Pathologies related to ATE in cancer include ischaemic stroke induced by AF or RT-induced carotid artery disease, embolization by tumour cells or non-bacterial thrombotic endocarditis, disseminated intravascular coagulationrelated peripheral microcirculatory thromboembolism, paradoxical cerebral embolism in the course of VTE, and cerebral sinus thrombosis.569
6.6.3. Intracardiac thrombosis
Intracardiac thrombus in patients with malignancies may result from the prothrombotic properties of cancer and its treatment and the use of central venous catheters. Thrombus is the most common intracardiac mass and it can occur within any cardiac chamber. Right atrial thrombi are often related to a venous catheter where the line has inappropriately advanced into the right atrium.
Intraventricular thrombi usually occur in the setting of CTRCD.
LAA thrombi are most commonly associated with AF, which may also be related to cancer or its therapy.
Patients with systemic embolization should be screened for cardiac origin of thrombus initially with TTE and/or transoesophageal echocardiography.528 CMR is more sensitive and speciﬁc than TTE
Thrombocytopaenia
GI/GU cancer, GI comorbidities, or GI toxicity
Recent or evolving intracranial lesions
Active bleeding or recent major bleeding
Severe renal dysfunction (eGFR <30 mL/min/1.73 m2)
Assess Bleeding risk:
Patient-related factors
Cancer-related factors
Treatment-related factors
Assess Thromboembolic risk:
Anticancer agents
Supportive therapies
Assess drug-drug Interactions (P-glycoprotein, CYP3A4):
Assess Patient preferences
T
B
I
P
Thromboembolic and bleeding risk reassessment
(Class I)
Very high bleeding riska
Conditions favouring
LMWH over NOACb
NOAC or LMWH 
(Class I)
LMWH
(Class I)
No anticoagulation
Patient’s preference
N
N
Structured approach to anticoagulation forVTE in patients with cancer
Y
Y
Figure 36 Structured approach to anticoagulation for venous thromboembolism in patients with active cancer. CrCl, creatinine clearance; eGFR, estimated glomerular ﬁltration rate; GI, gastrointestinal; GU, genitourinary; LMWH, low-molecular-weight heparins; N, no; NOAC, non-vitamin K antagonist oral anticoagulants; VTE, venous thromboembolism; Y, yes. aVery high bleeding risk: active or recent major bleeding (,1 month); recent/
evolving intracranial lesions; platelet count ,25 000/µL. According to the International Society on Thrombosis and Haemostasis,529 major bleeding is deﬁned as: fall in haemoglobin level ≥2 g/dL, transfusion of ≥2 units of red blood cells, fatal bleeding, or bleeding in a critical area (intracranial, intraspinal,
intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal). bConditions favouring LMWH: unoperated GI/GU cancer; GI comorbidities or toxicity; severe renal dysfunction (CrCl , 15 mL/min); NOAC major drug–drug interactions, platelet count , 50 000/µL.


<!-- PAGE 77 -->

### Page 77

for detecting intracardiac thrombi and late gadolinium enhancement
(LGE) CMR with the long inversion time technique is currently considered the gold standard.570,571
6.6.4. Anticoagulation therapy
Patients with cancer frequently have both an increased thrombotic risk and an increased bleeding risk associated with certain cancer locations
(e.g. GI, intracranial), thrombocytopaenia, and other coagulation defects (secondary to bone marrow invasion, cancer therapies, or cancer itself) and associated comorbidities (e.g. renal or hepatic dysfunction,
GI toxicities). Several anticancer agents are further characterized by drug–drug interactions with anticoagulants. All these factors may render anticoagulation in cancer quite challenging. A proposed approach to anticoagulation therapy in cancer-associated venous thrombosis,
based on the TBIP acronym (Thromboembolic risk, Bleeding risk,
drug–drug Interactions, Patient preferences), is outlined in Figure 36.527
6.6.4.1. Treatment and secondary prevention of venous thromboembolism
Several large RCTs and meta-analyses have shown that LMWH decrease the risk of recurrent VTE by 40% compared to VKA, with a similar risk of major bleeding.572–576 However, VKA are characterized by an unpredictable anticoagulation effect and low time in therapeutic range in patients with malignancies due to multiple drug–drug interactions, GI toxicity, malnutrition, and liver dysfunction.577
NOAC have been assessed as potential alternatives to LMWH for cancer-associated VTE, based on RCTs that compared edoxaban, rivaroxaban or apixaban to dalteparin.578–583 The totality of evidence derived by these trials and subsequent meta-analyses584–586 shows that
NOAC are non-inferior to dalteparin in reducing the risk of VTE recurrence. The risk of major bleeding was similar, although NOAC were associated with an increased risk of clinically relevant non-major bleeding,
particularly in patients with luminal GI and GU malignancies.586 As a result, edoxaban, rivaroxaban, and apixaban are recommended for the treatment of VTE (DVT and PE) in patients with cancer without any of the following bleeding risk factors: unoperated GI or GU malignancies, history of recent bleeding or within 7 days of major surgery, signiﬁcant thrombocytopaenia (platelet count, 50000/µL), severe renal dysfunction (creatinine clearance (CrCl, 15 mL/min), or GI comorbidities.582,586 In addition, drug–drug interactions between NOAC, cancer therapies, and other concomitant treatments should be checked.587
There are also concerns about NOAC in patients with GI toxicity such as vomiting or those having undergone gastrectomy or extensive intestine resection, as well as those with severely impaired renal function. Shared decision-making considering informed patient preferences should guide the choice of anticoagulation.
Incidentally encountered proximal DVT or PE should be treated in the same manner as symptomatic VTE as they bear similar rates of recurrence and mortality.588
The minimal duration of anticoagulation is 6 months and extended anticoagulation is suggested in the presence of active malignancy,
metastatic disease, or chemotherapy use. Cohort studies have shown that extended LMWH therapy beyond 6 and up to 12 months is safe in cancer-associated VTE.589,590 However, patients with cancer are also at high risk of bleeding during anticoagulant treatment and a periodic assessment of the risk/beneﬁt ratio should performed.
In VTE relapse under anticoagulation, the patient should be investigated for treatment adherence, cancer progression or relapse, while a different anticoagulation strategy should be endorsed (e.g. replacement of NOAC with LMWH). The management of patients with VTE and a platelet count ,25000/µL should be individualized by a MDT.299
The duration of anticoagulation in patients with catheterassociated thrombosis depends upon whether the catheter is removed or remains in situ. If removed, then anticoagulation should continue for a minimum of 3 months and until follow-up cardiac imaging conﬁrms resolution of the thrombus. If the catheter remains in situ, then long-term therapeutic anticoagulation should continue.
6.6.4.2. Primary prevention of venous thromboembolism
Patients undergoing surgery and those who are hospitalized or in prolonged bed rest require thromboprophylaxis with low-dose anticoagulation.298,299,592–594 The ENOXACAN (Enoxaparin and
Recommendation Table 34 — Recommendations for the management of venous thromboembolism in patients receiving anticancer treatment
Recommendations
Classa
Levelb
Apixaban, edoxaban, or rivaroxabanc are recommended for the treatment of symptomatic or incidental VTE in patients with cancer without contraindications.d,578–581,584,585
I
A
LMWH are recommended for the treatment of symptomatic or incidental VTE in patients with cancer with platelet count .50 000/µL.298,299,578–
581,584,585
I
A
In patients with cancer with platelet counts of
25 000–50 000/µL, anticoagulation with half-dose
LMWH may be considered after a multidisciplinary discussion.591
IIb
C
Prolongation of anticoagulation therapy beyond 6
months should be considered in selected patients with active cancere including metastatic disease.589,590
IIa
A
Catheter-associated VTE
Duration of anticoagulation in patients with cancer with a catheter-associated VTE is recommended for a minimum of 3 months and continuing longer if the catheter remains in situ.
I
C
© ESC 2022
CrCl,
creatinine clearance;
GI,
gastrointestinal;
GU,
genitourinary;
LMWH,
low-molecular-weight heparins;
ULN,
upper limit of normal;
VTE,
venous thromboembolism.
aClass of recommendation.
bLevel of evidence.
cDrugs are listed in alphabetical order dHigh risk of GI or GU bleeding, GI absorption concerns, signiﬁcant drug–drug interactions, severe renal dysfunction (CrCl , 15 mL/min), signiﬁcant liver disease
(alanine aminotransferase/aspartate aminotransferase . 2 × ULN),
or signiﬁcant thrombocytopaenia (platelet count , 50 000/µL). In addition, patients with primary brain tumours or brain metastases and acute leukaemia were excluded from the seminal apixaban trial.580
ePatients receiving cancer treatment, patients diagnosed with cancer in the past 6
months, and patients with progressive or advanced disease.
ESC Guidelines
4305


<!-- PAGE 78 -->

### Page 78

Cancer) II study showed favourable outcomes with LMWH as primary thromboprophylaxis for 4 weeks after major abdominal or pelvic cancer surgery.595 For ambulatory patients, VTE risk should be individually determined and proposed scores such as the Khorana or the COMPASS-CAT (prospective COmparison of Methods for thromboembolic risk assessment with clinical Perceptions and
AwareneSS in real-life patients—Cancer Associated Thrombosis)
score may be useful.596,597 Further trials and a meta-analysis have shown that LMWH signiﬁcantly reduced the incidence of symptomatic
VTE in ambulatory patients with cancer receiving chemotherapy with acceptable safety.598–600
Two randomized,
placebo-controlled,
double-blind clinical trials have assessed the role of NOAC in primary prevention of VTE in high-risk ambulatory patients receiving systemic cancer therapy (Khorana score ≥2).601,602 Over a follow-up period of
180 days, apixaban (2.5 mg twice a day)601 therapy resulted in a signiﬁcantly lower rate of VTE, although the rate of major bleeding episodes was higher than with placebo. Rivaroxaban (10 mg once a day)602
treatment resulted in a non-signiﬁcantly lower incidence of VTE or death due to VTE with low bleeding risk (no signiﬁcant differences with placebo). Further data on the use of NOAC in this setting are warranted. Consideration of such therapy should be accompanied by a discussion with the patient about the relative beneﬁts and harms,
cancer prognosis, drug cost, and duration of prophylaxis.
6.7. Bleeding complications
Bleeding complications are more common in patients with cancer than in patients without cancer. This may be directly related to the tumour itself,
or indirectly related to chemotherapyor
RT-induced weakening of mucosal barriers.530
6.7.1. High-risk patients
GI and GU cancers are associated with a signiﬁcant excess bleeding risk compared with other solid tumours.603 Thrombocytopaenia and platelet dysfunction due to haematological malignancies or bone marrow suppression can exacerbate bleeding. Other bleeding risk factors include advancing age, renal or hepatic impairment, metastatic disease, low body mass index, and treatment with ibrutinib, VEGFi, cetuximab, or bevacizumab.578,603–605
Gastric protection with routine proton pump inhibitor use should be considered in all patients with cancer on DAPT606,607
or anticoagulation.530
6.7.2. Antiplatelet therapy
Antiplatelet therapy, in particular DAPT, increases the risk of bleeding in patients with cancer.477 Following ACS and/or PCI, the risk of bleeding is approximately 1.6-fold greater in patients with cancer than in those without.477,605 The risk is greatest in those diagnosed with cancer in the preceding year, whereas more remote cancers carry lower excess risk.477 The PRECISE-DAPT (PREdicting bleeding
Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy) score appears not to perform well for predicting bleeding in patients with cancer.477 In order to reduce bleeding risk, the duration and intensity of DAPT should be minimized477,607 and triple therapy avoided whenever possible. At the same time, DAPT—if indicated—should not be withheld without good reason. A recent expert consensus statement suggests reduced platelet count thresholds for CV therapies, recommending aspirin initiation for platelet counts .10 000/µL and DAPT initiation (with aspirin and clopidogrel) for platelet counts .30 000/µL.608 In patients with platelet counts ,50 000/µL, clopidogrel is preferred over prasugrel or ticagrelor, and glycoprotein IIb/IIIa inhibitors should be avoided.608 To reduce peri-procedural bleeding, PCI
should preferably be undertaken via the radial approach484 and prophylactic platelet transfusion may be considered for patients with platelet count ,20 000/µL.609
6.7.3. Management of bleeding
Basic principles of bleeding management should be followed with control of the bleeding source whenever possible. Platelet transfusions for signiﬁcant thrombocytopaenia and withholding and reversal of anticoagulation for life-threatening bleeding may be needed as in the general population.530,610 Antiﬁbrinolytic agents, such as tranexamic acid or e-aminocaproic acid, can be considered. Non-speciﬁc support of haemostasis using coagulation factor concentrates and speciﬁc reversal agents may be needed for patients on a NOAC
with life-threatening bleeding.530 Recombinant activated factor VII
or activated prothrombin complex concentrates should be avoided in patients with recent thrombosis.
Recommendation Table 35 — Recommendations for venous thromboembolism prophylaxis during anticancer treatment
Recommendation
Classa
Levelb
Extended prophylaxis with LMWH for 4 weeks post-operatively is recommended for patients with cancer undergoing major open or laparoscopic abdominal or pelvic surgery with low bleeding risk and high VTE risk.c,298,299,595
I
B
Prophylactic LMWH for the primary prevention of VTE is indicated in hospitalized patients with cancer or those with prolonged bedrest or reduced mobility in the absence of bleeding or other contraindications.298,299,592,594
I
B
For ambulatory patients with cancer at high risk of thrombosis receiving systemic therapy,d primary thromboprophylaxis with a NOAC (apixaban or rivaroxaban) or LMWH may be considered,
provided there are no signiﬁcant contraindications.e,298,593,594,601,602
IIb
B
A discussion with the patient about the relative beneﬁts and harms, cancer prognosis, drug cost,
and duration of treatment is recommended prior to prophylactic anticoagulation for the primary prevention of VTE.
I
C
© ESC 2022
LMWH, low-molecular-weight heparins; NOAC, non-vitamin K antagonist oral anticoagulants; VTE, venous thromboembolism.
aClass of recommendation.
bLevel of evidence.
cReduced mobility, obesity, VTE history.
dLocally advanced or metastatic pancreas or lung cancer or Khorana score ≥2.
eRisk factors for bleeding, signiﬁcant drug–drug interactions, or severe renal dysfunction.


<!-- PAGE 79 -->

### Page 79

6.8. Peripheral artery disease
There is growing evidence that cancer therapy affects the vasculature. A recent meta-analysis showed a signiﬁcantly increased arterial stiffness after anthracycline and non-anthracycline treatment.611
Paraneoplastic acral vascular syndrome was described after initiation of nivolumab, with ﬁrst symptoms 3 weeks after initiation of therapy.612 Raynaud phenomenon has been associated with the use of bleomycin, cyclophosphamide, platinum compounds, vinca alkaloids,
and ﬂuoropyrimidines.491 Usual treatment of Raynaud’s includes non-pharmacological measures to help prevent an episode (avoidance of provoking factors such as cold temperature, vasoconstricting drugs)
and a
long-acting dihydropyridine
CCB
(amlodipine,
modiﬁed-release nifedipine).
Treatment with nilotinib or ponatinib may be associated with an increased risk of vascular adverse events, including arterial stiffness and PAD development.494 In a subgroup of patients, these events are severe or even life-threatening.613 Although the exact mechanisms remain unknown, we recommend screening for pre-existing
PAD and for vascular risk factors such as DM in all patients before and during nilotinib or ponatinib therapy. Pooled data from three clinical trials showed arterial occlusive disease to be related to dose intensity in ponatinib-treated patients,614 but PAD was not addressed separately. If rapidly progressive PAD occurs with secondgeneration TKI, it may be advisable to switch to an alternative lowerrisk TKI (e.g. imatinib). Platelet aggregation inhibitors or anticoagulation and statins should be considered. Despite lack of evidence, all risk factors should be corrected.615
6.9. Pulmonary hypertension
All ﬁve groups of the PH classiﬁcation can be observed in patients with cancer. Several cancer drugs can cause group 1 PH (pulmonary arterial hypertension [PAH]), including carﬁlzomib, bosutinib, dasatinib,616 ponatinib, interferon alpha, and alkylating agents (e.g. mitomycin C and cyclophosphamide, which mostly cause pulmonary veno-occlusive disease).617 PH associated with left heart disease
(group 2) is related to drugs causing HF (e.g. anthracyclines). PH associated with lung disease (group 3) is related to drugs and therapies causing pulmonary ﬁbrosis (e.g. bleomycin, thoracic radiation). The most common pulmonary vascular disease complicating cancer is
VTE, which can cause chronic thromboembolic PH (group 4). Of note, central venous catheters are important causes of group 4 PH
complicating cancer management. Other group 4 PH due to pulmonary artery obstructions includes angiosarcoma and other malignant tumours (e.g. renal carcinoma, uterine carcinoma, germ cell tumours of the testis).618
PH with unclear and/or multifactorial mechanisms (group 5) includes several conditions that may be complicated by complex and sometimes overlapping pulmonary vascular involvement. Tumoral
PH includes pulmonary tumour micro-embolism and pulmonary tumour thrombotic microangiopathy.619 Multiple causes of PH have been described in patients with chronic myeloproliferative disorders.
In chronic myelogenous leukaemia, spleen enlargement and anaemia can give rise to hyperkinetic syndrome. In polycythaemia vera and essential thrombocythemia, there is an increased risk of VTE and chronic thromboembolic PH. Moreover, formation of a blood clot within the hepatic veins can lead to Budd–Chiari syndrome and subsequent porto-PH. Pulmonary extramedullary haematopoiesis complicating idiopathic or secondary myeloﬁbrosis may also contribute to dyspnoea and PH.620
Symptoms of PH are non-speciﬁc, such as shortness of breath and fatigue. In later stages, symptoms of right-sided HF may develop. An
ECG should be performed and examined for RV hypertrophy, but a normal ECG does not exclude PH. Echocardiography is the ﬁrst choice for assessing PH probability in patients who develop symptoms and/or signs suggestive of PH during cancer treatment.
When peak tricuspid regurgitation velocity (TRV) is ≤2.8 m/s
(equating to an estimated systolic PAP [sPAP] of ≤35 mmHg)
and no other signs of PH are present, then the probability of PH
is low. In the absence of a tricuspid regurgitant jet, other echocardiography signs may increase suspicion of PH (e.g. RV/LV basal diameter ratio . 1, RV outﬂow tract acceleration time , 105 ms,
inferior vena cava diameter . 21 mm with decreased inspiratory collapse).620 Baseline TTE should be considered in patients receiving cancer drugs that can cause PH; however, a right-heart catheterization is required for deﬁnitive diagnosis of PH and to support
PAH treatment decisions. In the DASISION (DASatinib vs. Imatinib
Study In treatment-Naïve chronic myeloid leukemia patients) trial,
5% of patients randomized to dasatinib were diagnosed with
PH, compared with 0.4% of those randomized to imatinib.621 In patients who develop PH, dasatinib treatment should be interrupted and an alternative TKI should be used.616
Overall management of PH in oncology patients should be based on the 2022 ESC/European Respiratory Society (ERS) Guidelines for the diagnosis and treatment of pulmonary hypertension.620 Referral to a PH centre is recommended for multidisciplinary management with the oncology team. In patients with CML treated with drugs causing PH-induced PAH, discontinuation of the potential culprit therapy is recommended if there is a high probability of new PH
(peak
TRV . 3.4 m/s,
equating to an estimated sPAP
of
≥50 mmHg) until the diagnosis is conﬁrmed or ruled out by a rightheart catheterization. In CML patients on dasatinib, an alternative
BCR-ABL TKI is recommended if they develop symptomatic PAH
or an asymptomatic increase in peak TRV .3.4 m/s. Dasatinib dose reduction and close monitoring of peak TRV with TTE every
4 weeks should be considered in CML patients who develop new asymptomatic peak TRV ranging from 2.9 to 3.4 m/s.620 If peak
TRV remains normal or mildly elevated on serial monitoring, then dasatinib can continue, with reduced TTE monitoring to every 3
Recommendation Table 36 — Recommendation for management of peripheral artery disease during anticancer treatment
Recommendation
Classa
Levelb
In patients who develop new symptomatic PAD, a multidisciplinary approach regarding the decision to continue vs. interrupt culprit cancer therapyc is recommended.
I
C
© ESC 2022
PAD, peripheral artery disease; VEGFi, vascular endothelial growth factor inhibitors.
aClass of recommendation.
bLevel of evidence.
cVEGFi, nilotinib, ponatinib, platins, etc.
ESC Guidelines
4307


<!-- PAGE 80 -->

### Page 80

months. If peak TRV continues to rise, then right-heart catheterization should be performed, dasatinib treatment should be stopped,
and PAH drugs should be considered if PAH is conﬁrmed.
6.10. Pericardial diseases
Pericarditis and pericardial effusion can be related to a wide range of cancer treatments including chest radiation, cytotoxic therapies (anthracyclines, bleomycin, cyclophosphamide, cytarabine), targeted therapies (all-trans retinoic acid, arsenic trioxide, dasatinib), and immune-based therapies (interleukin-2, interferon-αICI). A combination of therapies may have a synergistic effect on the pericardium.
These therapy-induced complications must be differentiated from progressive cancer (local invasion, metastatic involvement, or mediastinal lymphatic drainage obstruction) and non-cancer-related causes such as infection, especially in immune-compromised patients.622 A
careful history and clinical examination are of help to determine the cause. TTE plays a central role in diagnosis and management. CT
and CMR can provide additional information on pericardial inﬂammation and constrictive physiology. The principles for the diagnosis and management should follow the 2015 ESC Guidelines for the diagnosis and management of pericardial diseases,444 but there are some speciﬁc issues to consider in patients with cancer.482
6.10.1. Pericarditis
The diagnosis of pericarditis in patients with cancer follows the same principles as in those without, but symptoms can be atypical.444
Acute pericarditis caused by radiation has become rare due to lower doses and improved radiation techniques. It occurs within days to weeks after treatment and is usually self-limiting, but can evolve towards constrictive pericarditis many years later (Section 8.6).
Pericarditis caused by conventional cancer therapies often resolves with standard therapy or after discontinuation of the treatment.444
Cancer treatment interruption should be discussed with the cardio-oncology team. Treatment with anti-inﬂammatory drugs
(e.g. ibuprofen) and colchicine, in the absence of contraindications,
is recommended as it reduces the rate of recurrence requiring repeat intervention.623 Low-to-moderate doses of steroids are only indicated for resistant cases except ICI-related pericarditis.444
ICI-associated pericarditis has a median time of onset of 30 days in retrospective surveillance studies and is associated with a poor prognosis, especially in case of concomitant myocarditis.444,624
In patients with severe ICI-associated pericarditis with moderate or severe effusion, ICI discontinuation and high-dose steroids (methylprednisolone 1 mg/kg/day) with or without colchicine are recommended, as well as pericardiocentesis in case of cardiac tamponade.624,625 In case of refractory pericarditis, immunosuppressive drugs should be considered.
For uncomplicated ICI-related pericarditis, the ICI might be continued and colchicine or non-steroidal anti-inﬂammatory drugs could be considered.326,444 For patients requiring ICI discontinuation, restarting ICI
can be considered in a MDT discussion after resolution of pericardial disease and under close monitoring.
6.10.2. Pericardial effusion
Pericardial effusions are often observed as an incidental ﬁnding in patients with cancer. Cancer therapy is the cause of a pericardial effusion in ,30% of cases, although this may increase with the expanding use of ICI in cancer. Malignancy-related pericardial effusions caused by direct (lung, oesophageal, breast) or metastatic invasion (haematological malignancies, ovarian, melanoma) or by lymph node obstruction are generally associated with poor prognosis.
Clinical presentation depends on the size of the effusion and the speed of its growth.444 Malignancy-related pericardial effusions make up .30% of patients presenting with cardiac tamponade626
and usually develop slowly, resulting in larger pericardial effusions at the time of diagnosis compared with non-malignant pericardial effusions. Management consists of determination of the cause and evaluation of the haemodynamic impact. Small-to-medium-sized effusions (.4 and ,20 mm) can be monitored with a reassessment
7–14 days after initial diagnosis and at further 4–6-weekly intervals.444,627 In unstable patients with signs of tamponade, immediate echocardiographic-guided percutaneous pericardiocentesis is preferred over surgical pericardiotomy to minimize potential complications.628 In patients with cardiac tamponade due to malignant pericardial effusions, colchicine may be useful to improve clinical outcomes and reduce the rate of repeat intervention.623 Drainage of a pericardial effusion related to ICI is rarely required629 and corticosteroids should be considered.630 Intrapericardial instillation of cytostatic/sclerosing agents,
colchicine,623
and radiation for radiation-sensitive tumours can reduce recurrence after drainage.
The creation of a pleuropericardial or pleuroperitoneal window with balloon pericardiotomy or surgery should be considered in case of recurrent malignant pericardial effusions after emergency pericardiocentesis.444
A surgical pericardial window should be considered if the percutaneous approach is not feasible and in stable patients with large
(≥20 mm) or rapidly expanding malignant pericardial effusions prior to the development of cardiac tamponade.
Recommendation Table 37 — Recommendations for the management of pulmonary hypertension during anticancer treatment
Recommendations
Classa
Levelb
Right-heart catheterization and discontinuation of dasatinib is recommended in patients who develop symptomatic or asymptomatic increase in peak TRV .3.4 m/s.
I
C
Dasatinib dose reduction and close monitoring of peak TRV with echocardiography should be considered in patients who develop new asymptomatic peak TRV ranging from 2.9 to
3.4 m/s.
IIa
C
In patients with conﬁrmed dasatinib-induced
PAHc or new asymptomatic peak TRV .3.4 m/s,
an alternative BCR-ABL inhibitor is recommended after peak TRV recovery to ,2.8 m/s.
I
C
© ESC 2022
BCL-ABL, breakpoint cluster region–Abelson oncogene locus; PAH, pulmonary arterial hypertension; TRV, tricuspid regurgitation velocity.
aClass of recommendation.
bLevel of evidence.
cDeﬁnite diagnosis of PAH requires a right-heart catheterization.


<!-- PAGE 81 -->

### Page 81

### 7 End-of-cancer therapy cardiovascular risk assessment

7.1. Cardiovascular evaluation during the
ﬁrst year after cardiotoxic anticancer therapy
End-of-cancer therapy CV risk assessment covers the ﬁrst 12
months after the last cardiotoxic cancer treatment. These recommendations are where cardiotoxic cancer therapy has been successfully completed with good long-term prognosis.
These recommendations are not indicated when cancer therapies are discontinued due to cancer progression and prognosis is poor, or where end-of-life care is indicated. Selected patients with cancer continue on long-term oncology therapies, e.g. women with oestrogen receptor-positive early invasive BC. In this example, the end-of-therapy risk assessment refers to the timepoint from the last anthracycline or trastuzumab dose.
High-risk patients can be identiﬁed at completion of their cardiotoxic cancer therapies by their clinical characteristics, history of
CTR-CVT during treatment, and by elevated cardiac biomarkers and/or abnormal CV imaging at follow up.53,54,92 Cardiac serum biomarkers (NP and cTn) are useful given their high negative predictive value for future CV events.197,631 In a prospective study of 2625 adult patients with cancer that assessed LVEF after anthracycline-based chemotherapy, the overall incidence of CTRCD was 9%; 98% of cases could be detected within 12 months after chemotherapy and the median time from chemotherapy to CTRCD detection was
3.5 months (interquartile range 3–6 months).208 The response to
ACE-I treatment declined when the interval between the end of chemotherapy and CTRCD detection lengthened; complete LVEF
recovery was not observed in patients where treatment was delayed by .6 months.425
Measurement of cTn after completion of anthracycline chemotherapy during the end-of-treatment assessment should be considered. Rises in cTnI after anthracycline chemotherapy identify patients at risk of future cardiac dysfunction who then beneﬁt from CV protection.4 Educating patients with cancer of their potential increased CVD risk and supporting them to make appropriate healthy lifestyle choices is recommended. CS should also be advised to promptly report early signs and symptoms of possible CVD and inform medical teams of their previous cardiotoxic cancer therapies.
CVRF including hypertension, DM, and dyslipidaemia correlate with the probability of future CV events in CS and should be well controlled after completion of cancer therapy.31,632,633
7.2. Which cancer survivors require cardiovascular surveillance in the ﬁrst year after cancer treatment?
The end-of-treatment risk assessment ideally identiﬁes those high-risk
CS, who require long-term CV surveillance, based on the following criteria (Table 10):
(1) Baseline high or very high risk based on HFA-ICOS risk assessment tools12 (Section 4).
(2) Cardiotoxic cancer therapy with a high risk of long-term CV
complications7,21 (Section 8).
(3) Moderate or severe CTR-CVT diagnosed during cancer treatment (Table 3).68
(4) New abnormalities in cardiac function detected by echocardiography, new elevated cardiac serum biomarkers, or newly CV
symptoms detected at the end-of-therapy assessment (3 or 12
months after treatment).68,208
The timing of the ﬁrst CV assessment after cardiotoxic cancer treatment depends on the risk deﬁned by baseline CV assessment,
the type of cancer therapy, and whether CTR-CVT was diagnosed during treatment.
In asymptomatic high-risk patients (Table 10), echocardiography and cardiac serum biomarkers are recommended at 3 and 12 months after completion of cancer therapy.53,54,59,61,68,148,208,425
In
Recommendation Table 38 — Recommendations for the management of pericardial diseases in patients receiving anticancer treatment
Recommendations
Classa
Levelb
General
Diagnosis and management of acute pericarditis in patients with cancer based on the 2015 ESC
Guidelines for the diagnosis and management of pericardial diseases is recommended and a multidisciplinary discussion is needed before interrupting cancer therapy.444
I
C
A surgical pericardial window should be considered if the percutaneous approach is not feasible or in cases of recurrent malignant pericardial effusions.
IIa
C
Intrapericardial instillation of cytostatic or sclerosing agents may be considered for prevention of recurrence.
IIb
C
Diagnosis and management of ICI-associated pericarditis
Multimodality CV imaging (echocardiography,
CMR + CT), ECG and measurement of cardiac biomarkers are recommended to conﬁrm the diagnosis, assess the haemodynamic consequences of pericardial disease, and rule out associated myocarditis.
I
C
Prednisolone and colchicine are recommended for patients with ICI-associated pericarditis.326,624,625,630
I
C
Interruption of ICI treatment in patients with conﬁrmed ICI-associated pericarditis with moderate-to-severe pericardial effusion is recommended.
I
C
A multidisciplinary discussion is recommended before restarting ICI treatment.
I
C
© ESC 2022
CMR, cardiac magnetic resonance; CT, computed tomography; CV, cardiovascular;
ECG, electrocardiogram; ESC, European Society of Cardiology; ICI, immune checkpoint inhibitors.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4309


<!-- PAGE 82 -->

### Page 82

asymptomatic moderate-risk patients (according to CV toxicity baseline risk stratiﬁcation), echocardiography and cardiac serum biomarkers should be considered within 12 months after completion of cancer therapy.53,54,59,61,68,148,208 In asymptomatic low-risk patients
(according to CV toxicity baseline risk stratiﬁcation), echocardiography and cardiac serum biomarkers may be considered within 12
months after completion of cancer therapy.634
All patients started on CV therapies (ACE-I/ARB/angiotensin receptor-neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, sodium-glucose co-transporter 2 inhibitors, antihypertensive medications, antiarrhythmic medications, antiplatelet therapies, statins) for any CTR-CVT (especially CTRCD) should have a clinical assessment, ECG, echocardiography, and cardiac serum biomarkers (if LV systolic dysfunction/HF is a potential risk) at 3,
6, and 12 months after completing cancer treatment. A MDT-based approach to palliative and end-of-life care for patients with cancer with HF or other CTR-CVT should be focused on symptom relief according to general ESC Guidelines.
7.3. Management of cancer therapy-related cardiac dysfunction at the end-of-therapy assessment
During this end-of-treatment assessment, a review of cardioprotective medications initiated during cancer therapy to treat CTRCD is recommended (Figure 37). In selected patients with asymptomatic mild or moderate CTRCD who have fully recovered with normal
TTE and cardiac serum biomarkers, a trial of weaning off CV
medication should be considered after MDT discussion. This is most common after asymptomatic mild or moderate CTRCD secondary to trastuzumab, particularly in younger otherwise healthy
HER2+ BC survivors with no exposure to anthracycline chemotherapy. Further assessment of cardiac function with TTE and cardiac serum biomarkers is recommended following withdrawal of CV
medication in patients with previous CTRCD to ensure cardiac function remains normal.
Continuing long-term CV medication is generally recommended in patients with moderate and severe symptomatic or severe asymptomatic CTRCD due to the high rate of recurrent HF. Long-term treatment is also recommended in CS with mild or moderate
CTRCD who fail to recover normal LV function at their end-of-therapy assessment (Figure 37).
7.4. Cardiopulmonary exercise testing and ﬁtness during the end-of-therapy assessment
CRF impairment is a strong predictor of patient outcome following cancer treatment and an intervention target in CS. Low CRF is associated with poor quality of life, increased morbidity, reduced exercise cardiac function and worse CVD risk proﬁle, and is a robust independent predictor of all-cause, cancer-related, and CVD-related mortality in CS.119,120 Recent evidence suggests the risk of
CVD-related mortality in CS decreases by 14% per 1 metabolic equivalent (3.5 mL O2/kg/min) increase in CRF.120
CPET may be considered for CS with exertional limitation, who may have substantial beneﬁt from cardiac rehabilitation. Eligible patients include those treated with higher doses of anthracycline chemotherapy and/or RT to a volume including the heart, high CV
toxicity risk at baseline, patients who developed CTRCD during cancer therapy, and those identiﬁed with new abnormalities in LV function at their end-of-therapy assessment.11 CPET can be an objective tool in the diagnosis of decreased physical capacity and identify CV vs.
non-CV causes.635
7.5. The role of cardiac rehabilitation
Exercise is a potent multitargeted therapy that prevents and treats multiple competing mechanisms of CTR-CVT in CS, including CRF impairment,636 CV injury, and pre-existing and new
CVRF.137 Prescribing exercise facilitates the delivery of therapeutic exercise that is individualized to a person’s ﬁtness level and systematically progressed to optimize physiological adaptation.637
Current evidence demonstrates that supervised exercise therapy
(including high-intensity interval training [HIIT]) is safe and well tolerated,638 attenuates CTR-CVT risk, and improves CRF.
Furthermore, HIIT reduces CVRF460 and CV risk639 in patients
Table 10
Risk factors for future cardiovascular disease at the end-of-cancer therapy cardiovascular risk assessment
High-risk conditions
High- and very-high baseline CV toxicity risk based on HFA-ICOS
assessment
Speciﬁc anticancer treatment proven to have a high risk of long-term CV
complicationsa
Doxorubicinb ≥250 mg/m2
RT . 15 Gy MHDc
Both doxorubicinb ≥100 mg/m2 and RT 5–15 Gy MHDd
High-risk HSCT patientse
Moderate or severe CTR-CVT during cancer treatment (especially
CTRCD), ICI-related myocarditis, cardiac arrhythmias, or severe vascular toxicities (ACS, stroke, PVD)
New CV symptoms or new asymptomatic abnormalities in echocardiography and/or cardiac serum biomarkers at the end of therapy assessment
© ESC 2022
ACS, acute coronary syndromes; CTRCD, cancer therapy-related cardiac dysfunction;
CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD,
cardiovascular disease; CVRF, cardiovascular risk factors; GVHD, graft vs. host disease; Gy, Gray; HFA, Heart Failure Association; HSCT, haematopoietic stem cell transplantation;
ICI,
immune checkpoint inhibitors;
ICOS,
International
Cardio-Oncology Society; MHD, mean heart dose; PVD, peripheral vascular disease;
RT, radiotherapy.
aRT risk categorization based on MHD is recommended over categorization based on prescribed dose, which may not accurately reﬂect cardiac radiation exposure.
Depending on dose distribution and exposure of speciﬁc cardiac substructures (as well as clinical risk factors), the treatment team may judge the patient to belong to a higher risk category. In addition, a patient may be judged to belong to a lower risk category if only a small part of the heart is exposed to a relatively high prescribed dose (i.e. RT to left breast or left chest wall only).
bOr doxorubicin equivalent.
cOr prescribed RT ≥35 Gy to a volume exposing the heart if MHD is not available.
dOr prescribed RT 15–34 Gy to a volume exposing the heart if MHD is not available.
eHigh-risk HSCT patients: allogenic HSCT; pre-existing CVD or multiple uncontrolled
CVRF; cancer treatment history (mediastinal or mantle ﬁeld radiation, alkylating agents, .250 mg/m2 doxorubicin or equivalent); conditioning schemes (total body irradiation, alkylating agents); development of GVHD.


<!-- PAGE 83 -->

### Page 83

with cancer in the pre-, active-, and post-treatment settings.
HIIT-related beneﬁts on CRF, physical activity behaviour, fatigue,
and quality of life persist months post-intervention.640,641 HIIT
may not be feasible in elderly and frail patients.642 Dedicated cardio-oncology rehabilitation programmes are currently under development.11
CTRCD
Mild or moderate
Partial or nonea
Fullb
High riskdk
Low riskek
MDT to consider weaning HF therapy p c
Recovery
Patient risk
Severe and very severe
N
Patients who develop CTRCD during cancer treatment and are being started on HF therapy p
Y
Continue HF therapy p
(Class I)
Continue
HF therapy p
(Class I)
Consider weaning
HF therapy p
(Class IIa)
Figure 37 Management of cancer therapy-related cardiac dysfunction after cancer therapy. CTRCD, cancer therapy-related cardiac dysfunction; CV,
cardiovascular; GLS, global longitudinal strain; HF, heart failure; HFA, Heart Failure Association; ICOS, International Cardio-Oncology Society; LV, left ventricular; LVEF, left ventricular ejection fraction; MDT, multidisciplinary team; N, no; Y, yes. aPartial or no recovery: patients who do not meet all of the criteria for full recovery. bFull recovery: no signs or symptoms of HF + LVEF . 50% + GLS within normal range or similar to baseline measurements + cardiac serum biomarkers within the normal range or similar to baseline measurements cThe CTRCD trajectory of each patient is unique and dynamic and withdrawal of HF therapy requires a MDT to consider several key points that help to stratify patients into low- or high-risk categories. Key points to consider during a MDT discussion are: HFA-ICOS baseline CV toxicity risk assessment, pre-existing indications for
CV medication, class of cancer treatment causing CTRCD (generally reversible vs. generally irreversible), magnitude and duration of CTRCD before recovery, intensity of HF therapy needed to recover LV function, family history of cardiomyopathy or known cardiomyopathy gene carrier (see Section 4.8).
dSee Table 10. eLow-risk patient characteristics: low to moderate baseline CV toxicity risk (HFA-ICOS risk assessment), no pre-existing indications for CV medication, cancer treatment generally associated with reversible myocardial damage, asymptomatic mild CTRCD, early cardiac function recovery
(3–6 months) under HF therapy, no family history of cardiomyopathy.
ESC Guidelines
4311


<!-- PAGE 84 -->

### Page 84

### 8 Long-term follow-up and chronic cardiovascular complications in cancer survivors

8.1. Cancer survivors
8.1.1. Adult survivors of childhood and adolescent cancer
The survival of children and adolescents with cancer has increased considerably in recent decades, with 5-year survival rates currently exceeding 80%.647 However, the long-term health effects in the growing population of childhood and adolescent CS are a major concern.648 CTR-CVT, as a consequence of treatment with anthracyclines, mitoxantrone, and/or chest-directed RT can manifest as
CTRCD but also as VHD, CAD, arrhythmias, autonomic dysfunction, pericardial disease, and premature CV mortality, depending on the type of cardiotoxic treatment.643,649
CTRCD is one of the most frequent late effects in childhood CS
who received cardiotoxic cancer treatment and contributes to signiﬁcant morbidity and non-cancer-related mortality later in life.650
The cumulative incidence of CTRCD varies depending on the diagnostic criteria applied and the population studied and ranges from
4.8% to 10.6% at 40–45 years of age.651 RT to a ﬁeld involving the heart increases the risk of CTRCD and valvular and vascular complications.652
Follow-up of paediatric CS according to the International Late
Effects of Childhood Cancer Guideline Harmonization Group is recommended.653 This includes risk stratiﬁcation based upon the total cumulative dose of anthracycline chemotherapy and MHD delivered
(Table 11). Annual review of CVRF and education to promote a healthy lifestyle is recommended. The frequency of CV review with TTE depends upon risk. A CV review should be considered every 5 years for moderate-risk childhood and adolescent adult CS
and every 2 years for high-risk childhood and adolescent adult CS.
A recent retrospective analysis has shown that quantiﬁcation of
LVEF .5 years after cancer diagnosis improves long-term childhood
Recommendation Table 39 — Recommendations for end-of-cancer therapy cardiovascular risk assessment
Recommendations
Classa
Levelb
Educating and supporting patients with cancer to make appropriate healthy lifestyle choices is recommended.c
I
C
Education is recommended for patients with cancer regarding recognition for early signs and symptoms of CVD.
I
C
CVRF assessment is recommended during the
ﬁrst year after cancer therapyc,12,22,31,632,643 and thereafter according to the 2021 ESC Guidelines on CVD prevention in clinical practice.19
I
B
In asymptomatic high-risk patients,d echocardiography and cardiac serum biomarkers are recommended at 3 and 12 months after completion of cancer therapy.53,54,59,61,68,148,208,425
I
B
In asymptomatic moderate-risk patients,e echocardiography and cardiac serum biomarkers should be considered within 12 months after completion of cancer therapy.53,54,59,61,68,148,208
IIa
B
In asymptomatic low-risk patients,e echocardiography and cardiac serum biomarkers may be considered within 12 months after completion of cancer therapy.634
IIb
C
Cardiology referralf is recommended in patients with cancer with new cardiac symptoms or new asymptomatic abnormalities in echocardiography and/or cardiac serum biomarkers at the end of therapy assessment.11
I
C
In selected patients with exercise intolerance persisting at 12 months after cancer treatment and with normal resting echocardiogram and cardiac biomarkers, exercise stress echocardiography and/or CPET may be considered.
IIb
C
Targeted cardiac rehabilitation should be considered in CS with high CV risk.638–640
IIa
B
Long-term continuation of cardiac medication is recommended in patients who develop severe
CTRCD during cancer therapy.
I
C
CV follow-up and treatment optimization is recommended in patients who developed
TKI-mediated hypertension during cancer therapy.644,645
I
C
CV follow-up and treatment optimization is recommended in patients who developed vascular toxicities during cancer therapy.10,237
I
C
Continued
ECG follow-up is recommended in patients who developed QT lengthening or LQTS during cancer therapy.646
I
C
© ESC 2022
CPET, cardiopulmonary exercise testing; CS, cancer survivors; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; CVD, cardiovascular disease;
CVRF, cardiovascular risk factors; DM, diabetes mellitus; ECG, electrocardiogram;
ESC, European Society of Cardiology; LQTS, long QT syndrome; TKI, tyrosine kinase inhibitors.
aClass of recommendation.
bLevel of evidence.
cIncluding regulation of hypertension, DM, dyslipidaemia, smoking cessation, weight loss in case of obesity, and an adequate amount of exercise.
dHigh-risk patients: see Table 10.
eModerate- or low-risk patients: according to CV toxicity baseline risk stratiﬁcation.
fCardio-oncology referral is recommended when available; alternatively, the patient should be referred to a cardiologist with expertise in managing CVD in patients with cancer.


<!-- PAGE 85 -->

### Page 85

CS risk stratiﬁcation. A LVEF of 40–49% is associated with an almost eight-fold increased risk for LVEF ,40% at 10-year follow-up compared with patients with a preserved LVEF (≥50%).654 Lifelong surveillance for high-risk survivors is recommended.7
8.1.2. Adult cancer survivors
Long-term cancer survivorship care is an advancing ﬁeld of research.
Many survivors will experience several cancer- and treatment-related late effects throughout their lives, including CTR-CVT. Besides affecting their physical and psychosocial health status, these might reduce life expectancy and quality of life. This is relevant in some cancer types,
when CVD risk—especially CTRCD risk—exceeds cancer mortality.658,659 The risk of fatal heart disease is increased more than twofold in survivors of several solid cancers and lymphoma compared with the general population.660–662
CV risk assessment at the end of therapy (Section 7) identiﬁes CS
who require long-term cardiology follow-up beyond the ﬁrst 12
months after completing their cancer treatment. Asymptomatic
CS with new or persisting abnormalities at their end-of-therapy assessment will be identiﬁed as at high risk for future CV events and require long-term surveillance.
Speciﬁc cancer treatments carry the highest risk of long-term CV
toxicity including anthracycline chemotherapy and RT where the heart is within the RT treatment volume. Progressive RT-related
CV toxicity typically develops 5–10 years after the initial treatment,
and may cause CAD and HF at an incidence up to six-fold higher than in the general population. An increased CV mortality compared with the general population has been attributed to radiation-associated heart disease in Hodgkin lymphoma, non-Hodgkin lymphoma, BC,
and patients with lung cancer.663–665 The incidence and progression of the radiation-related CV complications depends on the dose to the CV tissue and on concomitant cancer therapies and patient characteristics, such as pre-existing CVD, CVRF, and age.389,400
Late CV complications are also observed in CS who required HSCT.
The incidence of HF increases up to 14.5% in women 15 years after
HSCT. Risk factors for CVD following HSCT include age, anthracycline dose, chest radiation exposure, hypertension, DM, and smoking.666
Long-term follow-up surveillance, based on CV toxicity risks
(Table 12), includes patient education and CVRF optimization. An annual clinical CV risk assessment is recommended for all adult CS to optimize CVRF control, promote a healthy lifestyle, and symptom review. This can be done in collaboration with primary care or a
Table 11
Risk categories for asymptomatic adults who are childhood and adolescent cancer survivors
Risk category
RT dosea (Gy MHD)
Total cumulative doxorubicinb dose (mg/m2)
Combination therapy
RT dosea (Gy MHD)
Total cumulative doxorubicinb dose (mg/m2)
Very high risk
.25c
≥400
.15c
≥100
High risk
.15 to 25c
250–399
5–15d
≥100
Moderate risk
5–15d
100–249
,5e
≥100
Low risk
,5e
,100
–
© ESC 2022
Gy, Gray; MHD, mean heart dose; RT, radiotherapy.
aRT risk categorization based on MHD is recommended over categorization based on prescribed dose, which may not accurately reﬂect cardiac radiation exposure. Depending on dose distribution and exposure of speciﬁc cardiac substructures (as well as clinical risk factors), the treatment team may judge the patient to belong to a higher risk category. In addition, a patient may be judged to belong to a lower risk category if only a small part of the heart is exposed to a relatively high prescribed dose.
bOr doxorubicin equivalent.
cOr prescribed RT ≥35 Gy to a volume exposing the heart if MHD is not available. Note that in this case, the limited information about cardiac exposure does not allow one to distinguish between high- and very high-risk categories.
dOr prescribed RT 15–34 Gy to a volume exposing the heart if MHD is not available.
eOr prescribed RT , 15 Gy to a volume exposing the heart if MHD is not available.
Recommendation Table 40 — Recommendations for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer survivors
Recommendations
Classa
Levelb
Education of adults who are childhood and adolescent CS treated with anthracyclines,
mitoxantrone, and/or RT to a volume including the heart and their healthcare providers regarding their increased CV risk is recommended.655–657
I
B
Annual screening for modiﬁable CVRFc is recommended in adults who are childhood and adolescent CS treated with anthracyclines,
mitoxantrone, and/or RT to a volume including the heart.
I
C
CV assessmentd is recommended in female childhood and adolescent CS prior to pregnancy or in the ﬁrst trimester.
I
C
Echocardiography surveillance should be considered every 2 years in adults who are high-risk childhood and adolescente CS.7
IIa
B
Echocardiography surveillance should be considered every 5 years in adults who are moderate-risk childhood and adolescente CS.7,654
IIa
B
© ESC 2022
BP, blood pressure; CS, cancer survivors; CV, cardiovascular; CVRF, cardiovascular risk factors; DM, diabetes mellitus; ECG, electrocardiogram; HbA1c, glycated haemoglobin;
RT, radiotherapy; TTE, transthoracic echocardiography.
aClass of recommendation.
bLevel of evidence.
cObesity, sedentary lifestyle, cigarette smoking, alcohol intake, unhealthy diet,
dyslipidaemia, hypertension, DM.
dBP, lipids, fasting glucose, HbA1c, ECG, and TTE.
eSee Table 11.
ESC Guidelines
4313


<!-- PAGE 86 -->

### Page 86

specialist in CV medicine with expertise in CVRF management. CS at high or very high risk of future CVD can be divided into those at high early risk (within 5 years of completing cancer therapy) and those at high late risk (.30 years from completing treatment). The timing and frequency of other complementary tests depends upon the risk for
CTR-CVT (Figure 38).
CS with a high or very high baseline risk and patients with abnormal
LV function at the end-of-therapy assessment have a high or very high early risk, particularly in the ﬁrst 2 years.61,667,668 Annual CV assessment with clinical examination, ECG, and NP measurement is recommended in CS. TTE should be considered at years 1, 3, and 5 after completion of cardiotoxic cancer therapy and every 5 years thereafter in asymptomatic very high- and early high-risk adult CS.
In adult CS with late high CTR-CVT risk (e.g. young adults with
Hodgkin lymphoma or sarcomas who received a high total cumulative anthracycline dose or patients treated with high-dose radiation to a ﬁeld involving the heart, e.g. Mantle RT) there is a progressive risk of CTRCD.661,669 Annual CV assessment with clinical examination, ECG, and NP measurement is recommended, starting 5 years after the end of treatment, provided the end-of-therapy assessment at 12 months is normal. TTE should also be considered every 5 years,
as well as non-invasive screening for CAD (Section 8.3) and carotid disease (Section 8.5) according to local protocols.670
The long-term effects of CTRCD caused by trastuzumab and other targeted cancer therapies (e.g. TKI) beyond 10 years are unknown. Currently, there is no recommendation for lifelong surveillance in these CS unless they have another indication.
CV assessment with clinical examination, ECG, echocardiography,
and NP measurement every 5 years should be considered in asymptomatic adult CS at moderate risk of future CTR-CVT and a normal end-of-therapy CV assessment.
Table 12
Risk categories for asymptomatic adult cancer survivors
Risk categorya
Patient characteristics
Very high risk
• Very high baseline CV toxicity risk pre-treatment
• Doxorubicinb ≥400 mg/m2
• RT . 25 Gy MHDc
• RT . 15–25 Gy MHDc + doxorubicinb
≥100 mg/m2
Early high risk
(,5 years after therapy)
• High baseline CV toxicity risk
• Symptomatic or asymptomatic moderate-to-severe CTRCD during treatment
• Doxorubicinb 250–399 mg/m2
• High-risk HSCTd
Late high risk
• RT . 15–25 Gy MHDc
• RT 5–15 Gy MHDe + doxorubicinb
≥100 mg/m2
• Poorly controlled CVRF
Moderate risk
• Moderate baseline CV toxicity risk
• Doxorubicinb 100–249 mg/m2
• RT 5–15 Gy MHDe
• RT , 5 Gy MHDf + doxorubicinb ≥100 mg/
m2
Low risk
• Low baseline CV toxicity risk and normal end-of-therapy cardiac assessment
• Mild CTRCD during therapy but recovered by the end of cancer therapy
• RT , 5 Gy MHDf
• Doxorubicinb , 100 mg/m2
© ESC 2022
CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; CVD,
cardiovascular disease; CVRF, cardiovascular risk factors; GVHD, graft vs. host disease; Gy, Gray; HSCT, haematopoietic stell cell transplantation; MHD, mean heart dose; RT, radiotherapy. References:397,399,400,673,674
aRT risk categorization based on MHD is recommended over categorization based on prescribed dose, which may not accurately reﬂect cardiac radiation exposure.
Depending on dose distribution and exposure of speciﬁc cardiac substructures (as well as clinical risk factors), the treatment team may judge the patient to belong to a higher risk category. In addition, a patient may be judged to belong to a lower risk category in case only a small part of the heart is exposed to a relatively high prescribed dose.
bOr equivalent.
cOr prescribed RT≥35 Gy to a volume exposing the heart if MHD is not available. Note that in this case, the limited information about cardiac exposure does not allow one to distinguish between high- and very high-risk categories.
dHigh-risk HSCT patients: allogenic HSCT; pre-existing CVD or multiple uncontrolled
CVRF; cancer treatment history (mediastinal or mantle ﬁeld radiation, alkylating agents,
.250 mg/m2 doxorubicin or equivalent); conditioning schemes (total body irradiation,
alkylating agents); development of GVHD.
eOr prescribed RT 15–34 Gy to a volume exposing the heart if MHD is not available.
fOr prescribed RT , 15 Gy to a volume exposing the heart if MHD is not available.
Recommendation Table 41 — Recommendations for cardiovascular surveillance in asymptomatic adult cancer survivors
Recommendations
Classa
Levelb
Annual CV risk assessment,c including ECG and
NP, and CVRF management is recommended in
CS who were treated with a potentially cardiotoxic cancer drug or RT.d,631–633,671,672
I
B
CV toxicity risk restratiﬁcatione is recommended
5 years after therapy to organize long-term follow-up.
I
C
Echocardiography at years 1, 3, and 5 after completion of cardiotoxic cancer therapy and every 5 years thereafter should be considered in asymptomatic very high- and early high-risk adult
CS.f
IIa
C
Echocardiography should be considered in asymptomatic late high-risk adult CSf starting at 5
years after radiation to a volume including the heart and then every 5 years.
IIa
C
Echocardiography may be considered every 5
years in asymptomatic moderate-risk adult CS.f
IIb
C
Non-invasive screening for CADg should be considered every 5–10 years in asymptomatic patients who received .15 Gy MHD,d starting at
5 years after radiation.
IIa
C
Carotid ultrasound imaging should be considered every 5 years in asymptomatic patients with a history of head/neck RT, starting at 5 years after radiation and every 5–10 years thereafter.
IIa
C
Continued


<!-- PAGE 87 -->

### Page 87

8.2. Myocardial dysfunction and heart failure
HF treatment in CS should follow the current 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF.14
Treatment with ACE-I/ARB and/or beta-blockers is recommended for both symptomatic and asymptomatic CS who have LVEF ,
50% detected on CV assessment.14,61,208,675 In CS with mild asymptomatic CTRCD detected on CV assessment (LVEF . 50% but new fall in GLS and/or cardiac serum biomarker increase), treatment with
ACE-I/ARB and/or beta-blockers may be considered.
Renal artery ultrasound should be considered in patients with a history of abdominal and pelvic radiation who present with worsening renal function and/or systemic hypertension.
IIa
C
© ESC 2022
BP, blood pressure; CAD, coronary artery disease; CMR, cardiac magnetic resonance;
CS, cancer survivors; CT, computed tomography; CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF,
cardiovascular risk factors; ECG, electrocardiogram; HbA1c, glycated haemoglobin;
MHD, mean heart dose; NP, natriuretic peptides; RT, radiotherapy.
aClass of recommendation.
bLevel of evidence.
cClinical review, BP, lipid proﬁle, HbA1c.
dRT risk categorization based on MHD is recommended over categorization based on prescribed dose (≥35 Gy to a volume exposing the heart if MHD is not available).
eRestratiﬁcation includes evaluation of new or pre-existing CVRF and CVD (including
CTR-CVT).
fSee Table 12.
gStress echocardiography, cardiac CT, stress CMR, single-photon emission CT stress test, according to local protocol.234
Long-term surveillance in asymptomatic CS
High and 
very high 
risk
Moderate risk
Low risk
Class 1
Class 1Ia
Class 1Ib
TTE every 2 years in adults who are childhood and adolescent CS
TTE at years 1, 3, and 5 after cardiotoxic cancer therapy and every 5 years thereafter in adult CS
Annual CV risk 
assessmenta
CV toxicity risk 
re-stratificationc at 5 years 
Patient education and
CVRF optimization
Cardiology referralb if new CV
symptoms develop
TTE every 5 years in adults who are childhood and adolescent CS
TTE every 5 years in adult CS
Figure 38 Long-term follow-up in cancer survivors. BP, blood pressure; CAD, coronary artery disease; CS, cancer survivors; CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; ECG, electrocardiogram;
HbA1c, glycated haemoglobin; NP, natriuretic peptides; TTE, transthoracic echocardiography. aClinical review, BP, lipid proﬁle, HbA1c, ECG, NP. In selected patients, non-invasive screening for CAD and carotid or renal diseases every 5–10 years, starting at 5 years after radiation may be considered.
bCardio-oncology referral is recommended when available; alternatively, the patient should be referred to a specialized cardiologist with expertise in managing CVD in patients with cancer. cRestratiﬁcation includes evaluation of new or pre-existing CVRF and CVD (including CTR-CVT).
ESC Guidelines
4315


<!-- PAGE 88 -->

### Page 88

8.3. Coronary artery disease
Any vascular location within the RT treatment volume is at increased risk for both accelerated atherosclerosis and RT-related vasculopathy.173,392 RT to the chest (e.g. treatment of Hodgkin lymphoma,
early-stage BC, lung and oesophageal cancer, and for some patients receiving infradiaphragmatic irradiation if the apex of the heart is within the treatment volume) increases the risk of CAD. The latency between RT and the appearance of CAD varies from a few years to several decades, depending upon the presence or absence of preexisting atherosclerosis and the age of the patient at the time of
RT. This is a serious complication for young CS with a good prognosis and long-life expectancy (e.g. BC and Hodgkin lymphoma).389,390
Patients treated for mediastinal Hodgkin lymphoma have shown an increased risk of CAD as a ﬁrst cardiac event.400 RT-induced CAD
depends on the location of the RT treatment volume and most commonly affects either the proximal left anterior descending or the right coronary arteries. RT-related vasculopathy is progressive and typically manifests in severe, diffuse, long, smooth and concentric angiographic lesions.679,680
The risk and severity of CAD increases with radiation dose, larger volume exposed, younger age at time of treatment (,25 years),390
time from treatment, smoking,400 the presence of other typical
CVRF, type of radiation source, and concurrent metabolic risk factors.493 RT accelerates pre-existing atherosclerosis leading to increased ACS risk within 10 years of treatment.681
Patients with RT-induced CAD undergoing PCI with bare-metal stent or balloon angioplasty have an increased risk of all-cause and
CV mortality.682 Conversely, after PCI with a drug-eluting stent,
there is no difference in target lesion revascularization or cardiac mortality between patients with and without prior chest RT.683
Surgical revascularization in patients with prior RT may be complicated by poor tissue healing (skin and sternum), RT-induced injury to the left and right internal mammary arteries (LIMA and RIMA, respectively), inadequate target coronary vessels, and increased sternotomy-related pain.684 Pre-operative assessment of internal mammary artery viability, venous access, and sternal wound healing is recommended in CS with RT-induced CAD where CABG is considered. PCI with drug-eluting stents may be considered over CABG
in CS with RT-induced severe left main or three-vessel disease, with a high SYNTAX (SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery) score (.22), in whom the planned PCI is technically feasible given the increased complications associated with CABG after mediastinal RT.
Screening for CAD should be considered in high-risk patients who have received chest RT to a treatment volume including the heart.
Screening should take the form of functional imaging and/or CCTA beginning at 5 years post-RT.234,484 The natural history of RT-related vasculopathy is different to atherosclerosis and may accelerate rapidly.173
Functional cardiac imaging should be considered in asymptomatic CS
with pre-existing CAD or when new signiﬁcant CAD is detected on anatomical imaging. In asymptomatic patients with inducible ischaemia secondary to RT-induced CAD, a MDT is recommended to discuss revascularization needs according to the location of the RT-induced CAD,
the ischaemia burden, LV function, arrhythmia burden, time since treatment, time since previous normal review (if available), concomitant valvular disease, risks of surgical or percutaneous revascularization,
medical options, and patient preference.173
Platinum-based chemotherapies are now recognized to cause
CAD in CS. Cisplatin-based chemotherapy for testicular cancer is associated with a
1.5–7-fold increased risk of developing
CAD.421,493,685 Testicular CS who received platinum-based chemotherapy should have their CVRF tightly controlled and be educated to report any new chest pain or cardiac symptoms to their doctor promptly. The role of screening for CAD in patients who received platinum-based chemotherapy is unknown.
Aggressive risk-factor modiﬁcation and CV diagnostic work-up strongly enhance survival.5,672 Medical therapy with aspirin and statins for primary/secondary prevention, and beta-blockers and nitrates for symptom control, are recommended in CS.686,687
Recommendation Table 42 — Recommendations for adult cancer survivors who develop cancer therapy-related cardiac dysfunction late after cardiotoxic cancer therapy
Recommendations
Classa
Levelb
ACE-I/ARB and/or beta-blockers are recommended in adult CS with moderate asymptomatic CTRCD.c,208,425,675–678
I
C
ACE-I/ARB and/or beta-blockers may be considered in adult CS with mild asymptomatic
CTRCD.d
IIb
C
© ESC 2022
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
CS, cancer survivors; CTRCD, cancer therapy-related cardiac dysfunction; GLS,
global longitudinal strain; LVEF, left ventricular ejection fraction.
aClass of recommendation.
bLevel of evidence.
cNew LVEF reduction by ≥10 percentage points to an LVEF of 40–49% OR new LVEF
reduction by ,10 percentage points to an LVEF of 40–49% AND either new relative decline in GLS by .15% from baseline OR new rise in cardiac biomarkers.
dLVEF ≥50% and new relative decline in GLS by .15% from baseline AND/OR new rise in cardiac biomarkers.
Recommendation Table 43 — Recommendations for adult cancer survivors with coronary artery disease
Recommendations
Classa
Levelb
Asymptomatic radiation-induced CAD detected during surveillance
Non-invasive stress testingc is recommended in asymptomatic CS with new moderate or severe radiation-induced CAD detected on CCTA to guide ischaemia-directed management.635,688
I
C
A MDT discussion is recommended for clinical decision-making in patients with radiation-induced
CAD and inducible ischaemia or severe left main
CAD.
I
C
Symptomatic CAD
Pre-operative assessment of LIMA and RIMA
viability, venous access, and sternal wound healing is recommended in CS with radiation-induced
CAD where CABG is considered.
I
C
Continued


<!-- PAGE 89 -->

### Page 89

8.4. Valvular heart disease
VHD can appear in CS at any point in time but typically occurs
10 or more years after cancer treatment.691 Chest RT is the main risk factor in CS, in particular at higher dose ranges, which can cause either stenosis or regurgitation,
or both.391
The reported incidences of valvular regurgitation are up to
40% of CS survivors who received high-dose chest RT to a volume involving the heart, with ,10% presenting with clinically signiﬁcant VHD.670
Prognosis and management depend on the extent and severity of
VHD, as it does in patients without cancer.692 TAVI should be considered for patients with symptomatic RT-induced severe aortic stenosis at intermediate surgical risk.504,506,693,694 Similar strategies with percutaneous mitral valve repair or replacement can be considered.695 Importantly, commonly used calculators such STS PROM
(Society of Thoracic Surgeons–Predicted Risk of Mortality) or
EuroSCORE
(European
System for
Cardiac
Operative
Risk
Evaluation) II507 may underestimate the surgery-related risk in CS,
and especially those who develop RT-induced VHD, due to additional RT-related risk factors such as pericardial calciﬁcation, aortic calciﬁcation, increased bleeding risk, impaired skin healing, and RT-related pulmonary ﬁbrosis. A Heart Team with cardiac surgeons, interventional cardiologists, and cardio-oncology specialists should review each case to guide appropriate treatment. The Heart Team recommendation should be discussed with the patient, who can then make an informed treatment choice.
8.5. Peripheral artery disease and stroke
Peripheral arterial and cerebrovascular disease in CS can be due to the continuum of vascular disease pre-existing before, or developing during or after cancer therapy. Cancer therapies such as cisplatin,
BCR-ABL inhibitors, and RT can have a direct long-lasting effect on the vasculature. Approximately 30% of CML patients on nilotinib may develop PAD, which is clinically recognized 2–4 years after the start of therapy.698 The disease process may progress even after discontinuation of nilotinib. Long-term vascular effects, generally associated with vascular reactivity, can also be seen in patients treated with ponatinib, cisplatin, and bleomycin.699,700 Accelerated vascular aging, inﬂammation, ﬁbrosis, and atherosclerosis are characteristic consequences of RT.701 Up to 30% of patients may develop signiﬁcant carotid artery stenoses (.70%) after head/neck radiation.702,703
Vascular disease can also be an indirect consequence of cancer and its therapy, e.g. via reduction in physical activity, hyperlipidaemia, DM,
obesity, hypothyroidism, and/or kidney disease. These CVRF-related effects are mostly additive to the direct treatment-related effects.
Promoting vascular health and preventing vascular disease in CS is recommended.672 This should be in line with the 2021 ESC Guidelines on CVD prevention in clinical practice.19
8.6. Pericardial complications
The risk of long-term pericardial complications after cancer drug-induced acute pericarditis, caused by anthracyclines, cyclophosphamide, cytarabine, and bleomycin, is unknown but generally considered low. Long-term dasatinib treatment may lead to pericardial effusion and pericarditis. The incidence of long-term ICI-associated pericardial complications is low.10
RT-induced chronic pericardial diseases can appear months to decades after the initial RT and constrictive pericarditis is the most serious.173,392 Incidence is difﬁcult to determine, and many cases are initially asymptomatic.704 Five-yearly echocardiographic surveillance for pericardial constriction in CS following RT-induced acute pericarditis may be considered. The absolute risk is considerably reduced with modern radiation protocols,704 but a high rate of pericardial effusion has still been reported in patients with lung (grade ≥2,
.40%705) and oesophageal cancer (.25%706) treated with RT.
Pericardial disease has been less investigated than other
RT-induced CVD, and clear protocols for post-therapy surveillance are lacking.707,708 In CS with chronic pericardial effusions following
RT, cardiac imaging can assess for evidence of inﬂammation,
PCI may be considered in CS with radiation-induced CAD with severe left main or three-vessel disease with a high SYNTAX score
(.22) in whom the procedure is technically feasible.682,689,690
IIb
B
© ESC 2022
CABG, coronary artery bypass graft; CAD, coronary artery disease; CCTA, coronary computed tomography angiography; CS, cancer survivors; LIMA, left internal mammary artery;
MDT,
multidisciplinary team;
PCI,
percutaneous coronary intervention; RIMA, right internal mammary artery; SYNTAX, SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery.
aClass of recommendation.
bLevel of evidence.
cAccording to local protocols and Non-invasive imaging in coronary syndromes:
recommendations of the European Association of Cardiovascular Imaging and the
American Society of Echocardiography, in collaboration with the American Society of
Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance recommendations.234
Recommendation Table 44 — Recommendations for adult cancer survivors with valvular heart disease
Recommendations
Classa
Levelb
A MDT approach is recommended to discuss and deﬁne the surgical riskc in CS with severe VHD.
I
C
Continued
TAVI should be considered for patients with symptomatic severe aortic stenosis caused by radiation at intermediate surgical risk.504,506,693,694,696,697
IIa
B
© ESC 2022
CS, cancer survivors; EuroSCORE, European System for Cardiac Operative Risk
Evaluation; MDT, multidisciplinary team; STS PROM, Society of Thoracic Surgeons–
Predicted Risk of Mortality; TAVI, transcatheter aortic valve implantation; VHD,
valvular heart disease.
aClass of recommendation.
bLevel of evidence.
cSurgical risks include: vascular access, sternal and skin wound healing, concomitant cardiac disease,
radiation-induced lung and thoracic vessels disease,
aortic calciﬁcation, STS PROM/EuroSCORE II.
ESC Guidelines
4317


<!-- PAGE 90 -->

### Page 90

constriction, or tamponade.709 Percutaneous balloon pericardiotomy or pericardial window creation should be used in selected cases for large or growing chronic effusions if haemodynamic compromise develops. Management of these conditions should follow general guideline recommendations.14,444
8.7. Arrhythmias and autonomic disease
Arrhythmias, conduction disease, and autonomic disease are common complications in CS. Conduction disease after thoracic RT is typically associated with other CTR-CVT.710 It may include AV
block, bundle branch block, and sick sinus syndrome that should be monitored and treated according to the 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.443
Patients who require valve replacement after thoracic RT have a high risk of post-operative AV block requiring permanent pacemaker therapy.711 Supraventricular and ventricular arrhythmias are more common in patients after thoracic RT,712 possibly due to RT-induced myocardial ﬁbrosis. A common long-term complication after HSCT is supraventricular arrhythmia including AF and atrial ﬂutter,457 particularly in CS treated with anthracyclines or with new CVRF or CV toxicity.
Autonomic dysfunction is an emerging but poorly understood complication observed in CS, and is most frequently observed as a late complication after thoracic RT. Orthostatic hypotension, postural orthostatic tachycardia syndrome, inappropriate sinus tachycardia, and loss of circadian heart rate variability can occur.713,714
Physicians caring for these patients should consider referral for autonomic evaluation. In addition, the perception of angina pain may be impaired,714 making the diagnosis of post-radiation CAD challenging.
Evidence-based pharmacological treatment strategies are based on studies of patients with other autonomic dysfunction aetiologies
(e.g. DM or inﬁltrative diseases) and the reported effectiveness is generally poor.714
8.8. Metabolic syndrome, lipid abnormalities, diabetes mellitus, and hypertension
There is a growing understanding about shared CVRF that may be responsible for cancer development or progression and premature
CV morbi-mortality.34 Modiﬁable CVRF continue to be underdiagnosed and undertreated in CS, especially hypertension,715 obesity,
DM, metabolic syndrome,716 and dyslipidaemia. Early diagnosis via standardized risk-based screening and management of these conditions according to general ESC Guidelines is recommended19 to improve long-term outcomes in CS.672
Increasing numbers of patients with cancer are already overweight or obese at cancer diagnosis,717 and additional weight gain is a frequent complication of anticancer treatments.718 Obesity is associated with metabolic syndrome, worsening CVRF, and cancer.
Increasing evidence indicates that being overweight increases the risk of cancer recurrence and reduces the likelihood of disease-free survival and overall survival among those diagnosed with cancer.719–
724 There is also growing evidence to support intentional weight loss post-treatment in CS, which may result in improved prognosis and survival.719 Dietary patterns characterized by a high intake of vegetables/fruits and whole grains has been shown to be associated with reduced mortality and cancer recurrence when compared with a high intake of reﬁned grains, processed and red meats, and high-fat dairy products.725–727
The identiﬁcation and treatment of hyperlipidaemia in CS is associated with a profound impact on outcomes.182,183 There is a beneﬁt for CS from an all-cause mortality perspective as well as for decreasing cancer recurrence.728–730
Several studies have demonstrated the therapeutic beneﬁts of exercise during primary anticancer treatment,731,732 and exercise is recommended during and after anticancer treatment.11,733 For CS,734
aerobic exercise results in improved survival.735 Based on current guidelines, patients undergoing anticancer therapy and long-term
CS should be encouraged to exercise for at least 150 min per week.736
8.9. Pregnancy in cancer survivors
Improvements in the treatment of cancer have led to an increasing number of female paediatric and adolescent CS who experience pregnancy many years after their oncological treatments.
Approximately 60% of them will have been previously exposed to anthracycline chemotherapy or chest RT and they have a 15-fold increase in their lifetime risk of developing HF.737 As young CS enter their reproductive years and contemplate pregnancy, it is important to understand the impact of cancer and its treatment on fertility,
pregnancy outcomes, and CV health. There are limited data available regarding CV risk in pregnancy following cancer treatments. The overall incidence of LVD or HF associated with pregnancy in female adult CS varies according to the studied population. In a single institution report including 337 female CS treated with cardiotoxic therapies, 58 (17%) had a subsequent pregnancy.738 Cardiac events,
deﬁned as LVEF , 50% on two TTE or new CAD, were identiﬁed in 17 patients.738 Patients with cardiac events were likely to be younger at cancer diagnosis, received a higher cumulative dose of anthracycline, and had a longer delay (in years) from cancer treatment to ﬁrst pregnancy compared with pregnant women with no cardiac event.738 In a recent meta-analysis of six studies, the weighted risk of pregnancy-associated LVD or HF in CS treated with anthracyclines was 1.7% with no reported maternal cardiac deaths.739 Major risk factors for CV events during pregnancy in CS include CTRCD (incidence 28%; 47.4-fold higher odds),739 younger age at cancer diagnosis,738,740 longer time from cancer treatment to ﬁrst pregnancy, and cumulative anthracycline dose.738
Recommendation Table 45 — Recommendation for adult cancer survivors with pericardial complications
Recommendation
Classa
Levelb
Patients with acute pericarditis during RT to a volume including the heart are at higher risk of developing chronic constrictive pericarditis, hence echocardiography surveillance every 5 years may be considered.
IIb
C
© ESC 2022
RT, radiotherapy.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 91 -->

### Page 91

Management by an expert MDT (the pregnancy heart team) is recommended for all CS with CTRCD who are considering pregnancy.739,741,742 The risk of HF in CS without CTRCD is low,
although vigilance remains important for potential maternal cardiac complications.
8.10. Pulmonary hypertension
Long-term clinical evaluation may be considered in patients who develop PH during therapy (Section 6). In patients with new exertional dyspnoea, fatigue, or angina, a TTE is recommended to assess the probability of PH. As TTE alone is not enough to conﬁrm the diagnosis of PH, CS diagnosed with high PH probability require a right-heart catheterization to conﬁrm the diagnosis. PH should be treated according to general guidelines with referral to a specialist PH service.620
9. Special populations
9.1. Cardiac tumours
Cardiac tumours are classiﬁed as either benign or malignant.743 Over
90% of primary cardiac tumours are benign (myxomas are predominant in adults, rhabdomyomas in children).744 Malignant primary tumours most commonly consist of sarcomas (approximately
65%) or lymphomas (approximately 25%).745 Cardiac metastases
(from melanoma, lymphoma, leukaemia, breast, lung, and oesophageal cancers) are much more common than primary cardiac tumours
(Figure 39).746 Presenting symptoms are paraneoplastic (fever, weakness, fatigue), thromboembolic, haemodynamic (due to compression or obstruction from the tumour) or arrhythmic.747,748
The diagnostic pathway should be based on knowledge about tumour type epidemiology, imaging features, and usually the requirement for a histopathological diagnosis. This topic has been extensively reviewed in
ESC CardioMed,749 and here we summarize the main recommendations for differential diagnosis and management. Differential diagnosis should exclude cardiac thrombi or the presence of chemotherapy catheters. Imaging must assess the possibilities of cardiac surgery, and may include: (1) echocardiography (initial approach using TTE or transoesophageal echocardiography)748,750; (2) CMR (for cardiac tumour tissue characterization)751,752; and (3) CT and PET (to distinguish malignant from benign lesions and assess for non-cardiac metastatic disease or primary cancers) (Figure 40).753,754
Myxomas are primarily treated with surgery with a good prognosis. Malignant tumours are associated with a poor prognosis and evidence of the best treatment is lacking. Complete surgical resection is often impossible and adjuvant RT, systemic chemotherapy, and/or debulking palliative surgery are needed.755 Cardiac aggressive B-cell lymphomas require histopathological diagnosis (often obtained via analysis of pericardial effusion, EMB, or direct surgical biopsy) and are treated with chemotherapy,
possibly followed by
RT
(Table 13).756
9.2. Pregnant patients with cancer
The diagnosis of cancer during pregnancy is uncommon (1 in every
1000 pregnant women is diagnosed with cancer), with BC, melanoma, and cervical cancer being the most frequent diagnoses.757
Chemotherapy is generally not applied during the ﬁrst trimester due to the high risk of foetal congenital abnormalities (up to 20%)
and cytotoxic chemotherapies have different risk proﬁles during the second or third trimesters.758,759 Furthermore, chemotherapy administration is usually not given beyond week 34 of gestation to provide a 3-week window between the last cycle and delivery.757
Supplementary data, Table S19 summarizes the chemotherapies for pregnant patients with cancer.760,761
Cardiac assessment prior to chemotherapy in pregnant women with cancer should consist of clinical history, physical examination,
ECG, cardiac biomarker assessment and TTE (Figure 41).741
Baseline and follow-up TTE should be interpreted in the context of physiological haemodynamic alterations during pregnancy. In normal pregnancy, increase in stroke volume, heart rate, and pre-load blood volume, and decrease in systemic vascular resistance, lead to an increase in cardiac output from the ﬁrst trimester to 80–85%
above baseline by the third trimester.762–764 An increase in LV
mass and LV and RV volumes is observed in the third trimester.
During normal pregnancy, LVEF is usually unchanged and can be used for CTRCD monitoring. Although NP and cTn may be slightly elevated during normal pregnancy (NT-proBNP , 300 ng/L, BNP ,
100 pg/mL,14 and hs-cTnT765,766), serial evaluation may be useful for
Recommendation Table 46 — Recommendations for cardiovascular monitoring in cancer survivors during pregnancy
Recommendations
Classa
Levelb
In high-risk female CS, pre-pregnancy counselling and management during pregnancy and around delivery by a multidisciplinary pregnancy heart team is recommended.
I
C
A baseline CV evaluation including history,
physical examination, ECG, NP, and echocardiography is recommended in female CS
with a history of CTRCD who are considering pregnancy.
I
C
A baseline CV evaluation including history,
physical examination, ECG, and echocardiography should be considered in all female CS who received potentially cardiotoxic cancer therapy and are considering pregnancy.
IIa
C
A CV evaluation including echocardiography is recommended at 12 weeks of pregnancy in female
CS who are either high-risk or who received potentially cardiotoxic cancer therapy and did not have a baseline CV assessment.
I
C
A second CV evaluation including echocardiography should be considered at 20
weeks of pregnancy in high-risk female CSc who received potentially cardiotoxic cancer therapy.
IIa
C
© ESC 2022
CS, cancer survivors; CTRCD, cancer therapy-related cardiac dysfunction; CV,
cardiovascular; ECG, electrocardiogram, NP, natriuretic peptides.
aClass of recommendation.
bLevel of evidence.
cSee Tables 11 and 12.
ESC Guidelines
4319


<!-- PAGE 92 -->

### Page 92

close CTRCD monitoring during cancer treatment with the higher cut-off NP levels for pregnancy.
The topic of CVD during pregnancy has been extensively reviewed in the 2018 ESC Guidelines for the management of CVD
during pregnancy.741 Here we focus on speciﬁc recommendations in pregnant women with cancer receiving anthracycline chemotherapy.
9.2.1. Left ventricular dysfunction and heart failure
Medical history evaluating signs and symptoms of HF should be performed at every clinical visit of pregnant women with cancer receiving anthracycline chemotherapy. More frequent CV evaluations with
TTE during treatments with potential CTRCD risk should be advised
(e.g. every 4–8 weeks or every two cycles for a 3-weekly anthracycline chemotherapy cycle). The management of clinical HF or asymptomatic
LVD during pregnancy is fully described in the 2018 ESC Guidelines for the management of CVD during pregnancy.741
9.2.2. Venous thromboembolism and pulmonary embolism
Pregnant patients with cancer have an increased risk of developing
VTE,
especially when hospitalized.767–769
Identiﬁed risks for VTE in pregnant patients include having a history of BC or previous chemotherapy in the past 6 months.
Lipoma
Metastasis
Myxoma
Sarcoma
Left atrium
Lung tumours
Sarcoma
Pulmonary veins
Fibroelastoma
Metastasis
Valves
Left ventricle
Fibroma
Lipoma
Lymphoma
Metastasis
Rhabdomyoma
Sarcoma
Leiomyoma
Renal tumour
Inferior cava vein
Right atrium
Lipoma
Lymphoma
Metastasis
Myxoma
Sarcoma
Right ventricle
Fibroma
Lipoma
Lymphoma
Metastasis
Rhabdomyoma
Pericardium
Lipo-sarcoma
Lipoma
Lymphoma
Mesothelioma
Metastasis
Sarcoma
Pulmonary artery
Figure 39 Location of primary and secondary cardiac tumours.


<!-- PAGE 93 -->

### Page 93

CTb
Echocardiographya
PETd
CMRc
Secondary tumour
(metastasis)f
Benign primary tumour
Malignant primary tumour
Diagnostic algorithm for cardiac masses
Non-invasive assessment of single or multiple cardiac masses
Tumour
Type
Thrombus, vegetation, structural
Consider cardiac mass biopsy if malignant primary tumour suspected or diagnosis uncertain on imaginge
Lymphoma
Sarcoma
Angioma, lipoma, papillary fibroelastoma
Myxoma 
Leukaemias 
Lymphomas
Melanomas
Solid tumours: breast, lung,
and oesophageal cancers
Figure 40 Diagnostic algorithm for cardiac masses. CMR, cardiac magnetic resonance; CT, computed tomography; PET, positron emission tomography; TTE, transthoracic echocardiography. aTTE/transoesophageal echocardiography: location, size, and haemodynamic disturbances. Contrast echocardiography to assess vascularization. bIdentify primary extra-cardiac malignancy. Reveal extra-cardiac changes. Staging of malignant lesions. cTissue characterization (fat inﬁltration, necrosis, haemorrhage, calciﬁcation, and vascularization). Exclude thrombus. dDistinguish malignant vs. benign lesions.
Staging of malignant lesions. eMass biopsy of suspected primary malignant cardiac tumours and/or biopsy of extracardiac masses if detected and safer to biopsy. f20–30 times more likely than primary tumours.
Table 13
Management strategies and surgery indications for symptomatic and asymptomatic patients with benign and malignant cardiac tumours
Classiﬁcation
Management strategies
Surgery indications
Benign tumours
Asymptomatic
MDT discussion is required considering: tumour type,
location, size, growth rate, and likelihood of embolism.
Anticoagulation should be considered for left-sided tumours or right-sided tumours associated with an intracardiac shunt, according to the individual’s embolic and bleeding risk
If left-sided and endocardial: even if small and incidental, a
MDT is needed to consider the indication for surgical removal due to the embolic risk
Symptomatic
Non-surgical management for:
• Rhabdomyomas (possible spontaneous regression)
• Intramural haemangioma (possible response to corticosteroids)
• Unresectable cases: if antiarrhythmic therapy is sufﬁcient
Surgical resection is indicated in all other cases.
For large, benign, unresectable, symptomatic cardiac tumours (obstruction, severe HF, or malignant arrhythmias), heart transplantation may be indicated in some cases
Malignant tumours
Asymptomatic
Histopathological diagnosis is required
If primary cardiac sarcoma, a complete surgical resection may increase survival
Symptomatic
Chemotherapy and/or RT are the only therapeutic options for secondary cardiac tumours.
If primary cardiac lymphoma: chemotherapy
Secondary cardiac tumours may also be treated with palliative cardiac surgery
© ESC 2022
HF, heart failure; MDT, multidisciplinary team; RT, radiotherapy.
ESC Guidelines
4321


<!-- PAGE 94 -->

### Page 94

Recommendations for the diagnosis and treatment of PE during pregnancy are the same as in the general 2018 ESC Guidelines for the management of CVD during pregnancy741 and 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism.566
Determination of VTE risk score and the use of thromboprophylaxis protocols may be useful to prevent maternal morbidity and/or mortality due to VTE.770 LMWH have become the drug of choice for the prophylaxis and treatment of VTE in pregnant patients.741 The recommendation for thromboprophylaxis should be individualized, weighing the risks of bleeding vs. thromboembolism in pregnant patients with cancer.
1st trimester
Follow-up
Anthracycline chemotherapy
1st trimester
Anthracycline chemotherapy
Follow-up
ECG
TTE
Physical examination
Baseline
Week
12
Week
20
Every visit
Every
4–8 W
Week
34
Delivery
12 M
Cardiac monitoring protocol for pregnant women receiving anthracycline-based chemotherapy
ECG
cTn/NP
Class 1
Class 1Ia
Class 1Ib
Figure 41 Cardiac monitoring protocol for pregnant women receiving anthracycline-based chemotherapy. cTn, cardiac troponin; ECG, electrocardiogram; M, months; NP, natriuretic peptides; TTE, transoesophageal echocardiography; W, week.


<!-- PAGE 95 -->

### Page 95

9.3. Carcinoid valvular heart disease
Carcinoid tumours represent rare neuroendocrine malignancies originating from the enterochromafﬁn cells (Figure 42).771 Carcinoid syndrome is a rare cause of acquired VHD including mainly rightsided valvular lesions, but also left-sided involvement, pericardial effusion, and myocardial metastases.772 Coronary artery vasospasm and paroxysmal atrial or ventricular tachycardias may rarely occur due to sympathetic stimulation. Cardiac metastases are reported with an incidence of 3.8% on the ventricles, conﬁrmed by PET-CT
scans.773,774 Data from the SEER (Surveillance, Epidemiology, and
End Results) registry identiﬁed that approximately 20% of patients with neuroendocrine malignancies develop carcinoid syndrome
(7.6–32.4%), which is associated with shorter survival (4.7 years compared with 7.1 years in patients without carcinoid syndrome)
and poor quality of life.775 It is estimated that 20–50% of these patients present cardiac involvement, especially of the right-sided cardiac valves.771 In the presence of a patent foramen ovale, interatrial shunt, primary bronchial neuroendocrine tumour, or extensive liver metastases, humoral substances directly enter the systemic circulation, causing left-sided valvular involvement in up to one-third of cases.776
NP should be considered for screening and surveillance of patients at risk of carcinoid cardiac involvement and TTE is recommended in patients with NT-proBNP . 260 pg/mL or clinical signs or symptoms.777–780 In asymptomatic patients with NT-proBNP , 260 pg/
mL, repeat clinical and NP assessment should be considered every
6 months.
Survival has improved in carcinoid tumours, with the use of somatostatin analogues and surgical techniques in liver metastasis.
However, right HF still represents a major cause of death.781,782
Many patients with severe tricuspid regurgitation due to carcinoid syndrome require both tricuspid and pulmonary valve surgery.783
Administration of i.v. somatostatin analogues (e.g. octreotide) is recommended to avoid a peri-operative carcinoid crisis. The infusion should be started on the morning of the procedure (up to 12 h preoperatively), continued throughout the procedure (surgery, preoperative coronary angiography, pacemaker implantation), and postoperatively for at least 48 h following valve surgery or until stable if a carcinoid crisis is triggered post-operatively.772
The optimal choice of valve prosthesis is still a matter of debate due to the balance of risk of both accelerated bioprosthetic valve degeneration vs. bleeding risks in patients with extensive liver metastases requiring therapeutic anticoagulation for mechanical valves.784,785
Complications include AV block, requiring pacemaker implantation in 25% of patients.786 Frequently, the reduced RV function does not improve despite tricuspid valve replacement and HF persists.787
Thrombus formation on the tricuspid bioprosthesis can occur, especially during the ﬁrst 3 months post-operatively, and oral anticoagulation with VKA may be considered. Persistent serotonin elevation can cause recurrent bioprosthesis valve ﬁbrosis. Valve-in-valve transcatheter intervention has been reported in bioprosthetic valve failure in metastatic carcinoid heart disease; however, future research is needed to deﬁne its role.783,788,789
In patients with left-sided carcinoid valvular involvement, closure of interatrial shunts should be considered, although only sparse data exist for this approach.
Recommendation Table 47 — Recommendations for cardiovascular assessment and monitoring of pregnant women with cancer
Recommendations
Classa
Levelb
Management by an expert MDT (the pregnancy heart team) in an expert centre is recommended for pregnant women with cancer who require cardiotoxic cancer therapy.741
I
C
Cardiac assessment prior to cardiotoxic cancer therapy in pregnant women is recommended and consists of clinical history, physical examination,
ECG, and echocardiography.741
I
C
Monthly or bimonthly CV evaluation, including
TTE, should be considered during cardiotoxic cancer therapyc in pregnant women with cancer.
IIa
C
cTn may be considered at baseline and during anthracycline chemotherapy in pregnant women with cancer.
IIb
C
© ESC 2022
cTn,
cardiac troponin;
CV,
cardiovascular;
ECG,
electrocardiogram;
MDT,
multidisciplinary team; TTE, transthoracic echocardiography.
aClass of recommendation.
bLevel of evidence.
cFor patients receiving anthracycline-based chemotherapy.
Recommendation Table 48 — Recommendations for carcinoid valvular heart diseases
Recommendations
Classa
Levelb
Echocardiographyc is recommended for the detection of carcinoid cardiac involvement in all patients with carcinoid syndrome and elevated NP
levels and/or clinical signs of carcinoid heart disease, and for surveillance every 3 or 6 months depending on the severity of cardiac involvement and clinical status.772,790,791
I
B
NP should be considered for screening and surveillance of carcinoid heart disease every 6
months.777–780
IIa
B
A MDT discussion for optimal medial management to prevent carcinoid crisis is recommended before any invasive or surgical cardiac procedure.
I
C
Valve replacement surgery is recommended in symptomatic patients with severe carcinoid tricuspid or pulmonary VHD and an expected survival ≥12 months.d,783,785
I
C
Valve replacement surgery should be considered in patients with asymptomatic severe carcinoid tricuspid or pulmonary VHD, progressive RV
dysfunction/dilatation, and an expected survival
≥12 months.d,772
IIa
C
Continued
ESC Guidelines
4323


<!-- PAGE 96 -->

### Page 96

9.4. Amyloid light-chain cardiac amyloidosis
Amyloid light-chain amyloidosis is a plasma cell dyscrasia, which is typically treated with therapies very similar to those used in
MM, including PI-based therapy.792 It can occur in conjunction with myeloma or independently as a light-chain proteinproducing disorder. Amyloid light-chain amyloidosis is a systemic disease 793,794 and it is critical to have a high degree of suspicion for the diagnosis of cardiac involvement (amyloid light-chain cardiac amyloidosis [AL-CA]) because a combination of specialized tests is needed to make an accurate diagnosis (Figure 43).290,793,795,796
Valve replacement or repair surgery is recommended in symptomatic patients with severe carcinoid mitral or aortic VHD and an expected survival ≥12 months.783,785
I
C
© ESC 2022
MDT, multidisciplinary team; NP, natriuretic peptides; RV, right ventricular; VHD,
valvular heart disease.
aClass of recommendation.
bLevel of evidence.
cIncluding saline contrast infusion at baseline to rule out patent foramen ovale.
dWith controlled serotonin concentrations.
Flushing
Bronchoconstriction
Diarrhoea
Ascites
Peripheral oedema
Pleural effusion
Carcinoid heart disease: clinical featuresand diagnostic tests
Clinical features
Diagnostic and pronostic tools
TTE
Circulating serotonin
NP
Urinary 5HIAA
CMR
Figure 42 Carcinoid heart disease: clinical features and diagnostic tests. 5HIAA, 5-hydroxyindoleacetic acid; CMR, cardiac magnetic resonance; NP,
natriuretic peptides; TTE, transthoracic echocardiography.


<!-- PAGE 97 -->

### Page 97

Proteinuria
Renal impairment
Kidney
CV
Dyspnoea
Peripheral oedema
AF/flutter
HFpEF or unexplained right HF
Hypotension or syncope
Nerves
Orthostatic hypotension
Peripheral polyneuropathy
Polyneuropathy
GI
Constipation /diarrhoea
Macroglossia
Malabsorption/weight loss/nausea
Bruising
Skin
Laboratorya
ECGb
TTEc
Characteristic echo findingse
ECHO score ≥8d
CMRf
Non-invasive diagnosis of AL-CA
Clinical features
Investigations
Figure 43 Non-invasive diagnosis of amyloid light-chain cardiac amyloidosis. a′, late diastolic velocity of mitral annulus obtained by tissue Doppler imaging; AF, atrial ﬁbrillation; AL-CA, amyloid light-chain cardiac amyloidosis; CMR, cardiac magnetic resonance; CV, cardiovascular; E, mitral inﬂow early diastolic velocity obtained by pulsed wave; e′, early diastolic velocity of mitral annulus obtained by tissue doppler imaging; ECG, electrocardiogram; echo,
echocardiography; ECV, extracellular volume fraction; GI, gastrointestinal; GLS, global longitudinal strain; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; IVS, interventricular septum; LGE, late gadolinium enhancement; LV, left ventricular; LVEDD, left ventricular end diastolic diameter; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PW, left ventricular posterior wall; s′, systolic velocity of tricuspid annulus obtained by
Doppler tissue imaging; SPEP, serum protein electrophoresis; TAPSE, tricuspid annular plane systolic excursion; TTE, transthoracic echocardiography;
UPEP, urine protein electrophoresis. Individually, the clinical manifestations and ﬁndings on cardiac testing for AL-CA are non-speciﬁc. Integration of all clinical and diagnostic ﬁndings is necessary when assessing the likelihood of the diagnosis. aDisproportionately high NT-proBNP; persisting elevated troponin levels; abnormal free light-chain levels (AL-CA); positive SPEP and/or UPEP (AL-CA). bDisproportionally low QRS voltage; early conduction system disease; pseudo-infarct pattern. cUnexplained LV thickness ≥12 mm + 1 or 2 characteristic echo ﬁndings or ECHO score ≥8; idiopathic pericardial effusion. dECHO score: relative LV wall thickness (IVS + PW/LVEDD) . 0.6 (3 points), Doppler E/e′ . 11 (1 point); TAPSE ≤19 mm (2 points);
GLS ≥−13% (1 point); systolic longitudinal strain apex to base ratio.2.9 (3 points). eCharacteristic echocardiography ﬁndings: grade ≥2 diastolic dysfunction; reduced s′, e′, and a′ velocities (,5 cm/s); decreased GLS to ≥−15%. fDiffuse subendocardial or transmural LGE; elevated native T1 values;
abnormal gadolinium kinetics (myocardial nulling preceding or coinciding with the blood pool); ECV ≥0.40% (strongly supportive).
ESC Guidelines
4325


<!-- PAGE 98 -->

### Page 98

Cardiac serum biomarkers are an essential step in the diagnostic and prognostic assessments for these patients.797–799 AL-CA has been extensively reviewed in a recent position paper from the
Working Group on Myocardial and Pericardial Diseases.290
The classical non-invasive deﬁnition of AL-CA is based on clinical suspicion, biomarkers, TTE, CMR, and nuclear scintigraphy criteria
(Figure 43). Persistent troponin elevation and disproportionately high NT-proBNP (generally .300 ng/L in the absence of renal failure or AF) to ventricular function parameters on TTE is a characteristic red ﬂag for AL-CA.800 A decrease in GLS with a distinctive apical sparing pattern (preserved GLS values in the LV
apical region) is considered speciﬁc for cardiac amyloidosis, although it is not helpful to distinguish between amyloid light-chain and transthyretin amyloidosis.801 Additionally, GLS ≥−15% may serve as an independent prognostic factor of poor overall survival in patients with AL-CA.802 CMR with LGE and parametric imaging has emerged as a new non-invasive gold-standard for diagnosis
(Figure 43).803,804 Nuclear scintigraphy can differentiate transthyretin amyloidosis from AL-CA supported by the presence of monoclonal protein.290 EMB should be considered in patients with suspected AL-CA involvement if CMR is not diagnostic.290 A rare condition that may coexist with AL-CA is light-chain deposition disease, which frequently associates extensive renal involvement and poor prognosis.799
Recently, a staging system for AL-CA has demonstrated the prognostic impact of cTnT and NT-proBNP levels.797 Heart progression criteria are deﬁned by NT-proBNP progression (.30% and
.300 ng/L increase), cTnT progression (≥33% increase) or ejection fraction decrease (≥10% decrease).805–807 However, evaluating a cardiac response to treatment using a decrease in NT-proBNP levels and New York Heart Association class improvement is still challenging.
AL-CA frequently results in HF, major cardiac arrhythmias, orthostatic hypotension, sudden cardiac death, and an increased risk of arterial and venous thrombosis.808–810 Beta-blockers, ACE-I, ARB, or angiotensin receptor-neprilysin inhibitor may not be well tolerated because of hypotension.290 The management of AF is very complex in this population. Amiodarone is the preferred antiarrhythmic treatment and digitalis should be used with caution. Anticoagulation is recommended in all AL-CA patients with AF independent of the
CHA2DS2-VASc score due to the high prothrombotic risk unless there is a contraindication.290 Currently, the guidelines for implanted devices, including pacemakers and ICDs, do not provide speciﬁc recommendations for AL-CA and decisions should be individualized after a MDT discussion.811
Optimal systemic therapy for AL-CA is rapidly changing, and the efﬁcacy of certain combination therapies continues to improve.812,813 Autologous HSCT for AL-CA is not universally utilized but is a viable treatment option.814 Therapies for AL-CA are evolving, and daratumumab and PI show promise for improved outcomes.792,815–817 Clinical observations, but no RCT evidence,
suggest the potential role of doxycycline to improve survival in patients with AL-CA.818,819
9.5. Cardiac implantable electronic devices
RT can cause malfunction of cardiac implantable electronic devices (CIEDs).443,823 The risk of RT-induced CIED malfunction generally increases with the radiation dose,824,825 although the strongest predictor of malfunction is the magnitude of exposure to neutron emission from high-energy photon RT, conventionally deﬁned as a beam energy .10 megavolts (MV).824,826,827
Non-neutron-producing treatment is therefore preferable in patients with a CIED.826
RT-induced CIED malfunction can manifest in: (1) transient interference, with inappropriate triggering during the irradiation only; (2)
a reset, reverting to backup settings, recoverable with device reprogramming; and, rarely (3) permanent damage to the device due to direct CIED irradiation.826,827
The clinical consequences of a CIED malfunction include the inhibition of pacing and inappropriate pacing at maximum sensor rate.826
The clinical effects of device malfunction are greatest when the patient is pacing-dependent. Theoretically, oversensing might lead to inappropriate ICD shocks, although this has not been reported in the literature.826
More recent registries have reported minimal or no adverse effects of RT on CIED malfunction.827,828 Nevertheless, as it is not possible to predict the behaviour of a CIED within or close to an RT
treatment volume, general recommendations should be followed to minimize patient risk (Figures 44–46).188,824,825
Patients with a CIED should be reviewed by their cardiologist/
electrophysiologist to assess the risk of CIED malfunction and
Recommendation Table 49 — Recommendations for amyloid light-chain cardiac amyloidosis diagnosis and monitoring
Recommendations
Classa
Levelb
Echocardiography, NP, and cTn are recommended for the diagnosis of AL-CA in patients with plasma cell dyscrasia.290,820–822
I
B
CMR is recommended in patients with suspected
AL-CA.290,803,804
I
A
EMB should be considered in patients with suspected AL-CA involvement if CMR is not diagnostic.290
IIa
C
Admission with inpatient ECG monitoring should be considered for high-risk patients with AL-CA
requiring PI during their ﬁrst cycle of therapy.c,808,811
IIa
C
© ESC 2022
AL-CA, amyloid light-chain cardiac amyloidosis; CMR, cardiac magnetic resonance; cTn,
cardiac troponin; ECG, electrocardiogram; EMB, endomyocardial biopsy; HFA, Heart
Failure Association; ICOS, International Cardio-Oncology Society; NP, natriuretic peptides; PI, proteasome inhibitors.
aClass of recommendation.
bLevel of evidence.
cAccording to baseline evaluation using HFA-ICOS PI risk assessment tools (see
Section 4).


<!-- PAGE 99 -->

### Page 99

patients should be informed of the potential risks of RT.443 For patients with rate-adaptive pacemakers, consideration should be given to temporary deactivation of the sensor during RT. Although inactivation of antitachycardia therapies in patients with ICDs is recommended in several publications, by either reprogramming or application of a magnet to ICDs, it is infrequently performed in clinical practice.826
CIEDs should not be placed directly in the RT treatment volume and the cumulative dose should not exceed 2 Gy to a pacemaker or 1 Gy to an ICD.827 If the CIED is situated in the path of the planned radiation beam, it could also interfere with adequate tumour treatment. The photon beam energy should be kept ,10 MV as the risk of device malfunction/damage increases above this threshold. If higher doses are needed or if the CIED cannot be kept out of the beam, consideration should be given to removing and relocating the CIED away from the beam, although this will only very rarely be necessary. The main reason for device relocation is to allow adequate RT treatment of the tumour, but consideration should also be given to possible
RT-induced CIED malfunction/damage with consequent need for
CIED replacement.826 However, CIED explant and resiting carries signiﬁcant risks, including the risk of infection, which may be of
Pacingdependent or frequent ICD
therapies 
Pacingindependent
<5 Gy
≥5 Gy
<10 Gy or neutrons <10 MV
≥10 Gy or neutrons ≥10 MV 
Patient
Assessing risk of RT to CIED
Dose region and risk category
Low risk
High risk
Medium risk
CIED in the RT
treatment volume
YES
NO
Risk areas
Figure 44 Risk stratiﬁcation in patients with a cardiac implantable electronic device undergoing radiotherapy. CIED, cardiac implantable electronic device; Gy, Gray; ICD, implantable cardioverter deﬁbrillator; MV, megavolt; RT, radiotherapy.
ESC Guidelines
4327


<!-- PAGE 100 -->

### Page 100

particular importance in patients receiving chemotherapy or those who are immunosuppressed. For most patients in whom deﬁnitive tumour treatment is planned, the risk/beneﬁt ratio will usually favour device relocation, whereas for patients receiving palliative RT or with signiﬁcant comorbidities, relocation could be avoided.826 These decisions should be made by a MDT in conjunction with the patient. Device relocation is not recommended for CIEDs receiving a maximum cumulative incident dose of ,5 Gy, where the risk is considered negligible.826,828
There should be continuous visual and voice contact with the patient during each treatment fraction. CIEDs should be periodically checked in patients with ICDs, especially those receiving .10 MV
OR
Consider moving CIED
CIED evaluation:
Leave device in situ
CIED evaluation:
fof re RT
R
b
ECG and/or pulse oximetry monitoring and external pacing available a
during RT sessions
R
Week
W
ly during RT
R
Reduce radiation energ r y to minimize exposure to neutrons
Limit cumulative dose
Befof reRT
R
b (Class I)
Audio-visual monitoring ow-risk patients
High-risk patients
CIED in the RT t
R
reatment volume
MDTa
Consider RT type and dose
R
(Figure 46)
CIED check-up after completing RT
R
(Class I)
Pacing dependent or frequent ICD therapies
Maximum cumulative incident dose of >5 Gy
(Class I)
N
N
N
Risk stratification of patients with CIED underg r oing thoracic RT
R
Y
Y
Y
Figure 45 Management of patients with a cardiac implantable electronic device located in the radiotherapy treatment beam. CIED, cardiac implantable electronic device; ECG, electrocardiogram; Gy, Gray; ICD, implantable cardioverter deﬁbrillator; MDT, multidisciplinary team; N, no; RT, radiotherapy; Y,
yes. aMultidisciplinary discussion must consider: (1) whether the CIED is interfering with the RT dose delivered to the tumour; (2) whether the
RT is interfering with CIED function (aim to not exceed 2 Gy to permanent pacemaker and 1 Gy to ICD); (3) risks of moving the CIED: infection (especially in immunocompromised patients), procedural complications (e.g. bleeding with thrombocytopaenia); for younger patients with good prognosis,
consider long-term effects of losing an access site (lead extraction/RT-induced thrombosis). bIf last CIED check .3 months earlier.


<!-- PAGE 101 -->

### Page 101

photon beam energy.827,829 For patients receiving electron or kV
photon beam RT, CIED evaluation appears largely unnecessary.827
For patients treated with proton beam RT, special consideration should be paid to the neutron component of the beam, as the risk of CIED reset is potentially signiﬁcant.824,830 The CIED should be rechecked within 2 weeks of completion of RT treatment. Systematic remote CIED monitoring may be helpful to optimize the patient’s surveillance.831
Low-risk patients
High-risk patients
Low-risk patients
High-risk patients
High-risk patients
RT type and dose
R
Pacing-dependent
CIED evaluation:
CIED evaluation:
CIED evaluation:
CIED evaluation:
Befof reRT
R
a (Class I)
Audio-visual monitoring
Befof reRT
R
a
Week
W
ly during RT
R
ECG and/or pulse oximetry monitoring and external pacing available a
during RT sessions
R
Befof re RT
R
a
Week
W
ly during RT
R
ECG and/or pulse oximetry monitoring and external pacing available a
during RT sessions
R
Befof re RT
R
a (Class I)
Audio-visual monitoring
CIED check-up after completing radiotherapy p
(Class I)
(Class I)
(Class I)
Pacing-dependent or frequent ICD therapies
Neutron-generating RT
R
or dose ≥2 Gy
<10 MV photons or
2–9 Gy
≥10 MV photons or
≥10 Gy
Non-neutron-generating RT
R
or dose <2 Gy
Management of patients with CIED located outside the RT t
R
reatment volume
N
N
Y
Y
Figure 46 Management of patients with a cardiac implantable electronic device located outside the radiotherapy treatment volume. CIED, cardiac implantable electronic device; ECG, electrocardiogram; Gy, Gray; ICD, implantable cardioverter deﬁbrillator; MV, megavolt; N, no; RT, radiotherapy;
Y, yes. aIf last CIED check .3 months earlier.
ESC Guidelines
4329


<!-- PAGE 102 -->

### Page 102

### 10 Patient information,

communication, and self-management
Collaboration between different healthcare professionals and patients is of paramount importance for the most effective management of patients with cancer and CVD. Appropriate language and communication should be used to allow patients to receive clear and accurate information about their condition, and play an active role in managing their treatment.11
The ﬁrst goal of this process is to raise the patient’s awareness of the possible presence or development of a CVD, either during cancer or after having some oncological therapy. Patients should understand that cancer and CVD share many CVRF and reducing risk is vital for the prevention of cancer, cancer relapse, and the development or worsening of a CVD during or after treatment. Patients should be informed—at the end of chemotherapy—that a personalized follow-up plan and regular CV controls are needed to detect potential reversible stages of CV toxicities. Education, counselling,
and support to promote healthy lifestyle and to treat modiﬁable
Recommendation Table 50 — Recommendations for riskstratiﬁcationandmonitoringforpatientswithcardiac implantable electronic devices undergoing radiotherapy
Recommendations
Classa
Levelb
Risk stratiﬁcation including planned radiation type and energy, dose to CIED, the patient’s device type, and pacing dependence is recommended prior to starting treatment.824,825,827,828
I
C
In patients undergoing RT, a CIED check is recommended in all patients before and after completing RT, and during RT according to individual risk.824,826
I
C
In patients with a CIED undergoing RT at high risk of arrhythmia and/or device dysfunction, ECG
monitoring and/or pulse oximetry are recommended during every RT session.827,829,831
I
C
© ESC 2022
CIED, cardiac implantable electronic device; ECG, electrocardiogram; RT, radiotherapy.
aClass of recommendation.
bLevel of evidence.
Interaction between healthcare professionals and patients with cancer
Information
Raise awareness of possible CVD
with cancer
Understand shared risk factors for cancer and CVD
Appropriate lifestyle modification
Active treatment of CVRF
Recognition and report of early CV
symptoms and signs
Regular CV follow-up 
(also if asymptomatic)
Don’t stop cardioprotective therapy without medical advice
Timely EoL and
DNR discussion
Education, counselling, and support
Consider specific psychologic and social conditions
Aid of digital health tools or information leaflets
Appropriate language and communication
Figure 47 Patient information, communication, and self-management. CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; DNR, do not resuscitate; EoL, end of life.


<!-- PAGE 103 -->

### Page 103

CVRF should be offered to patients with cancer, in order to reduce the burden of complications during and after anticancer therapy.
Patients should receive guidance to recognize and to report signs and symptoms of CVD, in order to receive prompt and effective treatment, ideally without interfering with their cancer treatment. Patients should also be advised not to stop cardioprotective therapies without medical guidance, even if they recover their cardiac function. To help in this complex task, leaﬂets speciﬁcally designed for this context may be used,832,833 eventually with the aid of digital tools (Figure 47).
11. The role of scientiﬁc societies in the promotion and development of cardio-oncology in modern medicine
Cardio-oncology is a subspecialty that has seen huge development and growth in recent years with the formation—in almost all national and international societies—of cardio-oncology working groups.
Moreover, cancer and medical associations have also developed an increasing interest in cardio-oncology. Important roles of these scientiﬁc societies are clinical research, education, and advocacy. The ESC-CCO
strategic plan and mission include improvement of prevention, diagnosis, treatment, and management of CTR-CVT and enhancement of the standard of care for patients with cancer (Figure 48).
12. Key messages
This is the ﬁrst ESC cardio-oncology Guideline and contains 272 new recommendations. The key messages from this guideline are:
• A guiding principle of cardio-oncology is integration, and cardio-oncology providers must have knowledge of the broad scope of cardiology, oncology, and haematology. Communication between different healthcare professionals is critical to optimize the care of patients with cancer and CVD.
• Cardio-oncology programmes facilitate cancer treatment by minimizing unnecessary cancer therapy interruptions and CTR-CVT
The role of scientific societies in the promotion and development of cardio-oncology
Cardiooncology
Advocacy
Research
Education
Engagement
Basic and translational research
Clinical research
Long-term survivorship programmes
Appropriate resources
Communication
Knowledge
Organization
Community level
International level
National level
Regional level
Political strategies against cancer and CVD
Community
Healthcare authorities
Healthcare professionals
Patients
Communication strategies
Figure 48 The role of scientiﬁc societies in the promotion and development of cardio-oncology. CVD, cardiovascular disease.
ESC Guidelines
4331


<!-- PAGE 104 -->

### Page 104

across the entire continuum of cancer care. In patients who develop CTR-CVT, a MDT discussion is required to balance the risk/beneﬁt of cancer treatment discontinuation.
• There is a new international deﬁnition of CTR-CVT (Table 3).
• CV toxicity risk is a dynamic variable. This guideline is structured to provide a personalized approach to care based upon the baseline
CV toxicity risk. A baseline CV risk assessment is recommended for all patients with cancer scheduled to receive a potentially cardiotoxic anticancer therapy. This enables the oncology team to consider CV risk while making cancer treatment choices, educating patients regarding their CV risk, and personalizing CV surveillance and follow-up strategy.
• Primary prevention of CV toxicity from cancer therapy aims to avoid or minimize the development of CTR-CVT in patients without CVD.
• Secondary prevention refers to interventions in patients with preexisting CVD, including prior or new CTR-CVT. A MDT is recommended when patients with cancer have complex CVD that may impact on their cancer treatment.
• Deﬁning and delivering an appropriate prevention and surveillance plan for potential CV complications is recommended. Optimal management of CVRF and pre-existing CVD is mandatory to facilitate cancer therapy and to improve patients’ prognosis.
• Detailed monitoring pathways during cancer therapy—including
3D echocardiography, GLS, and cardiac biomarkers—are provided to detect CV toxicity based upon speciﬁc cancer therapies and baseline CV toxicity risk.
• Treatment recommendations for CTRCD during and after cancer therapy depend upon CTRCD severity and symptoms. New guidance on continuing trastuzumab in BC patients who develop asymptomatic moderate CTRCD (LVEF 40–49%) while starting cardioprotective medication is provided.
• Use of a structured algorithm to guide decisions regarding anticoagulation management in patients with cancer presenting with AF
or VTE encompassing the TBIP assessment is encouraged.
• After cancer treatment is completed,
the focus of the cardio-oncology team shifts to coordination of long-term followup. This starts with an ‘end-of-treatment’ assessment in the ﬁrst year after treatment, reviewing patients with cancer who have received cardiotoxic anticancer therapies to reassess their CV toxicity risk and guide long-term surveillance planning.
• A new algorithm (Figure 37) is provided to guide weaning off of CV
medication in CS.
• Patients with cancer, CS, and the patient’s family/carers should receive guidance to promote healthy lifestyle and recognize and report signs and symptoms of CVD, to receive prompt and effective treatment, without interfering with their cancer treatment.
• Patients must receive psychological support when needed and clear and accurate information about their condition to play an active role in managing their treatment and increase adherence to cancer and CV treatments.
13. Future needs
There are a low number of dedicated cardio-oncology services and most patients are reviewed in general cardiology clinics in Europe and worldwide. Strategic investments in cardio-oncology care networks and cardio-oncology services provision are needed to meet the projected increased clinical demand in the near future,834 and to facilitate research, training, and educational activities. A dedicated training core curriculum for a minimum of
1-year medical training is urgently needed. It may include: (1)
knowledge of the broad scope of cardiology, oncology, and haematology; (2) CV competencies for CTR-CVT prevention,
surveillance, and management of patients with cancer in dedicated outpatients’ cardio-oncology clinics; (3) inpatient consultative services; and (4) dedicated time to achieve competences in CV imaging, HF, and vascular cardiology.
Collaboration between healthcare providers, clinical and basic investigators, healthcare authorities, regulatory bodies, advocacy groups, and patients’ associations is needed to address future needs
(see Section 11).
As this Guideline was developed, it became clear that there is a signiﬁcant lack of RCT to guide decision-making, with many recommendations supported by level of evidence C. This is complicated by the fast-moving pace of new oncology treatment developments against a background of dynamic CV toxicity likelihood. Therefore, large numbers of patients and longer follow-up are required to provide sufﬁcient statistical power and deﬁnitive answers. In the future, the following strategies and areas of research are priorities:
• New trial designs focusing upon the ‘at-risk’ cancer patient populations.
• Validating current HFA-ICOS risk assessment tools and surveillance algorithms.
• Assessment of new technologies for the detection of early
CTRCD, broadening the biomarker panel and recognizing the speciﬁc patterns in early myocardial damage.
• Reﬁning
CV
risk scores
(e.g.
EuroSCORE
II,
SCORE2,
SCORE2-OP, CHA2DS2-VASc, HAS-BLED, SYNTAX) for application in cancer populations.
• Optimal treatment of steroid-resistant ICI CV toxicity and longterm CV effects of ICI therapy.
• Selection criteria for modern percutaneous structural (TAVI,
Mitraclip, LAA occluder devices) and electrophysiological (ablation) CV therapies in patients with active cancer.
• Patient-speciﬁc predictive algorithms for QTc prolongation with cancer drugs.
• Assessment of genetic proﬁles in more speciﬁc CTRCD risk prediction.
• Identiﬁcation of the cancer patient populations with mild or moderate CTRCD during treatment who can safely wean off long-term
CV medication.
• Optimal modalities for screening long-term survivor populations for the complications of anthracycline chemotherapy and mediastinal radiation.
• Creation of large cardio-oncology registries to collect ‘big data’ on large patient populations.
• Application of artiﬁcial intelligence and other new data analytics to identify new patients with cancer at risk and new parameters that can predict risk of CTR-CVT, response to speciﬁc cardioprotective interventions, and long-term risk and safety to wean off CV
therapies initiated during cancer treatment.


<!-- PAGE 105 -->

### Page 105

### 14 Gaps in evidence

Cancer and CVD are the two major public health problems with great economic and social impact. In addition, CTR-CVT are associated with anexcessofbothCVandoncologicalmortality,especiallywhenthey limit patients’ ability to complete effective treatments. However, the intersection of cancer and CVD has only recently gained wider interest and many areas with lack of evidence need to be addressed in future research.
Role of cardio-oncology services and cardio-oncology care networks
• Robust evidence on the impact of dedicated cardio-oncology programmes and cardio-oncology rehabilitation on the prognosis of patients with cancer and survivors.
• Speciﬁcation of roles of different healthcare professionals (including nurses and pharmacists) in cardio-oncology teams.
• Cardio-oncology care networks to improve the management of patients with cancer and to discuss difﬁcult cases.
• Cardio-oncology team support and involvement in oncology trials design (including patients’ representatives).
• Understand how to engage patients with cancer in their own CV
care (inclusion of digital tools).
Research, education, and training in cardio-oncology
• Consensus about CV toxicity deﬁnitions used in oncology trials.
• Deﬁne standards for CV toxicity monitoring in oncology trials to avoid unexpected CV toxicities when new drugs are approved for clinical use.
• Relevant model systems to allow high-throughput screening of new cancer treatments for CV toxicity.
• Improved knowledge on CV toxicity mechanisms of new targeted cancer therapies and ICI and optimal treatment of CV toxicities.
• Improved knowledge on the effects of radiation to speciﬁc cardiac substructures and the interactions between cardiotoxic systemic therapy and RT.
• Further research into the underlying mechanisms that connect
CVD and cancer, such as a genetic predisposition to CV toxicity.
• Personalized medicine and use of big data and artiﬁcial intelligence tools.
Cardiovascular toxicity risk stratiﬁcation
• Development of CV toxicity risk prediction tools including both treatment- and patient-related risk factors.
• Validated prospective CV toxicity risk scores based on clinical outcomes.
• Further research on the role of genetics in CV toxicity risk stratiﬁcation.
• Validation of CPET parameters for CV outcomes in patients with cancer.
Prevention, diagnosis, and management of CTR-CVT
• Raise awareness of the beneﬁts of minimizing CV risk in patients with cancer in order to reduce the risk of CTR-CVT.
• More data on new technologies (biomarkers, advanced echocardiography, CMR, etc.) and genetic proﬁles for the detection of early
CV toxicity.
• Prospective studies showing the impact on outcomes and/or quality of life (and frailty) of early CTR-CVT diagnosis and treatment.
• Further evidence from prospective RCTs to deﬁne when cardioprotective medications improve patients’ outcomes.
• Further research on the potential for aerobic exercise to reduce
CTR-CVT.
• RCTs of (new) CV therapies in patients with different types of
CTR-CVT.
Long-term cancer survivorship programmes
• Development of optimal CV follow-up programmes after treatment for cancer (research on risk stratiﬁcation, efﬁcacy, and frequency of screening protocols).
• Best screening strategies for RT-induced CAD.
• Further research on CV preventive strategies for long-term CS.
15. ‘What to do’ and ‘what not to do’ messages from the Guidelines
Recommendations
Classa
Levelb
Recommendation Table 1 for a general approach to cardiovascular toxicity risk categorization
CV toxicity risk stratiﬁcation before starting potentially cardiotoxic anticancer therapy is recommended in all patients with cancer.
I
B
Communicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is recommended.
I
C
It is recommended that patients categorized as low CV toxicity risk should proceed with anticancer therapy without delay.
I
C
Cardiology referral is recommended in high-risk and very high-risk patients before anticancer therapy.
I
C
Discussion of the risk/beneﬁt balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary approach prior to starting treatment is recommended.
I
C
Cardiology referral is recommended for patients with cancer and pre-existing CVD or abnormal ﬁndings at baseline CV toxicity risk assessment who require potentially cardiotoxic anticancer therapy.
I
C
Continued
ESC Guidelines
4333


<!-- PAGE 106 -->

### Page 106

Recommendation Table 2 for electrocardiogram baseline assessment
An ECG is recommended in all patients starting cancer therapy as part of their baseline CV risk assessment.
I
C
In patients with an abnormal baseline ECG, referral to a cardiologist is recommended.
I
C
Recommendation Table 3 for cardiac biomarker assessment prior to potentially cardiotoxic therapies
Baseline measurement of NP and/or cTn is recommended in all patients with cancer at risk of CTRCD if these biomarkers are going to be measured during treatment to detect CTRCD.
I
C
Recommendation Table 4 for cardiac imaging modalities in patients with cancer
General
Echocardiography is recommended as the ﬁrst-line modality for the assessment of cardiac function in patients with cancer.
I
C
3D echocardiography is recommended as the preferred echocardiographic modality to measure LVEF.
I
B
GLS is recommended in all patients with cancer having echocardiography, if available.
I
C
Baseline cardiac imaging prior to potentially cardiotoxic therapies
Baseline comprehensive TTE is recommended in all patients with cancer at high risk and very high risk of CV toxicity before starting anticancer therapy.
I
C
Recommendation Table 5 for primary prevention of cancer therapy-related cardiovascular toxicity
Management of CVRF according to the 2021 ESC Guidelines on CVD prevention in clinical practice is recommended before, during, and after cancer therapy.
I
C
Recommendation Table 6 for secondary prevention of cancer therapy-related cardiovascular toxicity
Management of CVD according to applicable ESC Guidelines is recommended before, during, and after cancer therapy.
I
C
Recommendation Table 7 for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months after therapy
TTE
Baseline echocardiography is recommended in all patients with cancer before anthracycline chemotherapy.
I
B
In all adults receiving anthracycline chemotherapy, an echocardiogram is recommended within 12 months after completing treatment.
I
B
In high- and very high-risk patients, echocardiography is recommended every two cycles and within 3 months after completing treatment.
I
C
Cardiac serum biomarkers
Baseline measurement of NP and cTn is recommended in high- and very high-risk patients prior to anthracycline chemotherapy.
I
B
cTn and NP monitoring before every cycle during anthracycline chemotherapy and 3 and 12 months after therapy completion is recommended in high- and very high-risk patients.
I
B
Recommendation Table 8 for baseline risk assessment and monitoring during HER2-targeted therapies and in the ﬁrst 12 months after therapy
TTE
Baseline echocardiography is recommended before HER2-targeted therapies in all patients.
I
B
In patients receiving neoadjuvant or adjuvant HER2-targeted therapies, echocardiography is recommended every 3 months and within
12 months after completing treatment.
I
B
In metastatic HER2+ disease, echocardiography is recommended every 3 months during the ﬁrst year; if the patient remains asymptomatic without CV toxicity, then surveillance can be reduced to every 6 months during future treatment.
I
C
Cardiac biomarkers
Baseline NP and cTn measurement are recommended in high- and very high-risk patients prior to anti-HER2-targeted therapies.
I
C
Continued


<!-- PAGE 107 -->

### Page 107

Recommendation Table 9 for baseline risk assessment and monitoring during ﬂuoropyrimidine therapy
Baseline CV risk assessment and evaluation including BP measurement, ECG, lipid proﬁle, HbA1c measurement, and SCORE2/SCORE2OP or equivalent is recommended before starting ﬂuoropyrimidines.
I
C
A baseline echocardiogram is recommended in patients with a history of symptomatic CVD before starting ﬂuoropyrimidines.
I
C
Recommendation Table 10 for baseline risk assessment and monitoring during VEGFi
BP monitoring
BP measurement is recommended for patients treated with VEGFi, bevacizumab, or ramucirumab at every clinical visit.
I
C
Daily home monitoring of BP for patients treated with VEGFi during the ﬁrst cycle, after each increase of VEGFi dose, and every 2–3
weeks thereafter is recommended.
I
C
ECG monitoring
In patients treated with VEGFi at moderate or high risk of QTc prolongation, QTc monitoring is recommended monthly during the ﬁrst
3 months and every 3–6 months thereafter.
I
C
Echocardiography
Baseline echocardiography is recommended in high- and very high-risk patients treated with VEGFi or bevacizumab.
I
C
Recommendation Table 11 for baseline risk assessment and monitoring during second- and third-generation BCR-ABL tyrosine kinase inhibitors
Baseline CV risk assessment is recommended in patients who require second- or third-generation BCR-ABL TKI.
I
C
In patients treated with nilotinib or ponatinib, CV risk assessment is recommended every 3 months during the ﬁrst year and every 6–12
months thereafter.
I
C
Baseline echocardiography is recommended in patients scheduled to receive dasatinib.
I
C
Recommendation Table 12 for baseline risk assessment and monitoring Bruton tyrosine kinase inhibitor therapy
BP monitoring and management
BP measurement is recommended for patients treated with BTK inhibitors at every clinical visit.
I
B
Echocardiography
Baseline echocardiography is recommended in high-risk patients scheduled to receive BTK inhibitors.
I
C
TTE is recommended in all patients who develop AF during BTK inhibitor therapy.
I
C
AF
Opportunistic screening for AF by pulse-taking or ECG rhythm strip is recommended at every clinical visit during BTK inhibitor therapy.
I
C
Recommendation Table 13 for baseline risk assessment and monitoring during multiple myeloma therapies
BP monitoring
BP measurement is recommended for patients treated with PI at every clinical visit.
I
C
Cardiac serum biomarkers
Measurement of NP is recommended prior to PI in high- and very high-risk patients.
I
C
NP and cTn measurements are recommended at baseline and every 3–6 months in patients with AL-CA.
I
B
TTE
Baseline echocardiography, including assessment for AL-CA, is recommended in all patients with MM scheduled to receive PI.
I
C
Continued
ESC Guidelines
4335


<!-- PAGE 108 -->

### Page 108

VTE prophylaxis
Therapeutic doses of LMWH are recommended in patients with MM with previous VTE.
I
B
Prophylactic doses of LMWH are recommended in patients with MM with VTE-related risk factors (excluding previous VTE) at least during the ﬁrst 6 months of therapy.
I
A
Recommendation Table 14 for baseline risk assessment and monitoring during combined RAF and MEK inhibitor therapy
BP monitoring at each clinical visit and weekly outpatient monitoring during the ﬁrst 3 months of treatment and monthly thereafter is recommended.
I
C
In patients treated with cobimetinib/vemurafenib, an ECG is recommended at 2 and 4 weeks after initiation of treatment and every 3
months thereafter.
I
C
Baseline echocardiography is recommended in all high- and very high-risk patients scheduled to receive combined RAF and MEK
inhibitors.
I
C
Recommendation Table 15 for baseline risk assessment and monitoring during immunotherapy
ECG, NP, and cTn measurements are recommended in all patients before starting ICI therapy.
I
B
Baseline echocardiography is recommended in high-risk patients before starting ICI therapy.
I
B
CV assessment is recommended every 6–12 months in high-risk patients who require long-term (.12 months) ICI treatment.
I
C
Recommendation Table 16 for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer
Baseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in patients treated with ADT without pre-existing CVD.
I
B
Baseline and serial ECGs are recommended in patients at risk of QTc prolongation during ADT therapy.
I
B
Annual CV risk assessment is recommended during ADT.
I
B
Recommendation Table 17 for baseline risk assessment and monitoring during endocrine therapy for breast cancer
Baseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in
BC patients receiving endocrine therapies without pre-existing CVD.
I
C
Annual CV risk assessment is recommended during endocrine therapy in BC patients with high 10-year risk of (fatal and non-fatal) CV
events according to SCORE2/SCORE2-OP.
I
C
Recommendation Table 18 for baseline risk assessment and monitoring during cyclin-dependent kinase 4/6 inhibitor therapy
QTc monitoring is recommended at baseline and 14 and 28 days in all patients with cancer receiving ribociclib.
I
A
QTc monitoring is recommended in patients treated with ribociclib with any dose increase.
I
B
Recommendation Table 19 for baseline risk assessment and monitoring during ALK and EGFR inhibitors
Baseline CV risk assessment is recommended in patients before ALK inhibitors and EGFR inhibitors.
I
C
Baseline echocardiography is recommended in all patients with cancer before starting osimertinib.
I
B
Recommendation Table 20 for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell and tumour-inﬁltrating lymphocytes therapies
Baseline ECG, NP, and cTn are recommended in all patients with cancer before starting CAR-T and TIL therapies.
I
C
A baseline echocardiography is recommended in patients with pre-existing CVD before starting CAR-T and TIL therapies.
I
C
Measurement of NP, cTn, and echocardiography are recommended in patients who develop CRS of ASTCT ≥2.
I
C
Continued


<!-- PAGE 109 -->

### Page 109

Recommendation Table 21 for baseline risk assessment of patients before radiotherapy to a volume including the heart
Baseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended.
I
B
Recommendation Table 22 for baseline risk assessment in haematopoietic stem cell transplantation patients
Baseline and serial CV risk assessment (3 and 12 months, then yearly) including BP measurement, ECG, lipid measurement, and HbA1c is recommended in HSCT patients.
I
C
Echocardiography is recommended in all patients before HSCT.
I
C
Recommendation Table 23 for the management of cardiovascular disease and cancer therapy-related cardiovascular toxicity in patients receiving anticancer treatment
A specialist CV assessment is recommended for optimal diagnostic workup and management of patients with cancer who present with new CV toxicity during and after cancer treatment.
I
C
Recommendation Table 24 for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy
Anthracycline chemotherapy-induced symptomatic CTRCD
HF therapy is recommended for patients who develop symptomatic CTRCD during anthracycline chemotherapy.
I
B
Discontinuation of anthracycline chemotherapy is recommended in patients who develop symptomatic severe CTRCD.
I
C
Temporary interruption of anthracycline chemotherapy is recommended in patients who develop symptomatic moderate CTRCD and a multidisciplinary approach regarding the decision to restart is recommended.
I
C
A multidisciplinary approach regarding interruption vs. continuation of anthracycline chemotherapy is recommended in patients who develop mild symptomatic CTRCD.
I
C
Anthracycline chemotherapy-induced asymptomatic CTRCD
Temporary interruption of anthracycline chemotherapy and initiation of HF therapy is recommended in patients who develop asymptomatic moderate or severe CTRCD.
I
C
A multidisciplinary approach regarding the decision when to restart is recommended in all patients with moderate or severe asymptomatic CTRCD.
I
C
Continuation of anthracycline chemotherapy is recommended in asymptomatic patients who have LVEF ≥50% and who have developed a signiﬁcant fall in GLS or a troponin or a NP elevation .ULN.
I
C
Recommendation Table 25 for the management of cancer treatment-related cardiac dysfunction during HER2-targeted therapies
HER2-targeted therapy-induced symptomatic CTRCD
HF therapy is recommended for patients who develop symptomatic moderate-to-severe CTRCD with LVEF , 50% during HER2targeted treatment.
I
B
Temporary interruption of HER2-targeted treatment is recommended in patients who develop moderate or severe symptomatic CTRCD
and the decision to restart should be based on a multidisciplinary approach after improvement of LV function and symptoms resolved.
I
C
In patients who develop mild symptomatic CTRCD, HF therapy and a multidisciplinary approach regarding the decision to continue vs.
interrupt HER2-targeted therapy are recommended.
I
C
HER2-targeted therapy-induced asymptomatic CTRCD
Temporary interruption of HER2-targeted therapy and initiation of HF therapy is recommended in patients who develop asymptomatic severe CTRCD.
I
C
A multidisciplinary approach regarding the decision to restart HER2-targeted treatment is recommended in patients with severe asymptomatic CTRCD.
I
C
Continuation of HER2-targeted therapy is recommended in patients who develop asymptomatic mild (LVEF ≥50%) CTRCDc with more frequent cardiac monitoring.
I
C
ACE-I/ARB and beta-blockers are recommended in patients who develop asymptomatic moderate (LVEF 40–49%) CTRCDc during
HER2-targeted treatment.
I
C
Recommendation Table 26 for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis cTn, ECG, and CV imaging (echocardiography and CMR) are recommended to diagnose ICI-associated myocarditis.
I
B
In patients with suspected ICI-associated myocarditis, temporary interruption of ICI treatment is recommended until the diagnosis is conﬁrmed or refuted.
I
C
Continued
ESC Guidelines
4337


<!-- PAGE 110 -->

### Page 110

Interruption of ICI treatment is recommended in patients with conﬁrmed ICI-associated myocarditis.
I
C
Continuous ECG monitoring to assess for new AV block and tachyarrhythmias during the acute phase is recommended for all patients with symptomatic ICI-associated myocarditis.
I
C
Early high-dose corticosteroids are recommended in patients with cancer and conﬁrmed ICI-associated myocarditis.
I
C
Continuation of high-dose corticosteroids is recommended for the treatment of ICI-associated myocarditis until resolution of symptoms, LV systolic dysfunction, conduction abnormalities, and signiﬁcant cTn reduction.
I
C
Admission to ICU (level 3), treatment with i.v. methylprednisolone, and optimal CV treatment including mechanical support (when indicated) is recommended for patients with ICI-associated fulminant myocarditis.
I
C
A multidisciplinary discussion is recommended before restarting ICI treatment in selected patients with previous uncomplicated ICIassociated myocarditis.
I
C
Recommendation Table 27 for the diagnosis and management of Takotsubo syndrome in patients with cancer
Coronary angiography (invasive or CCTA) is recommended to exclude ACS.
I
C
CMR is recommended to exclude myocarditis and MI.
I
B
QT-prolonging drugs are not recommended during the acute TTS phase.
III
C
Recommendation Table 28 for the management of acute coronary syndromes in patients receiving anticancer treatment
An invasive strategy is recommended in patients with cancer presenting with STEMI or high-risk NSTE-ACS with life expectancy ≥6
months.
I
B
A temporary interruption of cancer therapy is recommended in patients where the cancer therapy is suspected as a contributing cause.
I
C
In patients with cancer, thrombocytopaenia and ACS, aspirin is not recommended if platelets ,10 000/µL.
III
C
In patients with cancer, thrombocytopaenia and ACS, clopidogrel is not recommended if platelets ,30 000/µL and prasugrel or ticagrelor are not recommended if platelets ,50 000/µL.
III
C
Recommendation Table 29 for the management of chronic coronary syndromes in patients receiving anticancer treatment
Individualized duration of DAPT is recommended in patients with cancer with CCS, following revascularization, based upon thrombotic/
ischaemic and bleeding risk, type and stage of cancer, and current cancer treatment.
I
C
Recommendation Table 30 for the management of valvular heart disease in patients receiving anticancer treatment
In patients with cancer and pre-existing severe VHD, management according to the 2021 ESC/EACTS Guidelines for the management of VHD is recommended, taking into consideration cancer prognosis and patient preferences.
I
C
In patients with cancer developing new VHD during cancer therapy, management according to the 2021 ESC/EACTS Guidelines for the management of VHD is recommended, taking into consideration cancer prognosis and patient comorbidities.
I
C
Recommendation Table 31 for the management of atrial ﬁbrillation in patients receiving anticancer treatment
Long-term anticoagulation is recommended for stroke/systemic thromboembolism prevention in patients with cancer with AF and a
CHA2DS2-VASc score ≥2 (men) or ≥3 (women) as per the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation.
I
C
Thromboembolic and bleeding risk reassessment is recommended during follow-up in patients with cancer with AF.
I
C
Antiplatelet therapy or prophylactic LMWH are not recommended for stroke or systemic thromboembolism prevention in AF with cancer.
III
C
Recommendation Table 32 for the management of long QTc and ventricular arrhythmias in patients receiving anticancer treatment
How to manage QTc prolongation in patients with cancer
Discontinuation of QTc-prolonging cancer therapy is recommended in patients who develop TdP or sustained ventricular tachyarrhythmias during treatment.
I
C
Temporary interruption of QTc-prolonging cancer therapy is recommended in patients who develop asymptomatic QTcF ≥500 ms and an ECG should be repeated every 24 h until resolution of the QTcF prolongation.
I
C
Immediate withdrawal of any offending drug and correction of electrolyte abnormalities and other risk factors is recommended in patients with cancer who develop QTcF ≥500 ms.
I
C
Weekly ECG monitoring is recommended in asymptomatic patients with cancer with QTcF 480–500 ms who are treated with a QTcprolonging cancer therapy.
I
C
Continued


<!-- PAGE 111 -->

### Page 111

A 12-lead ECG is recommended after any dose increase of QTc-prolonging cancer therapy.
I
C
Restarting QTc-prolonging cancer therapy
A multidisciplinary discussion is recommended before restarting QTc-prolonging drugs in patients who have developed signiﬁcant QTcF
prolongation, to discuss alternative cancer treatments.
I
C
Weekly ECG monitoring during the ﬁrst 4–6 weeks and then monthly thereafter is recommended in patients with cancer after restarting QTc-prolonging cancer therapy.
I
C
Recommendation Table 33 for the management of arterial hypertension in patients receiving anticancer treatment
General
Effective treatment of cancer therapy-induced arterial hypertension to prevent cancer treatment interruption and CV complications is recommended.
I
C
A BP target ,140 mmHg systolic and ,90 mmHg diastolic is recommended during cancer therapy.
I
C
The competing cancer and CV risk evaluation is recommended if the systolic BP is ≥180 mmHg or diastolic BP ≥110 mmHg, and any cancer therapy associated with hypertension should be deferred or temporarily withheld until the BP is controlled to values
,160 mmHg (systolic) and ,100 mmHg (diastolic).
I
C
Cancer therapy-induced arterial hypertension treatment
ACE-I or ARB are the ﬁrst-line antihypertensive drugs recommended for BP management in patients with cancer.
I
B
Dihydropyridine CCB are recommended as second-line antihypertensive drugs for patients with cancer with uncontrolled BP.
I
C
Combination therapy with ACE-I or ARB and dihydropyridine CCB is recommended in patients with cancer with systolic
BP ≥160 mmHg and diastolic BP ≥100 mmHg.
I
C
Diltiazem and verapamil are not recommended to treat arterial hypertension in patients with cancer due to their drug–drug interactions.
III
C
Recommendation Table 34 for the management of venous thromboembolism in patients receiving anticancer treatment
Apixaban, edoxaban, or rivaroxaban are recommended for the treatment of symptomatic or incidental VTE in patients with cancer without contraindications.
I
A
LMWH are recommended for the treatment of symptomatic or incidental VTE in patients with cancer with platelet count .50 000/µL.
I
A
Catheter-associated VTE
Duration of anticoagulation in patients with cancer with a catheter-associated VTE is recommended for a minimum of 3 months and continuing longer if the catheter remains in situ.
I
C
Recommendation Table 35 for venous thromboembolism prophylaxis during anticancer treatment
Extended prophylaxis with LMWH for 4 weeks post-operatively is recommended for patients with cancer undergoing major open or laparoscopic abdominal or pelvic surgery with low bleeding risk and high VTE risk.
I
B
Prophylactic LMWH for the primary prevention of VTE is indicated in hospitalized patients with cancer or those with prolonged bed rest or reduced mobility in the absence of bleeding or other contraindications.
I
B
A discussion with the patient about the relative beneﬁts and harms, cancer prognosis, drug cost, and duration of treatment is recommended prior to prophylactic anticoagulation for the primary prevention of VTE.
I
C
Recommendation Table 36 for management of peripheral artery disease during anticancer treatment
In patients who develop new symptomatic PAD, a multidisciplinary approach regarding the decision to continue vs. interrupt culprit cancer therapy is recommended.
I
C
Recommendation Table 37 for the management of pulmonary hypertension during anticancer treatment
Right-heart catheterization and discontinuation of dasatinib is recommended in patients who develop symptomatic or asymptomatic increase in peak TRV . 3.4 m/s.
I
C
In patients with conﬁrmed dasatinib-induced PAH or new asymptomatic peak TRV . 3.4 m/s, an alternative BCR-ABL inhibitor is recommended after peak TRV recovery to ,2.8 m/s.
I
C
Recommendation Table 38 for the management of pericardial diseases in patients receiving anticancer treatment
General
Diagnosis and management of acute pericarditis in patients with cancer based on the 2015 ESC Guidelines for the diagnosis and management of pericardial diseases is recommended and a multidisciplinary discussion is needed before interrupting cancer therapy.
I
C
Continued
ESC Guidelines
4339


<!-- PAGE 112 -->

### Page 112

Diagnosis and management of ICI-associated pericarditis
Multimodality CV imaging (echocardiography, CMR + CT), ECG and measurement of cardiac biomarkers are recommended to conﬁrm the diagnosis, assess the haemodynamic consequences of pericardial disease, and rule out associated myocarditis.
I
C
Prednisolone and colchicine are recommended for patients with ICI-associated pericarditis.
I
C
Interruption of ICI treatment in patients with conﬁrmed ICI-associated pericarditis with moderate-to-severe pericardial effusion is recommended.
I
C
A multidisciplinary discussion is recommended before restarting ICI treatment.
I
C
Recommendation Table 39 for end-of-cancer therapy cardiovascular risk assessment
Educating and supporting patients with cancer to make appropriate healthy lifestyle choices is recommended.
I
C
Education is recommended for patients with cancer regarding recognition for early signs and symptoms of CVD.
I
C
CVRF assessment is recommended during the ﬁrst year after cancer therapy and thereafter according to the 2021 ESC Guidelines on
CVD prevention in clinical practice.
I
B
In asymptomatic high-risk patients, echocardiography and cardiac serum biomarkers are recommended at 3 and 12 months after completion of cancer therapy.
I
B
Cardiology referral is recommended in patients with cancer with new cardiac symptoms or new asymptomatic abnormalities in echocardiography and/or cardiac serum biomarkers at the end of therapy assessment.
I
C
Long-term continuation of cardiac medication is recommended in patients who develop severe CTRCD during cancer therapy.
I
C
CV follow-up and treatment optimization is recommended in patients who developed TKI-mediated hypertension during cancer therapy.
I
C
CV follow-up and treatment optimization is recommended in patients who developed vascular toxicities during cancer therapy.
I
C
ECG follow-up is recommended in patients who developed QT lengthening or LQTS during cancer therapy.
I
C
Recommendation Table 40 for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer survivors
Education of adults who are childhood and adolescent CS treated with anthracyclines, mitoxantrone, and/or RT to a volume including the heart and their healthcare providers regarding their increased CV risk is recommended.
I
B
Annual screening for modiﬁable CVRF is recommended in adults who are childhood and adolescent CS treated with anthracyclines,
mitoxantrone, and/or RT to a volume including the heart.
I
C
CV assessment is recommended in female childhood and adolescent CS prior to pregnancy or in the ﬁrst trimester.
I
C
Recommendation Table 41 for cardiovascular surveillance in asymptomatic adult cancer survivors
Annual CV risk assessment, including ECG and NP, and CVRF management is recommended in CS who were treated with a potentially cardiotoxic cancer drug or RT.
I
B
CV toxicity risk restratiﬁcation is recommended 5 years after therapy to organize long-term follow-up.
I
C
Recommendation Table 42 for adult cancer survivors who develop cancer therapy-related cardiac dysfunction late after cardiotoxic cancer therapy
ACE-I/ARB and/or beta-blockers are recommended in adult CS with moderate asymptomatic CTRCD.
I
C
Recommendation Table 43 for adult cancer survivors with coronary artery disease
Asymptomatic radiation-induced CAD detected during surveillance
Non-invasive stress testing is recommended in asymptomatic CS with new moderate or severe radiation-induced CAD detected on
CCTA to guide ischaemia-directed management.
I
C
A MDT discussion is recommended for clinical decision-making in patients with radiation-induced CAD and inducible ischaemia or severe left main CAD.
I
C
Continued


<!-- PAGE 113 -->

### Page 113

Symptomatic CAD
Pre-operative assessment of LIMA and RIMA viability, venous access, and sternal wound healing is recommended in CS with radiationinduced CAD where CABG is considered.
I
C
Recommendation Table 44 for adult cancer survivors with valvular heart disease
A MDT approach is recommended to discuss and deﬁne the surgical risk in CS with severe VHD.
I
C
Recommendation Table 46 for cardiovascular monitoring in cancer survivors during pregnancy
In high-risk female CS, pre-pregnancy counselling and management during pregnancy and around delivery by a multidisciplinary pregnancy heart team is recommended.
I
C
A baseline CV evaluation including history, physical examination, ECG, NP, and echocardiography is recommended in female CS with a history of CTRCD who are considering pregnancy.
I
C
A CV evaluation including echocardiography is recommended at 12 weeks of pregnancy in female CS who are either high-risk or who received potentially cardiotoxic cancer therapy and did not have a baseline CV assessment.
I
C
Recommendation Table 47 for cardiovascular assessment and monitoring of pregnant women with cancer
Management by an expert MDT (the pregnancy heart team) in an expert centre is recommended for pregnant women with cancer who require cardiotoxic cancer therapy.
I
C
Cardiac assessment prior to cardiotoxic cancer therapy in pregnant women is recommended and consists of clinical history, physical examination, ECG, and echocardiography.
I
C
Recommendation Table 48 for carcinoid valvular heart diseases
Echocardiography is recommended for the detection of carcinoid cardiac involvement in all patients with carcinoid syndrome and elevated NP levels and/or clinical signs of carcinoid heart disease, and for surveillance every 3 or 6 months depending on the severity of cardiac involvement and clinical status.
I
B
A MDT discussion for optimal medial management to prevent carcinoid crisis is recommended before any invasive or surgical cardiac procedure.
I
C
Valve replacement surgery is recommended in symptomatic patients with severe carcinoid tricuspid or pulmonary VHD and an expected survival ≥12 months.
I
C
Valve replacement or repair surgery is recommended in symptomatic patients with severe carcinoid mitral or aortic VHD and an expected survival ≥12 months.
I
C
Recommendation Table 49 for amyloid light-chain cardiac amyloidosis diagnosis and monitoring
Echocardiography, NP, and cTn are recommended for the diagnosis of AL-CA in patients with plasma cell dyscrasia.
I
B
CMR is recommended in patients with suspected AL-CA.
I
A
Recommendation Table 50 for risk stratiﬁcation and monitoring for patients with cardiac implantable electronic devices undergoing radiotherapy
Risk stratiﬁcation including planned radiation type and energy, dose to CIED, the patient’s device type, and pacing dependence is recommended prior to starting treatment.
I
C
In patients undergoing RT, a CIED check is recommended in all patients before and after completing RT, and during RT according to individual risk.
I
C
In patients with a CIED undergoing RT at high risk of arrhythmia and/or device dysfunction, ECG monitoring and/or pulse oximetry are recommended during every RT session.
I
C
© ESC 2022
3D, three-dimensional; ACE-I, angiotensin-converting enzyme inhibitors; ACS, acute coronary syndromes; ADT, androgen deprivation therapy; AF, atrial ﬁbrillation; AL-CA, amyloid light-chain cardiac amyloidosis; ALK, anaplastic lymphoma kinase;ARB, angiotensin receptorblocker; ASTCT, AmericanSociety for Transplantation and Cellular;AV, atrioventricular; BC, breast cancer; BCRABL, breakpoint cluster region–Abelson oncogene locus; BP, blood pressure; BTK, Bruton tyrosine kinase; CABG, coronary artery bypass graft; CAD, coronary artery disease; CAR-T, chimeric antigen receptor T cell; CCB, calcium channel blockers; CCS, chronic coronary syndromes; CCTA, coronary computed tomography angiography; CHA2DS2-VASc, Congestive heart failure,
Hypertension, Age .75 years (2 points), Diabetes mellitus, Stroke (2 points)—Vascular disease, Age 65–74 years, Sex category (female); CIED, cardiac implantable electronic device; CMR,
cardiac magnetic resonance; CRS, cytokine release syndrome; CT, computed tomography; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CS, cancer survivors;
CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; DAPT, dual antiplatelet therapy; EACTS, European Association for Cardio-Thoracic Surgery; ECG,
electrocardiogram; EGFR, epidermal growth factor receptor; ESC, European Society of Cardiology; GLS, global longitudinal strain; HbA1c, glycated haemoglobin; HER2, human epidermal receptor 2; HF, heart failure; HSCT, haematopoietic stem cell transplantation; ICI, immune checkpoint inhibitors; ICU, intensive care unit; i.v., intravenous; LIMA, left internal mammary artery; LMWH, low-molecular-weight heparins; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction; MDT, multidisciplinary team; MEK, mitogen-activated extracellular signal-regulated kinase; MI, myocardial infarction; MM, multiple myeloma; NP, natriuretic peptides; NSTE-ACS, non-ST-segment elevation acute coronary syndromes; PAD,
peripheral artery disease; PAH, pulmonary arterial hypertension; PI, proteasome inhibitors; QTc, corrected QT interval; QTcF, corrected QT interval using Fridericia correction; RAF, rapidly accelerated ﬁbrosarcoma; RIMA, right internal mammary artery; RT, radiotherapy; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk Estimation 2—
Older Persons; STEMI, ST-segment elevation myocardial infarction; TdP, torsade de pointes; TIL, tumour-inﬁltrating lymphocytes; TKI, tyrosine kinase inhibitors; TTE, transthoracic echocardiography; TTS, Takotsubo syndrome; TRV, tricuspid regurgitation velocity; ULN, upper limit of normal; VEGFi, vascular endothelial growth factor inhibitors; VHD, valvular heart disease; VTE, venous thromboembolism.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4341


<!-- PAGE 114 -->

### Page 114

### 16 Quality indicators for cardio-oncology

Quality indicators (QIs) are tools that may be used to evaluate care quality, including structural, process, and outcomes of care.835 They may also serve as a mechanism for enhancing adherence to guideline recommendations, through associated quality improvement initiatives and the benchmarking of care providers.836,837 As such, the role of QIs in improving care and outcomes for CVD is increasingly recognized by healthcare authorities, professional organizations,
payers, and the public.835
The ESC understands the need for measuring and reporting quality and outcomes of CV care and has established methods for the development of the ESC QIs for the quantiﬁcation of care and outcomes for CVD.835 These methods were used to develop QIs pertinent to cardio-oncology in parallel with the writing of this
Clinical Practice Guideline document and through the collaboration with patient representatives and domain experts. The QIs, alongside their measurement speciﬁcations and development process will be published separately.
17. Supplementary data
Supplementary data is available at European Heart Journal online.
18. Data availability statement
No new data were generated or analysed in support of this research.
19. Author information
Author/Task Force Member Afﬁliations: Liam S. Couch,
King’s College London BHF Centre, the Rayne Institute, St
Thomas’
Hospital,
King’s
College
London,
London,
United
Kingdom;
Riccardo
Asteggiano,
Cardiology,
LARC
(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School of
Medicine, Insubria University, Varese, Italy; Marianne C. Aznar,
Division of Cancer Sciences, Faculty of Biology, Medicine and
Health, University of Manchester, Manchester, United Kingdom;
Jutta
Bergler-Klein,
Department of
Cardiology,
Medical
University of
Vienna,
Vienna,
Austria;
Giuseppe
Boriani,
Cardiology Division, Department of Biomedical, Metabolic and
Neural
Sciences,
University of
Modena and
Reggio
Emilia,
Policlinico di
Modena,
Modena,
Italy;
Daniela
Cardinale,
Cardioncology Unit, European Institute of Oncology—I.R.C.C.S.,
Milan,
Italy;
Raul
Cordoba,
Department of
Hematology,
Fundacion Jimenez Diaz University Hospital, Madrid, Spain, and
Cancer Research Group, Health Research Institute IIS-FJD, Madrid,
Spain; Bernard Cosyns, Cardiology, Centrum voor Hart en
Vaatziekten
(CHVZ),
Universitair
Ziekenhuis
Brussel
(UZB),
Brussels, Belgium, and In Vivo Molecular and Cellular (ICMI)
Center,
Vrij
Universiteit
Brussel,
Brussels,
Belgium;
David
J. Cutter, Nufﬁeld Department of Population Health, University of Oxford, Oxford, United Kingdom, and Oxford Cancer Centre,
Oxford University Hospitals NHS Foundation Trust, Oxford,
United Kingdom; Evandro de Azambuja, Medical Oncology
Department, Institut Jules Bordet, Brussels, Belgium; Rudolf
A. de Boer, Cardiology, University Medical Center Groningen,
Groningen,
Netherlands;
Susan
F.
Dent,
Department of
Medicine, Duke Cancer Institute, Durham, NC, United States of
America; Dimitrios Farmakis, Medical School, University of
Cyprus, Nicosia, Cyprus; Soﬁe A. Gevaert, Cardiology, Ghent
University Hospital, Ghent, Belgium; Diana A. Gorog, Postgraduate
Medicine, University of Hertfordshire, Hatﬁeld, United Kingdom, and
National Heart and Lung Institute, Imperial College, London, United
Kingdom,
and
Cardiology
Department,
East and
North
Hertfordshire NHS Trust, Stevenage, United Kingdom; Joerg
Herrmann, Department of Cardiovascular Diseases, Mayo Clinic,
Rochester, MN, United States of America; Daniel Lenihan,
Cardio-Oncology, International Cardio-Oncology Society, Tampa, FL,
United States of America, and Cardiology, Saint Francis Healthcare,
Cape Girardeau, MO, United States of America; Javid Moslehi,
Section of
Cardio-Oncology
&
Immunology,
Cardiovascular
Research Institute, University of California, San Francisco (UCSF),
San Francisco, CA, United States of America; Brenda Moura,
Cardiology Department, Armed Forces Hospital, Porto, Portugal,
and Faculty of Medicine, University of Porto, Porto, Portugal; Sonja
S. Salinger, Clinic for Cardiovascular Disease, University Clinical
Center, Nis, Serbia, and Medical Faculty, University of Nis, Nis,
Serbia; Richard Stephens (United Kingdom), ESC Patient Forum,
Sophia Antipolis, France; Thomas M. Suter, Department of
Cardiology, Inselspital, Bern University Hospital, University of Bern,
Bern, Switzerland; Sebastian Szmit, Department of Pulmonary
Circulation, Thromboembolic Diseases and Cardiology, Centre of
Postgraduate Medical Education, Otwock, Poland, and Institute of
Hematology and
Transfusion
Medicine,
Transfusion
Medicine,
Warsaw, Poland; Juan Tamargo, Pharmacology and Toxicology,
Universidad
Complutense,
Madrid,
Spain;
Paaladinesh
Thavendiranathan,
Department of
Medicine,
Division of
Cardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter
Munk Cardiac Center, Toronto General Hospital, University Health
Network,
University of
Toronto,
Toronto,
Canada;
Carlo
G. Tocchetti, Cardio-Oncology Unit, Department of Translational
Medical Sciences, Federico II University, Naples, Italy, and Center for
Basic and
Clinical
Immunology
Research
(CISI),
Federico
II
University, Naples, Italy, and Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University, Naples,
Italy; Peter van der Meer, Cardiology, University Medical Center
Groningen, Groningen, Netherlands; Helena J.H. van der Pal,
Princess Máxima Center for Pediatric Oncology, Princess Máxima
Center for Pediatric Oncology, Utrecht, Netherlands.
20. Appendix
ESC Scientiﬁc Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document
Reviewers:
Patrizio
Lancellotti
(CPG
Review
Coordinator) (Belgium), Franck Thuny (CPG Review Coordinator)
(France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),
Berthe Aleman (Netherlands), Joachim Alexandre (France), Ana
Barac (United States of America), Michael A. Borger (Germany),


<!-- PAGE 115 -->

### Page 115

Ruben Casado-Arroyo (Belgium), Jennifer Cautela (France), Jolanta
Čelutkienė (Lithuania), Maja Cikes (Croatia), Alain Cohen-Solal
(France), Kreena Dhiman (United Kingdom), Stéphane Ederhy
(France), Thor Edvardsen (Norway), Laurent Fauchier (France),
Michael Fradley (United States of America), Julia Grapsa (United
Kingdom), Sigrun Halvorsen (Norway), Michael Heuser (Germany),
Marc Humbert (France), Tiny Jaarsma (Sweden), Thomas Kahan
(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos
C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom),
Bonnie Ky (United States of America), Ulf Landmesser (Germany),
Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory
Y.
H.
Lip
(United
Kingdom),
Maja-Lisa
Løchen
(Norway),
Katarzyna Malaczynska-Rajpold (United Kingdom), Marco Metra
(Italy),
Richard
Mindham
(United
Kingdom),
Marie
Moonen
(Belgium), Tomas G. Neilan (United States of America), Jens
Cosedis Nielsen (Denmark), Anna-Sonia Petronio (Italy), Eva
Prescott (Denmark), Amina Rakisheva (Kazakhstan), Joe-Elie Salem
(France), Gianluigi Savarese (Sweden), Marta Sitges (Spain), Jurrien ten
Berg
(Netherlands),
Rhian
M.
Touyz
(Canada/United
Kingdom),
Agnieszka
Tycinska
(Poland),
Matthias
Wilhelm
(Switzerland), Jose Luis Zamorano (Spain)
ESC National Cardiac Societies actively involved in the review process of the 2022 ESC Guidelines on cardio-oncology: Algeria:
Algerian Society of Cardiology, Nadia Laredj; Armenia: Armenian
Cardiologists Association, Parounak Zelveian; Austria: Austrian
Society of Cardiology, Peter P. Rainer; Azerbaijan: Azerbaijan
Society of Cardiology, Fuad Samadov; Belarus: Belorussian
Scientiﬁc
Society of
Cardiologists,
Uladzimir
Andrushchuk;
Belgium: Belgian Society of Cardiology, Bernhard L. Gerber;
Bosnia and Herzegovina: Association of Cardiologists of
Bosnia and Herzegovina, Mirsad Selimović; Bulgaria: Bulgarian
Society of Cardiology, Elena Kinova; Croatia: Croatian Cardiac
Society, Jure Samardzic; Cyprus: Cyprus Society of Cardiology,
Evagoras Economides; Czechia: Czech Society of Cardiology,
Radek Pudil; Denmark: Danish Society of Cardiology, Kirsten
M.
Nielsen;
Egypt:
Egyptian
Society of
Cardiology,
Tarek
A. Kafafy; Estonia: Estonian Society of Cardiology, Riina Vettus;
Finland: Finnish Cardiac Society, Suvi Tuohinen; France: French
Society of Cardiology, Stéphane Ederhy; Georgia: Georgian
Society of Cardiology, Zurab Pagava; Germany: German Cardiac
Society, Tienush Rassaf; Greece: Hellenic Society of Cardiology,
Alexandros Briasoulis; Hungary: Hungarian Society of Cardiology,
Dániel Czuriga; Iceland: Icelandic Society of Cardiology, Karl
K. Andersen; Ireland: Irish Cardiac Society, Yvonne Smyth;
Israel: Israel Heart Society, Zaza Iakobishvili; Italy: Italian
Federation of Cardiology, Iris Parrini; Kazakhstan: Association of
Cardiologists of
Kazakhstan,
Amina
Rakisheva;
Kosovo
(Republic of): Kosovo Society of Cardiology, Edita Pllana Pruthi;
Kyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirrakhimov;
Latvia: Latvian Society of Cardiology, Oskars Kalejs; Lebanon:
Lebanese Society of Cardiology, Hadi Skouri; Libya: Libyan
Cardiac Society, Hisham Benlamin; Lithuania: Lithuanian Society of Cardiology, Diana Žaliaduonytė; Luxembourg: Luxembourg
Society of Cardiology, Alessandra Iovino; Malta: Maltese Cardiac
Society, Alice M. Moore; Moldova (Republic of): Moldavian
Society of Cardiology, Daniela Bursacovschi; Morocco: Moroccan
Society of Cardiology, Aatif Benyass; Netherlands: Netherlands
Society of Cardiology, Olivier Manintveld; North Macedonia:
North
Macedonian
Society of Cardiology,
Marijan Bosevski;
Norway:
Norwegian
Society of
Cardiology,
Geeta
Gulati;
Poland: Polish Cardiac Society, Przemysław Leszek; Portugal:
Portuguese Society of Cardiology, Manuela Fiuza; Romania:
Romanian Society of Cardiology, Ruxandra Jurcut; Russian
Federation: Russian Society of Cardiology, Yury Vasyuk; San
Marino: San Marino Society of Cardiology, Marina Foscoli;
Serbia: Cardiology Society of Serbia, Dragan Simic; Slovakia:
Slovak
Society of
Cardiology,
Miroslav
Slanina;
Slovenia:
Slovenian Society of Cardiology, Luka Lipar; Spain: Spanish
Society of Cardiology, Ana Martin-Garcia; Sweden: Swedish
Society of Cardiology, Laila Hübbert; Switzerland: Swiss Society of Cardiology, Reto Kurmann; Syrian Arab Republic: Syrian
Cardiovascular Association, Ahmad Alayed; Tunisia: Tunisian
Society of Cardiology and Cardio-Vascular Surgery, Leila Abid;
Turkey: Turkish Society of Cardiology, Cafer Zorkun; Ukraine:
Ukrainian Association of Cardiology, Elena Nesukay; United
Kingdom of Great Britain and Northern Ireland: British
Cardiovascular
Society,
Charlotte
Manisty,
Uzbekistan:
Association of Cardiologists of Uzbekistan, Nigora Srojidinova.
ESC Clinical Practice Guidelines (CPG) Committee: Colin
Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid
(Egypt),
Victor
Aboyans
(France),
Sotiris
Antoniou
(United
Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy),
Andreas
Baumbach
(United
Kingdom),
Michael
A.
Borger
(Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia),
Jean-Philippe Collet (France), Volkmar Falk (Germany), Laurent
Fauchier
(France),
Chris
P.
Gale
(United
Kingdom),
Sigrun
Halvorsen
(Norway),
Bernard
Iung
(France),
Tiny
Jaarsma
(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos
C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf
Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech
Republic), Maja-Lisa Løchen (Norway), Richard Mindham (United
Kingdom), Jens Cosedis Nielsen (Denmark), Steffen E. Petersen
(United Kingdom), Eva Prescott (Denmark), Amina Rakisheva
(Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (Canada/United
Kingdom).
21. References
1. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Deﬁning cardiovascular toxicities of cancer therapies: an International Cardio-Oncology
Society (IC-OS) consensus statement. Eur Heart J 2022;43:280–299.
2. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: Cardio-oncology. Mayo
Clin Proc 2014;89:1287–1306.
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249.
4. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R,
Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice
Guidelines. Eur Heart J 2016;37:2768–2801.
5. Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van Der Meer P,
et al. Cardio-oncology services: rationale, organization, and implementation. Eur
Heart J 2019;40:1756–1763.
6. Michel G, Mulder RL, van der Pal HJH, Skinner R, Bárdi E, Brown MC, et al.
Evidence-based recommendations for the organization of long-term follow-up
ESC Guidelines
4343


<!-- PAGE 116 -->

### Page 116

care for childhood and adolescent cancer survivors: a report from the
PanCareSurFup Guidelines Working Group. J Cancer Surviv 2019;13:759–772.
7. Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, et al.
Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline
Harmonization Group. Lancet Oncol 2015;16:e123–e136.
8. van Kalsbeek RJ, Mulder RLRL, Skinner R, Kremer LCMCM. The concept of cancer survivorship and models for long-term follow-up. Front Horm Res 2021;54:1–15.
9. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol 2020;17:474–502.
10. Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol 2020;17:
503–522.
11. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al.
Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientiﬁc statement from the American Heart Association.
Circulation 2019;139:e997–e1012.
12. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al.
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the
European Society. Eur J Heart Fail 2020;22:1945–1960.
13. Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, et al.
Incidence of cardiotoxicity and validation of the Heart Failure Association–
International Cardio-Oncology Society risk stratiﬁcation tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Res Treat
2021;188:149–163.
14. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Eur Heart J 2021;42:3599–3726.
15. Jaffe AS, Vasile VC, Milone M, Saenger AK, Olson KN, Apple FS. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol 2011;58:1819–1824.
16. Schmid J, Liesinger L, Birner-Gruenberger R, Stojakovic T, Scharnagl H, Dieplinger
B, et al. Elevated cardiac troponin T in patients with skeletal myopathies. J Am Coll
Cardiol 2018;71:1540–1549.
17. Delombaerde D, Vervloet D, Franssen C, Croes L, Gremonprez F, Prenen H, et al.
Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy. ESMO Open 2021;6:100216.
18. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U,
et al. Cardiovascular magnetic resonance in nonischemic myocardial inﬂammation:
expert recommendations. J Am Coll Cardiol 2018;72:3158–3176.
19. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021
ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J
2021;42:3227–3337.
20. Vandenberk B, Vandael E, Robyns T, Vandenberghe J, Garweg C, Foulon V, et al.
Which QT correction formulae to use for QT monitoring? J Am Heart Assoc
2016;5:e003264.
21. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al.
Prevention and monitoring of cardiac dysfunction in survivors of adult cancers:
American Society of Clinical Oncology clinical practice guideline. J Clin Oncol
2017;35:893–911.
22. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020;31:171–190.
23. Rossello X, Dorresteijn JAN, Janssen A, Lambrinou E, Scherrenberg M,
Bonnefoy-Cudraz E, et al. Risk prediction tools in cardiovascular disease prevention: a report from the ESC Prevention of CVD Programme led by the
European Association of Preventive Cardiology (EAPC) in collaboration with the
Acute Cardiovascular Care Association (ACCA) and the Association of
Cardiovascular Nursing and Allied Professions (ACNAP). Eur J Cardiovasc Nurs
2019;18:534–544.
24. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE, Ewer MS, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP
plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:
3792–3799.
25. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart
Assoc 2014;3:e000472.
26. Rushton M, Johnson C, Dent S. Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population. Curr Oncol 2017;24:
176–180.
27. Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat 2008;
107:443–450.
28. Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu J V, et al.
Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. Eur Heart J 2019;40:3913–3920.
29. Kang Y, Assuncao BL, Denduluri S, McCurdy S, Luger S, Lefebvre B, et al.
Symptomatic heart failure in acute leukemia patients treated with anthracyclines.
JACC CardioOncology 2019;1:208–217.
30. Martín García A, Mitroi C, Mazón Ramos P, García Sanz R, Virizuela JA, Arenas M,
et al. Stratiﬁcation and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC,
and AECC. Rev Española Cardiol (English Ed) 2021;74:438–448.
31. Caro-Codón J, López-Fernández T, Álvarez-Ortega C, Zamora Auñón P,
Rodríguez IR, Gómez Prieto P, et al. Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. Eur J Prev Cardiol 2022;29(6):859–868.
32. Feijen EAM, Leisenring WM, Stratton KL, Ness KK, Van Der Pal HJH, Van Dalen EC,
et al. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol 2019;5:864–871.
33. Pareek N, Cevallos J, Moliner P, Shah M, Tan LL, Chambers V, et al. Activity and outcomes of a cardio-oncology service in the United Kingdom—a ﬁve-year experience. Eur J Heart Fail 2018;20:1721–1731.
34. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation 2016;133:1104–1114.
35. Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, et al. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the reallife practice are predicted by the Systematic Coronary Risk Evaluation (SCORE)
chart. Hematol Oncol 2019;37:296–302.
36. Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, et al. Clonal hematopoiesis:
crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week. J Am Coll Cardiol 2019;74:567–577.
37. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM,
et al. Genetic variants associated with cancer therapy-induced cardiomyopathy.
Circulation 2019;140:31–41.
38. Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. JACC
CardioOncology 2020;2:539–552.
39. Katzke VA, Kaaks R, Kühn T. Lifestyle and cancer risk. Cancer J 2015;21:104–110.
40. Shariﬁ-Rad J, Rodrigues CF, Sharopov F, Docea AO, Karaca AC, Shariﬁ-Rad M, et al.
Diet, lifestyle and cardiovascular diseases: linking pathophysiology to cardioprotective effects of natural bioactive compounds. Int J Environ Res Public Health 2020;17:
2326.
41. Turner MC, Andersen ZJ, Baccarelli A, Diver WR, Gapstur SM, Pope CA, et al.
Outdoor air pollution and cancer: an overview of the current evidence and public health recommendations. CA Cancer J Clin 2020;70 :460–479.
42. Lind PM, Lind L. Are persistent organic pollutants linked to lipid abnormalities, atherosclerosis and cardiovascular disease? A review. J Lipid Atheroscler 2020;9:
334–348.
43. Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, et al. The cancer patient and cardiology. Eur J Heart Fail 2020;22:2290–2309.
44. Fradley MG, Moslehi J. QT prolongation and oncology drug development. Card
Electrophysiol Clin 2015;7:341–355.
45. Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al.
Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc 2017;6:e007724.
46. Curigliano G, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, et al. Drug-induced
QTc interval prolongation: a proposal towards an efﬁcient and safe anticancer drug development. Eur J Cancer 2008;44:494–500.
47. Viganego F, Singh R, Fradley MG. Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation. Curr Cardiol Rep 2016;18:52.
48. Curigliano G, Spitaleri G, De Braud F, Cardinale D, Cipolla C, Civelli M, et al. QTc prolongation assessment in anticancer drug development: clinical and methodological issues. Ecancermedicalscience 2009;3:130.
49. Salem J-E, Nguyen LS, Moslehi JJ, Ederhy S, Lebrun-Vignes B, Roden DM, et al.
Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health
Organization pharmacovigilance study. Eur Heart J 2021;42:3915–3928.
50. Lentz R, Feinglass J, Ma S, Akhter N. Risk factors for the development of atrial ﬁbrillation on ibrutinib treatment. Leuk Lymphoma 2019;60:1447–1453.
51. Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J, et al. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial ﬁbrillation in patients with chronic lymphocytic leukemia. Cancer Biol Ther 2018;19:1–2.
52. Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, et al. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2013;19:1233–1237.


<!-- PAGE 117 -->

### Page 117

53. Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure
Association and the Cardio-Oncology Council of the European Society of
Cardiology. Eur J Heart Fail 2020;22:1966–1983.
54. Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P,
Bergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association
(HFA), the European Association of Cardiovascular Imaging (EACVI) and the
Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J
Heart Fail 2020;22:1504–1524.
55. Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, et al.
Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail 2020;22:350–361.
56. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with highrisk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012;30:1042–1049.
57. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004;351:145–153.
58. Xue K, Gu JJ, Zhang Q, Liu X, Wang J, Li XQ, et al. Cardiotoxicity as indicated by
LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: results from a randomized prospective clinical trial. Oncotarget 2016;
7:32519–32531.
59. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al.
Prognostic value of troponin I in cardiac risk stratiﬁcation of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749–2754.
60. Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem 2015;61:
1164–1172.
61. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al.
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910–3916.
62. Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol 2017;35:878–884.
63. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al.
Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715–731.
64. Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011;148:
194–198.
65. Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, et al.
Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. J Am Heart Assoc 2020;9:e014708.
66. Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma.
J Clin Oncol 2019;37:1946–1955.
67. Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, et al.
Cardiovascular biomarkers in patients with cancer and their association with allcause mortality. Heart 2015;101:1874–1880.
68. López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR,
Farmakis D, et al. Classiﬁcation, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 2020;41:
1720–1729.
69. Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag IA, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014;63:
809–816.
70. Gioffré S, Chiesa M, Cardinale DM, Ricci V, Vavassori C, Cipolla CM, et al.
Circulating microRNAs as potential predictors of anthracycline-induced troponin elevation in breast cancer patients: diverging effects of doxorubicin and epirubicin.
J Clin Med 2020;9:1418.
71. Beer LA, Kossenkov AV, Liu Q, Luning Prak E, Domchek S, Speicher DW, et al.
Baseline immunoglobulin e
levels as a
marker of doxorubicinand trastuzumab-associated cardiac dysfunction. Circ Res 2016;119:1135–1144.
72. Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient. JACC
Cardiovasc Imaging 2018;11:1173–1186.
73. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al.
Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantiﬁcation, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017;18:1301–1310.
74. De Azambuja E, Procter MJ, Van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O,
Steinseifer J, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01). J Clin Oncol 2014;32:
2159–2165.
75. Santoro C, Arpino G, Esposito R, Lembo M, Paciolla I, Cardalesi C, et al. 2D and 3D
strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: A balance with feasibility. Eur Heart J Cardiovasc Imaging 2017;18:930–936.
76. Zhang KW, Finkelman BS, Gulati G, Narayan HK, Upshaw J, Narayan V, et al.
Abnormalities in 3-dimensional left ventricular mechanics with anthracycline chemotherapy are associated with systolic and diastolic dysfunction. JACC
Cardiovasc Imaging 2018;11:1059–1068.
77. Lang RM, Badano LP, Mor-Avi V, Aﬁlalo J, Armstrong A, Ernande L, et al.
Recommendations for cardiac chamber quantiﬁcation by echocardiography in adults: an update from the American Society of Echocardiography and the
European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging
2015;16:233–270.
78. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH.
Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013;61:77–84.
79. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of
3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol 2012;59:
1799–1808.
80. Hoffmann R, Barletta G, Von Bardeleben S, Vanoverschelde JL, Kasprzak J, Greis C,
et al. Analysis of left ventricular volumes and function: a multicenter comparison of cardiac magnetic resonance imaging, cine ventriculography, and unenhanced and contrast-enhanced two-dimensional and three-dimensional echocardiography. J
Am Soc Echocardiogr 2014;27:292–301.
81. Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH. Left ventricular volume measurement with echocardiography: a comparison of left ventricular opaciﬁcation, three-dimensional echocardiography, or both with magnetic resonance imaging. Eur Heart J 2009;30:98–106.
82. Porter TR, Mulvagh SL, Abdelmoneim SS, Becher H, Belcik JT, Bierig M, et al. Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American
Society of Echocardiography Guidelines Update. J Am Soc Echocardiogr 2018;31:
241–274.
83. Houbois CP, Nolan M, Somerset E, Shalmon T, Esmaeilzadeh M, Lamacie MM, et al.
Serial cardiovascular magnetic resonance strain measurements to identify cardiotoxicity in breast cancer: comparison with echocardiography. JACC Cardiovasc
Imaging 2021;14:962–974.
84. Dobbin SJH, Mangion K, Berry C, Roditi G, Basak S, Sourbron S, et al. Cardiotoxicity and myocardial hypoperfusion associated with anti-vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer. Eur J Heart Fail 2020;22:1276–1277.
85. Mousavi N, Tan TC, Ali M, Halpern EF, Wang L, Scherrer-Crosbie M.
Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of
50–59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging 2015;16:
977–984.
86. Čelutkienė J, Plymen CM, Flachskampf FA, de Boer RA, Grapsa J, Manka R, et al.
Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the
European Society of Cardiology. Eur J Heart Fail 2018;20:1615–1633.
87. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart 2014;100:1673–1680.
88. Baron T, Berglund L, Hedin EM, Flachskampf FA. Test–retest reliability of new and conventional echocardiographic parameters of left ventricular systolic function. Clin
Res Cardiol 2019;108:355–365.
89. Lambert J, Lamacie M, Thampinathan B, Altaha MA, Esmaeilzadeh M, Nolan M, et al.
Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity. Heart 2020;106:817–823.
90. Thavendiranathan P, Negishi T, Coté MA, Penicka M, Massey R, Cho GY, et al.
Single versus standard multiview assessment of global longitudinal strain for the diagnosis of cardiotoxicity during cancer therapy. JACC Cardiovasc Imaging 2018;
11:1109–1118.
91. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 2014;15:324–331.
ESC Guidelines
4345


<!-- PAGE 118 -->

### Page 118

92. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll
Cardiol 2014;63:2751–2768.
93. Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D,
et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol 2019;4:1007–1018.
94. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc
Imaging 2014;15:1063–1093.
95. Farsalinos KE, Daraban AM, Ünlü S, Thomas JD, Badano LP, Voigt JU. Head-to-head comparison of global longitudinal strain measurements among nine different vendors: the EACVI/ASE inter-vendor comparison study. J Am Soc Echocardiogr
2015;28:1171–1181.e2.
96. Narayan HK, French B, Khan AM, Plappert T, Hyman D, Bajulaiye A, et al.
Noninvasive measures of ventricular–arterial coupling and circumferential strain predict cancer therapeutics–related cardiac dysfunction. JACC Cardiovasc Imaging
2016;9:1131–1141.
97. Nagiub M, Nixon JV, Kontos MC. Ability of nonstrain diastolic parameters to predict doxorubicin-induced cardiomyopathy: a systematic review with meta-analysis.
Cardiol Rev 2018;26:29–34.
98. Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L, et al.
Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC Cardiovasc Imaging 2020;13:198–210.
99. Phillips WJ, Johnson C, Law A, Turek M, Small AR, Dent S, et al. Comparison of
Framingham risk score and chest-CT identiﬁed coronary artery calciﬁcation in breast cancer patients to predict cardiovascular events. Int J Cardiol 2019;289:
138–143.
100. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al.
407–477.
101. Lopez-Mattei JC, Yang EH, Ferencik M, Baldassarre LA, Dent S, Budoff MJ. Cardiac computed tomography in cardio-oncology: JACC: CardioOncology primer. Cardio
Oncol 2021;3:635–649.
102. Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J, et al.
Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll
Cardiol 2021;77:392–401.
103. Esmaeilzadeh M, Fresno CMU, Somerset E, Shalmon T, Amir E, Fan CPS, et al. A
combined echocardiography approach for the diagnosis of cancer therapy-related cardiac dysfunction in women with early-stage breast cancer. JAMA Cardiol 2022;7:
330–340.
104. Drafts BC, Twomley KM, D’Agostino R, Lawrence J, Avis N, Ellis LR, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc
Imaging 2013;6:877–885.
105. Giusca S, Korosoglou G, Montenbruck M, Geršak B, Schwarz AK, Esch S, et al.
Multiparametric early detection and prediction of cardiotoxicity using myocardial strain, T1 and T2 mapping, and biochemical markers: a longitudinal cardiac resonance imaging study during 2 years of follow-up. Circ Cardiovasc Imaging 2021;14:e012459.
106. Dhir V, Yan AT, Nisenbaum R, Sloninko J, Connelly KA, Barfett J, et al. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study. Int J Cardiovasc Imaging
2019;35:2085–2093.
107. Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T, et al. Role of threedimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 2010;28:3429–3436.
108. Huang H, Nijjar PS, Misialek JR, Blaes A, Derrico NP, Kazmirczak F, et al. Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2017;19:34.
109. Hoppeler H, Weibel ER. Limits for oxygen and substrate transport in mammals. J
Exp Biol 1998;201:1051–1064.
110. Kaminsky LA, Imboden MT, Arena R, Myers J. Reference standards for cardiorespiratory ﬁtness measured with cardiopulmonary exercise testing using cycle ergometry: data from the Fitness Registry and the Importance of Exercise National
Database (FRIEND) registry. Mayo Clin Proc 2017;92:228–233.
111. Imboden MT, Harber MP, Whaley MH, Finch WH, Bishop DL, Kaminsky LA.
Cardiorespiratory ﬁtness and mortality in healthy men and women. J Am Coll
Cardiol 2018;72:2283–2292.
112. Jetté M, Sidney K, Blümchen G. Metabolic equivalents (METS) in exercise testing,
exercise prescription, and evaluation of functional capacity. Clin Cardiol 1990;13:
555–565.
113. Ross R, Blair SN, Arena R, Church TS, Després JP, Franklin BA, et al. Importance of assessing cardiorespiratory ﬁtness in clinical practice: a case for ﬁtness as a clinical vital sign: a scientiﬁc statement from the American Heart Association. Circulation
2016;134:e653–e699.
114. Schmid D, Leitzmann MF. Cardiorespiratory ﬁtness as predictor of cancer mortality: a systematic review and meta-analysis. Ann Oncol 2015;26:272–278.
115. Gupta S, Rohatgi A, Ayers CR, Willis BL, Haskell WL, Khera A, et al.
Cardiorespiratory ﬁtness and classiﬁcation of risk of cardiovascular disease mortality. Circulation 2011;123:1377–1383.
116. Holtermann A, Marott JL, Gyntelberg F, Søgaard K, Mortensen OS, Prescott E, et al.
Self-reported cardiorespiratory ﬁtness: prediction and classiﬁcation of risk of cardiovascular disease mortality and longevity—a prospective investigation in the
Copenhagen City Heart Study. J Am Heart Assoc 2015;4:e001495.
117. Stamatakis E, Hamer M, O’Donovan G, Batty GD, Kivimaki M. A non-exercise testing method for estimating cardiorespiratory ﬁtness: associations with all-cause and cardiovascular mortality in a pooled analysis of eight population-based cohorts. Eur
Heart J 2013;34:750–758.
118. Wickramasinghe CD, Ayers CR, Das S, De Lemos JA, Willis BL, Berry JD.
Prediction of 30-year risk for cardiovascular mortality by ﬁtness and risk factor levels: the Cooper Center Longitudinal Study. Circ Cardiovasc Qual Outcomes 2014;7:
597–602.
119. Fardman A, Banschick GD, Rabia R, Percik R, Fourey D, Segev S, et al.
Cardiorespiratory ﬁtness and survival following cancer diagnosis. Eur J Prev
Cardiol 2021;28:1242–1249.
120. Groarke JD, Payne DL, Claggett B, Mehra MR, Gong J, Caron J, et al. Association of post-diagnosis cardiorespiratory ﬁtness with cause-speciﬁc mortality in cancer. Eur
Heart J Qual Care Clin Outcomes 2020;6:315–322.
121. Jones LM, Stoner L, Brown C, Baldi JC, McLaren B. Cardiorespiratory ﬁtness predicts cardiovascular health in breast cancer survivors, independent of body composition, age and time post-treatment completion. Breast Cancer 2019;26:
729–737.
122. Ha D, Mazzone PJ, Ries AL, Malhotra A, Fuster M. The utility of exercise testing in patients with lung cancer. J Thorac Oncol 2016;11:1397–1410.
123. West MA, Lythgoe D, Barben CP, Noble L, Kemp GJ, Jack S, et al. Cardiopulmonary exercise variables are associated with postoperative morbidity after major colonic surgery: a prospective blinded observational study. Br J Anaesth 2014;112:665–671.
124. West MA, Parry MG, Lythgoe D, Barben CP, Kemp GJ, Grocott MPW, et al.
Cardiopulmonary exercise testing for the prediction of morbidity risk after rectal cancer surgery. Br J Surg 2014;101:1166–1172.
125. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC
guidelines on cardiovascular assessment and management of patients undergoing noncardiac surgery. Eur Heart J 2022;43:3826–3924.
126. Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet 2015;47:1079–1084.
127. Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, et al.
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children’s Oncology Group. J
Clin Oncol 2012;30:1415–1421.
128. Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, et al.
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.
Circulation
2005;112:
3754–3762.
129. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;
375:1749–1755.
130. European Society of Cardiology. ESC CardioMed. 3rd ed. Oxford: Oxford
University Press; 2018.
131. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med
2016;375:1457–1467.
132. Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, et al.
Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail 2018;20:879–887.
133. D’Ascenzi F, Anselmi F, Fiorentini C, Mannucci R, Bonifazi M, Mondillo S. The beneﬁts of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology. Eur J Prev Cardiol 2021;28:725–735.
134. Ogunmoroti O, Allen NB, Cushman M, Michos ED, Rundek T, Rana JS, et al.
Association between life’s simple 7 and noncardiovascular disease: the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2016;5:e003954.
135. Michos ED, Marshall CH. Healthy lifestyle beneﬁts both cancer and cardiovascular disease: more bang for the buck. JACC CardioOncology 2021;3:675–677.


<!-- PAGE 119 -->

### Page 119

136. Murray J, Bennett H, Bezak E, Perry R. The role of exercise in the prevention of cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy: systematic review. Eur J Prev Cardiol 2022;29:463–472.
137. Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular toxicity in cancer. Circulation 2018;137:1176–1191.
138. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/
ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;
39:3021–3104.
139. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41:255–323.
140. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019
ESC/EAS Guidelines for the management of dyslipidaemias: lipid modiﬁcation to reduce cardiovascular risk. Eur Heart J 2020;41:111–188.
141. Beavers CJ, Rodgers JE, Bagnola AJ, Beckie TM, Campia U, Di Palo KE, et al.
Cardio-oncology drug interactions: a scientiﬁc statement from the American
Heart Association. Circulation 2022;145:e811–e838.
142. Ferdinandy P, Baczkó I, Bencsik P, Giricz Z, Görbe A, Pacher P, et al. Deﬁnition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. Eur Heart J 2019;40:1771–1777.
143. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer
2013;49:2900–2909.
144. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
J Am Coll Cardiol 2012;60:2504–2512.
145. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, De Caralt TM, et al.
Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial
(preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive
ChemOtherapy for the treatment of
Malignant hEmopathies). J Am Coll Cardiol 2013;61:2355–2362.
146. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, das Dores Cruz F,
Gonçalves Brandão SM, Rigaud VOC, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 2018;71:
2281–2290.
147. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al.
Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril:
The
International
CardioOncology Society-one trial. Eur J Cancer 2018;94:126–137.
148. Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail
2015;17:81–89.
149. Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, et al. Efﬁciency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll
Cardiol 2011;58:988–989.
150. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al.
Prevention of cardiac dysfunction during adjuvant breast cancer therapy
(PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016;37:1671–1680.
151. Gulati G, Heck SL, Røsjø H, Ree AH, Hoffmann P, Hagve TA, et al. Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (Prevention of Cardiac
Dysfunction During Adjuvant Breast Cancer Therapy) study. J Am Heart Assoc
2017;6:e006513.
152. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W,
et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 2019;73:2859–2868.
153. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al.
Multidisciplinary approach to novel therapies in cardio-oncology research
(MANTICORE
101-Breast):
a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 2017;35:870–877.
154. Boekhout AH, Gietema JA, Kerklaan BM, VanWerkhoven ED, Altena R, Honkoop
A, et al. Angiotensin II receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer a randomized clinical trial. JAMA Oncol 2016;2:1030–1037.
155. Caspani F, Tralongo AC, Campiotti L, Asteggiano R, Guasti L, Squizzato A.
Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis. Intern Emerg Med 2021;16:477–486.
156. Huang S, Zhao Q, Yang ZG, Diao KY, He Y, Shi K, et al. Protective role of betablockers in chemotherapy-induced cardiotoxicity—a systematic review and meta-analysis of carvedilol. Heart Fail Rev 2019;24:325–333.
157. Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha VG, et al. Efﬁcacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC CardioOncology 2019;1:54–65.
158. Macedo AVS, Hajjar LA, Lyon AR, Nascimento BR, Putzu A, Rossi L, et al. Efﬁcacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC
CardioOncology 2019;1:68–79.
159. Li X, Li Y, Zhang T, Xiong X, Liu N, Pang B, et al. Role of cardioprotective agents on chemotherapy-induced heart failure:
a systematic review and network meta-analysis of randomized controlled trials. Pharmacol Res 2020;151:104577.
160. Fang K, Zhang Y, Liu W, He C. Effects of angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials. Heart Fail Rev 2021;26:101–109.
161. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer 1990;65:
870–873.
162. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH,
et al. American Society of Clinical Oncology 2008 clinical practice guideline update:
use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27:
127–145.
163. European Medicines Agency. Savene: EPAR—Product Information (Internet) 2008
(updated 2019).
164. Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 2014;64:938–945.
165. Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hortobagyi GN, Blum RH. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. Eur J Cancer 2015;51:2314–2320.
166. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997;15:
1333–1340.
167. van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev
2011;2011:CD003917.
168. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity proﬁles. Drug Saf 2001;24:903–920.
169. Verellen D, De Ridder M, Linthout N, Tournel K, Soete G, Storme G. Innovations in image-guided radiotherapy. Nat Rev Cancer 2007;7:949–960.
170. De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F.
Radiotherapy toxicity. Nat Rev Dis Prim 2019;5:13.
171. Meattini I, Poortmans PM, Aznar MC, Becherini C, Bonzano E, Cardinale D, et al.
Association of breast cancer irradiation with cardiac toxic effects: a narrative review. JAMA Oncol 2021;7:924–932.
172. Banﬁll K, Giuliani M, Aznar M, Franks K, McWilliam A, Schmitt M, et al. Cardiac toxicity of thoracic radiotherapy: existing evidence and future directions. J Thorac Oncol
2021;16:216–227.
173. Mitchell JD, Cehic DA, Morgia M, Bergrom C, Toohey J, Guerrero PA, et al.
Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the International Cardio-Oncology Society. JACC
CardioOncology 2021;3:360–380.
174. Kirwan CC, Coles CE, Bliss J, Kirwan C, Kilburn L, Fox L, et al. It’s PRIMETIME.
Postoperative avoidance of radiotherapy: biomarker selection of women at very low risk of local recurrence. Clin Oncol 2016;28:594–596.
175. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al.
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–2481.
176. Abdel-Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo-Argüelles O, Amir E,
et al. Statin exposure and risk of heart failure after anthracycline-or trastuzumabbased chemotherapy for early breast cancer: a propensity score⍰matched cohort study. J Am Heart Assoc 2021;10:e018393.
177. Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S,
Amir E, et al. Cardioprotective effect of statins in patients with HER2-positive breast cancer receiving trastuzumab therapy. Can J Cardiol 2019;35:153–159.
178. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol 2012;60:
2384–2390.
179. Chotenimitkhun R, D’Agostino R, Lawrence JA, Hamilton CA, Jordan JH, Vasu S,
et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol 2015;31:302–307.
180. Obasi M, Abovich A, Vo JB, Gao Y, Papatheodorou SI, Nohria A, et al. Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis. Cancer Causes Control 2021;32:
1395–1405.
181. Kim J, Nishimura Y, Kewcharoen J, Yess J. Statin use can attenuate the decline in left ventricular ejection fraction and the incidence of cardiomyopathy in cardiotoxic chemotherapy recipients: a systematic review and meta-analysis. J Clin Med 2021;
10:3731.
ESC Guidelines
4347


<!-- PAGE 120 -->

### Page 120

182. Sanﬁlippo KM, Keller J, Gage BF, Luo S, Wang TF, Moskowitz G, et al. Statins are associated with reduced mortality in multiple myeloma. J Clin Oncol 2016;34:
4008–4014.
183. Afzal A, Fiala MA, Gage BF, Wildes TM, Sanﬁlippo K. Statins reduce mortality in multiple myeloma: a population-based US study. Clin Lymphoma Myeloma Leuk
2020;20:e937–e943.
184. Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized,
single-blind, placebo-controlled trial. J Cardiovasc Pharmacol Ther 2019;24:233–241.
185. Shahid I, Yamani N, Ali A, Kumar P, Figueredo V, Unzek S, et al. Meta-analysis evaluating the use of statins to attenuate cardiotoxicity in cancer patients receiving anthracyclines and trastuzumab-based chemotherapy. Am J Cardiol 2021;156:
142–145.
186. Nabati M, Janbabai G, Baghyari S, Esmaili K, Yazdani J. Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol
2017;69:279–285.
187. Warrington L, Absolom K, Conner M, Kellar I, Clayton B, Ayres M, et al. Electronic systems for patients to report and manage side effects of cancer treatment: systematic review. J Med Internet Res 2019;21:e10875.
188. López-Fernández T, Martín García A, Santaballa Beltrán A, Montero Luis Á, García
Sanz R, Mazón Ramos P, et al. Cardio-onco-hematology in clinical practice. Position paper and recommendations. Rev Española Cardiol (English Ed) 2017;70:474–486.
189. Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res
Treat 2019;175:595–603.
190. Fornaro A, Olivotto I, Rigacci L, Ciaccheri M, Tomberli B, Ferrantini C, et al.
Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience. Eur J Heart Fail 2018;20:898–906.
191. Chow SL, Maisel AS, Anand I, Bozkurt B, De Boer RA, Felker GM, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientiﬁc statement from the American Heart Association. Circulation 2017;135:
e1054–e1091. Erratum in: Circulation 2017;136:e345.
192. De Boer RA, Daniels LB, Maisel AS, Januzzi JL. State of the art: newer biomarkers in heart failure. Eur J Heart Fail 2015;17:559–569.
193. Piek A, Du W, de Boer RA, Silljé HHW. Novel heart failure biomarkers: why do we fail to exploit their potential? Crit Rev Clin Lab Sci 2018;55:246–263.
194. Du W, Piek A, Marloes Schouten E, van de Kolk CWA, Mueller C, Mebazaa A, et al.
Plasma levels of heart failure biomarkers are primarily a reﬂection of extracardiac production. Theranostics 2018;8:4155–4169.
195. Suthahar N, Lau ES, Blaha MJ, Paniagua SM, Larson MG, Psaty BM, et al. Sex-speciﬁc associations of cardiovascular risk factors and biomarkers with incident heart failure. J Am Coll Cardiol 2020;76:1455–1465.
196. Bracun V, Aboumsallem JP, van der Meer P, de Boer RA. Cardiac biomarkers in patients with cancer: considerations, clinical implications, and future avenues. Curr
Oncol Rep 2020;22:67.
197. Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. J Cardiovasc
Transl Res 2020;13:431–450.
198. López-Fernández T, Thavendiranathan P. Emerging cardiac imaging modalities for the early detection of cardiotoxicity due to anticancer therapies. Rev Española
Cardiol (English Ed) 2017;70:487–495.
199. Eschenhagen T, Force T, Ewer MS, De Keulenaer GW, Suter TM, Anker SD, et al.
Cardiovascular side effects of cancer therapies: a position statement from the
Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail
2011;13:1–10.
200. Keramida K, Farmakis D, López Fernández T, Lancellotti P. Focused echocardiography in cardio-oncology. Echocardiography 2020;37:1149–1158.
201. Liu JE, Barac A, Thavendiranathan P, Scherrer-Crosbie M. Strain imaging in cardio-oncology. JACC CardioOncology 2020;2:677–689.
202. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013;26:493–498.
203. Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Aakhus S, Miyazaki S, et al.
Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy: 1 year results of the SUCCOUR trial. Eur Heart J 2020;41:
ehaa946.3282.
204. Vallabhaneni S, Zhang KW, Alvarez JA, Joshua C, Henning DM, Woodard PK, et al.
Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients. Int J Cardiovasc Imaging 2021;37:3003–3017.
205. Lapinskas T, Hireche-Chikaoui H, Zieschang V, Erley J, Stehning C, Gebker R, et al.
Effect of comprehensive initial training on the variability of left ventricular measures using fast-SENC cardiac magnetic resonance imaging. Sci Rep 2019;9:12223.
206. Korosoglou G, Giusca S, Montenbruck M, Patel AR, Lapinskas T, Götze C, et al. Fast strain-encoded cardiac magnetic resonance for diagnostic classiﬁcation and risk stratiﬁcation of heart failure patients. JACC Cardiovasc Imaging 2021;14:1177–1188.
207. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/
AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart
Association Task Force on Clinical Practice Guidelines and the Heart Failure
Society of America. Circulation 2017;136:e137–e161.
208. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981–1988.
209. Wang L, Tan TC, Halpern EF, Neilan TG, Francis SA, Picard MH, et al. Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy. Am J Cardiol 2015;116:442–446.
210. Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E, et al. Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy. Breast Cancer Res Treat
2019;176:261–270.
211. Lenihan DJ, Stevens PL, Massey M, Plana JC, Araujo DM, Fanale MA, et al. The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study. J Card Fail 2016;22:433–438.
212. Meessen JMTA, Cardinale D, Ciceri F, Sandri MT, Civelli M, Bottazzi B, et al.
Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. ESC Heart Fail 2020;7:1452–1466.
213. Jones M, O’Gorman P, Kelly C, Mahon N, Fitzgibbon MC. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury. Ann Clin Biochem 2017;54:149–157.
214. Brandão M, Pondé NF, Poggio F, Kotecki N, Salis M, Lambertini M, et al.
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects. Expert Rev Anticancer Ther 2018;18:629–649.
215. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell
Biol 2001;2:127–137.
216. Belmonte F, Das S, Sysa-Shah P, Sivakumaran V, Stanley B, Guo X, et al. ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity. Am J Physiol Heart Circ
Physiol 2015;309:H1271–H1280.
217. Martel S, Maurer C, Lambertini M, Pondé N, De Azambuja E. Breast cancer treatment-induced cardiotoxicity. Expert Opin Drug Saf 2017;16:1021–1038.
218. de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, et al. A
pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast
Cancer Res Treat 2020;179:161–171.
219. Eiger D, Pondé NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers FS, et al.
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab treatment optimization trial. Br J
Cancer 2020;122:1453–1460.
220. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, HER2-overexpressing breast cancer. J Clin Oncol 2005;23:
7811–7819.
221. Martin M, Press M, Ph D, Mackey J, Glaspy J, Chan A, et al. Adjuvant trastuzumab in
HER2-positive breast cancer. NEJM 2011;365:1273–1283.
222. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al.
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29–36.
223. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I,
et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
N Engl J Med 2005;353:1659–1672.
224. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–1684.
225. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de
Azambuja E, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: ﬁnal analysis of the HERceptin Adjuvant
(HERA) trial. Lancet 2017;389:1195–1205.
226. Tan TC, Bouras S, Sawaya H, Sebag IA, Cohen V, Picard MH, et al. Time trends of left ventricular ejection fraction and myocardial deformation indices in a cohort of women with breast cancer treated with anthracyclines, taxanes, and trastuzumab. J
Am Soc Echocardiogr 2015;28:509–514.
227. Ben Kridis W, Sghaier S, Charfeddine S, Toumi N, Daoud J, Kammoun S, et al. A
prospective study about trastuzumab-induced cardiotoxicity in HER2-positive breast cancer. Am J Clin Oncol Cancer Clin Trials 2020;43:510–516.
228. Yang ZY, Wang W, Wang X, Qin ZQ. Cardiotoxicity of epidermal growth factor receptor 2-targeted drugs for breast cancer. Front Pharmacol 2021;12:741451.
229. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden
C, et al. 2013 ESC guidelines on the management of stable coronary artery disease:
the Task Force on the management of stable coronary artery disease of the
European Society of Cardiology. Eur Heart J 2013;34:2949–3003.


<!-- PAGE 121 -->

### Page 121

230. Padegimas A, Carver JR. How to diagnose and manage patients with
ﬂuoropyrimidine-induced chest pain:
a single center approach.
JACC
CardioOncology 2020;2:650–654.
231. Kwakman JJM, Simkens LHJ, Mol L, Kok WEM, Koopman M, Punt CJA. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch
Colorectal Cancer Group. Eur J Cancer 2017;76:93–99.
232. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-ﬂuorouracil. Ann Oncol 2002;13:
797–801.
233. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-ﬂuorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014;
15:47.
234. Edvardsen T, Asch FM, Davidson B, Delgado V, DeMaria A, Dilsizian V, et al.
Non-invasive imaging in coronary syndromes: recommendations of the European
Association of
Cardiovascular
Imaging and the
American
Society of
Echocardiography, in collaboration with the American Society of Nuclear
Cardiology, Society of Cardiovascular Comuted Tomography, and Society for
Cardiovascular Magnetic Resonance. Eur Heart J Cardiovasc Imaging 2022;23:
e6–e33.
235. Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-ﬂuorouracil and cardiotoxicity: a review. Ther Adv Med Oncol 2018;10:1758835918780140.
236. Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends
Cardiovasc Med 2013;23:104–113.
237. Choueiri TK, Schutz FAB, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010;28:2280–2285.
238. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: With a special focus on cardiac repolarisation (QT interval). Drug Saf 2013;
36:295–316.
239. Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev 2017;53:120–127.
240. Desai A, Noor A, Joshi S, Kim AS. Takotsubo cardiomyopathy in cancer patients.
Cardio-Oncology 2019;5:7.
241. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension.
Circulation 2011;124:1687–1691.
242. Shah CP, Moreb JS. Cardiotoxicity due to targeted anticancer agents: a growing challenge. Ther Adv Cardiovasc Dis 2019;13:1753944719843435.
243. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008;358:95–97.
244. Hamnvik OPR, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015;121:311–319.
245. Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 2015;94:228–237.
246. Nhola LF, Abdelmoneim SS, Villarraga HR, Kohli M, Grothey A, Bordun KA, et al.
Echocardiographic assessment for the detection of cardiotoxicity due to vascular endothelial growth factor inhibitor therapy in metastatic renal cell and colorectal cancers. J Am Soc Echocardiogr 2019;32:267–276.
247. Uraizee I, Cheng S, Moslehi J. Reversible cardiomyopathy associated with sunitinib and sorafenib. N Engl J Med 2011;365:1649–1650.
248. Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension 2018;71:E1–E8.
249. Zang J, Wu S, Tang L, Xu X, Bai J, Ding C, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One 2012;7:e30353.
250. Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2015;112:296–305.
251. Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, et al. Identiﬁcation of anticancer drugs associated with atrial ﬁbrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother 2021;7:312–320.
252. EMA. Medicines | European Medicines Agency. Eur Med Agency Sci Med Heal n.d.
253. FDA. Drugs@FDA: FDA-Approved Drugs. FDA US Food Drug Adm n.d.
254. Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J 2012;163:156–163.
255. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst
2010;102:596–604.
256. Barber MC, Mauro MJ, Moslehi J. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematology 2017;
2017:110–114.
257. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 2015;33:4210–4218.
258. Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol 2015;66:1160–1178.
259. Buza V, Rajagopalan B, Curtis AB. Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies. Circ Arrhythmia Electrophysiol 2017;10:
e005443.
260. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al.
Vascular toxicities of cancer therapies: the old and the new—an evolving avenue.
Circulation 2016;133:1272–1289.
261. Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS). Cancers (Basel) 2020;12:826.
262. Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P, et al. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy:
European recommendations for clinical practice. Br J Haematol 2018;180:666–679.
263. Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, et al.
Atrial ﬁbrillation in patients with chronic lymphocytic leukemia (CLL). Leuk
Lymphoma 2017;58:1630–1639.
264. Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, et al.
Hypertension and incident cardiovascular events following ibrutinib initiation.
Blood 2019;134:1919–1928.
265. Brown JR, Moslehi J, O’Brien S, Ghia P, Hillmen P, Cymbalista F, et al.
Characterization of atrial ﬁbrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica 2017;102:1796–1805.
266. López-Fernández, T, Canales M, Farmakis D, García-Sanz R, Bosch F, Loscertales J,
et al. Ibrutinib-associated atrial ﬁbrillation: a practical approach. Ann Hematol Oncol
2018;5:1203.
267. Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB,
et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol 2019;74:
1667–1678.
268. Abdel-Qadir H, Sabrie N, Leong D, Pang A, Austin PC, Prica A, et al. Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a populationbased cohort study. J Clin Oncol 2021;39:3453–3462.
269. Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al.
Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia:
results of the ﬁrst randomized phase III trial. J Clin Oncol 2021;39:3441–3452.
270. Common Terminology Criteria for Adverse Events (CTCAE) v6.0. National Cancer Institute,
2022. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
271. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, et al.
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica 2022;
107:1335–1346.
272. Svennberg E, Tjong F, Goette A, Akoum N, Di Biaise L, Bordachar P, et al. How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace.
2022;24:979–1005.
273. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.
(EACTS). Eur Heart J 2021;42:373–498.
274. McMullen JR, Boey EJ, Ooi JYY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial ﬁbrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 2014;124:3829–3830.
275. Lee HJ, Chihara D, Wang M, Mouhayar E, Kim P. Ibrutinib-related atrial ﬁbrillation in patients with mantle cell lymphoma. Leuk Lymphoma 2016;57:2914–2916.
276. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratiﬁcation and management. Am J Hematol 2020;95:548–567.
277. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28:1122–1128.
278. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction—Alzheimer’s disease of the heart? N Engl J Med 2013;368:455–464.
279. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, et al.
Carﬁlzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N
Engl J Med 2015;372:142–152.
280. Chari A, Keith Stewart A, Russell SD, Moreau P, Herrmann J, Banchs J, et al. Analysis of carﬁlzomib cardiovascular safety proﬁle across relapsed and/or refractory multiple myeloma clinical trials. Blood Adv 2018;2:1633–1644.
ESC Guidelines
4349


<!-- PAGE 122 -->

### Page 122

281. Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, et al.
Carﬁlzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol 2018;4:e174519.
282. Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, et al. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J 2016;37:
378–385.
283. Gavazzoni M, Lombardi CM, Vizzardi E, Gorga E, Sciatti E, Rossi L, et al. Irreversible proteasome inhibition with carﬁlzomib as ﬁrst line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects. Eur J Pharmacol
2018;838:85–90.
284. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, et al. Integrated safety proﬁle of single-agent carﬁlzomib: experience from 526 patients enrolled in 4 phase
II clinical studies. Haematologica 2013;98:1753–1761.
285. RidolﬁRL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis.
Clinical and pathologic features of 23 patients. Am J Med 1977;62:677–686.
286. Fakhri B, Fiala MA, Shah N, Vij R, Wildes TM. Measuring cardiopulmonary complications of carﬁlzomib treatment and associated risk factors using the
SEER-Medicare database. Cancer 2020;126:808–813.
287. Feng DL, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al.
Intracardiac thrombosis and embolism in patients with cardiac amyloidosis.
Circulation 2007;116:2420–2426.
288. Mancuso S, Carlisi M, Sarocchi M, Napolitano M, Siragusa S. Cardio-oncology in multiple myeloma: is it time for a speciﬁc focus? Leuk Lymphoma 2018;59:
1764–1766.
289. Danhof S, Schreder M, Rasche L, Striﬂer S, Einsele H, Knop S. ‘Real-life’ experience of preapproval carﬁlzomib-based therapy in myeloma—analysis of cardiac toxicity and predisposing factors. Eur J Haematol 2016;97:25–32.
290. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of
Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail
2021;23:512–526.
291. Feng DL, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009;119:
2490–2497.
292. Sonneveld P, Asselbergs E, Zweegman S, Van Der Holt B, Kersten MJ, Vellenga E,
et al. Phase 2 study of carﬁlzomib, thalidomide, and dexamethasone as induction/
consolidation therapy for newly diagnosed multiple myeloma. Blood 2015;125:
449–456.
293. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, et al. Phase 2
dose-expansion study (PX-171-006) of carﬁlzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 2013;122:
3122–3128.
294. Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, et al.
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Br J
Haematol 2018;180:271–275.
295. Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, et al. Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. JAMA
Oncol 2017;3:980–988.
296. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B,
et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414–423.
297. Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC,
et al. High prevalence of intracardiac thrombi in cardiac amyloidosis. J Am Coll
Cardiol 2019;73:1733–1734.
298. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American
Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021;5:927–974.
299. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020;38:496–520.
300. Piedra K, Peterson T, Tan C, Orozco J, Hultcrantz M, Hassoun H, et al. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carﬁlzomib,
lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. Br J Haematol 2022;196:105–109.
301. Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Harrell S, et al.
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. Br J Haematol 2020;190:
555–561.
302. Swan D, Rocci A, Bradbury C, Thachil J. Venous thromboembolism in multiple myeloma—choice of prophylaxis, role of direct oral anticoagulants and special considerations. Br J Haematol 2018;183:538–556.
303. Lendvai N, Tsakos I, Devlin SM, Schaffer WL, Hassoun H, Lesokhin AM, et al.
Predictive biomarkers and practical considerations in the management of carﬁlzomib-associated cardiotoxicity. Leuk Lymphoma 2018;59:1981–1985.
304. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin,
warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol
2011;29:986–993.
305. Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al.
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012;119:933–939.
306. Chalayer E, Bourmaud A, Tinquaut F, Chauvin F, Tardy B. Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma. Thromb Res 2016;145:119–125.
307. Zoppellaro G, Veronese N, Granziera S, Gobbi L, Stubbs B, Cohen AT. Primary thromboembolic prevention in multiple myeloma patients: an exploratory meta-analysis on aspirin use. Semin Hematol 2018;55:182–184.
308. Mincu RI, Mahabadi AA, Michel L, Mrotzek SM, Schadendorf D, Rassaf T, et al.
Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw Open 2019;2:e198890.
309. Glen C, Tan YY, Waterston A, Evans TRJ, Jones RJ, Petrie MC, et al. Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC:
CardioOncology state-of-the-art review. Cardio Oncol 2022;4:1–18.
310. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;
367:107–114.
311. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D,
et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372:30–39.
312. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al.
Dabrafenib and trametinib versus dabrafenib and placebo for
Val600
BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444–451.
313. Bronte E, Bronte G, Novo G, Rinaldi G, Bronte F, Passiglia F, et al. Cardiotoxicity mechanisms of the combination of
BRAF-inhibitors and
MEK-inhibitors.
Pharmacol Ther 2018;192:65–73.
314. Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, et al.
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS
study: incidence, course and management. Eur J Cancer 2019;119:97–106.
315. Banks M, Crowell K, Proctor A, Jensen BC. Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism. Cardiovasc Toxicol 2017;17:487–493.
316. Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019;115:
854–868.
317. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158–168.
318. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 2020;142:2299–2311.
319. Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G,
Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail 2021;23:1739–1747.
320. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al.
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19:1579–1589.
321. Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer 2020;8:e000261.
322. D’Souza M, Nielsen D, Svane IM, Iversen K, Rasmussen PV, Madelaire C, et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J 2021;42:1621–1631.
323. Dolladille C, Akroun J, Morice P-M, Dompmartin A, Ezine E, Sassier M, et al.
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors:
a safety meta-analysis. Eur Heart J 2021;42:4964–4977.
324. Zamami Y, Niimura T, Okada N, Koyama T, Fukushima K, Izawa-Ishizawa Y, et al.
Factors associated with immune checkpoint inhibitor–related myocarditis. JAMA
Oncol 2019;5:1635–1637.
325. Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity:
JACC: CardioOncology primer. JACC CardioOncology 2021;3:35–47.
326. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 2018;19:e447–e458.
327. Schiffer WB, Deych E, Lenihan DJ, Zhang KW. Coronary and aortic calciﬁcation are associated with cardiovascular events on immune checkpoint inhibitor therapy. Int J
Cardiol 2021;322:177–182.


<!-- PAGE 123 -->

### Page 123

328. Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, et al. Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. J
Immunother Cancer 2019;7:225.
329. Allenbach Y, Anquetil
C, Manouchehri
A, Benveniste O, Lambotte
O,
Lebrun-Vignes B, et al. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.
Autoimmun Rev 2020;19:102586.
330. Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, et al.
Immune checkpoint inhibitor–associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution. Circulation 2018;138:
743–745.
331. Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al.
Myocarditis in the setting of cancer therapeutics: proposed case deﬁnitions for emerging clinical syndromes in cardio-oncology. Circulation 2019;140:80–91.
332. Lehmann LH, Cautela J, Palaskas N, Baik AH, Meijers WC, Allenbach Y, et al. Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review. JAMA Cardiol 2021;6:1329–1337.
333. Rini B, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, Choueiri TK, et al.
Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase 3 JAVELIN Renal 101 trial. J Clin Oncol 2022;40:1929–1938.
334. Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al.
Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol 2020;75:467–478.
335. Kondapalli L, Bottinor W, Lenneman C. By releasing the brakes with immunotherapy, are we accelerating atherosclerosis? Circulation 2020;142:2312–2315.
336. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: longterm implications of toxicity. Nat Rev Clin Oncol 2022;19:254–267.
337. Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One 2014;9:
e107516.
338. Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, et al.
Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE Steps to reduce cardiovascular disease in patients with prostate cancer. Circulation 2016;133:537–541.
339. Okwuosa TM, Morgans A, Rhee J-W, Reding KW, Maliski S, Plana J-C, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modiﬁcations: a scientiﬁc statement from the American Heart Association. Circ Genomic Precis Med 2021;14:
e000082.
340. Barber M, Nguyen L, Wassermann J, Spano J, Funck-Brentano C, Salem J. Cardiac arrhythmia considerations of hormone cancer therapies. Cardiovasc Res 2019;115:
878–894.
341. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J
Med 2020;382:2187–2196.
342. Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, et al. Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials. Eur Urol 2021;79:44–53.
343. Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, et al.
Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation 2021;
144:1295–1307.
344. Wilk M, Waśko-Grabowska A, Skoneczna I, Szmit S. Angiotensin system inhibitors may improve outcomes of patients with castration-resistant prostate cancer during abiraterone acetate treatment—a cardio-oncology study. Front Oncol 2021;11:
664741.
345. Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, et al.
Hypogonadism as a reversible cause of Torsades de Pointes in men. Circulation
2018;138:110–113.
346. Salem JE, Alexandre J, Bachelot A, Funck-Brentano C. Inﬂuence of steroid hormones on ventricular repolarization. Pharmacol Ther 2016;167:38–47.
347. Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, et al.
Androgenic effects on ventricular repolarization a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation
2019;140:1070–1080.
348. Hasegawa K, Ito H, Kaseno K, Miyazaki S, Shiomi Y, Tama N, et al. Impact of medical castration on malignant arrhythmias in patients with prostate cancer. J Am Heart
Assoc 2021;10:e017267.
349. Fradley MG, Beckie TM, Brown SA, Cheng RK, Dent SF, Nohria A, et al.
Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientiﬁc statement from the American Heart Association.
Circulation 2021;144:E41–E55.
350. Olsson H, Petri N, Erichsen L, Malmberg A, Grundemar L. Effect of degarelix, a gonadotropin-releasing hormone receptor antagonist for the treatment of prostate cancer, on cardiac repolarisation in a randomised, placebo and active comparator controlled thorough QT/QTc trial in healthy men. Clin Drug Investig 2017;37:
873–879.
351. Baum M, Buzdar AU, Cuzick J, Forbes J, Houghton J, Klijn JGM, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: ﬁrst results of the ATAC
randomised trial. Lancet 2002;359:2131–2139.
352. ARIMIDEX® (anastrozole). Highlights of Prescribing Information. Wilmington, DE:
AstraZeneca Pharmaceuticals LP, 2014.
353. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B,
Keshaviah A, Coates AS, Mouridsen H, Mauriac L, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med
2005;353:2747–2757.
354. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011;103:1299–1309.
355. Goldvaser H, Barnes TA, Seruga B, Cescon DW, Ocaña A, Ribnikar D, et al.
Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2018;110:31–39.
356. Curigliano G, Azambuja E, Lenihan D, Calabrò MG, Cardinale D, Cipolla CM.
Prevention, monitoring, and management of cardiac dysfunction in patients with metastatic breast cancer. Oncologist 2019;24:e1034–e1043.
357. KISQALI (ribociclib). Highlights of Prescribing Information. East Hanover, NJ: Novartis
Pharmaceuticals Corporation, 2018.
358. IBRANCE (palbociclib). Highlights of Prescribing Information. New York, NY: Pﬁzer,
2018.
359. VERZENIO (abemaciclib). Highlights of Prescribing Information. Indianapolis, IN: Eli
Lilly and Company, 2018.
360. Santoni M, Occhipinti G, Romagnoli E, Miccini F, Scoccia L, Giulietti M, et al.
Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications. BioDrugs 2019;33:613–620.
361. Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S,
et al. Ribociclib as ﬁrst-line therapy for HR-positive, advanced breast cancer. N
Engl J Med 2016;375:1738–1748.
362. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive,
advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet
Oncol 2018;19:904–915.
363. Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375:1925–1936.
364. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2–negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): ﬁnal analysis of the multicentre, double-blind, phas. Lancet Oncol 2016;17:425–439.
365. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III
randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer:
MONALEESA-3. J Clin Oncol 2018;36:2465–2472.
366. Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, et al.
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anticancer Drugs 2018;29:271–280.
367. Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381:
307–316.
368. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im S-A, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med
2020;382:514–524.
369. Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias:
a review. Drug Saf 2015;38:129–152.
370. Wang L, Wang W. Safety and efﬁcacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer (Review). Oncol Rep 2021;45:13–28.
371. Rao VU, Reeves DJ, Chugh AR, O’Quinn R, Fradley MG, Raghavendra M, et al.
Clinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC
state-of-the-art review. J Am Coll Cardiol 2021;77:2693–2716.
372. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 2020;383:
2018–2029.
373. Thein KZ, Swarup S, Ball S, Quirch M, Vorakunthada Y, Htwe KK, et al. Incidence of cardiac toxicities in patients with advanced non-small cell lung cancer treated with osimertinib: a combined analysis of two phase III randomized controlled trials. Ann
Oncol 2018;29:viii500.
ESC Guidelines
4351


<!-- PAGE 124 -->

### Page 124

374. Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-induced cardiotoxicity: a retrospective review of the FDA Adverse Events Reporting System (FAERS).
JACC CardioOncology 2019;1:172–178.
375. Kunimasa K, Kamada R, Oka T, Oboshi M, Kimura M, Inoue T, et al. Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib. JACC
CardioOncology 2020;2:1–10.
376. Ewer MS, Tekumalla SH, Walding A, Atuah KN. Cardiac safety of osimertinib: a review of data. J Clin Oncol 2021;39:328–337.
377. Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 2019;25:e123–e127.
378. Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al.
Cardiovascular events among adults treated with chimeric antigen receptor
T-cells (CAR-T). J Am Coll Cardiol 2019;74:3099–3108.
379. Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol 2021;78:1800–1813.
380. Fradley MG, Damrongwatanasuk R, Chandrasekhar S, Alomar M, Kip KE, Sarnaik
AA. Cardiovascular toxicity and mortality associated with adoptive cell therapy and tumor-inﬁltrating lymphocytes for advanced stage melanoma. J Immunother
2021;44:86–89.
381. Ghosh AK, Chen DH, Guha A, Mackenzie S, Walker JM, Roddie C. CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity? JACC CardioOncology 2020;2:97–109.
382. Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M.
Cardiovascular effects of CAR T cell therapy: a restrospective study. JACC
CardioOncology 2020;2:193–203.
383. Salem JE, Ederhy S, Lebrun-Vignes B, Moslehi JJ. Cardiac events associated with chimeric antigen receptor T-cells (CAR-T): a VigiBase perspective. J Am Coll Cardiol
2020;75:2521–2523.
384. Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik GA, et al. Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation 2020;142:1687–1690.
385. Lee JB, Vasic D, Kang H, Fang KKL, Zhang L. State-of-art of cellular therapy for acute leukemia. Int J Mol Sci 2021;22:4590.
386. Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435.
387. Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, et al.
Diagnosis, grading and management of toxicities from immunotherapies in children,
adolescents and young adults with cancer. Nat Rev Clin Oncol 2021;18:435–453.
388. Maus M V, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 2020;8:e001511.
389. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al.
Risk of ischemic heart disease in women after radiotherapy for breast cancer. N
Engl J Med 2013;368:987–998.
390. Van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CPM, Krol ADG, Hauptmann
M, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 2016;34:235–243.
391. Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, Van Nimwegen FA, Krol ADG,
et al. Risk for valvular heart disease after treatment for Hodgkin lymphoma. J Natl
Cancer Inst 2015;107:djv008.
392. Bergom C, Bradley JA, Ng AK, Samson P, Robinson C, Lopez-Mattei J, et al. Past,
present, and future of radiation-induced cardiotoxicity: reﬁnements in targeting,
surveillance, and risk stratiﬁcation. JACC CardioOncology 2021;3:343–359.
393. Belzile-Dugas E, Eisenberg MJ. Radiation-induced cardiovascular disease: review of an underrecognized pathology. J Am Heart Assoc 2021;10:e021686.
394. Carlson LE, Watt GP, Tonorezos ES, Chow EJ, Yu AF, Woods M, et al. Coronary artery disease in young women after radiation therapy for breast cancer. JACC
CardioOncology 2021;3:381–392.
395. Jacob S, Camilleri J, Derreumaux S, Walker V, Lairez O, Lapeyre M, et al. Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study). Radiat Oncol 2019;
14:29.
396. Hoppe BS, Bates JE, Mendenhall NP, Morris CG, Louis D, Ho MW, et al. The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era. Pract Radiat Oncol 2020;10:e147–e154.
397. Maraldo M V, Giusti F, Vogelius IR, Lundemann M, Van der Kaaij MAE, Ramadan S,
et al. Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol 2015;2:e492–e502.
398. Atkins KM, Bitterman DS, Chaunzwa TL, Kozono DE, Baldini EH, Aerts HJWL, et al.
Mean heart dose is an inadequate surrogate for left anterior descending coronary artery dose and the risk of major adverse cardiac events in lung cancer radiation therapy. Int J Radiat Oncol 2021;110:1473–1479.
399. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al.
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort. BMJ 2009;
339:b4606.
400. Van Nimwegen FA, Schaapveld M, Janus CPM, Krol ADG, Petersen EJ, Raemaekers
JMM, et al. Cardiovascular disease after Hodgkin lymphoma treatment 40-year disease risk. JAMA Intern Med 2015;175:1007–1017.
401. Jacobse JN, Duane FK, Boekel NB, Schaapveld M, Hauptmann M, Hooning MJ, et al.
Radiation dose-response for risk of myocardial infarction in breast cancer survivors. Int J Radiat Oncol Biol Phys 2019;103:595–604.
402. Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: ﬁnal results of the international, randomized phase III HD16 trial by the German Hodgkin
Study Group. J Clin Oncol 2019;37:2835–2845.
403. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med
2015;372:1598–1607.
404. Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015;16:266–273.
405. Song AJ, Manukian G, Taylor AK, Anne PR, Simone NL. Concerns for active breathing control (ABC) with breast cancer in the era of COVID-19: maximizing infection control while minimizing heart dose. Adv Radiat Oncol 2020;5:573–574.
406. Petersen PM, Aznar MC, Berthelsen AK, Loft A, Schut DA, Maraldo M, et al.
Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma:
beneﬁt of deep inspiration breath-hold. Acta Oncol (Madr) 2015;54:60–66.
407. Persson GF, Scherman Rydhög J, Josipovic M, Maraldo M V, Nygård L, Costa J, et al.
Deep inspiration breath-hold volumetric modulated arc radiotherapy decreases dose to mediastinal structures in locally advanced lung cancer. Acta Oncol (Madr)
2016;55:1053–1056.
408. Dabaja BS, Hoppe BS, Plastaras JP, Newhauser W, Rosolova K, Flampouri S, et al.
Proton therapy for adults with mediastinal lymphomas: the International
Lymphoma Radiation Oncology Group guidelines. Blood 2018;132:1635–1646.
Erratum in: Blood 2019;133:1384–1385.
409. Rotz SJ, Ryan TD, Hayek SS. Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation. J Thromb
Thrombolysis 2021;51:854–869.
410. Oliveira GH, Al-Kindi SG, Guha A, Dey AK, Rhea IB, DeLima MJ. Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation. Bone Marrow Transplant 2021;56:544–551.
411. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al.
Hematopoietic cell transplantation (HCT)-speciﬁc comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912–2919.
412. Tichelli A, Bucher C, Rovó A, Stussi G, Stern M, Paulussen M, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood
2007;110:3463–3471.
413. Alblooshi R, Kanfar S, Lord B, Atenafu EG, Michelis FV, Pasic I, et al. Clinical prevalence and outcome of cardiovascular events in the ﬁrst 100 days postallogeneic hematopoietic stem cell transplant. Eur J Haematol 2021;106:32–39.
414. Duléry R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, et al. Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC CardioOncology 2021;3:250–259.
415. López-Fernández T, Vadillo IS, de la Guía AL, Barbier KH. Cardiovascular issues in hematopoietic stem cell transplantation (HSCT). Curr Treat Options Oncol 2021;22:
51.
416. Ohmoto A, Fuji S. Cardiac complications associated with hematopoietic stem-cell transplantation. Bone Marrow Transplant 2021;56:2637–2643.
417. Takatsuka H, Nakajima T, Nomura K, Okikawa Y, Wakae T, Toda A, et al. Prognosis value of atrial natriuretic peptide and brain natriuretic peptide for heart failure in patients undergoing allogeneic bone marrow transplantation. Hematology 2006;
11:351–354.
418. Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E, et al.
Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000;26:309–313.
419. Alvarez-Cardona JA, Zhang KW, Mitchell JD, Zaha VG, Fisch MJ, Lenihan DJ.
Cardiac biomarkers during cancer therapy:
practical applications for cardio-oncology. JACC CardioOncology 2020;2:791–794.
420. Mohammed J, Smith SR, Burns L, Basak G, Aljurf M, Savani BN, et al. Role of physical therapy before and after hematopoietic stem cell transplantation: white paper report. Biol Blood Marrow Transplant 2019;25:e191–e198.
421. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al.
Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010;28:4649–4657.


<!-- PAGE 125 -->

### Page 125

422. Herrmann J. Cardiovascular toxicity with cisplatin in patients with testicular cancer:
looking for something heavier than heavy metal. JACC CardioOncology 2020;2:
456–459.
423. Cerchione C, Peleteiro Raíndo A, Mosquera Orgueira A, Mosquera Torre A, Bao
Pérez L, Marconi G, et al. Safety of FLT3 inhibitors in patients with acute myeloid leukemia. Expert Rev Hematol 2021;14:851–865.
424. Dong H, Yao L, Wang M, Wang M, Li X, Sun X, et al. Can ACEI/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer?—A
meta-analysis of randomized controlled trials. Transl Cancer Res 2020;11:
7034–7043.
425. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al.
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213–220.
426. Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020;382:
610–621.
427. Hussain Y, Drill E, Dang CT, Liu JE, Steingart RM, Yu AF. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction. Breast Cancer Res Treat 2019;175:239–246.
428. Leong DP, Cosman T, Alhussein MM, Kumar Tyagi N, Karampatos S, Barron CC,
et al. Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial.
JACC CardioOncology 2019;1:1–10.
429. Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review. Cardio Oncol 2022;4:
19–37.
430. Russell SD, Blackwell KL, Lawrence J, Pippen JE, Roe MT, Wood F, et al.
Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project
B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin
Oncol 2010;28:3416–3421.
431. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al.
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820–7826.
432. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson
Cancer Center experience. J Clin Oncol 2006;24:4107–4115.
433. Khoury K, Lynce F, Barac A, Geng X, Dang C, Yu AF, et al. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of
HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Res Treat 2021;185:863–868.
434. Mahmood SS, Fradley MG, Cohen J V, Nohria A, Reynolds KL, Heinzerling LM, et al.
Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol
2018;71:1755–1764.
435. Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek S, Asnani A, et al.
Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis.
Circulation 2021;144:1521–1523. Erratum in: Circulation 2021;144:e490.
436. Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al.
Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation 2020;141:
2031–2034.
437. Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Sufﬁotti M, Moslehi JJ, et al.
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis. J Immunother Cancer 2021;9:e003594.
438. Finke D, Heckmann MB, Herpel E, Katus HA, Haberkorn U, Leuschner F, et al. Early detection of checkpoint inhibitor-associated myocarditis using 68Ga-FAPI PET/CT.
Front Cardiovasc Med 2021;8:614997.
439. Chen Y, Jia Y, Liu Q, Shen Y, Zhu H, Dong X, et al. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review. Ann Palliat
Med 2021;10:8512–8517.
440. Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, et al.
Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail 2021;23:1725–1735.
441. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C, et al.
442. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022
ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43:3997–4126.
443. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.
Heart J 2021;42:3427–3520.
444. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015
ESC Guidelines for the diagnosis and management of pericardial diseases: the Task
Force for the Diagnosis and Management of Pericardial Diseases of the European
Society of Cardiology (ESC) Endorsed by: The European Association for
Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015;36:2921–2964.
445. Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al.
Management of acute myocarditis and chronic inﬂammatory cardiomyopathy: an expert consensus document. Circ Heart Fail 2020;13:e007405.
446. Thuny F, Alexandre J, Salem JE, Mirabel M, Dolladille C, Cohen-Solal A, et al.
Management of immune checkpoint inhibitor–induced myocarditis: the French
Working Group’s Plea for a pragmatic approach. JACC CardioOncology 2021;3:
157–161.
447. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, doubleblind, placebo-controlled, pilot trial of inﬂiximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure:
Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH)
trial. Circulation 2003;107:3133–3140.
448. Cautela J, Zeriouh S, Gaubert M, Bonello L, Laine M, Peyrol M, et al. Intensiﬁed immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. J Immunother Cancer 2020;8:e001887.
449. Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 2020;6:865–871.
450. Roth ME, Muluneh B, Jensen BC, Madamanchi C, Lee CB. Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma. Am J Ther 2016;23:
e1925–e1928.
451. Weinstock C, Khozin S, Suzman D, Zhang L, Tang S, Wahby S, et al. U.S. Food and
Drug Administration approval summary: atezolizumab for metastatic non–small cell lung cancer. Clin Cancer Res 2017;23:4534–4539.
452. Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Ghosh GC, Aronow WS,
et al. Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week. J Am Coll Cardiol 2019;74:1714–1727.
453. Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, et al.
Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor–associated myocarditis. J Am Coll Cardiol 2021;77:1503–1516.
454. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al.
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018;36:1714–1768.
455. Guha A, Addison D, Jain P, Gutierrez JM, Ghosh A, Roddie C, et al. Cardiovascular events associated with chimeric antigen receptor T cell therapy: cross-sectional
FDA adverse events reporting system analysis: cardiovascular events with CAR-T
therapy. Biol Blood Marrow Transplant 2020;26:2211–2216.
456. Kupari M, Volin L, Suokas A, Hekali P, Ruutu T. Cardiac involvement in bone marrow transplantation: serial changes in left ventricular size, mass and performance. J
Intern Med 1990;227:259–266.
457. Tonorezos ES, Stillwell EE, Calloway JJ, Glew T, Wessler JD, Rebolledo BJ, et al.
Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow
Transplant 2015;50:1212–1216.
458. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289–1367.
459. Abo S, Ritchie D, Denehy L, Panek-Hudson Y, Irving L, Granger CL. A hospital and home-based exercise program to address functional decline in people following allogeneic stem cell transplantation. Support Care Cancer 2018;26:1727–1736.
460. Squires RW, Shultz AM, Herrmann J. Exercise training and cardiovascular health in cancer patients. Curr Oncol Rep 2018;20:27.
461. Keen C, Skilbeck J, Ross H, Smith L, Collins K, Dixey J, et al. Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation? Protocol for the PREeMPT study. BMJ Open 2018;8:e021333.
462. Desai R, Desai A, Abbas SA, Patel U, Bansod S, Damarlapally N, et al. National prevalence, trends and outcomes of takotsubo syndrome in hospitalizations with prior history of mediastinal/intrathoracic cancer and radiation therapy. Int J
Cardiol 2020;309:14–18.
463. Sattler K, El-Battrawy I, Lang S, Zhou X, Schramm K, Tülümen E, et al. Prevalence of cancer in Takotsubo cardiomyopathy: short and long-term outcome. Int J Cardiol
2017;238:159–165.
464. Omerovic E, Citro R, Bossone E, Redfors B, Backs J, Bruns B, et al. Pathophysiology of Takotsubo syndrome—a joint scientiﬁc statement from the HFA TTS and
Myocardial Function Working Group of the ESC—Part 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications. Eur J Heart Fail 2022;24:274–286.
465. Omerovic E, Citro R, Bossone E, Redfors B, Backs J, Bruns B, et al. Pathophysiology of Takotsubo syndrome—a joint scientiﬁc statement from the HFA TTS Study
Group and Myocardial Function Working Group of the ESC—Part 1: overview and the central role for catecholamines and sympathetic nervous system. Eur J
Heart Fail 2022;24:257–273.
ESC Guidelines
4353


<!-- PAGE 126 -->

### Page 126

466. Couch LS, Fiedler J, Chick G, Clayton R, Dries E, Wienecke LM, et al. Circulating microRNAs predispose to Takotsubo syndrome following high-dose adrenaline exposure. Cardiovasc Res 2022;118:1758–1770.
467. Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International expert consensus document on Takotsubo syndrome (part II): diagnostic workup,
outcome, and management. Eur Heart J 2018;39:2047–2062.
468. Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J 2018;39:2032–2046.
469. Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, et al.
Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the
European Society of Cardiology. Eur J Heart Fail 2016;18:8–27.
470. Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, et al.
Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A 2012;109:13076–13081.
471. Mrotzek SM, Lena A, Hadzibegovic S, Ludwig R, Al-Rashid F, Mahabadi AA, et al.
Assessment of coronary artery disease during hospitalization for cancer treatment.
Clin Res Cardiol 2021;110:200–210.
472. Nykl R, Fischer O, Vykoupil K, Taborsky M. A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI)—systemic inﬂammatory response syndrome after use of pembrolizumab. Arch Med Sci
Atheroscler Dis 2017;2:100–102.
473. Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, et al.
Coronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case report and review of the literature and international registries. Target Oncol 2018;13:
509–515.
474. Iannaccone M, D’Ascenzo F, Vadalà P, Wilton SB, Noussan P, Colombo F, et al.
Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur
Heart Journal Acute Cardiovasc Care 2018;7:631–638.
475. Bharadwaj A, Potts J, Mohamed MO, Parwani P, Swamy P, Lopez-Mattei JC, et al.
Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur Heart J 2020;41:
2183–2193.
476. Velders MA, Boden H, Hofma SH, Osanto S, Van Der Hoeven BL, Heestermans
AACM, et al. Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol
2013;112:1867–1872.
477. Ueki Y, Vögeli B, Karagiannis A, Zanchin T, Zanchin C, Rhyner D, et al. Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention. JACC
CardioOncology 2019;1:145–155.
478. Potts JE, Iliescu CA, Lopez Mattei JC, Martinez SC, Holmvang L, Ludman P, et al.
Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J 2019;40:1790–1800.
479. Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a
10-year period. J Cancer Res Clin Oncol 2016;142:471–479.
480. Pothineni NV, Shah NN, Rochlani Y, Saad M, Kovelamudi S, Marmagkiolis K, et al.
Temporal trends and outcomes of acute myocardial infarction in patients with cancer. Ann Transl Med 2017;5:482.
481. Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol 2012;35:
443–450.
482. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al.
Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 2021;
10:947–959.
483. Mohamed MO, Van Spall HGC, Kontopantelis E, Alkhouli M, Barac A, Elgendy IY,
et al. Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care
2021;10:829–839.
484. Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, et al. SCAI
Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and Sociedad Latino Americana de
Cardiologıa Intervencionista). Catheter Cardiovasc Interv 2016;87:E202–E223.
485. Iliescu CA, Cilingiroglu M, Giza DE, Rosales O, Lebeau J, Guerrero-Mantilla I, et al.
‘Bringing on the light’ in a complex clinical scenario: optical coherence tomography–guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry). Am Heart J 2017;194:83–91.
486. Iliescu C, Balanescu DV, Donisan T, Giza DE, Muñoz Gonzalez ED, Cilingiroglu M,
et al. Safety of diagnostic and therapeutic cardiac catheterization in cancer patients with acute coronary syndrome and chronic thrombocytopenia. Am J Cardiol 2018;
122:1465–1470.
487. Cianci G, Morelli MF, Cannita K, Morese R, Ricevuto E, Di Rocco ZC, et al.
Prophylactic options in patients with 5-ﬂuorouracil-associated cardiotoxicity. Br J
Cancer 2003;88:1507–1509.
488. Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol 2012;110:1623–1626.
489. Akpek G, Hartshorn KL. Failure of oral nitrate and calcium channel blocker therapy to prevent 5-ﬂuorouracil-related myocardial ischemia: a case report. Cancer
Chemother Pharmacol 1999;43:157–161.
490. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2. J Am Coll Cardiol 2017;70:2552–2565.
491. Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, et al.
Cardio-oncology: vascular and metabolic perspectives: a scientiﬁc statement from the American Heart Association. Circulation 2019;139:e579–e602.
492. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence,
pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231–2247.
493. Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res 2016;118:1008–1020.
494. Novo G, Di Lisi D, Bronte E, MacAione F, Accurso V, Badalamenti G, et al.
Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors:
a real-world single-center experience. Oncology 2020;98:445–451.
495. Bharadwaj AS, Swamy PM, Mamas MA. Outcomes of percutaneous coronary interventions in cancer patients. Expert Rev Cardiovasc Ther 2020;18:25–32.
496. Kwok CS, Wong CW, Kontopantelis E, Barac A, Brown SA, Velagapudi P, et al.
Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. Eur Heart J 2021;
42:1019–1034.
497. van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ,
et al. Predictors of coronary stent thrombosis. The Dutch Stent Thrombosis
Registry. J Am Coll Cardiol 2009;53:1399–1409.
498. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al.
Deﬁning high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 2019;140:240–261.
499. Stewart MH, Jahangir E, Polin NM. Valvular heart disease in cancer patients: etiology, diagnosis, and management. Curr Treat Options Cardiovasc Med 2017;19:53.
500. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid,
subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. J Am Med Assoc 2003;290:2831–2837.
501. Salz T, Zabor EC, de Nully Brown P, Dalton SO, Raghunathan NJ, Matasar MJ, et al.
Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors. J Clin Oncol 2017;35:3837–3843.
502. Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, et al.
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2012;23:897–902.
503. Sato A, Yoshihisa A, Miyata-Tatsumi M, Oikawa M, Kobayashi A, Ishida T, et al.
Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer. Mol Clin Oncol 2019;10:37–42.
504. Watanabe Y, Kozuma K, Hioki H, Kawashima H, Nara Y, Kataoka A, et al.
Comparison of results of transcatheter aortic valve implantation in patients with versus without active cancer. Am J Cardiol 2016;118:572–577.
505. Nagata H, Kanzaki R, Kanou T, Ose N, Funaki S, Shintani Y, et al. Two cases of lobectomy for lung cancer after transcatheter aortic valve implantation. Surg Case
Reports 2018;4:139.
506. Landes U, Iakobishvili Z, Vronsky D, Zusman O, Barsheshet A, Jaffe R, et al.
Transcatheter aortic valve replacement in oncology patients with severe aortic stenosis. JACC Cardiovasc Interv 2019;12:78–86.
507. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021
ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J
2022;43:561–632.
508. López-Fernández T, Martín-García A, Roldán Rabadán I, Mitroi C, Mazón Ramos P,
Díez-Villanueva P, et al. Atrial ﬁbrillation in active cancer patients: expert position paper and recommendations. Rev Española Cardiol (English Ed) 2019;72:749–759.
509. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial ﬁbrillation in cancer. J Am Coll Cardiol 2014;63:945–953.
510. Yun JP, Choi EK, Do Han K, Park SH, Jung JH, Park SH, et al. Risk of atrial ﬁbrillation according to cancer type:
a nationwide population-based study.
JACC
CardioOncology 2021;3:221–232.
511. Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, et al.
Incidence, risk factors, and mortality of atrial ﬁbrillation in breast cancer: a
SEER-Medicare analysis. Eur Heart J 2021;43:300–312.


<!-- PAGE 127 -->

### Page 127

512. Hu YF, Liu CJ, Chang PMH, Tsao HM, Lin YJ, Chang SL, et al. Incident thromboembolism and heart failure associated with new-onset atrial ﬁbrillation in cancer patients. Int J Cardiol 2013;165:355–357.
513. Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP.
Anticoagulation strategies in patients with cancer: JACC review topic of the week. J Am Coll Cardiol 2019;73:1336–1349.
514. Malavasi VL, Fantecchi E, Gianolio L, Pesce F, Longo G, Marietta M, et al. Atrial ﬁbrillation in patients with active malignancy and use of anticoagulants: underprescription but no adverse impact on all-cause mortality. Eur J Intern Med 2019;
59:27–33.
515. Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in patients with different types of cancer the unmet need for onco-cardiology. Mayo
Clin Proc 2016;91:81–83.
516. Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE.
Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms. Pharmacol Ther 2018;189:89–103.
517. Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, et al. Practical management of ibrutinib in the real life: focus on atrial ﬁbrillation and bleeding. Hematol
Oncol 2018;36:624–632.
518. Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, et al.
Management of cardiovascular complications of Bruton tyrosine kinase inhibitors.
Br J Haematol 2022;196:70–78.
519. Pastori D, Marang A, Bisson A, Menichelli D, Herbert J, Lip GYH, et al.
Thromboembolism, mortality, and bleeding in 2,435,541 atrial ﬁbrillation patients with and without cancer: a nationwide cohort study. Cancer 2021;127:2122–2129.
520. Potpara TS, Lip GYH, Blomstrom-Lundqvist C, Boriani G, Van Gelder IC,
Heidbuchel H, et al. The 4S-AF scheme (Stroke Risk; Symptoms; Severity of
Burden; Substrate): a novel approach to in-depth characterization (rather than classiﬁcation) of atrial ﬁbrillation. Thromb Haemost 2021;121:270–278.
521. Boriani G, Bonini N, Albini A, Venturelli A, Imberti JF, Vitolo M. Cardioversion of recent-onset atrial ﬁbrillation: current evidence, practical considerations, and controversies in a complex clinical scenario. Kardiol Pol 2020;78:1088–1098.
522. Kanmanthareddy A, Vallakati A, Reddy Yeruva M, Dixit S, Di Biase L, Mansour M,
et al. Pulmonary vein isolation for atrial ﬁbrillation in the postpneumonectomy population: a feasibility, safety, and outcomes study. J Cardiovasc Electrophysiol
2015;26:385–389.
523. Lip GYH, Banerjee A, Boriani G, En Chiang C, Fargo R, Freedman B, et al.
Antithrombotic therapy for atrial ﬁbrillation: CHEST guideline and expert panel report. Chest 2018;154:1121–1201.
524. Proietti M, Lane DA, Boriani G, Lip GYH. Stroke prevention, evaluation of bleeding risk, and anticoagulant treatment management in atrial ﬁbrillation contemporary international guidelines. Can J Cardiol 2019;35:619–633.
525. Boriani G, Lee G, Parrini I, Lopez-Fernandez T, Lyon AR, Suter T, et al.
Anticoagulation in patients with atrial ﬁbrillation and active cancer: an international survey on patient management. Eur J Prev Cardiol 2021;28:611–621.
526. D’Souza M, Carlson N, Fosbøl E, Lamberts M, Smedegaard L, Nielsen D, et al.
CHA2DS2-VASC score and risk of thromboembolism and bleeding in patients with atrial ﬁbrillation and recent cancer. Eur J Prev Cardiol 2018;25:651–658.
527. Farmakis D. Anticoagulation for atrial ﬁbrillation in active cancer: what the cardiologists think. Eur J Prev Cardiol 2021;28:608–610.
528. Cohen A, Donal E, Delgado V, Pepi M, Tsang T, Gerber B, et al. EACVI recommendations on cardiovascular imaging for the detection of embolic sources: endorsed by the Canadian Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2021;
22:E24–E57.
529. Schulman S, Anger SU, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Deﬁnition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010;8:202–204.
530. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European
Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial ﬁbrillation. Europace 2021;23:1612–1676.
531. Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, et al.
Efﬁcacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial ﬁbrillation and a history of cancer: Observations from ROCKET AF. Eur Heart J Qual
Care Clin Outcomes 2019;5:145–152.
532. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, et al. Efﬁcacy and safety of apixaban versus warfarin in patients with atrial ﬁbrillation and a history of cancer: insights from the ARISTOTLE trial. Am J Med 2017;130:1440–1448.e1.
533. Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, et al. Efﬁcacy and safety of edoxaban in patients with active malignancy and atrial ﬁbrillation: analysis of the engage AF-TIMI 48 trial. J Am Heart Assoc 2018;7:e008987.
534. Sawant AC, Kumar A, McCray W, Tetewsky S, Parone L, Sridhara S, et al. Superior safety of direct oral anticoagulants compared to warfarin in patients with atrial ﬁbrillation and underlying cancer: a national Veterans Affairs database study. J Geriatr
Cardiol 2019;16:706–709.
535. Shah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial ﬁbrillation. Blood Adv 2018;2:200–209.
536. Mariani MV, Magnocavallo M, Straito M, Piro A, Severino P, Iannucci G, et al. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial ﬁbrillation and cancer a meta-analysis. J Thromb Thrombolysis 2021;51:419–429.
537. Deitelzweig S, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, et al.
Effectiveness and safety of oral anticoagulants among nonvalvular atrial ﬁbrillation patients with active cancer. JACC CardioOncology 2021;3:411–424.
538. Lin YS, Kuan FC, Chao TF, Wu M, Chen SW, Chen MC, et al. Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: dabigatran versus rivaroxaban. Cancer Med 2021;10:7079–7088.
539. Isogai T, Saad AM, Abushouk AI, Shekhar S, Kuroda S, Gad MM, et al. Procedural and short-term outcomes of percutaneous left atrial appendage closure in patients with cancer. Am J Cardiol 2021;141:154–157.
540. Boriani G, Fauchier L, Aguinaga L, Beattie JM, Blomstrom Lundqvist C, Cohen A,
et al. European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and postsurgery patient, endorsed by Heart Rhythm Society (HRS), Asia Paciﬁc Heart
Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa
(CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace 2019;
21:7–8.
541. Butt JH, Olesen JB, Havers-Borgersen E, Gundlund A, Andersson C, Gislason GH,
et al. Risk of thromboembolism associated with atrial ﬁbrillation following noncardiac surgery. J Am Coll Cardiol 2018;72:2027–2036.
542. Enriquez A, Biagi J, Redfearn D, Boles U, Kamel D, Ali FS, et al. Increased incidence of ventricular arrhythmias in patients with advanced cancer and implantable cardioverter-deﬁbrillators. JACC Clin Electrophysiol 2017;3:50–56.
543. Roden DM. Predicting drug-induced QT prolongation and torsades de pointes. J
Physiol 2016;594:2459–2468.
544. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al.
2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: a report of the American College of Cardiology/American Heart Association Task
Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart
Rhythm 2018;15:e190–e252.
545. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long
QT syndrome. An update. Circulation 1993;88:782–784.
546. Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, et al.
Drug-induced arrhythmias: a scientiﬁc statement from the American Heart
Association. Circulation 2020;142:E214–E233.
547. AZCERT. CredibleMeds.org n.d.
548. Coppola C, Rienzo A, Piscopo G, Barbieri A, Arra C, Maurea N. Management of
QT prolongation induced by anti-cancer drugs: target therapy and old agents.
Different algorithms for different drugs. Cancer Treat Rev 2018;63:135–143.
549. European Medicines Agency. ICH guideline E14/S7B on clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential—questions & answers. Sci Med Heal 2020:EMA/CHMP/ICH/415588/2020.
550. Atallah-Yunes SA, Kadado AJ, Kaufman GP, Hernandez-Montfort J. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J
Cancer Res Clin Oncol 2019;145:1527–1557.
551. Cirne F, Zhou S, Kappel C, El-Kadi A, Barron CC, Ellis PM, et al. ALK inhibitorinduced bradycardia: a systematic review and meta-analysis. Lung Cancer 2021;
161:9–17.
552. Hassen LJ, Lenihan DJ, Baliga RR. Hypertension in the cardio-oncology clinic. Heart
Fail Clin 2019;15:487–495.
553. Szmit S, Jurczak W, Zaucha JM, Drozd-Sokołowska J, Spychałowicz W, Joks M, et al.
Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. J Am
Soc Hypertens 2014;8:791–799.
554. Di Lorenzo G, Autorino R, Bruni G, Cartentì G, Ricevuto E, Tudini M, et al.
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009;20:1535–1542.
555. Penttilä P, Rautiola J, Poussa T, Peltola K, Bono P. Angiotensin inhibitors as treatment of sunitinib/pazopanib-induced hypertension in metastatic renal cell carcinoma. Clin Genitourin Cancer 2017;15:384–390.e3.
556. Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol 2015;26:1128–1133.
557. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OPR, Sabbisetti VS,
et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015;21:2471–2479.
558. Khorana
AA,
Francis
CW,
Culakova
E,
Kuderer
NM,
Lyman
GH.
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632–634.
ESC Guidelines
4355


<!-- PAGE 128 -->

### Page 128

559. Puurunen MK, Gona PN, Larson MG, Murabito JM, Magnani JW, O’Donnell CJ.
Epidemiology of venous thromboembolism in the Framingham Heart Study.
Thromb Res 2016;145:27–33.
560. Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer—a cohort study using linked United Kingdom databases. Eur J Cancer 2013;49:1404–1413.
561. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and beneﬁts of thromboprophylaxis. Cancer 2011;117:1334–1349.
562. Abdulla A, Davis WM, Ratnaweera N, Szefer E, Ballantyne Scott B, Lee AYY. A
meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. Thromb Haemost 2020;120:702–713.
563. Mulder FI, Carrier M, van Doormaal F, Robin P, Otten HM, Salaun PY, et al. Risk scores for occult cancer in patients with unprovoked venous thromboembolism:
results from an individual patient data meta-analysis. J Thromb Haemost 2020;18:
2622–2628.
564. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009;27:4839–4847.
565. Li X, Hu Y, Lin P, Zhang J, Tang Y, Yi Q, et al. Comparison of different clinical prognostic scores in patients with pulmonary embolism and active cancer. Thromb
Haemost 2021;121:834–844.
566. Konstantinides SV, Meyer G, Bueno H, Galié N, Gibbs JSR, Ageno W, et al. 2019
ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur
Heart J 2020;41:543–603.
567. Mazzolai L, Ageno W, Alatri A, Bauersachs R, Becattini C, Brodmann M, et al. Second consensus document on diagnosis and management of acute deep vein thrombosis:
updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. Eur J Prev Cardiol 2022;29:1248–1263
568. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MS V, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017;70:926–938.
569. Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J
Cardiol 2018;72:89–93.
570. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al.
Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012;
30:2876–2884.
571. Hooks M, Okasha O, Velangi PS, Nijjar PS, Farzaneh-Far A, Shenoy C. Left ventricular thrombus on cardiovascular magnetic resonance imaging in non-ischaemic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2020. doi:10.1093/ehjci/jeaa244.
Online ahead of print 7 October 2020.
572. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al.
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–153.
573. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062–1072.
574. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl
Thromb 2006;12:389–396.
575. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al.
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729–1735.
576. Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al.
Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA J Am Med Assoc 2015;314:
677–686.
577. Lee YJ, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, et al. Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. Int J Cardiol
2016;203:372–378.
578. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al.
Edoxaban for the treatment of cancer-associated venous thromboembolism. N
Engl J Med 2018;378:615–624.
579. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism:
results of a
randomized trial
(SELECT-D). J Clin Oncol 2018;36:2017–2023.
580. McBane II RD, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A,
et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020;18:411–421.
581. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman M V, Connors JM, et al.
Apixaban for the treatment of venous thromboembolism associated with cancer.
N Engl J Med 2020;382:1599–1607.
582. Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol 2019;30:
897–907.
583. Ageno W, Vedovati MC, Cohen A, Huisman M, Bauersachs R, Gussoni G, et al.
Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost 2021;
121:616–624.
584. Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, et al.
Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a US claims data analysis. Thromb Haemost 2021;121:383–395.
585. Giustozzi M, Agnelli G, Del Toro-Cervera J, Klok FA, Rosovsky RP, Martin AC, et al.
Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020;
120:1128–1136.
586. Sabatino J, De Rosa S, Polimeni A, Sorrentino S, IndolﬁC. Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis. JACC
CardioOncology 2020;2:428–440.
587. Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism.
Blood 2019;133:291–298.
588. Den Exter PL, Hooijer J, Dekkers OM, Huisman M V. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol
2011;29:2405–2409.
589. Jara-Palomares
L,
Solier-Lopez
A,
Elias-Hernandez
T,
Asensio-Cruz
M,
Blasco-Esquivias I, Marin-Barrera L, et al. Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study. Thromb Res 2017;157:90–96.
590. Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman M V, et al.
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 2015;13:1028–1035.
591. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020
ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint
Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021;77:e25–e197.
592. Riondino S, Ferroni P, Del Monte G, Formica V, Guadagni F, Roselli M. Venous thromboembolism in cancer patients on simultaneous and palliative care. Cancers
(Basel) 2020;12:1167.
593. Xin Z, Liu F, Du Y, Mao F, Wang X, Xu P, et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients: a systematic review and network meta-analysis. Ann Cardiothorac Surg 2020;9:2970–2981.
594. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019;20:e566–e581.
595. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al.
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975–980.
596. Khorana A, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood
2008;111:4902–4907.
597. Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El
Shemmari S, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS–cancer-associated thrombosis study. Oncologist 2017;22:1222–1231.
598. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al.
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943–949.
599. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al.
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601–609.
600. Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AWSS. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 2016;12:CD008500.
601. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al.
Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J
Med 2019;380:711–719.
602. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med
2019;380:720–728.
603. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol 2019;94:
780–785.
604. Menapace LA, McCrae KR, Khorana AA. Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. Thromb Res 2016;140:S93–S98.


<!-- PAGE 129 -->

### Page 129

605. Roule V, Verdier L, Blanchart K, Ardouin P, Lemaitre A, Bignon M, et al. Systematic review and meta-analysis of the prognostic impact of cancer among patients with acute coronary syndrome and/or percutaneous coronary intervention. BMC
Cardiovasc Disord 2020;20:38.
606. Freedberg DE, Kim LS, Yang YX. The risks and beneﬁts of long-term use of proton pump inhibitors: expert review and best practice advice from the American
Gastroenterological Association. Gastroenterology 2017;152:706–715.
607. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC
focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018;39:213–260.
608. Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, et al. SCAI clinical expert consensus statement on the classiﬁcation of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American
Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the
Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv
2019;94:29–37.
609. Schiffer CA, Bohlke K, Anderson KC. Platelet transfusion for patients with cancer:
American Society of Clinical Oncology Clinical Practice Guideline Update
Summary. J Oncol Pract 2018;14:129–133.
610. Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding,
and anticoagulation in patients with malignancy. Blood Adv 2019;3:3770–3779.
611. Parr SK, Liang J, Schadler KL, Gilchrist SC, Steele CC, Ade CJ. Anticancer therapy-related increases in arterial stiffness: a systematic review and meta-analysis.
J Am Heart Assoc 2020;9:e015598.
612. Gambichler T, Strutzmann S, Tannapfel A, Susok L. Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade. BMC Cancer 2017;17:327.
613. Aichberger
KJ,
Herndlhofer
S,
Schernthaner
GH,
Schillinger
M,
Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol
2011;86:533–539.
614. Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al.
Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res 2016;48:84–91.
615. Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, Le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2015;
125:901–906.
616. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:
2128–2137.
617. Ranchoux B, Günther S, Quarck R, Chaumais MC, Dorfmüller P, Antigny F, et al.
Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J
Pathol 2015;185:356–371.
618. Jevnikar M, Montani D, Savale L, Seferian A, Jutant EM, Boucly A, et al. Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. Eur Respir J 2021;57:2002208.
619. Price LC, Seckl MJ, Dorfmüller P, Wort SJ. Tumoral pulmonary hypertension. Eur
Respir Rev 2019;28:180065.
620. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022
ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
Eur Heart J 2022;43:3618–3731.
621. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J
Med 2010;362:2260–2270.
622. Imazio M, Colopi M, De Ferrari GM. Pericardial diseases in patients with cancer:
Contemporary prevalence, management and outcomes. Heart 2020;106:569–574.
623. Kim SR, Kim EK, Cho J, Chang SA, Park SJ, Lee SC, et al. Effect of anti-inﬂammatory drugs on clinical outcomes in patients with malignant pericardial effusion. J Am Coll
Cardiol 2020;76:1551–1561.
624. Gong J, Drobni ZD, Zafar A, Quinaglia T, Hartmann S, Gilman HK, et al. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer
2021;9:e002771.
625. Inno A, Maurea N, Metro G, Carbone A, Russo A, Gori S. Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.
Cancer Immunol Immunother 2021;70:3041–3053.
626. Sánchez-Enrique C, Nuñez-Gil IJ, Viana-Tejedor A, De Agustín A, Vivas D,
Palacios-Rubio J, et al. Cause and long-term outcome of cardiac tamponade. Am J
Cardiol 2016;117:664–669.
627. Saab J, Hoda RS, Narula N, Hoda SA, Geraghty BE, Nasar A, et al. Diagnostic yield of cytopathology in evaluating pericardial effusions: clinicopathologic analysis of 419
specimens. Cancer Cytopathol 2017;125:128–137.
628. Patel N, Raﬁque AM, Eshaghian S, Mendoza F, Biner S, Cercek B, et al. Retrospective comparison of outcomes, diagnostic value, and complications of percutaneous prolonged drainage versus surgical pericardiotomy of pericardial effusion associated with malignancy. Am J Cardiol 2013;112:1235–1239.
629. Palaskas N, Morgan J, Daigle T, Banchs J, Durand JB, Hong D, et al. Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors. Am J Cardiol 2019;123:1351–1357.
630. Shaheen S, Mirshahidi H, Nagaraj G, Hsueh CT. Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature.
Exp Hematol Oncol 2018;7:11.
631. Dixon SB, Howell CR, Lu L, Plana JC, Joshi VM, Luepker R V, et al. Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort.
Cancer 2021;127:458–466.
632. Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, et al. Association of cardiovascular risk factors with cardiac events and survival outcomes among patients with breast cancer enrolled in SWOG clinical trials. J Clin Oncol 2018;36:
2710–2717.
633. Nolan MT, Marwick TH, Plana JC, Li Z, Ness KK, Joshi VM, et al. Effect of traditional heart failure risk factors on myocardial dysfunction in adult survivors of childhood cancer. JACC Cardiovasc Imaging 2018;11:1202–1203.
634. Cho H, Lee S, Sim SH, Park IH, Lee KS, Kwak MH, et al. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients. Breast Cancer Res Treat 2020;182:333–343.
635. Smarz K, Jaxa-Chamiec T, Chwyczko T, Główczyńska R, Jegier A, Niedoszytko P,
et al. Cardiopulmonary exercise testing in adult cardiology: expert opinion of the
Working Group of Cardiac Rehabilitation and Exercise Physiology of the Polish
Cardiac Society. Kardiol Pol 2019;77:730–756.
636. Scott JM, Zabor EC, Schwitzer E, Koelwyn GJ, Adams SC, Nilsen TS, et al. Efﬁcacy of exercise therapy on cardiorespiratory ﬁtness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol 2018;36:2297–2304.
637. Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle 2015;6:
115–124.
638. Wallen MP, Hennessy D, Brown S, Evans L, Rawstorn JC, Wong Shee A, et al.
High-intensity interval training improves cardiorespiratory ﬁtness in cancer patients and survivors: a meta-analysis. Eur J Cancer Care (Engl) 2020;29:e13267.
639. Lee K, Tripathy D, Demark-Wahnefried W, Courneya KS, Sami N, Bernstein L,
et al. Effect of aerobic and resistance exercise intervention on cardiovascular disease risk in women with early-stage breast cancer: a randomized clinical trial.
JAMA Oncol 2019;5:710–714.
640. Adams SC, Delorey DS, Davenport MH, Fairey AS, North S, Courneya KS. Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors. Br J Cancer 2018;118:1313–1321.
641. Mijwel S, Jervaeus A, Bolam KA, Norrbom J, Bergh J, Rundqvist H, et al.
High-intensity exercise during chemotherapy induces beneﬁcial effects 12 months into breast cancer survivorship. J Cancer Surviv 2019;13:244–256.
642. Marriott CFS, Petrella AFM, Marriott ECS, Boa Sorte Silva NC, Petrella RJ.
High-intensity interval training in older adults: a scoping review. Sport Med - Open
2021;7:49.
643. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, et al.
Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol 2015;65:2739–2746.
644. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al.
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;
370:2011–2019.
645. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008;112:2500–2508.
646. Kim PY, Irizarry-Caro JA, Ramesh T, Iliescu C, Lopez-Mattei JC. How to diagnose and manage QT prolongation in cancer patients. JACC CardioOncology 2021;3:
145–149.
647. Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a populationbased study. Lancet Oncol 2014;15:35–47.
648. Geenen MM, Cardous-Ubbink MC, Kremer LCM, Van Den Bos C, Van Der Pal
HJH, Heinen RC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. J Am Med Assoc 2007;297:2705–2715.
649. Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, et al.
Cardiovascular disease in survivors of childhood cancer: insights into epidemiology,
pathophysiology, and prevention. J Clin Oncol 2018;36:2135–2144.
650. Fidler MM, Reulen RC, Henson K, Kelly J, Cutter D, Levitt GA, et al.
Population-based long-term cardiac-speciﬁc mortality among 34 489 ﬁve-year survivors of childhood cancer in Great Britain. Circulation 2017;135:951–963.
651. Kremer LCM, van Dalen EC, Offringa M, Voûte PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann
Oncol 2002;13:503–512.
ESC Guidelines
4357


<!-- PAGE 130 -->

### Page 130

652. Bates JE, Howell RM, Liu Q, Yasui Y, Mulrooney DA, Dhakal S, et al.
Therapy-related cardiac risk in childhood cancer survivors: an analysis of the childhood cancer survivor study. J Clin Oncol 2019;37:1090–1101.
653. van Dalen EC, Mulder RL, Suh E, Ehrhardt MJ, Aune GJ, Bardi E, et al. Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: a systematic review and recommendations from the International Late
Effects of Childhood Cancer Guideline Harmonization Group. Eur J Cancer 2021;
156:127–137.
654. Leerink JM, van der Pal HJH, Kremer LCM, Feijen EAM, Meregalli PG, Pourier MS,
et al. Reﬁning the 10-year prediction of left ventricular systolic dysfunction in longterm survivors of childhood cancer. JACC CardioOncology 2021;3:62–72.
655. Armstrong GT, Oefﬁnger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, et al.
Modiﬁable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013;31:3673–3680.
656. Armenian SH, Sun CL, Vase T, Ness KK, Blum E, Francisco L, et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood 2012;120:4505–4512.
657. Carpenter K, Scavotto M, McGovern A, Ma C, Kenney LB, Mack JW, et al. Early parental knowledge of late effect risks in children with cancer. Pediatr Blood Cancer
2022;69:e29473.
658. Herrmann J. From trends to transformation: where cardio-oncology is to make a difference. Eur Heart J 2019;40:3898–3900.
659. Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Triﬁletti DM, Jiang C, et al. A
population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019;40:3889–3897.
660. Stoltzfus KC, Zhang Y, Sturgeon K, Sinoway LI, Triﬁletti DM, Chinchilli VM, et al.
Fatal heart disease among cancer patients. Nat Commun 2020;11:2011.
661. Banke A, Fosbøl EL, Møller JE, Gislason GH, Andersen M, Bernsdorf M, et al.
Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. Eur J Heart Fail 2018;20:1447–1453.
662. Jacobse JN, Steggink LC, Sonke GS, Schaapveld M, Hummel YM, Steenbruggen TG,
et al. Myocardial dysfunction in long-term breast cancer survivors treated at ages
40–50 years. Eur J Heart Fail 2020;22:338–346.
663. Boyne DJ, Mickle AT, Brenner DR, Friedenreich CM, Cheung WY, Tang KL, et al.
Long-term risk of cardiovascular mortality in lymphoma survivors: a systematic review and meta-analysis. Cancer Med 2018;7:4801–4813.
664. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol 2005;
6:557–565.
665. de Vries S, Schaapveld M, Janus CPM, Daniëls LA, Petersen EJ, van der Maazen
RWM, et al. Long-term cause-speciﬁc mortality in Hodgkin lymphoma patients. J
Natl Cancer Inst 2021;113:760–769.
666. Armenian SH, Yang D, Teh JB, Atencio LC, Gonzales A, Wong FL, et al. Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood
Adv 2018;2:1756–1764.
667. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, De Azambuja E, Procter M, Suter
TM, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial. Lancet 2013;382:
1021–1028.
668. Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol
2016;34:581–587.
669. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007;25:3808–3815.
670. Lancellotti P, Nkomo VT, Badano LP, Bergler J, Bogaert J, Davin L, et al. Expert
Consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of
Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc
Echocardiogr 2013;26:1013–1032.
671. Tromp J, Boerman LM, Sama IE, Maass SWMC, Maduro JH, Hummel YM, et al.
Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inﬂammatory biomarker proﬁle compared to matched controls.
Eur J Heart Fail 2020;22:1239–1246.
672. Cao Z, Xu C, Yang H, Li S, Wang Y. The role of healthy lifestyle in cancer incidence and temporal transitions to cardiometabolic disease. JACC CardioOncology 2021;3:
663–674.
673. Limat S, Daguindau E, Cahn JY, Nerich V, Brion A, Perrin S, et al. Incidence and riskfactors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin’s lymphoma. J Clin Pharm Ther 2014;39:168–174.
674. Hershman DL, McBride RB, Eisenberger A, Wei YT, Grann VR, Jacobson JS.
Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse
B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:3159–3165.
675. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:
685–691.
676. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669–677.
677. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet
2001;357:1385–1390.
678. Abdel-Qadir H, Tai F, Croxford R, Austin PC, Amir E, Calvillo-Argüelles O, et al.
Characteristics and outcomes of women developing heart failure after early stage breast cancer chemotherapy: a population-based matched cohort study. Circ Heart
Fail 2021;14:e008110.
679. Curigliano G, Cardinale D, Suter T, Plataniotis G, De Azambuja E, Sandri MT, et al.
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol 2012;23:vii155–66.
680. Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003;45:55–75.
681. Taylor C, Duane FK, Dodwell D, Gray R, Wang Z, Wang Y, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol 2017;35:
1641–1649.
682. Reed GW, Masri A, Grifﬁn BP, Kapadia SR, Ellis SG, Desai MY. Long-term mortality in patients with radiation-associated coronary artery disease treated with percutaneous coronary intervention. Circ Cardiovasc Interv 2016;9:e003483.
683. Liang JJ, Sio TT, Slusser JP, Lennon RJ, Miller RC, Sandhu G, et al. Outcomes after percutaneous coronary intervention with stents in patients treated with thoracic external beam radiation for cancer. JACC Cardiovasc Interv 2014;7:1412–1420.
684. Cuomo JR, Javaheri SP, Sharma GK, Kapoor D, Berman AE, Weintraub NL. How to prevent and manage radiation-induced coronary artery disease. Heart 2018;104:
1647–1653.
685. Feldman DR, Schaffer WL, Steingart RM. Late cardiovascular toxicity following chemotherapy for germ cell tumors. JNCCN J Natl Compr Cancer Netw 2012;10:
537–544.
686. Sudhakar R. Response to treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol 2012;35:646.
687. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2013;368:574–577.
688. Han X-J, Li J-Q, Khannanova Z, Li Y. Optimal management of coronary artery disease in cancer patients. Chronic Dis Transl Med 2019;5:221–233.
689. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al.
(2018 ESC/EACTS Guidelines on myocardial revascularization). Kardiol Pol 2018;
76:1585–1664.
690. Wu W, Masri A, Popovic ZB, Smedira NG, Lytle BW, Marwick TH, et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation 2013;127:1476–1484.
691. Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease.
Heart 2016;102:269–276.
692. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/
EACTS Guidelines for the management of valvular heart disease. Eur Heart J
2017;38:2739–2791.
693. Lind A, Totzeck M, Mahabadi AA, Jánosi RA, El Gabry M, Ruhparwar A, et al. Impact of cancer in patients undergoing transcatheter aortic valve replacement: a singlecenter study. JACC CardioOncology 2020;2:735–743.
694. Yazdchi F, Hirji SA, Nohria A, Percy E, Harloff M, Malarczyk A, et al. Transcatheter compared with surgical aortic valve replacement in patients with previous chestdirected radiation therapy. JACC CardioOncology 2021;3:397–407.
695. Guha A, Dey AK, Omer S, Abraham WT, Attizzani G, Jneid H, et al. Contemporary trends and outcomes of percutaneous and surgical mitral valve replacement or repair in patients with cancer. Am J Cardiol 2020;125:1355–1360.
696. Elbadawi A, Albaeni A, Elgendy IY, Ogunbayo GO, Jimenez E, Cornwell L, et al.
Transcatheter versus surgical aortic valve replacement in patients with prior mediastinal radiation. JACC Cardiovasc Interv 2020;13:2658–2666.
697. Zafar MR, Mustafa SF, Miller TW, Alkhawlani T, Sharma UC. Outcomes after transcatheter aortic valve replacement in cancer survivors with prior chest radiation therapy: a systematic review and meta-analysis. Cardio-Oncology 2020;6:8.
698. Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F,
Eisenwort G, et al. Nilotinib-induced vasculopathy: identiﬁcation of vascular endothelial cells as a primary target site. Leukemia 2017;31:2388–2397.
699. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary
Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 1995;31A:2229–2238.
700. Stelwagen J, Lubberts S, Steggink LC, Steursma G, Kruyt LM, Donkerbroek JW,
et al. Vascular aging in long-term survivors of testicular cancer more than 20 years


<!-- PAGE 131 -->

### Page 131

after treatment with cisplatin-based chemotherapy. Br J Cancer 2020;123:
1599–1607.
701. Andreassi MG, Piccaluga E, Gargani L, Sabatino L, Borghini A, Faita F, et al.
Subclinical carotid atherosclerosis and early vascular aging from long-term lowdose ionizing radiation exposure: a genetic, telomere, and vascular ultrasound study in cardiac catheterization laboratory staff. JACC Cardiovasc Interv 2015;8:616–627.
702. Carmody BJ, Arora S, Avena R, Curry KM, Simpkins J, Cosby K, et al. Accelerated carotid artery disease after high-dose head and neck radiotherapy: is there a role for routine carotid duplex surveillance? J Vasc Surg 1999;30:1045–1051.
703. Carpenter DJ, Mowery YM, Broadwater G, Rodrigues A, Wisdom AJ, Dorth JA,
et al. The risk of carotid stenosis in head and neck cancer patients after radiation therapy. Oral Oncol 2018;80:9–15.
704. Szpakowski N, Desai MY. Radiation-associated pericardial disease. Curr Cardiol Rep
2019;21:97.
705. Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys
2007;67:10–18.
706. Ning MS, Tang L, Gomez DR, Xu T, Luo Y, Huo J, et al. Incidence and predictors of pericardial effusion after chemoradiation therapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2017;99:70–79.
707. Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with deﬁnitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 2008;70:707–714.
708. Gagliardi G, Constine LS, Moiseenko V, Correa C, Pierce LJ, Allen AM, et al.
Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010;76:
S77–S85.
709. Chiabrando JG, Bonaventura A, Vecchié A, Wohlford GF, Mauro AG, Jordan JH,
et al. Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:76–92.
710. Donnellan
E,
Phelan
D,
Mccarthy
CP,
Collier
P,
Desai
M,
Grifﬁn
B.
Radiation-induced heart disease: a practical guide to diagnosis and management.
Cleve Clin J Med 2016;83:914–922.
711. Crestanello JA, McGregor CGA, Danielson GK, Daly RC, Dearani JA, Orszulak TA,
et al. Mitral and tricuspid valve repair in patients with previous mediastinal radiation therapy. Ann Thorac Surg 2004;78:826–831.
712. Heidenreich PA, Kapoor JR. Radiation induced heart disease. Heart 2009;95:
252–258.
713. Walsh D, Nelson KA. Autonomic nervous system dysfunction in advanced cancer.
Support Care Cancer 2002;10:523–528.
714. Noor B, Akhavan S, Leuchter M, Yang EH, Ajijola OA. Quantitative assessment of cardiovascular autonomic impairment in cancer survivors: a single center case series. Cardio-Oncology 2020;6:11.
715. Gibson TM, Li Z, Green DM, Armstrong GT, Mulrooney DA, Srivastava DK, et al.
Blood pressure status in adult survivors of childhood cancer: a report from the
St. Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev 2017;26:
1705–1713.
716. Friedman DN, Tonorezos ES, Cohen P. Diabetes and metabolic syndrome in survivors of childhood cancer. Horm Res Paediatr 2019;91:118–127.
717. Pekmezi DW, Demark-Wahnefried W. Updated evidence in support of diet and exercise interventions in cancer survivors. Acta Oncol (Madr) 2011;50:167–178.
718. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002;20:1128–1143.
719. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010;123:
627–635.
720. Meyerhardt JA, Ma J, Courneya KS. Energetics in colorectal and prostate cancer. J
Clin Oncol 2010;28:4066–4073.
721. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007;109:675–684.
722. Siegel EM, Ulrich CM, Poole EM, Holmes RS, Jacobsen PB, Shibata D. The effects of obesity and obesity-related conditions on colorectal cancer prognosis. Cancer
Control 2010;17:52–57.
723. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 2005;23:1370–1378.
724. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: Findings from Cancer and Leukemia
Group B 89803. J Clin Oncol 2008;26:4109–4115.
725. Kroenke CH, Fung TT, Hu FB, Holmes MD. Dietary patterns and survival after breast cancer diagnosis. J Clin Oncol 2005;23:9295–9303.
726. Kwan ML, Weltzien E, Kushi LH, Castillo A, Slattery ML, Caan BJ. Dietary patterns and breast cancer recurrence and survival among women with early-stage breast cancer. J Clin Oncol 2009;27:919–926.
727. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. J Am Med Assoc 2007;298:754–764.
728. Yang J, Li C, Shen Y, Zhou H, Shao Y, Zhu W, et al. Impact of statin use on cancerspeciﬁc mortality and recurrence: a meta-analysis of 60 observational studies.
Medicine 2020;99:e19596.
729. Kim J, Choi EA, Han YE, Woo Lee J, Seul Kim Y, Kim Y, et al. Association between statin use and all-cause mortality in cancer survivors, based on the Korean health insurance service between 2002 and 2015. Nutr Metab Cardiovasc Dis 2020;30:
434–440.
730. Ren QW, Yu SY, Teng THK, Li X, Cheung KS, Wu MZ, et al. Statin associated lower cancer risk and related mortality in patients with heart failure. Eur Heart J 2021;42:
3049–3059.
731. Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010;28:340–347.
732. Speck RM, Courneya KS, Mâsse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J
Cancer Surviv 2010;4:87–100.
733. Campia U, Barac A. Exercise and aerobic ﬁtness to reduce cancer-related cardiovascular toxicity. Curr Treat Options Cardiovasc Med 2016;18:44.
734. Jones LW, Liu Q, Armstrong GT, Ness KK, Yasui Y, Devine K, et al. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study. J Clin Oncol 2014;32:
3643–3650.
735. Scott JM, Li N, Liu Q, Yasui Y, Leisenring W, Nathan PC, et al. Association of exercise with mortality in adult survivors of childhood cancer. JAMA Oncol 2018;4:1352–1358.
736. Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz
AL, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J
Clin 2012;62:242–274.
737. CDC. Cancer Data and Statistics | Survival Information from the National Cancer
Institute and Centers for Disease Control and Prevention. 2013.
738. Thompson KA, Hildebrandt MAT, Ater JL. Cardiac outcomes with pregnancy after cardiotoxic therapy for childhood cancer. J Am Coll Cardiol 2017;69:
594–595.
739. Nolan M, Oikonomou EK, Silversides CK, Hines MR, Thompson KA, Campbell BA,
et al. Impact of cancer therapy-related cardiac dysfunction on risk of heart failure in pregnancy. JACC CardioOncology 2020;2:153–162.
740. Chait-Rubinek L, Mariani JA, Goroncy N, Herschtal A, Wheeler GC, Dwyer MK,
et al. A retrospective evaluation of risk of peripartum cardiac dysfunction in survivors of childhood, adolescent and young adult malignancies. Cancers (Basel) 2019;
11:1046.
741. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C,
Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165–3241.
742. Mehta LS, Warnes CA, Bradley E, Burton T, Economy K, Mehran R, et al.
Cardiovascular considerations in caring for pregnant patients: a scientiﬁc statement from the American Heart Association. Circulation 2020;141:e884–e903.
743. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classiﬁcation of
Tumours of the Lung, Pleura, Thymus and Heart, 4th ed. 2015. ISBN 978-92-832-2436-5
744. Burke A, Tavora F. The 2015 WHO Classiﬁcation of tumors of the heart and pericardium. J Thorac Oncol 2016;11:441–452.
745. Cresti A, Chiavarelli M, Glauber M, Tanganelli P, Scalese M, Cesareo F, et al.
Incidence rate of primary cardiac tumors: a 14-year population study. J
Cardiovasc Med 2016;17:37–43.
746. Maleszewski JJ, Bois MC, Bois JP, Young PM, Stulak JM, Klarich KW. Neoplasia and the heart: pathological review of effects with clinical and radiological correlation. J
Am Coll Cardiol 2018;72:202–227.
747. Tyebally S, Chen S, Bhattacharyya S, Mughrabi S, Hussain Z, Manisty C, et al. Cardiac tumors: JACC CardioOncology state-of-the-art review. JACC CardioOncology 2020;2:
293–311.
748. Kirkpatrick JN, Wong T, Bednarz JE, Spencer KT, Sugeng L, Ward RP, et al.
Differential diagnosis of cardiac masses using contrast echocardiographic perfusion imaging. J Am Coll Cardiol 2004;43:1412–1419.
749. Thiene G, Rizzo S, Marra MP, Valente M, Basso C. Masses and cardiac tumours: classiﬁcation and diagnosis. ESC CardioMED, 2018. DOI:10.1093/med/9780198784906.
003.0386
750. Zaragosa-Macias E, Chen MA, Gill EA. Real time three-dimensional echocardiography evaluation of intracardiac masses. Echocardiography 2012;29:207–219.
751. Beroukhim RS, Prakash A, Valsangiacomo Buechel ER, Cava JR, Dorfman AL, Festa
P, et al. Characterization of cardiac tumors in children by cardiovascular magnetic resonance imaging: a multicenter experience. J Am Coll Cardiol 2011;58:1044–1054.
ESC Guidelines
4359


<!-- PAGE 132 -->

### Page 132

752. Rahbar K, Seifarth H, Schäfers M, Stegger L, Hoffmeier A, Spieker T, et al.
Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT. J
Nucl Med 2012;53:856–863.
753. Kassop D, Donovan MS, Cheezum MK, Nguyen BT, Gambill NB, Blankstein R, et al.
Cardiac masses on cardiac CT: a review. Curr Cardiovasc Imaging Rep 2014;7:9281.
754. D’Angelo EC, Paolisso P, Vitale G, Foà A, Bergamaschi L, Magnani I, et al. Diagnostic accuracy of cardiac computed tomography and 18F-ﬂuorodeoxyglucose with positron emission tomography in cardiac masses. JACC Cardiovasc Imaging 2020;13:
2400–2411.
755. Butany J, Nair V, Naseemuddin A, Nair GM, Catton C, Yau T. Cardiac tumours:
diagnosis and management. Lancet Oncol 2005;6:219–228.
756. Szmit S, Zagrodzka M, Kurzyna M, Opolski G, Szczylik C. Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma. Cardiology 2009;114:67–71.
757. Peccatori FA, Azim JA, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer,
pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:vi160–70.
758. Cubillo A, Morales S, Goñi E, Matute F, Muñoz JL, Pérez-Díaz D, et al.
Multidisciplinary consensus on cancer management during pregnancy. Clin Transl
Oncol 2021;23:1054–1066.
759. Silverstein J, Post AL, Chien AJ, Olin R, Tsai KK, Ngo Z, et al. Multidisciplinary management of cancer during pregnancy. JCO Oncol Pract 2020;16:545–557.
760. Amant F, Berveiller P, Boere IA, Cardonick E, Fruscio R, Fumagalli M, et al.
Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol 2019;30:1601–1612.
761. Dunleavy K, McLintock C. How I treat lymphoma in pregnancy. Blood 2020;136:
2118–2124.
762. Ducas RA, Elliott JE, Melnyk SF, Premecz S, Dasilva M, Cleverley K, et al.
Cardiovascular magnetic resonance in pregnancy: insights from the Cardiac
Hemodynamic Imaging and Remodeling in Pregnancy (CHIRP) study. J Cardiovasc
Magn Reson 2014;16:1.
763. Savu O, Jurcuţ R, Giuşcǎ
S, Van Mieghem T, Gussi I, Popescu BA, et al.
Morphological and functional adaptation of the maternal heart during pregnancy.
Circ Cardiovasc Imaging 2012;5:289–297.
764. Narayanan M, Elkayam U, Naqvi TZ. Echocardiography in pregnancy: part 2. Curr
Cardiol Rep 2016;18:90.
765. Furenäs E, Eriksson P, Wennerholm UB, Dellborg M. Pregnancy in a healthy population: dynamics of NTproBNP and hs-cTroponin T. Open Heart 2020;7:e001293.
766. Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, Parker JD, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010;56:
1247–1253.
767. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a
30-year population-based study. Ann Intern Med 2005;143:697–706.
768. Sultan AA, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of ﬁrst venous thromboembolism in pregnant women in hospital: population based cohort study from England. BMJ 2013;347:f6099.
769. Sultan AA, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of ﬁrst venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol 2012;156:366–373.
770. Hase EA, de Barros VIPVL, Igai AMK, Francisco RPV, Zugaib M. Risk assessment of venous thromboembolism and thromboprophylaxis in pregnant women hospitalized with cancer: preliminary results from a risk score. Clinics (Sao Paulo) 2018;
73:e368.
771. Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart 2004;90:1224–1228.
772. Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, et al.
Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. J Am Coll Cardiol 2017;69:1288–1304.
773. Dobson R, Burgess MI, Pritchard DM, Cuthbertson DJ. The clinical presentation and management of carcinoid heart disease. Int J Cardiol 2014;173:29–32.
774. Lichtenauer M, Pichler T, Eder S, Mirna M, Magnes T, Wernly B, et al. Carcinoid heart disease involving the left heart: a case report and biomarker analysis. ESC
Heart Fail 2019;6:222–227.
775. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet
Oncol 2017;18:525–534.
776. Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid heart disease. Circulation
2007;116:2860–2865.
777. Zuetenhorst JM, Korse CM, Bonfrer JMG, Bakker RH, Taal BG. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J
Cancer 2004;90:2073–2079.
778. Dobson R, Burgess MI, Banks M, Pritchard DM, Vora J, Valle JW, et al. The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. PLoS One 2013;8:e73679.
779. Korse CM, Taal BG, De Groot CA, Bakker RH, Bonfrer JMG. Chromogranin-A and
N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol 2009;27:4293–4299.
780. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol 2008;102:938–942.
781. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, et al.
Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol 2017;35:14–23.
782. Dumoulein M, Verslype C, Van Cutsem E, Meuris B, Herijgers P, Flameng W, et al.
Carcinoid heart disease: case and literature review. Acta Cardiol 2010;65:261–264.
783. Nguyen A, Schaff HV, Abel MD, Luis SA, Lahr BD, Halfdanarson TR, et al. Improving outcome of valve replacement for carcinoid heart disease. J Thorac Cardiovasc Surg
2019;158:99–107.e2.
784. Mabvuure N, Cumberworth A, Hindocha S. In patients with carcinoid syndrome undergoing valve replacement: will a biological valve have acceptable durability?
Interact Cardiovasc Thorac Surg 2012;15:467–471.
785. Connolly HM, Schaff HV, Abel MD, Rubin J, Askew JW, Li Z, et al. Early and late outcomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol 2015;
66:2189–2196.
786. Sunjic I, Shin D, Sunjic KM, Popat JV, Tran T, Chae SH, et al. Incidence of atrioventricular block after valve replacement in carcinoid heart disease. Cardiol Res 2020;
11:56–60.
787. Kuntze T, Owais T, Secknus MA, Kaemmerer D, Baum R, Girdauskas E. Results of contemporary valve surgery in patients with carcinoid heart disease. J Heart Valve
Dis 2016;25:356–363.
788. Luthra S, Olevano C, Richens T, Tsang GM. Percutaneous transcatheter valve-in-valve pulmonary and tricuspid replacement in carcinoid heart disease.
JACC Case Reports 2020;2:533–536.
789. Zacks JS, Lavine R. Avoiding a repeat sternotomy in recurrent carcinoid heart disease. JACC Case Reports 2020;2:537–538.
790. Bhattacharyya S, Toumpanakis C, Burke M, Taylor AM, Caplin ME, Davar J. Features of carcinoid heart disease identiﬁed by 2- and 3-dimensional echocardiography and cardiac MRI. Circ Cardiovasc Imaging 2010;3:103–111.
791. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, et al.
Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients.
Circulation 1993;87:1188–1196.
792. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood 2020;
136:2620–2627.
793. Witteles RM, Liedtke M. AL amyloidosis for the cardiologist and oncologist: epidemiology, diagnosis, and management. JACC CardioOncology 2019;1:117–130.
794. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013;121:5124–5130.
795. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis.
Circulation 2017;135:1357–1377.
796. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice
Guidelines in Oncology. Systemic Light Chain Amyloidosis Version 1. Natl Compr
Cancer Netw 2021. https://www.nccn.org/.
797. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989–995.
798. Zhang KW, Miao J, Mitchell JD, Alvarez-Cardona J, Tomasek K, Su YR, et al. Plasma hepatocyte growth factor for diagnosis and prognosis in light chain and transthyretin cardiac amyloidosis. JACC CardioOncology 2020;2:56–66.
799. Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, et al. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol 2017;92:739–745.
800. Grogan M, DIspenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart 2017;103:1065–1072.
801. Jurcuţ R, Onciul S, Adam R, Stan C, Coriu D, Rapezzi C, et al. Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. Eur Heart J Cardiovasc Imaging
2020;21:833–844.
802. Lee Chuy K, Drill E, Yang JC, Landau H, Hassoun H, Nahhas O, et al. Incremental value of global longitudinal strain for predicting survival in patients with advanced
AL amyloidosis. JACC CardioOncology 2020;2:223–231.
803. Brownrigg J, Lorenzini M, Lumley M, Elliott P. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. ESC Heart Fail 2019;6:1041–1051.
804. Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, et al.
Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC
Cardiovasc Imaging 2020;13:69–80.
805. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al.
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012;26:2317–2325.


<!-- PAGE 133 -->

### Page 133

806. Eckhert E, Witteles R, Kaufman G, Lafayette R, Arai S, Schrier S, et al. Grading cardiac response in AL amyloidosis: implications for relapse and survival. Br J Haematol
2019;186:144–146.
807. Vaxman I, Gertz M. Recent advances in the diagnosis, risk stratiﬁcation, and management of systemic light-chain amyloidosis. Acta Haematol 2019;141:93–106.
808. Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol 2020;6:351–361.
809. El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, et al.
Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol 2019;73:589–597.
810. Tahir UA, Doros G, Kim JS, Connors LH, Seldin DC, Sam F. Predictors of mortality in light chain cardiac amyloidosis with heart failure. Sci Rep 2019;9:8552.
811. Khanna S, Lo P, Cho K, Subbiah R. Ventricular arrhythmias in cardiac amyloidosis: a review of current literature. Clin Med Insights Cardiol 2020;14:1179546820963055.
812. Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, et al. Bortezomib,
melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol 2020;38:
3252–3260.
813. Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, et al.
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis:
safety run-in results of ANDROMEDA. Blood 2020;136:71–80.
814. Huang X, Ren G, Chen W, Guo J, Zhao L, Zeng C, et al. The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients. Amyloid 2021;28:75–83.
815. Barrett CD, Dobos K, Liedtke M, Tuzovic M, Haddad F, Kobayashi Y, et al. A changing landscape of mortality for systemic light chain amyloidosis. JACC Heart Fail
2019;7:958–966.
816. Zhang KW, Stockerl-Goldstein KE, Lenihan DJ. Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis. JACC Basic Transl Sci 2019;
4:438–448.
817. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al.
Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N
Engl J Med 2021;385:46–58.
818. Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J 2017;7:e546.
819. Shen K, Fu W, Wu Y, Dong Y, Huang Z, Wei Y, et al. Doxycycline combined with bortezomib–cyclophosphamide–dexamethasone chemotherapy for newly diagnosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial.
Circulation 2021;145:8–17.
820. Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, et al.
Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging
2017;18:1057–1064.
821. Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli F, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012;87:
465–471.
822. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751–3757.
823. Zaremba T, Jakobsen AR, SØgaard M, ThØgersen AM, Johansen MB, Madsen LæB,
et al. Risk of device malfunction in cancer patients with implantable cardiac device undergoing radiotherapy:
a population-based cohort study.
Pacing
Clin
Electrophysiol 2015;38:343–356.
824. Miften M, Mihailidis D, Kry SF, Reft C, Esquivel C, Farr J, et al. Management of radiotherapy patients with implanted cardiac pacemakers and deﬁbrillators: a report of the AAPM TG-203. Med Phys 2019;46:e757–e788.
825. Hurkmans CW, Knegjens JL, Oei BS, Maas AJJ, Uiterwaal GJ, van der Borden AJ,
et al. Management of radiation oncology patients with a pacemaker or ICD: a new comprehensive practical guideline in The Netherlands. Radiat Oncol 2012;7:
198.
826. Indik JH, Gimbel JR, Abe H, Alkmim-Teixeira R, Birgersdotter-Green U, Clarke GD,
et al. 2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices.
Heart Rhythm 2017;14:e97–e153.
827. Zaremba T, Jakobsen AR, Søgaard M, Thøgersen AM, Riahi S. Radiotherapy in patients with pacemakers and implantable cardioverter deﬁbrillators: a literature review. Europace 2016;18:479–491.
828. Grant JD, Jensen GL, Tang C, Pollard JM, Kry SF, Krishnan S, et al.
Radiotherapy-induced malfunction in contemporary cardiovascular implantable electronic devices: clinical incidence and predictors. JAMA Oncol 2015;1:624–632.
829. Zecchin M, Severgnini M, Fiorentino A, Malavasi VL, Menegotti L, Alongi F, et al.
Management of patients with cardiac implantable electronic devices (CIED) undergoing radiotherapy: a consensus document from Associazione Italiana Aritmologia e Cardiostimolazione (AIAC), Associazione Italiana Radioterapia Oncologica
(AIRO), Associazione Italiana Fisica Medica (AIFM). Int J Cardiol 2018;255:175–183.
830. Gomez DR, Poenisch F, Pinnix CC, Sheu T, Chang JY, Memon N, et al. Malfunctions of implantable cardiac devices in patients receiving proton beam therapy: incidence and predictors. Int J Radiat Oncol Biol Phys 2013;87:570–575.
831. Sharifzadehgan A, Laurans M, Thuillot M, Huertas A, Baudinaud P, Narayanan K,
et al. Radiotherapy in patients with a cardiac implantable electronic device. Am J
Cardiol 2020;128:196–201.
832. Stienen JJC, Ottevanger PB, Wennekes L, Dekker HM, van der Maazen RWM,
Mandigers CMPW, et al. Development and evaluation of an educational E-tool to help patients with non-Hodgkin’s lymphoma manage their personal care pathway. JMIR Res Protoc 2015;4:e6.
833. Murphy P, Levine A, Lerma T, Young S, Hwang J, Goldsby R. A portable survivorship care plan: a tool that helps educate and improve knowledge in childhood cancer survivors. Support Care Cancer 2021;29:169–177.
834. Asteggiano R, Aboyans V, Lee G, Salinger S, Richter D. Cardiology care delivered to cancer patients. Eur Heart J 2020;41:205–206.
835. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, et al. European Society of Cardiology methodology for the development of quality indicators for the quantiﬁcation of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes
2022;8:4–13.
836. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the
United Kingdom after removal of ﬁnancial incentives. N Engl J Med 2018;379:
948–957.
837. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality
8 years into global payment. N Engl J Med 2019;381:252–263.
ESC Guidelines
4361

<!-- 2022_Non_Cardiac_Surgery.md -->

# ESC Guidelines: Non Cardiac Surgery (2022)

**Source**: `2022_Non_Cardiac_Surgery.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 99

---

## Table of Contents

- [2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery](#2022-esc-guidelines-on-cardiovascular-assessment-a) *(p. 1)*
  - [Abbreviations and acronyms](#abbreviations-and-acronyms) *(p. 5)*
  - [1. Preamble](#1-preamble) *(p. 7)*
  - [2. Introduction](#2-introduction) *(p. 9)*
    - [2.1. What is new](#21-what-is-new) *(p. 9)*
    - [2.2. The magnitude of the problem](#22-the-magnitude-of-the-problem) *(p. 14)*
    - [2.3. Change in demographics](#23-change-in-demographics) *(p. 15)*
    - [2.4. Purpose](#24-purpose) *(p. 15)*
    - [2.5. The outcomes we want to prevent](#25-the-outcomes-we-want-to-prevent) *(p. 16)*
  - [3. Clinical risk evaluation](#3-clinical-risk-evaluation) *(p. 16)*
    - [3.1. Surgery-related risk](#31-surgery-related-risk) *(p. 16)*
      - [3.1.1. Timing of surgery](#311-timing-of-surgery) *(p. 17)*
    - [3.2. Type of surgical approach](#32-type-of-surgical-approach) *(p. 17)*
      - [3.2.1. Laparoscopy](#321-laparoscopy) *(p. 17)*
        - [3.2.1.1. Vascular and endovascular procedures](#3211-vascular-and-endovascular-procedures) *(p. 18)*
        - [3.2.1.2. Video-assisted non-cardiac surgery](#3212-video-assisted-non-cardiac-surgery) *(p. 18)*
    - [3.3. Patient-related risk](#33-patient-related-risk) *(p. 18)*
      - [3.3.1. Initial assessment](#331-initial-assessment) *(p. 18)*
        - [3.3.1.1. Patients aged <65 years without a history of cardiovascular disease or cardiovascular risk factors](#3311-patients-aged-<65-years-without-a-history-of-) *(p. 18)*
        - [3.3.1.2. Patients aged ≧65 years or with cardiovascular risk factors](#3312-patients-aged-≧65-years-or-with-cardiovascula) *(p. 18)*
        - [3.3.1.3. Patients with established cardiovascular disease](#3313-patients-with-established-cardiovascular-dise) *(p. 19)*
      - [3.3.2. Patients with murmurs, chest pain, dyspnoea, or peripheral oedema](#332-patients-with-murmurs,-chest-pain,-dyspnoea,-o) *(p. 20)*
        - [3.3.2.1. Murmurs](#3321-murmurs) *(p. 20)*
        - [3.3.2.2. Chest pain](#3322-chest-pain) *(p. 20)*
        - [3.3.2.3. Dyspnoea](#3323-dyspnoea) *(p. 20)*
        - [3.3.2.4. Peripheral oedema](#3324-peripheral-oedema) *(p. 20)*
    - [3.4. Timing of adequate risk evaluation](#34-timing-of-adequate-risk-evaluation) *(p. 21)*
    - [3.5. Avoidance or allowance for surgery in the individual patient](#35-avoidance-or-allowance-for-surgery-in-the-indiv) *(p. 21)*
    - [3.6. The patient perspective](#36-the-patient-perspective) *(p. 21)*
  - [4. Pre-operative assessment tools](#4-pre-operative-assessment-tools) *(p. 22)*
    - [4.1. Risk scores](#41-risk-scores) *(p. 22)*
      - [4.1.1. General risk calculators](#411-general-risk-calculators) *(p. 22)*
      - [4.1.2. Frailty](#412-frailty) *(p. 24)*
    - [4.2. Functional capacity](#42-functional-capacity) *(p. 24)*
    - [4.3. Electrocardiography](#43-electrocardiography) *(p. 25)*
    - [4.4. Biomarkers](#44-biomarkers) *(p. 25)*
    - [4.5. Non-invasive and invasive procedures](#45-non-invasive-and-invasive-procedures) *(p. 26)*
      - [4.5.1. Resting transthoracic echocardiography](#451-resting-transthoracic-echocardiography) *(p. 26)*
      - [4.5.2. Stress tests](#452-stress-tests) *(p. 27)*
        - [4.5.2.1. Exercise stress test](#4521-exercise-stress-test) *(p. 27)*
        - [4.5.2.2. Stress imaging](#4522-stress-imaging) *(p. 27)*
      - [4.5.3. Angiography](#453-angiography) *(p. 28)*
        - [4.5.3.1. Coronary computed tomography angiography](#4531-coronary-computed-tomography-angiography) *(p. 28)*
        - [4.5.3.2. Invasive coronary angiography](#4532-invasive-coronary-angiography) *(p. 28)*
  - [5. General risk-reduction strategies](#5-general-risk-reduction-strategies) *(p. 29)*
    - [5.1. Cardiovascular risk factors and lifestyle interventions](#51-cardiovascular-risk-factors-and-lifestyle-inter) *(p. 29)*
    - [5.2. Pharmacological](#52-pharmacological) *(p. 29)*
      - [5.2.1. Beta-blockers](#521-beta-blockers) *(p. 29)*
      - [5.2.2. Amiodarone](#522-amiodarone) *(p. 30)*
      - [5.2.3. Statins](#523-statins) *(p. 30)*
      - [5.2.4. Renin–angiotensin–aldosterone system inhibitors](#524-renin–angiotensin–aldosterone-system-inhibitor) *(p. 30)*
      - [5.2.5. Calcium channel blockers](#525-calcium-channel-blockers) *(p. 30)*
      - [5.2.6. Alpha-2 receptor agonists](#526-alpha-2-receptor-agonists) *(p. 31)*
      - [5.2.7. Diuretics](#527-diuretics) *(p. 31)*
      - [5.2.8. Ivabradine](#528-ivabradine) *(p. 31)*
      - [5.2.9. Sodium–glucose co-transporter-2 inhibitors](#529-sodium–glucose-co-transporter-2-inhibitors) *(p. 31)*
    - [5.3. Peri-operative handling of antithrombotic agents](#53-peri-operative-handling-of-antithrombotic-agent) *(p. 32)*
      - [5.3.1. Antiplatelets](#531-antiplatelets) *(p. 32)*
        - [5.3.1.1. Single antiplatelet therapy](#5311-single-antiplatelet-therapy) *(p. 32)*
        - [5.3.1.2. Dual antiplatelet therapy](#5312-dual-antiplatelet-therapy) *(p. 35)*
        - [5.3.1.3. De-escalation of antiplatelet effect](#5313-de-escalation-of-antiplatelet-effect) *(p. 37)*
        - [5.3.1.4. Platelet function guided peri-operative management of antiplatelet therapy](#5314-platelet-function-guided-peri-operative-manag) *(p. 37)*
      - [5.3.2. Oral anticoagulants](#532-oral-anticoagulants) *(p. 38)*
        - [5.3.2.1. Vitamin K antagonists](#5321-vitamin-k-antagonists) *(p. 38)*
          - [5.3.2.1.1. Vitamin K antagonists in patients with mechanical heart valves](#53211-vitamin-k-antagonists-in-patients-with-mecha) *(p. 38)*
          - [5.3.2.1.2. Vitamin K antagonists for atrial fibrillation/venous thromboembolism](#53212-vitamin-k-antagonists-for-atrial-fibrillatio) *(p. 39)*
          - [5.3.2.1.3. Restarting vitamin K antagonists after invasive procedures or surgery](#53213-restarting-vitamin-k-antagonists-after-invas) *(p. 39)*
          - [5.3.2.1.4. Reversal of vitamin K antagonists](#53214-reversal-of-vitamin-k-antagonists) *(p. 39)*
        - [5.3.2.2. Non-vitamin K antagonist oral anticoagulants](#5322-non-vitamin-k-antagonist-oral-anticoagulants) *(p. 39)*
          - [5.3.2.2.1. Unplanned surgery in patients on non-vitamin K antagonist oral anticoagulants and reversal for emergency procedures](#53221-unplanned-surgery-in-patients-on-non-vitamin) *(p. 39)*
          - [5.3.2.2.2. Planned interventions in patients on non-vitamin K oral anticoagulants](#53222-planned-interventions-in-patients-on-non-vit) *(p. 41)*
          - [5.3.2.2.3. Bridging](#53223-bridging) *(p. 41)*
          - [5.3.2.2.4. Laboratory testing before surgery](#53224-laboratory-testing-before-surgery) *(p. 41)*
          - [5.3.2.2.5. Considerations for specific procedures](#53225-considerations-for-specific-procedures) *(p. 42)*
          - [5.3.2.2.6. When to restart non-vitamin K antagonist oral anticoagulants after interventions](#53226-when-to-restart-non-vitamin-k-antagonist-ora) *(p. 43)*
        - [5.3.2.3. Combination therapy (antiplatelet and anticoagulant)](#5323-combination-therapy-(antiplatelet-and-anticoa) *(p. 43)*
    - [5.4. Peri-operative thromboprophylaxis](#54-peri-operative-thromboprophylaxis) *(p. 44)*
    - [5.5. Patient blood management](#55-patient-blood-management) *(p. 44)*
      - [5.5.1. Pre-operative anaemia—diagnosis and treatment](#551-pre-operative-anaemia—diagnosis-and-treatment) *(p. 45)*
      - [5.5.2. Bleeding and reduction of iatrogenic diagnostic/surgery-related blood loss](#552-bleeding-and-reduction-of-iatrogenic-diagnosti) *(p. 45)*
      - [5.5.3. Optimal blood component use with patient-centred clinical decision support](#553-optimal-blood-component-use-with-patient-centr) *(p. 46)*
  - [6. Specific diseases](#6-specific-diseases) *(p. 46)*
    - [6.1. Coronary artery disease](#61-coronary-artery-disease) *(p. 46)*
      - [6.1.1. Risk for patients with coronary artery disease](#611-risk-for-patients-with-coronary-artery-disease) *(p. 46)*
      - [6.1.2. Pre-operative risk assessment and management](#612-pre-operative-risk-assessment-and-management) *(p. 47)*
      - [6.1.3. Revascularization strategies](#613-revascularization-strategies) *(p. 47)*
        - [6.1.3.1. Chronic coronary syndromes](#6131-chronic-coronary-syndromes) *(p. 47)*
        - [6.1.3.2. Acute coronary syndromes](#6132-acute-coronary-syndromes) *(p. 47)*
    - [6.2. Chronic heart failure](#62-chronic-heart-failure) *(p. 49)*
      - [6.2.1. Risk for patients with heart failure](#621-risk-for-patients-with-heart-failure) *(p. 49)*
      - [6.2.2. Pre- and post-operative management strategies](#622-pre--and-post-operative-management-strategies) *(p. 49)*
      - [6.2.3. Hypertrophic obstructive cardiomyopathy](#623-hypertrophic-obstructive-cardiomyopathy) *(p. 50)*
      - [6.2.4. Patients with ventricular assist devices undergoing non-cardiac surgery](#624-patients-with-ventricular-assist-devices-under) *(p. 50)*
    - [6.3. Valvular heart disease](#63-valvular-heart-disease) *(p. 50)*
      - [6.3.1. Risk for patients with valvular heart disease](#631-risk-for-patients-with-valvular-heart-disease) *(p. 50)*
      - [6.3.2. Pre-operative management strategies and risk-reduction strategy](#632-pre-operative-management-strategies-and-risk-r) *(p. 51)*
        - [6.3.2.1. Aortic valve stenosis](#6321-aortic-valve-stenosis) *(p. 51)*
        - [6.3.2.2. Mitral valve stenosis](#6322-mitral-valve-stenosis) *(p. 52)*
        - [6.3.2.3. Aortic valve regurgitation](#6323-aortic-valve-regurgitation) *(p. 53)*
        - [6.3.2.4. Mitral valve regurgitation](#6324-mitral-valve-regurgitation) *(p. 53)*
        - [6.3.2.5. Patients with prosthetic valve(s)](#6325-patients-with-prosthetic-valve(s)) *(p. 53)*
        - [6.3.2.6. Prophylaxis of infective endocarditis](#6326-prophylaxis-of-infective-endocarditis) *(p. 53)*
    - [6.4. Known or newly diagnosed arrhythmias](#64-known-or-newly-diagnosed-arrhythmias) *(p. 54)*
      - [6.4.1. Peri-operative management—general measures](#641-peri-operative-management—general-measures) *(p. 54)*
      - [6.4.2. Supraventricular arrhythmias](#642-supraventricular-arrhythmias) *(p. 54)*
      - [6.4.3. Atrial fibrillation/flutter](#643-atrial-fibrillation/flutter) *(p. 54)*
      - [6.4.4. Ventricular arrhythmias](#644-ventricular-arrhythmias) *(p. 54)*
      - [6.4.5. Bradyarrhythmias](#645-bradyarrhythmias) *(p. 56)*
      - [6.4.6. Management of patients with cardiac implantable electronic devices](#646-management-of-patients-with-cardiac-implantabl) *(p. 56)*
    - [6.5. Adult congenital heart disease](#65-adult-congenital-heart-disease) *(p. 57)*
    - [6.6. Pericardial diseases](#66-pericardial-diseases) *(p. 58)*
    - [6.7. Pulmonary disease and pulmonary arterial hypertension](#67-pulmonary-disease-and-pulmonary-arterial-hypert) *(p. 59)*
      - [6.7.1. Pulmonary disease](#671-pulmonary-disease) *(p. 59)*
      - [6.7.2. Pulmonary arterial hypertension](#672-pulmonary-arterial-hypertension) *(p. 59)*
    - [6.8. Arterial hypertension](#68-arterial-hypertension) *(p. 60)*
    - [6.9. Peripheral artery disease](#69-peripheral-artery-disease) *(p. 61)*
      - [6.9.1. Peripheral artery disease and non-vascular non-cardiac surgery](#691-peripheral-artery-disease-and-non-vascular-non) *(p. 61)*
      - [6.9.2. Peripheral artery disease and vascular non-cardiac surgery](#692-peripheral-artery-disease-and-vascular-non-car) *(p. 61)*
    - [6.10. Cerebrovascular disease](#610-cerebrovascular-disease) *(p. 62)*
    - [6.11. Renal disease](#611-renal-disease) *(p. 62)*
    - [6.12. Obesity](#612-obesity) *(p. 63)*
    - [6.13. Diabetes](#613-diabetes) *(p. 64)*
    - [6.14. Cancer](#614-cancer) *(p. 64)*
    - [6.15. Coronavirus disease 2019](#615-coronavirus-disease-2019) *(p. 64)*
  - [7. Peri-operative monitoring and anaesthesia](#7-peri-operative-monitoring-and-anaesthesia) *(p. 65)*
    - [7.1. Peri-operative monitoring](#71-peri-operative-monitoring) *(p. 65)*
    - [7.2. Anaesthesia](#72-anaesthesia) *(p. 66)*
      - [7.2.1. Intra-operative haemodynamics](#721-intra-operative-haemodynamics) *(p. 66)*
      - [7.2.2. Choice of anaesthetic agent](#722-choice-of-anaesthetic-agent) *(p. 67)*
    - [7.3. Locoregional techniques](#73-locoregional-techniques) *(p. 67)*
    - [7.4. Peri-operative goal-directed haemodynamic therapy](#74-peri-operative-goal-directed-haemodynamic-thera) *(p. 68)*
    - [7.5. Post-operative management](#75-post-operative-management) *(p. 68)*
  - [8. Peri-operative cardiovascular complications](#8-peri-operative-cardiovascular-complications) *(p. 68)*
    - [8.1. Peri-operative myocardial infarction/injury](#81-peri-operative-myocardial-infarction/injury) *(p. 69)*
    - [8.2. Spontaneous myocardial infarction (after day 2)](#82-spontaneous-myocardial-infarction-(after-day-2)) *(p. 72)*
    - [8.3. Takotsubo syndrome](#83-takotsubo-syndrome) *(p. 72)*
    - [8.4. Acute heart failure](#84-acute-heart-failure) *(p. 72)*
    - [8.5. Venous thromboembolism](#85-venous-thromboembolism) *(p. 72)*
    - [8.6. Atrial fibrillation and other relevant arrhythmias](#86-atrial-fibrillation-and-other-relevant-arrhythm) *(p. 72)*
      - [8.6.1. Prevention of post-operative atrial fibrillation](#861-prevention-of-post-operative-atrial-fibrillati) *(p. 72)*
      - [8.6.2. Management of post-operative atrial fibrillation](#862-management-of-post-operative-atrial-fibrillati) *(p. 73)*
        - [8.6.2.1. Rate and/or rhythm control](#8621-rate-and/or-rhythm-control) *(p. 73)*
        - [8.6.2.2. Prevention of atrial fibrillation-related thromboembolic complications](#8622-prevention-of-atrial-fibrillation-related-thr) *(p. 74)*
    - [8.7. Peri-operative stroke](#87-peri-operative-stroke) *(p. 74)*
  - [9. Key messages](#9-key-messages) *(p. 75)*
  - [10. Gaps in evidence](#10-gaps-in-evidence) *(p. 75)*
  - [11. Sex differences](#11-sex-differences) *(p. 76)*
  - [12. ‘What to do’ and ‘what not to do’ messages from the Guidelines](#12-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 76)*
  - [13. Quality indicators](#13-quality-indicators) *(p. 81)*
  - [14. Central illustration](#14-central-illustration) *(p. 81)*
  - [15. Supplementary data](#15-supplementary-data) *(p. 82)*
  - [16. Data availability statement](#16-data-availability-statement) *(p. 82)*
  - [17. Author information](#17-author-information) *(p. 82)*
  - [Appendix](#appendix) *(p. 82)*
  - [References](#references) *(p. 83)*
  - [References](#references) *(p. 83)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the
European Society of Cardiology (ESC)
Endorsed by the European Society of Anaesthesiology and
Intensive Care (ESAIC)
Authors/Task Force Members: Sigrun Halvorsen
*† (Chairperson) (Norway),
Julinda Mehilli
*† (Chairperson) (Germany), Salvatore Cassese** (Task Force
Coordinator) (Germany), Trygve S. Hall** (Task Force Coordinator) (Norway),
Magdy Abdelhamid (Egypt), Emanuele Barbato (Italy/Belgium), Stefan De Hert1
(Belgium), Ingrid de Laval (Sweden), Tobias Geisler (Germany), Lynne Hinterbuchner
(Austria), Borja Ibanez (Spain), Radosław Lenarczyk (Poland), Ulrich R. Mansmann
(Germany), Paul McGreavy (United Kingdom), Christian Mueller (Switzerland),
Claudio Muneretto (Italy), Alexander Niessner (Austria), Tatjana S. Potpara (Serbia),
Arsen Ristić (Serbia), L. Elif Sade (United States of America/Turkey),
Henrik Schirmer (Norway), Stefanie Schüpke (Germany), Henrik Sillesen
(Denmark), Helge Skulstad (Norway), Lucia Torracca (Italy), Oktay Tutarel
(Germany), Peter Van Der Meer (Netherlands), Wojtek Wojakowski (Poland),
Kai Zacharowski1 (Germany), and ESC Scientiﬁc Document Group
* Corresponding authors: Sigrun Halvorsen, Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway, and University of Oslo, Oslo, Norway. Tel.: +47 91317460.
E-mail: sigrun.halvorsen@medisin.uio.no.
Julinda Mehilli, Department: Medizinische Klinik I, Landshut-Achdorf Hospital, Landshut, Germany, Klinikum der Universität München, Ludwig-Maximilians-Universität and German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany. Tel.: +49 871 4042782. E-mail: Julinda.mehilli@lakumed.de
† The two chairpersons contributed equally to the document and are joint corresponding authors.
** The two Task Force Coordinators contributed equally to the document
Author/Task Force Member afﬁliations: listed in author information.
1Representing the European Society of Anaesthesiology and Intensive Care (ESAIC)
ESC Clinical Practice Guidelines (CPG) Committee listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular
Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), and Heart Failure Association (HFA).
Councils: Council of Cardio-Oncology and Council on Valvular Heart Disease.
Working Groups: Adult Congenital Heart Disease, Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, Cardiovascular Surgery, and Thrombosis.
Patient Forum
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University
Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
https://doi.org/10.1093/eurheartj/ehac270
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document-Reviewers: Juhani Knuuti, (CPG Review Coordinator) (Finland), Steen Dalby Kristensen, (CPG
Review Coordinator) (Denmark), Victor Aboyans (France), Ingo Ahrens (Germany), Sotiris Antoniou (United
Kingdom), Riccardo Asteggiano (Italy), Dan Atar (Norway), Andreas Baumbach (United Kingdom),
Helmut Baumgartner (Germany), Michael Böhm (Germany), Michael A. Borger (Germany), Hector Bueno
(Spain), Jelena Čelutkienė (Lithuania), Alaide Chieffo (Italy), Maya Cikes (Croatia), Harald Darius (Germany),
Victoria Delgado (Spain), Philip J. Devereaux (Canada), David Duncker (Germany), Volkmar Falk (Germany),
Laurent Fauchier (France), Gilbert Habib (France), David Hasdai (Israel), Kurt Huber (Austria), Bernard Iung
(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian Federation), Konstantinos C. Koskinas
(Switzerland), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart
(Czech Republic), Maja-Lisa Løchen (Norway), Michael Maeng (Denmark), Stéphane Manzo-Silberman (France),
Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark),
Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Antti Saraste
(Finland), Dirk Sibbing (Germany), Jolanta Siller-Matula (Austria), Marta Sitges (Spain), Ivan Stankovic (Serbia),
Rob F. Storey (United Kingdom), Jurrien ten Berg (Netherlands), Matthias Thielmann (Germany), and
Rhian M. Touyz (Canada/United Kingdom)
All experts involved in the development of these guidelines have submitted declarations of interest. These have been compiled in a report and simultaneously published in a supplementary document to the guidelines. The report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary data that include background information and detailed discussion of the data that have provided the basis of the guidelines.
Click here to access the corresponding ESC CardioMed chapters.
Keywords
Guidelines • Non-cardiac surgery • Pre-operative cardiac risk assessment • Pre-operative cardiac testing •
Biomarkers • Pre-operative coronary artery revascularization • Peri-operative cardiac management •
Anti-thrombotic therapy • Peri-operative beta-blockers • Pre-operative treatment of valvular disease • Peri-operative treatment of arrhythmias • Post-operative cardiac surveillance • Peri-operative myocardial injury/infarction
Table of contents
1. Preamble ........................................................................................................
3832
2. Introduction .................................................................................................
3834
2.1. What is new ........................................................................................ 3834
2.2. The magnitude of the problem ................................................... 3839
2.3. Change in demographics ................................................................ 3840
2.4. Purpose .................................................................................................. 3840
2.5. The outcomes we want to prevent .......................................... 3841
3. Clinical risk evaluation ..............................................................................
3841
3.1. Surgery-related risk .......................................................................... 3841
3.1.1. Timing of surgery ......................................................................
3842
3.2. Type of surgical approach ............................................................. 3842
3.2.1. Laparoscopy ................................................................................
3842
3.2.1.1. Vascular and endovascular procedures ................... 3843
3.2.1.2. Video-assisted non-cardiac surgery ........................... 3843
3.3. Patient-related risk ............................................................................ 3843
3.3.1. Initial assessment .......................................................................
3843
3.3.1.1. Patients aged ,65 years without a history of cardiovascular disease or cardiovascular risk factors ........ 3843
3.3.1.2. Patients aged ≥65 years or with cardiovascular risk factors .................................................................................................... 3843
3.3.1.3. Patients with established cardiovascular disease . 3844
3.3.2. Patients with murmurs, chest pain, dyspnoea, or peripheral oedema ...............................................................................
3845
3.3.2.1. Murmurs ............................................................................... 3845
3.3.2.2. Chest pain ............................................................................ 3845
3.3.2.3. Dyspnoea .............................................................................. 3845
Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, particularly in relation to good use of health care or therapeutic strategies. Health professionals are encouraged to take the
ESC Guidelines fully into account when exercising their clinical judgment, and in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies;
however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. The ESC Guidelines do not exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
© The European Society of Cardiology 2022. All rights reserved. For permissions please e-mail: journals.permissions@oup.com
ESC Guidelines
3827


<!-- PAGE 3 -->

### Page 3

3.3.2.4. Peripheral oedema ........................................................... 3845
3.4. Timing of adequate risk evaluation ............................................ 3846
3.5. Avoidance or allowance for surgery in the individual patient
3846
3.6. The patient perspective .................................................................. 3846
4. Pre-operative assessment tools ...........................................................
3847
4.1. Risk scores ............................................................................................ 3847
4.1.1. General risk calculators ..........................................................
3847
4.1.2. Frailty ..............................................................................................
3849
4.2. Functional capacity ............................................................................ 3849
4.3. Electrocardiography ......................................................................... 3850
4.4. Biomarkers ........................................................................................... 3850
4.5. Non-invasive and invasive procedures ..................................... 3851
4.5.1. Resting transthoracic echocardiography .........................
3851
4.5.2. Stress tests ...................................................................................
3852
4.5.2.1. Exercise stress test ........................................................... 3852
4.5.2.2. Stress imaging ..................................................................... 3852
4.5.3. Angiography ................................................................................
3853
4.5.3.1. Coronary computed tomography angiography ... 3853
4.5.3.2. Invasive coronary angiography .................................... 3853
5. General risk-reduction strategies ........................................................
3854
5.1. Cardiovascular risk factors and lifestyle interventions ...... 3854
5.2. Pharmacological ................................................................................. 3854
5.2.1. Beta-blockers ..............................................................................
3854
5.2.2. Amiodarone ................................................................................
3855
5.2.3. Statins ............................................................................................
3855
5.2.4. Renin–angiotensin–aldosterone system inhibitors .....
3855
5.2.5. Calcium channel blockers ......................................................
3855
5.2.6. Alpha-2 receptor agonists ....................................................
3856
5.2.7. Diuretics .......................................................................................
3856
5.2.8. Ivabradine .....................................................................................
3856
5.2.9. Sodium–glucose co-transporter-2 inhibitors ................
3856
5.3. Peri-operative handling of antithrombotic agents ............... 3857
5.3.1. Antiplatelets ................................................................................
3857
5.3.1.1. Single antiplatelet therapy ............................................. 3857
5.3.1.2. Dual antiplatelet therapy ............................................... 3860
5.3.1.3. De-escalation of antiplatelet effect ............................ 3862
5.3.1.4. Platelet function guided peri-operative management of antiplatelet therapy ......................................... 3862
5.3.2. Oral anticoagulants ..................................................................
3863
5.3.2.1. Vitamin K antagonists ...................................................... 3863
5.3.2.1.1. Vitamin K antagonists in patients with mechanical heart valves ............................................................. 3863
5.3.2.1.2. Vitamin K antagonists for atrial ﬁbrillation/
venous thromboembolism ....................................................... 3864
5.3.2.1.3. Restarting vitamin K antagonists after invasive procedures or surgery ............................................................... 3864
5.3.2.1.4. Reversal of vitamin K antagonists ...................... 3864
5.3.2.2. Non-vitamin K antagonist oral anticoagulants ...... 3864
5.3.2.2.1. Unplanned surgery in patients on non-vitamin
K antagonist oral anticoagulants and reversal for emergency procedures .............................................................. 3864
5.3.2.2.2. Planned interventions in patients on nonvitamin K oral anticoagulants .................................................. 3866
5.3.2.2.3. Bridging ......................................................................... 3866
5.3.2.2.4. Laboratory testing before surgery .................... 3866
5.3.2.2.5. Considerations for speciﬁc procedures .......... 3867
5.3.2.2.6. When to restart non-vitamin K antagonist oral anticoagulants after interventions ......................................... 3868
5.3.2.3. Combination therapy (antiplatelet and anticoagulant) ...................................................................................... 3868
5.4. Peri-operative thromboprophylaxis .......................................... 3869
5.5. Patient blood management ........................................................... 3869
5.5.1. Pre-operative anaemia—diagnosis and treatment .....
3870
5.5.2. Bleeding and reduction of iatrogenic diagnostic/
surgery-related blood loss ................................................................
3870
5.5.3. Optimal blood component use with patient-centred clinical decision support .....................................................................
3871
6. Speciﬁc diseases ..........................................................................................
3871
6.1. Coronary artery disease ................................................................. 3871
6.1.1. Risk for patients with coronary artery disease ............
3871
6.1.2. Pre-operative risk assessment and management ........
3872
6.1.3. Revascularization strategies ..................................................
3872
6.1.3.1. Chronic coronary syndromes ...................................... 3872
6.1.3.2. Acute coronary syndromes .......................................... 3872
6.2. Chronic heart failure ........................................................................ 3874
6.2.1. Risk for patients with heart failure ....................................
3874
6.2.2. Pre- and post-operative management strategies ........
3874
6.2.3. Hypertrophic obstructive cardiomyopathy ...................
3875
6.2.4. Patients with ventricular assist devices undergoing non-cardiac surgery ..............................................................................
3875
6.3. Valvular heart disease ...................................................................... 3875
6.3.1. Risk for patients with valvular heart disease .................
3875
6.3.2. Pre-operative management strategies and riskreduction strategy .................................................................................
3876
6.3.2.1. Aortic valve stenosis ........................................................ 3876
6.3.2.2. Mitral valve stenosis ......................................................... 3877
6.3.2.3. Aortic valve regurgitation .............................................. 3878
6.3.2.4. Mitral valve regurgitation ............................................... 3878
6.3.2.5. Patients with prosthetic valve(s) ................................ 3878
6.3.2.6. Prophylaxis of infective endocarditis ........................ 3878
6.4. Known or newly diagnosed arrhythmias ................................ 3879
6.4.1. Peri-operative management—general measures ........
3879
6.4.2. Supraventricular arrhythmias ...............................................
3879
6.4.3. Atrial ﬁbrillation/ﬂutter ...........................................................
3879
6.4.4. Ventricular arrhythmias .........................................................
3879
6.4.5. Bradyarrhythmias ......................................................................
3881
6.4.6. Management of patients with cardiac implantable electronic devices ..................................................................................
3881
6.5. Adult congenital heart disease ..................................................... 3882
6.6. Pericardial diseases ........................................................................... 3883
6.7. Pulmonary disease and pulmonary arterial hypertension
3884
6.7.1. Pulmonary disease ....................................................................
3884
6.7.2. Pulmonary arterial hypertension ........................................
3884
6.8. Arterial hypertension ....................................................................... 3885
6.9. Peripheral artery disease ................................................................ 3886
6.9.1. Peripheral artery disease and non-vascular non-cardiac surgery .......................................................................................................
3886
6.9.2. Peripheral artery disease and vascular non-cardiac surgery .......................................................................................................
3886
6.10. Cerebrovascular disease .............................................................. 3887
6.11. Renal disease ..................................................................................... 3887
6.12. Obesity ................................................................................................ 3888


<!-- PAGE 4 -->

### Page 4

6.13. Diabetes .............................................................................................. 3889
6.14. Cancer ................................................................................................. 3889
6.15. Coronavirus disease 2019 ........................................................... 3889
7. Peri-operative monitoring and anaesthesia ....................................
3890
7.1. Peri-operative monitoring ............................................................. 3890
7.2. Anaesthesia .......................................................................................... 3891
7.2.1. Intra-operative haemodynamics .........................................
3891
7.2.2. Choice of anaesthetic agent .................................................
3892
7.3. Locoregional techniques ................................................................ 3892
7.4. Peri-operative goal-directed haemodynamic therapy ....... 3893
7.5. Post-operative management ......................................................... 3893
8. Peri-operative cardiovascular complications ..................................
3893
8.1. Peri-operative myocardial infarction/injury ............................ 3894
8.2. Spontaneous myocardial infarction (after day 2) ................ 3897
8.3. Takotsubo syndrome ....................................................................... 3897
8.4. Acute heart failure ............................................................................ 3897
8.5. Venous thromboembolism ........................................................... 3897
8.6. Atrial ﬁbrillation and other relevant arrhythmias ................ 3897
8.6.1. Prevention of post-operative atrial ﬁbrillation .............
3897
8.6.2. Management of post-operative atrial ﬁbrillation .........
3898
8.6.2.1. Rate and/or rhythm control ......................................... 3898
8.6.2.2. Prevention of atrial ﬁbrillation-related thromboembolic complications .................................................. 3899
8.7. Peri-operative stroke ....................................................................... 3899
9. Key messages ...............................................................................................
3900
10. Gaps in evidence ......................................................................................
3900
11. Sex differences .........................................................................................
3901
12. ‘What to do’ and ‘what not to do’ messages from the
Guidelines ...........................................................................................................
3901
13. Quality indicators ....................................................................................
3906
14. Central illustration ..................................................................................
3906
15. Supplementary data ................................................................................
3907
16. Data availability statement ...................................................................
3907
17. Author information ................................................................................
3907
18. Appendix .....................................................................................................
3907
19. References ..................................................................................................
3908
Tables of Recommendations
Recommendation Table 1 — Recommendations for selection of surgical approach and impact on risk .....................................................
3843
Recommendation Table 2 — Recommendations for all patients scheduled for non-cardiac surgery ..........................................................
3845
Recommendation Table 3 — Recommendations for patients aged ,65 years without signs, symptoms, or history of cardiovascular disease ...................................................................................
3845
Recommendation Table 4 — Recommendations for pre-operative assessment in patients with previously unknown murmur, angina, dyspnoea, or peripheral oedema ..........................
3845
Recommendation Table 5 — Recommendations for patient information ........................................................................................................
3847
Recommendation Table 6 — Recommendations for pre-operative assessment of frailty and functional capacity .........
3849
Recommendation Table 7 — Recommendations for pre-operative risk assessment—electrocardiography and biomarkers .........................................................................................................
3851
Recommendation Table 8 — Recommendations for transthoracic echocardiography ...............................................................
3852
Recommendation Table 9 — Recommendations for stress imaging
3853
Recommendation Table 10 — Recommendations for coronary angiography ........................................................................................................
3853
Recommendation Table 11 — Recommendations for lifestyle and cardiovascular risk factors ...........................................................................
3854
Recommendation Table 12 — Recommendations for pharmacological treatment .........................................................................
3856
Recommendation Table 13 — Recommendations for use of antiplatelet therapy in patients undergoing non-cardiac surgery
3862
Recommendation Table 14 — Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery ...............................................................
3868
Recommendation Table 15 — Recommendations for thromboprophylaxis ......................................................................................
3869
Recommendation Table 16 — Recommendations for intra- and post-operative complications associated with anaemia .................
3870
Recommendation Table 17 — Recommendations for intra- and post-operative complications associated with blood loss .............
3871
Recommendation Table 18 — Recommendations for intra- and post-operative complications associated with allogeneic blood transfusion ..........................................................................................................
3871
Recommendation Table 19 — Recommendations for the timing of non-cardiac surgery and revascularization in patients with known coronary artery disease ................................................................
3874
Recommendation Table 20 — Recommendations for management of heart failure in patients undergoing non-cardiac surgery .................................................................................................................
3875
Recommendation Table 21 — Recommendations for management of valvular heart disease in patients undergoing non-cardiac surgery ........................................................................................
3878
Recommendation Table 22 — Recommendations for management of known or newly diagnosed arrhythmias ......
3880
Recommendation Table 23 — Recommendations for management of bradyarrhythmia and patients carrying cardiac implantable devices ........................................................................................
3882
Recommendation Table 24 — Recommendations for management of patients with adult congenital heart disease undergoing non-cardiac surgery ...............................................................
3883
Recommendation Table 25 — Recommendations for pericardial diseases ................................................................................................................
3884
Recommendation Table 26 — Recommendations for patients with pulmonary arterial hypertension undergoing non-cardiac surgery .................................................................................................................
3885
Recommendation Table 27 — Recommendations for pre-operative management of hypertension ......................................
3886
Recommendation Table 28 — Recommendations for management of patients with peripheral artery disease and/or abdominal aortic aneurysm undergoing non-cardiac surgery ......................................................................................................... 3887
Recommendation Table 29 — Recommendations for management of patients with suspected or established carotid artery disease undergoing non-cardiac surgery .................................
3887
Recommendation Table 30 — Recommendations for management of patients with renal disease undergoing non-cardiac surgery ........................................................................................
3888
Recommendation Table 31 — Recommendations for management of patients with obesity undergoing non-cardiac surgery .................................................................................................................
3829


<!-- PAGE 5 -->

### Page 5

Recommendation Table 32 — Recommendations for management of patients with diabetes mellitus undergoing non-cardiac surgery ........................................................................................
3889
Recommendation Table 33 — Recommendations for peri-operative monitoring and anaesthesia .........................................
3893
Recommendation Table 34 — Recommendations for peri-operative cardiovascular complications .......................................
3899
List of tables
Table 1 Classes of recommendations ....................................................
3833
Table 2 Levels of evidence ..........................................................................
3833
Table 3 New concepts and sections in the current guidelines ...
3834
Table 4 What is new .....................................................................................
3834
Table 4A New recommendations ...........................................................
3834
Table 4B Revised recommendations ......................................................
3838
Table 5 Surgical risk estimate according to type of surgery or intervention .......................................................................................................
3842
Table 6 Risk score calculators ...................................................................
3848
Table 7 Pharmacokinetic and pharmacodynamic characteristics of antiplatelets ........................................................................................................
3857
Table 8 Pharmacokinetic and pharmacodynamic characteristics of oral anticoagulants ..........................................................................................
3858
Table 9 Bleeding risk according to type of non-cardiac surgery
3858
Table 10 Laboratory parameters for the diagnosis of absolute iron-deﬁciency anaemia ................................................................................
3870
Table 11 Peri-operative approach to patients with ventricular assist devices undergoing non-cardiac surgery ...................................
3875
Table 12 Peri-operative management of patients with arrhythmias
3880
Table 13 Risk stratiﬁcation for non-cardiac surgery in adults with congenital heart disease ...............................................................................
3883
Table 14 Patient-related and surgery-related factors to be considered when assessing peri-operative risk in patients with pulmonary arterial hypertension ..............................................................
3885
Table 15 Factors that could inﬂuence peri-operative risk during cancer surgery and preventive strategies .............................................
3890
List of ﬁgures
Figure 1 Total risk is an interaction of patient-related and surgery-related risk ........................................................................................
3841
Figure 2 Pre-operative assessment before non-cardiac surgery
3844
Figure 3 Examples of questions and concerns expressed by patients ................................................................................................................
3847
Figure 4 Recommended measurements to assess and detect the risk of post-operative cardiac complications ......................................
3850
Figure 5 Recommendations for management of antiplatelet therapy in patients undergoing non-cardiac surgery .......................
3859
Figure 6 P2Y12 inhibitor interruption after percutaneous coronary intervention before elective non-cardiac surgery .........
3860
Figure 7 Bridging with intravenous antiplatelet agents. ASA,
acetylsalicylic acid; FU, follow-up; LD, loading dose; NCS,
non-cardiac surgery; o.d., once a day ......................................................
3861
Figure 8 Recommendations for management of oral anticoagulation therapy in patients undergoing non-cardiac surgery .................................................................................................................
3863
Figure 9 Peri-operative management of non-vitamin K antagonist oral anticoagulant according to the periprocedural risk of bleeding
3865
Figure 10 Timing of last non-vitamin K antagonist oral anticoagulant dose before elective NCS according to renal function ...................... 3866
Figure 11 Suggested strategy for potential reversal of non-vitamin
K oral anticoagulants effect ........................................................................
3867
Figure 12 Management of patients with acute or chronic coronary syndrome scheduled for non-cardiac surgery ....................................
3873
Figure 13 Management of patients with severe aortic valve stenosis scheduled for non-cardiac surgery ........................................
3876
Figure 14 Management of patients with secondary mitral valve regurgitation scheduled for non-cardiac surgery ..............................
3877
Figure 15 Optimal location of return electrode during unipolar electrosurgery in patients with cardiac implantable electronic devices, depending on the surgery site ..................................................
3882
Figure 16 Pathophysiological approach to address intra-operative hypotension .......................................................................................................
3892
Figure 17 Factors associated with peri-operative cardiovascular complications. SNS, sympathetic nervous system ............................
3894
Figure 18 Differential diagnosis of elevated post-operative cardiac troponin concentrations ..............................................................................
3895
Figure 19 Systematic work-up (aetiology) and therapy of peri-operative myocardial infarction/injury ..........................................
3896
Figure 20 Prevention and management of post-operative atrial
ﬁbrillation ............................................................................................................
3898
Figure 21 Central illustration: the complex interplay between the intrinsic risk of surgery and the patient risk of peri-operative cardiovascular complications .....................................................................
3906
Abbreviations and acronyms
AAA
Abdominal aortic aneurysm
AAD
Antiarrhythmic drug
ACEI
Angiotensin-converting-enzyme inhibitor
ACHD
Adults with congenital heart disease
ACS
Acute coronary syndrome
ACS NSQIP
American College of Surgery National
Surgical Quality Improvement Program
AF
Atrial ﬁbrillation
AKI
Acute kidney injury aPTT
Activated partial thromboplastin time
AR
Aortic valve regurgitation
ARB
Angiotensin receptor blocker
ARNI
Angiotensin receptor neprilysin inhibitor
AS
Aortic valve stenosis
ASA
Acetylsalicylic acid
ASA–PS
American Society of Anesthesiology
Physical Status
ASCVD
Atherosclerotic cardiovascular disease
AUB-HAS2
American University of Beirut
(AUB)-HAS2
AUC
Area under curve
AVR
Aortic valve replacement
BAV
Balloon aortic valvuloplasty
BCSH
British Committee for Standards in
Haematology b.i.d.
Bis in die (twice a day)
BTKi
Bruton tyrosine kinase inhibitors
BMI
Body mass index


<!-- PAGE 6 -->

### Page 6

BMS
Bare metal stent
BNP
B-type natriuretic peptide
BP
Blood pressure b.p.m.
Beats per minute
BSA
Body surface area
CABG
Coronary artery bypass graft
CAD
Coronary artery disease
CARP
Coronary Artery Revascularization
Prophylaxis (trial)
CAS
Carotid artery stenting
CASS
Coronary Artery Surgery Study
CCB
Calcium channel blocker
CCS
Chronic coronary syndrome
CCTA
Coronary computed tomography angiography
CEA
Carotid endarterectomy
CHA2DS2-VASc
Congestive heart failure, hypertension,
age ≥75 years, diabetes mellitus, stroke,
vascular disease, age 65–74 years, sex category (female)
CI
Conﬁdence interval
CIED
Cardiac implantable electronic device
CK
Creatinine kinase
CKD
Chronic kidney disease
CKD-EPI
Chronic Kidney Disease Epidemiology
Collaboration
Cmax
Maximum serum concentration
CMR
Cardiac magnetic resonance
COAPT
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with
Functional Mitral Regurgitation (trial)
COPD
Chronic obstructive pulmonary disease
CORIDA
Per-procedural Concentration of Direct
Oral Anticoagulants (trial)
Coronary CTA VISION
Coronary Computed Tomographic
Angiography and Vascular Events in
Noncardiac Surgery Patients Cohort
Evaluation (trial)
COVID-19
Coronavirus disease 2019
CPET
Cardiopulmonary exercise testing
CRF
Cardiorespiratory ﬁtness
CRT
Cardiac resynchronization therapy
CT
Computed tomography cTn T/I
Cardiac troponin T/I
CTO
Chronic total occlusion
CV
Cardiovascular
CVD
Cardiovascular disease
DAPT
Dual antiplatelet therapy
DASI
Duke Activity Status Index
DES
Drug-eluting stent
DM
Diabetes mellitus
DSE
Dobutamine stress echocardiography dTT
Diluted thrombin time
EACTS
European Association for
Cardio-Thoracic Surgery
ECG
Electrocardiographic/electrocardiogram
EDKA
Euglycaemic diabetic ketoacidosis eGFR
Estimated glomerular ﬁltration rate
EMI
Electromagnetic interference
EORP
EURObservational Research
Programme
ESA
European Society of Anaesthesiology
ESC
European Society of Cardiology
ESH
European Society of Hypertension
ESTS
European Society of Thoracic
Surgeons
ESVS
European Society for Vascular Surgery
EuSOS
European Surgical Outcomes Study
EVAR
Endovascular abdominal aortic aneurysm repair
FDA
US Food and Drug Administration
FFR
Fractional ﬂow reserve
FIIa
Factor IIa
FOCUS
Focused cardiac ultrasound
FXa
Factor Xa
GDMT
Guideline-directed medical therapy
GFR
Glomerular ﬁltration rate
HbA1c
Glycated haemoglobin
HF
Heart failure
HIP-ATTACK
HIP Fracture Accelerated Surgical
TreaTment And Care tracK (trial)
HR
Hazard ratio hs-cTn
High-sensitivity cardiac troponin i.v.
Intravenous
ICA
Invasive coronary angiography
ICD
Implantable cardioverter–deﬁbrillator
ICU
Intensive care unit
ID
Iron deﬁciency
IHD
Ischaemic heart disease
INR
International normalized ratio
ISCHEMIA
International Study of Comparative
Health Effectiveness with Medical and
Invasive Approaches (trial)
iwFR
Instantaneous wave-free ratio
KDIGO
Kidney Disease: Improving Global
Outcomes
LD
Loading dose
LMWH
Low molecular weight heparin
LOAD
Lowering the Risk of Operative
Complications Using Atorvastatin
Loading Dose (trial)
LoE
Level of evidence
LV
Left ventricular
LVEF
Left ventricular ejection fraction
LVESD
Left ventricular end-systolic diameter
LVESDi
Left ventricular end-systolic dimension index
MACE
Major adverse cardiovascular event
MET
Metabolic equivalent
METS
Measurement of Exercise Tolerance before Surgery (trial)
MHV
Mechanical heart valve
MI
Myocardial infarction
ESC Guidelines
3831


<!-- PAGE 7 -->

### Page 7

MINS
Myocardial injury following non-cardiac surgery
MR
Mitral valve regurgitation
MS
Mitral valve stenosis
NCS
Non-cardiac surgery
NOAC
Non-vitamin K antagonist oral anticoagulant
NSAID
Non-steroidal anti-inﬂammatory drug
NSTE-ACS
Non-ST-segment elevation acute coronary syndrome
NT-proBNP
N-terminal pro-B-type natriuretic peptide
NYHA
New York Heart Association
OAC
Oral anticoagulant o.d.
Omnie die (once a day)
OR
Odds ratio
OSA
Obstructive sleep apnoea
PA
Pulmonary artery
PAD
Peripheral artery disease
PAH
Pulmonary arterial hypertension
PAUSE
Perioperative Anticoagulant Use for
Surgery Evaluation (trial)
PBM
Patient Blood Management
PCC
Prothrombin complex concentrate
PCI
Percutaneous coronary intervention
PE
Pulmonary embolism
PMC
Percutaneous mitral commissurotomy
PMI
Peri-operative myocardial infarction/
injury
POISE
PeriOperative ISchemic Evaluation Trial
PPC
Prothrombin complex concentrate
PT
Prothrombin time
PVC
Premature ventricular contractions
QI
Quality indicator
RAAS
Renin−angiotensin−aldosterone system
RBC
Red blood cell
RCRI
Revised Cardiac Risk Index
RCT
Randomized controlled trial
RF
Radiofrequency rHuEPO
Recombinant human erythropoietin
RR
Relative risk
RV
Right ventricular
SAPT
Single antiplatelet therapy
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
SAVR
Surgical aortic valve replacement
SCD
Sudden cardiac death
SGLT-2
Sodium–glucose co-transporter-2
SORT
Surgical Outcome Risk Tool
SPAP
Systolic pulmonary artery pressure
STEMI
ST-segment elevation myocardial infarction
SVT
Supraventricular tachycardia
TAVI
Transcatheter aortic valve implantation
TEE
Transoesophageal echocardiography
TEER
Transcatheter edge-to-edge repair
TIA
Transient ischaemic attack
TTE
Transthoracic echocardiography
UFH
Unfractionated heparin
ULN
Upper limit of normal
VAD
Ventricular assist device
VATS
Video-assisted thoracic surgery
VEGFi
Vascular endothelial grow factor inhibitor
VF
Ventricular ﬁbrillation
VHD
Valvular heart disease
VISION
Vascular Events in Noncardiac Surgery
Patients Cohort Evaluation (trial)
VKA
Vitamin K antagonist
VKORC1
Vitamin K epoxide reductase complex 1
VO2
Oxygen consumption
VT
Ventricular tachycardia
VTE
Venous thromboembolism
WHA
World Health Assembly
WPW
Wolff–Parkinson–White
1. Preamble
Guidelines summarize and evaluate available evidence, with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition.
Guidelines and their recommendations should facilitate decisionmaking of health professionals in their daily practice. Guidelines,
however, are not a substitute for the patient’s relationship with their practitioner. The ﬁnal decisions concerning an individual patient must be made by the responsible health professional(s), based on what they consider to be the most appropriate in the circumstances.
These decisions are made in consultation with the patient and caregiver as appropriate.
Guidelines are intended for use by health professionals. To ensure that all users have access to the most recent recommendations, the European Society of Cardiology (ESC) makes its guidelines freely available. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Many guidelines have been issued in recent years by the ESC.
Because of their impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website
(https://www.escardio.org/Guidelines). The ESC Guidelines represent the ofﬁcial position of the ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice Guidelines, the
ESC carries out the EURObservational Research Programme of international registries of cardiovascular diseases and interventions, which are essential to assess diagnostic/therapeutic processes, use of resources, and adherence to guidelines. These registries aim to provide a better understanding of medical practice in Europe and around the world, and are based on high-quality data collected during routine clinical practice. Furthermore, the
ESC develops sets of quality indicators (QIs)—which are tools to evaluate the level of implementation of the guidelines and may be used by the ESC, hospitals, healthcare providers, and


<!-- PAGE 8 -->

### Page 8

professionals to measure clinical practice, and in educational programmes—alongside the key messages from the guidelines, to improve quality of care and clinical outcomes.
The members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. The selection procedure aimed to ensure that there is a representative mix of members, predominantly from across the whole of the ESC region and from relevant ESC Subspecialty
Communities. Consideration was given to diversity and inclusion,
notably with respect to gender and country of origin. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk–beneﬁt ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and scored according to pre-deﬁned scales, as outlined below. The Task Force followed the ESC voting procedures.
All recommendations subject to a vote achieved at least 75% among voting members.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conﬂicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/
Guidelines) and have been compiled in a report and simultaneously published in a supplementary document to the guidelines. This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of
Table 1
Classes of recommendations
©ESC 2022
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is
Conflicting evidence and/or a divergence of opinion about the usefulness/ 
efficacy of the given treatment or procedure.
Is recommended or is indicated
Wording to use
Definition
Class III 
Evidence or general agreement that the given treatment or procedure is not may be harmful. 
useful/effective, and in some cases
Is not recommended
Class IIb established by evidence/opinion.
May be considered
Class IIa
W
favour of usefulness/efficacy.
Usefulness/efficacy is less well eight of evidence/opinion is in
Should be considered
Class II 
beneficial, useful, effective.
© ESC 2022
Table 2
Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2022
© ESC 2022
ESC Guidelines
3833


<!-- PAGE 9 -->

### Page 9

interest that arose during the writing period were notiﬁed to the
ESC and updated. The Task Force received its entire ﬁnancial support from the ESC without any involvement from the healthcare industry.
The ESC CPG Committee supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the approval process of these guidelines. The ESC Guidelines undergo extensive review by the CPG Committee and external experts, including a mix of members from across the whole of the ESC region and from relevant ESC Subspecialty Communities and National
Cardiac Societies. After appropriate revisions, the guidelines are signed-off by all the experts involved in the Task Force. The ﬁnalized document is signed-off by the CPG Committee for publication in the
The task of developing the ESC Guidelines also includes creating educational tools and implementating programmes for the recommendations, including condensed pocket guidelines versions, summary slides, summary cards for non-specialists, and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access the full text version of the guidelines, which is freely available via the ESC website and the European Heart Journal.
The National Cardiac Societies of the ESC are encouraged to endorse, adopt, translate, and implement all ESC Guidelines.
Implementation programmes are needed because it has been shown that the outcome of disease may be favourably inﬂuenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, and in determining and implementing preventive, diagnostic, or therapeutic medical strategies. However, the ESC Guidelines do not override,
in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in considering each patient’s health condition and in consulting with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and, where appropriate, to respect the ethical rules of their profession.
Off-label use of medication may be presented in these guidelines if a sufﬁcient level of evidence shows that it can be considered medically appropriate to a given condition and if patients could beneﬁt from the recommended therapy. However, the ﬁnal decisions concerning an individual patient must be made by the responsible health professional, giving special consideration to:
(a) the speciﬁc situation of the patient. In this respect, it is speciﬁed that, unless otherwise provided for by national regulations, offlabel use of medication should be limited to situations where it is in the patient’s interest to do so, with regard to the quality,
safety, and efﬁcacy of care, and only after the patient has been informed and provided consent;
(b) and country-speciﬁc health regulations, indications by governmental drug regulatory agencies, and the ethical rules to which health professionals are subject, where applicable.
2. Introduction
2.1. What is new
Table 3
New concepts and sections in the current guidelines
A new ﬂowchart for general assessment of patients before NCS.
A new section on pre-operative assessment of patients with newly detected murmurs, dyspnoea, oedema, or angina.
A new section on the patient perspective.
A new section on assessment of frailty.
A revised and expanded focus on use of biomarkers in NCS
A revised and expanded section on peri-operative management of antiplatelet therapy.
A revised and expanded section on peri-operative management of oral anticoagulants.
A new section on peri-operative thromboprophylaxis.
A dedicated section on patient blood management.
A new section on management of cardiovascular risk in patients with cancer undergoing NCS.
A small section on NCS in patients with recent COVID-19.
A new section on diagnosis and management of post-operative complications during NCS.
© ESC 2022
COVID-19, coronavirus 2019; NCS, non-cardiac surgery
Table 4
What is new
© ESC 2022
Table 4A
New recommendations
Recommendation
Class
Clinical risk evaluation—Section 3
Patients scheduled for NCS
In all patients scheduled for NCS, an accurate history, and clinical examination are recommended.
I
It is recommended to perform a pre-operative risk assessment,
ideally at the same time as the NCS is proposed.
I
If time allows, it is recommended to optimize guideline-recommended treatment of CVD and CV risk factors before NCS.
I
Endovascular or video-assisted procedures should be considered for patients with high CV risk undergoing vascular or pulmonary surgery.
IIa
Patients aged ,65 years without signs, symptoms, or history of CVD
In patients with a family history of genetic cardiomyopathy, it is recommended to perform an ECG and TTE before NCS,
regardless of age and symptoms.
I
In patients aged 45–65 years without signs, symptoms, or history of CVD, ECG and biomarkers should be considered before high-risk NCS.
IIa
Continued


<!-- PAGE 10 -->

### Page 10

Pre-operative assessment in patients with a newly detected murmur, chest pain, dyspnoea, or peripheral oedema
In patients with a newly detected murmur and symptoms or signs of CVD, TTE is recommended before NCS.
I
In patients with a newly detected murmur suggesting clinically signiﬁcant pathology, TTE is recommended before high-risk
NCS.
I
In patients with a newly detected murmur, but without other signs or symptoms of CVD, TTE should be considered before moderate and high-risk NCS.
IIa
If a patient scheduled for elective NCS has chest pain or other symptoms suggestive of undetected CAD, further diagnostic work-up before NCS is recommended.
I
If a patient in need of acute NCS also has chest pain or other symptoms suggestive of undetected CAD, a multidisciplinary assessment approach is recommended to choose the treatment with lowest total risk for the patient.
I
In patients with dyspnoea and/or peripheral oedema, an ECG
and an NT-proBNP/BNP test is indicated before NCS, unless there is a certain non-cardiac explanation.
I
In patients with dyspnoea and/or peripheral oedema and elevated NT-proBNP/BNP, TTE is recommended before NCS.
I
Patient information
It is recommended to give patients individualized instructions for pre-operative and post-operative changes in medication, in verbal and written formats with clear and concise directions.
I
It should be considered to set up a structured information list
(e.g. a checklist to help with common issues) for patients with
CVD or at high risk of CV complications scheduled for NCS.
IIa
Pre-operative assessment tools—Section 4
Frailty and functional capacity
In patients aged ≥70 years, being scheduled to undergo intermediate- or high-risk NCS, frailty screening should be considered using a validated screening tool.
IIa
Adjusting risk assessments according to self-reported ability to climb two ﬂights of stairs should be considered in patients referred for intermediate- or high-risk NCS.
IIa
Transthoracic echocardiography
TTE is recommended in patients with poor functional capacity and/or high NT-proBNP/BNP, or if murmurs are detected before high-risk NCS, in order to undertake risk-reduction strategies.
I
TTE should be considered in patients with suspected new CVD
or unexplained signs or symptoms before high-risk NCS.
IIa
TTE may be considered in patients with poor functional capacity, abnormal ECG, high NT-proBNP/BNP, or ≥1 clinical risk factor before intermediate-risk NCS.
IIb
To avoid delaying surgery, a FOCUS exam performed by trained specialists may be considered as an alternative to TTE
for pre-operative triage.
IIb
Stress imaging
Stress imaging should be considered before high-risk NCS in asymptomatic patients with poor functional capacity, and previous PCI or CABG.
IIa
Continued
Coronary angiography
CCTA should be considered to rule out CAD in patients with suspected CCS or biomarker-negative NSTE-ACS in case of low-to-intermediate clinical likelihood of CAD, or in patients unsuitable for non-invasive functional testing undergoing non-urgent, intermediate-, and high-risk NCS.
IIa
General risk-reduction strategies—Section 5
Cardiovascular risk factors and lifestyle interventions
Smoking cessation .4 weeks before NCS is recommended to reduce post-operative complications and mortality.
I
Control of CV risk factors—including blood pressure,
dyslipidaemia, and diabetes—is recommended before NCS.
I
Pharmacological treatment
For patients on diuretics to treat hypertension, transient discontinuation of diuretics on the day of NCS should be considered.
IIa
It should be considered to interrupt SGLT-2 inhibitor therapy for at least 3 days before intermediate- or high-risk NCS.
IIa
Antiplatelets
For patients undergoing high bleeding risk surgery (e.g.
intracranial, spinal neurosurgery, or vitreoretinal eye surgery),
it is recommended to interrupt aspirin for at least 7 days pre-operatively.
I
In high-risk patients with a recent PCI (e.g. STEMI patients or high-risk NSTE-ACS patients), a DAPT duration of at least 3
months should be considered before time-sensitive NCS.
IIa
Anticoagulants
When an urgent surgical intervention is required, it is recommended that NOAC therapy is immediately interrupted.
I
In non-minor bleeding risk procedures in patients using a
NOAC, it is recommended to use an interruption regimen based on the NOAC compound, renal function, and bleeding risk.
I
In minor bleeding risk surgery and other procedures where bleeding can easily be controlled, it is recommended to perform surgery without interruption of OAC therapy.
I
In patients using NOACs, it is recommended that minor bleeding risk procedures are performed at trough levels
(typically 12–24 h after last intake).
I
LMWH is recommended, as an alternative to UFH, for bridging in patients with MHVs and high surgical risk.
I
For patients with mechanical prosthetic heart valves undergoing NCS, bridging with UFH or LMWH should be considered if OAC interruption is needed and patients have: (i)
mechanical AVR and any thromboembolic risk factor; (ii)
old-generation mechanical AVR; or (iii) mechanical mitral or tricuspid valve replacement.
IIa
Idarucizumab should be considered in patients on dabigatran and requiring urgent surgical intervention with intermediate to high bleeding risk.
IIa
For interventions with a very high risk of bleeding, such as spinal or epidural anaesthesia, interruption of NOACs for up to ﬁve half-lives and re-initiation after 24 h should be considered.
IIa
Continued
ESC Guidelines
3835


<!-- PAGE 11 -->

### Page 11

When speciﬁc reversal agents are unavailable, PCC or activated
PCC should be considered for reversing NOAC effects.
IIa
If an urgent surgical intervention is required, speciﬁc coagulation tests and assessment of NOAC plasma levels should be considered to interpret routine coagulation tests and waning of anticoagulant effect.
IIa
If bleeding risk with resumption of full-dose anticoagulation outweighs the risk of thromboembolic events, postponing therapeutic anticoagulation 48–72 h after the procedure may be considered, using post-operative thromboprophylaxis until resumption of full OAC dose is deemed safe.
IIb
Bridging of OAC therapy is not recommended in patients with low/moderate thrombotic risk undergoing NCS.
III
Use of reduced-dose NOAC to attenuate the risk of post-operative bleeding is not recommended.
III
Thromboprophylaxis
It is recommended that decisions about peri-operative thromboprophylaxis in NCS are based on individual and procedure-speciﬁc risk factors.
I
If thromboprophylaxis is deemed necessary, it is recommended to choose the type and duration of thromboprophylaxis (LMWH, NOAC, or fondaparinux)
according to type of NCS, duration of immobilization, and patient-related factors.
I
In patients with a low bleeding risk, peri-operative thromboprophylaxis should be considered for a duration of up to 14 or 35 days, for total knee or hip arthroplasty, respectively.
IIa
NOACs in thromboprophylaxis dose may be considered as alternative treatments to LMWH after total knee and hip arthroplasty.
IIb
Patient blood management
It is recommended to measure haemoglobin pre-operatively in patients scheduled for intermediate- to high-risk NCS.
I
It is recommended to treat anaemia in advance of NCS in order to reduce the need for RBC transfusion during NCS.
I
In patients undergoing surgery with expected blood loss of
≥500 mL, use of washed cell salvage is recommended.
I
It is recommended to use point-of-care diagnostics for guidance of blood component therapy, when available.
I
The use of an algorithm to diagnose and treat anaemic patients before NCS should be considered.
IIa
In patients undergoing NCS and experiencing major bleeding,
administration of tranexamic acid should be immediately considered.
IIa
Use of closed-loop arterial blood sampling systems should be considered to avoid blood loss.
IIa
Application of meticulous haemostasis should be considered a routine procedure.
IIa
A feedback/monitoring programme or clinical decision support system should be considered to be assessed before blood transfusion.
IIa
Before allogenic blood transfusion, it should be considered to obtain an extensive consent about risks associated with transfusion.
IIa
Continued
Speciﬁc diseases—Section 6
Coronary artery disease
Pre-operative evaluation of patients with an indication for PCI
by an expert team (surgeon and cardiologist) should be considered before elective NCS.
IIa
Heart failure
In patients with HF undergoing NCS, it is recommended to regularly assess volume status and signs of organ perfusion.
I
A multidisciplinary team including VAD specialists is recommended for peri-operative management of patients with
HF receiving mechanical circulatory support.
I
Valvular heart disease
In patients with symptomatic severe AR or asymptomatic severe AR and LVESD .50 mm or LVESDi (LVESD/BSA)
.25 mm/m2 (in patients with small body size) or resting LVEF
≤50%, valve surgery is recommended prior to elective intermediate- or high-risk NCS.
I
In patients with moderate-to-severe rheumatic MS and symptoms or SPAP .50 mmHg, valve intervention (PMC or surgery) is recommended before elective intermediate- or high-risk NCS.
I
In asymptomatic patients with severe AS who are scheduled for elective high-risk NCS, AVR (SAVR or TAVI) should be considered after Heart Team discussion.
IIa
In patients with symptomatic severe primary MR or asymptomatic severe primary MR with LV dysfunction (LVESD
≥40 mm and/or LVEF ≤60%), valve intervention (surgical or transcatheter) should be considered prior to intermediate- or high-risk NCS, if time allows.
IIa
In patients with severe secondary MR who remain symptomatic despite guideline-directed medical therapy
(including CRT if indicated), valve intervention (transcatheter or surgical) should be considered before NCS, in eligible patients with an acceptable procedural risk.
IIa
In patients with severe symptomatic AS in need of time-sensitive NCS or in whom the TAVI and SAVR are unfeasible, BAV may be considered before NCS as a bridge to deﬁnitive aortic valve repair.
IIb
Arrhythmias
In AF patients with acute or worsening haemodynamic instability undergoing NCS, emergency electrical cardioversion is recommended.
I
In patients with symptomatic, monomorphic, sustained VT
associated with myocardial scar, recurring despite optimal medical therapy, ablation of arrhythmia is recommended before elective NCS.
I
It is recommended that all patients with CIEDs that are reprogrammed before surgery have a re-check and necessary reprogramming as soon as possible after the procedure.
I
If indications for pacing exist according to the 2021 ESC
Guidelines on cardiac pacing and cardiac resynchronization therapy, NCS surgery should be deferred and implantation of a permanent pacemaker should be considered.
IIa
Continued


<!-- PAGE 12 -->

### Page 12

Ablation should be considered in symptomatic patients with recurrent or persistent SVT, despite treatment, prior to high-risk, non-urgent NCS.
IIa
In high-risk CIED patients (e.g. with ICD or being pacing-dependant) undergoing NCS carrying a high probability of electromagnetic interference (e.g. involving unipolar electrosurgery above the umbilical area), CIED check-up and necessary reprogramming immediately before the procedure should be considered.
IIa
Adult congenital heart disease
In patients with ACHD, a consultation with an ACHD specialist is recommended before intermediate- or high-risk surgery.
I
In patients with ACHD, it is recommended that intermediateand high-risk elective surgery is performed in a centre with experience in the care of ACHD patients.
I
Pericardial diseases
In patients with acute pericarditis, deferring elective NCS until complete resolution of the underlying process should be considered.
IIa
Avoiding elective NCS procedures under general anaesthesia until colchicine or the immunosuppressive treatment course for pericardial disease is completed may be considered.
IIb
Pulmonary arterial hypertension
Inodilator drugs (dobutamine, milrinone, levosimendan),
which increase cardiac output and lower pulmonary vascular resistance, should be considered peri-operatively according to the haemodynamic status of the patient.
IIa
Peripheral artery disease and/or abdominal aortic aneurysm
Routine referral for cardiac work-up, coronary angiography, or
CPET prior to elective surgery for PAD or AAA is not recommended.
III
Renal disease
In patients with known risk factors (age .65 years, BMI .30,
diabetes, hypertension, hyperlipidaemia, CV disease, or smoking) undergoing intermediate- or high-risk NCS, it is recommended to screen for pre-operative renal disease by measuring serum creatinine and GFR.
I
In patients with renal disease requiring peri-operative contrast-enhanced radiography, balanced hydration with i.v.
isotonic ﬂuids, the use of a minimal volume of contrast media,
and the use of low-osmolar or iso-osmolar contrast media should be considered.
IIa
If a cystatin C measurement assay is available, cystatin C
measurement should be considered in patients with impaired eGFR (,45–59 mL/min/1.73 m2) to conﬁrm kidney disease.
IIa
Obesity
It is recommended to assess cardiorespiratory ﬁtness to estimate peri-operative CV risk in obese patients, with particular attention to those undergoing intermediate- and high-risk NCS.
I
In patients at high risk of obesity hypoventilation syndrome,
additional specialist investigation before major elective NCS
should be considered.
IIa
Continued
Diabetes mellitus
A pre-operative assessment for concomitant cardiac conditions is recommended in patients with diabetes with suspected or known CAD, and those with autonomic neuropathy, retinopathy, or renal disease and scheduled to undergo intermediate- or high-risk NCS.
I
Peri-operative monitoring and anaesthesia—Section 7
It is recommended to avoid post-operative acute pain.
I
Perioperative cardiovascular complications—Section 8
It is recommended to have high awareness of peri-operative
CV complications combined with surveillance for PMI in patients undergoing intermediate- or high-risk NCS.
I
Systematic PMI work-up is recommended to identify the underlying pathophysiology and to deﬁne therapy.
I
It is recommended to treat post-operative STEMI, NSTE-ACS,
acute HF, and tachyarrhythmias in accordance with guidelines for the non-surgical setting, after interdisciplinary discussion with the surgeon about bleeding risk.
I
In patients with post-operative PE of high or intermediate clinical probability, initiation of anticoagulation is recommended without delay, while diagnostic work-up is in progress, if bleeding risk is low.
I
Post-operative oral anticoagulation for PE is recommended to be administered for a period of at least 3 months.
I
In patients with a post-operative indication for OAC, NOACs are generally recommended over VKA.
I
In patients with post-operative AF after NCS, long-term OAC
therapy should be considered in all patients at risk of stroke,
considering the anticipated net clinical beneﬁt of OAC therapy,
and informed patient preferences.
IIa
In patients with MINS and at low risk of bleeding, treatment with dabigatran 110 mg orally b.i.d. may be considered from about 1 week after NCS.
IIb
Routine use of beta-blocker for the prevention of postoperative AF in patients undergoing NCS is not recommended.
III
© ESC 2022
AAA, abdominal aortic aneurysm; ACHD, adults with congenital heart disease; AF, atrial
ﬁbrillation; AR, aortic valve regurgitation; AS, aortic valve stenosis; AVR, aortic valve replacement; BAV, balloon aortic valvuloplasty; b.i.d., twice a day; BMI, body mass index;
BNP, B-type natriuretic peptide; BSA, body surface area; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiography; CIED, cardiac implantable electronic device; CPET,
cardiopulmonary exercise testing;
CRT,
cardiac resynchronization therapy;
CV,
cardiovascular; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; ECG,
electrocardiogram; eGFR, estimated glomerular ﬁltration rate; ESC, European Society of
Cardiology; FOCUS, focused cardiac ultrasound; GFR, glomerular ﬁltration rate; HF,
heart failure; i.v., intravenous; LMWH, low molecular weight heparin; LV, left ventricular;
LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter;
LVESDi, left ventricular end-systolic dimension index; MHV, mechanical heart valve;
MINS, myocardial injury following non-cardiac surgery; MR, mitral valve regurgitation; MS,
mitral valve stenosis; NCS, non-cardiac surgery; NOAC, non-vitamin K antagonist oral anticoagulant;
NSTE-ACS,
non-ST-segment elevation acute coronary syndrome;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; OAC, oral anticoagulant; PAD,
peripheral artery disease; PCC, prothrombin complex concentrate; PCI, percutaneous coronary intervention;
PE,
pulmonary embolism;
PMC,
percutaneous mitral commissurotomy; PMI, peri-operative myocardial infarction/injury; RBC, red blood cell;
SAVR, surgical aortic valve replacement; SGLT-2, sodium–glucose co-transporter-2;
SPAP, systolic pulmonary artery pressure; STEMI, ST-segment elevation myocardial infarction;
SVT,
supraventricular tachycardia;
TAVI,
transcatheter aortic valve implantation; TTE, transthoracic echocardiography; UFH, unfractionated heparin; VAD,
ventricular assist device; VKA, vitamin K antagonist; VT, ventricular tachycardia.
ESC Guidelines
3837


<!-- PAGE 13 -->

### Page 13

Table 4B
Revised recommendations
Recommendations in 2014 version
Class
Recommendations in 2022 version
Class
Preoperative assessment tools—Section 4
Electrocardiography and biomarkers
Pre-operative ECG is recommended for patients who have risk factor(s) and are scheduled for intermediate- or high-risk surgery.
I
In patients who have known CVD or CV risk factors (including age
≥65 years), or symptoms or signs suggestive of CVD it is recommended to obtain a pre-operative 12-lead ECG before intermediate- or high-risk NCS.
I
Assessment of cardiac troponins in high-risk patients, both before and 48–72 h after major surgery, may be considered.
IIb
In patients who have known CVD, CV risk factors (including age
≥65 years), or symptoms suggestive of CVD, it is recommended to measure hs-cTn T or hs-cTn I before intermediate- and high-risk
NCS, and at 24 h and 48 h afterwards.
I
NT-proBNP and BNP measurements may be considered for obtaining independent prognostic information for peri- operative and late cardiac events in high-risk patients.
IIb
In patients who have known CVD, CV risk factors (including age
≥65 years), or symptoms suggestive of CVD, it should be considered to measure BNP or NT-proBNP before intermediateand high-risk NCS.
IIa
Universal pre-operative routine biomarker sampling for risk stratiﬁcation and to prevent cardiac events is not recommended.
III
In low-risk patients undergoing low- and intermediate-risk NCS, it is not recommended to routinely obtain pre-operative ECG,
hs-cTn T/I, or BNP/NT-proBNP concentrations.
III
Coronary angiography
Pre-operative ICA is not recommended in cardiac-stable patients undergoing low-risk surgery.
III
Routine pre-operative ICA is not recommended in stable CCS
patients undergoing low- or intermediate-risk NCS.
III
General risk-reduction strategies—Section 5
Pharmacological treatment
Transient discontinuation of ACEIs or ARBs before NCS in hypertensive patients should be considered.
IIa
In patients without HF, withholding RAAS inhibitors on the day of
NCS should be considered to prevent peri-operative hypotension.
IIa
Antiplatelets
Consideration should be given to performing non-urgent NCS in patients who have had recent DES implantation no sooner than 12
months following the intervention. This delay may be reduced to 6
months for the new-generation DES.
IIa
It is recommended to delay elective NCS until 6 months after elective PCI and 12 months after an ACS.
I
It is recommended that aspirin be continued for 4 weeks after BMS
implantation and for 3–12 months after DES implantation, unless the risk of life-threatening surgical bleeding on aspirin is unacceptably high.
I
After elective PCI, it is recommended to delay time-sensitive NCS
until a minimum of 1 month of DAPT treatment has been given.
I
Continuation of aspirin, in patients previously thus treated, may be considered in the peri-operative period, and should be based on an individual decision that depends on the peri- operative bleeding risk, weighed against the risk of thrombotic complications.
IIb
In patients with a previous PCI, it is recommended to continue aspirin peri-operatively if the bleeding risk allows.
I
Discontinuation of aspirin therapy, in patients previously treated with it, should be considered in those in whom haemostasis is anticipated to be difﬁcult to control during surgery.
IIa
In patients without a history of PCI, interruption of aspirin at least 3
days before NCS may be considered if the bleeding risk outweighs the ischaemic risk, to reduce the risk of bleeding.
IIb
In patients treated with P2Y12 inhibitors, who need to undergo surgery, postponing surgery for at least 5 days after cessation of ticagrelor and clopidogrel—and for 7 days in the case of prasugrel
—if clinically feasible, should be considered unless the patient is at high risk of an ischaemic event.
IIa
If interruption of P2Y12 inhibitor is indicated, it is recommended to withhold ticagrelor for 3–5 days, clopidogrel for 5 days, and prasugrel for 7 days prior to NCS.
I
Speciﬁc diseases—Section 6
Coronary artery disease
If PCI is indicated before semi-urgent surgery, the use of new-generation DES, BMS or even balloon angioplasty is recommended.
I
If PCI is indicated before NCS, the use of new-generation DES is recommended over BMS and balloon angioplasty.
I
Continued


<!-- PAGE 14 -->

### Page 14

2.2. The magnitude of the problem
The annual volume of major surgery worldwide is estimated to be more than 300 million patients (about 5% of the world population),
which is a 34% increase from 2004 to 2012.1,2 Nearly 74% of these operations are performed in countries spending substantial amounts on health care. When applied to European Union countries, which had an overall population of 448 million in 2020 (27 countries),
this ﬁgure translates into a crude estimate of nearly 22 million major procedures annually.2
Nearly 85% of major operations are non-cardiac surgical procedures.3 In a recent report from the USA National Inpatient Sample database, nearly half of adults aged ≥45 years undergoing major nonArrhythmias
Patients with ICDs, whose devices have been pre-operatively deactivated, should be on continuous cardiac monitor throughout the period of deactivation. External deﬁbrillation equipment should be readily available.
I
It is recommended that patients with temporarily deactivated ICDs have continuous ECG monitoring, and during the peri-operative period are accompanied by personnel skilled in early detection and treatment of arrhythmias. In high-risk patients (e.g.
pacemaker-dependant or ICD patients), or if access to the torso will be difﬁcult during the procedure, it is recommended to place transcutaneous pacing/deﬁbrillation pads prior to NCS.
I
Hypertension
Large peri-operative ﬂuctuations in blood pressure in hypertensive patients should be avoided.
IIa
In patients with chronic hypertension undergoing elective NCS, it is recommended to avoid large peri-operative ﬂuctuations in blood pressure, particularly hypotension, during the peri-operative period.
I
Clinicians may consider not deferring NCS in patients with grade 1
or 2 hypertension (systolic blood pressure ,180 mmHg; diastolic blood pressure ,110 mmHg).
IIb
It is not recommended to defer NCS in patients with stage 1 or 2
hypertension.
III
Peripheral artery disease
Patients with PAD should be clinically assessed for ischaemic heart disease and, if more than two clinical risk factors are present, they should be considered for pre-operative stress or imaging testing.
IIa
In patients with poor functional capacity or with signiﬁcant risk factors or symptoms (such as moderate-to-severe angina pectoris,
decompensated HF, valvular disease and signiﬁcant arrhythmia),
referral for cardiac work-up and optimization is recommended prior to elective surgery for PAD or AAA.
I
Diabetes mellitus
In patients at high surgical risk, clinicians should consider screening for elevated HbA1c before major surgery and improving pre-operative glucose control.
IIa
In patients with diabetes or disturbed glucose metabolism, a pre-operative HbA1c test is recommended, if this measurement has not been performed in the previous 3 months. In case of
HbA1c ≥8.5% (≥69 mmol/mol), elective NCS should be postponed, if safe and practical.
I
Peri-operative monitoring and anaesthesia—Section 7
Patients with high cardiac and surgical risk should be considered for goal-directed therapy.
IIa
In order to preserve optimal CV stability, it is recommended to apply goal-directed haemodynamic therapy in patients undergoing high-risk NCS.
I
Avoiding arterial hypotension (mean arterial pressure
,60 mmHg) for prolonged cumulative periods (.30 min) may be considered.
IIb
In order to minimize the risk of post-operative organ dysfunction,
it is recommended to avoid an intra-operative mean arterial pressure decrease of .20% from baseline values or ,60–
70 mmHg for ≥10 min.
I
Avoiding non-steroidal anti- inﬂammatory drugs (especially cyclo-oxygenase-2 inhibitors) as the ﬁrst-line analgesics in patients with IHD or stroke may be considered.
IIb
Non-aspirin NSAIDs are not recommended as ﬁrst-line analgesics in patients with established or high risk of CVD.
III
© ESC 2022
AAA, abdominal aortic aneurysm; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; BMS, bare metal stent; CCS,
chronic coronary syndrome; CV, cardiovascular; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; ECG, electrocardiogram; HbA1c, glycated haemoglobin A1c; HF, heart failure; hs-cTn, high-sensitivity cardiac troponin; ICA, invasive coronary angiography; ICD, implantable cardioverter–deﬁbrillator; IHD, ischaemic heart disease; NCS, non-cardiac surgery; NSAID, non-steroidal anti-inﬂammatory drug; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAD, peripheral artery disease; PCI,
percutaneous coronary intervention; RAAS, renin−angiotensin−aldosterone system.
ESC Guidelines
3839


<!-- PAGE 15 -->

### Page 15

cardiac surgery (NCS) presented with at least two cardiovascular
(CV) risk factors, 18% had coronary artery disease (CAD), 4.7%
had a history of stroke, and 7.7% had a modiﬁed Revised Cardiac
Risk Index (RCRI) score ≥3 (range 0–6) in 2012–13. These prevalence rates show a substantial increase compared with the equivalent rates in 2008–09.4 In a large registry including 37 915 consecutive patients undergoing percutaneous coronary interventions (PCIs) with drug-eluting stent (DES), the rates of NCS after PCI were 11%
and 24%, 1 and 3 years after PCI respectively. The cut-off ages at which NCS was more likely to occur within 1 and 3 years of PCI
were 62 and 73 years respectively.5
The prevalence of comorbidities, the clinical condition of patients before surgery, and the urgency, magnitude, type, and duration of the surgical procedure determine the risk of peri-operative complications. In a recent cohort study of 40 000 patients aged ≥45 years undergoing inpatient NCS, one of seven experienced a major cardiac or cerebrovascular complication at 30 days.6 Cardiovascular complications can particularly occur in patients with documented or asymptomatic coronary heart disease, left ventricular (LV) dysfunction,
valvular heart disease (VHD), and arrhythmias, who undergo surgical procedures that are associated with prolonged haemodynamic and cardiac stress. In the case of peri-operative myocardial ischaemia,
three mechanisms are important: (i) oxygen supply–demand mismatch on the background of coronary artery stenosis that may become ﬂow-limiting by peri-operative haemodynamic ﬂuctuations;
(ii) acute coronary syndrome (ACS) due to stress-induced erosion or rupture of a vulnerable atherosclerotic plaque in combination with pro-inﬂammatory and hypercoagulable states induced by surgery, and the haemodynamic distress resulting from ﬂuid shifts and anaesthesia; and (iii) surgery-associated bleeding risk requiring interruption of antiplatelet therapies, which might lead to stent thrombosis among patients undergoing NCS after recent coronary stent placement. Left ventricular dysfunction and arrhythmias may occur for various reasons at all ages. Because the prevalence of CAD,
VHD, heart failure, and arrhythmias increases with age, perioperative CV mortality and morbidity are predominantly an issue in the adult population undergoing major NCS.
In Europe, recent systematic data on the annual number and type of operations, and on patient outcomes are unfortunately lacking.
Additionally, data deﬁnitions vary, as do data quantity and quality.
Based on the estimates outlined above, nearly 6.6 million procedures are performed annually in European patients with CAD, peripheral artery disease (PAD), and cerebrovascular disease who are at high risk of CV complications. In a 7 day cohort study, the European
Surgical Outcomes Study (EuSOS) group investigated the outcomes of NCS in 498 hospitals across 27 European nations and the UK; up to 8% of patients undergoing NCS required critical care admission,
while in-hospital mortality ranged 1.4–21.5% (mean 4.0%), depending on safety precautions.7 In a recent prospective study of 2265
high-risk patients undergoing NCS in Switzerland, one out of ﬁve developed major adverse events within 365 days.8 When applied to the population in European Union countries, these ﬁgures translate into at least 660 000 major cardiac or cerebrovascular complications occurring annually due to NCS procedures.
The 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing NCS focus on the pre-operative CV
risk assessment and peri-operative management of patients in whom cardiovascular disease (CVD) is a potential source of complications during NCS.
2.3. Change in demographics
Within the next 30 years, the ageing of the population will have a major impact on peri-operative patient management. Patients undergoing
NCS are older than the rest of the population. Furthermore, it is estimated that by 2030, one-ﬁfth of individuals aged .75 years will undergo surgery each year. In addition, between 2018 and 2050, the number of people in Europe aged 75–84 years is projected to increase by ≏60%. The total number of surgical procedures may increase even faster because of the greater need for interventions with increasing age. Demographics of patients undergoing surgery show trends towards increasing numbers of elderly patients and increasing numbers of patients with comorbidities, particularly CVDs. Thus, adults aged
≥75 years have a greater risk of peri-operative major adverse cardiovascular events (MACEs) (9.5% vs. 4.8% for younger adults [P ,
0.001]).9 However, age per se seems to be responsible for a small increase in the risk of complications; greater risks are associated with urgency and signiﬁcant CV, pulmonary, and renal disease.
2.4. Purpose
As many years have passed and new evidence has become available since the publication of the 2014 ESC/European Society of Anaethesiology
(ESA) Guidelines on non-cardiac surgery: cardiovascular assessment and management,10 the ESC has decided to revise the guidelines on
NCS. These new guidelines are based on the 2014 edition, but all sections have been revised or rewritten, and several new sections have been added. Some of the old recommendations are unchanged or have been revised, and new recommendations have been added.
These guidelines are intended for physicians, healthcare workers,
and collaborators involved in the pre-operative, operative, and postoperative care of patients undergoing NCS. The objective is to endorse a standardized and evidence-based approach to peri-operative
CV management. The guidelines recommend a stepwise evaluation of the patient that integrates clinical risk factors and test results with the estimated stress of the planned surgical procedure and the risks involved with the discontinuation of drugs. This results in an individualized risk assessment, with the opportunity of initiating medical therapy, coronary interventions, and speciﬁc surgical and anaesthetic techniques, or withholding medical therapy, in order to optimize the patient’s peri-operative condition. Further, it should be discussed in which institutions (specialized small hospital vs. tertiary care) the NCS will be performed. It is important that patients’ values and preferences with respect to the beneﬁts and risks of surgery are taken into consideration, and that patients are involved in the decisions. This is particularly important when it comes to decisions about undergoing elective surgery or not, the timing of surgery, and choice of surgical and anaesthetic techniques.
Compared with non-surgical settings, randomized controlled trials
(RCTs) are scarce in this ﬁeld. However, since the publication of the
2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management there has been a signiﬁcant increase in
RCTs that are relevant in this setting. When no trials are available on a speciﬁc CV management regimen in the surgical setting, data from the non-surgical setting may be extrapolated and similar recommendations made, but with different levels of evidence.


<!-- PAGE 16 -->

### Page 16

These guidelines have the potential to improve peri- and postoperative outcomes and highlight the existence of a clear opportunity for improving the quality of care. Following the publication of these updated guidelines on NCS, their effects on outcomes should be monitored. The objective evaluations of the quality of the assessments and the outcomes are described in quality indicators (Section 13).
2.5. The outcomes we want to prevent
The recommendations in these guidelines are intended to prevent peri-operative CV morbidity and mortality, for example: perioperative myocardial infarction/injury (PMI), stent thrombosis, acute heart failure (HF), haemodynamically relevant arrhythmias, pulmonary embolism (PE), ischaemic stroke, and death. It is also important to prevent bleeding complications, especially associated with antithrombotic treatment, since bleeding is associated with an increased risk of MI and death.6,11–13
3. Clinical risk evaluation
Cardiovascular morbidity and mortality in patients undergoing NCS
are determined by two main factors: patient-related risk and type of surgery or procedure, including the circumstances under which it takes place (experience of institution, elective vs. emergency procedure).14 The risk may be reduced by an adequate pre-operative evaluation and proper selection of type and timing of the surgical procedure (Figure 1).
3.1. Surgery-related risk
The surgery-related risk is determined by the type and duration of the surgery, and the urgency of the procedure or intervention.
The type of anaesthesia and anaesthetic drugs may also inﬂuence the risk of complications in patients at intermediate to high cardiac risk undergoing NCS (see Section 7).15 The surgical risk estimate is a broad approximation of 30 day risk of CV death, MI, and stroke,
which only takes into account the speciﬁc surgical intervention without considering the patient’s comorbidities (Table 5).10,16
Any surgical procedure may increase the level of cortisol and catecholamines as stress responses due to tissue injury and inﬂammation, and neuro–endocrine and sympathovagal imbalance. Changes in body core temperature, blood loss, and ﬂuid shifts may cause a rise in vascular resistance as well as hypotension,17 leading to imbalance between myocardial oxygen demand and delivery. Bleeding, transfusion of blood products, tissue injury, and inﬂammatory response may affect the coagulation system, inducing a prothrombotic state.
Consider postponing or avoiding  
High attention
Increased attention
Increased attention
Attention
Increased attention
Attention
High risk
Moderate risk
Low risk
CV risk reduction
(Patient)
Surgery- 
related risk
Patient-related risk
Risk reduction 
(Surgery)
High risk
Moderate risk
Low risk
High attention
Attention
Figure 1 Total risk is an interaction of patient-related and surgery-related risk. Ideally, the total risk should be as close as possible to the lower left corner, by choosing surgery/procedure/anaesthesia/institution with the lowest possible risk along with efforts to mitigate the patient’s CV risk.
ESC Guidelines
3841


<!-- PAGE 17 -->

### Page 17

3.1.1. Timing of surgery
In general, acute procedures carry a higher risk of complications than elective procedures. Uniform timing deﬁnitions are unfeasible, as the time spans may vary between diseases. These guidelines use the timing deﬁnitions below.
Immediate: surgery/intervention should be performed without any delay to save life or organ function.
Urgent: surgery/intervention should be performed without unnecessary delay to save life, limb, or organ function.
Time-sensitive: surgery/intervention should be performed as soon as possible as there is a time-dependent risk of losing limb or organ function, or increased risk of complications. Cancer surgery is typically time-sensitive, as is carotid surgery to prevent stroke in a symptomatic case. The time window for time-sensitive surgery will vary depending on the underlying disease.
Elective: surgery/intervention can be performed electively (not further deﬁned) without signiﬁcant risk of losing limb, or organ function, or increased risks of complications.
Many factors affect outcomes when comparing acute or timesensitive vs. elective surgery: the general condition of the patient vs. the stage of the acute illness, and how far it has progressed.
The best interests of the patient should be considered before deciding on treatment, informed consent to management should be obtained, if at all possible, and decisions should be clearly recorded.24
The degree of urgency should also be considered (i.e. does the procedure need to be performed outside working hours or can it wait until the next day?). In general, competences and supportive functions are not always present in the evenings or during the night; thus, an overall evaluation of what best serves the patient is necessary. The optimal timing of NCS
should be discussed within the multidisciplinary team, including an anaesthesiologist, in order to achieve optimized anaesthesia for each patient (see Section 7).
3.2. Type of surgical approach
New surgical techniques have been introduced to replace open surgery and to reduce the overall risk for the patient.
3.2.1. Laparoscopy
Laparoscopic procedures, compared with open surgical procedures,
have the advantage of causing less tissue trauma and intestinal paralysis,
resulting in less incisional pain, better post-operative pulmonary function, signiﬁcantly fewer wall complications, and diminished postoperative ﬂuid shifts related to bowel paralysis.25 However, the pneumoperitoneum required for these procedures results in elevated intra-abdominal pressure and a reduction in venous return. Typical physiological sequelae are secondary to increased intra-abdominal pressure and absorption of the gaseous medium used for insufﬂation.
While healthy individuals on controlled ventilation typically tolerate pneumoperitoneum, patients with CVD, some types of adults with congenital heart disease (ACHD), and obese patients may experience adverse consequences.26
Pneumoperitoneum and
Trendelenburg position result in increased mean arterial pressure,
central venous pressure, mean pulmonary artery pressure, pulmonary capillary wedge pressure, and systemic vascular resistance impairing cardiac function.27,28 Therefore, compared with open surgery, the CV risk in patients with CVD is not necessarily reduced in patients undergoing laparoscopy, and both should be evaluated in the same way. This is especially true in patients undergoing interventions for morbid obesity, but also in other types of surgery, considering the risk of conversion to an open procedure.29,30 Superior short-term outcomes of laparoscopic vs. open procedures have been reported, depending on type of surgery, operator experience,
Table 5
Surgical risk estimate according to type of surgery or intervention
Low surgical risk (,1%)
Intermediate surgical risk (1–5%)
High surgical risk (.5%)
• Breast
• Dental
• Endocrine: thyroid
• Eye
• Gynaecological: minor
• Orthopaedic minor (meniscectomy)
• Reconstructive
• Superﬁcial surgery
• Urological minor: (transurethral resection of the prostate)
• VATS minor lung resection
• Carotid asymptomatic (CEA or CAS)
• Carotid symptomatic (CEA)
• Endovascular aortic aneurysm repair
• Head or neck surgery
• Intraperitoneal: splenectomy, hiatal hernia repair, cholecystectomy
• Intrathoracic: non-major
• Neurological or orthopaedic: major (hip and spine surgery)
• Peripheral arterial angioplasty
• Renal transplants
• Urological or gynaecological: major
• Adrenal resection
• Aortic and major vascular surgery
• Carotid symptomatic (CAS)
• Duodenal-pancreatic surgery
• Liver resection, bile duct surgery
• Oesophagectomy
• Open lower limb revascularization for acute limb ischaemia or amputation
• Pneumonectomy (VATS or open surgery)
• Pulmonary or liver transplant
• Repair of perforated bowel
• Total cystectomy
© ESC 2022
CAS, carotid artery stenting; CEA, carotid endarterectomy; CV, cardiovascular; MI, myocardial infarction; VATS, video-assisted thoracic surgery.
Surgical risk estimate is a broad approximation of 30 day risk of CV death, MI, and stroke that takes into account only the speciﬁc surgical intervention, without considering the patient’s comorbidities.
Adapted from data in Glance et al., Muller et al., Bendixen et al., and Falcoz et al.18–23


<!-- PAGE 18 -->

### Page 18

and hospital volume; however, few studies provide direct measures of cardiac complications.31–33 The beneﬁt of laparoscopic procedures is probably greater in elderly patients, with reduced length of hospital stay, intra-operative blood loss, incidence of postoperative pneumonia, time to return of normal bowel function, incidence of post-operative cardiac complications, and wound infections.34
3.2.1.1. Vascular and endovascular procedures
Endovascular abdominal aortic aneurysm repair (EVAR) is a procedure using femoral artery access only, and is therefore associated with lower operative mortality and morbidity than open repair. It minimizes the surgical risk in simultaneous surgery for the treatment of abdominal aortic aneurysm (AAA) and a noncardiac disorder, and shortens the time delay from the treatment of AAA and the non-cardiac disorder in patients undergoing twophase surgery.35–37 The early gain in mortality from EVAR procedures is lost after 3–4 years, compared with open surgical treatment, due to general morbidity (especially CV mortality) of
AAA patients.
Various vascular and non-vascular NCS procedures bear different operative risks. While aortic and infra-inguinal vascular surgical procedures are both regarded as high-risk procedures, their risk can be modiﬁed by adequate peri-operative measures.38 For patients undergoing treatment of femoropopliteal artery disease,
an endovascular-ﬁrst approach may be advisable in case of additional signiﬁcant comorbidity. A meta-analysis of studies comparing open surgery with PCI for the treatment of femoropopliteal arterial disease showed that femoral bypass surgery was associated with higher morbidity (odds ratio [OR] 2.93; 95% conﬁdence interval [CI], 1.34–
6.41) but similar mortality at 30 days compared with endovascular treatment.39
3.2.1.2. Video-assisted non-cardiac surgery
Video-assisted thoracic surgery (VATS) is supported by a trial showing fewer peri-operative complications and a better quality of life in the ﬁrst year following surgery for stage 1 lung cancer compared with anterolateral thoracotomy.20 Also, a large propensity matched study conducted by the European Society of Thoracic
Surgeons (ESTS) showed fewer post-operative complications following VATS compared with open thoracotomy.21 Overall, the beneﬁts seem greatest in patients with reduced functional lung capacity.
3.3. Patient-related risk
3.3.1. Initial assessment
Patient-related risk is determined by patient’s age, the presence or absence of CV risk factors (e.g. smoking, hypertension, diabetes, dyslipidaemia, family disposition)40 or established CV disease, and comorbidities.41
Identiﬁcation of patients at risk of CV complications is of paramount importance to choice of therapy when non-surgical options are available, or when the type of surgery or anaesthesia impacts the risk of complications. When emergency surgery is needed, the evaluation must necessarily be limited; however, most clinical circumstances allow a systematic approach.
As an initial assessment, it is recommended that all patients scheduled for NCS are evaluated by accurate history and physical examination, with special emphasis on CV risk factors, established CV
disease, and comorbidities.40 It is also recommended to measure standard laboratory tests (e.g. haemoglobin and renal function) in all patients undergoing intermediate- to high-risk surgery. Based on this information, further assessment of patient-related risk can proceed depending on the surgery-related risk, as shown in Figure 2. It is recommended to perform an electrocardiogram (ECG), assess the functional capacity, and/or measure biomarkers (cardiac troponins and/or
N-terminal pro-B-type natriuretic peptide [NT-proBNP]/B-type natriuretic peptide [BNP]) depending on the patient-related and surgery-related risk (Figure 2). Detailed information on available tools for risk assessment, their prognostic ability, and indications to perform them is given in Section 4. More details on pre-operative management of patients with speciﬁc CV diseases are given in Section 6.
3.3.1.1. Patients aged ,65 years without a history of cardiovascular disease or cardiovascular risk factors
Patients aged ,65 years without signs, symptoms, or history of CVD
or CV risk factors are considered to be of low risk, and can proceed to low- and moderate-risk surgery without additional pre-operative risk assessment.41 Before high-risk surgery, ECG and biomarkers should be considered (see Sections 4.3 and 4.4).42
Patients without signs or symptoms of CVD, but with a family history of genetic cardiomyopathy (i.e. dilatated, hypertrophic, arrhythmic, or restrictive cardiomyopathy, or LV non-compaction) should be evaluated with an ECG and an echocardiographic examination to rule out the presence of the disease, irrespective of the age.43
No speciﬁc data are available in the literature regarding risk of family members without the phenotype; however, they are at risk of developing the disease, which may be subclinical at the time of the NCS.43
3.3.1.2. Patients aged ≥65 years or with cardiovascular risk factors
Patients who are aged ≥65 years and patients with risk factors for
CVD—such as hypertension, dyslipidaemia, or smoking—have an increased risk of having undetected CVD. The SCORE2 riskprediction tool can be used to estimate their 10 year CVD risk outside the setting of NCS.40 Patients who are aged ≥65 years and patients with risk factors for CVD also have an increased risk of peri-operative complications during NCS.41,44 These patients need additional assessment before intermediate- and high-risk surgery (Figure 2) and optimal treatment of risk factors.
Recommendation Table 1 — Recommendations for selection of surgical approach and impact on risk
Recommendations
Classa
Levelb
Endovascular or video-assisted procedures should be considered for patients with high CV risk undergoing vascular or pulmonary surgery.21,35–39
IIa
B
© ESC 2022
CV, cardiovascular.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
3843


<!-- PAGE 19 -->

### Page 19

This is also the case for patients with other diseases known to be associated with a high risk of concomitant undetected or known
CVD (Sections 6.8 and 6.11–6.14).
3.3.1.3. Patients with established cardiovascular disease
The surgical procedure has the potential to aggravate the disease and increase morbidity and mortality in patients with established
CVD. This may be preventable by implementing appropriate CV
risk stratiﬁcation prior to
NCS
and individually tailoring peri-operative therapy to reduce the risk.45 If time allows, it is also recommended to optimize guideline-recommended treatment of the disease before NCS. See Section 6 for a detailed discussion of risk assessment and management of patients with known CVD.
N
Management of patients befof re non-cardiac surgery (NCS)
Accurate history and clinical examination, including standa
,
rd lab tests (Class I)
Advise on stopping smoking, optimize guideline-
,
recommended medical therapy (Class I)
p
<65 years without any
CVD/CV risk factorsa
Patients with established CVD
Low-risk NCS
≥65 years or with CV risk factorsa
Emergent or urgent NCS
N
Time-sensitive NCS
Elective NCS
Cardiac testing not feasible f
e
Multidisciplinary decision of 
individualized cardiac testing.
If time, manage as electi
,
ve NCS
Y
Y
None (see section 6)
Intermediate-risk NCS
ECG, biomar
,
kers k
b (Class I)
Functional capacityc (Class IIa)
(see section 6)
High-risk NCS
ECG, biomar
,
kers k
b (Class I)
Functional capacityc (Class IIa)
+ cardiology consultationd
(see section 6)
Multidisciplinary decision
None
Intermediate-risk NCS
ECG, biomar
,
kers k
b (Class I)
Functional capacityc (Class IIa)
High-risk NCS
ECG, biomar
,
kers k
b (Class I)
Functional capacityc (Class IIa)
None
Intermediate-risk NCS
None
High-risk NCS
In patients >45 year, conside
,
r:
ECG, biomar
,
kers k
b
(Class IIa)
Low-risk NCS
Low-risk NCS
Figure 2 Pre-operative assessment before non-cardiac surgery. CV, cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; N, no; NCS,
non-cardiac surgery. Y, yes; aCV risk factors: hypertension, smoking, dyslipidaemia, diabetes, family history of CVD. bBiomarkers: hs-cTn T/I (Class I) and/
or BNP/NT-proBNP (Class IIa). If pathological, consult a cardiologist. cFunctional capacity based on Duke Activity Status Index (DASI) or the ability to climb two ﬂights of stairs. dFor diagnostic and therapeutic efforts to be considered, see Section 6. eClose follow-up after intervention and subsequent management of heart disease are advised.


<!-- PAGE 20 -->

### Page 20

3.3.2. Patients with murmurs, chest pain, dyspnoea,
or peripheral oedema
Patients without known CVD and scheduled for elective or acute
NCS are often referred to a cardiologist because of symptoms or signs that may be caused by CVD. Murmurs, chest pain, dyspnoea,
and oedema may suggest severe CVD, but may also be caused by non-cardiac disease. Thus, the medical history, family history, and risk factors have to be obtained and considered. The patient’s physical capacity should be assessed. The need for further evaluation of the patient should be decided according to the risk of the planned procedure or surgery.
3.3.2.1. Murmurs
In a patient with a heart murmur, but without any symptoms of CVD,
the value of performing an echocardiogram is not well-established and consensus is missing.54–56 However, if a heart murmur suggesting clinically signiﬁcant pathology is present before high-risk NCS, it is recommended to perform an echocardiogram, even in patients without any symptoms of CVD. Old age or increased NT-proBNP may increase the pre-test probability of haemodynamically signiﬁcant but asymptomatic valvular disease. If the patient with the murmur also has symptoms of CVD, an echocardiogram is indicated before all NCS. The pre-operative setting is challenging, as the need for
NCS and the risk of CVD have to be considered as independent factors. Thus, an echocardiogram may be useful in risk stratiﬁcation for some patients, but whether it would improve outcome is uncertain.
It is important to bear in mind that the time delay when performing additional but unnecessary examinations may worsen the patient’s prognosis.57 It has also been discussed that a focused cardiac ultrasound (FOCUS) could replace auscultation in general in the preoperative evaluation of patients.58 While cardiac auscultation has severe limitations,59,60 the value of performing a FOCUS as a standard pre-operative evaluation remains uncertain. Cardiac auscultation should not be replaced by FOCUS.
3.3.2.2. Chest pain
Patients scheduled for NCS may also present with previously unrecognized symptoms suggestive of CAD. The disease leading to the need for NCS may aggravate a subclinical CAD, or the patient may have a concomitant undetected CAD. In an elective setting, if the symptoms are suggestive of CAD, the guidelines for CAD patients in the non-surgical setting should be followed (see Sections 4.5.3
and 6.1.2). If immediate, urgent, or time-sensitive NCS is needed,
the time for and access to adequate diagnostic tools may be limited.
However, ECG and troponins can be used to detect or exclude ACS
(see Sections 4.3 and 4.4).
3.3.2.3. Dyspnoea
Dyspnoea is a symptom of a wide range of diseases and conditions. In a large series of patients, self-reported dyspnoea identiﬁed a subgroup of otherwise asymptomatic patients at increased risk of death from CVD and any cause.61 In the diagnostic work-up to ﬁnd the reason for dyspnoea, spirometry, D-dimer, NT-proBNP/BNP, arterial blood gases, and transthoracic echocardiography (TTE) have diagnostic utility61 but limited speciﬁcity. If NT-proBNP/BNP is elevated,
an echocardiogram should be performed. If NT-proBNP/BNP is not elevated, other reasons for dyspnoea should be explored.
3.3.2.4. Peripheral oedema
Increased hydrostatic pressure leading to oedema is a feature of a wide range of CV diseases, but an upright position is also a common cause of oedema. There is a spectrum of other diseases that can result in peripheral oedema not listed here.
Recommendation Table 2 — Recommendations for all patients scheduled for non-cardiac surgery
Recommendations
Classa
Levelb
In all patients scheduled for NCS, an accurate history and clinical examination are recommended.
I
C
It is recommended to perform a pre-operative risk assessment, ideally at the same time as the
NCS is proposed.46–53
I
B
If time allows, it is recommended to optimize guideline-recommended treatment of CVD and
CV risk factors before NCS.
I
C
© ESC 2022
CV, cardiovascular; CVD, cardiovascular disease; NCS, non-cardiac surgery.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 3 — Recommendations for patients aged ,65 years without signs, symptoms, or history of cardiovascular disease
Recommendations
Classa
Levelb
In patients with a family history of genetic cardiomyopathy, it is recommended to perform an ECG and TTE before NCS, regardless of age and symptoms.
I
C
In patients aged 45–65 years without signs,
symptoms, or history of CVD, ECG and biomarkers should be considered before high-risk
NCS.
IIa
C
© ESC 2022
ECG,
electrocardiogram;
NCS,
non-cardiac surgery;
TTE,
transthoracic echocardiography.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 4 — Recommendations for pre-operative assessment in patients with previously unknown murmur, angina, dyspnoea, or peripheral oedema
Recommendations
Classa
Levelb
Newly detected murmur
In patients with a newly detected murmur and symptoms or signs of CVD, TTE is recommended before NCS.
I
C
Continued
ESC Guidelines
3845


<!-- PAGE 21 -->

### Page 21

3.4. Timing of adequate risk evaluation
Pre-operative CV assessment should be performed prior to surgery,
ideally at the time when the decision for NCS has been made.
Accurate estimates of the risks and beneﬁts of surgery is a prerequisite for informed decision-making by both physicians and patients about the appropriateness of surgery. These estimates should also help in guiding surgical (endovascular/endoscopic vs. open approach) and monitoring
(intermediate care, screening for CV complications) approaches, and help to detect an unexpectedly high CV risk.47 Therefore, the prognostic value of pre-operative CV risk assessment is much higher in elective vs. immediate or urgent surgery. Explicit communication of perioperative CV risk, on the basis of the expected event rates,47 and risk communication tools such as the A to Z Inventory of Decision Aids
(https://decisionaid.ohri.ca/AZinvent.php) are recommended.
3.5. Avoidance or allowance for surgery in the individual patient
In the clinical setting it can be difﬁcult to decide whether CVD represents a contraindication to NCS. In general, the risk for the patient if not operated on must be considerably higher than the risk of the treatment. Ideally, an unstable cardiac patient should be stabilized before NCS, but waiting can be detrimental for acute surgical disease.
No deﬁnite list can be made for which cardiac disease is a clear contraindication to NCS, but in patients with severe HF (New York Heart
Association [NYHA] class IV), cardiogenic shock, severe pulmonary hypertension, or patients with severe frailty (see Section 4.1.2 for frailty assessment), high-risk NCS should probably be avoided. Life expectancy and quality of life should also be taken into consideration.
However, the decision should be made after discussions between the surgeon, anaesthesiologist, cardiologist, and also a geriatrician for elderly patients, along with the patient and relatives.
3.6. The patient perspective
Patients with established CVD may face concerns about their underlying disease and current CV medication, co-ordination between the surgical team and their cardiologist (examples provided in Figure 3),
and the potential excessive risk compared with the expected outcome of the surgery. Time should be allowed to address concerns and to provide evidence-based information on the risk–beneﬁt trade-offs and the surgical treatment options (including non-surgical or ‘do nothing’ alternatives) to ensure informed consent, and to allow patients to engage in shared decision-making with the aim of supporting the best decision. The team needs to understand the patient’s concerns and expectations about the treatment and shortand long-term goals, as the risk-beneﬁts of the intervention may not be aligned with patient preferences and wishes. Communicating in plain language (oral and written) and targeting communication to
ﬁt the individual level of health literacy is pivotal. Several studies have indicated a relatively high prevalence of limited health literacy in patients with CVD (e.g. with HF),62 and limited health literacy is associated with adverse outcomes.63 An example of a patient information sheet to be used in the communication with patients is given in the Supplementary data, Table S1.
Recent systematic reviews and meta-analyses have focused on shared decision-making in the ﬁeld of surgery across disease areas.64–67 In general, shared decision-making positively impacts decisional conﬂicts, knowledge gained, satisfaction, and decisional anxiety (although cultural variations may exist).67 In the breast cancer/
endocrine and urology specialties, decision-making and communication aids appear to be effective methods for supporting patients’ involvement in decision-making when undergoing elective surgery.
Moreover, educational information, provided through interactive multimedia, computer, or on DVD, used prior to the surgical consultation could enhance the decision-making process in addition to face-to-face communication.66
In Europe, the prevalence of pre-operative anxiety among patients undergoing surgical procedures varies from 27–80%.68 Although a certain level of anxiety in patients must be expected, peri-operative anxiety is associated with worse surgical outcomes and longer recovery,69–72 which highlights the importance of pre-surgical assessment and, in some patients, treatment of anxiety. Factors associated with pre-operative anxiety are complex and include, among others, age,
sex, educational level, type of surgery, and fear of post-operative complications or the outcome.68 Psychological reactions in patients undergoing high- or medium–high-risk procedures and/or patients with previous negative experiences of NCS may warrant particular attention. Concerns and fears expressed by patients and relatives should be taken seriously. A number of reviews and meta-analyses have summarized the effects of interventions on surgical outcomes in abdominal, cardiac, and orthopaedic surgery, which may also be applicable to patients with CV conditions in these settings.73–75
In patients with a newly detected murmur suggesting clinically signiﬁcant pathology, TTE is recommended before high-risk NCS.
I
C
In patients with a newly detected murmur, but without other signs or symptoms of CVD, TTE
should be considered before moderate-risk NCS.
IIa
C
Previously unknown angina
If a patient scheduled for elective NCS has chest pain or other symptoms suggestive of undetected
CAD, further diagnostic work-up before NCS is recommended.
I
C
If a patient in need of acute NCS also has chest pain or other symptoms suggestive of undetected
CAD, a multidisciplinary assessment approach is recommended to choose the treatment with lowest total risk for the patient.
I
C
Dyspnoea and/or peripheral oedema
In patients with dyspnoea and/or peripheral oedema, an ECG and an NT-proBNP/BNP test is indicated before NCS, unless there is a certain non-cardiac explanation.
I
C
In patients with dyspnoea and/or peripheral oedema and elevated NT-proBNP/BNP, TTE is recommended before NCS.c
I
C
© ESC 2022
BNP, B-type natriuretic peptide; CAD, coronary artery disease; CVD, cardiovascular disease; ECG, electrocardiogram; NCS, non-cardiac surgery; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TTE, transthoracic echocardiography.
aClass of recommendation.
bLevel of evidence.
cIf BNP/NT-proBNP testing is unavailable, TTE should be considered.


<!-- PAGE 22 -->

### Page 22

### 4 Pre-operative assessment tools

4.1. Risk scores
4.1.1. General risk calculators
Several risk indices have been developed based on multivariable analyses of observational data and have been validated during the last decade
(Table 6).47,49,76 Most risk calculators integrate both patient-related and surgery-related risk factors, but none of them include biomarkers among their variables. Calculators for most of the commonly used risk indices are available online (Table 6). The risk calculators can be used in addition, or as an alternative, to the assessment of surgery-related and patient-related risk factors described in Section 3.3. The Task Force decided against recommending one speciﬁc risk score. The Task Force also decided that the selection criteria for further pre-operative testing should be clinical criteria, and not based on a speciﬁc score.
Recommendation Table 5 — Recommendations for patient information
Recommendations
Classa
Levelb
It is recommended to give patients individualized instructions for pre-operative and post-operative changes in medication, in verbal and written formats with clear and concise directions.
I
C
It should be considered to set up a structured information list (e.g. a check list to help with common issues) for patients with CVD or at high risk of CV complications scheduled for NCS.
IIa
C
© ESC 2022
CV, cardiovascular; CVD, cardiovascular disease; NCS, non-cardiac surgery.
aClass of recommendation.
bLevel of evidence.
Do I need to take any cardioprotective medication before surgery?
Who will inform my cardiologist about my surgery?
Do I need to pause or reduce any of my medications, and what are the risks if I do so?
Who will take care of me and how will they communicate my history and needs during my hospital stay?
Can my heart medications cause any problems during surgery?
Are there any interactions or contraindications between my medications and drugs given during surgery?
How will the healthcare professionals involved in my care be informed about my heart condition?
Can you give me information on how I will be monitored before, during, and after surgery?
Figure 3 Examples of questions and concerns expressed by patients.
ESC Guidelines
3847


<!-- PAGE 23 -->

### Page 23

The RCRI estimates the risk of 30 day mortality, MI, or cardiac arrest, and is based on six variables.46,47 It has been validated in several countries and is easy to use.47 A score of
0 indicates a 4% risk of 30 day mortality, MI, or cardiac arrest; a score of 1 indicates a 6% risk; a score of 2, 10%; and a score of
≥3, 15%.47
The American College of Surgery National Surgical Quality
Improvement Program (ACS NSQIP) developed an interactive risk
Table 6
Risk score calculators
Revised Cardiac
Risk Index (RCRI)
(1999)a
Surgical Risk
Calculator (2011)
The American College of Surgery National
Surgical Quality
Improvement Program
(ACS NSQIP) (2013)
Surgical
Outcome
Risk Tool
(SORT)
(2014)
The American
University of Beirut
(AUB)-HAS2
Cardiovascular Risk
Index (2019)b
Variables
Ischaemic heart disease
Cerebrovascular disease
History of congestive heart failure
Insulin therapy for diabetes
Serum creatinine level
≥2 mg/dL
High-risk surgery
(each assigned 1 point)
Age
ASA–PS grade
Pre-operative dependent functional status
Creatinine .1.5 mg/dL
Type of surgery
Age
Sex
Functional status
Emergency case
ASA class
Current steroid use
Ascites within 30 days
Systemic sepsis within 48 h
Ventilator dependence
Disseminated cancer
Diabetes
Hypertension on treatment
Congestive HF
Dyspnoea
Current smoker
History of severe COPD
Dialysis
Acute renal failure
Body mass index
Surgery code
ASA–PS grade
Urgency of surgery
High-risk surgical specialty
Surgical severity
(from minor to complex major)
Cancer
Age ≥65 years or over
History of Heart disease
Symptoms of Heart disease (angina or dyspnoea)
Age ≥75 years
Anaemia (haemoglobin
,12 g/dL)
Vascular Surgery
Emergency Surgery
(2 H, 2 A and 2 S)
(each assigned 1 point)
Score range
Score 1; risk 6.0%
(4.9–7.4)
Score 2; risk 10.1%
(8.1–10.6)
Score ≥3; risk 15%
(11.1–20.0)
Absolute risk: 0–100%
Absolute risk: 0–100%
Absolute risk:
0–100%
Low risk (score 0–1); (0.3
and 1.6%)c
Intermediate risk (score 2–
3); (7.1 and 17%)c
High risk (score .3);
(.17%)c
Outcome
30 day MI, cardiac arrest, death
Intra-operative and 30
day MI or cardiac arrest
Serious complications and any complications at 30 days
30 day mortality
30 day death, MI, or stroke
Derivation population
1422
211 410
1 414 006
11 219
3284
Validation population
Externally validated in various surgical populations
257 385
Externally validated in various surgical populations
22 631
1 167 414
Model performance
(AUC)
0.68–0.76
0.81–0.85
0.73
0.81–0.92
0.82
Interactive calculator https://www.mdcalc.
com/revised-cardiacrisk-index-preoperative-risk http://www.
surgicalriskcalculator.
com/miorcardiacarrest https://riskcalculator.facs.
org http://www.
sortsurgery.
com
© ESC 2022
AUC, area under curve; ASA–PS, American Society of Anesthesiology Physical Status; COPD, chronic obstructive pulmonary disease; HF, heart failure; MI, myocardial infarction; RCRI,
Revised Cardiac Risk Index.
aThe RCRI was updated January 2019.
bDakik et al. 2019, 2020, and 2022, and Msheik et al.49–51,81
cThe percentages relate to general surgeries.50


<!-- PAGE 24 -->

### Page 24

calculator providing an estimate of the absolute 30 day probability of serious complications and any complications compared with the average patient.76 Evaluated in the US surgical database, the ACS
NSQIP model performed better than the RCRI, but an external validation in the Philippines found both to have excellent discriminative abilities for predicting any MACE.48 The RCRI can be used without a web connection, whereas the ACS NSQIP is procedure-speciﬁc and is only available on the web. For clinical use, the RCRI is more accessible, but the ACS NSQIP offers procedure-speciﬁc absolute risk estimates, which are valuable in patient-guided decision-making. In vascular surgery, both risk calculators have shown moderate accuracy with an area under curve (AUC) of 0.64 (95% CI, 0.57–0.70) for
ACS NSQIP and 0.60 (95% CI, 0.54–0.65) for RCRI, due to underestimation of the risk of MI.76a Attempts to generate procedurespeciﬁc vascular calculators have not given better predictions in validation cohorts.77
The Surgical Outcome Risk Tool (SORT) estimates 30 day mortality after NCS based on the American Society of Anesthesiologists
Physical Status (ASA–PS) grade, urgency of surgery, surgical speciality and severity, cancer, and age ≥65 years. In the validation study, combining subjective assessment with the SORT was signiﬁcantly better than using either alone.78,79 The Surgical Risk Calculator is another tool that predicts intra-operative and 30 day risk of MI or cardiac arrest based on age, ASA–PS grade, pre-operative dependent functional status, creatinine, and type of surgery.80
The American University of Beirut (AUB)-HAS2 Cardiovascular
Risk Index is the most recently developed index to assess 30 day event risk (death, MI, or stroke), and stratiﬁes patients undergoing
NCS into low (score 0–1), intermediate (score 2–3), and high risk
(score .3) based on six data elements (see Table 6); scores .3 denote a post-operative event rate of .10%.49 The AUB-HAS2 Index has been tested in a broad spectrum of surgical subpopulations and demonstrated superior discriminatory power compared with the commonly utilized RCRI (Table 6).50,51,81
There is signiﬁcant variability in the predicted risk of cardiac complications using different risk-prediction tools; none can be disqualiﬁed with current evidence.82
4.1.2. Frailty
Frailty is an age-related, multidimensional state of decreased physiological reserve that results in diminished resiliency, loss of adaptive capacity, and increased vulnerability to stressors.83,84 The perioperative evaluation of elderly patients (.70 years) who require elective intermediate- or high-risk NCS should include frailty screening, which has proven to be an excellent predictor of unfavourable health outcomes in the older surgical population.
Frailty has a relevant impact on mortality and MI risk but does not add to risk estimation derived from the ACS NSQIP calculator, as frailty is associated with variables already in the main model. By adding six variables, the ACS NSQIP predicts the risk of post-operative delirium, functional decline, need of a new mobility aid, or pressure ulcer.85 The use of this broader-inclusive score identiﬁes cases that proﬁt the most by involving a geriatrician in the pre- and postoperative team.86,87 A measure of frailty informs the patient and surgeon about further life expectancy and the chance of post-operative delirium, dependency of mobility support, and need of nursing home or other care support after planned surgery.
Of the available screening tools for frailty, the Frailty Index and the
Frail Phenotype are the most commonly recommended.88,89 Of note,
the Frailty Index includes cognitive testing, while both scores assess physical function.90,91 A simpler approach is offered by the Clinical
Frailty Scale, which relies on information from the history taking. The
Clinical Frailty Scale has been validated against the Frailty Index.88 For cognitive screening to incorporate with the Frailty Index, Mini-Cog©
is a simple and fast screening tool validated for pre-operative screening92 (Supplementary data, Figure S1, and Tables S2 and S3).
Once a diagnosis of frailty is conﬁrmed, the prognosis of a frail patient can be improved by shared decision-making between at least a treating physician (e.g. surgeon), anaesthesiologist, geriatrician, the patient, and the patient’s relatives. During the shared decision-making process, a careful discussion with a frail patient about goals of care could help them to have realistic expectations and make better informed decisions before surgery. After a shared decision to go ahead with a planned NCS,
multimodal pre-habilitation programmes—including exercise, nutrition,
and psychological interventions—could potentially improve the perioperative prognosis of frail patients by an individualized approach tailored to the patient’s baseline functional status, comorbidities, and cognitive/psychological function.90
4.2. Functional capacity
Quantifying functional capacity has been a pivotal step in preoperative cardiac risk assessment.10 Although the validity of interview-based assessment of functional capacity has been questioned,93 a recent large prospective cohort study of high-risk patients undergoing NCS found self-reported inability to climb two ﬂights of stairs added incremental value to the 30 day cardiac event rate when added to the RCRI.94
Metabolic equivalents (METs) ,4 have long been considered to indicate poor functional capacity; however, studies using METs have been based on subjective interviews and not shown proven value. In the Measurement of Exercise Tolerance before Surgery
(METS) study, the Duke Activity Status Index (DASI) (https://www.
mdcalc.com/duke-activity-status-index-dasi#evidence) had a more precise estimation of cardiac risk than subjectively assessed functional capacity, improving risk estimation using RCRI.95 A DASI score
,34 was associated with increased odds of 30 day death or MI.96
From the DASI score, METs can be calculated as VO2 max (maximal oxygen consumption)/3.5; where VO2 max (mL/kg/min) = 0.43 ×
DASI + 9.6.
Furthermore,
cardiopulmonary exercise testing
(CPET) did not predict 30 day mortality, post-operative MI, or cardiac arrest.94,95 It should be noted that a relatively low number of primary outcome events limited the statistical power of the analysis.
Recommendation Table 6 — Recommendations for pre-operative assessment of frailty and functional capacity
Recommendations
Classa
Levelb
In patients aged ≥70 years and scheduled to undergo intermediate- or high-risk NCS, frailty screening should be considered using a validated screening tool.84–87,90,91
IIa
B
Continued
ESC Guidelines
3849


<!-- PAGE 25 -->

### Page 25

4.3. Electrocardiography
The 12-lead ECG is a widely available, simple, and inexpensive tool that is able to semi-quantitatively assess cardiac risk (e.g. Q waves indicative of previous MI), and detect unknown CV conditions requiring therapy (e.g. atrial ﬁbrillation [AF] or AV-block).97–99 It is recommended to obtain a pre-operative 12-lead ECG in patients who are aged ≥65 years or have known CVD, CV risk factors, or symptoms suggestive of cardiac disorders, and scheduled to undergo intermediate- or high-risk surgery. It is not recommended to routinely obtain a pre-operative ECG in low-risk patients undergoing lowrisk NCS.100
Comparison with previous ECG recordings is helpful whenever relevant abnormalities are identiﬁed. Pre-operative recording of
ECG also enables identiﬁcation of intra- and post-operative ECG
changes.
4.4. Biomarkers
As the peri-operative risk for cardiac complications depends on the presence and extent of cardiac disease, widely available and simple biomarkers that detect and quantify essential prognostic aspects of cardiac involvement may aid in the evaluation. High-sensitivity cardiac troponin T/I (Hs-cTn T/I) quantiﬁes myocardial injury, and BNP and
NT-proBNP quantify haemodynamic cardiac wall stress (Figure 4).
Adjusting risk assessments according to self-reported ability to climb two ﬂights of stairs should be considered in patients referred for intermediate- or high-risk NCS.94
IIa
B
© ESC 2022
NCS, non-cardiac surgery.
aClass of recommendation.
bLevel of evidence.
0
1
hs-cTn
STEP 1
STEP 2
2
Days
ECG
Before NCS
After NCS
NCS
Δ hs-cTn
If no measurements 
available before NCS
Δ hs-cTn
Δ hs-cTn
PMI
=
If Δ hs-cTn ≥ ULN
STEP 3
ECG
Echo
Clinical assessment
+
+
Identify the cause of PMI
PMI
hs-cTn hs-cTn
Figure 4 Recommended measurements to assess and detect the risk of post-operative cardiac complications. ECG, electrocardiogram; hs-cTn, highsensitivity cardiac troponin; PMI, peri-operative myocardial infarction/injury; ULN, upper limit of normal. In patients scheduled to undergo intermediate- or high-risk surgery, pre-operative risk assessment is complemented by ECG, hs-cTn, and BNP/NT-proBNP. An absolute increase in hs-cTn concentration of more than the ULN on days 1 or 2 after surgery compared to the pre-operative level is deﬁned as PMI.109–111 In the absence of a pre-operative hs-cTn T/I
concentration, a very high hs-cTn T/I concentration on day 1 (e.g. more than ﬁve-times the ULN) or a relevant change from day 1 to day 2 (absolute increase or decrease more than the ULN vs. day 1) would also achieve a reliable diagnosis of PMI. Detection of PMI should trigger ECG recording and detailed clinical evaluation for PMI work-up and therapy. The differential diagnosis of PMI according to the fourth universal deﬁnition of MI is discussed in Section 8. The ESC
0/1/2 h algorithm has not been validated for the peri-operative setting and cannot be used here.


<!-- PAGE 26 -->

### Page 26

Both Hs-cTn T/I and BNP/NT-proBNP complement clinical assessment and ECG in risk prediction.9,52,53,101–103 Hs-cTn T/I and, to a lesser extent, BNP/NT-proBNP concentrations are higher in patients with stress-induced myocardial ischaemia vs. those without,
and very low hs-cTn T/I concentrations achieve a very high negative predictive value to rule out myocardial ischaemia.104–107
Several large prospective studies have shown that both hs-cTn T/I
and BNP/NT-proBNP have high and incremental prognostic value for peri-operative cardiac complications, including CV death, cardiac arrest, acute HF, and tachyarrhythmias. In a cohort of nearly 1000
subjects undergoing major elective NCS, individuals with preoperative hs-cTn T concentrations of .14 ng/L had an in-hospital mortality of 6.9% vs. 1.2% in patients with hs-cTn T concentrations
≤14 ng/L (P , 0.001; AUC 0.81).53 In a large prospective cohort study including 10 402 patients from 16 centres, NT-proBNP improved risk predication beyond the RCRI.52 Among 1923 patients undergoing NCS, NT-proBNP outperformed both RCRI and echocardiographic parameters in the prediction of peri-operative CV
events.103 Overall, hs-cTn T/I and BNP/NT-proBNP seem to have comparable accuracy in the prediction of cardiac complications.52,53,98–103,108 However, Hs-cTn T/I has four advantages over
BNP/NT-proBNP: (i) it is more widely available; (ii) it is less expensive; (iii) if normal, it enables acute MI to be ruled out in the preceding days; and (iv) availability of pre-operative hs-cTn T/I concentration enables accurate diagnosis of PMI on Day 1 after surgery.109–111
See Section 8 for more details on diagnosis and treatment of PMI.
B-type natriuretic peptide/NT-proBNP has two advantages. First,
if elevated, evidence from randomized controlled screening studies performed outside the peri-operative setting has supported the concept that BNP/NT-proBNP-triggered cardiac work-up and intensiﬁcation of therapy improve outcomes.112,113 Second, HF is a frequently undiagnosed condition in the elderly population most often undergoing NCS.47,114 Interpreting BNP/NT-proBNP concentrations as quantitative markers of HF with evolving rule-in cut-offs may facilitate detection of HF, optimal intra-operative monitoring,
and initiation or optimization of HF therapy after surgery.114
To date, there is insufﬁcient evidence in support of other CV biomarkers for this speciﬁc indication.115,116
4.5. Non-invasive and invasive procedures
4.5.1. Resting transthoracic echocardiography
In large retrospective cohorts, routine pre-operative TTE before high-risk NCS did not reduce the risk of post-operative MACE or provide more information than clinical risk models.120–122 Poor exercise tolerance, abnormal ECG, suspected new or signiﬁcant
CVDs without follow-up within the last 90 days, unexplained dyspnoea, or coexisting clinical risk factors are appropriate indications for TTE.123,124 Pre-operative TTE provides information on three main risk markers for post-operative cardiac events:
LV dysfunction, VHDs, and cardiomyopathies. Left ventricular systolic dysfunction is an important predictor of post-operative
HF.125
However,
low ventricular ejection fraction is a
borderline independent predictor of major post-operative CV
complications.126–128
Pre-operative FOCUS examination—with a hand-held ultrasound device for the assessment of murmurs, haemodynamic instability,
ventricular function, and dyspnea—may impact patient management by improving the diagnostic accuracy of clinical assessment, and help to triage candidates for standard TTE, plan surgery and anaesthesia technique, and with post-operative monitoring.129–131 However,
current evidence remains mostly conﬁned to uncontrolled or retrospective observational studies with no clear beneﬁts on the outcome,
despite a favourable impact on peri-operative management.130,132 In a multicentre randomized trial, preliminary results showed that preoperative FOCUS signiﬁcantly reduced all-cause mortality.133
Notably, because of the lack of spectral Doppler capabilities, the
FOCUS examination is only accurate for assessing main structural and functional abnormalities.
Patients with diastolic dysfunction are usually old, more hypertensive, obese, diabetic, and likely to have AF or chronic renal disease.
Several studies with different clinical end-points have underlined
Recommendation Table 7 — Recommendations for pre-operative risk assessment—electrocardiography and biomarkers
Recommendations
Classa
Levelb
In patients who have known CVD or CV risk factors (including age ≥65 years), or symptoms or signs suggestive of CVD it is recommended to obtain a pre-operative 12-lead ECG before intermediate- and high-risk NCS.97–99
I
C
In patients who have known CVD, CV risk factors (including age ≥65 years), or symptoms suggestive of CVD it is recommended to measure hs-cTn T or hs-cTn I before intermediate- and high-risk NCS, and at 24 h and
48 h afterwards.53,105–107,109–111,117
I
B
Continued
In patients who have known CVD, CV risk factors
(including age ≥65 years), or symptoms suggestive of CVD, it should be considered to measure BNP
or NT-proBNP before intermediate- and high-risk
NCS.52,104,112–114
IIa
B
In low-risk patients undergoing low- and intermediate-risk NCS, it is not recommended to routinely obtain pre-operative ECG, hs-cTn T/I,
or BNP/NT-proBNP concentrations.109,111,117–119
III
B
© ESC 2022
BNP, B-type natriuretic peptide; CV, cardiovascular; CVD, cardiovascular disease; ECG,
electrocardiogram; hs-cTn I, high-sensitivity cardiac troponin; hs-cTn T, high-sensitivity cardiac troponin T; NCS, non-cardiac surgery; NT-proBNP, N-terminal pro-BNP; ULN,
upper limit of normal.
Abnormal ECG: pathological Q wave, ST-T wave changes, non-sinus rhythm, left bundle branch block. Abnormal pre-operative hs-cTn T/I: more than ULN. Age, sex, and known cardiac disease should also be considered when interpreting the pre-operative concentration.98
Abnormal BNP: ≥35 pg/mL; abnormal NT-proBNP: ≥125 pg/mL. BNP/NT-proBNP
should be interpreted as quantitative markers of heart failure, and also take into account age, sex, obesity, and known cardiac disease.52,114 Please note that age, renal dysfunction, and obesity are important confounders in the age group in which measurement of BNP/NT-proBNP is recommended, while sex has less impact.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
3851


<!-- PAGE 27 -->

### Page 27

the association of diastolic dysfunction with post-operative adverse events, including pulmonary oedema, AF, and mortality.134–138 A
meta-analysis including 3876 patients undergoing NCS found preoperative diastolic dysfunction to be an independent risk factor for pulmonary oedema, congestive HF, and MI after surgery.139
However, a recent retrospective study, including 7312 patients,
showed no association between the degree of diastolic dysfunction and in-hospital mortality or hospital length of stay in
NCS patients.140 Awareness of diastolic dysfunction or high LV ﬁlling pressure (e.g. pulmonary hypertension, left atrial volume, E/e′ ratio)
seems necessary to optimize peri-operative patient management;
however, evidence does not support screening for diastolic dysfunction.
4.5.2. Stress tests
4.5.2.1. Exercise stress test
Physical exercise, using a treadmill or bicycle ergometer, provides an estimate of functional capacity, evaluates blood pressure (BP) and heart rate response, and detects myocardial ischaemia through pathological ST-segment changes with poor sensitivity (61–73%)
and speciﬁcity (60–80%).146 An exercise stress test alone should only be considered a valuable alternative to diagnose obstructive
CAD if non-invasive imaging tests are unavailable.146 An exercise stress test is of no diagnostic value in patients with pre-existing
ST-segment abnormalities (i.e. left bundle branch block, paced rhythm, Wolff–Parkinson–White [WPW] syndrome, ≥0.1 mV
ST-segment depression on resting ECG, or taking digitalis). In addition, an exercise test is unsuitable for patients with limited exercise capacity, owing to their inability to reach their target heart rate.
Therefore, an exercise stress test alone should only be considered a valuable alternative to diagnose obstructive CAD if non-invasive imaging tests are unavailable, or for assessing functional capacity when clinical history is ambiguous.146
4.5.2.2. Stress imaging
The use of stress imaging is appropriate for risk assessment in patients with clinical risk factors and poor functional capacity.147,148
The choice of the test is driven by local expertise. Selection, optimal,
and safe performance of stress imaging should comply with related guidelines and recommendations.146,148,149 Stress imaging is not recommended in patients undergoing urgent surgery or with an unstable clinical condition. Evidence on the role of stress imaging for peri-operative risk prediction and patient management is largely based on inducible ischaemia by pharmacological stress testing, although no evidence indicates the superiority of pharmacological stress to exercise stress imaging in patients who are able to perform an adequate level of physical exercise. Several studies and meta-analyses have consistently deﬁned clinical utility of pharmacological stress imaging for peri-operative risk assessment in patients undergoing NCS.150–154 Although RCTs related to post-operative outcome are lacking, there are large-scale prospective studies showing a risk-adjusted association of stress imaging results with perioperative cardiac complications.155–157
Studies and meta-analyses have demonstrated similar prognostic value of stress echocardiography and myocardial perfusion imaging for peri-operative risk assessment with slightly higher negative predictive value of stress echocardiography,152 but the overall accuracy varies with ischaemic heart disease (IHD) prevalence.151 A
moderate-to-large perfusion defect on either test is highly sensitive for post-operative cardiac events.152,158 Normal stress imaging exams without resting abnormalities have high negative predictive value.159,160 However, positive predictive value of stress imaging for peri-operative cardiac events is relatively low and requires conﬁrmation by other tests.150,152,161
In a recent retrospective study including 4494 patients, dobutamine stress echocardiography (DSE) provided modest incremental predictive value for peri-operative CV complications over clinical variables and was found to be useful as part of a stepwise approach in the risk stratiﬁcation of patients undergoing intermediate- to highrisk NCS.157 The strongest predictors of post-operative adverse events determined so far are signiﬁcant ischaemia (more than four ventricular segments) during DSE, ischaemic threshold (60% of agepredicted maximal heart rate), and a history of congestive HF.162,163
A negative DSE without resting wall motion abnormality has excellent negative predictive value, even when target heart rate cannot be achieved despite an aggressive DSE regimen.164 In asymptomatic patients if functional capacity is unknown, stress echocardiography also enables dynamic evaluation of LV systolic and diastolic function;
valvular diseases such as aortic valve stenosis (AS), mitral valve stenosis (MS), and hypertrophic obstructive cardiomyopathy; and pulmonary hypertension
165 However, the role of DSE for risk
Recommendation Table 8 — Recommendations for transthoracic echocardiography
Recommendations
Classa
Levelb
TTE is recommended in patients with poor functional capacityc and/or high NT-proBNP/
BNP,d or if murmurs are detected before high-risk
NCS, in order to undertake risk-reduction strategies.121,124,127,141–143
I
B
TTE should be considered in patients with suspected new CVD or unexplained signs or symptoms before high-risk NCS.59,124,125
IIa
B
TTE may be considered in patients with poor functional capacity, abnormal ECG, high
NT-proBNP/BNP,d or ≥1 clinical risk factor before intermediate-risk NCS.126–128
IIb
B
To avoid delaying surgery, a FOCUS exam performed by trained specialists may be considered as an alternative to TTE for pre-operative triage.129,130,132,133,144
IIb
B
Routine pre-operative evaluation of LV function is not recommended.122,145
III
C
© ESC 2022
BNP, B-type natriuretic peptide; CVD, cardiovascular disease; ECG, electrocardiogram;
FOCUS, focused cardiac ultrasound; LV, left ventricular; NCS, non-cardiac surgery;
NT-proBNP,
N-terminal pro-B-type natriuretic peptide;
TTE,
transthoracic echocardiography.
aClass of recommendation.
bLevel of evidence.
cSee Section 4.2.
d≥125 pg/mL/35 pg/mL.


<!-- PAGE 28 -->

### Page 28

estimation in non-ischaemic heart diseases before NCS has yet to be studied.
Myocardial perfusion imaging is particularly suitable if patients have poor acoustic windows for DSE. Meta-analyses of patients undergoing major NCS have demonstrated that, compared with ﬁxed defects, reversible perfusion defects were associated with higher risk of cardiac death or non-fatal MI. The risk of cardiac events correlates with the extent of reversible perfusion abnormalities (severe: .20%
of myocardium). Normal myocardial perfusion imaging in high-risk patients identiﬁes a low-risk subgroup comparable with those without clinical risk factors for adverse cardiac outcomes.154,159,160
Stress cardiac magnetic resonance (CMR) imaging and late gadolinium enhancement are also accurate tools for detection of IHD
and prognostication.166
4.5.3. Angiography
4.5.3.1. Coronary computed tomography angiography
Coronary computed tomography angiography (CCTA) is recommended as an initial test for diagnosing CAD in stable patients with a low clinical likelihood or no previous diagnosis of CAD, and characteristics associated with a high likelihood of good image quality.146 In addition, CCTA is recommended as an alternative to invasive coronary angiography (ICA) for excluding non-ST-segment elevation acute coronary syndrome (NSTE-ACS) when there is low-to-intermediate likelihood of CAD, and when cardiac troponin and/or ECG are normal or inconclusive.98 The practical utility of
CCTA is reduced when a high coronary calcium score is present.167
In patients undergoing NCS, the role of pre-operative CCTA to rule out CAD has been investigated in small- to medium-sized observational studies.
The
Coronary
Computed
Tomographic
Angiography and Vascular Events in Noncardiac Surgery Patients
Cohort Evaluation (Coronary CTA VISION) trial prospectively investigated the incremental predictive value of CCTA over RCRI in
955 patients with a history of or risk factors for CAD, or a history of congestive HF undergoing NCS.168 Coronary computed tomography angiography improved the risk estimation for the primary outcome of post-operative CV death and non-fatal MI within 30 days,
although CCTA was associated with more than ﬁve times inappropriate risk overestimations among patients not experiencing the primary outcome. The predictive value of CCTA further improved when associated with non-invasive functional testing, such as myocardial perfusion imaging, with a positive and negative predictive value of 50% (95% CI, 21–79) and 100% (95% CI, 79–100),
respectively.161
Coronary computed tomography angiography associated with additional functional assessment of coronary stenosis with fractional
ﬂow reserve (FFR) with computed tomography (CT) was able to identify functionally severe coronary stenosis in 57% of the asymptomatic patients with no history of cardiac disease undergoing carotid endarterectomy (CEA).169 In 135 asymptomatic patients with no history of cardiac disease undergoing peripheral vascular surgery,
pre-operative FFR with CT facilitated the identiﬁcation of functionally severe coronary stenosis in 53% of the patients. These patients beneﬁted from further revascularization, with a 1 year lower rate of CV death and MI.170
4.5.3.2. Invasive coronary angiography
There is a lack of information from RCTs relating to the usefulness of
ICA in patients scheduled for NCS. Adopting an ICA assessment may also cause an unnecessary and unpredictable delay in an already planned surgical intervention, and adding an independent procedural risk to the overall risk. Despite the fact that CAD may be present in a signiﬁcant number of patients requiring NCS, indications for preoperative coronary angiography and revascularization are similar to angiography indications in the non-surgical setting.98,146,171
Pre-operative treatment of patients with myocardial ischaemia, either medically or with intervention, is recommended.
Recommendation Table 9 — Recommendations for stress imaging
Recommendations
Classa
Levelb
Stress imaging is recommended before high-risk elective NCS in patients with poor functional capacityc and high likelihood of CADd or high clinical risk.e,146,156–158
I
B
Stress imaging should be considered before high-risk NCS in asymptomatic patients with poor functional capacity,d and previous PCI or
CABG.147
IIa
C
Stress imaging may be considered before intermediate-risk NCS when ischaemia is of concern in patients with clinical risk factors and poor functional capacity.d,152,157,158
IIb
B
Stress imaging is not recommended routinely before NCS.
III
C
© ESC 2022
CABG,
coronary artery bypass graft;
CAD,
coronary artery disease;
ECG,
electrocardiogram; LV, left ventricular; NCS, non-cardiac surgery; PCI, percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
cPhysical capacity based on Duke Activity Status Index (DASI) or inability to climb two
ﬂights of stairs.
dPre-test probability .15% based on age, sex, and nature of symptoms, or two or more risk factors for CVD (dyslipidaemia, diabetes, hypertension, smoking, family history of
CVD), or resting ECG changes (Q wave or ST-segment/T wave changes), or LV
dysfunction suggestive of CAD.146
eOne or more clinical risk factor according to the Revised Cardiac Risk Index (ischaemic heart disease, cerebrovascular disease, history of congestive heart failure, serum creatinine level .2 mg/dL, diabetes requiring insulin therapy).46,47
Recommendation Table 10 — Recommendations for coronary angiography
Recommendations
Classa
Levelb
It is recommended to use the same indications for
ICA and revascularization pre-operatively as in the non-surgical setting.98,146
I
C
CCTA should be considered to rule out CAD in patients with suspected CCS or biomarker-negative NSTE-ACS in case of low-to-intermediate clinical likelihood of CAD, or in patients unsuitable for non-invasive functional testing undergoing non-urgent, intermediate-, and high-risk NCS.
IIa
C
Continued
ESC Guidelines
3853


<!-- PAGE 29 -->

### Page 29

### 5 General risk-reduction strategies

5.1. Cardiovascular risk factors and lifestyle interventions
Control of CV risk factors—including BP, dyslipidaemia, and diabetes
—is important before NCS. For pre-operative management of BP
and diabetes, see Sections 6.8 and 6.13, respectively.
While lifestyle modiﬁcations before intervention reduce the risk of several peri-operative complications, the impact on CV complications has not been adequately explored. Of the lifestyle changes recommended before surgery,
smoking cessation is the best documented in RCTs. Smoking has been associated with a higher rate of post-operative complications at 30 days.173,174 Reviews of
RCTs have shown an effect of smoking cessation up to 6 months post-operatively, with a clear reduction in any post-operative complications by hazard ratio (HR) 0.42 (95% CI, 0.27–0.65), particularly wound infections (HR, 0.43; 95% CI, 0.21–0.85).173,175 Regarding timing of cessation, reviews of observational studies have shown consistent associations with better surgical outcome for cessation .4
weeks before surgery, with each additional week resulting in a further improvement of 19%.176–178
Pre-operative exercise programmes have only been tested in small
RCTs, and recent reviews have shown a relative risk (RR) reduction in post-operative complications of 67% (RR, 0.33; 95% CI, 0.17–
0.61).179 Referral to a pre-operative exercise programme may be considered for patients scheduled for major or complex elective surgery.176,179,180 Weight reduction of obese patients immediately prior to surgery is not recommended.
5.2. Pharmacological
5.2.1. Beta-blockers
Beta-blockers reduce myocardial oxygen consumption by reducing contractile force and heart rate. Beta-blockers are also effective antiarrhythmic agents. In addition, some beta-blockers such as metoprolol have an effect on acute inﬂammatory responses by inhibiting neutrophil hyperactivation in acute settings.184 These properties mean that beta-blockers have been some of the most frequently tested cardioprotective agents in patients undergoing NCS. Several
RCTs have evaluated the effects of peri-operative beta-blockade on clinical end-points in patients with different risk proﬁles (see
Supplementary data, Section 3.1.1.). Type, dosing and titration, timing of initiation, duration of beta-blocker therapy, type of surgery, and risk proﬁle of subjects signiﬁcantly differ between studies, making comparisons complex.
The question about pre-surgery initiation of beta-blockers has been a matter of intense controversy (see Supplementary data, Section
3.1.1.1). The largest and latest trial on the topic, the Perioperative
Ischemic Evaluation (POISE-1) trial, enrolled 8351 patients with or at risk of atherosclerotic disease, and not on beta-blockers before
NCS. Patients were randomized to extended-release metoprolol succinate 200 mg daily or placebo 185 Treatment was initiated 2–4 h before surgery and maintained for 30 days. The primary outcome
(composite of CV death, non-fatal MI, and non-fatal cardiac arrest)
was signiﬁcantly lower in the metoprolol arm (5.8% vs. 6.9% [P =
0.04]). Metoprolol was associated with signiﬁcant reductions in MIs,
coronary revascularizations, and AF. However, the incidences of allcause death, stroke, and clinically signiﬁcant hypotension or bradycardia were signiﬁcantly higher in the metoprolol arm. Post hoc analysis showed that hypotension carried the greatest attributable risk of death and stroke 186 The high dose of extended metoprolol might have played a role in the adverse events seen at follow-up.
Several meta-analyses, systematic reviews, and observational studies have also been reported (see Supplementary data, Table S4).187–
189 Overall, initiation of beta-blockers before NCS was not associated with a net clinical beneﬁt in most analyses, but they might be beneﬁcial in patients with high CV risk proﬁles or who are undergoing high-risk surgical interventions (including vascular interventions).188,190–192 When oral beta-blockade is initiated in CAD
patients who undergo NCS, the use of atenolol or bisoprolol as a
ﬁrst choice may be considered.190,193–195
In patients who are on chronic beta-blocker therapy before surgery, it is recommended to maintain these in the peri-operative period. Increased mortality following pre-operative beta-blocker withdrawal has been reported in ﬁve observational studies.190,196–199
Interruption of this therapy for .2 days post-operatively may double the risk of AF.200
Post-operative tachycardia should initially lead to treatment of the underlying cause— such as hypovolaemia, pain, blood loss, or infection—rather than simply increasing the beta-blocker dose. When beta-blockers are indicated, the optimal duration of the perioperative beta-blockade cannot be derived from randomized trials.
According to a meta-analysis of RCTs including 14 967 patients,
beta-blockers can reduce the risk of post-operative AF after
NCS;201 however, this comes at the cost of an increased risk of bradycardia, hypotension, and stroke.187
Recommendation Table 11 — Recommendations for lifestyle and cardiovascular risk factors
Recommendations
Classa
Levelb
Smoking cessation .4 weeks before NCS is recommended to reduce post-operative complications and mortality.181,182
I
B
Control of CV risk factors—including blood pressure, dyslipidaemia, and diabetes—is recommended before NCS.173,176–178,183
I
B
© ESC 2022
CV, cardiovascular; NCS, non-cardiac surgery.
aClass of recommendation.
bLevel of evidence.
Pre-operative ICA may be considered in stable
CCS patients undergoing elective surgical CEA.172
IIb
B
Routine pre-operative ICA is not recommended in stable CCS patients undergoing low- or intermediate-risk NCS.
III
C
© ESC 2022
CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiography; CEA, carotid endarterectomy; ICA, invasive coronary angiography; NCS, non-cardiac surgery; NSTE-ACS, non-ST-segment elevation acute coronary syndrome.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 30 -->

### Page 30

The ultra-short-acting beta-blockers esmolol and landiolol have the theoretical advantages of very fast onset of effects and short halflives. Notably, landiolol may lower BP to a lower extent than esmolol. Evidence of prevention of AF with landiolol after NCS is less robust and inconsistent than in the context of cardiac surgery.202–205 The timing of the initiation of beta-blockers to prevent
AF remains unclear, with most prophylactic regimens using shortacting agents being started intra-operatively.187
5.2.2. Amiodarone
Amiodarone is the most frequently used agent for prevention of post-operative AF,206 with a risk reduction of 58% in NCS in a meta-analysis evaluating different antiarrhythmic drugs (AADs), but may induce relevant non-cardiac side effects.201 In another meta-analysis, amiodarone (oral or intravenous [i.v.]) and betablockers were equally effective in reducing post-operative AF.207 In another prospective RCT, a combination of beta-blocker plus amiodarone outperformed beta-blockers alone in reducing postoperative AF.208 It should be noted that the two latter studies were undertaken in patients undergoing cardiac surgery.
Overall, while preventive amiodarone seems to reduce the incidence of AF, the clinical beneﬁts associated with its routine use are unclear.
5.2.3. Statins
Despite the wide-ranging use of statins in patients undergoing surgery, RCTs assessing the effects of initiating statin therapy during the peri-operative period are scarce. This should be viewed separately from patients already on statin therapy. The long-term use of statins in patients with CVD or high risk of CVD is well-established.40
Observational data suggest a potential beneﬁt of statins in the peri-operative phase. In a large, retrospective, and observational cohort, which included 180 000 veterans undergoing NCS, the use of statins on the day of or the day after surgery was associated with a reduction in mortality (RR, 0.82; 95% CI, 0.75–0.89).209 Similar results were seen in a retrospective cohort study using hospital discharge and pharmacy records.210 Although both studies used propensity matching to reduce bias, these analyses are prone to confounding, especially when discharge and pharmacy records are used.
As such, RCTs give a more reliable effect estimation, for example: the
Lowering the Risk of Operative Complications Using Atorvastatin
Loading Dose (LOAD) trial studied 648 statin-naïve patients, of whom 24% had a history of CVD and 49% had diabetes.211 In this randomized, placebo-controlled trial, patients received a loading dose of atorvastatin 80 mg within 18 h before surgery followed by
40 mg daily for 7 days. Use of atorvastatin did not reduce the risk of major events (all-cause mortality, non-fatal MI, or stroke at 30
days [HR, 0.87; 95% CI, 0.60–1.26; P = 0.46]). However, the trial was underpowered to draw deﬁnite conclusions. In addition, several meta-analyses have shown ambiguous results and most studies are of a limited size with less than 100 patients.212,213
Therefore, routine peri-operative initiation of statin therapy is not recommended. However, in patients in whom statin use is already indicated, treatment should be considered peri-operatively,
particularly in patients scheduled for high-risk surgery (e.g. vascular surgery).
5.2.4. Renin–angiotensin–aldosterone system inhibitors
Data on peri-operative use of renin–angiotensin–aldosterone system
(RAAS) inhibitors are inconclusive. The majority of studies suggest that continued use of RAAS inhibitors is associated with a higher risk of peri-operative hypotension and, as a consequence, higher use of vasopressors and inotropes. Furthermore, intra-operative hypotension and its duration is associated with end-organ damage,
including kidney injury, myocardial damage, and stroke.214 In a small trial of 275 subjects, randomized to either continuation of their angiotensin-converting-enzyme inhibitors (ACEIs) or omission of the ﬁnal pre-operative ACEI dose, patients randomized to omission of the last dose before surgery experienced intra-operative hypotension less frequently (76/137 [55%] vs. 95/138 [69%]) and vasopressor use was less likely.215 On the other hand, post-operative hypertension was more frequent in the omission group. Furthermore, in an observational cohort study consisting of 4802 patients undergoing
NCS and using an ACEI or angiotensin receptor blocker (ARB), discontinuation of these drugs in the 24 h before surgery was associated with a lower risk of intra-operative hypotension (adjusted RR, 0.80;
95% CI, 0.72–0.93; P , 0.001), and associated with a reduction in the composite end-point consisting of all-cause mortality, stroke, and MI
(adjusted RR, 0.82; 95% CI, 0.70–0.96; P = 0.01);216 8% of the patients in this cohort were diagnosed with HF, in whom RAAS inhibitors are the cornerstone of medical therapy. A systematic review,
including nine studies (ﬁve RCTs and four cohort studies), revealed that withholding ACEI/ARB on the morning of surgery was not associated with mortality or MACE;217 however, it did conﬁrm that withholding therapy was associated with less intra-operative hypotension
(OR, 0.63; 95% CI, 0.47–0.85). If an ACEI/ARB is withheld prior to
NCS, it should be restarted as soon as possible in order to prevent unintended long-term omission. No data on peri-operative effects of angiotensin receptor neprilysin inhibitors (ARNI) exist, but hypotension is more common compared with patients on ACEI.218
Some important RCTs in this ﬁeld are ongoing: the impact of renin–
angiotensin system inhibitors continuation vs. discontinuation on outcome after major surgery trial STOPorNOT219 (NCT03374449),
and the POISE-3 trial (NCT03505723) are both assessing a hypotension-avoidance strategy vs. a hypertension-avoidance strategy on the risk of vascular death and major vascular events in patients who are followed for 30 days after NCS.
5.2.5. Calcium channel blockers
The effects of calcium channel blockers (CCBs) on the balance between myocardial oxygen supply and demand makes them theoretically suitable for risk-reduction strategies. The relevance of randomized trials assessing the peri-operative effects of CCBs is limited by their small size, lack of risk stratiﬁcation, and the absence of systematic reporting of cardiac death and MI. A meta-analysis pooled 11 randomized trials totalling 1007 patients.220 Treatment with CCBs signiﬁcantly reduced the number of episodes of myocardial ischaemia and supraventricular tachycardia (SVT) in the pooled analyses. However, the decrease in mortality and MI reached statistical signiﬁcance only when both end-points were combined
(RR, 0.35; 95% CI, 0.08–0.83; P = 0.02). In contrast, a matched casecontrol study of 1000 patients undergoing acute or elective
ESC Guidelines
3855


<!-- PAGE 31 -->

### Page 31

aortic aneurysm surgery suggested that dihydropyridine use was independently associated with an increased incidence of peri-operative mortality.221 These observational data may be biased by the indications for the use of CCBs. In patients already on CCBs,
particularly in those with vasospastic angina, it is recommended to continue CCBs during the peri-operative period, but withholding the dose on the day of surgery in order to avoid post-operative hypotension.
5.2.6. Alpha-2 receptor agonists
Alpha-2 receptor agonists reduce post-ganglionic noradrenaline output and might therefore reduce catecholamine surge during surgery. The European Mivazerol trial randomized 1897 patients with IHD who underwent intermediate- or high-risk NCS.222
Mivazerol did not decrease the incidence of death or MI in the whole population. However, it did decrease the incidence of death in a subpopulation of 904 patients undergoing vascular surgery.222
The international Peri-Operative ISchemic Evaluation 2 (POISE-2)
trial randomized 10 010 patients undergoing NCS to clonidine or placebo.223 Clonidine did not reduce the rate of death or nonfatal MI in general or in patients undergoing vascular surgery (RR,
1.08; 95% Cl, 0.93–1.26; P = 0.29), but it did increase the risk of clinically important hypotension (RR, 1.32; 95% Cl, 1.24–1.40;
P , 0.001) and non-fatal cardiac arrest (RR, 3.20; 95% Cl, 1.17–
8.73; P = 0.02).
5.2.7. Diuretics
Diuretics are frequently used in patients with hypertension or HF. In general, therapy for treatment of hypertension should be continued to the day of surgery and resumed orally when possible. However,
the beneﬁt for continuing diuretics as antihypertensive therapy is unclear, and alternative antihypertensive agents may be considered. In
HF, the dosage of diuretics should be adjusted well in advance for an optimal ﬂuid balance before surgery, and to avoid ﬂuid retention or dehydration.
The possibility of electrolyte disturbance should be considered in any patient receiving diuretics. Hypokalaemia is reported to occur in up to 36% of patients undergoing surgery (mostly NCS).224,225
Special attention should be given to patients prone to developing arrhythmias. Any electrolyte disturbance, especially hypokalemia and hypomagnesaemia, should be corrected in due time before surgery.
Acute pre-operative repletion in asymptomatic patients may be associated with more risks than beneﬁts; thus, minor asymptomatic electrolyte disturbances should not delay acute surgery.
In the peri-operative period, volume status in patients with HF
should be carefully monitored and optimized by loop diuretics or
ﬂuids. However, retrospective data suggest that intra-operative prescription of diuretics may increase the risk of acute kidney injury
(AKI) after NCS.226
5.2.8. Ivabradine
Heart rate is an independent and modiﬁable risk factor for periprocedural MI (and maybe death) after NCS. Ivabradine is a negative chronotropic agent without associated hypotensive effect, and is therefore a possible alternative to beta-blockers. However, there are few studies about the value of ivabradine for high-risk patients undergoing NCS.227 The small (78 patients) PeRi-OperaTivE
CardioproTection
With
Ivabradine in
Non-cardiac
Surgery
(PROTECTIN) (NCT04436016) trial is ongoing.
5.2.9. Sodium–glucose co-transporter-2 inhibitors
The use of sodium–glucose co-transporter-2 (SGLT-2) inhibitors is increasing, due to proven CV beneﬁts for patients with type-2 diabetes mellitus (DM) and a beneﬁcial effect on outcomes for patients with HF and renal insufﬁciency. Euglycaemic diabetic ketoacidosis
(EDKA) is a rare but serious complication. While the incidence was not signiﬁcantly increased with SGLT-2 inhibitors in RCTs, several case reports indicate that EDKA may occasionally occur after
(non-cardiac) surgery in patients on SGLT-2 inhibitors.228 A systematic review indicated that precipitating factors include diabetes medication changes, diet modiﬁcations, and intercurrent illnesses.229 The
US Food and Drug Administration (FDA) recommends interrupting
SGLT-2 inhibitor therapy for at least 3–4 days before scheduled surgery and to be vigilant for symptoms related to EDKA, prompting measurement of ketones.
Recommendation Table 12 — Recommendations for pharmacological treatment
Recommendations
Classa
Levelb
Initiation
In patients with an indication for statins, it should be considered to initiate statins peri-operatively.
IIa
C
Pre-operative initiation of beta-blockers in advancec of high-risk NCS may be considered in patients who have two or more clinical risk factors,d in order to reduce the incidence of peri-operative myocardial infarction.188,190–192
IIb
A
Pre-operative initiation of beta-blocker in advance of NCS may be considered in patients who have known CAD or myocardial ischaemia.e,230–232
IIb
B
Routine initiation of beta-blocker peri-operatively is not recommended.185,187,189,233,234
III
A
Continuation
Peri-operative continuation of beta-blockers is recommended in patients currently receiving this medication.190,196–199
I
B
In patients already on statins, it is recommended to continue statins during the peri-operative period.235
I
B
In patients with stable HF, peri-operative continuation of RAAS inhibitors may be considered.
IIb
C
Continued


<!-- PAGE 32 -->

### Page 32

5.3. Peri-operative handling of antithrombotic agents
Management of patients taking antithrombotic agents and needing surgery or an invasive procedure should consider patient- and procedure-related risk of bleeding and thrombosis. Furthermore, the pharmacokinetic and pharmacodynamic characteristics of the antithrombotic drugs in use must be considered (Tables 7 and 8). The risk of bleeding associated with different types of interventions is shown in Table 9. Risk estimation and decision-making in patients requiring long-term antithrombotic therapy is challenging, since relevant associations exist between peri-operative antithrombotic management, bleeding, thrombotic events (MI and stroke), and mortality.6,11–13 Thus,
interdisciplinary risk assessment ahead of the intervention is crucial, in order to classify the patient-related ischaemic and bleeding risks (e.g. cardiologist, neurologist, vascular specialist, and haematologist), and the surgical risk (surgeon and anaesthesiologist).
Information on timing of intervention by indicated duration of antithrombotic therapy should be communicated with the patient and treating general physician.
5.3.1. Antiplatelets
5.3.1.1. Single antiplatelet therapy
In patients taking aspirin for primary prevention, the risk of ischaemic events is low and aspirin can be withdrawn prior to NCS. Permanent discontinuation should be considered post-operatively in low- and moderate-risk atherosclerotic cardiovascular disease (ASCVD) risk patients and/or in patients with high bleeding risk based on negative/neutral trials and the recommendations for primary prevention of CVD in the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.40,241
Due to the better risk–beneﬁt ratio, aspirin has an established role for the long-term prevention of new cardiovascular events in patients with established CVD.242ThePOISE-2 trial isthelargest, randomized,placebocontrolled trial of peri-operative aspirin in patients undergoing NCS.243
Interruption
In patients without HF, withholding RAAS
inhibitors on the day of NCS should be considered to prevent peri-operative hypotension.215,216
IIa
B
For patients on diuretics to treat hypertension,
transient discontinuation of diuretics on the day of
NCS should be considered.236
IIa
B
It should be considered to interrupt SGLT-2
inhibitor therapy for at least 3 days before intermediate- and high-risk NCS.
IIa
C
© ESC 2022
b.p.m., beats per minute; CAD, coronary artery disease; HF, heart failure; NCS,
non-cardiac surgery; RAAS, renin–angiotensin–aldosterone system; RCRI, Revised
Cardiac Risk Index; SGLT-2, sodium-glucose co-transporter 2.
aClass of recommendation.
bLevel of evidence.
cIdeally at least 1 week before surgery, starting with a low dose with dose titration for target heart rate.185,197,230,237 The target is a resting heart rate 60–70 b.p.m.191 with a systolic blood pressure .100 mmHg.230,238
dIschaemic heart disease, cerebrovascular disease, renal insufﬁciency, or diabetes mellitus, according to the RCRI score.239
eTreatment should ideally be initiated between 30 and (at least) 2 days before surgery,
starting at a low dose, and should be continued post-operatively.197,230,237
Table 7
Pharmacokinetic and pharmacodynamic characteristics of antiplatelets
ASA
Clopidogrel
Prasugrel
Ticagrelor
Cangrelor
Eptiﬁbatide
Tiroﬁban
Target
(type of blockade)
COX-1
(irreversible)
P2Y12
(irreversible)
P2Y12
(irreversible)
P2Y12
(reversible)
P2Y12
(reversible)
GPIIB/IIIa
(reversible)
GPIIB/IIIa
(reversible)
Application
Oral
Oral
Oral
Oral i.v.
i.v.
i.v.
Time to Cmax
0.5–1.0 h
2 h
(after 600 mg LD)a
0.5 h
(after 60 mg
LD)a
0.5 h
(after 180 mg
LD)a
2 min
5 min
5 min
Prodrug
No
Yes
Yes
No
No
No
No
Bioavailability (%)
≏50
≏50
80
36
100
100
100
Drug interactions
NSAIDs
(in particular ibuprofen +
naproxen)
CYP3A4, CYP3A5,
or CYP2C19
inhibitors or inducers
CYP3A4/A5
and CYP2B6
inhibitor
CYP3A4
inducers or inhibitors
None
None
None
Plasma half-life
20 min
0.5–1 h (active metabolite)
0.5–1 h (active metabolite)
6–12 h
3–6 min
2.5–2.8 h
1.2–2 h
Duration of action after last dose
7–10 days
3–10 daysb
7–10 daysb
3–5 days
1–2 h
4 h
8 h
Renal clearance of the active metabolite (%)
NR
NR
NR
NR
58
≏50
65
Dose regimen o.d.
o.d.
o.d.
b.i.d.
Bolus,
infusion
Bolus,
infusion
Bolus,
infusion
© ESC 2022
ASA, acetylsalicylic acid; b.i.d., twice a day; Cmax, maximum serum concentration; i.v., intravenous; LD, loading dose; NR, non-relevant; o.d., once a day.
aTime to Cmax for may be delayed by 8 h or more following a dose of opiate.
bDepending on response status.
ESC Guidelines
3857


<!-- PAGE 33 -->

### Page 33

Table 8
Pharmacokinetic and pharmacodynamic characteristics of oral anticoagulants
Warfarin
Phenprocoumon
Apixaban
Dabigatran
Edoxaban
Rivaroxaban
Target
(type of blockade)
VKORC1
VKORC1
FXa
FIIa
FXa
FXa
Application
Oral
Oral
Oral
Oral
Oral
Oral
Time to Cmax
2–6 h
1.52 h + 1.52
3–4 h
1.25–3 h
1–2 h
2–4 h
Prodrug
No
No
No
Yes
No
No
Bioavailability (%)
.95
100
50
6.5
62
80–100
Drug interactions
CYP2C9,
CYP2C19,
CYP2C8,
CYP2C18,
CYP1A2,
CYP3A4,
vitamin K
CYP2C9, CYP2C8,
vitamin K
CYP3A4 inhibitors or inductors,
P-glycoprotein inhibitors or inductors
P-glycoprotein inhibitors or inductors
P-glycoprotein inhibitors
CYP3A4 inhibitors or inductors,
P-glycoprotein inhibitors or inductors
Plasma half-life
36–48 h
≏100 h
12 h
12–14 h
6–11 h
7–11 h (11–13 h in the elderly)
Duration of action after last dose
≏5 days
≏7 days
24 h
24 h
24 h
24 h
Renal clearance of the active metabolite (%)
Non-renal
Non-renal
27
85
37–50
33
Dose regimen
Adjusted according to INR
Adjusted according to INR
b.i.d.
b.i.d.
o.d.
o.d./b.i.d.
© ESC 2022
b.i.d., twice a day; Cmax, maximum serum concentration; FIIa, factor IIa; FXa, factor Xa; INR, International normalized ratio; LD, loading dose; NOAC, non-vitamin K antagonist oral anticoagulant; o.d., once a day; VKORC1, vitamin K epoxide reductase complex 1.
Table 9
Bleeding risk according to type of non-cardiac surgery
Surgery with minor bleeding risk
Surgery with low bleeding risk
(infrequent or with low clinical impact)
Surgery with high bleeding risk
(frequent or with signiﬁcant clinical impact)
• Cataract or glaucoma procedure
• Dental procedures: extractions (1–3 teeth), periodontal surgery, implant positioning, endodontic (root canal)
procedures, subgingival scaling/cleaning
• Endoscopy without biopsy or resection
• Superﬁcial surgery (e.g. abscess incision, small skin excisions/
biopsy)
• Abdominal surgery: cholecystectomy,
hernia repair, colon resection
• Breast surgery
• Complex dental procedures (multiple tooth extractions)
• Endoscopy with simple biopsy
• Gastroscopy or colonoscopy with simple biopsy
• Large-bore needles procedures (e.g.
bone marrow or lymph node biopsy)
• Non-cataract ophthalmic surgery
• Small orthopaedic surgery (foot, hand arthroscopy)
• Abdominal surgery with liver biopsy,
extracorporeal shockwave lithotripsy
• Extensive cancer surgery (e.g. pancreas,
liver)
• Neuraxial (spinal or epidural) anaesthesia
• Neurosurgery (intracranial, spinal)
• Major orthopaedic surgery
• Procedures with vascular organ biopsy
(kidney or prostate)
• Reconstructive plastic surgery
• Speciﬁc interventions (colon polypectomy,
lumbar puncture, endovascular aneurysm repair)
• Thoracic surgery, lung resection surgery
• Urological surgery (prostatectomy,
bladder tumour resection)
• Vascular surgery (e.g. AAA repair, vascular bypass)
© ESC 2022
AAA, abdominal aortic aneurysm.
Adapted from Steffel et al.240


<!-- PAGE 34 -->

### Page 34

The trial randomized 10 010 patients undergoing NCS with established CVD, or who were at increased CV risk, to aspirin or placebo.
Patients were stratiﬁed according to whether they had not been taking aspirin before the study or were already on aspirin; 33% of the patients had known vascular disease (23% CAD, 9% PAD, and 5%
stroke). Aspirin did not reduce the rates of death or non-fatal MI
at 30 days (7.0% vs. 7.1% in the placebo group [HR, 0.99; 95% CI,
0.86–1.15; P = 0.92]). Major bleeding was more common in the aspirin group than in the placebo group (4.6% vs. 3.8% [HR, 1.23; 95%
CI, 1.01–1.49; P = 0.04]). The primary outcome results were similar,
irrespective of whether or not patients had been taking aspirin before the study, and were also similar in patients with and without vascular disease.
In a post hoc analysis of 470 patients (,5%) who had undergone previous PCI, aspirin use was associated with a signiﬁcant reduction in death or MI (HR, 0.50; 95% CI, 0.26–0.95; P = 0.036) and MI alone
(HR, 0.44; 95% CI, 0.22–0.87; P = 0.021), while the risk of major or life-threatening bleeding was not signiﬁcantly increased in this setting.244 Although the analysis carries several limitations, it supports the perception that the ischaemic beneﬁt of peri-operative aspirin use outweighs the bleeding risk in patients with previous PCI.
Thus, among patients with previous PCI, in the absence of a very high bleeding risk, low-dose aspirin should be continued during the peri-operative period.
In patients undergoing transcatheter aortic valve implantation
(TAVI) who have no other indication for oral anticoagulant (OAC)
therapy, low-dose aspirin has been recommended as standard therapy by recent guidelines based on an RCT.245,246 There are no randomized data available assessing the withdrawal vs. continuation of aspirin in patients after TAVI on aspirin alone undergoing NCS.
If the bleeding risk outweighs the potential CV beneﬁt, aspirin should be discontinued. For patients with high peri-operative bleeding risk (e.g. undergoing spinal surgery or certain neurosurgical or ophthalmological operations) aspirin should be discontinued for at least 7 days.
On rare occasions, chronic coronary syndrome (CCS) patients might be on clopidogrel monotherapy due to the results of recent trials247 and the recommendations of the 2020 ESC Guidelines for
NCS-related bleeding risk
N
N
N
Patients on dual antiplatelet therapy p
Y
Y
Y
High bleeding risk related to NCS
High thrombotic risk:
PCI <1 month or 
ACS <3 months or
High risk of stent thrombosisa
Continue aspirin
(Class I)
Defer NCS
f
(Class I)
Time-sensitive NCS
Thrombotic risk
Recommendations
Continue DAPT
D
Ticagrelor: 3–5 d
:
ays a
Clopidogrel: 5 d
:
ays a
Prasugrel: 7 d
:
ays a
(Class I)
Bridge with GPI
or cangrelorc
Interrupt P2Y12
inhibitorb
(Class IIa/b)
Figure 5 Recommendations for management of antiplatelet therapy in patients undergoing non-cardiac surgery. ACS, acute coronary syndrome;
DAPT, dual antiplatelet therapy; GPI, glycoprotein IIb/IIIa inhibitors; PCI, percutaneous coronary intervention; N, no; NCS, non-cardiac surgery.
Y, yes; aHigh risk of peri-operative stent thrombosis deﬁned by at least one of the following: history of stent thrombosis under antiplatelet therapy,
reduced left ventricular ejection fraction (,40%), poorly controlled diabetes, severely impaired renal function/haemodialysis, recent complex PCI (i.e.
severely calciﬁed lesion, left main PCI, chronic total occlusion, bifurcational/crush technique, bypass graft PCI), or stent malapposition/residual dissection.
bTiming of resumption after interdisciplinary risk assessment as soon as possible (within 48 h) after surgery. cFor dosing, see Figure 7.
ESC Guidelines
3859


<!-- PAGE 35 -->

### Page 35

the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation;98 therefore, periprocedural management of clopidogrel-based single antiplatelet therapy
(SAPT) is required. Consensus has been reached that a short interruption of P2Y12 inhibitor monotherapy is recommended in patients at high risk of bleeding.
Patients treated with P2Y12 inhibitor monotherapy as part of a deescalation strategy after PCI/ACS, or due to a recent stroke, PAD, or aspirin intolerance, might require peri-operative management of this monotherapy.248–250 A careful interdisciplinary evaluation of perioperative bleeding vs. ischaemic risk is warranted in these situations,
and individual decisions based on the peri-operative bleeding and ischaemic risk (e.g. surgery under P2Y12 monotherapy, switching to aspirin, short interruption, or bridging in the peri-operative phase) may be applicable, although evidence for these different regimens is missing. It should be recognized that the effects of ticagrelor or clopidogrel monotherapy on haemostasis are considerably less than when they are combined with aspirin.
5.3.1.2. Dual antiplatelet therapy
P2Y12 inhibitors in addition to aspirin are recommended for patients after PCI.98,146 The frequency of major NCS in the ﬁrst year after PCI
is ≏4%; most frequently orthopaedic, abdominal, and vascular surgery.251 Other observational data report cumulative incidences of
NCS after PCI for 30 days, 6 months, and 1 year of 1%, 5%, and
9%, respectively.252
Observational studies have reported a substantial rate of MACE—
including cardiac death, MI, and stent thrombosis—ranging between
2–8%251,253,254 in PCI patients undergoing NCS, with a more than two-fold increased risk compared with non-stented patients.255,256
N
P2Y12 inhibitor interruption after PCI before elective non-cardiac surgerya
ACS at index PCI or other high ischaemic risk featuresb
Time from DAPT
initiation
Y
1 month
3 months
6 months
12 months
Class IIIc
Class IIad
Class Ie
Class IIIf
Class IIbg
Class IIah
Class Ii
Figure 6 P2Y12 inhibitor interruption after percutaneous coronary intervention before elective non-cardiac surgery. LoE, level of evidence; MI, myocardial infarction; N, no; PCI, percutaneous coronary intervention. Y, yes; aAvailability of 24 h cath-lab service is suggested in case of major surgery within 6
months in non-ACS/non-high-risk patients and within 12 months in ACS/high-risk patients. bHigh risk of peri-operative stent thrombosis deﬁned by at least one of the following: history of recurrent MI, history of stent thrombosis under antiplatelet therapy, reduced left ventricular ejection fraction
(,40%), poorly controlled diabetes, severely impaired renal function/haemodialysis, recent complex PCI (i.e. severely calciﬁed lesion, left main PCI, chronic total occlusion, bifurcational/crush technique, bypass graft PCI), stent malapposition/residual dissection. cClass III LoE C. dClass IIa LoE B 250,265, 266,267.
eClass I LoE A 268,146. fClass III LoE B 269. gClass IIb LoE B 270, 271. hClass IIa LoE B 272,273,274, 275, 276,277,278. iClass I LoE A 279, 280, 281, 98.


<!-- PAGE 36 -->

### Page 36

The proportion of risk attributable to underlying CVD or stent implantation remains uncertain.254 Risk factors for MACE after NCS
are: time from PCI to surgery, with the highest risk in the ﬁrst month;
primary PCI for ST-segment elevation myocardial infarction (STEMI);
dual antiplatelet therapy (DAPT) interruptions/discontinuation; and lesion characteristics, including ostial and distal lesions.252,257–259
Urgency of surgery is a further risk factor. The ESC/ESA classiﬁcation of NCS is a validated tool with which to predict the impact of the type of surgery on MACE.16
A meta-analysis of observational data indicated that discontinuation of clopidogrel for at least 5 days reduced the risk of reoperation for major bleeding by 50%, without increasing the risk of MACE or death.260 Other observational data indicate an increase in MACE with brief DAPT interruptions.261 However, these nonrandomized data may have been biased by the type and urgency of surgery.260 Of note, the prognosis of stent thrombosis appears to be worse than for de novo coronary occlusion (and depends on the site of stent deployment), and premature interruption of
DAPT in patients with recent coronary stent implantation is the strongest predictor for stent thrombosis.
The preferred management of patients on DAPT due to PCI is to delay elective NCS until completion of the full course of DAPT
(6 months after elective PCI and 12 months after ACS).98,146
However, several recent trials have indicated that shortening
DAPT duration to 1–3 months after implantation of modern DES
is associated with acceptable rates of MACE and stent thrombosis in low- and moderate-risk patients. Based on these newer data, it is recommended to delay time-sensitive NCS until a minimum of
1 month of DAPT treatment has been effectuated. In high-risk CV
patients, for example due to an ACS, a DAPT duration of at least
3 months should be considered before time-sensitive NCS.
See Figure 5 for the recommended duration of DAPT before
Clopidogrel
(LD 300 mg),
followed by 75 mg o.d.
Infusion tirofiban/eptifibatidea or restart tirofiban/eptifibatideb ofiban/e ofiban/e
Infusion cangrelorc or restart cangrelorb on cangr on cangr
NCS
Prasugrel
Clopidogrel/
ticagrelor
Clopidogrel
(LD 300 mg),
followed by 75 mg o.d.
STOP
START
Prasugrel
Clopidogrel/
ticagrelor
NCS
Day
Low dose ASA throughout
-7
-6
-5
-4
-3
-2
-1
-4–6 h
0
FU/
discharge
+4–6 h
Day
-7
-6
-5
-4
-3
-2
-1
-1–6 h
0
FU/
discharge
+4–6 h
Low dose ASA throughout
Figure 7 Bridging with intravenous antiplatelet agents. ASA, acetylsalicylic acid; FU, follow-up; LD, loading dose; NCS, non-cardiac surgery; o.d., once a day. aTiroﬁban: 0.1 µg/kg/min; if creatinine clearance ,50 mL/min, adjust to 0.05 µg/kg/min. Eptiﬁbatide: 2.0 µ/kg/min; if creatinine clearance is ,50 mL/
min, adjust to 1.0 µg/kg/min. bUntil oral P2Y12 inhibitor therapy is possible. cInitiate within 72 h from P2Y12 inhibitor discontinuation at a dose of 0.75 μg/
kg/min for a minimum of 48 h and a maximum of 7 days.
ESC Guidelines
3861


<!-- PAGE 37 -->

### Page 37

time-sensitive NCS. Once the P2Y12 inhibitor has been discontinued,
surgery should be performed while the patient is still on aspirin.
Indications for long-term
DAPT
have recently emerged.
Long-term DAPT (beyond 1 year) with clopidogrel, prasugrel, or ticagrelor in addition to aspirin should be considered in patients with high ischaemic risk, and may be considered in patients with moderate ischaemic risk, both in the absence of increased risk of major or lifethreatening bleeding.98 When NCS is required, discontinuation of
P2Y12 inhibitors is recommended for 3–7 days (depending on the
P2Y12 inhibitor) for these additional indications for DAPT.
5.3.1.3. De-escalation of antiplatelet effect
The management of antiplatelet therapy in patients who have undergone recent PCI and are scheduled for NCS should be discussed by the surgeon and cardiologist, so that the balance between the risk of life-threatening surgical bleeding on antiplatelet therapy—best understood by the surgeon—and the risk of life-threatening stent thrombosis due to premature DAPT discontinuation—best understood by the cardiologist—can be considered (Figure 5 and Figure 6).
An increased risk of MACE as a consequence of (major) bleeding also needs to be taken into consideration when balancing risk.
When time-sensitive surgery cannot be postponed and be performed with the recommended DAPT on board, de-escalation or shortening of DAPT is recommended. This may encompass either a switch from the more potent P2Y12 inhibitors prasugrel or ticagrelor to clopidogrel, or cessation of aspirin and use of prasugrel or ticagrelor monotherapy. If neither of these options is deemed to be sufﬁcient, premature discontinuation of the P2Y12 inhibitor may be considered. If discontinuation is required, ticagrelor needs to be withheld for 3–5 days, clopidogrel for 5 days, and prasugrel for 7
days prior to surgery.262–264
Whenever possible, in patients with an indication for DAPT, surgery should be performed without discontinuation of aspirin. Aspirin might be discontinued as a last measure only with very high bleeding risk and a comparably low ischaemic risk. However, such surgical procedures should be performed in hospitals where 24/7 catheterization laboratories are available so as to treat patients immediately in case of peri-operative ischaemic events.
Although generally not recommended, bridging with i.v. compounds (eptiﬁbatide/tiroﬁban or cangrelor) might be applicable in rare cases when DAPT cannot be interrupted before NCS (e.g. in patients with very high risk of stent thrombosis, history of recurrent MI,
recent PCI) (see Figure 5 and Figure 7).282
For patients receiving antiplatelet therapy, who have excessive or life-threatening peri-operative bleeding, transfusion of platelets is recommended as a bail-out strategy. However, ticagrelor and its active metabolite may also inhibit aggregation of transfused platelets.
Experimental data indicate that administration of albumin binds ticagrelor and reduces its inhibitory effect on platelet aggregation.283 A
monoclonal antibody fragment (PB2452) for neutralizing ticagrelor is in development but is not yet clinically available.284
5.3.1.4. Platelet function guided peri-operative management of antiplatelet therapy
Platelet function testing has several theoretical advantages in the peri-operative setting, including: (i) the identiﬁcation of patients on antiplatelet therapy who are at increased risk of surgery-related bleeding; (ii) individualized timing of elective surgery after antiplatelet therapy cessation; and (iii) guiding therapy in bleeding complications.285–287 However, neither the optimal assay nor a universal cutoff value associated with bleeding has been deﬁned and validated in patients undergoing NCS.
Recommendation Table 13 — Recommendations for use of antiplatelet therapy in patients undergoing noncardiac surgery
Recommendations
Classa
Levelb
It is recommended to delay elective NCS until 6
months after elective PCI and 12 months after an
ACS.264,271
I
A
After elective PCI, it is recommended to delay time-sensitive NCS until a minimum of 1 month of
DAPT treatment has been given.266,271,288,289
I
B
In patients with a recent PCI scheduled for NCS, it is recommended that management of antiplatelet therapy is discussed between the surgeon,
anaesthesiologist, and cardiologist.
I
C
In high-risk patients with a recent PCI (e.g. STEMI
patients or high-risk NSTE-ACS patients), a DAPT
duration of at least 3 months should be considered before time-sensitive NCS.
IIa
C
Continuation of medication
In patients with a previous PCI, it is recommended to continue aspirin peri-operatively if the bleeding risk allows.244
I
B
Recommended time interval for drug interruption before
NCS
If interruption of P2Y12 inhibitor is indicated, it is recommended to withhold ticagrelor for 3–5
days, clopidogrel for 5 days, and prasugrel for 7
days prior to NCS.262–264
I
B
For patients undergoing high bleeding risk surgery
(e.g. intracranial, spinal neurosurgery, or vitreoretinal eye surgery), it is recommended to interrupt aspirin for at least 7 days pre-operatively.
I
C
In patients without a history of PCI, interruption of aspirin at least 3 days before NCS may be considered if the bleeding risk outweighs the ischaemic risk, to reduce the risk of bleeding.243
IIb
B
Resumption of medication
If antiplatelet therapy has been interrupted before a surgical procedure, it is recommended to restart therapy as soon as possible (within 48 h)
post-surgery, according to interdisciplinary risk assessment.
I
C
© ESC 2022
ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy; NCS, non-cardiac surgery; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; PCI,
percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 38 -->

### Page 38

5.3.2. Oral anticoagulants
Approximately one in four patients taking anticoagulant therapy will require a
surgical or invasive procedure within
2 years.290
Peri-operative management of oral anticoagulant (OAC) therapy depends on surgery- and patient-related factors and the speciﬁc OAC
agent (vitamin K antagonist [VKA] or a non-vitamin K antagonist oral anticoagulant [NOAC]). See Figure 8 for a summary of recommendations for the management of OACs in patients undergoing NCS.
Surgery-related factors include urgency of the intervention and the procedure-related bleeding risk (reﬂecting both the risk of bleeding occurrence and the risk of adverse outcome if bleeding occurs)
(see Table 8). Procedures where mechanical compression is unfeasible carry a high risk of serious bleeding complications.
Patient-related factors include age, individual thrombotic risk,
history of bleeding complications, renal function, concomitant medication, comorbidity, etc. Patients requiring a reversal agent need careful monitoring of haemostatic parameters and evaluation of thrombotic and bleeding risk in the peri-operative phase, as reversal might be insufﬁcient or prothrombotic rebound might occur. In the latter case, an interdisciplinary decision should be made with regard to early resumption of anticoagulation treatment.
5.3.2.1. Vitamin K antagonists
Three drugs are currently used: warfarin (half-life 36–48 h), acenocoumarol (half-life 12 h), and phenprocoumon (half-life 100 h).
5.3.2.1.1. Vitamin K antagonists in patients with mechanical heart valves. Maintenance of therapeutic international normalized ratio
(INR) is crucial for patients with mechanical heart valves (MHVs).
N
N
N
Patients on oral anticoagulation therapy
Y
Y
Y
High bleeding risk NCS
VKA
VKA/
NOAC
Continue with INR
in lower level or short interruption
(Class I)
Bridging is not recommended 
(Class III)
Short interruptione
(Class I)
Bridging is not recommended 
(Class III)
Interrupte
(Class I)
Bridging is not recommended 
(Class III)
Defer NCSd
Possible to defer NCS
High thrombotic risk
Selected patients with very high thromboembolic riskb
Mechanical heart valvea
NOAC
VKA
NCS-related bleeding risk
Thrombotic risk
Recommendations
Bridgec
(Class IIa)
Bridgec
(Class IIb)
Figure 8 Recommendations for management of oral anticoagulation therapy in patients undergoing non-cardiac surgery. CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke, vascular disease, age 65–74 years, sex category (female); N, no; NCS, non-cardiac surgery; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist; VTE, venous thromboembolism. Y, yes; aMechanical aortic valve replacement (AVR) and any thromboembolic risk factor (atrial ﬁbrillation, previous thromboembolism, severe left ventricular dysfunction, hypercoagulable state), or older-generation mechanical AVR, or a mechanical mitral valve replacement. bRecent stroke ,3 months, high risk of VTE recurrences (e.g.
antithrombin 3 deﬁciency or protein C and/or S deﬁciency), left ventricular apex thrombus, atrial ﬁbrillation with a very high stroke risk. cBridging with unfractionated heparin or low molecular weight heparin. dE.g. .3 months after stroke/VTE. eFor NOAC management during NCS, see Figures 9 and 10.
ESC Guidelines
3863


<!-- PAGE 39 -->

### Page 39

Minor surgical procedures and procedures where bleeding is easily controlled can be performed without VKA interruption. The INR
should be monitored and maintained at the lower level of the therapeutic range. Major surgical procedures needing INR ≤1.5 require
VKA interruption, and heparin bridging should be considered.
However, the evidence to support bridging therapy is limited and derived from cohort studies with poor or no comparator groups.291
Furthermore, the current-generation mechanical prosthetic valves in the aortic position are associated with a lower risk of thromboembolism compared with the older ones.291 Randomized controlled trials of bridging vs. no bridging therapy for patients with AF who do not have an MHV have shown higher risk of bleeding without a change in incidence of thromboembolic events, and increasing concerns have been raised that bridging therapy exposes patients to higher bleeding risks without reducing the risk of thromboembolism.292,293 The recently published PERI-OP trial compared bridging therapy vs. placebo in patients with either an MHV, AF, or atrial ﬂutter who required interruption of OAC therapy for surgery, and found no signiﬁcant beneﬁt for post-operative dalteparin bridging to prevent major thromboembolism.294 The results were consistent for the AF (n = 1166) and MHVs groups (n = 350). Therefore, in patients with MHVs with a low risk of thromboembolism (e.g. mechanical bileaﬂet aortic valve in patients with sinus rhythm), bridging may not be needed. In patients with MHVs with a high risk of thromboembolism (mechanical aortic valve replacement [AVR] and any thromboembolic risk factor, or an older-generation mechanical
AVR, or a mechanical mitral or tricuspid valve replacement), bridging with heparin should be considered during the peri-operative time interval when the INR is subtherapeutic (Figure 8). In all situations,
the risks of bleeding should be weighed against the beneﬁts of thromboembolism prevention.
Intravenous unfractionated heparin (UFH) is the only heparin treatment approved for bridging in patients with MHVs. Subcutaneous low molecular weight heparin (LMWH), although used off-label, has supplanted the use of UFH as a bridging therapy, owing to the lower incidence of thrombocytopenia, greater convenience, more predictable dose–response relationship, and signiﬁcant cost saving resulting from outpatient administration. A meta-analysis of nine studies of 1042 patients with MHVs showed no differences between LMWH and UFH in the risks of thromboembolic events or major bleeding events.295
When LMWH is used, it should be given at a therapeutic dose twice a day and adjusted for renal impairment, when applicable. Anti-factor
Xa (FXa) activity monitoring with target levels from 0.5–1.0 U/mL may be useful when the dosage may be difﬁcult to determine (e.g. in patients with renal dysfunction or obesity). Vitamin K antagonist bridging strategies are shown in Supplementary data, Figure S2.
5.3.2.1.2. Vitamin K antagonists for atrial ﬁbrillation/venous thromboembolism. In patients using VKA for AF or venous thromboembolism (VTE), invasive procedures with a low bleeding risk can be performed without VKA interruption.296–299 The INR
should be monitored and maintained at the lower level of the therapeutic range. When interruption is necessary due to high bleeding risk procedures, the BRIDGE trial in AF patients showed that 3–5
days of warfarin interruption without bridging was superior to heparin bridging, having the same incidence of arterial and venous thromboembolism and signiﬁcantly lower incidence of major bleeding.292
Bridging therapy may be considered for patients with a high thrombotic risk (i.e. AF with CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke, vascular disease, age 65–74 years, sex category [female]) score .6, recent cardioembolic stroke ,3 months, or high risk of VTE recurrence,
weighing the risk of bleeding against the risk of thromboembolism291,294,300 (see Supplementary data, Figure S3).
5.3.2.1.3. Restarting vitamin K antagonists after invasive procedures or surgery. Patients who have interrupted VKA treatment before surgery should restart the OAC 12–24 h after the invasive procedure, if the bleeding is well-controlled and gastric and intestinal reabsorption have been re-established. The restarting dose should be the maintenance dose plus a boosting dose of 50% for 2 days.
Patients managed with bridging therapy should start LMWH or
UFH together with VKA 24 h after surgery, if the bleeding is wellcontrolled and maintained, until the INR has reached the therapeutic range. In patients undergoing surgery with a high bleeding risk, therapeutic dose LMWH should be delayed for 48–72 h after haemostasis has been secured.
5.3.2.1.4. Reversal of vitamin K antagonists. Reversal of VKA can be managed with vitamin K, prothrombin complex concentrates
(PPCs), and plasma administration. Vitamin K (from 2–10 mg depending on the INR value) can be used orally, with a predictable reduction in INR in 18–24 h or i.v. (in 25–50 mL normal saline over 15–30 min) for more rapid INR reduction (4–6 h). It should be noted that coagulation factors can still be below normal despite
INR normalization, which means that bleeding risk might not yet be normalized. In patients needing reversal for immediate major surgery, PPCs or plasma should be used. Four-factor PPCs are the preferred option301 and are dosed on the basis of INR and body weight
(INR 2–4 at 25 U/kg, INR 4–6 at 35 U/kg, INR .6 at 50 U/kg, with a maximum dose of 5000 U at 100 kg of body weight). When fourfactor PPCs are unavailable, three-factor PPCs or plasma may be used. Patients requiring a reversal agent need careful monitoring of haemostatic parameters and evaluation of thrombotic and bleeding risks in the peri-operative phase, as reversal might be insufﬁcient or a prothrombotic rebound might occur. In the latter case, an interdisciplinary decision should be made with regard to early resumption of anticoagulation treatment.
5.3.2.2. Non-vitamin K antagonist oral anticoagulants
Four drugs are currently used: dabigatran (factor IIa inhibitor), apixaban, rivaroxaban, and edoxaban (FXa inhibitors). The pharmacokinetic and pharmacodynamic characteristics of these drugs are shown in Table 8.
5.3.2.2.1. Unplanned surgery in patients on non-vitamin K antagonist oral anticoagulants and reversal for emergency procedures.
When an urgent surgical intervention is required, it is recommended that NOAC therapy is immediately interrupted. Peri-operative management of NOAC therapy in speciﬁc procedural settings and suggested strategies for potential reversal of NOAC anticoagulant effect are shown in Figures 9–1199,240,302 (see Supplementary data,
Table S5).


<!-- PAGE 40 -->

### Page 40

Whereas the open-label prospective trial testing the speciﬁc reversal agent idarucizumab in patients on dabigatran enrolled participants experiencing acute major bleeding or requiring urgent surgical intervention,303 the trial with the reversal agent andexanet alpha for
FXa inhibitors included only patients with acute major bleeding under therapy, but not those requiring urgent surgery.304 However,
the off-label use of andexanet alpha in life-threatening situations requiring an immediate intervention may be considered, bearing in mind that andexanet alpha non-speciﬁcally binds all FXa inhibitors,
which may have important implications for further treatment, including the administration of UFH or LMWH.240 When speciﬁc reversal agents are unavailable, prothrombin complex concentrate (PCC) or activated PCC should be considered, although there is a lack of evidence on their efﬁcacy and safety for emergency procedures in patients taking a NOAC.290,305 Performing immediate or urgent surgery under general rather than spinal anaesthesia is prudent, in order to reduce the risk of epidural haematoma.
Prior to unplanned surgery, the full panel of coagulation blood tests (see Supplementary data, Table S6) should be obtained in order to assess the patient’s coagulation status. The indication for reversal
(and/or non-speciﬁc haemostatic) agents is primarily governed by the patient’s clinical presentation, but initial assessment of coagulation
Stopping and re-initiation of NOAC therapy in elective NCS according to the periprocedural risk of bleeding in patients with normal renal function
NOAC type
Frequency of NOAC administration
-3
-2
-1
NCS
1
2
STOP
START
Days
Rivaroxaban
Edoxaban
Low 
bleeding risk NCS
Dabigatran
Apixaban
Twice daily
Once daily
Twice daily
Once daily
No NOAC
No bridgingc
Twice daily
Once daily
Twice daily
Consider restarting
NOAC in the evening
Once daily
Rivaroxaban
Edoxaban
Dabigatran
Apixaban
Consider restarting
NOAC in the evening
No NOAC
No bridgingc
Rivaroxaban
Edoxaban
High 
bleeding risk NCS
Dabigatran
Apixaban
Twice daily
Once daily
Restart
NOAC
≥48–72 h after surgery
No NOAC
Consider prophylactic dose heparin post-operatively
No NOAC
No bridgingc
Rivaroxaban
Edoxaban
Dabigatran
Apixaban
No NOAC
No bridgingc
Restart
NOAC
≥48–72 h aft a er surgery
No NOAC
Consider prophylactic dose heparin post-operatively
Rivaroxaban
Edoxaban
Minor 
bleeding risk NCS
Dabigatran
Apixaban
Twice daily
Once daily
Twice daily
Once daily
May skip the evening dosea
Once dailyb
Twice daily
Once daily
Twice daily
Restart
NOAC ≥6 h after surgery
Once daily
Rivaroxaban
Edoxaban
Dabigatran
Apixaban
Restart
NOAC ≥6 h after surgery
May skip the a
evening dosea
Figure 9 Peri-operative management of non-vitamin K antagonist oral anticoagulant according to the periprocedural risk of bleeding. NCS, non-cardiac surgery; NOAC, non-vitamin K antagonist oral anticoagulant. aIn patients/circumstances favouring NOAC accumulation (e.g. renal dysfunction, older age, concomitant medication), the NOAC should be paused 12–24 h earlier. bIn patients on rivaroxaban or edoxaban taking the dose in the evening, the evening dose may be skipped. cNOACs have predictable weaning of the anticoagulant effect. Owing to the increase in bleeding risk associated with bridging, it is generally not recommended to use bridging in patients taking NOACs. Very few circumstances when bridging with heparin may be considered in patients taking a NOAC
include high thromboembolic risk conditions, such as: 1) patients with a recent (within 3 months) thromboembolic event (stroke, systemic embolism, or
VTE); 2) patients who experienced a thromboembolic event during previous interruption of NOAC therapy.
ESC Guidelines
3865


<!-- PAGE 41 -->

### Page 41

status may have important implications for treatment in the next few hours or days. Speciﬁc coagulation tests such as diluted thrombin time (dTT) or ecarin clotting assay for dabigatran and antiFXa chromogenic assays for FXa inhibitors, and the assessment of
NOAC plasma levels, may help in interpreting routine coagulation tests and waning of anticoagulant effect.240
5.3.2.2.2. Planned interventions in patients on non-vitamin K oral anticoagulants. Invasive surgical interventions may require temporary discontinuation of NOAC therapy, while many less-invasive procedures with a relatively low risk of bleeding may be performed under minimally interrupted or uninterrupted NOAC therapy (Figure 9).240
5.3.2.2.3. Bridging. In patients taking a NOAC, peri-operative bridging using heparin or LMWH was associated with increased risk of bleeding without reduction in thromboembolic events.290,306–308
Therefore, when NOAC interruption is required for surgery, bridging is not recommended, except in a few high thrombotic risk circumstances (see Figure 9). However, post-operative thromboprophylaxis with LMWH should be considered in patients in whom NOAC therapy cannot be quickly restarted. In patients receiving bridging with
LMWH, monitoring of antiFXa activity and dose adjustment to a target level of 0.5–1.0 U/mL may be considered.
5.3.2.2.4. Laboratory testing before surgery. Pre-operative assessment of anticoagulation status in patients on a NOAC undergoing planned surgery provides a direct assessment of residual drug concentration. Shorter NOAC interruption time intervals in patients undergoing low-risk procedures may result in mildly or moderately elevated NOAC levels, as seen in the Perioperative Anticoagulant
Use for Surgery Evaluation (PAUSE) trial,309 whereas creatinine clearance ,50 mL/min, standard NOAC dose (compared with reduced dose), body weight ,70 kg, and female sex were associated with elevated NOAC levels among patients undergoing high-risk surgery.
Apixaban, rivaroxaban, edoxaban
Low bleeding risk NCS
High bleeding risk NCS
Dabigatran
Low bleeding risk NCS
Renal function
High bleeding risk NCS
≥24 h
≥80
≥48 h
≥36 h
50–79
≥72 h
≥24 h
≥48 h
30–49
≥96 h
Not indicated
15–29
Not indicated
≥36 h
<15
No formal indication for use
≥48 h
Timing of last NOAC dose before elective NCS
according to renal function
Minor bleeding risk NCS
No peri-operative bridging with UFH/LMWH
(estimated GFR, mL/min)
No fo f rmal indication for use f
Low and high bleeding risk NCS
Perform intervention at NOAC through level (i.e. 12 h or 24 h after last intake for twice or once daily regimens, respectively). Resume same day or latest next day.
Figure 10 Timing of last non-vitamin K antagonist oral anticoagulant dose before elective NCS according to renal function. GFR, glomerular ﬁltration rate;
LMWH, low molecular weight heparin; NCS, non-cardiac surgery; NOAC, non-vitamin K antagonist oral anticoagulant; UFH, unfractionated heparin.


<!-- PAGE 42 -->

### Page 42

The use of amiodarone, verapamil, or diltiazem was also associated with elevated pre-operative NOAC levels in the prospective Per-procedural
Concentration of Direct Oral Anticoagulants (CORIDA) trial.310
Importantly, elevated NOAC levels were not found to be independently associated with bleeding complications.309,310
The evidence base for modifying the duration of pre-operative
NOAC interruption time intervals according to residual NOAC plasma levels is unavailable, and ‘safe’ plasma levels of NOACs for different procedures are largely unknown. The time-based NOAC
interruption (Figure 9) appears safe in most patients undergoing surgery.311,312 When NOACs are interrupted for .72 h, the likelihood of any residual NOAC plasma levels is very low.309,310
5.3.2.2.5. Considerations for speciﬁc procedures. Before interventions that carry a very high risk of bleeding—such as spinal or epidural anaesthesia, or lumbar puncture requiring intact haemostasis-–interruption of NOACs for up to ﬁve half-lives (i.e. 3 days for FXa inhibitors or
4–5 days for dabigatran) should be considered, whereas NOACs can usually be restarted 24 h after the intervention.313,314
Dental procedures are generally considered to be associated with minor bleeding risk, and adequate local haemostasis is usually easily achieved. Hence, most dental procedures can be performed in an outpatient setting, with uninterrupted NOAC (or a single skipped dose) and using speciﬁc local haemostatic measures (such as the application of oxidized cellulose or absorbable gelatine sponge, sutures,
Strategy for potential f
reversal of non-vitamin K oral anticoagulants efff ect f
Perform NCS
f
Perform NCS
f
Targeted haemostatic measu
T
res
Perform NCS
f
N
N
N
Y
Y
Y
Degree of urgency
Last intake of N
k
OACs >12 hc
Check for blood coagulation tests:
f full coagulation panel (PT,T aPT
,
T,T antiFXa
,
, dT
,
T,T et
,
c.)
Measurement of NOAC plasma levels, if
,
available a
Recheck coagulation panel if last NOAC intake <12 h,
k c
or initial coagulation tests pathological,
or clinically relevant bleeding situation
Surgery defef rral for 12 h,
f c
if safef , or after normalization
,
of coagulation parameterse
Reversal of NOAC depending on:
Surgery defef rral as for planned f
procedures, if sa
,
fe (see Figu f
re 8)
Surgery-related bleeding risk and agent availability a
d
IMMEDIATE
A
i.e. within mi
.
nutes
URGENT
i.e. within hours
.
a
TIME-SENSITIVE
i.e. within d
.
ays a
b
Step 1
Urgr ency
Step 2
Blood coagulation
Step 3
Timing last NOA
O C
Step 4
NCS
Step 5
Recheck blood coagulation
Figure 11 Suggested strategy for potential reversal of non-vitamin K oral anticoagulants effect. aPTT, activated partial thromboplastin time; dTT, diluted thrombin time; FXa, factor Xa; N, no; NOAC, non-vitamin K antagonist oral anticoagulant; PT, prothrombin time; UFH, unfractionated heparin. Y, yes;
aConditions that are potentially life-threatening or that may threaten the survival of limb or organ. bConditions that can be managed and procedure delayed for several days. c.24 h in case of signiﬁcantly reduced renal function (i.e. eGFR ,50 mL/min). dIf speciﬁc reversal agent is unavailable, consider non-speciﬁc haemostatic agents (prothrombin complex concentrate [PCC] or activated PCC [aPCCs]). Idarucizumab has only been tested in patients undergoing urgent surgery. Andexanet has not been tested in patients requiring urgent surgery. Andexanet binds all FXa inhibitors (including UFH) nonspeciﬁcally. eUpon re-check.
ESC Guidelines
3867


<!-- PAGE 43 -->

### Page 43

tranexamic acid mouthwash or compressive gauze). Most professional statements on dental surgery advise uninterrupted NOAC,
but these recommendations are mostly based on expert consensus,
while some studies are currently ongoing.315–317
5.3.2.2.6. When to restart non-vitamin K antagonist oral anticoagulants after interventions. In general, NOAC can be restarted
6–8 h after interventions with rapid and complete haemostasis.
When the bleeding risk with full-dose anticoagulation resumption outweighs the risk of thromboembolic events, therapeutic anticoagulation may be postponed to .48–72 h after the procedure,
using prophylactic post-operative thromboprophylaxis until the resumption of full-dose NOAC is deemed safe (Figure 9).240
Post-operative heparin administration should also be considered in patients unable to take oral therapy. Off-label use of reduced-dose
NOACs to attenuate the risk of post-operative bleeding is not recommended, as there is no evidence informing such an approach.
5.3.2.3. Combination therapy (antiplatelet and anticoagulant)
In general, according to the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery
(EACTS), dual antithrombotic therapy should be adopted in most patients with AF and a recent PCI.99 Elective surgery should be postponed until the period when antiplatelet therapy can be safely discontinued in combination therapy (6 months after elective PCI or
12 months after ACS).268 Peri-operative handling of NOACs should follow the above recommendations (Figures 9 and 10). In urgent/
emergency surgery with high bleeding risk, operative measures to reduce bleeding and/or reversal strategies of anticoagulation might be applied. In patients receiving combination therapy for other indications (e.g. TAVI and AF), according to recent trial results, antiplatelet therapy can be safely discontinued before NCS.318 In patients receiving low-dose OACs as part of a vascular protection strategy, rivaroxaban should be paused for at least 24 h before surgery and resumed according to the post-operative bleeding risk.
Recommendation Table 14 — Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery
Recommendations
Classa
Levelb
Interruption of anticoagulation
When an urgent surgical intervention is required,
it is recommended that NOAC therapy is immediately interrupted.
I
C
Idarucizumab should be considered in patients on dabigatran and requiring urgent surgical intervention with intermediate to high bleeding risk.303
IIa
B
Continued
In non-minor bleeding risk procedures in patients using a NOAC, it is recommended to use an interruption regimen based on the NOAC
compound, renal function, and bleeding risk.310,311
I
B
For interventions with a very high risk of bleeding,
such as spinal or epidural anaesthesia, interruption of NOACs for up to ﬁve half-lives and re-initiation after 24 h should be considered.
IIa
C
When speciﬁc reversal agents are unavailable,
PCC or activated PCC should be considered for reversing NOAC effects.
IIa
C
If an urgent surgical intervention is required,
speciﬁc coagulation tests and assessment of
NOAC plasma levels should be considered to interpret routine coagulation tests and waning of anticoagulant effect.
IIa
C
Continuation of medication
In minor bleeding risk surgery and other procedures where bleeding can be easily controlled, it is recommended to perform surgery without interruption of OAC therapy.240,296–299
I
B
LMWH is recommended, as an alternative to
UFH, for bridging in patients with MHVs and high surgical risk.295
I
B
In patients using NOACs, it is recommended that minor bleeding risk procedures are performed at trough levels (typically 12–24 h after last intake).
I
C
For patients with mechanical prosthetic heart valves undergoing NCS, bridging with UFH or
LMWH should be considered if OAC interruption is needed and patients have: (i) mechanical AVR
and any thromboembolic risk factor; (ii)
old-generation mechanical AVR; or (iii)
mechanical mitral or tricuspid valve replacement.
IIa
C
Bridging of OAC therapy is not recommended in patients with low/moderate thrombotic risk undergoing NCS.290,292,293,306–308,311
III
B
Start/resumption of medication
If bleeding risk with resumption of full-dose anticoagulation outweighs the risk of thromboembolic events, postponing therapeutic anticoagulation 48–72 h after the procedure may be considered, using post-operative thromboprophylaxis until resumption of full OAC
dose is deemed safe.
IIb
C
Use of reduced-dose NOAC to attenuate the risk of post-operative bleeding is not recommended.
III
C
© ESC 2022
AVR, aortic valve replacement; OAC, oral anticoagulant; LMWH, low molecular weight heparin; MHV, mechanical heart valve; NCS, non-cardiac surgery; NOAC, non-vitamin
K oral anticoagulant; PCC, prothrombin complex concentrate; UFH, unfractionated heparin.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 44 -->

### Page 44

5.4. Peri-operative thromboprophylaxis
Trends show that the case-fatality of peri-operative VTE has declined over the past few decades.319,320 Its causal relationship with preventable mortality has been challenged by a recent meta-analysis.321
Thus, peri-operative VTE should be regarded as a marker of increased mortality risk rather than a causal factor. Careful preoperative assessment is essential to identify patients with increased
VTE risk who might beneﬁt from peri-operative thromboprophylaxis. Procedure-related (e.g. type of surgery and likelihood of postoperative immobilization) and patient-related factors contribute to the risk of VTE. For non-orthopaedic surgical patients at low risk of VTE, mechanical methods of VTE prophylaxis (graduated compression stockings, intermittent pneumatic compression, or venous foot pump) rather than pharmacologic prophylaxis or no prophylaxis are recommended. Patients with CV disease (e.g. patients with recent MI or HF) have increased risk of peri-operative VTE.322 The
Caprini score has been developed for risk stratiﬁcation,323 and validated in different surgical settings (see Supplementary data,
Table S7).324–327
Thromboprophylaxis should be considered for patients with moderate (i.e. 5–8 points) and high scores (i.e. ≥9 points).
Thromboprophylaxis should be initiated during the hospital stay until
12 h before NCS and continued post-operatively based on individual risk assessment for bleeding. In most cases, thromboprophylaxis should be continued until the patient becomes fully mobilized or until hospital discharge (usually up to 10 days). Extended pharmacological
VTE prophylaxis beyond discharge is not routinely recommended in most non-orthopaedic surgical patients. Although there are insufﬁcient data regarding thromboprophylaxis after cancer surgery (particularly major abdominal and/or pelvic surgery for cancer), the consensus is to extend treatment duration with preferred use of
LMWH for 3–4 weeks. Decisions on prophylaxis in populations for which the Caprini score has not been validated (such as orthopaedic surgery) should be based on individual and procedure-speciﬁc risk factors. Among those, a previous VTE is the strongest risk predictor (see Supplementary data, Table S7).328 For special situations and populations (e.g. neurosurgery, elderly, obese), please refer to available speciﬁc practice guidelines.329–332
Large phase 3 and phase 4 studies comparing NOACs with
LMWH have shown similar results regarding efﬁcacy and safety after major orthopaedic surgery.333 The usual time period for thromboprophylaxis after total knee and hip arthroplasty was up to 14 days and 35 days in RCTs, respectively,334–339 but large-scale data suggest safety of foreshortening the duration restricted to the hospital stay after fast-track surgery.340 Recent practice guidelines and a meta-analysis suggest a rationale for the use of aspirin as thromboprophylaxis in modern elective total hip and knee arthroplasty.341,342
However, there is a need for more adequately powered clinical trials with appropriate end-points comparing aspirin with other pharmacological methods. Aspirin should not be used as the sole initial agent for VTE prophylaxis, but switching to aspirin following a short course
(e.g. 5 days) of rivaroxaban may be suitable for selected low-risk patients.343 It is recommended to implement patient care programmes
—including post-operative mobilization, electronic prophylaxis recommendations, and teaching sessions regarding daily use of thromboprophylaxis—as these have been shown to be beneﬁcial in reducing the risk of post-operative VTE complications.344
5.5. Patient blood management
Major surgery is associated with a high risk of peri-operative blood loss. Preferred treatment of acute anaemia related to peri-operative blood loss is transfusion of allogenic blood products. However, a large body of evidence indicates that inappropriate transfusion of red blood cells (RBCs) may be associated with inherent complications and impaired surgical outcome. Therefore, it is important to identify at-risk patients pre-operatively and manage peri-operative bleeding in any patients undergoing major surgery.
A hallmark study including .200 000 major surgical patients showed that even mild anaemia signiﬁcantly increased the risk of morbidity—including respiratory, urinary, wound,
septic, and thromboembolic complications—and mortality across all age groups.345 Moreover, Baron and colleagues analysed .39 000 surgical patients and showed that anaemia was signiﬁcantly associated with increased mortality rate, hospital length of stay, and postoperative admission to intensive care.346 Up to 48% of surgical patients suffer from anaemia, and therefore anaemia should be considered to be a risk factor any time during hospitalization.347 Von
Heymann and colleagues analysed 4494 cardiac surgical patients and showed that pre-operative anaemia and intra-operative transfusion were independently associated with decreased long-term survival.348 In addition, long-term survival was decreased by 50% in anaemic patients receiving blood transfusion compared with those without blood transfusion.
Anaemia may contribute to myocardial ischaemia, particularly if
CAD is present. Iron deﬁciency (ID) is the underlying cause of anaemia in ≏50% of all cases.347 It was recently shown that ID was associated with increased risk of 90 day mortality both in patients with
(4–14%) and without (2–5%) anaemia.349 In addition, the incidence
Recommendation Table 15 — Recommendations for thromboprophylaxis
Recommendations
Classa
Levelb
It is recommended that decisions about peri-operative thromboprophylaxis in NCS are based on individual and procedure-speciﬁc risk factors.328,332
I
A
If thromboprophylaxis is deemed necessary, it is recommended to choose the type and duration of thromboprophylaxis (LMWH, NOAC, or fondaparinux) according to type of NCS, duration of immobilization, and patient-related factors.328,332
I
A
In patients with a low bleeding risk, peri-operative thromboprophylaxis should be considered for a duration of up to 14 or 35 days, for total knee or hip arthroplasty, respectively.334–337
IIa
A
NOACs in thromboprophylaxis dose may be considered as alternative treatments to LMWH
after total knee and hip arthroplasty.333
IIb
A
© ESC 2022
LMWH, low molecular weight heparin; NCS, non-cardiac surgery; NOAC, non-vitamin
K oral anticoagulant.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
3869


<!-- PAGE 45 -->

### Page 45

of serious adverse events, major cardiac and cerebrovascular events,
allogenic blood transfusion requirements, and length of stay were increased in patients with ID.
Based on the possibility of preserving the patients’ own blood resources and to enable safe handling of donor blood, the
World Health Assembly (WHA) has endorsed the Patient
Blood Management (PBM) approach (WHA63.12). Patient Blood
Management is a patient-centred and multidisciplinary approach to manage anaemia, minimize iatrogenic blood loss and bleeding, and harness tolerance to anaemia in an effort to improve patient outcome.350–355 A comprehensive PBM programme addressing all three
PBM pillars was associated with reduced transfusion need of RBC
units, and lower complication and mortality rates.350
5.5.1. Pre-operative anaemia—diagnosis and treatment
A serum ferritin level ,30 ng/mL, transferrin saturation ,20%, and/
or microcytic hypochromic red cells (mean corpuscular volume
,80 ﬂ, mean corpuscular haemoglobin ,27 g/dL) are indicative of
ID. In the presence of inﬂammation or transferrin saturation
,20%, a ferritin level of ,100 ng/mL points to functional ID (iron sequestration) (Table 10).
Apart from compromised bone marrow function, most types of anaemia are correctable within a period of 2–4 weeks. Oral and i.v. iron therapy can be used to treat ID. Intravenous iron products consist of an iron core embedded in a carbohydrate shell, which inﬂuences the stability of the drug, for example: iron sucrose comprises a less stable shell, allowing a maximum dose of 200 mg per infusion, whereas ferric carboxymaltose, ferric derisomaltose, and ferumoxytol have a stable shell associated with slow iron release and allowing a higher dose. Administration of i.v. iron has been shown to effectively reverse anaemia in ID patients.356,357
Intravenous iron is efﬁcacious and safe359 and should be used in patients in whom oral iron is not tolerated, or if surgery is planned in short notice after the diagnosis of ID. A prospective observational study of 1728 major surgical patients showed that the prevalence of
ID was 50%, 46.3%, and 52.7% in patients with haemoglobin ,8.0,
8.0–8.9, and 9.0–9.9 g/dL, respectively.357 Furthermore, all iron supplemented iron-deﬁcient anaemic patients required fewer RBC
transfusions during the post-operative period, and a reduced intra-operative transfusion rate was observed if iron was supplemented .7 days before surgery. In addition, the length of stay was signiﬁcantly reduced by 2.8 days for iron supplemented patients. In the recent PREVENTT trial studying patients with anaemia undergoing major abdominal surgery, pre-operative iron transfusion failed to improve outcomes;360 however, due to a fault in the study design, all anaemic patients received i.v. iron but not all (≏50–70%) were suffering from ID.
Recombinant human erythropoietin (rHuEPO) has frequently been used together with iron supplementation to increase preoperative haemoglobin concentrations. A recent Cochrane review found that the administration of rHuEPO + iron to anaemic patients prior to NCS, compared with control treatment, reduced the need for RBC transfusion and increased the haemoglobin concentration pre-operatively; however, there were no important differences in the risk of adverse events or mortality within 30 days, or in length of hospital stay.361 Well-designed, adequately powered RCTs are required to more precisely estimate the impact of this combined treatment.
Pre-operative management of patients with anaemia can be simpliﬁed by making use of standard operating procedures or algorithms in which thresholds for diagnosis and treatment are depicted.362 An example of such an algorithm can be found in the PBM programme363
(see Supplementary data, Figure S4) and in the British Committee for
Standards in Haematology (BCSH) Guidelines on the Identiﬁcation and Management of Pre-Operative Anaemia.364
5.5.2. Bleeding and reduction of iatrogenic diagnostic/surgery-related blood loss
Blood loss associated with laboratory testing can either cause or aggravate hospital-acquired anaemia, which is associated with increased length of stay and complications. In 1867 patients undergoing cardiac surgery, an average of 115 tests per patient were performed, with a cumulative median volume of 454 mL.365
A reduction in blood drawn for laboratory analyses can be achieved by lowering the frequency of sampling and using paediatric-size collection tube sizes, for example. To decrease blood loss, blood-saving bundles could be used (e.g. a closed-loop arterial blood sampling system, smaller sampling tubes, reduction of frequency of blood
Table 10
Laboratory parameters for the diagnosis of absolute iron-deﬁciency anaemia
Parameter
Normal
Iron deﬁciency
Mean corpuscular haemoglobin (g/dL)
28–33
,27
Mean cellular volume (fL)
80–96
,80
Transferrin saturation (%)
16–45
,20
Ferritin (ng/mL)
18–360
,30a
Reticulocytes haemoglobin (ng/mL)
18–360
,30
© ESC 2022
aIn cases of chronic kidney disease, chronic heart failure or infections, iron deﬁciency is diagnosed with ferritin level ,100 ng/mL or transferrin saturation ,20%.358
Recommendation Table 16 — Recommendations for intra- and post-operative complications associated with anaemia
Recommendations
Classa
Levelb
It is recommended to measure haemoglobin pre-operatively in patients scheduled for intermediate- to high-risk NCS.350,354
I
B
It is recommended to treat anaemia in advance of
NCS, in order to reduce the need for RBC
transfusion during NCS.357,361
I
A
The use of an algorithm to diagnose and treat anaemic patients before NCS should be considered.
IIa
C
© ESC 2022
NCS, non-cardiac surgery; RBC, red blood cell.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 46 -->

### Page 46

drawings, and sample numbers). Such a strategy decreased mean blood loss per intensive care unit (ICU) day from 43.3 mL to
15.0 mL
(P , 0.001),366
mainly due to the introduction of closed-loop arterial blood sampling systems. In addition, units of transfused RBCs per 100 observation days decreased from 7 to
2.3 (P , 0.001).366
A reduction in surgery-related blood loss starts from the preoperative stage, with appropriate cessation strategies for anticoagulation and antiplatelet therapy. Intra-operative approaches to avoid blood loss include: (i) advanced anaesthetic; (ii) advanced surgical techniques with meticulous haemostasis, such as minimally invasive surgery and laparoscopic surgery; (iii) judicious use of diathermy dissection; (iv) physician’s mindfulness regarding limiting blood loss; and
(v) application of topical haemostatic agents.367–369
Adequate coagulation management to minimize blood loss needs to be a pre-condition before RBC transfusion is considered. In this respect, the use of a coagulation algorithm is recommended,370,371
encompassing pre-operative assessment,372 and ensuring basic conditions for haemostasis, reversal of anticoagulants, point-of-care diagnostics in bleeding patients, and optimized coagulation management with the use of clotting factor concentrates.373,374
Tranexamic acid is an antiﬁbrinolytic agent that is widely used for prophylaxis and treatment of bleeding caused by hyperﬁbrinolysis. A
meta-analysis including 129 trials encompassing more than 10 000
patients to assess the effect of tranexamic acid on blood transfusion showed that administration of tranexamic acid reduced allogeneic blood transfusion by 38% (P , 0.001).375 In the recent POISE-3
study, 9535 patients undergoing NCS were randomized to tranexamic acid (1 g i.v. bolus) or placebo at the start and end of surgery.
The incidence of the primary efﬁcacy outcome (composite bleeding outcome) at 30 days was signiﬁcantly lower with tranexamic acid than with placebo (HR, 0.76; 95% CI, 0.67–0.87).376 With respect to the primary safety outcome (composite CV outcome), the results did not meet the non-inferiority criteria (HR, 1.02; 95% CI,
0.92–1.14; P = 0.04 for non-inferiority).
The use of (washed) cell recovery is highly recommended in surgical settings where blood loss is routinely or anticipated to be
.500 mL, as it reduces the rate of exposure to allogeneic RBCs,
risk of infection, and length of stay. A meta-analysis including 47 trials encompassing 3433 patients of all surgical disciplines showed that the use of washed cell salvage reduced the rate of exposure to allogeneic
RBC transfusion by 39% (P , 0.001), risk of infection by 28% (P =
0.03), and length of stay by 2.31 days (P , 0.001).377
5.5.3. Optimal blood component use with patient-centred clinical decision support
In order to optimize utilization of allogeneic blood products and to ensure guideline-adherent transfusion strategies, computerized physician order-entry systems should be considered.390,391 For example, Kaserer and colleagues evaluated the effectiveness of a monitoring and feedback programme and compared transfusion rates of
.210 000 patients before and after implementation;392 overall,
transfusion of RBCs was reduced by 40%.
Informed consent should be obtained from patients prior to transfusion of allogeneic blood products. It is necessary to effectively communicate the risks and beneﬁts of the various potential interventions to the patient. It may further be recommended that any transfusion of allogeneic blood products should be mentioned in the discharge summary. In addition, the patient’s own preferences and values should be considered when developing a medical plan.
6. Speciﬁc diseases
Patients with CVD have an increased risk of peri-operative CV complications.45 Both the risk of complications and the peri-operative management depend on the speciﬁc type of CVD.
6.1. Coronary artery disease
6.1.1. Risk for patients with coronary artery disease
The peri-operative risk of CV complications for patients with established CAD depends on the baseline CV risk, type of surgery, and
Recommendation Table 17 — Recommendations for intra- and post-operative complications associated with blood loss
Recommendations
Classa
Levelb
In patients undergoing surgery with expected blood loss of ≥500 mL, use of washed cell salvage is recommended.377,378
I
A
It is recommended to use point-of-care diagnostics for guidance of blood component therapy, when available.370,379–383
I
A
Continued
In patients undergoing NCS and experiencing major bleeding, administration of tranexamic acid should be immediately considered.375,376,384–386
IIa
A
Use of closed-loop arterial blood sampling systems should be considered to avoid blood loss.366,378,387,388
IIa
B
Application of meticulous haemostasis should be considered a routine procedure.350,389
IIa
B
© ESC 2022
NCS, non-cardiac surgery.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 18 — Recommendations for intra- and post-operative complications associated with allogeneic blood transfusion
Recommendations
Classa
Levelb
A feedback/monitoring programme or clinical decision support system should be considered to be assessed before blood transfusion.392–396
IIa
B
Before allogenic blood transfusion, it should be considered to obtain an extensive consent about risks asssociated with transfusion.
IIa
C
© ESC 2022
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
3871


<!-- PAGE 47 -->

### Page 47

degree of urgency of the NCS. Older patients have a higher risk than younger patients, and patients with a recent ACS have a higher risk than those with CCS. The presence of comorbidities may also inﬂuence the risk.
6.1.2. Pre-operative risk assessment and management
The diagnostic evaluation and pre-operative management of patients with CCS undergoing NCS are outlined in Section 4. In particular, the value of CCTA and ICA are discussed in Sections 4.5.3.1. and 4.5.3.2.
In patients in need of immediate NCS, the operation must be performed without further delay and the time for pre-operative assessment is limited.
In patients scheduled for elective NCS who present with an ACS,
the management of ACS should follow the guidelines for ACS patients in the non-surgical setting.98,171 In such settings, it would be reasonable to consider treating the culprit lesion only before NCS.
Potential changes in timing of surgery and the peri-operative management (e.g. type of surgery, anaesthesia, medical therapy, and perioperative monitoring) should be considered.
In patients with known CAD, it is recommended to collect information regarding previous invasive and non-invasive diagnostic examinations, and therapeutic interventions for CAD, within a sufﬁcient time interval before the NCS, ideally at the time the proposal for NCS is made.
6.1.3. Revascularization strategies
The indication for coronary revascularization depends on the clinical presentation of CAD (ACS vs. CCS), urgency, and cardiac risk of
NCS. In general, there is clear evidence that routine revascularization improves outcomes in ACS patients and less support for such a strategy in patients with CCS. The process of decision-making related to revascularization in CCS should be individualized, in order to prioritize revascularization in case of involvement of a signiﬁcant amount of ischaemic myocardium or refractory symptoms, while medical management is a valuable option in patients with less relevant CAD
manifestations.
6.1.3.1. Chronic coronary syndromes
The rationale for coronary revascularization before NCS is to prevent peri-operative myocardial ischaemia leading to acute MI,
haemodynamic instability, and arrhythmia. Data from autopsy studies following fatal peri-operative MI showed that more than two-thirds of the patients had signiﬁcant left main or three-vessel disease.397 A
retrospective registry based on the Coronary Artery Surgery Study
(CASS) study found that coronary artery bypass graft (CABG) reduced the risk of peri-operative mortality and MI in patients undergoing major NCS, particularly in subjects with three-vessel disease and reduced left ventricular ejection fraction (LVEF).398 However,
the evidence in support of routine prophylactic revascularization before NCS is based on relatively small clinical trials and retrospective registries unrepresentative of current clinical practice.
In the Coronary Artery Revascularization Prophylaxis (CARP)
trial, 510 patients with CCS were randomized to either optimal medical therapy or coronary revascularization (surgical or percutaneous)
before major vascular surgery.399 In this study, patients receiving coronary revascularization compared with those who were medically treated did not differ in terms of acute MI after 30 days (8.4% vs.
8.4%, respectively) and mortality after 2.7 years (22% vs. 23%, respectively). Of note, this study excluded patients with signiﬁcant left main disease, while one-third of the patients presented with three-vessel disease.399 In another randomized trial, 426 patients without evidence of CAD and scheduled for CEA were randomized to either routine coronary angiography with provisional revascularization before CEA or CEA without previous coronary angiography.
There were no signiﬁcant differences between the treatment groups in all-cause mortality, acute MI, and stroke at 30 days.172 A subsequent meta-analysis including 3949 patients showed no clinical beneﬁt associated with routine prophylactic revascularization before
NCS.400 A recent retrospective analysis on 4414 patients undergoing total joint arthroplasty found that the risk of adverse CV events was increased in patients with CAD, regardless of coronary revascularization before surgery. However, in patients receiving coronary revascularization, the risk of adverse CV events decreased, as the interval between revascularization and total joint arthroplasty was
.2 years.401
The lack of evidence in support of routine prophylactic revascularization in CCS does not preclude a decision-process based on individual risk–beneﬁt assessment in patients with a signiﬁcant amount of ischaemic myocardium (as in the case of left main disease) and/or with refractory symptoms. The International Study of Comparative Health Effectiveness with Medical and Invasive
Approaches (ISCHEMIA) trial randomized 5179 patients with stable
CAD and moderate or severe ischaemia to an initial invasive strategy
(consisting of angiography plus revascularization, as appropriate) or to an initial strategy of medical therapy alone, with bail-out angiography if medical therapy failed.402 This trial did not ﬁnd a signiﬁcant difference in the primary composite end-point of death and MI between treatment groups. Interestingly, these neutral results were inapplicable to patients with severe left main disease, since these patients were excluded after a pre-randomization CCTA. It has yet to be demonstrated whether CCTA represents a valuable tool with which to select patients with stable CAD and/or moderate or severe ischaemia who might beneﬁt from an initial invasive strategy. A large angiography-based registry of 9016 CCS patients with high-risk coronary anatomy (three-vessel disease with ≥70%
stenosis in all three epicardial vessels or left main disease ≥50%
stenosis) showed improved outcomes (all-cause mortality or MI) in patients undergoing revascularization (both for PCI or CABG)
vs. conservative medical therapy (HR, 0.62; 95% CI, 0.58–0.66; P ,
0.001).403
The 2018 ESC/EACTS Guidelines on myocardial revascularization and the 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes generally apply to this population of patients, as long as the NCS can be postponed long enough to allow safe discontinuation of DAPT.146,404
Similarly, the choice between PCI and CABG should follow the general rules outlined in the above-mentioned guidelines.268,404
The use of intravascular imaging for planning and optimization of
PCI is encouraged.405,406
6.1.3.2. Acute coronary syndromes
There are no trials speciﬁcally addressing the strategy of revascularization in ACS patients scheduled for NCS. High- and very high-risk


<!-- PAGE 48 -->

### Page 48

patients should be treated according to the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation,98 with an early (,24 h) or immediate (,2 h) invasive strategy, respectively. In low-risk groups amenable to a selective invasive strategy, the decision-making should be consistent with the approach for CCS patients.
In a post hoc analyses of the HIP-ATTACK (HIP Fracture
Accelerated Surgical TreaTment And Care tracK) trial, patients
Optimize guideline-recommended medical therapy
(Class I )
Optimize guideline-recommended medical therapy
(Class I )
Diagnostic and therapeutic pathways according to ACS Guidelines and 
individual basis
(Class I)
Cardiologist–surgeon–anaesthesist discussion regarding myocardial revascularization options and antithrombotic strategy dependent on the options and acceptable time interval to postpone NCS
Low-risk NCS
No further screening
Intermediate-risk NCS
Clinical examination + ECG
+ biomarkersa (Class I)
Symptoms or abnormal ECG
or poor exercise tolerance or elevated biomarkers
Elevated hs-troponin or stress-induced ischaemia
High-risk NCS
Functional capacityb (Class IIa)
Clinical examination + ECG
+ biomarkersa (Class I)
Functional capacityb (Class IIa)
± TTE ± stress imaging
± TTE ± stress imaging
ICAc ± iwFR/FFR
Symptoms or abnormal ECG
or poor exercise tolerance or elevated biomarkers
N
N
N
Y
Y
CCS
ACS
Management of  patients with ACS or CCS scheduled for NCS
Y
Figure 12 Management of patients with acute or chronic coronary syndrome scheduled for non-cardiac surgery. ACS, acute coronary syndrome; BNP,
B-type natriuretic peptide; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCS, chronic coronary syndrome; ECG, electrocardiogram; FFR, fractional ﬂow reserve; hs-cTn, high-sensitivity cardiac troponin; ICA, invasive coronary angiography; iwFR, instantaneous wave-free ratio;
N, no; NCS, non-cardiac surgery; NT-proBNP, N-terminal proBNP; PCI, percutaneous coronary intervention; TTE, transthoracic echocardiography.
Y, yes; The ﬁgure provides a schematic representation of diagnostic tools and therapy to be implemented according to surgical risk and underlying cardiac condition. aBiomarkers: hs-cTn T/I (Class I) + BNP/NT-proBNP (Class IIa). bFunctional capacity based on Duke Activity Status Index (DASI) or the ability to climb two ﬂights of stairs. cICA + PCI/CABG on a case-by-case basis according to the Heart Team.
ESC Guidelines
3873


<!-- PAGE 49 -->

### Page 49

with increased baseline troponin before randomization showed lower risk of mortality with accelerated surgery (within 6 h from the diagnosis) vs. standard of care (HR, 0.38; 95% CI,
0.21–0.66).57
The selection of the type of revascularization (PCI or CABG)
should be based on the coronary anatomy and complexity of atherosclerosis, and the presence of diabetes.268,404 When PCI is chosen, the use of a DES is recommended.407 In case of a life-threatening clinical condition requiring undeferrable NCS and concomitant ACS-STEMI with an indication for coronary revascularization, a minimalistic approach with plain balloon angioplasty and delayed stenting might be considered.408,409 Figure 12 shows a summary of diagnostic and therapeutic pathways in patients with CAD scheduled for NCS.
6.2. Chronic heart failure
6.2.1. Risk for patients with heart failure
Heart failure is an established risk factor for post-operative mortality across a broad range of surgical specialties.410–412 Several tools for risk calculations in patients undergoing NCS include HF as a predictor of adverse post-operative events.411,413
The risk of adverse post-operative events associated with HF depends on whether the LV systolic function is preserved or reduced,
on the haemodynamic compensation, and on the presence of symptoms.414,415 In patients undergoing NCS, there is a risk of acute decompensated HF, with rapid onset or worsening of symptoms and/
or signs of HF, precipitated by ﬂuid accumulation and/or comorbid conditions.412
Patients with peri-operative acute or chronic HF are at increased risk of mortality during NCS. In a recently published analysis of 21
560 996 hospitalizations for NCS, the presence of any diagnosis of
HF was associated with signiﬁcantly higher in-hospital all-cause mortality compared with absence of HF (4.8% vs. 0.78%; adjusted OR,
2.15; 95% CI, 2.09–2.22).416 Among patients with a chronic HF diagnosis, peri-operative mortality was greater in those with acute exacerbation of chronic HF compared to those with compensated chronic HF. In a recent large-scale cohort study of individuals undergoing ambulatory surgery, the crude 90 day mortality was 2.0%
among patients with HF and 0.4% among patients without HF.417
The crude risk of 30 day post-operative complications was 5.7%
and 2.7%, respectively. Of note, the risk of mortality progressively increased with decreasing systolic function. It is not recommended to perform elective NCS in patients with decompensated HF.
The value of pre-operative assessment of LV function with
TTE
and measurement of natriuretic peptides
(BNP
or
NT-proBNP) is discussed in Section 4.4. The TTE should not be older than 6 months, or performed just before NCS in the case of clinical worsening.
6.2.2. Pre- and post-operative management strategies
In order to reduce the risk of acute decompensation and the risk of mortality, optimal guideline-directed medical treatment of HF before scheduled NCS is recommended.412 Special attention should be given to the ﬂuid balance, since high-volume infusion is often needed in the peri-operative period. Invasive monitoring of the arterial pressure aiming to obtain oximetric and metabolic parameters during NCS is frequently needed for intermediate- to high-risk
NCS among HF patients. Furthermore, dynamic variables derived from the arterial pressure waveform (cardiac output, pulse pressure variation, stroke volume variation) are useful for guiding protocolled goal-directed therapy. Use of more invasive tools,
such as right heart catheterization or transoesophageal echocardiography (TEE), might be considered on an individual patient level (see
Section 7.1).
Baseline medication should be continued throughout the perioperative period, in accordance with the recommendations provided in Section 5.2. It is recommended to perform ECG, measure biomarkers of myocardial injury (cTn T/I), and perform echocardiography to tailor the optimal treatment strategy in patients with acute decompensated HF post-operatively.
Recommendation Table 19 — Recommendations for the timing of non-cardiac surgery and revascularization in patients with known coronary artery disease
Recommendations
Classa
Levelb
Patients with CCS
If PCI is indicated before NCS, the use of new-generation DES is recommended over BMS
and balloon angioplasty.268
I
A
Pre-operative evaluation of patients with an indication for PCI by an expert team (surgeon and cardiologist) should be considered before elective
NCS.
IIa
C
Myocardial revascularization before high-risk elective NCS may be considered, depending on the amount of ischaemic myocardium, refractory symptoms, and ﬁndings at coronary angiography
(as in the case of left main disease).399,402,403
IIb
B
Routine myocardial revascularization before lowand intermediate-risk NCS in patients with CCS is not recommended.399,400
III
B
Patients with ACS
If NCS can safely be postponed (e.g. at least 3
months), it is recommended that patients with
ACS being scheduled for NCS undergo diagnostic and therapeutic interventions as recommended for ACS patients in general.98,268
I
A
In the unlikely combination of a life-threatening clinical condition requiring urgent NCS, and
NSTE-ACS with an indication for revascularization, the priorities for surgery on a case-by-case basis should be considered by the expert team.268
IIa
C
© ESC 2022
ACS, acute coronary syndrome; BMS, bare metal stent; CAD, coronary artery disease;
CCS, chronic coronary syndrome; DES, drug-eluting stent; NCS, non-cardiac surgery;
NSTE-ACS, non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 50 -->

### Page 50

The management of patients with cardiac implantable electronic devices (CIEDs) undergoing NCS is discussed in Section 6.4.5.
In patients with resynchronization devices (cardiac resynchronization therapy [CRT]), it is recommended to keep the device on to provide better haemodynamic stability.
6.2.3. Hypertrophic obstructive cardiomyopathy
Patients with hypertrophic cardiomyopathy with LV outﬂow tract obstruction (HOCM) have an increased risk of complications during NCS and require additional attention.418 It is recommended to perform TTE before NCS in order to determine the extent of the hypertrophy, obstruction, and diastolic function.419 Avoidance of prolonged pre-operative fasting and dehydration is important to maintain stroke volume and reduce the risk of increased obstruction. Furthermore, it is important to avoid vasodilating anaesthetic agents and maintain neutral ﬂuid balance during the peri-operative period. The heart rate should be kept low (60–65 beats per minute [b.p.m.]) and AF should be avoided. Medication used to treat LV outﬂow tract obstruction should remain on board during NCS.
6.2.4. Patients with ventricular assist devices undergoing non-cardiac surgery
Ventricular assist devices (VADs) play an important role in the treatment of patients with end-stage HF who require a bridge to heart transplantation or as a permanent destination therapy. As the number of patients receiving VAD as destination therapy increases,420,421
the need for NCS in this speciﬁc subset of patients is expected to increase in years to come. Non-cardiac surgery should be performed in surgical centres that have access to VAD teams (Table 11).
6.3. Valvular heart disease
6.3.1. Risk for patients with valvular heart disease
Valvular heart disease increases the risk of peri-operative CV
complications during NCS. The magnitude of risk is highly
Table 11
Peri-operative approach to patients with ventricular assist devices undergoing non-cardiac surgery
Pre-operative
Intra-operative
Post-operative
• Multidisciplinary team identiﬁed (primary surgical and anaesthesia teams, cardiac surgery,
HF cardiologist, VAD personnel)
• Pre-operative medical optimization when possible or necessary
• Physical examination focused on the sequelae of HF
• Baseline ECG, echocardiogram, and laboratory values
• Manage pacemaker/ICD settings when indicated
• CT examination to evaluate possible driveline interference with the operative ﬁeld
• Hold, bridge, or reverse anticoagulation when indicated, after VAD team consultation
• Standard American Society of Anesthesiologists monitors
• Cerebral tissue oxygenation, processed electroencephalogram, arterial line with ultrasound guidance,
central venous catheter if ﬂuid shifts are expected, PA catheter only if severe pulmonary hypertension, TEE available
• Monitor VAD control console
• External deﬁbrillator pads in place
• Optimize pre-load, support RV function, avoid increase in afterload
• Gradual peritoneal insufﬂations and position changes
• Standard post-anaesthesia care unit unless ICU is otherwise indicated
• Extubation criteria are unchanged
• Avoid hypoventilation, optimize oxygenation
• Resume heparin infusion when post-op bleeding risk is acceptable
© ESC 2022
CT, computed tomography; ECG, electrocardiogram; HF, heart failure; ICU, intensive care unit; PA, pulmonary artery; RV, right ventricular; TEE, transoesophageal echocardiography;
VAD, ventricular assist device.
Adapted from Roberts et al.421
Recommendation Table 20 — Recommendations for management of heart failure in patients undergoing non-cardiac surgery
Recommendations
Classa
Levelb
In patients with suspected or known HF scheduled for high-risk NCS, it is recommended to evaluate
LV function with echocardiography and measurement of NT-proBNP/BNP levels, unless this has recently been performed.112,113,422,423
I
B
It is recommended that patients with HF
undergoing NCS receive optimal medical treatment according to current ESC
guidelines.412
I
A
In patients with HF undergoing NCS, it is recommended to regularly assess volume status and signs of organ perfusion.
I
C
A multidisciplinary team including VAD specialists is recommended for peri-operative management of patients with HF receiving mechanical circulatory support.
I
C
© ESC 2022
BNP, B-type natriuretic peptide; ESC, European Society of Cardiology; HF, heart failure;
LV, left ventricular; MCS, mechanical circulatory support; NCS, non-cardiac surgery;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; VAD, ventricular assist device.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
3875


<!-- PAGE 51 -->

### Page 51

variable and depends on the severity of VHD and type of NCS.
It is particularly increased in patients with obstructive valve pathology, for example symptomatic AS or MS, where perioperative volume shifts and arrhythmia may lead to rapid decompensation.424
6.3.2. Pre-operative management strategies and risk-reduction strategy
Clinical and echocardiographic evaluation is recommended in all patients with known or suspected VHD who are scheduled for elective intermediate-or-high-risk NCS. Patients in whom mild-to-moderate
VHD was diagnosed .1 year earlier should have clinical and echocardiographic re-assessment. Heart team discussion may be helpful in patients with signiﬁcant VHD. The risks of valvular intervention and the risk of NCS-related complications should be estimated and communicated to the patient and the surgical team.
6.3.2.1. Aortic valve stenosis
The peri-operative risk associated with AS during NCS depends upon the presence of symptoms, stenosis severity, and coexisting cardiac disease (e.g. CAD, mitral insufﬁciency, or reduced LVEF).
Severe symptomatic AS is a signiﬁcant risk factor for post-operative
MI and HF, and a predictor for 30 day and long-term mortality after
NCS.425,426 Careful peri-operative management is essential in patients undergoing intermediate- and high-risk NCS, albeit the signiﬁcance of AS in patients undergoing low-risk NCS might have been overemphasized in studies that pre-date the more recent advances in anaesthesia, surgical techniques, and post-operative management.
Clinical examination + ECG + biomarkers + TTE ± TEE
(Class I)
Optimal guideline-recommended medical treatmenta
(Class I)
Low-risk NCS
Patient risk for valve procedures
AND
AND
Intermediate or high-risk NCS
Patient risk for valve procedures
Low
High
Low
High
Low- or intermediate-risk NCS
High-risk NCS
Patient risk for valve procedures
Low
High
Management of patients with severe aortic valve stenosis scheduled for elective or time-sensitive NCS
Multidisciplinary consultation
Symptoms
Individual decision about necessity of valve procedure before NCS
NCS without additional procedures
Heart Team
(TAVI or SAVR)
(Class I)
Consider BAV before
NCS if feasible, or NCS
under strict monitoring
(Class IIb)
NCS without additional procedures
Heart Team
(TAVI or SAVR)
(Class IIa)
Consider BAV before
NCS if feasible, or NCS
under strict monitoring
(Class IIb)
LV-dysfunction (LVEF <50%)
NCS without additional procedures
Y
Y
N
N
Figure 13 Management of patients with severe aortic valve stenosis scheduled for non-cardiac surgery. BAV, balloon aortic valvuloplasty; ECG, electrocardiogram; LV, left ventricular; LVEF, left ventricular ejection fraction; N, no; NCS, non-cardiac surgery; SAVR, surgical aortic valve replacement; TAVI,
transcatheter aortic valve implantation; TTE, transthoracic echocardiography; TEE, transoesophageal echocardiography. Y, yes; The ﬁgure provides a schematic representation of diagnostic assessment or therapy to be implemented according to surgical risk and underlying cardiac condition. aThis applies to treatment of complications (e.g. atrial ﬁbrillation, heart failure). No medical therapy is recommended for aortic stenosis per se.


<!-- PAGE 52 -->

### Page 52

Aortic valve replacement has been associated with reduced in-hospital and 30 day mortality and morbidity among patients with AS undergoing intermediate- to high-risk NCS.425,426 However, the decision regarding the timing of AVR in relation to NCS should be weighted according to the baseline risk proﬁle and the risk associated with the
NCS. The choice of surgical aortic valve replacement (SAVR) vs.
TAVI should follow the 2021 ESC/EACTS Guidelines for the management of valvular heart disease245 and patient’s informed preference
(Figure 13).
In patients with severe symptomatic AS, in whom NCS can be deferred, aortic valve intervention (SAVR or TAVI) is recommended before NCS. In patients requiring time-sensitive NCS, TAVI is a reasonable option.427 In patients with severe symptomatic AS in need of time-sensitive NCS in whom TAVI or SAVR are unfeasible, balloon aortic valvuloplasty (BAV) may be considered before NCS as a bridge to deﬁnitive aortic valve repair. Asymptomatic patients with severe
AS and normal LVEF can safely undergo low- to intermediate-risk
NCS, unless the NCS is associated with large volume shifts.245,428
6.3.2.2. Mitral valve stenosis
Non-cardiac surgery can be performed with a relatively low risk of complications in patients with mild MS (valve area .1.5 cm2) and in asymptomatic patients with moderate-to-severe MS (valve area
≤1.5 cm2)
and systolic pulmonary artery pressure
(SPAP)
,50 mmHg on echocardiography.429 As transmitral gradients are
ﬂow-sensitive, tachycardia and ﬂuid overload can cause pulmonary oedema during NCS. In this regard, arterial vasodilators should be avoided and surveillance for peri-operative AF is of paramount importance. Management of anticoagulation for patients with high thrombotic risk is discussed in Section 5.3.2. In asymptomatic patients with moderate-to-severe MS and SPAP .50 mmHg, and in symptomatic patients, the peri-operative risk of CV events is increased.
Intermediate-risk or high-risk NCS
Low-risk NCS
Management of severe secondary mitral valve regurgitation in patients scheduled for NCS
Clinical examination + ECG + biomarkers + TTE ± TEE (Class I)
Persistent symptoms despite GDMT
Elective NCS
Optimal GDMT including
CRT if indicated
(Class I)
± Myocardial revascularizationa
Optimal GDMT
(Class I)
Time-sensitive NCS
No additional procedures
Consider NCS under strict monitoring
Inoperable or at high procedural risk
TEER or surgery (repair when possible) depending on eligibility and according to the decision of the
Heart Team
(Class IIa)
Y
Y
Y
N
N
AND
AND
Multidisciplinary consultation
NCS
under strict monitoring
AND
Figure 14 Management of patients with secondary mitral valve regurgitation scheduled for non-cardiac surgery. ECG, electrocardiogram; GDMT,
guideline-directed medical therapy; N, no; NCS, non-cardiac surgery; TTE, transthoracic echocardiography; TEE, transoesophageal echocardiography;
TEER, transcatheter edge-to-edge repair. Y, yes; aCoronary angiography + PCI/CABG on a case-by-case according to the expert team.
ESC Guidelines
3877


<!-- PAGE 53 -->

### Page 53

In this case, a percutaneous mitral commissurotomy (PMC) should be considered before high-risk NCS. Otherwise, a multidisciplinary team should manage patients with moderate-to-severe MS who are ineligible for PMC, and NCS should be performed only if necessary. Intermediate-risk NCS may be performed in asymptomatic patients with severe MS with appropriate intra-operative and post-operative haemodynamic monitoring, if valve morphology is unsuitable for PMC.
6.3.2.3. Aortic valve regurgitation
In patients with mild-to-moderate aortic valve regurgitation (AR),
NCS can be performed without additional risk. Patients with severe
AR in whom valvular intervention is needed should be treated before intermediate-or-high-risk elective NCS (see Recommendation
Table 21 and the 2021 ESC/EACTS Guidelines for the management of valvular heart disease).245
6.3.2.4. Mitral valve regurgitation
In patients with severe symptomatic mitral valve regurgitation (MR),
the type of valve disease (primary or secondary) and LV function should be assessed. Patients with secondary MR, especially of ischaemic aetiology, are at increased risk of CV complications during NCS.430 Patients with severe symptomatic MR fulﬁlling the intervention criteria should be referred for valve treatment before intermediate- or high-risk elective NCS. In case of symptomatic moderate-to-severe secondary MR, patients meeting the
Cardiovascular
Outcomes
Assessment of the
MitraClip
Percutaneous Therapy for Heart Failure Patients With Functional
Mitral Regurgitation (COAPT) criteria should be considered for transcatheter edge-to-edge treatment before
NCS
(Figure 14).245,431 In patients with severe primary MR with symptoms or asymptomatic with LV dysfunction, valve repair is the recommended therapy (see Recommendation Table 21 and the 2021 ESC/
EACTS Guidelines for the management of valvular heart disease245).
In patients with reduced LVEF and concomitant AR or MR,
intra-operative haemodynamic monitoring, heart rate control, and careful ﬂuid balance are crucial to avoid haemodynamic deterioration, especially during high-risk surgery.
6.3.2.5. Patients with prosthetic valve(s)
Patients who have undergone previous surgical correction of VHD
and have a prosthetic valve can undergo NCS provided that there is no evidence of valve dysfunction. In current practice, the main problem is the need for a modiﬁcation of the anticoagulation regimen in the peri-operative period; this is discussed in detail in Section 5.3.
6.3.2.6. Prophylaxis of infective endocarditis
Prophylaxis against infective endocarditis in patients requiring NCS
should be consistent with the 2015 ESC Guidelines for the management of infective endocarditis.432
Recommendation Table 21 — Recommendations for management of valvular heart disease in patients undergoing non-cardiac surgery
Recommendations
Classa
Levelb
Clinical and echocardiographic evaluation (if not recently performed) is recommended in all patients with known or suspected VHD who are scheduled for elective intermediate- or high-risk
NCS.
I
C
Aortic valve stenosis
AVR (SAVR or TAVI) is recommended in symptomatic patients with severe AS who are scheduled for elective intermediate- or high-risk
NCS.
I
C
Continued
In asymptomatic patients with severe AS who are scheduled for elective high-risk NCS, AVR (SAVR
or TAVI) should be considered after Heart Team discussion.
IIa
C
In patients with severe symptomatic AS in need of time-sensitive NCS or in whom the TAVI and
SAVR are unfeasible, BAV may be considered before NCS as a bridge to deﬁnitive aortic valve repair.
IIb
C
Aortic valve regurgitation
In patients with symptomatic severe AR or asymptomatic severe AR and LVESD .50 mm or
LVESDi (LVESD/BSA) .25 mm/m2 (in patients with small body size) or resting LVEF ≤50%, valve surgery is recommended prior to elective intermediate- or high-risk NCS.
I
C
Mitral valve stenosis
In patients with moderate-to-severe rheumatic
MS and symptoms or SPAP .50 mmHg, valve intervention (PMC or surgery) is recommended before elective intermediate- or high-risk NCS.
I
C
Mitral valve regurgitation
In patients with symptomatic severe primary MR
or asymptomatic severe primary MR with LV
dysfunction (LVESD ≥40 mm and/or LVEF
≤60%), valve intervention (surgical or transcatheter) should be considered prior to intermediate- or high-risk NCS, if time allows.
IIa
C
In patients with severe secondary MR who remain symptomatic despite guideline-directed medical therapy (including CRT if indicated), valve intervention (transcatheter or surgical) should be considered before NCS, in eligible patients with an acceptable procedural risk.
IIa
C
© ESC 2022
AS, aortic valve stenosis; AR, aortic valve regurgitation; AVR, aortic valve replacement;
BAV,
balloon aortic valvuloplasty;
BSA,
body surface area;
CRT,
cardiac resynchronization therapy; LV, left ventricular; LVEF, left ventricular ejection fraction;
LVESD, left ventricular end-systolic diameter; LVESDi, left ventricular end-systolic dimension index; MR, mitral valve regurgitation; MS, mitral stenosis; NCS, non-cardiac surgery; PMC, percutaneous mitral commissurotomy; SAVR, surgical aortic valve replacement; SPAP, systolic pulmonary artery pressure; TAVI, transcatheter aortic valve implantation; VHD, valvular heart disease.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 54 -->

### Page 54

6.4. Known or newly diagnosed arrhythmias
Arrhythmias pose a signiﬁcant burden to patients undergoing NCS,
contributing to excessive morbidity and mortality.433,434
6.4.1. Peri-operative management—general measures
Arrhythmias—namely, supraventricular tachycardia (SVT) and ventricular tachycardia (VT)—may accompany acute surgical illness, but should not defer urgent surgical procedures, unless the arrhythmia is life-threatening. All patients with known arrhythmia undergoing elective surgery should have a 12-lead ECG performed preoperatively and undergo a cardiology check-up. Prevention of potential arrhythmic triggers is crucial: electrolyte and acid-base imbalance,
myocardial ischaemia (also caused by excessive blood loss and anaemia), and large volume shifts, which can provoke subsequent autonomic hyperactivity, should be avoided in the pre-, intra-, and post-operative periods. Patients with a systolic HF should receive optimal treatment, as such therapy reduces the risk of total mortality and sudden cardiac death (SCD).435 Patients already taking AADs should generally not stop taking these drugs. Patients at high-risk of malignant arrhythmias should have continuous ECG monitoring through the whole peri-operative period, with particular emphasis placed on patients who have had implantable cardioverter–deﬁbrillators (ICDs) deactivated during NCS.
6.4.2. Supraventricular arrhythmias
Supraventricular arrhythmias do not usually cause deferral of surgery. In rare cases, presence of pre-excitation and AF conducted rapidly over an accessory pathway ﬂag a patient at risk of SCD and may indicate the need for ablation, if surgery is not emergent.
Supraventricular premature beats usually do not require therapy.
Identiﬁcation and correction of potential triggers (electrolyte and acid-base imbalance, volume overload, etc.) are highly recommended. Peri-operative SVT typically responds well to vagal manoeuvres, or to a bolus of adenosine if unsuccessful. If SVT persists or reoccurs, i.v. beta-blockers, verapamil, or diltiazem can be used for rhythm conversion or temporal slowing of atrioventricular conduction.436 Prompt cardioversion should be performed in rare cases of haemodynamically unstable SVT. If prophylactic therapy is needed to prevent recurrent SVT, beta-blockers or non-dihydropyridine
CCBs (verapamil, diltiazem) can be used, and ﬂecainide/propafenone or amiodarone can be considered if ineffective. Rarely, when SVT
recurs despite therapy or becomes incessant, ablation should be considered in patients undergoing high-risk, non-emergent surgery. Recently published results of an RCT conﬁrmed the superiority of radiofrequency (RF) ablation over AADs for persistent atrioventricular nodal re-entry tachycardia. Large registries and meta-analyses have demonstrated efﬁcacy and safety of RF ablation in WPW syndrome and other SVTs, with a single-procedure success rate of .90.437–441
6.4.3. Atrial ﬁbrillation/ﬂutter
The majority of patients with AF receive lifelong OAC therapy for the prevention of stroke and systemic embolism,99 and the perioperative management of OAC therapy will depend on the type of surgery (see Section 5.3.2).99,240 Sometimes AF is asymptomatic442
and may be ﬁrst detected on admission for surgery, or may ﬁrst occur in the pre-operative period. The initial management of newly diagnosed
AF includes prevention of thromboembolism, and symptom control,
and should not be deferred awaiting consultation with a cardiologist.99
In patients with newly diagnosed AF who require systemic OAC therapy for stroke prevention, the choice of anticoagulant in the preoperative period depends on the type of surgery (see Section 5.3.2).
Optimal rate control (i.e. resting heart rate ,110 b.p.m.)99 is mandatory in all patients with AF, whereas rhythm control (i.e. achieving and maintenance of sinus rhythm) in the pre-operative period may be considered only if symptoms persist despite optimal rate control.
Rate control can be achieved using beta-blockers or nondihydropyridine CCBs (verapamil, diltiazem). Amiodarone can be used as ﬁrst-line therapy in patients with HF, whereas digoxin is usually ineffective in high adrenergic conditions such as surgery.
Pharmacological cardioversion of symptomatic recent-onset AF
can be attempted using ﬂecainide or propafenone; in patients without signiﬁcant LV hypertrophy, LV systolic dysfunction, or IHD,
the use of ﬂecainide or propafenone results in prompt (3–5 h) and safe restoration of sinus rhythm in .50% of patients. Intravenous amiodarone administration has a limited and delayed effect but can slow the heart rate within 12 h; i.v. vernakalant is the most rapidly cardioverting drug,
including patients with mild
HF
and/or
IHD.99,443 Dofetilide is not used in Europe, and ibutilide is effective to convert atrial ﬂutter to sinus rhythm.99,444 In patients with AF
and haemodynamic instability, emergency cardioversion (most commonly electrical direct current cardioversion)
is indicated.99
Alternatively, pharmacological cardioversion using i.v. AADs should be attempted, if consistent with the patient’s clinical status.
Systemic OAC therapy to prevent thromboembolic events should be started as soon as possible.99 Post-operative AF is discussed in
Section 8.6.
Management of atrial ﬂutter follows the same principles as AF with respect to OAC therapy. Rate control is usually an initial approach in patients with atrial ﬂutter;436 however, drugs that slow atrioventricular conduction (digoxin, beta-blockers, or non-dihydropyridine
CCBs) are usually less effective than in AF. In patients with a high ventricular rate, electrical cardioversion is frequently needed.445–448
Amiodarone may be an alternative used to control rate, especially in HF or critically compromised patients.449 Dofetilide and ibutilide are effective in converting atrial ﬂutter to sinus rhythm, whereas class
IA and IC drugs and amiodarone are less efﬁcient and should not be used.450–453
6.4.4. Ventricular arrhythmias
Premature ventricular contractions (PVC) and non-sustained VT are frequent in the general population and patients undergoing NCS.
Speciﬁc clinical features have been suggested as predictors of increasing incidence of PVC.454 These arrhythmias have historically been considered benign; however, recent studies have suggested that they may be associated with an adverse outcome, even in patients with apparently normal hearts, especially if frequent (e.g. .10–
20%).455–459 In patients with heart disease, the prognostic impact of PVC and non-sustained VT depends on type and extent of heart damage.460–466 In patients undergoing urgent NCS, they do not require treatment unless frequent and symptomatic.
ESC Guidelines
3879


<!-- PAGE 55 -->

### Page 55

If haemodynamically compromising, up-titration of beta-blockers is recommended; amiodarone (300 mg i.v. bolus) should be considered if beta-blockers are not tolerated or contraindicated.467 Further diagnostics to rule out signiﬁcant heart disease is necessary in patients awaiting elective NCS, especially if frequent, complex (non-sustained
VT), symptomatic, or in those with a positive family history of SCD.
Polymorphic VT and ventricular ﬁbrillation (VF) can be provoked by ischaemia, electrolyte imbalance, or may be manifestations of primary electrical disease, such as long-QT or Brugada syndrome.
Monomorphic VT is often associated with the presence of scarred myocardium. Hence, peri-operative VT or VF in a patient awaiting surgery should lead to a diagnostic work-up to exclude severe ventricular dysfunction (see Section 4.5.1), and to rule out CAD requiring prompt revascularization (see Section 6.1) and other potential causes of arrhythmia (primary electrical disease, dyselectrolytaemia).
Monomorphic VT in patients without overt structural or electrical heart disease (idiopathic VT, most commonly arising from outﬂow tract) is associated with good prognosis and may be left untreated or, if symptomatic, may be treated with beta-blockers, verapamil,
or sodium channel blockers. Patients with haemodynamically compromising VT should undergo electrical cardioversion (after i.v. sedation, if conscious) and VF should be terminated with prompt deﬁbrillation. Recurrent VT and VF in the setting of acute ischaemia may be effectively treated with beta-blockers and amiodarone, and myocardial revascularization in case of obstructive
CAD.468
Up-titration of beta-blockers to the maximal tolerated doses can prevent arrhythmia recurrence.469
Haemodynamically stable, sustained VT should be cardioverted as a ﬁrst-line treatment; i.v. procainamide or ﬂecainide may be considered in patients without HF or myocardial ischaemia. In cases in which these drugs are unavailable, i.v. amiodarone can be used. In selected cases, when monomorphic VT recurs in patients with scarred myocardium with no reversible causes, despite optimal therapy, invasive electrophysiological study and ablation should be performed pre-operatively, if NCS can be deferred. After extensive endocardial
VT ablation, treatment with an OAC for a limited period of time might be reasonable.470,471 A summary of diagnostic and therapeutic pathways in patients with SVT or VT is shown in Table 12.
Table 12
Peri-operative management of patients with arrhythmias
Type of arrhythmia
SVT
Idiopathic VT in structurally/functionally normal heart
VT in structural heart disease
Diagnostics
• ECG + TTEa
• ECG + TTE
• ECG + TTE +
biomarkersb
• + Coronary angiography
• + Cardiac CT/MRI
Acute management
• Vagal manoeuvres
• I.v. adenosine, beta-blocker, CCB
• Electrical cardioversion if unstable
• Vagal manoeuvres
• I.v. beta-blockers/ verapamil
• Electrical cardioversion if unstable
• Treatment of underlying heart disease
• I.v. beta-blocker
(uptitration), amiodarone
• Electrical cardioversion if unstable
Prevention of recurrence
• Per oral beta-blocker, CCB
• Catheter ablation if recurrent despite
OMT (only before high-risk NCS)
• No treatment or
• Per oral beta-blocker, CCB, class I AAD
• Catheter ablation in case of recurrence despite
AADs or drug-intolerance before high-risk NCS
• Per oral beta-blocker,
amiodarone
• Catheter ablation if recurrent despite OMT
© ESC 2022
AAD, antiarrhythmic drug; CCB, calcium channel blocker; CT, computer tomography; ECG, electrocardiogram; MRI, magnetic resonance imaging; NCS, non-cardiac surgery; OMT,
optimal medical therapy; SVT, supraventricular tachycardia; TTE, transthoracic echocardiography; VT, ventricular tachycardia.
aBefore high-risk surgery.
bHigh-sensitivity cardiac troponin T/I, and/or BNP/ N-terminal pro-BNP.
Recommendation Table 22 — Recommendations for management of known or newly diagnosed arrhythmias
Recommendations
Classa
Levelb
Supraventricular arrhythmias
In patients with SVT controlled by medication, it is recommended that AADs are continued during the peri-operative period.
I
C
Ablation should be considered in symptomatic patients with recurrent or persistent SVT,
despite treatment, prior to high-risk, non-urgent
NCS.437–441
IIa
B
AF with haemodynamic instability in patients undergoing
NCS
In AF patients with acute or worsening haemodynamic instability undergoing NCS,
emergency electrical cardioversion is recommended.99,472,473
I
B
In AF patients with haemodynamic instability,
amiodarone may be considered for acute control of heart rate.99
IIb
B
Continued


<!-- PAGE 56 -->

### Page 56

6.4.5. Bradyarrhythmias
Temporary cardiac pacing during the peri-operative period should be limited to patients undergoing urgent NCS, if bradycardia is haemodynamically compromising despite i.v. chronotropic drugs,
or provokes episodes of ventricular tachyarrhythmia.481 In patients undergoing elective NCS, surgery should be deferred if possible,
and permanent pacemaker should be implanted, if indications for pacing are fulﬁlled.481 Prophylactic pacing in the settings of asymptomatic bifascicular block, with or without ﬁrst-degree atrioventricular block, is generally not indicated, and chronotropic drugs (atropine,
isoprenaline, adrenaline, or, alternatively, aminophylline, dopamine,
or glucagon in beta-blocker or CCB overdosing) are usually effective.
Patients with bifascicular bundle branch block or prolonged
His-ventricular interval are at an increased risk of developing complete heart block.482,483 Equipment needed to perform emergent transcutaneous pacing and personnel able to perform such a procedure should be immediately available during NCS in patients with bifascicular block; alternatively, a permanent pacemaker may be implanted.481
6.4.6. Management of patients with cardiac implantable electronic devices
Patients with CIEDs can undergo NCS, pending adequate perioperative device management. A pre-operative check should have been performed at least once within the 12 months preceding surgery for pacemaker patients and within 6 months for patients with
ICD, in the absence of any malfunction (remote monitoring can also be used for check-ups).484,485 In pacing-dependent patients, patients with biventricular pacing for CRT, and ICD-recipients undergoing elective NCS associated with risk of electromagnetic interference (EMI) (e.g. involving the use of unipolar electrocoagulation, especially above the umbilicus), CIED check and reprogramming should be performed immediately before surgery. In pacemakerdependent patients, devices should be reprogrammed to nonsensing or asynchronous pacing mode to protect against inhibition of the pacemaker. This can be performed in the majority of pacemaker models by placing a magnet over the pacemaker can.486,487
However, magnet mode in modern pacemakers, except Medtronic and Sorin/Livanova/Microport, is programmable and may not be asynchronous pacing; thus, magnet application is not a universal remedy against EMI-induced malfunction. Furthermore, asynchronous pacing may lead to pacing on the T wave, which can provoke VT/
VF. However, the risk of clinically signiﬁcant EMI is low487–489 and a practical solution would be to monitor the patient via plethysmography or an arterial line, and limit the use of electrocautery if pauses occur during ECG monitoring.
Patients with leadless pacemakers may safely undergo surgery,
with precautions similar to patients with conventional pacemakers,
avoiding EMI and after reprogramming the pacemaker into nonsensing mode in pacing-dependent patients (due to its intracardiac location and lack of a Hall-effect sensor/reed switch, this device cannot be temporarily reprogrammed to an asynchronous mode with a magnet applied over the body of the pacemaker).490,491
In patients with ICDs undergoing NCS with anticipated risk of EMI,
arrhythmia detection or antiarrhythmic therapies through the device should be switched off before NCS,492 or a magnet should be put over the device.488,489,492 All modern ICDs will respond to magnet application by inhibiting antitachycardia therapy, while the brady pacing is left intact. Deactivation by programming mandates telemetry and cardioversion equipment until reactivation, which may be impractical. Furthermore, there is a risk that the patient is discharged without the device being reactivated. These factors would favour the use of a magnet instead of deactivation. In some patients where the device is inaccessible for magnet application, a magnet cannot be used and reprogramming is mandatory. From this point onwards,
throughout the whole procedure until reactivation of the ICD, the patient should have continuous ECG monitoring, and personnel skilled in early detection of arrhythmias, deﬁbrillation, and cardiopulmonary resuscitation manoeuvres should be present. As soon as possible after NCS, it is recommended that the ICD is checked and therapies switched on.485
Patients with subcutaneous ICD can undergo surgery after switching off the antiarrhythmic therapy or magnet application; however, if thoracic surgery is planned, especially with a median sternotomy, the surgeon should be aware of the presence of the ICD and the course of the subcutaneous electrode. This can prevent mechanical damage of the lead, the direct use of electrocautery on the electrode,
or the placement of sternal wires in close proximity to the sensing electrodes.493
In pacing-dependent patients, patients with CRT, and ICD patients, EMI with the device should be avoided (e.g. with electrocautery). Use of bipolar electrocautery, short bursts of impulses limited to several seconds (,5 s), with the lowest effective energy,
and operating with a pen or stylus away from the device (.15 cm)
can minimize the risk of interference with the device. In the case of unipolar electrocoagulation, the electrosurgical unit should be connected in a way that keeps the current circuit away from the
CIED can and electrodes. However, the manufacturer’s recommendations should be considered (usually recommending placement of the indifferent electrode on the opposite site of the body to the one operated on, but possibly close to the surgical site, on a wellvascularized, muscular area). Consequently, the indifferent return pad should be placed as far away from the CIED as possible, keeping the surgical site between the CIED and the return electrode
(Figure 15).494–497
In patients with implantable loop recorders (especially those not undergoing remote monitoring and regular downloads of the
CIED memory), the device memory download is to be considered
Ventricular arrhythmias
In patients with symptomatic, monomorphic,
sustained VT associated with myocardial scar,
recurring despite optimal medical therapy,
ablation of arrhythmia is recommended before elective NCS.474–480
I
B
It is not recommended to initiate treatment of asymptomatic PVC during NCS.
III
C
© ESC 2022
AAD, antiarrhythmic drug; AF, atrial ﬁbrillation; NCS, non-cardiac surgery; PVC,
premature ventricular contractions; SVT, supraventricular tachycardia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
3881


<!-- PAGE 57 -->

### Page 57

before procedures associated with possible EMI, or involving the anatomical location close to the device, to avoid misrecognizing and recording noise as arrhythmia or erasing the memory.498,499
6.5. Adult congenital heart disease
Adults with congenital heart disease (ACHD) account for .60% of the population with congenital heart disease
(CHD).500,501
Accordingly, ACHD represent an increasing proportion of NCS admissions502 and might be at high risk of CV events.
Pre-operative risk assessment in ACHD needs to focus on the underlying disease, type of surgery, residua, and sequelae.503
Coexistence of HF, pulmonary hypertension, arrhythmia, hypoxaemia, damage to other organs, and endocarditis may considerably inﬂuence the baseline risk of these patients from no additional risk to very high risk of worse prognosis.503,504 Thus, original medical and surgical reports should be obtained along with current data,
which should include symptoms, exercise capacity, oxygen saturation, laboratory values (BNP, haemoglobin, creatinine, etc.), and medication.
Recommendation Table 23 — Recommendations for management of bradyarrhythmia and patients carrying cardiac implantable devices
Recommendations
Classa
Levelb
If indications for pacing exist according to the
surgery should be deferred and implantation of a permanent pacemaker should be considered.
IIa
C
It is recommended that patients with temporarily deactivated ICDs have continuous ECG
monitoring, and during the peri-operative period are accompanied by personnel skilled in early detection and treatment of arrhythmias. In high-risk patients (e.g. pacemaker-dependant or
ICD patients), or if access to the torso will be difﬁcult during the procedure, it is recommended to place transcutaneous pacing/deﬁbrillation pads prior to NCS.
I
C
It is recommended that all patients with CIEDs that are reprogrammed before surgery have a re-check and necessary reprogramming as soon as possible after the procedure.
I
C
Continued
In high-risk CIED patients (e.g. with ICD or being pacing-dependant) undergoing NCS carrying a high probability of electromagnetic interference
(e.g. involving unipolar electrosurgery above the umbilical area), CIED check-up and necessary reprogramming immediately before the procedure should be considered.
IIa
C
© ESC 2022
CIED, cardiac implantable electronic device; ECG, electrocardiogram; ICD, implantable cardioverter–deﬁbrillator; NCS, non-cardiac surgery.
aClass of recommendation.
bLevel of evidence.
A
B
C
Electric knife
Return electrode
CIED
Figure 15 Optimal location of return electrode during unipolar electrosurgery in patients with cardiac implantable electronic devices, depending on the surgery site. CIED, cardiac implantable electronic device. Use of bipolar electrocautery, short (,5 s) bursts of impulses, with the lowest effective energy,
operating with pen or stylus away (.15 cm) from the device can minimize the risk of interference with the device. (A) Surgery site on ipsilateral site above
CIED. (B) Surgery on ipsilateral site below CIED. (C) Surgery on contralateral site.494


<!-- PAGE 58 -->

### Page 58

In a recent report, absolute mortality in ACHD patients undergoing NCS exceeded 4%.502 Mortality and peri-operative morbidity were greater in ACHD compared with a matched comparison cohort, and patients with severe ACHD had the highest mortality rate. It is well known that patients with pulmonary hypertension and with Eisenmenger syndrome have a higher risk of complications.505 A large registry conﬁrmed these ﬁndings: patients with severe CHD had an increased risk of 30 day mortality, overall mortality, and reintubation, while patients with intermediate CHD
had a moderate increase in overall mortality and risk of reintubation.506 Based on this study and recent guidelines,503 the classiﬁcation in Table 13 is proposed for risk stratiﬁcation.
A consultation by an ACHD specialist is necessary, especially in patients with intermediate or severe
ACHD
scheduled for intermediate- or high-risk NCS. It is recommended that elective surgery in intermediate- and severe-risk ACHD patients should take place in centres experienced in the management of ACHD patients.
It is generally recommended to perform the least invasive procedures and anaesthesia with as low an impact on haemodynamics as possible.
Optimal peri-operative care in ACHD undergoing NCS starts with a proper pre-operative evaluation. Adults with congenital heart disease can present with multiorgan involvement (kidneys, liver, lung,
and endocrine system), which should be considered during the diagnostic work-up.503 In many cases, patients with ACHD have a lifelong indication for OAC therapy or antithrombotic treatment, mainly due to arrhythmias or increased thromboembolic risk associated with speciﬁc ACHD. Oral anticoagulant therapy in the peri-operative phase should be re-evaluated on a case-by-case basis. The
CHA2DS2-VASc score has not been validated in ACHD patients and should not be used in this group.
Continuous haemodynamic monitoring can be necessary in patients with ACHD and should include invasive BP monitoring, especially in cases with ACHD of moderate or severe complexity. It is worth mentioning that, according to the type of ACHD or surgery
(e.g. coarctation of the aorta or following a Blalock-Taussig shunt),
the location of the arterial line for continuous BP and gas exchange monitoring requires careful attention. In patients with persistent right-to-left shunts, air ﬁlters must be used for venous access.
Ventilator management and extubation can be complicated by the presence of restrictive lung disease.507 Antibiotic prophylaxis for endocarditis should be given according to the 2015 ESC Guidelines for the management of infective endocarditis.432 Furthermore, postoperative care in an ICU with experience in handling ACHD patients is often necessary.
A prolonged monitoring period in this setting should be considered, with a special focus on arrhythmias and an optimal volume management, as it has been shown that up to 50% of adverse events were attributable to lapses in the post-operative monitoring and care.508 Two groups at special risk are patients with chronic cyanosis and those after the Fontan procedure. Chronic cyanosis is associated with multiorgan involvement. Furthermore, bleeding risk is higher due to multiple collaterals, platelet dysfunction, and alterations in the coagulation cascade.509 In patients with Eisenmenger syndrome,
conditions that increase pulmonary vascular resistance such as hypothermia, metabolic acidosis, hypercapnia, and hypovolaemia must be avoided.509 This is also true for patients after the Fontan procedure,
where venous return relies on low pulmonary pressures. If intra-abdominal pressure rises too high in these patients, venous return is drastically reduced, with a subsequent drop in cardiac output.
These haemodynamic aspects should be carefully considered in cases of laparoscopic or open NCS.
6.6. Pericardial diseases
Active pericardial disease is infrequent at the time of NCS, but potentially life-threatening. The clariﬁcation of underlying aetiology is of utmost importance for peri-operative management (viral or bacterial infection, malignant, systemic autoimmune, metabolic, or autoreactive disease). The treatment of these conditions should follow the recommendations provided in the 2015 ESC Guidelines for the diagnosis and management of pericardial diseases.510
Acute pericarditis is a clear indication to postpone an elective surgical procedure. However, in cases of undeferrable NCS, attention is required regarding drug-to-drug interactions. The frequently used colchicine is predominantly metabolized through the liver, while renal excretion accounts for only 10–20%. Colchicine may increase
Recommendation Table 24 — Recommendations for management of patients with adult congenital heart disease undergoing non-cardiac surgery
Recommendations
Classa
Levelb
In patients with ACHD, a consultation with an
ACHD specialist is recommended before intermediate- or high-risk surgery.
I
C
In patients with ACHD, it is recommended that intermediate- and high-risk elective surgery is performed in a centre with experience in the care of ACHD patients.
I
C
© ESC 2022
ACHD, adults with congenital heart disease.
aClass of recommendation.
bLevel of evidence.
Table 13
Risk stratiﬁcation for non-cardiac surgery in adults with congenital heart disease
Minor risk
Patients with small, uncorrected defects, and no need for medication or any other treatment
Patients with successfully corrected CHD with no symptoms, no relevant residua, and no need for medication
Intermediate risk
Patients with corrected or uncorrected conditions with residual haemodynamic abnormality, with or without medication
Severe risk
Patients with uncorrected cyanotic heart disease,
pulmonary hypertension, other complex CHD,
ventricular dysfunction requiring medication, and patients listed for heart transplantation
© ESC 2022
CHD, congenital heart disease.
ESC Guidelines
3883


<!-- PAGE 59 -->

### Page 59

sensitivity to central nervous system depressants and exert a respiratory depressant effect.511 Adverse events of peri-operative signiﬁcance include diarrhoea, worsening renal failure, and, very rarely,
bone marrow suppression, hepatotoxicity, paralysis, convulsions,
and cardiopulmonary collapse. Immunosuppressive drugs such as steroids and interleukin-1 receptor antagonist agents suppress the immune system, and may increase the risk of infection and delay wound healing in the peri-operative phase.511
Imminent cardiac tamponade is an absolute contraindication for all surgical procedures, especially when a general anaesthesia is required.510,512 Before NCS, pericardial effusion should ﬁrst be percutaneously drained, under local anaesthesia. In cases of small or moderate chronic pericardial effusion and constrictive pericarditis,
attention should be paid to take measurements to increase cardiac pre-load. The pre-load should be optimized peri-operatively with i.v. ﬂuids prior to general anaesthetic induction to facilitate ventricular ﬁlling. Manipulation and medication diminishing venous return to the heart should be avoided or minimized. Positive pressure ventilation might cause a dramatic decline in pre-load and should be avoided. If spontaneous breathing is not possible, ventilation with minimal inspiratory pressures (low tidal volumes, high respiratory rate) should be considered. Anaesthetics that minimize changes in heart rate, systemic vascular resistance, venous return, and myocardial contractility should be selected.189 Ketamine, a sympathetic stimulant that preserves spontaneous ventilation, is the drug of ﬁrst choice. Combinations of opiates, benzodiazepines, and nitric oxide,
with or without low doses of volatile anaesthetics, are acceptable for maintenance of anaesthesia. Muscle relaxants with minimal circulatory effects should be preferred, although the modest increase in heart rate observed with administration of pancuronium is also acceptable.
6.7. Pulmonary disease and pulmonary arterial hypertension
The coexistence of pulmonary disease in cardiac patients undergoing
NCS may increase the operative risk. Pre-existing pulmonary disease has a signiﬁcant impact on peri-operative risk, but the most common effect is an increase in the risk of post-operative pulmonary complications. These complications particularly occur after abdominal or thoracic surgery, and the risk seems to be increased in smokers.
Certain respiratory conditions are associated with CV pathology and may require special cardiac risk assessment and management,
in addition to dealing with the pulmonary disease per se. Three such conditions are chronic obstructive pulmonary disease
(COPD), obesity hypoventilation syndrome, and pulmonary arterial hypertension (PAH).
6.7.1. Pulmonary disease
Chronic obstructive pulmonary disease is as a major cause of morbidity and mortality.513 Although patients with COPD have an increased risk of CVD, there is no evidence that COPD is related to a higher risk of peri-operative cardiac complications. However,
post-operative pulmonary complications result in signiﬁcant mortality and morbidity. Pre-operative evaluation, using speciﬁc postoperative pulmonary complication tools, can be used to stratify at-risk patients and enable optimal pre-operative and perioperative management.514 In patients with COPD undergoing
NCS, the pre-operative treatment goals are to optimize pulmonary function and minimize post-operative respiratory complications; this includes using the pre-operative period for education,
including possible cessation of smoking (2 months before surgery),
instruction concerning chest physiotherapy and lung expansion manoeuvres, muscular endurance training, and re-nutrition if required. Beta-adrenergic agonists and anticholinergic agents should be continued until the day of surgery in all symptomatic COPD patients with bronchial hyper-reactivity. In some cases, short-term systemic/inhaled steroids may be considered. Where there is active pulmonary infection, appropriate antibiotics should be administered for at least 10 days and, if possible, elective NCS should be deferred.515
Obesity hypoventilation syndrome is deﬁned as the triad of obesity,
daytime hypoventilation,
and sleep-disordered breathing.
Although distinct from simple obesity and sleep apnoea, it is estimated that 90% patients with obesity hypoventilation syndrome also have obstructive sleep apnoea (OSA). The prevalence of obesity hypoventilation syndrome is 0.15–3% of adults and 7–22% in patients undergoing bariatric surgery.516 Obesity hypoventilation syndrome is associated with even higher morbidity,
including
HF
(and obesity-related cardiomyopathy), angina pectoris, pulmonary hypertension (30–88%) and cor pulmonale, and increased peri-operative mortality.516 Patients at high risk of obesity hypoventilation syndrome who are undergoing NCS should be referred for additional specialist investigation of sleep-disordered breathing and pulmonary hypertension,
with pre-operative initiation of appropriate positive airway pressure therapy, and planning of peri-operative techniques (anaesthetic and surgical) and post-operative positive airway pressure management within an appropriate monitored environment.516,517
6.7.2. Pulmonary arterial hypertension
Pulmonary arterial hypertension is associated with increased morbidity and mortality in patients undergoing
NCS.518
Recommendation Table 25 — Recommendations for pericardial diseases
Recommendations
Classa
Levelb
In patients with acute pericarditis, deferring elective NCS until complete resolution of the underlying process should be considered.
IIa
C
Avoiding elective NCS procedures under general anaesthesia until colchicine or the immunosuppressive treatment course for pericardial disease is completed may be considered.
IIb
C
© ESC 2022
NCS, non-cardiac surgery.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 60 -->

### Page 60

A meticulous pre-operative diagnostic work-up in this subset of patients should include assessment of functional status and severity of disease, in addition to comorbidities and the type of
NCS. Echocardiography and right heart catheterization (if clinically indicated) are key components in the pre-operative work-up.
The morbidity and mortality associated with PAH derive from the haemodynamic response of the right ventricle to acute increases in afterload.519
In patients with severe PAH, peri-operative mortality ranging between
3–18%
has been reported,
depending on the severity of the underlying disease, and the nature and urgency of the surgical procedure. Emergency procedures are also associated with a high risk of complications.520,521 Patient-related and surgery-related factors should be considered when assessing perioperative risk in patients with PAH (Table 14).522 Owing to the potential for anaesthesia and surgery to be complicated by acute right HF and pulmonary hypertensive crisis, elective NCS in patients with PAH should be adequately discussed in a multidisciplinary team. Ideally, patients with PAH undergoing NCS should have optimal medical treatment before surgery and be managed in a centre experienced in PAH. Patients scheduled for NCS should be discussed by a pneumologist, cardiologist, surgeon, and an anaesthesiologist.523 The management of patients with PAH in the peri-operative setting should follow the recommendations provided in the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.524
Several novel therapies aimed at reducing pulmonary pressures are used pre-operatively in patients undergoing NCS. Of these therapies, endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogues are the most used.525
This medication should be continued during the peri-operative phase because therapy disruption may lead to a critical rebound of the PAH. Inhaled nitric oxide allows selective pulmonary vasodilatation with rapidity of action and it can be given to patients who develop worsening pulmonary hypertension postoperatively to maintain right ventricular (RV) function and haemodynamic stability.526
6.8. Arterial hypertension
The prevalence of arterial hypertension in adults in Europe is
≏30–45%.527 Of these patients, ,40% have well-controlled BP
(,140/90 mmHg). A large observational study has shown that patients with untreated hypertension 1 month before surgery had a
69% increased risk of 90 day post-operative mortality.183 Further,
overall CV risk assessment, including the search for hypertensionmediated organ damage, is of paramount importance in hypertensive patients, and mandatory when there is newly detected BP
elevation.528
Postponing surgery is usually not advised in patients with grade
1 or 2 hypertension. In contrast, in subjects with a systolic BP
≥180 mmHg and/or diastolic BP ≥110 mmHg, deferring the intervention until BP is under control is advisable, except for emergency surgery.236,527,529,530 It also seems important to avoid large peri-operative BP ﬂuctuations. In a recent randomized trial among patients undergoing abdominal surgery, an individualized intra-operative treatment strategy with systolic BP values kept within a 10% difference from the pre-operative ofﬁce measurement resulted in a reduced risk of post-operative organ dysfunction.528 In a meta-analysis including 130 862 patients undergoing surgery,
intra-operative hypotension was associated with
Table 14
Patient-related and surgery-related factors to be considered when assessing peri-operative risk in patients with pulmonary arterial hypertension
Patient-related peri-operative risk factors in patients with PAH
Surgery-related peri-operative risk factors in patients with PAH
• Functional class .II
• Reduced six-minute walk distance
• Coronary heart disease
• Previous pulmonary embolism
• Chronic renal insufﬁciency
• Severe right ventricular dysfunction
• Emergency surgery
• Duration of anaesthesia .3 h
• Intra-operative requirement for vasopressors
© ESC 2022
PAH, pulmonary arterial hypertension.
Adapted from Olsson et al.522
Recommendation Table 26 — Recommendations for patients with pulmonary arterial hypertension undergoing non-cardiac surgery
Recommendations
Classa
Levelb
It is recommended to continue chronic therapy for PAH in the peri-operative phase of NCS.
I
C
It is recommended that haemodynamic monitoring of patients with severe PAH continues for at least 24 h in the post-operative period.
I
C
In the case of progression of right HF in the post-operative period in patients with PAH, it is recommended that the diuretic dose be optimized and, if necessary, i.v. prostacyclin analogues be initiated under the guidance of a physician experienced in the management of PAH.
I
C
Inodilator drugs (dobutamine, milrinone,
levosimendan), which increase cardiac output and lower pulmonary vascular resistance, should be considered peri-operatively according to the haemodynamic status of the patient.
IIa
C
© ESC 2022
HF, heart failure; i.v., intravenous; NCS, non-cardiac surgery; PAH, pulmonary arterial hypertension.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
3885


<!-- PAGE 61 -->

### Page 61

increased risk of morbidity (OR, 2.08; 95% CI, 1.56–2.77), mortality (OR, 1.94; 95% CI, 1.32–2.84), cardiac complications (OR,
2.44; 95% CI, 1.52–3.93), and AKI (OR, 2.68; 95% CI, 1.31–
5.55).531 In patients with hypertension, hypoperfusion may occur at higher BP levels and peri-operative BP control should be tailored to pre-operative levels.528
In patients referred for elective NCS, control of BP should be prioritized, especially in patients with systolic BP .160 mmHg.
The management of patients with hypertension in the pre-operative setting should follow the recommendation provided in the 2018
ESC/European Society of Hypertension (ESH) Guidelines for the management of arterial hypertension.529 These guidelines advocate an approach using RAAS inhibitors (in patients aged ,70 years) or
CCBs (in patients aged .70 years) as single therapy in moderate hypertension and both in combination where dual therapy is needed, adding a diuretic and an aldosterone antagonist if additional medication is needed for adequate control. Beta-blockers are restricted to patients where it is speciﬁcally indicated.529 In patients with hypertension and a clear indication for beta-blocker, thirdgeneration beta-blockers—such as carvedilol, celiprolol, labetolol,
and nebivolol—have superior antihypertensive effects compared with other beta-blockers and fewer adverse effects, but there are no RCTs reporting outcomes in hypertensive patients.529 In a large observational study, a beta-blocker prescription prior to
NCS was associated with lower 30 day mortality in patients with three or four cardiac risk factors.188 However, for patients with no cardiac risk factors, the risk of death was signiﬁcantly increased with beta-blockers.188,532
Most patients with stage 3 hypertension on the day of surgery will be classiﬁed as hypertensive urgencies. In these cases, the
2018 ESC/ESH Guidelines for the management of arterial hypertension recommend ACEIs, CCBs, or diuretics. Neither ACEIs nor diuretics are recommended on the day of surgery. The use of CCBs is supported by a meta-analysis of 11 studies of CCBs during NCS.220 Further, a study of 989 well-controlled patients with hypertension without hypertension-related organ damage, testing the use of fast-acting nasal nifedipine when stage 3 hypertension
(systolic BP .180 and/or diastolic BP .110 mmHg) was diagnosed the day of NCS, found no difference in outcome between administration of nifedipine and surgery on the same day compared with deferral for hypertension control before resuming surgery.533
Immediate nifedipine treatment was associated with shorter hospital stays. As this was the ﬁrst study testing the need for deferral of stage 3 hypertension, it challenged the need for this practice. For patients with hypertensive emergencies (systolic BP .180 and/or diastolic BP .110 mmHg and organ damage), the 2018 ESC/ESH
Guidelines for the management of arterial hypertension recommend labetolol, nitroglycerin, nitroprusside, etc., according to the affected organ.529
The timing of administration of the antihypertensive drugs, and their continuation or discontinuation in the peri-operative period is discussed in Section 5.2.
6.9. Peripheral artery disease
Patients with peripheral artery disease (PAD) usually have advanced atherosclerotic disease affecting multiple vascular beds in varying degrees and have a worse prognosis compared with patients without
PAD.534–538 Patients with PAD generally differ in their risk proﬁles, according to whether they undergo vascular or non-vascular NCS.
6.9.1. Peripheral artery disease and non-vascular non-cardiac surgery
Decisions on pre-operative treatment of pre-existing PAD and AAA
in patients scheduled for non-vascular NCS should be made on an individual basis, taking into account symptoms and risks of surgery.
Non-cardiac surgery should be prioritized in patients needing revascularization for PAD, but careful peri-operative monitoring of deterioration in lower extremity perfusion is warranted, particularly in those patients with chronic limb-threatening ischaemia (e.g. peripheral BP of ≤50–70 mmHg in the foot joint and ≤30–50 mmHg in the toes).539 For patients with AAA, pain control is essential to ensure stable BP, minimizing rupture risk. Patients with large AAA
(i.e. .5 cm in diameter for women and .5.5 cm for men) should be evaluated for aortic aneurysm repair (preferably EVAR)540–542
before non-vascular NCS is planned, particularly in the case of malignant tumours, depending on the stage of malignant disease.
6.9.2. Peripheral artery disease and vascular non-cardiac surgery
The 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases535 and the European Society for Vascular
Surgery (ESVS) 2019 Clinical Practice Guidelines on the management of abdominal aorto-iliac artery aneurysms35 provide detailed evidence and recommendations on the screening of patients before vascular
Recommendation Table 27 — Recommendations for pre-operative management of hypertension
Recommendations
Classa
Levelb
In patients with chronic hypertension undergoing elective NCS, it is recommended to avoid large peri-operative ﬂuctuations in blood pressure,
particularly hypotension, during the peri-operative period.528,531
I
A
It is recommended to perform pre-operative screening for hypertension-mediated organ damage and CV risk factors in newly diagnosed hypertensive patients who are scheduled for elective high-risk NCS.
I
C
It is not recommended to defer NCS in patients with stage 1 or 2 hypertension.
III
C
© ESC 2022
CV, cardiovascular; NCS, non-cardiac surgery.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 62 -->

### Page 62

NCS and their treatment modality selection. Notably, there is randomized evidence against prophylactic coronary revascularization before major vascular surgery in CCS patients due to lack of beneﬁt in improvement of peri-operative and long-term outcomes (2.7 years mean follow-up).399 Assessment of functional capacity might offer guidance to select candidates for cardiac assessment prior to major
NCS, although severe walking impairment may challenge this test.
The previously established risk predictive model to detect mortality in patients undergoing elective AAA repair may be helpful.543
Low-dose rivaroxaban plus aspirin initiated within 10 days after a lower limb revascularization procedure reduces post-operative thrombotic events (acute limb ischaemia, amputation, MI, ischaemic stroke, and CV death) in patients undergoing lower limb revascularization, whether it is carried out using an endovascular or open surgical approach.544 Handling of other co-drugs should follow the recommendations detailed in Section 5.2.
6.10. Cerebrovascular disease
Patients undergoing NCS should be questioned about previous neurological symptoms, and those with symptoms suggestive of transient ischaemic attack (TIA) or stroke in the preceding 6 months should undergo pre-operative neurological consultation and neurovascular and brain imaging, if appropriate. In the absence of dedicated studies addressingthisissue,thecriteriaforcarotidrevascularizationinsymptomaticand asymptomatic patients is described in detail in the 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the ESVS; these guidelines should also guide the management of patients with carotid disease who are undergoing NCS.535
In patients with symptomatic carotid disease, the beneﬁt of carotid revascularization is particularly high in patients with recent (,3
months) TIA or stroke, and ≥70% carotid artery stenosis. Thus, carotid revascularization should be performed ﬁrst and elective NCS
should be postponed.545
The question as to whether patients with severe asymptomatic carotid occlusive disease who are undergoing elective major NCS require pre-operative carotid revascularization remains a matter of debate. Importantly, the purpose of carotid revascularization in this setting is more the long-term prevention of stroke than perioperative stroke risk reduction; therefore, if carotid revascularization is indicated, this may be performed before or after the planned NCS.
Independent of the revascularization strategy, patients with carotid artery stenosis beneﬁt from aggressive CV risk-factor modiﬁcation to prevent peri-operative myocardial ischaemia.
6.11. Renal disease
Renal disease is associated with several cardiac comorbidities, including hypertension, HF, CAD, and arrhythmias.546 Consistently, renal disease portends a signiﬁcant increase in the post-operative risk of CV events,
including MI, stroke, and progression of HF in patients undergoing NCS.
For this reason, most risk indices for the quantiﬁcation of pre-operative risk in patients undergoing NCS include renal function.
Chronic kidney disease (CKD) is deﬁned as impaired kidney function or raised proteinuria, conﬁrmed on two or more occasions at least 3 months apart. The kidney function can be assessed through the estimated glomerular ﬁltration rate (eGFR) calculated using the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, including sex, age, ethnic origin, and serum creatinine concentration. A cut-off glomerular ﬁltration rate (GFR) value ,60 mL/min/
1.73 m2 signiﬁcantly correlates with MACEs. Identiﬁcation of cardiac patients at risk of worsening of renal function in the peri-operative phase of NCS is of paramount importance, in order to initiate supportive measures such as maintenance of adequate intravascular volume for renal perfusion and use of vasopressors.547
Patients with cardiac comorbidities are prone to develop AKI after major NCS, due to worsening of haemodynamic status associated with ﬂuids or blood loss, and withdrawal or continuation of cardio-active therapies. The peri-operative management of patients undergoing NCS and treated with cardio-active drugs has been discussed in Section 5.2. Acute kidney injury reduces long-term survival in patients with normal baseline renal function.548 Of interest,
≏30–40% of all cases of AKI occur after surgery and the incidence of post-operative AKI ranges 18–47%. Risk factors for the development of post-operative AKI following NCS include cardiac
Recommendation Table 28 — Recommendations for management of patients with peripheral artery disease and/or abdominal aortic aneurysm undergoing non-cardiac surgery
Recommendations
Classa
Levelb
In patients with poor functional capacity or signiﬁcant risk factors or symptoms (such as moderate-to-severe angina pectoris,
decompensated HF, valvular disease, and signiﬁcant arrhythmia), referral for cardiac work-up and optimization is recommended prior to elective surgery for PAD or AAA.
I
C
Routine referral for cardiac work-up, coronary angiography, or CPET prior to elective surgery for
PAD or AAA is not recommended.
III
C
© ESC 2022
AAA, abdominal aortic aneurysm; CPET, cardiopulmonary exercise testing; HF, heart failure; PAD, peripheral artery disease.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 29 — Recommendations for management of patients with suspected or established carotid artery disease undergoing non-cardiac surgery
Recommendations
Classa
Levelb
Pre-operative carotid artery and cerebral imaging is recommended in patients with a history of TIA
or stroke in the previous 6 months and who have not undergone ipsilateral revascularization.
I
C
For patients with carotid artery disease undergoing NCS, the same indications for carotid revascularization should be considered as for other patients with carotid stenosis.
IIa
C
Pre-operative carotid artery imaging is not recommended routinely in patients undergoing NCS.
III
C
© ESC 2022
NCS, non-cardiac surgery; TIA, transient ischaemic attack.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
3887


<!-- PAGE 63 -->

### Page 63

(decompensated or chronic HF, hypertension, cardio-active drugs)
and non-cardiac triggers (age, sex, emergent, and/or intraperitoneal surgery, mild pre-operative renal insufﬁciency, pre-operative creatinine elevation, CKD, and DM).549,550 The combination of a low cardiac output/high venous pressure and/or the administration of iodinated contrast media during diagnostic and operative procedures represent the most frequent causes of AKI in hospitalized cardiac patients, regardless of pre-existing impaired renal function.
Contrast-induced AKI is deﬁned as a rise in serum creatinine of
44 mmol/L (0.5 mg/dL) or a 25% relative rise from baseline at 48 h
(or 5–10% at 12 h) following contrast administration. It occurs in up to 15% of patients with CKD who are undergoing radiographic procedures.551 Although most cases of contrast-induced AKI are self-limiting, with renal function returning to normal within 7 days of the procedure, these patients occasionally (0.5–12% of cases) develop overt renal failure associated with increased morbidity and mortality. To reduce the risk of contrast-induced AKI in subjects requiring contrast-enhanced radiography,
the
Kidney
Disease:
Improving Global Outcomes (KDIGO) Clinical Practice Guidelines recommend: pre-operative hydration with i.v. isotonic ﬂuids; the use of the minimum volume of contrast media; and the use of lowosmolar or iso-osmolar contrast media, regardless of pre-existing renal disease.547 In the post-operative phase, kidney function should be monitored by applying established AKI scoring systems to raise awareness and enable early intervention.552
6.12. Obesity
The prevalence of people being overweight and having obesity is reaching epidemic proportions in Western countries557 and is the second leading cause of preventable death following tobacco use.558 Obesity is deﬁned as a body mass index (BMI) of ≥30 kg/m2,
morbid obesity as a BMI ≥35 kg/m2, and super-morbid obesity as a
BMI ≥50 kg/m2. Obese individuals have a higher prevalence of CV
risk factors and a higher risk of death,559 and are a population who are at increased risk of adverse events in the case of surgical procedures. There are speciﬁc recommendations for the pre-operative risk assessment of obese patients undergoing NCS, regardless of the presence of pre-existing cardiac conditions.560 However, while obesity accelerates the propensity for CVD, it seems that many types of
CVD may have a better prognosis in the overweight population compared with their leaner counterparts, a phenomenon that is known as the ‘obesity paradox’.561,562 Similarly, in cases of NCS, mildly obese patients present lower mortality risk compared with underweight and normal weight patients, both post-operatively and at long-term follow-up.563 This ﬁnding may be related to the lower prevalence of
PMI in mildly obese patients undergoing NCS.564
It has been suggested that cardiorespiratory ﬁtness (CRF), rather than BMI, should be used to assess CV risk in obese patients. While the classiﬁcation based on BMI is simple, highly reproducible, and widely adopted in clinical practice, it does not reﬂect fat distribution and body composition. Cardiorespiratory ﬁtness refers to the ability of the circulatory and respiratory systems to supply oxygen to skeletal muscles during sustained physical activity, which is of paramount importance, especially in patients with cardiac diseases. The primary measure of CRF is VO2 max.565 A cohort study of nearly 10 000 patients with CAD followed for almost 15 years showed that those with relatively good CRF had favourable prognosis regardless of body composition;566 however, a lower CRF was found to be a major predictor of mortality, regardless of BMI.561,567 Whether speciﬁc optimization and/or treatment strategies might have a positive impact on the outcome of obese patients with preexisting or newly diagnosed cardiac comorbidities and scheduled for NCS is a matter of ongoing controversy. Studies assessing the effect of weight loss interventions (low-energy diets with or without an exercise component) on clinical outcomes in patients undergoing NCS found inconsistent results in terms of perioperative morbidity or mortality.568,569
Recommendation Table 30 — Recommendations for management of patients with renal disease undergoing non-cardiac surgery
Recommendations
Classa
Levelb
In patients with renal disease requiring peri-operative contrast-enhanced radiography,
balanced hydration with i.v. isotonic ﬂuids, the use of a minimal volume of contrast media, and the use of low-osmolar or iso-osmolar contrast media should be considered.547,553–555
IIa
B
In patients with known risk factors (age .65
years, BMI .30 kg/m2, diabetes, hypertension,
hyperlipidaemia, CV disease, or smoking)
undergoing intermediate- or high-risk NCS, it is recommended to screen for pre-operative renal disease by measuring serum creatinine and GFR.
I
C
If a cystatin C measurement assay is available,
cystatin C measurement should be considered in patients with impaired eGFR (,45–59 mL/min/
1.73 m2) to conﬁrm kidney disease.556
IIa
C
© ESC 2022
BMI, body mass index; CV, cardiovascular; eGFR, estimated glomerular ﬁltration rate;
GFR, glomerular ﬁltration rate; i.v., intravenous; NCS, non-cardiac surgery.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 31 — Recommendations for management of patients with obesity undergoing noncardiac surgery
Recommendations
Classa
Levelb
It is recommended to assess cardiorespiratory
ﬁtness to estimate peri-operative CV risk in obese patients, with particular attention to those undergoing intermediate- and high-risk NCS.565,570
I
B
In patients at high risk of obesity hypoventilation syndrome, additional specialist investigation before major elective NCS should be considered.516
IIa
C
© ESC 2022
CV, cardiovascular; NCS, non-cardiac surgery.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 64 -->

### Page 64

6.13. Diabetes
Due to the progressive ageing of the population undergoing surgical procedures and the increasing prevalence of obesity worldwide, the prevalence of diabetes among patients undergoing
NCS is expected to increase in years to come.4,571 Several studies have demonstrated that diabetic patients undergoing
NCS have a higher prevalence of CAD than non-diabetic patients.
Furthermore, patients with diabetes are more likely to have silent ischaemia because of altered neural pain pathways in the heart.572
For this reason, patients with diabetes appear to have a greater risk of post-operative myocardial ischaemia. Different reasons exist behind the relation between DM and increased peri-operative mortality in patients undergoing NCS. First, patients with diabetes are known to have more comorbidity and/or advanced CAD at the time of intervention. Second, diabetes is a clear risk factor for stroke. Diabetes is associated with post-operative congestive
HF and wound infections. Many patients with diabetes have impaired renal function. The presence or a new diagnosis of impaired glucose metabolism in patients scheduled for NCS should follow the recommendations provided for the general population in the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases,573 including increased awareness regarding possible subclinical organ damage.
The glycated haemoglobin (HbA1c) test should be performed in all patients with diabetes or impaired glucose metabolism scheduled for NCS, if this measurement has not been performed in the previous 3 months. There is evidence to support that pre-admission optimal treatment of hyperglycaemia in patients scheduled for elective
NCS is effective in reducing the post-operative risk of CV events, including MI, stroke, and progression of HF.574 In contrast, no clear association has been shown between intra-operative blood glucose levels and the subsequent risk of surgical site infection, MI, stroke,
and death in patients undergoing NCS.575 The risk of acidosis associated with metformin use is also debated.576 Nevertheless, repeated blood glucose monitoring on the day of surgery is recommended,
with a general consensus to maintain peri-operative glucose levels
,10.0 mmol/L without causing hypoglycaemia (target level 5.6–
10.0 mmol/L). This can be achieved either with subcutaneous doses of rapid-acting insulin analogues or with i.v. insulin.577 Handling of SGLT2 inhibitors in relation to surgery has been discussed in
Section 5.2.
6.14. Cancer
Due to their generally older age, cancer patients have a high prevalence of CV risk factors and CVD, being a population at increased risk of adverse events in cases of NCS. It is therefore important to optimize treatment of CV risk factors and known CVD before
NCS, following the general and disease-speciﬁc recommendations provided in other sections of these guidelines. Furthermore, NCS
may be particularly challenging in cancer patients because of previous administration of potentially cardiotoxic chemotherapy or ﬁbrosis due to previous radiation. For example, the widely used anthracyclines have a dose-dependent relation with the incidence of HF
and the use of trastuzumab can lead to important cardiotoxicity and should be taken into account in the pre-operative assessment.
Furthermore, radiation therapy to areas that included the heart may lead to premature CAD and VHD; previous thoracic radiotherapy may predispose younger patients to heart disease who would otherwise not have an elevated risk. Post-operative AF is frequently observed in patients undergoing cancer surgery, with the highest incidence reported for lung surgery. Patients with cancer are at elevated risk of thrombosis due to both the disease itself and patientand treatment-related factors. In a small study of patients undergoing planned open surgery for abdominal or pelvic cancer, enoxaparin prophylaxis for 4 weeks compared with 1 week reduced the incidence of thrombosis (4.8% in the enoxaparin group vs.12.0% in the placebo group; P = 0.02).582 Although later studies have shown somewhat conﬂicting results, the consensus is to recommend extending thromboprophylaxis after major abdominal and/or pelvic surgery for cancer to 4–5 weeks, with preferred use of LMWH.583
A summary of patient-related and cancer therapy-related factors that could inﬂuence peri-operative risk is shown in Table 15.
Further information is available in the 2022 ESC Guidelines on cardio-oncology.584
6.15. Coronavirus disease 2019
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). In a recent observational study, among 140 231 patients scheduled for NCS, 2.2% of patients had a pre-operative diagnosis of SARS-CoV-2 infection.585 Patients undergoing surgery with peri-operative or recent SARS-CoV-2 appear to be at increased risk of post-operative VTE and mortality compared with patients with no history of SARS-CoV-2 infection.586 Furthermore, the possible myocardial injury associated with COVID-19 infection might increase the
Recommendation Table 32 — Recommendations for management of patients with diabetes mellitus undergoing non-cardiac surgery
Recommendations
Classa
Levelb
In patients with diabetes or disturbed glucose metabolism, a pre-operative HbA1c test is recommended, if this measurement has been not performed in the previous 3 months. In case of
HbA1c ≥8.5% (≥69 mmol/mol), elective NCS
should be postponed, if safe and practical.578–581
I
B
Continued
A pre-operative assessment for concomitant cardiac conditions (see Sections 3 and 4) is recommended in patients with diabetes with suspected or known CAD, and those with autonomic neuropathy, retinopathy, or renal disease and scheduled to undergo intermediateor high-risk NCS.
I
C
© ESC 2022
CAD, coronary artery disease; HbA1c, glycated haemoglobin; NCS, non-cardiac surgery.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
3889


<!-- PAGE 65 -->

### Page 65

intrinsic peri-operative risk of adverse cardiac events associated with surgical procedures.587,588
To date, there is no speciﬁc CV screening to be performed after
COVID-19 infection in patients scheduled for NCS. The preoperative evaluation of CV risk associated with NCS in this speciﬁc subset of patients should incorporate, beyond the general risk assessment outlined in these guidelines, the severity of COVID-19 disease, history of CV complications during COVID-19 infection, and functional capacity after recovery. This information is deemed of importance to further optimize timing of surgery and the treatment of
COVID-19-associated cardiovascular conditions affecting the perioperative risk of NCS.589
The optimal timing of NCS in patients with a history of COVID-19
infection is largely unknown. Generally, elective NCS should be postponed until complete recovery and optimization of coexisting comorbidities. Registry data of patients undergoing NCS after
COVID-19 infection report increased risks of mortality and morbidity up to 7 weeks post-COVID diagnosis.586 Another study has reported greater risk of post-operative complications up to 8 weeks post-diagnosis.590 However, it should be noted that almost all available data come from study periods with zero to low prevalence of vaccination, and no robust data exist on patients recovering from the more recent Delta and Omicron variants.
A joint statement on elective surgery and anaesthesia for patients after
COVID-19
infection from the
American
Society of
Anaesthesiologists and Anaesthesia Patient Safety Foundation591
suggests delaying elective surgery for 7 weeks after a SARS-CoV-2
infection in unvaccinated patients who are asymptomatic at the time of surgery. The clinical course of COVID-19 infection, presence and intensity of cardiopulmonary symptoms during the acute and late phases, and pre-existing comorbidities should be taken into consideration. In addition, persistence of COVID-19 symptoms—such as fatigue, shortness of breath, and chest discomfort—should be given attention, as this condition is associated with higher postoperative mortality independent of the timing of COVID-19 diagnosis.588,589 The evidence is currently insufﬁcient to make recommendations for those who become infected after vaccination.
7. Peri-operative monitoring and anaesthesia
7.1. Peri-operative monitoring
Despite the absence of prospective RCTs investigating the prognostic relevance of peri-operative monitoring, previous evidence clearly indicates that the routine use of monitoring improves safety of surgical procedures. Mandatory intra-operative monitoring of the CV
and respiratory systems, temperature, neuromuscular transmission,
and depth of anaesthesia is recommended.592,593
Routine CV monitoring includes ECG, automated non-invasive BP
measurement at regular intervals, and peripheral oxygen saturation with pulse oximetry. Near-infrared spectroscopy has recently been introduced to assess regional tissue perfusion and oxygenation. In selected cases, more invasive monitoring techniques can be applied such as continuous arterial BP measurement via an arterial catheter and monitoring of cardiac output. Mean arterial pressure and heart
Table 15
Factors that could inﬂuence peri-operative risk during cancer surgery and preventive strategies
Factors that could inﬂuence peri-operative risk during cancer surgery
Preventive strategies
• Patient-related factors
• Lifestyle risk factors—smoking, obesity, sedentary lifestyle
• Poorly controlled CV risk factors—hypertension, diabetes
• Pre-existing CVD, including cancer therapy-related cardiovascular toxicity
• Cardiac medication increasing peri-operative bleeding risk (e.g.
antiplatelets and anticoagulants)
• Historical primary malignancy
• Current cancer type, stage, and location
• Arrhythmias (due to myocardial cancer invasion, induced
QT-prolongation, AF, or imbalance of autonomic nervous system)
• Optimal management of CV risk factors and
CVD
• Optimize preventive strategies with respect to VTE and arterial thromboembolic events
• ECG monitoring for arrhythmias
• Correction of all proarrhythmic conditions
• Neoadjuvant cancer therapy
• Previous cardiotoxic cancer treatments (especially anthracycline chemotherapy and/or trastuzumab; immune checkpoint inhibitors,
VEGFi, ﬂuoropyrimidine and thoracic radiotherapy)
• Cancer treatments increasing peri-operative bleeding risk (e.g.
antiangiogenics, BTKi)
• Cancer treatments increasing risk of arrhythmias
• Ensure optimal CV monitoring of neoadjuvant therapy
• Optimize preventive strategies with respect to VTE and arterial thromboembolic events
© ESC 2022
AF, atrial ﬁbrillation; BTKi, Bruton tyrosine kinase inhibitors; CV, cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; VEGFi, vascular endothelial grow factor inhibitor;
VTE, venous thromboembolism.


<!-- PAGE 66 -->

### Page 66

rate remain stable, even with variation of up to 30% of total blood volume.594 Right heart catheterization can be used to continuously measure central venous pressure and/or pulmonary artery pressure,
pulmonary artery wedge pressure (as a reﬂection of LV diastolic pressure), and cardiac output. However, these are static variables that do not reliably reﬂect the CV ﬁlling status, and have been shown to accurately guide ﬂuid therapy in 50% of patients.595
While routine use of pulmonary catheterization is discouraged during NCS, using dynamic variables, such as stroke volume variation or pulse pressure variation, has become the gold standard. In addition, TEE is increasingly being used as an intra-operative monitoring technique in major surgery in cardiac compromised patients and during cardiac surgery. Decisions on the extent of peri-operative monitoring and implementation of speciﬁc strategies during NCS should always be based on an individual patient-directed assessment, taking into consideration the severity of surgery and the patient’s physical condition. Basic peri-operative monitoring of the respiratory system consists of pulse oximetry and capnography; both methods are noninvasive and easily applicable. Pulse oximetry enables in vivo measurement of arterial oxygen saturation, and capnometry measures endtidal carbon dioxide concentration during inspiration and expiration;
these monitors also provide information about the global haemodynamic status.
Patients, independent of the anaesthetic technique and information provided by the different monitoring systems, must be regularly controlled.596 In addition, blood loss and urine output should be checked, when appropriate, and overall clinical status.597 Special attention is required for the activation and setting of audible alarms,
as inadequate use or failure to respond to intra-operative alarms may result in patient hazard and undesirable outcomes.598
7.2. Anaesthesia
The decision on the optimal peri-operative strategy should be based on close exchange of clinical information between anaesthesiologists,
cardiologists, surgeons, and other relevant specialists. In addition, it is mandatory that any proposed strategy is presented to and discussed with the patient. An informed discussion with the patient describing the planned patient pathway and expectations during the pre-, peri-,
and post-operative phases of care, and what to expect from staff and surroundings, should be given using a clear, concise, and simple description. The ESA published Pre-operative evaluation of adults undergoing elective noncardiac surgery: updated Guideline from the European Society of Anaesthesiology in 2018.560 This current section focuses on issues that are speciﬁcally important to patients with CV risk factors and diseases, taking into account the most recent developments in peri-operative management of these patients.
7.2.1. Intra-operative haemodynamics
Most anaesthetic techniques reduce sympathetic tone, leading to a decrease in venous return due to increased compliance of the venous system, vasodilatation, and decreased BP. Therefore, maintenance of adequate organ ﬂow and perfusion pressure is of key importance in anaesthesiological management, especially in the
CV-compromised patient. The importance of keeping stable perioperative haemodynamics has been recognized for many years.599
In the past few years, several studies have focused on the relationship between intra-operative hypotension and post-operative patient outcome. A recent systematic review identiﬁed 42 studies looking at associations between various absolute and relative intra-operative hypotension deﬁnitions and post-operative adverse outcomes after NCS.214 The reported associations suggest that organ injury (myocardial injury, stroke, AKI) might occur when the mean arterial pressure decreases to ,80 mmHg for ≥10 min, and that this risk increases with BP becoming progressively lower.
However, most of the included studies had a retrospective observational design with a large variability in patient characteristics. In addition, the deﬁnitions of intra-operative hypotension varied widely across included studies. A recent study on the incidence of intra-operative hypotension as a function of the chosen cut-off definition described 48 different deﬁnitions of intra-operative hypotension. When applying these deﬁnitions to a cohort of 15 509
consecutive adult patients undergoing NCS under general anaesthesia, any episode of systolic BP ,80 mmHg was found in 41% of the patients, and 93% of the patients had at least one episode of systolic
BP .20% below baseline. The relation between threshold values from the literature and incidence of intra-operative hypotension showed a sigmoidal shaped cumulative incidence curve, with intra-operative hypotension occurrence frequencies varying from
5–99%.600 It seems that no universal target BP to deﬁne intra-operative hypotension can currently be deﬁned. In addition,
in studies on intra-operative hypotension, both the threshold to deﬁne hypotension and the method chosen to model intra-operative hypotension affected the association of intra-operative hypotension with outcome.601
As a
consequence,
different studies on intra-operative hypotension are uncomparable and clinical conclusions on reported results remain hazardous. A recent expert consensus statement concluded that intra-operative mean arterial pressures ,60–70 mmHg are associated with myocardial injury,
AKI, and death. These complications are a function of hypotension severity and duration.602 It remains to be established whether correction of intra-operative hypotension is also associated with improved post-operative outcome. To date, only one study has speciﬁcally addressed the question of whether an individualized BP management strategy reduces post-operative complications in a multicentre RCT
including 292 patients. An individualized management strategy of targeting a systolic BP within 10% of the patient’s normal resting value resulted in signiﬁcantly lower rates of post-operative organ dysfunction compared with standard practice (38.1% vs. 51.7%, respectively).528
These ﬁndings support the beneﬁts of personalizing care, especially in surgical patients at high-risk of cardiac complications. It is important to underscore the importance of a physiopathological approach in understanding the underlying mechanisms of intra-operative hypotension, taking into account the extent and severity of the patient’s comorbidities; only then will a tailored treatment targeting the cause of intra-operative hypotension be possible (Figure 16).
The severity of intra-operative hypotension is deﬁned both by the threshold decrease from baseline and the duration of the hypotensive episode. The underlying mechanisms for intra-operative hypotension need to be identiﬁed: sympathicolysis with vasodilation,
hypovolaemia, or other more complex causes such as peri-operative myocardial failure. Once the underlying mechanisms are identiﬁed, a targeted therapeutic strategy can be applied. This includes considering whether administration of speciﬁc chronic vasoactive medication such as ACEIs or ARBs should be interrupted 24 h prior to surgery.216
ESC Guidelines
3891


<!-- PAGE 67 -->

### Page 67

A detailed analysis of the strategies for the different chronic CV
medication is discussed in Section 5. Of note, post-operative outcome is not only negatively inﬂuenced by the occurrence of intra-operative hypotension, but also by hypotensive events during the initial four post-operative days.603 For adult non-cardiac surgical patients, there is insufﬁcient evidence to recommend a general upper limit of arterial pressure at which therapy should be initiated, although pressures .160 mmHg have been associated with myocardial injury and MI.602
Intra-operative tachycardia may adversely affect the myocardial oxygen balance and thus result in peri-operative myocardial injury. A retrospective analysis of 41 140 patients found that a heart rate ≥90 b.p.m. was associated with an increased risk of myocardial injury.604 These ﬁndings were similar to observations in the Vascular Events in Noncardiac Surgery Patients Cohort
Evaluation (VISION) trial.605 An analysis of high-risk surgical patients found that an HR .87 b.p.m., recorded at rest before pre-operative cardiopulmonary exercise testing, was strongly associated with distinct CV phenotypes, which may explain the unintended, adverse consequences of non-personalized treatments aimed at reducing intra-operative tachycardia in isolation from other haemodynamic factors.606 Finally, a recent study evaluated the association between intra-operative tachycardia and a composite of post-operative myocardial injury and all-cause mortality. The major
ﬁnding of this study was the lack of an association between intra-operative heart rate .90 b.p.m. and the composite outcome;
HR .80 b.p.m. or .100 b.p.m. were also not associated with the composite outcome.607 Taken together, the assumed association between intra-operative tachycardia and adverse peri-operative outcome remains a subject of ongoing controversy. However, it seems advisable to consider intra-operative tachycardia as an indicator of haemodynamic impairment.
7.2.2. Choice of anaesthetic agent
The choice of the anaesthetic agent has been considered to be of little importance in terms of patient outcome, provided that vital functions are adequately supported. Evidence from surgical myocardial revascularization studies indicates that a volatile vs. i.v. anaesthetic regimen is associated with less post-operative troponin release without impact on clinical outcomes.599,608 A recent large multicentre randomized trial found a neutral effect on 12 month mortality associated with volatile vs. i.v. anaesthetic regimen.609 In NCS, incidence of post-operative cardiac events is not inﬂuenced by the choice of a volatile or an i.v. anaesthetic regimen.610
7.3. Locoregional techniques
The analgesic effects of neuraxial analgesia are well-established. The main peri-operative indications for epidural analgesia include major open abdominal surgery and thoracotomy. Possible additional beneﬁts of epidural analgesia, such as accelerated recovery and decreased post-operative complications, remain a matter of debate.611,612
Neuraxial analgesia may induce sympathetic blockade. When reaching the thoracic dermatome level 4, a reduction in cardiac sympathetic drive may occur, with subsequent reduction in myocardial contractility, heart rate, and change in cardiac loading conditions. There are no studies speciﬁcally investigating the changes in outcomes related to neuraxial anaesthetic techniques in patients with cardiac disease.
Cardiac patients often take various types of drugs that interfere with coagulation; therefore, care should be taken to ensure sufﬁcient coagulation ability when neuraxial blocks are applied.613
Define severity:
(i) mean blood pressure decrease >20% from baseline
(ii) the duration of the hypotensive episode
Patients with intra-operative hypotension
Underlying mechanism
Sympathicolysis with vasodilatation
Hypovolaemia
Other more 
complex causesa
Smooth induction
Av
A oid ‘too deep’ anaesthesia positioning (Tr
T endelenburg,
legs up)
Vasoconstriction
V
(cav a e organ perfusion)
Advanced diagnosis
Appropriate treatment
Exclude impaired venous return
Restore circulating volume
Figure 16 Pathophysiological approach to address intra-operative hypotension. aE.g. peri-operative myocardial failure.


<!-- PAGE 68 -->

### Page 68

Current research is focusing on alternatives for neuraxial analgesia with similar effects on peri-operative pain control in patients with cardiac comorbidities undergoing NCS; these include alternative analgesic techniques such as i.v. analgesia, continuous wound inﬁltration, paravertebral bloc, and selective nerve blocks.
7.4. Peri-operative goal-directed haemodynamic therapy
Goal-directed therapy aims to optimize CV performance, in order to achieve normal or even supranormal oxygen delivery to tissues, by optimizing pre-load and inotropic function using pre-deﬁned haemodynamic targets.
In contrast to clinical signs or arterial pressure-orientated standard therapy, goal-directed therapy is based on ﬂow or ﬂuid responsiveness of haemodynamic variables, such as stroke volume, response to ﬂuid challenges, stroke volume or pulse pressure variation, or similar optimization of cardiac output.
Goal-directed therapy was initially based on the use of a pulmonary artery catheter. Less-invasive techniques have recently been developed, including: transoesophageal Doppler, transpulmonary dilution techniques, and advanced pressure waveform analysis. Early goaldirected ﬂuid therapy—in the right patient cohort and with a clearly deﬁned protocol—has been shown to decrease post-operative mortality and morbidity.614–618
7.5. Post-operative management
Several studies have demonstrated that it is possible to stratify the risk of post-operative complications and mortality with a simple surgical Apgar score. This post-event stratiﬁcation might enable patients to be redirected to higher-intensity care units. The importance of such risk stratiﬁcation is underscored by the results of the EuSOS
group. In this 7 day cohort study, 46 539 consecutive adult NCS patients in 498 hospitals across 28 European nations were included:
1855 patients (4%) died before hospital discharge and 1358 (73%)
of those patients were not admitted to critical care at any stage after surgery.7 This concept of failure-to-rescue has gained a lot of attention in peri-operative medicine in the last few years and strategies have been proposed to address this issue.619–622
Severe post-operative pain occurs in 5–10% of patients, increases sympathetic drive, and delays recovery.623,624 A recent study demonstrated that time-weighted average pain scores within 72 h after surgery were signiﬁcantly associated with myocardial injury in patients undergoing NCS;625 this ﬁnding underscores the importance of effective post-operative analgesia to reduce post-operative CV risk.
The place of non-steroidal anti-inﬂammatory drugs (NSAIDs) in the treatment of post-operative pain in cardiac patients undergoing
NCS is a point of debate. Diclofenac has been shown to carry the highest CV risk of any of the non-selective NSAIDs.626,627 The CV
risk of ibuprofen seems to be comparable with that of celecoxib.628
Naproxen has a better CV safety proﬁle than diclofenac and ibuprofen.629,630 One randomized trial found that parecoxib and valdecoxib did not increase thromboembolic events in patients undergoing
NCS. A meta-analysis of 32 randomized trials did not ﬁnd an increased CV risk when comparing parecoxib/valdecoxib with placebo,631 and a single-centre observational study with .10 000
patients undergoing arthroplasty found no association between
NSAID
use and post-operative
MI.632
In contrast,
another meta-analysis of three randomized trials including 2604 major surgery patients detected a 2.3-fold increase in MACEs in the group with COX-2 inhibitors. In a position paper, The ESC Working
Group on Cardiovascular Pharmacotherapy advises that non-aspirin
NSAIDs should generally not be used in patients with established or at high risk of CVD.633
8. Peri-operative cardiovascular complications
Speciﬁc challenges apply to detecting CV complications that occur peri-operatively. First, due to anaesthesia and analgesia, PMI, which is the most common CV complication, is largely asymptomatic in
≏90% of patients and is therefore missed in routine clinical practice in the absence of surveillance for PMI.41,101,111,413,636–641
Second, post-operative pain, nausea, surgical wounds, and drains may interfere with the early identiﬁcation of acute cardiac disorders, such as PMI, Takotsubo syndrome, tachyarrhythmias, and acute HF. Third, cardiologists are usually not directly involved in post-operative care; therefore, the early detection and early treatment of cardiac complications is performed by non-cardiologists,
sometimes with little training in the early detection of acute cardiac disorders. Given the relatively high prevalence of cardiac complications, their high morbidity and mortality, and the availability of effective therapy, high awareness combined with surveillance for
PMI in high-risk patients (known CAD, PAD, insulin-dependent
DM, or symptoms suggestive of cardiac disorders) undergoing intermediate- or high-risk NCS is recommended to overcome
Recommendation Table 33 — Recommendations for peri-operative monitoring and anaesthesia
Recommendations
Classa
Levelb
In order to preserve optimal CV stability, it is recommended to apply goal-directed haemodynamic therapy in patients undergoing high-risk NCS.614–618
I
A
It is recommended to avoid post-operative acute pain.614
I
B
In order to minimize the risk of post-operative organ dysfunction, it is recommended to avoid an intra-operative mean arterial pressure decrease of
.20% from baseline values or ,60–70 mmHg for
≥10 min.214,600–602,634
I
B
Non-aspirin NSAIDs are not recommended as
ﬁrst-line analgesics in patients with established or high risk of CVD.633,635
III
B
© ESC 2022
CV, cardiovascular; CVD, cardiovascular disease; NCS, non-cardiac surgery; NSAID,
non-steroidal anti-inﬂammatory drug.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
3893


<!-- PAGE 69 -->

### Page 69

these challenges.41,101,109–111,118,413,636–639,642,643 All measures need to be carefully aligned with the responsible surgeon.
Chronic cardiac disorders, such as CAD, seem to provide a substrate for cardiac complications during and after surgery.41,413,636,637
Several related chronic conditions (e.g. diabetes and renal insufﬁciency), which are likely to be surrogates for undiagnosed cardiac disease, are also strongly associated with peri-operative cardiac complications (Figure 17).41,413,636,637
Acute conditions such as trauma, surgery, and anaesthesia itself induce activation of the sympathetic nervous system, inﬂammation,
stress, hypercoagulable, and catabolic states, all of which may trigger cardiac complications.41,413,636,637 While the risk of CV complications after NCS is highest in the immediate peri-operative period,
it seems to remain increased for a prolonged ‘vulnerable period’ of
3–5 months.8
8.1. Peri-operative myocardial infarction/injury
Peri-operative MI (PMI) is deﬁned as acute cardiomyocyte injury
(post-operative hs-cTn T/I release) with or without accompanying symptoms, and with or without ECG or imaging evidence of acute myocardial ischaemia. Peri-operative MI can only be reliably and rapidly detected using PMI surveillance with hs-cTn T/I measurements before and serially after surgery (e.g. 24 and 48 h postoperatively). In the BASEL-PMI study, circa 15% of patients with pre-existing CAD/PAD or aged .65 years undergoing major NCS
developed PMI.8 As most PMI occurs during the operation itself or in the immediate post-operative period, during which high doses of anaesthetics and/or analgesics are required, ≏90% of patients with PMI do not report typical symptoms and are therefore missed in routine clinical practice.41,101,111,413,636–639 This is of major concern, as the mortality risk associated with PMI is also high in patients without symptoms.41,101,111,413,636–639
Similarly,
the mortality risk associated with PMI is high in patients without additional
ECG
and/or imaging evidence of myocardial ischaemia.8,41,101,109–111,118,413,564,636–639,641 Overall, 30 day mortality in patients developing PMI is ≏10%.8,41,101,109–111,118,413,564,636–639,641
No single intervention has yet been proven to be unequivocally beneﬁcial in the prevention of PMI.185,644
It is important to highlight that PMI is not a homogenous disease.
Several different pathophysiologies and clinical phenotypes may underlie PMI (Figure 18). At least one additional criterion (ischaemic pain; ischaemic ECG changes; imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology; and thrombus in coronary
Patient-related factors
Procedure-related factors (surgery and anaesthesia):
Factors associated with peri-operative cardiovascular complications
Urgency of the procedure, hypotension, hypercoagulability,
bleeding inflammation, tachycardia, hypothermia, SNS stimulation
Post-operative factors:
Hypotension, bleeding,
hypoxaemia, tachycardia, pain
Cardiovascular complications:
Type 1 myocardial infarction
Type 2 myocardial infarction
Acute heart failure, arrhythmias
Pulmonary embolism
Stroke
Cardiovascular death
Chronic:
Age >75 years
Coronary artery disease
Heart failure
Severe aortic stenosis
Peripheral arterial disease
Cerebrovascular disease
Renal insufficiency
Diabetes, anaemia
(Sub)-Acute:
Acute coronary syndrome
Acute aortic syndrome
Acute stroke
Acute trauma (e.g. hip fracture)
Figure 17 Factors associated with peri-operative cardiovascular complications. SNS, sympathetic nervous system.


<!-- PAGE 70 -->

### Page 70

angiography) is required for patients with PMI to also meet the definition of peri-operative myocardial infarction, according to the fourth universal deﬁnition.643 Because is often initially unclear whether the patient will end up fulﬁlling the criteria for perioperative myocardial infarction, the broad term PMI is preferred in the initial assessment. In order to properly interpret the aetiology of elevated post-operative hs-cTn T/I concentrations, a baseline preoperative concentration is necessary to determine whether the increase is acute or chronic (see Section 4).643 To identify the underlying pathophysiology and deﬁne causal therapy,
systematic work-up and early differentiation of primarily non-cardiac causes
(e.g. severe sepsis, PE) vs. the different cardiac causes—including type-1 MI, type-2 MI, tachyarrhythmia, and acute HF—is of major importance (Figures 18 and 19). Transthoracic echocardiography is helpful in the work-up of most patients with PMI.
The term myocardial injury following NCS (MINS) has been used for a selected subset of patients with cardiac PMI, in whom cardiomyocyte injury was deemed most likely due to CAD with myocardial ischaemia (i.e. secondary to supply–demand mismatch or thrombosis), in the absence of an atypical surgical physiological stress,
and no evidence of a cardiac non-CAD aetiology, e.g. rapid AF, acute
HF).101,109,638,641,642,645,646 In approximately half of all patients with
PMI, the underlying pathophysiology cannot be reliably ascertained based on the commonly available documentation and is assumed to be likely type-2 MI due to undocumented or relative hypotension,
but may also include missed type-1 MI, or missed PE in cases in which
CT angiography has not yet been performed post-operatively.110,647
It is therefore important to highlight that PMI surveillance also facilitates the detection of primarily non-cardiac disorders with immediate therapeutic consequences, such as PE, that would otherwise have been missed.
The prevalence of PMI depends on patient-related, proceduralrelated, and post-operative factors, and the required minimum extent of acute myocardial injury, quantiﬁed by absolute increase in hs-cTn T/I (e.g. the 99th percentile ULN) above the pre-operative hs-cTn
T/I
concentration.8,41,101,109–111,118,413,564,636–639,641,648
Cardiac troponin
Chronic cardiac troponin
Acute cardiac troponin = PMI
Primarily non-cardiac cause
Cardiac cause
Severe sepsis
Pulmonary embolism
Stroke
Atherothrombosis
Type 1 MI
Type 2 MI
Supply demand mismatch with obvious type 2
trigger
(hypotension,
anaemia)
Tachyarrhythmia
Supply demand mismatch
Acute heart failure
Multiple mechanisms
Likely type 2 MI
Missed type 1 MI
Undocumented hypotension
Mild hypotension
Day 1 or 2 after the NCS
CK
cTn T
cTn l
Myocardial injury
Figure 18 Differential diagnosis of elevated post-operative cardiac troponin concentrations. CK, creatinine kinase; cTn l, cardiac troponin I; cTn T,
cardiac troponin T; MI, myocardial infarction; PMI, peri-operative myocardial infarction/injury. Please be aware that the accuracy of physicians’ judgement in the classiﬁcation of type-1 vs. type-2 MI in the peri-operative setting may be lower vs. the non-operative setting.647
ESC Guidelines
3895


<!-- PAGE 71 -->

### Page 71

An absolute increase in more than the ULN above pre-operative concentrations has consistently been shown to be associated with a relevant increase in 30 day and long-term mortality, and other nonfatal post-operative cardiac complications, and can easily be determined for each hs-cTn T/I assay. This threshold is therefore recommended for clinical use.8,41,101,109–111,118,413,564,636–639,641,648
However, further studies are warranted regarding optimal thresholds.
Emerging data suggest that surveillance for
PMI
is cost-effective.117,119
Identiﬁcation of the most likely pathophysiology is critical for selection of the most appropriate therapy. Evidence from a large singlecentre retrospective cohort suggests that involvement of a cardiologist in the work-up and therapy of these patients was associated with lower mortality.649 Mortality substantially differs among the different phenotypes: 30 day all-cause mortality and the composite of 30 day
CV death, life-threatening arrhythmia, acute MI occurring after day 3,
and cardiac decompensation are highest in patients with acute HF
and primarily extra-cardiac PMI, such as severe sepsis or PE, intermediate for type-1 MI and tachyarrhythmias, and modestly elevated in likely type-2 MI.110 Type-2 MI patients are usually treated as for type-1 MI, although the evidence for this is limited.
In a randomized, placebo-controlled trial, 1754 patients (mean age
70 years) who had developed MINS after NCS (mainly orthopaedic,
general, and vascular surgery) were randomly assigned (1:1) to receive dabigatran 110 mg orally b.i.d. or matched placebo within 35
days of MINS;650 60% of patients were already on aspirin or a
N
N
Y
Y
Y
ST or ST or typical chest pain
Other cardiac cause
Transthoracic echocardiography
N
N
N
Relative or undocumented hypotensionb
Severe anaemiaa
Type 2 MI
Systematic work-up and treatment of peri-operative myocardial injury/infarction
12-lead ECG, symptoms, and haemoglobin
Immediate transfusion followed by reassessment for ICA
Aspirin,d statin,
stress imaging/CCTA/ICA
Y
Y
Severe anaemiaa
(Hb <80 g/L)
Severe (documented)
hypotensionb
Type 2 MI
Step 5
Step 4
Step 3
Step 2
Step 1
Type 1 MI
Tachyarrhythmia (type 2 MI)
Acute heart failure (injury)
Aortic valve stenosis (injury)
Y
Sepsis, pulmonary embolism, stroke (injury)
ICA, aspirin,c statin, monitoring
(Class I)
Treat cause
Treat cause
Treat cause
Non-cardiac cause
Type 2 MI or missed type 1 MI
Figure 19 Systematic work-up (aetiology) and therapy of peri-operative myocardial infarction/injury. CCTA, coronary computed tomography angiography; ECG, electrocardiogram; Hb, haemoglobin; ICA, invasive coronary angiography; MI, myocardial infarction; N, no; ST, ST-segment. Y, yes;
Most patients with type-2 MI and silent type-1 MI should be scheduled for stress imaging or CCTA/ICA as outpatients after discharge, depending on symptoms prior to or after surgery and known CAD. aOr active bleeding. bOr other type-2 MI trigger such as hypoxaemia, tachycardia, hypertension.
cDual antiplatelet therapy after coronary stenting. dPossibly in combination with dabigatran 110 mg b.i.d.


<!-- PAGE 72 -->

### Page 72

P2Y12 inhibitor. The median peak measured hs-cTn concentration associated with the diagnosis of MINS was 82 ng/L. More than
90% of MINS events occurred without a clinical symptom or sign of cardiac ischaemia. Dabigatran/placebo was initiated a median of
6 days after the operation and the average time on study drug was
≏9 months. Among patients with MINS randomly assigned to receive dabigatran (n = 877) or placebo (n = 877), the composite primary efﬁcacy outcome of a major vascular complication—including vascular mortality, MI, non-haemorrhagic stroke, peripheral arterial thrombosis, amputation, and symptomatic VTE—occurred in fewer patients randomized to dabigatran than placebo (97 [11%] of 877 patients assigned to dabigatran vs. 133 [15%] of 877 patients assigned to placebo; HR, 0.72; 95% CI, 0.55–0.93; P = 0.0115). There was no increase in major bleeding. Based on these data, in patients with
MINS and at low risk of bleeding, initiation of dabigatran 110 mg orally b.i.d. may be considered about 1 week after NCS.
8.2. Spontaneous myocardial infarction
(after day 2)
The incidence of post-operative spontaneous MI after day 2 seems to be about 0.5% within 30 days, and 1–2% within 365 days for patients undergoing major NCS with established CAD, PAD, or aged .65 years.8
In the immediate post-operative period (,5 days), bleeding is a major concern and limits the use of antiplatelet and anticoagulant therapy, depending on the site and extent of surgery. Otherwise, the same principles as for MI therapy should generally be applied following the recommendations of speciality guidelines.98,171
8.3. Takotsubo syndrome
The incidence of peri-operative Takotsubo syndrome remains unknown, as none of the studies with PMI screening used echocardiography in all patients during PMI work-up. Increased awareness in the non-operative setting has led to a substantial increase in the detection of Takotsubo syndrome, and the use of TTE in the work-up of PMI is strongly encouraged. Anecdotal evidence suggests that it is likely that the incidence is also higher than expected in the perioperative setting.8,41,101,109–111,118,413,564,636–639,641,644
8.4. Acute heart failure
The incidence of post-operative acute HF seems to be 1–2% within
30 days and 4–6% within 365 days in patients with established CAD,
PAD, or aged .65 years undergoing major NCS.8 Pre-existing diagnosed or undiagnosed chronic HF and volume loading in the perioperative and post-operative periods are important contributors.
In the absence of studies speciﬁcally investigating acute HF postoperatively, the general principles of acute HF diagnostic work-up and therapy should be applied.651
8.5. Venous thromboembolism
The incidence of VTE in the peri-operative phase is currently unknown and likely underreported due to the lack of systematic screening methods and the limited validity of diagnostic tools (e.g.
D-dimer, typical pain symptoms) in this setting. It is associated with high peri-operative mortality (≏17%).322 Risk factors for postoperative VTE/PE include type of surgery (e.g. high-risk hip arthroplasty, open prostatectomy, open surgery for malignancy), acute renal insufﬁciency,
MI,
and post-operative infection.322
Stratiﬁcation of the extent of embolism (e.g. massive, submassive,
and subsegmental; high risk, intermediate high/low risk, and low risk) is important to predict mortality and guide therapeutic strategy.652 Pulmonary embolism should be suspected in patients with
PMI without a clear cause. Close haemodynamic monitoring and monitoring of RV function (echocardiography, CT) is essential to determine which PE patients require aggressive therapy. There is currently a lack of evidence regarding adequate antithrombotic therapy in patients with post-operative PE, since recent major surgery or trauma was a contraindication in previous trials of thrombolytic or anticoagulant therapy.653 Small case series support the use of systemic thrombolysis, surgical thrombectomy,654 or catheter-directed therapies in massive PE. In general, anticoagulation, preferably
LMWH or fondaparinux, should be initiated as early as possible.652
Oral anticoalgulant therapy, preferably NOAC due to the lower bleeding risk, should be initiated, depending on post-operative renal function and bleeding risk, as early as possible for at least 3
months.652
Rescue thrombolytic therapy is recommended for patients with
PE and haemodynamic deterioration on anticoagulation treatment in the post-operative phase, if possible, according to bleeding risk.652 As an alternative to thrombolytic therapy for massive PE, surgical embolectomy or percutaneous catheter-directed treatment should be considered for patients with haemodynamic deterioration on anticoagulation treatment, particularly in patients with high bleeding risk.
8.6. Atrial ﬁbrillation and other relevant arrhythmias
Post-operative AF is deﬁned as new-onset AF in the immediate postoperative period; its incidence ranges between 2–30%, with peak incidence 2–4 days post-operatively.655,656
Although many post-operative AF episodes are self–terminating and some are asymptomatic, post-operative AF has been associated with a four- to ﬁve-fold risk of AF recurrence in the 5 years following cardiac surgery, while the risk of recurrence after NCS is less well described.656–660 Importantly, post-operative AF is a risk factor for stroke, MI, and death compared with non-post-operative AF patients.656,658,661 Post-operative AF may also lead to haemodynamic instability, prolonged hospital stay, infections, renal complications,
bleeding, increased in-hospital death, and greater healthcare costs.662–664 The essential principles of the prevention and management of post-operative AF are outlined in Figure 20.
8.6.1. Prevention of post-operative atrial
ﬁbrillation
Pre-operative use of beta-blockers is associated with reduced incidence of post-operative AF,204,665–667 but not major adverse events such as death, stroke, or AKI.668 Importantly, in a large
RCT, peri-operative metoprolol was associated with increased mortality risk.185 In a meta-analysis, amiodarone (oral or i.v.)
was equally effective in reducing post-operative AF as betablockers,207 whereas their combination was better than betablockers alone.208 Lower cumulative doses of amiodarone
(,3000 mg) may be effective, with fewer adverse events.669–671
ESC Guidelines
3897


<!-- PAGE 73 -->

### Page 73

Data for other interventions—such as statins,672,673 magnesium,674
sotalol,666 colchicine,675 or corticosteroids676—are not robust.677,678
8.6.2. Management of post-operative atrial
ﬁbrillation
8.6.2.1. Rate and/or rhythm control
In haemodynamically unstable patients with post-operative AF, an emergent electrical or possibly pharmacological (i.e. i.v. administration of amiodarone666 or vernakalant,679 if consistent with the clinical situation) cardioversion is indicated.99 In haemodynamically stable patients with post-operative AF, ensuring optimal ventricular rate control during the arrhythmia is mandatory (using, for example betablockers or verapamil, as needed). As post-operative AF is often selfterminating, non–emergent cardioversion may not be needed. If performed in patients with AF lasting ≥48 h, non-emergency cardioversion of post-operative AF should follow the principles of pericardioversion thromboprophylaxis (that is, can be performed only after the left atrial thrombosis is excluded by TEE or postponed for 3 weeks of therapeutic OAC therapy). Of note, a RCT of patients with post-operative AF after cardiac surgery showed no net clinical
N
N
Y
Y
Symptomatic or difficult rate control
Systemic anticoagulationa
Haemodynamic instability
Emergency cardioversion
Rhythm control
(electrical or pharmacological cardioversion)
Management of patients with intra- and post-operative AF
AADs (optional)
Normal LVEF:
Class I or III 
Reduced LVEF:
Amiodarone
Rate control | Target resting HR <110 b.p.m.
Preserved LVEF:
beta-blocker, CCB
and/or digoxinb
Reduced LVEF:
beta-blocker and/or digoxinb
Pre-operative 
prevention of AF
Peri-operatively
Discharge
Optimize fluid balance, oxygenation, and pain control 
Minimize inotropes and vasopressors 
Continue pre-operative pharmacological prophylaxis
Pharmacological AF prophylaxis:
Continue beta-blockers (if chronic therapy)
Other AADs in selected patients
Optimize haemodynamics 
Correct electrolyte imbalance 
Identify patients at increased risk for post-operative AF
Individualized follow-up planc
Re-assessment for rhythm and AADs
Long-term OAC in patients at risk of stroke (balanced with bleeding risk)
considering the anticipated net clinical benefit of OAC and informed patient preferences
(Class IIa)
Figure 20 Prevention and management of post-operative atrial ﬁbrillation. AAD, antiarrhythmic drug; AF, atrial ﬁbrillation; b.p.m., beats per minute;
CCB, calcium channel blocker; HR, heart rate; LVEF, left ventricular ejection fraction. N, no; Y, yes. aDepending on the CHA2DS2VASC-score, and postoperative bleeding risk. bIn the acute post-operative phase, unless blood pressure is high, combination of low-dose beta-blocker and loading with digoxin is preferred to avoid hypotension. cShould include a cardiology visit before month 3. Adapted from the 2020 ESC Guidelines on the Diagnosis and
Management of Atrial Fibrillation.99


<!-- PAGE 74 -->

### Page 74

advantage of rhythm (i.e. achieving and maintenance of sinus rhythm)
vs. rate control strategy.680 Therefore, rate or rhythm control treatment decisions in patients with haemodynamically stable postoperative AF should be based on patient’s symptoms and shared informed treatment decision-making.99
8.6.2.2. Prevention of atrial ﬁbrillation-related thromboembolic complications
In all patients with post-operative AF, it should be considered to initiate therapeutic anticoagulation as soon as possible during inhospital treatment, depending on the individual stroke risk
(CHA2DS2-VASc) and the bleeding risk after surgery. In a large meta-analysis, patients with post-operative AF had 62% higher risk of early stroke and 37% higher risk of long-term stroke compared with patients without post-operative AF (long-term stroke rates were 2.4% in post-operative AF vs. 0.4% in patients without AF),
and a 44% and 37% higher risk of early and long-term mortality, respectively.661 Importantly, post-operative AF was more strongly associated with the long-term stroke risk in patients undergoing NCS
(HR, 2.00; 95% CI, 1.70–2.35) than in patients undergoing cardiac surgery (HR, 1.20; 95% CI, 1.07–1.34; P , 0.0001).661
Evidence on the effects of long-term OAC therapy for the prevention of stroke or systemic embolism in patients with postoperative AF is from observational studies.664,681–685 In a recent study, post-operative AF following NCS was associated with similar long-term thromboembolic risk as common, non-surgical AF,
and OAC use was associated with comparable lower risk of thromboembolism and all–cause mortality in both groups (mean
CHA2DS2-VASc-score 3.0 + 1.7).686
Based on the available evidence, long-term OAC should be considered in all patients with post-operative AF at risk of stroke. If anticoagulation is parenterally initiated, LMWH or fondaparinux is recommended (over UFH) for most patients. Non-vitamin K antagonist oral anticoagulants should be preferred over VKA for longterm treatment. Re-evaluation of the continuation of OAC may be performed after a period of 3 months. A small RCT (ASPIRE-AF;
NCT03968393) on the optimal long-term OAC use among NCS patients developing post-operative AF is ongoing.
8.7. Peri-operative stroke
With respect to NCS, peri-operative stroke has been reported in
0.08–0.70% of patients undergoing general surgery, 0.2–0.9% of patients requiring orthopaedic surgery, 0.6–0.9% of lung operations,
and 0.8–3.0% of surgeries involving the peripheral vasculature.687,688
The associated mortality ranges from 18–26%.687,688 A more recent analysis of 523 059 patients undergoing NCS reported a lower incidence of peri-operative stroke (0.1%), although the occurrence of this adverse event was associated with an eight-fold increase in perioperative mortality within 30 days, corresponding to an absolute risk increase of .20%.689 Peri-operative stroke is mainly ischaemic or cardioembolic, and AF is often the leading underlying condition.
Triggers include withdrawal of anticoagulation and the hypercoagulable state related to surgery. Additional aetiologies include atheroembolism, originating from the aorta or the supra-aortic vessels,
and local atherothrombosis in the presence of intracranial small vessel disease. Hypoperfusion—related to peri-operative arterial hypotension and/or severe stenosis of the cervicocranial vessels—
is an unusual cause of peri-operative stroke.690 Rarely, peri-operative stroke may be due to air, fat, or paradoxical embolisms.
In an attempt to attenuate the risk of peri-operative stroke, antiplatelet/anticoagulant treatments should be continued whenever possible throughout the peri-operative period. Alternatively, the period of drug withdrawal should be kept as short as possible, while weighting thromboembolic and haemorrhagic risks (see Section 5.2).
Adequate selection of the anaesthetic technique (regional vs. neuraxial vs. general anaesthesia), prevention and treatment of AF, euglycaemic control (avoiding both hyperglycaemia and hypoglycaemia), and meticulous peri-operative control of BP may all contribute to reducing the risk of peri-operative stroke.
If post-operative stroke occurs, it must trigger immediate action:
angio-CT and neurology/neurosurgical consultation with the goal to restore ﬂow in the case of acute thrombotic occlusion.
Recommendation Table 34 — Recommendations for peri-operative cardiovascular complications
Recommendations
Classa
Levelb
It is recommended to have high awareness of peri-operative CV complications, combined with surveillance for PMI in patients undergoing intermediate- or high-risk NCS.41,101,109–
111,118,413,636–639
I
B
Systematic PMI work-up is recommended to identify the underlying pathophysiology and deﬁne therapy.41,101,109–111,118,413,636–639
I
B
It is recommended to treat post-operative STEMI,
NSTE-ACS, acute HF, and tachyarrhythmias in accordance with guidelines for the non-surgical setting, after interdisciplinary discussion with the surgeon about bleeding risk.98,99,171,651,652
I
C
In patients with post-operative PE of high or intermediate clinical probability, initiation of anticoagulation is recommended without delay,
while diagnostic work-up is in progress, if bleeding risk is low.650,652
I
C
Post-operative oral anticoagulation for PE is recommended to be administered for a period of at least 3 months.99,650
I
C
In patients with a post-operative indication for
OAC, NOAC is generally recommended over
VKA.99
I
A
In patients with post-operative AF after NCS,
long-term OAC therapy should be considered in all patients at risk of stroke, considering the anticipated net clinical beneﬁt of OAC therapy,
and informed patient preferences.99,682,683,685,686
IIa
B
In patients with MINS and at low risk of bleeding,
treatment with dabigatran 110 mg orally b.i.d. may be considered from ≏1 week after NCS.650
IIb
B
Continued
ESC Guidelines
3899


<!-- PAGE 75 -->

### Page 75

### 9 Key messages

• The occurrence of CV complications in the peri-operative phase of NCS has a dramatic impact on prognosis.
• The risk of CV complications in patients undergoing NCS is determined by patient-related factors, type of surgery or procedure, and the circumstances under which surgery takes place (elective vs. emergency procedure; local or tertiary hospital).
• Speciﬁc patient-related risk factors may be reduced by adequate pre-operative risk assessment and initiation of effective risk-reduction strategies.
• The quantiﬁcation of surgical risk as low, intermediate, and high is helpful in identifying the group of patients who should most beneﬁt from preventive, diagnostic, and therapeutic approaches to concomitant CV conditions.
• Proper selection of type and timing of the surgical procedure may reduce the risk of complications.
• It is important that patients’ values, quality of life, and preferences regarding the beneﬁts and risks of surgery are taken into consideration, and that well-informed patients are involved in the decisions.
Risk should be communicated to the patient in absolute terms (e.g.
1 out of 100).
• Clinical examination, patient-reported functional capacity, and non-invasive tests represent the cornerstone of pre-operative cardiac assessment.
• Instrumental and functional cardiac examination tools should be selected in view of the surgical risk, relative diagnostic proﬁciency,
and healthcare resource utilization and costs.
• The peri-operative evaluation of elderly patients who require elective major NCS should include frailty screening, which has proven to be an excellent predictor of unfavourable health outcomes in the older surgical population.
• Treatment of pre-existing or newly diagnosed CV conditions (e.g.
coronary and peripheral vascular disease, rhythm disorders, and
HF) should be individualized according to the pre-operative risk of NCS, and considering the recommendations of speciality guidelines.
• A multidisciplinary approach to evaluate whether the treatment of concomitant cardiac conditions before scheduled NCS improves peri-operative safety without unnecessary delay is encouraged.
• Efﬁcient peri-operative management of antithrombotic therapies in patients scheduled for NCS aims to offer the potential beneﬁt of preventing thrombotic events without excessive bleeding complications.
• It is important to clearly and concisely communicate with patients,
with simple verbal and written instructions, about changes in medication in the pre- and post-operative phases.
• Management in the peri-operative phase of NCS aims to avoid haemodynamic imbalance, while ensuring sufﬁcient cardioprotective action.
• Healthcare providers are recommended to have high awareness of peri-operative CV complications combined with surveillance for
PMI in high-risk patients undergoing intermediate- or high-risk
NCS.
• Routine assessment of treatment quality through speciﬁc indicators is important to document and measure the success of preventive and therapeutic strategies in patients undergoing NCS.
10. Gaps in evidence
• The age cut-off for individuals (considered to be cardiovascularly healthy) beneﬁting from risk stratiﬁcation work-out before NCS
needs to be evaluated.
• Further studies are needed to characterize outcome differences in
NCS between men and women, and between different countries,
in order to individualize peri-operative management and improve patient safety.
• Evidence on the additive value of cardiac biomarkers, hand-held ultrasound, problem FOCUS, and stress echocardiography for cardiac risk stratiﬁcation of patients scheduled for NCS presenting with previously unknown cardiac murmur, dyspnoea, oedema,
and chest pain is still lacking. The impact of FOCUS on outcomes of urgent or time-sensitive surgery needs further investigation.
• The impact of stress imaging (echocardiography or MRI) before
NCS on reduction of peri-operative CV complications in nonischaemic heart diseases needs further research.
• The role of right heart catheterization in patients with advanced
HF or patients with severe pulmonary hypertension undergoing
NCS is unknown.
• It is unknown whether artiﬁcial intelligence-based systems facilitate prompt detection and response to imminent adverse events in high-risk cardiac patients undergoing high-risk NCS.
• Systematic and structured research to investigate pathophysiology, causes, and time distribution of serious peri-operative arrhythmic events among patients undergoing NCS is still needed.
• Strategies for timing of pre-operative CIED control dependent on device type, urgency, and type of NCS, and risk of EMI during NCS
need to be developed to ensure maximal patient safety.
• Beneﬁt of routine myocardial revascularization of high-risk CCS
patients (except left main or three-vessel CAD, reduced LV function) before elective intermediate- and high-risk NCS is not well-established.
• More evidence regarding the need for bridging of anticoagulation in patients with MHVs is needed.
• There is a lack of evidence regarding the optimal strategies before emergent or time-sensitive NCS for patients on antithrombotic treatment at high risk of thromboembolic events, including the:
(i) use of extracorporeal haemoperfusion or NOAC antidotes
(ongoing trial NCT04233073); (ii) use of albumin, extracorporeal haemoperfusion, or PB2452-speciﬁc antidote to antagonized ticagrelor (ongoing trial NCT04286438 for PB2452); and (iii)
Routine use of beta-blocker for the prevention of post-operative AF in patients undergoing NCS is not recommended.185,201
III
B
© ESC 2022
AF, atrial ﬁbrillation; b.i.d., twice a day; CV, cardiovascular; HF, heart failure; MI,
myocardial infarction; MINS, myocardial injury following non-cardiac surgery; NCS,
non-cardiac surgery; NOAC, non-vitamin K antagonist oral anticoagulant; NSTE-ACS,
non-ST-elevation acute coronary syndrome; OAC, oral anticoagulant; PE, pulmonary embolism; PMI, peri-operative myocardial infarction/injury; STEMI, ST-segment elevation myocardial infarction; VKA, vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 76 -->

### Page 76

premature cessation or bridging during interruption of oral
P2Y12-receptor inhibitors (glycoprotein IIb/IIIa receptor inhibitors or cangrelor).
• There is lack of well-powered studies to evaluate the role of platelet function testing to guide the strategy for treatment of NCS patients on antiplatelet therapy.
• Evidence regarding the need for and beneﬁt of anticoagulation in
NCS patients with post-operative AF is still lacking (ongoing
ASPIRE-AF trial: NCT03968393).
• Prophylactic strategies to reduce the incidence of post-operative
AF in NCS patients additional to beta-blocker maintenance in patients already on this treatment need to be evaluated.
• The optimal cardiac work-up and therapy for patients with PMI
within and outside hospital settings need to be evaluated.
• Studies are needed to investigate the impact of the treatment of peri-operative hypotension on post-operative outcomes, the use of new HF drug classes (SGLT2 inhibitors and vericiguat), and the use of NSAIDs as a temporary treatment for acute postoperative pain.
• Prospective studies are needed to investigate the incremental value of anaemia algorithms and blood-sparing strategies (use of bloodsparing blood tubes) to reduce the risk of anaemia-associated adverse outcomes among CV patients undergoing NCS.
11. Sex differences
Sex and gender may signiﬁcantly affect the management and outcomes of patients with speciﬁc diseases undergoing NCS. There are sex- and gender-dependent clinical phenotypes of comorbidities and risk factors, which may have an impact on peri-operative morbidity and mortality. However, there is a paucity of data speciﬁcally addressing the interplay between sex, age, and comorbidities in patients scheduled for NCS.
The pre-operative assessment before NCS might take sex into consideration, since the age-adjusted incidence of CVD is lower in women than men, and the risk of undetected disease could therefore be lower in women. However, no data exist on sex-speciﬁc assessment strategies.
The in-hospital mortality during surgery was recently reported to be lower in women than men.41,691 In contrast, among 609 735 patients who underwent elective NCS between 2009 and 2016, the odds of post-operative 90 day mortality were higher among women with HF than men with HF.692 Further studies are needed to provide more information about outcome differences between men and women in NCS.
Some studies have reported a higher risk of bleeding in women than men, but other studies could not conﬁrm this. No trials have systematically investigated the impact of sex differences regarding efﬁcacy and safety of continuation vs. interruption of antithrombotic therapy in patients undergoing NCS.
The prevalence of anaemia in women of reproductive age is as high as 30% (WHO Global Anaemia estimates),693 resulting in millions of women undergoing surgery every year despite pre-operative anaemia.
Furthermore, since women have lower blood volumes and lower haemoglobin values than men, but face the same surgical blood loss as men, they are exposed to far higher risk of post-operative complications. Also, higher transfusion rates and volumes have been reported in women compared with men in elective surgery.694 It is therefore of particular importance that clinicians follow the Patient
Blood Management program in women undergoing NCS. Other sexrelated differences in physiology, and pharmacokinetics and pharmacodynamics of anaesthetic drugs may inﬂuence the anaesthesia plan,
pain management, post-operative recovery, and patient satisfaction.
Sex differences regarding presentation, electrophysiological substrate, complications, or long-term outcomes have been reported in patients undergoing CIED implantation,695,696 and female sex is a well-known risk factor for stroke in patients with AF.697
However, no speciﬁc data exist that suggest sex differences in risk proﬁle or outcomes of patients with CIEDs or arrhythmias who undergo NCS.
12. ‘What to do’ and ‘what not to do’ messages from the Guidelines
Recommendations
Classa
Levelb
Recommendations for clinical risk evaluation
In all patients scheduled for NCS, an accurate history and clinical examination are recommended.
I
C
It is recommended to perform a pre-operative risk assessment, ideally at the same time as the NCS is proposed.
I
B
If time allows, it is recommended to optimize guideline-recommended treatment of CVD and CV risk factors before NCS.
I
C
In patients with a family history of genetic cardiomyopathy, it is recommended to perform an ECG and TTE before NCS, regardless of age and symptoms.
I
C
In patients with a newly detected murmur and symptoms or signs of CVD, TTE is recommended before NCS.
I
C
In patients with a newly detected murmur suggesting clinically signiﬁcant pathology, TTE is recommended before high-risk NCS.
I
C
Continued
ESC Guidelines
3901


<!-- PAGE 77 -->

### Page 77

If a patient scheduled for elective NCS has chest pain or other symptoms suggestive of undetected CAD, further diagnostic work-up before NCS is recommended.
I
C
If a patient in need of acute NCS also has chest pain or other symptoms suggestive of undetected CAD, a multidisciplinary assessment approach is recommended to choose the treatment with lowest total risk for the patient.
I
C
In patients with dyspnoea and/or peripheral oedema, an ECG and an NT-proBNP/BNP test is indicated before NCS, unless there is a certain non-cardiac explanation.
I
C
In patients with dyspnoea and/or peripheral oedema and elevated NT-proBNP/BNP, TTE is recommended before NCS.
I
C
Recommendations for patient information
It is recommended to give patients individualized instructions for pre-operative and post-operative changes in medication, in verbal and written formats with clear and concise directions.
I
C
Recommendations for use of risk assessment tools
In patients who have known CVD or CV risk factors (including age ≥65 years), or symptoms or signs suggestive of CVD it is recommended to obtain a pre-operative 12-lead ECG before intermediate- and high-risk NCS.
I
C
In patients who have known CVD, CV risk factors (including age ≥65 years), or symptoms suggestive of CVD it is recommended to measure hs-cTn T or hs-cTn I before intermediate- and high-risk NCS, and at 24 h and 48 h afterwards.
I
B
TTE is recommended in patients with poor functional capacity and/or high NT-proBNP/BNP, or if murmurs are detected before high-risk NCS, in order to undertake risk-reduction strategies.
I
B
Stress imaging is recommended before high-risk elective NCS in patients with poor functional capacity and high likelihood of CAD or high clinical risk.
I
B
It is recommended to use the same indications for ICA and revascularization pre-operatively as in the non-surgical setting.
I
C
In low-risk patients undergoing low- and intermediate-risk NCS, it is not recommended to routinely obtain pre-operative ECG, hs-cTn
T/I, or BNP/NT-proBNP concentrations.
III
B
Routine pre-operative evaluation of LV function is not recommended.
III
C
Stress imaging is not recommended routinely before NCS.
III
C
Routine pre-operative ICA is not recommended in stable CCS patients undergoing low- and intermediate-risk NCS.
III
C
Recommendations for CV risk factors and lifestyle interventions
Smoking cessation .4 weeks before NCS is recommended to reduce post-operative complications and mortality.
I
B
Control of CV risk factors—including blood pressure, dyslipidaemia, and diabetes—is recommended before NCS.
I
B
Recommendations for pharmacological risk-reduction strategies
Beta-blockers
Peri-operative continuation of beta-blockers is recommended in patients currently receiving this medication.
I
B
Routine initiation of beta-blocker peri-operatively is not recommended.
III
A
Statins
In patients already on statins, it is recommended to continue statins during the peri-operative period.
I
B
Recommendations for peri-operative handling of antithrombotic agents
Antiplatelets
It is recommended to delay elective NCS until 6 months after elective PCI and 12 months after an ACS.
I
A
After elective PCI, it is recommended to delay time-sensitive NCS until a minimum of 1 month of DAPT treatment has been given.
I
B
In patients with a recent PCI scheduled for NCS, it is recommended that management of antiplatelet therapy is discussed between the surgeon, anaesthesiologist, and cardiologist.
I
C
Continued


<!-- PAGE 78 -->

### Page 78

In patients with a previous PCI, it is recommended to continue aspirin peri-operatively if the bleeding risk allows.
I
B
If interruption of P2Y12 inhibitor is indicated, it is recommended to withhold ticagrelor for 3–5 days, clopidogrel for 5 days, and prasugrel for 7 days prior to NCS.
I
B
For patients undergoing high bleeding risk surgery (e.g. intracranial, spinal neurosurgery, or vitroretinal eye surgery), it is recommended to interrupt aspirin for at least 7 days pre-operatively.
I
C
If antiplatelet therapy has been interrupted before a surgical procedure, it is recommended to restart therapy as soon as possible (within
48 h) post-surgery, according to interdisciplinary risk assessment.
I
C
Oral anticoagulants
When an urgent surgical intervention is required, it is recommended that NOAC therapy is immediately interrupted.
I
C
In minor bleeding risk surgery and other procedures where bleeding can easily be controlled, it is recommended to perform surgery without interruption of OAC therapy.
I
B
In non-minor bleeding risk procedures in patients using a NOAC, it is recommended to use an interruption regimen based on the
NOAC compound, renal function, and bleeding risk.
I
B
In patients using NOACs, it is recommended that minor bleeding risk procedures are performed at trough levels (typically 12–24 h after last intake).
I
C
LMWH is recommended, as an alternative to UFH, for bridging in patients with MHVs and high surgical risk.
I
B
Bridging of OAC therapy is not recommended in patients with low/moderate thrombotic risk undergoing NCS.
III
B
Use of reduced-dose NOAC to attenuate the risk of post-operative bleeding is not recommended.
III
C
Recommendations for peri-operative thromboprophylaxis
It is recommended that decisions about peri-operative thromboprophylaxis in NCS are based on individual and procedure-speciﬁc risk factors.
I
A
If thromboprophylaxis is deemed necessary, it is recommended to choose the type and duration of thromboprophylaxis (LMWH,
NOAC, or fondaparinux) according to type of NCS, duration of immobilization, and patient-related factors.
I
A
Recommendations for patient blood management in NCS
It is recommended to measure haemoglobin pre-operatively in patients scheduled for intermediate- to high-risk NCS.
I
B
It is recommended to treat anaemia in advance of NCS in order to reduce the need for RBC transfusion during NCS.
I
A
In patients undergoing surgery with expected blood loss of ≥500 mL, use of washed cell salvage is recommended.
I
A
It is recommended to use point-of-care diagnostics for guidance of blood component therapy, when available.
I
A
Recommendations for management of patients with speciﬁc diseases undergoing NCS
A) Patients with CAD
If PCI is indicated before NCS, the use of new-generation DES is recommended over BMS and balloon angioplasty.
I
A
If NCS can safely be postponed (e.g. at least 3 months), it is recommended that patients with ACS being scheduled for NCS undergo diagnostic and therapeutic interventions as recommended for ACS patients in general.
I
A
Routine myocardial revascularization before low- and intermediate-risk NCS in patients with CCS is not recommended.
III
B
B) Patients with heart failure
In patients with suspected or known HF scheduled for high-risk NCS, it is recommended to evaluate LV function with echocardiography and measurement of NT-proBNP/BNP levels, unless this has recently been performed.
I
B
It is recommended that patients with HF undergoing NCS receive optimal medical treatment according to current ESC Guidelines.
I
A
In patients with HF undergoing NCS, it is recommended to regularly assess volume status and signs of organ perfusion.
I
C
Continued
ESC Guidelines
3903


<!-- PAGE 79 -->

### Page 79

A multidisciplinary team including VAD specialists is recommended for peri-operative management of patients with HF receiving mechanical circulatory support.
I
C
C) Patients with VHD
Clinical and echocardiographic evaluation (if not recently performed) is recommended in all patients with known or suspected VHD
who are scheduled for elective intermediate- or high-risk NCS.
I
C
AVR (SAVR or TAVI) is recommended in symptomatic patients with severe AS who are scheduled for elective intermediate- or high-risk
NCS.
I
C
In patients with symptomatic severe AR or asymptomatic severe AR and LVESD .50 mm or LVESDi (LVESD/BSA) .25 mm/m2 (in patients with small body size) or resting LVEF ≤50%, valve surgery is recommended prior to elective intermediate- or high-risk NCS.
I
C
In patients with moderate-to-severe rheumatic MS and symptoms or SPAP .50 mmHg, valve intervention (percutaneous mitral commissurotomy or surgery) is recommended before elective intermediate- or high-risk NCS.
I
C
D) Patients with ACHD
In patients with ACHD, a consultation with an ACHD specialist is recommended before intermediate- or high-risk surgery.
I
C
In patients with ACHD, it is recommended that intermediate- and high-risk elective surgery is performed in a centre with experience in the care of ACHD patients.
I
C
E) Patients with arrhythmias
In patients with SVT controlled by medication, it is recommended that AADs are continued during the peri-operative period.
I
C
In AF patients with acute or worsening haemodynamic instability undergoing NCS, emergency electrical cardioversion is recommended.
I
B
In patients with symptomatic, monomorphic, and sustained VT associated with myocardial scar, recurring despite optimal medical therapy, ablation of arrhythmia is recommended before elective NCS.
I
B
It is recommended that patients with temporarily deactivated ICDs have continuous ECG monitoring, and during the peri-operative period are accompanied by personnel skilled in early detection and treatment of arrhythmias. In high-risk patients (e.g.
pacemaker-dependant or ICD patients), or if access to the torso will be difﬁcult during the procedure, it is recommended to place transcutaneous pacing/deﬁbrillation pads prior to NCS.
I
C
It is recommended that all patients with CIEDs that are reprogrammed before surgery have a re-check and necessary reprogramming as soon as possible after the procedure.
I
C
It is not recommended to initiate treatment of asymptomatic PVC during NCS.
III
C
F) Patients with pulmonary hypertension
It is recommended to continue chronic therapy for PAH in the peri-operative phase of NCS.
I
C
It is recommended that haemodynamic monitoring of patients with severe PAH continues for at least 24 h in the post-operative period.
I
C
In the case of progression of right HF in the post-operative period in patients with PAH, it is recommended that the diuretic dose be optimized and, if necessary, i.v. prostacyclin analogues be initiated under the guidance of a physician experienced in the management of
PAH.
I
C
G) Patients with hypertension
In patients with chronic hypertension undergoing elective NCS, it is recommended to avoid large peri-operative ﬂuctuations in blood pressure, particularly hypotension, during the peri-operative period.
I
A
It is recommended to perform pre-operative screening for hypertension-mediated organ damage and CV risk factors in newly diagnosed hypertensive patients who are scheduled for elective high-risk NCS.
I
C
It is not recommended to defer NCS in patients with stage 1 or 2 hypertension.
III
C
H) Patients with PAD
In patients with poor functional capacity or with signiﬁcant risk factors or symptoms (such as moderate-to-severe angina pectoris,
decompensated HF, valvular disease and signiﬁcant arrhythmia), referral for cardiac work-up and optimization is recommended prior to elective surgery for PAD or AAA.
I
C
Routine referral for cardiac work-up, coronary angiography, or CPET prior to elective surgery for PAD or AAA is not recommended.
III
C
Continued


<!-- PAGE 80 -->

### Page 80

I) Patients with cerebrovascular disease
Pre-operative carotid artery and cerebral imaging is recommended in patients with a history of TIA or stroke in the previous 6 months and who have not undergone ipsilateral revascularization.
I
C
Pre-operative routine carotid artery imaging is not recommended in patients undergoing NCS.
III
C
J) Patients with renal disease
In patients with known risk factors (age .65 years, BMI .30 kg/m2, diabetes, hypertension, hyperlipidaemia, CV disease, or smoking)
undergoing intermediate- or high-risk NCS, it is recommended to screen for pre-operative renal disease by measuring serum creatinine and GFR.
I
C
K) Patients with obesity
It is recommended to assess cardiorespiratory ﬁtness to estimate peri-operative CV risk in obese patients, with particular attention to those undergoing intermediate- and high-risk NCS.
I
B
L) Patients with diabetes mellitus
A pre-operative assessment for concomitant cardiac conditions is recommended in patients with diabetes with suspected or known
CAD, and those with autonomic neuropathy, retinopathy, or renal disease and scheduled to undergo intermediate- and high-risk NCS.
I
C
In patients with diabetes or disturbed glucose metabolism, a pre-operative HbA1c is recommended, if this measurement has been not performed in the previous 3 months. In case of HbA1c ≥8.5% (≥69 mmol/mol), elective NCS should be postponed, if safe and practical.
I
B
Recommendations for peri-operative monitoring and anaesthesia
In order to preserve optimal CV stability, it is recommended to apply goal-directed haemodynamic therapy in patients undergoing high-risk NCS.
I
A
It is recommended to avoid post-operative acute pain.
I
B
In order to minimize the risk of post-operative organ dysfunction, it is recommended to avoid an intra-operative mean arterial pressure decrease of .20% from baseline values or ,60–70 mmHg for ≥10 min.
I
B
Non-aspirin NSAIDs are not recommended as ﬁrst-line analgesics in patients with established or high risk of CVD.
III
B
Recommendations for treatment of post-operative cardiovascular complications
It is recommended to have high awareness of peri-operative CV complications, combined with surveillance for PMI in patients undergoing intermediate- or high-risk NCS.
I
B
Systematic PMI work-up is recommended to identify the underlying pathophysiology and deﬁne therapy.
I
B
It is recommended to treat post-operative STEMI, NSTE-ACS, acute HF, and tachyarrhythmias in accordance with guidelines for the non-surgical setting, after interdisciplinary discussion with the surgeon about bleeding risk.
I
C
In patients with post-operative PE of high or intermediate clinical probability, initiation of anticoagulation is recommended without delay, while diagnostic work-up is in progress, if bleeding risk is low.
I
C
Post-operative oral anticoagulation for PE is recommended to be administered for a period of at least 3 months.
I
C
In patients with a post-operative indication for OAC, NOAC is generally recommended over VKA.
I
A
Routine use of beta-blocker for the prevention of post-operative AF in patients undergoing NCS is not recommended.
III
B
© ESC 2022
AAA, abdominal aortic aneurysm; AAD, antiarrhythmic drug; ACHD, adults with congenital heart disease; ACS, acute coronary syndrome; AF, atrial ﬁbrillation; AR, aortic valve regurgitation; AS, aortic valve stenosis; AVR, aortic valve replacement; BMI, body mass index; BNP, B-type natriuretic peptide; BMS, bare metal stent; BSA, body surface area; CAD,
coronary artery disease; CCS, chronic coronary syndrome; CIED, cardiac implantable electronic device; CPET, cardiopulmonary exercise testing; CV, cardiovascular; CVD,
cardiovascular disease; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; ECG, electrocardiogram; ESC, European Society of Cardiology; GFR, glomerular ﬁltration rate;
HbA1c, glycated haemoglobin; HF, heart failure; hs-cTn, high-sensitivity cardiac troponin; ICA, invasive coronary angiography; ICD, implantable cardioverter–deﬁbrillator; LMWH,
low molecular weight heparin; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESDi, left ventricular end-systolic dimension index; MHV, mechanical heart valve; MS, mitral valve stenosis; NCS, non-cardiac surgery; NOAC, non-vitamin K antagonist oral anticoagulant; NSAID, non-steroidal anti-inﬂammatory drug; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OAC, oral anticoagulant; PAD,
peripheral artery disease; PAH, pulmonary arterial hypertension; PCI, percutaneous coronary intervention; PE, pulmonary embolism; PMI, peri-operative myocardial infarction/injury;
PVC, premature ventricular contractions; RBC, red blood cell; SAVR, surgical aortic valve replacement; SPAP, systolic pulmonary artery pressure; STEMI, ST-segment elevation myocardial infarction; SVT, supraventricular tachycardia; TAVI, transcatheter aortic valve implantation; TIA, transient ischaemic attack; TTE, transthoracic echocardiography; UFH,
unfractionated heparin; VAD, ventricular assist device; VHD, valvular heart disease; VKA, vitamin K antagonist; VT, ventricular tachycardia.
ESC Guidelines
3905


<!-- PAGE 81 -->

### Page 81

### 13 Quality indicators

Quality indicators (QIs) are tools that may be used to evaluate care quality, including structural, process, and outcomes of care.698 They may also serve as a mechanism for enhancing adherence to guideline recommendations, through associated quality improvement initiatives and the benchmarking of care providers.699,700 As such, the role of QIs in improving care and outcomes for CV disease is increasingly being recognized by healthcare authorities, professional organizations, payers, and the public.698
The ESC understands the need for measuring and reporting quality and outcomes of CV care and has established methods for the development of the ESC QIs for the quantiﬁcation of care and outcomes for
CV diseases.698 To date, the ESC has developed QI suites for a number of CV diseases701–703 and embedded these in respective ESC Clinical
Practice Guidelines (2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation; 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure; and 2021 ESC
Guidelines on cardiac pacing and cardiac resynchronization therapy).99,412,481,704 Furthermore, the ESC aims to integrate its QIs with clinical registries such as the EURObservational Research Programme
(EORP) and the European Uniﬁed Registries On Heart Care
Evaluation and Randomized Trials (EuroHeart) project705 to provide
‘real-world’ data about the patterns and outcomes of care for CV disease across Europe.
In parallel with the writing of this Clinical Practice Guideline document, a process has been initiated to develop QIs for patients undergoing NCS using the ESC methodology and through collaboration with patient representatives and domain experts. Such QIs may be used for evaluation of the quality of care for this group of patients and enable capture of important aspects of care delivery. The QIs,
alongside their measurement speciﬁcations and development process, will be published in a separate paper.
14. Central illustration
There is a complex interplay between the intrinsic risk of surgery and the patient-related risk of peri-operative CV complications. This latter risk depends on the baseline general and CV status of patients scheduled for NCS. For each patient, the proper quantiﬁcation and communication of the surgical risk require close cooperation between cardiologists, surgeons, anaesthesiologists, general practitioners, and other healthcare providers (Figure 21).
Comorbidity risk
Hypoxic/hypotensive/
hypovolaemic risk
Thrombotic/bleeding risk
Haemodynamic/
arrhythmic risk
Surgical risk
High
Intermediate
Low y
Ageing/metabolic and autonomic dysregulation/hypertension/
chronic kidney disease
Central/systemic gas-exchange balance
Diastolic/systolic dysfunction and pulmonary congestion
Rhythm diso device ther
Valvular heart disease
Withdrawal/continuation antithrombotic drugs
Acute/chronic coronary syndrome nic
Fluid/blood loss xchange balance s
alvu vula vu vu xchange balance exchange bal ex ular heart d seas dise y
Haemodyn
Haemody fu on sf on y
o dy mo d
m lul pu p
O2
CO2
ase y
lic tolic/systol t
ast a
Di
D
ic tolic/systolili t
ast a
Di
D
ic tolic/systoli t
ast a
Di
D
c tolic/systolicicic t
ast a
Di
D
o e
o e
o e
o er
CO2
O2
Figure 21 Central illustration: the complex interplay between the intrinsic risk of surgery and the patient risk of peri-operative cardiovascular complications.


<!-- PAGE 82 -->

### Page 82

### 15 Supplementary data

Supplementary data is available at European Heart Journal online.
16. Data availability statement
No new data were generated or analysed in support of this research.
17. Author information
Author/Task
Force
Member
Afﬁliations:
Salvatore
Cassese, Klinik für Herz- und Kreislauferkrankungen, Deutsches
Herzzentrum München, Munich, Germany; Trygve S. Hall,
Department of Cardiology, Oslo University Hospital, Ullevål, Oslo,
Norway; Magdy Abdelhamid, Cardiology Department, Faculty of Medicine, Kase Al Ainy, Cairo University, Cairo, Egypt;
Emanuele Barbato, Advanced Biomedical Sciences, University
Federico II, Naples, Italy, Cardiovascular Center Aalst, OLV
Hospital, Aalst, Belgium; Stefan De Hert, Department of
Anesthesiology and Perioperative Medicine, Ghent University
Hospital/Ghent University, Ghent, Belgium; Tobias Geisler,
Department of Cardiology and Angiology, University Hospital
Tübingen,
Tübingen,
Germany;
Lynne
Hinterbuchner,
Department of
Cardiology,
Clinic of
Internal
Medicine
II,
Paracelsus Medical University of Salzburg, Salzburg, Austria; Borja
Ibanez, Clinical Research Department, Centro Nacional de
Investigaciones
Cardiovasculares
(CNIC),
Madrid,
Spain,
Cardiology Department, Fundación Jiménez Díaz Hospital, Madrid,
Spain, CIBERCV Centro Investigacion Biomedica en Red, Madrid,
Spain; Ingrid de Laval (Sweden), ESC Patient Forum, Sophia
Antipolis,
France;
Radosław
Lenarczyk,
Department of
Cardiology, Congenital Heart Diseases and Electrotherapy, The
Medical University of Silesia, Division of Medical Sciences in
Zabrze, Zabrze, Poland, Silesian Center for Heart Disease, Zabrze,
Poland; Ulrich R. Mansmann, Institute for Medical Data
Processing,
Biometry,
and
Epidemiology,
Ludwig-Maximilian’s
University, Munich, Germany; Paul McGreavy (United Kingdom),
ESC Patient Forum, Sophia Antipolis, France; Christian Mueller,
Cardiovascular Research Institute Basel, University Heart Center,
University Hospital Basel, Basel, Switzerland, University of Basel,
Basel,
Switzerland;
Claudio
Muneretto,
Cardiothoracic,
University of Brescia Italy, Brescia, Italy; Alexander Niessner,
Department of Internal Medicine II, Division of Cardiology, Medical
University of Vienna, Vienna, Austria; Tatjana S. Potpara,
School of
Medicine,
Belgrade
University,
Belgrade,
Serbia,
Cardiology Clinic, University Clinical Center of Serbia, Belgrade,
Serbia; Arsen D. Ristić, Faculty of Medicine, Belgrade University,
Belgrade, Serbia, Department of Cardiology, University Clinical
Center of Serbia, Belgrade, Serbia; L. Elif Sade, Heart and
Vascular
Institute,
University of
Pittsburgh
Medical
Center,
Pittsburgh, PA, United States of America, Cardiology, University of
Baskent, Ankara, Turkey; Henrik Schirmer, Department of
Cardiology, Akershus University Hospital, Lørenskog, Norway,
Institute of Clinical Medicine, Campus Ahus, University of Oslo,
Lørenskog, Norway; Stefanie Schüpke, ISAResearch Center,
Deutsches
Herzzentrum
München,
Munich,
Germany,
Heart
Alliance, DZHK (German Center for Cardiovascular Research),
Munich,
Germany;
Henrik
Sillesen,
Vascular
Surgery,
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark,
Clinical
Medicine,
University of
Copenhagen,
Copenhagen,
Denmark; Helge Skulstad, Department of Cardiology, Clinic of heart-, lung- and vessel disease, Oslo University Hospital, Oslo,
Norway, Institute of Clinical Medicine, University of Oslo, Oslo,
Norway; Lucia Torracca, Cardiac Surgery, IRCCS Humanitas
Research Hospital, Milano, Italy; Oktay Tutarel, Department of
Congenital Heart Disease and Paediatric Cardiology, German
Heart Centre Munich, TUM School of Medicine, Technical
University of Munich, Munich, Germany, DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance,
Munich, Germany; Peter Van der Meer, Cardiology, University
Medical Center Groningen, Groningen, Netherlands; Wojtek
Wojakowski, Division of Cardiology and Structural Heart
Diseases, Medical University of Silesia, Katowice, Poland; and Kai
Zacharowski, Anaesthesiology, Intensive Care Medicine & Pain
Therapy,
University
Hospital
Frankfurt,
Goethe
University,
Frankfurt, Germany.
18. Appendix
ESC
Scientiﬁc
Document
Group:
includes
Document
Reviewers and ESC National Cardiac Societies.
Document
Reviewers:
Juhani
Knuuti
(CPG
Review
Coordinator) (Finland), Steen Dalby Kristensen (CPG Review
Coordinator) (Denmark), Victor Aboyans (France), Ingo Ahrens
(Germany),
Sotiris
Antoniou
(United
Kingdom),
Riccardo
Asteggiano (Italy), Dan Atar (Norway), Andreas Baumbach (United
Kingdom),
Helmut
Baumgartner
(Germany),
Michael
Böhm
(Germany), Michael A. Borger (Germany), Hector Bueno (Spain),
Jelena Čelutkienė (Lithuania), Alaide Chieffo (Italy), Maya Cikes
(Croatia), Harald Darius (Germany), Victoria Delgado (Spain),
Philip J. Devereaux (Canada), David Duncker (Germany), Volkmar
Falk (Germany), Laurent Fauchier (France), Gilbert Habib (France),
David Hasdai (Israel), Kurt Huber (Austria), Bernard Iung (France),
Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian Federation),
Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United
Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales
Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Michael
Maeng (Denmark), Stéphane Manzo-Silberman (France), Richard
Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens
Cosedis Nielsen (Denmark), Steffen E. Petersen (United Kingdom),
Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Antti
Saraste (Finland), Dirk Sibbing (Germany), Jolanta M. Siller-Matula
(Austria), Marta Sitges (Spain), Ivan Stankovic (Serbia), Rob
F. Storey (United Kingdom), Jurrien ten Berg (Netherlands),
Matthias Thielmann (Germany), and Rhian M. Touyz (Canada/
United Kingdom).
ESC National Cardiac Societies actively involved in the review process of the 2022 ESC Guidelines on assessment and management of patients undergoing non-cardiac surgery
Algeria: Algerian Society of Cardiology, Mohammed Amine
Bouzid; Armenia: Armenian Cardiologists Association, Hamayak
Sisakian; Austria: Austrian Society of Cardiology, Bernhard
ESC Guidelines
3907


<!-- PAGE 83 -->

### Page 83

Metzler; Belarus: Belorussian Scientiﬁc Society of Cardiologists,
Vadim Shumavets; Belgium: Belgian Society of Cardiology, Agnès
Pasquet; Bosnia and Herzegovina: Association of Cardiologists of Bosnia and Herzegovina, Elnur Smajic; Bulgaria: Bulgarian
Society of Cardiology, Maria Milanova; Croatia: Croatian Cardiac
Society, Boško Skorić; Cyprus: Cyprus Society of Cardiology,
Maria Karakyriou; Czechia: Czech Society of Cardiology, Hana
Skalicka; Denmark: Danish Society of Cardiology, Michael Maeng;
Egypt: Egyptian Society of Cardiology, Bassem Abd Elhamid;
Estonia:
Estonian
Society of
Cardiology,
Arno
Ruusalepp;
Finland: Finnish Cardiac Society, Kati Valtola; France: French
Society of Cardiology, Ariel Cohen; Georgia: Georgian Society of
Cardiology, Archil Chukhrukidze; Germany: German Cardiac
Society, Ilka Ott; Greece: Hellenic Society of Cardiology, Nikos
Kafkas; Hungary: Hungarian Society of Cardiology, Zoltán Járai;
Iceland:
Icelandic
Society of
Cardiology,
Thórdís
Jóna
Hrafnkelsdóttir; Ireland: Irish Cardiac Society, Patricia Campbell;
Israel: Israel Heart Society, Alon Eisen; Italy: Italian Federation of
Cardiology,
Stefano
Urbinati;
Kazakhstan:
Association of
Cardiologists of
Kazakhstan,
Nazipa
Aidargaliyeva;
Kosovo
(Republic of): Kosovo Society of Cardiology, Arlind Batalli;
Kyrgyzstan: Kyrgyz Society of Cardiology, Olga Lunegova;
Latvia: Latvian Society of Cardiology, Andrejs Erglis; Lebanon:
Lebanese Society of Cardiology, Georges Saade; Lithuania:
Lithuanian Society of Cardiology, Andrius Macas; Luxembourg:
Luxembourg Society of Cardiology, Cristiana Banu; Malta: Maltese
Cardiac Society, Tiziana Felice; Moldova: Moldavian Society of Cardiology, Aurel Grosu; Montenegro: Montenegro Society of
Cardiology,
Mihailo
Vukmirovic;
Morocco:
Moroccan
Society of Cardiology, Aida Souﬁani; Netherlands: Netherlands
Society of Cardiology, Eric Dubois; North Macedonia: North
Macedonian Society of Cardiology, Hristo Pejkov; Norway:
Norwegian Society of Cardiology, Erlend Aune; Poland: Polish
Cardiac Society, Stanisław Bartuś; Portugal: Portuguese Society of Cardiology, Mário Santos; Romania: Romanian Society of
Cardiology,
Elisabeta
Badila;
Russian
Federation:
Russian
Society of Cardiology, Olga Irtyuga; San Marino: San Marino
Society of Cardiology, Luca Bertelli; Serbia: Cardiology Society of
Serbia, Branko Beleslin; Slovakia: Slovak Society of Cardiology,
Martin Dúbrava; Slovenia: Slovenian Society of Cardiology, Zlatko
Fras; Spain: Spanish Society of Cardiology, José Luis Ferreiro;
Sweden:
Swedish
Society of
Cardiology,
Claes
Held;
Switzerland:
Swiss
Society of
Cardiology,
Philippe Meyer;
Syrian Arab Republic: Syrian Cardiovascular Association, Walid
Bsata;
Tunisia:
Tunisian
Society of
Cardiology and
Cardio-Vascular Surgery, Afef Ben Halima; Turkey: Turkish
Society of Cardiology, Murat Biteker, United Kingdom of
Great Britain and Northern Ireland: British Cardiovascular
Society, Andrew Archbold; Ukraine: Ukrainian Association of
Cardiology, Maksym Sokolov; and Uzbekistan: Association of
Cardiologists of Uzbekistan, Nodir Zakirov.
ESC Clinical Practice Guidelines (CPG) Committee:
Colin Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid
(Egypt),
Victor
Aboyans
(France),
Sotiris
Antoniou
(United
Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy),
Andreas
Baumbach
(United
Kingdom),
Michael
A.
Borger
(Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia),
Jean-Philippe Collet (France), Volkmar Falk (Germany), Laurent
Fauchier
(France),
Chris
P.
Gale
(United
Kingdom),
Sigrun
Halvorsen
(Norway),
Bernard
Iung
(France),
Tiny
Jaarsma
(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos
C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf
Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech
Republic), Maja-Lisa Løchen (Norway), Richard Mindham (United
Kingdom), Jens Cosedis Nielsen (Denmark), Steffen E. Petersen
(United Kingdom), Eva Prescott (Denmark), Amina Rakisheva
(Kazakhstan), Marta Sitges (Spain), and Rhian M. Touyz (Canada
/United Kingdom).
19. References
1. Weiser TG, Regenbogen SE, Thompson KD, Haynes AB, Lipsitz SR, Berry WR,
et al. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet 2008;372:139–144.
2. Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, et al.
Estimate of the global volume of surgery in 2012: an assessment supporting improved health outcomes. Lancet 2015;385:S11.
3. Eurostat. EU population in 2020: almost 448 million. https://ec.europa.eu/eurostat/
documents/2995521/11081093/3-10072020-AP-EN.pdf/d2f799bf-4412-05cca357-7b49b93615f1 (31 March 2022).
4. Smilowitz NR, Gupta N, Guo Y, Beckman JA, Bangalore S, Berger JS. Trends in cardiovascular risk factor and disease prevalence in patients undergoing non-cardiac surgery. Heart 2018;104:1180–1186.
5. Lee OH, Hong SJ, Ahn CM, Kim JS, Kim BK, Ko YG, et al. The incidence of noncardiac surgery in patients treated with drug-eluting stents according to age.
J Invasive Cardiol 2019;31:E9–E14.
6. Vascular Events in Noncardiac Surgery Patients Cohort Evaluation Study
Investigators, Spence J, LeManach Y, Chan MTV, Wang CY, Sigamani A, et al.
Association between complications and death within 30 days after noncardiac surgery. CMAJ 2019;191:E830–E837.
7. Pearse RM, Moreno RP, Bauer P, Pelosi P, Metnitz P, Spies C, et al. Mortality after surgery in Europe: a 7 day cohort study. Lancet 2012;380:1059–1065.
8. Sazgary L, Puelacher C, Lurati Buse G, Glarner N, Lampart A, Bolliger D, et al.
Incidence of major adverse cardiac events following non-cardiac surgery. Eur
Heart J Acute Cardiovasc Care 2020;10:550–558.
9. Smilowitz NR, Berger JS. Perioperative cardiovascular risk assessment and management for noncardiac surgery: a review. JAMA 2020;324:279–290.
10. Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, et al. 2014 ESC/
ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the
European Society of Anaesthesiology (ESA). Eur Heart J 2014;35:2383–2431.
11. Kamel H, Johnston SC, Kirkham JC, Turner CG, Kizer JR, Devereux RB, et al.
Association between major perioperative hemorrhage and stroke or Q-wave myocardial infarction. Circulation 2012;126:207–212.
12. CRASH-2 Trial Collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T,
et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with signiﬁcant haemorrhage (CRASH-2): a randomised,
placebo-controlled trial. Lancet 2010;376:23–32.
13. Kougias P, Sharath S, Barshes NR, Chen M, Mills JL, Sr. Effect of postoperative anemia and baseline cardiac risk on serious adverse outcomes after major vascular interventions. J Vasc Surg 2017;66:1836–1843.
14. Cohn SL. The cardiac consult for patients undergoing non-cardiac surgery. Heart
2016;102:1322–1332.
15. Guay J, Choi P, Suresh S, Albert N, Kopp S, Pace NL. Neuraxial blockade for the prevention of postoperative mortality and major morbidity: an overview of
Cochrane systematic reviews. Cochrane Database Syst Rev 2014:2014:CD010108.
16. Norderud K, Egholm G, Thim T, Olesen KKW, Madsen M, Jensen LO, et al.
Validation of the European Society of Cardiology and European Society of
Anaesthesiology non-cardiac surgery risk score in patients treated with coronary drug-eluting stent implantation. Eur Heart J Qual Care Clin Outcomes 2019;5:22–27.
17. Mangano DT. Perioperative medicine: NHLBI working group deliberations and recommendations. J Cardiothorac Vasc Anesth 2004;18:1–6.
18. Glance LG, Lustik SJ, Hannan EL, Osler TM, Mukamel DB, Qian F, et al. The Surgical
Mortality Probability Model: derivation and validation of a simple risk prediction rule for noncardiac surgery. Ann Surg 2012;255:696–702.


<!-- PAGE 84 -->

### Page 84

19. Muller MD, Lyrer P, Brown MM, Bonati LH. Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis. Cochrane Database Syst Rev
2020;2:CD000515.
20. Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial.
Lancet Oncol 2016;17:836–844.
21. Falcoz PE, Puyraveau M, Thomas PA, Decaluwe H, Hürtgen M, Petersen RH, et al.
Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the
European Society of Thoracic Surgeon database. Eur J Cardiothorac Surg 2016;49:
602–609.
22. Martin D, Mantziari S, Demartines N, Hubner M, Study Group ESA. Deﬁning major surgery: a Delphi consensus among European Surgical Association (ESA) members.
World J Surg 2020;44:2211–2219.
23. Bolliger M, Kroehnert JA, Molineus F, Kandioler D, Schindl M, Riss P. Experiences with the standardized classiﬁcation of surgical complications (Clavien-Dindo) in general surgery patients. Eur Surg 2018;50:256–261.
24. Bjorck M, Earnshaw JJ, Acosta S, Bastos Goncalves F, Cochennec F, Debus ES, et al.
Editor’s choice – European Society for Vascular Surgery (ESVS) 2020 Clinical
Practice Guidelines on the management of acute limb ischaemia. Eur J Vasc
Endovasc Surg 2020;59:173–218.
25. Holte K, Kehlet H. Postoperative ileus: a preventable event. Br J Surg 2000;87:
1480–1493.
26. Popescu WM, Bell R, Duffy AJ, Katz KH, Perrino AC. A pilot study of patients with clinically severe obesity undergoing laparoscopic surgery: evidence for impaired cardiac performance. J Cardiothorac Vasc Anesth 2011;25:943–949.
27. Lestar M, Gunnarsson L, Lagerstrand L, Wiklund P, Odeberg-Wernerman S.
Hemodynamic perturbations during robot-assisted laparoscopic radical prostatectomy in 45° Trendelenburg position. Anesth Analg 2011;113:1069–1075.
28. Hirvonen
EA,
Nuutinen
LS,
Kauko
M.
Hemodynamic changes due to
Trendelenburg positioning and pneumoperitoneum during laparoscopic hysterectomy. Acta Anaesthesiol Scand 1995;39:949–955.
29. Nguyen NT, Wolfe BM. The physiologic effects of pneumoperitoneum in the morbidly obese. Ann Surg 2005;241:219–226.
30. Keus F, Gooszen HG, van Laarhoven CJ. Open, small-incision, or laparoscopic cholecystectomy for patients with symptomatic cholecystolithiasis. An overview of Cochrane Hepato-Biliary Group reviews. Cochrane Database Syst Rev 2010;
2010:CD008318.
31. Mamidanna R, Burns EM, Bottle A, Aylin P, Stonell C, Hanna GB, et al. Reduced risk of medical morbidity and mortality in patients selected for laparoscopic colorectal resection in England: a population-based study. Arch Surg 2012;147:219–227.
32. Cirocchi R, Farinella E, Trastulli S, Sciannameo F, Audisio RA. Elective sigmoid colectomy for diverticular disease. Laparoscopic vs open surgery: a systematic review.
Colorectal Dis 2012;14:671–683.
33. Murr MM, Martin T, Haines K, Torrella T, Dragotti R, Kandil A, et al. A state-wide review of contemporary outcomes of gastric bypass in Florida: does provider volume impact outcomes? Ann Surg 2007;245:699–706.
34. Grailey K, Markar SR, Karthikesalingam A, Aboud R, Ziprin P, Faiz O. Laparoscopic versus open colorectal resection in the elderly population. Surg Endosc 2013;27:
19–30.
35. Wanhainen A, Verzini F, Van Herzeele I, Allaire E, Bown M, Cohnert T, et al.
Editor’s choice – European Society for Vascular Surgery (ESVS) 2019 Clinical
Practice Guidelines on the management of abdominal aorto-iliac artery aneurysms.
Eur J Vasc Endovasc Surg 2019;57:8–93.
36. Powell JT, Sweeting MJ, Ulug P, Blankensteijn JD, Lederle FA, Becquemin JP, et al.
Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE
trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years. Br J Surg 2017;104:166–178.
37. Lederle FA, Kyriakides TC, Stroupe KT, Freischlag JA, Padberg FT, Jr., Matsumura JS,
et al. Open versus endovascular repair of abdominal aortic aneurysm. N Engl J Med
2019;380:2126–2135.
38. Bauer SM, Cayne NS, Veith FJ. New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery. J Vasc Surg 2010;51:242–251.
39. Antoniou GA, Chalmers N, Georgiadis GS, Lazarides MK, Antoniou SA,
Serracino-Inglott F, et al. A meta-analysis of endovascular versus surgical reconstruction of femoropopliteal arterial disease. J Vasc Surg 2013;57:242–253.
40. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021
ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J
2021;42:3227–3337.
41. Botto F, Alonso-Coello P, Chan MT, Villar JC, Xavier D, Srinathan S, et al.
Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology 2014;120:564–578.
42. Noordzij PG, Boersma E, Bax JJ, Feringa HH, Schreiner F, Schouten O, et al.
Prognostic value of routine preoperative electrocardiography in patients undergoing noncardiac surgery. Am J Cardiol 2006;97:1103–1106.
43. Chivulescu M, Lie Ø, Popescu BA, Skulstad H, Edvardsen T, Jurcut RO, et al. High penetrance and similar disease progression in probands and in family members with arrhythmogenic cardiomyopathy. Eur Heart J 2020;41:1401–1410.
44. Hallqvist L, Granath F, Bell M. Myocardial infarction after noncardiac surgery in
Sweden: a national, retrospective observational cohort study. Br J Anaesth 2020;
125:47–54.
45. Chaudhry W, Cohen MC. Cardiac screening in the noncardiac surgery patient. Surg
Clin North Am 2017;97:717–732.
46. Ford MK, Beattie WS, Wijeysundera DN. Systematic review: prediction of perioperative cardiac complications and mortality by the Revised Cardiac Risk Index.
Ann Intern Med 2010;152:26–35.
47. Duceppe E, Parlow J, MacDonald P, Lyons K, McMullen M, Srinathan S, et al.
Canadian Cardiovascular Society guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. Can J
Cardiol 2017;33:17–32.
48. Yap MKC, Ang KF, Gonzales-Porciuncula LA, Esposo E. Validation of the American
College of Surgeons Risk Calculator for preoperative risk stratiﬁcation. Heart Asia
2018;10:e010993.
49. Dakik HA, Chehab O, Eldirani M, Sbeity E, Karam C, Abou Hassan O, et al. A new index for pre-operative cardiovascular evaluation. J Am Coll Cardiol 2019;73:
3067–3078.
50. Dakik HA, Sbaity E, Msheik A, Kaspar C, Eldirani M, Chehab O, et al. AUB-HAS2
Cardiovascular Risk Index: performance in surgical subpopulations and comparison to the Revised Cardiac Risk Index. J Am Heart Assoc 2020;9:e016228.
51. Dakik HA, Eldirani M, Kaspar C, Chehab O, Msheik A, Makki M, et al. Prospective validation of the AUB-HAS2 Cardiovascular Risk Index. Eur Heart J Qual Care Clin
Outcomes 2022;8:96–97.
52. Duceppe E, Patel A, Chan MTV, Berwanger O, Ackland G, Kavsak PA, et al.
Preoperative N-terminal pro-B-type natriuretic peptide and cardiovascular events after noncardiac surgery: a cohort study. Ann Intern Med 2020;172:96–104.
53. Weber M, Luchner A, Seeberger M, Mueller C, Liebetrau C, Schlitt A, et al.
Incremental value of high-sensitive troponin T in addition to the revised cardiac index for peri-operative risk stratiﬁcation in non-cardiac surgery. Eur Heart J 2013;34:
853–862.
54. Kueh SH, Pasley T, Wheeler M, Pemberton J. The not so innocent heart murmur: a
5-year experience. Intern Med J 2017;47:199–205.
55. Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, et al. ACCF/
ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use
Criteria for Echocardiography. A Report of the American College of Cardiology
Foundation
Appropriate
Use
Criteria
Task
Force,
American
Society of
Echocardiography, American Heart Association, American Society of Nuclear
Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for
Cardiovascular Angiography and Interventions, Society of Critical Care Medicine,
Society of Cardiovascular Computed Tomography, Society for Cardiovascular
Magnetic Resonance American College of Chest Physicians. J Am Soc Echocardiogr
2011;24:229–267.
56. Friedman JM, Couso R, Kitchens M, Vakhshori V, Hillin CD, Wu CH, et al. Benign heart murmurs as a predictor for complications following total joint arthroplasty.
J Orthop 2017;14:470–474.
57. Hip Attack Investigators. Accelerated surgery versus standard care in hip fracture
(HIP ATTACK): an international, randomised, controlled trial. Lancet 2020;395:
698–708.
58. Cowie B. The preoperative patient with a systolic murmur. Anesth Pain Med 2015;5:
e32105.
59. Attenhofer Jost CH, Turina J, Mayer K, Seifert B, Amann FW, Buechi M, et al.
Echocardiography in the evaluation of systolic murmurs of unknown cause. Am J
Med 2000;108:614–620.
60. Kobal SL, Trento L, Baharami S, Tolstrup K, Naqvi TZ, Cercek B, et al. Comparison of effectiveness of hand-carried ultrasound to bedside cardiovascular physical examination. Am J Cardiol 2005;96:1002–1006.
61. Abidov A, Rozanski A, Hachamovitch R, Hayes SW, Aboul-Enein F, Cohen I, et al.
Prognostic signiﬁcance of dyspnea in patients referred for cardiac stress testing.
N Engl J Med 2005;353:1889–1898.
62. Cajita MI, Cajita TR, Han HR. Health literacy and heart failure: a systematic review.
J Cardiovasc Nurs 2016;31:121–130.
63. Magnani JW, Mujahid MS, Aronow HD, Cene CW, Dickson VV, Havranek E, et al.
Health literacy and cardiovascular disease. Fundamental relevance to primary and secondary prevention:
a scientiﬁc statement from the
American
Heart
Association. Circulation 2018;138:e48–e74.
64. Shinkunas LA, Klipowicz CJ, Carlisle EM. Shared decision making in surgery: a scoping review of patient and surgeon preferences. BMC Med Inform Decis Mak 2020;20:
190.
ESC Guidelines
3909


<!-- PAGE 85 -->

### Page 85

65. de Mik SML, Stubenrouch FE, Balm R, Ubbink DT. Systematic review of shared decision-making in surgery. Br J Surg 2018;105:1721–1730.
66. Pham C, Lizarondo L, Karnon J, Aromataris E, Munn Z, Gibb C, et al. Strategies for implementing shared decision making in elective surgery by health care practitioners: a systematic review. J Eval Clin Pract 2020;26:582–601.
67. Niburski K, Guadagno E, Abbasgholizadeh-Rahimi S, Poenaru D. Shared decision making in surgery: a meta-analysis of existing literature. Patient 2020;13:667–681.
68. Abate SM, Cheko YA, Basu B. Global prevalence and determinants of preoperative anxiety among surgical patients: a systematic review and meta-analysis. Int J Surg
Open 2020;25:6–16.
69. Takagi H, Ando T, Umemoto T, Group ALICE. Perioperative depression or anxiety and postoperative mortality in cardiac surgery: a systematic review and meta-analysis. Heart Vessels 2017;32:1458–1468.
70. Tully PJ, Baker RA. Depression, anxiety, and cardiac morbidity outcomes after coronary artery bypass surgery: a contemporary and practical review. J Geriatr Cardiol
2012;9:197–208.
71. Rosenberger PH, Jokl P, Ickovics J. Psychosocial factors and surgical outcomes: an evidence-based literature review. J Am Acad Orthop Surg 2006;14:397–405.
72. Theunissen M, Peters ML, Bruce J, Gramke HF, Marcus MA. Preoperative anxiety and catastrophizing: a systematic review and meta-analysis of the association with chronic postsurgical pain. Clin J Pain 2012;28:819–841.
73. Szeverenyi C, Kekecs Z, Johnson A, Elkins G, Csernatony Z, Varga K. The use of adjunct psychosocial interventions can decrease postoperative pain and improve the quality of clinical care in orthopedic surgery: a systematic review and meta-analysis of randomized controlled trials. J Pain 2018;19:1231–1252.
74. Villa G, Lanini I, Amass T, Bocciero V, Scire Calabrisotto C, Chelazzi C, et al. Effects of psychological interventions on anxiety and pain in patients undergoing major elective abdominal surgery: a systematic review. Perioper Med (Lond) 2020;9:38.
75. Richards SH, Anderson L, Jenkinson CE, Whalley B, Rees K, Davies P, et al.
Psychological interventions for coronary heart disease. Cochrane Database Syst
Rev 2017;4:CD002902.
76. Bilimoria KY, Liu Y, Paruch JL, Zhou L, Kmiecik TE, Ko CY, et al. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. J Am Coll Surg 2013;217:833–-
842.e831–833.
76a. Fronczek J, Polok K, Devereaux PJ, et al. External validation of the Revised Cardiac
Risk Index and National Surgical Quality Improvement Program Myocardial
Infarction and Cardiac Arrest calculator in noncardiac vascular surgery. Br J
Anaesth. 2019;123(4):421–429. doi:10.1016/j.bja.2019.05.02.
77. Bertges DJ, Goodney PP, Zhao Y, Schanzer A, Nolan BW, Likosky DS, et al. The
Vascular Study Group of New England Cardiac Risk Index (VSG-CRI) predicts cardiac complications more accurately than the Revised Cardiac Risk Index in vascular surgery patients. J Vasc Surg 2010;52:674–683.683.e1–683.e3.
78. Protopapa KL, Simpson JC, Smith NC, Moonesinghe SR. Development and validation of the Surgical Outcome Risk Tool (SORT). Br J Surg 2014;101:1774–1783.
79. Wong DJN, Harris S, Sahni A, Bedford JR, Cortes L, Shawyer R, et al. Developing and validating subjective and objective risk-assessment measures for predicting mortality after major surgery: an international prospective cohort study. PLoS
Med 2020;17:e1003253.
80. Gupta PK, Gupta H, Sundaram A, Kaushik M, Fang X, Miller WJ, et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery.
Circulation 2011;124:381–387.
81. Msheik A, Kaspar C, Mailhac A, Hoballah JJ, Tamim H, Dakik HA. Performance of the AUB-HAS2 Cardiovascular Risk Index in vascular surgery patients. Vasc Med
2021;26:535–541.
82. Glance LG, Faden E, Dutton RP, Lustik SJ, Li Y, Eaton MP, et al. Impact of the choice of risk model for identifying low-risk patients using the 2014 American College of
Cardiology/American Heart Association Perioperative Guidelines. Anesthesiology
2018;129:889–900.
83. Robinson TN, Walston JD, Brummel NE, Deiner S, Brown C, Kennedy M, et al.
Frailty for surgeons: review of a National Institute on Aging Conference on frailty for specialists. J Am Coll Surg 2015;221:1083–1092.
84. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardiology: deﬁnition, assessment and clinical implications for general cardiology.
A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology
(EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart
Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology
(CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG
e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European
Primary Care Cardiology Society (EPCCS). Eur J Prev Cardiol 2022;29:216–227.
85. Hornor MA, Ma M, Zhou L, Cohen ME, Rosenthal RA, Russell MM, et al. Enhancing the American College of Surgeons NSQIP Surgical Risk Calculator to predict geriatric outcomes. J Am Coll Surg 2020;230:88–100 e101.
86. Tjeertes EKM, van Fessem JMK, Mattace-Raso FUS, Hoofwijk AGM, Stolker RJ.
Hoeks SE. Inﬂuence of frailty on outcome in older patients undergoing non-cardiac surgery – a systematic review and meta-analysis. Aging Dis 2020;11:1276–1290.
87. Mosquera C, Spaniolas K, Fitzgerald TL. Impact of frailty on surgical outcomes: the right patient for the right procedure. Surgery 2016;160:272–280.
88. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A
global clinical measure of ﬁtness and frailty in elderly people. CMAJ 2005;173:
489–495.
89. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:
M146–M156.
90. Alvarez-Nebreda ML, Bentov N, Urman RD, Setia S, Huang JC, Pfeifer K, et al.
Recommendations for preoperative management of frailty from the Society for
Perioperative Assessment and Quality Improvement (SPAQI). J Clin Anesth 2018;
47:33–42.
91. Grigoryan KV, Javedan H, Rudolph JL. Orthogeriatric care models and outcomes in hip fracture patients: a systematic review and meta-analysis. J Orthop Trauma 2014;
28:e49–e55.
92. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia:
validation in a population-based sample. J Am Geriatr Soc 2003;51:1451–1454.
93. Biccard BM. Relationship between the inability to climb two ﬂights of stairs and outcome after major non-cardiac surgery: implications for the pre-operative assessment of functional capacity. Anaesthesia 2005;60:588–593.
94. Lurati Buse GAL, Puelacher C, Menosi Gualandro D, Genini AS, Hidvegi R, Bolliger
D, et al. Association between self-reported functional capacity and major adverse cardiac events in patients at elevated risk undergoing noncardiac surgery: a prospective diagnostic cohort study. Br J Anaesth 2020;126:102–110.
95. Wijeysundera DN, Pearse RM, Shulman MA, Abbott TEF, Torres E, Ambosta A,
et al. Assessment of functional capacity before major non-cardiac surgery: an international, prospective cohort study. Lancet 2018;391:2631–2640.
96. Wijeysundera DN, Beattie WS, Hillis GS, Abbott TEF, Shulman MA, Ackland GL,
et al. Integration of the Duke Activity Status Index into preoperative risk evaluation:
a multicentre prospective cohort study. Br J Anaesth 2020;124:261–270.
97. Jeger RV, Probst C, Arsenic R, Lippuner T, Pﬁsterer ME, Seeberger MD, et al.
Long-term prognostic value of the preoperative 12-lead electrocardiogram before major noncardiac surgery in coronary artery disease. Am Heart J 2006;151:508–513.
98. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, et al. 2020
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289–1367.
99. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al.
(EACTS). Eur Heart J 2021;42:373–498.
100. Ganguli I, Lupo C, Mainor AJ, Raymond S, Wang Q, Orav EJ, et al. Prevalence and cost of care cascades after low-value preoperative electrocardiogram for cataract surgery in fee-for-service medicare beneﬁciaries. JAMA Intern Med 2019;179:
1211–1219.
101. Gualandro DM, Puelacher C, LuratiBuse G, Lampart A, Strunz C, Cardozo FA, et al.
Comparison of high-sensitivity cardiac troponin I and T for the prediction of cardiac complications after non-cardiac surgery. Am Heart J 2018;203:67–73.
102. Humble CAS, Huang S, Jammer I, Bjork J, Chew MS. Prognostic performance of preoperative cardiac troponin and perioperative changes in cardiac troponin for the prediction of major adverse cardiac events and mortality in noncardiac surgery:
a systematic review and meta-analysis. PLoS One 2019;14:e0215094.
103. Park SJ, Choi JH, Cho SJ, Chang SA, Choi JO, Lee SC, et al. Comparison of transthoracic echocardiography with N-terminal pro-brain natriuretic peptide as a tool for risk stratiﬁcation of patients undergoing major noncardiac surgery.
Korean Circ J 2011;41:505–511.
104. Lee G, Sou SM, Twerenbold R, Reichlin T, Oshima S, Hochgruber T, et al. B-type natriuretic peptide and clinical judgment in the detection of exercise-induced myocardial ischemia. Am J Med 2014;127:427–435.
105. Walter J, de Lavallaz J dF, Koechlin L, Zimmermann T, Boeddinghaus J, Honegger U,
et al. Using high-sensitivity cardiac troponin for the exclusion of inducible myocardial ischemia in symptomatic patients: a cohort study. Ann Intern Med 2020;172:175–185.
106. Walter JE, Honegger U, Puelacher C, Mueller D, Wagener M, Schaerli N, et al.
Prospective validation of a biomarker-based rule out strategy for functionally relevant coronary artery disease. Clin Chem 2018;64:386–395.
107. Mueller D, Puelacher C, Honegger U, Walter JE, Badertscher P, Schaerli N, et al.
Direct comparison of cardiac troponin T and I using a uniform and a sex-speciﬁc approach in the detection of functionally relevant coronary artery disease. Clin
Chem 2018;64:1596–1606.
108. Ackland GL, Abbott TEF, Cain D, Edwards MR, Sultan P, Karmali SN, et al.
Preoperative systemic inﬂammation and perioperative myocardial injury: prospective observational multicentre cohort study of patients undergoing non-cardiac surgery. Br J Anaesth 2019;122:180–187.


<!-- PAGE 86 -->

### Page 86

### 109 Writing Committee for the Vision Study Investigators, Devereaux PJ, Biccard BM,

Sigamani A, Xavier D, Chan MTV, et al. Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2017;317:1642–1651.
110. Puelacher C, Gualandro DM, Lurati Buse G, Bolliger D, Marbot S, Kindler C, et al.
Etiology of peri-operative myocardial infarction/injury after noncardiac surgery and associated outcome. J Am Coll Cardiol 2020;76:1910–1912.
111. Puelacher C, Lurati Buse G, Seeberger D, Sazgary L, Marbot S, Lampart A, et al.
Perioperative myocardial injury after noncardiac surgery: incidence, mortality,
and characterization. Circulation 2018;137:1221–1232.
112. Huelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, et al.
PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol 2013;62:1365–1372.
113. Ledwidge M, Gallagher J, Conlon C, Tallon E, O’Connell E, Dawkins I, et al.
Natriuretic peptide-based screening and collaborative care for heart failure: the
STOP-HF randomized trial. JAMA 2013;310:66–74.
114. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al.
Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715–731.
115. De Hert SG, Lurati Buse GA. Cardiac biomarkers for the prediction and detection of adverse cardiac events after noncardiac surgery: a narrative review. Anesth Analg
2020;131:187–195.
116. Mauermann E, Bolliger D, Seeberger E, Puelacher C, Corbiere S, Filipovic M, et al.
Incremental value of preoperative copeptin for predicting myocardial injury. Anesth
Analg 2016;123:1363–1371.
117. Buse GL, Manns B, Lamy A, Guyatt G, Polanczyk CA, Chan MTV, et al. Troponin T
monitoring to detect myocardial injury after noncardiac surgery: a costconsequence analysis. Can J Surg 2018;61:185–194.
118. Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study
Investigators, Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O,
et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2012;307:2295–2304.
119. Mantha S, Foss J, Ellis JE, Roizen MF. Intense cardiac troponin surveillance for longterm beneﬁts is cost-effective in patients undergoing open abdominal aortic surgery: a decision analysis model. Anesth Analg 2007;105:1346–1356.
120. Levitan EB, Graham LA, Valle JA, Richman JS, Hollis R, Holcomb CN, et al.
Pre-operative echocardiography among patients with coronary artery disease in the United States Veterans Affairs healthcare system: a retrospective cohort study.
BMC Cardiovasc Disord 2016;16:173.
121. Chang HY, Chang WT, Liu YW. Application of transthoracic echocardiography in patients receiving intermediate- or high-risk noncardiac surgery. PLoS One 2019;14:
e0215854.
122. Wijeysundera DN, Beattie WS, Karkouti K, Neuman MD, Austin PC, Laupacis A.
Association of echocardiography before major elective non-cardiac surgery with postoperative survival and length of hospital stay: population based cohort study.
BMJ 2011;342:d3695.
123. Faris JG, Hartley K, Fuller CM, Langston RB, Royse CF, Veltman MG. Audit of cardiac pathology detection using a criteria-based perioperative echocardiography service. Anaesth Intensive Care 2012;40:702–709.
124. Steeds RP, Garbi M, Cardim N, Kasprzak JD, Sade E, Nihoyannopoulos P, et al.
EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. Eur Heart J Cardiovasc
Imaging 2017;18:1191–1204.
125. Kertai MD, Boersma E, Bax JJ, Heijenbrok-Kal MH, Hunink MG, L’Talien G J, et al. A
meta-analysis comparing the prognostic accuracy of six diagnostic tests for predicting perioperative cardiac risk in patients undergoing major vascular surgery. Heart
2003;89:1327–1334.
126. Halm EA, Browner WS, Tubau JF, Tateo IM, Mangano DT. Echocardiography for assessing cardiac risk in patients having noncardiac surgery.
Study of
Perioperative Ischemia Research Group. Ann Intern Med 1996;125:433–441.
127. Rohde LE, Polanczyk CA, Goldman L, Cook EF, Lee RT, Lee TH. Usefulness of transthoracic echocardiography as a tool for risk stratiﬁcation of patients undergoing major noncardiac surgery. Am J Cardiol 2001;87:505–509.
128. Galasko GI, Barnes SC, Collinson P, Lahiri A, Senior R. What is the most costeffective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination? Eur Heart J 2006;27:193–200.
129. Cardim N, Dalen H, Voigt JU, Ionescu A, Price S, Neskovic AN, et al. The use of handheld ultrasound devices: a position statement of the European Association of Cardiovascular Imaging (2018 update). Eur Heart J Cardiovasc Imaging 2019;20:
245–252.
130. Canty DJ, Royse CF, Kilpatrick D, Bowman L, Royse AG. The impact of focused transthoracic echocardiography in the pre-operative clinic. Anaesthesia 2012;67:
618–625.
131. Heiberg J, El-Ansary D, Canty DJ, Royse AG, Royse CF. Focused echocardiography:
a systematic review of diagnostic and clinical decision-making in anaesthesia and critical care. Anaesthesia 2016;71:1091–1100.
132. Canty DJ, Royse CF. Audit of anaesthetist-performed echocardiography on perioperative management decisions for non-cardiac surgery. Br J Anaesth 2009;103:
352–358.
133. Canty DJ, Heiberg J, Yang Y, Royse AG, Margale S, Nanjappa N, et al. One-year results of the pilot multicentre randomised trial of preoperative focused cardiac ultrasound in hip fracture surgery. Anaesth Intensive Care 2019;47:207–208.
134. Matyal R, Hess PE, Subramaniam B, Mitchell J, Panzica PJ, Pomposelli F, et al.
Perioperative diastolic dysfunction during vascular surgery and its association with postoperative outcome. J Vasc Surg 2009;50:70–76.
135. Saito S, Takagi A, Kurokawa F, Ashihara K, Hagiwara N. Usefulness of tissue
Doppler echocardiography to predict perioperative cardiac events in patients undergoing noncardiac surgery. Heart Vessels 2012;27:594–602.
136. Higashi M, Yamaura K, Ikeda M, Shimauchi T, Saiki H, Hoka S. Diastolic dysfunction of the left ventricle is associated with pulmonary edema after renal transplantation.
Acta Anaesthesiol Scand 2013;57:1154–1160.
137. Brecher O, Gulati H, Roistacher N, Zhang H, Shi W, Thaler HT, et al. Preoperative echocardiographic indices of diastolic dysfunction and brain natriuretic peptide in predicting postoperative atrial ﬁbrillation after noncardiac surgery. Anesth Analg
2017;124:1099–1104.
138. Zhou Y, Liu L, Cheng T, Wang DX, Yang HY, Zhang BW, et al. Grade 3 echocardiographic diastolic dysfunction is associated with increased risk of major adverse cardiovascular events after surgery: a retrospective cohort study. Anesth Analg
2019;129:651–658.
139. Fayad A, Ansari MT, Yang H, Ruddy T, Wells GA. Perioperative diastolic dysfunction in patients undergoing noncardiac surgery is an independent risk factor for cardiovascular events: a systematic review and meta-analysis. Anesthesiology 2016;125:
72–91.
140. Willingham M, Ayoubi SA, Doan M, Wingert T, Scovotti J, Howard-Quijano K, et al.
Preoperative diastolic dysfunction and postoperative outcomes after noncardiac surgery. J Cardiothorac Vasc Anesth 2020;34:679–686.
141. Sougawa H, Ino Y, Kitabata H, Tanimoto T, Takahata M, Shimamura K, et al. Impact of left ventricular ejection fraction and preoperative hemoglobin level on perioperative adverse cardiovascular events in noncardiac surgery. Heart Vessels
2021;36:1317–1326.
142. Hreybe H, Zahid M, Sonel A, Good CB, Shaver J, Saba S. Noncardiac surgery and the risk of death and other cardiovascular events in patients with hypertrophic cardiomyopathy. Clin Cardiol 2006;29:65–68.
143. Kertai MD, Bountioukos M, Boersma E, Bax JJ, Thomson IR, Sozzi F, et al. Aortic stenosis: an underestimated risk factor for perioperative complications in patients undergoing noncardiac surgery. Am J Med 2004;116:8–13.
144. Marbach JA, Almuﬂeh A, Di Santo P, Jung R, Simard T, McInnes M, et al.
Comparative accuracy of focused cardiac ultrasonography and clinical examination for left ventricular dysfunction and valvular heart disease: a systematic review and meta-analysis. Ann Intern Med 2019;171:264–272.
145. Lurati Buse GAL, Puelacher C, Gualandro DM, Kilinc D, Glarner N, Hidvegi R, et al.
Adherence to the European Society of Cardiology/European Society of
Anaesthesiology recommendations on preoperative cardiac testing and association with positive results and cardiac events: a cohort study. Br J Anaesth 2021;127:
376–385.
146. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al.
147. Wolk MJ, Bailey SR, Doherty JU, Douglas PS, Hendel RC, Kramer CM, et al. ACCF/
AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate
Use Criteria Task Force, American Heart Association, American Society of
Echocardiography, American Society of Nuclear Cardiology, Heart Failure
Society of
America,
Heart
Rhythm
Society,
Society for
Cardiovascular
Angiography and
Interventions,
Society of
Cardiovascular
Computed
Tomography, Society for Cardiovascular Magnetic Resonance, and Society of
Thoracic Surgeons. J Am Coll Cardiol 2014;63:380–406.
148. Pellikka PA, Arruda-Olson A, Chaudhry FA, Chen MH, Marshall JE, Porter TR, et al.
Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: from the American Society of Echocardiography.
J Am Soc Echocardiogr 2020;33:1–41.e8.
149. Koh AS, Flores JL, Keng FY, Tan RS, Chua TS. Correlation between clinical outcomes and appropriateness grading for referral to myocardial perfusion imaging for preoperative evaluation prior to non-cardiac surgery. J Nucl Cardiol 2012;19:
277–284.
150. Nguyen P, Plotkin J, Fishbein TM, Laurin JM, Satoskar R, Shetty K, et al. Dobutamine stress echocardiography in patients undergoing orthotopic liver transplantation: a
ESC Guidelines
3911


<!-- PAGE 87 -->

### Page 87

pooled analysis of accuracy, perioperative and long term cardiovascular prognosis.
Int J Cardiovasc Imaging 2013;29:1741–1748.
151. Shaw LJ, Eagle KA, Gersh BJ, Miller DD. Meta-analysis of intravenous dipyridamole-thallium-201 imaging (1985 to 1994) and dobutamine echocardiography (1991 to 1994) for risk stratiﬁcation before vascular surgery. J Am Coll
Cardiol 1996;27:787–798.
152. Beattie WS, Abdelnaem E, Wijeysundera DN, Buckley DN. A meta-analytic comparison of preoperative stress echocardiography and nuclear scintigraphy imaging.
Anesth Analg 2006;102:8–16.
153. Bach DS, Eagle KA. Dobutamine stress echocardiography. Stressing the indications for preoperative testing. Circulation 1997;95:8–10.
154. Etchells E, Meade M, Tomlinson G, Cook D. Semiquantitative dipyridamole myocardial stress perfusion imaging for cardiac risk assessment before noncardiac vascular surgery: a meta-analysis. J Vasc Surg 2002;36:534–540.
155. Ballal RS, Kapadia S, Secknus MA, Rubin D, Arheart K, Marwick TH. Prognosis of patients with vascular disease after clinical evaluation and dobutamine stress echocardiography. Am Heart J 1999;137:469–475.
156. Boersma E, Poldermans D, Bax JJ, Steyerberg EW, Thomson IR, Banga JD, et al.
Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA 2001;285:
1865–1873.
157. Cullen MW, McCully RB, Widmer RJ, Schroeder DR, Salonen BR, Raslau D, et al.
Preoperative dobutamine stress echocardiography and clinical factors for assessment of cardiac risk after noncardiac surgery. J Am Soc Echocardiogr 2020;33:
423–432.
158. Van Damme H, Pierard L, Gillain D, Benoit T, Rigo P, Limet R. Cardiac risk assessment before vascular surgery: a prospective study comparing clinical evaluation, dobutamine stress echocardiography,
and dobutamine
Tc-99m sestamibi tomoscintigraphy. Cardiovasc Surg 1997;5:54–64.
159. Metz LD, Beattie M, Hom R, Redberg RF, Grady D, Fleischmann KE. The prognostic value of normal exercise myocardial perfusion imaging and exercise echocardiography: a meta-analysis. J Am Coll Cardiol 2007;49:227–237.
160. Cohen MC, Siewers AE, Dickens JD, Jr., Hill T, Muller JE. Perioperative and longterm prognostic value of dipyridamole Tc-99m sestamibi myocardial tomography in patients evaluated for elective vascular surgery. J Nucl Cardiol 2003;10:464–472.
161. Dowsley TF, Sheth T, Chow BJW. Complementary pre-operative risk assessment using coronary computed tomography angiography and nuclear myocardial perfusion imaging in non-cardiac surgery: a VISION-CTA sub-study. J Nucl Cardiol 2020;
27:1331–1337.
162. Das MK, Pellikka PA, Mahoney DW, Roger VL, Oh JK, McCully RB, et al.
Assessment of cardiac risk before nonvascular surgery: dobutamine stress echocardiography in 530 patients. J Am Coll Cardiol 2000;35:1647–1653.
163. Torres MR, Short L, Baglin T, Case C, Gibbs H, Marwick TH. Usefulness of clinical risk markers and ischemic threshold to stratify risk in patients undergoing major noncardiac surgery. Am J Cardiol 2002;90:238–242.
164. Labib SB, Goldstein M, Kinnunen PM, Schick EC. Cardiac events in patients with negative maximal versus negative submaximal dobutamine echocardiograms undergoing noncardiac surgery: importance of resting wall motion abnormalities.
J Am Coll Cardiol 2004;44:82–87.
165. Lancellotti P, Pellikka PA, Budts W, Chaudhry FA, Donal E, Dulgheru R, et al. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the
American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2016;17:
1191–1229.
166. Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, Carlos RC. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. J Am Coll Cardiol 2007;50:1343–1353.
167. Vavere AL, Arbab-Zadeh A, Rochitte CE, Dewey M, Niinuma H, Gottlieb I, et al.
Coronary artery stenoses: accuracy of 64-detector row CT angiography in segments with mild, moderate, or severe calciﬁcation – a subanalysis of the
CORE-64 trial. Radiology 2011;261:100–108.
168. Sheth T, Chan M, Butler C, Chow B, Tandon V, Nagele P, et al. Prognostic capabilities of coronary computed tomographic angiography before non-cardiac surgery:
prospective cohort study. BMJ 2015;350:h1907.
169. Krievins D, Zellans E, Latkovskis G, Jegere S, Kumsars I, Kaufmanis K, et al. Diagnosis and management of silent coronary ischemia in patients undergoing carotid endarterectomy. J Vasc Surg 2021;73:533–541.
170. Krievins D, Zellans E, Latkovskis G, Erglis A, Zvaigzne L, Kumsars I, et al.
Pre-operative diagnosis of silent coronary ischaemia may reduce post-operative death and myocardial infarction and improve survival of patients undergoing lower extremity surgical revascularisation. Eur J Vasc Endovasc Surg 2020;60:411–420.
171. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the
European Society of Cardiology (ESC). Eur Heart J 2018;39:119–177.
172. Illuminati G, Ricco JB, Greco C, Mangieri E, Calio F, Ceccanei G, et al. Systematic preoperative coronary angiography and stenting improves postoperative results of carotid endarterectomy in patients with asymptomatic coronary artery disease:
a randomised controlled trial. Eur J Vasc Endovasc Surg 2010;39:139–145.
173. Sorensen LT. Wound healing and infection in surgery. The clinical impact of smoking and smoking cessation: a systematic review and meta-analysis. Arch Surg 2012;
147:373–383.
174. Gourgiotis S, Aloizos S, Aravosita P, Mystakelli C, Isaia EC, Gakis C, et al. The effects of tobacco smoking on the incidence and risk of intraoperative and postoperative complications in adults. Surgeon 2011;9:225–232.
175. World Health Organization. WHO Tobacco and postsurgical outcomes. https://
apps.who.int/iris/rest/bitstreams/1265388/retrieve.
176. Mills E, Eyawo O, Lockhart I, Kelly S, Wu P, Ebbert JO. Smoking cessation reduces postoperative complications: a systematic review and meta-analysis. Am J Med
2011;124:144–154.e8.
177. Lee SM, Landry J, Jones PM, Buhrmann O, Morley-Forster P. Long-term quit rates after a perioperative smoking cessation randomized controlled trial. Anesth Analg
2015;120:582–587.
178. Wong J, Abrishami A, Riazi S, Siddiqui N, You-Ten E, Korman J, et al. A perioperative smoking cessation intervention with varenicline, counseling, and fax referral to a telephone quitline versus a brief intervention: a randomized controlled trial.
Anesth Analg 2017;125:571–579.
179. Cavalheri V, Granger C. Preoperative exercise training for patients with non-small cell lung cancer. Cochrane Database Syst Rev 2017;6:CD012020.
180. Tew GA, Ayyash R, Durrand J, Danjoux GR. Clinical guideline and recommendations on pre-operative exercise training in patients awaiting major non-cardiac surgery. Anaesthesia 2018;73:750–768.
181. Musallam KM, Rosendaal FR, Zaatari G, Soweid A, Hoballah JJ, Sfeir PM, et al.
Smoking and the risk of mortality and vascular and respiratory events in patients undergoing major surgery. JAMA Surg 2013;148:755–762.
182. Turan A, Mascha EJ, Roberman D, Turner PL, You J, Kurz A, et al. Smoking and perioperative outcomes. Anesthesiology 2011;114:837–846.
183. Im C, Oh TK, Song IA. Association between use of preoperative antihypertensive medication and 90-day mortality after noncardiac surgery: a retrospective cohort study. Am J Hypertens 2020;33:534–542.
184. Clemente-Moragon A, Gomez M, Villena-Gutierrez R, Lalama DV, Garcia-Prieto J,
Martinez F, et al. Metoprolol exerts a non-class effect against ischaemia-reperfusion injury by abrogating exacerbated inﬂammation. Eur Heart J 2020;41:4425–4440.
185. Poise Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839–1847.
186. Alonso-Coello P, Paniagua P, Mizera R, Devereaux PJ. Should physicians initiate beta-blocker therapy in patients undergoing non-cardiac surgery? Insights from the POISE trial. Pol Arch Med Wewn 2008;118:616–618.
187. Blessberger H, Lewis SR, Pritchard MW, Fawcett LJ, Domanovits H, Schlager O,
et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing non-cardiac surgery. Cochrane Database Syst Rev
2019;9:CD013438.
188. Friedell ML, Van Way CW, 3rd, Freyberg RW, Almenoff PL. Beta-blockade and operative mortality in noncardiac surgery: harmful or helpful? JAMA Surg 2015;150:
658–663.
189. Wijeysundera DN, Duncan D, Nkonde-Price C, Virani SS, Washam JB, Fleischmann
KE, et al. Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American
College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2014;64:2406–2425.
190. London MJ, Hur K, Schwartz GG, Henderson WG. Association of perioperative beta-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. JAMA 2013;309:1704–1713.
191. Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Gentile G, Reboldi G.
ß-Blockers reduce mortality in patients undergoing high-risk non-cardiac surgery.
Am J Cardiovasc Drugs 2010;10:247–259.
192. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM.
Perioperative beta-blocker therapy and mortality after major noncardiac surgery.
N Engl J Med 2005;353:349–361.
193. Wallace AW, Au S, Cason BA. Perioperative beta-blockade: atenolol is associated with reduced mortality when compared to metoprolol. Anesthesiology 2011;114:
824–836.
194. Redelmeier D, Scales D, Kopp A. Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study. BMJ 2005;331:932.
195. Ashes C, Judelman S, Wijeysundera DN, Tait G, Mazer CD, Hare GM, et al.
Selective beta1-antagonism with bisoprolol is associated with fewer postoperative


<!-- PAGE 88 -->

### Page 88

strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. Anesthesiology 2013;119:777–787.
196. Shammash JB, Trost JC, Gold JM, Berlin JA, Golden MA, Kimmel SE. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J
2001;141:148–153.
197. Wallace AW, Au S, Cason BA. Association of the pattern of use of perioperative beta-blockade and postoperative mortality. Anesthesiology 2010;113:794–805.
198. Kwon S, Thompson R, Florence M, Maier R, McIntyre L, Rogers T, et al.
Beta-blocker continuation after noncardiac surgery: a report from the surgical care and outcomes assessment program. Arch Surg 2012;147:467–473.
199. Kertai MD, Cooter M, Pollard RJ, Buhrman W, Aronson S, Mathew JP, et al. Is
Compliance With Surgical Care Improvement Project Cardiac (SCIP-Card-2) measures for perioperative beta-blockers associated with reduced incidence of mortality and cardiovascular-related critical quality indicators after noncardiac surgery?
Anesth Analg 2018;126:1829–1838.
200. Longrois D, Coufﬁgnal C, Ait-Hamou N, Amour J, Cholley B, Dilly M, et al.
Indispensable optimisation de la réintroduction des bêtabloquants après chirurgie cardiaque. Résultats de l’étude Bêtabloquants Avant et Après Chirurgie Cardiaque
(BBAACC). Anesthésie & Réanimation 2015;1:A248.
201. Oesterle A, Weber B, Tung R, Choudhry NK, Singh JP, Upadhyay GA. Preventing postoperative atrial ﬁbrillation after noncardiac surgery: a meta-analysis. Am J Med
2018;131:795–804 e795.
202. Aoki Y, Kawasaki Y, Ide K, Shimizu Y, Sato S, Yokoyama J. Landiolol hydrochloride for prevention of atrial ﬁbrillation during esophagectomy: a randomized controlled trial. JA Clin Rep 2020;6:34.
203. Aoyama H, Otsuka Y, Aoyama Y. Landiolol infusion during general anesthesia does not prevent postoperative atrial ﬁbrillation in patients undergoing lung resection.
Gen Thorac Cardiovasc Surg 2016;64:735–741.
204. Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Kato T, et al.
Randomized clinical trial of landiolol hydrochloride for the prevention of atrial ﬁbrillation and postoperative complications after oesophagectomy for cancer. Br J
Surg 2017;104:1003–1009.
205. Horikoshi Y, Goyagi T, Kudo R, Kodama S, Horiguchi T, Nishikawa T. The suppressive effects of landiolol administration on the occurrence of postoperative atrial ﬁbrillation and tachycardia, and plasma IL-6 elevation in patients undergoing esophageal surgery: a randomized controlled clinical trial. J Clin Anesth 2017;38:
111–116.
206. O’Brien B, Burrage PS, Ngai JY, Prutkin JM, Huang CC, Xu X, et al. Society of
Cardiovascular
Anesthesiologists/European
Association of
Cardiothoracic
Anaesthetists Practice Advisory for the management of perioperative atrial ﬁbrillation in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2019;33:
12–26.
207. Zhu J, Wang C, Gao D, Zhang C, Zhang Y, Lu Y, et al. Meta-analysis of amiodarone versus beta-blocker as a prophylactic therapy against atrial ﬁbrillation following cardiac surgery. Intern Med J 2012;42:1078–1087.
208. Auer J, Weber T, Berent R, Puschmann R, Hartl P, Ng CK, et al. A comparison between oral antiarrhythmic drugs in the prevention of atrial ﬁbrillation after cardiac surgery: the pilot Study of Prevention of Postoperative Atrial Fibrillation (SPPAF), a randomized, placebo-controlled trial. Am Heart J 2004;147:636–643.
209. London MJ, Schwartz GG, Hur K, Henderson WG. Association of perioperative statin use with mortality and morbidity after major noncardiac surgery. JAMA
Intern Med 2017;177:231–242.
210. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004;291:
2092–2099.
211. Berwanger O, de Barros ESPG, Barbosa RR, Precoma DB, Figueiredo EL, Hajjar LA,
et al. Atorvastatin for high-risk statin-naive patients undergoing noncardiac surgery:
the Lowering the Risk of Operative Complications Using Atorvastatin Loading
Dose (LOAD) randomized trial. Am Heart J 2017;184:88–96.
212. Sanders RD, Nicholson A, Lewis SR, Smith AF, Alderson P. Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.
Cochrane Database Syst Rev 2013;7:CD009971.
213. Putzu A, de Carvalho ESC, de Almeida JP, Belletti A, Cassina T, Landoni G, et al.
Perioperative statin therapy in cardiac and non-cardiac surgery: a systematic review and meta-analysis of randomized controlled trials. Ann Intensive Care 2018;8:95.
214. Wesselink EM, Kappen TH, Torn HM, Slooter AJC, van Klei WA. Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review.
Br J Anaesth 2018;121:706–721.
215. Shiffermiller JF, Monson BJ, Vokoun CW, Beachy MW, Smith MP, Sullivan JN, et al.
Prospective Randomized Evaluation of Preoperative Angiotensin-Converting
Enzyme Inhibition (PREOP-ACEI). J Hosp Med 2018;13:661–667.
216. Roshanov PS, Rochwerg B, Patel A, Salehian O, Duceppe E, Belley-Cote EP, et al.
Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers before noncardiac surgery: an analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort.
Anesthesiology 2017;126:16–27.
217. Hollmann C, Fernandes NL, Biccard BM. A systematic review of outcomes associated with withholding or continuing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers before noncardiac surgery. Anesth Analg 2018;
127:678–687.
218. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med
2014;371:993–1004.
219. Legrand M, Futier E, Leone M, Deniau B, Mebazaa A, Plaud B, et al. Impact of renin-angiotensin system inhibitors continuation versus discontinuation on outcome after major surgery: protocol of a multicenter randomized, controlled trial
(STOP-or-NOT trial). Trials 2019;20:1–7.
220. Wijeysundera DN, Beattie WS. Calcium channel blockers for reducing cardiac morbidity after noncardiac surgery: a meta-analysis. Anesth Analg 2003;97:
634–641.
221. Kertai MD, Westerhout CM, Varga KS, Acsady G, Gal J. Dihydropiridine calciumchannel blockers and perioperative mortality in aortic aneurysm surgery. Br J
Anaesth 2008;101:458–465.
222. Oliver MF, Goldman L, Julian DG, Holme I. Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT). Anesthesiology 1999;91:951–961.
223. Devereaux PJ, Sessler DI, Leslie K, Kurz A, Mrkobrada M, Alonso-Coello P, et al.
Clonidine in patients undergoing noncardiac surgery. N Engl J Med 2014;370:
1504–1513.
224. Hager B, Betschart M, Krapf R. Effect of postoperative intravenous loop diuretic on renal function after major surgery. Schweiz Med Wochenschr 1996;126:666–673.
225. Arora P, Pourafkari L, Visnjevac O, Anand EJ, Porhomayon J, Nader ND.
Preoperative serum potassium predicts the clinical outcome after non-cardiac surgery. Clin Chem Lab Med 2017;55:145–153.
226. Tagawa M, Ogata A, Hamano T. Pre- and/or intra-operative prescription of diuretics, but not renin-angiotensin-system inhibitors, is signiﬁcantly associated with acute kidney injury after non-cardiac surgery: a retrospective cohort study. PLoS
One 2015;10:e0132507.
227. Lo Sapio P, Gensini GF, Bevilacqua S, Chiti E, Paperetti L, Pratesi C, et al. The role of ivabradine in the incidence of perioperative coronary complications in patients undergoing vascular surgery. Int J Cardiol 2013;168:4352–4353.
228. Thiruvenkatarajan V, Meyer EJ, Nanjappa N, Van Wijk RM, Jesudason D.
Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth 2019;123:27–36.
229. Patoulias D, Manaﬁs A, Mitas C, Avranas K, Lales G, Zografou I, et al.
Sodium-glucose cotransporter 2 inhibitors and the risk of diabetic ketoacidosis;
from pathophysiology to clinical practice. Cardiovasc Hematol Disord Drug Targets
2018;18:139–146.
230. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative
Ischemia Research Group. N Engl J Med 1996;335:1713–1720.
231. McGory ML, Maggard MA, Ko CY. A meta-analysis of perioperative beta blockade:
what is the actual risk reduction? Surgery 2005;138:171–179.
232. Wallace A, Layug B, Tateo I, Li J, Hollenberg M, Browner W, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group.
Anesthesiology 1998;88:7–17.
233. Bouri S, Shun-Shin MJ, Cole GD, Mayet J, Francis DP. Meta-analysis of secure randomised controlled trials of beta-blockade to prevent perioperative death in noncardiac surgery. Heart 2014;100:456–464.
234. Hajibandeh S, Hajibandeh S, Antoniou SA, Torella F, Antoniou GA. Effect of betablockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis. Br J Anaesth 2017;118:11–21.
235. Xia J, Qu Y, Yin C, Xu D. Preoperative rosuvastatin protects patients with coronary artery disease undergoing noncardiac surgery. Cardiology 2015;131:30–37.
236. McEvoy MD, Gupta R, Koepke EJ, Feldheiser A, Michard F, Levett D, et al.
Perioperative Quality Initiative Consensus Statement on postoperative blood pressure, risk and outcomes for elective surgery. Br J Anaesth 2019;122:575–586.
237. Ellenberger C, Tait G, Beattie WS. Chronic beta blockade is associated with a better outcome after elective noncardiac surgery than acute beta blockade: a singlecenter propensity-matched cohort study. Anesthesiology 2011;114:817–823.
238. Zaugg M, Bestmann L, Wacker J, Lucchinetti E, Boltres A, Schulz C, et al. Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the
Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebocontrolled, multicenter trial with 1-year follow-up. Anesthesiology 2007;107:33–44.
239. Faloye AO, Gebre MA, Bechtel AJ. Predicting cardiac risk in noncardiac surgery: a narrative review. J Anesth 2021;35:122–129.
ESC Guidelines
3913


<!-- PAGE 89 -->

### Page 89

240. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European
Heart Rhythm Association Practical Guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial ﬁbrillation. Europace 2021;23:1612–1676.
241. Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis.
JAMA 2019;321:277–287.
242. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016
European Guidelines on cardiovascular disease prevention in clinical practice: the
Sixth Joint Task Force of the European Society of Cardiology and Other
Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention &
Rehabilitation (EACPR). Eur Heart J 2016;37:2315–2381.
243. Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurz A, et al.
Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014;370:
1494–1503.
244. Graham MM, Sessler DI, Parlow JL, Biccard BM, Guyatt G, Leslie K, et al. Aspirin in patients with previous percutaneous coronary intervention undergoing noncardiac surgery. Ann Intern Med 2018;168:237–244.
245. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021
ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J
2022;43:561–632.
246. Brouwer J, Nijenhuis VJ, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al.
Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N
Engl J Med 2020;383:1447–1457.
247. Koo BK, Kang J, Park KW, Rhee TM, Yang HM, Won KB, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention
(HOST-EXAM):
an investigator-initiated,
prospective,
randomised,
open-label, multicentre trial. Lancet 2021;397:2487–2496.
248. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019;381:
2032–2042.
249. Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label,
randomised superiority trial. Lancet 2018;392:940–949.
250. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the
STOPDAPT-2 randomized clinical trial. JAMA 2019;321:2414–2427.
251. Berger PB, Kleiman NS, Pencina MJ, Hsieh WH, Steinhubl SR, Jeremias A, et al.
Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of
Drug-Eluting Stents and Ischemic Events) Registry. JACC Cardiovasc Interv 2010;3:
920–927.
252. Saia F, Belotti LMB, Guastaroba P, Berardini A, Rossini R, Musumeci G, et al. Risk of adverse cardiac and bleeding events following cardiac and noncardiac surgery in patients with coronary stent: how important is the interplay between stent type and time from stenting to surgery? Circ Cardiovasc Qual Outcomes 2016;9:39–47.
253. Huber KC, Evans MA, Bresnahan JF, Gibbons RJ, Holmes DR, Jr. Outcome of noncardiac operations in patients with severe coronary artery disease successfully treated preoperatively with coronary angioplasty. Mayo Clin Proc 1992;67:15–21.
254. Egholm G, Kristensen SD, Thim T, Olesen KK, Madsen M, Jensen SE, et al. Risk associated with surgery within 12 months after coronary drug-eluting stent implantation. J Am Coll Cardiol 2016;68:2622–2632.
255. Holcomb CN, Graham LA, Richman JS, Itani KMF, Maddox TM, Hawn MT. The incremental risk of coronary stents on postoperative adverse events: a matched cohort study. Ann Surg 2016;263:924–930.
256. Mahmoud KD, Sanon S, Habermann EB, Lennon RJ, Thomsen KM, Wood DL, et al.
Perioperative cardiovascular risk of prior coronary stent implantation among patients undergoing noncardiac surgery. J Am Coll Cardiol 2016;67:1038–1049.
257. Holcomb CN, Hollis RH, Graham LA, Richman JS, Valle JA, Itani KM, et al.
Association of coronary stent indication with postoperative outcomes following noncardiac surgery. JAMA Surg 2016;151:462.
258. Rodriguez A, Guilera N, Mases A, Sierra P, Oliva JC, Colilles C, et al. Management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery: association with adverse events. Br J Anaesth 2018;120:67–76.
259. Armstrong EJ, Graham L, Waldo SW, Valle JA, Maddox TM, Hawn MT. Patient and lesion-speciﬁc characteristics predict risk of major adverse cardiovascular events among patients with previous percutaneous coronary intervention undergoing noncardiac surgery. Catheter Cardiovasc Interv 2017;89:617–627.
260. Siller-Matula JM, Petre A, Delle-Karth G, Huber K, Ay C, Lordkipanidze M, et al.
Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: a systematic review and meta-analysis. Eur Heart
J Acute Cardiovasc Care 2017;6:753–770.
261. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet
2013;382:1714–1722.
262. So DYF, Wells GA, Lordkipanidze M, Ruel M, Perrault LP, Yeong Chong A, et al. A
randomized study of early vs. delayed coronary artery bypass surgery among patients with acute coronary syndromes treated with ticagrelor: the RAPID CABG
study.
http://clinicaltrialresults.org/wp-content/uploads/2021/11/So_RAPID_
CABG.pdf.
263. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the
ONSET/OFFSET study. Circulation 2009;120:2577–2585.
264. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC
focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the
European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;
39:213–260.
265. Valgimigli M, Frigoli E, Heg D, Tijssen J, Juni P, Vranckx P, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med 2021;385:1643–1655.
266. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 2015;
373:2038–2047.
267. Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, et al.
Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J
Med 2020;382:1208–1218.
268. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al.
2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:
87–165.
269. Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, et al.
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet
Therapy with 12 Months of Dual Antiplatelet Therapy in Patients With Acute
Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA
Cardiol 2022;7:407–417.
270. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and
Efﬁcacy of
3-month dual antiplatelet
Therapy following
Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340–1348.
271. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the
OPTIMIZE randomized trial. JAMA 2013;310:2510–2522.
272. Schulz-Schupke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T,
et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12
months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36:
1252–1263.
273. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, et al. Six-month versus
12-month dual antiplatelet therapy after implantation of drug-eluting stents: the
Efﬁcacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting
(EXCELLENT) randomized, multicenter study. Circulation 2012;125:505–513.
274. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Shortversus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015–2026.
275. Han Y, Xu B, Xu K, Guan C, Jing Q, Zheng Q, et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 Trial. Circ Cardiovasc Interv 2016;
9:e003145.
276. Hong SJ, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, et al. 6-Month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the
IVUS-XPL randomized clinical trial. JACC Cardiovasc Interv 2016;9:1438–1446.
277. Hahn JY, Song YB, Oh JH, Cho DK, Lee JB, Doh JH, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label,
non-inferiority trial. Lancet 2018;391:1274–1284.
278. Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 2018;363:k3793.
279. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl
J Med 2009;361:1045–1057.


<!-- PAGE 90 -->

### Page 90

280. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al.
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J
Med 2007;357:2001–2015.
281. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without
ST-segment elevation. N Engl J Med 2001;345:494–502.
282. Sullivan AE, Nanna MG, Wang TY, Bhatt DL, Angiolillo DJ, Mehran R, et al. Bridging antiplatelet therapy after percutaneous coronary intervention: JACC review topic of the week. J Am Coll Cardiol 2021;78:1550–1563.
283. Angheloiu GO, Gugiu GB, Ruse C, Pandey R, Dasari RR, Whatling C. Ticagrelor removal from human blood. JACC Basic Transl Sci 2017;2:135–145.
284. Bhatt DL, Pollack CV, Weitz JI, Jennings LK, Xu S, Arnold SE, et al. Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med 2019;380:1825–1833.
285. Mahla E, Metzler H, Bornemann-Cimenti H, Prueller F, Raggam R, Pregartner G,
et al. Platelet inhibition and bleeding in patients undergoing non-cardiac surgery
—the BIANCA Observational Study. Thromb Haemost 2018;118:864–872.
286. Mahla E, Tantry US, Pruller F, Gurbel PA. Is there a role for preoperative platelet function testing in patients undergoing cardiac surgery during antiplatelet therapy?
Circulation 2018;138:2145–2159.
287. Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, Sequeira AJ, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012;5:
261–269.
288. Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, et al.
Antithrombotic therapy in patients with atrial ﬁbrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention: insights from the AUGUSTUS
trial. Circulation 2019;140:1921–1932.
289. Genereux P, Rutledge DR, Palmerini T, Caixeta A, Kedhi E, Hermiller JB, et al. Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: insights from the Xience V Coronary Stent System Trials. Circ Cardiovasc
Interv 2015;8:e001362.
290. Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Kohler C, Werth S, et al.
Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014;35:1888–1896.
291. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, 3rd, Gentile F, et al.
2020 ACC/AHA Guideline for the management of patients with valvular heart disease. Executive summary: a report of the American College of Cardiology/
American Heart Association Joint Committee on Clinical Practice Guidelines.
Circulation 2021;143:e35–e71.
292. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al.
Perioperative bridging anticoagulation in patients with atrial ﬁbrillation. N Engl J
Med 2015;373:823–833.
293. Kuo HC, Liu FL, Chen JT, Cherng YG, Tam KW, Tai YH. Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: a systematic review and meta-analysis. Clin Cardiol 2020;43:441–449.
294. Kovacs MJ, Wells PS, Anderson DR, Lazo-Langner A, Kearon C, Bates SM, et al.
Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ 2021;373:n1205.
295. Caldeira D, David C, Santos AT, Costa J, Pinto FJ, Ferreira JJ. Efﬁcacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis. J Thromb Haemost 2014;12:650–659.
296. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or deﬁbrillator surgery without interruption of anticoagulation. N Engl J Med 2013;
368:2084–2093.
297. Sant’anna RT, Leiria TL, Nascimento T, Sant’anna JR, Kalil RA, Lima GG, et al.
Meta-analysis of continuous oral anticoagulants versus heparin bridging in patients undergoing CIED surgery: reappraisal after the BRUISE study. Pacing Clin
Electrophysiol 2015;38:417–423.
298. Eichhorn W, Barsukov E, Al-Dam A, Gröbe A, Smeets R, Eichhorn M, et al.
Postoperative bleeding risk for cutaneous surgery in the head and neck region with continued phenprocoumon therapy. J Cranio-Maxillofac Surg 2014;42:
608–611.
299. Nandoe Tewarie RDS, Bartels RHMA. The perioperative use of oral anticoagulants during surgical procedures for carpal tunnel syndrome. A preliminary study. Acta
Neurochirurgica 2010;152:1211–1213.
300. Doherty JU, Gluckman TJ, Hucker WJ, Januzzi JL, Jr., Ortel TL, Saxonhouse SJ, et al.
2017 ACC Expert Consensus Decision Pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial ﬁbrillation: a report of the
American College of Cardiology Clinical Expert Consensus Document Task
Force. J Am Coll Cardiol 2017;69:871–898.
301. Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, et al.
Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal: a systematic review and meta-analysis. Thromb Haemost 2016;116:879–890.
302. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2016;14:623–627.
303. Pollack CV, Jr., Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al.
Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 2017;
377:431–441.
304. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH,
et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019;380:1326–1335.
305. Majeed A, Ågren A, Holmström M, Bruzelius M, Chaireti R, Odeberg J, et al.
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017;130:1706–1712.
306. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al.
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin:
results from the
Randomized
Evaluation of
Long-Term
Anticoagulation Therapy (RE-LY) Randomized Trial. Circulation 2012;126:
343–348.
307. Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, et al.
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood 2014;124:3692–3698.
308. Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, et al.
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial ﬁbrillation: results from the rivaroxaban once daily,
oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial ﬁbrillation (ROCKET AF). Circulation
2014;129:1850–1859.
309. Shaw JR, Li N, Vanassche T, Coppens M, Spyropoulos AC, Syed S, et al. Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Advances 2020;4:3520–3527.
310. Godier A, Dincq AS, Martin AC, Radu A, Leblanc I, Antona M, et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J 2017;38:2431–2439.
311. Douketis JD, Spyropoulos AC, Duncan J, Carrier M, Le Gal G, Tafur AJ, et al.
Perioperative management of patients with atrial ﬁbrillation receiving a direct oral anticoagulant. JAMA Intern Med 2019;179:1469–1478.
312. Colonna P, von Heymann C, Santamaria A, Saxena M, Vanassche T, Wolpert D,
et al. Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: the prospective, observational, and multinational EMIT-AF/VTE study. Clin Cardiol
2020;43:769–780.
313. Albaladejo P, Pernod G, Godier A, de Maistre E, Rosencher N, Mas JL, et al.
Management of bleeding and emergency invasive procedures in patients on dabigatran: updated guidelines from the French Working Group on Perioperative
Haemostasis (GIHP) – September 2016. Anaesth Crit Care Pain Med 2018;37:
391–399.
314. Narouze S, Benzon HT, Provenzano DA, Buvanendran A, De Andres J, Deer TR,
et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional
Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and
Pain Therapy, the American Academy of Pain Medicine, the International
Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med 2015;40:182–212.
315. Johnston S. An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery. Int J Oral Maxillofac Surg 2016;
45:618–630.
316. Sivolella S, De Biagi M, Brunello G, Berengo M, Pengo V. Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants. Odontology 2015;
103:258–263.
317. Ockerman A, Vanhaverbeke M, Miclotte I, Belmans A, Vanassche T, Politis C, et al.
Tranexamic acid to reduce bleeding after dental extraction in patients treated with non-vitamin K oral anticoagulants: design and rationale of the EXTRACT-NOAC
trial. Br J Oral Maxillofac Surg 2019;57:1107–1112.
318. Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al.
Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020;382:1696–1707.
319. Xu K, Chan NC, Ibrahim Q, Kruger P, Sinha S, Bhagirath V, et al. Reduction in mortality following elective major hip and knee surgery: a systematic review and meta-analysis. Thromb Haemost 2019;119:668–674.
320. Smilowitz NR, Gupta N, Guo Y, Maldonado TS, Eikelboom JW, Goldhaber SZ, et al.
Trends in perioperative venous thromboembolism associated with major noncardiac surgery. TH Open 2017;1:e82–e91.
ESC Guidelines
3915


<!-- PAGE 91 -->

### Page 91

321. Klemen ND, Feingold PL, Hashimoto B, Wang M, Kleyman S, Brackett A, et al.
Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis. Lancet Haematol 2020;7:e583–e593.
322. Gangireddy C, Rectenwald JR, Upchurch GR, Wakeﬁeld TW, Khuri S, Henderson
WG, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007;45:335–341; discussion 341–332.
323. Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg 2010;199:S3–S10.
324. Obi AT, Pannucci CJ, Nackashi A, Abdullah N, Alvarez R, Bahl V, et al. Validation of the Caprini venous thromboembolism risk assessment model in critically ill surgical patients. JAMA Surg 2015;150:941–948.
325. Lobastov K, Barinov V, Schastlivtsev I, Laberko L, Rodoman G, Boyarintsev V.
Validation of the Caprini risk assessment model for venous thromboembolism in high-risk surgical patients in the background of standard prophylaxis. J Vasc Surg
Venous Lymphat Disord 2016;4:153–160.
326. Hachey KJ, Hewes PD, Porter LP, Ridyard DG, Rosenkranz P, McAneny D, et al.
Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer.
J Thorac Cardiovasc Surg 2016;151:37–44 e31.
327. Sterbling HM, Rosen AK, Hachey KJ, Vellanki NS, Hewes PD, Rao SR, et al. Caprini risk model decreases venous thromboembolism rates in thoracic surgery cancer patients. Ann Thorac Surg 2018;105:879–885.
328. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al.
Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis,
9th ed:
American
College of
Chest
Physicians
Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e278S–e325S.
329. Faraoni D, Comes RF, Geerts W, Wiles MD, ESA VTE Guidelines Task Force.
European guidelines on perioperative venous thromboembolism prophylaxis:
neurosurgery. Eur J Anaesthesiol 2018;35:90–95.
330. Kozek-Langenecker S, Fenger-Eriksen C, Thienpont E, Barauskas G, ESA VTE
Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: surgery in the elderly. Eur J Anaesthesiol 2018;35:116–122.
331. Venclauskas L, Maleckas A, Arcelus JI, ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: surgery in the obese patient. Eur J Anaesthesiol 2018;35:147–153.
332. Afshari A, Ageno W, Ahmed A, Duranteau J, Faraoni D, Kozek-Langenecker S, et al.
European guidelines on perioperative venous thromboembolism prophylaxis: executive summary. Eur J Anaesthesiol 2018;35:77–83.
333. Cimminiello C, Prandoni P, Agnelli G, Di Minno G, Polo Friz H, Scaglione F, et al.
Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. Intern Emerg
Med 2017;12:1291–1305.
334. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med
2010;363:2487–2498.
335. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:
594–604.
336. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776–2786.
337. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al.
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N
Engl J Med 2008;358:2765–2775.
338. Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, et al.
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010;126:
175–182.
339. Kawai Y, Fuji T, Fujita S, Kimura T, Ibusuki K, Abe K, et al. Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efﬁcacy and safety endpoints from two phase 3 trials. Thromb J 2016;14:48.
340. Petersen PB, Kehlet H, Jorgensen CC. Lundbeck Foundation Centre for Fast-track,
Hip, Group KRC. Safety of in-hospital only thromboprophylaxis after fast-track total hip and knee arthroplasty: a prospective follow-up study in 17,582 procedures.
Thromb Haemost 2018;118:2152–2161.
341. Wilson DG, Poole WE, Chauhan SK, Rogers BA. Systematic review of aspirin for thromboprophylaxis in modern elective total hip and knee arthroplasty. Bone
Joint J 2016;98-B:1056–1061.
342. Jenny JY, Pabinger I, Samama CM, ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: aspirin. Eur J
Anaesthesiol 2018;35:123–129.
343. Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med
2018;378:699–707.
344. Cassidy MR, Rosenkranz P, McAneny D. Reducing postoperative venous thromboembolism complications with a standardized risk-stratiﬁed prophylaxis protocol and mobilization program. J Am Coll Surg 2014;218:1095–1104.
345. Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A, et al.
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 2011;378:1396–1407.
346. Baron DM, Franchini M, Goobie SM, Javidroozi M, Klein AA, Lasocki S, et al. Patient blood management during the COVID-19 pandemic: a narrative review.
Anaesthesia 2020;75:1105–1113.
347. Munoz M, Gomez-Ramirez S, Campos A, Ruiz J, Liumbruno GM. Pre-operative anaemia: prevalence, consequences and approaches to management. Blood Transfus
2015;13:370–379.
348. von Heymann C, Kaufner L, Sander M, Spies C, Schmidt K, Gombotz H, et al. Does the severity of preoperative anemia or blood transfusion have a stronger impact on long-term survival after cardiac surgery? J Thorac Cardiovasc Surg 2016;152:
1412–1420.
349. Rossler J, Schoenrath F, Seifert B, Kaserer A, Spahn GH, Falk V, et al. Iron deﬁciency is associated with higher mortality in patients undergoing cardiac surgery: a prospective study. Br J Anaesth 2020;124:25–34.
350. Althoff FC, Neb H, Herrmann E, Trentino KM, Vernich L, Fullenbach C, et al.
Multimodal patient blood management program based on a three-pillar strategy:
a systematic review and meta-analysis. Ann Surg 2019;269:794–804.
351. Meybohm P, Herrmann E, Steinbicker AU, Wittmann M, Gruenewald M, Fischer D,
et al. Patient blood management is associated with a substantial reduction of red blood cell utilization and safe for patient’s outcome: a prospective, multicenter cohort study with a noninferiority design. Ann Surg 2016;264:203–211.
352. Frew N, Alexander D, Hood J, Acornley A. Impact of a blood management protocol on transfusion rates and outcomes following total hip and knee arthroplasty.
Ann R Coll Surg Engl 2016;98:380–386.
353. Leahy MF, Hofmann A, Towler S, Trentino KM, Burrows SA, Swain SG, et al.
Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. Transfusion 2017;57:1347–1358.
354. So-Osman C, Nelissen R, Koopman-van GA, Kluyver E, Pöll R, Onstenk R, et al.
Patient blood management in elective total hip- and knee-replacement surgery
(Part 1): a randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive transfusion policy in erythropoietin-eligible patients. Anesthesiology 2014;120:839–851.
355. Theusinger OM, Kind SL, Seifert B, Borgeat l, Gerber C, Spahn DR. Patient blood management in orthopaedic surgery: a four-year follow-up of transfusion requirements and blood loss from 2008 to 2011 at the Balgrist University Hospital in
Zurich, Switzerland. Blood Transfus 2014;12:195–203.
356. Froessler B, Palm P, Weber I, Hodyl NA, Singh R, Murphy EM. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. Ann Surg 2016;264:41–46.
357. Triphaus C, Judd L, Glaser P, Goehring MH, Schmitt E, Westphal S, et al.
Effectiveness of preoperative iron supplementation in major surgical patients with iron deﬁciency: a prospective observational study. Ann Surg 2021;274:
e212–e219.
358. Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS,
et al. Iron deﬁciency across chronic inﬂammatory conditions: international expert opinion on deﬁnition, diagnosis, and management. Am J Hematol 2017;92:
1068–1078.
359. Auerbach M, Macdougall IC. Safety of intravenous iron formulations: facts and folklore. Blood Transfus 2014;12:296–300.
360. Richards T, Baikady RR, Clevenger B, Butcher A, Abeysiri S, Chau M, et al.
Preoperative intravenous iron to treat anaemia before major abdominal surgery
(PREVENTT): a randomised, double-blind, controlled trial. Lancet 2020;396:
1353–1361.
361. Kaufner L, von Heymann C, Henkelmann A, Pace NL, Weibel S, Kranke P, et al.
Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery. Cochrane Database Syst
Rev 2020;8:CD012451.
362. Munoz M, Acheson AG, Auerbach M, Besser M, Habler O, Kehlet H, et al.
International consensus statement on the peri-operative management of anaemia and iron deﬁciency. Anaesthesia 2017;72:233–247.
363. World Health Assembly. Availability, safety and quality of blood products. http://
apps.who.int/gb/ebwha/pdf_ﬁles/WHA63/A63_R12-en.pdf (27 October 2017).
364. Kotze A, Harris A, Baker C, Iqbal T, Lavies N, Richards T, et al. British Committee for Standards in Haematology Guidelines on the identiﬁcation and management of pre-operative anaemia. Br J Haematol 2015;171:322–331.
365. Koch CG, Reineks EZ, Tang AS, Hixson ED, Phillips S, Sabik JF, 3rd, et al.
Contemporary bloodletting in cardiac surgical care. Ann Thorac Surg 2015;99:
779–784.


<!-- PAGE 92 -->

### Page 92

366. Riessen R, Behmenburg M, Blumenstock G, Guenon D, Enkel S, Schafer R, et al. A
simple “blood-saving bundle” reduces diagnostic blood loss and the transfusion rate in mechanically ventilated patients. PLoS One 2015;10:e0138879.
367. Shander A, Kaplan LJ, Harris MT, Gross I, Nagarsheth NP, Nemeth J, et al. Topical hemostatic therapy in surgery: bridging the knowledge and practice gap. J Am Coll
Surg 2014;219:570–579.e574.
368. Menkis AH, Martin J, Cheng DC, Fitzgerald DC, Freedman JJ, Gao C, et al. Drug,
devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the
International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS)
2011. Innovations (Phila) 2012;7:229–241.
369. Anastasiadis K, Murkin J, Antonitsis P, Bauer A, Ranucci M, Gygax E, et al. Use of minimal invasive extracorporeal circulation in cardiac surgery: principles, deﬁnitions and potential beneﬁts. A position paper from the Minimal invasive Extra-Corporeal
Technologies international Society (MiECTiS). Interact Cardiovasc Thorac Surg 2016;
22:647–662.
370. Weber CF, Görlinger K, Meininger D, Herrmann E, Bingold T, Moritz A, et al.
Point-of-care testing: a prospective, randomized clinical trial of efﬁcacy in coagulopathic cardiac surgery patients. Anesthesiology 2012;117:531–547.
371. Weber CF, Zacharowski K, Meybohm P, Adam EH, Hofer S, Brün K, et al.
Hemotherapy algorithms for coagulopathic cardiac surgery patients. Clin Lab
2014;60:1059–1063.
372. Muñoz M, Gómez-Ramírez S, Kozek-Langeneker S. Pre-operative haematological assessment in patients scheduled for major surgery. Anaesthesia 2016;71 Suppl
1:19–28.
373. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E,
Filipescu DC, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013;30:
270–382.
374. Meybohm P, Zacharowski K, Weber CF. Point-of-care coagulation management in intensive care medicine. Crit Care 2013;17:218.
375. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012;344:e3054.
376. Devereaux PJ, Marcucci M, Painter TW, Conen D, Lomivorotov V, Sessler DI, et al.
Tranexamic acid in patients undergoing noncardiac surgery. N Engl J Med 2022.
377. Meybohm P, Choorapoikayil S, Wessels A, Herrmann E, Zacharowski K, Spahn DR.
Washed cell salvage in surgical patients: a review and meta-analysis of prospective randomized trials under PRISMA. Medicine (Baltimore) 2016;95:e4490.
378. Santos AA, Silva JP, Silva Lda F, Sousa AG, Piotto RF, Baumgratz JF. Therapeutic options to minimize allogeneic blood transfusions and their adverse effects in cardiac surgery: a systematic review. Rev Bras Cir Cardiovasc 2014;29:606–621.
379. Haensig M, Kempfert J, Kempfert PM, Girdauskas E, Borger MA, Lehmann S.
Thrombelastometry guided blood-component therapy after cardiac surgery: a randomized study. BMC Anesthesiol 2019;19:201.
380. Dias JD, Sauaia A, Achneck HE, Hartmann J, Moore EE. Thromboelastographyguided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: a systematic review and analysis. J Thromb Haemost 2019;17:984–994.
381. Chutipongtanate A, Yasaeng C, Virankabutra T, Chutipongtanate S. Systematic comparison of four point-of-care methods versus the reference laboratory measurement of hemoglobin in the surgical ICU setting: a cross-sectional method comparison study. BMC Anesthesiol 2020;20:92.
382. Terada R, Ikeda T, Mori Y, Yamazaki S, Kashiwabara K, Yamauchi H, et al.
Comparison of two point of care whole blood coagulation analysis devices and conventional coagulation tests as a predicting tool of perioperative bleeding in adult cardiac surgery – a pilot prospective observational study in Japan. Transfusion 2019;
59:3525–3535.
383. Cohen J, Scorer T, Wright Z, Stewart IJ, Sosnov J, Pidcoke H, et al. A prospective evaluation of thromboelastometry (ROTEM) to identify acute traumatic coagulopathy and predict massive transfusion in military trauma patients in Afghanistan.
Transfusion 2019;59:1601–1607.
384. Yates J, Perelman I, Khair S, Taylor J, Lampron J, Tinmouth A, et al. Exclusion criteria and adverse events in perioperative trials of tranexamic acid: a systematic review and meta-analysis. Transfusion 2019;59:806–824.
385. CRASH-2 trial Collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019;394:
1713–1723.
386. HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet 2020;395:1927–1936.
387. Mukhopadhyay A, Yip HS, Prabhuswamy D, Chan YH, Phua J, Lim TK, et al. The use of a blood conservation device to reduce red blood cell transfusion requirements: a before and after study. Crit Care 2010;14:R7.
388. Peruzzi WT, Parker MA, Lichtenthal PR, Cochran-Zull C, Toth B, Blake M. A clinical evaluation of a blood conservation device in medical intensive care unit patients.
Crit Care Med 1993;21:501–506.
389. Kataife ED, Said S, Braun J, Roche TR, Rossler J, Kaserer A, et al. The Haemostasis
Trafﬁc Light, a user-centred coagulation management tool for acute bleeding situations: a simulation-based randomised dual-centre trial. Anaesthesia 2021;76:
902–910.
390. Goodnough LT, Shieh L, Hadhazy E, Cheng N, Khari P, Maggio P. Improved blood utilization using real-time clinical decision support. Transfusion 2014;54:1358–1365.
391. Oliver JC, Grifﬁn RL, Hannon T, Marques MB. The success of our patient blood management program depended on an institution-wide change in transfusion practices. Transfusion 2014;54:2617–2624.
392. Kaserer A, Rössler J, Braun J, Farokhzad F, Pape HC, Dutkowski P, et al. Impact of a patient blood management monitoring and feedback programme on allogeneic blood transfusions and related costs. Anaesthesia 2019;74:1534–1541.
393. Sardar M, Azharuddin M, Subedi A, Ghatage P, Du D, Szallasi A. Improving blood transfusion practices in a community hospital setting: our experience with real-time clinical decision support. Med Sci (Basel) 2018;6.
394. Jenkins I, Doucet JJ, Clay B, Kopko P, Fipps D, Hemmen E, et al. Transfusing wisely:
clinical decision support improves blood transfusion practices. Jt Comm J Qual
Patient Saf 2017;43:389–395.
395. Staples S, Salisbury RA, King AJ, Polzella P, Bakhishli G, Staves J, et al. How do we use electronic clinical decision support and feedback to promote good transfusion practice. Transfusion 2020;60:1658–1665.
396. Derzon JH, Clarke N, Alford A, Gross I, Shander A, Thurer R. Restrictive transfusion strategy and clinical decision support practices for reducing RBC transfusion overuse. Am J Clin Pathol 2019;152:544–557.
397. Dawood MM, Gutpa DK, Southern J, Walia A, Atkinson JB, Eagle KA. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol 1996;57:37–44.
398. Eagle KA, Rihal CS, Mickel MC, Holmes DR, Foster ED, Gersh BJ. Cardiac risk of noncardiac surgery: inﬂuence of coronary disease and type of surgery in 3368 operations. CASS Investigators and University of Michigan Heart Care Program.
Coronary Artery Surgery Study. Circulation 1997;96:1882–1887.
399. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, et al.
Coronary-artery revascularization before elective major vascular surgery. N Engl
J Med 2004;351:2795–2804.
400. Wong EY, Lawrence HP, Wong DT. The effects of prophylactic coronary revascularization or medical management on patient outcomes after noncardiac surgery –
a meta-analysis. Can J Anaesth 2007;54:705–717.
401. Feng B, Lin J, Jin J, Qian W, Cao S, Weng X. The effect of previous coronary artery revascularization on the adverse cardiac events ninety days after total joint arthroplasty. J Arthroplasty 2018;33:235–240.
402. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE, et al.
Initial invasive or conservative strategy for stable coronary disease. N Engl J Med
2020;382:1395–1407.
403. Bainey KR, Alemayehu W, Welsh RC, Kumar A, King SB, 3rd, Kirtane AJ. Long-term clinical outcomes following revascularization in high-risk coronary anatomy patients with stable ischemic heart disease. J Am Heart Assoc 2021;10:e018104.
404. Windecker S, Neumann FJ, Juni P, Sousa-Uva M, Falk V. Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of the task force of the 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J
2019;40:204–212.
405. Raber L, Mintz GS, Koskinas KC, Johnson TW, Holm NR, Onuma Y, et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of
Percutaneous Cardiovascular Interventions. EuroIntervention 2018;14:656–677.
406. Johnson TW, Raber L, Di Mario C, Bourantas CV, Jia H, Mattesini A, et al. Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography ﬁndings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular
Interventions. EuroIntervention 2019;15:434–451.
407. Richardt G, Abdelghani M, Allali A, Toelg R, Abdellaoui M, Krackhardt F, et al.
Polymer-free drug-coated vs. bare-metal coronary stents in patients undergoing non-cardiac surgery: a subgroup analysis of the LEADERS FREE trial. Clin Res
Cardiol 2021;110:162–171.
408. Cassese S, Belle L, Ndrepepa G, Bosson JL, Fusaro M, Lonborg J, et al. Deferred vs immediate stenting in primary percutaneous coronary intervention: a collaborative meta-analysis of randomized trials with cardiac magnetic resonance imaging data.
Can J Cardiol 2018;34:1573–1580.
409. Belle L, Motreff P, Mangin L, Range G, Marcaggi X, Marie A, et al. Comparison of immediate with delayed stenting using the minimalist immediate mechanical
ESC Guidelines
3917


<!-- PAGE 93 -->

### Page 93

intervention approach in acute ST-segment-elevation myocardial infarction: the
MIMI Study. Circ Cardiovasc Interv 2016;9:e003388.
410. Hammill BG, Curtis LH, Bennett-Guerrero E, O’Connor CM, Jollis JG, Schulman
KA, et al. Impact of heart failure on patients undergoing major noncardiac surgery.
Anesthesiology 2008;108:559–567.
411. Goldman L, Caldera DL, Nussbaum SR, Southwick FS, Krogstad D, Murray B, et al.
Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med
1977;297:845–850.
412. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Eur Heart J 2021;42:3599–3726.
413. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, et al.
Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999;100:1043–1049.
414. Flu WJ, van Kuijk JP, Hoeks SE, Kuiper R, Schouten O, Goei D, et al. Prognostic implications of asymptomatic left ventricular dysfunction in patients undergoing vascular surgery. Anesthesiology 2010;112:1316–1324.
415. Cohn SL. Preoperative evaluation for noncardiac surgery. Ann Intern Med 2016;
165:ITC81–ITC96.
416. Smilowitz NR, Banco D, Katz SD, Beckman JA, Berger JS. Association between heart failure and perioperative outcomes in patients undergoing non-cardiac surgery. Eur Heart J Qual Care Clin Outcomes 2021;7:68–75.
417. Lerman BJ, Popat RA, Assimes TL, Heidenreich PA, Wren SM. Association between heart failure and postoperative mortality among patients undergoing ambulatory noncardiac surgery. JAMA Surg 2019;154:907–914.
418. Dhillon A, Khanna A, Randhawa MS, Cywinski J, Saager L, Thamilarasan M, et al.
Perioperative outcomes of patients with hypertrophic cardiomyopathy undergoing non-cardiac surgery. Heart 2016;102:1627–1632.
419. Nagueh SF, Bierig SM, Budoff MJ, Desai M, Dilsizian V, Eidem B, et al. American
Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy. Endorsed by the
American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic
Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc
Echocardiogr 2011;24:473–498.
420. Kormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, et al. The
Society of Thoracic Surgeons Intermacs database annual report: evolving indications, outcomes, and scientiﬁc partnerships. J Heart Lung Transplant 2019;38:
114–126.
421. Roberts SM, Hovord DG, Kodavatiganti R, Sathishkumar S. Ventricular assist devices and non-cardiac surgery. BMC Anesthesiol 2015;15:185.
422. Rodseth RN, Biccard BM, Le Manach Y, Sessler DI, Lurati Buse GA, Thabane L, et al.
The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and
N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis. J Am Coll Cardiol 2014;63:170–180.
423. Karthikeyan G, Moncur RA, Levine O, Heels-Ansdell D, Chan MT, Alonso-Coello P,
et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol 2009;54:1599–1606.
424. Agarwal S, Rajamanickam A, Bajaj NS, Grifﬁn BP, Catacutan T, Svensson LG, et al.
Impact of aortic stenosis on postoperative outcomes after noncardiac surgeries.
Circ Cardiovasc Qual Outcomes 2013;6:193–200.
425. Taniguchi T, Morimoto T, Shiomi H, Ando K, Shirai S, Kanamori N, et al. Elective non-cardiac surgery in patients with severe aortic stenosis – observations from the CURRENT AS Registry. Circ J 2020;84:1173–1182.
426. Luis SA, Dohaei A, Chandrashekar P, Scott CG, Padang R, Lokineni S, et al. Impact of aortic valve replacement for severe aortic stenosis on perioperative outcomes following major noncardiac surgery. Mayo Clin Proc 2020;95:727–737.
427. Okuno T, Yahagi K, Horiuchi Y, Sato Y, Tanaka T, Koseki K, et al. The role of transcatheter aortic valve replacement in the patients with severe aortic stenosis requiring major non-cardiac surgery. Cardiovasc Interv Ther 2019;34:345–351.
428. Calleja AM, Dommaraju S, Gaddam R, Cha S, Khandheria BK, Chaliki HP. Cardiac risk in patients aged .75 years with asymptomatic, severe aortic stenosis undergoing noncardiac surgery. Am J Cardiol 2010;105:1159–1163.
429. Sohrabi B, Kazemi B, Mehryar A, Teimouri-Dereshki A, Toufan M, Aslanabadi N.
Correlation between pulmonary artery pressure measured by echocardiography and right heart catheterization in patients with rheumatic mitral valve stenosis (a prospective study). Echocardiography 2016;33:7–13.
430. Bajaj NS, Agarwal S, Rajamanickam A, Parashar A, Poddar KL, Grifﬁn BP, et al.
Impact of severe mitral regurgitation on postoperative outcomes after noncardiac surgery. Am J Med 2013;126:529–535.
431. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al.
Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med
2018;379:2307–2318.
432. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al.
Force for the Management of Infective Endocarditis of the European Society of
Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic
Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur
Heart J 2015;36:3075–3128.
433. Polanczyk CA, Goldman L, Marcantonio ER, Orav EJ, Lee TH. Supraventricular arrhythmia in patients having noncardiac surgery: clinical correlates and effect on length of stay. Ann Intern Med 1998;129:279–285.
434. van Diepen S, Bakal JA, McAlister FA, Ezekowitz JA. Mortality and readmission of patients with heart failure, atrial ﬁbrillation, or coronary artery disease undergoing noncardiac surgery: an analysis of 38 047 patients. Circulation 2011;124:289–296.
435. Alberte C, Zipes DP. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J Cardiovasc Electrophysiol 2003;14:S87–S95.
436. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C, et al.
437. Calkins H, Yong P, Miller JM, Olshansky B, Carlson M, Saul JP, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: ﬁnal results of a prospective, multicenter clinical trial.
The Atakr Multicenter Investigators Group. Circulation 1999;99:262–270.
438. Chen SA, Chiang CE, Yang CJ, Cheng CC, Wu TJ, Wang SP, et al. Sustained atrial tachycardia in adult patients. Electrophysiological characteristics, pharmacological response, possible mechanisms, and effects of radiofrequency ablation. Circulation
1994;90:1262–1278.
439. Katritsis DG, Zografos T, Katritsis GD, Giazitzoglou E, Vachliotis V, Paxinos G, et al.
Catheter ablation vs. antiarrhythmic drug therapy in patients with symptomatic atrioventricular nodal re-entrant tachycardia: a randomized, controlled trial.
Europace 2017;19:602–606.
440. Pappone C, Vicedomini G, Manguso F, Saviano M, Baldi M, Pappone A, et al.
Wolff-Parkinson-White syndrome in the era of catheter ablation: insights from a registry study of 2169 patients. Circulation 2014;130:811–819.
441. Spector P, Reynolds MR, Calkins H, Sondhi M, Xu Y, Martin A, et al. Meta-analysis of ablation of atrial ﬂutter and supraventricular tachycardia. Am J Cardiol 2009;104:
671–677.
442. Potpara TS, Polovina MM, Marinkovic JM, Lip GY. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with
ﬁrst-diagnosed atrial ﬁbrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol
2013;168:4744–4749.
443. Mujovic N, Dobrev D, Marinkovic M, Russo V, Potpara TS. The role of amiodarone in contemporary management of complex cardiac arrhythmias. Pharmacol Res
2020;151:104521.
444. Dan GA, Martinez-Rubio A, Agewall S, Boriani G, Borggrefe M, Gaita F, et al.
Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European
Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Paciﬁc Heart Rhythm Society
(APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP).
Europace 2018;20:731–732an.
445. Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial ﬁbrillation and atrial ﬂutter: a multicenter study. J Am Coll Cardiol
1991;18:891–897.
446. Phillips BG, Gandhi AJ, Sanoski CA, Just VL, Bauman JL. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial ﬁbrillation and atrial ﬂutter.
Pharmacotherapy 1997;17:1238–1245.
447. Platia EV, Michelson EL, Porterﬁeld JK, Das G. Esmolol versus verapamil in the acute treatment of atrial ﬁbrillation or atrial ﬂutter. Am J Cardiol 1989;63:925–929.
448. Sethi NJ, Nielsen EE, SaﬁS, Feinberg J, Gluud C, Jakobsen JC. Digoxin for atrial ﬁbrillation and atrial ﬂutter: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. PLoS One 2018;13:e0193924.
449. Karth GD, Geppert A, NeunteuﬂT, Priglinger U, Haumer M, Gschwandtner M,
et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001;29:1149–1153.
450. Vos MA, Golitsyn SR, Stangl K, Ruda MY, Van Wijk LV, Harry JD, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial ﬂutter and atrial
ﬁbrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998;79:
568–575.
451. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, et al. Efﬁcacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial ﬁbrillation or atrial ﬂutter: the symptomatic atrial ﬁbrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000;102:2385–2390.
452. Volgman AS, Carberry PA, Stambler B, Lewis WR, Dunn GH, Perry KT, et al.
Conversion efﬁcacy and safety of intravenous ibutilide compared with intravenous


<!-- PAGE 94 -->

### Page 94

procainamide in patients with atrial ﬂutter or ﬁbrillation. J Am Coll Cardiol 1998;31:
1414–1419.
453. Bianconi L, Castro A, Dinelli M, Alboni P, Pappalardo A, Richiardi E, et al.
Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial ﬁbrillation and ﬂutter. A multicentre, randomized,
double-blind, placebo-controlled study. Eur Heart J 2000;21:1265–1273.
454. Kerola T, Dewland TA, Vittinghoff E, Heckbert SR, Stein PK, Marcus GM.
Modiﬁable predictors of ventricular ectopy in the community. J Am Heart Assoc
2018;7:e010078.
455. Yang J, Dudum R, Mandyam MC, Marcus GM. Characteristics of unselected highburden premature ventricular contraction patients. Pacing Clin Electrophysiol
2014;37:1671–1680.
456. Parreira L, Marinheiro R, Amador P, Mesquita D, Farinha J, Lopes A, et al. Frequent premature ventricular contractions. Association of burden and complexity with prognosis according to the presence of structural heart disease. Ann Noninvasive
Electrocardiol 2021;26:e12800.
457. Agarwal V, Vittinghoff E, Whitman IR, Dewland TA, Dukes JW, Marcus GM.
Relation between ventricular premature complexes and incident heart failure.
Am J Cardiol 2017;119:1238–1242.
458. Dukes JW, Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS,
et al. Ventricular ectopy as a predictor of heart failure and death. J Am Coll Cardiol
2015;66:101–109.
459. Marcus GM. Evaluation and management of premature ventricular complexes.
Circulation 2020;141:1404–1418.
460. Mukharji J, Rude RE, Poole WK, Gustafson N, Thomas LJ, Jr., Strauss HW, et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J
Cardiol 1984;54:31–36.
461. Chen J, Johnson G, Hellkamp AS, Anderson J, Mark DB, Lee KL, et al. Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverterdeﬁbrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden
Cardiac Death in Heart Failure Trial). J Am Coll Cardiol 2013;61:2161–2168.
462. Makimoto H, Zielke S, Clasen L, Lin T, Gerguri S, Muller P, et al. Clinical signiﬁcance of precedent asymptomatic non-sustained ventricular tachycardias on subsequent
ICD interventions and heart failure hospitalization in primary prevention ICD patients. Eur J Med Res 2020;25:5.
463. Sanchez Munoz JJ, Garcia-Alberola A, Martinez-Sanchez J, Penaﬁel-Verdu P,
Caro-Martinez C, Manzano-Fernandez S, et al. Premature ventricular complexes as a trigger for ventricular ﬁbrillation. Rev Esp Cardiol 2010;63:798–801.
464. Kakishita M, Kurita T, Matsuo K, Taguchi A, Suyama K, Shimizu W, et al. Mode of onset of ventricular ﬁbrillation in patients with Brugada syndrome detected by implantable cardioverter deﬁbrillator therapy. J Am Coll Cardiol 2000;36:1646–1653.
465. Srivathsan K, Gami AS, Ackerman MJ, Asirvatham SJ. Treatment of ventricular ﬁbrillation in a patient with prior diagnosis of long QT syndrome: importance of precise electrophysiologic diagnosis to successfully ablate the trigger. Heart Rhythm
2007;4:1090–1093.
466. Almendral J, Villacastin JP, Arenal A, Tercedor L, Merino JL, Delcan JL. Evidence favoring the hypothesis that ventricular arrhythmias have prognostic signiﬁcance in left ventricular hypertrophy secondary to systemic hypertension. Am J Cardiol
1995;76:60D–63D.
467. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al.
Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for
European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:
2793–2867.
468. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter deﬁbrillators: the OPTIC Study: a randomized trial.
JAMA 2006;295:165–171.
469. Brodine WN, Tung RT, Lee JK, Hockstad ES, Moss AJ, Zareba W, et al. Effects of beta-blockers on implantable cardioverter deﬁbrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic
Deﬁbrillator Implantation Trial-II). Am J Cardiol 2005;96:691–695.
470. Tilz RR, Lenarczyk R, Scherr D, Haugaa KH, Iliodromitis K, Purerfellner H, et al.
Management of ventricular tachycardia in the ablation era: results of the
European Heart Rhythm Association Survey. Europace 2018;20:209–213.
471. Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, et al. 2019 HRS/
EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace 2019;21:1143–1144.
472. Scheuermeyer FX, Grafstein E, Stenstrom R, Innes G, Heslop C, MacPhee J, et al.
Thirty-day and 1-year outcomes of emergency department patients with atrial ﬁbrillation and no acute underlying medical cause. Ann Emerg Med 2012;60:
755–765.e752.
473. Bonfanti L, Annovi A, Sanchis-Gomar F, Saccenti C, Meschi T, Ticinesi A, et al.
Effectiveness and safety of electrical cardioversion for acute-onset atrial ﬁbrillation in the emergency department: a real-world 10-year single center experience. Clin
Exp Emerg Med 2019;6:64–69.
474. Kheiri B, Barbarawi M, Zayed Y, Hicks M, Osman M, Rashdan L, et al.
Antiarrhythmic drugs or catheter ablation in the management of ventricular tachyarrhythmias in patients with implantable cardioverter-deﬁbrillators: a systematic review and meta-analysis of randomized controlled trials. Circ Arrhythm
Electrophysiol 2019;12:e007600.
475. Santangeli P, Muser D, Maeda S, Filtz A, Zado ES, Frankel DS, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverterdeﬁbrillators: a systematic review and meta-analysis of randomized controlled trials. Heart Rhythm 2016;13:1552–1559.
476. Martinez BK, Baker WL, Konopka A, Giannelli D, Coleman CI, Kluger J, et al.
Systematic review and meta-analysis of catheter ablation of ventricular tachycardia in ischemic heart disease. Heart Rhythm 2020;17:e206–e219.
477. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K,
et al. Prophylactic catheter ablation for the prevention of deﬁbrillator therapy. N
Engl J Med 2007;357:2657–2665.
478. Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med 2016;
375:111–121.
479. Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacretaz E, et al.
Catheter ablation of stable ventricular tachycardia before deﬁbrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375:31–40.
480. Briceno DF, Gupta T, Romero J, Kolte D, Khera S, Villablanca PA, et al. Catheter ablation of ventricular tachycardia in nonischemic cardiomyopathy: a propensity score-matched analysis of in-hospital outcomes in the United States. J Cardiovasc
Electrophysiol 2018;29:771–779.
481. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.
Heart J 2021;42:3427–3520.
482. Marti-Almor J, Cladellas M, Bazan V, Delclos J, Altaba C, Guijo MA, et al. Novel predictors of progression of atrioventricular block in patients with chronic bifascicular block. Rev Esp Cardiol 2010;63:400–408.
483. Santini M, Castro A, Giada F, Ricci R, Inama G, Gaggioli G, et al. Prevention of syncope through permanent cardiac pacing in patients with bifascicular block and syncope of unexplained origin: the PRESS study. Circ Arrhythm Electrophysiol 2013;6:
101–107.
484. Stone ME, Salter B, Fischer A. Perioperative management of patients with cardiac implantable electronic devices. Br J Anaesth 2011;107:i16–i26.
485. Cardiac implantable electronic device management (corrected). Anesthesiology
2020;132:225–252.
486. Gifford J, Larimer K, Thomas C, May P. ICD-ON Registry for perioperative management of CIEDs: most require no change. Pacing Clin Electrophysiol 2017;40:
128–134.
487. Mahlow WJ, Craft RM, Misulia NL, Cox JW, Jr., Hirsh JB, Snider CC, et al. A perioperative management algorithm for cardiac rhythm management devices: the
PACED-OP protocol. Pacing Clin Electrophysiol 2013;36:238–248.
488. Neubauer H, Wellmann M, Herzog-Niescery J, Wutzler A, Weber TP, Mugge A,
et al. Comparison of perioperative strategies in ICD patients: the perioperative
ICD management study (PIM study). Pacing Clin Electrophysiol 2018;41:1536–1542.
489. Feldman JB, Stone ME. Anesthesia teams managing pacemakers and ICDs for the perioperative period: enhanced patient safety and improved workﬂows. Curr
Opin Anaesthesiol 2020;33:441–447.
490. Mickus GJ, Soliman GI, Reed RR, Martin AK. Perioperative management of a leadless pacemaker: the paucity of evidence-based guidelines. J Cardiothorac Vasc Anesth
2016;30:1594–1598.
491. Karuppiah S, Prielipp R, Banik RK. Anesthetic consideration for patients with micra leadless pacemaker. Ann Card Anaesth 2020;23:493–495.
492. Gifford J, Larimer K, Thomas C, May P, Stanhope S, Gami A. Randomized controlled trial of perioperative ICD management: magnet application versus reprogramming. Pacing Clin Electrophysiol 2014;37:1219–1224.
493. Winter J, Kohlmeier A, Shin DI, O’Connor S. Subcutaneous implantable cardioverter-deﬁbrillators and sternal wires: a cautionary tale. Circ Arrhythm
Electrophysiol 2014;7:986–987.
494. Schulman PM, Treggiari MM, Yanez ND, Henrikson CA, Jessel PM, Dewland TA,
et al. Electromagnetic interference with protocolized electrosurgery dispersive electrode positioning in patients with implantable cardioverter deﬁbrillators.
Anesthesiology 2019;130:530–540.
495. Baeg MK, Kim SW, Ko SH, Lee YB, Hwang S, Lee BW, et al. Endoscopic electrosurgery in patients with cardiac implantable electronic devices. Clin Endosc 2016;49:
176–181.
ESC Guidelines
3919


<!-- PAGE 95 -->

### Page 95

496. Mangar D, Atlas GM, Kane PB. Electrocautery-induced pacemaker malfunction during surgery. Can J Anaesth 1991;38:616–618.
497. Rozner MA. Review of electrical interference in implanted cardiac devices. Pacing
Clin Electrophysiol 2003;26:923–925.
498. de Cock CC, Spruijt HJ, van Campen LM, Plu AW, Visser CA. Electromagnetic interference of an implantable loop recorder by commonly encountered electronic devices. Pacing Clin Electrophysiol 2000;23:1516–1518.
499. Suarez-Fuster L, Oh C, Baranchuk A. Transcutaneous electrical nerve stimulation electromagnetic interference in an implantable loop recorder. J Arrhythm 2018;
34:96–97.
500. Gilboa SM, Salemi JL, Nembhard WN, Fixler DE, Correa A. Mortality resulting from congenital heart disease among children and adults in the United States, 1999 to
2006. Circulation 2010;122:2254–2263.
501. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010.
Circulation 2014;130:749–756.
502. Maxwell BG, Wong JK, Kin C, Lobato RL. Perioperative outcomes of major noncardiac surgery in adults with congenital heart disease. Anesthesiology 2013;119:
762–769.
503. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, et al.
Heart J 2021;42:563–645.
504. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C,
Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165–3241.
505. Ammash NM, Connolly HM, Abel MD, Warnes CA. Noncardiac surgery in
Eisenmenger syndrome. J Am Coll Cardiol 1999;33:222–227.
506. Faraoni D, Zurakowski D, Vo D, Goobie SM, Yuki K, Brown ML, et al.
Post-operative outcomes in children with and without congenital heart disease undergoing noncardiac surgery. J Am Coll Cardiol 2016;67:793–801.
507. Alonso-Gonzalez R, Borgia F, Diller GP, Inuzuka R, Kempny A, Martinez-Naharro
A, et al. Abnormal lung function in adults with congenital heart disease: prevalence,
relation to cardiac anatomy, and association with survival. Circulation 2013;127:
882–890.
508. Maxwell BG, Posner KL, Wong JK, Oakes DA, Kelly NE, Domino KB, et al. Factors contributing to adverse perioperative events in adults with congenital heart disease:
a structured analysis of cases from the closed claims project. Congenit Heart Dis
2015;10:21–29.
509. Lui GK, Saidi A, Bhatt AB, Burchill LJ, Deen JF, Earing MG, et al. Diagnosis and management of noncardiac complications in adults with congenital heart disease: a scientiﬁc statement from the American Heart Association. Circulation 2017;136:
e348–e392.
510. Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, et al. 2015
ESC Guidelines for the diagnosis and management of pericardial diseases: the Task
Force for the Diagnosis and Management of Pericardial Diseases of the European
Society of Cardiology (ESC). Endorsed by: the European Association for
Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015;36:2921–2964.
511. Tuck BC, Townsley MM. Clinical update in pericardial diseases. J Cardiothorac Vasc
Anesth 2019;33:184–199.
512. Ristic AD, Imazio M, Adler Y, Anastasakis A, Badano LP, Brucato A, et al. Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and
Pericardial Diseases. Eur Heart J 2014;35:2279–2284.
513. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005;127:1952–1959.
514. Canet J, Gallart L, Gomar C, Paluzie G, Valles J, Castillo J, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort.
Anesthesiology 2010;113:1338–1350.
515. Edrich T, Sadovnikoff N. Anesthesia for patients with severe chronic obstructive pulmonary disease. Curr Opin Anaesthesiol 2010;23:18–24.
516. Chau EH, Lam D, Wong J, Mokhlesi B, Chung F. Obesity hypoventilation syndrome:
a review of epidemiology, pathophysiology, and perioperative considerations.
Anesthesiology 2012;117:188–205.
517. Kaw R, Gali B, Collop NA. Perioperative care of patients with obstructive sleep apnea. Curr Treat Options Neurol 2011;13:496–507.
518. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint
Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the
European Society of Cardiology (ESC) and the European Respiratory Society
(ERS). Endorsed by: Association for European Paediatric and Congenital
Cardiology (AEPC), International Society for Heart and Lung Transplantation
(ISHLT). Eur Heart J 2016;37:67–119.
519. Bowker D, Banks D. Pulmonary hypertension in noncardiac surgical patients. In:
Kaplan JA Cronin B and Maus TM, editors. Essentials of Cardiac Anesthesia for
Noncardiac Surgery. Philadelphia, PA: Elsevier; 2019. p138–164.
520. Meyer S, McLaughlin VV, Seyfarth HJ, Bull TM, Vizza CD, Gomberg-Maitland M,
et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J 2013;41:1302–1307.
521. Price LC, Montani D, Jais X, Dick JR, Simonneau G, Sitbon O, et al.
Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. Eur Respir J 2010;35:1294–1302.
522. Olsson KM, Halank M, Egenlauf B, Fistera D, Gall H, Kaehler C, et al.
Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: updated recommendations from the
Cologne Consensus Conference 2018. Int J Cardiol 2018;272S:46–52.
523. Pilkington SA, Taboada D, Martinez G. Pulmonary hypertension and its management in patients undergoing non-cardiac surgery. Anaesthesia 2015;70:56–70.
524. ESC. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43:3618–3731.
525. Thunberg CA, Gaitan BD, Grewal A, Ramakrishna H, Stansbury LG, Grigore AM.
Pulmonary hypertension in patients undergoing cardiac surgery: pathophysiology,
perioperative management, and outcomes. J Cardiothorac Vasc Anesth 2013;27:
551–572.
526. Hayward CS, Kelly RP, Macdonald PS. Inhaled nitric oxide in cardiology practice.
Cardiovasc Res 1999;43:628–638.
527. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence,
awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959–968.
528. Futier E, Lefrant JY, Guinot PG, Godet T, Lorne E, Cuvillon P, et al. Effect of individualized vs standard blood pressure management strategies on postoperative organ dysfunction among high-risk patients undergoing major surgery: a randomized clinical trial. JAMA 2017;318:1346–1357.
529. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018
ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;
39:3021–3104.
530. Howell SJ, Sear JW, Foex P. Hypertension, hypertensive heart disease and perioperative cardiac risk. Br J Anaesth 2004;92:570–583.
531. Messina A, Robba C, Calabro L, Zambelli D, Iannuzzi F, Molinari E, et al. Association between perioperative ﬂuid administration and postoperative outcomes: a 20-year systematic review and a meta-analysis of randomized goal-directed trials in major visceral/noncardiac surgery. Crit Care 2021;25:43.
532. Jorgensen ME, Hlatky MA, Kober L, Sanders RD, Torp-Pedersen C, Gislason GH,
et al. Beta-blocker-associated risks in patients with uncomplicated hypertension undergoing noncardiac surgery. JAMA Intern Med 2015;175:1923–1931.
533. Weksler N, Klein M, Szendro G, Rozentsveig V, Schily M, Brill S, et al. The dilemma of immediate preoperative hypertension: to treat and operate, or to postpone surgery? J Clin Anesth 2003;15:179–183.
534. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European
Guidelines on cardiovascular disease prevention in clinical practice (version 2012).
The Fifth Joint Task Force of the European Society of Cardiology and Other
Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:
1635–1701.
535. Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. 2017
ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric,
renal, upper and lower extremity arteries. Endorsed by: the European Stroke
Organization (ESO). The Task Force for the Diagnosis and Treatment of
Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763–816.
536. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al.
Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further
Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With
Elevated Risk). Circulation 2018;137:338–350.
537. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al.
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Lancet 2018;391:219–229.
538. Ashton CM, Petersen NJ, Wray NP, Kiefe CI, Dunn JK, Wu L, et al. The incidence of perioperative myocardial infarction in men undergoing noncardiac surgery. Ann
Intern Med 1993;118:504–510.
539. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc
Endovasc Surg 2019;58:S1–S109.e33.


<!-- PAGE 96 -->

### Page 96

540. Brown LC, Powell JT, Thompson SG, Epstein DM, Sculpher MJ, Greenhalgh RM.
The UK EndoVascular Aneurysm Repair (EVAR) trials: randomised trials of
EVAR versus standard therapy. Health Technol Assess 2012;16:1–218.
541. Paravastu SC, Jayarajasingam R, Cottam R, Palfreyman SJ, Michaels JA, Thomas SM.
Endovascular repair of abdominal aortic aneurysm. Cochrane Database Syst Rev
2014:CD004178. doi:10.1002/14651858.CD004178.pub2.
542. Stather PW, Sidloff D, Dattani N, Choke E, Bown MJ, Sayers RD. Systematic review and meta-analysis of the early and late outcomes of open and endovascular repair of abdominal aortic aneurysm. Br J Surg 2013;100:863–872.
543. Eslami MH, Rybin DV, Doros G, Siracuse JJ, Farber A. External validation of Vascular
Study Group of New England risk predictive model of mortality after elective abdominal aorta aneurysm repair in the Vascular Quality Initiative and comparison against established models. J Vasc Surg 2018;67:143–150.
544. Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al.
Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med
2020;382:1994–2004.
545. Cutlip DE, Pinto DS. Extracranial carotid disease revascularization. Circulation 2012;
126:2636–2644.
546. Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, et al.
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney
Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011;80:572–586.
547. Section 3: Prevention and Treatment of AKI. Kidney Int Suppl (2011) 2012;2:37–68.
548. Romagnoli S, Ricci Z, Ronco C. Perioperative acute kidney injury: prevention, early recognition, and supportive measures. Nephron 2018;140:105–110.
549. Kheterpal S, Tremper KK, Heung M, Rosenberg AL, Englesbe M, Shanks AM, et al.
Development and validation of an acute kidney injury risk index for patients undergoing general surgery: results from a national data set. Anesthesiology 2009;110:
505–515.
550. Rebholz CM, Inker LA, Chen Y, Liang M, Foster MC, Eckfeldt JH, et al. Risk of ESRD
and mortality associated with change in ﬁltration markers. Am J Kidney Dis 2017;70:
551–560.
551. McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, et al.
Contrast-induced acute kidney injury. J Am Coll Cardiol 2016;68:1465–1473.
552. Section 2: AKI Deﬁnition. Kidney Int Suppl (2011) 2012;2:19–36.
553. Goren O, Matot I. Perioperative acute kidney injury. Br J Anaesth 2015;115:ii3–ii14.
554. Zealley I, Wang H, Donnan PT, Bell S. Exposure to contrast media in the perioperative period confers no additional risk of acute kidney injury in surgical patients.
Nephrol Dial Transplant 2018;33:1751–1756.
555. STARSurg Collaborative. Perioperative intravenous contrast administration and the incidence of acute kidney injury after major gastrointestinal surgery: prospective, multicentre cohort study. Br J Surg 2020;107:1023–1032.
556. Meersch M, Schmidt C, Zarbock A. Patient with chronic renal failure undergoing surgery. Curr Opin Anaesthesiol 2016;29:413–420.
557. NCD Risk Factor Collaboration. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416
population-based measurement studies in 128.9 million children, adolescents,
and adults. Lancet 2017;390:2627–2642.
558. Lavie CJ, Arena R, Alpert MA, Milani RV, Ventura HO. Management of cardiovascular diseases in patients with obesity. Nat Rev Cardiol 2018;15:45–56.
559. Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res 2016;
118:1752–1770.
560. De Hert S, Staender S, Fritsch G, Hinkelbein J, Afshari A, Bettelli G, et al.
Pre-operative evaluation of adults undergoing elective noncardiac surgery: updated guideline from the European Society of Anaesthesiology. Eur J Anaesthesiol 2018;35:
407–465.
561. Lavie CJ, De Schutter A, Parto P, Jahangir E, Kokkinos P, Ortega FB, et al. Obesity and prevalence of cardiovascular diseases and prognosis – the obesity paradox updated. Prog Cardiovasc Dis 2016;58:537–547.
562. Elagizi A, Kachur S, Lavie CJ, Carbone S, Pandey A, Ortega FB, et al. An overview and update on obesity and the obesity paradox in cardiovascular diseases. Prog
Cardiovasc Dis 2018;61:142–150.
563. Valentijn TM, Galal W, Tjeertes EK, Hoeks SE, Verhagen HJ, Stolker RJ. The obesity paradox in the surgical population. Surgeon 2013;11:169–176.
564. Hidvegi
R,
Puelacher
C,
Gualandro
DM,
Lampart
A,
Lurati
Buse
G,
Hammerer-Lerchner A, et al. Obesity paradox and perioperative myocardial infarction/injury in non-cardiac surgery. Clin Res Cardiol 2020;109:1140–1147.
565. Ross R, Blair SN, Arena R, Church TS, Despres JP, Franklin BA, et al. Importance of assessing cardiorespiratory ﬁtness in clinical practice: a case for ﬁtness as a clinical vital sign: a scientiﬁc statement from the American Heart Association. Circulation
2016;134:e653–e699.
566. McAuley PA, Artero EG, Sui X, Lee DC, Church TS, Lavie CJ, et al. The obesity paradox, cardiorespiratory ﬁtness, and coronary heart disease. Mayo Clin Proc
2012;87:443–451.
567. Pedersen BK. Body mass index-independent effect of ﬁtness and physical activity for all-cause mortality. Scand J Med Sci Sports 2007;17:196–204.
568. Roman M, Monaghan A, Serraino GF, Miller D, Pathak S, Lai F, et al. Meta-analysis of the inﬂuence of lifestyle changes for preoperative weight loss on surgical outcomes.
Br J Surg 2019;106:181–189.
569. McCullough PA, Gallagher MJ, Dejong AT, Sandberg KR, Trivax JE, Alexander D,
et al. Cardiorespiratory ﬁtness and short-term complications after bariatric surgery. Chest 2006;130:517–525.
570. Smith TB, Stonell C, Purkayastha S, Paraskevas P. Cardiopulmonary exercise testing as a risk assessment method in non cardio-pulmonary surgery: a systematic review.
Anaesthesia 2009;64:883–893.
571. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R,
Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
Lancet 2010;375:2215–2222.
572. Kadoi Y. Anesthetic considerations in diabetic patients. Part II: intraoperative and postoperative management of patients with diabetes mellitus. J Anesth 2010;24:
748–756.
573. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41:255–323.
574. American Diabetes Association. 15. Diabetes care in the hospital: standards of medical care in diabetes - 2020. Diabetes Care 2021;44:S211–S220.
575. Shah NJ, Leis A, Kheterpal S, Englesbe MJ, Kumar SS. Association of intraoperative hyperglycemia and postoperative outcomes in patients undergoing non-cardiac surgery: a multicenter retrospective study. BMC Anesthesiol 2020;20:106.
576. Aharaz A, Pottegard A, Henriksen DP, Hallas J, Beck-Nielsen H, Lassen AT. Risk of lactic acidosis in type 2 diabetes patients using metformin: a case control study. PLoS
One 2018;13:e0196122.
577. Vogt AP, Bally L. Perioperative glucose management: current status and future directions. Best Pract Res Clin Anaesthesiol 2020;34:213–224.
578. Pasquel FJ, Gomez-Huelgas R, Anzola I, Oyedokun F, Haw JS, Vellanki P, et al.
Predictive value of admission hemoglobin A1c on inpatient glycemic control and response to insulin therapy in medicine and surgery patients with type 2 diabetes.
Diabetes Care 2015;38:e202–e203.
579. Carpenter DL, Gregg SR, Xu K, Buchman TG, Coopersmith CM. Prevalence and impact of unknown diabetes in the ICU. Crit Care Med 2015;43:e541–e550.
580. van den Boom W, Schroeder RA, Manning MW, Setji TL, Fiestan GO, Dunson DB.
Effect of A1C and glucose on postoperative mortality in noncardiac and cardiac surgeries. Diabetes Care 2018;41:782–788.
581. Dhatariya K, Levy N, Kilvert A, Watson B, Cousins D, Flanagan D, et al. NHS
Diabetes guideline for the perioperative management of the adult patient with diabetes. Diabet Med 2012;29:420–433.
582. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al.
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975–980.
583. Kirschner M, do OHN, Parmentier S, Hart C, Henze L, Bisping G, et al. Primary thromboprophylaxis in patients with malignancies: Daily Practice recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis
Research (GTH), and the Austrian Society of Hematology and Oncology
(OGHO). Cancers (Basel) 2021;13:2905.
584. ESC. 2022 ESC Guidelines on cardio-oncology. Eur Heart J 2022;XX:XX–XX.
585. COVIDSurg Collaborative, GlobalSurg Collaborative. Timing of surgery following
SARS-CoV-2 infection: an international prospective cohort study. Anaesthesia
2021;76:748–758.
586. COVIDSurg Collaborative, GlobalSurg Collaborative. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study.
Anaesthesia 2022;77:28–39.
587. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al.
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 2020;116:1666–1687.
588. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al.
Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:
1265–1273.
589. Rohatgi N, Smilowitz NR, Reejhsinghani R. Perioperative cardiovascular considerations prior to elective noncardiac surgery in patients with a history of COVID-19.
JAMA Surg 2022;157:187–188.
590. Deng JZ, Chan JS, Potter AL, Chen YW, Sandhu HS, Panda N, et al. The risk of postoperative complications after major elective surgery in active or resolved
COVID-19 in the United States. Ann Surg 2022;275:242–246.
591. Anesthesia Patient Safety Foundation. American Society of Anesthesiologists and
Anesthesia Patient Safety Foundation Joint Statement on Elective Surgery and
Anesthesia for Patients after COVID-19 Infection. https://www.apsf.org/newsupdates/asa-and-apsf-joint-statement-on-elective-surgery-and-anesthesia-forpatients-after-covid-19-infection/ (30 March 2022).
ESC Guidelines
3921


<!-- PAGE 97 -->

### Page 97

592. Mellin-Olsen J, Staender S, Whitaker DK, Smith AF. The Helsinki Declaration on patient safety in anaesthesiology. Eur J Anaesthesiol 2010;27:592–597.
593. De Hert S. Perioperative monitoring: anaesthesiology. In: Camm AJ Lüscher TF
Maurer G and Serruys PW, editors. ESC CardioMed. 3rd ed. Oxford: Oxford
University Press; 2018. p2683–2686.
594. Hamilton-Davies C, Mythen MG, Salmon JB, Jacobson D, Shukla A, Webb AR.
Comparison of commonly used clinical indicators of hypovolaemia with gastrointestinal tonometry. Intensive Care Med 1997;23:276–281.
595. Marik PE, Cavallazzi R. Does the central venous pressure predict ﬂuid responsiveness? An updated meta-analysis and a plea for some common sense. Crit Care Med
2013;41:1774–1781.
596. Gaba DM. Improving anesthesiologists’ performance by simulating reality.
Anesthesiology 1992;76:491–494.
597. Runciman WB. Commentary on equipment recommendations. Eur J Anaesthesiol
Suppl 1993;7:16–18.
598. Block FE, Jr., Nuutinen L, Ballast B. Optimization of alarms: a study on alarm limits,
alarm sounds, and false alarms, intended to reduce annoyance. J Clin Monit Comput
1999;15:75–83.
599. De Hert S, Moerman A. Anesthetic preconditioning: have we found the holy grail of perioperative cardioprotection? J Cardiothorac Vasc Anesth 2018;32:1135–1136.
600. Bijker JB, van Klei WA, Kappen TH, van Wolfswinkel L, Moons KG, Kalkman CJ.
Incidence of intraoperative hypotension as a function of the chosen deﬁnition: literature deﬁnitions applied to a retrospective cohort using automated data collection. Anesthesiology 2007;107:213–220.
601. Vernooij LM, van Klei WA, Machina M, Pasma W, Beattie WS, Peelen LM. Different methods of modelling intraoperative hypotension and their association with postoperative complications in patients undergoing non-cardiac surgery. Br J Anaesth
2018;120:1080–1089.
602. Sessler DI, Bloomstone JA, Aronson S, Berry C, Gan TJ, Kellum JA, et al.
Perioperative Quality Initiative consensus statement on intraoperative blood pressure, risk and outcomes for elective surgery. Br J Anaesth 2019;122:563–574.
603. Sessler DI, Meyhoff CS, Zimmerman NM, Mao G, Leslie K, Vasquez SM, et al.
Period-dependent associations between hypotension during and for four days after noncardiac surgery and a composite of myocardial infarction and death: a substudy of the POISE-2 trial. Anesthesiology 2018;128:317–327.
604. Ladha KS, Beattie WS, Tait G, Wijeysundera DN. Association between preoperative ambulatory heart rate and postoperative myocardial injury: a retrospective cohort study. Br J Anaesth 2018;121:722–729.
605. Abbott TE, Ackland GL, Archbold RA, Wragg A, Kam E, Ahmad T, et al.
Preoperative heart rate and myocardial injury after non-cardiac surgery: results of a predeﬁned secondary analysis of the VISION study. Br J Anaesth 2016;117:
172–181.
606. Abbott TEF, Minto G, Lee AM, Pearse RM, Ackland GL., POM-HR, POMO-O and
OPTIMISE study groups. Elevated preoperative heart rate is associated with cardiopulmonary and autonomic impairment in high-risk surgical patients. Br J Anaesth
2017;119:87–94.
607. Ruetzler K, Yilmaz HO, Turan A, Zimmerman NM, Mao G, Hung MH, et al.
Intra-operative tachycardia is not associated with a composite of myocardial injury and mortality after noncardiac surgery: a retrospective cohort analysis. Eur J
Anaesthesiol 2019;36:105–113.
608. Straarup TS, Hausenloy DJ, Rolighed Larsen JK. Cardiac troponins and volatile anaesthetics in coronary artery bypass graft surgery: a systematic review,
meta-analysis and trial sequential analysis. Eur J Anaesthesiol 2016;33:396–407.
609. Landoni G, Lomivorotov VV, Nigro Neto C, Monaco F, Pasyuga VV, Bradic N, et al.
Volatile anesthetics versus total intravenous anesthesia for cardiac surgery. N Engl J
Med 2019;380:1214–1225.
610. Lurati Buse GA, Schumacher P, Seeberger E, Studer W, Schuman RM, Fassl J, et al.
Randomized comparison of sevoﬂurane versus propofol to reduce perioperative myocardial ischemia in patients undergoing noncardiac surgery. Circulation 2012;
126:2696–2704.
611. Rodgers A, Walker N, Schug S, McKee A, Kehlet H, van Zundert A, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ 2000;321:1493.
612. Bos EME, Hollmann MW, Lirk P. Safety and efﬁcacy of epidural analgesia. Curr Opin
Anaesthesiol 2017;30:736–742.
613. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM, et al.
Regional anaesthesia and antithrombotic agents: recommendations of the
European Society of Anaesthesiology. Eur J Anaesthesiol 2010;27:999–1015.
614. Hamilton MA, Cecconi M, Rhodes A. A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. Anesth Analg 2011;112:1392–1402.
615. Grocott MP, Dushianthan A, Hamilton MA, Mythen MG, Harrison D, Rowan K,
et al. Perioperative increase in global blood ﬂow to explicit deﬁned goals and outcomes following surgery. Cochrane Database Syst Rev 2012;11:CD004082.
616. Cecconi M, Corredor C, Arulkumaran N, Abuella G, Ball J, Grounds RM, et al.
Clinical review: goal-directed therapy – what is the evidence in surgical patients?
The effect on different risk groups. Crit Care 2013;17:209.
617. Arulkumaran N, Corredor C, Hamilton MA, Ball J, Grounds RM, Rhodes A, et al.
Cardiac complications associated with goal-directed therapy in high-risk surgical patients: a meta-analysis. Br J Anaesth 2014;112:648–659.
618. Nicklas JY, Diener O, Leistenschneider M, Sellhorn C, Schon G, Winkler M, et al.
Personalised haemodynamic management targeting baseline cardiac index in highrisk patients undergoing major abdominal surgery: a randomised single-centre clinical trial. Br J Anaesth 2020;125:122–132.
619. Taenzer AH, Pyke JB, McGrath SP. A review of current and emerging approaches to address failure-to-rescue. Anesthesiology 2011;115:421–431.
620. Pyke J, Taenzer AH, Renaud CE, McGrath SP. Developing a continuous monitoring infrastructure for detection of inpatient deterioration. Jt Comm J Qual Patient Saf
2012;38:428–431.
621. McGrath SP, Taenzer AH, Karon N, Blike G. Surveillance monitoring management for general care units: strategy, design, and implementation. Jt Comm J Qual Patient
Saf 2016;42:293–302.
622. Taenzer AH, Spence BC. The afferent limb of rapid response systems: continuous monitoring on general care units. Crit Care Clin 2018;34:189–198.
623. Liu SS, Wu CL. The effect of analgesic technique on postoperative patient-reported outcomes including analgesia: a systematic review. Anesth Analg 2007;105:789–808.
624. White PF, Kehlet H. Postoperative pain management and patient outcome: time to return to work!. Anesth Analg 2007;104:487–489.
625. Turan A, Leung S, Bajracharya GR, Babazade R, Barnes T, Schacham YN, et al. Acute postoperative pain is associated with myocardial injury after noncardiac surgery.
Anesth Analg 2020;131:822–829.
626. Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, et al. Long-term cardiovascular risk of nonsteroidal anti-inﬂammatory drug use according to time passed after ﬁrst-time myocardial infarction: a nationwide cohort study.
Circulation 2012;126:1955–1963.
627. Schmidt M, Sorensen HT, Pedersen L. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ 2018;362:k3426.
628. Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inﬂammatory drugs. Am J Cardiol 2009;103:1227–1237.
629. Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, et al.
Cardiovascular risks of nonsteroidal antiinﬂammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009;2:
155–163.
630. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, et al. Use of nonsteroidal antiinﬂammatory drugs: an update for clinicians: a scientiﬁc statement from the American Heart Association. Circulation 2007;115:1634–1642.
631. Schug SA, Joshi GP, Camu F, Pan S, Cheung R. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data. Anesth Analg 2009;108:299–307.
632. Liu SS, Bae JJ, Bieltz M, Ma Y, Memtsoudis S. Association of perioperative use of nonsteroidal anti-inﬂammatory drugs with postoperative myocardial infarction after total joint replacement. Reg Anesth Pain Med 2012;37:45–50.
633. Schmidt M, Lamberts M, Olsen AM, Fosboll E, Niessner A, Tamargo J, et al.
Cardiovascular safety of non-aspirin non-steroidal anti-inﬂammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J 2016;37:1015–1023.
634. Gregory A, Stapelfeldt WH, Khanna AK, Smischney NJ, Boero IJ, Chen Q, et al.
Intraoperative hypotension is associated with adverse clinical outcomes after noncardiac surgery. Anesth Analg 2021;132:1654–1665.
635. Aldington S, Shirtcliffe P, Weatherall M, Beasley R. Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. N Z Med J
2005;118:U1755.
636. Devereaux PJ, Sessler DI. Cardiac complications in patients undergoing major noncardiac surgery. N Engl J Med 2015;373:2258–2269.
637. Sabate S, Mases A, Guilera N, Canet J, Castillo J, Orrego C, et al. Incidence and predictors of major perioperative adverse cardiac and cerebrovascular events in noncardiac surgery. Br J Anaesth 2011;107:879–890.
638. Smilowitz NR, Redel-Traub G, Hausvater A, Armanious A, Nicholson J, Puelacher
C, et al. Myocardial injury after noncardiac surgery: a systematic review and meta-analysis. Cardiol Rev 2019;27:267–273.
639. Smilowitz NR, Gupta N, Guo Y, Berger JS, Bangalore S. Perioperative acute myocardial infarction associated with non-cardiac surgery. Eur Heart J 2017;38:
2409–2417.
640. Master AM, Dack S, Jaffe HL. Postoperative coronary artery occlusion. JAMA 1938;
110:1415–1418.
641. Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti I, et al.
Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med 2011;
154:523–528.


<!-- PAGE 98 -->

### Page 98

642. Borges FK, Devereaux PJ. Physicians should obtain perioperative cardiac troponin measurements in at-risk patients undergoing noncardiac surgery. Clin Chem 2021;
67:50–53.
643. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth
Universal Deﬁnition of Myocardial Infarction (2018). Circulation 2018;138:
e618–e651.
644. Toda H, Nakamura K, Shimizu K, Ejiri K, Iwano T, Miyoshi T, et al. Effects of bisoprolol transdermal patches for prevention of perioperative myocardial injury in high-risk patients undergoing non-cardiac surgery: multicenter randomized controlled study. Circ J 2020;84:642–649.
645. Devereaux PJ, Szczeklik W. Myocardial injury after non-cardiac surgery: diagnosis and management. Eur Heart J 2020;41:3083–3091.
646. Ruetzler K, Smilowitz NR, Berger JS, Devereaux PJ, Maron BA, Newby LK, et al.
Diagnosis and management of patients with myocardial injury after noncardiac surgery: A scientiﬁc statement from the American Heart Association. Circulation 2021;
144:e287–e305.
647. Borges FK, Sheth T, Patel A, Marcucci M, Yung T, Langer T, et al. Accuracy of physicians in differentiating type 1 and type 2 myocardial infarction based on clinical information. CJC Open 2020;2:577–584.
648. Gualandro DM, Puelacher C, Lurati Buse G, Glarner N, Cardozo FA, Vogt R, et al.
Incidence and outcomes of perioperative myocardial infarction/injury diagnosed by high-sensitivity cardiac troponin I. Clin Res Cardiol 2021;110:1450–1463.
649. Park J, Oh AR, Kwon JH, Kim S, Kim J, Yang K, et al. Association between cardiologist evaluation and mortality in myocardial injury after non-cardiac surgery. Heart 2021.
650. Devereaux PJ, Duceppe E, Guyatt G, Tandon V, Rodseth R, Biccard BM, et al.
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE):
an international, randomised, placebo-controlled trial. Lancet 2018;391:2325–2334.
651. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:
the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–2200.
652. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al.
Eur Heart J 2020;41:543–603.
653. Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, et al.
Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2015;36:605–614.
654. Neely RC, Byrne JG, Gosev I, Cohn LH, Javed Q, Rawn JD, et al. Surgical embolectomy for acute massive and submassive pulmonary embolism in a series of 115 patients. Ann Thorac Surg 2015;100:1245–1251; discussion 1251–1242.
655. Conen D, Alonso-Coello P, Douketis J, Chan MTV, Kurz A, Sigamani A, et al. Risk of stroke and other adverse outcomes in patients with perioperative atrial ﬁbrillation
1 year after non-cardiac surgery. Eur Heart J 2020;41:645–651.
656. AlTurki A, MaraﬁM, Proietti R, Cardinale D, Blackwell R, Dorian P, et al. Major adverse cardiovascular events associated with postoperative atrial ﬁbrillation after noncardiac surgery: a systematic review and meta-analysis. Circ Arrhythm
Electrophysiol 2020;13:e007437.
657. Chebbout R, Heywood EG, Drake TM, Wild JRL, Lee J, Wilson M, et al. A systematic review of the incidence of and risk factors for postoperative atrial ﬁbrillation following general surgery. Anaesthesia 2018;73:490–498.
658. Albini A, Malavasi VL, Vitolo M, Imberti JF, Marietta M, Lip GYH, et al. Long-term outcomes of postoperative atrial ﬁbrillation following non cardiac surgery: a systematic review and metanalysis. Eur J Intern Med 2021;85:27–33.
659. Hyun J, Cho MS, Nam GB, Kim M, Do U, Kim J, et al. Natural course of new-onset postoperative atrial ﬁbrillation after noncardiac surgery. J Am Heart Assoc 2021;10:
e018548.
660. Heywood EG, Drake TM, Bradburn M, Lee J, Wilson MJ, Lee MJ. Atrial ﬁbrillation after gastrointestinal surgery: incidence and associated risk factors. J Surg Res 2019;
238:23–28.
661. Lin MH, Kamel H, Singer DE, Wu YL, Lee M, Ovbiagele B. Perioperative/postoperative atrial ﬁbrillation and risk of subsequent stroke and/or mortality. Stroke
2019;50:1364–1371.
662. Dobrev D, Aguilar M, Heijman J, Guichard JB, Nattel S. Postoperative atrial ﬁbrillation:
mechanisms, manifestations and management. Nat Rev Cardiol 2019;16:417–436.
663. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, et al. A multicenter risk index for atrial ﬁbrillation after cardiac surgery. JAMA 2004;291:1720–1729.
664. Villareal RP, Hariharan R, Liu BC, Kar B, Lee VV, Elayda M, et al. Postoperative atrial
ﬁbrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol
2004;43:742–748.
665. Cardinale D, Sandri MT, Colombo A, Salvatici M, Tedeschi I, Bacchiani G, et al.
Prevention of atrial ﬁbrillation in high-risk patients undergoing lung cancer surgery:
the PRESAGE Trial. Ann Surg 2016;264:244–251.
666. Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM, et al.
Interventions for preventing post-operative atrial ﬁbrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2013; 2013:CD003611.
667. Ozaydin M, Icli A, Yucel H, Akcay S, Peker O, Erdogan D, et al. Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial ﬁbrillation: a randomized, double-blind, placebo-controlled study. Eur Heart J 2013;34:597–604.
668. O’Neal JB, Billings F, Liu X, Shotwell MS, Liang Y, Shah AS, et al. Effect of preoperative beta-blocker use on outcomes following cardiac surgery. Am J Cardiol 2017;
120:1293–1297.
669. Buckley MS, Nolan PE, Jr., Slack MK, Tisdale JE, Hilleman DE, Copeland JG.
Amiodarone prophylaxis for atrial ﬁbrillation after cardiac surgery: meta-analysis of dose response and timing of initiation. Pharmacotherapy 2007;27:360–368.
670. Riber LP, Christensen TD, Jensen HK, Hoejsgaard A, Pilegaard HK. Amiodarone signiﬁcantly decreases atrial ﬁbrillation in patients undergoing surgery for lung cancer. Ann Thorac Surg 2012;94:339–344; discussion 345–336.
671. Tisdale JE, Wroblewski HA, Wall DS, Rieger KM, Hammoud ZT, Young JV, et al. A
randomized trial evaluating amiodarone for prevention of atrial ﬁbrillation after pulmonary resection. Ann Thorac Surg 2009;88:886–893; discussion 894–885.
672. Yuan X, Du J, Liu Q, Zhang L. Deﬁning the role of perioperative statin treatment in patients after cardiac surgery: a meta-analysis and systematic review of 20 randomized controlled trials. Int J Cardiol 2017;228:958–966.
673. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, et al. Perioperative rosuvastatin in cardiac surgery. N Engl J Med 2016;374:1744–1753.
674. Fairley JL, Zhang L, Glassford NJ, Bellomo R. Magnesium status and magnesium therapy in cardiac surgery: a systematic review and meta-analysis focusing on arrhythmia prevention. J Crit Care 2017;42:69–77.
675. Tabbalat RA, Hamad NM, Alhaddad IA, Hammoudeh A, Akasheh BF, Khader Y.
Effect of ColchiciNe on the InciDence of atrial ﬁbrillation in open heart surgery patients: END-AF trial. Am Heart J 2016;178:102–107.
676. Wang W, Mei YQ, Yuan XH, Feng XD. Clinical efﬁcacy of epicardial application of drug-releasing hydrogels to prevent postoperative atrial ﬁbrillation. J Thorac
Cardiovasc Surg 2016;151:80–85.
677. Dieleman JM, Nierich AP, Rosseel PM, van der Maaten JM, Hoﬂand J, Diephuis JC,
et al. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA 2012;308:1761–1767.
678. Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J, et al.
Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet 2015;386:1243–1253.
679. Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, et al. Vernakalant hydrochloride for the rapid conversion of atrial ﬁbrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol
2009;2:652–659.
680. Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME, et al. Rate control versus rhythm control for atrial ﬁbrillation after cardiac surgery. N Engl J
Med 2016;374:1911–1921.
681. Saxena A, Dinh DT, Smith JA, Shardey GC, Reid CM, Newcomb AE. Usefulness of postoperative atrial ﬁbrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients). Am J Cardiol 2012;109:219–225.
682. Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, et al.
Perioperative atrial ﬁbrillation and the long-term risk of ischemic stroke. JAMA
2014;312:616–622.
683. Horwich P, Buth KJ, Legare JF. New onset postoperative atrial ﬁbrillation is associated with a long-term risk for stroke and death following cardiac surgery.
J Card Surg 2013;28:8–13.
684. Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial ﬁbrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial ﬁbrillation and a doubled cardiovascular mortality. Eur J Cardiothorac Surg
2010;37:1353–1359.
685. Butt JH, Xian Y, Peterson ED, Olsen PS, Rorth R, Gundlund A, et al. Long-term thromboembolic risk in patients with postoperative atrial ﬁbrillation after coronary artery bypass graft surgery and patients with nonvalvular atrial ﬁbrillation. JAMA
Cardiol 2018;3:417–424.
686. Butt JH, Olesen JB, Havers-Borgersen E, Gundlund A, Andersson C, Gislason GH,
et al. Risk of thromboembolism associated with atrial ﬁbrillation following noncardiac surgery. J Am Coll Cardiol 2018;72:2027–2036.
687. Selim M. Perioperative stroke. N Engl J Med 2007;356:706–713.
688. Macellari F, Paciaroni M, Agnelli G, Caso V. Perioperative stroke risk in nonvascular surgery. Cerebrovasc Dis 2012;34:175–181.
689. Mashour GA, Shanks AM, Kheterpal S. Perioperative stroke and associated mortality after noncardiac, nonneurologic surgery. Anesthesiology 2011;114:1289–1296.
690. Ng JL, Chan MT, Gelb AW. Perioperative stroke in noncardiac, nonneurosurgical surgery. Anesthesiology 2011;115:879–890.
ESC Guidelines
3923


<!-- PAGE 99 -->

### Page 99

691. Walicka M, Tuszynska A, Chlebus M, Sanchak Y, Sliwczynski A, Brzozowska M, et al.
Predictors of in-hospital mortality in surgical wards: a multivariable retrospective cohort analysis of 2,800,069 hospitalizations. World J Surg 2021;45:480–487.
692. Mattingly AS, Lerman BJ, Popat R, Wren SM. Association of sex with postoperative mortality among patients with heart failure who underwent elective noncardiac operations. JAMA Netw Open 2019;2:e1914420.
693. World Health Organization. Prevalence of anaemia in women of reproductive age
(aged 15–49) (%). In: Global Health Observatory. Geneva: World Health Organiziation;
2022. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalenceof-anaemia-in-women-of-reproductive-age-(-)
694. Gombotz H, Schreier G, Neubauer S, Kastner P, Hofmann A. Gender disparities in red blood cell transfusion in elective surgery: a post hoc multicentre cohort study.
BMJ Open 2016;6:e012210.
695. Riesenhuber M, Spannbauer A, Rauscha F, Schmidinger H, Boszotta A, Pezawas T,
et al. Sex differences and long-term outcome in patients with pacemakers. Front
Cardiovasc Med 2020;7:569060.
696. Varma N, Mittal S, Prillinger JB, Snell J, Dalal N, Piccini JP. Survival in women versus men following implantation of pacemakers, deﬁbrillators, and cardiac resynchronization therapy devices in a large, nationwide cohort. J Am Heart Assoc 2017;6:e005031.
697. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial ﬁbrillation: the AnTicoagulation and Risk factors In Atrial ﬁbrillation (ATRIA) study.
Circulation 2005;112:1687–1691.
698. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, et al. European Society of Cardiology methodology for the development of quality indicators for the quantiﬁcation of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes
2022;8:4–13.
699. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the United
Kingdom after removal of ﬁnancial incentives. N Engl J Med 2018;379:948–957.
700. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality
8 years into global payment. N Engl J Med 2019;381:252–263.
701. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, et al. Quality indicators for the care and outcomes of adults with atrial ﬁbrillation. Europace 2021;23:
494–495.
702. Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet JP, et al. 2020 Update of the quality indicators for acute myocardial infarction: a position paper of the
Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group. Eur Heart J Acute Cardiovasc
Care 2021;10:224–233.
703. Aktaa S, Abdin A, Arbelo E, Burri H, Vernooy K, Blomstrom-Lundqvist C, et al.
European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality
Indicators in collaboration with the European Heart Rhythm Association of the
European Society of Cardiology. Europace 2022;24:165–172.
704. Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task
Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology
(ESC). Eur Heart J 2021;42:2298.
705. Batra G, Aktaa S, Wallentin L, Maggioni AP, Wilkinson C, Casadei B, et al.
Methodology for the development of international clinical data standards for common cardiovascular conditions: European Uniﬁed Registries for Heart Care
Evaluation and Randomised Trials (EuroHeart). Eur Heart J Qual Care Clin
Outcomes 2021:qcab052.

<!-- 2022_Pulmonary_Hypertension.md -->

# ESC Guidelines: Pulmonary Hypertension (2022)

**Source**: `2022_Pulmonary_Hypertension.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 114

---

## Table of Contents

- [2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension](#2022-esc/ers-guidelines-for-the-diagnosis-and-trea) *(p. 1)*
  - [Abbreviations and acronyms](#abbreviations-and-acronyms) *(p. 5)*
  - [1. Preamble](#1-preamble) *(p. 7)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. What is new](#21-what-is-new) *(p. 8)*
    - [2.2. Methods](#22-methods) *(p. 18)*
  - [3. Definitions and classifications](#3-definitions-and-classifications) *(p. 19)*
    - [3.1. Definitions](#31-definitions) *(p. 19)*
    - [3.2. Classifications](#32-classifications) *(p. 20)*
  - [4. Epidemiology and risk factors](#4-epidemiology-and-risk-factors) *(p. 21)*
    - [4.1. Group 1, pulmonary arterial hypertension](#41-group-1,-pulmonary-arterial-hypertension) *(p. 21)*
    - [4.2. Group 2, pulmonary hypertension associated with left heart disease](#42-group-2,-pulmonary-hypertension-associated-with) *(p. 23)*
    - [4.3. Group 3, pulmonary hypertension associated with lung diseases and/or hypoxia](#43-group-3,-pulmonary-hypertension-associated-with) *(p. 23)*
    - [4.4. Group 4, pulmonary hypertension associated with chronic pulmonary artery obstruction](#44-group-4,-pulmonary-hypertension-associated-with) *(p. 23)*
    - [4.5. Group 5, pulmonary hypertension with unclear and/or multifactorial mechanisms](#45-group-5,-pulmonary-hypertension-with-unclear-an) *(p. 23)*
  - [5. Pulmonary hypertension diagnosis](#5-pulmonary-hypertension-diagnosis) *(p. 23)*
    - [5.1. Diagnosis](#51-diagnosis) *(p. 23)*
      - [5.1.1. Clinical presentation](#511-clinical-presentation) *(p. 23)*
      - [5.1.2. Electrocardiogram](#512-electrocardiogram) *(p. 23)*
      - [5.1.3. Chest radiography](#513-chest-radiography) *(p. 24)*
      - [5.1.4. Pulmonary function tests and arterial blood gases](#514-pulmonary-function-tests-and-arterial-blood-ga) *(p. 24)*
      - [5.1.5. Echocardiography](#515-echocardiography) *(p. 25)*
      - [5.1.6. Ventilation/perfusion lung scan](#516-ventilation/perfusion-lung-scan) *(p. 26)*
      - [5.1.7. Non-contrast and contrast-enhanced chest computed tomography examinations, and digital subtraction angiography](#517-non-contrast-and-contrast-enhanced-chest-compu) *(p. 27)*
      - [5.1.8. Cardiac magnetic resonance imaging](#518-cardiac-magnetic-resonance-imaging) *(p. 28)*
      - [5.1.9. Blood tests and immunology](#519-blood-tests-and-immunology) *(p. 29)*
      - [5.1.10. Abdominal ultrasound](#5110-abdominal-ultrasound) *(p. 29)*
      - [5.1.11. Cardiopulmonary exercise testing](#5111-cardiopulmonary-exercise-testing) *(p. 29)*
      - [5.1.12. Right heart catheterization, vasoreactivity, exercise, and fluid challenge](#5112-right-heart-catheterization,-vasoreactivity,-) *(p. 29)*
        - [5.1.12.1. Right heart catheterization](#51121-right-heart-catheterization) *(p. 29)*
        - [5.1.12.2. Vasoreactivity testing](#51122-vasoreactivity-testing) *(p. 30)*
        - [5.1.12.3. Exercise right heart catheterization](#51123-exercise-right-heart-catheterization) *(p. 30)*
        - [5.1.12.4. Fluid challenge](#51124-fluid-challenge) *(p. 30)*
      - [5.1.13. Genetic counselling and testing](#5113-genetic-counselling-and-testing) *(p. 31)*
    - [5.2. Diagnostic algorithm](#52-diagnostic-algorithm) *(p. 31)*
      - [5.2.1 Step 1 (suspicion)](#521-step-1-(suspicion)) *(p. 31)*
      - [5.2.2. Step 2 (detection)](#522-step-2-(detection)) *(p. 31)*
      - [5.2.3. Step 3 (confirmation)](#523-step-3-(confirmation)) *(p. 33)*
    - [5.3. Screening and early detection](#53-screening-and-early-detection) *(p. 35)*
      - [5.3.1. Systemic sclerosis](#531-systemic-sclerosis) *(p. 36)*
      - [5.3.2. BMPR2 mutation carriers](#532-bmpr2-mutation-carriers) *(p. 36)*
      - [5.3.3. Portal hypertension](#533-portal-hypertension) *(p. 36)*
      - [5.3.4. Pulmonary embolism](#534-pulmonary-embolism) *(p. 36)*
  - [6. Pulmonary arterial hypertension (group 1)](#6-pulmonary-arterial-hypertension-(group-1)) *(p. 38)*
    - [6.1. Clinical characteristics](#61-clinical-characteristics) *(p. 38)*
    - [6.2. Severity and risk assessment](#62-severity-and-risk-assessment) *(p. 38)*
      - [6.2.1. Clinical parameters](#621-clinical-parameters) *(p. 38)*
      - [6.2.2. Imaging](#622-imaging) *(p. 39)*
        - [6.2.2.1. Echocardiography](#6221-echocardiography) *(p. 39)*
        - [6.2.2.2. Cardiac magnetic resonance imaging](#6222-cardiac-magnetic-resonance-imaging) *(p. 39)*
      - [6.2.3. Haemodynamics](#623-haemodynamics) *(p. 39)*
      - [6.2.4. Exercise capacity](#624-exercise-capacity) *(p. 40)*
      - [6.2.5. Biochemical markers](#625-biochemical-markers) *(p. 41)*
      - [6.2.6. Patient-reported outcome measures](#626-patient-reported-outcome-measures) *(p. 41)*
      - [6.2.7. Comprehensive prognostic evaluation, risk assessment, and treatment goals](#627-comprehensive-prognostic-evaluation,-risk-asse) *(p. 42)*
    - [6.3. Therapy](#63-therapy) *(p. 43)*
      - [6.3.1. General measures](#631-general-measures) *(p. 43)*
        - [6.3.1.1. Physical activity and supervised rehabilitation](#6311-physical-activity-and-supervised-rehabilitati) *(p. 43)*
        - [6.3.1.2. Anticoagulation](#6312-anticoagulation) *(p. 43)*
        - [6.3.1.3. Diuretics](#6313-diuretics) *(p. 44)*
        - [6.3.1.4. Oxygen](#6314-oxygen) *(p. 44)*
        - [6.3.1.5. Cardiovascular drugs](#6315-cardiovascular-drugs) *(p. 44)*
        - [6.3.1.6. Anaemia and iron status](#6316-anaemia-and-iron-status) *(p. 44)*
        - [6.3.1.7. Vaccination](#6317-vaccination) *(p. 44)*
        - [6.3.1.8. Psychosocial support](#6318-psychosocial-support) *(p. 44)*
        - [6.3.1.9. Adherence to treatments](#6319-adherence-to-treatments) *(p. 44)*
      - [6.3.2. Special circumstances](#632-special-circumstances) *(p. 45)*
        - [6.3.2.1. Pregnancy and birth control](#6321-pregnancy-and-birth-control) *(p. 45)*
          - [6.3.2.1.1. Pregnancy](#63211-pregnancy) *(p. 45)*
          - [6.3.2.1.2. Contraception](#63212-contraception) *(p. 45)*
        - [6.3.2.2. Surgical procedures](#6322-surgical-procedures) *(p. 45)*
        - [6.3.2.3. Travel and altitude](#6323-travel-and-altitude) *(p. 45)*
      - [6.3.3. Pulmonary arterial hypertension therapies](#633-pulmonary-arterial-hypertension-therapies) *(p. 46)*
        - [6.3.3.1. Calcium channel blockers](#6331-calcium-channel-blockers) *(p. 46)*
        - [6.3.3.2. Endothelin receptor antagonists](#6332-endothelin-receptor-antagonists) *(p. 47)*
          - [6.3.3.2.1. Ambrisentan](#63321-ambrisentan) *(p. 48)*
          - [6.3.3.2.2. Bosentan](#63322-bosentan) *(p. 48)*
          - [6.3.3.2.3. Macitentan](#63323-macitentan) *(p. 49)*
        - [6.3.3.3. Phosphodiesterase 5 inhibitors and guanylate cyclase stimulators](#6333-phosphodiesterase-5-inhibitors-and-guanylate-) *(p. 49)*
          - [6.3.3.3.1. Sildenafil](#63331-sildenafil) *(p. 50)*
          - [6.3.3.3.2. Tadalafil](#63332-tadalafil) *(p. 50)*
          - [6.3.3.3.3. Riociguat](#63333-riociguat) *(p. 50)*
        - [6.3.3.4. Prostacyclin analogues and prostacyclin receptor agonists](#6334-prostacyclin-analogues-and-prostacyclin-recep) *(p. 50)*
          - [6.3.3.4.1. Epoprostenol](#63341-epoprostenol) *(p. 50)*
          - [6.3.3.4.2. Iloprost](#63342-iloprost) *(p. 50)*
          - [6.3.3.4.3. Treprostinil](#63343-treprostinil) *(p. 50)*
          - [6.3.3.4.4. Beraprost](#63344-beraprost) *(p. 50)*
          - [6.3.3.4.5. Selexipag](#63345-selexipag) *(p. 50)*
      - [6.3.4. Treatment strategies for patients with idiopathic, heritable, drug-associated, or connective tissue disease-associated pulmonary arterial hypertension](#634-treatment-strategies-for-patients-with-idiopat) *(p. 50)*
        - [6.3.4.1. Initial treatment decision in patients without cardiopulmonary comorbidities](#6341-initial-treatment-decision-in-patients-withou) *(p. 51)*
        - [6.3.4.2. Treatment decisions during follow-up in patients without cardiopulmonary comorbidities](#6342-treatment-decisions-during-follow-up-in-patie) *(p. 52)*
        - [6.3.4.3. Pulmonary arterial hypertension with cardiopulmonary comorbidities](#6343-pulmonary-arterial-hypertension-with-cardiopu) *(p. 53)*
      - [6.3.5. Drug interactions](#635-drug-interactions) *(p. 54)*
      - [6.3.6. Interventional therapy](#636-interventional-therapy) *(p. 54)*
        - [6.3.6.1. Balloon atrial septostomy and Potts shunt](#6361-balloon-atrial-septostomy-and-potts-shunt) *(p. 54)*
        - [6.3.6.2. Pulmonary artery denervation](#6362-pulmonary-artery-denervation) *(p. 54)*
      - [6.3.7. Advanced right ventricular failure](#637-advanced-right-ventricular-failure) *(p. 55)*
        - [6.3.7.1. Intensive care unit management](#6371-intensive-care-unit-management) *(p. 55)*
        - [6.3.7.2. Mechanical circulatory support](#6372-mechanical-circulatory-support) *(p. 55)*
      - [6.3.8. Lung and heart–lung transplantation](#638-lung-and-heart–lung-transplantation) *(p. 55)*
      - [6.3.9. Evidence-based treatment algorithm](#639-evidence-based-treatment-algorithm) *(p. 56)*
      - [6.3.10. Diagnosis and treatment of pulmonary arterial hypertension complications](#6310-diagnosis-and-treatment-of-pulmonary-arterial) *(p. 56)*
        - [6.3.10.1. Arrhythmias](#63101-arrhythmias) *(p. 56)*
        - [6.3.10.2. Haemoptysis](#63102-haemoptysis) *(p. 56)*
        - [6.3.10.3. Mechanical complications](#63103-mechanical-complications) *(p. 56)*
      - [6.3.11. End-of-life care and ethical issues](#6311-end-of-life-care-and-ethical-issues) *(p. 57)*
      - [6.3.12. New drugs in advanced clinical development (phase 3 studies)](#6312-new-drugs-in-advanced-clinical-development-(p) *(p. 57)*
  - [7. Specific pulmonary arterial hypertension subsets](#7-specific-pulmonary-arterial-hypertension-subsets) *(p. 57)*
    - [7.1. Pulmonary arterial hypertension associated with drugs and toxins](#71-pulmonary-arterial-hypertension-associated-with) *(p. 57)*
    - [7.2. Pulmonary arterial hypertension associated with connective tissue disease](#72-pulmonary-arterial-hypertension-associated-with) *(p. 58)*
      - [7.2.1. Epidemiology and diagnosis](#721-epidemiology-and-diagnosis) *(p. 58)*
      - [7.2.2. Therapy](#722-therapy) *(p. 58)*
    - [7.3. Pulmonary arterial hypertension associated with human immunodeficiency virus infection](#73-pulmonary-arterial-hypertension-associated-with) *(p. 59)*
      - [7.3.1. Diagnosis](#731-diagnosis) *(p. 59)*
      - [7.3.2. Therapy](#732-therapy) *(p. 59)*
    - [7.4. Pulmonary arterial hypertension associated with portal hypertension](#74-pulmonary-arterial-hypertension-associated-with) *(p. 60)*
      - [7.4.1. Diagnosis](#741-diagnosis) *(p. 60)*
      - [7.4.2. Therapy](#742-therapy) *(p. 60)*
        - [7.4.2.1. Liver transplantation](#7421-liver-transplantation) *(p. 60)*
    - [7.5. Pulmonary arterial hypertension associated with adult congenital heart disease](#75-pulmonary-arterial-hypertension-associated-with) *(p. 61)*
      - [7.5.1. Diagnosis and risk assessment](#751-diagnosis-and-risk-assessment) *(p. 61)*
      - [7.5.2. Therapy](#752-therapy) *(p. 62)*
    - [7.6. Pulmonary arterial hypertension associated with schistosomiasis](#76-pulmonary-arterial-hypertension-associated-with) *(p. 63)*
    - [7.7. Pulmonary arterial hypertension with signs of venous/capillary involvement](#77-pulmonary-arterial-hypertension-with-signs-of-v) *(p. 63)*
      - [7.7.1. Diagnosis](#771-diagnosis) *(p. 64)*
      - [7.7.2. Therapy](#772-therapy) *(p. 64)*
    - [7.8. Paediatric pulmonary hypertension](#78-paediatric-pulmonary-hypertension) *(p. 64)*
      - [7.8.1. Epidemiology and classification](#781-epidemiology-and-classification) *(p. 64)*
      - [7.8.2. Diagnosis and risk assessment](#782-diagnosis-and-risk-assessment) *(p. 66)*
      - [7.8.3. Therapy](#783-therapy) *(p. 66)*
  - [8. Pulmonary hypertension associated with left heart disease (group 2)](#8-pulmonary-hypertension-associated-with-left-hear) *(p. 68)*
    - [8.1. Definition, prognosis, and pathophysiology](#81-definition,-prognosis,-and-pathophysiology) *(p. 68)*
    - [8.2. Diagnosis](#82-diagnosis) *(p. 70)*
      - [8.2.1. Diagnosis and control of the underlying left heart disease](#821-diagnosis-and-control-of-the-underlying-left-) *(p. 70)*
      - [8.2.2. Evaluation of pulmonary hypertension and patient phenotyping](#822-evaluation-of-pulmonary-hypertension-and-patie) *(p. 70)*
      - [8.2.3. Invasive assessment of haemodynamics](#823-invasive-assessment-of-haemodynamics) *(p. 70)*
    - [8.3. Therapy](#83-therapy) *(p. 71)*
      - [8.3.1. Pulmonary hypertension associated with left-sided heart failure](#831-pulmonary-hypertension-associated-with-left-si) *(p. 71)*
        - [8.3.1.1. Heart failure with reduced ejection fraction](#8311-heart-failure-with-reduced-ejection-fraction) *(p. 71)*
        - [8.3.1.2. Heart failure with preserved ejection fraction](#8312-heart-failure-with-preserved-ejection-fractio) *(p. 71)*
        - [8.3.1.3. Interatrial shunt devices](#8313-interatrial-shunt-devices) *(p. 72)*
        - [8.3.1.4. Remote pulmonary arterial pressure monitoring in heart failure](#8314-remote-pulmonary-arterial-pressure-monitoring) *(p. 72)*
      - [8.3.2. Pulmonary hypertension associated with valvular heart disease](#832-pulmonary-hypertension-associated-with-valvula) *(p. 72)*
        - [8.3.2.1. Mitral valve disease](#8321-mitral-valve-disease) *(p. 72)*
        - [8.3.2.2. Aortic stenosis](#8322-aortic-stenosis) *(p. 72)*
        - [8.3.2.3. Tricuspid regurgitation](#8323-tricuspid-regurgitation) *(p. 72)*
      - [8.3.3. Recommendations on the use of drugs approved for PAH in PH-LHD](#833-recommendations-on-the-use-of-drugs-approved-f) *(p. 72)*
  - [9. Pulmonary hypertension associated with lung diseases and/or hypoxia (group 3)](#9-pulmonary-hypertension-associated-with-lung-dise) *(p. 73)*
    - [9.1. Diagnosis](#91-diagnosis) *(p. 75)*
    - [9.2. Therapy](#92-therapy) *(p. 75)*
      - [9.2.1. Pulmonary hypertension associated with chronic obstructive pulmonary disease or emphysema](#921-pulmonary-hypertension-associated-with-chronic) *(p. 75)*
      - [9.2.2. Pulmonary hypertension associated with interstitial lung disease](#922-pulmonary-hypertension-associated-with-interst) *(p. 75)*
      - [9.2.3. Recommendations on the use of drugs approved for PAH in PH associated with lung disease](#923-recommendations-on-the-use-of-drugs-approved-f) *(p. 76)*
  - [10. Chronic thrombo-embolic pulmonary hypertension (group 4)](#10-chronic-thrombo-embolic-pulmonary-hypertension-) *(p. 76)*
    - [10.1. Diagnosis](#101-diagnosis) *(p. 77)*
    - [10.2. Therapy](#102-therapy) *(p. 78)*
      - [10.2.1. Surgical treatment](#1021-surgical-treatment) *(p. 78)*
      - [10.2.2. Medical therapy](#1022-medical-therapy) *(p. 78)*
      - [10.2.3. Interventional treatment](#1023-interventional-treatment) *(p. 79)*
      - [10.2.4. Multimodal treatment](#1024-multimodal-treatment) *(p. 80)*
      - [10.2.5. Follow-up](#1025-follow-up) *(p. 81)*
    - [10.3. Chronic thrombo-embolic pulmonary hypertension team and experience criteria](#103-chronic-thrombo-embolic-pulmonary-hypertension) *(p. 81)*
  - [11. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5)](#11-pulmonary-hypertension-with-unclear-and/or-mult) *(p. 82)*
    - [11.1. Haematological disorders](#111-haematological-disorders) *(p. 82)*
    - [11.2. Systemic disorders](#112-systemic-disorders) *(p. 83)*
    - [11.3. Metabolic disorders](#113-metabolic-disorders) *(p. 83)*
    - [11.4. Chronic kidney failure](#114-chronic-kidney-failure) *(p. 83)*
    - [11.5. Pulmonary tumour thrombotic microangiopathy](#115-pulmonary-tumour-thrombotic-microangiopathy) *(p. 83)*
    - [11.6. Fibrosing mediastinitis](#116-fibrosing-mediastinitis) *(p. 83)*
  - [12. Definition of a pulmonary hypertension centre](#12-definition-of-a-pulmonary-hypertension-centre) *(p. 84)*
    - [12.1. Facilities and skills required for a pulmonary hypertension centre](#121-facilities-and-skills-required-for-a-pulmonary) *(p. 85)*
    - [12.2. European Reference Network](#122-european-reference-network) *(p. 85)*
    - [12.3. Patient associations and patient empowerment](#123-patient-associations-and-patient-empowerment) *(p. 85)*
  - [13. Key messages](#13-key-messages) *(p. 86)*
  - [14. Gaps in evidence](#14-gaps-in-evidence) *(p. 86)*
    - [14.1. Pulmonary arterial hypertension (group 1)](#141-pulmonary-arterial-hypertension-(group-1)) *(p. 86)*
    - [14.2. Pulmonary hypertension associated with left heart disease (group 2)](#142-pulmonary-hypertension-associated-with-left-he) *(p. 86)*
    - [14.3. Pulmonary hypertension associated with lung diseases and/or hypoxia (group 3)](#143-pulmonary-hypertension-associated-with-lung-di) *(p. 87)*
    - [14.4. Chronic thrombo-embolic pulmonary hypertension (group 4)](#144-chronic-thrombo-embolic-pulmonary-hypertension) *(p. 87)*
    - [14.5. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5)](#145-pulmonary-hypertension-with-unclear-and/or-mul) *(p. 87)*
  - [15. ‘What to do’ and ‘What not to do’ messages from the Guidelines](#15-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 87)*
  - [16. Quality indicators](#16-quality-indicators) *(p. 93)*
  - [17. Supplementary data](#17-supplementary-data) *(p. 94)*
  - [18. Data availability statement](#18-data-availability-statement) *(p. 94)*
  - [19. Author information](#19-author-information) *(p. 94)*
  - [20. Appendix](#20-appendix) *(p. 94)*
    - [ESC/ERS Scientific Document Group](#esc/ers-scientific-document-group) *(p. 94)*
  - [21. References](#21-references) *(p. 95)*
  - [21. References](#21-references) *(p. 95)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology
(ESC) and the European Respiratory Society (ERS).
Endorsed by the International Society for Heart and Lung
Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG).
Authors/Task Force Members: Marc Humbert
(France), Gabor Kovacs (Austria),
Marius M. Hoeper (Germany), Roberto Badagliacca (Italy), Rolf M.F. Berger
(Netherlands), Margarita Brida (Croatia), Jørn Carlsen (Denmark),
Andrew J.S. Coats (United Kingdom), Pilar Escribano-Subias (Spain),
Pisana Ferrari (Italy), Diogenes S. Ferreira (Brazil), Hossein Ardeschir Ghofrani
(Germany), George Giannakoulas (Greece), David G. Kiely (United Kingdom),
Eckhard Mayer (Germany), Gergely Meszaros (Hungary), Blin Nagavci (Germany),
Karen M. Olsson (Germany), Joanna Pepke-Zaba (United Kingdom),
Jennifer K. Quint (United Kingdom), Göran Rådegran (Sweden),
Gerald Simonneau (France), Olivier Sitbon (France), Thomy Tonia (Switzerland),
Mark Toshner (United Kingdom), Jean-Luc Vachiery (Belgium),
Anton Vonk Noordegraaf (Netherlands), Marion Delcroix
*† (ERS Chairperson)
(Belgium), Stephan Rosenkranz
*† (ESC Chairperson) (Germany), and ESC/ERS
Scientiﬁc Document Group
* Corresponding authors: Stephan Rosenkranz, Clinic III for Internal Medicine (Department of Cardiology, Pulmonology and Intensive Care Medicine), and Cologne Cardiovascular
Research Center (CCRC), Heart Center at the University Hospital Cologne, Kerpener Str. 62, 50937 Köln, Germany. Tel.: +49-221-478-32356. Email: stephan.rosenkranz@ukkoeln.de; and
Marion Delcroix, Clinical Department of Respiratory Diseases, Centre of Pulmonary Vascular Diseases, University Hospitals of Leuven, Herestraat 49, 3000 Leuven, Belgium. Tel.: +32 16
346813. Email: marion.delcroix@uzleuven.be
† The two chairpersons contributed equally to the document and are joint corresponding authors.
Author/Task Force Member afﬁliations are listed in author information.
1 Representing the Association for European Paediatric and Congenital Cardiology (AEPC)
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), and Heart Failure Association (HFA).
Councils: Council on Cardiovascular Genomics.
Working Groups: Adult Congenital Heart Disease, Pulmonary Circulation and Right Ventricular Function, Thrombosis.
Patient Forum
The content of these European Society of Cardiology (ESC)/European Respiratory Society (ERS) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC/ERS Guidelines may be translated or reproduced in any form without written permission from the ESC and the ERS. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.
permissions@oup.com).
https://doi.org/10.1093/eurheartj/ehac237
ESC/ERS GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Markus Schwerzmann (ESC Review Coordinator) (Switzerland), Anh-Tuan Dinh-Xuan
(ERS Review Coordinator) (France), Andy Bush (United Kingdom), Magdy Abdelhamid (Egypt), Victor Aboyans
(France), Eloisa Arbustini (Italy), Riccardo Asteggiano (Italy), Joan-Albert Barberà (Spain), Maurice Beghetti
(Switzerland), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), Robin Condliffe (United Kingdom),
Frances de Man (Netherlands), Volkmar Falk (Germany), Laurent Fauchier (France), Sean Gaine (Ireland),
Nazzareno Galié (Italy), Wendy Gin-Sing (United Kingdom), John Granton (Canada), Ekkehard Grünig
(Germany), Paul M. Hassoun (United States of America), Merel Hellemons (Netherlands), Tiny Jaarsma
(Sweden), Barbro Kjellström (Sweden), Frederikus A. Klok (Netherlands), Aleksandra Konradi (Russian
Federation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Irene Lang (Austria),
Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip (United Kingdom), Maja-Lisa Løchen
(Norway), Alexander G. Mathioudakis (United Kingdom), Richard Mindham (United Kingdom),
Shahin Moledina1 (United Kingdom), Robert Naeije (Belgium), Jens Cosedis Nielsen (Denmark),
Horst Olschewski (Austria), Isabelle Opitz (Switzerland), Steffen E. Petersen (United Kingdom),
Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Abilio Reis (Portugal), Arsen D. Ristić (Serbia),
Nicolas Roche (France), Rita Rodrigues (Portugal), Christine Selton-Suty (France), Rogerio Souza (Brazil),
Andrew J. Swift (United Kingdom), Rhian M. Touyz (Canada/United Kingdom), Silvia Ulrich (Switzerland),
Martin R. Wilkins (United Kingdom), and Stephen John Wort (United Kingdom)
All experts involved in the development of these guidelines have submitted declarations of interest. These have been compiled in a report and simultaneously published in a supplementary document to the guidelines. The report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary data that includes background information and detailed discussion of the data that have provided the basis of the guidelines.
Keywords
Guidelines • Pulmonary hypertension • Pulmonary arterial hypertension • Chronic thrombo-embolic pulmonary hypertension • Left heart disease • Congenital heart disease • Lung disease • Connective tissue disease • Endothelin receptor antagonists • Phosphodiesterase type 5 inhibitors • Soluble guanylate cyclase stimulators • Prostacyclin analogues • Prostacyclin receptor agonists • Pulmonary endarterectomy • Balloon pulmonary angioplasty • Lung transplantation
Table of contents
1. Preamble .............................................................................................................
3624
2. Introduction ......................................................................................................
3625
2.1. What is new ............................................................................................
3625
2.2. Methods ....................................................................................................
3635
3. Deﬁnitions and classiﬁcations ....................................................................
3636
3.1. Deﬁnitions ................................................................................................
3636
3.2. Classiﬁcations ..........................................................................................
3637
4. Epidemiology and risk factors ....................................................................
3638
4.1. Group 1, pulmonary arterial hypertension ................................
3638
4.2. Group 2, pulmonary hypertension associated with left heart disease .................................................................................................................
3640
4.3. Group 3, pulmonary hypertension associated with lung diseases and/or hypoxia ..............................................................................
3640
4.4. Group 4, pulmonary hypertension associated with chronic pulmonary artery obstruction ..................................................................
3640
4.5. Group 5, pulmonary hypertension with unclear and/or multifactorial mechanisms ..........................................................................
3640
5. Pulmonary hypertension diagnosis ..........................................................
3640
5.1. Diagnosis ...................................................................................................
3640
5.1.1. Clinical presentation ..................................................................... 3640
5.1.2. Electrocardiogram ......................................................................... 3640
5.1.3. Chest radiography ......................................................................... 3641
5.1.4. Pulmonary function tests and arterial blood gases ......... 3641
5.1.5. Echocardiography .......................................................................... 3642
Disclaimer: The ESC/ERS Guidelines represent the views of the ESC and the ERS and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC and the ERS are not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC/ERS Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, particularly in relation to good use of health care or therapeutic strategies. Health professionals are encouraged to take the ESC/ERS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC/ERS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. The ESC/ERS Guidelines do not exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
This article has been co-published with permission in the European Heart Journal and European Respiratory Journal. © the European Society of Cardiology and the European Respiratory
Society 2022. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article. For permissions please e-mail: journals.permissions@oup.com.
ESC/ERS Guidelines
3619


<!-- PAGE 3 -->

### Page 3

5.1.6. Ventilation/perfusion lung scan ................................................ 3643
5.1.7. Non-contrast and contrast-enhanced chest computed tomography examinations, and digital subtraction angiography ................................................................................................... 3644
5.1.8. Cardiac magnetic resonance imaging .................................... 3645
5.1.9. Blood tests and immunology .................................................... 3646
5.1.10. Abdominal ultrasound ............................................................... 3646
5.1.11. Cardiopulmonary exercise testing ....................................... 3646
5.1.12. Right heart catheterization, vasoreactivity, exercise, and
ﬂuid challenge .............................................................................................. 3646
5.1.12.1. Right heart catheterization ............................................. 3646
5.1.12.2. Vasoreactivity testing ........................................................ 3647
5.1.12.3. Exercise right heart catheterization ........................... 3647
5.1.12.4. Fluid challenge ...................................................................... 3647
5.1.13. Genetic counselling and testing ............................................ 3648
5.2. Diagnostic algorithm ............................................................................
3648
5.2.1 Step 1 (suspicion) ........................................................................... 3648
5.2.2. Step 2 (detection) ......................................................................... 3648
5.2.3. Step 3 (conﬁrmation) ................................................................... 3650
5.3. Screening and early detection ..........................................................
3652
5.3.1. Systemic sclerosis .......................................................................... 3653
5.3.2. BMPR2 mutation carriers ........................................................... 3653
5.3.3. Portal hypertension ...................................................................... 3653
5.3.4. Pulmonary embolism ................................................................... 3653
6. Pulmonary arterial hypertension (group 1) .........................................
3655
6.1. Clinical characteristics .........................................................................
3655
6.2. Severity and risk assessment ............................................................
3655
6.2.1. Clinical parameters ....................................................................... 3655
6.2.2. Imaging ................................................................................................ 3656
6.2.2.1. Echocardiography .................................................................. 3656
6.2.2.2. Cardiac magnetic resonance imaging ........................... 3656
6.2.3. Haemodynamics ............................................................................. 3656
6.2.4. Exercise capacity ............................................................................ 3657
6.2.5. Biochemical markers .................................................................... 3658
6.2.6. Patient-reported outcome measures ................................... 3658
6.2.7. Comprehensive prognostic evaluation, risk assessment,
and treatment goals .................................................................................. 3659
6.3. Therapy .....................................................................................................
3660
6.3.1. General measures .......................................................................... 3660
6.3.1.1. Physical activity and supervised rehabilitation .......... 3660
6.3.1.2. Anticoagulation ...................................................................... 3660
6.3.1.3. Diuretics .................................................................................... 3661
6.3.1.4. Oxygen ...................................................................................... 3661
6.3.1.5. Cardiovascular drugs ........................................................... 3661
6.3.1.6. Anaemia and iron status .................................................... 3661
6.3.1.7. Vaccination ............................................................................... 3661
6.3.1.8. Psychosocial support ........................................................... 3661
6.3.1.9. Adherence to treatments .................................................. 3661
6.3.2. Special circumstances ................................................................... 3662
6.3.2.1. Pregnancy and birth control ............................................. 3662
6.3.2.1.1. Pregnancy ......................................................................... 3662
6.3.2.1.2. Contraception ................................................................ 3662
6.3.2.2. Surgical procedures .............................................................. 3662
6.3.2.3. Travel and altitude ................................................................ 3662
6.3.3. Pulmonary arterial hypertension therapies ........................ 3663
6.3.3.1. Calcium channel blockers .................................................. 3663
6.3.3.2. Endothelin receptor antagonists .................................... 3664
6.3.3.2.1. Ambrisentan ................................................................... 3665
6.3.3.2.2. Bosentan ........................................................................... 3665
6.3.3.2.3. Macitentan ....................................................................... 3666
6.3.3.3. Phosphodiesterase 5 inhibitors and guanylate cyclase stimulators ............................................................................................... 3666
6.3.3.3.1. Sildenaﬁl ............................................................................ 3667
6.3.3.3.2. Tadalaﬁl ............................................................................. 3667
6.3.3.3.3. Riociguat ........................................................................... 3667
6.3.3.4. Prostacyclin analogues and prostacyclin receptor agonists ...................................................................................................... 3667
6.3.3.4.1. Epoprostenol .................................................................. 3667
6.3.3.4.2. Iloprost .............................................................................. 3667
6.3.3.4.3. Treprostinil ...................................................................... 3667
6.3.3.4.4. Beraprost ......................................................................... 3667
6.3.3.4.5. Selexipag ........................................................................... 3667
6.3.4. Treatment strategies for patients with idiopathic,
heritable, drug-associated, or connective tissue diseaseassociated pulmonary arterial hypertension .................................. 3667
6.3.4.1. Initial treatment decision in patients without cardiopulmonary comorbidities ...................................................... 3668
6.3.4.2. Treatment decisions during follow-up in patients without cardiopulmonary comorbidities .................................... 3669
6.3.4.3. Pulmonary arterial hypertension with cardiopulmonary comorbidities ...................................................... 3670
6.3.5. Drug interactions ........................................................................... 3671
6.3.6. Interventional therapy ................................................................. 3671
6.3.6.1. Balloon atrial septostomy and Potts shunt ................ 3671
6.3.6.2. Pulmonary artery denervation ........................................ 3671
6.3.7. Advanced right ventricular failure .......................................... 3672
6.3.7.1. Intensive care unit management ..................................... 3672
6.3.7.2. Mechanical circulatory support ....................................... 3672
6.3.8. Lung and heart–lung transplantation ..................................... 3672
6.3.9. Evidence-based treatment algorithm .................................... 3673
6.3.10. Diagnosis and treatment of pulmonary arterial hypertension complications ................................................................... 3673
6.3.10.1. Arrhythmias .......................................................................... 3673
6.3.10.2. Haemoptysis ......................................................................... 3673
6.3.10.3. Mechanical complications ................................................ 3673
6.3.11. End-of-life care and ethical issues ........................................ 3674
6.3.12. New drugs in advanced clinical development (phase 3
studies) ........................................................................................................... 3674
7. Speciﬁc pulmonary arterial hypertension subsets ............................
3674
7.1. Pulmonary arterial hypertension associated with drugs and toxins ...................................................................................................................
3674
7.2. Pulmonary arterial hypertension associated with connective tissue disease ....................................................................................................
3675
7.2.1. Epidemiology and diagnosis ....................................................... 3675
7.2.2. Therapy .............................................................................................. 3675
7.3. Pulmonary arterial hypertension associated with human immunodeﬁciency virus infection ............................................................
3676
7.3.1. Diagnosis ........................................................................................... 3676
7.3.2. Therapy .............................................................................................. 3676
7.4. Pulmonary arterial hypertension associated with portal hypertension ....................................................................................................
3677
7.4.1. Diagnosis ........................................................................................... 3677
7.4.2. Therapy .............................................................................................. 3677
7.4.2.1. Liver transplantation ............................................................ 3677
7.5. Pulmonary arterial hypertension associated with adult congenital heart disease ..............................................................................
3678
7.5.1. Diagnosis and risk assessment ................................................. 3678
7.5.2. Therapy .............................................................................................. 3679
7.6. Pulmonary arterial hypertension associated with schistosomiasis ................................................................................................
3680
3620
ESC/ERS Guidelines


<!-- PAGE 4 -->

### Page 4

7.7. Pulmonary arterial hypertension with signs of venous/
capillary involvement ....................................................................................
3680
7.7.1. Diagnosis ........................................................................................... 3681
7.7.2. Therapy .............................................................................................. 3681
7.8. Paediatric pulmonary hypertension ...............................................
3681
7.8.1. Epidemiology and classiﬁcation ................................................ 3681
7.8.2. Diagnosis and risk assessment ................................................. 3683
7.8.3. Therapy .............................................................................................. 3683
8. Pulmonary hypertension associated with left heart disease
(group 2) ..................................................................................................................
3685
8.1. Deﬁnition, prognosis, and pathophysiology ...............................
3685
8.2. Diagnosis ...................................................................................................
3687
8.2.1. Diagnosis and control of the underlying left heart disease ................................................................................................ 3687
8.2.2. Evaluation of pulmonary hypertension and patient phenotyping .................................................................................................. 3687
8.2.3. Invasive assessment of haemodynamics ............................... 3687
8.3. Therapy .....................................................................................................
3688
8.3.1. Pulmonary hypertension associated with left-sided heart failure ............................................................................................................... 3688
8.3.1.1. Heart failure with reduced ejection fraction ............. 3688
8.3.1.2. Heart failure with preserved ejection fraction ......... 3688
8.3.1.3. Interatrial shunt devices ..................................................... 3689
8.3.1.4. Remote pulmonary arterial pressure monitoring in heart failure ............................................................................................. 3689
8.3.2. Pulmonary hypertension associated with valvular heart disease ............................................................................................................. 3689
8.3.2.1. Mitral valve disease ............................................................... 3689
8.3.2.2. Aortic stenosis ....................................................................... 3689
8.3.2.3. Tricuspid regurgitation ........................................................ 3689
8.3.3. Recommendations on the use of drugs approved for
PAH in PH-LHD ......................................................................................... 3689
9. Pulmonary hypertension associated with lung diseases and/or hypoxia (group 3) ................................................................................................
3690
9.1. Diagnosis ...................................................................................................
3692
9.2. Therapy .....................................................................................................
3692
9.2.1. Pulmonary hypertension associated with chronic obstructive pulmonary disease or emphysema ............................ 3692
9.2.2. Pulmonary hypertension associated with interstitial lung disease ............................................................................................................. 3692
9.2.3. Recommendations on the use of drugs approved for
PAH in PH associated with lung disease .......................................... 3693
10. Chronic thrombo-embolic pulmonary hypertension (group 4)
3693
10.1. Diagnosis ................................................................................................
3694
10.2. Therapy ...................................................................................................
3695
10.2.1. Surgical treatment ....................................................................... 3695
10.2.2. Medical therapy ............................................................................ 3695
10.2.3. Interventional treatment .......................................................... 3696
10.2.4. Multimodal treatment ............................................................... 3697
10.2.5. Follow-up ........................................................................................ 3698
10.3. Chronic thrombo-embolic pulmonary hypertension team and experience criteria ................................................................................
3698
11. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5) .......................................................................................
3699
11.1. Haematological disorders ................................................................
3699
11.2. Systemic disorders .............................................................................
3700
11.3. Metabolic disorders ...........................................................................
3700
11.4. Chronic kidney failure ......................................................................
3700
11.5. Pulmonary tumour thrombotic microangiopathy ................
3700
11.6. Fibrosing mediastinitis .......................................................................
3700
12. Deﬁnition of a pulmonary hypertension centre .............................
3701
12.1. Facilities and skills required for a pulmonary hypertension centre ..................................................................................................................
3702
12.2. European Reference Network .....................................................
3702
12.3. Patient associations and patient empowerment ...................
3702
13. Key messages .................................................................................................
3703
14. Gaps in evidence ...........................................................................................
3703
14.1. Pulmonary arterial hypertension (group 1) .............................
3703
14.2. Pulmonary hypertension associated with left heart disease
(group 2) ............................................................................................................
3703
14.3. Pulmonary hypertension associated with lung diseases and/
or hypoxia (group 3) ....................................................................................
3704
14.4. Chronic thrombo-embolic pulmonary hypertension
(group 4) ............................................................................................................
3704
14.5. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5) .................................................................................
3704
15. ‘What to do’ and ‘What not to do’ messages from the Guidelines .......................................................................................................
3704
16. Quality indicators .........................................................................................
3710
17. Supplementary data .....................................................................................
3711
18. Data availability statement .......................................................................
3711
19. Author information .....................................................................................
3711
20. Appendix ..........................................................................................................
3711
21. References .......................................................................................................
3712
Tables of Recommendations
Recommendation Table 1 — Recommendations for right heart catheterization and vasoreactivity testing ............................................
3648
Recommendation Table 2 — Recommendations for diagnostic strategy ................................................................................................................
3652
Recommendation Table 3 — Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension .......................
3654
Recommendation Table 4 — Recommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension .....................................................................................
3660
Recommendation Table 5 — Recommendations for general measures and special circumstances .......................................................
3662
Recommendation Table 6 — Recommendations for women of childbearing potential ....................................................................................
3663
Recommendation Table 7 — Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension ............................
3664
Recommendation Table 8 — Recommendations for the treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present without cardiopulmonary comorbiditiesa ...................................................
3668
Recommendation Table 9 — Recommendations for initial oral drug combination therapy for patients with idiopathic, heritable,
or drug-associated pulmonary arterial hypertension without cardiopulmonary comorbidities ................................................................
3669
Recommendation Table 10 — Recommendations for sequential drug combination therapy for patients with idiopathic, heritable,
or drug-associated pulmonary arterial hypertension ......................
3670
Recommendation Table 11 — Recommendations for the treatment of non-vasoreactive patients with idiopathic, heritable,
or drug-associated pulmonary arterial hypertension who present with cardiopulmonary comorbiditiesa ....................................................
3671
ESC/ERS Guidelines
3621


<!-- PAGE 5 -->

### Page 5

Recommendation Table 12 — Recommendations for intensive care management for pulmonary arterial hypertension ..................... 3672
Recommendation Table 13 — Recommendations for lung transplantation .................................................................................................
3673
Recommendation Table 14 — Recommendations for pulmonary arterial hypertension associated with drugs or toxins ...................
3674
Recommendation Table 15 — Recommendations for pulmonary arterial hypertension associated with connective tissue disease
3675
Recommendation Table 16 — Recommendations for pulmonary arterial hypertension associated with human immunodeﬁciency virus infection ...................................................................................................
3676
Recommendation Table 17 — Recommendations for pulmonary arterial hypertension associated with portal hypertension ..........
3677
Recommendation Table 18 — Recommendations for shunt closure in patients with pulmonary–systemic ﬂow ratio .1.5:1
based on calculated pulmonary vascular resistance .........................
3680
Recommendation Table 19 — Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease
3680
Recommendation Table 20 — Recommendations for pulmonary arterial hypertension with signs of venous/capillary involvement
3681
Recommendation Table 21 — Recommendations for paediatric pulmonary hypertension ..............................................................................
3685
Recommendation Table 22 — Recommendations for pulmonary hypertension associated with left heart disease ................................
3690
Recommendation Table 23 — Recommendations for pulmonary hypertension associated with lung disease and/or hypoxia ..........
3693
Recommendation Table 24 — Recommendations for chronic thrombo-embolic pulmonary hypertension and chronic thromboembolic pulmonary disease without pulmonary hypertension ........
3698
Recommendation Table 25 — Recommendations for pulmonary hypertension centres .....................................................................................
3702
List of tables
Table 1 Strength of the recommendations according to GRADE
3635
Table 2 Quality of evidence grades and their deﬁnitions ..............
3635
Table 3 Classes of recommendations ....................................................
3636
Table 4 Levels of evidence ..........................................................................
3636
Table 5 Haemodynamic deﬁnitions of pulmonary hypertension
3637
Table 6 Clinical classiﬁcation of pulmonary hypertension ............
3638
Table 7 Drugs and toxins associated with pulmonary arterial hypertension .....................................................................................................
3640
Table 8 Electrocardiogram abnormalities in patients with pulmonary hypertension ..............................................................................
3643
Table 9 Radiographic signs of pulmonary hypertension and concomitant abnormalities .........................................................................
3643
Table 10 Additional echocardiographic signs suggestive of pulmonary hypertension ..............................................................................
3645
Table 11 Haemodynamic measures obtained during right heart catheterization ..................................................................................................
3646
Table 12 Route of administration, half-life, dosages, and duration of administration of the recommended test compounds for vasoreactivity testing in pulmonary arterial hypertension .............
3647
Table 13 Phenotypic features associated with pulmonary arterial hypertension mutations ...............................................................................
3649
Table 14 Characteristic diagnostic features of patients with different forms of pulmonary hypertension ........................................
3651
Table 15 World Health Organization classiﬁcation of functional status of patients with pulmonary hypertension ...............................
3656
Table 16 Comprehensive risk assessment in pulmonary arterial hypertension (three-strata model) ..........................................................
3657
Table 17 Suggested assessment and timing for the follow-up of patients with pulmonary arterial hypertension ..................................
3658
Table 18 Variables used to calculate the simpliﬁed four-strata risk-assessment tool .......................................................................................
3659
Table 19 Dosing of pulmonary arterial hypertension medication in adults ...............................................................................................................
3664
Table 20 Criteria for lung transplantation and listing in patients with pulmonary arterial hypertension ...................................................
3672
Table 21 Clinical classiﬁcation of pulmonary arterial hypertension associated with congenital heart disease ..............................................
3678
Table 22 Use of pulmonary arterial hypertension therapies in children ................................................................................................................
3684
Table 23 Patient phenotyping and likelihood for left heart disease as cause of pulmonary hypertension ......................................................
3688
Table 24 Pulmonary hypertension with unclear and/or multifactorial mechanisms ...........................................................................
3699
List of ﬁgures
Figure 1 Central illustration ........................................................................
3639
Figure 2 Symptoms in patients with pulmonary hypertension ...
3641
Figure 3 Clinical signs in patients with pulmonary hypertension
3642
Figure 4 Transthoracic echocardiographic parameters in the assessment of pulmonary hypertension ................................................
3644
Figure 5 Echocardiographic probability of pulmonary hypertension and recommendations for further assessment ......
3645
Figure 6 Diagnostic algorithm of patients with unexplained dyspnoea and/or suspected pulmonary hypertension ....................
3650
Figure 7 Pathophysiology and current therapeutic targets of pulmonary arterial hypertension (group 1) .........................................
3655
Figure 8 Vasoreactivity testing algorithm of patients with presumed diagnosis of idiopathic, heritable, or drug-associated pulmonary arterial hypertension ..............................................................
3665
Figure 9 Evidence-based pulmonary arterial hypertension treatment algorithm for patients with idiopathic, heritable,
drug-associated, and connective tissue disease-associated pulmonary arterial hypertension ..............................................................
3666
Figure 10 Neonatal and paediatric vs. adult pulmonary hypertension .....................................................................................................
3682
Figure 11 Pathophysiology of pulmonary hypertension associated with left heart disease (group 2) ..............................................................
3686
Figure 12 Pathophysiology of pulmonary hypertension associated with lung disease (group 3) ........................................................................
3691
Figure 13 Diagnostic strategy in chronic thrombo-embolic pulmonary hypertension ..............................................................................
3694
Figure 14 Management strategy in chronic thrombo-embolic pulmonary hypertension ..............................................................................
3696
Figure 15 Overlap in treatments/multimodality approaches in chronic thrombo-embolic pulmonary hypertension .......................
3697
Figure 16 Pulmonary hypertension centre schematic .....................
3701
Abbreviations and acronyms
6MWD
6-minute walking distance
6MWT
6-minute walking test
ABG
Arterial blood gas analysis
ACEi
Angiotensin-converting enzyme inhibitor
3622
ESC/ERS Guidelines


<!-- PAGE 6 -->

### Page 6

ALAT
Alanine aminotransferase
ARB
Angiotensin receptor blocker
ARNI
Angiotensin receptor–neprilysin inhibitor
ASAT
Aspartate aminotransferase
ASIG
Australian Scleroderma Interest Group
BNP
Brain natriuretic peptide
BPA
Balloon pulmonary angioplasty
BPD
Bronchopulmonary dysplasia
CAMPHOR
Cambridge Pulmonary Hypertension Outcome
Review
CCB
Calcium channel blocker
CDH
Congenital diaphragmatic hernia cGMP
Cyclic guanosine monophosphate
CHD
Congenital heart disease
CI
Cardiac index; Conﬁdence interval cMRI
Cardiac magnetic resonance imaging
CO
Cardiac output
COMPERA
Comparative, Prospective Registry of Newly
Initiated Therapies for PH
COPD
Chronic obstructive pulmonary disease
CpcPH
Combined post- and pre-capillary pulmonary hypertension
CPET
Cardiopulmonary exercise testing
CPFE
Combined pulmonary ﬁbrosis and emphysema
CT
Computed tomography
CTD
Connective tissue disease
CTEPD
Chronic thrombo-embolic pulmonary disease
CTEPH
Chronic thrombo-embolic pulmonary hypertension
CTPA
Computed tomography pulmonary angiography
DECT
Dual-energy computed tomography
DLCO
Lung diffusion capacity for carbon monoxide
DPAH
Drug- or toxin-associated pulmonary arterial hypertension dPAP
Diastolic pulmonary arterial pressure
DPG
Diastolic pressure gradient
DSA
Digital subtraction angiography
ECG
Electrocardiogram
ECMO
Extracorporeal membrane oxygenation
EHJ
EMA
European Medicines Agency
EOV
Exercise oscillatory ventilation
ERA
Endothelin receptor antagonist
ERJ
European Respiratory Journal
ERN
European Reference Network
ERN-LUNG
European Reference Network on rare respiratory diseases
ERS
European Respiratory Society
ESC
European Society of Cardiology
EtD
Evidence to Decision
FPHR
French Pulmonary Hypertension Registry
FVC
Forced vital capacity
GRADE
Grading of Recommendations, Assessment,
Development, and Evaluations
HAART
Highly active antiretroviral therapy
Hb
Haemoglobin
HF
Heart failure
HFpEF
Heart failure with preserved ejection fraction
HIV
Human immunodeﬁciency virus
HPAH
Heritable pulmonary arterial hypertension
HPS
Hepatopulmonary syndrome
HR
Hazard ratio
HR-QoL
Health-related quality of life
ICU
Intensive care unit
IgG4
Immunogolobulin G4
ILD
Interstitial lung disease
IPAH
Idiopathic pulmonary arterial hypertension
IpcPH
Isolated post-capillary pulmonary hypertension
IP receptor
Prostacyclin I2 receptor
ISWT
Incremental shuttle walking test i.v.
Intravenous
LA
Left atrium/left atrial
LAS
Lung allocation score
LHD
Left heart disease
LTx
Lung transplantation
LV
Left ventricle/left ventricular
LVAD
Left ventricular assist device mPAP
Mean pulmonary arterial pressure
MR
Magnetic resonance
MRI
Magnetic resonance imaging
NOAC
Novel oral anticoagulant
NT-proBNP
N-terminal pro-brain natriuretic peptide
OR
Odds ratio
PA
Pulmonary artery
PAC
Pulmonary arterial compliance
PaCO2
Partial pressure of arterial carbon dioxide
PADN
Pulmonary artery denervation
PAH
Pulmonary arterial hypertension
PAH-CTD
Pulmonary arterial hypertension associated with connective tissue disease
PAH-SSc
Pulmonary arterial hypertension associated with systemic sclerosis
PAH-SYMPACT
Pulmonary Arterial Hypertension-Symptoms and Impact
PaO2
Partial pressure of arterial oxygen
PAP
Pulmonary arterial pressure
PAVM
Pulmonary arteriovenous malformation
PAWP
Pulmonary arterial wedge pressure
PCH
Pulmonary capillary haemangiomatosis
PDE5i
Phosphodiesterase 5 inhibitor
PE
Pulmonary embolism
PEA
Pulmonary endarterectomy
PET
Positron emission tomography
PETCO2
End-tidal partial pressure of carbon dioxide
PFT
Pulmonary function test
PH
Pulmonary hypertension
PH-LHD
Pulmonary hypertension associated with left heart disease
PICO
Population, Intervention, Comparator, Outcome
PoPH
Porto-pulmonary hypertension
PPHN
Persistent pulmonary hypertension of the newborn
PROM
Patient-reported outcome measure
PVD
Pulmonary vascular disease
ESC/ERS Guidelines
3623


<!-- PAGE 7 -->

### Page 7

PVOD
Pulmonary veno-occlusive disease
PVR
Pulmonary vascular resistance
PVRI
Pulmonary vascular resistance index
QI
Quality indicator
Qp/Qs
Pulmonary blood ﬂow/systemic blood ﬂow
RA
Right atrium/right atrial
RAP
Right atrial pressure
RCT
Randomized controlled trial
REVEAL
Registry to Evaluate Early and Long-Term PAH
Disease Management
RHC
Right heart catheterization
RR
Relative risk
RV
Right ventricle/right ventricular
RVEF
Right ventricular ejection fraction
RV-FAC
Right ventricular fractional area change
RVOT AT
Right ventricular outﬂow tract acceleration time
SaO2
Arterial oxygen saturation s.c.
Subcutaneous
SCD
Sickle cell disease sGC
Soluble guanylate cyclase
SGLT-2i
Sodium–glucose cotransporter-2 inhibitor
SLE
Systemic lupus erythematosus
SPAHR
Swedish Pulmonary Arterial Hypertension Registry sPAP
Systolic pulmonary arterial pressure
SPECT
Single-photon emission computed tomography
SSc
Systemic sclerosis
SV
Stroke volume
SVI
Stroke volume index
SvO2
Mixed venous oxygen saturation
TAPSE
Tricuspid annular plane systolic excursion
TGF-β
Transforming growth factor-β
TPR
Total pulmonary resistance
TR
Tricuspid regurgitation
TRPG
Tricuspid regurgitation pressure gradient
TRV
Tricuspid regurgitation velocity
TSH
Thyroid-stimulating hormone
V/Q
Ventilation perfusion
VE/VCO2
Ventilatory equivalent for carbon dioxide
VKA
Vitamin K antagonist
VO2
Oxygen uptake
VO2/HR
Oxygen pulse
VTE
Venous thrombo-embolism
WHO-FC
World Health Organization functional class
WSPH
World Symposium on Pulmonary Hypertension
WU
Wood units
1. Preamble
Guidelines summarize and evaluate available evidence, with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision-making of health professionals in their daily practice. However, guidelines are not a substitute for the patient’s relationship with their practitioner. The ﬁnal decisions concerning an individual patient must be made by the responsible health professional(s), based on what they consider to be the most appropriate in the circumstances. These decisions are made in consultation with the patient and caregiver as appropriate.
Guidelines are intended for use by health professionals. To ensure that all physicians have access to the most recent recommendations, both the
European Society of Cardiology (ESC) and European Respiratory Society
(ERS) make their guidelines freely available in their own journals. The ESC
and ERS warn non-medical readers that the technical language may be misinterpreted and decline any responsibility in this respect.
Many Guidelines have been issued in recent years by the ESC and
ERS. Because of their impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The ERS and ESC guidance and procedure to formulate and issue clinical practice recommendations can be found on the societies’ relevant website or journal (https://www.escardio.org/Guidelines and https://openres.
ersjournals.com/content/8/1/00655-2021).
The
ESC
and
ERS
Guidelines represent the ofﬁcial position of the ESC and ERS on a given topic and are regularly updated.
The panel of experts of these speciﬁc guidelines comprised an equal number of ERS and ESC members, including representatives from relevant subspecialty groups involved in the medical care of patients with this pathology.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conﬂicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/
Guidelines). They have been compiled in a report and co-published in a supplementary document of the guidelines. This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arose during the writing period were notiﬁed to the ESC and updated. The Task
Force received its entire ﬁnancial support from the ESC and ERS without any involvement from the health care industry.
The ESC Clinical Practice Guidelines (CPG) Committee and the ERS
Guidelines Director reporting to the ERS Science Council supervise and co-ordinate the preparation of new guidelines. These Guidelines underwent extensive review by the ESC CPG Committee, the ERS
Guidelines Working Group, and external experts. The guidelines were developed after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of drafting. After appropriate revisions, the guidelines were signed off by all the experts in the Task Force. The ﬁnalized document was signed off by the ESC CPG
Committee and endorsed by the ERS Executive Committee before being simultaneously published in the European Heart Journal (EHJ)
and the European Respiratory Journal (ERJ). The decision to publish the guidelines in both journals was made to ensure adequate dissemination of the recommendations in both the cardiology and respiratory ﬁelds.
The task of developing the ESC/ERS Guidelines also included creating educational tools and implementation programmes for the recommendations, including condensed pocket guidelines versions, summary slides, a lay summary, and an electronic version for digital applications
(smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access the full-text version of the guidelines, which is freely available via the ESC and ERS websites,
and hosted on the EHJ and ERJ websites. The National Cardiac
Societies of the ESC are encouraged to endorse, adopt, translate,
3624
ESC/ERS Guidelines


<!-- PAGE 8 -->

### Page 8

and implement all ESC Guidelines. Pulmonary national societies are also encouraged to share these guidelines with their members and develop a summary or editorials in their own language, if appropriate.
Implementation programmes are needed because it has been shown that the outcome of disease may be favourably inﬂuenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC/ERS Guidelines fully into account when exercising their clinical judgement, as well as in determining and implementing preventive, diagnostic, or therapeutic medical strategies. However, the ESC/ERS Guidelines do not override,
in any way, the individual responsibility of health professionals to make appropriate and accurate decisions in considering each patient’s health condition and in consulting with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription and, where appropriate, to respect the ethical rules of their profession in each country.
Off-label use of medication may be presented in these guidelines if a sufﬁcient level of evidence shows that it can be considered medically appropriate to a given condition and if patients could beneﬁt from the recommended therapy. However, the ﬁnal decisions concerning an individual patient must be made by the responsible health professional, giving special consideration to:
• The speciﬁc situation of the patient. In this respect, it is speciﬁed that, unless otherwise provided for by national regulations, offlabel use of medication should be limited to situations where it is in the patient’s interest to do so, with regards to the quality,
safety, and efﬁcacy of care, and only after the patient has been fully informed and provided consent.
• Country-speciﬁc health regulations, indications by governmental drug regulatory agencies, and the ethical rules to which health professionals are subject, where applicable.
2. Introduction
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases. The complexity of managing PH requires a multifaceted, holistic, and multidisciplinary approach, with active involvement of patients with PH in partnership with clinicians. Streamlining the care of patients with PH in daily clinical practice is a challenging but essential requirement for effectively managing PH. In recent years, substantial progress has been made in detecting and managing PH, and new evidence has been timeously integrated in this fourth edition of the ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Reﬂecting the multidisciplinary input into managing patients with PH and interpreting new evidence,
the Task Force included cardiologists and pneumologists, a thoracic surgeon, methodologists, and patients. These comprehensive clinical practice guidelines cover the whole spectrum of PH, with an emphasis on diagnosing and treating pulmonary arterial hypertension (PAH) and chronic thrombo-embolic pulmonary hypertension (CTEPH).
2.1. What is new
One of the most important proposals from the 6th World
Symposium on Pulmonary Hypertension (WSPH) was to reconsider the haemodynamic deﬁnition of PH.1 After careful evaluation, the new deﬁnitions of PH have been endorsed and expanded in these guidelines, including a revised cut-off level for pulmonary vascular resistance (PVR) and a deﬁnition of exercise PH.
The classiﬁcation of PH has been updated, including repositioning of vasoreactive patients with idiopathic pulmonary arterial hypertension (IPAH) and a revision of group 5 PH, including repositioning of
PH in lymphangioleiomyomatosis in group 3.
Concerning the diagnosis of PH, a new algorithm has been developed aiming at earlier detection of PH in the community. In addition,
expedited referral is recommended for high-risk or complex patients. Screening strategies are also proposed.
The risk-stratiﬁcation table has been expanded to include additional echocardiographic and cardiac magnetic resonance imaging (cMRI)
prognostic indicators. The recommendations for initial drug therapies have been simpliﬁed, building on this revised, three-strata, multiparametric risk model to replace functional classiﬁcation. At follow-up, a four-strata risk-assessment tool is now proposed based on reﬁned cut-off levels for World Health Organization functional class
(WHO-FC), 6-minute walking distance (6MWD), and N-terminal pro-brain natriuretic peptide (NT-proBNP), categorizing patients as low, intermediate–low, intermediate–high, or high risk.
The PAH treatment algorithm has been modiﬁed, highlighting the importance of cardiopulmonary comorbidities, risk assessment both at diagnosis and follow-up, and the importance of combination therapies.
Treatment strategies during follow-up have been based on the fourstrata model intended to facilitate more granular decision-making.
The recommendations for managing PH associated with left heart disease (PH-LHD) and lung disease have been updated, including a new haemodynamic deﬁnition of severe PH in patients with lung disease.
In group 4 PH, the term chronic thrombo-embolic pulmonary disease (CTEPD) with or without PH has been introduced, acknowledging the presence of similar symptoms, perfusion defects, and organized ﬁbrotic obstructions in patients with or without PH at rest. Interventional treatment by balloon pulmonary angioplasty
(BPA) in combination with medical therapy has been upgraded in the therapeutic algorithm of CTEPH.
New standards for PH centres have been presented and, for the
ﬁrst time, patient representatives were actively involved in developing these guidelines.
Questions with direct consequences for clinical practitioners regarding each PH classiﬁcation subgroup were selected and addressed, namely guidance on: initial treatment strategy for group 1 PH (Population,
Intervention, Control, Outcome [PICO] I); use of oral phosphodiesterase 5 inhibitors (PDE5is) for the treatment of group 2 PH (PICO II); use of oral PDE5is for the treatment of group 3 PH (PICO III); and use of PH
drugs prior to BPA for the treatment of group 4 PH (PICO IV). These questions were considered to be important because: most contemporary PH registries describe variable use of initial oral monotherapy and combination therapy; large case series show widespread use of
PDE5is in group 2 PH, despite a class III recommendation in the 2015
ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension; large case series show widespread use of PDE5is in group
3 PH, despite a class III recommendation in the 2015 ESC/ERS
Guidelines for the diagnosis and treatment of pulmonary hypertension;
and there is no clear guidance for therapy with PH drugs in patients with inoperable CTEPH prior to BPA.
ESC/ERS Guidelines
3625


<!-- PAGE 9 -->

### Page 9

Selected revised recommendations (R) and new recommendations (N)
New or revised
Recommendation in 2015 version
Classa
Recommendation in 2022 version
Classa
Right heart catheterization and vasoreactivity testing – Recommendation Table 1
N
It is recommended that RHC comprises a complete set of haemodynamics and is performed following standardized protocols
I
R
Adenosine should be considered for performing vasoreactivity testing as an alternative
Inhaled iloprost may be considered for performing vasoreactivity testing as an alternative
IIa
Inhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol are recommended for performing vasoreactivity testing
I
Diagnostic strategy – Recommendation Table 2
N
It is recommended to assign an echocardiographic probability of PH, based on an abnormal TRV and the presence of other echocardiographic signs suggestive of
PH (see Table 10)
I
N
It is recommended to maintain the current threshold for
TRV (.2.8 m/s) for echocardiographic probability of PH
according to the updated haemodynamic deﬁnition
I
N
Based on the probability of PH by echocardiography,
further testing should be considered in the clinical context (i.e. symptoms and risk factors or associated conditions for PAH/CTEPH)
IIa
N
In symptomatic patients with intermediate echocardiographic probability of PH, CPET may be considered to further determine the likelihood of PH
IIb
Screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension –
Recommendation Table 3
N
In patients with SSc, an annual evaluation of the risk of having PAH is recommended
I
R
Resting echocardiography is recommended as a screening test in asymptomatic patients with SSc, followed by annual screening with echocardiography, DLCO, and biomarkers
I
In adult patients with SSc of .3 years’ disease duration,
an FVC ≥40%, and a DLCO ,60%, the DETECT
algorithm is recommended to identify asymptomatic patients with PAH
I
N
In patients with SSc, where breathlessness remains unexplained following non-invasive assessment, RHC is recommended to exclude PAH
I
N
Assessing the risk of having PAH, based on an evaluation of breathlessness, in combination with echocardiogram or PFTs and BNP/NT-proBNP, should be considered in patients with SSc
IIa
N
Policies to evaluate the risk of having PAH should be considered in hospitals managing patients with SSc
IIa
R
RHC is recommended in all cases of suspected PAH
associated with CTD
I
In symptomatic patients with SSc, exercise echocardiography or CPET, or CMR may be considered to aid decisions to perform RHC
IIb
N
In patients with CTD with overlap features of SSc, an annual evaluation of the risk of PAH may be considered
IIb
R
In PE survivors with exercise dyspnoea, CTEPH should be considered
IIa
In patients with persistent or new-onset dyspnoea or exercise limitation following PE, further diagnostic evaluation to assess for CTEPH/CTEPD is recommended
I
Continued
3626
ESC/ERS Guidelines


<!-- PAGE 10 -->

### Page 10

N
For symptomatic patients with mismatched perfusion lung defects beyond 3 months of anticoagulation for acute PE, referral to a PH/CTEPH centre is recommended after considering the results of echocardiography, BNP/NT-proBNP, and/or CPET
I
N
Counselling regarding the risk of PAH, and annual screening is recommended for individuals who test positive for PAH-causing mutations and in ﬁrst-degree relatives of patients with HPAH
I
N
In patients referred for liver transplantation,
echocardiography is recommended as a screening test for
PH
I
N
Further tests (echocardiography, BNP/NT-proBNP,
PFTs, and/or CPET) should be considered in symptomatic patients with CTD, portal hypertension, or HIV to screen for PAH
IIa
Evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension – Recommendation Table 4
N
For risk stratiﬁcation at the time of diagnosis, the use of a three-strata model (low, intermediate, and high risk) is recommended, taking into account all available data including haemodynamics
I
N
For risk stratiﬁcation during follow-up, the use of a four-strata model (low, intermediate–low, intermediate–
high, and high risk) based on WHO-FC, 6MWD, and
BNP/NT-proBNP is recommended, with additional variables taken into account as necessary
I
R
Achievement/maintenance of an intermediate-risk proﬁle should be considered an inadequate treatment response for most patients with PAH
IIa
In some PAH aetiologies and in patients with comorbidities, optimization of therapy should be considered on an individual basis while acknowledging that a low-risk proﬁle is not always achievable
IIa
General measures and special circumstances – Recommendation Table 5
R
Supervised exercise training should be considered in physically deconditioned PAH patients under medical therapy
IIa
Supervised exercise training is recommended in patients with PAH under medical therapy
I
R
Immunization of PAH patients against inﬂuenza and pneumococcal infection is recommended
I
Immunization of patients with PAH against SARS-CoV-2,
inﬂuenza, and Streptococcus pneumoniae is recommended
I
R
Correction of anaemia and/or iron status may be considered in PAH patients
IIb
In the presence of iron-deﬁciency anaemia, correction of iron status is recommended in patients with PAH
I
N
In the absence of anaemia, iron repletion may be considered in patients with PAH with iron deﬁciency
IIb
R
Oral anticoagulant treatment may be considered in patients with IPAH, HPAH, and PAH due to use of anorexigens
IIb
Anticoagulation is not generally recommended in patients with PAH but may be considered on an individual basis
IIb
R
The use of angiotensin-converting enzyme inhibitors,
angiotensin-2 receptor antagonists, beta-blockers, and ivabradine is not recommended in patients with PAH
unless required by comorbidities (i.e. high blood pressure,
coronary artery disease, or left HF)
III
The use of ACEis, ARBs, ARNIs, SGLT-2is, beta-blockers,
or ivabradine is not recommended in patients with PAH
unless required by comorbidities (i.e. high blood pressure,
coronary artery disease, left HF, or arrhythmias)
III
R
In-ﬂight O2 administration should be considered for patients in WHO-FC III and IV and those with arterial blood O2 pressure consistently ,8 kPa (60 mmHg)
IIa
In-ﬂight O2 administration is recommended for patients using oxygen or whose arterial blood oxygen pressure is
,8 kPa (60 mmHg) at sea level
I
R
In elective surgery, epidural rather than general anaesthesia should be preferred whenever possible
IIa
For interventions requiring anaesthesia, multidisciplinary consultation at a PH centre to assess risk and beneﬁt should be considered
IIa
Continued
ESC/ERS Guidelines
3627


<!-- PAGE 11 -->

### Page 11

Women of childbearing potential – Recommendation Table 6
R
It is recommended that PAH patients avoid pregnancy
I
It is recommended that women of childbearing potential with PAH are counselled at the time of diagnosis about the risks and uncertainties associated with becoming pregnant; this should include advice against becoming pregnant, and referral for psychological support where needed
I
N
It is recommended that women of childbearing potential with PAH be provided with clear contraceptive advice,
considering the individual needs of the woman but recognizing that the implications of contraceptive failure are signiﬁcant in PAH
I
N
It is recommended that women with PAH who consider pregnancy or who become pregnant receive prompt counselling in an experienced PH centre to facilitate genetic counselling and shared decision-making, and to provide psychological support to the patients and their families where needed
I
N
For women with PAH having termination of pregnancy, it is recommended that this be performed in PH centres,
with psychological support provided to the patient and her family
I
N
For women with PAH who desire to have children, where available, adoption and surrogacy with pre-conception genetic counselling may be considered
IIb
N
As teratogenic potential has been reported in preclinical models for endothelin receptor antagonists and riociguat,
these drugs are not recommended during pregnancy
III
Treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension –
Recommendation Table 7
R
Continuation of high doses of CCBs is recommended in patients with IPAH, HPAH, and DPAH in WHO-FC I or II
with marked haemodynamic improvement (near normalization)
I
Continuing high doses of CCBs is recommended in patients with IPAH, HPAH, or DPAH in WHO-FC I or II
with marked haemodynamic improvement (mPAP
,30 mmHg and PVR ,4 WU)
I
N
In patients with a positive vasoreactivity test but insufﬁcient long-term response to CCBs who require additional PAH therapy, continuation of CCB therapy should be considered
IIa
Treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present without cardiopulmonary comorbiditiesb – Recommendation Table 8
N
In patients with IPAH/HPAH/DPAH who present at high risk of death, initial combination therapy with a PDE5i, an
ERA, and i.v./s.c. prostacyclin analogues should be consideredc
IIa
N
In patients with IPAH/HPAH/DPAH who present at intermediate–low risk of death while receiving ERA/
PDE5i therapy, the addition of selexipag should be considered
IIa
N
In patients with IPAH/HPAH/DPAH who present at intermediate–high or high risk of death while receiving
ERA/PDE5i therapy, the addition of i.v./s.c. prostacyclin analogues and referral for lung transplantation (LTx)
evaluation should be considered
IIa
Continued
3628
ESC/ERS Guidelines


<!-- PAGE 12 -->

### Page 12

N
In patients with IPAH/HPAH/DPAH who present at intermediate–low risk of death while receiving ERA/
PDE5i therapy, switching from PDE5i to riociguat may be considered
IIb
Initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension without cardiopulmonary comorbidities – Recommendation Table 9
R
Ambrisentan + tadalaﬁl
I
Initial combination therapy with ambrisentan and tadalaﬁl is recommended
I
N
Initial combination therapy with macitentan and tadalaﬁl is recommended
I
R
Other ERA + PDE-5i
IIa
Initial combination therapy with other ERAs and PDE5is should be considered
IIa
N
Initial combination therapy with macitentan, tadalaﬁl, and selexipag is not recommended
III
Sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension –
Recommendation Table 10
N
It is recommended to base treatment escalations on risk assessment and general treatment strategies (see treatment algorithm)
I
R
Macitentan added to sildenaﬁl
I
The addition of macitentan to PDE5is or oral/inhaled prostacyclin analogues is recommended to reduce the risk of morbidity/mortality events
I
N
The addition of oral treprostinil to ERA or PDE5i/
riociguat monotherapy is recommended to reduce the risk of morbidity/mortality events
I
R
Bosentan added to sildenaﬁl
IIb
The addition of bosentan to sildenaﬁl is not recommended to reduce the risk of morbidity/mortality events
III
R
Riociguat added to bosentan
I
The addition of riociguat to bosentan should be considered to improve exercise capacity
IIa
Treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present with cardiopulmonary comorbiditiesb – Recommendation Table 11
N
In patients with IPAH/HPAH/DPAH and cardiopulmonary comorbidities, initial monotherapy with a PDE5i or an ERA should be considered
IIa
N
In patients with IPAH/HPAH/DPAH with cardiopulmonary comorbidities who present at intermediate or high risk of death while receiving PDE5i or ERA monotherapy, additional PAH medication may be considered on an individual basis
IIb
Efﬁcacy of intensive care management for pulmonary arterial hypertension – Recommendation Table 12
N
When managing patients with right HF in the ICU, it is recommended to involve physicians with expertise, treat causative factors, and use supportive measures including inotropes and vasopressors, ﬂuid management, and PAH
drugs as appropriate
I
N
Mechanical circulatory support may be an option for selected patients as a bridge to transplantation or to recovery, and interhospital transfer should be considered if such resources are unavailable on site
IIa
Continued
ESC/ERS Guidelines
3629


<!-- PAGE 13 -->

### Page 13

Lung transplantation – Recommendation Table 13
R
Lung transplantation is recommended soon after inadequate clinical response on maximal medical therapy
I
It is recommended that potentially eligible candidates are referred for LTx evaluation when they have an inadequate response to oral combination therapy,
indicated by an intermediate–high or high risk or by a
REVEAL risk score .7
I
N
It is recommended to list patients for LTx who present with a high risk of death or with a REVEAL risk score ≥10
despite receiving optimized medical therapy, including s.c.
or i.v. prostacyclin analogues
I
Pulmonary arterial hypertension associated with drugs or toxins – Recommendation Table 14
N
It is recommended to make a diagnosis of drug- or toxin-associated PAH in patients who had relevant exposure and in whom other causes of PH have been excluded
I
N
In patients with suspected drug- or toxin-associated PAH,
it is recommended to discontinue the causative agent immediately whenever possible
I
N
Immediate PAH therapy should be considered in patients who present with intermediate/high-risk PAH at diagnosis
IIa
N
Patients with low-risk PAH should be re-evaluated 3–4
months after discontinuing the suspected drug or toxin,
and PAH therapy may be considered when the haemodynamics have not normalized
IIb
Pulmonary arterial hypertension associated with connective tissue disease – Recommendation Table 15
N
In patients with PAH associated with CTD, treatment of the underlying condition according to current guidelines is recommended
I
Pulmonary arterial hypertension associated with human immunodeﬁciency virus infection – Recommendation Table 16
N
In patients with PAH associated with HIV infection,
antiretroviral treatment according to current guidelines is recommended
I
N
In patients with PAH associated with HIV infection, initial monotherapy should be considered, followed by sequential combination if necessary, taking into consideration comorbidities and drug–drug interactions
IIa
Pulmonary arterial hypertension associated with portal hypertension – Recommendation Table 17
R
Echocardiographic assessment for signs of PH is recommended in symptomatic patients with liver disease or portal hypertension and in all candidates for liver transplantation
I
Echocardiography is recommended in patients with liver disease or portal hypertension with signs or symptoms suggestive of PH, and as a screening tool in patients evaluated for liver transplantation or transjugular portosystemic shunt
I
R
It is recommended that the treatment algorithm for patients with other forms of PAH should be applied to patients with PAH associated with portal hypertension,
taking into account the severity of liver disease
I
In patients with PAH associated with portal hypertension,
initial monotherapy should be considered, followed by sequential combination if necessary, taking into consideration the underlying liver disease and indication for liver transplantation
IIa
R
Liver transplantation may be considered in selected patients responding well to PAH therapy
IIb
Liver transplantation should be considered on an individual basis in patients with PAH associated with portal hypertension, as long as PVR is normal or near normal with PAH therapy
IIa
Continued
3630
ESC/ERS Guidelines


<!-- PAGE 14 -->

### Page 14

N
Drugs approved for PAH are not recommended for patients with portal hypertension and unclassiﬁed PH (i.e.
elevated mPAP, high CO, and a normal PVR)
III
Shunt closure in patients with pulmonary–systemic ﬂow ratio .1.5:1 based on calculated pulmonary vascular resistance–
Recommendation Table 18
N
In patients with ASD, VSD, or PDA and a PVR ,3 WU,
shunt closure is recommended
I
N
In patients with ASD, VSD, or PDA and a PVR of 3–5
WU, shunt closure should be considered
IIa
N
In patients with ASD and a PVR .5 WU that declines to
,5 WU with PAH treatment, shunt closure may be considered
IIb
N
In patients with VSD or PDA and a PVR .5 WU, shunt closure may be considered after careful evaluation in specialized centres
IIb
N
In patients with ASD and a PVR .5 WU despite PAH
treatment, shunt closure is not recommended
III
Pulmonary arterial hypertension associated with adult congenital heart disease – Recommendation Table 19
N
Risk assessment is recommended for patients with persistent PAH after defect closure
I
N
Risk assessment should be considered in patients with
Eisenmenger syndrome
IIa
R
Bosentan is recommended in WHO-FC III patients with
Eisenmenger syndrome
I
Bosentan is recommended in symptomatic patients with
Eisenmenger syndrome to improve exercise capacity
I
R
The use of supplemental iron treatment may be considered in patients with low ferritin plasma levels
IIb
Supplemental iron treatment should be considered in patients with iron deﬁciency
IIa
R
Combination drug therapy may be considered in patients with Eisenmenger syndrome
IIb
In patients with PAH after corrected adult CHD, initial oral combination therapy with drugs approved for PAH
should be considered for patients at low and intermediate risk, while initial combination therapy including i.v./s.c.
prostacyclin analogues should be considered for patients at high risk
IIa
R
Combination drug therapy may be considered in patients with Eisenmenger syndrome
IIb
In patients with adult CHD, including Eisenmenger syndrome, sequential combination therapy should be considered if patients do not meet treatment goals
IIa
N
In women with Eisenmenger syndrome, pregnancy is not recommended
III
R
If symptoms of hyperviscosity are present, phlebotomy with isovolumic replacement should be considered, usually when the haematocrit is .65%
IIa
In patients with Eisenmenger syndrome, routine phlebotomy to lower elevated haematocrit is not recommended
III
Pulmonary arterial hypertension with signs of venous/capillary involvement – Recommendation Table 20
R
A combination of clinical ﬁndings, physical examination,
bronchoscopy, and radiological ﬁndings is recommended to diagnose PVOD/PCH
I
A combination of clinical and radiological ﬁndings, ABG,
PFTs, and genetic testing is recommended to diagnose
PAH with signs of venous and/or capillary involvement
(PVOD/PCH)
I
N
In patients with PVOD/PCH, the use of drugs approved for PAH may be considered with careful monitoring of clinical symptoms and gas exchange
IIb
N
Lung biopsy is not recommended to conﬁrm a diagnosis of PVOD/PCH
III
Paediatric pulmonary hypertension – Recommendation Table 21
N
It is recommended to perform the diagnostic work-up,
including RHC and acute vasoreactivity testing, and treat children with PH at centres with speciﬁc expertise in paediatric PH
I
Continued
ESC/ERS Guidelines
3631


<!-- PAGE 15 -->

### Page 15

R
A PH diagnostic algorithm work-up is recommended for diagnosis and deﬁnition of the speciﬁc aetiology group in paediatric PH patients
I
In children with PH, a comprehensive work-up for conﬁrming diagnosis and speciﬁc aetiology is recommended (similar to that in adults, but adapted for age)
I
N
For conﬁrming PH diagnosis, RHC is recommended,
preferably before initiating any PAH therapy
I
N
In children with IPAH/HPAH, acute vasoreactivity testing is recommended to detect those who may beneﬁt from calcium channel blocker therapy
I
N
It is recommended to deﬁne a positive response to acute vasoreactivity testing in children similar to adults by a reduction of mPAP ≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg, with an increased or unchanged CO
I
R
A PAH-speciﬁc therapeutic algorithm is recommended in paediatric PH patients
I
In children with PAH, a therapeutic strategy based on risk stratiﬁcation and treatment response is recommended,
extrapolated from that in adults but adapted for age
I
R
Speciﬁc paediatric determinants of risk should be considered
IIa
It is recommended to monitor the treatment response in children with PAH by serially assessing a panel of data derived from clinical assessment, echocardiographic evaluation, biochemical markers, and exercise tolerance tests
I
N
Achieving and maintaining a low-risk proﬁle should be considered as an adequate treatment response for children with PAH
IIa
N
It is recommended to screen infants with bronchopulmonary dysplasia for PH
I
N
In infants with (or at risk of) bronchopulmonary dysplasia and PH, treating lung disease, including hypoxia,
aspiration, and structural airway disease, and optimizing respiratory support is recommended before initiating
PAH therapy
I
N
In neonates and infants, a diagnostic and therapeutic approach to PH distinct from that in older children and adults should be considered, given the frequent association with developmental vascular and parenchymal lung disease
IIa
Pulmonary hypertension associated with left heart disease – Recommendation Table 22
N
RHC is recommended for suspected PH in patients with
LHD, if it aids management decisions
I
N
RHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair
I
R
Patients with PH-LHD and a severe pre-capillary component as indicated by a high DPG and/or high PVR
should be referred to an expert PH centre for a complete diagnostic work-up and an individual treatment decision
IIa
For patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV
dysfunction, referral to a PH centre for a complete diagnostic work-up is recommended
I
N
In patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is recommended
I
N
When patients with PH and multiple risk factors for LHD,
who have a normal PAWP at rest but an abnormal response to exercise or ﬂuid challenge, are treated with
PAH drugs, close monitoring is recommended
I
Continued
3632
ESC/ERS Guidelines


<!-- PAGE 16 -->

### Page 16

N
In patients with PH at RHC, a borderline PAWP (13–
15 mmHg) and features of HFpEF, additional testing with exercise or ﬂuid challenge may be considered to uncover post-capillary PH
IIb
Pulmonary hypertension associated with lung disease and/or hypoxia – Recommendation Table 23
R
Echocardiography is recommended for the non-invasive diagnostic assessment of suspected PH in patients with lung disease
I
If PH is suspected in patients with lung disease, it is recommended that echocardiographyd be performed and the results interpreted in conjunction with ABG,
PFTs including DLCO, and CT imaging
I
R
Optimal treatment of the underlying lung disease, including long-term O2 therapy in patients with chronic hypoxaemia, is recommended in patients with PH due to lung diseases
I
In patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where indicated, hypoxaemia,
sleep-disordered breathing, and/or alveolar hypoventilation
I
R
Referral to an expert centre is recommended in patients with echocardiographic signs of severe PH and/or severe right ventricular dysfunction
I
In patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH,
referral to a PH centre is recommendede
I
N
In patients with lung disease and severe PH, an individualized approach to treatment is recommended
I
N
It is recommended to refer eligible patients with lung disease and PH for LTx evaluation
I
R
RHC is not recommended for suspected PH in patients with lung disease, unless therapeutic consequences are to be expected (e.g. LTx, alternative diagnoses such as PAH
or CTEPH, and potential enrolment in a clinical trial)
III
In patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions
I
N
Inhaled treprostinil may be considered in patients with
PH associated with ILD
IIb
N
The use of ambrisentan is not recommended in patients with PH associated with IPF
III
N
The use of riociguat is not recommended in patients with
PH associated with IIP
III
Chronic thrombo-embolic pulmonary hypertension and chronic thrombo-embolic pulmonary disease without pulmonary hypertension – Recommendation Table 24
R
Lifelong anticoagulation is recommended in all patients with CTEPH
I
Lifelong therapeutic doses of anticoagulation are recommended in all patients with CTEPH
I
N
Antiphospholipid syndrome testing is recommended in patients with CTEPH
I
N
In patients with CTEPH and antiphospholipid syndrome,
anticoagulation with VKAs is recommended
I
R
It is recommended that all patients with CTEPH receive assessment of operability and decisions regarding other treatment strategies made by a multidisciplinary team of experts
I
It is recommended that all patients with CTEPH are reviewed by a CTEPH team for the assessment of multimodality management
I
R
Surgical PEA in deep hypothermia circulatory arrest is recommended for patients with CTEPH
I
PEA is recommended as the treatment of choice for patients with CTEPH and ﬁbrotic obstructions within pulmonary arteries accessible by surgery
I
R
Interventional BPA may be considered in patients who are technically inoperable or carry an unfavourable risk:beneﬁt ratio for PEA
IIb
BPA is recommended in patients who are technically inoperable or have residual PH after PEA and distal obstructions amenable to BPA
I
R
Riociguat is recommended in symptomatic patients who have been classiﬁed as having persistent/recurrent CTEPH
after surgical treatment or inoperable CTEPH by a CTEPH
team including at least one experienced PEA surgeon
I
Riociguat is recommended for symptomatic patients with inoperable CTEPH or persistent/recurrent PH after PEA
I
Continued
ESC/ERS Guidelines
3633


<!-- PAGE 17 -->

### Page 17

N
Long-term follow-up is recommended after PEA and
BPA, as well as for patients with CTEPH established on medical therapy
I
N
A multimodality approach should be considered for patients with persistent PH after PEA and for patients with inoperable CTEPH
IIa
N
In patients with CTEPD without PH, long-term anticoagulant therapy should be considered on an individual basisf
IIa
N
PEA or BPA should be considered in selected symptomatic patients with CTEPD without PH
IIa
N
Treprostinil s.c. may be considered in patients in
WHO-FC III–IV who have inoperable CTEPH or persistent/recurrent PH after PEA
IIb
R
Off-label use of drugs approved for PAH may be considered in symptomatic patients who have been classiﬁed as having inoperable CTEPH by a CTEPH team including at least one experienced PEA surgeon
IIb
Off-label use of drugs approved for PAH may be considered in symptomatic patients who have inoperable
CTEPH
IIb
N
In patients with inoperable CTEPH, a combination of sGC stimulator/PDE5i, ERA, or parenteral prostacyclin analogues may be considered
IIb
N
BPA may be considered for technically operable patients with a high proportion of distal disease and an unfavourable risk:beneﬁt ratio for PEA
IIb
Pulmonary hypertension centres – Recommendation Table 25
N
It is recommended that PH centres maintain a patient registry
I
N
It is recommended that PH centres collaborate with patient associations
I
N
Accreditation of the PH centres should be considered
(e.g. https://ec.europa.eu/health/ern/assessment_en)
IIa
R
It should be considered that a referral centre follow at least 50 patients with PAH or CTEPH and should receive at least two new referrals per month with documented
PAH or CTEPH
IIa
PH centres should follow-up a sufﬁcient number of patients to maintain expertise (at least 50 patients with
PAH or CTEPH and at least two new referrals per month with documented PAH or CTEPH) and consider establishing collaborations with high-volume centres
IIa
© ESC/ERS 2022
6MWD, 6-minute walking distance; ABG, arterial blood gas analysis; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–
neprilysin inhibitor; ASD, atrial septal defect; BNP, brain natriuretic peptide; BPA, balloon pulmonary angioplasty; CCB, calcium channel blocker; CHD, congenital heart disease; CI,
cardiac index; CMR, cardiac magnetic resonance; CO, cardiac output; CpcPH, combined post- and pre-capillary pulmonary hypertension; CPET, cardiopulmonary exercise testing;
CT, computed tomography; CTD, connective tissue disease; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension;
DLCO, Lung diffusion capacity for carbon monoxide; DPAH, drug-associated pulmonary arterial hypertension; DPG, diastolic pressure gradient; ERA, endothelin receptor antagonist; FVC, forced vital capacity; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HIV, human immunodeﬁciency virus; HPAH, heritable pulmonary arterial hypertension; ICU, intensive care unit; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; IPF, idiopathic pulmonary ﬁbrosis; i.v., intravenous; LHD, left heart disease; LTx, lung transplantation; mPAP, mean pulmonary arterial pressure; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; PAP, pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PCH, pulmonary capillary haemangiomatosis; PDA,
patent ductus arteriosus; PDE5i, phosphodiesterase 5 inhibitor; PE, pulmonary embolism; PEA, pulmonary endarterectomy; PFTs, pulmonary function tests; PH, pulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVOD, pulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; RAP, mean right atrial pressure; RHC, right heart catheterization; RV, right ventricle; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; s.c., subcutaneous; sGC, soluble guanylate cyclase; SGLT-2i, sodium–glucose cotransporter-2 inhibitor; SSc, systemic sclerosis; SVI, stroke volume index; TRV, tricuspid regurgitation velocity; VKA, vitamin K antagonist; VSD,
ventricular septal defect; VTE, venous thrombo-embolism; WHO-FC, World Health Organization functional class; WU, Wood units.
aClass of recommendation.
bCardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF, such as obesity, diabetes, coronary heart disease, a history of hypertension, and/or a low DLCO.
cInitial triple-combination therapy including i.v./s.c. prostacyclin analogues may also be considered in patients presenting at intermediate risk but severe haemodynamic impairment (e.g.
RAP ≥20 mmHg, CI ,2.0 L/min/m2, SVI ,31 mL/m2, and/or PVR ≥12 WU).
dAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise PAP.
eThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.
fLong-term anticoagulant therapy is recommended when the risk of PE recurrence is intermediate or high, or when there is no history of VTE.
3634
ESC/ERS Guidelines


<!-- PAGE 18 -->

### Page 18

2.2. Methods
Three main methodological approaches were used in these guidelines, depending on the type of questions addressed:
(i) Four questions that were considered highly important were formulated in the PICO format, and assessed with full systematic reviews and application of the Grading of Recommendations,
Assessment, Development, and Evaluations (GRADE) approach2 and the Evidence to Decision (EtD) framework3 (see
Supplementary
Data,
Section
2.1
for full methodology description and supportive material). The resulting recommendations were rated as strong or conditional, based on four potential levels of evidence (high, moderate, low, or very low;
Tables 1 and 2). All Task Force members approved the recommendations. In addition, these recommendations were also presented and voted following the usual ESC approach.
(ii) Eight questions that were considered of key importance (key narrative questions) were assessed with systematic literature searches and application of the EtD framework.6 The evidence grading was performed following the usual ESC
approach.
(iii) The remaining topics of interest were assessed using the process commonly followed in ESC Guidelines. Structured literature searches were undertaken and grading tables, as outlined in
Tables 3 and 4, were created to describe level of conﬁdence in
New recommendations developed with GRADE Evidence to Decision framework
GRADE
Recommendations
Quality of evidence
Strength of recommendation
Classa
Levelb
In patients with IPAH/HPAH/DPAH who present at low or intermediate risk of death, initial combination therapy with a PDE5i and an ERA is recommended
Low
Conditional
I
B
The use of PDE5i in patients with HFpEF and isolated post-capillary PH is not recommended
Low
Conditional
III
C
PDE5i may be considered in patients with severe PH associated with ILD (individual decision-making in PH centres)
Very low
Conditional
IIb
C
The use of PDE5i in patients with ILD and non-severe PH is not recommended
Very low
Conditional
III
C
In patients with CTEPH who are candidates for BPA, medical therapy should be considered prior to the intervention
Very low
Conditional
IIa
B
© ESC/ERS 2022
BPA, balloon pulmonary angioplasty; CTEPH, chronic thrombo-embolic pulmonary hypertension; DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; HPAH, heritable pulmonary arterial hypertension; HFpEF, heart failure with preserved ejection fraction; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; PH, pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
Table 1
Strength of the recommendations according to GRADE
Recommendation strength
Rationale
Strong recommendation for
The panel is certain that the desirable outweigh the undesirable effects
Conditional recommendation for
The panel is less conﬁdent that the desirable outweigh the undesirable effects
Conditional recommendation against
The panel is less conﬁdent that the undesirable outweigh the desirable effects
Strong recommendation against
The panel is certain that the undesirable outweigh the desirable effects
No recommendation
The conﬁdence in the results might be very low to make a recommendation, or the trade-offs between desirable and undesirable effects are ﬁnely balanced, or no data are available.
© ESC/ERS 2022
Adapted from the ERS Handbook for Clinical Practice Guidelines.4
Table
2
Quality of evidence grades and their deﬁnitions5
Quality
Deﬁnition
High
We are very conﬁdent that the true effect lies close to that of the estimate of the effect
Moderate
We are moderately conﬁdent in the effect estimate: the true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different
Low
Our conﬁdence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low
We have very little conﬁdence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
© ESC/ERS 2022
ESC/ERS Guidelines
3635


<!-- PAGE 19 -->

### Page 19

the recommendation provided and the quality of evidence supporting the recommendation. The Task Force discussed each draft recommendation during web-based conference calls dedicated to speciﬁc sections, followed by consensus modiﬁcations and an online vote on each recommendation. Only recommendations that were supported by at least 75% of the Task Force members were included in the guidelines. The recommendation tables were colour-coded for ease of interpretation.
3. Deﬁnitions and classiﬁcations
3.1. Deﬁnitions
The deﬁnitions for PH are based on haemodynamic assessment by right heart catheterization (RHC). Although haemodynamics represent the central element of characterizing PH, the ﬁnal diagnosis and classiﬁcation should reﬂect the whole clinical context and consider the results of all investigations.
Table 3
Classes of recommendations
©ESC/ERS 2022
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.
efficacy of the given treatment or procedure.
favour of usefulness/efficacy.
Usefulness/efficacy is less well useful/effective, and in some cases
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not may be harmful. 
Is not recommended
     Class IIb established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in
Should be considered
Class II 
© ESC/ERS 2022
Table 4
Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC/ERS 2022
© ESC/ERS 2022
3636
ESC/ERS Guidelines


<!-- PAGE 20 -->

### Page 20

Pulmonary hypertension is deﬁned by a mean pulmonary arterial pressure (mPAP) .20 mmHg at rest (Table 5). This is supported by studies assessing the upper limit of normal pulmonary arterial pressure (PAP) in healthy subjects,7–9 and by studies investigating the prognostic relevance of increased PAP (key narrative question
1, Supplementary Data, Section 3.1).10–12
It is essential to include PVR and pulmonary arterial wedge pressure (PAWP) in the deﬁnition of pre-capillary PH, in order to discriminate elevated PAP due to pulmonary vascular disease (PVD)
from that due to left heart disease (LHD), elevated pulmonary blood
ﬂow, or increased intrathoracic pressure (Table 5). Based on the available data, the upper limit of normal PVR and the lowest prognostically relevant threshold of PVR is ≏2 Wood units (WU).7,8,13,14
Pulmonary vascular resistance depends on body surface area and age, with elderly healthy subjects having higher values. The available data on the best threshold for PAWP discriminating pre- and postcapillary PH are contradictory. Although the upper limit of normal
PAWP is considered to be 12 mmHg,15 previous ESC/ERS
Guidelines for the diagnosis and treatment of PH, as well as the recent consensus recommendation of the ESC Heart Failure
Association,16 suggest a higher threshold for the invasive diagnosis of heart failure (HF) with preserved ejection fraction (HFpEF)
(PAWP ≥15 mmHg). In addition, almost all therapeutic studies of
PAH have used the PAWP ≤15 mmHg threshold. Therefore, it is recommended keeping PAWP ≤15 mmHg as the threshold for precapillary PH, while acknowledging that any PAWP threshold is arbitrary and that the patient phenotype, risk factors, and echocardiographic ﬁndings, including left atrial (LA) volume, need to be considered when distinguishing pre- from post-capillary PH.
Patients with PAH are haemodynamically characterized by precapillary PH in the absence of other causes of pre-capillary PH,
such as CTEPH and PH associated with lung diseases. All PH groups may comprise both pre- and post-capillary components contributing to PAP elevation. In particular, older patients may present with several conditions predisposing them to PH. The primary classiﬁcation should be based on the presumed predominant cause of the pulmonary pressure increase.
Post-capillary
PH
is haemodynamically deﬁned as mPAP
.20 mmHg and PAWP .15 mmHg. Pulmonary vascular resistance is used to differentiate between patients with post-capillary PH who have a signiﬁcant pre-capillary component (PVR .2 WU—combined post- and pre-capillary PH [CpcPH]) and those who do not
(PVR ≤2 WU—isolated post-capillary PH [IpcPH]).
There are patients with elevated mPAP (.20 mmHg) but low
PVR (≤2 WU) and low PAWP (≤15 mmHg). These patients are frequently characterized by elevated pulmonary blood ﬂow and, although they have PH, they do not fulﬁl the criteria of pre- or post-capillary PH. This haemodynamic condition may be described by the term ‘unclassiﬁed PH’. Patients with unclassiﬁed PH may present with congenital heart disease (CHD), liver disease, airway disease, lung disease, or hyperthyroidism explaining their mPAP
elevation. Clinical follow-up of these patients is generally recommended. In the case of elevated pulmonary blood ﬂow, its aetiology should be explored.
As the groups of PH according to clinical classiﬁcation represent different clinical conditions, there may be additional clinically relevant haemodynamic thresholds (e.g. for PVR) for the individual PH groups besides the general thresholds of the haemodynamic deﬁnition of
PH, which are discussed in the corresponding sections.
Exercise PH, deﬁned by an mPAP/cardiac output (CO) slope
.3 mmHg/L/min between rest and exercise,17 has been reintroduced. The mPAP/CO slope is strongly age dependent and its upper limit of normal ranges from 1.6–3.3 mmHg/L/min in the supine position.17 An mPAP/CO slope .3 mmHg/L/min is not physiological in subjects aged ,60 years and may rarely be present in healthy subjects aged .60 years.17 A pathological increase in pulmonary pressure during exercise is associated with impaired prognosis in patients with exercise dyspnoea18 and in several cardiovascular conditions.19–22 Although an increased mPAP/CO slope deﬁnes an abnormal haemodynamic response to exercise, it does not allow for differentiation between pre- and post-capillary causes. The PAWP/
CO slope with a threshold .2 mmHg/L/min may best differentiate between pre- and post-capillary causes of exercise PH.23,24
3.2. Classiﬁcations
The basic structure of the classiﬁcation from the 2015 ESC/ERS
Guidelines for the diagnosis and treatment of PH25,26 and the
Proceedings of the 6th WSPH1 has been kept (Table 6). The general purpose of the clinical classiﬁcation of PH remains to categorize clinical conditions associated with PH, based on similar pathophysiological mechanisms,
clinical presentation,
haemodynamic characteristics, and therapeutic management (Figure 1). The main changes are as follows:
(i) The subgroups ‘non-responders at vasoreactivity testing’ and
‘acute responders at vasoreactivity testing’ have been added to IPAH as compared with the 2015 ESC/ERS Guidelines for the diagnosis and treatment of PH.25,26 In addition to patients with IPAH, some patients with heritable PAH (HPAH) or
Table 5
Haemodynamic deﬁnitions of pulmonary hypertension
Deﬁnition
Haemodynamic characteristics
PH
mPAP .20 mmHg
Pre-capillary PH
mPAP .20 mmHg
PAWP ≤15 mmHg
PVR .2 WU
IpcPH
mPAP .20 mmHg
PAWP .15 mmHg
PVR ≤2 WU
CpcPH
mPAP .20 mmHg
PAWP .15 mmHg
PVR .2 WU
Exercise PH
mPAP/CO slope between rest and exercise
.3 mmHg/L/min
© ESC/ERS 2022
CO, cardiac output; CpcPH, combined post- and pre-capillary pulmonary hypertension;
IpcPH, isolated post-capillary pulmonary hypertension; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PH, pulmonary hypertension;
PVR, pulmonary vascular resistance; WU, Wood units.
Some patients present with elevated mPAP (.20 mmHg) but low PVR (≤2 WU) and low PAWP (≤15 mmHg); this haemodynamic condition may be described by the term
‘unclassiﬁed PH’ (see text for further details).
ESC/ERS Guidelines
3637


<!-- PAGE 21 -->

### Page 21

drug- or toxin-associated PAH (DPAH) might be acute responders.
(ii) The groups ‘PAH with features of venous/capillary (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis
[PVOD/PCH]) involvement’ and ‘persistent PH of the newborn (PPHN)’ have been included in group 1 (PAH) as compared with the 2015 ESC/ERS Guidelines for the diagnosis and treatment of PH and in line with the Proceedings of the
6th WSPH.1
(iii) Instead of the general term ‘sleep-disordered breathing’, the term ‘hypoventilation syndromes’ should be used within group
3 to describe conditions with increased risk of PH. Sole nocturnal obstructive sleep apnoea is generally not a cause of PH, but
PH is frequent in patients with hypoventilation syndromes causing daytime hypercapnia.
4. Epidemiology and risk factors
Pulmonary hypertension is a major global health issue. All age groups are affected. Present estimates suggest a PH prevalence of ≏1% of the global population. Due to the presence of cardiac and pulmonary causes of PH, prevalence is higher in individuals aged .65 years.29
Globally, LHD is the leading cause of PH.29 Lung disease, especially chronic obstructive pulmonary disease (COPD), is the second most common cause.29 In the UK, the observed PH prevalence has doubled in the last 10 years and is currently 125 cases/million inhabitants.30 Irrespective of the underlying condition, developing PH
is associated with worsening symptoms and increased mortality.29
In developing countries, CHD, some infectious diseases (schistosomiasis, human immunodeﬁciency virus [HIV]), and high altitude represent important but under-studied causes of PH.29
4.1. Group 1, pulmonary arterial hypertension
Recent registry data from economically developed countries indicate a PAH incidence and prevalence of ≏6 and 48–55 cases/million adults, respectively.31 It has been thought to predominantly affect younger individuals, mostly females;32,33 this is currently true for
HPAH, which affects twice as many females as males. However, recent data from the USA and Europe suggest that PAH is now frequently diagnosed in older patients (i.e. those aged ≥65 years,
who often present with cardiovascular comorbidities, resulting in a more equal distribution between sexes).32 In most PAH registries,
IPAH was the most common subtype (50–60% of all cases), followed by PAH associated with connective tissue disease (CTD), CHD, and portal hypertension (porto-pulmonary hypertension [PoPH]).32
A number of drugs and toxins are associated with the development of PAH.1,34–45 The association between exposure to drugs and toxins and PAH is classiﬁed as deﬁnite or possible, as proposed at the 6th WSPH (Table 7).1 There is a deﬁnite association with drugs, with available data based on outbreaks, epidemiological casecontrol studies, or large multicentre series. A possible association is suggested by multiple case series or cases with drugs with similar mechanisms of action.1
Table
6
Clinical classiﬁcation of pulmonary hypertension
GROUP 1 Pulmonary arterial hypertension (PAH)
1.1 Idiopathic
1.1.1 Non-responders at vasoreactivity testing
1.1.2 Acute responders at vasoreactivity testing
1.2 Heritablea
1.3 Associated with drugs and toxinsa
1.4 Associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.5 PAH with features of venous/capillary (PVOD/PCH) involvement
1.6 Persistent PH of the newborn
GROUP 2 PH associated with left heart disease
2.1 Heart failure:
2.1.1 with preserved ejection fraction
2.1.2 with reduced or mildly reduced ejection fractionb
2.2 Valvular heart disease
2.3 Congenital/acquired cardiovascular conditions leading to post-capillary PH
GROUP 3 PH associated with lung diseases and/or hypoxia
3.1 Obstructive lung disease or emphysema
3.2 Restrictive lung disease
3.3 Lung disease with mixed restrictive/obstructive pattern
3.4 Hypoventilation syndromes
3.5 Hypoxia without lung disease (e.g. high altitude)
3.6 Developmental lung disorders
GROUP 4 PH associated with pulmonary artery obstructions
4.1 Chronic thrombo-embolic PH
4.2 Other pulmonary artery obstructionsc
GROUP 5 PH with unclear and/or multifactorial mechanisms
5.1 Haematological disordersd
5.2 Systemic disorderse
5.3 Metabolic disordersf
5.4 Chronic renal failure with or without haemodialysis
5.5 Pulmonary tumour thrombotic microangiopathy
5.6 Fibrosing mediastinitis
© ESC/ERS 2022
HF, heart failure; HIV, human immunodeﬁciency virus; PAH, pulmonary arterial hypertension;
PCH,
pulmonary capillary haemangiomatosis;
PH,
pulmonary hypertension; PVOD, pulmonary veno-occlusive disease.
aPatients with heritable PAH or PAH associated with drugs and toxins might be acute responders.
bLeft ventricular ejection fraction for HF with reduced ejection fraction: ≤40%; for HF
with mildly reduced ejection fraction: 41–49%.
cOther causes of pulmonary artery obstructions include: sarcomas (high or intermediate grade or angiosarcoma), other malignant tumours (e.g. renal carcinoma,
uterine carcinoma, germ-cell tumours of the testis), non-malignant tumours (e.g.
uterine leiomyoma), arteritis without connective tissue disease, congenital pulmonary arterial stenoses, and hydatidosis.
dIncluding inherited and acquired chronic haemolytic anaemia and chronic myeloproliferative disorders.
eIncluding sarcoidosis, pulmonary Langerhans’s cell histiocytosis, and neuroﬁbromatosis type 1.
fIncluding glycogen storage diseases and Gaucher disease.
3638
ESC/ERS Guidelines


<!-- PAGE 22 -->

### Page 22

1%
1%
Global population
Rare
Pulmonary arterial hypertension (PAH)
PH associated with left heart disease
PH associated with lung disease
PH associated with pulmonary artery obstructions
PH with unclear and/or multifactorial mechanisms
Very common
Common
Rare
Rare
Medical therapy 
Idiopathic/heritable
Associated 
conditions
CpcPH
IpcPH
Non-severe PH
Severe PH
CTEPH
Other pulmonary 
obstructions
Haematological disorders
Systemic disorders
PAH drugs
CCB in 
responders
Potentially: PAH
drugs (trials)
Lung transplantation 
IpcPH:
Treatment of LHDa
CpcPH:
Treatment of LHDa
PH-lung disease:
Optimized care of underlying lung 
disease
Severe PH:
Potentially: PAH 
drugs (trials)
Surgical therapy:
PEA
Interventional:
BPA
Medical therapy:
PH drugs
Optimized treatment of underlying disease
Pulmonary congestion in post-capillary PH
Pulmonary vascular disease /
obstruction in pre-capillary PH
Mortality Hazard Ratio mPAP (mmHg)
Mortality Hazard Ratio
PVR (Wood units)
Right heart failure
Prevalence
Potentially: PAH
drugs (trials)
6
5
4
3
1
2
10
20
30
40
50
60
5
4
3
1
2
0
2
3
4
5
6
0
1
CLINICAL CLASSIFICATION
PULMONARY HYPERTENSION
PREVALENCE
THERAPEUTIC STRATEGIES
Figure 1 Central illustration. BPA, balloon pulmonary angioplasty; CCB, calcium channel blocker; CTEPH, chronic thrombo-embolic pulmonary hypertension; CpCPH, combined post- and pre-capillary pulmonary hypertension; IpcPH, isolated post-capillary pulmonary hypertension; LHD, left heart disease; PAH, pulmonary arterial hypertension; PEA, pulmonary endarterectomy; PH, pulmonary hypertension. aTreatment of heart failure according to the
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.27 Treatment of left-sided valvular heart disease according to the 2021
ESC/EACTS Guidelines for the management of valvular heart disease.28
ESC/ERS Guidelines
3639


<!-- PAGE 23 -->

### Page 23

4.2. Group 2, pulmonary hypertension associated with left heart disease
In 2013, the Global Burden of Disease Study reported 61.7 million cases of HF worldwide, which represented almost a doubling since
1990.46 In Europe and the USA, .80% of patients with HF are aged ≥65 years. Post-capillary PH, either isolated or combined with a pre-capillary component, is a frequent complication mainly in HFpEF, affecting at least 50% of these patients.47,48 The prevalence of PH increases with severity of left-sided valvular diseases, and PH
can be found in 60–70% of patients with severe and symptomatic mitral valve disease49 and in up to 50% of those with symptomatic aortic stenosis.50
4.3. Group 3, pulmonary hypertension associated with lung diseases and/or hypoxia
Mild PH is common in advanced parenchymal and interstitial lung disease. Studies have reported that ≏1–5% of patients with advanced
COPD with chronic respiratory failure or candidates for lung volume reduction surgery or lung transplantation (LTx) have an mPAP .35–
40 mmHg.51,52
In idiopathic pulmonary
ﬁbrosis,
an mPAP
≥25 mmHg has been reported in 8–15% of patients upon initial work-up, with greater prevalence in advanced (30–50%) and endstage (.60%) disease.52 Hypoxia is a public health problem for the estimated 120 million people living at altitudes .2500 m. Altitude dwellers are at risk of developing PH and chronic mountain sickness.
However, it remains unclear to what extent PH and right HF are public health problems in high-altitude communities; this should be addressed with updated methodology and large-scale population studies.53
4.4. Group 4, pulmonary hypertension associated with chronic pulmonary artery obstruction
The number of patients diagnosed with CTEPH is increasing, probably due to a deeper understanding of the disease and more active screening for this condition in patients who remain dyspnoeic after pulmonary embolism (PE) or who have risk factors for developing CTEPH.
Registry data indicate a CTEPH incidence and prevalence of 2–6 and
26–38 cases/million adults, respectively.31,54,55 Patients with chronic thrombo-embolic pulmonary disease (CTEPD) without PH still represent a small proportion of the patients referred to CTEPH centres.56
4.5. Group 5, pulmonary hypertension with unclear and/or multifactorial mechanisms
Group 5 PH consists of a complex group of disorders that are associated with PH.57 The cause is often multifactorial and can be secondary to increased pre- and post-capillary pressure, as well as direct effects on pulmonary vasculature. The incidence and prevalence of PH in most of these disorders are unknown. However, high-quality registries have recently enabled estimation of PH prevalence in adult patients with sarcoidosis.58,59 Studies suggest that PH can be common and its presence is often associated with increased morbidity and mortality.58,59
5. Pulmonary hypertension diagnosis
5.1. Diagnosis
The diagnostic approach to PH is mainly focused on two tasks. The primary goal is to raise early suspicion of PH and ensure fast-track referral to PH centres in patients with a high likelihood of PAH,
CTEPH, or other forms of severe PH. The second objective is to identify underlying diseases, especially LHD (group 2 PH) and lung disease (group 3 PH), as well as comorbidities, to ensure proper classiﬁcation, risk assessment, and treatment.
5.1.1. Clinical presentation
Symptoms of PH are mainly linked to right ventricle (RV) dysfunction, and typically associated with exercise in the earlier course of the disease.25,26 The cardinal symptom is dyspnoea on progressively minor exertion. Other common symptoms are related to the stages and severity of the disease, and are listed in Figure 2.60–62 Potential clinical signs and physical ﬁndings are summarized in Figure 3.60,61
Importantly, the physical examination may also be the key to identifying the underlying cause of PH (see Figure 3).
5.1.2. Electrocardiogram
Electrocardiogram (ECG) abnormalities (Table 8) may raise suspicion of PH, deliver prognostic information, and detect arrhythmias and signs of LHD. In adults with clinical suspicion of PH (e.g. unexplained dyspnoea on exertion), right axis deviation has a high predictive value for PH.63 A normal ECG does not exclude the presence of PH, but a normal ECG in combination with normal biomarkers (BNP/
NT-proBNP) is associated with a low likelihood of PH in patients referred for suspected PH or at risk of PH (i.e. after acute PE).64,65
Table 7
Drugs and toxins associated with pulmonary arterial hypertension
Deﬁnite association
Possible association
Aminorex
Benﬂuorex
Dasatinib
Dexfenﬂuramine
Fenﬂuramine
Methamphetamines
Toxic rapeseed oil
Alkylating agents (cyclophosphamide,
mitomycin C)a
Amphetamines
Bosutinib
Cocaine
Diazoxide
Direct-acting antiviral agents against hepatitis
C virus (sofosbuvir)
Indirubin (Chinese herb Qing-Dai)
Interferon alpha and beta
Leﬂunomide
L-tryptophan
Phenylpropanolamine
Ponatinib
Selective proteasome inhibitors (carﬁlzomib)
Solvents (trichloroethylene)a
St John’s Wort
© ESC/ERS 2022
aPulmonary veno-occlusive disease.
3640
ESC/ERS Guidelines


<!-- PAGE 24 -->

### Page 24

5.1.3. Chest radiography
Chest radiography presents abnormal ﬁndings in most patients with
PH; however, a normal chest X-ray does not exclude PH.68
Radiographic signs of PH include a characteristic conﬁguration of the cardiac silhouette due to right heart (right atrium [RA]/RV)
and PA enlargement, sometimes with pruning of the peripheral vessels. In addition, signs of the underlying cause of PH, such as LHD or lung disease, may be found (Table 9).25,26,60,69,70
5.1.4. Pulmonary function tests and arterial blood gases
Pulmonary function tests (PFTs) and analysis of arterial blood gas
(ABG) or arterialized capillary blood are necessary to distinguish between PH groups, assess comorbidities and the need for supplementary oxygen, and determine disease severity. The initial work-up of patients with suspected PH should comprise forced spirometry,
body plethysmography, lung diffusion capacity for carbon monoxide
(DLCO), and ABG.
In patients with PAH, PFTs are usually normal or may show mild restrictive, obstructive, or combined abnormalities.71,72 More severe
PFT abnormalities are occasionally found in patients with PAH associated with CHD,73 and those with group 3 PH. The DLCO may be normal in patients with PAH, although it is usually mildly reduced.71 A
severely reduced DLCO (,45% of the predicted value) in the presence of otherwise normal PFTs can be found in PAH associated with systemic sclerosis (SSc), PVOD, in PH group 3—associated with emphysema, interstitial lung disease (ILD), or combined pulmonary ﬁbrosis and emphysema—and in some PAH phenotypes.74 A low
DLCO is associated with a poor prognosis in several forms of
PH.75–78
Patients with PAH usually have normal or slightly reduced partial pressure of arterial oxygen (PaO2). Severe reduction of PaO2 might raise suspicion for patent foramen ovale, hepatic disease, other abnormalities with right-to-left shunt
(e.g.
septal defect),
or low-DLCO-associated conditions.
Partial pressure of arterial carbon dioxide (PaCO2) is typically lower than normal due to alveolar hyperventilation.79 Low PaCO2
Symptoms
Dyspnoea on exertion (WHO-FC)
Fatigue and rapid exhaustion
Dyspnoea when bending forward (bendopnoea)
Palpitations
Haemoptysis
Exercise-induced abdominal distension and nausea
Weight gain due to fluid retention
Syncope (during or shortly after physical exertion)
Rare symptoms due to pulmonary artery dilationa
Exertional chest pain:
dynamic compression of the left main coronary artery
Early
Late
Hoarseness (dysphonia):
compression of the left laryngeal recurrent nerve
(cardiovocal or Ortner´s syndrome)
Shortness of breath, wheezing, cough, lower respiratory tract infection, atelectasis:
compression of the bronchi
Figure 2 Symptoms in patients with pulmonary hypertension. WHO-FC, World Health Organization functional class. aThoracic compression syndromes are found in a minority of patients with PAH with pronounced dilation of the pulmonary artery, and may occur at any disease stage and even in patients with otherwise mild functional impairment.
ESC/ERS Guidelines
3641


<!-- PAGE 25 -->

### Page 25

at diagnosis and follow-up is common in PAH and associated with unfavourable outcomes.80 Elevated PaCO2 is very unusual in PAH
and reﬂects alveolar hypoventilation, which in itself may be a cause of PH. Overnight oximetry or polysomnography should be performed if there is suspicion of sleep-disordered breathing or hypoventilation.81
5.1.5. Echocardiography
Independent of the underlying aetiology, PH leads to RV pressure overload and dysfunction, which can be detected by echocardiography.82–84 When performed accurately, echocardiography provides comprehensive information on right and left heart morphology, RV
and LV function, and valvular abnormalities, and gives estimates of haemodynamic parameters. Echocardiography is also a valuable tool with which to detect the cause of suspected or conﬁrmed
PH, particularly with respect to PH associated with LHD or CHD.
Yet, echocardiography alone is insufﬁcient to conﬁrm a diagnosis of PH, which requires RHC.
Given the heterogeneous nature of PH and the peculiar geometry of the RV, there is no single echocardiographic parameter that reliably informs about PH status and underlying aetiology.
Therefore, a comprehensive echocardiographic evaluation for suspected PH includes estimating the systolic pulmonary arterial pressure (sPAP) and detecting additional signs suggestive of PH,
aiming at assigning an echocardiographic level of probability of
PH. Echocardiographic ﬁndings of PH, including estimating pressure and signs of RV overload and/or dysfunction, are summarized in Figure 4.
Signs of PH
Central, peripheral, or mixed cyanosis
Accentuated pulmonary component of the second heart sound
RV third heart sound
Systolic murmur of tricuspid regurgitation
Diastolic murmur of pulmonary regurgitation
Signs pointing towards underlying cause of PH
Digital clubbing: Cyanotic CHD, fibrotic lung disease, bronchiectasis, PVOD, or liver disease
Differential clubbing/cyanosis:
PDA/Eisenmenger’s syndrome
Auscultatory findings (crackles or wheezing,
murmurs): lung or heart disease
Sequelae of DVT, venous insufficiency: CTEPH
Telangiectasia: HHT or SSc 
Sclerodactyly, Raynaud’s phenomenon, digital ulceration, GORD: SSc
Signs of RV backward failure
Signs of RV forward failure
Distended and pulsating jugular veins
Abdominal distension
Hepatomegaly
Ascites
Peripheral oedema
Peripheral cyanosis (blue lips and tips)
Dizziness
Pallor
Cool extremities 
Prolonged capillary refill the on tation lung disease ezing,
CTEPH
digital
Sig
S
Dis
Ab
He
Asc
Per
Per
Diz
Pal
Co
Pro
Figure 3 Clinical signs in patients with pulmonary hypertension. CHD, congenital heart disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; DVT, deep venous thrombosis; GORD, gastro-oesophageal reﬂux disease; HHT, hereditary haemorrhagic telangiectasia; PDA, patent ductus arteriosus; PH, pulmonary hypertension; PVOD, pulmonary veno-occlusive disease; RV, right ventricle; SSc, systemic sclerosis.
3642
ESC/ERS Guidelines


<!-- PAGE 26 -->

### Page 26

Estimates of sPAP are based on the peak tricuspid regurgitation velocity (TRV) and the TRV-derived tricuspid regurgitation pressure gradient (TRPG)—after excluding pulmonary stenosis—taking into account non-invasive estimates of RA pressure (RAP). Considering the inaccuracies in estimating RAP and the ampliﬁcation of measurement errors by using derived variables,85–87 these guidelines recommend using the peak TRV (and not the estimated sPAP) as the key variable for assigning the echocardiographic probability of
PH. A peak TRV .2.8 m/s may suggest PH; however, the presence or absence of PH cannot be reliably determined by TRV alone.88
Lowering the TRV threshold in view of the revised haemodynamic deﬁnition of PH is not supported by available data (key narrative question 2, Supplementary Data, Section 5.1).89–92 Tricuspid regurgitation (TR) velocity may underestimate (e.g. in patients with severe
TR)28 or overestimate (e.g. in patients with high CO in liver disease or sickle cell disease [SCD],93,94 misinterpretation of tricuspid valve closure artefact for the TR jet, or incorrect assignment of a peak TRV
in the case of maximum velocity boundary artefacts) pressure gradients. Hence, additional variables related to RV morphology and function are used to deﬁne the echocardiographic probability of PH
(Table 10),82–84,95 which may then be determined as low, intermediate, or high. When interpreted in a clinical context, this probability can be used to decide the need for further investigation, including cardiac catheterization in individual patients (Figure 5).
Echocardiographic measures of RV function include the tricuspid annular plane systolic excursion (TAPSE), RV fractional area change
(RV-FAC), RV free-wall strain, and tricuspid annulus velocity (S′
wave) derived from tissue Doppler imaging, and potentially RV ejection fraction
(RVEF)
derived from
3D
echocardiography.
Furthermore, the TAPSE/sPAP ratio—representing a non-invasive measure of RV–PA coupling96—may aid in diagnosing PH.90,97,98
The pattern of RV outﬂow tract (RVOT) blood ﬂow (mid-systolic
‘notching’) may suggest pre-capillary PH.99,100
To separate between group 2 PH and other forms of PH, and to assess the likelihood of left ventricle (LV) diastolic dysfunction, LA
size and signs of LV hypertrophy should always be measured, and
Doppler echocardiographic signs (e.g. E/A ratio, E/E′) should be assessed even if the reliability of the latter is considered low.16 To identify CHD, 2D Doppler and contrast examinations are helpful, but transoesophageal contrast echocardiography or other imaging techniques (e.g. computer tomography [CT] angiography, cMRI) are needed in some cases to detect or exclude sinus venosus atrial septal defects, patent ductus arteriosus, and/or anomalous pulmonary venous return.101 The clinical value of exercise Doppler echocardiography in identifying exercise PH remains uncertain because of the lack of validated criteria and prospective conﬁrmatory data. In most cases, increases in sPAP during exercise are caused by diastolic
LV dysfunction.16
5.1.6. Ventilation/perfusion lung scan
A ventilation/perfusion (V/Q) lung scan (planar or single-photon emission computed tomography [SPECT]) is recommended in the diagnostic work-up of patients with suspected or newly diagnosed
PH, to rule out or detect signs of CTEPH.102,103 The V/Q SPECT
is superior to planar imaging and is the methodology of choice; however, SPECT has been widely evaluated in assessing PE, but not to the same degree in CTEPH.68 In the absence of parenchymal lung disease, a normal perfusion scan excludes CTEPH with a negative predicted value of 98%.104,105 In most patients with PAH, V/Q
scintigraphy is normal or shows a speckled pattern but no typical perfusion defects characteristic of PE or CTEPH, whereas matched
V/Q defects may be found in patients with lung disease (i.e. group
3 PH). Non-matched perfusion defects similar to those seen in
Table 9
Radiographic signs of pulmonary hypertension and concomitant abnormalities
Signs of PH and concomitant abnormalities
Signs of left heart disease/
pulmonary congestion
Signs of lung disease
Right heart enlargement
Central air space opaciﬁcation
Flattening of diaphragm (COPD/
emphysema)
PA enlargement
(including aneurysmal dilatation)
Interlobular septal thickening ‘Kerley B’
lines
Hyperlucency
(COPD/
emphysema)
Pruning of the peripheral vessels
Pleural effusions
Lung volume loss
(ﬁbrotic lung disease)
‘Water-bottle’ shape of cardiac silhouettea
Left atrial enlargement
(including splayed carina)
Left ventricular dilation
Reticular opaciﬁcation
(ﬁbrotic lung disease)
© ESC/ERS 2022
COPD, chronic obstructive pulmonary disease; PA, pulmonary artery; PH, pulmonary hypertension.
aMay be present in patients with PH with advanced right ventricular failure and moderate pericardial effusion.
Table 8
Electrocardiogram abnormalities in patients with pulmonary hypertension
Typical ECG abnormalities in PH66
• P pulmonale (P .0.25 mV in lead II)
• Right or sagittal axis deviation (QRS axis .90° or indeterminable)
• RV hypertrophy (R/S .1, with R .0.5 mV in V1; R in V1 + S in lead V5
. 1 mV)
• Right bundle branch block—complete or incomplete (qR or rSR
patterns in V1)
• RV strain patterna (ST depression/T-wave inversion in the right pre-cordial V1–4 and inferior II, III, aVF leads)
• Prolonged QTc interval (unspeciﬁc)b
© ESC/ERS 2022
ECG, electrocardiogram; PH, pulmonary hypertension; QTc, corrected QT interval;
RV, right ventricular.
aPresent in advanced PH.
bPatients with pulmonary arterial hypertension can present with a prolonged QTc interval (although non-speciﬁc), which may reﬂect RV dysfunction and delayed myocardial repolarization, and is an independent predictor of mortality.67
ESC/ERS Guidelines
3643


<!-- PAGE 27 -->

### Page 27

CTEPH may be present in 7–10% of patients with PVOD/PCH or
PAH.106,107 Deposition of the perfusion agent in extrapulmonary organs may hint to cardiac or pulmonary right-to-left shunting and has been reported in CHD, hepato-pulmonary syndrome, and pulmonary arteriovenous malformations (PAVMs).68
5.1.7. Non-contrast and contrast-enhanced chest computed tomography examinations, and digital subtraction angiography
Computed tomography (CT) imaging may provide important information for patients with unexplained dyspnoea or suspected/conﬁrmed PH. The CT signs suggesting the presence of PH include an enlarged PA diameter, a PA-to-aorta ratio .0.9, and enlarged right heart chambers.68 A combination of three parameters (PA diameter
≥30 mm, RVOT wall thickness ≥6 mm, and septal deviation ≥140°
[or RV:LV ratio ≥1]) is highly predictive of PH.108 Non-contrast chest CT can help determine the cause of PH when there are features of parenchymal lung disease, and may also point towards the presence of PVOD/PCH by showing centrilobular ground-glass opacities (which may also be found in PAH), septal lines, and lymphadenopathy.68
Computed tomography pulmonary angiography (CTPA) is mainly used to detect direct or indirect signs of CTEPH, such as ﬁlling defects (including thrombus adhering to the vascular wall), webs or bands in the PAs, PA retraction/dilatation, mosaic perfusion, and enlarged bronchial arteries. Importantly, the diagnostic accuracy of
CTPA for CTEPH is limited (at the patient level, sensitivity and speciﬁcity are 76% and 96%, respectively),109 but was reported to be higher when modern, high-quality multi-detector CT scanners were used and when interpreted by experienced readers.109,110
Computed tomography pulmonary angiography may also be used to detect other cardiovascular abnormalities, including intracardiac shunts, abnormal pulmonary venous return, patent ductus arteriosus, and PAVMs.
RV
Ao
LA
LV
Enlarged right ventricle;
parasternal long-axis view
A
RV
RA
LV
Dilated RV with basal RV/LV 
ratio >1.0;
four-chamber view
B
RV
LV
Flattened interventricular septum
(arrows) leading to ‘D-shaped’ LV;
decreased LV eccentricity index;
parasternal short-axis view
C
RA
IVC
Distended inferior vena cava 
with diminished inspiratory collapsibility; subcostal view 
D
RVOT acceleration time of pulmonary ejection <105 ms mid-systolic ‘notch’ indicative of pre-capillary PH
E
Reduced right ventricular fractional area change (<35%);
four-chamber view
F
RV
RA
RVOT AT <105 ms
‘notch’
Diastole
Systole
RV
RA
LV
TAPSE 
<18 mm
M-Mode
Decreased tricuspid annular plane systolic excursion (TAPSE)
measured with M-Mode (<18 mm)
G
Decreased peak systolic (S’)
velocity of tricuspid annulus 
(<9.5 cm/s) measured with tissue Doppler
H
Enlarged right atrial area 
(>18 cm2);
four-chamber view
I
E’
S’
S’ <9.5 cm/s
RV
RA
A’
RV
Increased systolic peak tricuspid regurgitation velocity (peak TRV);
measured with continuous wave Doppler
J
Estimation of systolic pulmonary artery pressure (sPAP);
sPAP = TR pressure gradient + 
estimated RAP
K
Presence of pericardial effusion;
four-chamber view;
parasternal short-axis view;
other views (e.g. subcostal view)
L
RV
RA
Estimated RAP
RV
RA
IVC
IVC
Collapsea eRAP
<2.1 cm >50%
3 (0-5)
Peak TRV
>2.8 m/s
>2.1 cm >50%
8 (5-10)
>2.1 cm <50% 15 (10-20)
RV
LV
Peak TRV
>2.8 m/s
End-systolic
RA >18 cm2
Figure 4 Transthoracic echocardiographic parameters in the assessment of pulmonary hypertension. Ao, aorta; IVC, inferior vena cava; LA, left atrium;
LV, left ventricle; PH, pulmonary hypertension; RA, right atrium; RAP, right atrial pressure; RV, right ventricle; RVOT AT, right ventricular outﬂow tract acceleration time; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; TRV, tricuspid regurgitation velocity. aRefers to collapse on inspiration.
3644
ESC/ERS Guidelines


<!-- PAGE 28 -->

### Page 28

In patients presenting with a clinical picture of acute PE, chest CT
may be helpful in detecting signs of hitherto undetected CTEPH,
which may include the presence of the above CTEPH signs, and
RV hypertrophy as a sign for chronicity.111,112 Detecting ‘acute on chronic’ PE is important, as it may impact the management of patients with presumed acute PE.
Dual-energy CT (DECT) angiography and iodine subtraction mapping may provide additional diagnostic information by creating iodine maps,113 which reﬂect lung perfusion, thereby possibly increasing the diagnostic accuracy for CTEPH.114 Although increasingly used, the diagnostic value of DECT in the work-up of patients with PH has not been established.
Digital subtraction angiography (DSA) is mainly used to conﬁrm the diagnosis of CTEPH and to assess treatment options (i.e. operability or accessibility for BPA). Most centres use conventional two- or three-planar DSA. However, C-arm CT imaging may provide a higher spatial resolution, potentially identifying more target vessels for BPA and providing procedural guidance.115,116
5.1.8. Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging accurately and reproducibly assesses atrial and ventricular size, morphology, and function.
Additional information on RV/LV myocardial strain can be obtained by applying tagging or by post-processing feature tracking. In addition, cMRI can be used to measure blood ﬂow in the PA, aorta,
and vena cava, allowing for quantifying stroke volume (SV),
Table 10
Additional echocardiographic signs suggestive of pulmonary hypertension
A: The ventricles
B: Pulmonary artery
C: Inferior vena cava and RA
RV/LV basal diameter/
area ratio .1.0
RVOT AT
,105 ms and/or mid-systolic notching
IVC diameter
.21 mm with decreased inspiratory collapse (,50% with a sniff or ,20% with quiet inspiration)
Flattening of the interventricular septum (LVEI .1.1 in systole and/or diastole)
Early diastolic pulmonary regurgitation velocity .2.2 m/s
RA area (end-systole)
.18 cm2
TAPSE/sPAP ratio
,0.55 mm/mmHg
PA diameter .AR
diameter
PA diameter
.25 mm
© ESC/ERS 2022
AR, aortic root; IVC, inferior vena cava; LV, left ventricle; LVEI, left ventricle eccentricity index; PA, pulmonary artery; RA, right atrium; RV, right ventricle; RVOT AT, right ventricular outﬂow tract acceleration time; sPAP, systolic pulmonary arterial pressure;
TAPSE,
tricuspid annular plane systolic excursion;
TRV,
tricuspid regurgitation velocity.
aSigns contributing to assessing the probability of PH in addition to TRV (see Figure 5).
Signs from at least two categories (A/B/C) must be present to alter the level of echocardiographic probability of PH.
Peak tricuspid regurgitation velocity (m/s)
Presence of other echo PH signsb (see Table 10)
T
N
N
≤2.8a
2.9–3.4
PH PRO
R BABILITY
INTERMEDIATE
A
PH PRO
R BABILITY
HIGH
PH PRO
R BABILITY
LOW
>3.4
Y
Y
Yes/No
Y
Risk factors or associated conditions o
for 
f
PAH or CTEPH
P
N
N
Echo foll f
ow-up
(Class IIa)
Further interventionc/
RHC (if indicatedd)
(Class I) 
Alternative diagnosis
(Class IIa)
Y
Y
Yes/No
Y
Figure 5 Echocardiographic probability of pulmonary hypertension and recommendations for further assessment. CPET, cardiopulmonary exercise testing; CTEPH, chronic thrombo-embolic pulmonary hypertension; echo, echocardiography; LHD, left heart disease; N, no; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; RHC, right heart catheterization; TRV, tricuspid regurgitation velocity; Y, yes. aOr unmeasurable. The
TRV threshold of 2.8 m/s was not changed according to the updated haemodynamic deﬁnition of PH. bSigns from at least two categories in Table 10
(A/B/C) must be present to alter the level of echocardiographic probability of PH. cFurther testing may be necessary (e.g. imaging, CPET). dRHC should be performed if useful information/a therapeutic consequence is anticipated (e.g. suspected PAH or CTEPH), and may not be indicated in patients without risk factors or associated conditions for PAH or CTEPH (e.g. when mild PH and predominant LHD or lung disease are present).
ESC/ERS Guidelines
3645


<!-- PAGE 29 -->

### Page 29

intracardiac shunt, and retrograde ﬂow. By combining contrast magnetic resonance (MR) angiography and pulmonary perfusion imaging with late gadolinium-enhancement imaging of the myocardium, a complete picture of the heart and pulmonary vasculature can be obtained (see Supplementary Data, Table S2 for cMRI indices and normal values). A limitation is that there is no established method with which to estimate PAP. Even though the cost and availability of the technique precludes its use in the early diagnosis of PAH, it is sensitive in detecting early signs of PH and diagnosing CHD.117
5.1.9. Blood tests and immunology
The initial diagnostic assessment of patients with newly diagnosed
PH/PAH aims to identify comorbidities and possible causes or complications of PH. Laboratory tests that should be obtained at the time of PH diagnosis include: blood counts (including haemoglobin [Hb]);
serum electrolytes (sodium, potassium); kidney function (creatinine,
calculation of estimated glomerular ﬁltration rate, and urea); uric acid; liver parameters (alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase, γ-glutamyl transpeptidase, bilirubin); iron status (serum iron, transferrin saturation, and ferritin);
and BNP or NT-proBNP. In addition, serological studies should include testing for hepatitis viruses and HIV. Basic immunology laboratory work-up is recommended, including screening tests for anti-nuclear antibodies, anti-centromere antibodies, and anti-Ro.
Screening for biological markers of antiphospholipid syndrome is recommended in patients with CTEPH. Additional thrombophilia screening is not generally recommended, unless therapeutic consequences are to be expected.118 Pulmonary arterial hypertension and other forms of severe PH can be associated with thyroid function disorders; hence, laboratory screening should include at least thyroid-stimulating hormone.
5.1.10. Abdominal ultrasound
An abdominal ultrasound examination should be part of the comprehensive diagnostic work-up of patients with newly diagnosed PH,
particularly if liver disease is suspected. A major objective is to search for liver disease and/or portal hypertension, or portocaval shunt
(Abernethy malformation). During the course of the disease, patients with PH may develop secondary organ dysfunction mainly affecting the liver and kidneys.119 In these patients, abdominal ultrasound is needed for differential diagnostic reasons and to assess the extent of organ damage.
5.1.11. Cardiopulmonary exercise testing
Cardiopulmonary exercise testing (CPET) is a useful tool to assess the underlying pathophysiologic mechanisms leading to exercise intolerance. Patients with PAH show a typical pattern, with a low endtidal partial pressure of carbon dioxide (PETCO2), high ventilatory equivalent for carbon dioxide (VE/VCO2), low oxygen pulse (VO2/
HR), and low peak oxygen uptake (VO2).120 These ﬁndings should prompt consideration of PVD. In patients with LHD or COPD,
such a pattern may indicate an additional pulmonary vascular limitation.121,122 In populations at risk of PAH, such as those with SSc, a normal peak VO2 seems to exclude the diagnosis of PAH.123
5.1.12. Right heart catheterization, vasoreactivity,
exercise, and ﬂuid challenge
5.1.12.1. Right heart catheterization
Right heart catheterization is the gold standard for diagnosing and classifying PH. Performing RHC requires expertise and meticulous methodology following standardized protocols. In addition to diagnosing and classifying PH, clinical indications include haemodynamic assessment of heart or LTx candidates124 and evaluating congenital cardiac shunts. Interpreting invasive haemodynamics should be done in the context of the clinical picture and other diagnostic investigations. When performed in PH centres, the frequencies of serious adverse events (1.1%) and procedure-related mortality (0.055%) are low.125 A known thrombus or tumour in the RV or RA, recently implanted (,1 month) pacemaker, mechanical right heart valve,
TriClip, and an acute infection are contraindications to RHC; the risk:beneﬁt ratio should be individually assessed before each examination and discussed with the patient. The most feared complication of RHC is perforation of a PA.
The adequate preparation of patients for RHC is of major relevance. Pre-existing medical conditions should be optimally controlled at the time of the examination (particularly blood pressure and volume control). In the supine position, the mid-thoracic level is recommended as the zero reference level, which is at the level of the LA in most patients.126
For a complete assessment of cardiopulmonary haemodynamics,
all measures listed in Table 11 must be measured or calculated.
Table 11
Haemodynamic measures obtained during right heart catheterization
Measured variables
Normal value
Right atrial pressure, mean (RAP)
2–6 mmHg
Pulmonary artery pressure, systolic (sPAP)
15–30 mmHg
Pulmonary artery pressure, diastolic (dPAP)
4–12 mmHg
Pulmonary artery pressure, mean (mPAP)
8–20 mmHg
Pulmonary arterial wedge pressure, mean (PAWP)
≤15 mmHg
Cardiac output (CO)
4–8 L/min
Mixed venous oxygen saturation (SvO2)a
65–80%
Arterial oxygen saturation (SaO2)
95–100%
Systemic blood pressure
120/80 mmHg
Calculated parameters
Pulmonary vascular resistance (PVR)b
0.3–2.0 WU
Pulmonary vascular resistance index (PVRI)
3–3.5 WU·m2
Total pulmonary resistance (TPR)c
,3 WU
Cardiac index (CI)
2.5–4.0 L/min·m2
Stroke volume (SV)
60–100 mL
Stroke volume index (SVI)
33–47 mL/m2
Pulmonary arterial compliance (PAC)d
.2.3 mL/mmHg
© ESC/ERS 2022
WU, Wood units.
aDerived from blood sample taken from the pulmonary artery; compartmental oximetry to exclude an intracardiac shunt is recommended when SvO2 .75%.
bPVR, (mPAP−PAWP)/CO.
cTPR, mPAP/CO.
dPAC, SV/(sPAP−dPAP).
3646
ESC/ERS Guidelines


<!-- PAGE 30 -->

### Page 30

Incomplete assessments must be avoided, as this may lead to misdiagnosis. As a minimum, mixed venous oxygen saturation (SvO2)
and arterial oxygen saturation (SaO2) should be determined. A stepwise assessment of oxygen saturation should be performed in patients with SvO2 .75% and whenever a left-to-right shunt is suspected. Cardiac output (CO) should be assessed by the direct
Fick method or thermodilution (mean values of at least three measurements). The indirect Fick method is considered to be less reliable than thermodilution;127 however, thermodilution should not be used in the presence of shunts.
Pulmonary vascular resistance
([mPAP−PAWP]/CO) should be calculated for each patient. All pressure measurements, including PAWP, should be performed at end expiration (without breath-holding manoeuvre). In patients with large intrathoracic pressure changes during the respiratory cycle (i.e. COPD, obesity, during exercise), it is appropriate to average over at least three to four respiratory cycles. If no reliable PAWP
curve can be obtained, or if the PAWP values are implausible, additional measurement of LV end-diastolic pressure should be considered to avoid misclassiﬁcation. Saturations taken with the catheter in the wedged position can conﬁrm an accurate PAWP.128
5.1.12.2. Vasoreactivity testing
The purpose of vasoreactivity testing in PAH is to identify acute vasoresponders who may be candidates for treatment with high-dose calcium channel blockers (CCBs). Pulmonary vasoreactivity testing is only recommended in patients with IPAH, HPAH, or DPAH.
Inhaled nitric oxide129 or inhaled iloprost130,131 are the recommended test compounds for vasoreactivity testing (Table 12). There is similar evidence for intravenous (i.v.) epoprostenol, but due to incremental dose increases and repetitive measurements, testing takes much longer and is therefore less feasible.129 Adenosine i.v. is no longer recommended due to frequent side effects.132 A positive acute response is deﬁned as a reduction in mPAP by ≥10 mmHg to reach an absolute value ≤40 mmHg, with increased or unchanged CO.129 In patients with PH-LHD, vasoreactivity testing is restricted to evaluating heart transplantation candidacy (see Section 8.1), and in patients with PH
in the context of CHD with initial systemic-to-pulmonary shunting, vasoreactivity testing can be performed to evaluate the possibility of defect closure (see Section 7.5).101
5.1.12.3. Exercise right heart catheterization
Right heart catheterization is the gold standard method to assess cardiopulmonary haemodynamics during exercise and to deﬁne exercise PH.133 The main reason to perform exercise RHC is to investigate patients with unexplained dyspnoea and normal resting haemodynamics in order to detect early PVD or left heart dysfunction. In addition, exercise haemodynamics may reveal important prognostic and functional information in patients at risk of PAH
and CTEPH.22,134,135 To maximize the amount of information, exercise RHC may be combined with CPET. According to the available data and experience, exercise RHC is not associated with an additional risk of complications compared with resting RHC and
CPET.133
Incremental exercise tests (step or ramp protocol) with repeated haemodynamic measurements provide the most clinical information on pulmonary circulation. The minimally required haemodynamic variables measured at each exercise level include mPAP, sPAP, diastolic PAP (dPAP), PAWP, CO, heart rate, and systemic blood pressure. In addition, RAP, SvO2, and SaO2 should at least be measured at rest and peak exercise. Total pulmonary resistance (TPR), PVR, and cardiac index (CI) should be calculated at each exercise level, as well as arteriovenous difference in oxygen at peak exercise. The mPAP/
CO and PAWP/CO slopes should also be calculated.136,137 In patients with early PVD, PVR may be normal or mildly elevated at rest, but may change during exercise with a steep increase in mPAP, reﬂected by an mPAP/CO slope .3 mmHg/L/min, while the PAWP/CO slope usually remains ,2 mmHg/L/min. Patients with left heart dysfunction, such as those with HFpEF23 and/or dynamic mitral regurgitation,138 and a normal PAWP at rest, usually show a steep increase in mPAP and PAWP (and mPAP/CO,
PAWP/CO slope) during exercise.
According to recent studies, a PAWP/CO slope .2 mmHg/L/min may be helpful in recognizing an abnormal PAWP increase and,
therefore, a cardiac exercise limitation, especially in patients with
PAWP
12–15 mmHg at rest.23,24,139
A
PAWP
cut-off of
.25 mmHg during supine exercise has been recommended for diagnosing HFpEF.16 In patients with lung disease, increased intrathoracic pressure may contribute to mPAP elevation; this is exaggerated during exercise and can be recognized by a concomitant increase in
RAP.140 Some exercise haemodynamics are age dependent, with healthy elderly subjects presenting with steeper mPAP/CO and
PAWP/CO slopes than healthy young individuals.9,141
5.1.12.4. Fluid challenge
Fluid challenge may reveal LV diastolic dysfunction in patients with
PAWP ≤15 mmHg, but a clinical phenotype suggestive of LHD.
Table 12
Route of administration, half-life, dosages, and duration of administration of the recommended test compounds for vasoreactivity testing in pulmonary arterial hypertension
Compound
Route
Half-life
Dosage
Duration
Nitric oxide129
inh
15–30 s
10–20 p.p.m.
5–10 mina
Iloprost130,131
inh
30 min
5–10 µgb
10–15 minc
Epoprostenol129
i.v.
3 min
2–12 ng/kg/min
10 mind
© ESC/ERS 2022
Inh, inhaled; i.v., intravenous.
aMeasurement as a single step within the dose range.
bAt mouth piece.
cMeasurement as a single step, temporize full effect.
dIncremental increase in 2 ng/kg/min intervals, duration of 10 min at each step.
ESC/ERS Guidelines
3647


<!-- PAGE 31 -->

### Page 31

Most available data are derived from studies aiming to uncover
HFpEF (increase in PAWP) rather than identify group 2 PH (increase in PAP; see Section 8.1). It is generally accepted that rapid infusion
(over 5–10 min) of ≏500 mL (7–10 mL/kg) of saline would be sufﬁcient to detect an abnormal increase in PAWP to ≥18 mmHg (suggestive of HFpEF),142 although validation and long-term evaluation of these data are needed.143 There are insufﬁcient data on the haemodynamic response to ﬂuid challenge in patients with PAH. Recent data suggest that passive leg raise during RHC may also help to uncover occult HFpEF.144
5.1.13. Genetic counselling and testing
Mutations in PAH genes have been identiﬁed in familial PAH, IPAH,
PVOD/PCH, and anorexigen-associated PAH (Table 13).148 The screening recommendations herein speciﬁcally relate to patients with an a priori diagnosis of PAH and not ‘at-risk’ populations being screened for PAH (see Section 5.3). All patients with these conditions should be informed about the possibility of a genetic condition and that family members could carry a mutation that increases the risk of PAH, allowing for screening and early diagnosis.33,148 Even if genetic testing is not performed, family members should be made aware of early signs and symptoms, to ensure that a timely and appropriate diagnosis is made.148
Genetic counselling by appropriately trained PAH providers or geneticists should be performed prior to genetic testing, to address the complex questions related to penetrance, genetically at-risk family members, reproduction, genetic discrimination, and psychosocial issues. Careful genetic counselling with genetic counsellors or medical geneticists is critical prior to genetic testing for asymptomatic family members.148
If the familial mutation is known and an unaffected family member tests negative for that mutation, the risk of PAH for that person is the same as for the general population.148
Many of the less common mutations outlined have a potential additional set of syndromic features. These are summarized in Table 13
where speciﬁc clinical history, examination, and investigations are suggested. In particular, clinicians should undertake a thorough history and examination, as syndromic PAH diagnoses may be missed if not interrogated. For example, in one of the largest studies to date, TBX4, ALK1, and ENG mutations were represented in the top six most common genetic ﬁndings in adults with previously diagnosed
IPAH.149 These ﬁndings have been conﬁrmed and extended in international genetics consortia in 4241 patients with PAH.150 It is therefore apparent that there is either phenotypic heterogeneity of these syndromes or missed diagnostic features. As more genes associated with PAH are discovered, it will become increasingly difﬁcult to individually test for each. Next-generation sequencing has enabled the development of gene panels to simultaneously interrogate several genes.151 It is, however, important to check the genes included in the panel at the time of testing, since the composition changes as genetic discoveries advance.
5.2. Diagnostic algorithm
A multistep, pragmatic approach to diagnosis should be considered in patients with unexplained dyspnoea or symptoms/signs raising suspicion of PH. This strategy is depicted in detail in Figure 6 and
Table 14. The diagnostic algorithm does not address screening for speciﬁc groups at risk of PH.
5.2.1 Step 1 (suspicion)
Patients with PH are likely to be seen by ﬁrst-line physicians, mainly general practitioners, for non-speciﬁc symptoms. Initial evaluation should include a comprehensive medical (including familial) history,
thorough physical examination (including measurement of blood pressure, heart rate, and pulse oximetry), blood test to determine
BNP/NT-proBNP, and resting ECG. This ﬁrst step may raise a suspicion of a cardiac or respiratory disorder causing the symptoms.
5.2.2. Step 2 (detection)
The second step includes classical, non-invasive lung and cardiac testing. Among those tests, echocardiography is an important step in the
Recommendation Table 1 — Recommendations for right heart catheterization and vasoreactivity testing
Recommendations
Classa
Levelb
Right heart catheterization
It is recommended that RHC is performed to conﬁrm the diagnosis of PH (especially PAH or
CTEPH) and to support treatment decisions25,26
I
B
In patients with suspected or known PH, it is recommended that RHC is performed in experienced centres125
I
C
It is recommended that RHC comprises a complete set of haemodynamics and is performed following standardized protocols25,26,145
I
C
Vasoreactivity testing
Vasoreactivity testing is recommended in patients with I/H/DPAH to detect those who can be treated with high doses of a CCB129,146
I
B
It is recommended that vasoreactivity testing is performed at PH centres
I
C
It is recommended to consider a positive response to vasoreactivity testing by a reduction in mPAP
≥10 mmHg to reach an absolute value of mPAP
≤40 mmHg with an increased or unchanged
COc129
I
C
Inhaled nitric oxide, inhaled iloprost, or i.v.
epoprostenol are recommended for performing vasoreactivity testing129–132
I
C
Vasoreactivity testing, for identifying candidates for CCB therapy, is not recommended in patients with PAH other than I/H/DPAH, and in PH groups
2, 3, 4, and 5124,129
III
C
© ESC/ERS 2022
CCB, calcium channel blocker; CO, cardiac output; CTEPH, chronic thrombo-embolic pulmonary hypertension; I/H/DPAH, idiopathic, heritable, drug-associated pulmonary arterial hypertension; i.v., intravenous; mPAP, mean pulmonary arterial pressure;
PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; RHC, right heart catheterization.
aClass of recommendation.
bLevel of evidence.
cTesting should also be performed in patients with a baseline mPAP ≤40 mmHg, in whom the same responder criteria apply.
3648
ESC/ERS Guidelines


<!-- PAGE 32 -->

### Page 32

Table 13
Phenotypic features associated with pulmonary arterial hypertension mutations
Gene
Pulmonary hypertension phenotypic association
Putative molecular mechanism
Inheritance pattern
Potential distinguishing clinical and examination features
Investigations
Populations
Reference
BMPR2
Heritable and idiopathic PAH
Haploinsufﬁciency
Autosomal dominant
No speciﬁc or diagnostic clinical features described
No discriminative investigations described
Paediatric and adult
152
ATP13A3
Unknown
Autosomal dominant
Adult
149
AQP1
Unknown
Autosomal dominant
Adult
149
ABCC8
Haploinsufﬁciency
Autosomal dominant
Adult
153
KCNK3
Haploinsufﬁciency
Autosomal dominant
Adult
154
SMAD9
Haploinsufﬁciency
Autosomal dominant
Adult
155
Sox17
Heritable and idiopathic PAH
Congenital heart disease
Unknown
Autosomal dominant
Paediatric and adult
149
CAV1
Heritable and idiopathic PAH
Lipodystrophy
Gain of function;
dominant negative
Autosomal dominant
Deﬁciency of subcutaneous adipose tissue
Fasting triglyceride and leptin levels
Paediatric and adult
156
TBX4
Heritable and idiopathic PAH
Small patella syndrome
(ischiopatellar dysplasia)
Parenchymal lung disease
Bronchopulmonary dysplasia
Persistent pulmonary hypertension of the neonate
Unknown
Autosomal dominant
Patellar aplasia
Skeletal abnormalities,
particularly pelvis, knees, and feet
Skeletal X-rays: pelvis, knees, and feet
CT chest: diffuse parenchymal lung disease
Paediatric and (less commonly) adult
149,157
EIF2AK4
Pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis
Loss of function
Autosomal recessive
Distal phalangeal clubbing
Reduced DLCO
CT chest: interlobular septal thickening and mediastinal lymphadenopathy, and centrilobular ground-glass nodular opacities
Adult
158
KDR
Heritable and idiopathic PAH
Loss of function
Autosomal dominant
No speciﬁc or diagnostic clinical features described
Possible reduced DLCO
Older-onset adult
159
ENG
Heritable and idiopathic PAH
Hereditary haemorrhagic telangiectasia
Unknown
Autosomal dominant
Telangiectasia
Abnormal blood vessel formation
Visceral arteriovenous malformations
Bleeding diathesis
Iron-deﬁciency anaemia
Presence on imaging of pulmonary, hepatic,
cerebral, or spinal arteriovenous malformations
Invasive endoscopic assessment of gastrointestinal telangiectasia
Adult and paediatric
160
ACVRL1
Haploinsufﬁciency
Autosomal dominant
Adult and paediatric
160
GDF2
Haploinsufﬁciency
Autosomal dominant
Adult and paediatric
149
© ESC/ERS 2022
CT, computed tomography; DLCO, Lung diffusion capacity for carbon monoxide; PAH, pulmonary arterial hypertension.
ESC/ERS Guidelines
3649


<!-- PAGE 33 -->

### Page 33

diagnostic algorithm (Figure 6), as it assigns a level of probability of
PH, irrespective of the cause. In addition, it is an important step in identifying other cardiac disorders. Based on this initial assessment,
if causes other than PH are identiﬁed and/or in case of low probability of PH, patients should be managed accordingly.
5.2.3. Step 3 (conﬁrmation)
Patients should be referred to a PH centre for further evaluation in the following situations: (1) when an intermediate/high probability of
PH is established; (2) in the presence of risk factors for PAH, or a history of PE. A comprehensive work-up should be performed, with the goal of establishing the differential diagnoses and distinguishing between the various causes of PH according to the current clinical classiﬁcation. The PH centre is responsible for performing an invasive assessment according to the clinical scenario.
At any time, warning signs must be recognized, as they are associated with worse outcomes and warrant immediate intervention.
Such warning signs include: rapidly evolving or severe symptoms
Diagnostic algorithm of patients with unexplained exertional dyspnoea and/or suspected PH
Suspected cause
PH probability
Causes other than
PH identified
Medical history
Physical exam
ECG
BNP/NT-p
T roBNP
O2 saturation
Gene
G
ral practitioner
N
PFT
ABG
Chest X-ray a
Chest CTc
CPET
Lung assessmentb
Echocardiography
(see Figures 4–5,
Table 10)
T
CPET
Heartr  assessmentb
Y
Lung disease
Low
PH or cardiac disease
Intermediate/High
Fast-track refef rral at any time in case of i
warning signs g
a,
or when e PAH
P
or CTEPH
T
e are suspected s
Refer to PH cent f
re
(Class I)
Comprehensive PH
work-up (Table 14
T
and ReCo Table 2)
T
Invasive assessment as needed
(ReCo Table 2)
T
Rapid cross-refef rral as needed
Further diagnostic work-up
Risk factors for 
f
PAH
P
d or CTEPHe
Manage accordingly
Figure 6 Diagnostic algorithm of patients with unexplained dyspnoea and/or suspected pulmonary hypertension. ABG, arterial blood gas analysis; BNP,
brain natriuretic peptide; CPET, cardiopulmonary exercise testing; CT, computed tomography; CTEPH, chronic thrombo-embolic pulmonary hypertension; ECG, electrocardiogram; HIV, human immunodeﬁciency virus; N, no; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; PE, pulmonary embolism; PFT, pulmonary function tests; PH, pulmonary hypertension; ReCo, recommendation; Y, yes. aWarning signs include rapid progression of symptoms, severely reduced exercise capacity, pre-syncope or syncope on mild exertion, signs of right heart failure.
bLung and heart assessment by specialist as per local practice. cAs indicated; CT pulmonary angiography recommended if PH suspected. dIncludes connective tissue disease (especially systemic sclerosis), portal hypertension, HIV infection, and family history of PAH. eHistory of PE, permanent intravascular devices, inﬂammatory bowel diseases, essential thrombocythaemia, splenectomy, high-dose thyroid hormone replacement, and malignancy.
3650
ESC/ERS Guidelines


<!-- PAGE 34 -->

### Page 34

Table 14
Characteristic diagnostic features of patients with different forms of pulmonary hypertension
Diagnostic tool
Characteristic
ﬁndings/
features
Group 1 (PAH)
Group 2 (PH
associated with left heart disease)
Group 3 (PH
associated with lung disease)
Group 4 (PH
associated with pulmonary artery obstructions)
5.1.1 Clinical presentation
Clinical features
Variable age, but young,
female patients may be predominantly affected.a161 Clinical presentation depends on associated conditions and phenotype
See Section 5.1.1
Mostly elderly patients,
female predominance in case of HFpEF.161
History and clinical
ﬁndings suggestive of
LHD
Mostly elderly patients,
male predominance.161
History and clinical
ﬁndings suggestive of lung disease. Smoking history common
Variable age, but elderly male and female equally affected.
History of VTE (CTEPH
may occur in the absence of a VTE
history).
Risk factors for CTEPH
See Section 10.1
Oxygen requirement for hypoxaemia
Uncommon, except for conditions with low
DLCO or right-to-left shunting
Uncommon
Common, often profound hypoxaemia in severe PH
Uncommon; common in severe cases with predominantly distal pulmonary artery occlusions
5.1.3 Chest radiography
RA/RV/PA size ↑
Pruning of peripheral vessels
LA/LV size ↑
Cardiomegaly
Occasional signs of congestion (interstitial oedema/Kerley lines,
alveolar oedema,
pleural effusion)
Signs of parenchymal lung disease
RA/RV/PA size ↑
Number and size of peripheral vessels ↓
Occasional signs of pulmonary infarction
5.1.4 Pulmonary function tests and
ABG
Spirometry/PFT
impairment
Normal or mildly impaired
Normal or mildly impaired
Abnormal as determined by the underlying lung disease
Normal or mildly impaired
DLCO
Normal or mild-to-moderately reduced (low DLCO in
SSc-PAH, PVOD, and some IPAH phenotypes)
Normal or mild-to-moderately reduced, especially in
HFpEF
Often very low (,45%
predicted)
Normal or mild-to-moderately reduced
Arterial blood gas
PaO2
PaCO2
Normal or reduced
Reduced
Normal or reduced
Usually normal
Reduced
Reduced, normal, or increased
Normal or reduced
Normal or reduced
5.1.5
Echocardiography
Signs of PH (increased sPAP, enlarged RA/RV)
Congenital heart defects may be present
See Section 5.1.5
Signs of LHD (HFrEF,
HFpEF, valvular) and PH
(increased sPAP,
enlarged RA/RV)
See Section 8
Signs of PH (increased sPAP, enlarged RA/RV)
See Section 5.1.5
Signs of PH (increased sPAP, enlarged RA/RV)
See Section 5.1.5
5.1.6 Lung scintigraphy
Planar –
SPECT V/Q
Normal or matched
Normal or matched
Normal or matched
Mismatched perfusion defect
5.1.7 Chest CT
Signs of PH or PVOD
See Section 5.1.7
Signs of LHD
Pulmonary oedema
Signs of PH
Signs of parenchymal lung disease
Signs of PH
Intravascular ﬁlling defects, mosaic perfusion, enlarged bronchial arteries
Signs of PH
5.1.11
Cardiopulmonary exercise testing
High VE/VCO2 slope
Low PETCO2, decreasing during exercise
No EOV
Mildly elevated VE/
VCO2 slope
Normal PETCO2,
increasing during
Mildly elevated VE/
VCO2 slope
Normal PETCO2,
High VE/VCO2 slope
Low PETCO2,
decreasing during
Continued
ESC/ERS Guidelines
3651


<!-- PAGE 35 -->

### Page 35

(WHO-FC III/IV), clinical signs of RV failure, syncope, signs of low CO
state, poorly tolerated arrhythmias, and compromised or deteriorated haemodynamic status (hypotension, tachycardia). Such cases must be immediately managed as inpatients for initial work-up at a nearby hospital or PH centre. The presence of RV dysfunction by echocardiography, elevated levels of cardiac biomarkers, and/or haemodynamic instability must prompt referral to a PH centre for immediate assessment.
This diagnostic process emphasizes the importance of sufﬁcient awareness and collaboration between ﬁrst-line, specialized medicine and PH centres. Effective and rapid collaboration between each partner permits earlier diagnosis and management, and improves outcomes.
5.3. Screening and early detection
Despite the advent of PAH therapies that prevent clinical worsening166–168 and effective interventions for CTEPH,102 the time from symptom onset to PH diagnosis remains at .2 years,169,170 with most patients presenting with advanced disease. Decreasing the time to diagnosis may reduce emotional uncertainty in patients,171
reduce the use of health care resources, and enable treatment at an earlier stage when therapies may be more effective.172
A proposed multifaceted approach172 to facilitate an earlier diagnosis includes: (1) screening asymptomatic, high-risk groups (with exercise
EOV
increasing during exercise exercise
No EOV
5.1.12 Right heart catheterization
Pre-capillary PH
Post-capillary PH
Pre-capillary PH
Pre- (or post-) capillary
PH
© ESC/ERS 2022
ABG, arterial blood gas analysis; CT, computed tomography; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon monoxide; EOV,
exercise oscillatory ventilation; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IPAH, idiopathic pulmonary arterial hypertension;
LA, left atrium; LHD, left heart disease; LV, left ventricle; PA, pulmonary artery; PaCO2, partial pressure of arterial carbon dioxide; PAH, pulmonary arterial hypertension; PaO2, partial pressure of arterial oxygen; PETCO2, end-tidal partial pressure of carbon dioxide; PFT, pulmonary function test; PH, pulmonary hypertension; PVOD, pulmonary veno-occlusive disease;
RA, right atrium; RV, right ventricle; sPAP, systolic pulmonary arterial pressure; SPECT, single-photon emission computed tomography; SSc-PAH, systemic sclerosis-associated pulmonary arterial hypertension; VE/VCO2, ventilatory equivalent for carbon dioxide; V/Q, ventilation perfusion scintigraphy; VTE, venous thrombo-embolism.
↓, reduced; ↑, increased.
aHowever, it may affect individuals of all ages and sexes; diagnosis in males should not be delayed.
Recommendation Table 2 — Recommendations for diagnostic strategy
Recommendation
Classa
Levelb
Echocardiography
Echocardiography is recommended as the
ﬁrst-line, non-invasive, diagnostic investigation in suspected PH82,84,91
I
B
It is recommended to assign an echocardiographic probability of PH, based on an abnormal TRV and the presence of other echocardiographic signs suggestive of PH (see Table 10)91,92,162
I
B
It is recommended to maintain the current threshold for TRV (.2.8 m/s) for echocardiographic probability of PH according to the updated haemodynamic deﬁnition88
I
C
Based on the probability of PH by echocardiography, further testing should be considered in the clinical context (i.e. symptoms and risk factors or associated conditions for PAH/
CTEPH)92
IIa
B
In symptomatic patients with intermediate echocardiographic probability of PH, CPET may be considered to further determine the likelihood of PH123,163
IIb
C
Continued
Imaging
Ventilation/perfusion or perfusion lung scan is recommended in patients with unexplained PH to assess for CTEPH105
I
C
CT pulmonary angiography is recommended in the work-up of patients with suspected
CTEPH104
I
C
Routine biochemistry, haematology, immunology,
HIV testing, and thyroid function tests are recommended in all patients with PAH, to identify associated conditions
I
C
Abdominal ultrasound is recommended for the screening of portal hypertension164
I
C
Chest CT should be considered in all patients with PH
IIa
C
Digital subtraction angiography should be considered in the work-up of patients with
CTEPH
IIa
C
Other diagnostic tests
Pulmonary function tests with DLCO are recommended in the initial evaluation of patients with PH78
I
C
Open or thoracoscopic lung biopsy is not recommended in patients with PAH
III
C
© ESC/ERS 2022
CPET, cardiopulmonary exercise testing; CT, computed tomography; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon monoxide; HIV, human immunodeﬁciency virus; PAH, pulmonary arterial hypertension;
PH, pulmonary hypertension; TRV, tricuspid regurgitation velocity.
aClass of recommendation.
bLevel of evidence.
3652
ESC/ERS Guidelines


<!-- PAGE 36 -->

### Page 36

high prevalence or where the diagnosis signiﬁcantly impacts the proposed intervention), including individuals with SSc (prevalence: 5–
19%),173,174 BMPR2 mutation carriers (14–42%),33 ﬁrst-degree relatives of patients with HPAH,148 and patients undergoing assessment for liver transplantation (2–9%);175 (2) early detection of symptomatic patients in at-risk groups with conditions such as portal hypertension,176 HIV infection (0.5%),177 and non-SSc CTD, where the lower prevalence rates do not support asymptomatic screening; and (3) applying population-based strategies by deploying early detection approaches in PE follow-up clinics,178,179 breathlessness clinics,172 or in at-risk patients identiﬁed from their health care behaviour and/
or previous investigations.180
Screening can be deﬁned as the systematic application of a test or tests to identify at-risk, asymptomatic individuals. Screening approaches can also be extended to individuals who would not otherwise have sought medical attention on account of their symptoms, to facilitate early detection. Tools used to screen for PH have primarily been assessed, but not exclusively, in SSc,172,174 and include blood biomarkers (NT-proBNP), ECG, echocardiography (primarily using estimates of sPAP at rest, but also exercise studies),182 PFTs
(DLCO and forced vital capacity [FVC]/DLCO ratio), and exercise testing including CPET (which has been used in combination with screening algorithms to reduce the need for RHC).123,163
5.3.1. Systemic sclerosis
In SSc, the prevalence of PAH is 5–19%,174 with an annual incidence of developing PAH of 0.7–1.5%.183–185 Evidence for the clinical value of detecting PAH early in SSc was provided by a screening programme,186 which showed less severe haemodynamic impairment and better survival in screened patients compared with a contemporaneous, non-screened cohort,187 providing a strong rationale for screening for PAH in patients with SSc.
The diagnostic accuracy of echocardiography or other tests alone in detecting PAH is suboptimal.173 Several screening algorithms have been studied using a combination of clinicalfeatures, echocardiography, PFTs,
and NT-proBNP to select patients with SSc for RHC (DETECT;173
Australian Scleroderma Interest Group [ASIG]188). Such combined approaches have improved diagnostic accuracy compared with the use of echocardiography, NT-proBNP, or PFTs alone, and are able to prevent unnecessary RHC and identify patients with mPAP 21–24 mmHg.189
Therefore, a multimodal approach is warranted when screening patients with SSc for PAH; the echocardiographic assessment should follow the strategy described in Section 5.1.5.
Beyond initial screening, the frequency with which screening should be undertaken in asymptomatic subjects with SSc is unclear.
A study from the Australian Scleroderma Study Cohort, where annual screening was recommended (some patients were screened up to 10 times), noted that most patients were diagnosed with
PAH at their ﬁrst screening; however, those diagnosed on subsequent screening had a lower mPAP, PVR, and WHO-FC, and better survival than those diagnosed at ﬁrst screening.190 Based on current evidence, annual screening for PAH in patients with SSc is sufﬁcient.
Given the ﬁnancial and emotional cost associated with regular screening, stratifying subjects with SSc into those at highest and lowest risk of PAH would be desirable. Risk factors for PAH include: (1)
clinical and demographic factors (i.e. breathlessness, longer disease duration, sicca symptoms, digital ulceration, older age, and male sex);
and
(2)
the results of investigations
(e.g.
positive anti-centromere antibody proﬁle, mild ILD, low DLCO, elevated
FVC/DLCO ratio, or elevated NT-proBNP).174,191 A recent meta-analysis showed that reduced digital capillary density, as assessed by video-capillaroscopy, or progression to a severe active/
late pattern of vascular involvement is also a risk factor for
PAH.192 In addition to identifying patients at increased risk of PAH,
a simple prediction model integrating symptoms, DLCO, and
NT-proBNP identiﬁed subjects at very low probability of PAH
who could potentially avoid further speciﬁc testing for PH.183
Furthermore, CPET may help to identify patients with SSc with a low risk of having PAH and thus to avoid unnecessary RHC.123
The recommendations on screening for PAH in SSc have been established based on key narrative question 3 (Supplementary Data,
Section 5.2).
5.3.2. BMPR2 mutation carriers
In the evolving list of genes known to be associated with PAH, experience is largely restricted to BMPR2 mutation carriers who carry a lifetime risk of developing PAH of ≏20%, with penetrance higher in female carriers (42%) compared with male carriers (14%).33,148,193 There is currently no accepted screening strategy for evaluating PAH in
BMPR2 mutation carriers. At present, based on expert consensus,
asymptomatic relatives who screen positive for PAH-causing mutations are often offered yearly screening echocardiography.25,26 The
DELPHI-2 study, which prospectively screened carriers and relatives,
recently demonstrated a 9.1% pick up over 47+ 27 months of
PAH, with 2/55 diagnosed at baseline and 3/55 at follow-up; this equates to an incidence of 2.3%/year.33 The screening schedule included ECG, NT-proBNP, DLCO, echocardiography, CPET, and optional RHC; however, none of the cases would have been picked up by echocardiography alone. Screening programmes should adopt a multimodal approach, although the optimal strategy and screening period remains undeﬁned and will require multinational, multicentre study.
5.3.3. Portal hypertension
An estimated 1–2% of patients with liver disease and portal hypertension develop PoPH,176,194 which is of particular relevance in patients considered for transjugular portosystemic shunting or liver transplantation. In such patients, echocardiography is recommended to screen for PAH, even in the absence of symptoms. By using echocardiography,
sPAP can be measured in ≏80% of patients with portal hypertension,
which aids decisions to perform RHC. In patients assessed for liver transplantation, one study showed that an sPAP of .50 mmHg had
97% sensitivity and 77% speciﬁcity for detecting moderate-to-severe
PAH.195 Other investigators have recommended RHC when sPAP is
.38 mmHg.196 When screening for PoPH, it is advised to assess the echocardiographic probability of PH (see Section 5.1.5). In agreement with the International Liver Transplant Society, for patients awaiting liver transplantation, it is recommended to reassess for PAH annually,
although the optimal interval remains unclear.175
5.3.4. Pulmonary embolism
Chronic thrombo-embolic pulmonary hypertension is an uncommon and under-diagnosed complication of acute PE.112 The reported cumulative incidence of CTEPH after acute, symptomatic PE ranges
0.1–11.8%, depending on the collective investigated.112,178,197–199 A
ESC/ERS Guidelines
3653


<!-- PAGE 37 -->

### Page 37

systematic review and meta-analysis reported a CTEPH incidence of
0.6% in all patients with acute PE, 3.2% in survivors, and 2.8% in survivors without major comorbidities.178 A multicentre, observational, screening study reported a CTEPH incidence of 3.7/1000
patient-years and a 2 year cumulative incidence of 0.79% following acute PE.200 A recent prospective observational study (FOCUS,
Follow-up After Acute Pulmonary Embolism) showed a cumulative
2 year incidence of 2.3% and 16.0% for CTEPH and post-PE impairment, respectively, which were both associated with a higher risk of rehospitalization and death.201 Due to insufﬁcient awareness, some patients may have a delayed diagnosis of CTEPH because they may initially be misclassiﬁed as acute PE.112 In this context, the current guidelines do not recommend routine follow-up of patients with PE
by imaging methods of the pulmonary vascular tree, but suggest evaluating the index imaging test used to diagnose acute PE for signs of
CTEPH. Echocardiography is the preferred ﬁrst-line diagnostic test in patients with suspected CTEPH.103
Up to 50% of patients have persistent perfusion defects after an acute PE; however, the clinical relevance is unclear.202–204 All patients in whom symptoms can be attributed to post-thrombotic deposits within PAs are considered to have CTEPD, with or without PH.54
While persistent dyspnoea is common after acute PE,205 the prevalence of CTEPD without PH is unknown and requires further study
(see Section 10.1). A study exploring screening for CTEPH following acute PE identiﬁed, using echocardiography, a low yield of additional
CTEPH diagnoses in asymptomatic patients.206 Current PE guidelines recommend that further diagnostic evaluation may be considered in asymptomatic patients with risk factors for CTEPH at 3–6
months’ follow-up.103,207 Approaches to early detection of CTEPH
following acute PE are based on identifying patients at increased risk.208 In patients with persistent or new-onset dyspnoea after PE,
non-invasive approaches use echocardiography to assess for PH
and cross-sectional imaging to assess for persistent perfusion defects.
Limited data exist on strategies using DECT, CT lung subtraction iodine mapping, or 3D MR perfusion imaging. Scoring systems, including the Leiden CTEPH rule-out criteria206,209 can be used to inform diagnostic strategies. Cardiopulmonary exercise testing may identify characteristic features of exercise limitation due to PVD, or suggest an alternative diagnosis. The optimal timing for assessing symptoms to aid early detection of CTEPH may be 3–6 months after acute
PE, coinciding with the routine evaluation of anticoagulant treatment,
but earlier assessment may be necessary in highly symptomatic or deteriorating patients.54,103
Recommendation Table 3 — Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension
Recommendations
Classa
Levelb
Systemic sclerosis
In patients with SSc, an annual evaluation of the risk of having PAH is recommended183,186
I
B
Continued
In adult patients with SSc with .3 years’
disease duration, an FVC ≥40%, and a DLCO
,60%, the DETECT algorithm is recommended to identify asymptomatic patients with PAH173,186
I
B
In patients with SSc, where breathlessness remains unexplained following non-invasive assessment,
RHC is recommended to exclude PAH185–187
I
C
Assessing the risk of having PAH based on an evaluation of breathlessness, in combination with echocardiogram or PFTs and BNP/NT-proBNP,
should be considered in patients with
SSc172,173,186,188,190
IIa
B
Policies to evaluate the risk of having PAH
should be considered in hospitals managing patients with SSc
IIa
C
In symptomatic patients with SSc, exercise echocardiography or CPET, or CMR may be considered to aid decisions to perform RHC
IIb
C
In patients with CTD with overlap features of SSc,
an annual evaluation of the risk of PAH may be considered
IIb
C
CTEPH/CTEPD
In patients with persistent or new-onset dyspnoea or exercise limitation following PE, further diagnostic evaluation to assess for CTEPH/
CTEPD is recommended103
I
C
For symptomatic patients with mismatched perfusion lung defects beyond 3 months of anticoagulation for acute PE, referral to a PH/
CTEPH centre is recommended after considering the results of echocardiography, BNP/
NT-proBNP, and/or CPET203,206
I
C
Other
Counselling regarding the risk of PAH and annual screening are recommended in individuals who test positive for PAH-causing mutations and in
ﬁrst-degree relatives of patients with HPAH33
I
B
In patients referred for liver transplantation,
echocardiography is recommended as a screening test for PH
I
C
Further tests (echocardiography, BNP/
NT-proBNP, PFTs, and/or CPET) should be considered in symptomatic patients with CTD,
portal hypertension, or HIV to screen for PAH172
IIa
B
© ESC/ERS 2022
BNP,
brain natriuretic peptide;
CMR,
cardiac magnetic resonance;
CPET,
cardiopulmonary exercise testing; CTD, connective tissue disease; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon monoxide; FVC, forced vital capacity; HIV, human immunodeﬁciency virus; HPAH, heritable pulmonary arterial hypertension;
NT-proBNP,
N-terminal pro-brain natriuretic peptide;
PAH,
pulmonary arterial hypertension; PE, pulmonary embolism; PFT, pulmonary function test; PH, pulmonary hypertension; RHC, right heart catheterization; SSc, systemic sclerosis.
aClass of recommendation.
bLevel of evidence.
3654
ESC/ERS Guidelines


<!-- PAGE 38 -->

### Page 38

### 6 Pulmonary arterial hypertension (group 1)

6.1. Clinical characteristics
The symptoms of PAH are non-speciﬁc and mainly related to progressive RV dysfunction (see Section 5.1.1) as a consequence of progressive pulmonary vasculopathy (Figure 7). The presentation of PAH
may be modiﬁed by diseases that are associated with PAH, as well as comorbidities. More detailed descriptions of the individual PAH subsets are reported in Section 7.
6.2. Severity and risk assessment
6.2.1. Clinical parameters
Clinical assessment is a key part of evaluating patients with PAH, as it provides valuable information for determining disease severity, improvement, deterioration, or stability. At follow-up, changes in
WHO-FC (Table 15), episodes of chest pain, arrhythmias, haemoptysis, syncope, and signs of right HF provide important information.
Physical examination should assess heart rate, rhythm, blood pressure, cyanosis, enlarged jugular veins, oedema, ascites, and pleural effusions. The WHO-FC is one of the strongest predictors of survival,
Intimal proliferation, fibrosis
Pulmonary vasculopathy
Right heart failure
Medial hypertrophy
Vascular remodelling
Plexiform lesion
Thrombosis
Vasoconstriction
Pulmonary artery
Vascular obstruction
Right ventricular remodelling /
dysfunction
Current therapeutic targets
Medial hyperplasia
Intimal proliferation
Plexiform lesions
NO-sGC-cGMP pathway
Endothelin pathway
Prostacyclin pathway
L-arginine
Nitric oxide
(Vasodilatation and antiproliferation)
sGC
PDE5
GTP
cGMP
GMP
Arachidonic acid
Prostacyclin
(Vasodilatation and antiproliferation)
cAMP
IP receptor
Pro-endothelin-1
Endothelin-1
(Vasoconstriction and proliferation)
Endothelin receptor A
Endothelin receptor B
P
P
MP
G
MP
Figure 7 Pathophysiology and current therapeutic targets of pulmonary arterial hypertension (group 1). cAMP, cyclic adenosine monophosphate; (c)
GMP, (cyclic) guanosine monophosphate; GTP, guanosine-5′-triphosphate; IP receptor, prostacyclin I2 receptor; NO, nitric oxide; PDE5, phosphodiesterase 5; sGC, soluble guanylate cyclase.
ESC/ERS Guidelines
3655


<!-- PAGE 39 -->

### Page 39

both at diagnosis and follow-up,210–212 and worsening WHO-FC is one of the most alarming indicators of disease progression, which should trigger further investigations to identify the cause(s) of clinical deterioration.210,213,214
6.2.2. Imaging
Imaging of the heart plays an essential role in the follow-up of patients with PAH. Several echocardiographic and cMRI parameters have been proposed to monitor RV function during the course of
PAH. Table S2 provides a list of imaging parameters and relative cutoff values associated with increased and decreased risk of adverse events.
6.2.2.1. Echocardiography
Echocardiography is a widely available imaging modality and is readily performed at the patient’s bedside. It is crucial that a high-quality echocardiographic assessment by PH specialists is undertaken to reduce intraobserver and interobserver variability. Of note, estimated sPAP at rest is not prognostic and irrelevant to therapeutic decisionmaking.212,215,216 An increase in sPAP does not necessarily reﬂect disease progression and a decrease in sPAP does not necessarily reﬂect improvement.
Despite the complex geometry of the right heart, echocardiographic surrogates of the true right heart dimensions, which include a description of RV and RA areas, and the LV eccentricity index, provide useful clinical information in PAH.217,218 Right ventricular dysfunction can be evaluated measuring fractional area change, TAPSE, tissue Doppler, and 2D speckle tracking myocardial strain recording of RV free-wall motion, all of which represent isovolumetric and ejection-phase indices of load-induced RV
pump failure.219–224 The rationale for the reported measurements is strong, as RV systolic function metrics assess the adaptation of RV contractility to increased afterload, and increased right heart dimension and inferior vena cava dilation reﬂect failure of this mechanism, hence maladaptation.225 Pericardial effusion and tricuspid regurgitation (TR) grading further explore
RV overload and are of prognostic relevance in these patients.218,226–228 All of these variables are physiologically interdependent and their combination provides additional prognostic information over single measurements.223
Echocardiography also enables combined parameters to be measured, such as the TAPSE/sPAP ratio, which is tightly linked to RV–
PA coupling and predicts outcome.96,97 Echocardiographic measurements of RV and RA sizes combined with LV eccentricity index are crucial for assessing RV reverse remodelling as an emerging marker of treatment efﬁcacy.220,229 Three-dimensional echocardiography may achieve better estimation than standard 2D assessment, but underestimations of volumes and ejection fraction have been reported,
and technical issues are, as yet, unresolved.230
6.2.2.2. Cardiac magnetic resonance imaging
The role of cMRI in evaluating patients with PAH has been addressed in several studies, and RV volumes, RVEF, and SV are essential prognostic determinants in PAH.225,231–236 In patients with PAH, initial cMRI measurements added prognostic value to current risk scores.231,232 In addition, risk assessment at 1 year of follow-up based on cMRI was at least equal to risk assessment based on RHC.237 The cMRI risk-assessment variables based on the current literature are included in Table 16.117,225,231–235,237 The stroke volume index (SVI)
cut-off levels are based on the consensus of the literature;238 a change of 10 mL in SV (LV end-diastolic volume−LV end-systolic volume) during follow-up is considered clinically signiﬁcant.239 The value of cMRI in the follow-up of patients has been shown in several studies, and cMRI enables treatment effects to be monitored and treatment strategies adapted in time to prevent clinical failure.240–242
6.2.3. Haemodynamics
Cardiopulmonary haemodynamics assessed by RHC provide important prognostic information, both at the time of diagnosis and at follow-up.129,212,213,216,238,243–245,247,248 Currently available riskstratiﬁcation tools include haemodynamic variables for prognostication: RAP and PVR in REVEAL risk scores,213,249,250 and RAP, CI, and
SvO2 in the ESC/ERS risk-stratiﬁcation table.25,26 The mPAP provides little prognostic information, except in acute vasodilator responders.129 A recent study from France, which combined clinical and haemodynamic parameters, found that WHO-FC, 6MWD,
RAP, and SVI (but not SV and SvO2) were independent predictors of outcome.238
To reﬁne the risk-stratiﬁcation table (Table 16), SVI criteria are now added with the cut-off values of .38 mL/m2 and ,31 mL/m2
to determine low-risk and high-risk status, respectively.238
The optimal timing of follow-up RHC has not been determined.
While some centres regularly perform invasive follow-up assessments, others perform them as clinically indicated, and there is no evidence that any of these strategies is associated with better outcomes (Table 17).
Table 15
World Health Organization classiﬁcation of functional status of patients with pulmonary hypertension
Class
Descriptiona
WHO-FC I
Patients with PH but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnoea or fatigue, chest pain, or near syncope
WHO-FC II
Patients with PH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnoea or fatigue, chest pain, or near syncope
WHO-FC III
Patients with PH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnoea or fatigue,
chest pain, or near syncope
WHO-FC IV
Patients with PH with an inability to carry out any physical activity without symptoms. These patients manifest signs of right HF. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity
© ESC/ERS 2022
PH, pulmonary hypertension; WHO-FC, World Health Organization functional class.
aFunctional classiﬁcation of PH modiﬁed after the New York Heart Association functional classiﬁcation according to the World Health Organization 1998.147
3656
ESC/ERS Guidelines


<!-- PAGE 40 -->

### Page 40

6.2.4. Exercise capacity
The 6-minute walking test (6MWT) is the most widely used measure of exercise capacity in PH centres. The 6MWT is easy to perform,
inexpensive, and widely accepted by patients, health professionals,
and medicines agencies as an important and validated variable in
PH. As with all PH assessments, 6MWT results must always be interpreted in the clinical context. The 6MWD is inﬂuenced by factors such as sex, age, height, weight, comorbidities, need for oxygen,
learning curve, and motivation. Test results are usually given in absolute distance (metres) rather than the percentage of predicted values. Change in 6MWD is one of the most commonly used parameters in PAH clinical trials as a primary endpoint, key secondary endpoint, or component of clinical worsening.251 A recent investigation showed that the best absolute-threshold values for 1 year mortality and 1 year survival, respectively, were 165 m and 440 m,
respectively.252 Improvements in 6MWD have had less predictive value than deterioration on key clinical outcomes (mortality and survival).250,252,253 These results are consistent with observations from clinical trials and registries;254,255 however, there is no single threshold that would apply to all patients.256 Some studies have also suggested that adding SaO2 measured by pulse oximetry and heart rate responses may improve prognostic relevance.246,257 Hypoxaemia observed during the 6MWT is associated with worse survival, but these
ﬁndings still await conﬁrmation in large multicentre studies.
The incremental shuttle walking test (ISWT) is an alternative maximal test for assessing patients with PAH. The ISWT has a potential advantage over the 6MWT in that it does not have a ceiling effect;
furthermore, it keeps the simplicity of a simple-to-perform ﬁeld test, in contrast to CPET. However, the ISWT experience in PAH
is currently limited.258
Cardiopulmonary exercise testing is a non-invasive method for assessing functional capacity and exercise limitation. It is usually
Table 16
Comprehensive risk assessment in pulmonary arterial hypertension (three-strata model)
Determinants of prognosis (estimated
1-year mortality)
Low risk
(,5%)
Intermediate risk
(5–20%)
High risk
(.20%)
Clinical observations and modiﬁable variables
Signs of right HF
Absent
Absent
Present
Progression of symptoms and clinical manifestations
No
Slow
Rapid
Syncope
No
Occasional syncopea
Repeated syncopeb
WHO-FC
I, II
III
IV
6MWDc
.440 m
165–440 m
,165 m
CPET
Peak VO2 .15 mL/min/kg
(.65% pred.)
VE/VCO2 slope ,36
Peak VO2 11–15 mL/min/kg
(35–65% pred.)
VE/VCO2 slope 36–44
Peak VO2 ,11 mL/min/kg
(,35% pred.)
VE/VCO2 slope .44
Biomarkers: BNP or NT-proBNPd
BNP ,50 ng/L
NT-proBNP ,300 ng/L
BNP 50–800 ng/L
NT-proBNP 300–1100 ng/L
BNP .800 ng/L
NT-proBNP .1100 ng/L
Echocardiography
RA area ,18 cm2
TAPSE/sPAP .0.32 mm/mmHg
No pericardial effusion
RA area 18–26 cm2
TAPSE/sPAP 0.19–0.32 mm/
mmHg
Minimal pericardial effusion
RA area .26 cm2
TAPSE/sPAP ,0.19 mm/mmHg
Moderate or large pericardial effusion cMRIe
RVEF .54%
SVI .40 mL/m2
RVESVI ,42 mL/m2
RVEF 37–54%
SVI 26–40 mL/m2
RVESVI
42–54 mL/m2
RVEF ,37%
SVI ,26 mL/m2
RVESVI .54 mL/m2
Haemodynamics
RAP ,8 mmHg
CI ≥2.5 L/min/m2
SVI .38 mL/m2
SvO2 .65%
RAP 8–14 mmHg
CI 2.0–2.4 L/min/m2
SVI 31–38 mL/m2
SvO2 60–65%
RAP .14 mmHg
CI ,2.0 L/min/m2
SVI ,31 mL/m2
SvO2 ,60%
© ESC/ERS 2022
6MWD, 6-minute walking distance; BNP, brain natriuretic peptide; CI, cardiac index; cMRI, cardiac magnetic resonance imaging; CPET, cardiopulmonary exercise testing; HF, heart failure;
NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; pred., predicted; RA, right atrium; RAP, right atrial pressure; sPAP, systolic pulmonary arterial pressure; SvO2, mixed venous oxygen saturation; RVESVI, right ventricular end-systolic volume index; RVEF, right ventricular ejection fraction; SVI, stroke volume index;
TAPSE, tricuspid annular plane systolic excursion; VE/VCO2, ventilatory equivalents for carbon dioxide; VO2, oxygen uptake; WHO-FC, World Health Organization functional class.
aOccasional syncope during heavy exercise or occasional orthostatic syncope in a stable patient.
bRepeated episodes of syncope even with little or regular physical activity.
cObserve that 6MWD is dependent upon age, height, and burden of comorbidities.
dTo harmonize with the four-strata model shown in Table 18, the BNP and NT-proBNP cut-off levels have been updated from the 2015 version based on data from the REVEAL registry,
acknowledging that the European validation studies have used the original cut-off levels.274,292,293,295,296,302
ecMRI parameters adapted from Section 6.2.2.2.
ESC/ERS Guidelines
3657


<!-- PAGE 41 -->

### Page 41

performed as a maximal exercise test, and is safe even in patients with severe exercise limitation.259,260 Most PH centres use an incremental ramp protocol, although the test has not yet been standardized for this patient population. Robust prognostic evidence for peak VO2 and VE/VCO2 has been found in three studies, all powered for multivariable analysis.261–263 When associated with SVI, peak
VO2 provided useful information to further stratify patients with
PAH at intermediate risk.264 However, the added value of CPET
on top of common clinical and haemodynamic variables remains largely unexplored.
6.2.5. Biochemical markers
Considerable efforts have been made to identify additional biomarkers of PVD, addressing prognosis,265–272 diagnosis, and differentiation of PH subtypes,270,273–276 as well as PAH treatment response.266 Emerging proteins related to PAH and vascular remodelling include bone morphogenetic proteins 9 and 10 and translationally controlled tumour protein.270,277,278 Proteome-wide screening in IPAH and HPAH identiﬁed a multimarker panel with prognostic information in addition to the REVEAL risk score.271 Another study found that early development of SSc-associated PAH (PAH-SSc) was predicted by high circulating levels of C-X-C motif chemokine 4 in patients with SSc.276 However, none of these biomarkers have been introduced in clinical practice.
Thus, BNP and NT-proBNP remain the only biomarkers routinely used in clinical practice at PH centres, correlating with myocardial stress and providing prognostic information.279 Brain natriuretic peptide and NT-proBNP are not speciﬁc for PH, as they can be elevated in other forms of heart disease, exhibiting great variability. The previously proposed cut-off levels of BNP (,50, 50–300, and
.300 ng/L) and NT-proBNP (,300, 300–1400, and .1400 ng/L)
for low, intermediate, and high risk, respectively, in the ESC/ERS
risk-assessment model at baseline and during follow-up are prognostic for long-term outcomes and can be used to predict response to treatment.266 Reﬁned cut-off values for BNP (,50, 50–199, 200–
800, and .800 ng/L) and NT-pro-BNP (,300, 300–649, 650–
1100, and .1100 ng/L) for low, intermediate–low, intermediate–
high, and high risk, respectively, have recently been introduced as part of a four-strata risk-assessment strategy (see Section 6.2.7).280
6.2.6. Patient-reported outcome measures
A patient-reported outcome measure (PROM) is a term for health outcomes that are ‘self-reported’ by the patient. It is the patient’s experience of living with PH and its impact on them and their caregivers, including symptomatic, intellectual, psychosocial, spiritual,
and goal-orientated dimensions of the disease and its treatment.
Despite treatment advances improving survival, patients with PAH
present with a range of non-speciﬁc yet debilitating symptoms, which affect health-related quality of life (HR-QoL).281,282
Patient-reported outcome measures remain an underused outcome measure. Tools validated in patients with PAH should be used to assess HR-QoL282,283 in individual patients. There has been a reliance on generic PROMs, which have been studied in patients with PAH but may lack sensitivity to detect changes in
PAH.284,285 To address this, a number of PH-speciﬁc HR-QoL instruments have been developed and validated (e.g.
Cambridge
Pulmonary
Hypertension
Outcome
Review
[CAMPHOR],286
emPHasis-10,282,287 Living with Pulmonary Hypertension,288 and
Pulmonary
Arterial
Hypertension-Symptoms and
Impact
[PAH-SYMPACT]).289
These disease-speciﬁc
PROMs track
Table 17
Suggested assessment and timing for the follow-up of patients with pulmonary arterial hypertension
At baseline
3–6 months after changes in therapya
Every 3–6 months in stable patientsa
In case of clinical worsening
Medical assessment (including
WHO-FC)
6MWT
Blood test (including
NT-proBNP)b,c
ECG
Echocardiography or cMRI
ABG or pulse oximetryd
Disease-speciﬁc HR-QoL
CPET
RHC
© ESC/ERS 2022
6MWT, 6-minute walking test; ABG, arterial blood gas analysis; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; BNP, brain natriuretic peptide; cMRI, cardiac magnetic resonance imaging; CPET, cardiopulmonary exercise testing; ECG, electrocardiogram; HR-QoL, health-related quality of life; INR, international normalized ratio; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; RHC, right heart catheterization; TSH, thyroid-stimulating hormone; WHO-FC, World Health Organization functional class.
Green: is indicated; yellow: should be considered; orange: may be considered.
aIntervals to be adjusted according to patient needs, PAH aetiology, risk category, demographics, and comorbidities.
bBasic laboratory tests include blood count, INR (in patients receiving vitamin K antagonists), serum creatinine, sodium, potassium, ASAT/ALAT, bilirubin, and BNP/NT-proBNP.
cExtended laboratory tests (e.g. TSH, troponin, uric acid, iron status, etc.) according to clinical circumstances.
dABG should be performed at baseline but may be replaced by pulse oximetry in stable patients at follow-up.
3658
ESC/ERS Guidelines


<!-- PAGE 42 -->

### Page 42

functional status, clinical deterioration, and prognosis in PAH, and are more sensitive to the differences in the risk status than generic
PROMs.290,291 In addition, HR-QoL scores provide independent prognostic information.287
6.2.7. Comprehensive prognostic evaluation, risk assessment, and treatment goals
In the 2015 ESC/ERS Guidelines for the diagnosis and treatment of
PH, risk assessment was based on a multiparametric approach using a three-strata model to classify patients at low, intermediate, or high risk of death. Originally, these strata were based on estimated 1 year mortality rates of ,5%, 5–10%, and .10%, respectively.25,26 Since then, registry data have shown that observed 1 year mortality rates in the intermediate- and high-risk groups were sometimes higher than predicted (i.e. up to 20% in the intermediate-risk group and
.20% in the high-risk group). These numbers have been updated accordingly in the revised three-strata risk model (Table 16).292–294
Several abbreviated approaches of the 2015 ESC/ERS riskstratiﬁcation tool have been introduced and independently validated using the Swedish Pulmonary Arterial Hypertension Registry
(SPAHR),292 the Comparative, Prospective Registry of Newly
Initiated Therapies for PH (COMPERA),293 and the French PH
Registry (FPHR).295 Other risk-stratiﬁcation tools have been developed from the US REVEAL, including the REVEAL 2.0 risk score calculator, and an abridged version (REVEAL Lite 2).249,296 In all these studies, WHO-FC, 6MWD, and BNP/NT-proBNP emerged as the variables with the highest predictive value.
The main limitation of the
2015
ESC/ERS
three-strata,
risk-assessment tool is that 60–70% of the patients are classiﬁed as intermediate risk.292–295,297–303 An initial attempt to substratify the intermediate-risk group has been proposed, using a modiﬁed mean score in the SPAHR equation (with low–intermediate, 1.5–1.99
and high–intermediate, 2.0–2.49 as cut-offs), where the high–intermediate group was associated with worse survival.302 There have also been attempts to further improve risk stratiﬁcation by exploring the additional value of new biomarkers,304 or by measuring RV structure and function by echocardiography and cMRI.231,305,306 Other strategies have included incorporating renal function307 or combining 6MWD with TAPSE/sPAP ratio;96,97 however, all of these strategies have to be further validated.
Two recent registry studies have evaluated a four-strata,
risk-assessment tool based on reﬁned cut-off levels for WHO-FC,
6MWD, and NT-proBNP (Table 18).280,308 Patients were categorized as low, intermediate–low, intermediate–high, or high risk. Together,
these studies included .4000 patients with PAH and showed that the four-strata model performed at least as well as the three-strata model in predicting mortality. The four-strata model predicted survival in patients with IPAH, HPAH, DPAH, and PAH associated with CTD (including the SSc subgroup), and in patients with PoPH.
The observed 1-year mortality rates in the four risk strata were 0–
3%, 2–7%, 9–19%, and .20%, respectively. Compared with the three-strata model, the four-strata model was more sensitive to changes in risk from baseline to follow-up, and these changes were associated with changes in the long-term mortality risk. The main advantage of the four-strata model over the three-strata model is better discrimination within the intermediate-risk group, which helps guide therapeutic decision-making (see Section 6.3.4). For these reasons,
the four-strata model is included in the updated treatment algorithm
(see Figure 9). However, the three-strata model is maintained for initial assessment, which should be comprehensive and include echocardiographic and haemodynamic variables, for which cut-off values for the four-strata model have yet to be established.
Several studies have identiﬁed WHO-FC, 6MWD, and BNP/
NT-proBNP as the strongest prognostic predictors.293,295,296 With the abbreviated risk-assessment tools, missing values become an important limitation. REVEAL Lite 2 provides accurate prediction when one key variable (WHO-FC, 6MWD, or BNP/NT-proBNP) is unavailable, but is no longer accurate when two of these variables are missing.293,296 The original three-strata SPAHR/COMPERA risk tool was developed with at least two variables available, while the four-strata model was developed and validated in patients for whom all three variables were available. It is therefore recommended to use at least these three variables for risk stratiﬁcation. However,
two components may be used when variables are missing, especially when a functional criterion (WHO-FC or 6MWD) is combined with
BNP or NT-proBNP.296
Collectively,
the available studies support a
risk-based,
goal-orientated treatment approach in patients with PAH, where achieving and/or maintaining a low-risk status is favourable and recommended (key narrative question 4, Supplementary Data,
Section 6.1).298,300,303,309,310 For risk stratiﬁcation at diagnosis, use of the three-strata model is recommended taking into account as many factors as possible (Table 16), with a strong emphasis on disease type, WHO-FC, 6MWD, BNP/NT-proBNP, and haemodynamics.
Table 18
Variables used to calculate the simpliﬁed four-strata risk-assessment tool
Determinants of prognosis
Low risk
Intermediate–low risk
Intermediate–high risk
High risk
Points assigned
1
2
3
4
WHO-FC
I or IIa
-
III
IV
6MWD, m
.440
320–440
165–319
,165
BNP or
NT-proBNP,a ng/L
,50
,300
50–199
300–649
200–800
650–1100
.800
.1100
© ESC/ERS 2022
6MWD, 6-minute walking distance; BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide; WHO-FC, World Health Organization functional class.
Risk is calculated by dividing the sum of all grades by the number of variables and rounding to the next integer.
aWHO-FC I and II are assigned 1 point as both are associated with good long-term survival.
ESC/ERS Guidelines
3659


<!-- PAGE 43 -->

### Page 43

At follow-up, the four-strata model (Table 18) is recommended as a basic risk-stratiﬁcation tool, but additional variables should be considered as needed, especially right heart imaging and haemodynamics. At any stage, individual factors such as age,
sex, disease type, comorbidities, and kidney function should also be considered.
6.3. Therapy
According to the revised haemodynamic deﬁnition, PAH may be diagnosed in patients with mPAP .20 mmHg and PVR .2 WU. Yet,
the efﬁcacy of drugs approved for PAH has only been demonstrated in patients with mPAP ≥25 mmHg and PVR .3 WU (see
Supplementary Data, Table S1). No data are available for the efﬁcacy of drugs approved for PAH in patients whose mPAP is ,25 mmHg and whose PVR is ,3 WU. Hence, for such patients, the efﬁcacy of drugs approved for PAH has not been established. The same is true for patients with exercise PH, who, by deﬁnition, do not fulﬁl the diagnostic criteria for PAH. Patients at high risk of developing
PAH, for instance patients with SSc or family members of patients with HPAH, should be referred to a PH centre for individual decision-making.
6.3.1. General measures
Managing patients with PAH requires a comprehensive treatment strategy and multidisciplinary care. In addition to applying PAH drugs,
general measures and care in special situations represent integral components of optimized patient care. In this context, the systemic consequences of PH and right-sided HF, often contributing to disease burden, should be appropriately managed.119
6.3.1.1. Physical activity and supervised rehabilitation
The 2015 ESC/ERS Guidelines for the diagnosis and treatment of PH
suggested that patients with PAH should be encouraged to be active within symptom limits.25,26 Since then, additional studies have shown the beneﬁcial impact of exercise training on exercise capacity
(6MWD) and quality of life.312–316 A large, randomized controlled trial (RCT) in 11 centres across 10 European countries, including
116 patients with PAH/CTEPH on PAH drugs, showed a signiﬁcant improvement in 6MWD of 34.1 + 8.3 m, quality of life, WHO-FC,
and peak VO2 compared with standard of care.315 Since most of the studies included patients who were stable on medical treatment,
patients with PAH should be treated with the best standard of pharmacological treatment and be in a stable clinical condition before embarking on a supervised rehabilitation programme. Establishing specialized rehabilitation programmes for patients with PH would further enhance patient access to this intervention.317
6.3.1.2. Anticoagulation
There are several reasons to consider anticoagulation in patients with
PAH. Histopathological specimens from PAH patients’ lungs have shown in situ thrombosis of pulmonary vessels. Patients with CHD
or PA aneurysms may develop thrombosis of the central PAs.
Abnormalities in the coagulation and ﬁbrinolytic system indicating a pro-coagulant state have been reported in patients with PAH.318
Data from RCTs on anticoagulation in PAH are lacking, and registry data have yielded conﬂicting results. The largest registry analysis so far suggested a potential survival beneﬁt associated with anticoagulation in patients with IPAH,319 but this ﬁnding was not conﬁrmed by others.320 Two recent meta-analyses also concluded that using anticoagulants may improve survival in patients with IPAH;321,322
however, none of the included studies were methodologically robust. Despite the lack of evidence, registry data obtained between
2007 and 2016 showed that anticoagulation was used in 43% of patients with IPAH.293 In PAH associated with SSc, registry data and meta-analyses uniformly indicated that anticoagulation may be harmful.320–322 In CHD, there are also no RCTs on anticoagulation. There is also no consensus about the use of anticoagulants in patients who have permanent i.v. lines for therapy with prostacyclin analogues; this is left to local centre practice.
As anticoagulation is associated with an increased bleeding risk,
and in the absence of robust data, no general recommendation has been made for or against the use of anticoagulants in patients with
PAH.; therefore, individual decision-making is required.
Recommendation Table 4 — Recommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension
Recommendations
Classa
Levelb
It is recommended to evaluate disease severity in patients with PAH with a panel of data derived from clinical assessment, exercise tests,
biochemical markers, echocardiography, and haemodynamic evaluations212,213,216,249,292,293,295,296,302,307
I
B
Achieving and maintaining a low-risk proﬁle on optimized medical therapy is recommended as a treatment goal in patients with
PAH210,212,213,216,298,300,303,309,310
I
B
For risk stratiﬁcation at the time of diagnosis, the use of a three-strata model (low, intermediate,
and high risk) is recommended, taking into account all available data, including haemodynamics292,293,295
I
B
For risk stratiﬁcation during follow-up, the use of a four-strata model (low, intermediate–low,
intermediate–high, and high risk) based on
WHO-FC, 6MWD, and BNP/NT-proBNP is recommended, with additional variables taken into account as necessary280,308
I
B
In some PAH aetiologies and patients with comorbidities, optimization of therapy should be considered on an individual basis, while acknowledging that a low-risk proﬁle is not always achievable293,294,299,311
IIa
B
© ESC/ERS 2022
6MWD, 6-minute walking distance; BNP, brain natriuretic peptide; NT-proBNP,
N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension;
WHO-FC, World Health Organization functional class.
aClass of recommendation.
bLevel of evidence.
3660
ESC/ERS Guidelines


<!-- PAGE 44 -->

### Page 44

6.3.1.3. Diuretics
Right HF is associated with systemic ﬂuid retention, reduced renal blood ﬂow, and activation of the renin–angiotensin–aldosterone system. Increased right-sided ﬁlling pressures are transmitted to the renal veins, increasing interstitial and tubular hydrostatic pressure within the encapsulated kidney, which decreases net glomerular ﬁltration rate and oxygen delivery.119
Avoiding ﬂuid retention is one of the key objectives in managing patients with PH. Once these patients develop signs of right-sided HF and oedema, restricting ﬂuid intake and using diuretics is recommended.
The three main classes of diuretics—loop diuretics, thiazides, and mineralocorticoid receptor antagonists—are used as monotherapy or in combination, as determined by the patient’s clinical need and kidney function. Patients requiring diuretic therapy should be advised to regularly monitor their body weight and to seek medical advice in case of weight gain. Close collaboration between patients, PH centres, especially PH nurses, and primary care physicians plays a vital role. Kidney function and serum electrolytes should be regularly monitored, and intravascular volume depletion must be avoided as it may cause a further decline in CO and systemic blood pressure. Physicians should bear in mind that ﬂuid retention and oedema may not necessarily signal right-sided HF, but may also be a side effect of PAH therapy.323
6.3.1.4. Oxygen
Although oxygen administration reduces PVR and improves exercise tolerance in patients with PAH, there are no data to suggest that longterm oxygen therapy has sustained beneﬁts on the course of the disease. Most patients with PAH, except those with CHD and pulmonary-to-systemic shunts, have minor degrees of arterial hypoxaemia at rest, unless they have a patent foramen ovale. Data show that nocturnal oxygen therapy does not modify the natural history of advanced Eisenmenger syndrome.324 In the absence of robust data on the use of oxygen in patients with PAH, guidance is based on evidence in patients with COPD;325 when PaO2 is ,8 kPa (60 mmHg; alternatively, SaO2 ,92%) on at least two occasions, patients are advised to take oxygen to achieve a PaO2 .8 kPa. Ambulatory oxygen may be considered when there is evidence of symptomatic beneﬁt and correctable desaturation on exercise.326,327 Nocturnal oxygen therapy should be considered in case of sleep-related desaturation.328
6.3.1.5. Cardiovascular drugs
No data from rigorous clinical trials are available on the usefulness and safety of drugs that are effective in systemic hypertension or leftsided HF, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers (ARBs), angiotensin receptor–neprilysin inhibitors
(ARNIs),
sodium–glucose cotransporter-2
inhibitors
(SGLT-2is), beta-blockers, or ivabradine in patients with PAH. In this group of patients, these drugs may lead to potentially dangerous drops in blood pressure, heart rate, or both. Likewise, the efﬁcacy of digoxin/digitoxin has not been documented in PAH, although these drugs may be administered to slow ventricular rate in patients with
PAH who develop atrial tachyarrhythmias.
6.3.1.6. Anaemia and iron status
Iron deﬁciency is common in patients with PAH and is deﬁned by serum ferritin ,100 µg/L, or serum ferritin 100–299 µg/L and transferrin saturation ,20%.329 The underlying pathological mechanisms are complex.330–333 In patients with PAH, iron deﬁciency is associated with impaired myocardial function, aggravated symptoms, and increased mortality risk.333,334 Based on these data, regular monitoring of iron status (serum iron, ferritin, transferrin saturation,
soluble transferrin receptors) is recommended in patients with PAH.
In patients with severe iron deﬁciency anaemia (Hb ,7–8 g/dL),
i.v. supplementation is recommended.335–337 Oral iron formulations containing ferrous (Fe2+) sulfate, ferrous gluconate, and ferrous fumarate are often poorly tolerated, and drug efﬁcacy may be impaired in patients with PAH.330,331 Ferric maltol is a new, orally available formulation of ferric (Fe3+) iron and maltol. One small, open-label study suggested good tolerability and efﬁcacy in patients with severe PH
with mild-to-moderate iron deﬁciency and anaemia.338 In contrast,
two small, 12 week, randomized, cross-over trials studying iron supplementation in PAH patients without anaemia provided no signiﬁcant clinical beneﬁt.339 Randomized controlled trials comparing oral and i.v. iron supplementation in patients with PAH are lacking.
6.3.1.7. Vaccination
As a general health care measure, it is recommended that patients with PAH be vaccinated at least against inﬂuenza, Streptococcus pneumoniae, and SARS-CoV-2.
6.3.1.8. Psychosocial support
Receiving a diagnosis of PH—often after a substantial delay—and experiencing the physical limitations have a substantial impact on psychological, emotional, and social aspects of patients and their families. Symptoms of depression and anxiety, as well as adjustment disorders, have a high prevalence in patients with PAH. Pulmonary arterial hypertension also has grave repercussions on ability to work and income.281,340–344
Empathic and hopeful communication is essential for physicians caring for patients with PAH. Awareness and knowledge about the disease and its treatment options empower patients to engage in shared decision-making. Adequate diagnostic screening tools are the key to identifying patients in need of referral for psychological/
psychiatric support, including psychopharmacological medication,345
or social assistance. Patient support groups may play an important role, and patients should be advised to join such groups. Given the life-limiting character of PAH, advanced care planning with referral to specialist palliative care services should be supported at the right time.346
6.3.1.9. Adherence to treatments
Adhering to medical therapy is key to successfully managing PAH. In general, factors that affect adherence are patient related (e.g. demographics, cognitive impairment, polypharmacy, adverse reactions/
side effects, psychological health, health literacy, patient understanding of the treatment rationale, and comorbidities), physician related
(expertise, awareness of guidelines, and multidisciplinary team approach), and health care system related (work setting, access to treatments, and cost).347
Recent studies have indicated that adherence to drug therapy in patients with PAH may be suboptimal.348,349 Given the complexity of PAH treatment, potential side effects, and risks associated with treatment interruptions,
adherence should be periodically
ESC/ERS Guidelines
3661


<!-- PAGE 45 -->

### Page 45

monitored by a member of the multidisciplinary team, to identify non-adherence and any changes to the treatment regimen spontaneously triggered by patients or non-expert physicians. To promote adherence, it is important to ensure that patients are involved in care decisions and appropriately informed about treatment options and rationale, expectations, side effects, and potential consequences of non-adherence. Patients should be advised that any changes in treatment should be made in cooperation with the PH centre.
6.3.2. Special circumstances
6.3.2.1. Pregnancy and birth control
6.3.2.1.1. Pregnancy. Historically, pregnancy in women with PAH
and other forms of severe PH has been associated with maternal mortality rates of up to 56% and neonatal mortality rates of up to
13%.350 With improved treatment of PAH and new approaches to managing women during pregnancy and the peri-partum period, maternal mortality has declined but remains high, ranging 11–25%.351–355
For these reasons, previous ESC/ERS Guidelines for the diagnosis and treatment of PH have recommended that patients with PAH should avoid pregnancy.25,26 However, there are reports of favourable pregnancy outcomes in women with PH, including, but not limited to, women with IPAH who respond to CCB therapy.353,354,356,357
Nonetheless, pregnancy remains associated with unforeseeable risks,
and may accelerate PH progression.358 Women with PH can deteriorate at any time during or after pregnancy. Therefore, physicians have a responsibility to inform patients about the risks of pregnancy,
so that women and their families can make informed decisions.
Women with poorly controlled disease, indicated by an intermediate- or high-risk proﬁle and signs of RV dysfunction, are at high risk of adverse outcomes; in the event of pregnancy, they should be carefully counselled and early termination should be advised. For patients with well-controlled disease, a low-risk proﬁle,
and normal or near-normal resting haemodynamics who consider becoming pregnant, individual counselling and shared decisionmaking are recommended. In such cases, alternatives such as adoption and surrogacy may also be explored. Pre-conception genetic counselling should also be considered in HPAH.
Women with PH who become pregnant or present during pregnancy with newly diagnosed PAH should be treated, whenever possible, in centres with a multidisciplinary team experienced in managing PH in pregnancy. If pregnancy is continued, PAH therapy may have to be adjusted. It is recommended to stop endothelin receptor antagonists (ERAs), riociguat, and selexipag because of potential or unknown teratogenicity.359 Despite limited evidence, CCBs,
PDE5is, and inhaled/i.v./subcutaneous (s.c.) prostacyclin analogues are considered safe during pregnancy.356,360
Pregnancy in PH is a very sensitive topic and requires empathic communication. Psychological support should be offered whenever needed.
6.3.2.1.2. Contraception. Women with PH of childbearing potential should be provided with clear contraceptive advice, considering the individual needs of the woman but recognizing that the implications of contraceptive failure are signiﬁcant in PH. With appropriate use, many forms of contraception, including oral contraceptives, are highly effective. In patients treated with bosentan, reduced efﬁcacy of hormonal contraceptives should be carefully considered.361 Using hormonal implants or an intrauterine device are alternative options with low failure rates. Surgical sterilization may be considered but is associated with peri-operative risks. Emergency post-coital hormonal contraception is safe in PH.
6.3.2.2. Surgical procedures
Surgical procedures in patients with PH are associated with an elevated risk of right HF and death. In a prospective, multinational registry including 114 patients with PAH who underwent non-cardiac and non-obstetric surgery, the peri-operative mortality rate was 2% in elective procedures and 15% in emergency procedures.362 The mortality risk was associated with the severity of PH. The decision to perform surgery should be made by a multidisciplinary team involving a
PH physician, and must be based on an individual risk:beneﬁt assessment considering various factors, including indication, urgency, PH
severity, and patient preferences. Risk scores to predict the perioperative mortality risk have been developed but require further validation.363 General recommendations cannot be made. The same is true regarding the preferred mode of anaesthesia. Pre-operative optimization of PAH therapy should be attempted whenever possible
(see also the 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery).364
6.3.2.3. Travel and altitude
Hypobaric hypoxia may induce arterial hypoxaemia, additional hypoxic pulmonary vasoconstriction, and increased RV load in
PAH.365,366 Cabin aircraft pressures are equivalent to altitudes up to 2438 m,367 at which the PaO2 decreases to that of an inspired
O2 fraction of 15.1% at sea level.365 However, evidence suggests that short-term (less than 1 day) normobaric hypoxia is generally well tolerated in clinically stable patients with PAH.365,368–372
In-ﬂight oxygen administration is advised for patients using oxygen at sea level and for those with PaO2 ,8 kPa (60 mmHg) or SaO2
,92%.25,26,325,369,372 An oxygen ﬂow rate of 2 L/min will raise inspired oxygen pressure to values as at sea level, and patients already using oxygen at sea level should increase their oxygen ﬂow rate.25,26,373
As the effects of moderate to long-term (hours–days) hypoxia exposure in PAH remain largely unexplored,374,375 patients should avoid altitudes .1500 m without supplemental oxygen.25,26,369
However, patients with PAH who are not hypoxaemic at sea level have tolerated day trips to 2500 m reasonably well.376 Patients should travel with written information about their disease, including a medication list, bring extra doses of their medication, and be informed about local PH centres near their travel destination.25,26
Recommendation Table 5 — Recommendations for general measures and special circumstances
Recommendations
Classa
Levelb
General measures
Supervised exercise training is recommended in patients with PAH under medical therapy314,315,317
I
A
Continued
3662
ESC/ERS Guidelines


<!-- PAGE 46 -->

### Page 46

6.3.3. Pulmonary arterial hypertension therapies
6.3.3.1. Calcium channel blockers
Patients with PAH who respond favourably to acute vasoreactivity testing (Figure 8) may respond favourably to treatment with
CCBs.129,146 Less than 10% of patients with IPAH, HPAH, or DPAH
are responders, while an acute vasodilator response does not predict a favourable long-term response to CCBs in patients with other forms of PAH.129,146,378 The CCBs that have predominantly been used in
PAH are nifedipine, diltiazem, and amlodipine.129,146 Amlodipine and felodipine are increasingly being used in clinical practice due to their long half-life and good tolerability. The daily doses that have shown efﬁcacy in PAH are relatively high and they must be reached progressively (Table 19). The most common adverse events are systemic hypotension and peripheral oedema.
Patients who meet the criteria for a positive acute vasodilator response and treated with CCBs should be closely followed for safety and efﬁcacy, with a complete reassessment after 3–6 months of therapy, including RHC. Additional acute vasoreactivity testing should be performed at re-evaluation to detect persistent vasodilator response, supporting possible increases in CCB dosage. Patients with a satisfactory chronic response present with WHO-FC I/II and marked haemodynamic improvement (ideally, mPAP ,30 mmHg and PVR ,4 WU) while on CCB therapy. In the absence of a satisfactory response, additional PAH therapy should be instituted. In some cases, a combination of CCBs with approved PAH drugs is required because of clinical deterioration with CCB withdrawal
Psychosocial support is recommended in patients with PAH
I
C
Immunization of patients with PAH against
SARS-CoV-2, inﬂuenza, and Streptococcus pneumoniae is recommended
I
C
Diuretic treatment is recommended in patients with PAH with signs of RV failure and ﬂuid retention
I
C
Long-term oxygen therapy is recommended in patients with PAH whose arterial blood oxygen pressure is ,8 kPa (60 mmHg)c
I
C
In the presence of iron-deﬁciency anaemia,
correction of iron status is recommended in patients with PAH
I
C
In the absence of anaemia, iron repletion may be considered in patients with PAH with iron deﬁciency
IIb
C
Anticoagulation is not generally recommended in patients with PAH but may be considered on an individual basis
IIb
C
The use of ACEis, ARBs, ARNIs, SGLT-2is,
beta-blockers, or ivabradine is not recommended in patients with PAH unless required by comorbidities (i.e. high blood pressure, coronary artery disease, left HF, or arrhythmias)
III
C
Special circumstances
In-ﬂight oxygen administration is recommended for patients using oxygen or whose arterial blood oxygen pressure is ,8 kPa (60 mmHg) at sea level
I
C
For interventions requiring anaesthesia,
multidisciplinary consultation at a PH centre to assess risk and beneﬁt should be considered
IIa
C
© ESC/ERS 2022
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
ARNI, angiotensin receptor–neprilysin inhibitor; HF, heart failure; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; RV, right ventricle; SARS-CoV-2,
severe acute respiratory syndrome coronavirus-2;
SGLT-2i,
sodium–glucose cotransporter-2 inhibitor.
aClass of recommendation.
bLevel of evidence.
cMeasured on at least two occasions.
Recommendation Table 6 — Recommendations for women of childbearing potential
Recommendations
Classa
Levelb
It is recommended that women of childbearing potential with PAH are counselled at the time of diagnosis about the risks and uncertainties associated with becoming pregnant; this should include advice against becoming pregnant, and referral for psychological support where needed
I
C
Continued
It is recommended to provide women of childbearing potential with PAH with clear contraceptive advice, considering the individual needs of the woman but recognizing that the implications of contraceptive failure are signiﬁcant in PAH
I
C
It is recommended that women with PAH who consider pregnancy or who become pregnant receive prompt counselling in an experienced PH
centre, to facilitate genetic counselling and shared decision-making, and to provide psychological support to the patients and their families where needed
I
C
For women with PAH having a termination of pregnancy, it is recommended that this be performed in PH centres, with psychological support provided to the patients and their families
I
C
For women with PAH who desire to have children,
where available, adoption and surrogacy with preconception genetic counselling may be considered
IIb
C
As teratogenic potential has been reported in pre-clinical models for endothelin receptor antagonists and riociguat, these drugs are not recommended during pregnancy359,377
III
B
© ESC/ERS 2022
PAH, pulmonary arterial hypertension; PH, pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
ESC/ERS Guidelines
3663


<!-- PAGE 47 -->

### Page 47

attempts. Patients who have not undergone a vasoreactivity study or those with a negative test should not be started on CCBs because of potentially severe side effects (e.g. severe hypotension, syncope, and
RV failure), unless prescribed at standard doses for other indications.379
6.3.3.2. Endothelin receptor antagonists
Binding of endothelin-1 to endothelin receptors A and B on PA
smooth-muscle cells promotes vasoconstriction and proliferation
(Figure 7).380 Endothelin B receptors are mostly expressed on
Recommendation Table 7 — Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension
Recommendations
Classa
Levelb
High doses of CCBs are recommended in patients with IPAH, HPAH, or DPAH who are responders to acute vasoreactivity testing
I
C
Close follow-up with complete reassessment after 3–4 months of therapy (including RHC) is recommended in patients with IPAH, HPAH, or
DPAH treated with high doses of CCBs
I
C
Continuing high doses of CCBs is recommended in patients with IPAH, HPAH, or DPAH in
WHO-FC I or II with marked haemodynamic improvement (mPAP ,30 mmHg and PVR ,4
WU)
I
C
Initiating PAH therapy is recommended in patients who remain in WHO-FC III or IV or those without marked haemodynamic improvement after high doses of CCBs
I
C
In patients with a positive vasoreactivity test but insufﬁcient long-term response to CCBs who require additional PAH therapy, continuation of
CCB therapy should be considered
IIa
C
CCBs are not recommended in patients without a vasoreactivity study or non-responders, unless prescribed for other indications (e.g. Raynaud’s phenomenon)
III
C
© ESC/ERS 2022
CCB, calcium channel blocker; DPAH, drug-associated pulmonary arterial hypertension;
HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; RHC, right heart catheterization;
WHO-FC, World Health Organization functional class; WU, Wood units.
aClass of recommendation.
bLevel of evidence.
Table 19
Dosing of pulmonary arterial hypertension medication in adults
Starting dose
Target dose
Calcium channel blockers
Amlodipine
5 mg o.d.
15–30 mg o.d.a
Diltiazem
60 mg b.i.d.b
120–360 mg b.i.d.b
Felodipine
5 mg o.d.
15–30 mg o.d.a
Continued
Nifedipine
10 mg t.i.d.
20–60 mg b.i.d. or t.i.d.
Endothelin receptor antagonists (oral administration)
Ambrisentan
5 mg o.d.
10 mg o.d.
Bosentan
62.5 mg b.i.d.
125 mg b.i.d.
Macitentan
10 mg o.d.
10 mg o.d.
Phosphodiesterase 5 inhibitors (oral administration)
Sildenaﬁl
20 mg t.i.d.
20 mg t.i.d.c
Tadalaﬁl
20 or 40 mg o.d.
40 mg o.d.
Prostacyclin analogues (oral administration)
Beraprost sodium
20 µg t.i.d.
Maximum tolerated dose up to
40 µg t.i.d.
Beraprost extended release
60 µg b.i.d.
Maximum tolerated dose up to
180 µg b.i.d.
Treprostinil
0.25 mg b.i.d.
or
0.125 mg t.i.d.
Maximum tolerated dose
Prostacyclin receptor agonist (oral administration)
Selexipag
200 µg b.i.d.
Maximum tolerated dose up to
1600 µg b.i.d.
Soluble guanylate cyclase stimulator (oral administration)
Riociguatd
1 mg t.i.d.
2.5 mg t.i.d.
Prostacyclin analogues (inhaled administration)
Iloproste
2.5 µg 6–9
times per day
5.0 µg 6–9 times per day
Treprostinile
18 µg 4 times per day
54–72 µg 4 times per day
Prostacyclin analogues (i.v. or s.c. administration)
Epoprostenol i.v.
2 ng/kg/min
Determined by tolerability and effectiveness; typical dose range at 1 year is 16–30 ng/kg/min,
with wide individual variability
Treprostinil s.c. or i.v.
1.25 ng/kg/
min
Determined by tolerability and effectiveness; typical dose range at 1 year is 25–60 ng/kg/min,
with wide individual variability
© ESC/ERS 2022
b.i.d., twice daily; i.v., intravenous; o.d., once daily; s.c., subcutaneous; t.i.d., three times daily.
Dosages are those commonly used in clinical practice. This does not exclude the use of alternative dosages.
aThe daily dosages of amlodipine and felodipine can be administered in a single dose or divided into two doses.
bThere are different release formulations of diltiazem, some of which should be administered o.d. or t.i.d.
cSildenaﬁl is approved at a dose of 20 mg t.i.d. but doses used in practice vary widely and are sometimes higher.
dIn patients at risk of systemic hypotension, riociguat may be started at 0.5 mg t.i.d.
eDoses provided are for nebulizers and may differ with the use of other formulations and other inhalation devices.
3664
ESC/ERS Guidelines


<!-- PAGE 48 -->

### Page 48

pulmonary endothelial cells, promoting vasodilation through accelerated production of prostacyclin and nitric oxide, and clearance of endothelin-1.380 Nevertheless, selective blocking of endothelin A receptors alone or non-selective blocking of both A and B receptors has shown similar effectiveness in PAH.380 Endothelial receptor antagonists have teratogenic effects and should not be used during pregnancy.381
6.3.3.2.1. Ambrisentan. Ambrisentan is an oral ERA that preferentially blocks the endothelin A receptors. The approved dosages in adults are 5 mg and 10 mg o.d. In patients with PAH, it has demonstrated efﬁcacy for symptoms, exercise capacity, haemodynamics,
and time to clinical worsening.382 An increased incidence of peripheral oedema was reported with ambrisentan use, while there was no increased incidence of abnormal liver function.
6.3.3.2.2. Bosentan. Bosentan is an oral, dual ERA that improves exercise capacity, WHO-FC, haemodynamics, and time to clinical worsening in patients with PAH.383 The approved target dose in adults is 125 mg b.i.d. Dose-dependent increases in liver transaminases can occur in ≏10% of treated patients (reversible after dose reduction or discontinuation).384 Thus, liver function testing should be performed monthly in patients receiving bosentan.384 Due to pharmacokinetic interactions, bosentan may render hormonal contraceptives unreliable and lower serum levels of warfarin, sildenaﬁl,
and tadalaﬁl.361,385–387
Y
Vaso
V
reactivity testing algorithm in patients with presumed diagnosis of I/H/D-PAH and t
P
reatment of responders
Refer to PH cent f
re
Reassess after 3–6 months
Continue therapy and p
reassess every 6–12 months
Right heart catheterization with pulmonary vasoreactivity testinga
(Class I)
Initiate therapy with calcium channel bloc p
kers k
and titrate to optimized individual doseb
(Class I)
≥10 mmHg mPAP d
P
rop from baseline to ≤40 mmHg with increased or unchanged cardiac output
Y
WHO-FC I/II, BNP <50 ng/L or NT-p
T
roBNP <300 ng/L,
normal or near-normal resting haemodynamicsc
Treat according to Figure 9
N
N
Figure 8 Vasoreactivity testing algorithm of patients with presumed diagnosis of idiopathic, heritable, or drug-associated pulmonary arterial hypertension. BNP, brain natriuretic peptide; I/H/D-PAH, idiopathic, heritable, drug-associated pulmonary arterial hypertension; mPAP, mean pulmonary arterial pressure; N, no; NT-proBNP, N-terminal pro-brain natriuretic peptide; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; WHO-FC,
World Health Organization functional class; WU, Wood units; Y, yes. aInhaled nitric oxide and inhaled iloprost are recommended; intravenous epoprostenol can be used if inhaled nitric oxide or inhaled iloprost are unavailable. bSee text for details. cmPAP ≤30 mmHg and PVR ≤4 WU.
ESC/ERS Guidelines
3665


<!-- PAGE 49 -->

### Page 49

6.3.3.2.3. Macitentan. Macitentan is an oral, dual ERA that has been found to increase exercise capacity and reduce a composite endpoint of clinical worsening in patients with PAH.167 While no liver toxicity has been shown, a reduction in Hb to ≤8 g/dL was observed in 4.3% of patients receiving 10 mg of macitentan.167
6.3.3.3. Phosphodiesterase 5 inhibitors and guanylate cyclase stimulators
Stimulating soluble guanylate cyclase (sGC) by nitric oxide results in production of the intracellular second messenger cyclic guanosine monophosphate (cGMP) (Figure 7). This pathway is controlled by a
Risk (3 strata)
(Table 16)
T
Initial ERA
R
+ PDE5i therapy p
(Class I)
Initial ERA + PDE5i and i.v.v/s.c. P
. CAb
(Class IIa)
Initial oral monotherapy p
with PDE5i or ERA
R
(Class IIa)
Add i.v.v o
. r s r .c. P
. CA and/or evaluate a
fof r lung transplantati a on
(Class IIa)
Regular fof llow-up assessment and individualized therapy p
Regular fof llow-up assessment
(Tab
T le 17)
Low or intermediate
High
Risk (4 strata) 
(Table 18)
T
Continue initial therapy p
(Class I)
Low
Intermediate-low
Intermediate-high or high
OR
Add PRA
R
(Class IIa)
Switch from
PDE5i to sGCs
(Class IIb)
Tr
T eatment of patients with I/H/D-PAH or 
P
PAH-CTD
P
Diagnosis confirmed at PH centre, vaso
,
reactivity testing negative
General measures throughout the course of the disease
(ReCo Table 5)
T
(Class I)
Patient without cardiopulmonary comorbiditiesa
Patient with cardiopulmonary comorbiditiesa
All risk categories
Figure 9 Evidence-based pulmonary arterial hypertension treatment algorithm for patients with idiopathic, heritable, drug-associated, and connective tissue disease-associated pulmonary arterial hypertension. DLCO, Lung diffusion capacity for carbon monoxide; ERA, endothelin receptor antagonist; I/
H/D-PAH, idiopathic, heritable, or drug-associated pulmonary arterial hypertension; i.v., intravenous; PAH-CTD, PAH associated with connective tissue disease; PCA, prostacyclin analogue; PDE5i, phosphodiesterase 5 inhibitor; PH, pulmonary hypertension; PRA, prostacyclin receptor agonist; ReCo, recommendation; s.c., subcutaneous; sGCs, soluble guanylate cyclase stimulator. aCardiopulmonary comorbidities are conditions associated with an increased risk of left ventricular diastolic dysfunction, and include obesity, hypertension, diabetes mellitus, and coronary heart disease; pulmonary comorbidities may include signs of mild parenchymal lung disease and are often associated with a low DLCO (,45% of the predicted value).
bIntravenous epoprostenol or i.v./s.c. treprostinil.
3666
ESC/ERS Guidelines


<!-- PAGE 50 -->

### Page 50

negative feedback loop through degradation of cGMP via different phosphodiesterases, among which subtype 5 (PDE5) is abundantly expressed in the pulmonary vasculature.388 Phosphodiesterase 5 inhibitors and sGC stimulators must not be combined with each other and with nitrates, as this can result in systemic hypotension.389
6.3.3.3.1. Sildenaﬁl. Sildenaﬁl is an orally active, potent, and selective inhibitor of PDE5. Several RCTs of patients with PAH treated with sildenaﬁl (with or without background therapy) have conﬁrmed favourable results on exercise capacity, symptoms, and/or haemodynamics.390–392 The approved dose of sildenaﬁl is 20 mg t.i.d.
Most side effects of sildenaﬁl are mild to moderate and mainly related to vasodilation (headache, ﬂushing, and epistaxis).
6.3.3.3.2. Tadalaﬁl. Tadalaﬁl is a once-daily administered PDE5i. An
RCT of 406 patients with PAH (53% on background bosentan therapy) treated with tadalaﬁl at doses up to 40 mg o.d. showed favourable results on exercise capacity, symptoms, haemodynamics, and time to clinical worsening.393 The side effect proﬁle was similar to that of sildenaﬁl.
6.3.3.3.3. Riociguat. While PDE5is augment the nitric oxide–cGMP
pathway by slowing cGMP degradation, sGC stimulators enhance cGMP production by directly stimulating the enzyme, both in the presence and absence of endogenous nitric oxide.394 An RCT of
443 patients with PAH (44% and 6% on background therapy with
ERAs or prostacyclin analogues, respectively) treated with riociguat up to 2.5 mg t.i.d. showed favourable results on exercise capacity,
haemodynamics, WHO-FC, and time to clinical worsening.395 The side effect proﬁle was similar to that of PDE5is.
6.3.3.4. Prostacyclin analogues and prostacyclin receptor agonists
The prostacyclin metabolic pathway (Figure 7) is dysregulated in patients with PAH, with less prostacyclin synthase expressed in PAs and reduced prostacyclin urinary metabolites.396 Prostacyclin analogues and prostacyclin receptor agonists induce potent vasodilation,
inhibit platelet aggregation, and also have both cytoprotective and anti-proliferative activities.397 The most common adverse events observed with these compounds are related to systemic vasodilation and include headache, ﬂushing, jaw pain, and diarrhoea.
6.3.3.4.1. Epoprostenol. Epoprostenol has a short half-life (3–
5 min) and needs continuous i.v. administration via an infusion pump and a permanent tunnelled catheter. A thermo-stable formulation is available to maintain stability up to 48 h.398 Its efﬁcacy has been demonstrated in three unblinded RCTs in patients with IPAH
(WHO-FC
III
and
IV)399,400
and
SSc-associated
PAH.401
Epoprostenol improved symptoms, exercise capacity, haemodynamics, and mortality.399 Long-term, persistent efﬁcacy has also been shown in IPAH,212,245 as well as in other associated PAH conditions.402–404 Serious adverse events related to the delivery system include pump malfunction, local site infection, catheter obstruction,
and sepsis. Recommendations for preventing central venous catheter bloodstream infections have been proposed.405,406
6.3.3.4.2. Iloprost. Iloprost is a prostacyclin analogue approved for inhaled administration. Inhaled iloprost has been evaluated in one
RCT, in which six to nine repetitive iloprost inhalations were compared with placebo in treatment-naïve patients with PAH or
CTEPH.407 The study showed an increase in exercise capacity and improvement in symptoms, PVR, and clinical events in the iloprost group compared with the placebo group.
6.3.3.4.3. Treprostinil. Treprostinil is available for s.c., i.v., inhaled,
and oral administration. Treprostinil s.c. improved exercise capacity,
haemodynamics, and symptoms in PAH.408 Infusion-site pain was the most common adverse effect, which led to treatment discontinuation in 8% of cases.408 Based on its chemical stability, i.v. treprostinil may also be administered via implantable pumps, improving convenience and likely decreasing the occurrence of line infections.409,410
Inhaled treprostinil improved the 6MWD, NT-proBNP, and quality of life measures in patients with PAH on background therapy with either bosentan or sildenaﬁl.411 Inhaled treprostinil is not approved in Europe.
Oral treprostinil has been evaluated in two RCTs of patients with
PAH on background therapy with bosentan and/or sildenaﬁl. In both trials, the primary endpoint—6MWD—did not reach statistical signiﬁcance.412,413 An additional RCT in treatment-naïve patients with
PAH showed improved 6MWD.414 An event-driven RCT that enrolled 690 patients with PAH demonstrated that oral treprostinil reduced the risk of clinical worsening events in patients who were receiving oral monotherapy with ERAs or PDE5is.415 Oral treprostinil is not approved in Europe.
6.3.3.4.4. Beraprost. Beraprost is a chemically stable and orally active prostacyclin analogue. Two RCTs have shown a modest, shortterm improvement in exercise capacity in patients with PAH;416,417
however, there were no haemodynamic improvements or long-term outcome beneﬁts. Beraprost is not approved in Europe.
6.3.3.4.5. Selexipag. Selexipag is an orally available, selective, prostacyclin receptor agonist that is chemically distinct from prostacyclin,
with different pharmacology. In a pilot RCT in patients with PAH (receiving stable ERA and/or PDE5i therapy), selexipag reduced PVR
after 17 weeks.418 An event-driven, phase 3 RCT that enrolled
1156 patients419 showed that selexipag alone or on top of mono or double therapy with an ERA and/or a PDE5i reduced the relative risk of composite morbidity/mortality events by 40%. The most common side effects were headache, diarrhoea, nausea, and jaw pain.
6.3.4. Treatment strategies for patients with idiopathic, heritable, drug-associated, or connective tissue disease-associated pulmonary arterial hypertension
Pulmonary arterial hypertension is a rare and life-threatening disease and should be managed, where possible, at PH centres in close collaboration with the patient’s local physicians.
This section describes drug treatment and is focused on nonvasoreactive patients with IPAH/HPAH/DPAH and on patients with PAH associated with connective tissue disease (PAH-CTD).
Information on the dosing of PAH medication is summarized in
Table 19. For other forms of PAH, treatment strategies have to be modiﬁed (see Section 7). The approach to vasoreactive patients with IPAH/HPAH/DPAH is described in Section 6.3.3.1.
ESC/ERS Guidelines
3667


<!-- PAGE 51 -->

### Page 51

In addition to targeted drug treatment, the comprehensive management of patients with PAH includes general measures that may include supplementary oxygen, diuretics to optimize volume status,
psychosocial support, and standardized exercise training (Section
6.3.1).315 Prior to the treatment decisions, patients and their next of kin should be provided with appropriate and timely information about the risks and beneﬁts of the treatment options so they can make the ﬁnal, informed, and joint decision about the treatment with the medical team. Treatment decisions in patients with IPAH/
HPAH/DPAH or PAH-CTD should be stratiﬁed according to the presence or absence of cardiopulmonary comorbidities (Section
6.3.4.3) and according to disease severity assessed by risk stratiﬁcation (Section 6.2.7).
6.3.4.1. Initial treatment decision in patients without cardiopulmonary comorbidities
The initial treatment of patients with PAH should be based on a comprehensive, multiparameter risk assessment, considering disease type and severity, comorbidities, access to therapies, economic aspects, and patient preference.
The following considerations predominantly apply to patients with
IPAH/HPAH/DPAH or PAH-CTD without cardiopulmonary comorbidities, as patients with comorbidities were under-represented in the clinical studies addressing treatment strategies and combination therapy in patients with PAH. Treatment considerations for patients with PAH and cardiopulmonary comorbidities are summarized in Section 6.3.4.3.
For patients presenting at low or intermediate risk, initial combination therapy with an ERA and a PDE5i is recommended. This approach was assessed in the AMBITION study, which compared initial combination therapy using ambrisentan at a target dose of
10 mg o.d. and tadalaﬁl at a target dose of 40 mg o.d. with initial monotherapy with either drug.166 AMBITION predominantly included patients with IPAH/HPAH/DPAH or PAH-CTD. The primary endpoint was the time to ﬁrst clinical failure event (a composite of death, hospitalization for worsening PAH, disease progression, or unsatisfactory long-term clinical response). The hazard ratio (HR)
for the primary endpoint in the combination-therapy group vs. the pooled monotherapy group was 0.50 (95% conﬁdence interval
[CI], 0.35–0.72; P , 0.001) and there were signiﬁcant improvements in 6MWD and NT-proBNP with initial combination therapy. At the end of the study, 10% of the patients assigned to initial combination therapy had died compared with 14% of the patients assigned to initial monotherapy (HR 0.67; 95% CI, 0.42–1.08).420
In the TRITON study, treatment-naïve patients with PAH were assigned to initial dual-combination therapy with macitentan and tadalaﬁl, or initial triple-combination therapy with macitentan
10 mg o.d., tadalaﬁl at a target dose of 40 mg o.d., and selexipag up to 1600 µg o.d.421 TRITON predominantly included patients with IPAH/HPAH/DPAH or PAH-CTD. At week 26, PVR was reduced by 52% and 54%, with double- or triple-combination therapy, respectively, and 6MWD had increased by 55 m and 56 m,
respectively. The geometric means of the NT-proBNP ratio from baseline to week 26 were 0.25 and 0.26, respectively.
Hence, TRITON did not show a beneﬁt of oral triple- vs. oral double-combination therapy but conﬁrmed that substantial improvements in haemodynamics and exercise capacity can be obtained with initial ERA/PDE5i combination therapy. Further studies are needed to determine whether oral triple-combination therapy impacts long-term outcomes.
Based on the evidence generated by these and other studies,303,422–424 initial dual-combination therapy with an ERA and a
PDE5i is recommended for newly diagnosed patients who present at low or intermediate risk. Initial oral triple-combination therapy is not recommended, given the current lack of evidence supporting this strategy. In patients presenting at high risk, initial triplecombination therapy including an i.v./s.c. prostacyclin analogue should be considered.426,427 While it is acknowledged that the evidence for this approach is limited to case series, there is consensus that this strategy has the highest likelihood of success, especially in view of registry data from France showing that initial triplecombination therapy including an i.v./s.c. prostacyclin analogue was associated with better long-term survival than monotherapy or dualcombination therapy.428 Initial triple-combination therapy including an i.v./s.c. prostacyclin analogue should also be considered in patients at intermediate risk presenting with severe haemodynamic impairment (e.g. RAP ≥20 mmHg, CI ,2.0 L/min/m2, SVI ,31 mL/m2,
and/or PVR ≥12 WU).238,426
The recommendations for initial oral double-combination therapy are based on PICO question I (Supplementary Data, Section 6.2).
Although the quality of evidence is low, initial oral combination therapy with an ERA and a PDE5i achieves important targets in symptom improvement (functional class), exercise capacity, cardiac biomarkers, and reduction of hospitalizations.
Recommendation Table 8 — Recommendations for the treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present without cardiopulmonary comorbiditiesa
Recommendation Table 8A
Recommendations
Classb
Levelc
Recommendations for initial therapy
In patients with IPAH/HPAH/DPAH who present at high risk of death, initial combination therapy with a PDE5i, an ERA, and i.v./s.c. prostacyclin analogues should be consideredd
IIa
C
Recommendations for treatment decisions during follow-up
In patients with IPAH/HPAH/DPAH who present at intermediate–low risk of death while receiving
ERA/PDE5i therapy, the addition of selexipag should be considered419
IIa
B
In patients with IPAH/HPAH/DPAH who present at intermediate–high or high risk of death while receiving ERA/PDE5i therapy, the addition of i.v./
s.c. prostacyclin analogues and referral for LTx evaluation should be considered
IIa
C
In patients with IPAH/HPAH/DPAH who present at intermediate–low risk of death while receiving
ERA/PDE5i therapy, switching from PDE5i to riociguat may be considered429
IIb
B
© ESC/ERS 2022
3668
ESC/ERS Guidelines


<!-- PAGE 52 -->

### Page 52

6.3.4.2. Treatment decisions during follow-up in patients without cardiopulmonary comorbidities
Patients with PAH require regular follow-up, including risk stratiﬁcation and an assessment of patient concordance with therapy.
Patients who achieve a low-risk status have a much superior long-term survival compared with patients with intermediateor high-risk status.292,295,296 Achieving and maintaining a lowrisk proﬁle is therefore a key objective in managing patients with PAH.
Several clinical trials have assessed the safety and efﬁcacy of sequential combination therapy in patients with PAH. SERAPHIN enrolled 742 patients with PAH, mostly with IPAH/HPAH/DPAH and
PAH-CTD, of whom 63.7% were receiving other PAH medication at the time of enrolment, mostly sildenaﬁl.167 In the subgroup of patients with background PAH therapy, macitentan at a daily dose of
10 mg reduced the risk of clinical worsening events compared with placebo (HR 0.62; 95% CI, 0.43–0.89).167
GRIPHON assessed the safety and efﬁcacy of selexipag.419 This study enrolled 1156 patients with PAH, also mostly with IPAH/
HPAH/DPAH or PAH-CTD, who were treatment naïve or receiving background therapy with an ERA, PDE5i, or a combination of both. Selexipag at a dose of up to 1600 µg b.i.d. was associated with a reduced risk of clinical worsening events independent of the background medication. In patients receiving ERA/PDE5i combination therapy (n = 376), the risk of clinical worsening events was lower with selexipag than with placebo (HR 0.63; 95% CI, 0.44–
0.90).431
The effects of combination therapy on long-term survival in patients with PAH remain unclear. A 2016 meta-analysis demonstrated that combination therapy (initial and sequential) was associated with a signiﬁcant risk reduction for clinical worsening (relative risk [RR]
0.65; 95% CI, 0.58–0.72; P , 0.0001);432 however, all-cause mortality was not improved (RR 0.86; 95% CI, 0.72–1.03; P = 0.09) and a substantial proportion of patients had clinical worsening events or died despite receiving combination therapy. In addition, registry data showed that the use of combination therapy increased since 2015
but there was no clear improvement in overall survival rates.428,433,434 These data were corroborated by a study showing that less than half of patients receiving initial combination therapy with an ERA and a PDE5i achieved and maintained a low-risk proﬁle.422
Switching from PDE5is to riociguat has also been investigated as a treatment-escalation strategy.429,435 REPLACE was a randomized, controlled, open-label study that enrolled patients on a
PDE5i-based therapy who were in WHO-FC III and had a
6MWD of 165–440 m.429 The study predominantly included patients with IPAH/HPAH/DPAH or PAH-CTD who were randomized to continue their PDE5i or to switch from a PDE5i to riociguat up to 2.5 mg t.i.d. The study met its primary endpoint,
termed ‘clinical improvement’, which was a composite of prespeciﬁed improvements in 6MWD, WHO-FC, and NT-proBNP
at week 24. Clinical improvement at week 24 was demonstrated in 41% of the patients who switched to riociguat and in 20% of the patients who maintained their PDE5i (odds ratio [OR] 2.78;
95% CI, 1.53–5.06; P = 0.0007). In addition, fewer patients in the riociguat group experienced a clinical worsening event (OR 0.10;
95% CI, 0.01–0.73; P = 0.0047).
Based on the evidence summarized above, the following recommendations for treatment decisions during follow-up are:
Recommendation Table 8B
GRADE
Recommendations
Quality of evidence
Strength of recommendation
Classa
Levelb
Recommendations for initial therapy
In patients with IPAH/
HPAH/DPAH who present at low or intermediate risk of death, initial combination therapy with a PDE5i and an
ERA is recommended166
Low
Conditional
I
B
© ESC/ERS 2022
CI, cardiac index; DLCO, Lung diffusion capacity for carbon monoxide; DPAH,
drug-associated pulmonary arterial hypertension;
ERA,
endothelin receptor antagonist; HFpEF, heart failure with preserved ejection fraction; HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension;
i.v., intravenous; LTx, lung transplantation; PAH, pulmonary arterial hypertension;
PDE5i, phosphodiesterase 5 inhibitor; PVR, pulmonary vascular resistance; RAP, right atrial pressure; s.c., subcutaneous; SVI, stroke volume index; WU, Wood units.
aCardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF such as obesity, diabetes, coronary heart disease, a history of hypertension, and/or a low DLCO.
bClass of recommendation.
cLevel of evidence.
dInitial triple-combination therapy including i.v./s.c. prostacyclin analogues may also be considered in patients presenting at intermediate risk but severe haemodynamic impairment (e.g. RAP ≥20 mmHg, CI ,2.0 L/min/m2, SVI ,31 mL/m2, and/or PVR
≥12 WU).
Recommendation Table 9 — Recommendations for initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension without cardiopulmonary comorbidities
Recommendations
Classa
Levelb
Initial combination therapy with ambrisentan and tadalaﬁl is recommended166,420,423
I
B
Initial combination therapy with macitentan and tadalaﬁl is recommended421,430
I
B
Initial combination therapy with other ERAs and
PDE5is should be considered430
IIa
B
Initial combination therapy with macitentan,
tadalaﬁl, and selexipag is not recommended421
III
B
© ESC/ERS 2022
ERA, endothelin receptor antagonist; PDE5i, phosphodiesterase 5 inhibitor.
aClass of recommendation.
bLevel of evidence.
ESC/ERS Guidelines
3669


<!-- PAGE 53 -->

### Page 53

(i) In patients who achieve a low-risk status with their initial PAH
therapy, continuation of treatment is recommended.
(ii) In patients who are at intermediate–low risk despite receiving
ERA/PDE5i therapy, adding selexipag should be considered to reduce the risk of clinical worsening. In these patients, switching from PDE5i to riociguat may also be considered.
(iii) In patients who are at intermediate–high or high risk while receiving oral therapies, the addition of i.v. epoprostenol or i.v./
s.c. treprostinil and referral for LTx evaluation should be considered.309,436 If adding i.v./s.c. prostacyclin analogues is unfeasible,
adding selexipag or switching from PDE5i to riociguat may be considered.
6.3.4.3. Pulmonary arterial hypertension with cardiopulmonary comorbidities
Over the past decade, the demographics and characteristics of patients with IPAH have changed, especially in industrialized countries.447 In several contemporary registries, the average age of patients diagnosed with IPAH is ≏60 years or older.161,295,299,447,448
Many elderly patients have cardiopulmonary comorbidities, making the distinction from group 2 and group 3 PH challenging.
Among elderly patients diagnosed with IPAH, two main disease phenotypes have emerged. One phenotype (herein called the left heart phenotype) consists of elderly, mostly female patients with risk factors for HFpEF (e.g. hypertension, obesity, diabetes,
or coronary heart disease) but pre-capillary PH rather than postcapillary PH;449,450 ≏30% of these patients have a history of atrial
ﬁbrillation.161 The other phenotype (called the cardiopulmonary phenotype) consists of elderly, predominantly male patients who have a low DLCO (,45% of the predicted value), are often hypoxaemic, have a signiﬁcant smoking history, and have risk factors for LHD.77,78,161,451 In a cluster analysis of 841 newly diagnosed patients with IPAH from the COMPERA registry,
12.6% had a classic phenotype of young, mostly female patients without cardiopulmonary comorbidities, while 35.8% presented with a left heart phenotype and 51.6% with a cardiopulmonary phenotype.161
Recommendation Table 10 — Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension
Recommendations
Classa
Levelb
General recommendation for sequential combination therapy
It is recommended to base treatment escalations on risk assessment and general treatment strategies (see Figure 9)
I
C
Evidence from studies with a composite morbidity/mortality endpoint as the primary outcome measure
The addition of macitentan to PDE5is or oral/
inhaled prostacyclin analogues is recommended to reduce the risk of morbidity/mortality events167,168,437
I
B
The addition of selexipag to ERAsc and/or PDE5is is recommended to reduce the risk of morbidity/
mortality events418,419
I
B
The addition of oral treprostinil to ERA or PDE5i/
riociguat monotherapy is recommended to reduce the risk of morbidity/mortality events412,413,415
I
B
The addition of bosentan to sildenaﬁl is not recommended to reduce the risk of morbidity/
mortality events419a
III
B
Evidence from studies with change in 6MWD as the primary outcome measure
The addition of sildenaﬁl to epoprostenol is recommended to improve exercise capacity392,438
I
B
The addition of inhaled treprostinil to sildenaﬁl or bosentan monotherapy should be considered to improve exercise capacity411,439
IIa
B
The addition of riociguat to bosentan should be considered to improve exercise capacity395,440
IIa
B
Continued
The addition of tadalaﬁl to bosentan may be considered to improve exercise capacity393
IIb
C
The addition of inhaled iloprost to bosentan may be considered to improve exercise capacity441,442
IIb
B
The addition of ambrisentan to sildenaﬁl may be considered to improve exercise capacity443
IIb
C
The addition of bosentan to sildenaﬁl may be considered to improve exercise capacity419,444
IIb
C
The addition of sildenaﬁl to bosentan may be considered to improve exercise capacity444–446
IIb
C
Other sequential double- or triple-combination therapies may be considered to improve exercise capacity and/or alleviate PH symptoms
IIb
C
Evidence from studies with safety of combination therapy as the primary outcome measure
Combining riociguat and PDE5is is not recommendedd 389
III
B
© ESC/ERS 2022
6MWD, 6-minute walking distance; ERA, endothelin receptor antagonist; PDE5i,
phosphodiesterase 5 inhibitor; PH, pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
cERAs used in the GRIPHON study were bosentan and ambrisentan.
dThe PATENT plus study investigated the combination of sildenaﬁl and riociguat;
however, combining riociguat with any PDE5i is contraindicated.
3670
ESC/ERS Guidelines


<!-- PAGE 54 -->

### Page 54

There are no evidence-based rules for determining a
patient’s phenotype. The AMBITION study used the presence of more than three risk factors for LHD together with certain haemodynamic criteria to exclude patients from the primary analysis.166 However, the COMPERA cluster analysis mentioned above found that the presence of a single risk factor may change the phenotype.161 Pending further data, it is the overall proﬁle that should be used to determine a patient’s phenotype.
Compared with patients without cardiopulmonary comorbidities,
patients with cardiopulmonary comorbidities respond less well to
PAH medication, are more likely to discontinue this medication due to efﬁcacy failure or lack of tolerability, are less likely to reach a low-risk status, and have a higher mortality risk. While the age-adjusted mortality of patients with the left heart phenotype seems to be similar to that of patients with classical PAH, patients with a cardiopulmonary phenotype and a low DLCO have a particularly high mortality risk.77,78,161,450,451
As patients with cardiopulmonary comorbidities were underrepresented in or excluded from PAH trials, no evidence-based treatment recommendations can be made for this patient population. Registry data suggest that most physicians use PDE5is as primary treatment for these patients.
Endothelin receptor antagonists or PDE5i/ERA combinations are occasionally used,
but the drug discontinuation rate is higher than in patients with classical PAH.447,450 A subgroup analysis from AMBITION, which assessed the response to PAH therapy in 105 patients who were excluded from the primary analysis set because of a left heart phenotype, found that these patients—compared with patients in the primary analysis set—had less clinical improvement and a higher likelihood of drug discontinuations due to safety and tolerability with both monotherapy and initial combination therapy.449
Data from the ASPIRE registry demonstrated that patients with
IPAH and a cardiopulmonary phenotype had less improvement in exercise capacity and PROMs compared with patients with classical IPAH.451
In patients with a left heart phenotype, ERA therapy is associated with an elevated risk of ﬂuid retention.449 Moreover,
in patients with a cardiopulmonary phenotype, PAH medication may cause a decline in the peripheral oxygen saturation.452
There is little published experience on the use of prostacyclin analogues or prostacyclin receptor agonists in this patient population.453
The lack of solid evidence for treating elderly patients with PAH
and cardiopulmonary comorbidities makes treatment recommendations challenging, and patients should be counselled accordingly.
In the absence of evidence on treatment strategies in these patients,
risk stratiﬁcation is of limited usefulness in guiding therapeutic decision-making. Initial monotherapy (see Supplementary Data,
Table S3) is recommended for most of these patients, with
PDE5is being the most widely used compounds according to registry data.161 Further treatment decisions should be made on an individual basis in collaboration with the PH centre and local physicians.
The treatment algorithm for patients with PAH is shown in
Figure 9 and the accompanying section describing the treatment algorithm.
6.3.5. Drug interactions
Among PAH drugs, clinically relevant pharmacokinetic interactions are observed between bosentan and sildenaﬁl (reduced sildenaﬁl plasma concentration385), bosentan and hormonal contraceptives
(reduced contraception efﬁcacy361), and bosentan and vitamin K antagonists (VKAs) (potential need for VKA dose adjustment386).
Additional pharmacokinetic interactions of potential clinical relevance are listed in Supplementary Data, Table S4.
6.3.6. Interventional therapy
6.3.6.1. Balloon atrial septostomy and Potts shunt
Balloon atrial septostomy,454,455 by creating an interatrial shunt, and
Potts shunt,456–459 by connecting the left PA and descending aorta,
aim to decompress the right heart and increase systemic blood
ﬂow, thereby improving systemic oxygen transport despite arterial oxygen desaturation. As these procedures are complex and associated with high risk, including substantial procedure-related mortality, they are rarely performed in patients with PAH and may only be considered in centres with experience in the techniques.
6.3.6.2. Pulmonary artery denervation
The rationale for performing a PA denervation (PADN) is based on the increased sympathetic overdrive characterizing PAH, which is associated with poor outcome.460,461 Although the contribution of this mechanism to developing PAH is not completely understood, it is associated with vasoconstriction and vascular remodelling through a baroreﬂex mediated by stretch receptors located at the bifurcation of the PAs.462,463 Applying radiofrequency at the latter acutely and
Recommendation Table 11 — Recommendations for the treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present with cardiopulmonary comorbiditiesa
Recommendations
Classb
Levelc
Recommendations for initial therapy
In patients with IPAH/HPAH/DPAH and cardiopulmonary comorbidities, initial monotherapy with a PDE5i or an ERA should be considered
IIa
C
Recommendations for treatment decisions during follow-up
In patients with IPAH/HPAH/DPAH with cardiopulmonary comorbidities who present at intermediate or high risk of death while receiving
PDE5i or ERA monotherapy, additional PAH
medication may be considered on an individual basis
IIb
C
© ESC/ERS 2022
DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PDE5i,
phosphodiesterase 5 inhibitor.
aCardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF such as obesity, diabetes, coronary heart disease, a history of hypertension, and/or a low DLCO.
bClass of recommendation.
cLevel of evidence.
ESC/ERS Guidelines
3671


<!-- PAGE 55 -->

### Page 55

chronically improves haemodynamic variables.464 However, there is little evidence yet from multicentre RCTs demonstrating a beneﬁt of PADN in patients already receiving recommended medical therapy.
A small multicentre study tested the feasibility of PADN using an intravascular ultrasound catheter in patients receiving dual or triple therapy for PAH;465 the procedure was safe and associated with a reduction in
PVR, and increases in 6MWD and daily activity. Although potentially promising, PADN should be considered experimental.
6.3.7. Advanced right ventricular failure
6.3.7.1. Intensive care unit management
Patients with PH may require intensive care treatment for right HF,
comorbidities (including major surgery), or both. The mortality risk is high in such patients,466,467 and specialized centres should be involved whenever possible. In addition to basic intensive care unit
(ICU) standards, RV function in these patients should be carefully monitored. Non-speciﬁc clinical signs of right HF with low CO include pale skin with peripheral cyanosis, hypotension, tachycardia,
declining urine output, and increasing lactate levels. Non-invasive monitoring should include biomarkers (NT-proBNP and troponin)
and echocardiography. Minimum invasive monitoring consists of an upper body central venous catheter to measure central venous pressure and central venous oxygen saturation, the latter reﬂecting CO.
Right heart catheterization or other forms of advanced haemodynamic assessment should be considered in patients with advanced right HF or in complex situations.468
Treating right HF should focus on treatable triggers such as infection, arrhythmia, anaemia, and other comorbidities. Fluid management is of utmost importance in these patients, most of whom require a negative ﬂuid balance to reduce RV pre-load, thereby improving RV geometry and function.468 Patients with a low CO may beneﬁt from treatment with inotropes; dobutamine and milrinone are the most frequently used substances in this setting. Maintaining the mean systemic blood pressure .60 mmHg is a key objective when treating right HF, and patients with persistent hypotension may require vasopressors such as norepinephrine or vasopressin.
Intubation and invasive mechanical ventilation should be avoided whenever possible in patients with advanced RV failure because of a high risk of further haemodynamic deterioration and death.
Pulmonary arterial hypertension medication should be considered on an individual basis, taking into account underlying disease, comorbidities, and existing medication. In patients with newly diagnosed PAH presenting with low CO, combination therapy including i.v./s.c. prostacyclin analogues should be considered.426
6.3.7.2. Mechanical circulatory support
In specialist centres, various forms of mechanical circulatory support are available for managing RV failure, with veno-arterial extracorporeal membrane oxygenation (ECMO) being the most widely used approach. Mechanical circulatory support has become an established bridging tool to transplantation in patients with irreversible right HF,
but is occasionally used as a bridge to recovery in patients with treatable causes and potentially reversible RV failure.468 No general recommendations can be made regarding the indication for mechanical circulatory support, which needs to be individualized, considering patient factors and local resources.469,470 Long-term mechanical support analogous to left ventricular assist devices (LVADs) is not yet available for patients with PH and end-stage right HF.
6.3.8. Lung and heart–lung transplantation
Lung transplantation remains an important treatment option for patients with PAH refractory to optimized medical therapy. In patients with PAH, referral to an LTx centre should be considered early
(Table 20):
Recommendation Table 12 — Recommendations for intensive care management for pulmonary arterial hypertension
Recommendations
Classa
Levelb
When managing patients with right HF in the ICU,
it is recommended to involve physicians with expertise, treat causative factors, and use supportive measures, including inotropes and vasopressors, ﬂuid management, and PAH drugs,
as appropriate
I
C
Mechanical circulatory support may be an option for selected patients as a bridge to transplantation or recovery, and interhospital transfer should be considered if such resources are unavailable on site
IIa
C
© ESC/ERS 2022
HF, heart failure; ICU, intensive care unit; PAH, pulmonary arterial hypertension.
aClass of recommendation.
bLevel of evidence.
Table 20
Criteria for lung transplantation and listing in patients with pulmonary arterial hypertension
Referral
Potentially eligible patients for whom LTx might be an option in case of treatment failure
ESC/ERS intermediate–high or high risk or REVEAL risk score .7 on appropriate PAH medication
Progressive disease or recent hospitalization for worsening PAH
Need for i.v. or s.c. prostacyclin therapy
Known or suspected high-risk variants, such as PVOD or PCH, systemic sclerosis, or large and progressive pulmonary artery aneurysms
Signs of secondary liver or kidney dysfunction due to PAH or other potentially life-threatening complications, such as recurrent haemoptysis
Listing
Patient has been fully evaluated and prepared for transplantation
ESC/ERS high risk or REVEAL risk score .10 on appropriate PAH
medication, usually including i.v. or s.c. prostacyclin analogues
Progressive hypoxaemia, especially in patients with PVOD or PCH
Progressive, but not end-stage liver of kidney dysfunction due to PAH, or life-threatening haemoptysis
© ESC/ERS 2022
ERS, European Respiratory Society; ESC, European Society of Cardiology; i.v.,
intravenous; LTx, lung transplantation; PAH, pulmonary arterial hypertension; PCH,
pulmonary capillary haemangiomatosis; PVOD, pulmonary veno-occlusive disease;
s.c., subcutaneous.
3672
ESC/ERS Guidelines


<!-- PAGE 56 -->

### Page 56

(1) when they present with an inadequate response to treatment despite optimized combination therapy; (2) when they present with an intermediate–high or high risk of death (i.e. 1-year mortality
.10% when estimated with established risk-stratiﬁcation tools)471
(see Section 6.2.7), which exceeds the current mortality rate after
LTx;472 (3) when patients have a disease variant that poorly responds to medical therapy, such as PVOD or PCH.
Both heart–lung and bilateral LTx have been performed for PAH.
Currently, most patients receive bilateral LTx, while combined heart–lung transplantation is reserved for patients who have additional non-correctable cardiac conditions.473 With the introduction of the lung allocation score (LAS), waiting list mortality has decreased and the odds of receiving a donor organ have increased.474 In some countries, an ‘exceptional LAS’ can be obtained for patients with severe PH. Some other countries not using the LAS have successfully implemented high-priority programmes for these patients.475 The patient and their next of kin should be fully engaged in the transplant assessment process and informed of the risks and beneﬁts, and the
ﬁnal decision should be jointly made between the patient and medical team (see Section 6.3.1.8). For patients with PAH who survive the early post-transplant period, long-term outcomes are good. A study found that for primary transplant patients with IPAH who survived to 1 year, conditional median survival was 10.0 years.476
6.3.9. Evidence-based treatment algorithm
A treatment algorithm for patients with IPAH/HPAH/DPAH or
PAH-CTD is shown in Figure 9. The evidence supporting this algorithm has mainly been generated in patients with IPAH/HPAH/
DPAH or PAH-CTD who present without cardiopulmonary comorbidities. Patients with HIV-associated PAH, PoPH, and PAH associated with congenital heart disease were not enrolled or under-represented in most PAH therapy trials. Treatment recommendations for these patients are provided in Section 7.
6.3.10. Diagnosis and treatment of pulmonary arterial hypertension complications
6.3.10.1. Arrhythmias
The most common types of arrhythmias observed in PAH are supraventricular, mainly atrial ﬁbrillation and atrial ﬂutter, while the frequency of ventricular arrhythmias and bradyarrhythmias appears to be considerably lower.477–479 Of note, age is an independent risk factor for atrial arrhythmias. In prospective studies, the incidence of atrial arrhythmias was 3–25% over an observation time of 5 years in cohorts primarily containing patients with IPAH.479–481
In the absence of speciﬁc evidence for PAH, managing anticoagulation in patients with PAH and atrial arrhythmia should follow the recommendations for patients with other cardiac conditions.477
Patients with PAH are especially sensitive to haemodynamic stress during atrial arrhythmias due to tachycardia and loss of atrioventricular synchrony. Maintaining sinus rhythm is an important treatment objective in these patients. New-onset arrhythmias frequently lead to clinical deterioration and are associated with increased mortality.481
Observational studies have shown that a variety of rhythm control strategies are feasible, including pharmacological cardioversion with anti-arrhythmic drugs, electrical cardioversion, and invasive catheter ablation procedures. To achieve or maintain a stable sinus rhythm,
prophylaxis with anti-arrhythmic drugs without negative inotropic effects, such as oral amiodarone, should be considered, even if speciﬁc data regarding their efﬁcacy are lacking. Low-dose beta-blockers and/or digoxin may be used on an individual patient basis.
Catheter ablation is the preferred approach in managing atrial ﬂutter and some other atrial tachycardias, although catheter ablation in patients with PAH is often more technically challenging than in patients with a structurally normal right heart chamber.482 The safety and efﬁcacy of ablation techniques for atrial ﬁbrillation speciﬁcally in the PAH population are uncertain, and it is possible that, due to remodelling of the RA, non-pulmonary vein triggers may play a more important role than in patients without PAH.483
6.3.10.2. Haemoptysis
Haemoptysis, ranging from mild to life-threatening, may occur in all forms of PH but is particularly common in HPAH and PAH associated with CHD. Pulmonary bleeding frequently originates from enlarged bronchial arteries;484–486 hence, the diagnostic evaluation of patients with
PAH
and haemoptysis should include a
contrast-enhanced CT scan with an arterial phase. Even if the source of bleeding cannot be determined, embolization of enlarged bronchial arteries is recommended in patients who present with moderate-to-severe haemoptysis or recurrent episodes of mild haemoptysis. Lung transplant should be considered in patients with recurrent and severe haemoptysis despite optimized treatment.
6.3.10.3. Mechanical complications
Mechanical complications in patients with PAH usually arise from progressive dilatation of the PA and include PA aneurysms, rupture,
and dissection, and compression of adjacent structures such as the left main coronary artery, pulmonary veins, main bronchi, and recurrent laryngeal nerves.487–492
Pulmonary artery aneurysm was independently related to an increased risk of sudden cardiac death in one study.492 Symptoms and signs are non-speciﬁc; in most cases, patients are asymptomatic and these complications are incidentally diagnosed. Pulmonary artery aneurysms are usually detected during echocardiography and best visualized by contrast-enhanced CT or MRI. Treatment options for asymptomatic
PA aneurysm or PA dissection are not well deﬁned. LTx has to be considered on an individual basis.490,493
Recommendation Table 13 — Recommendations for lung transplantation
Recommendations
Classa
Levelb
It is recommended that potentially eligible candidates are referred for LTx evaluation when they have an inadequate response to oral combination therapy, indicated by an intermediate–
high or high risk or by a REVEAL risk score .7
I
C
It is recommended to list patients for LTx who present with a high risk of death or with a REVEAL
risk score ≥10 despite receiving optimized medical therapy including s.c. or i.v. prostacyclin analogues
I
C
© ESC/ERS 2022
i.v., intravenous; LTx, lung transplantation; s.c., subcutaneous.
aClass of recommendation.
bLevel of evidence.
ESC/ERS Guidelines
3673


<!-- PAGE 57 -->

### Page 57

For patients with left main coronary artery compression syndrome, percutaneous coronary stenting is an effective and safe treatment.62 For patients with asymptomatic left main coronary artery compression or non-severe compromise of its anatomy, evaluation with intravascular ultrasound or coronary pressure wire may help to avoid unnecessary interventions.494
6.3.11. End-of-life care and ethical issues
The clinical course of PAH may be characterized by progressive deterioration and occasional episodes of acute decompensation. Life expectancy is difﬁcult to predict, as patients may either die slowly because of progressive right HF or experience sudden death.
Patient-orientated care is essential in managing PAH. Information about disease severity and possible prognosis should be provided at initial diagnosis but empathic and hopeful communication, as well as yielding hope, is essential, in line with Section 6.3.1.8. At the right time, open and sensitive communication will enable advanced planning and discussion of a patient’s fears, concerns, and wishes, and will ultimately contribute to making the ﬁnal, well-informed, and joint decision about treatment with the medical team.
Patients approaching end of life require frequent assessment of their full needs by a multidisciplinary team. In advanced stages, recognizing that cardiopulmonary resuscitation in severe PAH has a poor outcome may enable a do not resuscitate order; this may facilitate patients being in their preferred place of care at end of life.
Attention should be given to controlling distressing symptoms and prescribing appropriate drugs while withdrawing medication that is no longer needed,
which may include
PAH
medication.
Well-informed psychological, social, and spiritual support is also vital.
Specialist palliative care should be consulted for patients whose needs are beyond the expertise of the PH team.346
6.3.12. New drugs in advanced clinical development
(phase 3 studies)
Pulmonary arterial hypertension remains an incurable condition with a high mortality rate, despite use of PAH drugs mainly targeting imbalance of vasoactive factors. Novel agents, which are currently in phase 3 development, are ralinepag and sotatercept. Ralinepag is an orally available prostacyclin receptor agonist, which, in a phase
2 RCT that included 61 patients with PAH, improved PVR compared with placebo after 22 weeks of therapy.495 Sotatercept—a fusion protein comprising the extracellular domain of the human activin receptor type IIA linked to the Fc domain of human immunoglobulin
G1—acts as a ligand trap for members of the transforming growth factor (TGF)-β superfamily, thus restoring balance between growthpromoting and growth-inhibiting pathways.496 In a phase 2 RCT that included 106 patients with PAH treated over 24 weeks, s.c. sotatercept reduced PVR in patients receiving background PAH therapy;496
improvements were also observed in 6MWD and NT-proBNP.496
7. Speciﬁc pulmonary arterial hypertension subsets
7.1. Pulmonary arterial hypertension associated with drugs and toxins
Several drugs and toxins are associated with developing PAH or
PVOD/PCH. Historically, certain appetite suppressants and toxic rapeseed oil were the most prominent examples, whereas methamphetamines, interferons, and some tyrosine kinase inhibitors are more common causes nowadays (Table 7). Pulmonary arterial hypertension is a rare complication in patients exposed to these drugs, and many of these drugs have also been linked to other pulmonary complications such as parenchymal lung disease or pleural effusions.
These pulmonary complications may occur concurrently.
Methamphetamine-associated PAH has mainly been reported from the USA, where some centres have found that 20–29% of their otherwise idiopathic cases of PAH were associated with methamphetamine use.497,498 Compared with patients with IPAH, those with methamphetamine-associated PAH had more severe haemodynamic impairment and a higher mortality risk.498 Alpha and beta interferons have also been associated with developing PAH.499 The same is true of some tyrosine kinase inhibitors, especially dasatinib,
but also bosutinib and ponatinib.40,500
Drug- or toxin-induced PAH should always be considered in patients presenting with unexplained exertional dyspnoea or other warning signs. The diagnostic approach should be the same as in other forms of PH, and the diagnosis is usually made by excluding other forms of PH in patients who have been exposed to drugs associated with developing PAH.
Treatment of DPAH follows the same basic principles as treating other forms of PAH. Importantly, partial or full reversal of PAH has been reported after discontinuing the causative agent, at least for interferons and dasatinib.499,500 Hence, multidisciplinary management of the patient should include discontinuing the presumed causative agents once PAH is diagnosed (also see the 2022 ESC Guidelines on Cardio-Oncology).501 In patients with mild PH and a low-risk proﬁle, discontinuing the trigger alone may be sufﬁcient, and it is recommended that these patients be observed over 3–4 months before considering PAH therapy. Pulmonary arterial hypertension therapy should be initiated in patients who do not normalize their haemodynamics after withdrawing or in patients presenting with more advanced PAH at diagnosis. Unlike in other forms of PAH, de-escalation of PAH therapy is often possible during the course of the disease.500
Physicians should bear in mind that DPAH may have features of
PVOD/PCH, especially in patients treated with alkylating agents such as mitomycin C or cyclophosphamide. Health professional awareness is essential in identifying cases of DPAH and reporting adverse effects of pharmaceutical products.
Recommendation Table 14 — Recommendations for pulmonary arterial hypertension associated with drugs or toxins
Recommendations
Classa
Levelb
It is recommended to make a diagnosis of drug- or toxin-associated PAH in patients who had relevant exposure and in whom other causes of
PH have been excluded
I
C
In patients with suspected drug- or toxin-associated PAH, it is recommended to immediately discontinue the causative agent whenever possible
I
C
Continued
3674
ESC/ERS Guidelines


<!-- PAGE 58 -->

### Page 58

7.2. Pulmonary arterial hypertension associated with connective tissue disease
Pulmonary arterial hypertension is a well-known pulmonary vascular complication of
SSc,173,502–504
systemic lupus erythematosus
(SLE),505–507 mixed CTD,506 and, rarely, dermatomyositis508 and
Sjögren’s syndrome.509 Conversely, the relationship between rheumatoid arthritis and PAH is not established.510 After IPAH, PAH-CTD is the second most prevalent type of PAH in western countries.511
Systemic sclerosis, particularly in its limited variant, represents the main cause of PAH-CTD in Europe and the USA (SLE being more common in Asia).173,502,506 The prevalence of pre-capillary PH in large cohorts of patients with SSc is 5–19%.173,502 In these patients, PH may occur in association with ILD504,512 or as a result of PAH,173,502–504,506
sometimes with features of venous/capillary involvement.504,513
Moreover, group 2 PH-LHD is also common due to myocardial SSc involvement.504,514 Of note, patients with SLE may also present with PAH, LHD, ILD, and CTEPH (mostly in the setting of antiphospholipid syndrome). It is therefore essential to carefully determine which mechanism is operative in a given patient, since this will dictate treatment in the context of a multifaceted disease.
Cluster analysis performed in patients with SSc has shown that pre-capillary PH can be characterized into distinct clusters that differ in prognosis.503 One cluster, characterized by the presence of extensive ILD, and another by severely impaired haemodynamics carried a dismal prognosis, while the two others showed either the absence of
ILD or the presence of limited ILD, with mild-to-moderate risk PAH
and a relatively favourable overall prognosis.503
7.2.1. Epidemiology and diagnosis
There is a strong female predominance in PAH-CTD (female/male ratio 4:1), and mean age at diagnosis is commonly .50 years, especially in SSc.173,502–511,513,515,516 In the setting of a CTD, patients may present with concomitant disorders such as ILD, and have shorter survival compared with patients with IPAH.503 The unadjusted risk of death for PAH-SSc compared with IPAH is 2.9, and the predictors of outcome are broadly similar to those for IPAH.516,517 Symptoms and clinical presentation are also similar to IPAH, and some patients thought to have IPAH can be identiﬁed as having an associated CTD
by careful clinical examination and immunological screening tests.
Chest CT is recommended for evaluating the presence of associated
ILD or PVOD/PCH.504,513,515 An isolated reduction of DLCO is common in PAH-CTD.173,502–504
Resting echocardiography combined with other tests is recommended as a screening test in asymptomatic patients with SSc, followed by annual assessments. Screening/early detection is discussed in Section 5.3.1. In other CTDs, PH screening in the absence of suggestive symptoms is not recommended, while echocardiography should be performed in the presence of symptoms. As in other forms of PAH, RHC is recommended in all cases of suspected PAH-CTD to conﬁrm diagnosis, determine severity, and rule out LHD.504
7.2.2. Therapy
Drugs for PAH should be prescribed in PAH-CTD according to the same treatment algorithm as in IPAH (Figure 9). Patients with
PAH-CTD have been included in most of the major RCTs for regulatory approval of PAH therapy.518 Some aspects of PAH-CTD
treatment differ according to the associated
CTD.506
Immunosuppressive therapy combining glucocorticosteroids and cyclophosphamide may result in clinical improvement in patients with SLE- or mixed CTD-associated PAH,506 while it is not recommended in PAH-SSc.519 Patients with SSc and other CTDs may have
ILD and/or HFpEF, which needs to be considered when initiating
PAH therapy.504,515 In SSc, the long-term risk/beneﬁt ratio of oral anticoagulation is unfavourable because of an increased risk of bleeding,
while VKAs are recommended in PAH-CTD with a thrombophilic predisposition (e.g. antiphospholipid syndrome).319
Subgroup analyses of patients with PAH-SSc enrolled in RCTs performed with monotherapy or combination therapy of ERAs, PDE5is,
sGC stimulators, prostacyclin receptor agonists, epoprostenol, and prostacyclin analogues have shown positive effects vs.
placebo.301,401,519,520 In some of these trials, the magnitude of the response in the PAH-CTD subgroup was lower than in the IPAH
subgroup.519,520 Continuous i.v. epoprostenol therapy improved exercise capacity, symptoms, and haemodynamics in a 3-month RCT in
PAH-SSc.401 However, a retrospective analysis showed a better effect of i.v. epoprostenol on survival in IPAH compared with
PAH-SSc.521 The choice of PAH therapy in the context of SSc and its systemic manifestations may consider other vascular damage such as digital ulcers.522
Connective tissue disease should not be considered as an a priori contraindication for LTx.523 This has been extensively studied in SSc,
where a multidisciplinary approach optimizing SSc management before, during, and after surgery is recommended.523 Indications and contraindications for transplantation have to be adapted to the speciﬁcities of CTD, with a special focus on digestive (gastrooesophageal reﬂux disease and intestinal disease), cardiac, renal,
and cutaneous involvement.523
Immediate PAH therapy should be considered in patients who present with intermediate-/high-risk
PAH at diagnosis
IIa
C
Patients with low-risk PAH should be re-evaluated
3–4 months after discontinuing the suspected drug or toxin, and PAH therapy may be considered when the haemodynamics have not normalized
IIb
C
© ESC/ERS 2022
PAH, pulmonary arterial hypertension; PH, pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 15 — Recommendations for pulmonary arterial hypertension associated with connective tissue disease
Recommendations
Classa
Levelb
In patients with PAH associated with CTD,
treatment of the underlying condition according to current guidelines is recommended166,167,419,524
I
A
Continued
ESC/ERS Guidelines
3675


<!-- PAGE 59 -->

### Page 59

7.3. Pulmonary arterial hypertension associated with human immunodeﬁciency virus infection
The use of highly active antiretroviral therapy (HAART), and advances in managing opportunistic infections have contributed to increased life expectancy in patients with HIV.525,526 Consequently,
the spectrum of complications has shifted towards other long-term conditions, including PAH. Clinical and histopathological ﬁndings in
PAH associated with HIV infection (PAH-HIV) share many similarities with IPAH.1,527 With the availability of HAART given in combination with PAH therapies, the prognosis of PAH-HIV has markedly improved in recent years.526,528 In addition, the incidence of
PAH-HIV has declined in parallel with the increasing availability of
HAART.528 Taken together, these effects on survival and incidence have resulted in a stable PAH prevalence in patients with HIV over recent decades. A French population study indicated that the prevalence of PAH in individuals with HIV infection was 0.46%, which is very similar to the prevalence before the HAART era.177
The pathogenesis of PAH-HIV remains unclear. There is no evidence of a direct role of HIV in the pathogenesis of PAH and, although present in inﬂammatory cells in the lungs, the virus itself has never been found in pulmonary vascular lesions of patients with PAH-HIV.529 This suggests that an indirect action of viral infection on inﬂammation and growth factors may act as a trigger in a predisposed patient.
7.3.1. Diagnosis
Pulmonary arterial hypertension associated with HIV shares a clinical presentation with IPAH. Before the availability of HAART most patients were in WHO-FC III or IV at diagnosis. Nowadays, patients are diagnosed with much less severe symptoms and haemodynamics.
Patients may present with other risk factors for PAH such as liver disease (chronic viral hepatitis B or C) or exposure to drugs or toxins.
Patients with PAH-HIV are more likely to be male and i.v. drug abusers.403,526 There is no correlation between the severity of PAH and the stage of HIV infection or the degree of immunodeﬁciency.403,530
Because of its low prevalence, asymptomatic patients with HIV
should not be screened for PAH. However, echocardiography should be performed in patients with unexplained dyspnoea to detect HIV-related cardiovascular complications such as myocarditis,
cardiomyopathy, or PAH. Right heart catheterization is mandatory to conﬁrm the diagnosis of PAH-HIV and to rule out LHD.527
Pulmonary arterial hypertension is an independent risk factor for death in patients with HIV. In the 1990s, before the availability of
HAART, patients with PAH-HIV had poor outcomes, with a 3 year survival of ,50%.403 The overall survival has now improved and patients with PAH-HIV have a better prognosis than most patients with other forms of PAH.526
7.3.2. Therapy
Current recommendations for the treatment of PAH-HIV are largely based on data from IPAH.25,26
Treatment of PAH-HIV with HAART has improved functional status and survival in some retrospective studies.525,526,531 The use of
HAART in PAH-HIV is therefore recommended, irrespective of viral load and CD4+ cell count.
Anticoagulation is not recommended because of an increased risk of bleeding and drug interactions.319,527 Patients with PAH-HIV are usually non-responders to acute vasoreactivity testing and therefore should not receive CCBs.378
The prospective, open-label, BREATHE-4 study showed that bosentan markedly improved WHO-FC, exercise capacity, quality of life,
and haemodynamics after
16
weeks in patients with
PAH-HIV.532 In a long-term, retrospective series, bosentan therapy was associated with haemodynamic normalization in 10/59 patients.533 Bosentan potentially interacts with antiretroviral drugs,
and close monitoring is required when combined with HAART.
Very few patients with PAH-HIV have been included in RCTs with ambrisentan and macitentan, and no deﬁnite conclusion can be drawn from those studies.
Positive effects of sildenaﬁl and tadalaﬁl in PAH-HIV have been established in case studies.534,535 Interactions have been reported between PDE5is and protease inhibitors, resulting in major increases in PDE5i concentrations; these drugs should be introduced at low dosages with careful monitoring of potential side effects, including hypotension.536,537 There are no data on the use of the sGC stimulator riociguat in PAH-HIV.
Treatment with i.v. epoprostenol resulted in signiﬁcant improvement in WHO-FC, exercise capacity, haemodynamics, and survival in selected patients with PAH-HIV.403,538 There are very few data on the use of i.v. or s.c. treprostinil or inhaled iloprost in
PAH-HIV.539,540
There are no clinical trial data on the use of combination therapy for PAH-HIV. Given the lack of supporting evidence and potential safety concerns when PAH drugs are co-administered with antiretroviral drugs, initial monotherapy with PAH medication is recommended, followed by an individualized use of combination therapy in patients who do not reach a low-risk proﬁle.
In patients with PAH associated with CTD, the same treatment algorithm as for patients with
IPAH is recommended
I
C
© ESC/ERS 2022
PAH-CTD, pulmonary arterial hypertension associated with connective tissue disease;
IPAH, idiopathic pulmonary arterial hypertension.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 16 — Recommendations for pulmonary arterial hypertension associated with human immunodeﬁciency virus infection
Recommendations
Classa
Levelb
In patients with PAH associated with HIV
infection, antiretroviral treatment according to current guidelines is recommended541,542
I
A
In patients with PAH associated with HIV
infection, initial monotherapy should be considered, followed by sequential combination if necessary, taking into consideration comorbidities and drug–drug interactions
IIa
C
© ESC/ERS 2022
HIV, Human immunodeﬁciency virus; PAH, pulmonary arterial hypertension.
aClass of recommendation.
bLevel of evidence.
3676
ESC/ERS Guidelines


<!-- PAGE 60 -->

### Page 60

7.4. Pulmonary arterial hypertension associated with portal hypertension
Pulmonary arterial hypertension associated with portal hypertension, commonly referred to as PoPH, develops in 2–6% of patients with portal hypertension, with or without liver disease. In PAH registries, PoPH represents 5–15% of the patients.543–545 Rarely, some patients with PoPH have portosystemic shunts in the absence of portal hypertension (congenital extrahepatic cavoportal shunts).546
However, PoPH is distinct from hepatopulmonary syndrome
(HPS), which is characterized by intrapulmonary vascular dilatations and hypoxaemia. Of note, HPS and PoPH can occur sequentially or concurrently in patients with portal hypertension.547
7.4.1. Diagnosis
The diagnosis of PoPH is based on the presence of otherwise unexplained pre-capillary PH in patients with portal hypertension or a portosystemic shunt. The diagnostic approach is the same as in other patients with suspected or newly detected PH. Transthoracic echocardiography is usually the ﬁrst non-invasive assessment in patients with suspected PH, and echocardiography is also recommended as a screening tool in patients evaluated for liver transplantation. As patients with liver disease often have an elevated CO, TRV tends to overestimate
PAP in these patients. Hence, RHC with comprehensive haemodynamic assessment is essential to conﬁrm the diagnosis of PH and to distinguish
PAH (with elevated PVR) from unclassiﬁed PH (with a normal PVR).
7.4.2. Therapy
Patients with unclassiﬁed PH (i.e. mPAP .20 mmHg, elevated CO,
and PVR ≤2.0 WU) should be regularly followed-up but should not be treated with drugs approved for PAH.
In patients with an established diagnosis of PoPH, treatment should follow the same general principles as in other patients with
PAH, taking into account the severity of underlying liver disease,
the indication for liver transplantation, and the potential effects of
PAH medication on gas exchange, which may deteriorate with vasodilators in patients with PoPH.548,549 All drugs approved for PAH can principally be used to treat patients with PoPH, bearing in mind that these patients are usually excluded from registration studies.
Nevertheless, various case series support the use of approved
PAH medication in patients with PoPH. The largest series published so far reported on 574 patients with PoPH treated with various PAH
drugs, mostly PDE5is or ERAs, alone and in combination.545 Most patients (56.8%) were in Child–Pugh class A at the time of PAH diagnosis. At the ﬁrst follow-up, which took place 4.5 months after starting treatment, improvements were seen in haemodynamics,
WHO-FC, 6MWD, and BNP/NT-proBNP; survival at 5 years was
51%. In patients presenting with mild liver disease, the main causes of death were PAH progression and malignancy, whereas complications of liver disease were the most common causes of death in patients with advanced liver disease. The 5 year survival of patients who underwent liver transplantation (n = 63) was 81%.
The only RCT dedicated to the treatment of PoPH was PORTICO,
a 12 week study that randomized 85 patients to macitentan (n = 43)
or placebo (n = 42).168 PORTICO met its primary endpoint, demonstrating a signiﬁcant reduction in PVR from baseline (ratio of geometric mean 0.65; 95% CI, 0.59–0.72; P , 0.0001). There were, however,
no differences between the two treatment groups in secondary outcome measures, including WHO-FC, 6MWD, and NT-proBNP.
7.4.2.1. Liver transplantation
Porto-pulmonary hypertension is not per se an indication for liver transplantation. Pulmonary arterial hypertension poses a major threat to patients who undergo liver transplantation when indicated for the severity of liver disease. In a historical series from the Mayo Clinic, severe PAH with mPAP ≥50 mmHg was associated with a 100% perioperative mortality rate. In patients with mPAP 35–50 mmHg and
PVR .3.0 WU, mortality was still 50%.550 In liver transplantation candidates with PAH, targeted medical therapy successfully improves haemodynamics and establishes eligibility for transplantation.545,551–
554 However, haemodynamic criteria for successful liver transplantation have not been ﬁrmly established. The International Liver
Transplant Society proposed haemodynamic targets of mPAP
,35 mmHg and PVR ,5 WU, or mPAP ≥35 mmHg and PVR ,3
WU in patients receiving PAH therapy, while acknowledging that these criteria need to be further validated.175 An mPAP ≥45 mmHg is regarded as an absolute contraindication to liver transplantation.175
In patients with PoPH who successfully underwent liver transplantation, de-escalation or discontinuation of PAH medication is often feasible, but this has to be performed on an individual basis.551,554
Recommendation Table 17 — Recommendations for pulmonary arterial hypertension associated with portal hypertension
Recommendations
Classa
Levelb
Echocardiography is recommended in patients with liver disease or portal hypertension with signs or symptoms suggestive of PH, and as a screening tool in patients evaluated for liver transplantation or transjugular portosystemic shunt
I
C
It is recommended that patients with PAH
associated with portal hypertension are referred to centres with expertise in managing both conditions
I
C
In patients with PAH associated with portal hypertension, initial monotherapy should be considered, followed by sequential combination if necessary, taking into consideration the underlying liver disease and indication for liver transplantation
IIa
C
Liver transplantation should be considered on an individual basis in patients with PAH associated with portal hypertension, as long as PVR is normal or near normal with PAH therapy
IIa
C
Drugs approved for PAH are not recommended for patients with portal hypertension and unclassiﬁed PH (i.e. elevated mPAP, high CO, and a normal PVR)
III
C
© ESC/ERS 2022
mPAP, mean pulmonary arterial pressure; CO, cardiac output; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PVR, pulmonary vascular resistance.
aClass of recommendation.
bLevel of evidence.
ESC/ERS Guidelines
3677


<!-- PAGE 61 -->

### Page 61

7.5. Pulmonary arterial hypertension associated with adult congenital heart disease
The presence of PH in adults with CHD has a negative impact on the natural course of CHD, and worsens clinical status and overall outcome.555 Pulmonary arterial hypertension associated with adult CHD
is included in group 1 of the PH clinical classiﬁcation (Table 6) and represents a heterogeneous patient population. Post-capillary PH in adult
CHD (e.g. systolic or diastolic, systemic, ventricular dysfunction in combination with shunt lesions or complex adult CHD, and systemic atrioventricular valve dysfunction) should be excluded to determine further management. A speciﬁc clinical classiﬁcation (Table 21) is provided to better characterize PAH associated with adult CHD. Some complex
CHDs are associated with congenital abnormalities of the pulmonary vascular tree leading to segmental PH. In segmental PH, one or more,
but not all, segments of the lung(s) are hypertensive and each hypertensive area may present with PH of different severity, while other parts of the lung vasculature may be hypoplastic. Pulmonary atresia with ventricular septal defect and systemic-to-pulmonary collaterals is the most frequent condition, but other complex CHDs may also lead to segmental PH.
Approximately 3–7% of patients with adult CHD will eventually develop PAH; it is more frequently encountered in females, and the incidence depends on the underlying lesion and increases with age and age at defect closure.556 The estimated prevalence of PAH
in patients after correcting a simple cardiac defect is 3%.557 The epidemiology of PAH associated with adult CHD is expected to change due to advances in diagnostic and therapeutic paediatric cardiology,
resulting in fewer patients with simple adult CHD and more patients with complex lesions and/or closed defects who develop PAH in adulthood.558
The clinical presentation of Eisenmenger syndrome, an advanced form of adult CHD-associated PAH, is characterized by the multiorgan effects of chronic hypoxaemia, including cyanosis, and haematological changes, including secondary erythrocytosis and thrombocytopenia;
the main symptoms are dyspnoea, fatigue, and syncope. Eisenmenger syndrome may also present with haemoptysis, chest pain, cerebrovascular accidents, brain abscesses, coagulation abnormalities, and sudden death. Patients with adult CHD and Down syndrome are at an increased risk of developing Eisenmenger syndrome.
7.5.1. Diagnosis and risk assessment
The diagnostic work-up of PAH associated with adult CHD should be based on the presence of symptoms and includes medical history, physical examination, PFTs, ABG, imaging (especially echocardiography), and exercise and laboratory testing. Of note, standard echocardiographic criteria for detecting PH may not be applicable in complex adult CHD.559 Right heart catheterization with compartmental oximetry for calculating pulmonary blood ﬂow/systemic blood ﬂow (Qp/Qs) is required to conﬁrm PAH diagnosis and guide therapeutic interventions. Thermodilution should be avoided in the presence of intracardiac shunts, and direct Fick is the most accurate method. Pulmonary vascular resistance may be overestimated due to erythrocytosis.560 Interpreting invasive haemodynamics (see Section 5.1.12) should be made in the context of multiparametric assessment of exercise capacity, laboratory testing, and imaging.
Predictors of worse outcomes in adult CHD-associated PAH are
WHO-FC III–IV, exercise intolerance assessed by 6MWD or peak
VO2, history of hospitalization for right HF, biomarkers (NT-proBNP
.500 pg/mL, C-reactive protein .10 mg/mL, high serum creatinine,
and low albumin levels), iron deﬁciency, and echocardiographic indices of RV dysfunction.559,561 When compared with patients with IPAH, patients with Eisenmenger syndrome may have a relatively stable longterm clinical course. The right ventricle is unloaded by the right-to-left shunt, sustaining CO at the expense of hypoxaemia and cyanosis.
However, due to immortal time bias, prognosis of Eisenmenger syndrome is not as favourable as previously thought.562
As in other forms of PAH, risk assessment is important to guide therapy, and speciﬁc risk factors have been described in Eisenmenger syndrome. A large multicentre study showed that mortality in adults with Eisenmenger syndrome was predicted by the presence of pretricuspid shunt, advancing age, low rest oxygen saturation, absence of sinus rhythm, and presence of pericardial effusion.563
Table 21
Clinical classiﬁcation of pulmonary arterial hypertension associated with congenital heart disease
(1) Eisenmenger syndrome
Includes all large intra- and extracardiac defects that begin as systemic-to-pulmonary shunts and progress to severely elevated
PVR and to reverse (pulmonary-to-systemic) or bidirectional shunting. Cyanosis, secondary erythrocytosis, and multiple organ involvement are usually present. Closing the defects is contraindicated.
(2) PAH associated with prevalent systemic-to-pulmonary shunts
• Correctablea
• Non-correctable
Include moderate-to-large defects. PVR is mildly to moderately increased and systemic-to-pulmonary shunting is still prevalent,
whereas cyanosis at rest is not a feature.
(3) PAH with small/coincidentalb defects
Markedly elevated PVR in the presence of cardiac defects considered haemodynamically non-signiﬁcant (usually ventricular septal defects
,1 cm and atrial septal defects ,2 cm of effective diameter assessed by echocardiography), which themselves do not account for the development of elevated PVR. The clinical picture is very similar to IPAH. Closing the defects is contraindicated.
(4) PAH after defect correction
Congenital heart disease is repaired, but PAH either persists immediately after correction or recurs/develops months or years after correction in the absence of signiﬁcant, post-operative,
haemodynamic lesions.
© ESC/ERS 2022
IPAH,
idiopathic pulmonary arterial hypertension;
PAH,
pulmonary arterial hypertension; PVR, pulmonary vascular resistance.
aWith surgery or intravascular percutaneous procedure, see also the Recommendation
Table 18 for shunt closure.
bThe size applies to adult patients. However, also in adults, the simple diameter may be insufﬁcient for deﬁning the haemodynamic relevance of the defect, and also the pressure gradient, the shunt size and direction, and the pulmonary-to-systemic ﬂows ratio should be considered.
3678
ESC/ERS Guidelines


<!-- PAGE 62 -->

### Page 62

7.5.2. Therapy
Outcomes in adult CHD-associated PAH have improved with the availability of new PAH therapies, advances in surgical and perioperative management, and a team-based, multidisciplinary approach in PH centres. These patients should be managed by specialized health professionals.
Patient education,
behavioural modiﬁcations, and social and psychological support are all important aspects of management.
Shunt closure (surgical or interventional) may only be considered in patients with prevalent systemic-to-pulmonary shunting without signiﬁcantly increased PVR. Criteria for defect closure based on Qp/Qs ratio and (baseline and/or after targeted PAH
treatment)
PVR
have been proposed by the
2020
ESC
Guidelines for the management of adult congenital heart disease.101 Decisions on shunt closure should not be made on haemodynamic numbers alone, and a multiparametric strategy should be followed. For instance, shunt closure is not indicated in the case of desaturation during exercise in the 6MWT or
CPET, or when there is secondary erythrocytosis suggesting dynamic reversal of shunt. There is no evidence for a long-term beneﬁt of a treat-and-repair approach in patients with adult
CHD-associated PAH with prevalent systemic-to-pulmonary shunts; therefore, there is a need for future prospective studies.564 Defect closure is contraindicated in all patients with
Eisenmenger syndrome, and may also adversely affect patients with small/coincidental defects that behave similarly to IPAH.565
There are no prospective data available on the usefulness of vasoreactivity testing, balloon closure testing, or lung biopsy for assessing operability and normalization of PVR after closure.566
Patients with adult CHD-associated PAH may present with clinical deterioration in different circumstances, such as arrhythmia, during non-cardiac surgery requiring general anaesthesia, dehydration or bleeding, thrombo-embolism, and lung infections. Surgeries should be limited to those deemed essential, and performed in specialized centres with anaesthetists experienced in adult CHD and PAH.
Endocarditis should be suspected in patients with sepsis, whereas a cerebral abscess should be excluded in those with neurological symptoms or new headache, especially in those with low oxygen saturations and complex anatomies. It is recommended to avoid strenuous exercise, but mild and moderate activities seem to be beneﬁcial.567 Patients should receive all recommended vaccinations and endocarditis prophylaxis in the presence of cyanosis. Although pregnant patients with left-to-right shunts and stable, well-controlled
PAH have tolerated pregnancy well under specialized care, pregnancy is still associated with both high maternal mortality and foetal complications in Eisenmenger syndrome and should be discouraged in this setting;568,569 hence, effective contraception is highly recommended. Levonorgestrel-based, long-acting, reversible contraception implants or intrauterine devices have been recommended for these patients.570
Secondary erythrocytosis is beneﬁcial for adequate oxygen transport and delivery, and routine phlebotomy should be avoided whenever possible. Symptoms of hyperviscosity in the presence of haematocrit .65% should be approached with appropriate hydration. Iron deﬁciency should be corrected. When i.v. iron supplementation is administered, special care should be taken to avoid air emboli during administration.571 Supplemental oxygen therapy has not been shown to impact survival.
Oral anticoagulant treatment with VKAs may be considered in patients with large PA aneurysms with thrombus, atrial arrhythmias,
and previous thrombo-embolic events, but with low bleeding risk.
In patients with very high Hb levels (.20 mg/dL), standard international normalized ratio measures are less accurate,
and citrate-adjusted blood bottles must be used. Regarding using novel oral anticoagulants (NOACs), a large, nationwide, German, adult
CHD
database
(including
106
NOAC-treated patients with
Eisenmenger syndrome) showed that NOAC users had higher longterm risk of bleeding, major adverse cardiovascular events, and mortality compared with those on VKAs, suggesting that initiating
NOACs should be reserved for experienced adult CHD centres,
carefully weighing potential beneﬁts and risks.572,573
Compared with other group 1 subgroups, limited data exist on the use of drugs approved for PAH in patients with adult CHD-associated
PAH. Bosentan improved 6MWD and decreased PVR in patients with
Eisenmenger syndrome in WHO-FC III.574 Patients with more complex lesions were less likely to respond to PAH therapies compared with patients with simple lesions. An RCT investigating the efﬁcacy of macitentan found no effect on 6MWD in a mixed cohort of patients with Eisenmenger syndrome (6MWD improved in both treatment and placebo arms), although decreases in NT-proBNP and PVR
were noted in the macitentan arm.575
Experiences with other ERAs and PDE5is have shown favourable functional and haemodynamic results in Eisenmenger syndrome.576
In a small, single-centre, pilot study, adding nebulized iloprost to a background of oral PAH therapy failed to improve 6MWD in
Eisenmenger syndrome.577 In case symptoms persist or in clinical deterioration, a sequential and symptom-orientated treatment strategy is recommended in Eisenmenger syndrome, starting with an oral
ERA (or PDE5i) and escalating therapy. Should symptoms not adequately improve with oral therapies, i.v./s.c. options should be proactively considered.578 There is a theoretical risk of paradoxical embolism in right-to-left shunt lesions with the presence of a central venous catheter for i.v. therapy; therefore, s.c. prostacyclin analogue infusion may be considered.
The effect of PAH therapies in patients with prevalent systemic-to-pulmonary shunts is less well established. Patients with small/coincidental defects should be treated with PAH medication.557 This is also the case for patients with PAH after defect correction who have increased mortality compared with those with
Eisenmenger syndrome.579 These patients were included in major
RCTs with PAH therapies and should be evaluated based on comprehensive risk assessment (Table 16).580 The effect of PAH therapies in patients with segmental PH remains a matter of debate.101,581
While some series have reported promising results, there have been cases where therapies were not tolerated.581 Similarly, using PAH
therapies in Fontan circulation has yielded conﬂicting results, and results of further studies are awaited.582–584
Heart–lung transplantation or LTx with heart surgery is an option in highly selected cases not responsive to medical treatment; however, it is limited by organ availability and lesion complexity.
Mortality is high during the ﬁrst year after surgery, especially after heart–lung transplantation, but remains relatively low thereafter.585
ESC/ERS Guidelines
3679


<!-- PAGE 63 -->

### Page 63

7.6. Pulmonary arterial hypertension associated with schistosomiasis
Schistosomiasis is one of the most common chronic infectious diseases worldwide, affecting around 200 million people.586,587
Schistosomiasis-associated PAH is present in 5% of patients with the hepatosplenic form of the disease.586 It is thus a leading cause of PAH, especially in some regions of South America, Africa, and
Asia.
Compared with patients with
IPAH,
patients with schistosomiasis-associated PAH present with higher CO and lower
PVR, and have a better survival.587 Registry data suggest that survival in schistosomiasis-associated PAH has improved in recent years with the use of PAH drugs.588
7.7. Pulmonary arterial hypertension with signs of venous/capillary involvement
The common risk factors, identical genetic substrate, and indistinguishable clinical presentations of PCH and PVOD necessitate their consideration as a single disease belonging to the group 1 PH spectrum of diseases (PAH with signs of venous/capillary involvement).1,425,589 In PVOD/PCH, post-capillary lesions affecting septal veins and pre-septal venules consist of loose, ﬁbrous remodelling of the intima that may totally occlude the lumen.1,425,589,590 These changes are frequently associated with PCH consisting of capillary
Recommendation Table 18 — Recommendations for shunt closure in patients with pulmonary–systemic
ﬂow ratio .1.5:1 based on calculated pulmonary vascular resistance
Recommendations
Classa
Levelb
In patients with an ASD, VSD, or PDA and a PVR
,3 WU, shunt closure is recommended
I
C
In patients with an ASD, VSD, or PDA and a PVR
of 3–5 WU, shunt closure should be considered
IIa
C
In patients with an ASD and a PVR .5 WU that declines to ,5 WU with PAH treatment, shunt closure may be considered
IIb
C
In patients with a VSD or PDA and a PVR .5 WU,
shunt closure may be considered after careful evaluation in specialized centres
IIb
C
In patients with an ASD and a PVR .5 WU
despite PAH treatment, shunt closure is not recommended
III
C
© ESC/ERS 2022
ASD, atrial septal defect; PAH, pulmonary arterial hypertension; PDA, patent ductus arteriosus; PVR, pulmonary vascular resistance; VSD, ventricular septal defect; WU,
Wood units.
Decisions on shunt closure should not be made on haemodynamic numbers alone; a multiparametric strategy should be followed (see Section 7.5.2).
aClass of recommendation.
bLevel of evidence.
Recommendation Table 19 — Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease
Recommendations
Classa
Levelb
Risk assessment
Risk assessment is recommended for patients with persistent PAH after defect closure
I
C
Risk assessment should be considered in patients with Eisenmenger syndrome
IIa
C
Treatment
Bosentan is recommended in symptomatic patients with Eisenmenger syndrome to improve exercise capacity574
I
B
In patients with Eisenmenger syndrome, the use of supplemental oxygen therapy should be considered in cases where it consistently increases arterial oxygen saturation and reduces symptoms
IIa
C
Supplemental iron treatment should be considered in patients with iron deﬁciency
IIa
C
In patients with adult CHD, including Eisenmenger syndrome, other ERAs, PDE5is, riociguat,
prostacyclin analogues, and prostacyclin receptor agonists should be considered
IIa
C
Continued
In patients with PAH after corrected adult CHD,
initial oral combination therapy with drugs approved for PAH should be considered for patients at low and intermediate risk, while initial combination therapy including i.v./s.c. prostacyclin analogues should be considered for patients at high risk
IIa
Cc
In patients with adult CHD, including Eisenmenger syndrome, sequential combination therapy should be considered if patients do not meet treatment goals
IIa
C
In the absence of signiﬁcant haemoptysis, oral anticoagulant treatment may be considered in patients with Eisenmenger syndrome with pulmonary artery thrombosis
IIb
C
In women with Eisenmenger syndrome,
pregnancy is not recommended
III
C
In patients with Eisenmenger syndrome, routine phlebotomy to lower elevated haematocrit is not recommended
III
C
© ESC/ERS 2022
CHD, congenital heart disease; ERA, endothelin receptor antagonist; i.v., intravenous;
PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; s.c.,
subcutaneous.
aClass of recommendation.
bLevel of evidence.
cLevel of evidence differs from the 2020 ESC Guidelines for the management of adult congenital heart disease because the number of patients with adult CHD included in the AMBITION study was very low.
3680
ESC/ERS Guidelines


<!-- PAGE 64 -->

### Page 64

ectasia and proliferation, with doubling and tripling of the alveolar septal capillary layers that may be focally distributed within the alveolar interstitium.425,590
The proportion of patients with IPAH that fulﬁl the criteria for
PVOD/PCH is ≏10%, resulting in a lowest estimate of PVOD/PCH
incidence and prevalence of ,1 case/million.425 In contrast to
IPAH, there is a male predominance in PVOD/PCH and its prognosis is worse.425,589,591 Familial PVOD/PCH typically occurs in the young siblings of one generation, with unaffected and sometimes consanguineous parents, indicating that the disease segregates as a recessive trait.158,425,591 Biallelic mutations in the EIF2AK4 gene cause heritable PVOD/PCH.158 In addition, PVOD/PCH can complicate the course of associated conditions, such as SSc,425 or be associated with exposure to environmental triggers, such as alkylating agents (cyclophosphamide, mitomycin C)34 and solvents
(trichloroethylene).38
7.7.1. Diagnosis
Most patients complain of non-speciﬁc dyspnoea on exertion and fatigue.590 Physical examination may reveal digital clubbing and bibasal crackles on lung auscultation.590 Pulmonary arterial hypertension and PVOD/PCH share the same haemodynamic proﬁle as precapillary PH.590,591 The PAWP is not elevated because the pulmonary vascular changes occur in small venulae and capillaries, while the
LA ﬁlling pressure remains normal.590,591 A diagnosis of PVOD/PCH
is based on the results of tests suggesting venous post-capillary involvement, chronic interstitial pulmonary oedema, and capillary proliferation.1,590,591 These tests include PFTs (decreased DLCO,
frequently ,50% theoretical values), ABG (hypoxaemia), and non-contrast chest CT (subpleural thickened septal lines, centrilobular ground-glass opacities,
and mediastinal lymphadenopathy).1,425,589,591,592 Importantly, these patients are at risk of drug-induced pulmonary oedema with PAH therapy, a ﬁnding suggestive of PVOD/PCH.425,591 Detecting biallelic EIF2AK4 mutations is sufﬁcient to conﬁrm a
diagnosis of heritable
PVOD/
PCH.158,591,592 Lung biopsy is hazardous in PH and is not recommended for diagnosing PVOD/PCH.1,425
7.7.2. Therapy
There is no established medical therapy for PVOD/PCH.425
Compared with IPAH, PVOD/PCH has a poor prognosis and limited response to PAH therapy, with a risk of pulmonary oedema due to pulmonary venous obstruction.425,591 However, there are reports of incomplete and transient clinical improvement in individual patients with PVOD/PCH treated with PAH therapy, which should be used with great caution in this setting.425,591 Diuretics, oxygen therapy, and slow titration of PAH therapy can be used on an individual basis.425 Therefore, therapy for PVOD/PCH should be undertaken at centres with extensive experience in managing
PH, and patients should be fully informed about the risks.425
Anecdotal reports suggest a potential beneﬁt of immunomodulatory treatments, but this approach requires further study.593
The only curative therapy for PVOD/PCH is LTx, and eligible patients should be referred to a transplant centre for evaluation upon diagnosis.425,591 Pathological examination of the explanted lungs will conﬁrm the diagnosis.590
7.8. Paediatric pulmonary hypertension
Pulmonary hypertension may present at all ages, including in infants and children. Pulmonary hypertension in childhood shares many common features with PH in adulthood; however, there are also important differences, which concern epidemiology, aetiology, genetic background, age-dependent diagnostic and treatment approaches,
and disease monitoring. An important and conceptually distinctive feature of paediatric PH is injury to developing foetal, neonatal, or paediatric lung circulation.
7.8.1. Epidemiology and classiﬁcation
The reported annual incident rate for paediatric PH is 64/million children.594 The distribution of the various aetiologies of PH in childhood differs from PH in adulthood.594–596 Pulmonary arterial hypertension is the most frequent type of PH in children, with the vast majority (82%) of cases being infants with transient PAH (i.e.
PPHN or repairable cardiac shunt defects). Of the remaining children with PAH, most have either IPAH, HPAH, or irreversible
CHD-associated PAH. The reported incidences of IPAH/HPAH
and (non-transient) CHD-associated PAH are 0.7 and 2.2/million children, respectively, with a prevalence of 4.4 and 15.6/million children, respectively.594 Other conditions associated with PAH
(Table 6) do occur in children but are rare.
Another signiﬁcant proportion (34–49%) of children with nontransient PH are neonates and infants with PH associated with respiratory disease, especially developmental lung diseases, including bronchopulmonary dysplasia (BPD), congenital diaphragmatic hernia
(CDH), and congenital pulmonary vascular abnormalities.594–598
These children form a prominent and distinctive group in paediatric
PH and are currently classiﬁed as PH group 3 associated with
Recommendation Table 20 — Recommendations for pulmonary arterial hypertension with signs of venous/
capillary involvement
Recommendations
Classa
Levelb
A combination of clinical and radiological ﬁndings,
ABG, PFTs, and genetic testing is recommended to diagnose PAH with signs of venous and/or capillary involvement (PVOD/PCH)591
I
A
Identiﬁcation of biallelic EIF2AK4 mutations is recommended to conﬁrm a diagnosis of heritable
PVOD/PCH158,591
I
A
Referral of eligible patients with PVOD/PCH to a transplant centre for evaluation is recommended as soon as the diagnosis is established
I
C
In patients with PVOD/PCH, the use of drugs approved for PAH may be considered with careful monitoring of clinical symptoms and gas exchange
IIb
C
Lung biopsy is not recommended to conﬁrm a diagnosis of PVOD/PCH
III
C
© ESC/ERS 2022
ABG, arterial blood gas analysis; PAH, pulmonary arterial hypertension; PCH,
pulmonary capillary haemangiomatosis; PFT, pulmonary function test; PVOD,
pulmonary veno-occlusive disease.
aClass of recommendation.
bLevel of evidence.
ESC/ERS Guidelines
3681


<!-- PAGE 65 -->

### Page 65

developmental lung disease (Table 6; Table S7). A signiﬁcant and growing proportion of children with PH associated with respiratory disease is made up of pre-term infants with BPD. Also, newly recognized genetic developmental lung disorders—including alveolar capillary dysplasia, TBX4-mutation-related lung disorders, and surfactant abnormalities—are currently classiﬁed in this category (Figure 10).599
Another distinctive feature of PH in children is the high burden of genetic disorders. Childhood PH is often associated with chromosomal, genetic, and syndromic anomalies (11–52%). Like in adults,
gene mutations implicated in the pathogenesis of HPAH are found in 20–30% of sporadic cases, where paediatric HPAH seems to be characterized by an enrichment in
TBX4
and
ACVRL1
Comorbidities
Risk factors for outcome
Risk assessment tool
Risk assessment tool
Therapy
Treatment algorithm
Treatment algorithm
Evidence
Diabetes
Hypertension
Heart failure
Renal failure
Chromosomal abnormalities
Syndromic features
+/-
Cohort studies
+++
RCTs
Diagnosis
RHC+AVTa
Diagnostic algorithm
RHC+AVTa
Diagnostic algorithm
~
~
~
Child
Adult
A
Infant
PPHN
IPAH/HPAH
PAH-CHD
PAH-CTD
PoPH
PAH-HIV
IPAH/HPAH
PAH-CHD
1
Congenital PVS
Left heart failure
Congenital MS
Cardiomyopathy
2
Metabolic disorders
Haematologic diseases
Systemic diseases
5
Developmental lung diseases
Bronchopulmonary dysplasia
Congenital diaphragmatic hernia
Alveolar capillary dysplasia
Trisomy 21
chILD
Hypoventilation syndrome
COPD
ILD
3
Congenital PS
Congenital PS
CTEPH
4
Congenital malformations
Optimize respiratory support
Nutritional support
GORD treatment
Inhaled NO,
PAH drugs
Respiratory support
Suprasystemic PH
Necrotizing enterocolitis
Steroids
ASD/VSD
Echocardiography
RHC?
Extremely limited
Simple CHD
Complex CHD
PH classification
Figure 10 Neonatal and paediatric vs. adult pulmonary hypertension. ASD, atrial septal defect; AVT, acute vasoreactivity testing; CHD, congenital heart disease; COPD, chronic obstructive pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; GORD, gastro-oesophageal reﬂux disease; HPAH, heritable pulmonary arterial hypertension; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; MS, mitral stenosis; NO, nitric oxide; PAH, pulmonary arterial hypertension; PAH-CHD, PAH associated with congenital heart disease; PAH-CTD, PAH associated with connective tissue disease; PAH-HIV, PAH associated with HIV infection; PH, pulmonary hypertension; PoPH, porto-pulmonary hypertension; PPHN,
persistent pulmonary hypertension of the newborn; PS, pulmonary arterial stenosis; PVS, pulmonary vein stenosis; RCT, randomized controlled trial;
RHC, right heart catheterization; VSD, ventricular septal defect. aIn patients with idiopathic, heritable or drug-associated PAH. Pulmonary hypertension in neonates and infants signiﬁcantly differs in aetiology, pathophysiology, risk assessment, and treatment from older children and adults, while PH in older children has more similarities with PH in adults.
3682
ESC/ERS Guidelines


<!-- PAGE 66 -->

### Page 66

variations.600,601 Additionally, 17% of children with PAH have other disorders known to be associated with PAH, including trisomy 21.
Finally, 23% of children with PAH have copy number variations not previously associated with PH.600,602,603
Given the frequent association of paediatric PAH with chromosomal, genetic, and syndromic anomalies (for which the mechanistic basis for PAH is generally uncertain), genetic testing may be considered for deﬁning aetiology and comorbidities, stratifying risk, and identifying family members at risk; however, this should be after appropriate expert genetic counselling for the child and family (see
Section 5.1.13).
The clinical PH classiﬁcation (Table 6) is also followed for paediatric PH. To improve applicability of this classiﬁcation in infants and children with PH, it has been adapted to give room to PH associated with various congenital cardiovascular and pulmonary diseases or speciﬁc paediatric conditions (Tables S5–S8).599
7.8.2. Diagnosis and risk assessment
Historically, the deﬁnition of PH in children aged .3 months has been the same as in adults. The deﬁnition for PH has now been redeﬁned to mPAP .20 mmHg in adults as well as in children. The impact of an mPAP 21–24 mmHg on outcomes in children is unknown.
However, in the interest of consistency and to facilitate transition from paediatric to adult PH care, it is recommended that the updated deﬁnition for PH also be followed in children. No treatment recommendations currently exist for this group of children (mPAP 21–
24 mmHg).
Regarding the newly introduced criterion to include PVR .2 WU
to identify pre-capillary PH in adults, PVR had previously been included in the deﬁnition for PAH in children. In children, blood ﬂows are traditionally indexed assuming that systemic and pulmonary blood ﬂows change proportionally with body size, while the transpulmonary pressure gradient does not. Since blood ﬂow is the denominator in the equation for calculating PVR, the need for indexing of
PVR in children is emphasized, and the criterion of pulmonary vascular resistance index (PVRI) ≥3 WU·m2 in the deﬁnition for PAH in children remains unchanged.599
Since the aetiology of paediatric PH is very diverse, a methodical and comprehensive diagnostic approach is crucial to reach an accurate diagnosis and treatment plan. As in adults, IPAH is a diagnosis ‘per exclusion’. A diagnostic work-up, similar to that in adults but customized for paediatric PH, is recommended.599 Pre-term infants with
BPD should be screened for PH, since PH is prevalent in this population and seriously affects outcome.604
Also in children, RHC is the gold standard for deﬁnitively diagnosing and establishing the nature of PH, and provides important data for stratifying risk.604a,605 To identify those suitable for high-dose CCB
treatment, acute vasoreactivity testing is recommended in children with IPAH/HPAH. The criteria used in adults for a positive acute response have identiﬁed children who will show sustained beneﬁt from
CCB therapy; however, these criteria do not deﬁne reversibility of
PAH or operability in children with CHD. Since RHC in children with PH may be associated with major complications (in 1–3% of cases, especially in young infants and those in worse clinical condition),
risks and beneﬁts have to be balanced in the individual child.605 Heart catheterization in children with PAH should be exclusively performed in experienced paediatric PH centres. Indications for repeated RHC in children with PH are currently not well deﬁned.
Treatment of children with PAH is based on risk stratiﬁcation.599
Predictors of worse outcome in paediatric PAH are similar to those in adults, and include clinical evidence of RV failure, progression of symptoms, WHO-FC III–IV, certain echocardiographic parameters
(e.g. TAPSE), and elevated serum NT-proBNP. A 6MWD ,350 m has also been suggested as a predictor of worse outcome in paediatric PH, but its value in young children is less established. Further prognosticators identiﬁed in paediatric PAH are failure to thrive and haemodynamic variables, such as RAP .10 mmHg, the ratio of mean pulmonary-to-systemic blood pressure .0.75, and PVRI
.20 WU·m2.602,606,607 Paediatric risk-assessment tools based on these parameters have been retrospectively validated in observational paediatric registries.599,604a
7.8.3. Therapy
The ultimate goal of treatment should be to improve survival and facilitate normal childhood activities without limitations. In the absence of RCTs in paediatric PAH, recommended treatment algorithms are extrapolated from those in adults and enhanced with data from observational studies in children with PAH.599
Observational cohort studies support treatment algorithms designed for adults to be used for children (including the superiority of combination therapy over monotherapy).608 Drugs investigated in children, with or without formal approval by the European
Medicines Agency (EMA) for treating children with PAH, are shown in Table 22.
A paediatric treatment algorithm, derived from that for adults, is based on risk stratiﬁcation, recommending general measures, highdose CCB therapy for responders to acute vasoreactivity testing
(where close follow-up is mandatory, as some patients may fail longterm therapy), oral or inhaled combination therapy for children at low risk, and combination therapy with i.v./s.c. prostacyclin analogues for those at high risk.599
In the case of insufﬁcient response to recommended drug therapy,
or when drugs are unavailable, a Potts shunt (a surgical or interventional connection between the left PA and the descending aorta),
BAS, or LTx may be considered in children with severe PH (see
Sections 6.3.6.1 and 6.3.8).599 Reported clinical experience with
Potts shunts is limited to just over 100 patients, predominantly children, with a mortality of 12–25% and long-term clinical beneﬁt in a subset of children with long-term follow-up.456–459
Monitoring of treatment effect and disease course is pivotal in managing all patients with PAH (adults and in children). In children with PAH, clinical risk scores including WHO-FC, TAPSE, and serum
NT-proBNP are potential treatment targets for goal-orientated treatment.604a,609
Contemporary treatment algorithms for infants with PPHN have been proposed but are outside the scope of these guidelines.610
The recommendations discussed above apply to children with
PAH, whereas the speciﬁc group of infants with neonatal PVD, mostly classiﬁed as PH associated with developmental lung disease and with heterogeneous aetiology, require a distinct and customized approach (Figure 10).
In pre-term infants with BPD and PH, the underlying lung disease should primarily be treated. Frequently, these infants are additionally
ESC/ERS Guidelines
3683


<!-- PAGE 67 -->

### Page 67

Table 22
Use of pulmonary arterial hypertension therapies in children
Drug
Paediatric study data
European Medicines Agency approval for use in children with PAH
Ref.
Phosphodiesterase 5 inhibitors (oral)
Sildenaﬁl
RCT, open-label extension: tolerability, efﬁcacy
Yes, for ≥1 year of age
Recommended dosing:
,20 kg: 30 mg/day in 3 doses; ≥20 kg: 60 mg/
day in 3 doses
Avoid higher dosing in children (.3 mg/kg/day)
613,614
Tadalaﬁl
RCT, open-label: safety, tolerability, pharmacokinetics
No
Suggested dosing:
0.5–1 mg/kg/day in one dose
Max: 40 mg/day
Evaluated only in children aged .3 years
615,616
Endothelin receptor antagonists (oral)
Bosentan
Open-label, uncontrolled: safety, tolerability, pharmacokinetics,
efﬁcacy
Yes, for ≥1 year of age
Paediatric formulation
Recommended dosing:
4 mg/kg/day in 2 doses
Max: 250 mg/day
617–620
Ambrisentan
Open-label, uncontrolled: safety, tolerability, pharmacokinetics
Yes, for children aged .8 years
Recommended dosing:
2.5–10 mg/day in one dose
621,622
Macitentan
Insufﬁcient data in children
Open-label, ongoing: efﬁcacy, safety, pharmacokinetics in children aged 2–18 years
No
Prostacyclin analogues (i.v./s.c.)
Epoprostenol i.v.
Cohort studies, retrospective
No
Suggested dosing:
Starting dose: 1–2 ng/kg/min without a known maximum
In children, a stable dose is usually 40–80 ng/kg/min
Dose increases may be required
623–626
Treprostinil i.v./
s.c.
Cohort studies, retrospective: pharmacokinetics
No
Suggested dosing:
Starting dose: 2 ng/kg/min without a known maximum
In children, a stable dose is usually 50–100 ng/kg/min
Dose increases may be required
624,626,627
Other
Iloprost
(inhaled)
Insufﬁcient data in children
Small case series, retrospective
No
Selexipag (oral)
Insufﬁcient data in children
Randomized, placebo-controlled, add-on, ongoing: safety,
tolerability, pharmacokinetics in children aged 2–18 years
No
Riociguat (oral)
Insufﬁcient data in children
Open-label, ongoing: safety, tolerability, pharmacokinetics in children aged 6–18 years
No
© ESC/ERS 2022
i.v., intravenous; PAH, pulmonary arterial hypertension; RCT, randomized controlled trial; s.c., subcutaneous.
3684
ESC/ERS Guidelines


<!-- PAGE 68 -->

### Page 68

treated with therapies for PAH, including sildenaﬁl and bosentan;
however, these are not approved by the EMA for use in infants with group 3 PH and developmental lung diseases (BPD, CDH).
Their effects on outcomes in this population are unclear, and data enabling robust treatment recommendations are lacking. These children should be treated by multidisciplinary teams involving cardiologists, neonatologists, pulmonologists, and nutritionists. Pulmonary hypertension in these infants may disappear with lung healing, although long-term cardiovascular sequelae have been reported.611,612
8. Pulmonary hypertension associated with left heart disease
(group 2)
8.1. Deﬁnition, prognosis, and pathophysiology
Among patients with LHD, PH and RV dysfunction are frequently present and associated with high mortality.47 This includes patients with HF with reduced, mildly reduced, or preserved ejection fraction
(HFrEF, HFmrEF, or HFpEF), left-sided valvular heart disease, and congenital/acquired cardiovascular conditions leading to postcapillary PH.13,631–635 Arguably, PH-LHD represents the most prevalent form of PH, accounting for 65–80% of cases.47
Consistent with the general deﬁnitions of PH, PH-LHD (group 2
PH) is deﬁned by an mPAP .20 mmHg and a PAWP .15 mmHg.
Within this haemodynamic condition of post-capillary PH, IpcPH is deﬁned by PVR ≤2 WU and CpcPH by PVR .2 WU (Table 5).
The diastolic pressure gradient (DPG) (calculated as the difference between dPAP and PAWP) is no longer used to distinguish between
IpcPH and CpcPH because of conﬂicting data on prognostication in
LHD.142
Across the spectrum of LHD, increases in PAP and PVR are associated with an increased disease burden and a worse outcome.13,631,633,635 In a large patient cohort—predominantly with post-capillary PH—a PVR ≥2.2 WU was associated with adverse outcomes and considered abnormal.13 However, even within this subgroup of patients with LHD and CpcPH, the risk of mortality increases with progressive elevation in PVR. In patients with advanced
HFrEF and those with HFpEF or valvular heart disease, a PVR
.5 WU carries additional prognostic information and is considered clinically meaningful by physicians.142,450,631–639 Elevated PVR also appears to be associated with decreased survival in special situations,
such as in patients undergoing interventions for correcting valvular heart disease,634 heart transplantation,142,633 or LVAD implantation.142,637 Based on available data, a PVR .5 WU may indicate a severe pre-capillary component, the presence of which may prompt physicians to refer patients to PH centres for specialized care.
The prevalence of PH in patients with LHD is difﬁcult to assess and depends on the methodology of diagnostic testing (echocardiography or invasive haemodynamics), cut-off values used to deﬁne
PH, and populations studied. Observational studies suggest an estimated prevalence of PH of 40–72% in patients with HFrEF and
36–83% in those with HFpEF.48,639–643 When PVR is used to deﬁne
Recommendation Table 21 — Recommendations for paediatric pulmonary hypertension
Recommendations
Classa
Levelb
Children
It is recommended to perform the diagnostic work-up, including RHC and acute vasoreactivity testing, and treat children with PH at centres with speciﬁc expertise in paediatric PH
I
C
In children with PH, a comprehensive work-up for conﬁrming diagnosis and speciﬁc aetiology is recommended (similar to that in adults, but adapted for age)
I
C
For conﬁrming PH diagnosis, RHC is recommended,
preferably before initiating any PAH therapy
I
C
In children with IPAH/HPAH, acute vasoreactivity testing is recommended to detect those who may beneﬁt from CCB therapy
I
C
It is recommended to similarly deﬁne a positive response to acute vasoreactivity testing in children and adults by a reduction in mPAP ≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg,
with an increased or unchanged CO
I
C
In children with PAH, a therapeutic strategy based on risk stratiﬁcation and treatment response is recommended, extrapolated from that in adults but adapted for age
I
C
It is recommended to monitor the treatment response in children with PAH by serially assessing a panel of data derived from clinical assessment,
echocardiographic evaluation, biochemical markers, and exercise tolerance tests
I
C
Achieving and maintaining a low-risk proﬁle should be considered as an adequate treatment response for children with PAH
IIa
C
Infants
It is recommended to screen infants with bronchopulmonary dysplasia for PH628,629
I
B
In infants with (or at risk of) bronchopulmonary dysplasia and PH, treating lung disease—including hypoxia, aspiration, and structural airway disease
—and optimizing respiratory support is recommended before initiating PAH therapy630
I
B
Continued
In neonates and infants, a diagnostic and therapeutic approach to PH distinct from that in older children and adults should be considered,
given the frequent association with developmental vascular and parenchymal lung disease
IIa
C
© ESC/ERS 2022
CCB, calcium channel blocker; CO, cardiac output; HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; RHC, right heart catheterization.
aClass of recommendation.
bLevel of evidence.
ESC/ERS Guidelines
3685


<!-- PAGE 69 -->

### Page 69

a pre-capillary component in patients with HF and post-capillary PH,
≏20–30% of patients are categorized as having CpcPH.47,644,645 In patients with valvular heart disease, echocardiographic studies have shown that PH is present in up to 65% of patients with symptomatic aortic stenosis,646–651 while virtually all patients with severe mitral valve stenosis develop PH,652 which can also be found in most patients with signiﬁcant degenerative or functional mitral regurgitation.
The pathophysiology of PH-LHD combines several mechanisms
(Figure 11): (1) an initial passive increase in LV ﬁlling pressures and backward transmission into the pulmonary circulation; (2) PA
Variable degree of pulmonary congestion, vasoconstriction, vascular remodelling
Left ventricular phenotype
Right ventricular phenotype
Pulmonary vascular disease
Pulmonary congestion
No PH
IpcPH
CpcPHa
HFrEF
Aortic valve
HFmrEF
LA pressure
Remodelling
Right heart strain
Congestion
HFpEF
Mitral valve
EF ≤40%
Stenosis/Regurgitation 
EF 41–49%
EF ≥50%
Heart failure/cardiomyopathy
Valvular heart disease
Controlled
LHD
LA dysfunction
Vasoconstriction
Arteriolar
RV dysfunction
Venous
RV–PA 
uncoupling
LA pressure (mmHg)
LA volume (ml)
20
15
5
10
20
40
60
80
100
120
Figure 11 Pathophysiology of pulmonary hypertension associated with left heart disease (group 2). CpcPH, combined post- and pre-capillary pulmonary hypertension; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IpcPH, isolated post-capillary pulmonary hypertension; LA, left atrial; LHD, left heart disease; RV, right ventricle/right ventricular; PA, pulmonary artery; PH, pulmonary hypertension. aCpcPH is deﬁned by post-capillary PH and PVR .2 WU; a PVR .5 WU may be considered a severe pre-capillary component.
3686
ESC/ERS Guidelines


<!-- PAGE 70 -->

### Page 70

endothelial dysfunction (including vasoconstriction); (3) vascular remodelling (which may occur in both venules and/or arterioles); (4)
RV dilatation/dysfunction and functional TR;653–656 and (5) altered
RV–PA coupling.655–657 The haemodynamic proﬁle of CpcPH vs.
IpcPH and elevated PVR reﬂects pulmonary vascular abnormalities,
which contribute to an increased RV afterload. Resulting dysfunction of the RV is frequent and associated with a worse prognosis in patients with PH-LHD. In HFpEF, where RV dysfunction may occur via distinct mechanisms (Figure S1), deterioration of RV, but not LV
systolic function, has been observed over time, and both prevalent and incident RV dysfunction are predictors of mortality.658
The occurrence of PH in patients with LHD may also be due to other causes, including undetected CTEPH or PAH. Further, respiratory comorbidities such as COPD and sleep apnoea are also common in patients with LHD and may contribute to PH and impact prognosis. Patients with HFpEF and PH associated with HFpEF75,76
may also present with a low DLCO, which is an independent predictor of outcome.75
8.2. Diagnosis
In patients with LHD, symptoms (e.g. exertional dyspnoea) and physical signs of PH (e.g. peripheral oedema) frequently overlap with those of the underlying left heart condition and are mostly nonspeciﬁc. However, while pulmonary congestion or pleural effusion indicate LHD as the underlying cause of PH, other features may suggest the presence of relevant PH (see Section 5.1.1).
Routine diagnostic tests including BNP/NT-proBNP, ECG, and echocardiography may show signs of underlying LHD, but may also indicate PH. While BNP/NT-proBNP cannot discriminate between left- or right-sided HF, ECG ﬁndings such as right axis deviation or
RV strain may suggest the presence of PH in patients with LHD.
Echocardiography can diagnose HFrEF and HFpEF; identify speciﬁc cardiac conditions, including those with restrictive ﬁlling pattern;
and diagnose additional valvular heart disease; it may also detect elevated sPAP and other features of PH (RA area, PA enlargement, RV/
LV ratio, LV eccentricity index, RV forming the apex), leading to an echocardiographic probability of PH (see Section 5.1.5). A stepwise,
composite echocardiographic score may discriminate pre- vs. postcapillary PH and predict PVD in patients with LHD.659,660
Additional information may be gathered from further testing, including biomarkers, imaging-derived markers of RV dysfunction, and
CPET-derived variables.142
Given the complexity and variability of cardiopulmonary haemodynamics in patients with LHD, the distinction between post- and pre-capillary PH and the diagnosis of PH-LHD vs. other forms of
PH can be challenging. Diagnostic clues in the evaluation of suspected
PH in LHD include: (1) diagnosis and control of the underlying LHD;
(2) evaluation for PH and patient phenotyping; and (3) invasive haemodynamic evaluation, when indicated.
8.2.1. Diagnosis and control of the underlying left heart disease
Patients with suspected PH-LHD will have an established diagnosis of
LHD, such as HFrEF/HFmrEF, HFpEF, valvular heart disease, and/or
CHD. The distinction between PH associated with HFpEF and other forms of PH (e.g. PAH, CTEPH) may be challenging, particularly given the increased burden of cardiovascular comorbidities in real-world
PAH populations.142,450,661 In this context, validated scores for diagnosing HFpEF (HFA-PEFF, H2FPEF)16,662,663 may be helpful for detecting it as an underlying condition in PH, and the presence or absence of risk factors for PAH or CTEPH should be determined.
Patients with signs of predominant RV strain and/or PH should be further evaluated. Patients should be assessed or reassessed when they are fully recompensated and in a clinically stable condition.
8.2.2. Evaluation of pulmonary hypertension and patient phenotyping
Patients with LHD and suspected PH should be evaluated following the diagnostic strategy for PH (see Section 5). This requires identifying clinical features and a multimodal approach using non-invasive diagnostic tests such as echocardiography, ECG, and BNP/
NT-proBNP levels. In the presence of mild PH and predominant
LHD, no further testing may be necessary. Otherwise, CTEPH and signiﬁcant lung disease should be ruled out by V/Q scan and PFTs,
and additional cardiac imaging including cMRI may be considered in selected cases. For phenotyping, a combination of variables may help to determine the likelihood of LHD, and HFpEF in particular,
vs. other causes of PH (Table 23). Pulmonary hypertension associated with left heart disease is likely in the presence of known cardiac disease, multiple cardiovascular comorbidities/risk factors, atrial
ﬁbrillation at diagnosis, and speciﬁc imaging ﬁndings (LV hypertrophy,
increased LA size, and reduced LA strain). Although exercise echocardiography has been proposed to uncover HFpEF, it is unable to diagnose or classify PH in this context. A combination of clinical ﬁndings and phenotyping is required to decide about the need for further invasive assessment.
8.2.3. Invasive assessment of haemodynamics
The decision to perform cardiac catheterization and to invasively assess cardiopulmonary haemodynamics should depend on the presence of an intermediate to high echocardiographic probability of
PH, and should be determined by the need to obtain relevant information for prognostication or management. In patients with a high likelihood of LHD as the main cause of PH, or with established underlying LHD and mild PH (Table 23), invasive assessment for
PH is usually not indicated. Indications for RHC in LHD include:
(1) suspected PAH or CTEPH; (2) suspected CpcPH with a severe pre-capillary component, where further information will aid phenotyping and treatment decisions (Figure S2); and (3) advanced HF and evaluation for heart transplantation. While several haemodynamic measures (mPAP, PVR, pulmonary arterial compliance [PAC], transpulmonary pressure gradient, and DPG) are associated with outcomes in PH-LHD,142,632,635 the most robust and consistent data are available for PVR. Invasive assessment should be conducted in experienced centres, when management of the underlying LHD has been optimized and patients are in a clinically stable condition.
With respect to respiratory variations of intrathoracic pressures,
all pressure readings should be taken at end-expiration.
Additional testing during RHC may be useful for distinguishing between PAH and HFpEF,18,23,664–669 and to uncover LHD in patients with a high likelihood of PH-LHD and normal resting PAWP;670–673
both exercise testing and ﬂuid challenge may be considered in special situations (see Section 5.1.12). Conditions associated with reduced
LV diastolic compliance or valvular heart disease may be associated
ESC/ERS Guidelines
3687


<!-- PAGE 71 -->

### Page 71

with a rapid increase in PAWP when challenged with increased systemic venous return.674 While the upper limit of normal remains controversial,142,143,665,667 a PAWP cut-off of .18 mmHg has been suggested to identify HFpEF as the underlying cause of PH, despite normal PAWP at baseline.143 While this may help to classify PH,
therapeutic consequences of such testing remain to be determined.
As differentiating between severe PH associated with HFpEF and
IPAH with cardiac comorbidities is challenging, patients with an unclear diagnosis, particularly those with a predominant pre-capillary component (e.g. PVR .5 WU), should be referred to a PH centre for individualized management.
8.3. Therapy
The primary strategy in managing PH-LHD is optimizing treatment of the underlying cardiac disease. Nevertheless, a pathophysiological sequence ranging from left-sided heart disease via pulmonary circulation to chronic right heart strain (at rest or exercise) is present in many patients.47 Since deterioration of RV function over time is associated with poor outcomes in HFpEF,658 preserving RV function should be considered an important treatment goal. Diuretics remain the cornerstone of medical therapy in the presence of ﬂuid retention due to PH-LHD.
There is limited and conﬂicting evidence for the use of drugs approved for PAH in patients with group 2 PH. Some medications may have variable and potentially detrimental effects in such patients and are therefore not indicated in PH-LHD. Management strategies for PH in various left heart aetiologies are described below.
8.3.1. Pulmonary hypertension associated with left-sided heart failure
8.3.1.1. Heart failure with reduced ejection fraction
Patients with HFrEF or HFmrEF require guideline-directed treatment including established medical and interventional therapies.27
In patients with advanced HFrEF, implanting an LVAD may signiﬁcantly reduce or even normalize mPAP,675 although this is not achieved in all patients,676 and an increased DPG emerged as a negative prognostic factor after LVAD implantation.677 With regards to
PAH drugs, bosentan was assessed in an RCT of patients with PH
associated with HFrEF,678 showing no efﬁcacy but an increase in adverse events compared with placebo, predominantly related to
ﬂuid retention.
Small studies have suggested that sildenaﬁl may improve haemodynamics and exercise capacity in PH and
HFrEF,679–681 but RCTs are lacking.
8.3.1.2. Heart failure with preserved ejection fraction
In patients with HFpEF, blood pressure, volume load, and risk factors should be controlled, which may lower ﬁlling pressures and PAP.27
Recently, the SGLT-2i empagliﬂozin improved outcomes in patients
Table 23
Patient phenotyping and likelihood for left heart disease as cause of pulmonary hypertension
Feature
PH-LHD unlikely
Intermediate probability
PH-LHD likely
Age
,60 years
60–70 years
.70 years
Obesity, hypertension, dyslipidaemia, glucose intolerance/
diabetes
No factors
1–2 factors
.2 factors
Presence of known LHD
No
Yes
Yes
Previous cardiac intervention
No
No
Yes
Atrial ﬁbrillation
No
Paroxysmal
Permanent/persistent
Structural LHD
No
No
Present
ECG
Normal or signs of RV
strain
Mild LVH
LBBB or LVH
Echocardiography
No LA dilation
E/e′ ,13
No LA dilation
Grade ,2 mitral ﬂow
LA dilation (LAVI .34 mL/
m2)
LVH
Grade .2 mitral ﬂow
CPET
High VE/VCO2 slope
No EOV
Elevated VE/VCO2 slope
EOV
Mildly elevated VE/VCO2
slope
EOV
cMRI
No left heart abnormalities
LVH
LA dilation (strain or LA/RA
.1)
© ESC/ERS 2022
cMRI, cardiac magnetic resonance imaging; CPET, cardiopulmonary exercise testing; E/e’, ratio between early mitral inﬂow velocity and mitral annular early diastolic velocity; ECG,
electrocardiogram; EOV, exercise oscillatory ventilation; LA, left atrial; LAVI, left atrial volume index; LBBB, left bundle branch block; LHD, left heart disease; LVH, left ventricular hypertrophy; PH, pulmonary hypertension; PH-LHD, left heart disease associated with pulmonary hypertension; RA, right atrium; RV, right ventricle; VE/VECO2, ventilatory equivalents for carbon dioxide.
Assigning the likelihood of LHD as a cause of PH. This assessment may help to decide which patients should undergo a full work-up, including invasive haemodynamic assessment (see
Figure 11 and Figure S2).
3688
ESC/ERS Guidelines


<!-- PAGE 72 -->

### Page 72

with an LV ejection fraction of 40–60%.682 Endothelin receptor antagonists have not proved successful in this population, as both bosentan683 and macitentan684 failed to show efﬁcacy but rather led to more adverse events (ﬂuid retention) vs. placebo in patients with
HFpEF-associated
PH
and
HF
with ejection fraction
.35%-associated CpcPH, respectively. Phosphodiesterase 5 inhibitors were assessed in two small RCTs in patients with HFpEF and
PH with distinct haemodynamic characteristics. In patients with a predominantly IpcPH proﬁle, sildenaﬁl had no effect on mPAP (primary endpoint) or other haemodynamic and clinical measures vs.
placebo.685 In patients with a predominantly CpcPH proﬁle, sildenaﬁl improved haemodynamics, RV function, and quality of life at 6 and 12
months vs. placebo.686 Furthermore, retrospective analyses and registry data suggested improvements in exercise capacity with
PDE5i therapy in patients with HFpEF-associated CpcPH and with a severe pre-capillary component (PVR mostly .5 WU).450,687
8.3.1.3. Interatrial shunt devices
Recent data suggest that speciﬁc interventions may be considered in selected cases of HFpEF, such as interatrial shunt devices to unload the left heart. While this was associated with short-term improvements in pulmonary vascular function,688 the long-term effect on the pulmonary circulation remains unknown. The recent REDUCE LAP-HF II trial failed to show a reduction in HF events after placement of an atrial shunt device in a population of HF patients with LVEF ≥40%,689 with worse outcomes in the presence of PVD.690 In addition, a sustained increase in PA blood ﬂow may be a matter of concern, as this may trigger vascular remodelling in patients with pre-existing PH.
8.3.1.4. Remote pulmonary arterial pressure monitoring in heart failure
The importance of decongestion in patients with HF is underscored by the use of implantable pressure sensors, remotely monitoring
PAP as a surrogate of left-sided ﬁlling pressure. Pulmonary arterial pressure-based adjustment of HF therapy substantially reduced HF
hospitalizations and improved outcomes in both patients with
HFpEF and HFrEF,691–694 with adjustment of diuretic therapy being the most prominent therapeutic consequence. Further strategies to optimize management depending on the haemodynamic phenotype in PH-LHD remain to be established. In HFrEF, novel medical therapies such as ARNIs and SGLT-2is reduced remotely monitored
PAP and diuretic use,695–698 potentially providing opportunities to further optimize PAP-guided HF therapy.
8.3.2. Pulmonary hypertension associated with valvular heart disease
Pulmonary hypertension frequently occurs as a consequence of valvular heart disease. While surgical or interventional approaches for valvular repair improve cardiopulmonary haemodynamics by reducing PAWP and PAP and improving forward SV,699 persistent PH
after correcting valvular heart disease is frequent and associated with adverse outcomes.634,700
8.3.2.1. Mitral valve disease
Both mitral stenosis and regurgitation regularly lead to post-capillary
PH. Functional (secondary) mitral regurgitation occurs in both HFrEF
and HFpEF, and is an important contributor to PH in LHD. Reducing mitral regurgitation according to the recommendations of the 2021
ESC/EACTS Guidelines for the management of valvular heart disease28 has a crucial role in improving haemodynamics in patients with HFrEF, as this reduces mPAP and PAWP and improves the
CI.699 Nevertheless, registry data have demonstrated that even moderately elevated sPAP negatively impacts post-procedural outcomes after catheter-based therapy.700
8.3.2.2. Aortic stenosis
In patients with aortic stenosis undergoing surgical or catheter-based aortic valve repair, pre-interventional PH is associated with a higher risk of in-hospital adverse events and adverse long-term outcomes.646–651 Although post-procedural improvement in PH correlates with symptom relief and favourable outcomes, persistence of
PH is common, and even moderate PH is associated with a higher all-cause mortality.646–651
Of note, medical therapy of PH post-valvular repair may be harmful. A randomized study of 231 patients with surgically corrected valvular heart disease and persistent PH showed that sildenaﬁl therapy vs. placebo was associated with worse outcome when compared with placebo;701 however, this study did not distinguish between different types of PH (pre-capillary, IpcPH, and CpcPH).
8.3.2.3. Tricuspid regurgitation
Severe TR is associated with volume overload, increased RV workload, and maladaptive remodelling, leading to symptomatic right HF
and impaired survival.702,703 While primary TR is relatively rare, functional TR may arise from annular dilation in the presence of both PH
and LHD. Transcatheter tricuspid valve interventions have recently emerged, aiming at reducing TR and RV volume overload. Of note,
correcting TR in patients with PAH or PH in (non-valvular) LHD
with signiﬁcantly elevated PVR and/or RV dysfunction must be considered with great caution, as this may be hazardous.704 Right ventricle–
PA coupling is an independent predictor of all-cause mortality in such patients.705 Patient selection appears crucial, and a comprehensive diagnostic approach integrating imaging modalities and invasive haemodynamic assessment is necessary in the evaluation process prior to tricuspid valve repair, particularly since echocardiography underestimates sPAP in the presence of severe TR.
8.3.3. Recommendations on the use of drugs approved for PAH in PH-LHD
The recommendations on the use of drugs approved for PAH in patients with PH-LHD have been established based on key narrative question 5 (Supplementary Data, Section 8.3).
The recommendations on the use of PDE5is in patients with
CpcPH associated with HFpEF are based on PICO question II
(Supplementary Data, Section 8.4). Two RCTs that enrolled patients with HFpEF and PH were identiﬁed, but no study that speciﬁcally enrolled patients with HFpEF and CpcPH. Harmful effects cannot be excluded, even if the available data from clinical studies, case series, and registries suggest that PDE5is may be safely administered to patients with HFpEF-associated CpcPH. As a result, a general recommendation for or against the use of PDE5is in patients with HFpEF and CpcPH cannot be made. However, it is clinically relevant to make a recommendation against their use for patients with HFpEF and IpcPH.
ESC/ERS Guidelines
3689


<!-- PAGE 73 -->

### Page 73

### 9 Pulmonary hypertension associated with lung diseases and/

or hypoxia (group 3)
Pulmonary hypertension is frequently observed in patients with
COPD and/or emphysema, ILD, combined pulmonary ﬁbrosis and emphysema (CPFE), and hypoventilation syndromes.52,165,707,708
Pulmonary hypertension is uncommon in obstructive sleep apnoea unless other conditions coexist, such as COPD or daytime hypoventilation.709 At high altitude (.2500 m) hypoxia-induced PH is thought to affect .5% of the population, the development of PH
being related to geography and genetic factors.710
A PH screening study performed on a large cohort of .100
patients with lymphangioleiomyomatosis conﬁrmed that PH is usually mild in that setting: from six patients (5.7%) presenting with pre-capillary PH, none had mPAP .30 mmHg and
PH was associated with PFT alteration, suggesting that the rise in mPAP is associated with parenchymal involvement.711
Thus, PH in lymphangioleiomyomatosis is now classiﬁed in group 3 PH.1
In patients with lung disease, PH is categorized as non-severe or severe, depending on haemodynamic ﬁndings (Figure 12). In the
2015 ESC/ERS Guidelines for the diagnosis and treatment of
PH, severe PH was deﬁned by mPAP .35 mmHg or mPAP
≥25 mmHg with CI ,2.5 L/min/m2.25,26 However, two recent studies have demonstrated that a PVR .5 WU is a better threshold for predicting worse prognosis in patients with PH associated with both COPD and ILD.712,713 Based on these data, the current guidelines used PVR to distinguish between non-severe PH (PVR
Recommendation Table 22 — Recommendations for pulmonary hypertension associated with left heart disease
Recommendation Table 22A
Recommendations
Classa
Levelb
In patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of suspected
PH27,28
I
A
RHC is recommended for suspected PH in patients with LHD, if it aids management decisions
I
C
RHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair
I
C
For patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral to a PH centre for a complete diagnostic work-up is recommended29,47,142
I
C
In patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is recommended
I
C
When patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or
ﬂuid challenge, are treated with PAH drugs, close monitoring is recommended
I
C
In patients with PH at RHC, a borderline PAWP (13–15 mmHg) and features of HFpEF, additional testing with exercise or ﬂuid challenge may be considered to uncover post-capillary PH133,143
IIb
C
Drugs approved for PAH are not recommended in PH-LHDc 631,678,683,684,701,706
III
A
© ESC/ERS 2022
Recommendation Table 22B
GRADE
Recommendations
Quality of evidence
Strength of recommendation
Classa
Levelb
No recommendation can be given for or against the use of PDE5is in patients with HFpEF and combined post- and pre-capillary PH
Low
None
–
–
The use of PDE5is in patients with HFpEF and isolated post-capillary PH is not recommended
Low
Conditional
III
C
© ESC/ERS 2022
CpcPH, combined post- and pre-capillary PH; ERA, endothelin receptor antagonist; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LHD, left heart disease; PAH, pulmonary arterial hypertension; PAWP, pulmonary arterial wedge pressure; PDE5is, phosphodiesterase 5 inhibitors; PH,
pulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right ventricular; WU, Wood units.
aClass of recommendation.
bLevel of evidence.
cSafety concerns have been identiﬁed when ERAs are used in patients with HF (HFpEF and HFrEF, with or without PH) and when sildenaﬁl is used in patients with persistent PH after correction of valvular heart disease.
3690
ESC/ERS Guidelines


<!-- PAGE 74 -->

### Page 74

≤5 WU) and severe PH (PVR .5 WU). Whereas non-severe PH
is common in advanced COPD and ILD deﬁned by spirometric criteria, severe PH is uncommon, occurring in 1–5% of cases of
COPD and ,10% of patients with advanced ILD, with limited data in obesity hypoventilation syndrome.714,715 Even non-severe
PH in lung disease negatively impacts symptoms and survival, and is associated with increased hospitalization.715–717 Patients with lung disease and severe PH have a worse outcome than those with non-severe PH, providing evidence that this distinction has clinical signiﬁcance.51,712,713,718,719 It is noteworthy that developing severe PH is largely independent of spirometry but usually accompanied by hypoxaemia, low PaCO2, and a signiﬁcant reduction in DLCO.51,714,718,719
Pulmonary hypertension presenting in patients with lung disease may be due to a number of causes, including undiagnosed CTEPH
or PAH.714,720 Cardiac comorbidities are also common in patients with lung disease and may contribute to PH. A number of distinct phenotypes of PH in patients with lung disease, including a pulmonary vascular phenotype, have been proposed.51,720 The pulmonary vascular phenotype is characterized by better preserved spirometry,
low DLCO, hypoxaemia, a range of parenchymal involvement on lung imaging, and a circulatory limitation to exercise.51,714,718–722
Recent studies have shown that the clinical characteristics, disease trajectory, response to treatment,451,718,719 and histological correlates723,724 of patients with severe PH and minor lung disease are different to those in patients with IPAH, including a poorer prognosis.
Remodelling of airways, lung parenchyma, and vessels
Prevalence
~70%
~20%
~5–10%
Mostly ventilatory exercise limitation
Mostly circulatory exercise limitation
Remodelling of pulmonary vessels
Remodelling of airways and parenchyma
Hypoxaemia at rest and/or during exercise
No PH
Non-severe PH
Severe PH
(PVR >5 WU)
COPD
ILD
CPFE
R
Emphysema
Fibrosis
Vascular pruning
CPFE
Figure 12 Pathophysiology of pulmonary hypertension associated with lung disease (group 3). COPD, chronic obstructive pulmonary disease; CPFE,
combined pulmonary ﬁbrosis and emphysema; ILD, interstitial lung disease; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; WU,
Wood units. Shown are underlying lung diseases (upper panel); contributing pathogenic pulmonary alterations of airways, parenchyma, and vessels
(middle panel); and the relation of airway/parenchymal remodelling and vascular remodelling to the degree of PH and its consequences for exercise limitation (ventilatory vs. circulatory, lower panel).
ESC/ERS Guidelines
3691


<!-- PAGE 75 -->

### Page 75

9.1. Diagnosis
In patients with lung disease, symptoms of PH, especially exertional dyspnoea, overlap with those of the underlying condition. Physical
ﬁndings may also be non-speciﬁc, for example: ankle swelling is common during episodes of ventilatory failure in COPD, where activation of the renin–angiotensin–aldosterone system may cause ﬂuid retention, usually in the setting of preserved RV function.
Non-invasive tests—such as ECG showing right axis deviation or
RV strain, elevated levels of BNP/NT-proBNP, CPET, or features on cross-sectional imaging—may suggest the diagnosis of PH in patients with lung disease.725,726 Echocardiography remains the most widely used non-invasive diagnostic tool for assessing PH; however, the accuracy of echocardiography in patients with advanced respiratory diseases is low, with a TRV unmeasurable in .50% of patients in some studies, and there is a tendency to overestimate PAP and misclassify patients with PH.86,87,727 More recent data suggest that a stepwise, composite, echocardiographic score can identify patients with severe PH, with and without an estimate of TRV, using other echocardiographic features including RA area, RV:LV ratio, and LV eccentricity index.728 Where PH is suspected, combining echocardiography with a contrast-enhanced CT may aid diagnostic assessment and disease classiﬁcation.108,729–731 Pulmonary artery enlargement, RV outﬂow hypertrophy, and increased RV:LV ratio may suggest a diagnosis of
PH.108 Ideally, assessments should be made or repeated when the patient is clinically stable, as exacerbations can signiﬁcantly raise PAP.
Key parts of evaluating suspected PH in lung disease include integrating: (1) the presence or absence of risk factors for PAH, CTEPH, or
LHD; (2) clinical features, including disease trajectory (e.g. rapid recent deterioration vs. gradual change over years, and oxygen requirements);
(3) PFTs, including DLCO and blood gas analysis; (4) NT-proBNP measurements, ECG, and echocardiography; and (5) cross-sectional imaging with contrast-enhanced CT, SPECT, or V/Q lung scan and, in selected cases, cMRI732 to assess the need for RHC. Cardiopulmonary exercise testing may be helpful in assessing ventilatory or cardiac limitation in patients with lung disease,121,733 although data are limited regarding its clinical use in identifying patients with PH in lung disease.
Indications for RHC in lung disease include assessment for surgical treatments (selected patients considered for LTx and lung volume reduction surgery), suspected PAH or CTEPH, and where further information will aid phenotyping of disease and consideration of therapeutic interventions (Figure S3).712,718,734 Such testing should ideally be conducted in PH centres when patients are clinically stable and treatment of underlying lung disease has been optimized. Consideration should be given to how pressure measurements are made, due to the impact of changing intrathoracic pressures on pulmonary haemodynamics during the respiratory cycle (see Section 5.1.12).735
9.2. Therapy
The therapeutic approach to group 3 PH starts with optimizing the treatment of the underlying lung disease, including supplementary oxygen and non-invasive ventilation, where indicated, as well as enrolment into pulmonary rehabilitation programmes.736 There is limited and conﬂicting evidence for the use of medication approved for PAH in patients with group 3 PH, and these drugs may have variable and sometimes detrimental effects on haemodynamics, exercise capacity, gas exchange,
and outcomes in this patient population.181,737–740
9.2.1. Pulmonary hypertension associated with chronic obstructive pulmonary disease or emphysema
Studies using drugs approved for PAH in patients with PH associated with COPD or emphysema have yielded conﬂicting results and are mostly limited by small sample size, short duration, and insufﬁcient haemodynamic characterization of PH.739,741,742 In a 16 week RCT
of 28 patients with COPD and severe PH conﬁrmed by RHC, sildenaﬁl therapy resulted in statistically signiﬁcant improvements in PVR
and quality of life.743 Registry data identiﬁed that ≏30% of patients with COPD and severe PH, predominantly treated with PDE5is,
had improved WHO-FC, 6MWD, and PVR vs. baseline, and those with a treatment response had improved transplant-free survival.51,718 However, in the absence of large randomized trials, the evidence is insufﬁcient to support the general use of medication approved for PAH in patients with COPD and PH. Patients with COPD
and suspected or conﬁrmed severe PH should be referred to PH
centres for individual decision-making.
9.2.2. Pulmonary hypertension associated with interstitial lung disease
Numerous phase 2 and phase 3 studies have investigated the use of
ERAs to treat ILD, all with negative results.740,744,745 In addition, the
PDE5i sildenaﬁl has been investigated in phase 3 trials of patients with
ILD, also with negative results.746,747 Few data from RCTs are available for patients with PH associated with ILD, and many of the studies performed for this indication748,749 suffered from the same limitations as the aforementioned studies in PH associated with COPD. In addition,
there were several adverse safety signals: ambrisentan was associated with an increased risk of clinical worsening in patients with ILD with and without PH,740,750 while riociguat was associated with an increased risk of clinical worsening events, including potential excess mortality, in patients with PH associated with idiopathic interstitial pneumonia.181
In contrast, promising results have been obtained with the use of inhaled treprostinil. A phase 3 RCT (INCREASE) examined inhaled treprostinil at a target dose of 72 µg given four times daily in 326 patients with PH associated with ILD.734,751 The PH diagnosis was conﬁrmed by RHC within 1 year prior to enrolment. At week 16, the placebo-corrected 6MWD improved by 31 m with inhaled treprostinil. There were also improvements in NT-proBNP and clinical worsening events, the latter driven by a lower proportion of patients whose 6MWD declined by .15% from baseline.
Given the signiﬁcant impact of even non-severe PH in patients with lung disease, eligible patients should be referred for LTx evaluation. In patients with ILD and PH, inhaled treprostinil may be considered based on the ﬁndings from the INCREASE study, but further data are needed, especially on long-term outcomes. The routine use of other medication approved for PAH is not recommended in patients with ILD and non-severe PH. For patients with severe PH
and/or severe RV dysfunction, or where there is uncertainty regarding the treatment of PH, referral to a PH centre is recommended for careful evaluation, to facilitate entry into RCTs, and consider PAH
therapies on an individual basis (Figure S3). Registry data show that some patients with group 3 PH are being treated with PAH medication, predominantly PDE5is,718,752,753 but it is unclear if and to what extent these patients beneﬁt from this treatment.
3692
ESC/ERS Guidelines


<!-- PAGE 76 -->

### Page 76

9.2.3. Recommendations on the use of drugs approved for PAH in PH associated with lung disease
The recommendations on the use of drugs approved for PAH in patients with PH associated with COPD and ILD have been established based on key narrative questions 6 and 7 (Supplementary Data,
Sections 9.1 and 9.2, respectively).
The recommendations on the use of PDE5is in patients with severe PH associated with ILD are based on PICO question III
(Supplementary Data, Section 9.3). There are no direct data from
RCTs on the safety, tolerability, and efﬁcacy of PDE5is in patients with PH associated with ILD. The indirect data included in the guidelines do not enable ﬁrm conclusions to be drawn. Given the lack of robust evidence, the Task Force members felt unable to provide a recommendation for or against the use of PDE5is in patients with ILD and severe PH, and recommend that these patients are referred to a PH centre for individualized decision-making.
10. Chronic thrombo-embolic pulmonary hypertension (group 4)
All patients whose symptoms can be attributed to post-thrombo-embolic ﬁbrotic obstructions within the PA are
Recommendation Table 23 — Recommendations for pulmonary hypertension associated with lung disease and/or hypoxia
Recommendation Table 23A
Recommendations
Classa
Levelb
If PH is suspected in patients with lung disease, it is recommended that echocardiographyc be performed and the results interpreted in conjunction with ABG, PFTs including DLCO, and CT imaging
I
C
In patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where indicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation
I
C
In patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH
centre is recommendedd
I
C
In patients with lung disease and severe PH, an individualized approach to treatment is recommended
I
C
It is recommended to refer eligible patients with lung disease and PH for LTx evaluation
I
C
In patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions
I
C
Inhaled treprostinil may be considered in patients with PH associated with ILD734
IIb
B
The use of ambrisentan is not recommended in patients with PH associated with IPF740
III
B
The use of riociguat is not recommended in patients with PH associated with IIP181
III
B
The use of PAH medication is not recommended in patients with lung disease and non-severe PHe
III
C
© ESC/ERS 2022
Recommendation Table 23B
GRADE
Recommendations
Quality of evidence
Strength of recommendation
Classa
Levelb
PDE5is may be considered in patients with severe PH associated with ILD
(individual decision-making in PH centres)
Very low
Conditional
IIb
C
The use of PDE5is in patients with ILD and non-severe PH is not recommended
Very low
Conditional
III
C
© ESC/ERS 2022
ABG, arterial blood gas analysis; CT, computed tomography; DLCO, Lung diffusion capacity for carbon monoxide; IIP, idiopathic interstitial pneumonia; IPF, idiopathic pulmonary
ﬁbrosis; ILD, interstitial lung disease; LTx, lung transplantation; PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; PFT, pulmonary function test; PH,
pulmonary hypertension; RHC, right heart catheterization.
aClass of recommendation.
bLevel of evidence.
cAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise pulmonary artery pressure.
dThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.
eThis does not include inhaled treprostinil, which may be considered in patients with PH associated with ILD, irrespective of PH severity.
ESC/ERS Guidelines
3693


<!-- PAGE 77 -->

### Page 77

considered to have CTEPD with or without PH; CTEPH remains the preferred term for patients with PH, as deﬁned in Section 3.1
(Table 5).54 Chronic thrombo-embolic pulmonary disease describes symptomatic patients with mismatched perfusion defects on V/Q
scan and with signs of chronic, organized, ﬁbrotic clots on CTPA or
DSA, such as ring-like stenoses, webs/slits, and chronic total occlusions
(pouch lesions or tapered lesions), after at least 3 months of therapeutic anticoagulation. Pulmonary hypertension in this setting is not only a consequence of PA obstruction by organized ﬁbrotic clots but can also be related to the associated microvasculopathy. In those patients without PH at rest, breathlessness could be due to exercise PH (see deﬁnition in Section 3.1, Table 5) and/or increased dead space ventilation.54 Excluding ventilatory limitation, deconditioning and psychogenic hyperventilation syndrome by CPET and LV myocardial or valvular disease by echocardiography is of upmost importance when making therapeutic decisions in patients with CTEPD without PH.
10.1. Diagnosis
Chronic thrombo-embolic pulmonary hypertension is a common and important cause of PH, with a distinct management strategy.
Thus, the possibility of CTEPH should be carefully considered in all patients with PH (Figure 13). In the context of acute PE, CTEPH
CTEPH diagnostic algorithm for symptomatic patients f
Patients with confirmed CTEPH
CTEPH suspected from history of PEa or risk factors for CTEPH
f
Tr
T eatment assessment by MDT at CTEPH centre
(Class I)
PH work-up
N
Y
Perfusion imaging
(V/Q scan or new modalityb)
Any mismatched perfusion defects f
Echocardiography
Intermediate or high probability of PH
Refer to CTEPH/PH centre
Comprehensive work-upd
(Table 14
T
, ReCo
,
Table 2)
T
Abnormal exercise tests
(CPETc, st
,
ress echocardiography)
suggestive for CTEPD
f
AND
CTPA + D
P
SA
when CTPA is inconclusi
P
ve
RHC
AND
Figure 13 Diagnostic strategy in chronic thrombo-embolic pulmonary hypertension. CPET, cardiopulmonary exercise test; CTEPD, chronic thromboembolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; CTPA, computed tomography pulmonary angiography; DECT,
dual-energy computed tomography; DSA, digital subtraction angiography; MDT, multidisciplinary team; MRI, magnetic resonance imaging; N, no; PE, pulmonary embolism; PETCO2, end-tidal partial pressure of carbon dioxide; PH, pulmonary hypertension; ReCo, recommendation; RHC, right heart catheterization; sPAP, systolic pulmonary arterial pressure; V/Q, ventilation/perfusion; VE/VCO2, ventilatory equivalents for carbon dioxide; VO2/HR, oxygen pulse; VO2, oxygen uptake; Y, yes. aCTEPH suspected from history of PE, including elevated sPAP on echocardiography and signs suggesting CTEPH on
CTPA performed at the time of the acute PE (Section 5.1.7). bAlternative perfusion imaging techniques—such as iodine subtraction mapping, DECT, and
MRI perfusion—are currently under evaluation. cTypical pattern, including low PETCO2, high VE/VCO2, low VO2/HR, and low peak VO2 (Section 5.1.11).
dComprehensive work-up after 3 months of therapeutic anticoagulation or sooner in unstable or rapidly deteriorating patients. Ideally, CTPA, DSA, and
RHC are performed in CTEPH centres, but they are sometimes performed in PH centres, depending on the country and organization.
3694
ESC/ERS Guidelines


<!-- PAGE 78 -->

### Page 78

should be considered: (1) if radiological signs (detailed in Section
5.1.7) suggest CTEPH on the CTPA performed to diagnose PE,112
and/or if estimated sPAP is .60 mmHg112 on echocardiogram; (2)
when dyspnoea or functional limitations persist in the clinical course post-PE;754 and (3) in asymptomatic patients with risk factors for
CTEPH or a high CTEPH prediction score.755 Clinical conditions such as permanent intravascular devices (pacemaker, long-term central lines, ventriculoatrial shunts), inﬂammatory bowel diseases, essential thrombocythaemia,
polycythaemia vera,
splenectomy,
antiphospholipid syndrome, high-dose thyroid hormone replacement, and malignancy are risk factors for CTEPH.54,103,756
Alternative causes of PA obstructions (also included in group 4 of the
PH classiﬁcation)—including PA sarcomas, other malignant tumours
(e.g. renal carcinoma, uterine carcinoma, and germ-cell tumours of the testis), non-malignant tumours (e.g. uterine leiomyoma), arteriitis without CTD, congenital or acquired PA stenoses, parasites (hydatid cyst), and foreign-body embolism—have to be considered in the differential diagnosis of CTEPD.757 They can be explored by speciﬁc additional imaging such as 18F-2-ﬂuoro-2-deoxy-D-glucose-positron emission tomography (PET) scan, which can provide additional information when PA sarcoma is suspected.758
Ventilation/perfusion scintigraphy207 remains the most effective tool in excluding CTEPD. Alternative perfusion imaging techniques
—such as iodine subtraction mapping, DECT, and MRI perfusion—
have numerous theoretical advantages over V/Q but are more technically challenging and expensive, have limited availability, and currently lack multicentre validation.
Computed tomography pulmonary angiography with bi-planar reconstruction is broadly used for diagnosing CTEPD and assessing operability, but a negative CTPA, even if high quality, does not exclude
CTEPD, as distal disease can be missed. Digital subtraction angiography is still used to assess treatment options when CTPA is inconclusive. Selective segmental angiography, cone-beam CT, and area detector CT allow for more accurate visualization of subsegmental vasculature and are useful for procedural guidance for BPA. The beneﬁts of the new technologies require validating in prospective trials before being recommended for routine clinical use; a large,
European, multicentre study is currently ongoing.759
10.2. Therapy
The CTEPH treatment algorithm includes a multimodal approach of combinations of pulmonary endarterectomy (PEA), BPA, and medical therapies to target the mixed anatomical lesions: proximal, distal,
and microvasculopathy, respectively (Figures 14 and 15).
General measures recommended for PAH also apply to CTEPH,
including supervised exercise training, which is effective and safe in inoperable CTEPH patients,760 as well as early after PEA.761
Lifelong therapeutic anticoagulation is recommended for patients with CTEPH, as recurrent pulmonary thrombo-embolism accompanied by insufﬁcient clot resolution are key pathophysiological features of this disease. There are no RCTs in CTEPH with any of the approved anticoagulants; however, despite this lack of evidence, VKAs are recommended by experts, and are most widely used as background therapy for patients with CTEPH. More recently, NOACs have more frequently been used as alternatives to VKAs, again, lacking evidence from RCTs. A
retrospective case series from the UK and a multicentre prospective registry (EXPERT) showed comparable bleeding rates for VKAs and
NOACs in CTEPH, but recurrent venous thrombo-embolism rates were higher in those receiving NOACs.762,763 In patients with antiphospholipid syndrome (10% of the CTEPH population), VKAs are recommended.103,764,765 Screening for antiphospholipid syndrome should be performed at CTEPH diagnosis. In the absence of any evidence in favour or against prolonged anticoagulation in patients with CTEPD without
PH, long-term anticoagulant therapy is based on individual decisionmaking. It is recommended when the risk of PE recurrence is intermediate or high, thereby following the 2019 ESC/ERS Guidelines for the diagnosis and management of acute pulmonary embolism (Table 11).103
10.2.1. Surgical treatment
Surgical PEA is the treatment of choice for patients with accessible
PA lesions.102 As surgery may normalize pulmonary haemodynamics
(65% decrease in PVR)766 and functional capacity, an expert multidisciplinary team including an experienced PEA surgeon (on-site or closely collaborating) is mandatory for evaluating operability and deciding ﬁnal treatment.102
Operability is based on team experience, accessibility of PA lesions, correlation between severity of PH and degree of PA obstructions, and comorbidities.767 The surgical technique is complex but well standardized with .30 years of experience. It consists of a complete bilateral endarterectomy of the PAs down to segmental and subsegmental levels in phases of deep hypothermic circulatory arrest
(Figure 15).767,768 In CTEPH centres, surgical outcomes are favourable, with peri-operative mortality rates ,2.5% due to improved management of cardiac and pulmonary complications and wellestablished use of ECMO.768 Post-operative PH is frequently observed (≏25%),766 but long-term outcomes after PEA surgery are excellent regarding survival (averaging 90% at 3 years) and quality of life,769–771 even in patients with distal PA obstructions.772 On the other hand, patients with proximal operable disease declining surgery have a poor long-term outcome, with a 5 year survival of
53%
compared with
83%
in patients undergoing
PEA.773
Therefore, PEA should be offered to all operable patients with a favourable risk:beneﬁt ratio, ideally during a personal consultation between the patient and the PEA surgeon.102
Selected symptomatic patients with CTEPD without PH can be successfully treated by PEA, with clinical and haemodynamic improvements at rest and exercise.135,774 Those patients would require careful discussion to balance risk and beneﬁt.
10.2.2. Medical therapy
To manage the microvascular component of CTEPH (Figure 15),
medical therapies have been used off-label based on uncontrolled studies and/or regional approvals. Meanwhile, three RCTs have successfully been conducted. The ﬁrst phase 3 RCT investigated the efﬁcacy of riociguat in patients with inoperable CTEPH or those with persistent/recurrent PH after PEA.775 Riociguat, after 16 weeks of therapy, improved 6MWD and reduced PVR by 31% compared with placebo, and is approved for this indication. Treprostinil s.c.
was investigated in a phase 3 RCT, which showed improved
6MWD at week 24 in patients with inoperable CTEPH or those with persistent/recurrent PH after PEA receiving a high dose compared with a low dose;776 s.c. treprostinil is approved for this indication. In a phase 2 study including only patients with inoperable
CTEPH, macitentan 10 mg improved PVR and 6MWD vs. placebo
ESC/ERS Guidelines
3695


<!-- PAGE 79 -->

### Page 79

at 16 and 24 weeks, respectively.777 A phase 3 RCT is ongoing to evaluate the safety and efﬁcacy of macitentan 75 mg in inoperable or persistent/recurrent CTEPH (NCT04271475).
Other medical therapies—PDE5is (e.g. sildenaﬁl) and ERAs (e.g.
bosentan)—have been used off-label, as their efﬁcacy in inoperable
CTEPH has not been proven by RCTs or registry data.769,778,779
However, oral combination therapy, including PDE5is and ERAs, is common practice in patients with CTEPH with severe haemodynamic compromise.780
10.2.3. Interventional treatment
Balloon pulmonary angioplasty (Figure 15) has become an established treatment for selected patients with inoperable CTEPH or persistent/recurrent PH after PEA, improving haemodynamics (PVR decrease 49–66%), right heart function, and exercise capacity.781–794
Long-term outcomes are promising, but evidence is still scarce.795
A staged interventional procedure with a limited number of dilated PA segments per session is preferred.102,788 The number of sessions needed and haemodynamic results are dependent on experience.781 While BPA is effective, it is associated with serious complications, which may be fatal. Procedural and post-interventional complications include vascular injury due to wire perforation, and lung injury with haemoptysis and/or hypoxia.102,781,796,797 As with all interventional procedures, a signiﬁcant learning curve has been shown, with reducing complication rates over time;781 therefore,
this procedure should be performed in high-volume CTEPH centres.
As the rates of interventional complications can be reduced by medical pre-treatment, patients with a PVR .4 WU should be treated before BPA (Figure 15).798
Selected symptomatic patients with CTEPD without PH and segmental/subsegmental lesions can successfully be treated by BPA,
with clinical and haemodynamic improvements at rest and exercise.799
Preliminary data on PADN point towards improved exercise capacity and pulmonary haemodynamics in patients with persistent PH
after PEA;800 further conﬁrmation is being awaited.
Patients with confirmed CTEPHa
Lifelong ther f
apeutic anticoagulation
(Class I)
Tr
T eatment assessment by MDTb
(Class I)
PEA as treatment of choicec
(Class I)
Long-term foll f
ow-up at a CTEPH/PH centrec
(Class I)
Medical therapy (ReCo p
Table 24)
T
(Class I)
BPA
P
d
(Class I)
Operable
Persistent/recurrent symptomatic PH
N
N
Y
Y
Figure 14 Management strategy in chronic thrombo-embolic pulmonary hypertension. BPA, balloon pulmonary angioplasty; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; MDT, multidisciplinary team; N, no; PAH, pulmonary arterial hypertension; PEA, pulmonary endarterectomy; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; ReCo, recommendation; WU,
Wood units; Y, yes. aSelected symptomatic patients with CTEPD without PH can also be treated by PEA and BPA. bMDT meeting can be virtual.
cTreatment assessment may differ, depending on the level of expertise in PEA and BPA. dFor inoperable patients with PVR .4 WU, medical therapy should be considered prior to BPA; there are limited data on BPA as ﬁrst-line therapy.
3696
ESC/ERS Guidelines


<!-- PAGE 80 -->

### Page 80

10.2.4. Multimodal treatment
Multimodal therapy including surgery, medication, and intervention is offered to selected patients with CTEPH (Figure 15).102
Using medical therapy in patients with high pre-operative PVR to improve pulmonary haemodynamics before PEA is common practice but still controversial, as it is felt to delay timely surgical referral and therefore deﬁnitive treatment.801–803
A signiﬁcant proportion of symptomatic patients may have persistent or recurrent PH following PEA, which may also beneﬁt from medical and/or interventional therapies (Figure 15).804–806 An mPAP ≥30 mmHg has been associated with initiation of medical therapies post-PEA, and an mPAP ≥38 mmHg and PVR ≥5 WU
with worse long-term survival.806
Some patients with CTEPH may have mixed anatomical lesions, with surgically accessible lesions in one lung and inoperable lesions in the other lung. Such patients might beneﬁt from a combined approach with BPA (prior to or at the same time as surgery) and PEA to decrease the surgical risk and improve the ﬁnal result.807
The recommendations on BPA and medical therapy in patients with inoperable CTEPH have been established based on key narrative question 8 (Supplementary Data, Section 10.1).
The recommendation on the use of medical therapy before interventional therapy in patients with CTEPH who are considered inoperable but candidates for BPA is based on PICO question IV
(Supplementary Data, Section 10.2). The included evidence suggests
A
B
C
D
E
PEA
Medical therapy
Microvasculopathy
Proximal PA fibrotic obstructions
Multimodal CTEPH treatment
Distal PA fibrotic obstructions
BPA
1
2
3
Figure 15 Overlap in treatments/multimodality approaches in chronic thrombo-embolic pulmonary hypertension. BPA, balloon pulmonary angioplasty; CTEPH, chronic thrombo-embolic pulmonary hypertension; PA, pulmonary artery; PEA, pulmonary endarterectomy. Top panels: (A) Proximal
PA ﬁbrotic obstructions (vessel diameter 10–40 mm). (B) Distal segmental and subsegmental PA ﬁbrotic obstruction potentially suitable for both
PEA and BPA interventions (vessel diameter 2–10 mm). (C) Distal subsegmental PA ﬁbrotic obstructions form a web-lesion in a subsegmental branch of the PA suitable for BPA interventions (vessel diameter 0.5–5 mm). (D) Distal subsegmental PA ﬁbrotic obstructions form web-like lesions, which might be accompanied by microvasculopathy (vessel diameter ,0.5 mm). (E) Microvasculopathy (vessel diameter ,0.05 mm) treated with medical therapy.
Bottom panels: (A) bottom left: PEA; vessel diameter (0.2–3 cm). The right PA is opened and the suction dissector is introduced between the artery wall and ﬁbrosis. Following the inside of the artery down to segmental and subsegmental levels, the ﬁbrotic material is subsequently freed from the wall and removed with forceps. (A) bottom right: PEA specimen with ‘tails’ to subsegmental branches of the PA; cross-section of partially organized and permeabilized thrombotic lesion of the large PA dissected during PEA. (B, C, D) The wire is introduced between the ﬁbrotic material (1), then the balloon is inﬂated, leading to a rupture of the web (2). Fibrotic material is connected to the vessel wall (3). (E) Small muscular PA displaying eccentric intimal ﬁbrosis involving intimal thickening and proliferation—target for medical therapies.
ESC/ERS Guidelines
3697


<!-- PAGE 81 -->

### Page 81

that pre-treatment improves pulmonary haemodynamics and safety of the procedure. This is conﬁrmed by the clinical experience of Task
Force members. However, due to the low certainty of the evidence,
the recommendation is conditional.
10.2.5. Follow-up
Regardless of the result of PEA/BPA, patients should be regularly followed-up, including invasive assessment with RHC 3–6 months after intervention, allowing for consideration of a multimodal treatment approach. After successful treatment, yearly non-invasive followup, including echocardiography and an evaluation of exercise capacity,
is indicated because recurrent PH has been described (Figure 14).806
Risk assessment with either the ESC/ERS or REVEAL risk score developed for PAH has been validated in medically treated patients with CTEPH,300,808,809 but it is unknown if its use has any therapeutic implication or affects outcome.
Therearenodataorconsensusonwhatisthetherapeutictargetafter
PEA/BPAormedicaltherapyinCTEPH.Mostexpertsacceptachievinga good functional class (WHO-FC I–II) and/or normalization or near normalization of haemodynamics at rest, obtained at RHC 3–6 months post-procedure (PEA or last BPA), and improvement in quality of life.
10.3. Chronic thrombo-embolic pulmonary hypertension team and experience criteria
To optimize patients’ outcomes, CTEPH centres should fulﬁl criteria for a PH centre (Section 12) and have a CTEPH multidisciplinary team consisting of a PEA surgeon, BPA interventionist, PH specialist, and thoracic radiologist, trained in high-volume PEA and/or BPA centres.
The team should meet regularly to review new referrals and posttreatment follow-up cases. Ideally, CTEPH centres should have
PEA activities (.50/year)810 and BPAs (.30 patients/year or
.100 procedures/year),781 as these ﬁgures have been associated with better outcome. The CTEPH centres should also manage medically treated patients. Based on regional requirements, these numbers may be adjusted for the country’s population, ideally concentrating care and expertise in high-volume centres.
Recommendation Table 24 — Recommendations for chronic thrombo-embolic pulmonary hypertension and chronic thrombo-embolic pulmonary disease without pulmonary hypertension
Recommendation Table 24A
Recommendations
Classa
Levelb
CTEPH
Lifelong, therapeutic doses of anticoagulation are recommended in all patients with CTEPH762
I
C
Antiphospholipid syndrome testing is recommended in patients with CTEPH
I
C
In patients with CTEPH and antiphospholipid syndrome, anticoagulation with VKAs is recommended103,764,765
I
C
It is recommended that all patients with CTEPH are reviewed by a CTEPH team for the assessment of multimodality management54
I
C
PEA is recommended as the treatment of choice for patients with CTEPH and ﬁbrotic obstructions within pulmonary arteries accessible by surgery54,102
I
B
BPA is recommended in patients who are technically inoperable or have residual PH after PEA and distal obstructions amenable to
BPA54,102,783,784,789,793,798,811
I
B
Riociguat is recommended for symptomatic patients with inoperable CTEPH or persistent/recurrent PH after PEA775
I
B
Long-term follow-up is recommended after PEA and BPA, as well as for patients with CTEPH established on medical therapy782,805,806,812
I
C
A multimodality approach should be considered for patients with persistent PH after PEA and for patients with inoperable CTEPH804,805,812
IIa
C
Treprostinil s.c. may be considered in patients in WHO-FC III–IV who have inoperable CTEPH or persistent/recurrent PH after PEA776
IIb
B
Off-label use of drugs approved for PAH may be considered in symptomatic patients who have inoperable CTEPH55,777–779,801
IIb
B
In patients with inoperable CTEPH, a combination of sGC stimulator/PDE5i, ERA,777 or parenteral prostacyclin analogues776 may be considered
IIb
C
BPA may be considered for technically operable patients with a high proportion of distal disease and an unfavourable risk:beneﬁt ratio for PEA
IIb
C
CTEPD without PH
In patients with CTEPD without PH, long-term anticoagulant therapy should be considered on an individual basisc
IIa
C
PEA or BPA should be considered in selected symptomatic patients with CTEPD without PH
IIa
C
© ESC/ERS 2022
3698
ESC/ERS Guidelines


<!-- PAGE 82 -->

### Page 82

### 11 Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5)

Pulmonary hypertension with unclear and/or multifactorial mechanisms (Table 24) includes several conditions that may be complicated by complex and sometimes overlapping pulmonary vascular involvement. Although group 5 PH represents less-studied forms of PH, it constitutes a signiﬁcant part of the worldwide burden of PH.1 Group 5 PH includes: haematological disorders, such as
SCD and chronic myeloproliferative neoplasms; systemic disorders, such as sarcoidosis; metabolic diseases, such as glycogen storage disease; and others, such as chronic renal failure, pulmonary tumour thrombotic microangiopathy, and ﬁbrosing mediastinitis.
A common feature of these diseases is that the mechanisms of
PH are poorly understood and contributing factors may include,
alone or in combination: hypoxic pulmonary vasoconstriction, pulmonary vascular remodelling, thrombosis, ﬁbrotic destruction and/
or extrinsic compression of pulmonary vasculature, pulmonary vasculitis, high-output cardiac failure, and left HF. These patients need careful assessment and treatment should be directed to the underlying condition.
11.1. Haematological disorders
In haemoglobinopathies and chronic haemolytic anaemias, including
SCD, PH has emerged as a major cause of morbidity and mortality.
The prevalence of PH conﬁrmed by RHC was 6–10% in studies of adult patients with stable SCD.93,94,813 Patients with SCD with precapillary PH are more commonly homozygous for haemoglobin S,
while some have S-β0 thalassaemia (S-β0 thal) or haemoglobin
SCD.814 Thrombotic lesions are a major component of PH related to SCD, more frequently in haemoglobin SCD.814 Patients with
PH and SCD should be followed by multidisciplinary SCD and PH
teams, since treatment of the anaemia is a key part of management.814 There is a lack of data to support the use of PAH drugs in patients with SCD-associated PH. In a study in patients with
SCD with TRV ≥2.7 m/s and a 6MWD of 150–500 m, sildenaﬁl showed no treatment effect on 6MWD, TRV, or NT-proBNP, but appeared to increase hospitalization rates for pain.815 Preliminary evidence supports the short- and long-term beneﬁts of chronic blood-exchange transfusions in patients with pre-capillary PH complicating SCD.816 Pre-capillary PH complicating SCD has an important impact on survival, with an overall death rate of 2.0–5.3% in different populations with similar follow-up (26 months and 18
months, respectively).94,817 In β-thalassaemia, invasive haemodynamic evaluation conﬁrmed pre-capillary PH in 2.1% of cases, while a post-capillary proﬁle was found in 0.3%.818 Potential treatment strategies are awaiting an enhanced understanding of the
Recommendation Table 24B
GRADE
Recommendations
Quality of evidence
Strength of recommendation
Classa
Levelb
In patients with CTEPH who are candidates for BPA, medical therapy should be considered prior to the intervention798
Very low
Conditional
IIa
B
© ESC/ERS 2022
BPA, balloon pulmonary angioplasty; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; ERA, endothelin receptor antagonist; PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; PEA, pulmonary endarterectomy; PE, pulmonary embolism; PH, pulmonary hypertension;
s.c., subcutaneous; sGC, soluble guanylate cyclase; VKA, vitamin K antagonist; WHO-FC, World Health Organization functional class.
aClass of recommendation.
bLevel of evidence.
cLong-term anticoagulant therapy is recommended when the risk of PE recurrence is intermediate or high,103 or when there is no history of venous thrombo-embolism.
Table 24
Pulmonary hypertension with unclear and/
or multifactorial mechanisms
Disorders associated with pulmonary hypertension
1 Haematological disorders
Inherited and acquired chronic haemolytic anaemia
• Sickle cell disease
• β-thalassaemia
• Spherocytosis
• Stomatocytosis
• Autoimmune disorders
Chronic myeloproliferative disorders
• Chronic myelogenous leukaemia
• Polycythaemia vera
• Idiopathic myeloﬁbrosis
• Essential thrombocytopenia
• Others
2 Systemic disorders
Sarcoidosis
Pulmonary Langerhans’s cell histiocytosis
Neuroﬁbromatosis type 1
3 Metabolic disorders
Glycogen storage disease
Gaucher disease
4 Chronic renal failure with/
without haemodialysis
5 Pulmonary tumour thrombotic microangiopathy
6 Fibrosis mediastinitis
© ESC/ERS 2022
ESC/ERS Guidelines
3699


<!-- PAGE 83 -->

### Page 83

pathophysiological mechanisms. In spherocytosis, splenectomy is a risk factor for CTEPH.819
Multiple causes of PH have been described in patients with chronic myeloproliferative disorders.820 In chronic myelogenous leukaemia,
spleen enlargement and anaemia can give rise to hyperkinetic syndrome. Hepatosplenic enlargement can also cause PoPH. Cases of potentially reversible DPAH have been described with dasatinib, bosutinib, and ponatinib. In polycythaemia vera and essential thrombocythaemia, there is an increased risk of venous thrombo-embolic disease and CTEPH; moreover, a blood clot within the hepatic veins can lead to Budd–Chiari syndrome and subsequent PoPH.
Pulmonary extramedullary haematopoiesis complicating idiopathic or secondary myeloﬁbrosis may also contribute to dyspnoea and PH.
Group 5 PH may be described in other haematological disorders,
such as common variable immunodeﬁciency; immunoglobulin G4
(IgG4)-related disease; Castleman disease; and polyneuropathy, organomegaly, endocrinopathy, monoclonal immunoglobulin, skin changes (POEMS) syndrome.821–823
11.2. Systemic disorders
The reported prevalence of PH in patients with sarcoidosis is 6–
20%.824 The causes are multifactorial, including ﬁbrosing lung disease,
granulomata in the PAs and/or pulmonary veins, ﬁbrosing mediastinitis and/or extrinsic compression by lymph nodes, pulmonary vasculitis, CTEPH, and PoPH.58,825 It is associated with signiﬁcant morbidity and increased mortality compared with sarcoidosis without PH.58,825 In a registry, factors independently associated with outcomes included physiological (forced expiratory volume in 1 s/FVC
ratio and DLCO) and functional (6MWD) parameters.58 In a large study of severe, sarcoidosis-associated PH, PAH drugs improved short-term pulmonary haemodynamics without improving
6MWD.59 Small RCTs have suggested efﬁcacy of PAH drugs in these patients,
which requires conﬁrmation in larger studies.826
Corticosteroids or immunosuppressive therapy may improve haemodynamics in selected patients with active granulomatous disease. Of note, when pulmonary vascular compression is suspected
(ﬁbrosing mediastinitis and/or extrinsic compression by lymph nodes), results from pulmonary angiography and PET scans provide additional information justifying endovascular and/or antiinﬂammatory approaches. Long-term survival remains poor in sarcoidosis-associated PH, which makes LTx a reasonable option for selected severe cases.
In pulmonary Langerhans’s cell histiocytosis, diminished exercise capacity does not appear to be due to ventilatory limitation but may be related to pulmonary vascular dysfunction. In 29 patients with PH associated with pulmonary Langerhans’s cell histiocytosis,
PAH drugs improved haemodynamics without worsening oxygen levels.827
Pulmonary hypertension associated with neuroﬁbromatosis type
1 is a rare but severe complication characterized by female predominance (female/male ratio 3.9:1).828 Speciﬁc pulmonary vascular involvement exists in these patients, and despite a potential short-term beneﬁt of PAH drugs, prognosis remains poor, and
LTx should be considered in selected patients with severe disease.
In the presence of dyspnoea, screening for ILD by non-contrast
CT and for PH by echocardiography is required.828
11.3. Metabolic disorders
Glycogen storage diseases are caused by genetic alterations of glycogen metabolism, and PH case reports have been related to glycogen storage disease type 1 and 2.829 The occurrence of PH has predominantly been described in glycogen storage disease type 1, where it may partly be due to vasoconstrictive amines such as serotonin.
Drugs for PAH have been used in some cases.830
Untreated patients with Gaucher disease may develop PH, which is caused by a combination of factors, including asplenia, plugging of the vasculature by abnormal macrophages, and pulmonary vascular remodelling. Treatment with enzyme-replacement therapy may improve PH.
11.4. Chronic kidney failure
Although commonly recognized in chronic renal failure, the pathogenesis of PH remains poorly understood and PH is observed in patients prior to and while receiving different dialysis modalities.831 A
recent RHC study of 3504 patients with chronic kidney disease found that CpcPH was the most common phenotype, and the phenotype with the highest mortality.832 Post-capillary PH has been described in 65% of patients receiving haemodialysis and 71%
of patients without kidney replacement.833
11.5. Pulmonary tumour thrombotic microangiopathy
Pulmonary tumour thrombotic microangiopathy describes tumourcell microemboli with occlusive ﬁbrointimal remodelling in small PAs,
pulmonary veins, and lymphatics. It is a rare cause of PH, which arises due to multiple mechanisms, but probably remains under-diagnosed,
as evidenced by autopsy ﬁndings.834 The disorder is associated with carcinomas, notably gastric carcinoma. Progressive vessel occlusion ultimately results in PH, which is often severe, of sudden onset, rapidly progressive, and accompanied by progressive hypoxaemia. Chest
CT may show patchy ground-glass and septal markings (masquerading as PVOD).
11.6. Fibrosing mediastinitis
Fibrosing mediastinitis is caused by ﬁbrous tissue proliferating in the mediastinum, encasing mediastinal viscera and compressing mediastinal bronchovascular structures.835 Pre- or post-capillary PH can complicate the course of ﬁbrosing mediastinitis due to extrinsic compression of the
PAs and/or pulmonary veins. Fibrosing mediastinitis can be idiopathic or caused by irradiation, infection (tuberculosis, histoplasmosis), and systemic diseases, such as sarcoidosis and IgG4-related disease, a ﬁbroinﬂammatory disease characterized by elevated serum IgG4 levels with inﬁltration of IgG4+ plasma cells and severe ﬁbrosis in affected tissues.821 Treatment should be directed to the underlying condition.
No clear clinical improvement has been described with PAH drugs.
Surgical and endovascular procedures have been proposed to de-obstruct or bypass the arterial and/or venous compressions.
In the absence of positive RCTs studying the use of PAH drugs for treating group 5 PH, treating the underlying disorder remains the standard of care.836 Importantly, some of the diseases described in
Table 24 may have a pulmonary venous component that could be made worse with PAH drugs, implying that off-label use of drugs approved for PAH should be considered with great caution, if at all.
3700
ESC/ERS Guidelines


<!-- PAGE 84 -->

### Page 84

Placebo-controlled, randomized trials are currently recruiting in well-phenotyped subgroups of PH with unclear and/or multifactorial mechanisms, such as sarcoidosis-associated PH.
12. Deﬁnition of a pulmonary hypertension centre
While PH is not an uncommon condition, severe forms of PH, especially PAH and CTEPH, require highly specialized management.
Since medical centres with multidisciplinary teams and a high volume of patients generally offer best standard of care, which translates into better clinical outcomes, establishing PH centres is clinically and economically highly desirable and is supported by patient organizations and scientiﬁc societies. The purpose of a
PH centre is to: receive new referrals; assess and investigate the cause of PH; carefully phenotype and routinely manage patients with medical, interventional, and surgical approaches; work closely with other health care providers to achieve the best outcomes for patients; undertake audits (reporting patient case mix and quality indicators); and be involved in clinical and translational research,
and education. The requirements—comprising deﬁnition, multidisciplinary structure, number of cases, procedures, and stafﬁng levels, as well as the skills and resources needed in a PH referral centre—are described below and in Figure 16. Criteria for paediatric and CTEPH centres are described elsewhere (Sections 7.8.3 and 10.3,
respectively).
Co-ordinated by a core MDT member responsible for the multidisciplinary approach
Core MDT
Extended MDT
Social worker
Study nurse
Paediatric cardiologist
Psychologist
Adult CHD specialist
Lung pathologist
Hepatologist
Physiotherapist
Rheumatologist
Intensive care specialist
Thoracic radiologist
Palliative care specialist
Cardiac radiologist
Lung transplant physician/surgeonc
Clinical geneticist/
Genetic counsellorc
At least 2 PH nurses
Nurse specialist
For diagnostic pulmonary angiography, embolization
Interventional radiologist/cardiologist
Cardiologist/Pneumologist
At least 2 surgeons
(ECMO)
Cardiothoracic surgeon
Case managerb
Responsible for data 
collection, analysis, and organization of audit meetings
Data manager
MDT meeting
Regular, to discuss multidisciplinary aspects of individual patient care
Patient empowerment and advocacy
Clear verbal, and written information for patients that describes diagnostic procedures and treatment options;
shared decision-making; collaboration with advocacy group
Interaction with external healthcare providers and other relevant stakeholders
GP, local specialist, social services, rehabilitation centres, national health services, labs,
insurers, school, work, sport club, psychologist, etc.
Quality control/Audits
Data collection/registration; monitoring of quality indicators; regular internal audits
Research, training, and education
Involvement in clinical and translational research: teaching courses on local, national, or international basis
Patient care pathway and clinical management protocol
Steps from diagnosis to follow-up including advanced disease, palliative stage, and end of life
At least 2 PH specialists treating a sufficient number of patientsa
Responsible for the co-ordination of care on patient level
Gynaecologist/
Obstetrician
Cardiothoracic 
anaesthetist
Processes
Pulmonary hypertension centre working 50% on PH care 
Figure 16 Pulmonary hypertension centre schematic. CHD, congenital heart disease; ECMO, extracorporeal membrane oxygenation; GP, general practitioner; MDT, multidisciplinary team; PH, pulmonary hypertension. aNumber adapted according to speciﬁc country characteristics. bCase manager can be a nurse specialist, social worker, physiotherapist, or administrative assistant in function of the centre organization. cCan be located in partner centres. Adapted from Biganzoli et al.846
ESC/ERS Guidelines
3701


<!-- PAGE 85 -->

### Page 85

12.1. Facilities and skills required for a pulmonary hypertension centre
Pulmonary hypertension centres care for a sufﬁcient number of patients on PH therapy, as well as new referrals, to warrant this status.
According to the 2015 ESC/ERS Guidelines for the diagnosis and treatment of PH and the European Reference Network on rare respiratory diseases (ERN-LUNG) competency requirements, the ideal number of patients seen by an adult centre each year is no fewer than 200, of which at least half have a ﬁnal diagnosis of PAH; a PH
centre follows at least 50 patients with PAH or CTEPH and receives at least two new referrals per month with documented PAH or
CTEPH.25,26,837–839 These numbers can be adapted according to speciﬁc country characteristics (small population, large geographical area) provided that strong working collaborations are established with high-volume centres. This is currently facilitated by the availability of secure virtual platforms (e.g. ERN clinical patient management system).840
Proper training of staff members includes core competencies, such as those outlined in the ERS Pulmonary Vascular Diseases Continuing
Professional Development framework,841 and builds on entrustable professional activities, described in the ESC Core Curriculum.842
Clinical, laboratory, and imaging facilities include: a ward where health care providers have expertise in PH; a specialist outpatient service; an intermediate/ICU; 24/7 emergency care; an interventional radiology unit; diagnostic investigations, including echocardiography,
CT scanning, nuclear medicine, MRI, exercise tests, and PFTs; a cardiac catheterization laboratory; access to genetic counselling and testing; and fast and easy access to cardiothoracic and vascular surgery. Key diagnostic procedures are performed in sufﬁcient numbers to guarantee expertise (e.g. ERN-LUNG requirements).837 In analogy with the ‘advanced heart failure units’,843 PH centres offer the full range of PAH therapies available in their country (including i.v./
s.c. prostacyclin derivatives) and have early referral protocols to
CTEPH, LTx, and rehabilitation centres. Since evaluation and early availability of new drugs and techniques are critical, PH centres participate in collaborative clinical research.
Regular multidisciplinary team meetings, including core members and on-demand invited members (extended multidisciplinary team)
as needed (Figure 16), are required to establish and adapt individual patient care pathways. Case management (co-ordination of individual patient pathways) should include administrative, social, and care support. Remote accessibility of the PH centre by phone, mail, or other is a vital part of the care. Strategies have to be implemented in order to improve health literacy and shared decision-making,
with the support of dedicated patient decision tools. Transitioning from a paediatric PH centre to an adult PH centre requires adequate planning to prevent gaps in care. Involving national and/or international patient associations helps to design patient-centric care and to spread medical knowledge among patients and their carers.
Pulmonary hypertension centres should record patients’ data using local, national, or international patient registries, and be able to report process indicators (compliance with diagnostic and treatment guidelines, including LTx) and outcome indicators, such as
WHO-FC, exercise capacity, haemodynamics, quality of life, complications, and survival. They should undergo regular audits to assess the quality of delivered care.
12.2. European Reference Network
In 2017, the European Commission launched European Reference
Networks (ERNs) for rare diseases that included the ERN-LUNG
with a PH core network. European Reference Networks are patientcentred networks of commissioned centres offering guidance and cross-border best standard of care in the European Union. The
PH network includes over 20 full members, contributing each year
≏1500 new patients with PAH or CTEPH.844 It also includes UK
supporting centres, and afﬁliated partners (who do not necessarily have to fulﬁl the minimum competency criteria of the ERN-LUNG
PH network). The ERN-LUNG requires and monitors standards for these centres.
12.3. Patient associations and patient empowerment
Pulmonary hypertension centres should inform patients about patient associations and encourage them to join such groups. Patient associations are a valuable resource for managing patients, as they provide educational and emotional support, and can have positive effects on coping, conﬁdence, and outlook.845 It is recommended that
PH centres collaborate with patient associations on initiatives to
Recommendation Table 25 — Recommendations for pulmonary hypertension centres
Recommendations
Classa
Levelb
It is recommended that PH centres provide care by a multidisciplinary team (cardiologist,
pneumologist, rheumatologist, nurse specialist,
radiologist, psychological and social work support,
and appropriate on-call expertise)
I
C
It is recommended that PH centres have direct links and quick referral patterns to other services
(such as genetic counselling, PEA/BPA, LTx, and adult congenital heart disease service)
I
C
It is recommended that PH centres maintain a patient registry
I
C
It is recommended that PH centres collaborate with patient associations
I
C
Accreditation of the PH centres should be considered (e.g. https://ec.europa.eu/health/ern/
assessment_en)
IIa
C
PH centres’ participation in collaborative clinical research should be considered
IIa
C
PH centres should follow-up a sufﬁcient number of patients to maintain expertise (at least 50
patients with PAH or CTEPH and at least two new referrals per month with documented PAH
or CTEPH), and consider establishing collaborations with high-volume centres
IIa
C
© ESC/ERS 2022
BPA, balloon pulmonary angioplasty; CTEPH, chronic thrombo-embolic pulmonary hypertension; LTx, lung transplantation; PAH, pulmonary arterial hypertension; PEA,
pulmonary endarterectomy; PH, pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
3702
ESC/ERS Guidelines


<!-- PAGE 86 -->

### Page 86

empower patients and improve the patient experience, addressing issues such as health literacy, digital skills, healthy lifestyles, mental health, and self-management. Health care can be delivered more effectively and efﬁciently if patients are full partners in the process.
13. Key messages
(1) The haemodynamic deﬁnition of PH has been updated as mPAP .20 mmHg. The deﬁnition of PAH also implies a PVR
.2 WU and PAWP ≤15 mmHg. These cut-off values better reﬂect the limits of normal ranges, but do not yet translate into new therapeutic recommendations, since the efﬁcacy of
PAH therapy in patients with PVD and an mPAP 21–
24 mmHg and/or PVR 2–3 WU is still unknown.
(2) The main diagnostic algorithm for PH has been simpliﬁed following a three-step approach, from suspicion by ﬁrst-line physicians, detection by echocardiography, and conﬁrmation with
RHC in PH centres. Warning signs associated with worse outcomes have been identiﬁed, which justify immediate referral and management in PH centres.
(3) Screening strategies for PAH in patients with SSc and in those at risk of HPAH are proposed based on the results of published cohort studies. Their implementation may shorten the time from symptom onset to diagnosis of PAH.
(4) An improved recognition of CT and echocardiographic signs of
CTEPH at the time of an acute PE event, together with a systematic follow-up of patients with acute PE, as indicated in the 2019 ESC/ERS Guidelines for the diagnosis and management of acute pulmonary embolism, should help to remediate the underdiagnosis of CTEPH.
(5) The three-strata risk-stratiﬁcation assessment in PAH has been reﬁned after being validated in multiple registries. The MRI and echocardiographic criteria have been added to the ESC/ERS table, reﬁning non-invasive evaluation at diagnosis.
(6) A four-strata risk stratiﬁcation, dividing the large, intermediate-risk group into intermediate–low and intermediate–high risk, is proposed at follow-up.
(7) The treatment algorithm for PAH has been simpliﬁed, with a clear focus on risk assessment, cardiopulmonary comorbidities,
and treatment goals. Initial combination therapy and treatment escalation at follow-up when appropriate are current standards.
(8) The Task Force has attempted to close the gap between paediatric and adult PAH care, with therapeutic and follow-up strategies based on risk stratiﬁcation and treatment response,
extrapolated from that in adults but adapted for age.
(9) The recommendations on sex-related issues in patients with
PAH, including pregnancy, have been updated, with information and shared decision-making as key points.
(10) The recommendations for rehabilitation and exercise programmes in PH have been updated following the release of additional supportive evidence.
(11) For the ﬁrst time, there is a recommendation for PH medical therapy in group 3 PH, based on a single positive RCT in patients with ILD.
(12) The concept of CTEPD with or without PH has been introduced, enabling further research on the natural history and management in the absence of PH.
(13) The treatment algorithm for CTEPH has been modiﬁed, including multimodal therapy with surgery, PH drugs, and BPA.
14. Gaps in evidence
14.1. Pulmonary arterial hypertension
(group 1)
• The efﬁcacy and safety of PAH drugs in group 1 patients with an mPAP 21–24 mmHg, PVR 2–3 WU, and exercise PH has to be established.
• The role of PAH drugs in different PAH subgroups, including schistosomiasis-associated PAH, needs to be explored.
• Risk-stratiﬁcation assessment in PAH needs to be further prospectively validated through goal-orientated outcome studies,
and optimized for patients with PAH and comorbidities.
• New PAH phenotypes observed in patients with signiﬁcant cardiopulmonary comorbidities are common and should be the focus of more research.
• The importance of PAH patient phenotypes and the relevance of comorbidities on treatment goals and outcomes must be further evaluated.
• The impact of PAH therapies and treatment strategies on survival needs to be further assessed.
• Pulmonary arterial hypertension drugs targeting novel pathways are emerging and the impact of add-on use of this medication on outcomes has to be evaluated in RCTs.
• The role of RV imaging techniques (echocardiography, cMRI) in diagnosing and stratifying risk in PAH needs to be further studied.
The proposed cut-off values for risk stratiﬁcation need to be properly validated in multicentre studies.
• The role of CPET in the early diagnosis of PAH in populations at risk of developing PAH, and in assessing prognosis in PAH on top of clinical and haemodynamic data, needs further investigation.
• The role of exercise echocardiography and exercise RHC in patients at risk of developing PAH, with abnormal CPET but normal rest echocardiogram, also needs further evaluation.
• The use of mechanical circulatory support, particularly in reversible PH or in patients with advanced right HF with an exit strategy
(such as LTx), has to be further studied.
• Differences in natural history and treatment response between adults and children should be further investigated.
• Further studies are needed on the effects of PADN in PAH and in other PH groups.
• The impact of centre volume, organization, and expertise on treatment outcome needs further investigation.
14.2. Pulmonary hypertension associated with left heart disease (group 2)
• The management of patients with group 2 PH needs further study with RCTs.
• Additional research is needed to facilitate non-invasive diagnosis of
HFpEF-associated PH and distinguishing it from PAH.
• The role of ﬂuid challenge and exercise testing to reveal left HF
needs further validation.
ESC/ERS Guidelines
3703


<!-- PAGE 87 -->

### Page 87

• Further studies focusing on PDE5is in patients with HFpEF and a
CpcPH phenotype are needed and currently underway.
• The effects that new HF medication (ARNIs, SGLT-2is) has on PH,
through reverse remodelling of the LV, need further investigation.
14.3. Pulmonary hypertension associated with lung diseases and/or hypoxia
(group 3)
• The management of patients with group 3 PH has to be further studied in RCTs.
• Reﬁning phenotypes will be crucial, as this will inform development of trials.
• Clinical relevance and therapeutic implications of severe PH in lung disease need to be investigated.
• Long-term data on the effects of inhaled treprostinil (and other
PAH drugs) in patients with PH associated with lung disease are needed.
• The impact of the hypobaric and hypoxic environment of the .150
million people living at .2500 m altitude has tobe clariﬁed, and studies need to be performed to assess potential treatment strategies for PH.
14.4. Chronic thrombo-embolic pulmonary hypertension (group 4)
• The differentiation between acute and chronic PE in imaging
(CTPA) has to be improved.
• In patients with suspected CTEPH, the diagnostic role of DECT or iodine subtraction mapping vs. V/Q lung scintigraphy has to be validated.
• The effect of drug therapy on the outcome of patients with
CTEPH needs to be established.
• The treatment goals in patients with CTEPH have to be clariﬁed, as it is still unclear if normalizing mPAP and PVR translates into improved outcomes.
• The role of BPA vs. PEA should be further clariﬁed: which treatment in which patient? Are they equivalent for the treatment of segmental/subsegmental disease?
• In inoperable CTEPH or persistent/recurrent PH after PEA, the potential role of combination therapy of PH drugs must be assessed.
• The role of medical treatments as bridges to interventional and operative treatments needs to be formally tested.
• Randomized controlled trials are needed to discriminate the effects of PEA and early follow-up rehabilitation.
• The effect of PEA, BPA, and medical therapy on patients with
CTEPD without PH is not established.
14.5. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5)
• Further research needs to inform management of group 5 PH,
such as SCD-associated PH and sarcoidosis-associated PH.
15. ‘What to do’ and ‘What not to do’ messages from the Guidelines
Recommendations
Classa
Levelb
Recommendations for right heart catheterization and vasoreactivity testing
Right heart catheterization
It is recommended that RHC is performed to conﬁrm the diagnosis of PH (especially PAH or CTEPH) and to support treatment decisions
I
B
In patients with suspected or known PH, it is recommended that RHC is performed in experienced centres
I
C
It is recommended that RHC comprises a complete set of haemodynamics and is performed following standardized protocols
I
C
Vasoreactivity testing
Vasoreactivity testing is recommended in patients with I/H/DPAH to detect those who can be treated with high doses of a CCB
I
B
It is recommended that vasoreactivity testing is performed at PH centres
I
C
It is recommended to consider a positive response to vasoreactivity testing by a reduction in mPAP ≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg with an increased or unchanged COc
I
C
Inhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol are recommended for performing vasoreactivity testing
I
C
Vasoreactivity testing, for identifying candidates for CCB therapy, is not recommended in patients with PAH other than I/H/DPAH and in PH groups 2, 3, 4, and 5
III
C
Continued
3704
ESC/ERS Guidelines


<!-- PAGE 88 -->

### Page 88

Recommendations for diagnostic strategy
Echocardiography
Echocardiography is recommended as the ﬁrst-line, non-invasive, diagnostic investigation in suspected PH
I
B
It is recommended to assign an echocardiographic probability of PH, based on an abnormal TRV and the presence of other echocardiographic signs suggestive of PH (see Table 10)
I
B
It is recommended to maintain the current threshold for TRV (.2.8 m/s) for echocardiographic probability of PH according to the updated haemodynamic deﬁnition
I
C
Imaging
Ventilation/perfusion or perfusion lung scan is recommended in patients with unexplained PH to assess for CTEPH
I
C
CT pulmonary angiography is recommended in the work-up of patients with suspected CTEPH
I
C
Routine biochemistry, haematology, immunology, HIV testing, and thyroid function tests are recommended in all patients with PAH, to identify associated conditions
I
C
Abdominal ultrasound is recommended for the screening of portal hypertension
I
C
Other diagnostic tests
Pulmonary function tests with DLCO are recommended in the initial evaluation of patients with PH
I
C
Open or thoracoscopic lung biopsy is not recommended in patients with PAH
III
C
Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension
Systemic sclerosis
In patients with SSc, an annual evaluation of the risk of having PAH is recommended
I
B
In adult patients with SSc with .3 years’ disease duration, an FVC ≥40%, and a DLCO ,60%, the DETECT algorithm is recommended to identify asymptomatic patients with PAH
I
B
In patients with SSc, where breathlessness remains unexplained following non-invasive assessment, RHC is recommended to exclude
PAH
I
C
CTEPH/CTEPD
In patients with persistent or new-onset dyspnoea or exercise limitation following PE, further diagnostic evaluation to assess for
CTEPH/CTEPD is recommended
I
C
For symptomatic patients with mismatched perfusion lung defects beyond 3 months of anticoagulation for acute PE, referral to a PH/
CTEPH centre is recommended after considering the results of echocardiography, BNP/NT-proBNP, and/or CPET
I
C
Other
Counselling regarding the risk of PAH and annual screening are recommended in individuals who test positive for PAH-causing mutations and in ﬁrst-degree relatives of patients with HPAH
I
B
In patients referred for liver transplantation, echocardiography is recommended as a screening test for PH
I
C
Recommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension
It is recommended to evaluate disease severity in patients with PAH with a panel of data derived from clinical assessment, exercise tests,
biochemical markers, echocardiography, and haemodynamic evaluations
I
B
Achieving and maintaining a low-risk proﬁle on optimized medical therapy is recommended as a treatment goal in patients with PAH
I
B
For risk stratiﬁcation at the time of diagnosis, the use of a three-strata model (low, intermediate, and high risk) is recommended, taking into account all available data including haemodynamics
I
B
For risk stratiﬁcation during follow-up, the use of a four-strata model (low, intermediate–low, intermediate–high, and high risk) based on
WHO-FC, 6MWD, and BNP/NT-proBNP is recommended, with additional variables taken into account as necessary
I
B
Continued
ESC/ERS Guidelines
3705


<!-- PAGE 89 -->

### Page 89

Recommendations for general measures and special circumstances
General measures
Supervised exercise training is recommended in patients with PAH under medical therapy
I
A
Psychosocial support is recommended in patients with PAH
I
C
Immunization of patients with PAH against SARS-CoV-2, inﬂuenza, and Streptococcus pneumoniae is recommended
I
C
Diuretic treatment is recommended in patients with PAH with signs of RV failure and ﬂuid retention
I
C
Long-term oxygen therapy is recommended in patients with PAH whose arterial blood oxygen pressure is ,8 kPa (60 mmHg)d
I
C
In the presence of iron-deﬁciency anaemia, correction of iron status is recommended in patients with PAH
I
C
The use of ACEis, ARBs, ARNIs, SGLT-2is, beta-blockers, or ivabradine is not recommended in patients with PAH unless required by comorbidities (i.e. high blood pressure, coronary artery disease, left HF, or arrhythmias)
III
C
Special circumstances
In-ﬂight oxygen administration is recommended for patients using oxygen or whose arterial blood oxygen pressure is ,8 kPa
(60 mmHg) at sea level
I
C
Recommendations for women of childbearing potential
It is recommended that women of childbearing potential with PAH are counselled at the time of diagnosis about the risks and uncertainties associated with becoming pregnant; this should include advice against becoming pregnant, and referral for psychological support where needed
I
C
It is recommended to provide women of childbearing potential with PAH with clear contraceptive advice, considering the individual needs of the woman but recognizing that the implications of contraceptive failure are signiﬁcant in PAH
I
C
It is recommended that women with PAH who consider pregnancy or who become pregnant receive prompt counselling in an experienced PH centre, to facilitate genetic counselling and shared decision-making, and to provide psychological support to the patients and their families where needed
I
C
For women with PAH having termination of pregnancy, it is recommended that this be performed in PH centres, with psychological support provided to the patients and their families
I
C
As teratogenic potential has been reported in pre-clinical models for endothelin receptor antagonists and riociguat, these drugs are not recommended during pregnancy
III
B
Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension
High doses of CCBs are recommended in patients with IPAH, HPAH, or DPAH who are responders to acute vasoreactivity testing
I
C
Close follow-up with complete reassessment after 3–4 months of therapy (including RHC) is recommended in patients with IPAH,
HPAH, or DPAH treated with high doses of CCBs
I
C
Continuing high doses of CCBs is recommended in patients with IPAH, HPAH, or DPAH in WHO-FC I or II with marked haemodynamic improvement (mPAP ,30 mmHg and PVR ,4 WU)
I
C
Initiating PAH therapy is recommended in patients who remain in WHO-FC III or IV or those without marked haemodynamic improvement after high doses of CCBs
I
C
CCBs are not recommended in patients without a vasoreactivity study or non-responders, unless prescribed for other indications (e.g.
Raynaud’s phenomenon)
III
C
Recommendations for initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension without cardiopulmonary comorbiditiese
Initial combination therapy with ambrisentan and tadalaﬁl is recommended
I
B
Initial combination therapy with macitentan and tadalaﬁl is recommended
I
B
Initial combination therapy with macitentan, tadalaﬁl, and selexipag is not recommended
III
B
Continued
3706
ESC/ERS Guidelines


<!-- PAGE 90 -->

### Page 90

Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension
General recommendation for sequential combination therapy
It is recommended to base treatment escalations on risk assessment and general treatment strategies (see treatment algorithm)
I
C
Evidence from studies with a composite morbidity/mortality endpoint as the primary outcome measure
The addition of macitentan to PDE5is or oral/inhaled prostacyclin analogues is recommended to reduce the risk of morbidity/mortality events
I
B
The addition of selexipag to ERAsf and/or PDE5is is recommended to reduce the risk of morbidity/mortality events
I
B
The addition of oral treprostinil to ERA or PDE5i/riociguat monotherapy is recommended to reduce the risk of morbidity/mortality events
I
B
The addition of bosentan to sildenaﬁl is not recommended to reduce the risk of morbidity/mortality events
III
B
Evidence from studies with change in 6MWD as the primary outcome measure
The addition of sildenaﬁl to epoprostenol is recommended to improve exercise capacity
I
B
Evidence from studies with safety of combination therapy as primary outcome measure
Combining riociguat and PDE5is is not recommendedg
III
B
Recommendations for intensive care management for pulmonary arterial hypertension
When managing patients with right HF in the ICU, it is recommended to involve physicians with expertise, treat causative factors, and use supportive measures, including inotropes and vasopressors, ﬂuid management, and PAH drugs, as appropriate
I
C
Recommendations for lung transplantation
It is recommended that potentially eligible candidates are referred for LTx evaluation when they have an inadequate response to oral combination therapy, indicated by an intermediate–high or high risk or by a REVEAL risk score .7
I
C
It is recommended to list patients for LTx who present with a high risk of death or with a REVEAL risk score ≥10 despite receiving optimized medical therapy including s.c. or i.v. prostacyclin analogues
I
C
Recommendations for pulmonary arterial hypertension associated with drugs or toxins
It is recommended to make a diagnosis of drug- or toxin-associated PAH in patients who had relevant exposure and in whom other causes of PH have been excluded
I
C
In patients with suspected drug- or toxin-associated PAH, it is recommended to immediately discontinue the causative agent whenever possible
I
C
Recommendations for pulmonary arterial hypertension associated with connective tissue disease
In patients with PAH associated with CTD, treatment of the underlying condition according to current guidelines is recommended
I
A
In patients with PAH associated with CTD, the same treatment algorithm as for patients with IPAH is recommended
I
C
Recommendations for pulmonary arterial hypertension associated with human immunodeﬁciency virus infection
In patients with PAH associated with HIV infection, antiretroviral treatment according to current guidelines is recommended
I
A
Recommendations for pulmonary arterial hypertension associated with portal hypertension
Echocardiography is recommended in patients with liver disease or portal hypertension with signs or symptoms suggestive of PH, and as a screening tool in patients evaluated for liver transplantation or transjugular portosystemic shunt
I
C
It is recommended that patients with PAH associated with portal hypertension are referred to centres with expertise in managing both conditions
I
C
Drugs approved for PAH are not recommended for patients with portal hypertension and unclassiﬁed PH (i.e. elevated mPAP, high CO,
and a normal PVR)
III
C
Continued
ESC/ERS Guidelines
3707


<!-- PAGE 91 -->

### Page 91

Recommendations for shunt closure in patients with pulmonary-systemic ﬂow ratio .1.5:1 based on calculated pulmonary vascular resistance
In patients with an ASD, VSD, or PDA and a PVR ,3 WU, shunt closure is recommended
I
C
In patients with an ASD and a PVR .5 WU despite PAH treatment, shunt closure is not recommended
III
C
Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease
Risk assessment
Risk assessment is recommended for patients with persistent PAH after defect closure
I
C
Treatment
Bosentan is recommended in symptomatic patients with Eisenmenger syndrome to improve exercise capacity
I
B
In women with Eisenmenger syndrome, pregnancy is not recommended
III
C
In patients with Eisenmenger syndrome, routine phlebotomy to lower elevated haematocrit is not recommended
III
C
Recommendations for pulmonary arterial hypertension with signs of venous/capillary involvement
A combination of clinical and radiological ﬁndings, ABG, PFTs, and genetic testing is recommended to diagnose PAH with signs of venous and/or capillary involvement (PVOD/PCH)
I
A
Identiﬁcation of biallelic EIF2AK4 mutations is recommended to conﬁrm a diagnosis of heritable PVOD/PCH
I
A
Referral of eligible patients with PVOD/PCH to a transplant centre for evaluation is recommended as soon as the diagnosis is established
I
C
Lung biopsy is not recommended to conﬁrm a diagnosis of PVOD/PCH
III
C
Recommendations for paediatric pulmonary hypertension
Children
It is recommended to perform the diagnostic work-up, including RHC and acute vasoreactivity testing, and treat children with PH at centres with speciﬁc expertise in paediatric PH
I
C
In children with PH, a comprehensive work-up for conﬁrming diagnosis and speciﬁc aetiology is recommended (similar to that in adults,
but adapted for age)
I
C
For conﬁrming PH diagnosis, RHC is recommended, preferably before initiating any PAH therapy
I
C
In children with IPAH/HPAH, acute vasoreactivity testing is recommended to detect those who may beneﬁt from CCB therapy
I
C
It is recommended to similarly deﬁne a positive response to acute vasoreactivity testing in children and adults by a reduction in mPAP
≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg, with an increased or unchanged CO
I
C
In children with PAH, a therapeutic strategy based on risk stratiﬁcation and treatment response is recommended, extrapolated from that in adults, but adapted for age
I
C
It is recommended to monitor the treatment response in children with PAH by serially assessing a panel of data derived from clinical assessment, echocardiographic evaluation, biochemical markers, and exercise tolerance tests
I
C
Infants
It is recommended to screen infants with bronchopulmonary dysplasia for PH
I
B
In infants with (or at risk of) bronchopulmonary dysplasia and PH, treating lung disease—including hypoxia, aspiration, and structural airway disease—and optimizing respiratory support is recommended before initiating PAH therapy
I
B
Recommendations for pulmonary hypertension associated with left heart disease
In patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of suspected PH
I
A
RHC is recommended for suspected PH in patients with LHD, if it aids management decisions
I
C
Continued
3708
ESC/ERS Guidelines


<!-- PAGE 92 -->

### Page 92

RHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair
I
C
For patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral to a PH centre for a complete diagnostic work-up is recommended
I
C
In patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is recommended
I
C
When patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or
ﬂuid challenge, are treated with PAH drugs, close monitoring is recommended
I
C
Drugs approved for PAH are not recommended in PH-LHDh
III
A
Recommendations for pulmonary hypertension associated with lung disease and/or hypoxia
If PH is suspected in patients with lung disease, it is recommended that echocardiographyi be performed and results interpreted in conjunction with ABG, PFTs including DLCO, and CT imaging
I
C
In patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where indicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation
I
C
In patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH
centre is recommendedj
I
C
In patients with lung disease and severe PH, an individualized approach to treatment is recommended
I
C
It is recommended to refer eligible patients with lung disease and PH for LTx evaluation
I
C
In patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions
I
C
The use of ambrisentan is not recommended in patients with PH associated with IPF
III
B
The use of riociguat is not recommended in patients with PH associated with IIP
III
B
The use of PAH medication is not recommended in patients with lung disease and non-severe PHk
III
C
Recommendations for chronic thrombo-embolic pulmonary hypertension and chronic thrombo-embolic pulmonary disease without pulmonary hypertension
CTEPH
Lifelong, therapeutic doses of anticoagulation are recommended in all patients with CTEPH
I
C
Antiphospholipid syndrome testing is recommended in patients with CTEPH
I
C
In patients with CTEPH and antiphospholipid syndrome, anticoagulation with VKAs is recommended
I
C
It is recommended that all patients with CTEPH are reviewed by a CTEPH team for the assessment of multimodality management
I
C
PEA is recommended as the treatment of choice for patients with CTEPH and ﬁbrotic obstructions within pulmonary arteries accessible by surgery
I
B
BPA is recommended in patients who are technically inoperable or have residual PH after PEA and distal obstructions amenable to BPA
I
B
Riociguat is recommended for symptomatic patients with inoperable CTEPH or persistent/recurrent PH after PEA
I
B
Long-term follow-up is recommended after PEA and BPA, as well as for patients with CTEPH established on medical therapy
I
C
Recommendations for pulmonary hypertension centres
It is recommended that PH centres provide care by a multidisciplinary team (cardiologist, pneumologist, rheumatologist, nurse specialist,
radiologist, psychological and social work support, appropriate on-call expertise)
I
C
It is recommended that PH centres have direct links and quick referral patterns to other services (such as genetic counselling, PEA/BPA,
LTx, adult congenital heart disease service)
I
C
Continued
ESC/ERS Guidelines
3709


<!-- PAGE 93 -->

### Page 93

### 16 Quality indicators

Quality indicators (QIs) are tools that may be used to evaluate care quality, including structural, process, and outcomes of care.847 They may also serve as a mechanism for enhancing adherence to guideline recommendations through associated quality-improvement initiatives and benchmarking of care providers.848,849 As such, the role of QIs in improving care and outcomes for cardiovascular disease is increasingly being recognized by health care authorities, professional organizations, payers, and the public.847
The ESC understands the need for measuring and reporting quality and outcomes of cardiovascular care, and has established methods for developing the ESC QIs for the quantiﬁcation of care and outcomes for cardiovascular diseases.847 To date, the ESC has developed QI suites for a number of cardiovascular diseases850–852
and embedded these in respective ESC Clinical Practice guidelines.27,477,853,854 Furthermore, the ESC aims to integrate its QIs with clinical registries such as the EurObservational Research
Programme and the European Uniﬁed Registries On Heart Care
Evaluation and Randomized Trials (EuroHeart) project855 to provide real-world data about the patterns and outcomes of care for cardiovascular disease across Europe.
In parallel with the writing of this Clinical Practice Guideline, a process has been initiated to develop QIs for patients with PH using the
It is recommended that PH centres maintain a patient registry
I
C
It is recommended that PH centres collaborate with patient associations
I
C
© ESC/ERS 2022
6MWD, 6-minute walking distance; ABG, arterial blood gas analysis; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–
neprilysin inhibitor; ASD, atrial septal defect; BNP/NT-proBNP, brain natriuretic peptide/N-terminal pro-brain natriuretic peptide; BPA, balloon pulmonary angioplasty; CCB,
calcium channel blocker; CpcPH, combined post- and pre-capillary pulmonary hypertension; CPET, cardiopulmonary exercise testing; CT, computed tomography; CTD, connective tissue disease; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon monoxide; DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; FVC, forced vital capacity; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HIV, human immunodeﬁciency virus; HPAH, heritable pulmonary arterial hypertension; ICU, intensive care unit; I/H/DPAH, idiopathic, heritable,
drug-associated pulmonary arterial hypertension; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; IPF, idiopathic pulmonary ﬁbrosis; i.v., intravenous; LHD, left heart disease; LTx, lung transplantation; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PAWP,
pulmonary arterial wedge pressure; PCH, pulmonary capillary haemangiomatosis; PDA, patent ductus arteriosus; PDE5i, phosphodiesterase 5 inhibitor; PE, pulmonary embolism;
PEA, pulmonary endarterectomy; PFTs, pulmonary function tests; PH, pulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVOD,
pulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right ventricular; s.c., subcutaneous; SGLT-2i, sodium–glucose cotransporter-2 inhibitor; SSc, systemic sclerosis; TRV, tricuspid regurgitation velocity; VKA, vitamin K antagonist; VSD, ventricular septal defect; WHO-FC, World Health
Organization functional class; WU, Wood units.
aClass of recommendation.
bLevel of evidence.
cTesting should also be performed in patients with a baseline mPAP ≤40 mmHg, in whom the same responder criteria apply.
dMeasured on at least two occasions.
eCardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF such as obesity, diabetes, coronary heart disease, a history of hypertension, and/or a low DLCO.
fERA used in the GRIPHON study were bosentan and ambrisentan.
gThe PATENT plus study investigated the combination of sildenaﬁl and riociguat; however, combining riociguat with any PDE5i is contraindicated.
hSafety concerns have been identiﬁed when ERAs are used in patients with HF (HFpEF and HFrEF, with or without PH) and when sildenaﬁl is used in patients with persistent PH after correction of valvular heart disease.
iAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise pulmonary artery pressure.
jThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.
kThis does not include inhaled treprostinil, which may be considered in patients with PH associated with ILD irrespective of PH severity.
‘What to do’ and ‘What not to do’ messages developed with GRADE Evidence to Decision framework
GRADE
Recommendations
Quality of evidence
Strength of recommendation
Classa
Levelb
In patients with IPAH/HPAH/DPAH who present at low or intermediate risk of death, initial combination therapy with a PDE5i and an ERA is recommended
Low
Conditional
I
B
The use of PDE5i in patients with HFpEF and isolated post-capillary PH is not recommended
Low
Conditional
III
C
The use of PDE5i in patients with ILD and non-severe PH is not recommended
Very low
Conditional
III
C
© ESC/ERS 2022
DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; HPAH, heritable pulmonary arterial hypertension; HFpEF, heart failure with preserved ejection fraction; ILD, interstitial lung disease; PDE5i, phosphodiesterase 5 inhibitor; PH, pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
3710
ESC/ERS Guidelines


<!-- PAGE 94 -->

### Page 94

ESC methodology and through collaboration with domain experts and the Heart Failure Association of the ESC. Such QIs may be used for evaluating the quality of care for patients with PH, and enable important aspects of care delivery to be captured. These QIs,
alongside their speciﬁcations and development process, will be published separately.
17. Supplementary data
Supplementary data is available at European Heart Journal online including key narrative question (1-8) and PICO questions (I-IV).
18. Data availability statement
No new data were generated or analysed in support of this research.
19. Author information
Author/Task Force Member Afﬁliations: Marc Humbert*,
Faculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre,
France, Service de Pneumologie et Soins Intensifs Respiratoires,
Centre de Référence de l’Hypertension Pulmonaire, Hôpital
Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre,
France, INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le
Plessis-Robinson, France; Gabor Kovacs, University Clinic of
Internal Medicine, Division of Pulmonology, Medical University of
Graz, Graz, Austria, Ludwig Boltzmann Institute for Lung Vascular
Research,
Graz,
Austria;
Marius
M.
Hoeper,
Respiratory
Medicine,
Hannover
Medical
School,
Hanover,
Germany,
Biomedical Research in End-stage and Obstructive Lung Disease
(BREATH), member of the German Centre of Lung Research
(DZL), Hanover, Germany; Roberto Badagliacca, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari,
Sapienza
Università
di
Roma,
Roma,
Italy,
Dipartimento
Cardio-Toraco-Vascolare e
Chirurgia dei
Trapianti d’Organo,
Policlinico Umberto I, Roma, Italy; Rolf M.F. Berger, Center for
Congenital Heart Diseases, Beatrix Children’s Hospital, Dept of
Paediatric
Cardiology,
University
Medical
Center
Groningen,
University of Groningen, Groningen, Netherlands; Margarita
Brida, Department of Sports and Rehabilitation Medicine, Medical
Faculty University of Rijeka, Rijeka, Croatia, Adult Congenital Heart
Centre and National Centre for Pulmonary Hypertension, Royal
Brompton & Hareﬁeld Hospitals, Guys & St Thomas’s NHS Trust,
London,
United
Kingdom;
Jørn
Carlsen,
Department of
Cardiology,
Copenhagen
University
Hospital,
Rigshospitalet,
Copenhagen, Denmark, Department of Clinical Medicine; Faculty of
Health and
Medical
Sciences,
University of
Copenhagen,
Copenhagen, Denmark; Andrew J.S. Coats, Faculty of Medicine,
University of Warwick, Coventry, United Kingdom, Faculty of
Medicine,
Monash
University
Melbourne,
Australia;
Pilar
Escribano-Subias, Pulmonary Hypertension Unit, Cardiology
Department, Hospital Universitario 12 de Octubre, Madrid, Spain,
CIBER-CV (Centro de Investigaciones Biomédicas En Red de enfermedades CardioVasculares), Instituto de Salud Carlos III, Madrid,
Spain, Facultad de Medicina, Universidad Complutense, Madrid,
Spain; Pisana Ferrari (Italy), ESC Patient Forum, Sophia Antipolis,
France, AIPI, Associazione Italiana Ipertensione Polmonare, Bologna,
Italy; Diogenes S. Ferreira, Alergia e Imunologia, Hospital de
Clinicas, Universidade Federal do Parana, Curitiba, Brazil; Hossein
Ardeschir
Ghofrani,
Department of
Internal
Medicine,
University
Hospital
Giessen,
Justus-Liebig
University,
Giessen,
Germany, Department of Pneumology, Kerckhoff Klinik, Bad
Nauheim, Germany, Department of Medicine, Imperial College
London, London, United Kingdom; George Giannakoulas,
Cardiology
Department,
Aristotle
University of
Thessaloniki,
AHEPA University Hospital, Thessaloniki, Greece; David G. Kiely,
Department of Infection, Immunity and Cardiovascular Disease,
University of
Shefﬁeld,
Shefﬁeld,
United
Kingdom,
Shefﬁeld
Pulmonary Vascular Disease Unit, Shefﬁeld Teaching Hospitals NHS
Foundation Trust, Shefﬁeld, United Kingdom, Insigneo Institute,
University of Shefﬁeld, Shefﬁeld, United Kingdom; Eckhard
Mayer,
Thoracic
Surgery,
Kerckhoff
Clinic,
Bad
Nauheim,
Germany; Gergely Meszaros (Hungary), ESC Patient Forum,
Sophia
Antipolis,
France,
European
Lung
Foundation
(ELF),
Shefﬁeld, United Kingdom; Blin Nagavci, Institute for Evidence in
Medicine, Faculty of Medicine and Medical Center, University of
Freiburg, Freiburg, Germany; Karen M. Olsson, Clinic of
Respiratory Medicine, Hannover Medical School, member of the
German Center of Lung Research (DZL), Hannover, Germany;
Joanna Pepke-Zaba, Pulmonary Vascular Diseases Unit, Royal
Papworth
Hospital,
Cambridge,
United
Kingdom;
Jennifer
K. Quint, NHLI, Imperial College London, London, United
Kingdom; Göran Rådegran, Department of Cardiology, Clinical
Sciences
Lund,
Faculty of
Medicine,
Lund,
Sweden,
The
Haemodynamic Lab, The Section for Heart Failure and Valvular
Disease, VO. Heart and Lung Medicine, Skåne University Hospital,
Lund, Sweden; Gerald Simonneau, Faculté Médecine, Université
Paris Saclay, Le Kremlin-Bicêtre, France, Centre de Référence de l’Hypertension
Pulmonaire,
Hopital
Marie-Lannelongue,
Le
Plessis-Robinson, France; Olivier Sitbon, Faculty of Medicine,
Université Paris-Saclay, Le Kremlin-Bicêtre, France, Service de
Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l’Hypertension Pulmonaire, Hôpital Bicêtre, Assistance Publique
Hôpitaux de Paris, Le Kremlin-Bicêtre, France, INSERM UMR_S
999,
Hôpital Marie-Lannelongue,
Le
Plessis-Robinson,
France;
Thomy Tonia, Institute of Social and Preventive Medicine,
University of Bern, Bern, Switzerland; Mark Toshner, Heart Lung
Research Institute, Dept of Medicine, University of Cambridge,
Cambridge,
United
Kingdom,
Royal
Papworth
NHS
Trust;
Jean-Luc Vachiery, Department of Cardiology, Pulmonary
Vascular Diseases and Heart Failure Clinic, HUB Hôpital Erasme,
Brussels, Belgium; and Anton Vonk Noordegraaf, Pulmonology,
Amsterdam UMC, Amsterdam, Netherlands.
* Marc Humbert is supported by the Investissement d’Avenir programme managed by the French National Research Agency under the grant contract ANR-18-RHUS-0006 (DESTINATION 2024).
20. Appendix
ESC/ERS Scientiﬁc Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
ESC/ERS Guidelines
3711


<!-- PAGE 95 -->

### Page 95

Document Reviewers: Markus Schwerzmann (ESC Review
Coordinator) (Switzerland), Anh-Tuan Dinh-Xuan (ERS Review
Coordinator)
(France),
Andy
Bush
(United
Kingdom),
Magdy
Abdelhamid (Egypt), Victor Aboyans (France), Eloisa Arbustini (Italy),
Riccardo Asteggiano (Italy), Joan-Albert Barberà (Spain), Maurice
Beghetti (Switzerland), Jelena Čelutkienė (Lithuania), Maja Cikes
(Croatia), Robin Condliffe (United Kingdom), Frances de Man
(Netherlands), Volkmar Falk (Germany), Laurent Fauchier (France),
Sean Gaine (Ireland), Nazzareno Galié (Italy), Wendy Gin-Sing
(United
Kingdom),
John
Granton
(Canada),
Ekkehard
Grünig
(Germany), Paul M. Hassoun (United States of America), Merel
Hellemons (Netherlands), Tiny Jaarsma (Sweden), Barbro Kjellström
(Sweden), Frederikus A. Klok (Netherlands), Aleksandra Konradi
(Russian Federation), Konstantinos C. Koskinas (Switzerland), Dipak
Kotecha (United Kingdom), Irene Lang (Austria), Basil S. Lewis
(Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip (United
Kingdom), Maja-Lisa Løchen (Norway), Alexander G. Mathioudakis
(United Kingdom), Richard Mindham (United Kingdom), Shahin
Moledina (United Kingdom), Robert Naeije (Belgium), Jens Cosedis
Nielsen (Denmark), Horst Olschewski (Austria), Isabelle Opitz
(Switzerland), Steffen E. Petersen (United Kingdom), Eva Prescott
(Denmark), Amina Rakisheva (Kazakhstan), Abilio Reis (Portugal),
Arsen D. Ristić (Serbia), Nicolas Roche (France), Rita Rodrigues
(Portugal), Christine Selton-Suty (France), Rogerio Souza (Brazil),
Andrew J. Swift (United Kingdom), Rhian M. Touyz (Canada/United
Kingdom), Silvia Ulrich (Switzerland), Martin R. Wilkins (United
Kingdom), and Stephen John Wort (United Kingdom).
ESC National Cardiac Societies actively involved in the review process of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Algeria: Algerian Society of
Cardiology,
Messaad
Krim;
Armenia:
Armenian Cardiologists
Association, Hamlet Hayrapetyan; Austria: Austrian Society of
Cardiology,
Irene
Lang;
Azerbaijan:
Azerbaijan
Society of
Cardiology, Oktay Musayev; Belarus: Belorussian Scientiﬁc Society of
Cardiologists,
Irina
Lazareva;
Bosnia and Herzegovina:
Association of Cardiologists of Bosnia and Herzegovina, Šekib
Sokolović; Bulgaria: Bulgarian Society of Cardiology, Vasil Velchev;
Croatia: Croatian Cardiac Society, Maja Cikes; Cyprus: Cyprus
Society of Cardiology, Ioannis Michaloliakos; Czechia: Czech Society of Cardiology, Pavel Jansa; Denmark: Danish Society of Cardiology,
Søren Mellemkjær; Egypt: Egyptian Society of Cardiology, Ahmed
Hassan; Estonia: Estonian Society of Cardiology, Ly Anton;
Finland: Finnish Cardiac Society, Markku Pentikäinen; France:
French Society of Cardiology, Nicolas Meneveau; Georgia: Georgian
Society of Cardiology, Mikheil Tsverava; Germany: German Cardiac
Society, Mareike Lankeit; Greece: Hellenic Society of Cardiology,
Athanasios Manginas; Hungary: Hungarian Society of Cardiology,
Istvan Hizoh; Ireland: Irish Cardiac Society, Vincent Maher; Israel:
Israel Heart Society, Rafael Hirsch; Italy: Italian Federation of
Cardiology,
Nazzareno
Galié;
Kazakhstan:
Association of
Cardiologists of Kazakhstan, Murat A. Mukarov; Kosovo (Republic of): Kosovo Society of Cardiology, Pranvera Ibrahimi; Kyrgyzstan:
Kyrgyz Society of Cardiology, Sooronbaev Talant, Latvia: Latvian
Society of Cardiology, Ainars Rudzitis; Lebanon: Lebanese Society of Cardiology, Ghassan Kiwan; Lithuania: Lithuanian Society of
Cardiology, Lina Gumbienė; Luxembourg: Luxembourg Society of
Cardiology, Andrei Codreanu; Malta: Maltese Cardiac Society, Josef
Micallef; Moldova (Republic of): Moldavian Society of Cardiology,
Eleonora
Vataman;
Montenegro:
Montenegro
Society of
Cardiology, Nebojsa Bulatovic; Morocco: Moroccan Society of
Cardiology, Said Chraibi; Netherlands: Netherlands Society of
Cardiology, Marco C. Post; North Macedonia: North Macedonian
Society of Cardiology, Elizabeta Srbinovska Kostovska; Norway:
Norwegian
Society of
Cardiology,
Arne
Kristian
Andreassen;
Poland:
Polish
Cardiac
Society,
Marcin
Kurzyna;
Portugal:
Portuguese Society of Cardiology, Rui Plácido; Romania: Romanian
Society of Cardiology, Ioan Mircea Coman; Russian Federation:
Russian Society of Cardiology, Oksana Vasiltseva; San Marino: San
Marino Society of Cardiology, Marco Zavatta; Serbia: Cardiology
Society of Serbia, Arsen D. Ristić; Slovakia: Slovak Society of
Cardiology,
Iveta
Šimkova;
Slovenia:
Slovenian
Society of
Cardiology, Gregor Poglajen; Spain: Spanish Society of Cardiology,
María Lázaro Salvador; Sweden: Swedish Society of Cardiology,
Stefan Söderberg; Switzerland: Swiss Society of Cardiology, Silvia
Ulrich; Syrian Arab Republic: Syrian Cardiovascular Association,
Mhd Yassin Bani Marjeh; Tunisia: Tunisian Society of Cardiology and Cardio-Vascular Surgery, Fatma Ouarda; Turkey: Turkish
Society of Cardiology, Bulent Mutlu; Ukraine: Ukrainian Association of Cardiology, Yuriy Sirenko; United Kingdom of Great Britain and Northern Ireland: British Cardiovascular Society, J. Gerry
Coghlan;
and
Uzbekistan:
Association of
Cardiologists of
Uzbekistan, Timur Abdullaev.
ESC Clinical Practice Guidelines (CPG) Committee: Colin
Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid (Egypt),
Victor Aboyans (France), Sotiris Antoniou (United Kingdom), Elena
Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas Baumbach
(United Kingdom), Michael A. Borger (Germany), Jelena Čelutkienė
(Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France),
Volkmar Falk (Germany), Laurent Fauchier (France), Chris P. Gale
(United
Kingdom),
Sigrun
Halvorsen
(Norway),
Bernard
Iung
(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian
Federation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha
(United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel),
Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Richard
Mindham (United Kingdom), Jens Cosedis Nielsen (Denmark),
Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark),
Amina Rakisheva (Kazakhstan), Marta Sitges (Spain), and Rhian
M. Touyz (Canada/ United Kingdom).
Independent Research Methodologists: Rebecca L. Morgan
(United States of America) and Kapeena Sivakumaran (Canada).
21. References
1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M,
et al. Haemodynamic deﬁnitions and updated clinical classiﬁcation of pulmonary hypertension. Eur Respir J 2019;53:1801913.
2. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines:
1. Introduction-GRADE evidence proﬁles and summary of ﬁndings tables. J Clin
Epidemiol 2011;64:383–394.
3. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M,
et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ 2016;353:i2089.
3712
ESC/ERS Guidelines


<!-- PAGE 96 -->

### Page 96

4. Nagavci B, Tonia T, Roche N, Genton C, Vaccaro V, Humbert M, et al. European
Respiratory Society clinical practice guidelines: methodological guidance. ERJ Open
Res 2022;8:0655–2021.
5. Schünemann HB, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group; 2013.
6. Miravitlles M, Tonia T, Rigau D, Roche N, Genton C, Vaccaro V, et al. New era for
European Respiratory Society clinical practice guidelines: joining efﬁciency and high methodological standards. Eur Respir J 2018;51:1800221.
7. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009;34:
888–894.
8. Kovacs G, Olschewski A, Berghold A, Olschewski H. Pulmonary vascular resistances during exercise in normal subjects: a systematic review. Eur Respir J 2012;
39:319–328.
9. Wolsk E, Bakkestrom R, Thomsen JH, Balling L, Andersen MJ, Dahl JS, et al. The inﬂuence of age on hemodynamic parameters during rest and exercise in healthy individuals. JACC Heart Fail 2017;5:337–346.
10. Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, et al.
Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs Clinical
Assessment, Reporting, and Tracking program. Circulation 2016;133:1240–1248.
11. Douschan P, Kovacs G, Avian A, Foris V, Gruber F, Olschewski A, et al. Mild elevation of pulmonary arterial pressure as a predictor of mortality. Am J Respir Crit Care
Med 2018;197:509–516.
12. Kolte D, Lakshmanan S, Jankowich MD, Brittain EL, Maron BA, Choudhary G. Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis. J Am Heart Assoc 2018;7:e009729.
13. Maron BA, Brittain EL, Hess E, Waldo SW, Baron AE, Huang S, et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension:
a retrospective cohort study. Lancet Respir Med 2020;8:873–884.
14. Xanthouli P, Jordan S, Milde N, Marra A, Blank N, Egenlauf B, et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new deﬁnition of pulmonary arterial hypertension. Ann Rheum Dis 2020;79:370–378.
15. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE,
et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur
Heart J 2007;28:2539–2550.
16. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA)
of the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297–3317.
17. Zeder K, BanﬁC, Steinrisser-Allex G, Maron BA, Humbert M, Lewis GD, et al.
Diagnostic, prognostic and differential-diagnostic relevance of pulmonary hemodynamics during exercise - a systematic review. Eur Respir J 2022;2:103181.
18. Ho JE, Zern EK, Lau ES, Wooster L, Bailey CS, Cunningham T, et al. Exercise pulmonary hypertension predicts clinical outcomes in patients with dyspnea on effort.
J Am Coll Cardiol 2020;75:17–26.
19. Stamm A, Saxer S, Lichtblau M, Hasler ED, Jordan S, Huber LC, et al. Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. Eur
Respir J 2016;48:1658–1667.
20. Hasler ED, Muller-Mottet S, Furian M, Saxer S, Huber LC, Maggiorini M, et al.
Pressure-ﬂow during exercise catheterization predicts survival in pulmonary hypertension. Chest 2016;150:57–67.
21. Lewis GD, Murphy RM, Shah RV, Pappagianopoulos PP, Malhotra R, Bloch KD, et al.
Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes. Circ Heart Fail 2011;4:
276–285.
22. Zeder K, Avian A, Bachmaier G, Douschan P, Foris V, Sassmann T, et al. Exercise pulmonary resistances predict long-term survival in systemic sclerosis. Chest
2021;159:781–790.
23. Eisman AS, Shah RV, Dhakal BP, Pappagianopoulos PP, Wooster L, Bailey C, et al.
Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure. Circ Heart Fail 2018;11:e004750.
24. Bentley RF, Barker M, Esfandiari S, Wright SP, Valle FH, Granton JT, et al. Normal and abnormal relationships of pulmonary artery to wedge pressure during exercise.
J Am Heart Assoc 2020;9:e016339.
25. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint
Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the
European Society of Cardiology (ESC) and the European Respiratory Society
(ERS): Endorsed by: Association for European Paediatric and Congenital
Cardiology (AEPC), International Society for Heart and Lung Transplantation
(ISHLT). Eur Respir J 2015;46:903–975.
26. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint
Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the
European Society of Cardiology (ESC) and the European Respiratory Society
(ERS): Endorsed by: Association for European Paediatric and Congenital
Cardiology (AEPC), International Society for Heart and Lung Transplantation
(ISHLT). Eur Heart J 2016;37:67–119.
27. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Eur Heart J 2021;42:3599–3726.
28. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021
ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J
2022;43:561–632.
29. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A
global view of pulmonary hypertension. Lancet Respir Med 2016;4:306–322.
30. NHS Digital. National Audit of Pulmonary Hypertension 10th Annual Report,
Great Britain, 2018-19. https://digital.nhs.uk/data-and-information/publications/
statistical/national-pulmonary-hypertension-audit/2019# (24 March 2022, date last accessed 22 July 2022).
31. Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identiﬁcation of the most accurate estimates from a systematic literature review. Pulm Circ 2021;11:
2045894020977300.
32. Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol 2017;14:603–614.
33. Montani D, Girerd B, Jais X, Laveneziana P, Lau EMT, Bouchachi A, et al. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. The Eur
Respir J 2020;58:2004229.
34. Certain MC, Chaumais MC, Jais X, Savale L, Seferian A, Parent F, et al.
Characteristics and long-term outcomes of pulmonary venoocclusive disease induced by mitomycin C. Chest 2021;159:1197–1207.
35. Cornet L, Khouri C, Roustit M, Guignabert C, Chaumais MC, Humbert M, et al.
Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. Eur Respir J 2019;53:1802472.
36. McGee M, Whitehead N, Martin J, Collins N. Drug-associated pulmonary arterial hypertension. Clin Toxicol 2018;56:801–809.
37. McGregor PC, Boosalis V, Aragam J. Carﬁlzomib-induced pulmonary hypertension with associated right ventricular dysfunction: A case report. SAGE Open Med Case
Rep 2021;9:2050313X21994031.
38. Montani D, Lau EM, Descatha A, Jais X, Savale L, Andujar P, et al. Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. Eur
Respir J 2015;46:1721–1731.
39. Savale L, Chaumais MC, Cottin V, Bergot E, Frachon I, Prevot G, et al. Pulmonary hypertension associated with benﬂuorex exposure. Eur Respir J 2012;40:
1164–1172.
40. Weatherald J, Bondeelle L, Chaumais MC, Guignabert C, Savale L, Jais X, et al.
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. Eur Respir J 2020;
56:2000279.
41. Philen RM, Posada M. Toxic oil syndrome and eosinophilia-myalgia syndrome: May
8–10, 1991, World Health Organization meeting report. Semin Arthritis Rheum
1993;23:104–124.
42. Hertzman PA, Clauw DJ, Kaufman LD, Varga J, Silver RM, Thacker HL, et al. The eosinophilia-myalgia syndrome: status of 205 patients and results of treatment 2
years after onset. Ann Intern Med 1995;122:851–855.
43. Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience.
Am Heart J 2006;152:521–526.
44. Chen SC, Dastamani A, Pintus D, Yau D, Aftab S, Bath L, et al. Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the UK. Clin Endocrinol (Oxf) 2019;91:770–775.
45. Timlin MR, Black AB, Delaney HM, Matos RI, Percival CS. Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review. Pediatr Cardiol 2017;38:1247–1250.
46. Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global
Burden of Disease Study 2013. Lancet 2015;386:743–800.
47. Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiery JL.
Left ventricular heart failure and pulmonary hypertension. Eur Heart J 2016;37:
942–954.
48. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redﬁeld MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009;53:1119–1126.
49. Tichelbacker T, Dumitrescu D, Gerhardt F, Stern D, Wissmuller M, Adam M, et al.
Pulmonary hypertension and valvular heart disease. Herz 2019;44:491–501.
ESC/ERS Guidelines
3713


<!-- PAGE 97 -->

### Page 97

50. Weber L, Rickli H, Haager PK, Joerg L, Weilenmann D, Brenner R, et al.
Haemodynamic mechanisms and long-term prognostic impact of pulmonary hypertension in patients with severe aortic stenosis undergoing valve replacement.
Eur J Heart Fail 2019;21:172–181.
51. Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, Davies C, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013;41:
1292–1301.
52. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al.
Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019;
53:1801914.
53. Naeije R. Pulmonary hypertension at high altitude. Eur Respir J 2019;53:1900985.
54. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2020;57:
2002828.
55. Kramm T, Wilkens H, Fuge J, Schäfers H-J, Guth S, Wiedenroth CB, et al. Incidence and characteristics of chronic thromboembolic pulmonary hypertension in
Germany. Clinical research in cardiology: ofﬁcial journal of the German Cardiac
Society 1–6 (2018) doi:10.1007/s00392-018-1215-5.
56. Swietlik EM, Ruggiero A, Fletcher AJ, Taboada D, Knightbridge E, Harlow L, et al.
Limitations of resting haemodynamics in chronic thromboembolic disease without pulmonary hypertension. Eur Respir J 2019;53:1801787.
57. Kalantari S, Gomberg-Maitland M. Group 5 pulmonary hypertension: the orphan’s orphan disease. Cardiol Clin 2016;34:443–449.
58. Shlobin OA, Kouranos V, Barnett SD, Alhamad EH, Culver DA, Barney J, et al.
Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. Eur Respir J 2020;55:
1901747.
59. Boucly A, Cottin V, Nunes H, Jais X, Tazi A, Prevot G, et al. Management and longterm outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J
2017;50:1700465.
60. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al.
Primary pulmonary hypertension. A national prospective study. Ann Intern Med
1987;107:216–223.
61. Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007;132:373–379.
62. Galiè N, Saia F, Palazzini M, Manes A, Russo V, Bacchi Reggiani ML, et al. Left main coronary artery compression in patients with pulmonary arterial hypertension and angina. J Am Coll Cardiol 2017;69:2808–2817.
63. Kovacs G, Avian A, Foris V, Tscherner M, Kqiku X, Douschan P, et al. Use of ECG
and other simple non-invasive tools to assess pulmonary hypertension. PLoS One
2016;11:e0168706.
64. Bonderman D, Wexberg P, Martischnig AM, Heinzl H, Lang MB, Sadushi R, et al. A
noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J
2011;37:1096–1103.
65. Klok FA, Surie S, Kempf T, Eikenboom J, van Straalen JP, van Kralingen KW, et al. A
simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Thromb
Res 2011;128:21–26.
66. Henkens IR, Mouchaers KT, Vonk-Noordegraaf A, Boonstra A, Swenne CA, Maan
AC, et al. Improved ECG detection of presence and severity of right ventricular pressure load validated with cardiac magnetic resonance imaging. Am J Physiol
Heart Circ Physiol 2008;294:H2150–H2157.
67. Rich JD, Thenappan T, Freed B, Patel AR, Thisted RA, Childers R, et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol 2013;167:669–676.
68. Remy-Jardin M, Ryerson CJ, Schiebler ML, Leung ANC, Wild JM, Hoeper MM, et al.
Imaging of pulmonary hypertension in adults: a position paper from the Fleischner
Society. Eur Respir J 2021;57:2004455.
69. Ascha M, Renapurkar RD, Tonelli AR. A review of imaging modalities in pulmonary hypertension. Ann Thorac Med 2017;12:61–73.
70. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al.
Deﬁnitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62:
D42–D50.
71. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 2003;41:1028–1035.
72. Meyer FJ, Ewert R, Hoeper MM, Olschewski H, Behr J, Winkler J, et al. Peripheral airway obstruction in primary pulmonary hypertension. Thorax 2002;57:473–476.
73. Alonso-Gonzalez R, Borgia F, Diller GP, Inuzuka R, Kempny A, Martinez-Naharro A,
et al. Abnormal lung function in adults with congenital heart disease: prevalence, relation to cardiac anatomy, and association with survival. Circulation 2013;127:882–890.
74. Hoeper MM, Dwivedi K, Pausch C, Lewis RA, Olsson KM, Huscher D, et al.
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet
Respir Med 2022. Jun
28:S2213-2600(22)00097-2. doi: 10.1016/S2213-2600(22)
00097-2. Epub ahead of print. PMID: 35777416
75. Hoeper MM, Meyer K, Rademacher J, Fuge J, Welte T, Olsson KM. Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. JACC Heart Fail 2016;4:441–449.
76. Olson TP, Johnson BD, Borlaug BA. Impaired pulmonary diffusion in heart failure with preserved ejection fraction. JACC Heart Fail 2016;4:490–498.
77. Olsson KM, Fuge J, Meyer K, Welte T, Hoeper MM. More on idiopathic pulmonary arterial hypertension with a low diffusing capacity. Eur Respir J 2017;50:1700354.
78. Trip P, Nossent EJ, de Man FS, van den Berk IA, Boonstra A, Groepenhoff H, et al.
Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension:
patient characteristics and treatment responses. Eur Respir J 2013;42:1575–1585.
79. Melot C, Naeije R. Pulmonary vascular diseases. Compr Physiol 2011;1:593–619.
80. Harbaum L, Fuge J, Kamp JC, Hennigs JK, Simon M, Sinning C, et al. Blood carbon dioxide tension and risk in pulmonary arterial hypertension. Int J Cardiol 2020;318:
131–137.
81. Jilwan FN, Escourrou P, Garcia G, Jais X, Humbert M, Roisman G. High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest 2013;143:47–55.
82. Rudski LG, Lai WW, Aﬁlalo J, Hua L, Handschumacher MD, Chandrasekaran K,
et al. Guidelines for the echocardiographic assessment of the right heart in adults:
a report from the American Society of Echocardiography endorsed by the
European Association of Echocardiography, a registered branch of the European
Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc
Echocardiogr 2010;23:685–713.
83. Lang RM, Badano LP, Mor-Avi V, Aﬁlalo J, Armstrong A, Ernande L, et al.
Recommendations for cardiac chamber quantiﬁcation by echocardiography in adults:
an update from the American Society of Echocardiography and the European
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233–270.
84. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al.
Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantiﬁcation, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017;18:1301–1310.
85. Farber HW, Foreman AJ, Miller DP, McGoon MD. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail 2011;17:56–64.
86. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al.
Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735–740.
87. Fisher MR, Forﬁa PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, et al.
Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009;179:615–621
88. D’Alto M, Di Maio M, Romeo E, Argiento P, Blasi E, Di Vilio A, et al.
Echocardiographic probability of pulmonary hypertension: a validation study.
Eur Respir J. 2022;2102548. doi:10.1183/13993003.02548-2021. Epub ahead of print.
89. Jankowich M, Maron BA, Choudhary G. Mildly elevated pulmonary artery systolic pressure on echocardiography: bridging the gap in current guidelines. Lancet
Respir Med 2021;9:1185–1191.
90. Huston JH, Maron BA, French J, Huang S, Thayer T, Farber-Eger EH, et al.
Association of mild echocardiographic pulmonary hypertension with mortality and right ventricular function. JAMA Cardiol 2019;4:1112–1121.
91. Gall H, Yogeswaran A, Fuge J, Sommer N, Grimminger F, Seeger W, et al. Validity of echocardiographic tricuspid regurgitation gradient to screen for new deﬁnition of pulmonary hypertension. E Clin Med 2021;34:100822.
92. D’Alto M, Romeo E, Argiento P, D’Andrea A, Vanderpool R, Correra A, et al.
Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension. Int J Cardiol 2013;168:4058–4062.
93. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 2012;
39:112–118.
94. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011;365:44–53.
95. Grunig E, Henn P, D’Andrea A, Claussen M, Ehlken N, Maier F, et al. Reference values for and determinants of right atrial area in healthy adults by 2-dimensional echocardiography. Circ Cardiovasc Imaging 2013;6:117–124.
96. Tello K, Wan J, Dalmer A, Vanderpool R, Ghofrani HA, Naeije R, et al. Validation of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension. Circ Cardiovasc Imaging 2019;12:e009047.
97. Tello K, Axmann J, Ghofrani HA, Naeije R, Narcin N, Rieth A, et al. Relevance of the
TAPSE/PASP ratio in pulmonary arterial hypertension. Int J Cardiol 2018;266:
229–235.
98. Guazzi M, Dixon D, Labate V, Beussink-Nelson L, Bandera F, Cuttica MJ, et al. RV
contractile function and its coupling to pulmonary circulation in heart failure with
3714
ESC/ERS Guidelines


<!-- PAGE 98 -->

### Page 98

preserved ejection fraction: stratiﬁcation of clinical phenotypes and outcomes.
JACC Cardiovasc Imaging 2017;10:1211–1221.
99. Arkles JS, Opotowsky AR, Ojeda J, Rogers F, Liu T, Prassana V, et al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med 2011;183:268–276.
100. Takahama H, McCully RB, Frantz RP, Kane GC. Unraveling the RV ejection Doppler envelope: insight into pulmonary artery hemodynamics and disease severity. JACC
Cardiovasc Imaging 2017;10:1268–1277.
101. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, et al.
Heart J 2021;42:563–645.
102. Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019;53:1801915.
103. Konstantinides SV, Meyer G, Becattini C, Fauueno H, Bueno H, Geersing GJ, et al.
Eur Heart J 2020;41:543–603.
104. He J, Fang W, Lv B, He JG, Xiong CM, Liu ZH, et al. Diagnosis of chronic thromboembolic pulmonary hypertension: comparison of ventilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. Nucl Med Commun 2012;33:459–463.
105. Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P, et al.
Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007;48:680–684.
106. Giordano J, Khung S, Duhamel A, Hossein-Foucher C, Bellevre D, Lamblin N, et al.
Lung perfusion characteristics in pulmonary arterial hypertension (PAH) and peripheral forms of chronic thromboembolic pulmonary hypertension (pCTEPH):
dual-energy CT experience in 31 patients. Eur Radiol 2017;27:1631–1639.
107. Seferian A, Helal B, Jais X, Girerd B, Price LC, Gunther S, et al. Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. Eur Respir J 2012;40:75–83.
108. Swift AJ, Dwivedi K, Johns C, Garg P, Chin M, Currie BJ, et al. Diagnostic accuracy of
CT pulmonary angiography in suspected pulmonary hypertension. Eur Radiol 2020;
30:4918–4929.
109. Dong C, Zhou M, Liu D, Long X, Guo T, Kong X. Diagnostic accuracy of computed tomography for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. PLoS One 2015;10:e0126985.
110. Rajaram S, Swift AJ, Capener D, Telfer A, Davies C, Hill C, et al. Diagnostic accuracy of contrast-enhanced MR angiography and unenhanced proton MR imaging compared with CT pulmonary angiography in chronic thromboembolic pulmonary hypertension. Eur Radiol 2012;22:310–317.
111. Ende-Verhaar YM, Meijboom LJ, Kroft LJM, Beenen LFM, Boon GJAM, Middeldorp
S, et al. Usefulness of standard computed tomography pulmonary angiography performed for acute pulmonary embolism for identiﬁcation of chronic thromboembolic pulmonary hypertension: results of the InShape III study. J Heart Lung
Transplant 2019;38:731–738.
112. Guerin L, Couturaud F, Parent F, Revel MP, Gillaizeau F, Planquette B, et al.
Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb
Haemost 2014;112:598–605.
113. Tamura M, Yamada Y, Kawakami T, Kataoka M, Iwabuchi Y, Sugiura H, et al.
Diagnostic accuracy of lung subtraction iodine mapping CT for the evaluation of pulmonary perfusion in patients with chronic thromboembolic pulmonary hypertension: correlation with perfusion SPECT/CT. Int J Cardiol 2017;243:538–543.
114. Masy M, Giordano J, Petyt G, Hossein-Foucher C, Duhamel A, Kyheng M, et al.
Dual-energy CT (DECT) lung perfusion in pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2018;28:5100–5110.
115. Hinrichs JB, Marquardt S, von Falck C, Hoeper MM, Olsson KM, Wacker FK, et al.
Comparison of C-arm computed tomography and digital subtraction angiography in patients with chronic thromboembolic pulmonary hypertension. Cardiovasc
Intervent Radiol 2016;39:53–63.
116. Hinrichs JB, Renne J, Hoeper MM, Olsson KM, Wacker FK, Meyer BC. Balloon pulmonary angioplasty: applicability of C-Arm CT for procedure guidance. Eur Radiol
2016;26:4064–4071.
117. Swift AJ, Lu H, Uthoff J, Garg P, Cogliano M, Taylor J, et al. A machine learning cardiac magnetic resonance approach to extract disease features and automate pulmonary arterial hypertension diagnosis. Eur Heart J Cardiovasc Imaging 2021;22:
236–245.
118. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med 2017;
377:2298.
119. Rosenkranz S, Howard LS, Gomberg-Maitland M, Hoeper MM. Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation
2020;141:678–693.
120. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001;104:429–435.
121. Boerrigter BG, Bogaard HJ, Trip P, Groepenhoff H, Rietema H, Holverda S, et al.
Ventilatory and cardiocirculatory exercise proﬁles in COPD: the role of pulmonary hypertension. Chest 2012;142:1166–1174.
122. Caravita S, Faini A, Deboeck G, Bondue A, Naeije R, Parati G, et al. Pulmonary hypertension and ventilation during exercise: role of the pre-capillary component.
J Heart Lung Transplant 2017;36:754–762.
123. Dumitrescu D, Nagel C, Kovacs G, Bollmann T, Halank M, Winkler J, et al.
Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Heart 2017;103:774–782.
124. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The
2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 2016;35:1–23.
125. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al.
Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006;48:2546–2552.
126. Kovacs G, Avian A, Olschewski A, Olschewski H. Zero reference level for right heart catheterisation. Eur Respir J 2013;42:1586–1594.
127. Opotowsky AR, Hess E, Maron BA, Brittain EL, Baron AE, Maddox TM, et al.
Thermodilution vs estimated Fick cardiac output measurement in clinical practice:
an analysis of mortality from the Veterans Affairs Clinical Assessment, Reporting,
and Tracking (VA CART) Program and Vanderbilt University. JAMA Cardiol 2017;
2:1090–1099.
128. Viray MC, Bonno EL, Gabrielle ND, Maron BA, Atkins J, Amoroso NS, et al. Role of pulmonary artery wedge pressure saturation during right heart catheterization: a prospective study. Circ Heart Fail 2020;13:e007981.
129. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105–3111.
130. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A
comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am
Coll Cardiol 2000;35:176–182.
131. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, et al.
Assessment of the vasodilator response in primary pulmonary hypertension.
Comparing prostacyclin and iloprost administered by either infusion or inhalation.
Eur Heart J 2003;24:356–365.
132. Jing ZC, Jiang X, Han ZY, Xu XQ, Wang Y, Wu Y, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009;33:
1354–1360.
133. Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, et al. An ofﬁcial
European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J 2017;50:1700578.
134. Claeys M, Claessen G, La Gerche A, Petit T, Belge C, Meyns B, et al. Impaired cardiac reserve and abnormal vascular load limit exercise capacity in chronic thromboembolic disease. JACC Cardiovasc Imaging 2019;12:1444–1456.
135. Guth S, Wiedenroth CB, Rieth A, Richter MJ, Gruenig E, Ghofrani HA, et al.
Exercise right heart catheterization before and after pulmonary endarterectomy in patients with chronic thromboembolic disease. Eur Respir J 2018;52:1800458.
136. Godinas L, Lau EM, Chemla D, Lador F, Savale L, Montani D, et al. Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure. Eur Respir J 2016;48:254–257.
137. Naeije R, Vanderpool R, Dhakal BP, Saggar R, Saggar R, Vachiery JL, et al.
Exercise-induced pulmonary hypertension: physiological basis and methodological concerns. Am J Respir Crit Care Med 2013;187:576–583.
138. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, et al.
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 2014;148:e1–e132.
139. Esfandiari S, Wright SP, Goodman JM, Sasson Z, Mak S. Pulmonary artery wedge pressure relative to exercise work rate in older men and women. Med Sci Sports
Exerc 2017;49:1297–1304.
140. Boerrigter BG, Waxman AB, Westerhof N, Vonk-Noordegraaf A, Systrom DM.
Measuring central pulmonary pressures during exercise in COPD: how to cope with respiratory effects. Eur Respir J 2014;43:1316–1325.
141. Andersen MJ, Wolsk E, Bakkestrom R, Thomsen JH, Balling L, Dahl JS, et al.
Hemodynamic response to rapid saline infusion compared with exercise in healthy participants aged 20–80 years. J Cardiac Failure 2019;25:902–910.
142. Vachiery JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al.
Pulmonary hypertension due to left heart disease. Eur Respir J 2019;53:1801897.
143. D’Alto M, Romeo E, Argiento P, Motoji Y, Correra A, Di Marco GM, et al. Clinical relevance of ﬂuid challenge in patients evaluated for pulmonary hypertension. Chest
2017;151:119–126.
ESC/ERS Guidelines
3715


<!-- PAGE 99 -->

### Page 99

144. van de Bovenkamp AA, Wijkstra N, Oosterveer FPT, Vonk Noordegraaf A,
Bogaard HJ, van Rossum AC, et al. The value of passive leg raise during right heart catheterization in diagnosing heart failure with preserved ejection fraction. Circ
Heart Fail 2022;15:e008935.
145. D’Alto M, Dimopoulos K, Coghlan JG, Kovacs G, Rosenkranz S, Naeije R. Right heart catheterization for the diagnosis of pulmonary hypertension: controversies and practical issues. Heart Fail Clin 2018;14:467–477.
146. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76–81.
147. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al.
Diagnosis and differential assessment of pulmonary arterial hypertension. J Am
Coll Cardiol 2004;43:40S–47S.
148. Morrell NW, Aldred MA, Chung WK, Elliott CG, Nichols WC, Soubrier F, et al.
Genetics and genomics of pulmonary arterial hypertension. Eur Respir J 2019;53:
1801899.
149. Graf S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, et al. Identiﬁcation of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat
Commun 2018;9:1416.
150. Zhu N, Swietlik EM, Welch CL, Pauciulo MW, Hagen JJ, Zhou X, et al. Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Med
2021;13:80.
151. Song J, Eichstaedt CA, Viales RR, Benjamin N, Harutyunova S, Fischer C, et al.
Identiﬁcation of genetic defects in pulmonary arterial hypertension by a new gene panel diagnostic tool. Clin Sci (Lond) 2016;130:2043–2052.
152. International PPHC, Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA
III, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81–84.
153. Bohnen MS, Ma L, Zhu N, Qi H, McClenaghan C, Gonzaga-Jauregui C, et al.
Loss-of-function ABCC8 mutations in pulmonary arterial hypertension. Circ
Genom Precis Med 2018;11:e002087.
154. Ma L, Roman-Campos D, Austin ED, Eyries M, Sampson KS, Soubrier F, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013;369:
351–361.
155. Nasim MT, Ogo T, Ahmed M, Randall R, Chowdhury HM, Snape KM, et al.
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 2011;32:1385–1389.
156. Garg A, Kircher M, Del Campo M, Amato RS, Agarwal AK, University of
Washington Center for Mendelian Genomics. Whole exome sequencing identiﬁes de novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome. Am J Med Genet A 2015;167A:1796–1806.
157. Kerstjens-Frederikse WS, Bongers EM, Roofthooft MT, Leter EM, Douwes JM, Van
Dijk A, et al. TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension. J Med Genet 2013;50:500–506.
158. Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014;46:65–69.
159. Swietlik EM, Greene D, Zhu N, Megy K, Cogliano M, Rajaram S, et al. Bayesian inference associates rare KDR variants with speciﬁc phenotypes in pulmonary arterial hypertension. Circ Genom Precis Med 2020;14:e003155.
160. Chida A, Shintani M, Yagi H, Fujiwara M, Kojima Y, Sato H, et al. Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers. Am J
Cardiol 2012;110:586–593.
161. Hoeper MM, Pausch C, Grünig E, Klose H, Staehler G, Huscher D, et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transpl 2020;39:1435–1444.
162. Badagliacca R, Poscia R, Pezzuto B, Papa S, Nona A, Mancone M, et al. Pulmonary arterial dilatation in pulmonary hypertension: prevalence and prognostic relevance.
Cardiology 2012;121:76–82.
163. Santaniello A, Casella R, Vicenzi M, Rota I, Montanelli G, De Santis M, et al.
Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2020;59:
1581–1586.
164. Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley
R, et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999;353:1579–1583.
165. Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, et al. Pulmonary hypertension in patients with combined pulmonary ﬁbrosis and emphysema syndrome. Eur Respir J 2010;35:105–111.
166. Galiè N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al.
Initial use of ambrisentan plus tadalaﬁl in pulmonary arterial hypertension. N Engl
J Med 2015;373:834–844.
167. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al.
Macitentan and morbidity and mortality in pulmonary arterial hypertension. N
Engl J Med 2013;369:809–818.
168. Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, et al.
Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet
Respir Med 2019;7:594–604.
169. Armstrong I, Billings C, Kiely DG, Yorke J, Harries C, Clayton S, et al. The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients. BMC Pulm Med 2019;19:67.
170. Strange G, Gabbay E, Kermeen F, Williams T, Carrington M, Stewart S, et al. Time from symptoms to deﬁnitive diagnosis of idiopathic pulmonary arterial hypertension: the delay study. Pulm Circ 2013;3:89–94.
171. Ivarsson B, Johansson A, Kjellstrom B. The odyssey from symptom to diagnosis of pulmonary hypertension from the patients and spouses perspective. J Prim Care
Community
Health
2021;12:21501327211029241.
doi:
10.1177/
21501327211029241
172. Kiely DG, Lawrie A, Humbert M. Screening strategies for pulmonary arterial hypertension. Eur Heart J Suppl 2019;21:K9–K20.
173. Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al.
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis:
the DETECT study. Ann Rheum Dis 2014;73:1340–1349.
174. Weatherald J, Montani D, Jevnikar M, Jais X, Savale L, Humbert M. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2019;28:
190023.
175. Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MA, et al.
International Liver Transplant Society Practice Guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension.
Transplantation 2016;100:1440–1452.
176. Mancuso L, Scordato F, Pieri M, Valerio E, Mancuso A. Management of portopulmonary hypertension:
new perspectives.
World
J
Gastroenterol
2013;19:
8252–8257.
177. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, RafﬁF, De Zuttere D, et al.
Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008;177:108–113.
178. Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P,
Mairuhu AT, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature.
Eur Respir J 2017;49:1601792.
179. Ende-Verhaar YM, Huisman MV, Klok FA. To screen or not to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism.
Thromb Res 2017;151:1–7.
180. Kiely DG, Doyle O, Drage E, Jenner H, Salvatelli V, Daniels FA, et al. Utilising artiﬁcial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension. Pulm Circ 2019;9:2045894019890549.
181. Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP):
a randomised, placebo-controlled phase 2b study. Lancet Respir Med 2019;7:
780–790.
182. Nagel C, Henn P, Ehlken N, D’Andrea A, Blank N, Bossone E, et al. Stress Doppler echocardiography for early detection of systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Res Ther 2015;17:165.
183. Semalulu T, Rudski L, Huynh T, Langleben D, Wang M, Canadian Scleroderma
Research Group, et al. An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. Semin Arthritis Rheum 2020;50:1421–1427.
184. Vandecasteele E, Drieghe B, Melsens K, Thevissen K, De Pauw M, Deschepper E,
et al. Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. Eur Respir J 2017;49:1602275.
185. Coghlan JG, Wolf M, Distler O, Denton CP, Doelberg M, Harutyunova S, et al.
Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J 2018;51:1701197.
186. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792–3800.
187. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011;63:3522–3530.
188. Thakkar V, Stevens W, Prior D, Youssef P, Liew D, Gabbay E, et al. The inclusion of
N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis
Res Ther 2013;15:R193.
189. Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 2015;17:7.
190. Morrisroe K, Stevens W, Sahhar J, Rabusa C, Nikpour M, Proudman S, et al.
Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. Arthritis Res
Ther 2017;19:42.
3716
ESC/ERS Guidelines


<!-- PAGE 100 -->

### Page 100

191. Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman SM, Nikpour M, et al. Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. BMC Pulm Med
2016;16:134.
192. Smith V, Vanhaecke A, Vandecasteele E, Guerra M, Paolino S, Melsens K, et al.
Nailfold videocapillaroscopy in systemic sclerosis-related pulmonary arterial hypertension: a systematic literature review. J Rheumatol 2020;47:888–895.
193. Larkin EK, Newman JH, Austin ED, Hemnes AR, Wheeler L, Robbins IM, et al.
Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:892–896.
194. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003;37:401–409.
195. Kim WR, Krowka MJ, Plevak DJ, Lee J, Rettke SR, Frantz RP, et al. Accuracy of
Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000;6:453–458.
196. Raevens S, Colle I, Reyntjens K, Geerts A, Berrevoet F, Rogiers X, et al.
Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: an analysis of cutoff values. Liver Transpl 2013;19:602–610.
197. Golpe
R,
Perez-de-Llano
LA,
Castro-Anon
O,
Vazquez-Caruncho
M,
Gonzalez-Juanatey C, Veres-Racamonde A, et al. Right ventricle dysfunction and pulmonary hypertension in hemodynamically stable pulmonary embolism. Respir
Med 2010;104:1370–1376.
198. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al.
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257–2264.
199. Simonneau G, Hoeper MM. Evaluation of the incidence of rare diseases: difﬁculties and uncertainties, the example of chronic thromboembolic pulmonary hypertension. Eur Respir J 2017;49:1602522.
200. Coquoz N, Weilenmann D, Stolz D, Popov V, Azzola A, Fellrath JM, et al.
Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism. Eur Respir J 2018;51:1702505.
201. Valerio LM, Mavromanoli AC, Barco S, Abele C, Becker D, Bruch L, et al.
FOCUS Investigators. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J 2022;43:
3387–3398.
202. Nijkeuter M, Hovens MM, Davidson BL, Huisman MV. Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review. Chest 2006;
129:192–197.
203. Sanchez O, Helley D, Couchon S, Roux A, Delaval A, Trinquart L, et al. Perfusion defects after pulmonary embolism: risk factors and clinical signiﬁcance. J Thromb
Haemost 2010;8:1248–1255.
204. Wartski M, Collignon MA. Incomplete recovery of lung perfusion after 3 months in patients with acute pulmonary embolism treated with antithrombotic agents.
THESEE Study Group. Tinzaparin ou heparin standard: evaluation dans l’Embolie
Pulmonaire study. J Nucl Med 2000;41:1043–1048.
205. Nilsson LT, Andersson T, Larsen F, Lang IM, Liv P, Soderberg S. Dyspnea after pulmonary embolism: a nation-wide population-based case-control study. Pulm Circ
2021;11:20458940211046831.
206. Boon G, Ende-Verhaar YM, Bavalia R, El Bouazzaoui LH, Delcroix M,
Dzikowska-Diduch O, et al. Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II
study. Thorax 2021;76:1002–1009.
207. Helmersen D, Provencher S, Hirsch AM, Van Dam A, Dennie C, de Perrot M, et al.
Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian
Thoracic Society clinical practice guideline update. Can J Respir Crit Care Sleep
Med 2019;3:177–198.
208. Delcroix M, Kerr K, Fedullo P. Chronic thromboembolic pulmonary hypertension.
Epidemiology and risk factors. Ann Am Thorac Soc 2016;13:S201–S206.
209. Klok FA, Tesche C, Rappold L, Dellas C, Hasenfuss G, Huisman MV, et al. External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thromb Res 2015;135:796–801.
210. Barst RJ, Chung L, Zamanian RT, Turner M, McGoon MD. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest 2013;144:160–168.
211. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012;39:589–596.
212. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780–788.
213. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al.
Predicting survival in pulmonary arterial hypertension: insights from the Registry to
Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease
Management (REVEAL). Circulation 2010;122:164–172.
214. Humbert M, Sitbon O, Yaici A, Montani D, O’Callaghan DS, Jais X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.
Eur Respir J 2010;36:549–555.
215. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival with
ﬁrst-line bosentan in patients with primary pulmonary hypertension. Eur Respir J
2005;25:244–249.
216. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012;39:589–596.
217. Amsallem M, Sweatt AJ, Aymami MC, Kuznetsova T, Selej M, Lu H, et al. Right heart end-systolic remodeling index strongly predicts outcomes in pulmonary arterial hypertension: comparison with validated models. Circ Cardiovasc Imaging 2017;
10:e005771.
218. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, et al.
Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214–1219.
219. Badagliacca R, Papa S, Valli G, Pezzuto B, Poscia R, Manzi G, et al. Echocardiography combined with cardiopulmonary exercise testing for the prediction of outcome in idiopathic pulmonary arterial hypertension. Chest 2016;150:1313–1322.
220. Badagliacca R, Papa S, Manzi G, Miotti C, Luongo F, Sciomer S, et al. Usefulness of adding echocardiography of the right heart to risk-assessment scores in prostanoid-treated pulmonary arterial hypertension. JACC Cardiovasc Imaging
2020;13:2054–2056.
221. Ernande L, Cottin V, Leroux PY, Girerd N, Huez S, Mulliez A, et al. Right isovolumic contraction velocity predicts survival in pulmonary hypertension. J Am Soc
Echocardiogr 2013;26:297–306.
222. Forﬁa PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al.
Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J
Respir Crit Care Med 2006;174:1034–1041.
223. Ghio S, Mercurio V, Fortuni F, Forﬁa PR, Gall H, Ghofrani A, et al. A comprehensive echocardiographic method for risk stratiﬁcation in pulmonary arterial hypertension. Eur Respir J 2020;56:2000513.
224. Sachdev A, Villarraga HR, Frantz RP, McGoon MD, Hsiao JF, Maalouf JF, et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest 2011;139:1299–1309.
225. Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR,
et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J 2019;53:1801900.
226. Batal O, Dardari Z, Costabile C, Gorcsan J, Arena VC, Mathier MA. Prognostic value of pericardial effusion on serial echocardiograms in pulmonary arterial hypertension. Echocardiography 2015;32:1471–1476.
227. Chen L, Larsen CM, Le RJ, Connolly HM, Pislaru SV, Murphy JG, et al. The prognostic signiﬁcance of tricuspid valve regurgitation in pulmonary arterial hypertension.
Clin Respir J 2018;12:1572–1580.
228. Fenstad ER, Le RJ, Sinak LJ, Maradit-Kremers H, Ammash NM, Ayalew AM, et al.
Pericardial effusions in pulmonary arterial hypertension: characteristics, prognosis,
and role of drainage. Chest 2013;144:1530–1538.
229. Badagliacca R, Poscia R, Pezzuto B, Papa S, Reali M, Pesce F, et al. Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. J Heart Lung Transpl 2018;37:195–205.
230. Badano LP, Addetia K, Pontone G, Torlasco C, Lang RM, Parati G, et al. Advanced imaging of right ventricular anatomy and function. Heart 2020;106:1469–1476.
231. Lewis RA, Johns CS, Cogliano M, Capener D, Tubman E, Elliot CA, et al.
Identiﬁcation of cardiac magnetic resonance imaging thresholds for risk stratiﬁcation in pulmonary arterial hypertension. Am J Respir Crit Care Med 2020;201:
458–466.
232. Swift AJ, Capener D, Johns C, Hamilton N, Rothman A, Elliot C, et al. Magnetic resonance imaging in the prognostic evaluation of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2017;196:228–239.
233. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ,
et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011;58:2511–2519.
234. van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG,
Spreeuwenberg MD, et al. Prognostic value of right ventricular mass, volume,
and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007;28:
1250–1257.
235. Alabed S, Shahin Y, Garg P, Alandejani F, Johns CS, Lewis RA, et al. Cardiac-MRI
predicts clinical worsening and mortality in pulmonary arterial hypertension: a systematic review and meta-analysis. JACC Cardiovasc Imaging 2021;14:931–942.
236. Swift AJ, Wilson F, Cogliano M, Kendall L, Alandejani F, Alabed S, et al. Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study.
Thorax 2021;76:1032–1035.
237. van der Bruggen CE, Handoko ML, Bogaard HJ, Marcus JT, Oosterveer FPT,
Meijboom LJ, et al. The value of hemodynamic measurements or cardiac MRI in
ESC/ERS Guidelines
3717


<!-- PAGE 101 -->

### Page 101

the follow-up of patients with idiopathic pulmonary arterial hypertension. Chest
2021;159:1575–1585.
238. Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, et al. Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. Circulation 2018;137:693–704.
239. van Wolferen SA, van de Veerdonk MC, Mauritz GJ, Jacobs W, Marcus JT, Marques
KMJ, et al. Clinically signiﬁcant change in stroke volume in pulmonary hypertension.
Chest 2011;139:1003–1009.
240. Huis In ‘t Veld AE, Van de Veerdonk MC, Spruijt O, Groeneveldt JA, Marcus JT,
Westerhof N, et al. EXPRESS: preserving right ventricular function in patients with pulmonary arterial hypertension: single centre experience with a cardiac magnetic resonance imaging-guided treatment strategy.
Pulm
Circ
2019.
doi:10.1177/2045894018824553. Epub ahead of print.
241. van de Veerdonk MC, Huis In T Veld AE, Marcus JT, Westerhof N, Heymans MW,
Bogaard HJ, et al. Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension. Eur Respir J 2017;49:1700007.
242. van de Veerdonk MC, Marcus JT, Westerhof N, de Man FS, Boonstra A, Heymans
MW, et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest 2015;147:1063–1071.
243. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al.
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–349.
244. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156–163.
245. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension:
the impact of epoprostenol therapy. Circulation 2002;106:1477–1482.
246. Provencher S, Chemla D, Herve P, Sitbon O, Humbert M, Simonneau G. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur
Respir J 2006;27:114–120.
247. Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, et al. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J
2015;46:152–164.
248. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratiﬁcation equation. Eur Respir J 2010;35:1079–1087.
249. Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE,
et al. Predicting survival in patients with pulmonary arterial hypertension: the
REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest 2019;156:323–337.
250. Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, et al.
The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012;141:354–362.
251. Savarese G, Paolillo S, Costanzo P, D’Amore C, Cecere M, Losco T, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol
2012;60:1192–1201.
252. Zelniker TA, Huscher D, Vonk-Noordegraaf A, Ewert R, Lange TJ, Klose H, et al.
The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clin Res Cardiol 2018;107:460–470.
253. Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance.
J Heart Lung Transpl 2015;34:362–368.
254. Heresi GA, Rao Y. Follow-up functional class and 6-minute walk distance identify long-term survival in pulmonary arterial hypertension. Lung 2020;198:933–938.
255. Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, et al. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: data from the randomized SERAPHIN trial. PLoS
One 2018;13:e0193226.
256. Halliday SJ, Wang L, Yu C, Vickers BP, Newman JH, Fremont RD, et al. Six-minute walk distance in healthy young adults. Respir Med 2020;165:105933.
257. Khirfan G, Naal T, Abuhalimeh B, Newman J, Heresi GA, Dweik RA, et al.
Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension. PLoS One 2018;13:e0191869.
258. Lewis RA, Billings CG, Hurdman JA, Smith IA, Austin M, Armstrong IJ, et al. Maximal exercise testing using the incremental shuttle walking test can be used to riskstratify patients with pulmonary arterial hypertension. Ann Am Thorac Soc 2021;
18:34–43.
259. Laveneziana P, Di Paolo M, Palange P. The clinical value of cardiopulmonary exercise testing in the modern era. Eur Respir Rev 2021;30:200187.
260. Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002;106:319–324.
261. Badagliacca R, Papa S, Poscia R, Valli G, Pezzuto B, Manzi G, et al. The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension. J Heart Lung Transpl 2019;38:306–314.
262. Deboeck G, Scoditti C, Huez S, Vachiery JL, Lamotte M, Sharples L, et al. Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension. Eur Respir J 2012;40:1410–1419.
263. Wensel R, Francis DP, Meyer FJ, Opitz CF, Bruch L, Halank M, et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol 2013;167:1193–1198.
264. Badagliacca R, Rischard F, Giudice FL, Howard L, Papa S, Valli G, et al. Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. J Heart Lung Transplant 2022;41:780–790.
265. Bouzina H, Rådegran G. Low plasma stem cell factor combined with high transforming growth factor-α identiﬁes high-risk patients in pulmonary arterial hypertension. ERJ Open Res 2018;4:00035-02018.
266. Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, et al. Association of
N-terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension: insights from the phase III GRIPHON study.
Circulation 2019;139:2440–2450.
267. Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, et al.
Baseline and serial brain natriuretic peptide level predicts 5-year overall survival in patients with pulmonary arterial hypertension: data from the REVEAL registry.
Chest 2018;154:126–135.
268. Harbaum L, Ghataorhe P, Wharton J, Jimenez B, Howard LSG, Gibbs JSR, et al.
Reduced plasma levels of small HDL particles transporting ﬁbrinolytic proteins in pulmonary arterial hypertension. Thorax 2019;74:380–389.
269. Naal T, Abuhalimeh B, Khirfan G, Dweik RA, Tang WHW, Tonelli AR. Serum chloride levels track with survival in patients with pulmonary arterial hypertension. Chest
2018;154:541–549.
270. Nikolic I, Yung LM, Yang P, Malhotra R, Paskin-Flerlage S, Dinter T, et al. Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension.
Am J Respir Crit Care Med 2019;199:891–902.
271. Rhodes CJ, Wharton J, Ghataorhe P, Watson G, Girerd B, Howard LS, et al. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respir Med 2017;5:717–726.
272. Wetzl V, Tiede SL, Faerber L, Weissmann N, Schermuly RT, Ghofrani HA, et al.
Plasma MMP2/TIMP4 ratio at follow-up assessment predicts disease progression of idiopathic pulmonary arterial hypertension. Lung 2017;195:489–496.
273. Arvidsson M, Ahmed A, Bouzina H, Rådegran G. Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension. Pulm Circ 2019;9:
2045894019895414.
274. Kylhammar D, Hesselstrand R, Nielsen S, Scheele C, Radegran G. Angiogenic and inﬂammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension. Scand J Rheumatol 2018;47:319–324.
275. Saleby J, Bouzina H, Ahmed S, Lundgren J, Radegran G. Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation. ERJ
Open Res 2019;5:00037–02019.
276. van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, et al.
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl
J Med 2014;370:433–443.
277. Ferrer E, Dunmore BJ, Hassan D, Ormiston ML, Moore S, Deighton J, et al. A potential role for exosomal translationally controlled tumor protein export in vascular remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2018;59:
467–478.
278. Lavoie JR, Ormiston ML, Perez-Iratxeta C, Courtman DW, Jiang B, Ferrer E, et al.
Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension.
Circulation 2014;129:2125–2135.
279. Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur
Respir J 2008;32:503–512.
280. Hoeper M, Pausch C, Olsson K, Huscher D, Pittrow D, Grünig E, et al. COMPERA
2.0: a reﬁned 4-strata risk assessment model for pulmonary arterial hypertension.
Eur Respir J 2022;60:2102311.
281. Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev 2015;24:621–629.
282. Yorke J, Corris P, Gaine S, Gibbs JS, Kiely DG, Harries C, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur
Respir J 2014;43:1106–1113.
283. McGoon MD, Ferrari P, Armstrong I, Denis M, Howard LS, Lowe G, et al. The importance of patient perspectives in pulmonary hypertension. Eur Respir J 2019;53:
1801919.
284. Twiss J, McKenna S, Ganderton L, Jenkins S, Ben-L’amri M, Gain K, et al.
Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension. BMC Pulm Med 2013;13:45.
3718
ESC/ERS Guidelines


<!-- PAGE 102 -->

### Page 102

285. Chen H, De Marco T, Kobashigawa EA, Katz PP, Chang VW, Blanc PD.
Comparison of cardiac and pulmonary-speciﬁc quality-of-life measures in pulmonary arterial hypertension. Eur Respir J 2011;38:608–616.
286. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge
Pulmonary
Hypertension
Outcome
Review
(CAMPHOR):
a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006;15:103–115.
287. Lewis RA, Armstrong I, Bergbaum C, Brewis MJ, Cannon J, Charalampopoulos A,
et al. EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. Eur Respir J 2021;57:2000124.
288. Bonner N, Abetz L, Meunier J, Sikirica M, Mathai SC. Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients. Health Qual Life Outcomes 2013;11:161.
289. McCollister D, Shaffer S, Badesch DB, Filusch A, Hunsche E, Schuler R, et al.
Development of the Pulmonary Arterial Hypertension-Symptoms and Impact
(PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH. Respir Res 2016;17:72.
290. McCabe C, Bennett M, Doughty N, MacKenzie Ross R, Sharples L, Pepke-Zaba J.
Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest 2013;144:522–530.
291. Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, et al. Prediction of health-related quality of life and hospitalization in pulmonary arterial hypertension:
the Pulmonary Hypertension Association Registry. Am J Respir Crit Care Med 2021;
203:761–764.
292. Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S, et al.
A comprehensive risk stratiﬁcation at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 2018;39:4175–4181.
293. Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, et al.
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratiﬁcation model. Eur Respir J 2017;50:
1700740.
294. Hjalmarsson C, Kjellström B, Jansson K, Nisell M, Kylhammar D, Kavianipour M,
et al. Early risk prediction in patients with idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a reﬁned assessment.
ERJ Open Res 2021;7:00854-02020.
295. Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G, et al. Risk assessment,
prognosis and guideline implementation in pulmonary arterial hypertension. Eur
Respir J 2017;50:1700889.
296. Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL
Lite 2, for use in patients with pulmonary arterial hypertension. Chest 2021;159:
337–346.
297. Bouzina H, Rådegran G, Butler O, Hesselstrand R, Hjalmarsson C, Holl K, et al.
Longitudinal changes in risk status in pulmonary arterial hypertension. ESC Heart
Fail 2021;8:680–690.
298. D’Alto M, Badagliacca R, Lo Giudice F, Argiento P, Casu G, Corda M, et al.
Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan–tadalaﬁl in pulmonary arterial hypertension. J Heart Lung
Transpl 2020;39:1389–1397.
299. Hjalmarsson C, Rådegran G, Kylhammar D, Rundqvist B, Multing J, Nisell MD, et al.
Impact of age and comorbidity on risk stratiﬁcation in idiopathic pulmonary arterial hypertension. Eur Respir J 2018;51:1702310.
300. Humbert M, Farber HW, Ghofrani HA, Benza RL, Busse D, Meier C, et al. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J 2019;53:1802004.
301. Kuwana M, Blair C, Takahashi T, Langley J, Coghlan JG. Initial combination therapy of ambrisentan and tadalaﬁl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modiﬁed intention-to-treat population of the AMBITION study: post hoc analysis. Ann Rheum Dis 2020;79:626–634.
302. Kylhammar D, Hjalmarsson C, Hesselstrand R, Jansson K, Kavianipour M,
Kjellstrom B, et al. Predicting mortality during long-term follow-up in pulmonary arterial hypertension. ERJ Open Res 2021;7:00837-02020.
303. Sitbon O, Chin KM, Channick RN, Benza RL, Di Scala L, Gaine S, et al. Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study. J
Heart Lung Transpl 2020;39:300–309.
304. Rhodes CJ, Wharton J, Swietlik EM, Harbaum L, Girerd B, Coghlan JG, et al. Using the plasma proteome for risk stratifying patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2022;205:1102–1111.
305. Benza RL, Lohmueller LC, Kraisangka J, Kanwar M. Risk assessment in pulmonary arterial hypertension patients: the long and short of it. Adv Pulm Hypertens 2018;
16:125–135.
306. Yogeswaran A, Richter MJ, Sommer N, Ghofrani HA, Seeger W, Tello K, et al.
Advanced risk stratiﬁcation of intermediate risk group in pulmonary arterial hypertension. Pulm Circ 2020;10:2045894020961739.
307. Zelt JGE, Hossain A, Sun LY, Mehta S, Chandy G, Davies RA, et al. Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension. J
Heart Lung Transplant 2020;39:675–685.
308. Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prévot G, et al. External validation of a reﬁned 4-strata risk assessment score from the French pulmonary hypertension registry. Eur Respir J 2022;59:2102419.
309. Olsson KM, Richter MJ, Kamp JC, Gall H, Heine A, Ghofrani HA, et al. Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. J
Heart Lung Transplant 2019;38:748–756.
310. Tonelli AR, Sahay S, Gordon KW, Edwards LD, Allmon AG, Broderick M, et al.
Impact of inhaled treprostinil on risk stratiﬁcation with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies. Pulm Circ 2020;10:
2045894020977025.
311. Weatherald J, Boucly A, Launay D, Cottin V, Prévot G, Bourlier D, et al.
Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. Eur Respir J 2018;52:1800678.
312. Chan L, Chin LMK, Kennedy M, Woolstenhulme JG, Nathan SD, Weinstein AA,
et al. Beneﬁts of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. Chest 2013;143:
333–343.
313. de Man FS, Handoko ML, Groepenhoff H, van ‘t Hul AJ, Abbink J, Koppers RJ, et al.
Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009;34:669–675.
314. Ehlken N, Lichtblau M, Klose H, Weidenhammer J, Fischer C, Nechwatal R, et al.
Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur Heart J 2016;37:35–44.
315. Grunig E, MacKenzie A, Peacock AJ, Eichstaedt CA, Benjamin N, Nechwatal R, et al.
Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large
European multicentre randomized controlled trial. Eur Heart J 2021;42:2284–2295.
316. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, et al.
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006;114:
1482–1489.
317. Grunig E, Eichstaedt C, Barbera JA, Benjamin N, Blanco I, Bossone E, et al. ERS
statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. Eur Respir J 2019;53:1800332.
318. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006;130:545–552.
319. Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al.
Anticoagulation and survival in pulmonary arterial hypertension: results from the
Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary
Hypertension (COMPERA). Circulation 2014;129:57–65.
320. Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension
(PAH) in the Registry to Evaluate Early and Long-term PAH Disease
Management (REVEAL). Circulation 2015;132:2403–2411.
321. Khan MS, Usman MS, Siddiqi TJ, Khan SU, Murad MH, Mookadam F, et al. Is anticoagulation beneﬁcial in pulmonary arterial hypertension? Circ Cardiovasc Qual
Outcomes 2018;11:e004757.
322. Wang P, Hu L, Yin Y, Yan D, Zheng H, Zhang J, et al. Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis. Thromb Res 2020;196:251–256.
323. Stickel S, Gin-Sing W, Wagenaar M, Gibbs JSR. The practical management of ﬂuid retention in adults with right heart failure due to pulmonary arterial hypertension.
Eur Heart J Suppl 2019;21:K46–K53.
324. Sandoval J, Aguirre JS, Pulido T, Martinez-Guerra ML, Santos E, Alvarado P, et al.
Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J
Respir Crit Care Med 2001;164:1682–1687.
325. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;131:493–498.
326. Ulrich S, Saxer S, Hasler ED, Schwarz EI, Schneider SR, Furian M, et al. Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomised, placebo-controlled trial. Eur Respir J 2019;54:1900276.
327. Ulrich S, Hasler ED, Saxer S, Furian M, Muller-Mottet S, Keusch S, et al. Effect of breathing oxygen-enriched air on exercise performance in patients with precapillary pulmonary hypertension: randomized, sham-controlled cross-over trial. Eur
Heart J 2017;38:1159–1168.
ESC/ERS Guidelines
3719


<!-- PAGE 103 -->

### Page 103

328. Adir Y, Humbert M, Chaouat A. Sleep-related breathing disorders and pulmonary hypertension. Eur Respir J 2021;57:2002258.
329. McDonagh T, Damy T, Doehner W, Lam CSP, Sindone A, van der Meer P, et al.
Screening, diagnosis and treatment of iron deﬁciency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail 2018;20:1664–1672.
330. Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JS, et al. Iron deﬁciency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol 2011;58:300–309.
331. Ruiter G, Lankhorst S, Boonstra A, Postmus PE, Zweegman S, Westerhof N, et al.
Iron deﬁciency is common in idiopathic pulmonary arterial hypertension. Eur Respir
J 2011;37:1386–1391.
332. Ruiter G, Lanser IJ, de Man FS, van der Laarse WJ, Wharton J, Wilkins MR, et al. Iron deﬁciency in systemic sclerosis patients with and without pulmonary hypertension.
Rheumatology 2014;53:285–292.
333. Van De Bruaene A, Delcroix M, Pasquet A, De Backer J, De Pauw M, Naeije R, et al.
Iron deﬁciency is associated with adverse outcome in Eisenmenger patients. Eur
Heart J 2011;32:2790–2799.
334. Sonnweber T, Nairz M, Theurl I, Petzer V, Tymoszuk P, Haschka D, et al. The crucial impact of iron deﬁciency deﬁnition for the course of precapillary pulmonary hypertension. PLoS One 2018;13:e0203396.
335. Ruiter G, Manders E, Happe CM, Schalij I, Groepenhoff H, Howard LS, et al.
Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deﬁciency. Pulm Circ 2015;5:466–472.
336. Viethen T, Gerhardt F, Dumitrescu D, Knoop-Busch S, Ten Freyhaus H, Rudolph
TK, et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deﬁciency: a pilot study. Int J
Cardiol 2014;175:233–239.
337. Kramer T, Wissmuller M, Natsina K, Gerhardt F, Ten Freyhaus H, Dumitrescu D,
et al. Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deﬁciency: a long-term study. J Cachexia Sarcopenia Muscle 2021;12:
1501–1512.
338. Olsson KM, Fuge J, Brod T, Kamp JC, Schmitto J, Kempf T, et al. Oral iron supplementation with ferric maltol in patients with pulmonary hypertension. Eur Respir J
2020;56:2000616.
339. Howard LSGE, He J, Watson GMJ, Huang L, Wharton J, Luo Q, et al.
Supplementation with iron in pulmonary arterial hypertension. Two randomized crossover trials. Ann Am Thorac Soc 2021;18:981–988.
340. Larisch A, Neeb C, de Zwaan M, Pabst C, Tiede H, Ghofrani A, et al. Mental distress and wish for psychosomatic treatment of patients with pulmonary hypertension.
Psychother Psychosom Med Psychol 2014;64:384–389.
341. Olsson KM, Meltendorf T, Fuge J, Kamp JC, Park DH, Richter MJ, et al. Prevalence of mental disorders and impact on quality of life in patients with pulmonary arterial hypertension. Front Psychiatry 2021;31:667602.
342. Pfeuffer E, Krannich H, Halank M, Wilkens H, Kolb P, Jany B, et al. Anxiety, depression, and health-related QOL in patients diagnosed with PAH or CTEPH. Lung
2017;195:759–768.
343. Zhou X, Shi H, Yang Y, Zhang Z, Zhai Z, Wang C. Anxiety and depression in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: results from a Chinese survey. Exp Ther Med 2020;19:
3124–3132.
344. Kingman M, Hinzmann B, Sweet O, Vachiery JL. Living with pulmonary hypertension: unique insights from an international ethnographic study. BMJ Open 2014;4:
e004735.
345. Harzheim D, Klose H, Pinado FP, Ehlken N, Nagel C, Fischer C, et al. Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Res 2013;14:104.
346. Anand V, Vallabhajosyula S, Cheungpasitporn W, Frantz RP, Cajigas HR, Strand JJ,
et al. Inpatient palliative care use in patients with pulmonary arterial hypertension:
temporal trends, predictors, and outcomes. Chest 2020;158:2568–2578.
347. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:
487–497.
348. Kjellstrom B, Sandqvist A, Hjalmarsson C, Nisell M, Nasman P, Ivarsson B.
Adherence to disease-speciﬁc drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ERJ Open
Res 2020;6:00299-02020.
349. Shah NB, Mitchell RE, Proctor ST, Choi L, DeClercq J, Jolly JA, et al. High rates of medication adherence in patients with pulmonary arterial hypertension: an integrated specialty pharmacy approach. PLoS One 2019;14:e0217798.
350. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998;
31:1650–1657.
351. Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur
Heart J 2009;30:256–265.
352. Duarte AG, Thomas S, Safdar Z, Torres F, Pacheco LD, Feldman J, et al.
Management of pulmonary arterial hypertension during pregnancy: a retrospective,
multicenter experience. Chest 2013;143:1330–1336.
353. Jais X, Olsson KM, Barbera JA, Blanco I, Torbicki A, Peacock A, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur
Respir J 2012;40:881–885.
354. Kiely DG, Condliffe R, Webster V, Mills GH, Wrench I, Gandhi SV, et al. Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach. BJOG 2010;117:565–574.
355. Luo J, Shi H, Xu L, Su W, Li J. Pregnancy outcomes in patients with pulmonary arterial hypertension: a retrospective study. Medicine 2020;99:e20285.
356. Kamp JC, von Kaisenberg C, Greve S, Winter L, Park DH, Fuge J, et al. Pregnancy in pulmonary arterial hypertension: midterm outcomes of mothers and offspring. J
Heart Lung Transplant 2021;40:229–233.
357. Corbach N, Berlier C, Lichtblau M, Schwarz EI, Gautschi F, Groth A, et al. Favorable pregnancy outcomes in women with well-controlled pulmonary arterial hypertension. Front Med (Lausanne) 2021;8:689764.
358. Bostock S, Sheares K, Cannon J, Taboada D, Pepke-Zaba J, Toshner M. The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade. Eur Respir J 2017;50:1701141.
359. de Raaf MA, Beekhuijzen M, Guignabert C, Vonk Noordegraaf A, Bogaard HJ.
Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension. Reprod Toxicol 2015;56:45–51.
360. Dunn L, Greer R, Flenady V, Kumar S. Sildenaﬁl in pregnancy: a systematic review of maternal tolerance and obstetric and perinatal outcomes. Fetal Diagn Ther 2017;41:
81–88.
361. van Giersbergen PL, Halabi A, Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin
Pharmacol Ther 2006;44:113–118.
362. Meyer S, McLaughlin VV, Seyfarth HJ, Bull TM, Vizza CD, Gomberg-Maitland M,
et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J 2013;41:1302–1307.
363. Hassan HJ, Housten T, Balasubramanian A, Simpson CE, Damico RL, Mathai SC,
et al. A novel approach to perioperative risk assessment for patients with pulmonary hypertension. ERJ Open Res 2021;7:00257-02021.
364. Non-cardiac surgery: Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M,
Barbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J 2022. https://doi.
org/10.1093/eurheartj/ehac270.
365. Burns RM, Peacock AJ, Johnson MK, Church AC. Hypoxaemia in patients with pulmonary arterial hypertension during simulated air travel. Respir Med 2013;107:
298–304.
366. Kylhammar D, Rådegran G. The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension. Acta Physiol 2017;219:728–756.
367. Code of Federal Regulations. Chapter I, Subchapter C, Part 25, Subpart D, Subjgrp -
Pressurization. Section 25.841 - Pressurized cabins. Washington, DC: US
Government Printing Ofﬁce; 2012.
368. Groth A, Saxer S, Bader PR, Lichtblau M, Furian M, Schneider SR, et al. Acute hemodynamic changes by breathing hypoxic and hyperoxic gas mixtures in pulmonary arterial and chronic thromboembolic pulmonary hypertension. Int J Cardiol 2018;
270:262–267.
369. Roubinian N, Elliott CG, Barnett CF, Blanc PD, Chen J, De Marco T, et al. Effects of commercial air travel on patients with pulmonary hypertension air travel and pulmonary hypertension. Chest 2012;142:885–892.
370. Schneider SR, Mayer LC, Lichtblau M, Berlier C, Schwarz EI, Saxer S, et al. Effect of normobaric hypoxia on exercise performance in pulmonary hypertension: randomized trial. Chest 2021;159:757–771.
371. Seccombe LM, Chow V, Zhao W, Lau EMT, Rogers PG, Ng ACC, et al. Right heart function during simulated altitude in patients with pulmonary arterial hypertension.
Open Heart 2017;4:e000532.
372. Thamm M, Voswinckel R, Tiede H, Lendeckel F, Grimminger F, Seeger W, et al. Air travel can be safe and well tolerated in patients with clinically stable pulmonary hypertension. Pulm Circ 2011;1:239–243.
373. Cramer D, Ward S, Geddes D. Assessment of oxygen supplementation during air travel. Thorax 1996;51:202–203.
374. Dubroff J, Melendres L, Lin Y, Beene DR, Ketai L. High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude.
Pulm Circ 2020;10:2045894019894534.
375. Fakhri S, Hannon K, Moulden K, Peterson R, Hountras P, Bull T, et al. Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary
Hypertension Association Registry. Pulm Circ 2020;10:2045894020964342.
3720
ESC/ERS Guidelines


<!-- PAGE 104 -->

### Page 104

376. Schneider SR, Mayer LC, Lichtblau M, Berlier C, Schwarz EI, Saxer S, et al. Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension:
randomised crossover trial. ERJ Open Res 2021;7:00314-02021.
377. Makowski CT, Rissmiller RW, Bullington WM. Riociguat: a novel new drug for treatment of pulmonary hypertension. Pharmacotherapy 2015;35:502–519.
378. Montani D, Savale L, Natali D, Jais X, Herve P, Garcia G, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur
Heart J 2010;31:1898–1907.
379. Galiè N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995;
75:55A–62A.
380. Clozel M, Maresta A, Humbert M. Endothelin receptor antagonists. Handb Exp
Pharmacol 2013;218:199–227.
381. Xing J, Cao Y, Yu Y, Li H, Song Z, Yu H. In vitro micropatterned human pluripotent stem cell test (microP-hPST) for morphometric-based teratogen screening. Sci Rep
2017;7:8491.
382. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al.
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind,
placebo-controlled, multicenter, efﬁcacy (ARIES) study 1 and 2. Circulation 2008;
117:3010–3019.
383. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896–903.
384. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of
European post-marketing surveillance of bosentan in pulmonary hypertension.
Eur Respir J 2007;30:338–344.
385. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenaﬁl when coprescribed in pulmonary hypertension. Br J Clin
Pharmacol 2005;60:107–112.
386. Weber C, Banken L, Birnboeck H, Schulz R. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J
Clin Pharmacol 1999;39:847–854.
387. Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI.
Pharmacokinetic interaction between tadalaﬁl and bosentan in healthy male subjects. J Clin Pharmacol 2008;48:610–618.
388. Ghofrani HA, Osterloh IH, Grimminger F. Sildenaﬁl: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006;5:
689–702.
389. Galiè N, Muller K, Scalise AV, Grunig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenaﬁl in pulmonary arterial hypertension. Eur
Respir J 2015;45:1314–1322.
390. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenaﬁl citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:
2148–2157.
391. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efﬁcacy of sildenaﬁl in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind,
crossover study. J Am Coll Cardiol 2004;43:1149–1153.
392. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenaﬁl to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521–530.
393. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al.
Tadalaﬁl therapy for pulmonary arterial hypertension. Circulation 2009;119:
2894–2903.
394. Schermuly RT, Janssen W, Weissmann N, Stasch JP, Grimminger F, Ghofrani HA.
Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig
Drugs 2011;20:567–576.
395. Ghofrani HA, Galiè N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:
330–340.
396. Galiè N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J
Respir Med 2003;2:123–137.
397. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995;48:
890–896.
398. Sitbon O, Delcroix M, Bergot E, Boonstra AB, Granton J, Langleben D, et al.
EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.
Am Heart J 2014;167:210–217.
399. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study
Group. N Engl J Med 1996;334:296–302.
400. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin
(epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112:485–491.
401. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al.
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med
2000;132:425–434.
402. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH.
Improvement in pulmonary hemodynamics during intravenous epoprostenol
(prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641–648.
403. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, et al. Prognostic factors for survival in human immunodeﬁciency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:1433–1439.
404. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858–1865.
405. Boucly A, O’Connell C, Savale L, O’Callaghan DS, Jais X, Montani D, et al. Tunnelled central venous line-associated infections in patients with pulmonary arterial hypertension treated with intravenous prostacyclin. Presse Med 2016;45:20–28.
406. Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL, et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008;(160):5–9.
407. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322–329.
408. Simonneau G, Barst RJ, Galiè N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J
Respir Crit Care Med 2002;165:800–804.
409. Bourge RC, Waxman AB, Gomberg-Maitland M, Shapiro SM, Tarver JH III, Zwicke
DL, et al. Treprostinil administered to treat pulmonary arterial hypertension using a fully implantable programmable intravascular delivery system: results of the
DelIVery for PAH trial. Chest 2016;150:27–34.
410. Richter MJ, Harutyunova S, Bollmann T, Classen S, Gall H, Gerhardt Md F, et al.
Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. J Heart Lung Transplant 2018;37:1235–1244.
411. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al.
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension:
a randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915–1922.
412. Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the
FREEDOM-C2 study): a randomized controlled trial. Chest 2013;144:952–958.
413. Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012;142:
1383–1390.
414. Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, et al. Efﬁcacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013;127:624–633.
415. White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY,
et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med 2020;
201:707–717.
416. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119–2125.
417. Galiè N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol
2002;39:1496–1502.
418. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galiè N, et al.
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012;40:874–880.
419. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015;373:2522–2533.
419a. McLaughlin V, Channick RN, Ghofrani H-A, Lemarié J-C, Naeije R, Packer M, et al.
Bosentan added to sildenaﬁl therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015;46:405–413.
420. Hoeper MM, McLaughlin VV, Barbera JA, Frost AE, Ghofrani HA, Peacock AJ, et al.
Initial combination therapy with ambrisentan and tadalaﬁl and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med 2016;4:894–901.
421. Chin KM, Sitbon O, Doelberg M, Feldman J, Gibbs JSR, Grunig E, et al. Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J Am Coll Cardiol 2021;78:1393–1403.
ESC/ERS Guidelines
3721


<!-- PAGE 105 -->

### Page 105

422. Badagliacca R, D’Alto M, Ghio S, Argiento P, Bellomo V, Brunetti ND, et al. Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension. Am J Respir Crit Care Med 2021;203:484–492.
423. Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, et al.
Ambrisentan and tadalaﬁl up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192:1102–1110.
424. Kirtania L, Maiti R, Srinivasan A, Mishra A. Effect of combination therapy of endothelin receptor antagonist and phosphodiesterase-5 inhibitor on clinical outcome and pulmonary haemodynamics in patients with pulmonary arterial hypertension: a meta-analysis. Clin Drug Investig 2019;39:1031–1044.
425. Montani D, Lau EM, Dorfmuller P, Girerd B, Jais X, Savale L, et al. Pulmonary veno-occlusive disease. Eur Respir J 2016;47:1518–1534.
426. Sitbon O, Jais X, Savale L, Cottin V, Bergot E, Macari EA, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014;
43:1691–1697.
427. D’Alto M, Badagliacca R, Argiento P, Romeo E, Farro A, Papa S, et al. Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension. Chest 2020;157:376–383.
428. Boucly A, Savale L, Jais X, Bauer F, Bergot E, Bertoletti L, et al. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension.
Am J Respir Crit Care Med 2021;204:842–854.
429. Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label,
randomised controlled trial. Lancet Respir Med 2021;9:573–584.
430. Sitbon O, Cottin V, Canuet M, Clerson P, Gressin V, Perchenet L, et al. Initial combination therapy of macitentan and tadalaﬁl in pulmonary arterial hypertension. Eur
Respir J 2020;56:2000673. doi:10.1183/13993003.00673-2020.
431. Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs 2018;18:37–47.
432. Lajoie AC, Lauziere G, Lega JC, Lacasse Y, Martin S, Simard S, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.
Lancet Respir Med 2016;4:291–305.
433. Hoeper MM, Pausch C, Grunig E, Staehler G, Huscher D, Pittrow D, et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.
Eur Respir J 2022;59:2102024. doi:10.1183/13993003.02024-2021.
434. Zelt JGE, Sugarman J, Weatherald J, Partridge ACR, Liang JC, Swiston J, et al.
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS Guideline Era. Eur Respir J 2022;59:2101552. doi:
10.1183/13993003.01552-2021.
435. Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, et al.
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017;50:
1602425.
436. Bartolome SD, Sood N, Shah TG, Styrvoky K, Torres F, Chin KM. Mortality in patients with pulmonary arterial hypertension treated with continuous prostanoids.
Chest 2018;154:532–540.
437. Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, et al. SERAPHIN
haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
Eur Heart J 2017;38:1147–1155.
438. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, et al. Long-term sildenaﬁl added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2014;33:689–697.
439. Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, et al.
Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary
Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung
Transplant 2011;30:1327–1333.
440. Rubin LJ, Galiè N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study
(PATENT-2). Eur Respir J 2015;45:1303–1313.
441. Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, et al.
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691–694.
442. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al.
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257–1263.
443. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, et al. ARIES-3:
ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012;30:93–99.
444. Dardi F, Manes A, Palazzini M, Bachetti C, Mazzanti G, Rinaldi A, et al. Combining bosentan and sildenaﬁl in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J 2015;46:414–421.
445. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination therapy with bosentan and sildenaﬁl in Eisenmenger syndrome: a randomized, placebocontrolled, double-blinded trial. Eur Heart J 2010;31:1124–1131.
446. Vizza CD, Jansa P, Teal S, Dombi T, Zhou D. Sildenaﬁl dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovasc Disord 2017;17:239.
447. Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al.
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013;168:871–880.
448. Khou V, Anderson JJ, Strange G, Corrigan C, Collins N, Celermajer DS, et al.
Diagnostic delay in pulmonary arterial hypertension: insights from the Australian and New Zealand pulmonary hypertension registry. Respirology 2020;25:863–871.
449. McLaughlin VV, Vachiery JL, Oudiz RJ, Rosenkranz S, Galiè N, Barbera JA, et al.
Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: results from the AMBITION trial. J Heart Lung Transplant 2019;38:
1286–1295.
450. Opitz CF, Hoeper MM, Gibbs JS, Kaemmerer H, Pepke-Zaba J, Coghlan JG, et al.
Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 2016;68:368–378.
451. Lewis RA, Thompson AAR, Billings CG, Charalampopoulos A, Elliot CA, Hamilton
N, et al. Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Eur Respir J 2020;55:2000041.
452. Valentin S, Maurac A, Sitbon O, Beurnier A, Gomez E, Guillaumot A, et al.
Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. Eur Respir J 2021;58:2004066.
453. Rosenkranz S, Channick R, Chin KM, Jenner B, Gaine S, Galiè N, et al. The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. Eur J Heart Fail 2022;24:205–214.
454. Khan MS, Memon MM, Amin E, Yamani N, Khan SU, Figueredo VM, et al. Use of balloon atrial septostomy in patients with advanced pulmonary arterial hypertension: a systematic review and meta-analysis. Chest 2019;156:53–63.
455. Sandoval J, Gaspar J, Pulido T, Bautista E, Martinez-Guerra ML, Zeballos M, et al.
Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment.
J Am Coll Cardiol 1998;32:297–304.
456. Aggarwal M, Grady RM, Choudhry S, Anwar S, Eghtesady P, Singh GK. Potts shunt improves right ventricular function and coupling with pulmonary circulation in children with suprasystemic pulmonary arterial hypertension. Circ Cardiovasc Imaging
2018;11:e007964.
457. Baruteau AE, Belli E, Boudjemline Y, Laux D, Levy M, Simonneau G, et al. Palliative
Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the ﬁrst 24 patients. Eur J Cardiothorac Surg 2015;
47:e105–e110.
458. Grady RM, Canter M, Shmalts A, Coleman R, Beghetti M, Berger RM, et al.
Pulmonary-to-systemic arterial shunt in children with severe pulmonary hypertension. J Am Coll Cardiol 2021;78:468–477.
459. Rosenzweig EB, Ankola A, Krishnan U, Middlesworth W, Bacha E, Bacchetta M. A
novel unidirectional-valved shunt approach for end-stage pulmonary arterial hypertension: early experience in adolescents and adults. J Thorac Cardiovasc Surg 2021;
161:1438–1446.e1432.
460. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic signiﬁcance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J
Respir Crit Care Med 2010;181:1269–1275.
461. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 2004;
110:1308–1312.
462. Juratsch CE, Jengo JA, Castagna J, Laks MM. Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature. Chest
1980;77:525–530.
463. Rothman A, Jonas M, Castel D, Tzafriri AR, Traxler H, Shav D, et al. Pulmonary artery denervation using catheter-based ultrasonic energy. EuroIntervention 2019;15:
722–730.
464. Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective,
ﬁrst-in-man PADN-1 study (ﬁrst-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol 2013;62:1092–1100.
465. Rothman AMK, Vachiery JL, Howard LS, Mikhail GW, Lang IM, Jonas M, et al.
Intravascular ultrasound pulmonary artery denervation to treat pulmonary arterial hypertension (TROPHY1): multicenter, early feasibility study. JACC Cardiovasc Interv
2020;13:989–999.
3722
ESC/ERS Guidelines


<!-- PAGE 106 -->

### Page 106

466. Sztrymf B, Souza R, Bertoletti L, Jais X, Sitbon O, Price LC, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J
2010;35:1286–1293.
467. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, et al.
Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J 2011;38:359–367.
468. Hoeper MM, Benza RL, Corris P, de Perrot M, Fadel E, Keogh AM, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J 2019;53:1801906.
469. Kapur NK, Esposito ML, Bader Y, Morine KJ, Kiernan MS, Pham DT, et al.
Mechanical circulatory support devices for acute right ventricular failure.
Circulation 2017;136:314–326.
470. Konstam MA, Kiernan MS, Bernstein D, Bozkurt B, Jacob M, Kapur NK, et al.
Evaluation and management of right-sided heart failure: a scientiﬁc statement from the American Heart Association. Circulation 2018;137:e578–e622.
471. Olsson KM, Richter MJ, Kamp JC, Gall H, Ghofrani HA, Fuge J, et al. Reﬁned risk stratiﬁcation in pulmonary arterial hypertension and timing of lung transplantation.
Eur Respir J 2022. doi:10.1183/13993003.03087-2021. Epub ahead of print.
472. Moser B, Jaksch P, Taghavi S, Murakozy G, Lang G, Hager H, et al. Lung transplantation for idiopathic pulmonary arterial hypertension on intraoperative and postoperatively prolonged extracorporeal membrane oxygenation provides optimally controlled reperfusion and excellent outcome. Eur J Cardiothorac Surg 2018;53:
178–185.
473. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F,
et al.
The
Registry of the
International
Society for
Heart and
Lung
Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart
Lung Transplant 2012;31:1073–1086.
474. Egan TM, Edwards LB. Effect of the lung allocation score on lung transplantation in the United States. J Heart Lung Transplant 2016;35:433–439.
475. Savale L, Le Pavec J, Mercier O, Mussot S, Jais X, Fabre D, et al. Impact of highpriority allocation on lung and heart-lung transplantation for pulmonary hypertension. Ann Thorac Surg 2017;104:404–411.
476. Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB,
et al.
The
Registry of the
International
Society for
Heart and
Lung
Transplantation:
Thirty-second
Ofﬁcial
Adult
Lung and
Heart-Lung
Transplantation Report–2015; Focus Theme: Early Graft Failure. J Heart Lung
Transplant 2015;34:1264–1277.
477. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al.
(EACTS): the Task Force for the diagnosis and management of atrial ﬁbrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;
42:373–498.
478. Wanamaker B, Cascino T, McLaughlin V, Oral H, Latchamsetty R, Siontis KC. Atrial arrhythmias in pulmonary hypertension: pathogenesis, prognosis and management.
Arrhythm Electrophysiol Rev 2018;7:43–48.
479. Andersen MO, Diederichsen SZ, Svendsen JH, Carlsen J. Assessment of cardiac arrhythmias using long-term continuous monitoring in patients with pulmonary hypertension. Int J Cardiol 2021;334:110–115.
480. Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial ﬂutter and ﬁbrillation in patients with pulmonary hypertension. Int J Cardiol 2013;167:2300–2305.
481. Wen L, Sun ML, An P, Jiang X, Sun K, Zheng L, et al. Frequency of supraventricular arrhythmias in patients with idiopathic pulmonary arterial hypertension. Am J
Cardiol 2014;114:1420–1425.
482. Luesebrink U, Fischer D, Gezgin F, Duncker D, Koenig T, Oswald H, et al. Ablation of typical right atrial ﬂutter in patients with pulmonary hypertension. Heart Lung
Circ 2012;21:695–699.
483. Santangeli P, Zado ES, Hutchinson MD, Riley MP, Lin D, Frankel DS, et al.
Prevalence and distribution of focal triggers in persistent and long-standing persistent atrial ﬁbrillation. Heart Rhythm 2016;13:374–382.
484. Ghigna MR, Guignabert C, Montani D, Girerd B, Jais X, Savale L, et al. BMPR2 mutation status inﬂuences bronchial vascular changes in pulmonary arterial hypertension. Eur Respir J 2016;48:1668–1681.
485. Rasciti E, Sverzellati N, Silva M, Casadei A, Attina D, Palazzini M, et al. Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension.
Radiol Med 2017;122:257–264.
486. Yang S, Wang J, Kuang T, Gong J, Ma Z, Shen YH, et al. Efﬁcacy and safety of bronchial artery embolization on hemoptysis in chronic thromboembolic pulmonary hypertension: a pilot prospective cohort study. Crit Care Med 2019;47:e182–e189.
487. Demerouti
EA,
Manginas
AN,
Athanassopoulos
GD,
Karatasakis
GT.
Complications leading to sudden cardiac death in pulmonary arterial hypertension.
Respir Care 2013;58:1246–1254.
488. Kreibich M, Siepe M, Kroll J, Hohn R, Grohmann J, Beyersdorf F. Aneurysms of the pulmonary artery. Circulation 2015;131:310–316.
489. Mak SM, Strickland N, Gopalan D. Complications of pulmonary hypertension: a pictorial review. Br J Radiol 2017;90:20160745.
490. Nuche J, Montero Cabezas JM, Alonso Charterina S, Escribano Subias P.
Management of incidentally diagnosed pulmonary artery dissection in patients with pulmonary arterial hypertension. Eur J Cardiothorac Surg 2019;56:210–212.
491. Russo V, Zompatori M, Galiè N. Extensive right pulmonary artery dissection in a young patient with chronic pulmonary hypertension. Heart 2012;98:265–266.
492. Zylkowska J, Kurzyna M, Florczyk M, Burakowska B, Grzegorczyk F, Burakowski J,
et al. Pulmonary artery dilatation correlates with the risk of unexpected death in chronic arterial or thromboembolic pulmonary hypertension. Chest 2012;142:
1406–1416.
493. Florczyk M, Wieteska M, Kurzyna M, Gosciniak P, Pepke-Zaba J, Biederman A, et al.
Acute and chronic dissection of pulmonary artery: new challenges in pulmonary arterial hypertension? Pulm Circ 2018;8:2045893217749114.
494. Velazquez Martin M, Montero Cabezas JM, Huertas S, Nuche J, Albarran A, Delgado
JF, et al. Clinical relevance of adding intravascular ultrasound to coronary angiography for the diagnosis of extrinsic left main coronary artery compression by a pulmonary artery aneurysm in pulmonary hypertension. Catheter Cardiovasc Interv
2021;98:691–700.
495. Torres F, Farber H, Ristic A, McLaughlin V, Adams J, Zhang J, et al. Efﬁcacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.
Eur Respir J 2019;54:1901030.
496. Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston
IR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J
Med 2021;384:1204–1215.
497. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006;130:1657–1663.
498. Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jorden M, et al.
Features and outcomes of methamphetamine-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2018;197:788–800.
499. Savale L, Sattler C, Gunther S, Montani D, Chaumais MC, Perrin S, et al. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J 2014;44:
1627–1634.
500. Weatherald J, Chaumais MC, Savale L, Jais X, Seferian A, Canuet M, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a populationbased study. Eur Respir J 2017;50:1700217.
501. Cardio-Oncology: Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar
MC, Bergler-Klein J, et al. Guidelines on cardio-oncology. Eur Heart J 2022.
https://doi.org/10.1093/eurheartj/ehac244.
502. Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010;37:2290–2298.
503. Launay D, Montani D, Hassoun PM, Cottin V, Le Pavec J, Clerson P, et al. Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. PLoS One 2018;13:e0197112.
504. Launay D, Sobanski V, Hachulla E, Humbert M. Pulmonary hypertension in systemic sclerosis: different phenotypes. Eur Respir Rev 2017;26:170056.
505. Hachulla E, Jais X, Cinquetti G, Clerson P, Rottat L, Launay D, et al. Pulmonary arterial hypertension associated with systemic lupus erythematosus: results from the
French Pulmonary Hypertension Registry. Chest 2018;153:143–151.
506. Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O, et al.
Immunosuppressive therapy in lupusand mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008;58:521–531.
507. Qian J, Li M, Zhang X, Wang Q, Zhao J, Tian Z, et al. Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. Eur Respir J 2019;53:1800081.
508. Sanges S, Yelnik CM, Sitbon O, Benveniste O, Mariampillai K, Phillips-Houlbracq M,
et al. Pulmonary arterial hypertension in idiopathic inﬂammatory myopathies: data from the French pulmonary hypertension registry and review of the literature.
Medicine (Baltimore) 2016;95:e4911.
509. Wang J, Li M, Wang Q, Zhang X, Qian J, Zhao J, et al. Pulmonary arterial hypertension associated with primary Sjogren’s syndrome: a multicentre cohort study from
China. Eur Respir J 2020;56:1902157.
510. Montani D, Henry J, O’Connell C, Jais X, Cottin V, Launay D, et al. Association between rheumatoid arthritis and pulmonary hypertension: data from the French
Pulmonary Hypertension Registry. Respiration 2018;95:244–250.
511. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al.
Pulmonary arterial hypertension in France: results from a national registry. Am J
Respir Crit Care Med 2006;173:1023–1030.
512. Humbert M, Khaltaev N, Bousquet J, Souza R. Pulmonary hypertension: from an orphan disease to a public health problem. Chest 2007;132:365–367.
513. Gunther S, Jais X, Maitre S, Berezne A, Dorfmuller P, Seferian A, et al. Computed tomography ﬁndings of pulmonary venoocclusive disease in scleroderma patients
ESC/ERS Guidelines
3723


<!-- PAGE 107 -->

### Page 107

presenting with precapillary pulmonary hypertension. Arthritis Rheum 2012;64:
2995–3005.
514. Hsu S, Kokkonen-Simon KM, Kirk JA, Kolb TM, Damico RL, Mathai SC, et al. Right ventricular myoﬁlament functional differences in humans with systemic sclerosis-associated versus idiopathic pulmonary arterial hypertension. Circulation
2018;137:2360–2370.
515. Chauvelot L, Gamondes D, Berthiller J, Nieves A, Renard S, Catella-Chatron J, et al.
Hemodynamic response to treatment and outcomes in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis: data from a study identifying prognostic factors in pulmonary hypertension associated with interstitial lung disease. Arthritis Rheum 2021;73:
295–304.
516. Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013;72:1940–1946.
517. Ramjug S, Hussain N, Hurdman J, Billings C, Charalampopoulos A, Elliot CA, et al.
Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes.
Chest 2017;152:92–102.
518. Pan J, Lei L, Zhao C. Comparison between the efﬁcacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Clin Exp Rheumatol 2018;36:
1095–1102.
519. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest
2006;130:182–189.
520. Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, et al.
Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum
Dis 2017;76:422–426.
521. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE.
Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344–350.
522. Trombetta AC, Pizzorni C, Ruaro B, Paolino S, Sulli A, Smith V, et al. Effects of longterm treatment with bosentan and iloprost on nailfold absolute capillary number,
ﬁngertip blood perfusion, and clinical status in systemic sclerosis. J Rheumatol 2016;
43:2033–2041.
523. Pradere P, Tudorache I, Magnusson J, Savale L, Brugiere O, Douvry B, et al. Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study. J Heart Lung Transplant 2018;37:903–911.
524. Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
Eur Respir J 2017;50:1602493.
525. Barbaro G, Lucchini A, Pellicelli AM, Grisorio B, Giancaspro G, Fauarbarini G, et al.
Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 2006;92:
1164–1166.
526. Degano B, Guillaume M, Savale L, Montani D, Jais X, Yaici A, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010;24:67–75.
527. Sitbon O. HIV-related pulmonary arterial hypertension: clinical presentation and management. AIDS 2008;22:S55–S62.
528. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS (London, England) 2008;22:S35–S40.
529. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, et al.
Platelet-derived growth factor expression in primary pulmonary hypertension:
comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;
11:554–559.
530. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000;118:1133–1141.
531. Zuber JP, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004;38:1178–1185.
532. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, et al.
Bosentan for the treatment of human immunodeﬁciency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170:1212–1217.
533. Degano B, Yaici A, Le Pavec J, Savale L, Jais X, Camara B, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur
Respir J 2009;33:92–98.
534. Carlsen J, Kjeldsen K, Gerstoft J. Sildenaﬁl as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002;16:1568–1569.
535. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenaﬁl in HIV-related pulmonary hypertension. AIDS 2001;15:1747–1748.
536. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenaﬁl and saquinavir/ritonavir. Br J Clin Pharmacol 2000;50:
99–107.
537. Garraffo R, Lavrut T, Ferrando S, Durant J, Rouyrre N, MacGregor TR, et al. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalaﬁl in healthy volunteers. J Clin Pharmacol 2011;51:1071–1078.
538. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000;162:1846–1850.
539. Cea-Calvo L, Escribano Subias P, Tello de Menesses R, Lazaro Salvador M, Gomez
Sanchez MA, Delgado Jimenez JF, et al. Treatment of HIV-associated pulmonary hypertension with treprostinil. Rev Esp Cardiol 2003;56:421–425.
540. Ghofrani HA, Friese G, Discher T, Olschewski H, Schermuly RT, Weissmann N,
et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 2004;23:321–326.
541. Bigna JJ, Sime PS, Koulla-Shiro S. HIV related pulmonary arterial hypertension: epidemiology in Africa, physiopathology, and role of antiretroviral treatment. AIDS Res
Ther 2015;12:36.
542. Ryom L, Cotter A, De Miguel R, Beguelin C, Podlekareva D, Arribas JR, et al. 2019
update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Med 2020;21:617–624.
543. Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, et al.
Portopulmonary hypertension: a report from the US-based REVEAL Registry.
Chest 2012;141:906–915.
544. Lazaro Salvador M, Quezada Loaiza CA, Rodriguez Padial L, Barbera JA,
Lopez-Meseguer M, Lopez-Reyes R, et al. Portopulmonary hypertension: prognosis and management in the current treatment era - results from the REHAP registry.
Intern Med J 2021;51:355–365.
545. Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, et al.
Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol 2020;73:130–139.
546. Baiges A, Turon F, Simon-Talero M, Tasayco S, Bueno J, Zekrini K, et al. Congenital extrahepatic portosystemic shunts (Abernethy malformation): an international observational study. Hepatology 2020;71:658–669.
547. Fussner LA, Iyer VN, Cartin-Ceba R, Lin G, Watt KD, Krowka MJ. Intrapulmonary vascular dilatations are common in portopulmonary hypertension and may be associated with decreased survival. Liver Transpl 2015;21:1355–1364.
548. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502–508.
549. Olsson KM, Meyer K, Berliner D, Hoeper MM. Development of hepatopulmonary syndrome during combination therapy for portopulmonary hypertension. Eur
Respir J 2019;53:1801880.
550. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl
2000;6:443–450.
551. Cartin-Ceba R, Burger C, Swanson K, Vargas H, Aqel B, Keaveny AP, et al. Clinical outcomes after liver transplantation in patients with portopulmonary hypertension. Transplantation 2021;105:2283–2290.
552. Deroo R, Trepo E, Holvoet T, De Pauw M, Geerts A, Verhelst X, et al.
Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis. Hepatology 2020;72:
1701–1716.
553. Sadd CJ, Osman F, Li Z, Chybowski A, Decker C, Henderson B, et al. Long-term outcomes and survival in moderate-severe portopulmonary hypertension after liver transplant. Transplantation 2021;105:346–353.
554. Savale L, Sattler C, Coilly A, Conti F, Renard S, Francoz C, et al. Long-term outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology
2017;65:1683–1692.
555. Diller GP, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Li W, et al. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation 2015;132:
2118–2125.
556. van Riel AC, Schuuring MJ, van Hessen ID, Zwinderman AH, Cozijnsen L, Reichert
CL, et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classiﬁcation. Int J Cardiol
2014;174:299–305.
557. Lammers AE, Bauer LJ, Diller GP, Helm PC, Abdul-Khaliq H, Bauer UMM, et al.
Pulmonary hypertension after shunt closure in patients with simple congenital heart defects. Int J Cardiol 2020;308:28–32.
558. Ntiloudi D, Zanos S, Gatzoulis MA, Karvounis H, Giannakoulas G. How to evaluate patients with congenital heart disease-related pulmonary arterial hypertension.
Expert Rev Cardiovasc Ther 2019;17:11–18.
559. Dimopoulos K, Condliffe R, Tulloh RMR, Clift P, Alonso-Gonzalez R, Bedair R, et al.
Echocardiographic screening for pulmonary hypertension in congenital heart disease: JACC review topic of the week. J Am Coll Cardiol 2018;72:2778–2788.
3724
ESC/ERS Guidelines


<!-- PAGE 108 -->

### Page 108

560. Kempny A, Dimopoulos K, Fraisse A, Diller GP, Price LC, Raﬁq I, et al. Blood viscosity and its relevance to the diagnosis and management of pulmonary hypertension. J Am Coll Cardiol 2019;73:2640–2642.
561. Arvanitaki A, Giannakoulas G, Baumgartner H, Lammers AE. Eisenmenger syndrome: diagnosis, prognosis and clinical management. Heart 2020;106:1638–1645.
562. Diller GP, Korten MA, Bauer UM, Miera O, Tutarel O, Kaemmerer H, et al. Current therapy and outcome of Eisenmenger syndrome: data of the German National
Register for congenital heart defects. Eur Heart J 2016;37:1449–1455.
563. Kempny A, Hjortshoj CS, Gu H, Li W, Opotowsky AR, Landzberg MJ, et al.
Predictors of death in contemporary adult patients with Eisenmenger syndrome:
a multicenter study. Circulation 2017;135:1432–1440.
564. Arvind B, Relan J, Kothari SS. “Treat and repair” strategy for shunt lesions: a critical review. Pulm Circ 2020;10:2045894020917885.
565. Brida M, Nashat H, Gatzoulis MA. Pulmonary arterial hypertension: closing the gap in congenital heart disease. Curr Opin Pulm Med 2020;26:422–428.
566. van der Feen DE, Bartelds B, de Boer RA, Berger RMF. Assessment of reversibility in pulmonary arterial hypertension and congenital heart disease. Heart 2019;105:
276–282.
567. Becker-Grunig T, Klose H, Ehlken N, Lichtblau M, Nagel C, Fischer C, et al. Efﬁcacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol 2013;168:375–381.
568. Hartopo AB, Anggrahini DW, Nurdiati DS, Emoto N, Dinarti LK. Severe pulmonary hypertension and reduced right ventricle systolic function associated with maternal mortality in pregnant uncorrected congenital heart diseases. Pulm Circ 2019;
9:2045894019884516.
569. Li Q, Dimopoulos K, Liu T, Xu Z, Liu Q, Li Y, et al. Peripartum outcomes in a large population of women with pulmonary arterial hypertension associated with congenital heart disease. Eur J Prev Cardiol 2019;26:1067–1076.
570. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C,
Cifkova R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165–3241.
571. Blanche C, Alonso-Gonzalez R, Uribarri A, Kempny A, Swan L, Price L, et al. Use of intravenous iron in cyanotic patients with congenital heart disease and/or pulmonary hypertension. Int J Cardiol 2018;267:79–83.
572. Bertoletti L, Mismetti V, Giannakoulas G. Use of anticoagulants in patients with pulmonary hypertension. Hamostaseologie 2020;40:348–355.
573. Freisinger E, Gerss J, Makowski L, Marschall U, Reinecke H, Baumgartner H, et al.
Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44 000 patients. Eur
Heart J 2020;41:4168–4177.
574. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48–54.
575. Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efﬁcace M, Gesang S, et al.
Evaluation of Macitentan in patients with Eisenmenger syndrome. Circulation
2019;139:51–63.
576. Zuckerman WA, Leaderer D, Rowan CA, Mituniewicz JD, Rosenzweig EB.
Ambrisentan for pulmonary arterial hypertension due to congenital heart disease.
Am J Cardiol 2011;107:1381–1385.
577. Nashat H, Kempny A, Harries C, Dormand N, Alonso-Gonzalez R, Price LC, et al. A
single-centre, placebo-controlled, double-blind randomised cross-over study of nebulised iloprost in patients with Eisenmenger syndrome: A pilot study. Int J
Cardiol 2020;299:131–135.
578. D’Alto M, Constantine A, Balint OH, Romeo E, Argiento P, Ablonczy L, et al. The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome. Eur Respir J 2019;54:1901401.
579. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galiè N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 2014;35:
716–724.
580. Savale L, Manes A. Pulmonary arterial hypertension populations of special interest:
portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease. Eur Heart J Suppl 2019;21:K37–K45.
581. Dimopoulos K, Diller GP, Opotowsky AR, D’Alto M, Gu H, Giannakoulas G, et al.
Deﬁnition and management of segmental pulmonary hypertension. J Am Heart
Assoc 2018;7:e008587.
582. Amedro P, Gavotto A, Abassi H, Picot MC, Matecki S, Malekzadeh-Milani S, et al.
Efﬁcacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design. ESC Heart Fail 2020;7:747–756.
583. Goldberg DJ, Zak V, Goldstein BH, Schumacher KR, Rhodes J, Penny DJ, et al.
Results of the FUEL Trial. Circulation 2020;141:641–651.
584. Ridderbos FS, Hagdorn QAJ, Berger RMF. Pulmonary vasodilator therapy as treatment for patients with a Fontan circulation: the Emperor’s new clothes? Pulm Circ
2018;8:2045894018811148.
585. Dimopoulos K, Muthiah K, Alonso-Gonzalez R, Banner NR, Wort SJ, Swan L, et al.
Heart or heart-lung transplantation for patients with congenital heart disease in
England. Heart 2019;105:596–602.
586. Lapa M, Dias B, Jardim C, Fernandes CJ, Dourado PM, Figueiredo M, et al.
Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation
2009;119:1518–1523.
587. KnaﬂD, Gerges C, King CH, Humbert M, Bustinduy AL. Schistosomiasis-associated pulmonary arterial hypertension: a systematic review. Eur Respir Rev 2020;29:190089.
588. Fernandes CJC, Piloto B, Castro M, Gavilanes Oleas F, Alves JL Jr, Lopes Prada LF,
et al. Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. Eur Respir J 2018;51:1800307.
589. Weatherald J, Dorfmuller P, Perros F, Ghigna MR, Girerd B, Humbert M, et al.
Pulmonarycapillaryhaemangiomatosis: a distinct entity?Eur Respir Rev 2020;29:190168.
590. Humbert M, Guignabert C, Bonnet S, Dorfmuller P, Klinger JR, Nicolls MR, et al.
Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 2019;53:1801887.
591. Montani D, Girerd B, Jais X, Levy M, Amar D, Savale L, et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med 2017;5:125–134.
592. Perez-Olivares C, Segura de la Cal T, Flox-Camacho A, Nuche J, Tenorio J, Martinez
Menaca A, et al. The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease. Eur Respir J 2021;57:2100115.
593. Bergbaum C, Samaranayake CB, Pitcher A, Weingart E, Semple T, Kokosi M, et al. A
case series on the use of steroids and mycophenolate mofetil in idiopathic and heritable pulmonary veno-occlusive disease: is there a role for immunosuppression?
Eur Respir J 2021;57:2004354.
594. vanLoonRL,RoofthooftMT,HillegeHL,tenHarkelAD,vanOsch-GeversM,Delhaas
T, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 2011;124:1755–1764.
595. del Cerro Marin MJ, Sabate Rotes A, Rodriguez Ogando A, Mendoza Soto A,
Quero Jimenez M, Gavilan Camacho JL, et al. Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry. Am J Respir Crit
Care Med 2014;190:1421–1429.
596. Li L, Jick S, Breitenstein S, Hernandez G, Michel A, Vizcaya D. Pulmonary arterial hypertension in the USA: an epidemiological study in a large insured pediatric population. Pulm Circ 2017;7:126–136.
597. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012;379:537–546.
598. Abman SH, Mullen MP, Sleeper LA, Austin ED, Rosenzweig EB, Kinsella JP, et al.
Characterisation of paediatric pulmonary hypertensive vascular disease from the
PPHNet Registry. Eur Respir J 2021;59:2003337.
599. Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al.
Paediatric pulmonary arterial hypertension: updates on deﬁnition, classiﬁcation,
diagnostics and management. Eur Respir J 2019;53:1801916.
600. Haarman MG, Kerstjens-Frederikse WS, Vissia-Kazemier TR, Breeman KTN,
Timens W, Vos YJ, et al. The genetic epidemiology of pediatric pulmonary arterial hypertension. J Pediatr 2020;225:65–73.e65.
601. Levy M, Eyries M, Szezepanski I, Ladouceur M, Nadaud S, Bonnet D, et al. Genetic analyses in a cohort of children with pulmonary hypertension. Eur Respir J 2016;48:
1118–1126.
602. Mourani PM, Abman SH. Pulmonary hypertension and vascular abnormalities in bronchopulmonary dysplasia. Clin Perinatol 2015;42:839–855.
603. van Loon RL, Roofthooft MT, van Osch-Gevers M, Delhaas T, Strengers JL, Blom
NA, et al. Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr 2009;155:176–182.e171.
604. Arjaans S, Zwart EAH, Ploegstra MJ, Bos AF, Kooi EMW, Hillege HL, et al.
Identiﬁcation of gaps in the current knowledge on pulmonary hypertension in extremely preterm infants: a systematic review and meta-analysis. Paediatr Perinatal
Epidemiol 2018;32:258–267.
604a. Haarman MG, Do JM, Ploegstra MJ, Roofthooft MTR, Vissia-Kazemier TR, Hillege
HL, et al. The clinical value of proposed risk stratiﬁcation tools in pediatric pulmonary arterial hypertension. Am J Respir Crit Care Med 2019;200:1312–1315.
605. Beghetti M, Schulze-Neick I, Berger RM, Ivy DD, Bonnet D, Weintraub RG, et al.
Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension). Int J Cardiol 2016;203:
325–330.
606. Ploegstra MJ, Zijlstra WMH, Douwes JM, Hillege HL, Berger RMF. Prognostic factors in pediatric pulmonary arterial hypertension: a systematic review and meta-analysis. Int J Cardiol 2015;184:198–207.
607. Ivy DD, Rosenzweig EB, Lemarie JC, Brand M, Rosenberg D, Barst RJ. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 2010;106:1332–1338.
608. Zijlstra WMH, Douwes JM, Rosenzweig EB, Schokker S, Krishnan U, Roofthooft
MTR, et al. Survival differences in pediatric pulmonary arterial hypertension: clues
ESC/ERS Guidelines
3725


<!-- PAGE 109 -->

### Page 109

to a better understanding of outcome and optimal treatment strategies. J Am Coll
Cardiol 2014;63:2159–2169.
609. Ploegstra MJ, Douwes JM, Roofthooft MT, Zijlstra WM, Hillege HL, Berger RM.
Identiﬁcation of treatment goals in paediatric pulmonary arterial hypertension.
Eur Respir J 2014;44:1616–1626.
610. Singh Y, Lakshminrusimha S. Pathophysiology and management of persistent pulmonary hypertension of the newborn. Clin Perinatol 2021;48:595–618.
611. Arjaans S, Haarman MG, Roofthooft MTR, Fries MWF, Kooi EMW, Bos AF, et al.
Fate of pulmonary hypertension associated with bronchopulmonary dysplasia beyond 36 weeks postmenstrual age. Arch Dis Child Fetal Neonatal Ed 2021;106:
45–50.
612. Goss KN, Beshish AG, Barton GP, Haraldsdottir K, Levin TS, Tetri LH, et al. Early pulmonary vascular disease in young adults born preterm. Am J Respir Crit Care Med
2018;198:1549–1558.
613. Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, et al. STARTS-2:
long-term survival with oral sildenaﬁl monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation 2014;129:1914–1923.
614. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A randomized,
double-blind, placebo-controlled, dose-ranging study of oral sildenaﬁl citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012;
125:324–334.
615. Ivy D, Bonnet D, Berger R, Meyer G, Baygani S, Li B. Efﬁcacy and safety of tadalaﬁl in a pediatric population with pulmonary arterial hypertension: phase 3 randomized,
double-blind placebo-controlled study. Pulm Circ 2021;11:20458940211024955.
616. Small D, Ferguson-Sells L, Dahdah N, Bonnet D, Landry J, Li B. Pharmacokinetics and safety of tadalaﬁl in a paediatric population with pulmonary arterial hypertension: a multiple ascending-dose study. Br J Clin Pharmacol 2019;85:2302–2309.
617. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al.
Pharmacokinetics, safety, and efﬁcacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003;73:372–382.
618. Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, et al.
Pharmacokinetic and clinical proﬁle of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol
2009;68:948–955.
619. Berger RM, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Galiè N, et al. FUTURE-2:
results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J
Cardiol 2016;202:52–58.
620. Berger RMF, Gehin M, Beghetti M, Ivy D, Kusic-Pajic A, Cornelisse P, et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. Br J Clin Pharmacol 2017;83:
1734–1744.
621. Ivy D, Beghetti M, Juaneda-Simian E, Miller D, Lukas M, Ioannou C, et al. A randomized study of safety and efﬁcacy of two doses of ambrisentan to treat pulmonary arterial hypertension in pediatric patients aged 8 years up to 18 years. J Pediatr
2020;5:100055.
622. Takatsuki S, Rosenzweig EB, Zuckerman W, Brady D, Calderbank M, Ivy DD.
Clinical safety, pharmacokinetics, and efﬁcacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol 2013;48:27–34.
623. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999;99:1197–1208.
624. Hopper RK, Wang Y, DeMatteo V, Santo A, Kawut SM, Elci OU, et al. Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension. Pulm Circ 2018;8:2045894018759247.
625. Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in children with severe pulmonary hypertension. Heart 2007;93:739–743.
626. Douwes JM, Zijlstra WM, Rosenzweig EB, Ploegstra MJ, Krishnan US, Haarman MG,
et al. Parenteral prostanoids in pediatric pulmonary arterial hypertension: start early, dose high, combine. Ann Am Thorac Soc 2022;19:227–237.
627. Tella JB, Kulik TJ, McSweeney JE, Sleeper LA, Lu M, Mullen MP. Prostanoids in pediatric pulmonary hypertension: clinical response, time-to-effect, and dose-response.
Pulm Circ 2020;10:2045894020944858.
628. Krishnan U, Feinstein JA, Adatia I, Austin ED, Mullen MP, Hopper RK, et al.
Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. J Pediatr 2017;188:24–34.e21.
629. Vayalthrikkovil S, Vorhies E, Stritzke A, Bashir RA, Mohammad K, Kamaluddeen M,
et al. Prospective study of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Pediatr Pulmonol 2019;54:171–178.
630. Abman SH, Collaco JM, Shepherd EG, Keszler M, Cuevas-Guaman M, Welty SE,
et al. Interdisciplinary care of children with severe bronchopulmonary dysplasia. J
Pediatr 2017;181:12–28.e11.
631. Bermejo J, Gonzalez-Mansilla A, Mombiela T, Fernandez AI, Martinez-Legazpi P,
Yotti R, et al. Persistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long-term survival. J Am Heart Assoc 2021;10:
e019949.
632. Caravita S, Dewachter C, Soranna D, D’Araujo SC, Khaldi A, Zambon A, et al.
Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis. Eur Respir J 2018;51:1702427.
633. Crawford TC, Leary PJ, Fraser CD III, Suarez-Pierre A, Magruder JT, Baumgartner
WA, et al. Impact of the new pulmonary hypertension deﬁnition on heart transplant outcomes: expanding the hemodynamic risk proﬁle. Chest 2020;157:
151–161.
634. O’Sullivan CJ, Wenaweser P, Ceylan O, Rat-Wirtzler J, Stortecky S, Heg D, et al.
Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classiﬁcation. Circ Cardiovasc Interv 2015;8:e002358.
635. Vanderpool RR, Saul M, Nouraie M, Gladwin MT, Simon MA. Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol 2018;3:298–306.
636. Murali S, Kormos RL, Uretsky BF, Schechter D, Reddy PS, Denys BG, et al.
Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience. Am Heart J 1993;126:896–904.
637. Zimpfer D, Zrunek P, Roethy W, Czerny M, Schima H, Huber L, et al. Left ventricular assist devices decrease ﬁxed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg 2007;133:689–695.
638. Al-Naamani N, Preston IR, Paulus JK, Hill NS, Roberts KE. Pulmonary arterial capacitance is an important predictor of mortality in heart failure with a preserved ejection fraction. JACC Heart Fail 2015;3:467–474.
639. Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail 2013;1:290–299.
640. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 2010;106:284–286.
641. Shah AM, Shah SJ, Anand IS, Sweitzer NK, O’Meara E, Heitner JF, et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline
ﬁndings from the echocardiographic study of the Treatment of Preserved
Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart
Fail 2014;7:104–115.
642. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001;37:
183–188.
643. Tampakakis E, Leary PJ, Selby VN, De Marco T, Cappola TP, Felker GM, et al. The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail 2015;3:9–16.
644. Naeije R, Gerges M, Vachiery JL, Caravita S, Gerges C, Lang IM. Hemodynamic phenotyping of pulmonary hypertension in left heart failure. Circ Heart Fail 2017;10:
e004082.
645. Guazzi M, Naeije R. Pulmonary hypertension in heart failure: pathophysiology,
pathobiology, and emerging clinical perspectives. J Am Coll Cardiol 2017;69:
1718–1734.
646. Zlotnick DM, Ouellette ML, Malenka DJ, DeSimone JP, Leavitt BJ, Helm RE, et al.
Effect of preoperative pulmonary hypertension on outcomes in patients with severe aortic stenosis following surgical aortic valve replacement. Am J Cardiol
2013;112:1635–1640.
647. Melby SJ, Moon MR, Lindman BR, Bailey MS, Hill LL, Damiano RJ Jr. Impact of pulmonary hypertension on outcomes after aortic valve replacement for aortic valve stenosis. J Thorac Cardiovasc Surg 2011;141:1424–1430.
648. Lucon A, Oger E, Bedossa M, Boulmier D, Verhoye JP, Eltchaninoff H, et al.
Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: study from the
FRANCE 2 Registry. Circ Cardiovasc Interv 2014;7:240–247.
649. Faggiano P, Antonini-Canterin F, Ribichini F, D’Aloia A, Ferrero V, Cervesato E,
et al. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol 2000;85:204–208.
650. Zuern CS, Eick C, Rizas K, Stoleriu C, Woernle B, Wildhirt S, et al. Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement. Clin Res Cardiol 2012;101:81–88.
651. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE
multinational database of 19030 patients. Eur J Cardiothorac Surg 1999;15:
816–822; discussion 822–813.
652. Chandrashekhar Y, Westaby S, Narula J. Mitral stenosis. Lancet 2009;374:
1271–1283.
653. Dreyfus GD, Martin RP, Chan KM, Dulguerov F, Alexandrescu C. Functional tricuspid regurgitation: a need to revise our understanding. J Am Coll Cardiol 2015;65:
2331–2336.
3726
ESC/ERS Guidelines


<!-- PAGE 110 -->

### Page 110

654. Muraru D, Parati G, Badano L. The importance and the challenges of predicting the progression of functional tricuspid regurgitation. JACC Cardiovasc Imaging 2020;13:
1652–1654.
655. Andersen MJ, Hwang SJ, Kane GC, Melenovsky V, Olson TP, Fetterly K, et al.
Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction. Circ Heart Fail
2015;8:542–550.
656. Tedford RJ, Hassoun PM, Mathai SC, Girgis RE, Russell SD, Thiemann DR, et al.
Pulmonary capillary wedge pressure augments right ventricular pulsatile loading.
Circulation 2012;125:289–297.
657. Bosch L, Lam CSP, Gong L, Chan SP, Sim D, Yeo D, et al. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. Eur J
Heart Fail 2017;19:1664–1671.
658. Obokata M, Reddy YNV, Melenovsky V, Pislaru S, Borlaug BA. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J 2019;40:689–697.
659. D’Alto M, Romeo E, Argiento P, Pavelescu A, Melot C, D’Andrea A, et al.
Echocardiographic prediction of pre- versus postcapillary pulmonary hypertension.
J Am Soc Echocardiogr 2015;28:108–115.
660. D’Alto M, Romeo E, Argiento P, Pavelescu A, D’Andrea A, Di Marco GM, et al. A
simple echocardiographic score for the diagnosis of pulmonary vascular disease in heart failure. J Cardiovasc Med 2017;18:237–243.
661. Hoeper MM, Lam CSP, Vachiery JL, Bauersachs J, Gerges C, Lang IM, et al.
Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. Eur Heart J 2017;38:2869–2873.
662. Churchill TW, Li SX, Curreri L, Zern EK, Lau ES, Liu EE, et al. Evaluation of 2 existing diagnostic scores for heart failure with preserved ejection fraction against a comprehensively phenotyped cohort. Circulation 2021;143:289–291.
663. Reddy YNV, Carter RE, Obokata M, Redﬁeld MM, Borlaug BA. A simple, evidencebased approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018;138:861–870.
664. Andersen MJ, Ersboll M, Bro-Jeppesen J, Gustafsson F, Hassager C, Kober L, et al.
Exercise hemodynamics in patients with and without diastolic dysfunction and preserved ejection fraction after myocardial infarction. Circ Heart Fail 2012;5:444–451.
665. Andersen MJ, Olson TP, Melenovsky V, Kane GC, Borlaug BA. Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure. Circ Heart Fail 2015;8:41–48.
666. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redﬁeld MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ
Heart Fail 2010;3:588–595.
667. Fujimoto N, Borlaug BA, Lewis GD, Hastings JL, Shafer KM, Bhella PS, et al.
Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation 2013;127:55–62.
668. Ho JE, Zern EK, Wooster L, Bailey CS, Cunningham T, Eisman AS, et al. Differential clinical proﬁles, exercise responses, and outcomes associated with existing HFpEF
deﬁnitions. Circulation 2019;140:353–365.
669. Baratto C, Caravita S, Soranna D, Faini A, Dewachter C, Zambon A, et al. Current limitations of invasive exercise hemodynamics for the diagnosis of heart failure with preserved ejection fraction. Circ Heart Fail 2021;14:e007555.
670. Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension.
Eur Respir J 2013;42:1083–1091.
671. Lewis GD, Bossone E, Naeije R, Grunig E, Saggar R, Lancellotti P, et al. Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases.
Circulation 2013;128:1470–1479.
672. Maor E, Grossman Y, Balmor RG, Segel M, Fefer P, Ben-Zekry S, et al. Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension. Eur J Heart Fail 2015;17:151–158.
673. Robbins IM, Hemnes AR, Pugh ME, Brittain EL, Zhao DX, Piana RN, et al. High prevalence of occult pulmonary venous hypertension revealed by ﬂuid challenge in pulmonary hypertension. Circ Heart Fail 2014;7:116–122.
674. Borlaug BA. Invasive assessment of pulmonary hypertension: time for a more ﬂuid approach? Circ Heart Fail 2014;7:2–4.
675. Selim AM, Wadhwani L, Burdorf A, Raichlin E, Lowes B, Zolty R. Left ventricular assist devices in pulmonary hypertension group 2 with signiﬁcantly elevated pulmonary vascular resistance: a bridge to cure. Heart Lung Circ 2019;28:946–952.
676. Al-Kindi SG, Farhoud M, Zacharias M, Ginwalla MB, ElAmm CA, Benatti RD, et al.
Left ventricular assist devices or inotropes for decreasing pulmonary vascular resistance in patients with pulmonary hypertension listed for heart transplantation.
J Card Fail 2017;23:209–215.
677. Imamura T, Chung B, Nguyen A, Rodgers D, Sayer G, Adatya S, et al. Decoupling between diastolic pulmonary artery pressure and pulmonary capillary wedge pressure as a prognostic factor after continuous ﬂow ventricular assist device implantation. Circ Heart Fail 2017;10:e003882.
678. Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension–a multi-center randomized study. Cardiology 2008;109:273–280.
679. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, et al.
Sildenaﬁl improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007;116:1555–1562.
680. Dumitrescu D, Seck C, Mohle L, Erdmann E, Rosenkranz S. Therapeutic potential of sildenaﬁl in patients with heart failure and reactive pulmonary hypertension. Int J
Cardiol 2012;154:205–206.
681. Wu X, Yang T, Zhou Q, Li S, Huang L. Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. Eur J Heart Fail 2014;16:444–453.
682. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliﬂozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–1461.
683. Koller B, Steringer-Mascherbauer R, Ebner CH, Weber T, Ammer M, Eichinger J,
et al. Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-trial). Heart Lung Circ 2017;26:
433–441.
684. Vachiery JL, Delcroix M, Al-Hiti H, Efﬁcace M, Hutyra M, Lack G, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018;51:
1701886.
685. Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, et al.
Effects of sildenaﬁl on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015;36:2565–2573.
686. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a
1-year study. Circulation 2011;124:164–174.
687. Kramer T, Dumitrescu D, Gerhardt F, Orlova K, Ten Freyhaus H, Hellmich M, et al.
Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. Int J Cardiol 2019;283:152–158.
688. Obokata M, Reddy YNV, Shah SJ, Kaye DM, Gustafsson F, Hasenfubeta G, et al.
Effects of interatrial shunt on pulmonary vascular function in heart failure with preserved ejection fraction. J Am Coll Cardiol 2019;74:2539–2550.
689. Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction
(REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.
Lancet 2022;399:1130–1140.
690. Borlaug BA, Blair J, Bergmann MW, Bugger H, Burkhoff D, Bruch L, et al. Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure. Circulation 2022;145:1592–1604.
691. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB,
et al. Sustained efﬁcacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 2016;387:453–461.
692. Angermann CE, Assmus B, Anker SD, Asselbergs FW, Brachmann J, Brett ME, et al.
Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure
(MEMS-HF). Eur J Heart Fail 2020;22:1891–1901.
693. Shavelle DM, Desai AS, Abraham WT, Bourge RC, Raval N, Rathman LD, et al.
Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the
CardioMEMS Post-Approval Study. Circ Heart Fail 2020;13:e006863.
694. Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, et al.
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 2021;398:991–1001.
695. Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, et al.
Empagliﬂozin effects on pulmonary artery pressure in patients with heart failure:
results from the EMBRACE-HF trial. Circulation 2021;143:1673–1686.
696. Tran JS, Havakuk O, McLeod JM, Hwang J, Kwong HY, Shavelle D, et al. Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Fail 2021;8:1706–1710.
697. Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, et al.
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail 2019;21:337–341.
698. Wachter R, Fonseca AF, Balas B, Kap E, Engelhard J, Schlienger R, et al. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany.
Eur J Heart Fail 2019;21:588–597.
699. Gaemperli O, Moccetti M, Surder D, Biaggi P, Hurlimann D, Kretschmar O, et al.
Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 2012;98:126–132.
700. Tigges E, Blankenberg S, von Bardeleben RS, Zurn C, Bekeredjian R, Ouarrak T,
et al. Implication of pulmonary hypertension in patients undergoing MitraClip
ESC/ERS Guidelines
3727


<!-- PAGE 111 -->

### Page 111

therapy: results from the German transcatheter mitral valve interventions (TRAMI)
registry. Eur J Heart Fail 2018;20:585–594.
701. Bermejo J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, Castano M,
Segovia-Cubero J, et al. Sildenaﬁl for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter,
double-blind, randomized clinical trial. Eur Heart J 2018;39:1255–1264.
702. Chorin E, Rozenbaum Z, Topilsky Y, Konigstein M, Ziv-Baran T, Richert E, et al.
Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc
Imaging 2020;21:157–165.
703. Topilsky Y, Nkomo VT, Vatury O, Michelena HI, Letourneau T, Suri RM, et al.
Clinical outcome of isolated tricuspid regurgitation. JACC Cardiovasc Imaging
2014;7:1185–1194.
704. Lurz P, Orban M, Besler C, Braun D, Schlotter F, Noack T, et al. Clinical characteristics, diagnosis, and risk stratiﬁcation of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair. Eur Heart J
2020;41:2785–2795.
705. Brener MI, Lurz P, Hausleiter J, Rodes-Cabau J, Fam N, Kodali SK, et al. Right ventricular-pulmonary arterial coupling and afterload reserve in patients undergoing transcatheter tricuspid valve repair. J Am Coll Cardiol 2022;79:448–461.
706. Cao JY, Wales KM, Cordina R, Lau EMT, Celermajer DS. Pulmonary vasodilator therapies are of no beneﬁt in pulmonary hypertension due to left heart disease:
A meta-analysis. Int J Cardiol 2018;273:213–220.
707. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, et al.
“Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001;164:219–224.
708. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A,
Charpentier C, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995;107:
1193–1198.
709. Thurnheer R, Ulrich S, Bloch KE. Precapillary pulmonary hypertension and sleepdisordered breathing: is there a link? Respiration 2017;93:65–77.
710. Leon-Velarde F, Maggiorini M, Reeves JT, Aldashev A, Asmus I, Bernardi L, et al.
Consensus statement on chronic and subacute high altitude diseases. High Alt
Med Biol 2005;6:147–157.
711. Freitas CSG, Baldi BG, Jardim C, Araujo MS, Sobral JB, Heiden GI, et al. Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method. Orphanet J Rare Dis
2017;12:74.
712. Zeder K, Avian A, Bachmaier G, Douschan P, Foris V, Sassmann T, et al. Elevated pulmonary vascular resistance predicts mortality in COPD patients. Eur Respir J
2021;58:2100944.
713. Olsson KM, Hoeper MM, Pausch C, Grunig E, Huscher D, Pittrow D, et al.
Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. Eur Respir J 2021;58:2101483.
714. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 2005;172:189–194.
715. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary ﬁbrosis. Chest
2006;129:746–752.
716. Medrek SK, Sharafkhaneh A, Spiegelman AM, Kak A, Pandit LM. Admission for
COPD exacerbation is associated with the clinical diagnosis of pulmonary hypertension: results from a Retrospective Longitudinal Study of a Veteran Population.
COPD 2017;14:484–489.
717. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:158–164.
718. Vizza CD, Hoeper MM, Huscher D, Pittrow D, Benjamin N, Olsson KM, et al.
Pulmonary hypertension in patients with COPD: results from COMPERA. Chest
2021;160:678–689.
719. Dauriat G, Reynaud-Gaubert M, Cottin V, Lamia B, Montani D, Canuet M, et al.
Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a prospective French multicenter cohort. J Heart Lung Transplant 2021;
40:1009–1018.
720. Kovacs G, Agusti A, Barbera JA, Celli B, Criner G, Humbert M, et al. Pulmonary vascular involvement in COPD - is there a pulmonary vascular phenotype? Am J Respir
Crit Care Med 2018;198:1000–1011.
721. Andersen KH, Iversen M, Kjaergaard J, Mortensen J, Nielsen-Kudsk JE, Bendstrup E,
et al. Prevalence, predictors, and survival in pulmonary hypertension related to endstage chronic obstructive pulmonary disease. J Heart Lung Transplant 2012;31:
373–380.
722. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, et al.
Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005;127:1531–1536.
723. Carlsen J, Hasseriis Andersen K, Boesgaard S, Iversen M, Steinbruchel D, Bogelund
Andersen C. Pulmonary arterial lesions in explanted lungs after transplantation correlate with severity of pulmonary hypertension in chronic obstructive pulmonary disease. J Heart Lung Transplant 2013;32:347–354.
724. Bunel V, Guyard A, Dauriat G, Danel C, Montani D, Gauvain C, et al. Pulmonary arterial histologic lesions in patients with COPD with severe pulmonary hypertension. Chest 2019;156:33–44.
725. Kovacs G, Avian A, Douschan P, Foris V, Olschewski A, Olschewski H. Patients with pulmonary arterial hypertension less represented in clinical trials - who are they and how are they? Am J Respir Crit Care Med 2016;193:A3979.
726. Torres-Castro R, Gimeno-Santos E, Vilaro J, Roque-Figuls M, Moises J,
Vasconcello-Castillo L, et al. Effect of pulmonary hypertension on exercise tolerance in patients with COPD: a prognostic systematic review and meta-analysis.
Eur Respir Rev 2021;30:200321.
727. Nathan SD, Shlobin OA, Barnett SD, Saggar R, Belperio JA, Ross DJ, et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary ﬁbrosis. Respir Med 2008;102:1305–1310.
728. Bax S, Bredy C, Kempny A, Dimopoulos K, Devaraj A, Walsh S, et al. A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease. ERJ Open Res 2018;4:00124-2017.
729. Bax S, Jacob J, Ahmed R, Bredy C, Dimopoulos K, Kempny A, et al. Right ventricular to left ventricular ratio at CT pulmonary angiogram predicts mortality in interstitial lung disease. Chest 2020;157:89–98.
730. Chin M, Johns C, Currie BJ, Weatherley N, Hill C, Elliot C, et al. Pulmonary artery size in interstitial lung disease and pulmonary hypertension: association with interstitial lung disease severity and diagnostic utility. Front Cardiovasc Med 2018;5:53.
731. Kiely DG, Levin D, Hassoun P, Ivy DD, Jone PN, Bwika J, et al. Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute
(PVRI). Pulm Circ 2019;9:2045894019841990.
732. Johns CS, Rajaram S, Capener DA, Oram C, Elliot C, Condliffe R, et al. Non-invasive methods for estimating mPAP in COPD using cardiovascular magnetic resonance imaging. Eur Radiol 2018;28:1438–1448.
733. Pynnaert C, Lamotte M, Naeije R. Aerobic exercise capacity in COPD patients with and without pulmonary hypertension. Respir Med 2010;104:121–126.
734. Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A,
et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease.
N Engl J Med 2021;384:325–334.
735. Kovacs G, Avian A, Pienn M, Naeije R, Olschewski H. Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am J Respir Crit Care Med 2014;190:252–257.
736. Blanco I, Santos S, Gea J, Guell R, Torres F, Gimeno-Santos E, et al. Sildenaﬁl to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J
2013;42:982–992.
737. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N,
et al. Sildenaﬁl for treatment of lung ﬁbrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895–900.
738. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B,
Grimminger F, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung ﬁbrosis. Am J Respir Crit Care Med 1999;160:600–607.
739. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619–628.
740. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary ﬁbrosis with ambrisentan: a parallel, randomized trial. Ann Intern
Med 2013;158:641–649.
741. Goudie AR, Lipworth BJ, Hopkinson PJ, Wei L, Struthers AD. Tadalaﬁl in patients with chronic obstructive pulmonary disease: a randomised, double-blind,
parallel-group, placebo-controlled trial. Lancet Respir Med 2014;2:293–300.
742. Lederer DJ, Bartels MN, Schluger NW, Brogan F, Jellen P, Thomashow BM, et al.
Sildenaﬁl for chronic obstructive pulmonary disease: a randomized crossover trial.
COPD 2012;9:268–275.
743. Vitulo P, Stanziola A, Confalonieri M, Libertucci D, Oggionni T, Rottoli P, et al.
Sildenaﬁl in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. J Heart
Lung Transplant 2017;36:166–174.
744. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al.
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary ﬁbrosis. Am J Respir Crit Care Med 2008;177:75–81.
745. King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary ﬁbrosis. Am J
Respir Crit Care Med 2011;184:92–99.
746. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M,
Anstrom KJ, Collard HR, Flaherty KR, et al. A controlled trial of sildenaﬁl in advanced idiopathic pulmonary ﬁbrosis. N Engl J Med 2010;363:620–628.
3728
ESC/ERS Guidelines


<!-- PAGE 112 -->

### Page 112

747. Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, et al. Nintedanib plus sildenaﬁl in patients with idiopathic pulmonary ﬁbrosis. N Engl J Med 2018;379:
1722–1731.
748. Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parﬁtt L, et al. Bosentan in pulmonary hypertension associated with ﬁbrotic idiopathic interstitial pneumonia.
Am J Respir Crit Care Med 2014;190:208–217.
749. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, et al. Sildenaﬁl preserves exercise capacity in patients with idiopathic pulmonary ﬁbrosis and rightsided ventricular dysfunction. Chest 2013;143:1699–1708.
750. Raghu G, Nathan SD, Behr J, Brown KK, Egan JJ, Kawut SM, et al. Pulmonary hypertension in idiopathic pulmonary ﬁbrosis with mild-to-moderate restriction. Eur
Respir J 2015;46:1370–1377.
751. Nathan SD, Tapson VF, Elwing J, Rischard F, Mehta J, Shapiro S, et al. Efﬁcacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to parenchymal lung disease in the INCREASE trial. Am J
Respir Crit Care Med 2022;205:198–207.
752. Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R, et al. The Giessen pulmonary hypertension registry: survival in pulmonary hypertension subgroups. J
Heart Lung Transplant 2017;36:957–967.
753. Hoeper MM, Behr J, Held M, Grunig E, Vizza CD, Vonk-Noordegraaf A, et al.
Pulmonary hypertension in patients with chronic ﬁbrosing idiopathic interstitial pneumonias. PLoS One 2015;10:e0141911.
754. Klok FA, Delcroix M, Bogaard HJ. Chronic thromboembolic pulmonary hypertension from the perspective of patients with pulmonary embolism. J Thromb Haemost
2018;16:1040–1051.
755. Klok FA, Dzikowska-Diduch O, Kostrubiec M, Vliegen HW, Pruszczyk P, Hasenfuss
G, et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost 2016;14:
121–128.
756. Bonderman D, Wilkens H, Wakounig S, Schafers HJ, Jansa P, Lindner J, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009;
33:325–331.
757. Narechania S, Renapurkar R, Heresi GA. Mimickers of chronic thromboembolic pulmonary hypertension on imaging tests: a review. Pulm Circ 2020;10:
2045894019882620.
758. Xi XY, Gao W, Gong JN, Guo XJ, Wu JY, Yang YH, et al. Value of (18)F-FDG PET/
CT in differentiating malignancy of pulmonary artery from pulmonary thromboembolism: a cohort study and literature review. Int J Cardiovasc Imaging 2019;35:
1395–1403.
759. Lasch F, Karch A, Koch A, Derlin T, Voskrebenzev A, Alsady TM, et al. Comparison of MRI and VQ-SPECT as a screening test for patients with suspected CTEPH:
CHANGE-MRI study design and rationale. Front Cardiovasc Med 2020;7:51.
760. Nagel C, Prange F, Guth S, Herb J, Ehlken N, Fischer C, et al. Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension. PLoS One 2012;7:e41603.
761. Nagel C, Nasereddin M, Benjamin N, Egenlauf B, Harutyunova S, Eichstaedt CA,
et al. Supervised exercise training in patients with chronic thromboembolic pulmonary hypertension as early follow-up treatment after pulmonary endarterectomy: a prospective cohort study. Respiration 2020;99:577–588.
762. Bunclark K, Newnham M, Chiu YD, Ruggiero A, Villar SS, Cannon JE, et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2020;18:114–122.
763. Humbert MS, Simonneau G, Pittrow D, Delcroix M, Pepke-Zaba J, Langleben D,
et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2022;41:716–721.
764. Ordi-Ros
J,
Saez-Comet L, Perez-Conesa M, Vidal X, Riera-Mestre
A,
Castro-Salomo A, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019;171:
685–694.
765. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018;132:
1365–1371.
766. Hsieh WC, Jansa P, Huang WC, Niznansky M, Omara M, Lindner J. Residual pulmonary hypertension after pulmonary endarterectomy: a meta-analysis. J Thorac
Cardiovasc Surg 2018;156:1275–1287.
767. Madani MM, Auger WR, Pretorius V, Sakakibara N, Kerr KM, Kim NH, et al.
Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg 2012;94:97–103; discussion 103.
768. Lankeit M, Krieg V, Hobohm L, Kolmel S, Liebetrau C, Konstantinides S, et al.
Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension.
J Heart Lung Transplant 2018;37:250–258.
769. Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D’Armini AM, Snijder R, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation 2016;133:859–871.
770. Newnham M, Bunclark K, Abraham N, Ali S, Amaral-Almeida L, Cannon JE, et al.
CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. Eur Respir J
2020;56:1902096.
771. Vuylsteke A, Sharples L, Charman G, Kneeshaw J, Tsui S, Dunning J, et al.
Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial. Lancet 2011;378:1379–1387.
772. D’Armini AM, Morsolini M, Mattiucci G, Grazioli V, Pin M, Valentini A, et al.
Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2014;148:1005–1011.
773. Quadery SR, Swift AJ, Billings CG, Thompson AAR, Elliot CA, Hurdman J, et al. The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. Eur Respir J 2018;52:1800589.
774. Taboada D, Pepke-Zaba J, Jenkins DP, Berman M, Treacy CM, Cannon JE, et al.
Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J 2014;44:1635–1645.
775. Ghofrani HA, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al.
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
N Engl J Med 2013;369:319–329.
776. Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA, et al.
Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med 2019;7:239–248.
777. Ghofrani HA, Simonneau G, D’Armini AM, Fedullo P, Howard LS, Jais X, et al.
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised,
double-blind, placebo-controlled study. Lancet Respir Med 2017;5:785–794.
778. Jais X, D’Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension:
BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol
2008;52:2127–2134.
779. Reichenberger F, Voswinckel R, Enke B, Rutsch M, El Fechtali E, Schmehl T, et al.
Long-term treatment with sildenaﬁl in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007;30:922–927.
780. Guth S, D’Armini AM, Delcroix M, Nakayama K, Fadel E, Hoole SP, et al. Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Res 2021;7:00850–02020.
781. Brenot P, Jais X, Taniguchi Y, Garcia Alonso C, Gerardin B, Mussot S, et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J 2019;53:1802095.
782. Darocha S, Pietura R, Pietrasik A, Norwa J, Dobosiewicz A, Pilka M, et al.
Improvement in quality of life and hemodynamics in chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty. Circ J 2017;81:
552–557.
783. Fukui S, Ogo T, Morita Y, Tsuji A, Tateishi E, Ozaki K, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J 2014;43:1394–1402.
784. Kataoka M, Inami T, Hayashida K, Shimura N, Ishiguro H, Abe T, et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012;5:756–762.
785. Kriechbaum SD, Wiedenroth CB, Peters K, Barde MA, Ajnwojner R, Wolter JS,
et al. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension. Biomarkers 2020;25:578–586.
786. Kriechbaum SD, Scherwitz L, Wiedenroth CB, Rudolph F, Wolter JS, Haas M, et al.
Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH. ERJ Open Res 2020;6:00356-02020.
787. Lang I, Meyer BC, Ogo T, Matsubara H, Kurzyna M, Ghofrani HA, et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Eur
Respir Rev 2017;26:160119.
788. Mahmud E, Behnamfar O, Ang L, Patel MP, Poch D, Kim NH. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Interv Cardiol
Clin 2018;7:103–117.
789. Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H. Reﬁned balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012;5:748–755.
790. Ogawa A, Matsubara H. After the dawn-balloon pulmonary angioplasty for patients with chronic thromboembolic pulmonary hypertension. Circ J 2018;82:1222–1230.
791. Olsson KM, Wiedenroth CB, Kamp JC, Breithecker A, Fuge J, Krombach GA, et al.
Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J
2017;49:1602409.
792. Roller FC, Kriechbaum S, Breithecker A, Liebetrau C, Haas M, Schneider C, et al.
Correlation of native T1 mapping with right ventricular function and pulmonary
ESC/ERS Guidelines
3729


<!-- PAGE 113 -->

### Page 113

haemodynamics in patients with chronic thromboembolic pulmonary hypertension before and after balloon pulmonary angioplasty. Eur Radiol 2019;29:1565–1573.
793. Sugimura K, Fukumoto Y, Satoh K, Nochioka K, Miura Y, Aoki T, et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 2012;76:485–488.
794. Ogawa A, Satoh T, Fukuda T, Sugimura K, Fukumoto Y, Emoto N, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: results of a multicenter registry. Circ Cardiovasc Qual Outcomes 2017;10:e004029.
795. Inami T, Kataoka M, Yanagisawa R, Ishiguro H, Shimura N, Fukuda K, et al.
Long-term outcomes after percutaneous transluminal pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.
Circulation
2016;134:
2030–2032.
796. Ejiri K, Ogawa A, Fujii S, Ito H, Matsubara H. Vascular injury is a major cause of lung injury after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2018;11:e005884.
797. Shimokawahara H, Ogawa A, Mizoguchi H, Yagi H, Ikemiyagi H, Matsubara H.
Vessel stretching is a cause of lumen enlargement immediately after balloon pulmonary angioplasty: intravascular ultrasound analysis in patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2018;11:e006010.
798. Jaïs X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med
2022. doi:10.1016/S2213-2600(22)00214-4.
799. Wiedenroth CB, Olsson KM, Guth S, Breithecker A, Haas M, Kamp JC, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. Pulm Circ 2018;8:2045893217753122.
800. Romanov A, Cherniavskiy A, Novikova N, Edemskiy A, Ponomarev D, Shabanov V,
et al. Pulmonary artery denervation for patients with residual pulmonary hypertension after pulmonary endarterectomy. J Am Coll Cardiol 2020;76:916–926.
801. Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, et al.
Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 2004;23:595–600.
802. Nagaya N, Sasaki N, Ando M, Ogino H, Sakamaki F, Kyotani S, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003;123:338–343.
803. Reesink HJ, Surie S, Kloek JJ, Tan HL, Tepaske R, Fedullo PF, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2010;139:85–91.
804. Araszkiewicz A, Darocha S, Pietrasik A, Pietura R, Jankiewicz S, Banaszkiewicz M,
et al. Balloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol 2019;278:
232–237.
805. Shimura N, Kataoka M, Inami T, Yanagisawa R, Ishiguro H, Kawakami T, et al.
Additional percutaneous transluminal pulmonary angioplasty for residual or recurrent pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol 2015;
183:138–142.
806. Cannon JE, Su L, Kiely DG, Page K, Toshner M, Swietlik E, et al. Dynamic risk stratiﬁcation of patient long-term outcome after pulmonary endarterectomy: results
From the UK National Cohort. Circulation 2016;133:1761–1771.
807. Wiedenroth CB, Liebetrau C, Breithecker A, Guth S, Lautze HJ, Ortmann E, et al.
Combined pulmonary endarterectomy and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. J Heart Lung
Transplant 2016;35:591–596.
808. Delcroix M, Staehler G, Gall H, Grunig E, Held M, Halank M, et al. Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. Eur
Respir J 2018;52:1800248.
809. Benza RL, Farber HW, Frost A, Grunig E, Hoeper MM, Busse D, et al. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. J Heart Lung Transplant 2018;37:836–843.
810. Mayer E, Jenkins D, Lindner J, D’Armini A, Kloek J, Meyns B, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg
2011;141:702–710.
811. Andreassen AK, Ragnarsson A, Gude E, Geiran O, Andersen R. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart 2013;99:1415–1420.
812. Wiedenroth CB, Ghofrani HA, Adameit MSD, Breithecker A, Haas M, Kriechbaum
S, et al. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulm
Circ 2018;8:2045894018783996.
813. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA 2012;307:1254–1256.
814. Savale L, Habibi A, Lionnet F, Maitre B, Cottin V, Jais X, et al. Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. Eur
Respir J 2019;54:1900585.
815. Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, et al.
Hospitalization for pain in patients with sickle cell disease treated with sildenaﬁl for elevated TRV and low exercise capacity. Blood 2011;118:855–864.
816. Turpin M, Chantalat-Auger C, Parent F, Driss F, Lionnet F, Habibi A, et al. Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. Eur Respir J 2018;52:1800272.
817. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J
Med 2004;350:886–895.
818. Derchi G, Galanello R, Bina P, Cappellini MD, Piga A, Lai ME, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of beta-thalassemia patients using right heart catheterization: a Webthal study. Circulation 2014;129:
338–345.
819. Jais X, Ioos V, Jardim C, Sitbon O, Parent F, Hamid A, et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 2005;60:1031–1034.
820. Adir Y, Humbert M. Pulmonary hypertension in patients with chronic myeloproliferative disorders. Eur Respir J 2010;35:1396–1406.
821. Takanashi S, Akiyama M, Suzuki K, Otomo K, Takeuchi T. IgG4-related ﬁbrosing mediastinitis diagnosed with computed tomography-guided percutaneous needle biopsy: two case reports and a review of the literature. Medicine 2018;97:e10935.
822. Montani D, Achouh L, Marcelin AG, Viard JP, Hermine O, Canioni D, et al.
Reversibility of pulmonary arterial hypertension in
HIV/HHV8-associated
Castleman’s disease. Eur Respir J 2005;26:969–972.
823. Jouve P, Humbert M, Chauveheid MP, Jais X, Papo T. POEMS syndrome-related pulmonary hypertension is steroid-responsive. Respir Med 2007;101:353–355.
824. Savale L, Huitema M, Shlobin O, Kouranos V, Nathan SD, Nunes H, et al. WASOG
statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. Eur Respir Rev 2022;31:210165.
825. Bandyopadhyay D, Humbert M. An update on sarcoidosis-associated pulmonary hypertension. Curr Opin Pulm Med 2020;26:582–590.
826. Baughman RP, Shlobin OA, Gupta R, Engel PJ, Stewart JI, Lower EE, et al. Riociguat for sarcoidosis-associated pulmonary hypertension: results of a 1-year doubleblind, placebo-controlled trial. Chest 2022;161:448–457.
827. Le Pavec J, Lorillon G, Jais X, Tcherakian C, Feuillet S, Dorfmuller P, et al. Pulmonary
Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012;142:
1150–1157.
828. Jutant EM, Jais X, Girerd B, Savale L, Ghigna MR, Perros F, et al. Phenotype and outcomes of pulmonary hypertension associated with neuroﬁbromatosis type 1. Am J
Respir Crit Care Med 2020;202:843–852.
829. Oliveros, E, Vaidya, A. Metabolic disorders of pulmonary hypertension. Adv Pulm
Hypertens 2021;20:35–39.
830. Humbert M, Labrune P, Simonneau G. Severe pulmonary arterial hypertension in type 1 glycogen storage disease. Eur J Pediatr 2002;161:S93–S96.
831. Kawar B, Ellam T, Jackson C, Kiely DG. Pulmonary hypertension in renal disease:
epidemiology, potential mechanisms and implications. Am J Nephrol 2013;37:
281–290.
832. Edmonston DL, Parikh KS, Rajagopal S, Shaw LK, Abraham D, Grabner A, et al.
Pulmonary hypertension subtypes and mortality in CKD. Am J Kidney Dis 2020;
75:713–724.
833. Pabst S, Hammerstingl C, Hundt F, Gerhardt T, Grohe C, Nickenig G, et al.
Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. PLoS One 2012;7:e35310.
834. Price LC, Seckl MJ, Dorfmuller P, Wort SJ. Tumoral pulmonary hypertension. Eur
Respir Rev 2019;28:180065.
835. Seferian A, Steriade A, Jais X, Planche O, Savale L, Parent F, et al. Pulmonary hypertension complicating ﬁbrosing mediastinitis. Medicine 2015;94:e1800.
836. Baughman RP, Culver DA, Cordova FC, Padilla M, Gibson KF, Lower EE, et al.
Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 2014;145:810–817.
837. Humbert MG, Galié N, Meszaros G. Competency requirements for ERN-lung
PH centres. https://ern-lung.eu/inhalt/wp-content/uploads/2020/10/PH-MCC.pdf.
(24 June 2022, date last accessed 22 July 2022).
838. Doyle-Cox C, Nicholson G, Stewart T, Gin-Sing W. Current organization of specialist pulmonary hypertension clinics: results of an international survey. Pulm Circ
2019;9:2045894019855611.
839. Saunders H, Helgeson SA, Abdelrahim A, Rottman-Pietrzak K, Reams V, Zeiger TK,
et al. Comparing diagnosis and treatment of pulmonary hypertension patients at a pulmonary hypertension center versus community centers. Diseases 2022;10:5.
840. European Reference Network. Clinical Patient Management System (CPMS).
https://ern-euro-nmd.eu/clinical-patient-management-system/ (24 March 2022,
date last accessed 22 July 2022).
3730
ESC/ERS Guidelines


<!-- PAGE 114 -->

### Page 114

841. ERS. Continuing Professional Development - Pulmonary Vascular Diseases. https://
www.ersnet.org/wp-content/uploads/2021/02/Continuing-professional-developmentPulmonary-Vascular-Diseases.pdf (24 March 2022, date last accessed 22 July 2022).
842. Tanner FC, Brooks N, Fox KF, Goncalves L, Kearney P, Michalis L, et al. ESC core curriculum for the cardiologist. Eur Heart J 2020;41:3605–3692.
843. Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al.
Advanced heart failure: a position statement of the Heart Failure Association of the
European Society of Cardiology. Eur J Heart Fail 2018;20:1505–1535.
844. Google Maps. ERN-LUNG reference centres. https://www.google.com/maps/d/
viewer?mid=1VVJW2YWYN1q6NYMWPdk78nltgTOptt4C&ll=50.
878853000000014%2C4.6743529999999955&z=8 (24 March 2022, date last accessed 22 July 2022).
845. Giri PC, Stevens GJ, Merrill-Henry J, Oyoyo U, Balasubramanian VP. Participation in pulmonary hypertension support group improves patient-reported health quality outcomes: a patient and caregiver survey. Pulm Circ 2021;11:20458940211013258.
846. Biganzoli L, Cardoso F, Beishon M, Cameron D, Cataliotti L, Coles CE, et al. The requirements of a specialist breast centre. Breast 2020;51:65–84.
847. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, et al. European Society of Cardiology methodology for the development of quality indicators for the quantiﬁcation of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes
2022;8:4–13.
848. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the UK
after removal of ﬁnancial incentives. N Engl J Med 2018;379:948–957.
849. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality
8 years into global payment. N Engl J Med 2019;381:252–263.
850. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, et al. Quality indicators for the care and outcomes of adults with atrial ﬁbrillation. Europace 2021;23:
494–495.
851. Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet JP, et al. 2020 Update of the quality indicators for acute myocardial infarction: a position paper of the
Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group. Eur Heart J Acute Cardiovasc
Care 2021;10:224–233.
852. Aktaa S, Abdin A, Arbelo E, Burri H, Vernooy K, Blomstrom-Lundqvist C, et al.
European Society of Cardiology quality indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality
Indicators in collaboration with the European Heart Rhythm Association of the
European Society of Cardiology. Europace 2022;24:165–172.
853. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.
Heart J 2021;42:3427–3520.
854. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, et al. 2020
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:
1289–1367.
855. Batra G, Aktaa S, Wallentin L, Maggioni AP, Wilkinson C, Casadei B, et al.
Methodology for the development of international clinical data standards for common cardiovascular conditions: European Uniﬁed Registries for Heart Care
Evaluation and Randomised Trials (EuroHeart). Eur Heart J Qual Care Clin
Outcomes 2021. doi:10.1093/ehjqcco/qcab052. Epub ahead of print.
ESC/ERS Guidelines
3731

<!-- 2022_Ventricular_Arrhythmias_SCD.md -->

# ESC Guidelines: Ventricular Arrhythmias SCD (2022)

**Source**: `2022_Ventricular_Arrhythmias_SCD.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 130

---

## Table of Contents

- [2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death](#2022-esc-guidelines-for-the-management-of-patients) *(p. 1)*
  - [Abbreviations and acronyms](#abbreviations-and-acronyms) *(p. 6)*
  - [1. Preamble](#1-preamble) *(p. 7)*
  - [2. Introduction](#2-introduction) *(p. 9)*
    - [2.1. What is new](#21-what-is-new) *(p. 9)*
  - [3. Definitions](#3-definitions) *(p. 15)*
    - [3.1. Ventricular arrhythmia subtypes](#31-ventricular-arrhythmia-subtypes) *(p. 15)*
    - [3.2. Sudden cardiac death](#32-sudden-cardiac-death) *(p. 15)*
    - [3.3. Syncope](#33-syncope) *(p. 15)*
    - [3.4. Specialized centres](#34-specialized-centres) *(p. 15)*
    - [3.5. Genetics](#35-genetics) *(p. 15)*
  - [4. Epidemiology of sudden cardiac death, public awareness, and risk stratification](#4-epidemiology-of-sudden-cardiac-death,-public-awa) *(p. 15)*
    - [4.1. Incidence of sudden cardiac death](#41-incidence-of-sudden-cardiac-death) *(p. 15)*
    - [4.2. Causes of sudden cardiac death in different age groups](#42-causes-of-sudden-cardiac-death-in-different-age) *(p. 16)*
    - [4.3. Population vs. individual risk prediction](#43-population-vs-individual-risk-prediction) *(p. 16)*
    - [4.4. Risk calculators for sudden cardiac death and review of the methodology](#44-risk-calculators-for-sudden-cardiac-death-and-r) *(p. 16)*
    - [4.5. Awareness and intervention: public basic life support, and access to automated external defibrillators](#45-awareness-and-intervention:-public-basic-life-s) *(p. 16)*
  - [5. Evaluation and treatment. General aspects](#5-evaluation-and-treatment-general-aspects) *(p. 18)*
    - [5.1. Diagnostic tools](#51-diagnostic-tools) *(p. 18)*
      - [5.1.1. History and physical examination](#511-history-and-physical-examination) *(p. 18)*
      - [5.1.2. Laboratory testing](#512-laboratory-testing) *(p. 18)*
      - [5.1.3. Non-invasive and invasive tests](#513-non-invasive-and-invasive-tests) *(p. 18)*
        - [5.1.3.1. Electrocardiogram and ambulatory electrocardiographic monitoring2](#5131-electrocardiogram-and-ambulatory-electrocardi) *(p. 18)*
        - [5.1.3.2. Signal-averaged electrocardiogram](#5132-signal-averaged-electrocardiogram) *(p. 18)*
        - [5.1.3.3. Exercise testing](#5133-exercise-testing) *(p. 18)*
        - [5.1.3.4. Imaging](#5134-imaging) *(p. 18)*
        - [5.1.3.5. Provocative diagnostic tests](#5135-provocative-diagnostic-tests) *(p. 19)*
        - [5.1.3.6. Electrophysiological study](#5136-electrophysiological-study) *(p. 19)*
      - [5.1.4. Genetic testing](#514-genetic-testing) *(p. 19)*
    - [5.2. Diagnostic evaluation at first presentation with ventricular arrhythmia in patients without known cardiac disease](#52-diagnostic-evaluation-at-first-presentation-wit) *(p. 22)*
      - [5.2.1. Scenario 1: Incidental finding of a non-sustained ventricular tachycardia](#521-scenario-1:-incidental-finding-of-a-non-sustai) *(p. 22)*
      - [5.2.2. Scenario 2: First presentation of sustained monomorphic ventricular tachycardia](#522-scenario-2:-first-presentation-of-sustained-mo) *(p. 22)*
      - [5.2.3. Scenario 3: Sudden cardiac arrest survivor](#523-scenario-3:-sudden-cardiac-arrest-survivor) *(p. 24)*
      - [5.2.4. Scenario 4: Sudden death victim](#524-scenario-4:-sudden-death-victim) *(p. 27)*
      - [5.2.5. Scenario 5: Relatives of sudden arrhythmic death syndrome decedents](#525-scenario-5:-relatives-of-sudden-arrhythmic-dea) *(p. 28)*
  - [6. Therapies for ventricular arrhythmias. General aspects](#6-therapies-for-ventricular-arrhythmias-general-as) *(p. 31)*
    - [6.1. Acute management](#61-acute-management) *(p. 31)*
      - [6.1.1. Treatment of reversible causes](#611-treatment-of-reversible-causes) *(p. 31)*
      - [6.1.2. Acute management of sustained monomorphic ventricular tachycardia](#612-acute-management-of-sustained-monomorphic-vent) *(p. 33)*
      - [6.1.3. Management of electrical storm and incessant ventricular tachycardia](#613-management-of-electrical-storm-and-incessant-v) *(p. 34)*
    - [6.2. Long-term management](#62-long-term-management) *(p. 38)*
      - [6.2.1. Pharmacotherapy](#621-pharmacotherapy) *(p. 38)*
      - [6.2.2. Device therapy](#622-device-therapy) *(p. 42)*
        - [6.2.2.1. Implantable cardioverter defibrillator](#6221-implantable-cardioverter-defibrillator) *(p. 42)*
        - [6.2.2.2. Adding cardiac resynchronization therapy2](#6222-adding-cardiac-resynchronization-therapy2) *(p. 44)*
        - [6.2.2.3. Wearable cardioverter defibrillator](#6223-wearable-cardioverter-defibrillator) *(p. 44)*
      - [6.2.3. Special aspects of device therapy](#623-special-aspects-of-device-therapy) *(p. 45)*
        - [6.2.3.1. Optimization of device programming](#6231-optimization-of-device-programming) *(p. 45)*
        - [6.2.3.2. Concomitant treatment to avoid inappropriate implantable cardioverter defibrillator therapy](#6232-concomitant-treatment-to-avoid-inappropriate-) *(p. 45)*
        - [6.2.3.3. Psychosocial impact of implantable cardioverter defibrillator treatment](#6233-psychosocial-impact-of-implantable-cardiovert) *(p. 46)*
        - [6.2.3.4. Patients with left ventricular assist devices](#6234-patients-with-left-ventricular-assist-devices) *(p. 46)*
        - [6.2.3.5. Complications of devices](#6235-complications-of-devices) *(p. 46)*
        - [6.2.3.6. End-of-life issues](#6236-end-of-life-issues) *(p. 47)*
      - [6.2.4. Interventional therapy](#624-interventional-therapy) *(p. 47)*
        - [6.2.4.1. Catheter ablation](#6241-catheter-ablation) *(p. 47)*
          - [6.2.4.1.1. Patients with structural heart disease](#62411-patients-with-structural-heart-disease) *(p. 47)*
          - [6.2.4.1.2. Patients without apparent structural heart disease](#62412-patients-without-apparent-structural-heart-d) *(p. 48)*
        - [6.2.4.2. Autonomic modulation](#6242-autonomic-modulation) *(p. 48)*
  - [7. Diagnostic evaluation, management, and risk stratification according to clinical presentation and known (likely) disease](#7-diagnostic-evaluation,-management,-and-risk-stra) *(p. 48)*
    - [7.1. Specific structural heart diseases](#71-specific-structural-heart-diseases) *(p. 48)*
      - [7.1.1. Coronary artery disease](#711-coronary-artery-disease) *(p. 48)*
        - [7.1.1.1. Acute coronary syndromes and vasospasm](#7111-acute-coronary-syndromes-and-vasospasm) *(p. 48)*
          - [7.1.1.1.1. Acute coronary syndromes](#71111-acute-coronary-syndromes) *(p. 48)*
          - [7.1.1.1.2. Vasospasm](#71112-vasospasm) *(p. 49)*
        - [7.1.1.2. Early after myocardial infarction](#7112-early-after-myocardial-infarction) *(p. 50)*
        - [7.1.1.3. Chronic coronary artery disease](#7113-chronic-coronary-artery-disease) *(p. 50)*
          - [7.1.1.3.1. Primary prevention of sudden cardiac death in patients with reduced ejection fraction](#71131-primary-prevention-of-sudden-cardiac-death-i) *(p. 50)*
          - [7.1.1.3.2. Primary prevention of sudden cardiac death in patients with preserved or mildly reduced ejection fraction](#71132-primary-prevention-of-sudden-cardiac-death-i) *(p. 51)*
          - [7.1.1.3.3. Secondary prevention of sudden cardiac death](#71133-secondary-prevention-of-sudden-cardiac-death) *(p. 51)*
          - [7.1.1.3.4. Management of patients with haemodynamically tolerated ventricular tachycardia and preserved and mildly reduced ejection fraction](#71134-management-of-patients-with-haemodynamically) *(p. 52)*
          - [7.1.1.3.5. Management of recurrent ventricular tachycardia in implantable cardioverter defibrillator carriers](#71135-management-of-recurrent-ventricular-tachycar) *(p. 53)*
        - [7.1.1.4. Coronary anomalies](#7114-coronary-anomalies) *(p. 53)*
      - [7.1.2. Idiopathic premature ventricular complexes/ventricular tachycardia and premature ventricular complex-induced cardiomyopathy](#712-idiopathic-premature-ventricular-complexes/ven) *(p. 54)*
        - [7.1.2.1. Idiopathic premature ventricular complexes/ventricular tachycardia](#7121-idiopathic-premature-ventricular-complexes/ve) *(p. 54)*
        - [7.1.2.2. Premature ventricular complex-induced/-aggravated cardiomyopathy](#7122-premature-ventricular-complex-induced/-aggrav) *(p. 56)*
      - [7.1.3. Cardiomyopathies](#713-cardiomyopathies) *(p. 58)*
        - [7.1.3.1. Dilated cardiomyopathy and hypokinetic non-dilated cardiomyopathy](#7131-dilated-cardiomyopathy-and-hypokinetic-non-di) *(p. 58)*
          - [7.1.3.1.1. Diagnostic evaluation and risk stratification](#71311-diagnostic-evaluation-and-risk-stratificatio) *(p. 58)*
          - [7.1.3.1.2. Primary prevention of sudden cardiac death](#71312-primary-prevention-of-sudden-cardiac-death) *(p. 59)*
          - [7.1.3.1.3. Secondary prevention of sudden cardiac death and management of ventricular arrhythmias](#71313-secondary-prevention-of-sudden-cardiac-death) *(p. 61)*
        - [7.1.3.2. Arrhythmogenic right ventricular cardiomyopathy](#7132-arrhythmogenic-right-ventricular-cardiomyopat) *(p. 62)*
          - [7.1.3.2.1. Risk stratification](#71321-risk-stratification) *(p. 62)*
          - [7.1.3.2.2. Treatment](#71322-treatment) *(p. 64)*
        - [7.1.3.3. Hypertrophic cardiomyopathy](#7133-hypertrophic-cardiomyopathy) *(p. 64)*
          - [7.1.3.3.1. Risk stratification and primary prevention of sudden cardiac death](#71331-risk-stratification-and-primary-prevention-o) *(p. 65)*
          - [7.1.3.3.2. Treatment to prevent ventricular arrhythmia recurrence](#71332-treatment-to-prevent-ventricular-arrhythmia-) *(p. 66)*
        - [7.1.3.4. Left ventricular non-compaction](#7134-left-ventricular-non-compaction) *(p. 67)*
        - [7.1.3.5. Restrictive cardiomyopathy](#7135-restrictive-cardiomyopathy) *(p. 67)*
        - [7.1.3.6. Neuromuscular disorders](#7136-neuromuscular-disorders) *(p. 67)*
      - [7.1.4. Inflammatory cardiac diseases](#714-inflammatory-cardiac-diseases) *(p. 70)*
        - [7.1.4.1. Myocarditis](#7141-myocarditis) *(p. 70)*
        - [7.1.4.2. Cardiac sarcoidosis](#7142-cardiac-sarcoidosis) *(p. 71)*
        - [7.1.4.3. Chagas’ cardiomyopathy](#7143-chagas’-cardiomyopathy) *(p. 72)*
      - [7.1.5. Valvular heart disease](#715-valvular-heart-disease) *(p. 74)*
      - [7.1.6. Congenital heart disease](#716-congenital-heart-disease) *(p. 75)*
    - [7.2. Primary electrical disease](#72-primary-electrical-disease) *(p. 77)*
      - [7.2.1. Idiopathic ventricular fibrillation](#721-idiopathic-ventricular-fibrillation) *(p. 77)*
      - [7.2.2. Long QT syndrome (including acquired long QT syndrome)](#722-long-qt-syndrome-(including-acquired-long-qt-s) *(p. 78)*
      - [7.2.3. Andersen–Tawil syndrome Type 1](#723-andersen–tawil-syndrome-type-1) *(p. 83)*
      - [7.2.4. Brugada syndrome](#724-brugada-syndrome) *(p. 83)*
      - [7.2.5. Early repolarization syndromes](#725-early-repolarization-syndromes) *(p. 85)*
      - [7.2.6. Catecholaminergic polymorphic ventricular tachycardia](#726-catecholaminergic-polymorphic-ventricular-tach) *(p. 88)*
      - [7.2.7. Short QT syndrome](#727-short-qt-syndrome) *(p. 90)*
  - [8. Special aspects in selected populations](#8-special-aspects-in-selected-populations) *(p. 92)*
    - [8.1. Pregnant patients and peri-partum cardiomyopathy](#81-pregnant-patients-and-peri-partum-cardiomyopath) *(p. 92)*
      - [8.1.1. Electrocardioversion and implantable cardioverter defibrillator therapy in pregnancy](#811-electrocardioversion-and-implantable-cardiover) *(p. 92)*
      - [8.1.2. Pharmacological treatment](#812-pharmacological-treatment) *(p. 92)*
      - [8.1.3. Catheter ablation](#813-catheter-ablation) *(p. 92)*
    - [8.2. Heart transplantation](#82-heart-transplantation) *(p. 93)*
    - [8.3. Sudden cardiac death in athletes](#83-sudden-cardiac-death-in-athletes) *(p. 93)*
    - [8.4. Wolff–Parkinson–White syndrome](#84-wolff–parkinson–white-syndrome) *(p. 94)*
    - [8.5. Prevention of sudden cardiac death in the elderly](#85-prevention-of-sudden-cardiac-death-in-the-elder) *(p. 94)*
  - [9. Key messages](#9-key-messages) *(p. 94)*
    - [9.1. General aspects](#91-general-aspects) *(p. 94)*
    - [9.2. Structural heart disease](#92-structural-heart-disease) *(p. 94)*
    - [9.3. Primary electrical disease](#93-primary-electrical-disease) *(p. 95)*
  - [10. Gaps in evidence](#10-gaps-in-evidence) *(p. 95)*
    - [10.1. General aspects](#101-general-aspects) *(p. 95)*
    - [10.2. Structural heart disease—general](#102-structural-heart-disease—general) *(p. 95)*
    - [10.3. Idiopathic premature ventricular complexes/ventricular tachycardia](#103-idiopathic-premature-ventricular-complexes/ven) *(p. 95)*
    - [10.4. Coronary artery disease](#104-coronary-artery-disease) *(p. 95)*
    - [10.5. Cardiomyopathies](#105-cardiomyopathies) *(p. 95)*
    - [10.6. Valvular heart disease](#106-valvular-heart-disease) *(p. 95)*
    - [10.7. Congenital heart disease](#107-congenital-heart-disease) *(p. 95)*
    - [10.8. Primary electrical disease](#108-primary-electrical-disease) *(p. 95)*
  - [11. ‘What to do’ and ‘what not to do’ messages from the Guidelines](#11-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 96)*
  - [12. Quality indicators](#12-quality-indicators) *(p. 103)*
  - [13. Supplementary data](#13-supplementary-data) *(p. 103)*
  - [14. Data availability statement](#14-data-availability-statement) *(p. 103)*
  - [15. Author information](#15-author-information) *(p. 103)*
  - [Appendix](#appendix) *(p. 104)*
  - [References](#references) *(p. 105)*
  - [References](#references) *(p. 105)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC)
Endorsed by the Association for European Paediatric and
Congenital Cardiology (AEPC)
Authors/Task Force Members: Katja Zeppenfeld*† (Chairperson) (Netherlands),
Jacob Tfelt-Hansen
*† (Chairperson) (Denmark), Marta de Riva** (Task Force
Coordinator) (Netherlands), Bo Gregers Winkel** (Task Force Coordinator)
(Denmark), Elijah R. Behr (United Kingdom), Nico A. Blom1 (Netherlands),
Philippe Charron (France), Domenico Corrado (Italy), Nikolaos Dagres
(Germany), Christian de Chillou (France), Lars Eckardt (Germany), Tim Friede
(Germany), Kristina H. Haugaa (Norway), Mélèze Hocini (France), Pier
D. Lambiase (United Kingdom), Eloi Marijon (France), Jose L. Merino (Spain),
Petr Peichl (Czech Republic), Silvia G. Priori (Italy), Tobias Reichlin (Switzerland),
Jeanette Schulz-Menger (Germany), Christian Sticherling (Switzerland),
Stylianos Tzeis (Greece), Axel Verstrael (Belgium), Maurizio Volterrani (Italy),
and ESC Scientiﬁc Document Group
*Corresponding authors: Katja Zeppenfeld, Department of Cardiology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, Netherlands. Tel +31 715262020, E-mail:
K.Zeppenfeld@LUMC.nl
Jacob Tfelt-Hansen, The Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark. Tel +45 61360399,
E-mail: jacob.tfelt@regionh.dk
†The two chairpersons contributed equally to the document and are joint corresponding authors.
**The two task force Coordinators contributed equally to the document.
Author/task force Member afﬁliations are listed in Author information.
1Representing the Association for European Paediatric and Congenital Cardiology (AEPC).
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular
Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Working Groups: Cardiac Cellular Electrophysiology, Myocardial and Pericardial Diseases.
Patient Forum
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University
Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (Journals.Permissions@oup.com).
https://doi.org/10.1093/eurheartj/ehac262
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document-Reviewers: Maja Cikes (CPG Review Coordinator) (Croatia), Paulus Kirchhof (CPG Review
Coordinator) (Germany), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Elena Arbelo (Spain),
Fernando Arribas (Spain), Riccardo Asteggiano (Italy), Cristina Basso (Italy), Axel Bauer (Austria),
Emanuele Bertaglia (Italy), Tor Biering-Sørensen (Denmark), Carina Blomström-Lundqvist (Sweden),
Michael A. Borger (Germany), Jelena Čelutkienė (Lithuania), Bernard Cosyns (Belgium), Volkmar Falk
(Germany), Laurent Fauchier (France), Bulent Gorenek (Turkey), Sigrun Halvorsen (Norway), Robert Hatala
(Slovakia), Hein Heidbuchel (Belgium), Stefan Kaab (Germany), Aleksandra Konradi (Russian Federation),
Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany),
Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Lars H. Lund (Sweden),
Andreas Metzner (Germany), Richard Mindham (United Kingdom), Jens Cosedis Nielsen (Denmark),
Tone M. Norekvål (Norway), Monica Patten (Germany), Eva Prescott (Denmark), Amina Rakisheva
(Kazakhstan), Carol Ann Remme (Netherlands), Ivo Roca-Luque (Spain), Andrea Sarkozy (Belgium),
Daniel Scherr (Austria), Marta Sitges (Spain), Rhian M. Touyz (Canada/United Kingdom), Nicolas Van Mieghem
(Netherlands), Vedran Velagic (Croatia), Sami Viskin (Israel), and Paul G. A. Volders (Netherlands)
All experts involved in the development of these guidelines have submitted declarations of interest. These have been compiled in a report and published in a supplementary document simultaneously to the guidelines. The report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary data that includes background information and detailed discussion of the data that have provided the basis of the guidelines.
Click here to access the corresponding ESC CardioMed chapters.
Keywords
Guidelines • Anti-arrhythmic drugs • Cardiac magnetic resonance • Cardiomyopathies • Catheter ablation •
Chronic coronary artery disease • Genetic testing • Implantable cardioverter deﬁbrillator • Premature ventricular complex • Primary electrical disease • Recommendations • Risk calculator • Risk stratiﬁcation • Sudden cardiac death • Sudden death • Ventricular arrhythmia • Ventricular ﬁbrillation • Ventricular tachycardia
Table of contents
1. Preamble ........................................................................................................
4003
2. Introduction .................................................................................................
4005
2.1. What is new ........................................................................................ 4005
3. Deﬁnitions .....................................................................................................
4011
3.1. Ventricular arrhythmia subtypes ................................................ 4011
3.2. Sudden cardiac death ....................................................................... 4011
3.3. Syncope ................................................................................................. 4011
3.4. Specialized centres ............................................................................ 4011
3.5. Genetics ................................................................................................. 4011
4. Epidemiology of sudden cardiac death, public awareness, and risk stratiﬁcation ..............................................................................................
4011
4.1. Incidence of sudden cardiac death ............................................. 4011
4.2. Causes of sudden cardiac death in different age groups . 4012
4.3. Population vs. individual risk prediction .................................. 4012
4.4. Risk calculators for sudden cardiac death and review of the methodology ................................................................................................ 4012
4.5. Awareness and intervention: public basic life support, and access to automated external deﬁbrillators ................................... 4012
5. Evaluation and treatment. General aspects ....................................
4014
5.1. Diagnostic tools ................................................................................. 4014
5.1.1. History and physical examination ......................................
4014
5.1.2. Laboratory testing ....................................................................
4014
5.1.3. Non-invasive and invasive tests ..........................................
4014
5.1.3.1. Electrocardiogram and ambulatory electrocardiographic monitoring ................................................ 4014
5.1.3.2. Signal-averaged electrocardiogram ............................ 4014
5.1.3.3. Exercise testing .................................................................. 4014
5.1.3.4. Imaging ................................................................................... 4014
5.1.3.5. Provocative diagnostic tests ......................................... 4015
5.1.3.6. Electrophysiological study ............................................. 4015
Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the
ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
© The European Society of Cardiology 2022. All rights reserved. For permissions please e-mail: Journals.Permissions@oup.com


<!-- PAGE 3 -->

### Page 3

5.1.4. Genetic testing ...........................................................................
4015
5.2. Diagnostic evaluation at ﬁrst presentation with ventricular arrhythmia in patients without known cardiac disease .................................................................................................... 4018
5.2.1. Scenario 1: Incidental ﬁnding of a non-sustained ventricular tachycardia ........................................................................
4018
5.2.2. Scenario 2: First presentation of sustained monomorphic ventricular tachycardia .........................................
4018
5.2.3. Scenario 3: Sudden cardiac arrest survivor ...................
4020
5.2.4. Scenario 4: Sudden death victim ........................................
4023
5.2.5. Scenario 5: Relatives of sudden arrhythmic death syndrome decedents ...........................................................................
4024
6. Therapies for ventricular arrhythmias. General aspects ...........
4027
6.1. Acute management .......................................................................... 4027
6.1.1. Treatment of reversible causes ..........................................
4027
6.1.2. Acute management of sustained monomorphic ventricular tachycardia ........................................................................
4029
6.1.3. Management of electrical storm and incessant ventricular tachycardia ........................................................................
4030
6.2. Long-term management ................................................................. 4034
6.2.1. Pharmacotherapy ......................................................................
4034
6.2.2. Device therapy ...........................................................................
4038
6.2.2.1. Implantable cardioverter deﬁbrillator ....................... 4038
6.2.2.2. Adding cardiac resynchronization therapy ............. 4040
6.2.2.3. Wearable cardioverter deﬁbrillator .......................... 4040
6.2.3. Special aspects of device therapy ......................................
4041
6.2.3.1. Optimization of device programming ...................... 4041
6.2.3.2. Concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy ..................... 4041
6.2.3.3. Psychosocial impact of implantable cardioverter deﬁbrillator treatment .................................................................... 4042
6.2.3.4. Patients with left ventricular assist devices ............ 4042
6.2.3.5. Complications of devices ............................................... 4042
6.2.3.6. End-of-life issues ................................................................ 4043
6.2.4. Interventional therapy ............................................................
4043
6.2.4.1. Catheter ablation .............................................................. 4043
6.2.4.1.1. Patients with structural heart disease ............. 4043
6.2.4.1.2. Patients without apparent structural heart disease ............................................................................................... 4044
6.2.4.2. Autonomic modulation .................................................. 4044
7. Diagnostic evaluation, management, and risk stratiﬁcation according to clinical presentation and known (likely)
disease ..................................................................................................................
4044
7.1. Speciﬁc structural heart diseases ................................................ 4044
7.1.1. Coronary artery disease ........................................................
4044
7.1.1.1. Acute coronary syndromes and vasospasm .......... 4044
7.1.1.1.1. Acute coronary syndromes ................................. 4044
7.1.1.1.2. Vasospasm ................................................................... 4045
7.1.1.2. Early after myocardial infarction ................................. 4046
7.1.1.3. Chronic coronary artery disease ................................ 4046
7.1.1.3.1. Primary prevention of sudden cardiac death in patients with reduced ejection fraction ............................. 4046
7.1.1.3.2. Primary prevention of sudden cardiac death in patients with preserved or mildly reduced ejection fraction ............................................................................................. 4047
7.1.1.3.3. Secondary prevention of sudden cardiac death .................................................................................................. 4047
7.1.1.3.4. Management of patients with haemodynamically tolerated ventricular tachycardia and preserved and mildly reduced ejection fraction ............. 4048
7.1.1.3.5. Management of recurrent ventricular tachycardia in implantable cardioverter deﬁbrillator carriers .............................................................................................. 4049
7.1.1.4. Coronary anomalies ......................................................... 4049
7.1.2. Idiopathic premature ventricular complexes/
ventricular tachycardia and premature ventricular complexinduced cardiomyopathy ...................................................................
4050
7.1.2.1. Idiopathic premature ventricular complexes/
ventricular tachycardia .................................................................... 4050
7.1.2.2. Premature ventricular complex-induced/-
aggravated cardiomyopathy .......................................................... 4052
7.1.3. Cardiomyopathies ....................................................................
4054
7.1.3.1. Dilated cardiomyopathy and hypokinetic nondilated cardiomyopathy .................................................................. 4054
7.1.3.1.1. Diagnostic evaluation and risk stratiﬁcation .. 4054
7.1.3.1.2. Primary prevention of sudden cardiac death
4055
7.1.3.1.3. Secondary prevention of sudden cardiac death and management of ventricular arrhythmias ................... 4057
7.1.3.2. Arrhythmogenic right ventricular cardiomyopathy ................................................................................. 4058
7.1.3.2.1. Risk stratiﬁcation ....................................................... 4058
7.1.3.2.2. Treatment .................................................................... 4060
7.1.3.3. Hypertrophic cardiomyopathy .................................... 4060
7.1.3.3.1. Risk stratiﬁcation and primary prevention of sudden cardiac death .................................................................. 4061
7.1.3.3.2. Treatment to prevent ventricular arrhythmia recurrence ....................................................................................... 4062
7.1.3.4. Left ventricular non-compaction ................................ 4063
7.1.3.5. Restrictive cardiomyopathy .......................................... 4063
7.1.3.6. Neuromuscular disorders ............................................. 4063
7.1.4. Inﬂammatory cardiac diseases .............................................
4066
7.1.4.1. Myocarditis ........................................................................... 4066
7.1.4.2. Cardiac sarcoidosis ........................................................... 4067
7.1.4.3. Chagas’ cardiomyopathy ................................................ 4068
7.1.5. Valvular heart disease .............................................................
4070
7.1.6. Congenital heart disease ........................................................
4071
7.2. Primary electrical disease ............................................................... 4073
7.2.1. Idiopathic ventricular ﬁbrillation .........................................
4073
7.2.2. Long QT syndrome (including acquired long QT
syndrome) ................................................................................................
4074
7.2.3. Andersen–Tawil syndrome Type 1 ..................................
4079
7.2.4. Brugada syndrome ...................................................................
4079
7.2.5. Early repolarization syndromes ..........................................
4081
7.2.6. Catecholaminergic polymorphic ventricular tachycardia ...............................................................................................
4084
7.2.7. Short QT syndrome ................................................................
4086
8. Special aspects in selected populations ............................................
4088
8.1. Pregnant patients and peri-partum cardiomyopathy ......... 4088
8.1.1. Electrocardioversion and implantable cardioverter deﬁbrillator therapy in pregnancy ..................................................
4088
8.1.2. Pharmacological treatment ...................................................
4088
8.1.3. Catheter ablation ......................................................................
4088
8.2. Heart transplantation ...................................................................... 4089
8.3. Sudden cardiac death in athletes ................................................ 4089
ESC Guidelines
3999


<!-- PAGE 4 -->

### Page 4

8.4. Wolff–Parkinson–White syndrome .......................................... 4090
8.5. Prevention of sudden cardiac death in the elderly ............. 4090
9. Key messages ...............................................................................................
4090
9.1. General aspects .................................................................................. 4090
9.2. Structural heart disease .................................................................. 4090
9.3. Primary electrical disease ............................................................... 4091
10. Gaps in evidence ......................................................................................
4091
10.1. General aspects ............................................................................... 4091
10.2. Structural heart disease—general ........................................... 4091
10.3. Idiopathic premature ventricular complexes/ventricular tachycardia .................................................................................................... 4091
10.4. Coronary artery disease .............................................................. 4091
10.5. Cardiomyopathies .......................................................................... 4091
10.6. Valvular heart disease ................................................................... 4091
10.7. Congenital heart disease .............................................................. 4091
10.8. Primary electrical disease ............................................................ 4091
11. ‘What to do’ and ‘what not to do’ messages from the
Guidelines ...........................................................................................................
4092
12. Quality indicators ....................................................................................
4099
13. Supplementary data ................................................................................
4099
14. Data availability statement ...................................................................
4099
15. Author information ................................................................................
4099
16. Appendix .....................................................................................................
4100
17. References ..................................................................................................
4101
Tables of Recommendations
Recommendation Table 1 — Recommendations for public basic life support and access to automated external deﬁbrillators ............................................................................................ 4014
Recommendation Table 2 — Recommendations for genetic testing ...................................................................................................................
4018
Recommendation Table 3 — Recommendations for evaluation of patients presenting with newly documented ventricular arrhythmia ..........................................................................................................
4018
Recommendation Table 4 — Recommendations for evaluation of patients presenting with a ﬁrst episode of sustained monomorphic ventricular tachycardia ...................................................
4020
Recommendation Table 5 — Recommendations for evaluation of sudden cardiac arrest survivors ................................................................
4022
Recommendation Table 6 — Recommendations for evaluation of sudden death victims .....................................................................................
4023
Recommendation Table 7 — Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents ........
4027
Recommendation Table 8 — Recommendations for treatment of reversible conditions ......................................................................................
4029
Recommendation Table 9 — Recommendations for the acute management of sustained ventricular tachycardia and electrical storm ....................................................................................................................
4033
Recommendation Table 10 — Recommendations for treatment with heart failure medication .....................................................................
4034
Recommendation Table 11 — Recommendations for implantable cardioverter deﬁbrillator implantation (general aspects) ..............
4040
Recommendation Table 12 — Recommendations for secondary prevention of sudden cardiac death .......................................................
4040
Recommendation Table 13 — Recommendations for subcutaneous implantable cardioverter deﬁbrillator .......................
4040
Recommendation Table 14 — Recommendations for adding cardiac resynchronization therapy to implantable cardioverter deﬁbrillator ........................................................................................................
4040
Recommendation Table 15 — Recommendations for wearable cardioverter deﬁbrillator ..............................................................................
4040
Recommendation Table 16 — Recommendations for optimization of device programming .....................................................
4041
Recommendation Table 17 — Recommendations for concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy ............................................................
4042
Recommendation Table 18 — Recommendations for psychosocial management after implantable cardioverter deﬁbrillator implantation .............................................................................
4042
Recommendation Table 19 — Recommendations for implantable cardioverter deﬁbrillator implantation in left ventricular assist device recipients ..............................................................................................
4042
Recommendation Table 20 — Recommendations for prevention of implantable cardioverter deﬁbrillator complications .................
4043
Recommendation Table 21 — Recommendations for end-of-life issues in implantable cardioverter deﬁbrillator carriers .................
4043
Recommendation Table 22 — Recommendations for treatment of ventricular arrhythmias in acute coronary syndrome and vasospasm ..........................................................................................................
4046
Recommendation Table 23 — Recommendations for risk stratiﬁcation and treatment of ventricular arrhythmias early after myocardial infarction .....................................................................................
4046
Recommendation Table 24 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in chronic coronary artery disease .........
4047
Recommendation Table 25 — Recommendations for sudden cardiac death prevention in patients with coronary anomalies .......
4050
Recommendation Table 26 — Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia ..........................................................
4052
Recommendation Table 27 — Recommendations for the management of patients with premature ventricular complex-induced or premature ventricular complex-aggravated cardiomyopathy ............................................................................................................. 4053
Recommendation Table 28 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/
hypokinetic non-dilated cardiomyopathy ......................................
4057
Recommendation Table 29 — Recommendations for diagnostic,
risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy ........................................................................
4060
Recommendation Table 30 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in hypertropic cardiomyopathy ...............
4062
Recommendation Table 31 — Recommendations for implantable cardioverter deﬁbrillator implantation in left ventricular non-compaction ..............................................................................................
4063
Recommendation Table 32 — Recommendations for implantable cardioverter deﬁbrillator implantation in patients with cardiac amyloidosis .........................................................................................................
4063
Recommendation Table 33 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in neuromuscular diseases .........................
4065


<!-- PAGE 5 -->

### Page 5

Recommendation Table 34 — Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in myocarditis ..........................................................................
4066
Recommendation Table 35 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in cardiac sarcoidosis ....................................
4067
Recommendation Table 36 — Recommendations for the treatment of ventricular arrhythmias in Chagas’
cardiomyopathy ....................................................................................... 4070
Recommendation Table 37 — Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in valvular heart disease ......................................................
4070
Recommendation Table 38 — Recommendations for risk stratiﬁcation and primary prevention of sudden cardiac death in congenital heart disease ...............................................................................
4072
Recommendation Table 39 — Recommendations for secondary prevention of sudden cardiac death and treatment of ventricular arrhythmia in congenital heart disease ..................................................
4072
Recommendation Table 40 — Recommendations for the management of patients with idiopathic ventricular ﬁbrillation ..
4073
Recommendation Table 41 — Recommendations for the management of patients with long QT syndrome ...........................
4077
Recommendation Table 42 — Recommendations for management of patients with Andersen–Tawil syndrome ...........
4079
Recommendation Table 43 — Recommendations for management of patients with Brugada syndrome ............................
4080
Recommendation Table 44 — Recommendations for the management of patients with early repolarization pattern/
syndrome ............................................................................................................
4083
Recommendation Table 45 — Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia ..................................................................................
4086
Recommendation Table 46 — Recommendations for the management of patients with short QT syndrome .........................
4087
Recommendation Table 47 — Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy ..............................................
4088
Recommendation Table 48 — Recommendations for the prevention of sudden cardiac death before and after heart transplantation .................................................................................................
4089
Recommendation Table 49 — Recommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes
4089
Recommendation Table 50 — Recommendations for implantable cardioverter deﬁbrillator implantation in the elderly ......................
4090
List of tables
Table 1 Classes of recommendations ....................................................
4003
Table 2 Levels of evidence ..........................................................................
4004
Table 3 New sections and concepts ......................................................
4005
Table 4 New recommendations in 2022 .............................................
4005
Table 5 Changes in recommendations since 2015 ...........................
4010
Table 6 Intravenous provocative diagnostic tests .............................
4016
Table 7 Genetic tests and suggested work-up of probands and relatives with primary electrical diseases ..............................................
4017
Table 8 Anti-arrhythmic drugs (acute and chronic treatment) ..
4035
Table 9 Summary of the recommendations for the treatment of patients with frequent idiopathic premature ventricular complexes/ventricular tachycardia or premature ventricular complex-induced cardiomyopathy ..........................................................
4051
Table 10 Modiﬁed long QT syndrome diagnostic score ...................... 4076
List of ﬁgures
Figure 1 Central ﬁgure ..................................................................................
4013
Figure 2 Algorithm for the evaluation of patients presenting with an incidental ﬁnding of non-sustained ventricular tachycardia ....
4019
Figure 4 Algorithm for the evaluation of patients presenting with a
ﬁrst sustained monomorphic ventricular tachycardia episode ....
4021
Figure 3 Typical idiopathic ventricular tachycardia morphologies
4020
Figure 5 Bundle branch re-entrant ventricular tachycardia ..........
4022
Figure 6 Part One. Algorithm for the evaluation of sudden cardiac arrest survivors ................................................................................................
4024
Figure 6 Part Two. Algorithm for the evaluation of sudden cardiac arrest survivors ................................................................................................
4025
Figure 7 Algorithm for the evaluation of sudden death victims .
4026
Figure 8 Algorithm for the evaluation of relatives of unexplained sudden death decedents ..............................................................................
4028
Figure 9 Algorithm for the acute management of regular wide
QRS complex tachycardia ...........................................................................
4029
Figure 10 Repetitive runs of ventricular tachycardia interrupted by occasional sinus beats .............................................................................
4030
Figure 11 Part One. Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges ......................................................................................................... 4031
Figure 11 Part Two.Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges ................................................................................................... 4032
Figure 11 Part Three. Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges ...........................................................................................................
4033
Figure 12 Algorithm for evaluation before initiation and follow-up of patients requiring sodium channel blocking agents ....................
4038
Figure 13 Algorithm for evaluation before initiation and follow-up of patients requiring drugs associated with QT prolongation ....
4039
Figure 14 Algorithm for the prevention and management of ventricular arrhythmias in ST-elevation myocardial infarction .........
4045
Figure 15 Algorithm for risk stratiﬁcation and primary prevention of sudden cardiac death in patients with chronic coronary artery disease and reduced ejection fraction ....................................................
4048
Figure 16 Algorithm for the management of sustained monomorphic ventricular tachycardia in patients with chronic coronary artery disease ................................................................................
4049
Figure 17 Algorithm for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia and non-apparent structural heart disease .................
4051
Figure 18 Algorithm for the management of patients with premature ventricular complex-induced/-aggravated cardiomyopathy ...............................................................................................
4053
Figure 19 Algorithm for risk stratiﬁcation and primary prevention of sudden cardiac death in patients with dilated cardiomyopathy/
hypokinetic non-dilated cardiomyopathy .............................................
4001


<!-- PAGE 6 -->

### Page 6

Figure 20 Typical features of dilated cardiomyopathy associated with lamin A/C gene mutation with ventricular arrhythmias ......
4056
Figure 21 Typical features of arrhythmogenic right ventricular cardiomyopathy associated with ventricular arrhythmias ................................................................................................ 4059
Figure 22 Typical features of hypertrophic cardiomyopathy associated with sustained monomorphic ventricular tachycardia ................................................................................................. 4061
Figure 23 Algorithm for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in myotonic dystrophy .......................................................................................................................... 4064
Figure 24 Algorithm for sudden cardiac death prevention and treatment of ventricular arrhythmia in patients with cardiac sarcoidosis ..........................................................................................................
4068
Figure 25 Typical features of cardiac sarcoidosis associated with sustained monomorphic ventricular tachycardia ..............................
4069
Figure 26 Algorithm for the management of sustained ventricular arrhythmia in patients with congenital heart disease ......................
4071
Figure 27 Algorithm for the management of patients with idiopathic ventricular ﬁbrillation ...............................................................
4074
Figure 28 Idiopathic ventricular ﬁbrillation triggered by short-coupled premature ventricular complexes .............................
4075
Figure 29 Long QT syndrome electrocardiograms and torsade-de-pointes ventricular tachycardia .........................................
4076
Figure 30 Brisk standing electrocardiogram changes and T wave alternans in Long QT syndrome patients .............................................
4077
Figure 31 Algorithm for the management of patients with long
QT syndrome ...................................................................................................
4078
Figure 32 Typical examples of (A) Brugada type 1
electrocardiogram, and (B) early repolarization pattern electrocardiogram ...........................................................................................
4080
Figure 33 Part One. Algorithm for the management of patients with Brugada pattern electrocardiogram .............................................
4082
Figure 33 Part Two. Algorithm for the management of patients with Brugada pattern electrocardiogram .............................................
4083
Figure 34 Management of patients with early repolarization pattern/syndrome ...........................................................................................
4084
Figure 35 Management of patients with catecholaminergic polymorphic ventricular tachycardia ......................................................
4085
Figure 36 Exercise test of a patient with catecholaminergic polymorphic ventricular tachycardia ......................................................
4086
Figure 37 Short QT syndrome .................................................................
4087
Abbreviations and acronyms
AAD
Anti-arrhythmic drug
ACE-I
Angiotensin-converting enzyme inhibitor
ACS
Acute coronary syndrome
AED
Automated external deﬁbrillator
AF
Atrial ﬁbrillation
AH
Atrial–His interval
ALS
Advanced life support
ARB
Angiotensin receptor blocker
ARNI
Angiotensin receptor neprilysin inhibitor
ARVC
Arrhythmogenic right ventricular cardiomyopathy
ATP
Anti-tachycardia pacing
AV
Atrioventricular
AVRT
AV re-entry tachycardia
BBR-VT
Bundle branch re-entrant ventricular tachycardia
BrS
Brugada syndrome
CA
Cardiac arrest cAMP
Cyclic adenosine monophosphate
CAD
Coronary artery disease
CAG
Coronary angiogram
CCB
Calcium channel blocker
CHD
Congenital heart disease
CIED
Cardiac implantable electronic devices
CMR
Cardiac magnetic resonance
CPR
Cardiopulmonary resuscitation
CPVT
Catecholaminergic polymorphic ventricular tachycardia
CRT
Cardiac resynchronization therapy
CT/CTA
Computed tomography/Computed tomography angiography
DCM
Dilated cardiomyopathy
DNA
Deoxyribonucleic acid
ECG
Electrocardiogram
EF
Ejection fraction
ERP
Early repolarization pattern
ERS
Early repolarization syndrome
FBI
Fast, broad, irregular
HCM
Hypertrophic cardiomyopathy
HFrEF
Heart failure with reduced ejection fraction
HNDCM
Hypokinetic non-dilated cardiomyopathy
HTX
Heart transplantation
HV
His–ventricular interval
ICD
Implantable cardioverter deﬁbrillator
ILR
Implantable loop recorder
IVF
Idiopathic ventricular ﬁbrillation
LBBB
Left bundle branch block
LCSD
Left cardiac sympathetic denervation
LGE
Late gadolinium enhancement
LMNA
Lamin A/C
LQTS
Long QT syndrome
LV
Left ventricular
LVAD
Left ventricular assist device
LVEF
Left ventricular ejection fraction
LVH
Left ventricular hypertrophy
LVNC
Left ventricular non-compaction
LVOT
Left ventricle outﬂow tract
MI
Myocardial infarction
MRA
Mineralocorticoid receptor antagonist
MVP
Mitral valve prolapse
MVT
Monomorphic ventricular tachycardia
NSVT
Non-sustained ventricular tachycardia
NYHA
New York Heart Association
OHCA
Out-of-hospital cardiac arrest
OMT
Optimal medical treatment
PCI
Percutaneous coronary intervention
PCR
Polymerase chain reaction
PES
Programmed electrical stimulation
PET-CT
Positron emission tomography computed tomography
PPCM
Peri-partum cardiomyopathy
PVC
Premature ventricular complex
PVT
Polymorphic ventricular tachycardia
QI
Quality indicators
RBBB
Right bundle branch block


<!-- PAGE 7 -->

### Page 7

RCM
Restrictive cardiomyopathy
RCT
Randomized control trial
RV
Right ventricular
RVOT
Right ventricle outﬂow tract
SADS
Sudden arrhythmic death syndrome
SaECG
Signal-averaged ECG
SCA
Sudden cardiac arrest
SCD
Sudden cardiac death
SD
Sudden death
SGLT2
Sodium–glucose co-transporter 2
SHD
Structural heart disease
S-ICD
Subcutaneous implantable cardioverter deﬁbrillator
SMVT
Sustained monomorphic ventricular tachycardia
SPTV
Sustained polymorphic ventricular tachycardia
SQTS
Short QT syndrome
STEMI
ST elevation myocardial infarction
SVT
Supraventricular tachycardia
TAVI
Transcatheter aortic valve implantation
TdP
Torsades de pointes
TOF
Tetralogy of Fallot
VA
Ventricular arrhythmia
VF
Ventricular ﬁbrillation
VT
Ventricular tachycardia
WCD
Wearable cardioverter deﬁbrillator
WPW
Wolff–Parkinson–White
1. Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition.
Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, guidelines are not a substitute for the patient’s relationship with their practitioner. The ﬁnal decisions concerning an individual patient must be made by the responsible health professional(s), based on what they consider to be the most appropriate in the circumstances. These decisions are made in consultation with the patient and caregiver as appropriate.
Guidelines are intended for use by health professionals. To ensure that all users have access to the most recent recommendations, the
ESC makes its guidelines freely available. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
A great number of guidelines have been issued in recent years by the ESC. Because of their impact on clinical practice, quality criteria for the development of guidelines have been established to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website
(https://www.escardio.org/Guidelines). The ESC Guidelines represent the ofﬁcial position of the ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice Guidelines, the
ESC carries out the EURObservational Research Programme of international registries of cardiovascular diseases and interventions that are essential to assess diagnostic/therapeutic processes, use of resources, and adherence to guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on high-quality data collected during routine clinical practice.
Furthermore, the ESC develops sets of quality indicators (QIs),
which are tools to evaluate the level of implementation of the guidelines and may be used by the ESC, hospitals, healthcare providers,
and professionals to measure clinical practice, and in educational
Table 1
Classes of recommendations
©ESC 2022
Classes of recommendations
Class I 
Evide beneficial, useful, effective.
effcacy of the given treatment or procedure.
nce and/or general agreement that a given treatment or procedure is
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given tr useful/effective, and in some cases eatment or procedure is not may be harmful. 
Is not recommended
Class IIb established by evidence/opinion.
May be considered
Class IIa
W
favour of usefulness/effcacy.
eight of 
Usefulness/efficacy is less well evidence/opinion is in
Should be considered
Class II 
© ESC 2022
ESC Guidelines
4003


<!-- PAGE 8 -->

### Page 8

programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes.
The Members of this task force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. The selection procedure aimed to ensure that there is a representative mix of members predominantly from across the whole of the ESC region and from relevant ESC Subspecialty
Communities. Consideration was given to diversity and inclusion,
notably with respect to gender and country of origin. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk–beneﬁt ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and scored according to predeﬁned scales, as outlined below. The task force followed the ESC voting procedures.
All recommendations subject to a vote achieved at least 75% among voting members.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conﬂicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/
Guidelines) and have been compiled in a report and published in a supplementary document simultaneously to the guidelines.
This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arise during the writing period were notiﬁed to the ESC
and updated. The task force received its entire ﬁnancial support from the ESC without any involvement from the healthcare industry.
The ESC CPG Committee supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the approval process of these guidelines. The ESC Guidelines undergo extensive review by the CPG Committee and external experts, including a mix of members from across the whole of the ESC region and from relevant ESC Subspecialty Communities and National
Cardiac Societies. After appropriate revisions, the guidelines are signed off by all the experts involved in the task force. The ﬁnalized document is signed off by the CPG Committee for publication in the
The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommendations, including condensed pocket guideline versions,
summary slides, summary cards for non-specialists, and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access the full-text version of the guidelines, which is freely available via the ESC website and the European Heart
Journal. The National Cardiac Societies of the ESC are encouraged to endorse, adopt, translate, and implement all ESC Guidelines.
Implementation programmes are needed because it has been shown that the outcome of disease may be favourably inﬂuenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive,
diagnostic, or therapeutic medical strategies. However, the ESC
Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient‘s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and, where appropriate, to respect the ethical rules of their profession.
Off-label use of medication may be presented in this guideline if sufﬁcient level of evidence shows that it can be considered medically appropriate to a given condition and if patients could beneﬁt from the recommended therapy. However, the ﬁnal decisions concerning an individual patient must be made by the responsible health professional giving special consideration to:
(1) the speciﬁc situation of the patient. In this respect, it is speciﬁed that, unless otherwise provided for by national regulations, offTable 2
Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2022


<!-- PAGE 9 -->

### Page 9

label use of medication should be limited to situations where it is in the patient’s interest to do so, with regard to the quality,
safety, and efﬁcacy of care, and only after the patient has been informed and has provided consent;
(2) country-speciﬁc health regulations, indications by governmental drug regulatory agencies, and the ethical rules to which health professionals are subject, where applicable.
2. Introduction
This document presents an update of the 2015 ESC Guidelines for the management of patients with ventricular arrhythmias (VA)
and the prevention of sudden cardiac death (SCD). New insights into the epidemiology of SCD, new evidence on genetics, imaging,
and clinical ﬁndings for risk stratiﬁcation for VA and SCD, and advances in diagnostic evaluation and therapeutic strategies made this revision necessary. The committee was composed of 25 members including 23 expert physicians, one methodologist, and one patient representative. Experts were selected to cover all areas of VA and
SCD as well as subspecialties of cardiology with the assistance of related ESC working groups.
All 25 members of the task force committee approved the guideline recommendations after an anonymous voting process.
Ninety-nine peer reviewers reviewed the document. A systematic literature survey was conducted, after instructions by the methodologist in the group, that led to the incorporation of 1155 references,
of which 485 were selected to support the recommendations and further speciﬁed in the table of evidence (Supplementary data).
2.1. What is new
The diagnostic and management parts of the guidelines have been adapted to facilitate their use in everyday clinical decision-making.
The ﬁrst general part has new sections on diagnostic evaluation,
including pharmacologic provocative tests, genetic testing, and a systematic work-up of probands and relatives with primary electrical diseases. Comprehensive ﬂowcharts and recommendations for the diagnostic evaluation at ﬁrst presentation with a VA of patients without a previously known cardiac disease are provided for ﬁve frequently encountered clinical scenarios. Practical recommendations for optimization of implantable cardioverter deﬁbrillator (ICD) programming and algorithms for management of patients experiencing regular wide complex tachycardia and electrical storm are presented
(Table 3).
Table 3
New sections and concepts
New sections and concepts
Section
Provocative diagnostic tests
5.1.3.5
Genetic testing
5.1.4
Diagnostic evaluation at ﬁrst presentation with VA in patients without known cardiac disease
5.2
Management of patients with electrical storm
6.1.3
Special aspects of device therapy
6.2.3
© ESC 2022
Table 4
New recommendations in 2022
Recommendations
Class
Public basic life support and access to AEDs
It is recommended that public-access deﬁbrillation be available at sites where cardiac arrest is more likely to occur.a
I
Prompt CPR by bystanders is recommended at OHCA.
I
It is recommended to promote community training in basic life support to increase bystander CPR rate and AED use.
I
Mobile phone-based alerting of basic life support-trained bystander volunteers to assist nearby OHCA victims should be considered.
IIa
Treatment of VA. General aspects
DC cardioversion is recommended as the ﬁrst-line treatment for patients presenting with tolerated SMVT provided that the anaesthetic/sedation risk is low.
I
Optimal medical treatment including ACE-I/ARB/ARNIs,
MRAs, beta-blockers, and SGLT2 inhibitors is indicated in all heart failure patients with reduced EF.
I
Implantation of a cardioverter deﬁbrillator is only recommended in patients who have an expectation of good-quality survival .1 year.
I
In patients presenting with a haemodynamically tolerated
SMVT and known or suspected SHD, intravenous procainamide should be considered.
IIa
In patients presenting with a haemodynamically tolerated
SMVT in the absence of an established diagnosis, intravenous amiodarone may be considered.
IIb
In patients with SMVT or SPVT/VF triggered by a PVC with similar morphology and an indication for ICD, catheter ablation may be considered when an ICD is not available,
contraindicated for concurrent medical reasons, or declined by the patient.
IIb
The WCD may be considered in the early phase after MI in selected patients.
IIb
Coronary artery disease
In patients with CAD and recurrent, symptomatic SMVT, or
ICD shocks for SMVT despite chronic amiodarone therapy,
catheter ablation is recommended in preference to escalating
AAD therapy.
I
Cardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test after surgery in patients with anomalous aortic origin of a coronary artery with a history of aborted CA.
I
In SCA survivors with coronary artery spasm, implantation of an ICD should be considered.
IIa
ICD therapy should be considered in patients with CAD,
NYHA class I, and LVEF ≤30% despite ≥3 months of OMT.
IIa
ICD implantation should be considered in patients with CAD,
LVEF ≤40% despite ≥3 months of OMT and NSVT, if they are inducible for SMVT by PES.
IIa
Continued
ESC Guidelines
4005


<!-- PAGE 10 -->

### Page 10

In patients with CAD and haemodynamically well-tolerated
SMVT and LVEF ≥40%, catheter ablation in experienced centres should be considered as an alternative to ICD therapy,
provided that established endpoints have been reached.b
IIa
Catheter ablation should be considered in patients with CAD
and recurrent, symptomatic SMVT, or ICD shocks for SMVT
despite beta-blocker or sotalol treatment.
IIa
Idiopathic PVC/VT and PVC-induced cardiomyopathy
Catheter ablation as ﬁrst-line treatment is recommended for symptomatic idiopathic VT/PVCs from the RVOT or the left fascicles.
I
Beta-blockers or non-dihydropyridine CCBs are indicated in symptomatic patients with idiopathic VT/PVCs from an origin other than the RVOT or the left fascicles.
I
In patients with PVCs/VT and a presentation not typical for an idiopathic origin,c CMR should be considered, despite a normal echocardiogram.
IIa
Beta-blockers, non-dihydropyridine CCBs or ﬂecainide should be considered when catheter ablation is not available, not desired, or is particularly risky in symptomatic patients with idiopathic VT/PVCs from the RVOT or the left fascicles.
IIa
Catheter ablation or ﬂecainide should be considered in symptomatic patients with idiopathic VT/PVCs from an origin other than the RVOT or the left fascicles.
IIa
In patients with an unexplained reduced EF and a PVC burden of at least 10%, PVC-induced cardiomyopathy should be considered.
IIa
In patients with suspected PVC-induced cardiomyopathy, CMR
should be considered.
IIa
In non-responders to CRT with frequent, predominately monomorphic PVCs limiting optimal biventricular pacing despite pharmacological therapy, catheter ablation or AADs should be considered.
IIa
Catheter ablation may be considered for idiopathic VT/PVCs in asymptomatic patients with repeatedly more than 20% of
PVCs per day at follow-up.
IIb
Amiodarone as a ﬁrst-line treatment is not recommended in patients with idiopathic VTs/PVCs.
III
DCM/HNDCM
Genetic testing (including at least LMNA, PLN, RBM20, and
FLNC genes) is recommended in patients with DCM/HNDCM
and AV conduction delay at ,50 years, or who have a family history of DCM/HNDCM or SCD in a ﬁrst-degree relative (at age ,50 years).
I
In a ﬁrst-degree relative of a DCM/HNDCM patient, an ECG,
and an echocardiogram are recommended if:
• the index patient was diagnosed ,50 years of age or has clinical features suggestive of an inherited cause, or
• there is a family history of DCM/HNDCM, or premature unexpected SD.
I
CMR with LGE should be considered in DCM/HNDCM
patients for assessing the aetiology and the risk of VA/SCD.
IIa
Continued
Genetic testing (including at least LMNA, PLN, RBM20, and
FLNC genes) should be considered for risk stratiﬁcation in patients with apparently sporadic DCM/HNDCM, who present at young age or with signs suspicious for an inherited aetiology.
IIa
ICD implantation should be considered in DCM/HNDCM
patients with an LVEF ,50% and ≥2 risk factors (syncope, LGE
on CMR, inducible SMVT at PES, pathogenic mutations in
LMNA, PLN, FLNC, and RBM20 genes).
IIa
ICD implantation should be considered in patients with DCM/
HNDCM and haemodynamically tolerated SMVT.
IIa
In a ﬁrst-degree relative of a patient with apparently sporadic
DCM/HNDCM, an ECG, and an echocardiogram may be considered.
IIb
Participation in high-intensity exercise including competitive sports is not recommended for individuals with DCM/
HNDCM and a LMNA mutation.
III
ARVC
In patients with suspected ARVC, CMR is recommended.
I
In patients with a suspected or deﬁnite diagnosis of ARVC,
genetic counselling and testing are recommended.
I
ICD implantation should be considered in symptomaticd patients with deﬁnite ARVC, moderate right or left ventricular dysfunction, and either NSVT or inducibility of SMVT at PES.
IIa
In ARVC patients with indication for ICDs, a device with the capability of ATP programming for SMVT up to high rates should be considered.
IIa
Avoidance of high-intensitye exercise may be considered in carriers of ARVC-related pathogenic mutations and no phenotype.
IIb
Beta-blocker therapy may be considered in all patients with a deﬁnite diagnosis of ARVC.
IIb
In patients with ARVC and symptoms highly suspicious for VA,
PES may be considered for risk stratiﬁcation.
IIb
HCM
CMR with LGE is recommended in HCM patients for diagnostic work-up.
I
Genetic counselling and testing are recommended in HCM
patients.
I
In a ﬁrst-degree relative of a patient with HCM, ECG, and echocardiogram are recommended.
I
ICD implantation should be considered in HCM patients aged
16 years or more with an intermediate 5-year risk of SCD (≥4
to ,6%)f, and with (a) signiﬁcant LGE at CMR (usually ≥15% of
LV mass); or (b) LVEF ,50%; or (c) abnormal blood pressure response during exercise testg; or (d) LV apical aneurysm; or
(e) presence of sarcomeric pathogenic mutation.
IIa
In children ,16 years of age with HCM and an estimated
5-year risk of SD ≥6% (based on HCM Risk-Kids scoreh), ICD
implantation should be considered.
IIa
In patients with HCM presenting with haemodynamically tolerated SMVT, ICD implantation should be considered.
IIa
Continued


<!-- PAGE 11 -->

### Page 11

In patients with HCM and recurrent, symptomatic VA, or recurrent symptomatic ICD therapy, AAD treatment should be considered.
IIa
Participation in high-intensity exercise may be considered for asymptomatic adult HCM patients without risk markers.
IIb
ICD implantation may be considered in HCM patients aged 16
years or more with a low estimated 5-year risk of SCD (,4%),f and with (a) signiﬁcant LGE at CMR (usually ≥15% of LV mass);
or (b) LVEF , 50%; or (c) LV apical aneurysm.
IIb
Catheter ablation in specialized centres may be considered in selected patients with HCM and recurrent, symptomatic
SMVT, or ICD shocks for SMVT, in whom AADs are ineffective, contraindicated, or not tolerated.
IIb
LVNC and RCM
In patients with an LVNC cardiomyopathy phenotype based on
CMR or echocardiography, implantation of an ICD for primary prevention of SCD should be considered to follow DCM/
HNDCM recommendations.
IIa
An ICD should be considered in patients with light-chain amyloidosis or transthyretin-associated cardiac amyloidosis and haemodynamically not-tolerated VT.
IIa
Neuromuscular diseases
Invasive electrophysiological evaluation is recommended in patients with myotonic dystrophy and palpitations or syncope suggestive of VA or surviving a CA.
I
ICD implantation is recommended in patients with myotonic dystrophy and SMVT or aborted CA not caused by BBR-VT.
I
Invasive electrophysiological evaluation should be considered in patients with myotonic dystrophy and a sudden increase in the PR interval or QRS duration.
IIa
Invasive electrophysiological evaluation should be considered in patients with myotonic dystrophy and a PR interval ≥240 ms or QRS duration ≥120 ms or who are older than 40 years and have supraventricular arrhythmias, or who are older than 40
years and have signiﬁcant LGE on CMR
IIa
In myotonic dystrophy patients without AV conduction delay and a syncope highly suspicious for VA, ICD implantation should be considered.
IIa
In myotonic dystrophy patients with palpitations highly suspicious for VA and induction of a non-BBR-VT, ICD
implantation should be considered.
IIa
In patients with limb-girdle type 1B or Emery–Dreifuss muscular dystrophies and indication for pacing, ICD
implantation should be considered.
IIa
Implantation of an ICD may be considered in patients with
Duchenne/Becker muscular dystrophy and signiﬁcant LGE at
CMR.
IIb
Implantation of an ICD over a permanent pacemaker may be considered in myotonic dystrophy patients with additional risk factorsi for VA and SCD.
IIb
In patients with myotonic dystrophy, serial electrophysiological evaluation of AV conduction and arrhythmia induction is not recommended without arrhythmia suspicion or progression of
ECG conduction disorders.
III
Continued
Inﬂammatory diseases
In patients with haemodynamically not-tolerated sustained VT
or VF during the acute phase of myocarditis, ICD implantation before hospital discharge should be considered.
IIa
In post-myocarditis patients with recurrent, symptomatic VT,
AAD treatment should be considered.
IIa
Catheter ablation, performed in specialized centres, should be considered in post-myocarditis patients with recurrent,
symptomatic SMVT, or ICD shocks for SMVT in whom AADs are ineffective, not tolerated, or not desired.
IIa
In patients with haemodynamically tolerated SMVT occurring in the chronic phase of myocarditis, ICD implantation should be considered.
IIa
In patients with cardiac sarcoidosis who have an LVEF .35%
but signiﬁcant LGE at CMR after resolution of acute inﬂammation, ICD implantation should be considered.
IIa
In patients with cardiac sarcoidosis who have an LVEF 35–50%
and minor LGE at CMR, after resolution of acute inﬂammation,
PES for risk stratiﬁcation should be considered.
IIa
In patients with cardiac sarcoidosis, LVEF 35–50%, and inducible SMVT at PES, ICD implantation should be considered.
IIa
In patients with cardiac sarcoidosis and recurrent, symptomatic
VA, AAD treatment should be considered.
IIa
Amiodarone should be considered to reduce arrhythmia burden in patients with Chagas’ cardiomyopathy who present with symptomatic PVCs or VT.
IIa
In patients with Chagas’ cardiomyopathy and recurrent,
symptomatic SMVT, or ICD shocks for SMVT in whom AADs are ineffective, contraindicated, or not tolerated, catheter ablation in specialized centres should be considered.
IIa
In patients with haemodynamically well-tolerated SMVT
occurring in the chronic phase of myocarditis, preserved LV
function and a limited scar amenable to ablation, catheter ablation may be considered as an alternative to ICD therapy,
after discussion with the patient and provided that established endpoints have been reached.b
IIb
Catheter ablation, in specialized centres, may be considered in cardiac sarcoidosis ICD recipients with recurrent, symptomatic
SMVT, or ICD shocks for SMVT, in whom AADs are ineffective, contraindicated, or not tolerated.
IIb
Congenital heart disease
In patients with CHD presenting with sustained VAs,
evaluation for residual lesions or new structural abnormalities is recommended.
I
In selected patients with CHD (including atrial bafﬂe repair for transposition of the great arteries, Fontan operation, and
Ebstein anomaly) presenting with CA, evaluation and treatment of SVT with rapid ventricular conduction should be considered.
IIa
In patients with repaired TOF undergoing surgical or transcutaneous pulmonary valve replacement, pre-operative catheter mapping and transection of VT-related anatomical isthmuses before or during the intervention may be considered.
IIb
Continued
ESC Guidelines
4007


<!-- PAGE 12 -->

### Page 12

In patients with repaired TOF with a preserved biventricular function and symptomatic SMVT, catheter ablation or concomitant surgical ablation performed in specialized centres may be considered as an alternative to ICD therapy.
IIb
Idiopathic VF
It is recommended that idiopathic VF is diagnosed in a SCA
survivor, preferably with documentation of VF, after exclusion of an underlying structural, channelopathic, metabolic, or toxicological aetiology.
I
Isoproterenol infusion, verapamil, or quinidine for acute treatment of an electrical storm or recurrent ICD discharges should be considered in idiopathic VF.
IIa
Quinidine should be considered for chronic therapy to suppress an electrical storm or recurrent ICD discharges in idiopathic VF.
IIa
Clinical testing (history, ECG, and high precordial lead ECG,
exercise test, echocardiogram) of ﬁrst-degree family members of idiopathic VF patients may be considered.
IIb
In idiopathic VF patients, genetic testing of genes related to channelopathy and cardiomyopathy may be considered.
IIb
Long QT syndrome
In patients with clinically diagnosed LQTS, genetic testing, and genetic counselling are recommended.
I
Beta-blockers, ideally non-selective beta-blockers (nadolol or propranolol), are recommended in LQTS patients with documented QT interval prolongation, to reduce risk of arrhythmic events.
I
Mexiletine is indicated in LQT3 patients with a prolonged QT
interval.
I
In LQTS, it should be considered to calculate the arrhythmic risk before initiation of therapy based on the genotype and the duration of QTc interval.
IIa
ICD implantation may be considered in asymptomatic LQTS
patients with high-risk proﬁle (according to the 1-2-3 LQTS
Risk calculator) in addition to genotype-speciﬁc medical therapies (mexiletine in LQT3 patients).
IIb
Routine diagnostic testing with epinephrine challenge is not recommended in LQTS.
III
Andersen–Tawil syndrome
Genetic testing is recommended in patients with suspected
Andersen–Tawil syndrome.
I
ICD implantation is recommended in patients with Andersen–
Tawil syndrome after aborted CA or not-tolerated sustained
VT.
I
Andersen–Tawil syndrome should be considered in patients without SHD who present with at least two of the following:
• Prominent U waves with or without prolongation of the QT
interval
• Bidirectional and/or polymorphic PVCs/VT
• Dysmorphic features
• Periodic paralysis
• KCNJ2 pathogenic loss of function mutation.
IIa
Continued
Beta-blockers and/or ﬂecainide with or without acetazolamide should be considered in patients with Andersen–Tawil syndrome to treat VA.
IIa
An ILR should be considered in patients with Andersen–Tawil syndrome and unexplained syncope.
IIa
ICD implantation may be considered in patients with
Andersen–Tawil syndrome who have a history of unexplained syncope or suffer from tolerated sustained VT.
IIb
Brugada syndrome
Genetic testing for SCN5A gene is recommended for probands with BrS.
I
BrS should be considered in patients with no other heart disease and induced type 1 Brugada pattern who have at least one of the following:
• Arrhythmic syncope or nocturnal agonal respiration
• A family history of BrS
• A family history of SD (,45 years old) with a negative autopsy and circumstance suspicious for BrS.
IIa
Implantation of a loop recorder should be considered in BrS
patients with an unexplained syncope.
IIa
BrS may be considered as a diagnosis in patients with no other heart disease who exhibit an induced type 1 Brugada ECG.
IIb
PES may be considered in asymptomatic patients with a spontaneous type I BrS ECG.
IIb
Sodium channel blocker test is not recommended in patients with a prior type I Brugada pattern.
III
Catheter ablation in asymptomatic BrS patients is not recommended.
III
Early repolarization syndrome
It is recommended that the ERP is diagnosed as J-point elevation of ≥1 mm in two adjacent inferior and/or lateral ECG leads.
I
It is recommended that the ERS is diagnosed in a patient resuscitated from unexplained VF/PVT in the presence of ERP.
I
ICD implantation is recommended in patients with a diagnosis of ERS who have survived a CA.
I
In a SCD victim with a negative autopsy and medical chart review, and an ante-mortem ECG demonstrating the ERP, the diagnosis of ERS should be considered.
IIa
First-degree relatives of ERS patients should be considered for clinical evaluation for ERP with additional high-risk features.j
IIa
ILR should be considered in individuals with ERP and at least one risk featurek or arrhythmic syncope.
IIa
Isoproterenol infusion should be considered for ERS patients with electrical storm.
IIa
Quinidine in addition to an ICD should be considered for recurrent VF in ERS patients.
IIa
PVC ablation should be considered in ERS patients with recurrent VF episodes triggered by a similar PVC
non-responsive to medical treatment.
IIa
Genetic testing in ERS patients may be considered.
IIb
ICD implantation or quinidine may be considered in individuals with ERP and arrhythmic syncope and additional risk features.k
IIb
Continued


<!-- PAGE 13 -->

### Page 13

The second part of the guidelines is structured according to disease-speciﬁc management, providing a link to the updated
ESC CardioMed chapter for additional content. Risk stratiﬁcation, SCD prevention, treatment of VA, and management of family members are addressed in a systematic fashion. Indications for cardiac magnetic resonance (CMR) imaging, genetic testing,
and updated indications for catheter ablation of ventricular arrhythmias are presented. Flowcharts summarizing the workﬂow for diagnostic and treatment are provided for the disease entities.
The colour-coding of the ﬂowcharts reﬂects the class of recommendation according to this guideline and other ESC Guidelines.1–3
ICD implantation or quinidine may be considered in asymptomatic individuals who demonstrate a high-risk ERPj in the presence of a family history of unexplained juvenile SD.
IIb
Clinical evaluation is not recommended routinely in asymptomatic subjects with ERP.
III
ICD implantation is not recommended in asymptomatic patients with an isolated ERP.
III
CPVT
Genetic testing and genetic counselling are indicated in patients with clinical suspicion or clinical diagnosis of CPVT.
I
Beta-blockers, ideally non-selective (nadolol or propranolol)
are recommended in all patients with a clinical diagnosis of CPVT.
I
Epinephrine or isoproterenol challenge may be considered for the diagnosis of CPVT when an exercise test is not possible.
IIb
Short QT syndrome
Genetic testing is indicated in patients diagnosed with SQTS.
I
SQTS should be considered in the presence of a QTc
≤320 ms.
IIa
SQTS should be considered in the presence of a QTc ≥320 ms and ≤360 ms and arrhythmic syncope.
IIa
ILR should be considered in young SQTS patients.
IIa
ICD implantation should be considered in SQTS patients with arrhythmic syncope.
IIa
SQTS may be considered in the presence of a
QTc ≥320 ms and ≤360 ms and a family history of SD
at age ,40 years.
IIb
Quinidine may be considered in (a) SQTS patients who qualify for an ICD but present a contraindication to the ICD or refuse it, and (b) asymptomatic SQTS patients and a family history of
SCD.
IIb
Isoproterenol may be considered in SQTS patients with an electrical storm.
IIb
Selected populations
It is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current guidelines for sports eligibility.
I
Continuation of beta-blockers should be considered during pregnancy in women with ARVC.
IIa
Oral metoprolol, propranolol, or verapamil should be considered for long-term management of idiopathic sustained
VT during pregnancy.
IIa
Catheter ablation using non-ﬂuoroscopic mapping systems should be considered, preferably after the ﬁrst trimester, in women with highly symptomatic recurrent SMVT refractory or who are intolerant to AADs.
IIa
Continued
In selected transplanted patients with cardiac allograft vasculopathy or treated rejection, ICD implantation may be considered.
IIb
In elderly patients in whom a beneﬁt from the deﬁbrillator is not expected due to the patient’s age and comorbidities,
omission of ICD implantation for primary prevention may be considered.
IIb
© ESC 2022
AAD, anti-arrhythmic drug; ACE-Is, angiotensin-converting enzyme inhibitors; AED,
automated external deﬁbrillator; ARBs, angiotensin receptor blockers; ARNIs,
angiotensin receptor neprilysin inhibitors; ARVC, arrhythmogenic right ventricular cardiomyopathy; ATP, anti-tachycardia pacing; AV, atrioventricular; BBR-VT, bundle branch re-entry; BrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization therapy; DC,
direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome; HCM,
hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy;
ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; LGE, late gadolinium enhancement; LMNA, lamin A/C; LQTS, long QT syndrome; LV, left ventricular;
LVEF,
left ventricular ejection fraction;
LVNC,
left ventricular non-compaction;
MI,
myocardial infarction;
MRAs, mineralocorticoid receptor antagonists; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart
Association; OHCA, out-of-hospital cardiac arrest; OMT, optimal medical therapy;
PES, programmed electrical stimulation; PVC, premature ventricular complex; RCM,
restrictive cardiomyopathy; RVOT, right ventricular outﬂow tract; SCA, sudden cardiac arrest;
SCD,
sudden cardiac death;
SD,
sudden death;
SGLT2,
sodium–glucose co-transporter 2; SHD, structural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SPVT, sustained polymorphic ventricular tachycardia; SQTS, short QT syndrome; SVT, supraventricular tachycardia; TOF,
tetralogy of Fallot; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT,
ventricular tachycardia; WCD, wearable cardioverter deﬁbrillator.
aShopping malls, stadiums, public transport stations, casinos.
bVT non-inducibility and elimination of electrograms consistent with conduction delay.
cIncluding but not limited to older age, right bundle branch block (RBBB) morphology,
SMVT consistent with re-entry.
dPresyncope or palpitations suggestive of VA.
eThe 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease.4
fBased on the HCM Risk SCD: https://doc2do.com/hcm/webHCM.html gDeﬁned as a failure to increase systolic pressure by at least 20 mmHg from rest to peak exercise, or a fall of .20 mmHg from peak pressure.
hBased on the HCM Kid Risk score: https://hcmriskkids.org iFactors favouring ICD implantation: Age,5,6,11 CTG expansion,6–9,13,16 SD or family history of SD,5 ECG conduction abnormalities,16 PR prolongation,13 LBBB,5 atrial arrhythmias,6,16
non-sustained VT,5 LV dysfunction,17 structural abnormalities in CMR.14,15,18
jERP high risk features: J waves . 2 mm, dynamic changes in J point and ST morphology.
kHigh-risk ERP: family history of unexplained SD ,40 years, family history of ERS.
ESC Guidelines
4009


<!-- PAGE 14 -->

### Page 14

Another novel concept of this document is the table of evidence
(see Supplementary data). The trials and studies that have been selected to support a recommendation are systematically described in the table of evidence after careful review of the available data and the applied methodology, prioritizing papers published after 2015. Recommendations with level of evidence C that are not accompanied by a reference are supported by this panel of experts. To assist physicians in their daily clinical practice, diagnostic and therapeutic procedures with promising usefulness, typically classiﬁed as class IIb, but for which evidence is limited and difﬁcult to collect in the near future, the related recommendations are not only described in the narratives but are listed in the table of recommendation.
Table 5
Changes in recommendations since 2015
Class
2015
2022
Coronary artery disease
In patients with syncope and previous STEMI, PES is indicated when syncope remains unexplained after non-invasive evaluation.
IIa
I
Intravenous amiodarone treatment should be considered for patients with recurrent PVT/VF
during the acute phase of ACS.
I
IIa
In patients with CAD eligible for ICD implantation,
catheter ablation may be considered just before (or immediately after) ICD implantation to decrease subsequent VT burden and ICD shocks.
IIa
IIb
PVC-induced cardiomyopathy
In patients with a cardiomyopathy suspected to be caused by frequent and predominately monomorphic
PVCs, catheter ablation is recommended.
IIa
I
DCM/HNDCM
ICD implantation should be considered in patients with DCM/HNDCM, symptomatic heart failure
(NYHA class II–III) and LVEF ≤35% after ≥3 months of OMT.
I
IIa
Catheter ablation in specialized centres should be considered in patients with DCM/HNDCM and recurrent, symptomatic SMVT, or ICD shocks for
SMVT, in whom AADs are ineffective,
contraindicated, or not tolerated.
IIb
IIa
ARVC
ICD implantation should be considered in patients with deﬁnite ARVC and an arrhythmic syncope.
IIb
IIa
ICD implantation should be considered in patients with deﬁnite ARVC and severe RV or LV systolic dysfunction.
IIb
IIa
Inﬂammatory diseases
In patients with haemodynamically not-tolerated
SMVT occurring in the chronic phase of myocarditis,
ICD implantation is recommended.
IIa
I
ICD implantation is recommended in patients with cardiac sarcoidosis who have an LVEF ≤35%.
IIb
I
ICD implantation is recommended in patients with cardiac sarcoidosis who (1) have documented sustained VT, or (2) aborted CA.
IIb
I
In patients with cardiac sarcoidosis who have an indication for permanent cardiac pacing related to high-degree AV block, ICD implantation should be considered, regardless of LVEF.
IIb
IIa
In patients with Chagas’ cardiomyopathy and symptomatic VT in whom AADs (amiodarone and beta-blockers) are ineffective or not tolerated, ICD
implantation may be considered.
IIa
IIb
Continued
CHD
In patients after repair of TOF without arrhythmia symptoms, but with a combination of other risk factors,a electrophysiologic evaluation, including PES,
may be considered.
IIa
IIb
In patients with CHD and recurrent, symptomatic
SMVT, or ICD shocks for SMVT not manageable by medical therapy or ICD reprogramming, catheter ablation performed in specialized centres should be considered.
I
IIa
Primary electrical disease and selected populations
ICD implantation is recommended in patients with
LQTS who are symptomaticb while receiving beta-blockers and genotype-speciﬁc therapies.
IIa
I
ICD implantation should be considered in patients with CPVT who experience arrhythmic syncope and/
or documented bidirectional/PVT while on the highest tolerated beta-blocker dose and on ﬂecainide.
I
IIa
Pre-participation cardiovascular evaluation of competitive athletes should be considered.
I
IIa
Catheter ablation of triggering PVCs and/or RVOT
epicardial substrate should be considered in BrS
patients with recurrent appropriate ICD shocks refractory to drug therapy.
IIb
IIa
LCSD should be considered in patients with diagnosis of CPVT when the combination of beta-blockers and
ﬂecainide at therapeutic dosage are either not effective, not tolerated, or contraindicated.
IIb
IIa
© ESC 2022
AAD, anti-arrhythmic drug; ACS, acute coronary syndrome; ARVC, arrhythmogenic right ventricular cardiomyopathy; AV, atrioventricular; BrS, Brugada syndrome; CA,
cardiac arrest; CAD, coronary artery disease; CHD, congenital heart disease; CPVT,
catecholaminergic polymorphic ventricular tachycardia;
DCM,
dilated cardiomyopathy;
HNDCM,
hypokinetic non-dilated cardiomyopathy;
ICD,
implantable cardioverter deﬁbrillator; LCSD, left cardiac sympathetic denervation;
LQTS, long QT syndrome; LV, left ventricle; LVEF, left ventricular ejection fraction;
NYHA, New York Heart Association; OMT, optimal medical treatment; PES,
programmed electrical stimulation; PVC, premature ventricular complex; PVT,
polymorphic ventricular tachycardia; RV, right ventricle; RVOT, right ventricular outﬂow tract; SMVT, sustained monomorphic ventricular tachycardia; STEMI, ST
elevation myocardial infarction; TdP, torsade de pointes; TOF, tetralogy of Fallot; VF,
ventricular ﬁbrillation; VT, ventricular tachycardia.
aOther risk factors include moderate RV or LV dysfunction, extensive RV scarring on
CMR, QRS duration ≥180 ms, and severe QRS fragmentation.
bArrhythmic syncope or haemodynamically not-tolerated VA.


<!-- PAGE 15 -->

### Page 15

### 3 Deﬁnitions

3.1. Ventricular arrhythmia subtypes
Premature ventricular complex (PVC): Premature occurrence of an abnormal QRS complex (duration typically ≥120 ms, corresponding
T-wave typically broad and in the opposite direction of the major
QRS deﬂection, no preceding P-wave).
Unifocal or monomorphic PVCs: PVCs with a single QRS morphology.
Multifocal, multiform, or polymorphic PVCs: PVCs with different QRS
morphologies.
Short-coupled PVC: A PVC that interrupts the T-wave of the preceding conducted beat.
Ventricular tachycardia (VT): ≥3 consecutive beats with a rate
.100 b.p.m. originating from the ventricles, independent from atrial and atrioventricular (AV) nodal conduction.
Non-sustained ventricular tachycardia (NSVT): Run of consecutive ventricular beats persisting for 3 beats to 30 s.
Monomorphic ventricular tachycardia (MVT): Same QRS morphology from beat to beat.
Polymorphic ventricular tachycardia (PVT): Continually changing QRS
morphology.
Sustained monomorphic/polymorphic ventricular tachycardia (SMVT/
SPVT): Continuous VT for at least 30 s, or which requires an intervention for termination.
Bidirectional ventricular tachycardia: Beat to beat alternation of the frontal QRS axis (e.g. in catecholaminergic polymorphic ventricular tachycardia
[CPVT],
Andersen–Tawil,
digoxin toxicity,
acute myocarditis).
Torsades de pointes ventricular tachycardia (TdP): Subtype of a polymorphic VT in the context of QT prolongation with continually changing QRS complexes that appear to spiral around the baseline of the electrocardiogram (ECG) lead in a sinusoidal pattern.
Ventricular ﬁbrillation (VF): A chaotic rhythm with undulations that are irregular in timing and morphology, without discrete QRS complexes on the surface ECG.
Electrical storm: VA that occurs 3 or more times within 24 h (separated by at least 5 min), each requiring termination by an intervention.
Incessant VT: Continuous sustained VT that recurs promptly despite repeated intervention for termination over several hours.
3.2. Sudden cardiac death
Sudden cardiac arrest (SCA): Sudden cessation of normal cardiac activity with haemodynamic collapse.
Sudden cardiac death (SCD): Sudden natural death presumed to be of cardiac cause that occurs within 1 h of onset of symptoms in witnessed cases, and within 24 h of last being seen alive when it is unwitnessed. SCD in autopsied cases is deﬁned as the natural unexpected death of unknown or cardiac cause.
Sudden unexplained death: Unexplained sudden death occurring in an individual older than 1 year.
Sudden infant death syndrome (SIDS): Unexplained sudden death occurring in an individual younger than 1 year with negative pathological and toxicological assessment and negative forensic examination of the circumstances of death.
Sudden arrhythmic death syndrome (SADS): Unexplained sudden death occurring in an individual older than 1 year with negative pathological and toxicological assessment. Note: Synonymous with
‘autopsy-negative sudden unexplained death’.
3.3. Syncope
Unexplained syncope: Transient loss of consciousness due to cerebral hypoperfusion, characterized by a rapid onset, short duration, and spontaneous complete recovery, but unexplained after conventional workup. Work-up and differential diagnosis are provided in the 2018
ESC Guidelines for the diagnosis and management of syncope.1
Arrhythmic syncope: as above, but highly suspicious for intermittent bradycardia, rapid supraventricular tachycardia (SVT), or VA.
3.4. Specialized centres
Multidisciplinary teams: A multidisciplinary team across specialties is characterized by open communication, positive management and leadership,
appropriate resources,
and a
mix of skills.
Decision-making should be shared in the team.
Specialized centre for catheter ablation of VA: Patient and procedural complexity vary widely. Some patients require a more experienced operator and a centre with more capabilities, which is more likely in patients with a non-ischaemic aetiology. A specialized centre has at least one operator with appropriate experience in interventions that may be required for a successful procedure (e.g. percutaneous epicardial access). The centre performs catheter ablation of VT in structural heart disease (SHD) on a regular basis. In addition, the centre has the required resources to manage medical conditions, comorbidities, and potential complications in patients undergoing complex VA ablation; this includes interventional cardiology expertise, acute placement of mechanical circulatory assist devices, and cardiothoracic surgical back-up. Considering the variable availability across European countries, it is preferable to treat complex patients in the most experienced centre within reasonable distance.
3.5. Genetics
Pathogenic variant and likely pathogenic variant: The American College of Medical Genetics has provided a framework for the interpretation of disease causation by genetic variants standardized into classes. The genetic variants most likely to cause an associated disease are termed
V, ‘pathogenic’, and IV, ‘likely pathogenic’.
Mutation: This term is used in this document to mean a Class IV or
V variant.
Variant of uncertain signiﬁcance: A change in a gene’s deoxyribonucleic acid (DNA) sequence that has an unknown effect on a person’s health.
4. Epidemiology of sudden cardiac death, public awareness, and risk stratiﬁcation
4.1. Incidence of sudden cardiac death
SCD accounts for approximately 50% of all cardiovascular deaths,
with up to 50% being the ﬁrst manifestation of cardiac disease.19–24
Ideally, cases suspicious of SCD should be identiﬁed from multiple
ESC Guidelines
4011


<!-- PAGE 16 -->

### Page 16

sources and undergo autopsy, which is required to reliably exclude non-cardiac causes of sudden death (SD).
The incidence of SCD increases markedly with age. With a very low incidence during infancy and childhood (1 per 100 000 personyears),25–27 the incidence is approximately 50 per 100 000 personyears in middle-aged individuals (in the ﬁfth to sixth decades of life).28–30 In the eighth decade of life, it reaches an annual incidence of at least 200 per 100 000 person-years.20 At any age, males have higher SCD rates compared with females, even after adjustment for risk factors of coronary artery disease (CAD).24,31–33 Ethnic background also seems to have large effects.34,35 It is estimated that 10–20% of all deaths in Europe are SCD.36,37 Approximately
300 000 people in Europe have out-of-hospital cardiac arrest
(OHCA) treated by emergency medical systems every year.38,39
In the Western world, the epidemiology of SCD is closely related to CAD, which is responsible for up to 75–80% of SCD cases.40
While the prevalence of CAD has not decreased, there has been a signiﬁcant decline in mortality due to CAD. Reports show that the incidence of SCD is declining,40–42 but the risk of SCD as a proportion of the overall cardiovascular deaths may have increased.43,44
Although regular physical activity beneﬁts cardiovascular health,
sport, particularly when practiced vigorously, has been shown to be associated with SCD during or shortly after exercise in selected populations.45–51 Reports have suggested that the majority of sportsrelated SCD occurs in a recreational52,53 rather than competitive setting, especially among middle-aged male participants, suggesting that CAD is the most common underlying cause.46,54,55
4.2. Causes of sudden cardiac death in different age groups
Cardiac diseases associated with SCD vary depending on the individual’s age. In the young there is a predominance of primary electric diseases and cardiomyopathies, as well as myocarditis, and coronary anomalies.25,27,56–61 However, half of SCD cases during the fourth decade are related to CAD, especially acute coronary syndrome
(ACS).62,63
In older populations, chronic structural diseases predominate
(CAD either through acute coronary events or chronic coronary stenoses, valvular heart diseases, and heart failure), while potentially inherited electrical diseases or structural non-ischaemic diseases may cause more than 50% of SCD in individuals under the age of 50
years.27
Age distribution at presentation with ventricular arrhythmias and sudden cardiac death, dominant arrhythmia subtypes, triggers, genetic factors, and gender associated with increased risk for ventricular arrhythmias in selected primary electrical and structural heart diseases are presented in Figure 1.
4.3. Population vs. individual risk prediction
In the general population (individuals without known heart disease),
the most effective approach for preventing SCD resides in quantiﬁcation of the individual risk of developing CAD based on risk score charts.64,65 Several studies have provided evidence that there is a genetic predisposition to die suddenly during acute ischaemia.66–70
The goal would be to identify the relatively small, high-risk subgroups from the general population at risk of SCD as their ﬁrst cardiac event.
Models for novel SCD risk stratiﬁcation in the general population have recently been proposed.71–73 There are no clear data supporting the beneﬁt of mass screening programs in the general population for preventing SCD.74–76
For decades, investigators have envisioned a broad range of ‘indicators’ for SCD, especially occurring in the setting of CAD. Several non-invasive markers of risk have been proposed (including late potentials, heart rate variability, periodic repolarization dynamics, and baroreﬂex sensitivity).77 Despite the promising outcomes of initial studies, however, these ‘predictors’ have not yet inﬂuenced clinical practice. Left ventricular ejection fraction (LVEF) is only used, often in combination with New York Heart Association (NYHA) class, for primary prevention indication of an ICD in the setting of chronic
CAD and dilated cardiomyopathy (DCM). Risk stratiﬁcation schemes and calculators have been developed for inheritable arrhythmogenic diseases, such as hypertrophic cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and lamin A/C
(LMNA) cardiomyopathy.78–82
What is considered low, intermediate, or high risk will depend on the type of event (e.g. fatal or not) and the risk of an event in the background population. For instance, mortality depends on age,
sex, and other risk factors including comorbidities. The situation is further complicated when considering a speciﬁc type of death, e.g.
SCD. Then non-SCD deaths are competing events (or competing risks) to SCD in the sense that their occurrence prevents the observation of SCD, and may make interventions to prevent SCD, such as an ICD, of limited beneﬁt.
4.4. Risk calculators for sudden cardiac death and review of the methodology
A number of risk calculators for SCD have been proposed for adult and paediatric populations.80,81,83–85 The ﬁeld of prediction modelling has evolved over the past decades, establishing standards for the development, validation (internal and external), and reporting of prediction models in SCD.86,87 In addition to discrimination measures such as the c-index, measures of calibration such as the calibration slope have recently received more attention because it is not only important to distinguish patients with higher risks from those with lower risks but also to obtain a robust quantiﬁcation of the risk itself from the risk calculators.88 Typical shortcomings in the development and validation of risk calculators include, but are not limited to, the use of historic samples not representative of contemporary patient cohorts, missing values, composite outcomes with composite events of different clinical importance, lack of external validation, and missing calibration. In this document different cut-off for 5 years risk of
SCD/VA is used for indication of ICD. Each cut-off was chosen by the original authors and the task force group considering the competing risk, the outcome measured (SCD vs VA) and the robustness of each risk calculator.
4.5. Awareness and intervention: public basic life support, and access to automated external deﬁbrillators
Survival rate remains strikingly low after OHCA,89–95 although major regional disparities have been described.96 Early implementation of


<!-- PAGE 17 -->

### Page 17

resuscitative interventions, especially prior to emergency medical system arrival, has been identiﬁed as key elements to improve survival.95,97 Bystander cardiopulmonary resuscitation (CPR) and use of public automated external deﬁbrillators (AEDs) have demonstrated improvement of neurological and functional outcome as well as survival of OHCA patients. Data support the need for increased availability of public access deﬁbrillators and community training in basic life support,89–95 preferably initiated in childhood and repetitive.98–100 Finally, dispatch of basic life support-trained volunteers, through speciﬁc mobile apps networks, has been shown to increase the rate of bystander-initiated CPR, and as a result, greatly reduces the resuscitation-free interval and improves the outcome of
Genetic risks and triggers for VA/SCD
CPVT
LQT
BrS
ACS
Sarcoid
HCM
DCM
ARVC
rTOF
chronic
CAD
Age at 
VA/SCD
Dominant subtype of VA (%)
10
20
30
40
50
60
70
80
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
0
50
100
Figure 1 Central ﬁgure. Genetic risk for VA/SCD, typical triggers for VA/SCD, age at presentation with VA/SCD, sex predominance, and typical VA
(PVT/VF vs. MVT) in different diseases associated with VA/SCD. ACS, acute coronary syndrome; ARVC, arrhythmogenic right ventricular cardiomyopathy; BrS, Brugada syndrome; CAD, coronary artery disease; CPVT, catecholaminergic polymorphic ventricular tachycardia; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LQT, long QT syndrome; MVT, monomorphic ventricular tachycardia; PVT, polymorphic ventricular tachycardia; rTOF, repaired tetralogy of Fallot; SCD, sudden cardiac death; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation.
ESC Guidelines
4013


<!-- PAGE 18 -->

### Page 18

OHCA victims.101–103 Education of public ofﬁcials and community members regarding the importance of increasing rates of bystander
CPR and promoting the use of early deﬁbrillation by lay and professional rescuers is critical to increasing survival rates.
5. Evaluation and treatment.
General aspects
5.1. Diagnostic tools
5.1.1. History and physical examination
History should focus on ‘red ﬂags’, including features of arrhythmic syncope, e.g. absence of vagal prodrome, and family history of premature or SCD including, e.g. drowning or car accident in long QT
syndrome (LQTS), and CPVT.1,106 Subtle features to suggest inherited causes include a family history of epilepsy, sudden infant death syndrome, deafness (LQTS), heart failure, or pacemaker implantation at ,50 years old. Features of diseases related to pro-arrhythmic conditions include mid-systolic click in mitral valve prolapse (MVP) and outﬂow tract murmurs with Valsalva in HCM. Speciﬁc skin features may be relevant, e.g. Lupus pernio, erythema nodosum in sarcoidosis,
angiokeratoma in Fabry’s disease, xanthelasma/xanthoma, and palmoplantar keratosis in ARVC.
5.1.2. Laboratory testing
Natriuretic peptides (b-type-natriuretic peptide, or N-terminal pro-b-type-natriuretic peptide) may have a role in the identiﬁcation of individuals at increased risk of SCD in the general population107,108
or in patients with CAD.109 There is not sufﬁcient evidence to use b-type-natriuretic peptide as a method to select the need for an
ICD.110,111
5.1.3. Non-invasive and invasive tests
5.1.3.1. Electrocardiogram and ambulatory electrocardiographic monitoring2
The 12-lead ECG is an important tool for the diagnosis of underlying disease, for risk stratiﬁcation in selected populations, and for the diagnosis of the VA subtype, if captured. Documentation of arrhythmias related to symptoms is clinically pivotal but may be challenging with sporadic events. The type of ECG-monitoring device and the recording time should therefore match the frequency of clinical events.
Monitoring over a period of 24–48 h (typically ‘Holter recording’) is appropriate for daily arrhythmias,112 while intermittent monitoring over a longer period, with patient-activated ECG recorders (or mobile-health/smartphones), should be preferred for infrequent events.113 Implantable loop recorders (ILR) can be useful in diagnosing arrhythmias in patients with potentially life-threatening symptoms, such as unexplained syncope.114
5.1.3.2. Signal-averaged electrocardiogram
Signal-averaged electrocardiogram (SaECG) can detect very low amplitude signals (‘late potentials’) in the terminal QRS segment115
using three time-domain measurements: QRS duration, low-amplitude
(,40 µV) signal duration and root mean square voltage of terminal
40 ms QRS.112 Abnormalities in the SaECG can also be assessed by frequency-domain analysis.112 SaECG can contribute to the diagnosis of ARVC.116
5.1.3.3. Exercise testing
Exercise testing is useful for the diagnosis and for evaluating response to therapy in patients with suspected/proven adrenergic-dependent rhythm disturbances, such as exercise-induced idiopathic MVT, PVT,
or bidirectional VT in CPVT.117,118 The 4-minute recovery QTc after exercise testing can contribute to the diagnosis LQTS.119
5.1.3.4. Imaging
Imaging is crucial to assess cardiac function and detect cardiomyopathies (
ESC CardioMed chapter 10).120 A negative imaging study supports primary electrical disease in a patient with VA.
Echocardiography is a readily available and ﬁrst-line diagnostic and risk stratiﬁcation tool for valve diseases, CAD and DCM, HCM, ARVC,121
and left ventricular non-compaction (LVNC). Echocardiographic strainrate imaging allows differentiation between active and passive movement of myocardial segments and early detection of myocardial dysfunction. Wall motion abnormalities can indicate previous infarcts,
cardiomyopathies, or inﬂammatory disease. Global longitudinal strain is a robust measure of left ventricular (LV) function and can detect subtle changes in LV function while LVEF is still preserved.122 Strain imaging can assess mechanical dispersion reﬂecting inhomogeneous contraction that could be associated with increased risk of VA.122–125
CMR currently provides the most accurate and reproducible measurement of atrial, biventricular global and regional systolic function,
and can detect myocardial oedema, ﬁbrosis, inﬁltration, and
Recommendation Table 1 — Recommendations for public basic life support and access to automated external deﬁbrillators
Recommendations
Classa
Levelb
It is recommended that public access deﬁbrillation be available at sites where cardiac arrest is more likely to occur.c,90–92
I
B
Prompt CPR by bystanders is recommended at
OHCA.93–95
I
B
It is recommended to promote community training in basic life support to increase bystander
CPR rate and AED use.93,97,104
I
B
Mobile phone-based alerting of basic life support-trained bystander volunteers to assist nearby OHCA victims should be considered.101–103,105
IIa
B
© ESC 2022
AED, automated external deﬁbrillator; CPR, cardiopulmonary resuscitation; OHCA,
out-of-hospital cardiac arrest.
aClass of recommendation.
bLevel of evidence.
cShopping centres, stadiums, public transport stations, casinos.


<!-- PAGE 19 -->

### Page 19

perfusion defects (
ESC CardioMed chapter 11.4).126 CMR is more sensitive than echocardiography to diagnose ARVC,127 is diagnostic in LVNC, and can detect apical aneurysms in HCM. Fibrosis detection by late gadolinium enhancement (LGE) contributes to
VA risk stratiﬁcation in HCM,128 DCM,129 and potentially in mitral valve prolapse arrhythmic syndrome.130,131 Novel myocardial mapping techniques can detect diffuse ﬁbrosis and can suggest the aetiology of left ventricular hypertrophy (LVH) for speciﬁc therapy guiding, e.g. Fabry disease and amyloidosis. The prognostic value remains to be evaluated.
Cardiac imaging by computed tomography (CT) has the advantage of a high spatial resolution (
ESC CardioMed chapter 12.1).132
ECG synchronization, additional breath-hold sequences, and betablocker to lower the heart rate improve the quality. Radiation exposure is in the range of an invasive coronary angiogram
(CAG). Coronary computed tomography angiography (CTA) is the preferred method to rule out coronary artery stenosis in patients with low probability of CAD.133,134 The quality of almost all image modalities is inﬂuenced by the presence of frequent
PVCs.
5.1.3.5. Provocative diagnostic tests
These are summarized in Table 6. Common tests performed are sodium channel blocker testing for Brugada syndrome (BrS) and adenosine test to exclude latent pre-excitation.135,136 Epinephrine challenge may be useful in CPVT when exercise cannot be performed. Epinephrine test is not recommended for LQTS due to the high false positive rate and utility of exercise testing.137
Coronary vasospasm as a cause of VF in the absence of obstructive coronary diseases/cardiomyopathy can be tested with incremental intracoronary doses of acetylcholine/ergonovine.
5.1.3.6. Electrophysiological study
Electrophysiological studies including measurement of baseline intervals (e.g. atrial–His interval [AH] and His–ventricular interval [HV]),
programmed electrical stimulation (PES), and electroanatomical mapping can be used for diagnostic purposes and to guide therapy.145–150 The yield of PES varies with the underlying cardiac condition and its severity, the presence or absence of spontaneous VT,
concomitant drug therapy, stimulation protocol, and site(s) of stimulation. Typical protocols include stimulation from 2 right ventricular
(RV) sites with 2–3 basic drive cycle lengths, introduction of 3 extrastimuli, and isoprenaline administration.148,151,152
In the current era, PES is mainly employed to conﬁrm the diagnosis of VT and induce mappable VAs with non-inducibility being an ablation endpoint. Patients with heart failure and LVEF ≤35% generally will have an indication for an ICD; therefore, VT/VF induction before implantation is not necessary. In patients with SHD and mildly reduced or preserved LVEF who present with unexplained syncope, induction of SMVT with PES can be helpful to identify the underlying cause and to predict subsequent events.146,153 PVT/VF induction in
SHD is in general considered as a non-speciﬁc ﬁnding.154–156
In primary electrical diseases, PES is not of prognostic value, although there is some evidence to consider its use in BrS.127
Invasive electrophysiological evaluation can have important clinical implications in patients with myotonic dystrophy.157
With advances in high-density mapping, voltage mapping, conduction/repolarisation metrics, and electrogram fractionation can be employed to identify ablation targets,
or to diagnose cardiomyopathic disease. Endocardial mapping may be helpful in the differentiation of ARVC from benign outﬂow tract VT and for targeting biopsy in suspected myocarditis, ARVC, and sarcoidosis cases.158–162
5.1.4. Genetic testing
Massive parallel or next-generation sequencing has led to increasing availability of genetic testing at reduced cost. Most diagnostic cardiac genetic testing employs large gene panels determined by associations with disease generated by prior research, i.e. candidate genes.163
Many previous gene associations have, however, been challenged for their diagnostic utility. Therefore, it is not recommended to include questionable genes in routine diagnostic panels.164–168
Genome-wide association studies have identiﬁed that common genetic variation single nucleotide polymorphisms can cause or modify phenotypes in BrS, LQTS, HCM, and DCM. Polygenic risk scores,
measures derived from the cumulative effects of these single nucleotide polymorphisms, may therefore play a role in diagnosis and prognostication in these conditions in the future.168–173
Sequencing produces digital data that require subsequent bioinformatic analysis, permitting accurate ascertainment of most
DNA alterations affecting the coding frame of each gene.174 The most common ﬁndings are single nucleotide variants causing simple amino acid substitutions (missense), premature terminations, or splicing abnormalities. Insertions and/or deletions are rarer. The clinical importance of most non-coding variants is still to be determined.174,175
A framework for the interpretation of disease causation by genetic variants has standardized adjudication into ﬁve classes: V ‘pathogenic’; IV ‘likely pathogenic’; III ‘variant of uncertain signiﬁcance’; II ‘likely benign’; and I ‘benign’. A combination of evidence is employed: gene–
disease association; presence of a variant in healthy and/or diseased populations; in silico data; in vitro and in vivo functional data; and family segregation data.176
A mutation (Class IV or V variant) can be used immediately either for conﬁrmation of diagnosis in probands (the ﬁrst affected family member), or for initial diagnosis of relatives and may help to guide therapy and/or prognosis. Periodic reassessment of all class IV and
III variants is indicated.176
Pre-implantation genetic testing is an early form of pre-natal genetic diagnosis. Genetic diagnoses of in vitro fertilized embryos are identiﬁed by biopsies, thereby allowing transfer of genetically normal embryos into the uterus. If the technique is available, it is important to provide information to patients with monogenic heart diseases in child-bearing age. The legislation for pre-implantation genetic testing varies in different countries and strategies differ.
Genetic and clinical testing should be undertaken only by multidisciplinary teams including professionals with skills to counsel on the implications and the uncertainty of results and experienced cardiologists able to direct testing to the correct phenotype.135,177–179 A
negative result does not exclude a diagnosis and should not be used for this purpose. A framework for genetic and other clinical diagnostic tests for primary electrical diseases based on evidence where available has been provided in Table 7.
ESC Guidelines
4015


<!-- PAGE 20 -->

### Page 20

Table 6
Intravenous provocative diagnostic tests
Diagnostic test
Indication
Protocols
Dose/infusion rate/duration
Positive test
Contraindications
Criteria to stop test,
counselling and management
Observation times
Location
Ref
Ajmaline
Family history of BrS
or SADS.
Resuscitated CA
without SHD.
1 mg/kg over 5–10 min
(maximum dose
100 mg) or 1 mg/kg at 10 mg/min.
Record in standard and high precordial leads over 30 min.
BrS type 1 ECG.
Type I BrS ECG, HF.
Precaution if evidence of conduction disease (consider temporary pacing wire).
VT/VF, Type 1 BrS ECG,
PVCs, QRS widening
.150%.
If VT/VF, administer iv isoprenaline, iv sodium bicarbonate.
30 min if negative test; 4 h if positive test.
Cath lab or outpatient testing location with full resuscitation equipment.
136,138,139
Flecainide
Same as ajmaline.
2 mg/kg over 10 min
(maximum dose
150 mg).
Record in standard and high precordial leads over 30 min.
Same as ajmaline.
Same as ajmaline.
Same as ajmaline.
4 h if negative test;
24 h if positive test.
Same as ajmaline.
140
Epinephrine
CPVT and resuscitated CA
with or without
SHD when exercise test not feasible.
Family history of
SADS.
Rest 10 min.
Start at 0.025 µg/ kg/
min for 10 min increase sequentially to 0.05, 0.1 and 0.2 µg/
kg/min in 5 min steps.
≥3 beats of PVT
or bidirectional
VT.
QTc prolongation ≥480 ms.
Systolic blood pressure ≥
200 mmHg,
non-sustained VT or PVT,
.10 PVCs /min, T-wave alternans, or patient intolerance.
If symptoms persist after discontinuation, iv metoprolol 2.5–5 mg over 1 min.
30 min.
Same as ajmaline.
141
Acetylcholine
Suspicion of coronary vasospasm.
Intracoronary injection: RCA: 20 and
50 µg. LCA: 20, 50,
and 100 µg over 20 s.
.3-min intervals between injections.
Maximal dose of 50 µg in the RCA and 100 µg in the LCA.
Coronary artery spasm visualized during procedure.
Left main stenosis .50%,
3-vessel disease, 2-vessel disease with total occlusion,
NYHA III/IV HF, renal failure,
severe bronchial asthma.
Temporary wire for back-up pacing.
Risk of cardiogenic shock.
Normal post-procedure observational time.
Cath lab.
142
Continued


<!-- PAGE 21 -->

### Page 21

Table 7
Genetic tests and suggested work-up of probands and relatives with primary electrical diseases
LQTS
BrS
CPVT
Idiopathic VF
ERS
Genetic test
Class Ia
Class I
Class Ia
Class IIb
Class IIb
Proband
Initial clinical test
Cornerstone for diagnosis
ECG
Exercise test
ECG and high precordial lead ECG
Sodium channel blockers provocative testc
Exercise test
See Section 5.2.3, scenario 3
ECG
Other tests/processes
Exclude acquired
LQTS
Exclude phenocopyb
Exclude phenocopyb/SHD
Holter
Echocardiography
Follow-up
1–3 years dependent on level of risk
Relatives
Clinical screening
ECG
Exercise test
(when feasible)
From birth
ECG and high precordial lead ECGs: start at 10 years
Sodium channel blockers provocative testc: start .16
years unless clinically indicated180,181
ECG
Exercise test
From birth
ECG and high precordial lead ECGs
Exercise test
Echocardiogram182
ECG
Echocardiogram
Follow-up
Positive phenotype and/or
Class IV/V variant
1–3 years dependent on level of risk
Negative phenotype and no
Class IV/V variant
Discharge
© ESC 2022
BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ECG, electrocardiogram; ERS, early repolarization syndrome; LQTS, long QT syndrome; VF, ventricular ﬁbrillation.
aIncluding neonatal genetic testing.
bA phenocopy has characteristics of a genetic disease but is produced environmentally.
cNot in case of a documented type 1 Brugada pattern.
Ergonovine
Same as acetylcholine.
Intracoronary stepwise injection:
RCA (20–60 mg)
LCA (20–60 mg) over a period of 2–5 min.
Same as acetylcholine
Left main stenosis .50%,
3-vessel disease, 2-vessel disease with total occlusion,
NYHA III/V HF, renal failure.
Temporary wire should be placed for back-up pacing.
Risk of cardiogenic shock.
Same as acetylcholine.
Cath lab.
143
Adenosine
Exclude latent pre-excitation.
6, 12, 18 mg boluses up to maximum dose
24 mg or until AV
block or pre-excitation occurs.
Identiﬁcation of accessory pathway.
Asthma, sinus node disease,
allergy to adenosine.
Side effects:
Bronchospasm,
bradycardia, asystole, AF,
seizure. Antagonist:
theophylline.
5 min.
Same as ajmaline.
144
© ESC 2022
AF, atrial ﬁbrillation; AV, atrioventricular; BrS, Brugada syndrome; CA, cardiac arrest; CPVT, catecholaminergic polymorphic ventricular tachycardia; ECG, electrocardiogram; HF, heart failure; LCA, left coronary artery; NYHA, New York Heart
Association; PVCs, premature ventricular complexes; PVT, polymorphic ventricular tachycardia; RCA, right coronary artery; SADS, sudden arrhythmic death syndrome; SHD, structural heart disease; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
ESC Guidelines
4017


<!-- PAGE 22 -->

### Page 22

5.2. Diagnostic evaluation at ﬁrst presentation with ventricular arrhythmia in patients without known cardiac disease
VA and (aborted) SCD are common ﬁrst manifestations of a previously not known cardiac condition. A comprehensive diagnostic evaluation is provided for ﬁve frequently encountered scenarios.
5.2.1. Scenario 1: Incidental ﬁnding of a non-sustained ventricular tachycardia
An algorithm for the evaluation of patients presenting with an incidental ﬁnding of NSVT is presented in Figure 2.
Incidental NSVT is a common ﬁnding during routine cardiological evaluation (e.g. for non-cardiac diseases, pre-initiation of oncological treatments, pre-participation in sports) and monitoring before induction of anaesthesia/sedation for non-cardiac procedures.184
Patients with incidentally found NSVT require further evaluation.
A recent syncope suspicious for cardiac origin is a high-risk symptom and may prompt admission to hospital.1,185 The morphology of
NSVT (polymorphic or monomorphic) is important to assess.
Typical MVT morphologies (Figure 3) can suggest an idiopathic origin with favourable prognosis. In contrast, short-coupled PVC initiating non-sustained PVT or monomorphic NSVT with short cycle length
(usually ,300 ms, average 245 + 28, in one series) may identify patients at higher risk of SCD.186,187 Resting 12-lead ECG is a ﬁrst-line evaluation and may show signs of SHD or primary electrical diseases
(
ESC CardioMed chapter 8.6).188 Echocardiography is the ﬁrstline imaging modality that provides important information about cardiac function and potential SHD (
ESC CardioMed 10.3, 10.10,
10.12).120,189,190 Holter monitoring is useful to assess the frequency of NSVT and related PVCs (
ESC CardioMed chapter 8.9).191 In addition, an at least 3-lead Holter (V1, two inferior leads) may give a
ﬁrst estimate if NSVT/PVC are unifocal or multifocal and of the
NSVT site(s) of origin. The latter is important if the NSVT has not been previously documented on a 12-lead ECG.192
An exercise test can be helpful to capture the 12-lead ECG of
NSVT and to identify exercise-induced arrhythmias. Increasing arrhythmias with exercise, not suggestive of idiopathic origin, should raise suspicion of SHD and may necessitate advice to refrain from physical exercise until diagnosis and initiation of appropriate treatment. Underlying signiﬁcant CAD should be ruled out according to the patient’s pre-test probability.
CMR should be considered when cardiomyopathies or inﬂammatory diseases are suspected on initial evaluation (
ESC
CardioMed chapter 10.4).193 In addition, CMR can identify areas of
ﬁbrosis as substrates of NSVT.129
5.2.2. Scenario 2: First presentation of sustained monomorphic ventricular tachycardia
An algorithm for the evaluation of patients presenting with a ﬁrst
SMVT episode is presented in Figure 4.
The majority of patients presenting with SMVT have underlying SHD. SMVT in SHD is mainly due to scar-related re-entry and only occasionally due to re-entry involving a diseased conduction system or due to focal sources.
Recommendation Table 3 — Recommendations for evaluation of patients presenting with newly documented ventricular arrhythmia
Recommendations
Classa
Levelb
In patients with newly documented VA (frequent
PVCs, NSVT, SMVT), a baseline 12-lead ECG,
recording of the VA on 12-lead ECG, whenever possible, and an echocardiogram are recommended as ﬁrst-line evaluation.
I
C
In patients with newly documented VA (frequent
PVCs, NSVT, SMVT) and suspicion of SHD other than CAD after initial evaluation, a CMR should be considered.194,195
IIa
B
In patients with an incidental ﬁnding of a NSVT,
a ≥24 h Holter ECG should be considered.
IIa
C
© ESC 2022
CAD,
coronary artery disease;
CMR,
cardiac magnetic resonance;
ECG,
electrocardiogram; NSVT, non-sustained ventricular tachycardia, PVCs, premature ventricular contractions;
SHD,
structural heart disease;
SMVT,
sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 2 — Recommendations for genetic testing
Recommendations
Classa
Levelb
Genetic testing is recommended when a condition is diagnosed in a living or deceased individual with a likely genetic basis and a risk of VA and
SCD.56,183
I
B
When a putative causative variant is ﬁrst identiﬁed,
evaluation for pathogenicity is recommended using an internationally accepted framework.176
I
C
When a Class IV or Class V variant has been identiﬁed in a living or deceased individual with a condition that carries a risk of VA and SCD,
genetic testing of ﬁrst-degree and symptomatic relatives and obligate carriers is recommended.
I
C
It is recommended that genetic testing and counselling on its potential consequences should be undertaken by an expert multidisciplinary team.179
I
C
It is recommended that Class III (variants of uncertain signiﬁcance) and Class IV variants should be evaluated for segregation in families where possible, and the variant re-evaluated periodically.
I
C
It is not recommended to undertake genetic testing in index patients with insufﬁcient evidence of a genetic disease.
III
C
© ESC 2022
SCD, sudden cardiac death; VA, ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 23 -->

### Page 23

The diagnosis of the underlying aetiology and identiﬁcation of patients with idiopathic VT is important. Initial evaluation includes a comprehensive clinical and family history, 12-lead
ECG, and echocardiography. Recording of the 12-lead VT ECG
is indicated as it provides important information on the VT
site of origin. Speciﬁc VT morphologies (e.g. right ventricular outﬂow tract [RVOT] or fascicular origin) (Figure 3) in the absence of a family history for cardiomyopathies and without evidence for SHD are suggestive for idiopathic VTs.196 Atypical
ECG morphologies and uncommon clinical presentations should raise suspicions for underlying SHD even if baseline ECG and echocardiogram are normal. In this scenario, additional evaluation with CMR should be considered.194 Bundle branch reentrant ventricular tachycardia (BBR-VT), resembling bundle branch block conﬁguration on the ECG, is a feature of conduction impairment, e.g. in DCM, myotonic dystrophy, and post-cardiac valve surgery (Figure 5).
If initial evaluation raises suspicion of underlying CAD, a CAG can exclude signiﬁcant CAD. If ECG and echocardiography are suggestive for a cardiomyopathy, CMR provides important diagnostic information on scar distribution and tissue characteristics (Section 5.1.3.4).
When non-invasive evaluation is inconclusive, electroanatomical mapping and PES may be considered for the differential diagnosis between idiopathic VT and early ARVC.197 Electroanatomical mappingguided biopsy can be of value to provide a tissue diagnosis for ARVC
and inﬂammatory diseases with a focal distribution (e.g. cardiac sarcoidosis).198,199 In cases of suspected inﬂammatory diseases, positron emission tomography CT (PET-CT), autoimmune serology,
and biopsies of affected tissue are part of the diagnostic evaluation.200,201
N
N
Patient with incidental finding of NSVT
Arrhythmic syncope or fast monomorphic NSVT
or short coupled PVC foll f
owed by polymorphic NSVT
Dischargee
Go to section
Idiopathic PVC/VT
Suggestive of idiopathic origina
NSVT/PVC burden >10%
12-lead ECG
(Class I)
Ambulatory evaluation
Consider admission
Echocardiogram
(Class I)
≥24 h Holter
(Class IIa)
Suggestive of SHDb
Suggestive/Diagnostic of primary electrical diseasec
Further evaluati a on according to most like k ly diagnosis
Go to section
Primary electrical disease
Y
Y
NSVT evaluation
(Cycle length, morpholo
,
gy,y exercise induced)
(Class I)
Personal history
(Cardiovascular r r isk factors,
symptoms, co
,
-morbidities,
medicati a on)
Family history
 (SCD, prima
,
ry electrical disease, ca
,
rdiomyopathy)
Laboratory
(Electrolytes,
(NT-)p
T
roBNP,P TSH/T4)
CMR
(Class IIa)
Exclude
CADd
Figure 2 Algorithm for the evaluation of patients presenting with an incidental ﬁnding of non-sustained ventricular tachycardia. CAD, coronary artery disease; CMR, cardiac magnetic resonance; ECG, electrocardiogram; N, No; NSVT, non-sustained ventricular tachycardia; PVC, premature ventricular complex; SCD, sudden cardiac death; SHD, structural heart disease; Y, Yes. aECG morphology suggestive of RVOT or fascicular origin, negative family history,
normal 12-lead ECG, and echocardiogram. be.g. atrioventricular conduction abnormalities, Q waves, broad QRS complex, ST/T waves deviations, abnormally high or low voltages. Ventricular dysfunction/dilatation/hypertrophy/wall thinning, wall motion abnormalities, multitopic PVCs/NSVTs/increasing ventricular arrhythmia (VA) burden with exercise. ce.g. Brugada pattern, long/short QT, polymorphic/bidirectional VA with exercise. dDiagnostic test to exclude CAD
according to patient proﬁle and symptoms. eConsider re-evaluation in case of new symptoms or changes in patient clinical condition.
ESC Guidelines
4019


<!-- PAGE 24 -->

### Page 24

5.2.3. Scenario 3: Sudden cardiac arrest survivor
An algorithm for the evaluation of sudden cardiac arrest survivors is presented in Figure 6.
Urgent CAG is recommended for patients presenting with ST elevation myocardial infarction (STEMI).203–206 Despite disparate ﬁndings of pooled data analyses,207–211 three randomized controlled trials
(RCTs) have found no signiﬁcant beneﬁt for early CAG in cardiac arrest (CA) without ST-elevation. In case of electrical instability after
CA, suspicious for ongoing ischaemia, this panel found a CAG indicated. Brain and chest CT scan may acutely identify non-cardiac causes of aborted SD,212 as well as blood test results for pertinent toxicological analysis.213–215 Retention and storage of suitable blood samples will allow subsequent diagnostic evaluation, including DNA analysis.213
LV fascicular VT (RBBB- like, superior axis, QRS 130 ms)
RVOT VT (LBBB-like, inferior axis, V4 transition)
Figure 3 Typical idiopathic ventricular tachycardia morphologies. LBBB, left bundle branch block; LV, left ventricle; RBBB, right bundle branch block;
RVOT, right ventricular outﬂow tract; VT, ventricular tachycardia.
Recommendation Table 4 — Recommendations for evaluation of patients presenting with a ﬁrst episode of sustained monomorphic ventricular tachycardia
Recommendations
Classa
Levelb
In patients presenting with a ﬁrst SMVT episode,
electrophysiological study, electroanatomical mapping, and mapping-guided biopsies may be considered for aetiological evaluation.197–199,202
IIb
C
© ESC 2022
SMVT, sustained monomorphic ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 25 -->

### Page 25

Exclude
CADd
CMR
(Class IIa)
Autoimmune serology
Cardiac/tissue biopsy
PET-CT
T
Mapping-guided biopsy
(if regional ventricular involvement)
(Class IIb)
Go to section
Inflammatory cardiac diseases r
Further evaluation according to most like k ly diagnosis
Go to section
ARVC
EP study and RV
R
electro-anatomical mapping
(± mapping-guided biopsy)
(Class IIb)
Suggestive of SHD other than CADc
Suggestive of CADb
Suggestive of idiopathic origina
Suggestive of inflammatory diseaseg
Suggestive of other cardiomyopathyf
Suggestive of ARVC
R
e
Go to section Idiopathic PVC/VT
CAG
CAD
positive negative
No CAD
Go to section CAD
C
N
Y
Patient with first SMVT episode
12-lead ECG
(Class I)
Echocardiogram
(Class I)
VT 12-lead ECG
(Cycle length, morpholo
,
gy,y exercise induced)
(Class I)
Personal history
(Cardiovascular risk factors,
symptoms, co
,
-morbidities,
medicati a on)
Family history
 (SCD, prima
,
ry electrical disease, ca
,
rdiomyopathy)
Laboratory
(Electrolytes,
(NT-)p
T
roBNP,P TSH/T4)
Figure 4 Algorithm for the evaluation of patients presenting with a ﬁrst sustained monomorphic ventricular tachycardia episode. ARVC, arrhythmogenic RV cardiomyopathy; CAD, coronary artery disease; CAG, coronary angiography; CMR, cardiac magnetic resonance; ECG, electrocardiogram; EP,
electrophysiological; LV, left ventricular; N, No; PET-CT, positron emission tomography and computed tomography; PVC, premature ventricular complex; RV, right ventricular; SCD, sudden cardiac death; SHD, structural heart disease; SMVT, sustained monomorphic ventricular tachycardia; VT, ventricular tachycardia; Y, Yes. aECG morphology suggestive of RV outﬂow tract or fascicular origin, negative family history, normal 12-lead ECG, and echocardiogram. be.g. Q waves, QRS fragmentation, ST/T abnormalities, wall motion abnormalities in coronary territories. ce.g. atrioventricular (AV)
conduction abnormalities, Q waves, broad QRS complex, T-wave inversion, abnormally high or low voltages. Ventricular dysfunction/dilatation/hypertrophy/wall thinning/wall motion abnormalities/diffuse hypokinesia. dDiagnostic test to exclude CAD according to patient proﬁle and symptoms.
eAccording to revised task force criteria.116 fe.g. AV conduction abnormalities, abnormally high or low voltages, broad QRS, ST/T wave deviations, LV
dilatation and dysfunction, late gadolinium enhancement with non-ischaemic distribution. ge.g. AV conduction abnormalities, broad QRS, ST/T deviations,
multifocal PVCs, inﬂammatory hyperaemia and oedema, ﬁbrosis, LV and RV systolic dysfunction, pericardial effusion.
ESC Guidelines
4021


<!-- PAGE 26 -->

### Page 26

Any ECG tracing from emergency services, as well as recordings from interrogation of cardiovascular implantable electronic devices
(CIEDs) can also contribute to diagnosis.216–219 The resting 12-lead
ECG (including high precordial lead)220 is fundamental and should be repeated regularly during recovery. Continuous heart rhythm monitoring is recommended until deﬁnite treatment.221,222
Echocardiography may allow early diagnosis to identify any structural abnormality.222,223 Coronary imaging will be important to exclude
CAD, dissection, or anomalies.62,224 Coronary optical coherence tomography and/or intravascular ultrasound may be helpful to characterize stenosis/plaque stability and underlying mechanism of stenosis.225 CMR has repeatedly been shown to provide signiﬁcant incremental diagnostic value, in particular for concealed cardiomyopathy.131,226–228 Primary electrical diseases may be uncovered by provocative manoeuvres such as sodium channel blocker challenge,136,229–231 lying to standing ECGs,232,233 adenosine challenge,144,234
epinephrine challenge,141,152,235–239
ergonovine/
acetylcholine,222,240
mental stress,241,242
and exercise testing.116,117,119,232,243 Electrophysiological study and electroanatomic mapping may be useful to provide patient-speciﬁc insights into the mechanism of CA and to offer therapeutic options in some patients.244–248 Genetic testing may identify a molecular cause of SCA by identifying pathogenic mutations in genes associated with speciﬁc phenotypes.213,249,250
Recommendation Table 5 — Recommendations for evaluation of sudden cardiac arrest survivors
Recommendations
Classa
Levelb
Diagnostic evaluation
The investigation of a SCA survivor without obvious extra-cardiac cause is recommended to be overseen by a multidisciplinary team.177,251–256
I
B
In electrically unstable patients after SCA, with suspicion of ongoing myocardial ischaemia, a coronary angiogram is indicated.
I
C
Continued
ECG during BBR-VT
ECG during sinus rhythm
I
II
III
aVR
aVL
aVF
V1
V4
V5
V6
V2
V3
I
II
III
aVR
aVL
aVF
V1
V4
V5
V6
V2
V3
Figure 5 Bundle branch re-entrant ventricular tachycardia. BBR-VT, bundle branch re-entrant ventricular tachycardia; ECG, electrocardiogram.


<!-- PAGE 27 -->

### Page 27

5.2.4. Scenario 4: Sudden death victim
An algorithm for the evaluation of SD victims is presented in Figure 7.
Potential genetic cardiac disease can be identiﬁed in 25–49% of cases of SCD in the young (,50 years of age). This may also affect relatives of the deceased.25,56,59 To ﬁnd the cause of death, it is important to collect all available data on prior symptoms, comorbidities, and family history.25,56,215,262,263
The main role of autopsy in SD is to establish the cause of death.
An expert cardiac pathologist alters the initial diagnosis in 41% of cases, highlighting the need for expert evaluation.263–265 Inherited cardiac diseases identiﬁed at autopsy include cardiomyopathies
(HCM, DCM, ARVC) and premature CAD.25,27,56,266 A toxicology screen can reveal drug overdose or polypharmacy in 31–56% of young SD cases.267,268 In autopsy-negative cases with negative toxicology, the term sudden arrhythmic death syndrome (SADS) may be applied and primary electrical diseases are potential causes.56,183,223,253 Retaining tissue for DNA extraction is important for post-mortem genetic analysis, where the yield can be as high as one out of three.183,269,270
Clinical evaluation of ﬁrst-degree relatives is important if the cause of death after autopsy is unknown (Section 5.2.5, scenario 5) or suspected to be inherited, with a reported combined diagnostic yield of genetic and clinical evaluation of 18–53%.252,266,271 Post-mortem genetic testing on the deceased, targeted to the cause of death, identiﬁed mutations in around one-third of cases.56,266,269
In SCA survivors, brain/chest CT scan should be considered when patient characteristics, ECG, and echocardiography are not consistent with a cardiac cause.212,257
IIa
C
In SCA survivors, collection of blood samples at presentation is recommended for potential toxicology and genetic testing.56,214
I
B
Retrieval of recordings from CIEDs and wearable monitors is recommended for all SCA
survivors.217,218
I
B
In SCA survivors, repeated 12-lead ECGs during stable rhythm (including high precordial lead
ECG), as well as continuous cardiac monitoring,
are recommended.220,222
I
B
Echocardiography is recommended for evaluation of cardiac structure and function in all SCA survivors.
I
C
Coronary imaging and CMR with LGE are recommended for evaluation of cardiac structure and function in all SCA survivors without a clear underlying cause.62,222,223,226
I
B
Sodium channel blocker test and exercise testing is recommended in SCA survivors without a clear underlying cause.117,222,258–260
I
B
In SCA survivors, ergonovine, acetylcholine, or hyperventilation testing may be considered for the diagnosis of coronary vasospasm.240,261
IIb
B
© ESC 2022
CIEDs, cardiac insertable electronic devices; CMR, cardiac magnetic resonance; CT,
computed tomography; ECG, electrocardiogram; LGE, late gadolinium enhancement;
SCA, sudden cardiac arrest.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 6 — Recommendations for evaluation of sudden death victims
Recommendations
Classa
Levelb
Investigation of unexpected SD, especially in case of suspicion of inherited disease, should be made a public health priority.20,25,56
I
B
In cases of SD, it is recommended to collect a detailed description of circumstances of death,
symptoms prior to death, the family history, and to review prior medical ﬁles.25,56
I
B
A comprehensive autopsy is recommended,
ideally, in all cases of unexpected SD, and always in those ,50 years of age.183,264,265,267,269,270
I
B
In cases of SCD, it is recommended to retain samples suitable for DNA extraction and consult a cardiac pathologist when an inherited cause is suspected or the cause of death unexplained.264,265
I
B
Toxicology screens are recommended in SD cases with uncertain cause of death.267,268
I
B
For SCD where the cause is known or suspected to be heritable, genetic testing targeted to the cause is recommended.56,266,269
I
B
Following SADS, post-mortem genetic testing targeted to primary electrical disease is recommended when the decedent is young (,50)
and/or the circumstances and/or family history support a primary electrical disease.56,183,223
I
B
When an autopsy diagnoses possible heritable cardiac disease, it is recommended to refer
ﬁrst-degree relatives for cardiac assessment in a specialized clinic.271,272
I
B
In non-autopsied cases of SD where inherited cardiac disease is suspected, it is recommended to refer ﬁrst-degree relatives for cardiac assessment in a specialized clinic.223,253,273
I
B
Following SADS, post-mortem genetic testing in the decedent for additional genes may be considered.
IIb
C
Following SADS, hypothesis-free post-mortem genetic testing using exome or genome sequencing is not recommended.274,275
III
B
© ESC 2022
DNA, deoxyribonucleic acid; SADS, sudden arrhythmic death syndrome; SCD, sudden cardiac death; SD, sudden death.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4023


<!-- PAGE 28 -->

### Page 28

5.2.5. Scenario 5: Relatives of sudden arrhythmic death syndrome decedents
An algorithm for the evaluation of relatives of SADS decedents is presented in Figure 8.
Studies evaluating families of SADS decedents have identiﬁed underlying genetic heart disease in relatives that is presumed to be the cause of death in the absence of other
ﬁndings. The overall diagnostic yield ranged from 18 to 53%,
depending on population and clinical investigative protocols.276 Aetiologies included LQTS, BrS, CPVT, and other disorders, such as cardiomyopathy.276 All study protocols relied upon a similar initial approach of evaluating the decedent’s pathological reports, medical history, and circumstances of death, and then offering clinical evaluation to relatives with a minimum of personal history, family history, physical examination,
ECG and exercise test, and echocardiography.223,252,253,277–282
12-lead ECG (Class I)
STEMI
Suspicious for extraca f
rdiac cause
Extracardiac cause identified
Preexcitation or suggestive of primary electrical disease
Non-cardiac
Brain and chest CT scan (Class IIa)
Acute culprit lesion
Further evaluation according to STEMI guidelines
Electrical instability suspicious for on f
going myocardial ischaemia
Urgent CAGa (Class I)
N
N
N
N
N
N
SCA survivor
Y
Y
Y
Y
Y
Preexcited AF
or probable primary electrical diseaseb, c
,
Y
Evaluation of patient characteristics and circumstances of SCA
(Class I)
Echocardiogram
(Class I)
Collect blood sample for t f
oxicology and genetic testing (Class I)
Review/Repeat ECG (Class I)
Figure 6 Part One. Algorithm for the evaluation of sudden cardiac arrest survivors.


<!-- PAGE 29 -->

### Page 29

CAD/coronary anomaly
LGE on CMR
Primary electrical disease
Echocardiogram suggestive of CAD/
cardiomyopathy/valvular heart disease/other SHD
N
Cardiac CT/CAG (if previously not performed)
f
(Class I)
N
High lead and repeated 12-lead ECGs
(Class I)
N
CMR
(Class I)
N
Vasospasm
V
Y
Further evaluation according to most like k ly diagnosis.
If SMVT,T go to scenario 2:
Patient with
P
fif rst
SMVT episoded
CAD/Coronary anomaly
Y
Primary electrical disease
Y
Y
Y
Y
Y
N
Positive
IdiopathicVF
Test
T
for co f
ronary vasospam
(Class IIb)
N
N
Primary electrical disease
N
Suspicion of vasospasme
Exercise test (Class I)
Sodium channel blocker test (Class I)
k
Figure 6 Part Two. Algorithm for the evaluation of sudden cardiac arrest survivors. AF, atrial ﬁbrillation; CAD, coronary artery disease; CAG, coronary angiogram; CMR, cardiac magnetic resonance; CT, computed tomography; ECG, electrocardiogram; LGE, late gadolinium enhancement; N, No;
SCA, sudden cardiac arrest; SHD, structural heart disease; SMVT, sustained monomorphic ventricular tachycardia; STEMI, ST elevation myocardial infarction; VF, ventricular ﬁbrillation; Y, Yes. aThe 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with
ST-segment elevation.3 bRule out SHD according to patient age and characteristics; QT duration needs to be reassessed several days after arrest.
cConsider cardiac CT/CAG depending on patient characteristics and clinical context. dLeft ventricular function on echocardiogram needs to be reassessed several days after arrest to exclude stunning as cause of systolic dysfunction. eIn case of high clinical suspicion (typical symptoms and transient ST elevation during monitoring), it can be considered to test for coronary vasospasm earlier.
ESC Guidelines
4025


<!-- PAGE 30 -->

### Page 30

Sudden death victim
Sav a e tissue for potential genetic testing f
(Class I)
Comprehensive autopsya
(Class I)
Refer first-deg f
ree relatives for ca f
rdiac assessment
(Class I)
Post-mortem genetic testing with genetic counsellingc 
(Class I)
Sav a e blood for potential t f
oxicology testing
(Class I)
Targeted genetic testing
T
(Class I)
Refer first-deg f
ree relatives for ca f
rdiac assessment
(Class I)
To
T xicology testing
(Class I)
Collect detailed description about:
Non-cardiac cause of SD
SCD of non-inherited cause
Cause diagnosed
Negative autopsy
Go to Scenario 5:
Relatives of unexplained SD decedent
SADS decedent age <50 years or circumstances or family history suggestive of heritable disease
SCD of suspected inherited causeb
Cause of death not due to drug overdose
Sudden arrhythmic death syndrome
(SADS)
Drug overdose
(Class I)
Circumstances of death
Symptoms and prior history of deceased
Family history
Figure 7 Algorithm for the evaluation of sudden death victims. SADS, sudden arrhythmic death syndrome; SCD, sudden cardiac death; SD, sudden death. aAutopsy is recommended, ideally in all cases of unexpected SD and always in those under 50 years. Autopsy should include full macroscopic examination and histopathology of all organs. The heart should ideally be examined by an expert cardiac pathologist. Samples suitable for DNA extraction should be retained when inherited causes or unexplained death are suspected. bBased on all circumstances, this includes negative autopsies, autopsies with uncertain ﬁndings, non-ischaemic cardiomyopathies, coronary artery disease where familial hypercholesterolaemia is suspected and thoracic aortic dissections. cAfter informed consent of relatives.


<!-- PAGE 31 -->

### Page 31

Where they diverged was the frequency of usage of additional tests such as high-lead ECGs, Holter monitoring, signal-averaged
ECG, CMR, and provocative testing.135 Sodium channel blocker drug challenge and high-lead ECGs systematically performed in
SADS relatives provided a yield of 28% BrS diagnoses in one study281; however, there are concerns about false positives.139
Furthermore, epinephrine challenge has not been studied systematically in SADS families but, in the opinion of this panel,
may be of utility in CPVT-suspected patients who are unable to exercise.137
Recent data indicated at least a 13% genetic yield in SADS
cases.135,178,183,276,283 Routine follow-up of families without a diagnosis yields little in new diagnoses,284 although children of decedents may be followed for age-penetrant disease until adulthood.181
If an autopsy is ambiguous, or if an autopsy was not undertaken in a young SCD case with family or personal history suspicious for inherited heart disease, then the yield of familial evaluation was similar to that in clear SADS cases.223,253,271
6. Therapies for ventricular arrhythmias. General aspects
6.1. Acute management
6.1.1. Treatment of reversible causes
Reversible causes may account for up to 50% of SCA.285,286 However,
most of the time it is difﬁcult to determine the exact underlying cause of
SCA and whether it is reversible. A comprehensive evaluation of patients with SCA is mandatory if the underlying cardiac disease is unknown or disease progression is suspected (Section 5.2.3, scenario 3).
Electrolyte imbalances, such as hypokalaemia, may trigger VA, and a rapid rise in extracellular potassium may lead to asystole.287–289 Other factors such as bradycardia, ischaemia, coronary spasm, thrombosis, fever,
acute starvation, and dieting may contribute to the occurrence of VA.
290–292 Acute correction of these reversible factors is recommended.
Drug-induced arrhythmias should be suspected in patients being treated with agents known to alter the electrical properties of the heart
(e.g. inducing QRS and/or QT prolongation) or causing electrolyte abnormalities (e.g. thiazide and loop diuretics). When drug-induced arrhythmias are presumed, any offending drug needs to be withdrawn and substances that are known to prolong QT (e.g. sotalol) should be avoided.293,294 Hypomagnesaemia and/or hypokalaemia may be associated with Torsades de pointes (TdP). Intravenous magnesium is an effective therapy for TdP even in the absence of hypomagnesaemia.295
In refractory cases of recurrent TdP in the setting of acquired long QT,
the arrhythmia can be suppressed by increasing the underlying heart rate using isoproterenol (isoprenaline) or transvenous pacing.
Patients who survive SCA in the context of a presumed reversible cause may have a high mortality rate.286 In a recent large observational study296 on survivors of SCA attributed to a reversible and correctable cause, subsequent ICD implantation was associated with lower all-cause mortality except for aborted CA occurring in the presence of acute myocardial infarction (MI). Thus, the need for prophylactic ICD implantation should be considered based on the underlying cardiac disease and an individual evaluation of the future risk of life-threatening VA.
Recommendation Table 7 — Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents
Recommendations
Classa
Levelb
Familial evaluation of SADS decedents is recommended:
• for ﬁrst-degree relatives
• for relatives who must carry a mutation based on analysis of the family history
• for relatives with suspicious symptoms
• when the decedent’s age is ,50 years, or if there is other circumstantial data or family history to suggest heritable disease.223,252,253,277,281
I
B
Familial evaluation of SADS decedents is recommended to include genetic testing when post-mortem genetic testing in a SADS decedent detects a pathogenic mutation.183,253,277,281
I
B
Baseline familial evaluation of SADS decedents is recommended to include taking a medical history and performing physical examination, standard and high precordial lead ECG, echocardiography, and exercise testing.223,252,253,277,281
I
B
In SADS families without a diagnosis after clinical evaluation, follow-up is recommended for children of decedents until they reach adulthood.181,284
I
C
Pharmacological testing with a sodium channel blocker should be considered in relatives of SADS
decedents who are 16 years or older when baseline testing and/or proband ﬁndings increase the suspicion of BrS.277,281
IIa
B
Continued
Ambulatory cardiac rhythm monitoring and CMR
may be considered in relatives of SADS
decedents.223,253,277,281
IIb
C
Pharmacological testing including epinephrine challenge (if exercise testing is impractical) and sodium channel blocker challenge may be considered in ﬁrst-degree relatives of SADS
decedents with normal baseline testing.223,281
IIb
B
In SADS families without a diagnosis after clinical evaluation, follow-up is not recommended for asymptomatic adults who can be discharged with advice to return if they develop symptoms or if the family history changes.181,284
III
C
© ESC 2022
BrS, Brugada syndrome; CMR, cardiac magnetic resonance; ECG, electrocardiogram;
SADS, sudden arrhythmic death syndrome.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4027


<!-- PAGE 32 -->

### Page 32

Diagnosis
N
Diagnosis
N
Diagnosis
N
Relatives of unexplained sudden death decedent
Medical history
Physical examination
Standard and high precordial lead ECG
Echocardiography
Exercise testing
Clinical and/or genetic diagnosis
Manage relatives according to condition
Ambulatory cardiac rhythm monitoring and CMR
(Class IIb)
Follow-up for child f
ren of decedent
Discharge asymptomatic adultsc
(Class I)
Non-autopsied sudden death decedent with young age, fami
,
ly history of
SCD or circumstances suggestive of heritable heart disease
SADS decedent
Genetic testing negative or not performed f
(age <50 years or circumstances or family history suggestive of heritable disease)
SADS decedent
Pathogenic mutation identified
Familial evaluation in first-degree relatives,
or relatives with suspicious symptoms
(Class I)
(Class I)
Y
Y
Y
Familial evaluation in first-degree relatives,
obligate carriers or relatives with suspicious symptoms according to condition
(Class I)
Genetic counselling and cascade testing for 
f relatives
(Class I)
Sodium channel blocker test k
a
(Class IIa)
Epinephrine testb
(Class IIb)
Figure 8 Algorithm for the evaluation of relatives of unexplained sudden death decedents. CMR, cardiac magnetic resonance; ECG, electrocardiogram;
N, No; SADS, sudden arrhythmic death syndrome; SCD, sudden cardiac death; Y, Yes. aOver 16 years old + any suspicions for Brugada syndrome on tests or decedent circumstances of death. bIf exercise is not feasible. cRe-evaluate if change in family history or new symptoms.


<!-- PAGE 33 -->

### Page 33

6.1.2. Acute management of sustained monomorphic ventricular tachycardia
Patients presenting with SMVT should be treated according to symptoms and aetiology (Figure 9). Patients presenting with haemodynamic instability require immediate synchronized cardioversion. If synchronization is not possible, an unsynchronized shock should be used. Cardioversion is not indicated in patients with repetitive
NSVTs (Figure 10). Documentation of any haemodynamically tolerated wide QRS tachycardia on 12-lead ECG is important.
Administration of adenosine300 or vagal manoeuvres with continuous recording of 12-lead ECG should be considered if supraventricular tachycardia (SVT) is likely. Intravenous adenosine may also terminate speciﬁc VT subtypes. Such a response supports cyclic adenosine monophosphate (cAMP)-mediated triggered activity as an underlying
VT mechanism.301 Pre-excited atrial ﬁbrillation (AF) can be recognized by the ‘FBI’ (fast, broad, irregular) ECG pattern. It may mimic
VT, and intravenous administration of drugs that slow AV conduction,
such as adenosine, beta-blockers, and amiodarone, should be avoided.302 Prompt termination of SMVT is recommended even for tolerated SMVT, as rapid haemodynamical deterioration may occur.
Recommendation Table 8 — Recommendations for treatment of reversible conditions
Recommendations
Classa
Levelb
Withdrawal of offending agents is recommended whenever drug-induced VAs are suspected.293,294,297
I
B
Investigation for reversible causes (e.g. electrolyte imbalances, ischaemia, hypoxaemia, fever)c is recommended in patients with VA.292,298
I
C
Despite a possible correctable cause for the presenting VA, the need for ICD implantation should be considered based on an individual evaluation of the risk of subsequent VA/
SCD.286,296,299
IIa
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; SCD, sudden cardiac death; VA, ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
cList not exhaustive.
N
N
N
Acute management of a patient with regular wide QRS complex tachycardia
Cardioversion (Class I)
Procainamide
(Class IIa)
Flecainide
Ajmaline
Sotalol
Amiodaronec
(Class IIb)
Procainamide
(Class IIa)
Amiodarone
(Class IIb)
Verapamil
(Class I)
Cardioversion/defibrillation/ALS
(Class I)
History, physical examination,
12-lead ECG
Known or suspicion of structural heart disease
Adenosine or vagal manoeuvres if SVT likelya
(Class IIa)
Beta-blockers
(Class I)
Anaesthetic risk for cardioversionb
Haemodynamically tolerated
Other type 
or uncertain
Known outflow tractVT
Known 
fascicularVT
Y
N
Anaesthetic risk for cardioversionb
Y
Y
Y
IdiopathicVT
Figure 9 Algorithm for the acute management of regular wide QRS complex tachycardia. ALS, advanced life support; ECG, electrocardiogram; N, No;
SVT, supraventricular tachycardia; VT, ventricular tachycardia; Y, Yes. aBesides SVT, adenosine may also terminate idiopathic VT, which then indicates triggered activity as the mechanism underlying the arrhythmia. bBeneﬁt of cardioversion should be weighed against risks related to anaesthesia/sedation.
cConsidering limited availability of the other anti-arrhythmic drugs.
ESC Guidelines
4029


<!-- PAGE 34 -->

### Page 34

Termination can be achieved with electrical cardioversion, antiarrhythmic medications, or pacing techniques. All anti-arrhythmic drugs (AADs) may lead to hypotension, but the individual risk of anaesthesia/sedation required for cardioversion also needs to be considered. For pharmacological termination of a haemodynamically tolerated VT of unknown aetiology, intravenous procainamide or amiodarone can be used. In the PROCAMIO trial,303 procainamide therapy was associated with a higher proportion of tachycardia termination and fewer major cardiac adverse events than amiodarone. Intravenous procainamide should not be used in patients with severe heart failure, acute MI, and end-stage renal disease.
Administration of other AADs (ajmaline, sotalol, and ﬂecainide)304,305
may be considered in patients without signiﬁcant heart disease, but the risk of adverse events should be carefully weighed. Availability of AADs has to be taken into account, e.g. procainamide is not available in many European countries. In patients with an ICD, manual overdrive pacing may terminate those VTs with a cycle length under the programmed ICD detection rate. In case of a known idiopathic VT
(Figure 4), treatment with beta-blockers (for RVOT VT)306 or verapamil (for fascicular VT)307 is recommended for acute conversion.
Although verapamil may terminate other types of idiopathic VT,307
important adverse effects such as severe hypotension may occur.
If the VT aetiology is uncertain, intravenous administration of verapamil is not recommended.308,309 A comprehensive evaluation of patients presenting with SMVT is mandatory if the underlying cardiac disease is unknown or disease progression is suspected
(Section 5.2.2, scenario 2).
6.1.3. Management of electrical storm and incessant ventricular tachycardia
An electrical storm is common in ICD patients and has been deﬁned as three or more episodes of sustained VA occurring within 24 h,
00:00
mm:ss
00:30
01:00
01:30
02:00
02:30
03:00
03:30
04:00
04:30
05:00
05:30
06:00
06:30
07:00
07:30
08:00
08:30
09:00
Repetitive runs of VT
Figure 10 Repetitive runs of ventricular tachycardia interrupted by occasional sinus beats. VT, ventricular tachycardia.


<!-- PAGE 35 -->

### Page 35

requiring either anti-tachycardia pacing (ATP) or cardioversion/
deﬁbrillation, with each event separated by at least 5 min.310–312
Patients who experience an electrical storm are prone to psychological disorders, heart failure decompensation, and increased mortality.313,314 The severity of an electrical storm can range from recurrent asymptomatic VT episodes terminated by ATP to a lifethreatening electrical instability with VA that recurs frequently after multiple shocks. Frequent ICD shocks can also be inappropriately delivered (Figure 11).
In cases of inappropriate ICD shocks (e.g. due to SVTs or lead defects) or unnecessary ICD therapy (e.g. for NSVT or for repetitive VTs that terminate and restart spontaneously), disabling of ICD therapies is recommended. If an electrophysiology specialist or programmer is not available, the ICD can be disabled by placing a magnet over the device.
Patient with electrical storm or repeated ICD discharges
ALS including external cardioversion/defibrillation
(Class I)
Rhythm assessment/ICD
interrogation
Inappropriate therapy due to AF/SVT/lead oversensing
Recurrent non-sustained
VA episodes
Inappropriate or unnecessary therapies
Electrical storm
Sedation (for comfort)
(Class I)
Assessment of haemodynamic status
N
N
Y
Y
Haemodynamically stable
VA type
Assessment of VA type
STEP 1
STEP 2
STEP 3
ICD
programming optimizationa
(Class I)
Treatment of AF/SVTa
(Class I)
Disable ICD by magnet placement if programmer not available
(Class I)
ICD
programming optimizationa
(Class I)
Disable ICD by magnet placement if programmer not available
(Class I)
PolymorphicVA
MonomorphicVA
Figure 11 Part One. Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges.
ESC Guidelines
4031


<!-- PAGE 36 -->

### Page 36

In case of haemodynamic instability at initial evaluation, institution of advanced life support (ALS) is recommended.315 Reversible conditions contributing to initiation and perpetuation of VA need to be corrected (see Section 6.1.1). Further management depends on the type of VA and the underlying aetiology.312,316 A multifaceted approach is often required for management, consisting of ICD reprogramming when appropriate, AAD therapy, sedation, catheter ablation, autonomic modulation, and mechanical circulatory support.
Elevated sympathetic tone needs to be addressed. For patients with recurrent ICD shocks, sedation is indicated to alleviate psychological distress and decrease pro-arrhythmogenic sympathetic tone.
Initial treatment with beta-blockers, preferably non-selective betablockers like propranolol, which was superior to metoprolol in one study,317 combined with amiodarone318 is most commonly used. In patients with recurrent haemodynamically not-tolerated
VTs resistant to amiodarone,
landiolol
(ultra-short-acting
β1-selective blocker) was found to be effective for arrhythmia suppression in two smaller studies.319,320 Administration of other
AADs such as procainamide,321 lidocaine,322 or quinidine296,297 depends on the speciﬁc situation, type of VA, and underlying aetiology.
When electrical storm remains intractable, with multiple shocks in a few hours, despite available anti-arrhythmic therapies, deep sedation/intubation should be considered, along with mechanical ventilation.325 If beta-blocker treatment is insufﬁcient or not tolerated to decrease sympathetic tone, selected patients may beneﬁt from autonomic modulation, i.e. percutaneous ganglionic stellate blockade,326
thoracic epidural anaesthesia,327
or left cardiac sympathetic denervation.328
The most common arrhythmia underlying electrical storm is
SMVT associated with SHD that is amenable to catheter ablation.313,329 Successful ablation was associated with a signiﬁcant reduction in VT and electrical storm recurrence and improved long-term survival in retrospective analyses.330,331 In patients with incessant slow MVT, catheter ablation is preferred over AAD therapy,
Underlying aetiology
Go to
ﬂowchart
STEMI
(Figure 14)
Treatment according to underlying condition
(Class I)
Polymorphic VA
Acute ischaemia
External precipitating factors
Polymorphic
VA triggered by unifocal
PVC
Acquired long QT
Primary electrical disease
Catheter ablation
(Class IIa)
Catheter ablation
(Class IIa)
Remove precipitating factors
(Class I)
Mg++/K + i.v. 
(Class I)
Mg++/K + i.v. 
(Class I)
Isoproterenol
(Class I)
Isoproterenol
(Class IIa)
Brugada, ERS
Recurrent VA
Idiopathic VF
Long QT, CPVT
Quinidine 
(Class IIa)
Catheter ablation of
PVC triggers
(Class IIa)
Autonomic modulation
(Class IIa)
AAD
according to underlying disease
(Class IIa)
Isoproterenol
(Class IIa)
Beta-blocker
(Class I)
Quinidine 
(Class IIa)
Verapamil
(Class IIa)
Pacing
(Class I)
Pacingd
(Class I)
Quinidineb
(Class IIb)
Deep sedation/ intubation
(Class IIa)
Mechanical circulatory support
(Class IIb)
Figure 11 Part Two.Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges.


<!-- PAGE 37 -->

### Page 37

which may only further slow VT. Catheter ablation should also be considered in patients with recurrent symptomatic episodes of PVT or VF triggered by a similar PVC.221,332–334 Institution of mechanical circulatory support may be considered for haemodynamic stabilization, when conventional therapy fails,
and to provide circulatory support during ablation.335 In a recent meta-analysis336 including 2465 patients, a substantially lower mortality was observed with prophylactic mechanical circulatory support treatment among patients suffering from electrical storm or high-risk PAINESD score.337 In contrast, rescue use of mechanical circulatory support during ablation was associated with a high mortality rate.338 In patients with electrical storm due to recurrent PVT/VF, the underlying aetiology determines further management (Figure 11).
N
Y
VA burdenc
MonomorphicVA
High
Low
ICD programming optimizationa
(Class I)
ICD programming optimizationa
(Class I)
On amiodarone or amiodarone not desirable
Catheter ablation
(Class I)
AAD according to underlying disease and cardiac function
Beta-blocker/sedation
(Class I)
Catheter ablation
(Class I)
Deep sedation/intubation
(Class IIa)
Autonomic modulation
(Class IIb)
Mechanical circulatory support
(Class IIb)
Overdrive pacinge
Amiodarone i.v.
(Class I)
Recurrent VA
Recurrent VA
Figure 11 Part Three. Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges. AAD, antiarrhythmic drug; AF, atrial ﬁbrillation, ALS, Advanced life support; CPVT, catecholaminergic polymorphic ventricular tachycardia; ERS, early repolarization syndrome; ICD, implantable cardioverter deﬁbrillator; N, No; PVC, premature ventricular complex; STEMI, ST-elevation myocardial infarction; SVT, supraventricular tachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; Y, Yes. aSpecial aspects of device therapy section. bNo data on effect of quinidine on PVC-triggered polymorphic VAs in patients with cardiomyopathies. cHigh VA burden refers to a clinical scenario of very frequent VA episodes requiring ICD shocks, when only short periods of stable rhythm can be achieved. Low VA burden refers to a clinical scenario of repeated ATPs/ICD
shocks followed by stable rhythm. dIf bradycardia or post-extrasystolic pauses facilitate initiation of PVT/VF. eOverdrive pacing (by pacing with a slightly higher rate than the baseline rhythm) can be useful to temporarily suppress slow recurrent/incessant VT.
Recommendation Table 9 — Recommendations for the acute management of sustained ventricular tachycardia and electrical storm
Recommendations
Classa
Levelb
Acute management of sustained VT
DC cardioversion is recommended as the
ﬁrst-line treatment for patients with haemodynamically not-tolerated SMVT.303,339
I
B
DC cardioversion is recommended as the
ﬁrst-line treatment for patients presenting with tolerated SMVT provided that the anaesthetic/
sedation risk is low.
I
C
Continued
ESC Guidelines
4033


<!-- PAGE 38 -->

### Page 38

6.2. Long-term management
6.2.1. Pharmacotherapy
Optimal medical treatment of the underlying cardiac disease, including the maximal tolerated doses of heart failure medication, is mandatory.341
In patients with heart failure with reduced ejection fraction
(HfrEF), the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure recommend angiotensinconverting enzyme inhibitor (ACE-I)/angiotensin receptor blocker
(ARB)/angiotensin receptor neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs), beta-blockers, and sodium–
glucose co-transporter 2 (SGLT2) inhibitors to reduce mortality due to heart failure and SCD.342
AADs have an important role as adjunctive therapy in the management of VA, especially in symptomatic patients (Table 8). Until now,
no AAD except for beta-blockers has demonstrated reduction in allcause mortality. Each drug has a signiﬁcant potential for causing adverse events, including pro-arrhythmia. For example, numerous AADs, as well as a large number of drugs with other therapeutic indications,
can prolong the QT interval (http://www.crediblemeds.org) and provoke TdP, have negative chronotropic effects, may deteriorate heart failure, and cause bradycardia. Several drugs increase the risk of VA in patients with BrS (http://www.brugadadrugs.org).
In patients presenting with a haemodynamically tolerated idiopathic VT, treatment with intravenous beta-blocker (RVOT VT) or verapamil (fascicular VT) is recommended.306,307
I
C
In patients presenting with a regular haemodynamically tolerated wide QRS complex tachycardia suspected for SVT, administration of adenosine or vagal manoeuvres should be considered.300
IIa
C
In patients presenting with a haemodynamically tolerated SMVT and known or suspected SHD,
intravenous procainamide should be considered.303
IIa
B
In patients presenting with a haemodynamically tolerated SMVT in the absence of an established diagnosis, intravenous amiodarone may be considered.303
IIb
B
In patients presenting with a haemodynamically tolerated SMVT in the absence of signiﬁcant SHD,
ﬂecainide, ajmaline, or sotalol may be considered.304,305
IIb
C
Intravenous verapamil is not recommended in broad QRS complex tachycardia of unknown mechanism.308,309
III
B
Management of electrical storm
Mild to moderate sedation is recommended in patients with electrical storm to alleviate psychological distress and reduce sympathetic tone.
I
C
Antiarrhythmic therapy with beta-blockers
(non-selective preferred) in combination with intravenous amiodarone is recommended in patients with SHD and electrical storm unless contraindicated.317,318
I
B
Intravenous magnesium with supplementation of potassium is recommended in patients with
TdP.295
I
C
Isoproterenol or transvenous pacing to increase heart rate is recommended in patients with acquired LQT syndrome and recurrent TdP
despite correction of precipitating conditions and magnesium.
I
C
Catheter ablation is recommended in patients presenting with incessant VT or electrical storm due to SMVT refractory to AADs.330,331
I
B
Deep sedation/intubation should be considered in patients with an intractable electrical storm refractory to drug treatment.325
IIa
C
Catheter ablation should be considered in patients with recurrent episodes of PVT/VF triggered by a similar PVC, non-responsive to medical treatment or coronary revascularization.221,332,333
IIa
C
Quinidine may be considered in patients with
CAD and electrical storm due to recurrent PVT
when other AAD therapy fails.323,324
IIb
C
Continued
Autonomic modulation may be considered in patients with electrical storm refractory to drug treatment and in whom catheter ablation is ineffective or not possible.326,328,340
IIb
C
Institution of mechanical circulatory support may be considered in the management of drug-refractory electrical storm and cardiogenic shock.335
IIb
C
© ESC 2022
AAD, anti-arrhythmic drug; CAD, coronary artery disease; DC, direct current; LQT,
long QT; PVC, premature ventricular complex; PVT, polymorphic VT; RVOT, right ventricular outﬂow tract;
SHD,
structural heart disease;
SMVT,
sustained monomorphic ventricular tachycardia;
SVT,
supraventricular tachycardia;
TdP,
Torsades de pointes; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 10 — Recommendations for treatment with heart failure medication
Recommendations
Classa
Levelb
Optimal medical treatment including ACE-I/ARB/
ARNIs, MRAs, beta-blockers, and SGLT2
inhibitors is indicated in all heart failure patients with reduced EF.343–347
I
A
© ESC 2022
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
ARNIs, angiotensin receptor neprilysin inhibitor; EF, ejection fraction; MRA,
mineralocorticoid receptor antagonists; SGLT2, sodium–glucose co-transporter 2.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 39 -->

### Page 39

Table 8
Anti-arrhythmic drugs (acute and chronic treatment)
Anti-arrhythmic drug
Effects on ECG
Indications
(speciﬁc indication)
Oral dose per day
(i.v. dose)
Side effects
Contraindications,
precautions, other considerations
Amiodarone
Decreases sinus node frequency,
prolongs QT
intervala
PVC, VT, VF
200–400 mg
Loading dose:
600–1200 mg/
24 h 8–10 days.
(Loading dose:
5 mg/kg in
20 min–2 h, 2–3
times in 24 h, then
600–1200 mg/
24 h 8–10 days)
Cardiac:
Bradycardia, TdP
(infrequent)
Extracardiac:
Photosensitivity, corneal deposits, hypothyroidism,
hyperthyroidism,
pulmonary toxicity,
hepatotoxicity,
polyneuropathy, skin discoloration
Precautions:
Sinus node dysfunction,
severe AV conduction disturbances,
hyperthyroidism
Other considerations:
Can be used in patients with heart failure. Increases the risk of myopathy when used with statins
Adenosine
Transitory AV block
Regular wide complex tachycardia of unknown origin
(outﬂow tract
VT)
No oral use
(6–18 mg bolus)
Chest pain, ﬂushing,
bronchoconstriction
Contraindications:
Severe asthma, pre-excited
AF
Other considerations:
Antagonist: theophylline
Ajmaline
Prolongs QRS
duration and QT
intervala
VT
(unmasking BrS
ECG)
No oral use
(1 mg/kg over
5–10 min
(maximum dose
100 mg) or
1 mg/kg at
10 mg/min)
Cardiac:
VF (rare in suspected BrS),
occasional TdP, negative inotrope
Extracardiac:
Cholestatic jaundice,
headache, nausea,
thrombocytopenia
Contraindications:
BrS ECG type I, QT
prolongation
Beta-blocker
Decreases sinus node frequency,
prolongs PR interval,
shortens QT interval
PVC, VT
(LQTS, CPVT)
Various
(various)
Cardiac:
Bradycardia, AV block,
hypotension, negative inotrope
Extracardiac:
Fatigue, bronchospasm,
sexual disturbances,
depression, cold extremities
Contraindications:
Severe sinus node dysfunction, severe AV
conduction disturbances,
decompensated heart failure,
coronary vasospasm, severe asthma, BrS
Landiolol
(Ultra-short acting
β1-selective blocker)
See beta-blocker
VT, electrical storm
No oral use
100 µg/kg bolus in
1 min, infusion
10–40 µg/kg/min
(max 80 µg/kg/
min; max 24 h total dose
57.6 mg/kg/day)
See beta-blocker
Contraindications:
See beta-blocker.
Bradycardia, hypotension
Other considerations:
Limited experience with its use beyond 24 h
Nadolol
(Non-selective
β1β2 blocker)
See beta-blocker
PVC, VT
(LQTS, CPVT)
40–120 mg
See beta-blocker
Contraindications:
See beta-blocker
Other considerations:
Plasma half-life 20–24 h
Propranolol
(Non-selective β1β2
blocker)
See beta-blocker
PVC, VT
(electrical storm,
LQTS, CPVT)
80–320 mg
(160 mg/24 h)
See beta-blocker
Contraindications:
See beta-blocker
Disopyramide
Increases sinus node frequency and prolongs PR interval,
QRS duration, and
QT intervala
PVC, VT
250–750 mg
Cardiac:
Negative inotrope, AV
block, pro-arrhythmia
(MVT, occasional TdP)
Contraindications:
Severe sinus node dysfunction, severe AV
conduction disturbances,
severe intraventricular
Continued
ESC Guidelines
4035


<!-- PAGE 40 -->

### Page 40

Extracardiac:
Anticholinergic effects conduction disturbances,
prior MI, signiﬁcant SHD,
hypotension
Other considerations:
Reduces LV outﬂow tract obstruction and symptoms in
HCM
Flecainide
Prolongs PR interval,
QRS duration, and
QT intervala
PVC, VT
(unmasking BrS
ECGb)
200–400 mg
(1–2 mg/kg over
10 min)
Cardiac:
Pro-arrhythmia (MVT,
occasional TdP), negative inotrope, sinus bradycardia, AV block, 1:1
AV conduction during
ﬂutter
Extracardiac:
Central nervous system effects (e.g. drowsiness,
diplopia, headache)
Contraindications:
Prior MI, signiﬁcant SHD, BrS,
severe sinus node dysfunction, severe AV or intraventricular conduction disturbances, inherited LQTS
(other than LQTS3), severe kidney disease (CrCl
,35 mL/min/1.73 m2)
Other considerations:
Discontinue if QRS widening
.25% or bundle branch block
Isoproterenol
Increases sinus node frequency, shortens
QT interval
(Electrical storm in BrS, idiopathic
VF, and ERS, TdP,
beta-blocker overdose;
acquired LQTS)
No oral use
(0.5–10 µg/min)
Cardiac:
Sinus tachycardia,
vasodilation
Extracardiac:
Headache, sweating,
tremor
Contraindications:
ACS, LQTS
Other considerations:
Short plasma half time
(2 min)
Lidocaine
No signiﬁcant effects
(VT/VF
associated with
ACS)
No oral use
(50–200 mg bolus,
then 2–4 mg/min)
Cardiac:
Sinoatrial arrest
Extracardiac:
Central nervous system effects (e.g. drowsiness,
dizziness)
Precautions:
Reduced dose with reduced liver blood ﬂow (e.g. shock,
β-blockade, severe heart failure)
Other considerations:
More effective with high potassium level. Few haemodynamic side effects
Mexiletine
No signiﬁcant effects
PVC, VT
(LQT3)
600–1200 mg
Loading dose:
400 mg initially followed by
600 mg in the ﬁrst
24 h
Cardiac:
Sinus bradycardia in sinus node dysfunction,
hypotension
Extracardiac:
Central nervous system effects (e.g. tremor,
dysarthria, dizziness),
gastrointestinal complaints
Contraindications:
Sinus node dysfunction,
severe AV conduction disturbances, severe heart failure
Procainamide
Prolongs PR interval,
QRS duration, and
QT intervala
VT
(100 mg bolus,
can be repeated after 5 min if no effect, max 500–
750 mg [max
50 mg/min]. Then,
2–6 mg/min)
Cardiac:
Sinus bradycardia,
hypotension, TdP
Extracardiac:
Rash, myalgia, vasculitis,
systemic lupus,
agranulocytosis
Contraindications:
Severe sinus node dysfunction, severe AV
conduction disturbances,
severe intraventricular conduction disturbances,
severe LV dysfunction hypotension, BrS
Propafenone
Prolongs PR interval,
QRS duration, and
QT intervala
PVC, VT
450–900 mg
Cardiac:
Sinus bradycardia, AV
block, negative inotrope,
pro-arrhythmia (MVT,
occasional TdP)
Extracardiac:
Gastrointestinal disturbances, headache,
dry mouth
Contraindications:
Prior MI, signiﬁcant SHD, BrS,
severe sinus node dysfunction,
severe AV or intraventricular conduction disturbances,
LQTS, signiﬁcant renal or liver disease
Other considerations:
Discontinue if QRS widening
.25% or bundle branch block
Continued


<!-- PAGE 41 -->

### Page 41

Quinidine
Increases sinus node frequency and prolongs PR interval,
QRS duration, and
QT intervala
(VFc, BrS, SQTS)
600–1600 mg
Loading dose:
Start 200 mg every 3 h until effect, max. 3 g in
ﬁrst 24 h
Cardiac:
Hypotension, TdPd
Extracardiac:
Gastrointestinal disturbances, auditory and visual disturbances,
confusion, leukopenia,
haemolytic anaemia,
thrombocytopenia,
anaphylaxis
Contraindications:
Severe sinus node dysfunction, severe AV or intraventricular conduction disturbances, previous MI,
signiﬁcant SHD, hypotension,
LQTS
Ranolazine
Decreases sinus node frequency,
prolongs QT
intervala
VT
(LQTS3)
750–2000 mg
Cardiac:
Sinus bradycardia,
hypotension
Extracardiac:
Dizziness, nausea,
constipation,
gastrointestinal disturbance, headache,
rash
Contraindications:
Severe sinus node dysfunction, severe heart failure, LQTS (other than
LQTS3)
Precautions:
Concomitant treatments associated with QT interval prolongation
Sotalol
Decreases sinus node frequency,
prolongs QT
intervala
VT
160–640 mg
(0.5–1.5 mg/kg in
10 min. If necessary, can be repeated after
6 h)
See beta-blockers, TdPd
(.2% of patients, close monitoring of QT interval and CrCl)
Contraindications:
Severe sinus node dysfunction, severe AV
conduction disturbances,
severe heart failure with reduced LVEF, signiﬁcant
LVH, CrCl ,30 ml/min,
coronary vasospasm, LQTS
Precautions:
Concomitant treatments associated with QT interval prolongation, hypokalaemia
Other considerations:
Potassium channel blocker effects require higher dose than beta-blocker effects
Verapamil
Prolongs PR interval
(LV fascicular tachycardia)
120–480 mg
(5–10 mg in slow bolus. If necessary,
can be repeated in
30 min)
Cardiac:
Sinus bradycardia in sinus node dysfunction, AV
block, negative inotrope,
hypotension
Extracardiac:
Gastrointestinal disturbances, peripheral oedema, ﬂushing
Contraindications:
Heart failure with reduced
LVEF, severe sinus node dysfunction, and severe AV
conduction disturbances, VT
of unknown origin, ACS,
WPW syndrome
Other considerations:
Increase the risk of myopathy when used with statins
© ESC 2022
ACS, acute coronary syndrome; AF, atrial ﬁbrillation; AV, atrioventricular; BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; CrCl, creatinine clearance; ECG, electrocardiogram; ERS, early repolarization syndrome; HCM, hypertrophic cardiomyopathy; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; MI, myocardial infarction; MVT, monomorphic ventricular tachycardia; PVC, premature ventricular complex; SHD, structural heart disease; SQTS, short QT syndrome; TdP, torsades de pointes; VF, ventricular ﬁbrillation; VT, ventricular tachycardia; WPW, Wolff–Parkinson–White.
aPrecaution with concomitant conditions or drugs that prolong QT interval. Should be discontinued if QTc .500 ms. See Figure 13 Algorithm for evaluation before initiation and follow-up of patients requiring drugs associated with QT prolongation.
bIf ajmaline not available.
cSubacute MI, multifocal ectopic Purkinje-related premature contractions, ERS, idiopathic VF.
dProarrhythmic side effects require strong indication in patients without ICD.
ESC Guidelines
4037


<!-- PAGE 42 -->

### Page 42

Modiﬁcation of risk factors, when possible, is important for prevention of pro-arrhythmia. In patients who require a potentially arrhythmiainducing drug, regular ECG and other tests according to the patient’s proﬁle and AAD characteristics are recommended (Figures 12 and 13).
6.2.2. Device therapy
6.2.2.1. Implantable cardioverter deﬁbrillator
ICD is an integral part of treating patients surviving a CA due to a VA
or those deemed to be at high risk thereof. Drawbacks are the high up-front device costs, device-associated complications, and the relatively high number-to-treat needed to prevent one SCD in primary prevention.
A patient-level meta-analysis of the three early ICD trials349–351
comparing ICD to medical therapy for secondary prevention of
SCD demonstrated a 28% mortality reduction (HR 0.72; 95% CI
0.6–0.87; P = 0.0006) almost entirely due to reduction of arrhythmic death (HR 0.5; 95% CI 0.37–0.67; P , 0.0001) in the ICD group.352
Therefore, the use of an ICD for secondary prevention of SCD
that occurred in the absence of reversible causes is widely accepted.
Several randomized controlled trials353–356 have established the role of the ICD for primary prevention of SCD in heart failure patients with an LVEF ≤35%. The reported mortality reduction has recently been supported by two large contemporary prospective registries enrolling more than
5000
patients.357,358
In the
EU-CERT-ICD trial, primary prevention ICD implantation was associated with a 27% lower mortality with similar results in CAD and
DCM.357 Results of the DANISH trial, however, indicate that the mortality beneﬁt may be less clear in contemporary patients with non-ischaemic heart failure (see Section 7.1.3.1).359
In the work-up for ICD therapy, it is of paramount importance to consider the patient’s life expectancy, quality of life, and comorbidities,
and to reassess and discuss these issues with the patient at the time of generator change. There is evidence that patients with end-stage renal disease, with diabetes, and elderly patients beneﬁt less or not at all from
Patient requiring sodium channel blocking agents
Assessment of patient risk proﬁle before initiation
ECG 1–2 weeks after initiation or increase in dosagee
Initiate treatmentc
Initiate treatment on individual decision (risk/beneﬁt)d
Known cardiac disease or
ECG abnormalities 
or 
Abnormal echocardiogram
ΔQRS > 25%f or
Abnormal exercise test?
(new BBB, ΔQRS >25%
or QRS >130 ms)
Contraindications:
N
N
Brugada syndrome a
Prior MI (ﬂecainide)b
Severe LV dysfunction
Severe valvular heart disease
Severe bradycardia, BBB, > ﬁrst degree AV block
Precaution:
Any degree of LV dysfunction
LV hypertrophy
Any signiﬁcant valvular heart disease
First degree AV block
Prolonged QT interval (disopyramide, quinidine)
Consider to change to dffierent drug
Consider to reduce dose
Consider to measure drug serum level
Y
Y
Continue treatment
Inform patient about warning symptoms (syncope)
Periodic ECG for QRS width evaluation
Control changes in renal and hepatic function
Be aware of potential drug interactions
Figure 12 Algorithm for evaluation before initiation and follow-up of patients requiring sodium channel blocking agents. AV, atrioventricular; BBB, bundle branch block; ECG, electrocardiogram; LV, left ventricular; MI, myocardial infarction; N, No; Y, Yes. ahttp://www.brugadadrugs.org. bFlecainide, encainide.
cCo-administration of drugs with AV nodal blocking effect in patients with atrial ﬁbrillation or atrial ﬂutter. dIn implantable cardioverter deﬁbrillator carriers, a higher risk of drug-induced pro-arrhythmia might be accepted. eAccording to the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation.348
fA ΔQRS .25% is not an absolute cut-off value but dependent on QRS width before drug initiation and individualized patient risk–beneﬁt considerations.


<!-- PAGE 43 -->

### Page 43

a primary prevention ICD.357,360–362 Women have been underrepresented in all primary prevention trials and data suggest that they may beneﬁt less.361 In general, the SCD risk needs to be weighed against the individual’s competing risk of a non-arrhythmic death.363,364
In the context of patient-centred medicine, physicians and healthcare professionals should engage ICD candidates and recipients in a joint decision process. Communication of relevant information, ensuring a good understanding of the beneﬁts, risks, and potential consequences of different options, to enable the patient to partake in decision-making is mandatory. This shared decision-making process should discuss the different scenarios including primary prevention
ICD implantation, consideration of ICD generator replacement,
and end-of-life care. Importantly, the perception of ‘good quality of life’ depends on numerous factors that are weighed differently by people with different cultural, religious, and socioeconomic backgrounds.
Although clinical prediction scores,
such as the
MADIT-ICD beneﬁt score,365 may provide helpful additional information, clinical decision-making should not only rely on such scores.
Complications of ICD therapy include inappropriate therapies,
lead fractures, and device-related infections. A subcutaneous implantable cardioverter deﬁbrillator (S-ICD) has been introduced to address problems related to transvenous leads. S-ICD has no intravascular lead and therefore cannot deliver ATP. In the
PRAETORIAN trial, 849 patients with an ICD but no pacing indication were randomized to an S-ICD or a transvenous ICD.366 Over a mean follow-up of 49 months, non-inferiority was shown for the primary endpoint of device-related complications and inappropriate shocks. The rate of inappropriate shocks was 9.7% in the S-ICD
group and 7.3% in the ICD group (HR 1.43; 95% CI 0.89–2.30)
and the rate of device related complications was 5.9% in the S-ICD
and 9.8% in the ICD group (HR 0.69; 95% CI 0.44–1.09). There was also no difference in the secondary endpoint of death and appropriate shocks, but the trial had not been powered to show noninferiority for this secondary endpoint. Of note, more than 80% of the included patients were in NYHA class I and II and the included patients were younger than in prior ICD trials.
Patient requiring a drug associated with QT prolongationa
Assessment of patient
 risk profile befof re initiation
ECG at baseline, after 1 d
,
ay and after1–2
a weeks of initiation or increase in dosagec
Continue treatment
Inform patient about warning symptoms (syncope)
f
Control changes in renal and hepatic function
Be awa a
re of potential drug interactions
Initiate treatment
QTc >500 ms
Contraindicated: Do not initiate t
:
reatment
Start drug if strong indication with close foll f
ow-up
Long QT syndrome or baseline QTc >500 msb
Hypokalaemia/hypomagnesaemia/
Renal failure/liver failure/
LV 
L hypertrophy/
Heart failure/
Additional QT prolonging drug
N
N
N
Consider to change to difff ef rent drug
If strong indication, consider to 
,
reduce dose
Consider to assess drug serum level
Y
Y
Y
Figure 13 Algorithm for evaluation before initiation and follow-up of patients requiring drugs associated with QT prolongation. ECG, electrocardiogram; LV, left ventricular; N, No; Y, Yes. ahttp://www.crediblemeds.org. bIf strong indication and no alternative treatment, consult a specialist. cAccording to the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation.348
ESC Guidelines
4039


<!-- PAGE 44 -->

### Page 44

6.2.2.2. Adding cardiac resynchronization therapy2
Cardiac resynchronization therapy (CRT) does reduce mortality in heart failure,367 and careful evaluation of the potential beneﬁt of
CRT in patients with ICD indication before implantation is mandatory.2 The role of the addition of a deﬁbrillator is less well established.368,369 The ongoing randomized controlled RESET-CRT trial aims to determine the impact of CRT-deﬁbrillator on overall mortality and SCD in heart failure patients with a CRT indication.
6.2.2.3. Wearable cardioverter deﬁbrillator
The wearable cardioverter deﬁbrillator (WCD) is an external deﬁbrillator that has been shown to successfully detect and treat VT and
VF.370 It is therefore suitable for patients who are at risk but temporarily not candidates for an ICD owing, for example, to extraction of an infected device and subsequent antibiotic treatment.371 An unsolved problem is the protection of patients in the early phase (40
days) after an MI. The VEST trial enrolled 2302 patients with acute
MI and an LVEF ≤35% and randomized them early in a 2:1 fashion to receive a WCD or not under guideline-directed optimal medical treatment (OMT).372 After a follow-up of 90 days there was no difference in the primary endpoint of arrhythmic death (1.6 vs. 2.4%; RR
0.67; 95% CI 0.37–1.21; P = 0.18). Concern was raised regarding the low median wear time of 18 h (IQR 3.8–22.7). The median wear time was higher (23.4 h, IQR 22.2–23.8) in a recent multicentre registry after structured patient education.371 However, based on the available data, the task force does not recommend routine use of the
WCD in the early post-MI phase. Nevertheless, the use of the device may be considered in selected post-MI patients deemed to be at high risk for SCD.
Data on the beneﬁt of the WCD for primary prevention of SCD in other clinical situations (e.g. acute myocarditis, primary prevention indication during pregnancy) are sparse and no recommendations can be currently made.
Recommendation Table 12 — Recommendations for secondary prevention of sudden cardiac death*
Recommendations
Classa
Levelb
ICD implantation is recommended in patients with documented VF or haemodynamically not-tolerated VT in the absence of reversible causes.349–352
I
A
In patients with VT/VF, an indication for ICD, and no contraindication for amiodarone, amiodarone may be considered when an ICD is not available,
contraindicated for concurrent medical reasons,
or declined by the patient.
IIb
C
In patients with SMVT or SPVT/VF triggered by a
PVC with similar morphology and an indication for ICD, catheter ablation may be considered when an ICD is not available, contraindicated for concurrent medical reasons, or declined by the patient.
IIb
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; PVC, premature ventricular complex;
SMVT, sustained monomorphic VT; SPVT, sustained polymorphic VT; VF, ventricular
ﬁbrillation; VT, ventricular tachycardia.
*For primary prevention and speciﬁc aspects of secondary prevention, go to Section 7.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 14 — Recommendations for adding cardiac resynchronization therapy to implantable cardioverter deﬁbrillator
Recommendations
Classa
Levelb
When an ICD is indicated, it is recommended to evaluate whether the patient could beneﬁt from
CRT-deﬁbrillator.367
I
C
© ESC 2022
CRT, cardiac resynchronization therapy; ICD, implantable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 11 — Recommendations for implantable cardioverter deﬁbrillator implantation
(general aspects)
Recommendations
Classa
Levelb
Implantation of a cardioverter deﬁbrillator is only recommended in patients who have an expectation of good quality survival .1 year.
I
C
It is not recommended to implant an ICD in patients with incessant VAs until the VA is controlled.
III
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; VA, ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 15 — Recommendations for wearable cardioverter deﬁbrillator
Recommendations
Classa
Levelb
The WCD should be considered for adult patients with a secondary prevention ICD indication, who are temporarily not candidates for ICD
implantation.
IIa
C
Continued
Recommendation Table 13 — Recommendations for subcutaneous implantable cardioverter deﬁbrillator
Recommendations
Classa
Levelb
Subcutaneous deﬁbrillator should be considered as an alternative to transvenous deﬁbrillator in patients with an indication for an ICD when pacing therapy for bradycardia, cardiac resynchronization, or ATP is not needed.366
IIa
B
© ESC 2022
ATP, anti-tachycardia pacing; ICD, implantable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 45 -->

### Page 45

6.2.3. Special aspects of device therapy
6.2.3.1. Optimization of device programming
Optimization of ICD programming is essential to minimize the burden of ICD therapy and to improve patient outcome.373–375 Detailed recommendations are available in expert consensus papers.376,377
Bradycardia mode should be customized to prevent unnecessary
RV pacing, thus reducing heart failure hospitalizations and all-cause mortality378–380 (
ESC CardioMed chapter 43.21).381 A tachycardia detection programming strategy incorporating prolonged settings and high rate thresholds (≥188 b.p.m. Advance III trial,382 ≥200
MADIT-RIT383) reduces ICD therapies and all-cause mortality without increasing the risk of syncope.373,382,383 The evidence is stronger for primary prevention compared to secondary prevention indications382 (
ESC CardioMed chapter 43.21).381 Consistent use of SVT/VT discriminators even in rates up to 230 b.p.m. is recommended in ICD recipients without complete heart block to reduce inappropriate therapies.383–385 Proper atrial sensing is a prerequisite for activation of dual-chamber discriminators376
(
ESC
CardioMed chapter 43.21).381 In general, a multi-zone detection programming is favoured to enable tailored use of detection and therapy settings at different tachycardia rates.383,386 A single-zone programming with a high cut-off rate may be considered in patients with a high likelihood of VF only (e.g. primary electrical diseases).387 In subcutaneous ICDs, a dual-zone conﬁguration should be adopted.
Standardized programming including a lower ‘conditional shock’
zone with activated discrimination algorithms and a higher ‘shock zone’ based on rate criteria only has been shown to reduce inappropriate shock rates without compromising patient safety.388–390
Systematic use of ATP before shock delivery, also for very fast ventricular tachyarrhythmias, has been shown to reduce shock therapy without increase in arrhythmic syncope.375,384,391 Burst ATP is preferred over ramp due to increased efﬁcacy in ﬁrst tachycardia termination.392 Incorporation of remote monitoring into follow-up practice of ICD recipients should be promoted to optimize surveillance of device integrity, to enable prompt detection and management of actionable events,
and to prevent occurrence of inappropriate shocks393–396 (
ESC CardioMed chapter 43.
21).381 The proposed recommendations for optimal device programming are applicable to the majority of ICD recipients.
Customization may be needed in individual patients.
6.2.3.2. Concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy
Apart from optimization of device programming, pharmacological and/or invasive management may prevent inappropriate ICD
therapy. Beta-blockers (carvedilol superior to metoprolol in
MADIT-CRT) should be titrated to the maximal tolerated dose in heart failure patients to reduce the risk of inappropriate therapy.400 In patients with inappropriate therapies due to recurrent
SVT, catheter ablation should be ﬁrst-line treatment, given its high success and low complication rate.302,401–403 In case of AF-related inappropriate therapies, unresponsive to optimized pharmacological rate control treatment, individualized treatment strategy
(rate vs. rhythm) dependent on patient characteristics is suggested.348 In patients with early AF, adoption of a rhythm control strategy improved patient outcome in the EAST-AFNET 4 trial.404
In CRT-deﬁbrillator patients, AV node ablation has been associated with reduced inappropriate ICD shocks and lower hospitalization rates compared to drug treatment405
(
ESC
CardioMed chapter 41.14).406
The WCD may be considered in the early phase after MI in selected patients.371,372
IIb
B
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; WCD, wearable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 16 — Recommendations for optimization of device programming
Recommendations
Classa
Levelb
Optimization of ICD programming is indicated to avoid inappropriate and unnecessary therapies and to reduce mortality.373–375
I
A
Continued
In single- or dual-chamber ICD patients without bradycardia pacing indications,
it is recommended to minimize ventricular pacing.378–380
I
A
Programming of prolonged detection settings is indicated (duration criteria of at least 6–12 s or 30
intervals).373,382,383
I
A
It is recommended to program the slowest tachycardia therapy zone limit ≥188 b.p.m. in primary prevention ICD patients.382,383
I
A
In patients with SHD, programming of at least one
ATP therapy is recommended in all tachyarrhythmias zones.375,384,391
I
A
It is recommended to program algorithms for SVT
vs. VT discrimination for tachycardias with rates up to 230 b.p.m.383–385
I
B
It is recommended to activate lead failure alerts.397–399
I
B
Remote monitoring is recommended to reduce the incidence of inappropriate shocks.395
I
B
Programming of burst ATP as ﬁrst attempt is recommended over ramp ATP.392
I
B
For S-ICDs, a dual detection zone conﬁguration is recommended with activation of discrimination algorithm in the lower conditional shock zone.388–390
I
B
For routine ICD programming, activation of more than one tachycardia detection zone should be considered.383,386
IIa
B
© ESC 2022
ATP, anti-tachycardia pacing; ICD, implantable cardioverter deﬁbrillator; SHD,
structural heart disease; S-ICD, subcutaneous ICD; SVT, supraventricular tachycardia;
VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4041


<!-- PAGE 46 -->

### Page 46

6.2.3.3. Psychosocial impact of implantable cardioverter deﬁbrillator treatment
Almost 20% of ICD recipients suffer from anxiety and depression that are associated with increased mortality.408–411 In ICD patients,
psychological distress is mainly caused by the concern of potentially receiving ICD shocks rather than by having experienced an ICD
shock.412,413 Thus, assessment of ICD concerns is recommended in all ICD patients before ICD shocks occur. Systematic screening of ICD patients for psychological distress is feasible with the use of speciﬁc questionnaires.413–416
A signiﬁcant proportion of ICD patients with clinically relevant symptoms of anxiety and depression remains undertreated.417
Communication with all ICD recipients is needed to clarify misconceptions about the device function, to discuss concerns about sexual functioning, driving restrictions, and to recommend an action plan in case of shock therapy.418,419 Referral to mental health professionals may be needed for speciﬁc interventions.418,420 Cognitive behavioural therapy intervention may also be provided by trained cardiac nurses to alleviate anxiety.421 Web-based interventions may also prove useful in improving psychosocial well-being in ICD patients with increased psychosocial distress.422
6.2.3.4. Patients with left ventricular assist devices
VAs are common among left ventricular assist device (LVAD) carriers.425–428 VAs are usually well-tolerated, as LVADs maintain adequate cardiac output and prevent circulatory collapse.429
However, sustained untreated VAs may lead to circulatory collapse even in the presence of an LVAD, especially early after device implantation and in patients with higher pulmonary vascular resistance.430 VAs pre- and post-LVAD implantation are associated with an increased risk of cardiovascular and all-cause mortality, while
ICD can signiﬁcantly reduce sustained VA.425,426,431–434 These data support ICD implantation for secondary prevention in LVAD recipients with symptomatic VA.
Observational studies in patients with previous-generation, pulsatile LVADs reported a longer survival with ICD435–437 (
ESC
CardioMed chapter 37.32).438
Recent registries enrolling continuous-ﬂow LVAD carriers have questioned ICD mortality reduction, but available data are inconsistent.425,426,428,439,440 An analysis of the INTERMACS registry, enrolling the largest continuous-ﬂow LVAD cohort, showed that ICD
presence was not associated with prolonged survival.428 The lack of documented survival beneﬁt among continuous-ﬂow LVAD carriers, in conjunction with the likelihood of VA tolerance and the associated risks of ICD placement in these patients (risk of infection,
device interaction), favours an individualized approach.
6.2.3.5. Complications of devices
Prevention of ICD complications is important to reduce associated morbidity, mortality, and ﬁnancial burden. During implantation of devices, antibiotic prophylaxis, peri-procedural patient preparation,
and appropriate surgical technique should be implemented to prevent device infections and formation of pocket haematoma.441–443
Cephalic or axillary vein access is preferred over the subclavian vein route to reduce the risk of pneumothorax and lead failure.444–446
Proper selection of
ICD
systems is important.
Single-chamber ICDs are recommended in primary prevention patients without atrial or AV sequential pacing indications. This reduces peri-procedural complications and generator replacements as compared to dual-chamber ICDs. This approach does not increase the risk of inappropriate shocks if optimal device programming is used.447–450 Routine use of single-coil deﬁbrillator leads is favoured due to reduced risk of complications during lead removal without associated differences in shock efﬁcacy.451,452 Use of dual-coil leads can be considered in clinical settings where a higher deﬁbrillator threshold is suspected, e.g. HCM, right-sided implantations.453,454
Recommendation Table 17 — Recommendations for concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy
Recommendations
Classa
Levelb
Catheter ablation is recommended for ICD
patients with recurrent SVT resulting in inappropriate ICD therapies.401,402
I
C
Pharmacological treatment or catheter ablation is recommended in patients with AF-related inappropriate ICD therapies despite optimal ICD
programming.401,405,407
I
C
© ESC 2022
AF, atrial ﬁbrillation; ICD, implantable cardioverter deﬁbrillator; SVT, supraventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 18 — Recommendations for psychosocial management after implantable cardioverter deﬁbrillator implantation
Recommendations
Classa
Levelb
Assessment of psychological status and treatment of distress is recommended in ICD
patients.421–423
I
C
Communication between patient and physician/
healthcare professional is recommended to address ICD-related concerns and to discuss quality-of-life issues before ICD implantation and during disease progression.412,424
I
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 19 — Recommendations for implantable cardioverter deﬁbrillator implantation in left ventricular assist device recipients
Recommendations
Classa
Levelb
ICD implantation should be considered in LVAD
recipients with symptomatic sustained VAs.425,431
IIa
B
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; LVAD, left ventricular assist devices; VA,
ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 47 -->

### Page 47

6.2.3.6. End-of-life issues
Patients with active ICDs experience a considerable rate of shocks in the last phase of life.455 In terminally ill patients and at the end of life,
healthcare professionals can facilitate a decision by the patient and the patient’s family by explaining in a sensitive and understandable manner the beneﬁts and burdens of continued ICD therapy.456
Patients should be informed about the options of ICD deactivation.
In general, deactivation of anti-bradycardia therapy is discouraged to avoid quality-of-life impairment, and in some countries deactivation in pacemaker-dependent patients may be prohibited by law.457
Deactivation should be discussed before device implantation and when there is signiﬁcant deterioration of the patient’s health status.
Despite an increasing trend to address and perform device deactivation after careful consideration, current rates are still low and improved patient care is needed.458,459
6.2.4. Interventional therapy
6.2.4.1. Catheter ablation
6.2.4.1.1. Patients with structural heart disease. In patients with
SHD, SMVTs are primarily due to a scar-related re-entrant mechanism.460–465
Because of a higher risk of SCD, an ICD implantation is usually recommended in patients with sustained VAs associated with
SHD.466–468 However, ICDs do not prevent VA, and many of these patients will experience symptomatic VT/VF recurrences resulting in syncope or ICD shocks and may require additional treatment.330,383,419,469–471
In patients with SHD, the choice of anti-arrhythmic agents is mostly limited to beta-blockers, sotalol, and amiodarone to help control
VT/VF recurrences, and this treatment is frequently hampered by side effects.318,472
Owing to advances made over the last three decades, catheter ablation has become increasingly important for the management of scar-related VTs.473 Since the early 1990s, catheter ablation of
BBR-VT has been very successful474–477 and is considered as ﬁrstline therapy466,467 (Figure 5). Subsequently, catheter ablation has been shown to be very effective in controlling incessant VTs or electrical storms330,331 and in reducing subsequent VT burden.
Many observational studies have shown a positive effect of VT ablation on clinical outcome in terms of VT recurrences.478–483 In patients with CAD, three randomized trials471,484,485 have reported that catheter ablation, compared to conventional treatment, decreases the likelihood of subsequent ICD shocks and prevents recurrent VT episodes.
The critical part of re-entrant VT circuits, referred to as the ‘protected VT isthmus’, is the primary target for ablation,460,486 but it is very challenging to unmask in haemodynamically not-tolerated
VT.487,488 Due to the high likelihood of multiple re-entry circuits in a scar and difﬁculties in identifying critical isthmuses, the ablation strategy has gradually evolved over the years towards more extended ablation of the arrhythmogenic substrate.489–492 Special attention should be paid to cases of PVT/VF initiated by similar
PVCs, where the triggering PVC (often related to the Purkinje network) should be targeted for ablation.221,332,333,493
The electrophysiological characteristics of VT circuits depend on the underlying SHD. Thus, post-infarct VTs are mainly related to an endocardial VT circuit (amenable to endocardial ablation), while the location of re-entrant VT circuits is more variable in patients with cardiomyopathies.494–496 Here, intramural and/or epicardial involvement are more common. This signiﬁcantly contributes to the difference in the clinical outcomes of VT ablation in relation to the underlying heart disease with a better outcome in CAD as compared to non-ischaemic aetiologies.497–499
Effective ablation requires durable ablation lesions to arrhythmogenic tissue. In some cases, such as intramural VTs, difﬁculties remain in achieving this objective with current catheters, regardless of the approach (endocardial/epicardial).500 To improve the formation of myocardial lesions, new catheter-based techniques are being evaluated (e.g. bipolar/needle ablation, transcoronary alcohol ablation),501–506 as well as radiotherapy ablation507,508 or surgical ablation,509 which are currently bailout treatments.
When planning VT ablation, it is important to collect all available information about the arrhythmogenic substrate, especially to identify scars (using CMR or CT scan),510–514 and to help determine the exit site of VAs with the 12-lead ECG documentation of clinical VTs or PVCs that induce PVT/VF.
The mean long-term success rate of VT ablation varies from
30%
to
70%,
depending on the underlying
SHD.481,515–518
Peri-procedural complications, in particular stroke, cardiac tamponade, or death, may occur.519–522
Recommendation Table 21 — Recommendations for end-of-life issues in implantable cardioverter deﬁbrillator carriers
Recommendations
Classa
Levelb
Informed discussion with patient and family about
ICD deactivation options and shared decision-making is indicated prior to implantation and in case of signiﬁcant health status deterioration.458
I
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 20 — Recommendations for prevention of implantable cardioverter deﬁbrillator complications
Recommendations
Classa
Levelb
Single-chamber ICD is recommended over dual-chamber ICD in primary prevention patients without current or expected indication for atrial or AV sequential pacing due to a lower risk of device-related complications.447,448,450
I
A
The use of single-coil leads over dual-coil ICD
leads should be considered due to lower complication rate during transvenous lead extraction.451
IIa
C
© ESC 2022
AV, atrioventricular; ICD, implantable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4043


<!-- PAGE 48 -->

### Page 48

6.2.4.1.2. Patients without apparent structural heart disease.
‘Idiopathic VTs’ is the term for VTs that are not associated with
SHD or a genetic arrhythmic syndrome. Most idiopathic VTs are mediated by triggered activity, but a re-entrant mechanism (involving the LV Purkinje network) explains verapamil-sensitive fascicular
VTs.523 Three important key features distinguish idiopathic VTs from VTs associated with SHD. First, idiopathic VTs mostly originate from a single site and speciﬁc region of the heart (namely the right or left ventricular outﬂow tracts,524,525 along the valve annuli,526–528
papillary muscle,529 or the LV Purkinje network).523 Second, no detectable scar is found in idiopathic VTs.530 Finally, idiopathic VTs have a benign prognosis so that ICD implantation is generally not recommended.466
The earliest site of activation during VT is the ablation target for focal sources, while abnormal Purkinje tissue (with diastolic activity during VT) is the ablation target of left fascicular VTs.531,532
Catheter ablation is curative in most idiopathic VT patients and peri-procedural complications are rare.533–537
6.2.4.2. Autonomic modulation
The role of the autonomic nervous system in promoting arrhythmias has long been recognized, leading to the concept of Coumel’s triangle of arrhythmogenesis.538
Sympathetic activation has been demonstrated as playing a key role in inducing VAs in some entities, such as congenital LQTS and
CPVT,539,540 and left cardiac sympathetic denervation was shown to be associated with a decrease in the frequency of arrhythmogenic syncope in congenital LQTS.541,542 The efﬁcacy of cardiac sympathetic blockade by different approaches (thoracic epidural anaesthesia, percutaneous stellate ganglion anaesthesia, or surgical stellate ganglion resection) in reducing the arrhythmia burden in refractory VT/VF has been recognized in several small observational studies.326,328,340 Further studies are needed to assess which patients may beneﬁt from a modulation of the autonomic nervous system to better control VT/VF.
7. Diagnostic evaluation,
management, and risk stratiﬁcation according to clinical presentation and known (likely)
disease
7.1. Speciﬁc structural heart diseases
7.1.1. Coronary artery disease
7.1.1.1. Acute coronary syndromes and vasospasm
7.1.1.1.1. Acute coronary syndromes. SCD is a major cause of mortality in ACS, mostly caused by sustained VAs, in particular
VF. The majority of studies have reported on patients with
STEMI. Of patients with STEMI, 4–12% develop VA within the
ﬁrst 48 h after the onset of symptoms.69,543,544 Pre-reperfusion
VAs are more common than reperfusion-induced or postreperfusion arrhythmias in STEMI.545 Haemodynamic instability,
cardiogenic shock, LVEF , 40%, and the sum of ST-segment deviations in all leads are independent predictors of VA both in
STEMI and non-STEMI.69,546 In addition, an early repolarization pattern has been associated with increased risk of VAs and
SCD in ACS.547
Prevention of ventricular arrhythmias in ST elevation myocardial infarction
Urgent reperfusion is the most important therapy,292,548 as acute ischaemia triggers arrhythmias. Beta-blocker treatment is also recommended to prevent VA.3,549 In a recent randomized trial of patients with STEMI, early intravenous metoprolol before percutaneous coronary intervention reduced the incidence of arrhythmias in the acute phase and was not associated with an increase in adverse events.550 Prophylactic treatment with AADs has not proven beneﬁcial, and may even be harmful.322 Correction of electrolyte imbalances is strongly recommended.289
Management of sustained ventricular tachycardia and ventricular
ﬁbrillation in acute coronary syndrome
Electrical cardioversion or deﬁbrillation is the intervention of choice to acutely terminate VAs in ACS patients (Figure 14).205,339
Recurrent sustained VT, especially when polymorphic, or recurrent
VF can indicate incomplete reperfusion or recurrence of acute ischaemia. In this case, immediate coronary angiography is indicated.3
For recurrent PVT degenerating into VF, beta-blockers are recommended.551,552 In addition, deep sedation may be helpful to reduce episodes of VT or VF.553 Intravenous amiodarone should be considered to acutely suppress recurrent haemodynamically relevant VAs,
although there is a paucity of controlled studies for amiodarone during STEMI554 and the evidence in this setting is mainly extrapolated from studies of OHCA.555 If treatment with beta-blockers and amiodarone is not effective, lidocaine may be considered.322 The use of other AADs in ACS is not recommended.549,556 In haemodynamically unstable patients with refractory VA, mechanical circulatory support may be considered.336,557 For VA in the context of relative bradycardia or pause-related, pacing may be effective to prevent re-initiation.
The prognostic signiﬁcance of early ventricular arrhythmias
Early VAs are deﬁned as VT/VF occurring within 48 h after a
STEMI. In the contemporary percutaneous coronary intervention
(PCI)-based revascularization era, almost all VA occur within the ﬁrst
24 h.558 Early VA have been associated with an up to six-fold increase in in-hospital mortality, whereas long-term prognosis seems not to be signiﬁcantly affected.543,559,560 In a prospective cohort study, patients with VF during the acute STEMI phase had low and very similar incidence of late SCD as compared with VF-free patients during
5-year observation.560 Of note, early monomorphic VT was associated with signiﬁcantly higher incidence of adequate ICD interventions compared with early VF, and was an independent predictor of death during long-term follow-up.561 Thus, the prognostic signiﬁcance of VT and VF occurring in the acute phase of MI may be different. The impact of VA occurring late after reperfusion (.48 h) on late SCD is less clear.
Podolecki et al.559 recently demonstrated that long-term all-cause mortality after STEMI was predicted by VA occurring late after reperfusion (.48 h after reperfusion), while early reperfusion VAs did not affect 5-year outcome. Further studies are required to clarify


<!-- PAGE 49 -->

### Page 49

the impact of VA occurring .48 h after STEMI on late SCD in contemporary patients undergoing acute PCI.
7.1.1.1.2. Vasospasm. Coronary artery spasms might have an important role in the pathogenesis of VA. The long-term prognosis
Prevention and treatment of  VAs in the acute phase of STEMI
Beta-blocker i.v. prior to PCI, if not contraindicateda,b
(Class IIa)
Urgent CAG and revascularizationa
(Class I)
Further revascularization if appropriatea
(Class I)
Repletion of K+, Mg2+ a
(Class I)
Beta-blocker i.v.b
(Class I)
Amiodarone i.v.
(Class IIa)
Lidocaine i.v.
(Class IIb)
Deep sedation/intubation c
(Class IIb)
Sedation (for comfort)c
(Class I)
VA
Recurrent VA
Autonomic modulationc
(Class IIb)
Catheter ablationd
(Class IIa)
Mechanical circulatory support c
(Class IIb)
Overdrive pacinga
(Class IIa)
Recurrent VA
Figure 14 Algorithm for the prevention and management of ventricular arrhythmias in ST-elevation myocardial infarction. CAG, coronary angiogram; PCI,
percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; VA, ventricular arrhythmias. aThe 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.3 bIntravenous beta-blockers must be avoided in patients with hypotension, acute heart failure, AV block or severe bradycardia. cFlowchart for the management of electrical storm. dIf similar PVC triggers recurrent polymorphic VA.
ESC Guidelines
4045


<!-- PAGE 50 -->

### Page 50

of patients with variant angina who survive a CA is worse than in other patients with variant angina.562,563 In a recent multicentre
European survey,564 patients with life-threatening VAs secondary to coronary vasospasm were at high risk for recurrence, especially when insufﬁcient medical therapy was administered. While calcium channel blockers (CCB) are capable of suppressing episodes, betablockers may trigger VAs. As medical intervention and multiple vasodilator drugs may not be sufﬁciently protective, placement of an ICD
should still be considered in SCA survivors with variant angina.
7.1.1.2. Early after myocardial infarction
The ﬁrst weeks after a STEMI carry the highest risk both for allcause death and for SCD, particularly in patients with reduced
LVEF.565,566 For this reason, early assessment of LVEF, i.e. before discharge, is recommended.567,568 Early routine prophylactic ICD
implantation in the ﬁrst 40 days after MI did not reduce mortality in post-MI patients with reduced LVEF in two randomized trials
(DINAMIT and IRIS),569,570 and is therefore not recommended.
Early assessment by further non-invasive tests, apart from LVEF
measurement, has also not proven to be useful for risk stratiﬁcation with regard to SCD.571 Limited evidence suggests that invasive risk stratiﬁcation by PES in the early post-MI phase may be helpful for identiﬁcation of high-risk patients with reduced LVEF.572
However, the utility of this approach has not been conﬁrmed so far in randomized studies. The PROTECT-ICD randomized trial
(NCT03588286) is currently examining whether PES may guide the decision on ICD implantation in patients with reduced EF in the early phase after STEMI.
Reverse remodelling following an MI is associated with signiﬁcantly lower rates of death, SCA, and other adverse clinical outcomes.573,574
Therefore,
assessment of the indication for prophylactic ICD implantation, usually performed by repeat echocardiography, should take place in the post-remodelling phase of the MI after the ﬁrst 6 weeks in patients with a pre-discharge
LVEF ≤40%. Reassessment of the LVEF before 6 weeks following
MI may not discriminate between myocardial stunning and remodelling.
In the early post-MI phase, electrical storm and/or recurrent episodes of PVT or VF are immediately life-threatening conditions. In this setting, it is important to exclude ischaemia as the triggering factor for the arrhythmias. If medical treatment is not sufﬁcient to suppress the arrhythmic episodes, catheter ablation is potentially effective particularly if the episodes are focally triggered by similar PVCs.332,575 If PVT recurs despite betablocker and amiodarone treatment, suppression by quinidine therapy has been reported.323
7.1.1.3. Chronic coronary artery disease
7.1.1.3.1. Primary prevention of sudden cardiac death in patients with reduced ejection fraction. Forty days after STEMI, approximately 5% of patients will have an LVEF ≤35%.576 These patients are at risk for SCD. Therefore, in patients with LVEF ≤35% and
Recommendation Table 22 — Recommendations for treatment of ventricular arrhythmias in acute coronary syndrome and vasospasm
Recommendations
Classa
Levelb
Treatment of VAs in ACS
Intravenous beta-blocker treatment is indicated for patients with recurrent PVT/VF during STEMI
unless contraindicated.551,552
I
B
Intravenous amiodarone treatment should be considered for patients with recurrent PVT/VF
during the acute phase of ACS.552,554,555
IIa
C
Intravenous lidocaine may be considered for the treatment of recurrent PVT/VF not responding to beta-blockers or amiodarone, or if amiodarone is contraindicated during the acute phase of ACS.554
IIb
C
Prophylactic treatment with AADs (other than beta-blockers) is not recommended in ACS.322
III
B
Vasospasm
In SCA survivors with coronary artery spasm, implantation of an ICD should be considered.562–564
IIa
C
© ESC 2022
AAD, anti-arrhythmic drug; ACS, acute coronary syndrome; ICD, implantable cardioverter deﬁbrillator; PVT, polymorphic ventricular tachycardia; SCA, sudden cardiac arrest;
STEMI, ST elevation myocardial infarction; VA, ventricular arrhythmia; VF,
ventricular ﬁbrillation.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 23 — Recommendations for risk stratiﬁcation and treatment of ventricular arrhythmias early after myocardial infarction
Recommendations
Classa
Levelb
Risk stratiﬁcation
Early (before discharge) assessment of LVEF is recommended in all patients with acute MI.567,568
I
B
In patients with pre-discharge LVEF ≤40%,
re-evaluation of LVEF 6–12 weeks after MI is recommended to assess the potential need for primary prevention ICD implantation.568,573,574
I
C
Treatment of VAs
Catheter ablation should be considered in patients with recurrent episodes of PVT/VF triggered by a similar PVC non-responsive to medical treatment or coronary revascularization in the subacute phase of MI.332
IIa
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; MI,
myocardial infarction; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 51 -->

### Page 51

heart failure symptoms NYHA class II and III, primary preventive
ICD implantation is recommended.356 ICD implantation should also be considered for asymptomatic patients with an EF ≤30%.354
In this population, mortality reduction by an ICD has been demonstrated in four RCTs.353–356 In patients with CAD, a reduced LVEF (≤40%), and asymptomatic NSVT, inducibility by
PES identiﬁes patients who beneﬁt from an ICD, independent from NYHA class.355
Since the publication of the aforementioned trials, early revascularization strategies and modern heart failure medication have reduced the overall risk of SCD in heart failure patients.577 Although total mortality has been reduced, the relative reduction by the
ICD is a consistent 27%, which has been corroborated in two recent large prospective registry studies enrolling 2327 European patients between 2014 and 2018 (EU-CERT-ICD)357 and 2610
Swedish patients enrolled between 2000 and 2016 (SwedeHF
registry).358
7.1.1.3.2. Primary prevention of sudden cardiac death in patients with preserved or mildly reduced ejection fraction. There are no data supporting primary prophylactic ICD implantation in post-infarct patients with preserved or mildly reduced LVEF. These patients are heterogeneous with regard to their potential arrhythmic substrate,
and efforts are under way to identify those with the highest risk for SCD. PES is recommended in post-infarct patients in whom syncope remains unexplained after non-invasive evaluation to guide patient management (Figure 15).146
In the PRESERVE-EF study, 41 of 575 post-infarct patients with an
LVEF ≥40% and one non-invasive ECG risk factor more than 40 days post-MI were inducible for VT/VF during PES and received an ICD.151
During the 32-month follow-up period, no SCD occurred and 9 of
37 ICD patients received an appropriate ICD therapy. However,
the role of appropriate ICD treatment as surrogate for SCD in patients with preserved LVEF is unknown, and randomized trials are needed. Prophylactic treatment with AADs other than beta-blockers is not indicated regardless of the LVEF.556,578,579
7.1.1.3.3. Secondary prevention of sudden cardiac death. The three pivotal secondary prevention ICD trials enrolled 1866 patients between
1990
and
1997.349–351
A
patient-level
Recommendation Table 24 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention,
and treatment of ventricular arrhythmias in chronic coronary artery disease
Recommendations
Classa
Levelb
Risk stratiﬁcation and primary prevention of SCD
In patients with syncope and previous STEMI, PES
is indicated when syncope remains unexplained after non-invasive evaluation.146,584
I
C
ICD therapy is recommended in patients with CAD, symptomatic heart failure (NYHA
class II–III), and LVEF ≤35% despite ≥3 months of OMT.354,356
I
A
ICD therapy should be considered in patients with
CAD, NYHA class I, and LVEF ≤30% despite ≥3
months of OMT.354
IIa
B
ICD implantation should be considered in patients with CAD, LVEF ≤40% despite ≥3 months of
OMT, and NSVT, if they are inducible for SMVT by
PES.355
IIa
B
In patients with CAD, prophylactic treatment with AADs other than beta-blockers is not recommended.556,578,579
III
A
Secondary prevention of SCD and treatment of VAs
ICD implantation is recommended in patients without ongoing ischaemia with documented VF
or haemodynamically not-tolerated VT occurring later than 48 h after MI.349–351
I
A
In patients with CAD and recurrent, symptomatic
SMVT, or ICD shocks for SMVT despite chronic amiodarone therapy, catheter ablation is recommended in preference to escalating AAD
therapy.471
I
B
Continued
The addition of oral amiodarone or beta-blocker replacement by sotalol should be considered in patients with CAD with recurrent, symptomatic SMVT, or ICD shocks for SMVT while on beta-blocker treatment.318,581
IIa
B
In patients with CAD and haemodynamically well-tolerated SMVT and LVEF ≥40%, catheter ablationinexperiencedcentresshouldbeconsidered as an alternative to ICD therapy, provided that established endpoints have been reached.c,480,580
IIa
C
ICD implantation should be considered in patients with a haemodynamically tolerated SMVT and an
LVEF ≥40% if VT ablation fails, is not available, or is not desired.
IIa
C
Catheter ablation should be considered in patients with CAD and recurrent, symptomatic SMVT, or
ICD shocks for SMVT despite beta-blockers or sotalol treatment.471
IIa
C
In patients with CAD eligible for ICD implantation,
catheter ablation may be considered just before (or immediately after) ICD implantation to decrease subsequent VT burden and ICD shocks.484,485,582,583
IIb
B
© ESC 2022
AAD, anti-arrhythmic drug; CAD, coronary artery disease; ICD, implantable cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart
Association; OMT, optimal medical therapy; PES, programmed electrical stimulation;
SCD, sudden cardiac death; SMVT, sustained monomorphic ventricular tachycardia;
STEMI, ST elevation myocardial infarction; VA, ventricular arrhythmia; VF, ventricular
ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cVT non-inducibility and elimination of electrograms consistent with conduction delay.
ESC Guidelines
4047


<!-- PAGE 52 -->

### Page 52

meta-analysis demonstrated a 28% mortality reduction (HR 0.72;
95% CI 0.60–0.87; P = 0.0006) almost entirely due to reduction of arrhythmic death (HR 0.50; 95% CI 0.37–0.67; P , 0.0001) in the ICD group.352 This translates to an extension of survival of
4.4 months over a mean follow-up of 6 years by the ICD.
Around 80% of the study population suffered from CAD.
Patients with well-tolerated SMVT were excluded from secondary prevention trials (Figure 16).
7.1.1.3.4. Management of patients with haemodynamically tolerated ventricular tachycardia and preserved and mildly reduced ejection fraction. With the better understanding of the mechanisms of VT after MI, as well as improved ablation and imaging technologies,
catheter ablation has become an option for the treatment of haemodynamically well-tolerated VT in selected post-MI patients with preserved or mildly reduced EF, even without ICD back-up. One small monocentric retrospective trial studied patients with CAD, LVEF
.40%, and haemodynamically tolerated VT who underwent catheter ablation as ﬁrst-line therapy.580 The investigators could abolish
90% of the clinical and 58% of all inducible VTs. Subsequently, 42% of the patients received an ICD. After a mean follow-up of 3.8 years,
42% of the patients died irrespective of the presence or absence of an ICD (P = 0.47).
A larger multicentre retrospective study looked at 166 patients with an LVEF .30% presenting with well-tolerated SMVT, which were treated by catheter ablation only, and compared the outcome to a control group of 378 patients implanted with an
ICD.480 Of the 166 patients undergoing ablation as ﬁrst therapy,
55% suffered from CAD. The mean LVEF was 50%, and after a mean follow-up of 32 months, overall mortality did not differ between the groups (12%).
These data suggest that either ICD implantation or ablation in experienced centres should be considered in patients with a preserved or mildly reduced EF presenting with haemodynamically tolerated
SMVT. Of note, although ICDs have been commonly implanted in this population, the secondary preventive ICD trials failed to show a survival beneﬁt in patients with an LVEF ≥35%.352 Although
SMVT is rarely caused by ischaemia and revascularization alone
NSVT or unexplained syncope
NYHA class ≥II
LVEF
L
≤30%
LVEF 
L
≤35%
LVEF 36–40%
L
N
N
N
Patient with chronic CAD
LVEF
L
evaluation 6–12 weeks after acute MI
in patients with LVEF
L
≤40% at discharge
(Class I) 
ILR implantationa
(Class I)
PES
(Class I)
ICD
(Class I)
No SMVT inducible and unexplained syncope
SMVT inducible
ICD implantation
(Class IIa)
Follow-up
ICD implantation
(Class IIa)
Y
Y
Y
Figure 15 Algorithm for risk stratiﬁcation and primary prevention of sudden cardiac death in patients with chronic coronary artery disease and reduced ejection fraction. CAD, coronary artery disease; ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; LVEF, left ventricular ejection fraction; MI, myocardial infarction; N, No; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; PES, programmed electrical stimulation; SMVT, sustained monomorphic ventricular tachycardia; Y, Yes. aThe 2018 ESC Guidelines for the diagnosis and management of syncope.1


<!-- PAGE 53 -->

### Page 53

does not prevent VT recurrence, exclusion or treatment of signiﬁcant CAD before catheter ablation is reasonable.
7.1.1.3.5. Management of recurrent ventricular tachycardia in implantable cardioverter deﬁbrillator carriers. Frequent, symptomatic VT in ICD recipients should be treated medically with either amiodarone or sotalol.318,581 In patients with CAD in whom SMVT
recurs while on amiodarone treatment, catheter ablation is recommended over escalation of AAD therapy. In the VANISH trial, the composite endpoint of death, VT storm, and appropriate ICD therapy was reached signiﬁcantly less often in the ablation group as compared to the escalated amiodarone-therapy group over a mean follow-up of 28 months (59% vs. 68.5%; HR 0.72; 95% CI 0.53–
0.98; P = 0.04).471 The ongoing VANISH2 trial (ClinicalTrials.gov
Identiﬁer: NCT02830360) addresses the question of whether catheter ablation as ﬁrst-line treatment is superior to AAD therapy in post-MI patients with SMVT.
Preventive VT ablation after a ﬁrst documented SMVT, which was followed by ICD implantation, reduced neither mortality nor hospitalizations for arrhythmia or worsening heart failure when compared to a deferred ablation strategy only after the third ICD shock.582
However, in patients who present with a ﬁrst VT episode and in whom an ICD is indicated, catheter ablation performed immediately before or shortly after ICD implantation may be considered to decrease subsequent VT and ICD shocks.484,485,583
7.1.1.4. Coronary anomalies
Anomalous aortic origin of a coronary artery, either the left or the right, arising from the opposite sinus of Valsalva, is associated with an increased risk of SCD, especially in individuals ,35 years during or following vigorous exercise.585 Anomalous aortic origin of the left coronary artery is less common but more malignant than anomalous aortic origin of the right coronary artery. Other risk factors for SCD are interarterial course between the aorta and pulmonary artery, slit-like shaped oriﬁce, high oriﬁce, acuteangle take-off, and intramural course and its length.585,586
Indications for surgical intervention, especially in asymptomatic patients, are based on the evaluation of high-risk anatomy by CTA and the assessment of exercise-induced ischaemia using advanced imaging modalities.586–588 Cardiac stress imaging is also indicated to evaluate exercise-induced ischaemia after surgical intervention, especially in patients with an aborted CA.588
SMVT in a patient with chronic CAD
ICD implantation
(Class I)
Catheter ablation
(Class IIb)
Catheter ablation
(Class IIa)
Amiodaroneb
(Class IIa)
Catheter ablation
(Class IIa)
Amiodarone
(Class IIa)
Catheter ablation
(Class I)
Y
Y
N
N
Haemodynamically tolerated
On amiodarone
Go to flowchart electrical storm
(Figure 11)
Symptomatic SMVT
SMVT in ICD carriersa
First presentation
Electrical storm
LVE
L
F
<40%
≥40%
Sotalolc
(Class IIa)
ICD implantationb
(Class IIa)
Figure 16 Algorithm for the management of sustained monomorphic ventricular tachycardia in patients with chronic coronary artery disease. CAD,
coronary artery disease; ICD, implantable cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; N, No; SMVT, sustained monomorphic ventricular tachycardia; Y, Yes. aIncessant ventricular tachycardia in monitor zone: consider catheter ablation. bIf catheter ablation is not available, not successful or not desired by the patient. cTo reduce ICD shocks.
ESC Guidelines
4049


<!-- PAGE 54 -->

### Page 54

7.1.2. Idiopathic premature ventricular complexes/
ventricular tachycardia and premature ventricular complex-induced cardiomyopathy
7.1.2.1. Idiopathic premature ventricular complexes/ventricular tachycardia
PVCs/VT in patients without SHD are deﬁned as idiopathic
(Figure 17). In patients with presumed idiopathic PVCs/VT based on a negative history and normal physical examination, 12-lead
ECG and transthoracic echocardiography are important ﬁrst diagnostic steps to exclude underlying SHD. Twenty-four-hour ECG
Holter monitoring is usually performed to determine the PVC burden.
Multiform PVCs at prolonged ECG monitoring and subtle changes on
ECG or echocardiography need to be recognized.589 CMR should be performed whenever ECG and echocardiography are inconclusive to rule out SHD, or the clinical presentation raises suspicion for SHD.590,591
Patients need to be treated when PVCs/VT are symptomatic or associated with deterioration of cardiac function. The clinical course and responses to different treatments have been mostly studied in those originating from the RVOT or the left fascicles.
Several drugs have been used to treat idiopathic PVCs/VT.
Recommendations are based on small or non-controlled series.
Beta-blockers and CCBs are the most-studied drugs and both have been shown to be effective at arrhythmia suppression.304 The evidence for ﬂecainide is scarce.592 In case of a higher burden of
PVCs with higher heart rate or during exercise, beta-blockers should be preferred.593 If there is not such a correlation, the use of ﬂecainide or CCB drugs have been associated with more effective PVC suppression. Beta-blockers should also be selected when a focal triggered activity mechanism is suspected. CCB should be the drug of choice for fascicular PVC/VT. Although data are lacking, betablockers or CCBs are considered ﬁrst choice for PVCs with an origin outside the RVOT or the left fascicles because ﬂecainide may have proarrhythmic side effects. Amiodarone is associated with severe systemic toxicity and should be used only if ablation or other drugs fail or cannot be used.594 A summary of the recommendations for the treatment of idiopathic PVCs/VT and PVC-induced or aggravated cardiomyopathy with AADs is provided in Table 9.
A high success rate of catheter ablation of idiopathic PVCs/VT has been reported with rare complications, particularly for the RVOT
and fascicular types.535 In a randomized study including patients with RVOT PVCs, ablation was superior to AAD therapy for arrhythmia suppression with no differences in complications.595
Ablation is therefore recommended as the ﬁrst-line therapy for
RVOT and fascicular PVCs/VT. The available information for other forms of idiopathic PVCs/VT is limited and mostly restricted to the acute success of ablation, which, in general, is lower and associated with more recurrences than for RVOT and fascicular PVCs/VT.540
In addition, access to and ablation at speciﬁc locations (e.g. sinus of
Valsalva, LV summit) may increase the risk for procedural complications. Therefore, when the 12-lead ECG is highly suspicious of a
PVC/VT source outside the RVOT or left fascicles, the level of recommendation for ablation is lower.
In general, treatment of children should be similar to that of adults.
However, ablation should be deferred in young and small children due to the risk of complications and the relatively larger size of the ablation lesion as compared to the child’s heart.596,597 Verapamil is not recommended as the ﬁrst-line therapy in children ,1 year old because it has been associated with hypotension in some case reports.542 Of note, all reported patients had either heart failure, overdosing of verapamil, or other concurrent AADs at the time verapamil was given.598
Patients may present with asymptomatic frequent PVCs/VTs.
Only a minority of patients with .1000 PVCs per day will develop ventricular dysfunction after 5 years follow-up.599 A PVC burden of 10% seems to be the minimal threshold for development of LV
dysfunction,
with higher risk when the
PVC
burden is
.20%.535,600,601 Regular assessment of LVEF in this setting is therefore indicated. To date, there are no data supporting the beneﬁt of arrhythmia treatment for asymptomatic patients with preserved ventricular function. In addition, PVC burden often decreases spontaneously over time, particularly in children.599,602 In selected patients, e.g. patients who do not want to be followed, catheter ablation may be considered. In patients with PVC burden , 10%, reevaluation may be appropriate in case of development of new symptoms or change in patient condition.
Recommendation Table 25 — Recommendations for sudden cardiac death prevention in patients with coronary anomalies
Recommendations
Classa
Levelb
Diagnostic evaluation
Cardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test in patients with anomalous aortic origin of a coronary artery with an interarterial course to conﬁrm/exclude myocardial ischaemia.587
I
C
Cardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test after surgery in patients with anomalous aortic origin of a coronary artery with a history of aborted CA.
I
C
Treatment
Surgery is recommended in patients with anomalous aortic origin of a coronary artery with
CA, syncope suspected to be due to VAs, or angina when other causes have been excluded.585,586,588
I
C
Surgery should be considered in asymptomatic patients with anomalous aortic origin of a coronary artery and evidence of myocardial ischaemia or abnormal aortic origin of the left coronary artery with high-risk anatomy.c,585,586,588
IIa
C
© ESC 2022
CA, cardiac arrest; VA, ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
cHigh-risk anatomy is deﬁned as interarterial course, slit-like shaped oriﬁce, high oriﬁce,
acute-angle take-off, and intramural course and its length.


<!-- PAGE 55 -->

### Page 55

Patient with PVCs / MonomorphicVT and non-apparent SHDa
ECG, Holte
,
r, and echoca
,
rdiogram
Assessment
Assessment
>20% PVCs
RV
R OT / Fascicular PVC/VT
O
d
Symptomsc
>10% PVCs
Dischargee
Go to flowchart
PVC-induced cardio r
myopathy
(Figure 18)
SHD or PVC-induced cardiomyopathy
CMR (Class IIa)
Inconclusive or atypical presentationb
Catheter ablation
(Class I)
Beta-blockers,
k
CCB or 
Flecainide
(Class IIa)
Beta-blocker k  o r r CCB
(Class I)
Flecainide
(Class IIa)
Catheter ablation
(Class IIa)
Regular foll f
ow-up LVEF
L
(Class I)
Structural abnormal heart
Idiopathic PVC/VT
Structural normal heart
Regular foll f
ow-up LVEF
L
(Class I)
Catheter ablation
(Class IIb)
Y
Y
Y
Y
N
N
N
N
Figure 17 Algorithm for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia and non-apparent structural heart disease. CCB, calcium channel blocker; CMR, cardiac magnetic resonance; ECG, electrocardiogram; LVEF, left ventricular ejection fraction; N, No;
PVC, premature ventricular complex; RVOT, right ventricular outﬂow tract; SHD, structural heart disease; VT, ventricular tachycardia; Y, Yes. aNon-apparent
SHD is deﬁned by lack of signiﬁcant abnormalities in physical examination, basal ECG, and echocardiogram. bAtypical presentation: e.g. older age, right bundle branch block morphology, sustained monomorphic VT consistent with re-entry. cSymptoms should be relevant and related to PVC/VT. dOrigin suspected by
ECG or conﬁrmed during electrophysiological evaluation. eConsider re-evaluation in case of new symptoms or changes in patient clinical condition.
Table 9
Summary of the recommendations for the treatment of patients with frequent idiopathic premature ventricular complexes/ventricular tachycardia or premature ventricular complex-induced cardiomyopathy
Ablation
Beta-blocker
CCB
Flecainide
Amiodarone
RVOT/fascicular PVC/VT:
Symptomatic, normal LV function
Class I
Class IIa
Class IIa
Class IIa
Class III
PVC/VT other than RVOT/fascicular:
Symptomatic, normal LV function
Class IIa
Class I
Class I
Class IIa
Class III
RVOT/fascicular PVC/VT:
LV dysfunction
Class I
Class IIa
Class IIIa
Class IIab
Class IIa
PVC/VT other than RVOT/fascicular:
LV dysfunction
Class I
Class IIa
Class IIIa
Class IIab
Class IIa
PVC:
Burden .20%, asymptomatic, normal LV function
Class IIb
Class III
© ESC 2022
CCB, calcium channel blocker; LV, left ventricular; PVC, premature ventricular complex; RVOT, right ventricular outﬂow tract; VT, ventricular tachycardia.
aIntravenous calcium channel blockers.
bIn selected patients (only moderate LV dysfunction).
ESC Guidelines
4051


<!-- PAGE 56 -->

### Page 56

7.1.2.2. Premature ventricular complex-induced/-aggravated cardiomyopathy
The importance of PVC-induced cardiomyopathy as a secondary and reversible cause of LV dysfunction in patients without
SHD has been recognized.607,608 The patient’s medical and family history, 12-lead ECG, Holter-ECG, and echocardiography form the cornerstones of the evaluation of patients with suspected
PVC-induced cardiomyopathy
(Figure
18).
PVC burden has been shown to be the strongest independent predictor of PVC-induced cardiomyopathy in several studies.600,609–611 Day-by-day ﬂuctuations of PVC burden have been reported in patients undergoing 14-day monitoring, but most data are based on 24-h registrations.611 A PVC burden of at least 10% appears to be the minimal threshold for development of PVC-induced cardiomyopathy, and the risk increases further with a PVC burden .20%.600,611 In patients with a PVC
burden ,10%, other cardiomyopathy aetiologies should be suspected and further diagnostic work-up undertaken. In such patients, Holter-ECG should be repeated to assess ﬂuctuations in
PVC burden. Factors predicting adverse LV remodelling in patients with frequent PVCs include superior PVC axis, epicardial origin,
NSVT,
shorter coupling interval,
and male gender.535,611–613
Frequent PVCs can also aggravate LV dysfunction in patients with
SHD. In such cases, LV dysfunction can either be a direct consequence of PVCs as in PVC-induced cardiomyopathy, or due to the limiting effect of PVCs on optimal biventricular pacing in CRT patients. Parameters such as smaller LV end diastolic diameter and shorter intrinsic
QRS
duration might help to distinguish
PVC-induced cardiomyopathy from PVC-aggravated cardiomyopathy.614 CMR should be considered for patients suspected to have
PVC-induced cardiomyopathy to exclude subtle forms of SHD.590,615
In a patient with frequent PVCs, the presence of LGE suggests SHD
with frequent PVCs rather than PVC-induced cardiomyopathy, in which LGE is mostly absent. Given that PVCs with a RBBB morphology have been reported to show a stronger association with LGE,616 those patients should be particularly considered for CMR.
The diagnosis of PVC-induced cardiomyopathy vs. PVC-aggravated cardiomyopathy can be conﬁrmed only after LVEF improvement/normalization (reverse remodelling) following suppression of the PVCs.
Catheter ablation of the PVCs is very efﬁcient, with reported success rates of 75–90%, and is considered ﬁrst-line treatment for
PVC-induced cardiomyopathy.535,600,609,610,612,617–620 Factors affecting acute ablation success and clinical outcome include the site of origin of PVCs (highest for outﬂow tract PVCs), the number of
PVC morphologies, and the absence of LGE on CMR.535,610,614 In patients with SHD, catheter ablation of frequent monomorphic PVCs has also been shown to improve LVEF in patients with both CAD and cardiomyopathies with and without CRT.609,617,621–623 Similarly, the use of anti-arrhythmic medications for PVC suppression has been shown to improve LVEF. In one RCT, amiodarone resulted in a better PVC suppression and a higher LVEF improvement compared to placebo.624 Sodium channel blockers can also effectively suppress
PVCs.625 In one study, ﬂecainide reduced the PVC burden from
36% to 10% and resulted in LVEF increase from 37% to 49%.626
Recommendation Table 26 — Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia
Recommendations
Classa
Levelb
General recommendations
Regular assessment of ventricular function of patients with PVC burden .10% and normal ventricular function is indicated.602,603
I
C
In patients with PVCs/VT and a presentation not typical for an idiopathic origin,c CMR should be considered,
despite a normal echocardiogram.195
IIa
C
Treatment
Catheter ablation as ﬁrst-line treatment is recommended for symptomatic idiopathic VT/
PVCs from the RVOT or the left fascicles.d,535,595,596,604
I
B
Beta-blockers or non-dihydropyridine CCBs are indicated in symptomatic patients with idiopathic
VT/PVCs from an origin other than the RVOT or the left fascicles.304,593
I
C
Beta-blockers, non-dihydropyridine CCBs, or
ﬂecainide should be considered when catheter ablation is not available, desired, or is particularly risky in symptomatic patients with idiopathic VT/
PVCs from the RVOT or the left fascicles.304,592,593
IIa
B
Catheter ablation or ﬂecainide should be considered in symptomatic patients with idiopathic VT/PVCs from an origin other than the
RVOT or the left fascicles.535,604,605
IIa
C
Catheter ablation may be considered for idiopathic VT/PVCs in asymptomatic patients with repeatedly more than 20% of PVCs per day at follow-up.535,600,601
IIb
B
Catheter ablation of idiopathic VT/PVCs is not recommended in children ,5 years of age or
,10 kg weight except when previous medical therapy fails or when VT is not haemodynamically tolerated.597
III
C
Amiodarone as a ﬁrst-line treatment is not recommended in patients with idiopathic VTs/
PVCs.594
III
C
Verapamil is not recommended in children ,1 year of age with PVC/VT, particularly if they have signs of heart failure or concurrent use of other AADs.606
III
C
© ESC 2022
AAD, anti-arrhythmic drug; CCB, calcium channel blocker; CMR, cardiac magnetic resonance; PVC, premature ventricular complex; RVOT, right ventricular outﬂow tract;
SMVT, sustained monomorphic ventricular tachycardia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cIncluding but not limited to older age, right bundle branch block (RBBB) morphology,
SMVT consistent with re-entry.
dLevel of evidence C for VT/PVCs from left fascicles.


<!-- PAGE 57 -->

### Page 57

While ﬂecainide have a more favourable adverse effect proﬁle regarding organ toxicity, increased mortality has previously been shown in patients with MI.556 For selected patients with suspected
PVC-induced cardiomyopathy and PVC-aggravated cardiomyopathy,
ﬂecainide can still be considered, particularly if an ICD is in place
(Table 9).
A rare monogenetic cause of PVC-induced cardiomyopathy, referred to as multifocal ectopic Purkinje-related premature contractions, has been reported. It is characterized by a DCM phenotype and the presence of numerous PVCs with RBBB and/or left bundle branch block (LBBB) morphologies and an increased risk of SCD.627
Pathogenic mutations in the SCN5A gene lead to a gain of function of the sodium channel responsible for hyperexcitability of the fascicular Purkinje system.627,628 Limited data suggest that patients with multifocal ectopic Purkinje-related premature contractions do not respond to beta-blockers but might beneﬁt from therapy with ﬂecainide, quinidine, or amiodarone.627–631
N
N
N
N
Patient with PVC-Burden >10% and mildly reduced or reduced LVEF
L
CMR
(Class IIa)
Suspected PVC induced cardiomyopathy
SHD aggravated a
by frequent PVC’s
Further evaluation according to most like k ly diagnosis
(suspicious) CAD,
valvular heart disease or inflammatory heart disease
LV dysfunction
L
explained by underlying heart disease
Known SHD
LGE
Follow-up
Y
Y
Y
Y
Amiodarone
(Class IIa)
Catheter ablation
(Class IIa)
Catheter ablation
(Class I)
AAD
(Class IIa)
Figure 18 Algorithm for the management of patients with premature ventricular complex-induced/-aggravated cardiomyopathy. AAD, anti-arrhythmic drug; CAD, coronary artery disease; CMR, cardiac magnetic resonance; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left ventricular ejection fraction; N, No; PVC, premature ventricular complex; SHD, structural heart disease; Y, Yes.
Recommendation Table 27 — Recommendations for the management of patients with premature ventricular complex-induced or premature ventricular complexaggravated cardiomyopathy
Recommendation
Classa
Levelb
Diagnostic evaluation
In patients with an unexplained reduced EF and a
PVC burden of at least 10%, PVC-induced cardiomyopathy should be considered.600,609,610
IIa
C
In patients with suspected PVC-induced cardiomyopathy, CMR should be considered.590,615
IIa
B
Treatment
In patients with a cardiomyopathy suspected to be caused by frequent and predominately monomorphic PVCs, catheter ablation is recommended.535,600,609,612,617,618,620
I
C
Continued
ESC Guidelines
4053


<!-- PAGE 58 -->

### Page 58

7.1.3. Cardiomyopathies
7.1.3.1. Dilated cardiomyopathy and hypokinetic non-dilated cardiomyopathy
DCM is characterized by LV dilatation and systolic dysfunction unexplained by CAD or abnormal loading conditions.632 The true prevalence is difﬁcult to estimate. Older studies reported a prevalence of 1
in 2700 individuals.633
Historic data in adults with DCM showed a 1-year mortality of
20–25% and a 50% survival at 5 years.634 Recent trials of DCM patients with systolic heart failure and OMT report 5-year mortality rates in the range of 21–28%.356,359 SCD occurs in up to 12% of patients with DCM and still accounts for 25–35% of all deaths.359,634,635
In children, the annual incidence of DCM is 0.57 cases per
100 000.636 The prognosis in children is poor, with a 5-year incidence of heart transplantation or heart failure-related death of 40%.
However, in contrast to adults, the incidence of SCD in paediatric
DCM patients is much lower, with a 5-year incidence of 2.4–3% as reported in two large paediatric cardiomyopathy registries from the United States and Australia.637,638
Causes of DCM can be genetic or acquired.639 Genetic predisposition may also interact with extrinsic factors such as in peri-partum, alcoholic,
or chemotherapy-related cardiomyopathies.639 The phenotype, particularly of genetic aetiologies, can change over time and/or may not meet standard disease criteria at the time of disease manifestation. As a consequence, a new category of a hypokinetic non-dilated cardiomyopathy (HNDCM) has been proposed.639
7.1.3.1.1. Diagnostic evaluation and risk stratiﬁcation. An algorithm for risk stratiﬁcation and primary prevention of SCD in patients with DCM/HNDCM is presented in Figure 19.
Careful diagnostic work-up, including genetic testing and CMR,
should be considered to identify the underlying cause for aetiology-oriented risk stratiﬁcation and treatment.341,639
Pathogenic mutations are identiﬁed in 25–55% of DCM patients,634,639,640 most often with autosomal dominant inheritance. Truncated mutations in the titin gene (TTN) are most frequently found, followed by LMNA, sarcomeric, and desmosomal mutations. Mutations in genes such as LMNA, PLN,
RBM20, and FLNC are associated with a higher risk of VA and
SCD.641–645 Carriers of desmosomal and LMNA variants experienced the highest rate of VA/SCD, which was independent of the
LVEF in one series.645
The yield of genetic testing is particularly high in DCM patients with familial forms of DCM or SCD in a ﬁrst-degree relative at younger age.
An inherited DCM is also more likely in patients who present at young age or with signs suspicious for a speciﬁc aetiology (e.g. prolonged AV
conduction for LMNA) (Figure 20).634,639,640,646 First-degree relatives of DCM/HNDCM patients should undergo clinical diagnostic evaluation, especially if an inherited cause is suspected.
Discrimination between high- and low-risk patients for SCD
remains challenging. Beyond LVEF and NYHA class,357,359,635,647–650
recent data suggest that both genetic and CMR ﬁndings can contribute to risk stratiﬁcation. A meta-analysis of 29 studies combining
2948 patients studied the role of CMR in patients with DCM.129
LGE was signiﬁcantly associated with the arrhythmic endpoint,
even when including only studies that performed multivariate analysis
(HR 6.7; P , 0.001). Interestingly, the association between LGE and the arrhythmic endpoint remained signiﬁcant among patients with mean LVEF .35%. Similarly, a recent study of 1020 consecutive patients with DCM and CMR observed that LGE and LVEF were both risk markers for all-cause mortality and cardiac death, but only LGE
was signiﬁcantly associated with SCD risk.651
SCD risk stratiﬁcation has been reﬁned in the subgroup of patients with LMNA mutations, which represent 5–10% of all DCM patients.
LMNA mutations are associated with early atrial and ventricular arrhythmias, premature conduction disease, a high risk of SCD, and progression to end-stage heart failure.80,642,652,653 In a multicentre registry of 269 LMNA mutation carriers, NSVT, LVEF ,45% at ﬁrst evaluation, male sex, and non-missense mutations were identiﬁed as independent risk factors for VA.652 VA occurred only in persons with at least two of these risk factors. The risk stratiﬁcation was subsequently externally validated.653 Another study, which involved 589
LMNA mutation carriers, identiﬁed AV block as an additional predictor. Recently a risk calculator has been developed (https://lmna-riskvta.fr/) to predict the risk of life-threatening VA (C-index of 0.776
[95% CI: 0.711–0.842]).80 In patients with a 5-year estimated risk
≥10% and a manifest cardiac phenotype (NSVT, LVEF , 50%, or
AV conduction delay), a primary prevention ICD implantation should be considered to avoid potential over-implantation in mutation carriers without a cardiac phenotype. In LMNA mutation carriers with a DCM
phenotype, high-intensity exercise has been associated with a high risk of SCD and impaired LVEF and is therefore not recommended.654,655
A risk score for VA prediction has been recently proposed for patients with DCM or ARVC related to the p.Arg14del mutation in the
PLN gene.656 Validation studies are needed before it can be recommended for clinical use.
Beyond genetics and CMR, additional SCD predictors have been suggested, often derived from small cohorts with no or few replication studies. An unexplained syncope requires further evaluation and
PES may determine the underlying cause. The risk for arrhythmic
In patients with a cardiomyopathy suspected to be caused by frequent and predominately monomorphic PVCs, treatment with AADsc should be considered if catheter ablation is not desired,
suspected to be high-risk, or unsuccessful.624,626
IIa
C
In patients with SHD in whom predominately monomorphic frequent PVCs are suspected to be contributing to the cardiomyopathy, AAD
(amiodarone) treatment or catheter ablation should be considered. 617,621,622,624
IIa
B
In non-responders to CRT with frequent,
predominately monomorphic PVCs limiting optimal biventricular pacing despite pharmacological therapy, catheter ablation or
AADs should be considered.623
IIa
C
© ESC 2022
AAD, anti-arrhythmic drug; CMR, cardiac magnetic resonance; CRT, cardiac resynchronization therapy; EF, ejection fraction; ICD, implantable cardioverter deﬁbrillator; LV, left ventricular; PVC, premature ventricular complex; SHD,
structural heart disease.
aClass of recommendation.
bLevel of evidence.
cFlecainide only in selected patients (ICD recipients, only moderate LV dysfunction).


<!-- PAGE 59 -->

### Page 59

events in DCM patients with a low LVEF and an unexplained syncope was similar to those with prior CA657 and high, independent from the outcome of PES.148 However, data in DCM patients with a mildly reduced EF suggest an incremental value of PES. Among DCM patients with an EF ≥40% and an unexplained syncope, who underwent
ICD implantation after a positive PES, 80% had appropriate ICD
therapy during follow-up. No SCD or symptomatic VA occurred in non-inducible patients.146
7.1.3.1.2. Primary prevention of sudden cardiac death. In patients with DCM/HNDCM, OMT according to current 2021 ESC
Guidelines for the diagnosis and treatment of acute and chronic heart failure is mandatory.342 Re-evaluation of cardiac function and clinical status after 3 months’ OMT is required before primary prevention ICD implantation. LV function is more likely to improve in
DCM caused by myocarditis or TTN mutations.
The efﬁcacy of primary prevention ICDs in DCM patients with
HFrEF has been addressed in six RCTs.635
Five studies were published between 2002 and 2005 (CAT,
AMIOVIRT, DEFINITE, COMPANION, and SCD-HeFT). The
ﬁrst three were smaller studies enrolling only DCM patients,
whereas
SCD-HeFT
and
COMPANION
were larger and
Patient with DCM/HNDCM
Suspicious of cause requiring specific treatment
Family history of DCM/HNDCM or 
family history of SCD (<50 y, first-degree relative) or 
AV block <50 y
5-year risk ofVA ≥10% 
and LVEF <50%
or NSVT
or AV conduction delay
Pathogenic 
mutation LMNA
ICD implantation
(Class IIa)
ICD implantation
(Class IIa)
ICD implantation
(Class IIa)
ICD implantation
(Class IIa)
Genetic testing
(Class IIa)
(Class I)
Go to specific sections for specific aetiology-directed management,
especially for inflammatory diseases
CMR (Class IIa)
Annual reevaluation
LVEF
≥2 risk factorsa
SMVT inducible
PES (Class IIa)
ILRb (Class I)
Follow-up
Unexplained syncope
Y
Y
Y
Y
Y
Y
N
N
N
N
N
N
≤35%
36–50%
Figure 19 Algorithm for risk stratiﬁcation and primary prevention of sudden cardiac death in patients with dilated cardiomyopathy/hypokinetic nondilated cardiomyopathy. AV, atrioventricular; CMR, cardiac magnetic resonance; DCM, dilated cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; LMNA: lamin A/C gene; LVEF, left ventricular ejection fraction;
N, No; NSVT, non-sustained ventricular tachycardia; PES, programmed electrical stimulation; SCD, sudden cardiac death; SMVT, sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmias; Y, Yes. aRisk factors: unexplained syncope, pathogenic variants in PLN, FLNC, or RBM20, LGE on
CMR, inducible SMVT at PES. bThe 2018 ESC Guidelines for the diagnosis and management of syncope.1
ESC Guidelines
4055


<!-- PAGE 60 -->

### Page 60

included patients with CAD and DCM. The COMPANION study differed from the others as it compared CRT-deﬁbrillator,
CRT-pacemaker, and OMT. A meta-analysis of the ﬁve trials
(1854 patients with DCM) demonstrated a 31% reduction in allcause mortality with ICD relative to medical therapy (RR 0.69
[95% CI 0.55, 0.87], P , 0.002).658 This effect persisted when
COMPANION was excluded.
More recently, the DANISH trial enrolled 1116 symptomatic patients
(NYHA class II or III) with non-ischaemic systolic heart failure (LVEF ≤
35%). Patients were randomized to ICD or no ICD after OMT.359 No reduction in the primary endpoint of all-cause death for patients randomized to ICD therapy (HR 0.87; 95% CI 0.68–1.12; P = 0.28)
was observed, despite a signiﬁcant reduction in SCD in the ICD group
(HR 0.50; 95% CI 0.31–0.82; P = 0.005). Potential explanations are the low SCD rate in the trial (4.3% in the ICD group and 8.2% in the control group), the excellent medical treatment (.90% of patients on ACE inhibitors and beta-blockers, .50% on MRA), and the high prevalence
(58%) of CRT. A meta-analysis of all six primary prevention trials still demonstrated a reduction, although lower, in overall mortality with ICD
therapy (RR 0.76; 95% CI 0.65–0.91; P= 0.002).635 In a sensitivity analysis, the beneﬁt of ICD therapy was maintained after the removal of any single study from the pooled analysis.
ECG sinus rhythm – Small amplitude P waves and first degree AV block
ECG VT – RBBB-like, inferior axis (LV summit origin)
CMR – Mid-wall septal LGE
4-chamber
Short axis
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
Figure 20 Typical features of dilated cardiomyopathy associated with lamin A/C gene mutation with ventricular arrhythmias. AV, atrioventricular; CMR,
cardiac magnetic resonance; ECG, electrocardiogram; LGE, late gadolinium enhancement; LV, left ventricle; RBBB, right bundle branch block; VT, ventricular tachycardia.


<!-- PAGE 61 -->

### Page 61

The results of the DANISH trial emphasize the need for further reﬁning the indication for primary prevention ICDs in contemporary DCM patients. Age and comorbidity need to be considered.635
In the DANISH trial, ICD implantation was associated with a signiﬁcantly lower rate of death in younger patients.359 A further analysis of the DANISH data647 showed an association between reduced all-cause mortality and ICDs in patients ≤70 years of age (HR,
0.70; 95% CI 0.51–0.96; P = 0.03), but not in patients .70 years of age.
Prospective studies evaluating the beneﬁt of ICDs in DCM/
HNDCM patients with intermediate LV dysfunction, but with risk factors that have been associated with VA and SCD (including
LGE on CMR, pathogenic mutations in PLN, FLNC, RBM20, unexplained syncope,
and inducibility of
SMVT),
are lacking.129,641,643,644,659–662 Given the limitation of LVEF as the only risk marker in DCM/HNDCM, this panel of experts shares the opinion that in the presence of a combination of risk markers an
ICD should be considered.
7.1.3.1.3. Secondary prevention of sudden cardiac death and management of ventricular arrhythmias. Three randomized trials
(AVID, CASH, and CIDS) have compared ICD therapy and medical treatment for secondary prevention in patients after aborted CA or not-tolerated VT.349,351,352 The three trials enrolled a total of 1963
patients, of whom only 292 (14.8%) had non-ischaemic aetiologies. A
signiﬁcant reduction in death from any cause in patients with ICDs was demonstrated, which was almost entirely due to a 50% reduction in arrhythmic death.352 In the subgroup of patients with cardiomyopathies there was a similar but non-signiﬁcant trend in the reduction of death.352 RCTs have excluded patients with haemodynamically tolerated VT. In DCM patients the VT substrate is less well deﬁned, and disease progression needs to be considered.
Therefore, despite the lack of data, this panel of experts shares the opinion that an ICD should also be considered in DCM patients with haemodynamically tolerated VT.
Optimization of ICD programming (see Section 6.2.3.1) can reduce ICD shocks delivered in response to VT, but additional therapy to reduce symptomatic VA episodes is often required. In the OPTIC
trial, 412 patients with ICD implantation within 21 days of VT/VF
were randomized to amiodarone plus beta-blockers, sotalol alone,
or beta-blocker alone. ICD shock rates after one year were 10.3%,
24.3%, and 38.5%, respectively. The higher efﬁcacy of amiodarone plus beta-blockers compared to sotalol needs to be weighed against the higher rate of medication-related adverse events on an individual basis.318 Although only limited data are available, sodium channel blockers may control VT in SHD and may be beneﬁcial in ICD recipients without advanced heart failure. The majority of SMVT is due to scar-related re-entry, which can be targeted by catheter ablation.
Acute ablation outcome has been reported to be similar for CAD
and DCM.497,663 However, VT recurrence rates are usually higher in DCM patients (VT-free survival 40.5% in DCM vs. 57% in CAD
at 1 year).497 After multiple procedures in 36% of the patients, longterm freedom of VT could be achieved in 69% of cases in a retrospective, single-centre cohort of 282 patients treated between
1999 and 2014.664
Epicardial ablation is needed in 27–30% of the procedures.497,664
Outcome is particularly poor, and bailout strategies (transcoronary ethanol ablation, bipolar ablation, surgical ablation) may be required in patients with pathogenic mutations (LMNA gene) and in those with deep intramural, anteroseptal substrate locations.499,665,666 Considering the complexity of the ablation procedure, DCM patients should therefore be treated only in specialized centres.
Recommendation Table 28 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy
Recommendation
Classa
Levelb
Diagnostic evaluation and general recommendations
Genetic testing (including at least LMNA, PLN,
RBM20, and FLNC genes) is recommended in patients with DCM/HNDCM and AV conduction delay at ,50 years, or who have a family history of
DCM/HNDCM or SCD in a ﬁrst-degree relative
(at age ,50 years).641–645
I
B
CMR with LGE should be considered in DCM/
HNDCM patients for assessing the aetiology and the risk of VA/SCD.129,651,667
IIa
B
Genetic testing (including at least LMNA, PLN,
RBM20, and FLNC genes) should be considered for risk stratiﬁcation in patients with apparently sporadic DCM/HNDCM, who present at young age, or with signs suspicious for an inherited aetiology.641–645
IIa
C
Participation in high-intensity exercise including competitive sports is not recommended for individuals with DCM/HNDCM and a LMNA
mutation.655
III
C
Risk stratiﬁcation and primary prevention of SCD
ICD implantation should be considered in patients with DCM/HNDCM, symptomatic heart failure
(NYHA class II–III), and LVEF ≤35% after ≥3
months of OMT.357,359,635,650
IIa
A
ICD implantation should be considered in DCM/
HNDCM patients with a pathogenic mutation in
LMNA gene, if the estimated 5-year risk of life-threatening VA is ≥10%c and in the presence of NSVT or LVEF , 50% or AV conduction delay.80,652,653
IIa
B
ICD implantation should be considered in DCM/
HNDCM patients with a LVEF ,50% and ≥2 risk factors (syncope, LGE on CMR, inducible SMVT at
PES, pathogenic mutations in LMNA,d PLN, FLNC,
and RBM20 genes).
IIa
C
In DCM/HNDM patients, electrophysiological evaluation should be considered when syncope remains unexplained after non-invasive evaluation.661,668
IIa
C
Continued
ESC Guidelines
4057


<!-- PAGE 62 -->

### Page 62

7.1.3.2. Arrhythmogenic right ventricular cardiomyopathy
ARVC is an inherited disease characterized by ﬁbrofatty myocardial replacement.670 The prevalence ranges from 1:1000 to 1:5000 individuals, with male predominance among probands.671 Patients with
SCD/VF at ﬁrst presentation are typically younger (median age 23
[range 13–57]) compared to those who present with a SMVT
(median age 36 years [range 14–78]).672
ARVC is caused by pathogenic mutations in desmosomal genes and less commonly in non-desmosomal genes. Genetic testing is indicated and identiﬁcation of a mutation (in up to 73% of probands) is a major criterion for the diagnosis.116,671 In 4–16% compound/
digenic mutations are found, which have been associated with an increased risk of VA at younger age.672,673 The disease penetrance in
ﬁrst-degree relatives is 28–58%,674,675 supporting regular clinical evaluation of relatives.
ARVC is characterized by a predominant RV involvement. The
2010 revised international diagnostic task force criteria are based on a multiparametric strategy116 (Figure 21). Tissue characterization by CMR was not included. However, RV fatty inﬁltration and LV LGE
are frequently observed (in 29–53% and 35.5–45% of probands, respectively) and may be present before patients meet major task force imaging criteria.676–678 Both wall motion alterations and pre-/
post-contrast signal abnormalities have been suggested to enhance the diagnostic accuracy of CMR for ARVC.679 The identiﬁcation of biventricular and left-dominant involvement in ARVC
patients680,681 has recently led to the proposed term ‘arrhythmogenic cardiomyopathy’.682
Restriction from high-intensity exercise is regarded as a preventive tool in clinically affected ARVC patients to reduce the risk of VAs and disease progression.683–685 Whether sport restriction is beneﬁcial in all mutation carriers without disease expression has not been evaluated in prospective cohorts, but avoidance of competitive, highintensity exercise seems to be reasonable.686,687 SCD and VA occur disproportionately during exercise in affected patients,
and high-dose isoproterenol infusion may provoke PVT in .90% of
ARVC patients, supporting the role of sympathetic stimulation for arrhythmogeneity.152,688,689 Whether beta-blockers can prevent spontaneous VA is, however, unclear. Limited data suggest a potential beneﬁcial role of atenolol.690
7.1.3.2.1. Risk stratiﬁcation. In ARVC patients not implanted with
ICDs, CA occurs in 4.6–6.1%, while 23% of patients experience a non-fatal SMVT during an average follow-up of 8–11 years.691–694
Whether a SMVT is acutely life-threatening depends on the VT cycle length, cardiac function, and the circumstances under which VT occurs. Among deﬁnite/probable ARVC patients considered at high risk for VA, 23–48% will experience appropriate ICD intervention during a mean follow-up of 4.7 years. In 16–19% of cases, ICD intervention is triggered by fast VT ≥250 b.p.m. or VF, which is considered as surrogate for a life-threatening event.695–698 In a large cohort of 864
ARVC patients (38.8% with a prior VA), 43% had VT/VF during a median follow-up of 5.75 years, but only 10.8% a potentially lifethreatening event. Thus, in 3 out of 4 ARVC patients, ICD therapy is appropriate but may not be considered acutely life-saving. This is relevant because risk prediction algorithms and models are based on combined arrhythmic endpoints, which are often equated with
ICD indications to prevent SCD. This is particularly important for the young ARVC patients with a lifetime risk of ICD-related complications.695,699
Randomized studies of ICD therapy for secondary prevention are lacking, but the high rates of appropriate ICD therapy triggered by fast VT/VF episodes in patients implanted after CA or haemodynamically poorly tolerated VT strongly suggest a survival beneﬁt from
ICD.700 In patients who present with a haemodynamically tolerated
VT, the survival beneﬁt from ICD is less clear.691,700–702 Identiﬁcation of ARVC patients at risk for SCD is difﬁcult, and the evidence supporting risk factors for life-threatening VAs is limited. Arrhythmic syncope was a predictor for subsequent events in most series of patients with deﬁnitive
ARVC
(pooled
HR
3.67;
CI
2.75–
4.9)81,696,701,703 and, in these patients, an ICD should be considered.
RV and LV dysfunction have been associated with a higher arrhythmic risk.675,704 Cut-off values are difﬁcult to determine but, in
Secondary prevention of SCD and treatment of VAs
ICD implantation is recommended in patients with DCM/HNDCM, who survive SCA due to VT/
VF or experience haemodynamically not-tolerated SMVT.349,351,352
I
B
Catheter ablation in specialized centres should be considered in patients with DCM/HNDCM and recurrent, symptomatic SMVT or ICD shocks for
SMVT, in whom AADs are ineffective,
contraindicated, or not tolerated.481,497,664,669
IIa
C
The addition of oral amiodarone or replacement of beta-blockers by sotalol should be considered in patients with DCM/HNDCM and an ICD who experience recurrent, symptomatic VA despite optimal device programming and beta-blocker treatment.318
IIa
B
ICD implantation should be considered in patients with DCM/HNDCM and haemodynamically tolerated SMVT.
IIa
C
Management of relatives of a patient or SCD victim with
DCM/HNDCM
In a ﬁrst-degree relative of a DCM/HNDCM
patient, an ECG and an echocardiogram are recommended if:
•theindexpatientwasdiagnosed,50yearsofageor hasclinicalfeaturessuggestiveofaninheritedcause,or
• there is family history of DCM/HNDCM, or premature unexpected SD.646
I
C
In a ﬁrst-degree relative of a patient with apparently sporadic DCM/HNDCM, an ECG and an echocardiogram may be considered.646
IIb
C
© ESC 2022
AAD, anti-arrhythmic drug; AV, atrioventricular; CMR, cardiac magnetic resonance; DCM,
dilated cardiomyopathy; ECG, electrocardiogram; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OMT, optimal medical therapy; PES,
programmed electrical stimulation; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SMVT, sustained monomorphic ventricular tachycardia; VA,
ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cBased on the risk calculator https://lmna-risk-vta.fr/
dSee speciﬁc recommendations for LMNA.


<!-- PAGE 63 -->

### Page 63

patients with severe RV dysfunction (RV fractional area change ≤17%
or RV ejection fraction ≤35%), an ICD should be considered.
Likewise, ARVC patients with signiﬁcant LV involvement (LVEF
≤35%) should be treated according to the current DCM recommendation regarding ICD implantation. There are conﬂicting data on the independent predictive value of NSVT for subsequent sustained arrhythmic events.695,696,701 Likewise, the role of PES in risk stratiﬁcation, particularly in asymptomatic patients, is not well deﬁned.695,696,705 In one series including mainly symptomatic patients,
both NSVT and a positive PES independently predicted arrhythmic events, while others report a low diagnostic accuracy.696 Risk prediction based on a single parameter does not consider the potential combined effect and interactions between factors. Therefore,
although supporting data are lacking, this panel of experts supports that an ICD should be considered706 in symptomatic ARVC patients with moderate RV (,40%) and/or LV dysfunction (,45%) and who have either NSVT or have SMVT inducible at PES. An internally validated risk model has recently been developed from 528 patients with deﬁnite ARVC and no prior VA, including age, sex, arrhythmic syncope, NSVT, PVC burden, leads with T-wave inversion and RV
ejection fraction, to predict any sustained VA (c-index 0.77).81 In addition, a prediction model for speciﬁcally life-threatening VA has been promoted based on 864 ARVC patients, with predictors including male sex, age, 24 h PVC count, and leads with T-wave inversion
(c-index 0.74).702 However, validation studies are needed before these risk models can be recommended for clinical use.
ECG sinus rhythm – Negative T wavesV1-V4, terminal QRS duration >55 ms
ECG VT – LBBB-like, superior axis (basal RV origin)
CMR – Dilated RV with basal aneurysm
4-chamber
3-chamber
Short axis
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
Figure 21 Typical features of arrhythmogenic right ventricular cardiomyopathy associated with ventricular arrhythmias. CMR, cardiac magnetic resonance; ECG, electrocardiogram; LBBB, left bundle branch block; RV, right ventricle; VT, ventricular tachycardia.
ESC Guidelines
4059


<!-- PAGE 64 -->

### Page 64

7.1.3.2.2. Treatment. Up to 97.4% of all VA episodes in ARVC ICD
recipients are SMVT. The very high termination rate by ATP (92% of all episodes) independent from VT cycle length strongly supports devices with the capability for ATP.698 S-ICDs reduce lead-related complications and have been proven to effectively shock terminate
VA
in small cohorts of ARVC
patients during short-term follow-up.707
Additional treatment to supress VA is often required. Although not conﬁrmed by clinical data, beta-blockers are recommended as
ﬁrst-line therapy in symptomatic patients.
Data on AADs to prevent VT recurrence are limited to small observational studies and registries. In general, AAD therapy has limited efﬁcacy. Although sotalol was effective to prevent inducibility of
VT,708 it did not supress clinically relevant arrhythmias.690,708
Treatment with amiodarone or class 1 drugs was associated with a trend to lower VT recurrence as compared with sotalol.709 The addition of ﬂecainide to beta-blockers/sotalol was beneﬁcial in a small cohort.710 Catheter ablation provides an alternative. Endocardial and adjuvant epicardial substrate ablation, if needed, has been associated with promising VT-free survival. Potential procedural risks, drug side effects, and the patient’s preference need to be taken into consideration.482
7.1.3.3. Hypertrophic cardiomyopathy
HCM is characterized by increased LV wall thickness not explained by abnormal loading conditions (such as hypertension or valvular disease).128,715 Because the natural history and management differs according to the underlying aetiology of LVH, diagnostic work-up is of paramount importance (see Section 7.1.3.5) and includes CMR and genetic testing.716–725 HCM is usually caused by a mutation with autosomal dominant inheritance, supporting cardiac screening in
ﬁrst-degree relatives, in parallel with genetic testing in the index patient. A sarcomeric gene mutation is identiﬁed in 30–60%, most frequently in patients who are younger at diagnosis or with a family history of HCM.646,722
The estimated prevalence of HCM in adults is 1 in 500.726 In children, the prevalence is much lower.
Recommendation Table 29 — Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy
Recommendations
Classa
Levelb
Diagnostic evaluation and general recommendations
In patients with suspected ARVC, CMR is recommended.676–678
I
B
In patients with a suspected or deﬁnite diagnosis of ARVC, genetic counselling and testing are recommended.672,673
I
B
Avoidance of high-intensity exercise is recommended in patients with a deﬁnite diagnosis of ARVC.683–685
I
B
Avoidance of high-intensityc exercise may be considered in carriers of ARVC-related pathogenic mutations and no phenotype.683,687
IIb
C
Beta-blocker therapy may be considered in all patients with a deﬁnite diagnosis of ARVC.
IIb
C
Risk stratiﬁcation and primary prevention of SCD
ICD implantation should be considered in patients with deﬁnite ARVC and an arrhythmic syncope.696,701,711–713
IIa
B
ICD implantation should be considered in patients with deﬁnite ARVC and severe RV or LV systolic dysfunction.675,691
IIa
C
ICD implantation should be considered in symptomaticd patients with deﬁnite ARVC,
moderate right or left ventricular dysfunction, and
IIa
C
Continued either NSVT or inducibility of SMVT at
PES.695,696,701,703,705
In patients with ARVC and symptoms highly suspicious for VA, PES may be considered for risk stratiﬁcation.695,705
IIb
C
Secondary prevention of SCD and treatment of VAs
ICD implantation is recommended in ARVC
patients with haemodynamically not-tolerated VT
or VF.700
I
C
In patients with ARVC and non-sustained or sustained VAs, beta-blocker therapy is recommended.
I
C
In patients with ARVC and recurrent,
symptomatic SMVT or ICD shocks for SMVT
despite beta-blockers, catheter ablation in specialized centres should be considered.482,709,714
IIa
C
In ARVC patients with indication for ICDs, a device with the capability of ATP programming for
SMVT up to high rates should be considered.698
IIa
B
ICD implantation should be considered in ARVC
patients with a haemodynamically tolerated
SMVT.692
IIa
C
In patients with ARVC and recurrent,
symptomatic VT despite beta-blockers, AAD
treatment should be considered.709,710
IIa
C
Management of relatives of a patient with ARVC
In a ﬁrst-degree relative of a patient with ARVC,
ECG and echocardiogram are recommended.675
I
C
© ESC 2022
AAD, anti-arrhythmic drug; ARVC, arrhythmogenic right ventricular cardiomyopathy;
ATP,
anti-tachycardia pacing;
CMR,
cardiac magnetic resonance;
ECG,
electrocardiogram; ICD, implantable cardioverter deﬁbrillator; LV, left ventricle;
NSVT, non-sustained ventricular tachycardia; PES, programmed electrical stimulation;
RV, right ventricle; SCD, sudden cardiac death; SMVT, sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cThe 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease.4
dPresyncope or palpitations suggestive of VA.


<!-- PAGE 65 -->

### Page 65

Annual mortality related to HCM is 1–2% in most studies with contemporary management strategies,128,715 and may be as low as 0.5%.727 The annual rate of SCD or appropriate ICD therapy is about 0.8% but is largely dependent on age and risk proﬁle.85,728–730 HCM patients are at risk for heart failure, AF, and stroke.128,715 Most HCM-related deaths at age ≤60 years occur suddenly, while older patients die more often of stroke or heart failure.731 SCD is often related to VA, which can be a consequence of ischaemia, left ventricle outﬂow tract (LVOT) obstruction, or supraventricular arrhythmias. SCD may also be triggered by exercise, and participation in competitive sport has been discouraged.732 However, recent data suggest that even vigorous exercise in HCM patients without risk markers may not be associated with VA.733,734
7.1.3.3.1. Risk stratiﬁcation and primary prevention of sudden cardiac death. In primary prevention, the challenge remains to identify the relatively small group of patients with the highest risk of SCD.
NSVT is identiﬁed on continuous (24/48h) ambulatory ECG monitoring in 20–25% of patients.128,715 Its prevalence increases with age and correlates with LV wall thickness and LGE on CMR.716–721,735
The prognostic value of NSVT for SCD is more important in young patients (,30 years).735 The relation between the duration, frequency, or rate of NSVT and HCM prognosis remains unclear.735
ECG sinus rhythm – Negative T wavesV2-V6 and inferior leads
ECG VT – RBBB-like, superior axis (apical LV origin)
CMR – Apical aneurysm with LGE
4-chamber
2-chamber
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
Figure 22 Typical features of hypertrophic cardiomyopathy associated with sustained monomorphic ventricular tachycardia. CMR, cardiac magnetic resonance; ECG, electrocardiogram; LGE, late gadolinium enhancement; LV, left ventricular; RBBB, right bundle branch block; VT,
ventricular tachycardia.
ESC Guidelines
4061


<!-- PAGE 66 -->

### Page 66

Documented NSVT during exercise test is very rare, but was associated with a higher risk of SCD.732 Additional risk factors have been identiﬁed and a 5-year SCD risk stratiﬁcation score based on seven factors (age, LV wall thickness, LA size, LVOT gradient, NSVT, unexplained syncope, and family history of SCD) has been developed85
(HCM Risk-SCD: https://doc2do.com/hcm/webHCM.html) and externally validated.85,728,729 The calculator is not intended for use in elite athletes, or in individuals with metabolic or inﬁltrative diseases,
or after myectomy or alcohol septal ablation.85
Additional factors not captured by the Risk-SCD model should also be considered in patients with intermediate or low calculated risk, including LV systolic dysfunction, apical aneurysm, extensive
LGE on CMR, and presence of single or multiple sarcomeric mutations (Figure 22).716,717,722,736–739 Extensive LGE on CMR deﬁned as ≥15% of LV mass has been suggested as good predictor of
SCD in adults. However, thresholds may be difﬁcult to use because
LGE quantiﬁcation is dependent on CMR acquisition, type, and amount of contrast.
Periodic reassessment is mandatory as part of the longitudinal evaluation of patients. VA induced by PES is considered non-speciﬁc,
although conﬂicting results have been reported.740,741
In children few data on primary prevention were available until the recent development of scores and related risk calculators.83,84 The
HCM Risk-Kids score84 has been developed and externally validated742 speciﬁcally in children with HCM (1–16 years of age) and includes unexplained syncope, maximal LV wall thickness, large left atrial diameter, low LVOT gradient, and NSVT (https://hcmriskkids.
org). In contrast to adults, including age and family history of SCD
did not improve the performance of the paediatric model. Patients with prior VF or sustained VT, known inborn errors of metabolism,
and syndromic causes of HCM were excluded. The predictive value of LGE in children is less deﬁned, although preliminary data were reported.743
7.1.3.3.2. Treatment to prevent ventricular arrhythmia recurrence. Patients surviving a CA due to VT/VF or haemodynamically not-tolerated VT remain at high risk for future life-threatening VA,
and will beneﬁt from ICD therapy.128,744–746
There are no RCTs in HCM or cohort studies supporting a signiﬁcant role of drugs to prevent SCD.128,715,747 Amiodarone may reduce VA but with conﬂicting results regarding SCD prevention.747,748 Disopyramide and beta-blockers are efﬁcient to control symptoms and LVOT obstruction, but there is no evidence that they reduce the risk of SCD.128,715 Similarly, surgical myectomy or alcohol ablation are not recommended with the aim to reduce risk of SCD in patients with LVOT obstruction.128,715 Following ICD implantation for primary or secondary prevention, the most common documented VA subtype is SMVT, and ATP is successful in 69–76.5%
of all episodes.749–751 Although data on drug efﬁcacy are lacking,
AADs (beta-blockers, amiodarone, sotalol, sodium channel blockers)
should be considered in HCM patients with symptomatic VA.
Catheter ablation may also be considered in highly selected HCM patients with SMVT, in whom AADs are ineffective, contraindicated or not tolerated, as outcome after ablation is inferior compared to other non-ischaemic aetiologies.752–754
Recommendation Table 30 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention,
and treatment of ventricular arrhythmias in hypertropic cardiomyopathy
Recommendation
Classa
Levelb
Diagnostic evaluation and general recommendations
CMR with LGE is recommended in HCM patients for diagnostic work-up.716–718
I
B
Genetic counselling and testing are recommended in HCM patients.721–725
I
B
Participation in high-intensity exercise may be considered for asymptomatic adult HCM patients without risk markers.733
IIb
C
Risk stratiﬁcation and primary prevention of SCD
It is recommended that the 5-year risk of SCD is assessed at ﬁrst evaluation and at 1–3-year intervals, or when there is a change in clinical status.
I
C
ICD implantation should be considered in patients aged 16 years or more with an estimated 5-year risk of SD ≥6%.c,85,728,729
IIa
B
ICD implantation should be considered in HCM
patients aged 16 years or more with an intermediate 5-year risk of SCD (≥4 to ,6%)c and with (a) signiﬁcant LGE at CMR (usually ≥15%
of LV mass); or (b) LVEF , 50%; or (c) abnormal blood pressure response during exercise testd; or
(d) LV apical aneurysm; or (e) presence of sarcomeric pathogenic mutation.716,717,722,736–739
IIa
B
In children less than 16 years of age with HCM and an estimated 5-year risk of SD ≥6% (based on
HCM Risk-Kids scoree), ICD implantation should be considered.84,742
IIa
B
ICD implantation may be considered in HCM
patients aged 16 years or more with an estimated
5-year risk of SCD of ≥4 to ,6%.c,85,728,729
IIb
B
ICD implantation may be considered in HCM
patients aged 16 years or more with a low estimated 5-year risk of SCD (,4%)c and with (a)
signiﬁcant LGE at CMR (usually ≥15% of LV mass);
or (b) LVEF , 50%; or (c) LV apical aneurysm.716,717,722,736–739
IIb
B
Secondary prevention of SCD and treatment of VAs
ICD implantation is recommended in HCM
patients with haemodynamically not-tolerated VT
or VF.744–746
I
B
In patients with HCM presenting with haemodynamically tolerated SMVT, ICD
implantation should be considered.
IIa
C
In patients with HCM and recurrent, symptomatic
VA, or recurrent ICD therapy, AAD treatment should be considered.
IIa
C
Continued


<!-- PAGE 67 -->

### Page 67

7.1.3.4. Left ventricular non-compaction
LVNC comprises a heterogeneous group of diseases. The diagnosis is challenging, and various diagnostic criteria have been proposed. The yield of genetic tests in index patients is low.755
The morphological phenotype of non-compaction based on imaging parameters may also appear in a healthy population.756
A meta-analysis including 2501 LVNC patients revealed a risk of cardiovascular mortality similar to that of DCM patients, with no relation to the extent of trabeculation.757 CMR-based detection of focal ﬁbrosis using LGE in LVNC with preserved ejection was associated with serious cardiac events (aborted death, ICD therapy,
heart transplantation [HTX]/LVAD) in another meta-analysis including 574 patients (OR 6.1; CI 2.1–17.5; P , 0.001).758 A combination of CMR criteria with systematic genotyping may overcome current uncertainties regarding risk stratiﬁcation.759
7.1.3.5. Restrictive cardiomyopathy
The phenotype of restrictive cardiomyopathy (RCM) is rare and can be the consequence of different aetiologies, including inﬁltrative disorders (e.g. amyloidosis) and storage disease (e.g. Andersen–Fabry disease), the identiﬁcation of which is crucial for guiding therapy.
Heart failure is one of the leading symptoms in primary and secondary RCM.760
In Fabry disease the majority of the reported cardiovascular deaths have been categorized as SCD in a recent systematic review of 13 studies including 4185 patients.761 Higher age, male gender,
LVH, LGE, and NSVT have been identiﬁed as potential risk factors associated with SCD events. However, SCD rates were reported in only 11 of the studies, including 623 patients. The retrospective,
observational nature of most of these small, single-centre studies and the low absolute number of cardiovascular deaths (36/623)
and SCD (30/623) do not currently allow guidance for primary prevention ICD implantation.761
Amyloidosis can be caused by different misfolded precursor proteins leading to deposits in tissue and organs. Cardiac amyloidosis is mainly related to light-chain amyloid or transthyretin amyloid. The latter can be subdivided into wild-type, also called senile amyloid,
more often complicated by AV conduction delay and atrial arrhythmias, and amyloid due to pathogenic mutations in the TTR gene.
Disease manifestation depends on the mutation. Despite advances in the treatment of amyloid light-chain amyloidosis, outcome is still poor in patients with manifest cardiac involvement.762 Causes of death are progressive heart failure, autonomic dysfunction, and electromechanical dissociation.762,763 The beneﬁt of primary prevention ICD implantation in patients with cardiac amyloidosis is uncertain. Currently, an ICD should be considered in patients with haemodynamically not-tolerated VT after careful discussion of the competing risks of non-arrhythmic death and non-cardiac death.
7.1.3.6. Neuromuscular disorders
An algorithm for risk stratiﬁcation, SCD prevention, and treatment of VAs in myotonic dystrophy is presented in Figure 23.
Arrhythmias are common and often the ﬁrst manifestation of neuromuscular disorders.764 Myotonic dystrophy is the most common muscular dystrophy in the adult population (prevalence 1 in 8000).
Myotonic dystrophy is the consequence of trinucleotide repeat expansion in the end of DMPK gene, which results in mis-splicing of SCN5A
and cardiac conduction system delays and arrhythmia. Duchenne dystrophy also has a high incidence (1 in 3500 male births). As most patients die before the age of 20, it is rarely seen in adulthood. Other neuromuscular disorders, such as Becker (1 in 100000 male births)
and facioscapulohumeral (1 in 100000) dystrophies, are less common.
Most of these disorders are associated with conduction and rhythm
Catheter ablation in specialized centres may be considered in selected patients with HCM and recurrent, symptomatic SMVT or ICD shocks for
SMVT, in whom AAD are ineffective,
contraindicated, or not tolerated.753,754
IIb
C
Management of relatives of a patient with HCM
In a ﬁrst-degree relative of a patient with HCM,
ECG and echocardiogram are recommended.
I
C
© ESC 2022
AAD,
anti-arrhythmic drug;
CMR,
cardiac magnetic resonance;
ECG,
electrocardiogram;
HCM,
hypertrophic cardiomyopathy;
ICD,
implantable cardioverter deﬁbrillator; LGE, late gadolinium enhancement; LV, left ventricle; LVEF,
left ventricular ejection fraction; SCD, sudden cardiac death; SD, sudden death;
SMVT, sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmia;
VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cBased on the HCM Risk-SCD: https://doc2do.com/hcm/webHCM.html dDeﬁned as a failure to increase systolic pressure by at least 20 mmHg from rest to peak exercise, or a fall of .20 mmHg from peak pressure.
eBased on the HCM kid risk score: https://hcmriskkids.org
Recommendation Table 31 — Recommendations for implantable cardioverter deﬁbrillator implantation in left ventricular non-compaction
Recommendations
Classa
Levelb
In patients with a LVNC cardiomyopathy phenotype based on CMR or echocardiography,
implantation of an ICD for primary prevention of
SCD should be considered to follow DCM/
HNDCM recommendations.
IIa
C
© ESC 2022
CMR,
cardiac magnetic resonance;
DCM,
dilated cardiomyopathy;
HNDCM,
hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator;
LVNC, left ventricular non-compaction; SCD, sudden cardiac death.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 32 — Recommendations for implantable cardioverter deﬁbrillator implantation in patients with cardiac amyloidosis
Recommendations
Classa
Levelb
An ICD should be considered in patients with light-chain amyloidosis or transthyretin-associated cardiac amyloidosis and haemodynamically not-tolerated VT.
IIa
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4063


<!-- PAGE 68 -->

### Page 68

disturbances, some life-threatening, and with mechanisms amenable to speciﬁc anti-arrhythmic therapy.17 Anti-arrhythmic therapy should be considered, as muscular function and life expectancy are often only moderately limited.765 It is generally recommended to treat patients with neuromuscular diseases who have survived a CA or have VAs or ventricular dysfunction in the same way as patients without extracardiac manifestations. However, the beneﬁt of ICD implantation should be balanced with the overall prognosis in some subtypes,
such as Duchenne dystrophy.
Symptoms may be the result of bradycardia or tachyarrhythmias and invasive electrophysiological evaluation is warranted unless a cause, such as AV block, has been clinically documented.153 Sudden increase of PR interval and QRS duration have been associated with AV block and SCD in myotonic dystrophy despite the absence of symptoms, and electrophysiological evaluation should be considered.766,767 An HV interval ≥70 ms should prompt pacemaker implantation regardless of symptoms.
Induction of BBR-VT in a symptomatic patient strongly supports
BBR-VT (
ESC CardioMed chapter 42.5)768 as an underlying cause of symptoms, and ablation of the right bundle branch is recommended.153 Following bundle branch ablation, the risk of AV
block at follow-up is considered particularly high due to
BBR-VT
Pacemaker/ICD
k c
implantation
(Class I)
Pacemaker/ICD
k c
implantation
(Class I)
Spontaneous
AV block
A
b
Spontaneous
AV block
A
b
EP evaluation
(Class I)
Catheter ablation
(Class I)
Follow-up
(Class I)
PR/QRS
sudden increase
ICD implantation
(Class I)
Follow-up
(Class I)
ICD implantation
(Class IIa)
Aborted cardiac arrest/VT and non-BBRVT or 
noVT induction
HV ≥70 ms or subnodal
AV block
A
Asymptomatic/
palpitations and negative
EP evaluation
Syncopea or palpitations and non-BBRVT
N
N
PR ≥240 ms or
QRS >120 ms or
>40 y and atrial arrhythmias or
>40 y and LGE
on CMR
N
N
Y
Y
Y
Y
Patient with myotonic dystrophy
Asymptomatic
Syncope or palpitationsa
Aborted cardiac arrest
VT
Pacemaker/ICD
k c
implantation
(Class IIb)
EP evaluationd
(Class IIa)
Figure 23 Algorithm for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in myotonic dystrophy. AV, atrioventricular; BBR-VT, bundle branch re-entrant ventricular tachycardia; CMR, cardiac magnetic resonance; EP, invasive electrophysiological evaluation; HV,
His-to-ventricle interval; ICD, implantable cardioverter deﬁbrillation; LGE, late gadolinium enhancement; N, No; VT, ventricular tachycardia, Y, Yes. aSyncope or palpitations highly suspicious of arrhythmic origin. bSpontaneous AV block: third or advanced second-degree AV block. cFactors favouring ICD implantation:
age,5,6,11 CTG expansion,6–9,13,16 sudden death (SD) orfamily history of SD,5 ECG conduction abnormalities,16 PRprolongation,13 left bundle branch block,5 atrial arrhythmias,6,16 non-sustained VT,5 LV dysfunction,17 signiﬁcant LGE in CMR.14,15,18 dFurther management according to outcome of EP evaluation.


<!-- PAGE 69 -->

### Page 69

progressive His–Purkinje disease, and a pacemaker should be implanted. Prolonged PR or QRS intervals,13,16,80 concurrent atrial arrhythmias,6,16,80 and LGE at CMR14,15,18 in patients older than
40 years have all been associated with AV block and SCD at follow-up in myotonic dystrophy. Accordingly, pacemaker implantation may be considered even in the absence of symptoms.
Although data are lacking, implantation of an ICD rather than a pacemaker may be preferred in myotonic dystrophy patients,
with additional risk factors for VA and SCD (Figure 23).
Permanent pacemaker implantation may also be considered in patients with
Kearns–Sayre syndrome,
Emery–Dreiffus,
or limb–girdle muscular dystrophy with any degree of AV block because of the substantial risk of rapid progression to total block.
In patients with limb–girdle type 1B or Emery–Dreifuss muscular dystrophies who have an indication for pacing or signiﬁcant LGE
on CMR, ICD implantation should be considered.769
Implantation of an ICD rather than a pacemaker may be also considered in patients with Duchenne/Becker, when there is signiﬁcant
LGE on CMR.770,771 However, the general prognosis of these diseases should be taken into consideration. In patients who have survived a CA due to a SMVT, implantation of an ICD is recommended when other than BBR-VTs (e.g. scar-related VTs) are inducible or if
VT is not inducible. Myotonic dystrophy patients with a syncope likely due to a VA, even if not inducible, and those with palpitations and induction of a non-BBR-VT are considered at risk for arrhythmic
SCD, and ICDs should be considered.
Due to the progressive nature, annual follow-up with an ECG is recommended, even in the concealed phase of the disease when patients are asymptomatic and the ECG is normal.6,13 Due to slow progression and the fact that signiﬁcant changes are often reﬂected on the surface ECG, serial electrophysiological evaluation to assess
AV conduction and arrhythmia induction is not recommended in patients without arrhythmia suspicion or progression of ECG conduction disorders.767,772
Recommendation Table 33 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention,
and treatment of ventricular arrhythmias in neuromuscular diseases
Recommendations
Classa
Levelb
General recommendations
Annual follow-up with at least a 12-lead ECG is recommended in patients with muscular dystrophies, even in the concealed phase of the disease.6,13
I
C
It is recommended that patients with neuromuscular disorders who have VAs or ventricular dysfunction are treated in the same way for arrhythmia as patients without neuromuscular disorders.17,765
I
C
Risk stratiﬁcation, primary and secondary prevention of SCD
Invasive electrophysiological evaluation is recommended in patients with myotonic dystrophy and palpitations or syncope suggestive of VA or surviving a CA.153
I
C
Continued
ICD implantation is recommended in patients with myotonic dystrophy and SMVT or aborted
CA not caused by BBR-VT.766
I
C
Invasive electrophysiological evaluation should be considered in patients with myotonic dystrophy and a sudden increase in the PR interval or QRS
duration.766,767
IIa
B
Invasive electrophysiological evaluation should be considered in patients with myotonic dystrophy and a PR interval ≥240 ms or QRS duration
≥120 ms or who are older than 40 years and have supraventricular arrhythmiasc or who are older than 40 years and have signiﬁcant LGE on
CMR.c,5,14,16,766
IIa
B
In myotonic dystrophy patients without AV
conduction delay and a syncope highly suspicious for VA, ICD implantation should be considered.766
IIa
C
In myotonic dystrophy patients with palpitations highly suspicious for VA and induction of a non-BBR-VT, ICD implantation should be considered.766
IIa
C
In patients with limb–girdle type 1B or Emery–
Dreifuss muscular dystrophies and indication for pacing, ICD implantation should be considered.769
IIa
C
Implantation of an ICD may be considered in patients with Duchenne/Becker muscular dystrophy and signiﬁcant LGE at CMR.770,771
IIb
C
Implantation of an ICD over a permanent pacemaker may be considered in myotonic dystrophy patients with additional risk factorsd for
VAs and SCD.
IIb
C
In myotonic dystrophy patients, serial electrophysiological evaluation of AV conduction and arrhythmia induction is not recommended without arrhythmia suspicion or progression of
ECG conduction disorders.772
III
C
Management of VA
In symptomatic patients with BBR-VT, catheter ablation is recommended.e,153,474,475,477
I
C
In patients with myotonic dystrophy undergoing ablation for BBR-VT, pacemaker/ICD
implantation is recommended.153
I
C
© ESC 2022
AV, atrioventricular; BBR-VT, bundle branch re-entrant ventricular tachycardia; CA,
cardiac arrest; CMR, cardiac magnetic resonance; ECG, electrocardiogram; ICD,
implantable cardioverter deﬁbrillator; LBBB, left bundle branch block; LGE, late gadolinium enhancement; LV, left ventricular; SCD, sudden cardiac death; SD, sudden death; SHD, structural heart disease; SMVT, sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cLevel of evidence C.
dFactors favouring ICD implantation: Age,5,6,11 CTG expansion,6–9,13,16 SD or family history of SD,5 ECG conduction abnormalities,16 PR prolongation,13 LBBB,5 atrial arrhythmias,6,16 non-sustained VT,5 LV dysfunction,17 structural abnormalities in
CMR.14,15,18
eIn other cardiac conditions (e.g. aortic valve replacement) with BBR-VT, catheter ablation is also recommended.
ESC Guidelines
4065


<!-- PAGE 70 -->

### Page 70

7.1.4. Inﬂammatory cardiac diseases
Cardiac inﬂammation has been associated with altered myocardial electrical properties and arrhythmias, and has been reported in various cardiomyopathies such as, obviously, myocarditis, but also inherited cardiomyopathies or after MI.773,774
Inﬂammatory cardiomyopathies are characterized by myocardial inﬂammation (i.e. myocarditis) as the primary cause of cardiac damage, whereas secondary myocardial inﬂammations are caused by an initial myocardial pathology.775,776
Myocarditis, sarcoidosis, and Chagas’ disease are among the major entities within inﬂammatory cardiomyopathies.
7.1.4.1. Myocarditis
The diagnosis of myocarditis can be challenging. There is no pathognomonic clinical presentation of this disease,777 with cardiac manifestations ranging from subtle symptoms to severe heart failure,
complete AV block, and SCD.778 In young people, it is estimated that 2–12% of SCD are related to myocarditis.779–781
Myocarditis is diagnosed on endomyocardial biopsy by established histological, immunological, and immunohistochemical criteria, as well as polymerase chain reaction (PCR) to detect viral genomes.782,783 This implies that endomyocardial biopsy, although not widely used, is the diagnostic gold standard for myocarditis.778,784
In current practice, the diagnosis of myocarditis relies on clinical presentation, elevated troponin level, ECG changes, evidence of LV
dysfunction, absence of signiﬁcant CAD or valvular heart disease,
and suggestive ﬁndings on CMR or PET-CT.
In the context of suspected or conﬁrmed acute myocarditis, patients with a life-threatening presentation (fulminant myocarditis,
sustained VAs, or complete AV block) are to be referred to a specialized centre.785,786 A specialized centre must have the capacity to perform cardiac catheterization, endomyocardial biopsies, use mechanical circulatory support devices, and manage complex VAs.
Sustained VAs may occur in acute myocarditis. In a large series of patients,786 in-hospital VF or CA was reported in 2.5% of cases. In another series of acute myocarditis in children,787 sustained tachyarrhythmias were reported in 11.5% of patients, with VAs accounting for most cases (79.5%). Tachyarrhythmias were associated with a
2.3-fold increased risk of death.787 Giant cell myocarditis, although rare, has a higher risk of life-threatening VAs, which are seen in
14% of giant cell myocarditis patients on initial presentation, and then develop as refractory arrhythmias in more than half of the patients during the course of the disease.788,789
The management of acute myocarditis depends on clinical presentation, viral PCR from myocardial biopsies, and histological ﬁndings.
In patients with suspected myocarditis who present with mild heart failure, it is recommended to avoid exercise and use beta-blockers and ACE inhibitors.790 Patients with VAs or AV block must be admitted to the hospital and continuously monitored.
Treatment of arrhythmias in patients with inﬂammatory heart disease does not differ from generally accepted clinical principles.
Symptomatic VAs may require AADs such as amiodarone and/or beta-blockers.791–793 Of note, in a retrospective observational study,
patients with sustained VAs during the acute phase of myocarditis
(LVEF 53 + 10%) had a high risk (45% at 3 years) of VT/VF recurrences during follow-up.794
Myocarditis may resolve without sequelae, recur, or become chronic. Thus, myocarditis is often considered a precursor of
DCM.795 Development of DCM has been observed in 21% of patients with acute myocarditis over a mean follow-up period of 3
years.796 The exact proportion of chronic DCM consecutive to the progression of acute myocarditis remains unknown, but myocarditis has been identiﬁed as the cause of DCM in up to 12% of cases in a large retrospective study.797 In patients with SMVT of unclear aetiology, myocarditis should be suspected especially when CMR reveals subepicardial and/or intramural abnormal ﬁbrotic myocardial tissue.
The presence of LGE at CMR has also been associated with the late occurrence of VAs in patients with endomyocardial biopsy-proven viral myocarditis.798–800
The management of documented VAs in chronic myocarditis is similar to that of patients with DCM, including ICD implantation and the use of AADs. Catheter ablation can be effective to treat
SMVT, the arrhythmogenic substrate of which is often found on the epicardium of the lateral/basal left ventricle.752,801–803 In one publication,802 non-inducibility of VT after catheter ablation led to avoidance of ICD implantation in one-third of patients, with subsequently no VT recurrence during follow-up.
Recommendation Table 34 — Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in myocarditis
Recommendations
Classa
Levelb
General recommendations
In conﬁrmed or clinically suspected acute myocarditis, it is recommended that patients who present with life-threatening VAs are referred to a specialized centre.786,804
I
C
Secondary prevention of SCD and treatment of VA
In patients with haemodynamically not-tolerated
SMVT occurring in the chronic phase of myocarditis, an ICD implantation is recommended.794,805
I
C
In patients with haemodynamically not-tolerated sustained VT or VF during the acute phase of myocarditis, ICD implantation before hospital discharge should be considered.788,794,806
IIa
C
AADs should be considered (preferably amiodarone and beta-blockers) in patients with symptomatic non-sustained or sustained VAs during the acute phase of myocarditis.
IIa
C
In post-myocarditis patients with recurrent,
symptomatic VT, AAD treatment should be considered.
IIa
C
Catheter ablation, performed in specialized centres, should be considered in post-myocarditis patients with recurrent, symptomatic SMVT or
ICD shocks for SMVT in whom AADs are ineffective, not tolerated, or not desired.752,801,802
IIa
C
In patients with haemodynamically tolerated
SMVT occurring in the chronic phase of myocarditis, ICD implantation should be considered.
IIa
C
Continued


<!-- PAGE 71 -->

### Page 71

7.1.4.2. Cardiac sarcoidosis
Sarcoidosis is a multisystem inﬂammatory disease of unknown cause,
with a genetic predisposition,807 characterized by the accumulation of T lymphocytes, mononuclear phagocytes, and non-caseating granulomas leading to tissue scarring.808 Although lung involvement is most frequent, any organ can be affected. It is estimated that 5% of patients with sarcoidosis have symptoms indicative of cardiac involvement. However, using advanced cardiac imaging modalities
(CMR/PET-CT), subclinical cardiac sarcoidosis is increasingly diagnosed.808–811
The diagnosis of cardiac sarcoidosis is challenging. It can mimic the
ARVC phenotype in the event of a predominant RV involvement810
or the heart is the only organ affected by sarcoidosis (so-called ‘isolated cardiac sarcoidosis’).812 Cardiac electroanatomical voltage mapping may help in the differential diagnosis between isolated cardiac sarcoidosis and ARVC.813 The three usual cardiac manifestations of cardiac sarcoidosis are LV dysfunction, AV conduction abnormalities, and VAs. Complete AV block develops primarily during the acute inﬂammatory phase as opposed to sustained VT, which frequently develops in the advanced stage of the disease (Figure 24).814
In addition to isolated cardiac sarcoidosis,812 three independent factors have been found associated with an adverse outcome and,
particularly, the risk of VAs: (i) an LVEF ,35%812; (ii) documentation of high-degree AV block815,816; and (iii) presence of RV or LV scarring at CMR (Figure 25).817–821 However, VAs and SCD may occur in patients with a mildly reduced or normal LVEF. PES,822–825 PET-CT,826
and LGE-CMR help stratify the risk of VAs in such patients.827 In a series of 120 patients with biopsy-proven extracardiac sarcoidosis and preserved LV/RV systolic function, VT inducibility at PES was low (6%) but associated with the composite endpoint of VAs and
SCD, which occurred in 3 patients, all with abnormal PET or CMR
(P = 0.009).825 In a cohort of 66 asymptomatic patients with biopsyproven extracardiac sarcoidosis and abnormal PET-CT or CMR, 8
(11%) were inducible at PES and 6 of 8 had VA or died during followup, compared to 1 of 68 non-inducible patients (P , 0.0001). Of note, inducible patients had a lower LVEF at PES, which further deteriorated at 2-year follow-up.823
The beneﬁt of ICDs, both for primary and secondary prevention, has been reported.828–832 Data support the use of ICDs for primary prevention of SCD in patients with LVEF ≤35%.812,830 In addition,
whatever the LVEF, ICD should also be considered in patients with anindication for permanent cardiacpacingor the presence of signiﬁcant scaratCMR.833,834Indeed,asshownintworecent meta-analyses,821,832
the occurrence of VA is higher in patients with complete AV block (OR
= 2.19; P , 0.01), and the presence of scar at CMR is associated with a higher risk of the composite endpoint of ventricular arrhythmic events and mortality (OR= 10.74; P , 0.00001). A widely accepted deﬁnition of signiﬁcant LGE is not available. LGE in ≥9/29 segments (17 LV and 12
RV segments) and LGE affecting ≥22% of the LV mass have been associated with arrhythmic endpoints.820,827,835
Corticosteroid therapy is a mainstay of cardiac sarcoidosis treatment, but the effect of this treatment on the occurrence of
VAs has only been ascertained from observational studies.836–838
Obviously, based upon pathophysiology of the disease, inﬂammation plays a role in the development of ventricular scar in patients with cardiac sarcoidosis. However, so far there is no evidence that
VAs are directly triggered by active inﬂammation itself. Indeed, a scar-related intramural or epicardial substrate (with a predilection in peri-valvular regions) explains most VTs in patients with cardiac sarcoidosis.839 The VT substrate was more likely located in segments with scar transmurality at CMR and a lower degree of inﬂammation on PET-scan.840 Catheter ablation may help to prevent VT,839,841,842 in particular if AAD treatment fails,837 but
VT recurrences are still frequent,752,839 in particular if catheter ablation is performed during active inﬂammation, with AADs continued in many patients.839,843
In patients with haemodynamically well-tolerated
SMVT occurring in the chronic phase of myocarditis, preserved LV function and a limited scar amenable to ablation, catheter ablation may be considered as an alternative to ICD therapy,
after discussion with the patient and provided that established endpoints have been reached.c
IIb
C
© ESC 2022
AAD, anti-arrhythmic drug; ICD, implantable cardioverter deﬁbrillator; LV, left ventricular; SCD, sudden cardiac death; SMVT, sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cVT non-inducibility and elimination of electrograms consistent with conduction delay.
Recommendation Table 35 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention,
and treatment of ventricular arrhythmias in cardiac sarcoidosis
Recommendations
Classa
Levelb
Risk stratiﬁcation and primary prevention of SCD
ICD implantation is recommended in patients with cardiac sarcoidosis who have a LVEF
≤35%.812,828–830,832
I
B
In patients with cardiac sarcoidosis who have an indication for permanent cardiac pacing related to high-degree AV block, ICD implantation should be considered, regardless of LVEF.816
IIa
C
In patients with cardiac sarcoidosis who have a LVEF .35% but signiﬁcant LGE at CMR
after resolution of acute inﬂammation,
ICD implantation should be considered.817–819,821,833,834
IIa
B
In patients with cardiac sarcoidosis who have a
LVEF 35–50% and minor LGE at CMR, after resolution of acute inﬂammation, PES for risk stratiﬁcation should be considered.
IIa
C
In patients with cardiac sarcoidosis, LVEF 35–50%
and inducible SMVT at PES, ICD implantation should be considered.823–825
IIa
C
Continued
ESC Guidelines
4067


<!-- PAGE 72 -->

### Page 72

7.1.4.3. Chagas’ cardiomyopathy
Chagas’ disease, a myocardial disease caused by the parasite
Trypanosoma cruzi, is the most common cause of non-ischaemic cardiomyopathy in Latin America. After the incubation period, the vast majority of infected persons have minor or no symptoms, and very few (,1%) develop acute myocarditis.845 However, people are infected for life, and years to decades after the initial infection 20–
30% of them will develop cardiomyopathy,846 which can lead to heart failure, heart block and atrial and ventricular arrhythmias.
SCD, particularly due to VF, is the most common cause of death in patients with Chagas’ cardiomyopathy.847,848 A risk score developed by Rassi et al.849 as well as the presence of myocardial ﬁbrosis at LGE-CMR850 are useful in assessing the risk of death in Chagas’ disease patients. However, whether such risk stratiﬁcation can translate into clinical beneﬁt through ICD treatment needs to be assessed in prospective trials, also considering the high annual mortality in
Chagas patients with ICDs.851
Although ICD implantation may seem reasonable for the secondary prevention of SCD in patients with Chagas’ cardiomyopathy,
there are controversial studies851–856 about the beneﬁts and risks
N
Patients with cardiac sarcoidosis
Amiodarone
(Class IIa)
Catheter ablation
(Class IIb)
Indication for permanent f
cardiac pacing
N
Significant LGEa
N
N
N
LVEF 35-50%
L
and minor LGE
PES
(Class IIa) 
ICD implantation
(Class IIa) 
Follow-up
Aborted cardiac arrest or sustainedVT or LVEF
L
≤35%
SMVT inducible
Symptomatic recurrentVA
V
Y
Y
ICD implantation
(Class I)
Y
Y
Y
Figure 24 Algorithm for sudden cardiac death prevention and treatment of ventricular arrhythmia in patients with cardiac sarcoidosis. ICD, implantable cardioverter deﬁbrillator; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; N, No; PES, programmed electrical stimulation;
SMVT, sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmia; VT, ventricular tachycardia; Y, Yes. aLGE affecting ≥9/22 segments or ≥22% of the LV mass has been associated with arrhythmic endpoints.
Secondary prevention of SCD and treatment of VAs
ICD implantation is recommended in patients with cardiac sarcoidosis who (1) have documented sustained VT, or (2) aborted
CA.812,828–830,832
I
B
In patients with cardiac sarcoidosis and recurrent,
symptomatic VA, AAD treatment should be considered.
IIa
C
Catheter ablation, in specialized centres, may be considered in cardiac sarcoidosis ICD-recipients with recurrent, symptomatic SMVT or ICD
shocks for SMVT, in whom AADs are ineffective,
contraindicated, or not tolerated.839,841,842
IIb
C
© ESC 2022
AAD, anti-arrhythmic drug; AV, atrio-ventricular; CA, cardiac arrest; CMR, cardiac magnetic resonance; ICD, implantable cardioverter deﬁbrillator; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; PES, programmed electrical stimulation; SCD, sudden cardiac death; SMVT, sustained monomorphic VT; AV,
ventricular arrhythmia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 73 -->

### Page 73

of ICD implantation in these patients. Indeed, a meta-analysis of observational studies found no beneﬁt of ICD (n = 483) vs. amiodarone
(n = 115) for the secondary prevention of SCD in patients with
Chagas’ disease as all-cause annual mortality rates were comparable in both groups
(9.7%
and
9.6%,
respectively).856
Another meta-analysis found a 4.7% annual incidence of inappropriate shocks and a high 9.0% annual mortality rate in 1041 ICD patients with
Chagas’ disease.851
Amiodarone857 and catheter ablation858–860 have been successfully used to control recurrent VAs in some patients. As with various forms of myocarditis, the arrhythmogenic substrate is often found at the epicardium in Chagas’ cardiomyopathy.
ECG sinus rhythm – Prominent R’wave inV1-V3a
ECG VT – LBBB-like, inferior axis (RVOT origin)
CMR
Basal LV and RV free wall LGE
PET-CT
Lateral and basal-septal LV increased 18FDG uptake
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
Figure 25 Typical features of cardiac sarcoidosis associated with sustained monomorphic ventricular tachycardia. CMR, cardiac magnetic resonance;
ECG, electrocardiogram; LBBB, left bundle branch block; LGE, late gadolinium enhancement; LV, left ventricle; PET-CT, positron emission tomography
CT; RV, right ventricle; RVOT, right ventricular outﬂow tract; VT, ventricular tachycardia. aNote the prominent R′ in V1 to V3, a pattern frequently found in cardiac sarcoidosis with RV involvement.844
ESC Guidelines
4069


<!-- PAGE 74 -->

### Page 74

7.1.5. Valvular heart disease
Valvular heart diseases predispose to SCD both in the preoperative period and after valvular surgery. In old cohorts of symptomatic, non-operated patients with severe aortic stenosis or severe mitral regurgitation, the incidence of SCD was 50–60%. In these studies, the rate of SCD secondary to VA was not speciﬁed.861,862
Rates of SCD in patients with prosthetic valves range from 15%
to 30%, with an estimated annual risk of 0.2–0.9%.863 In a large series of 1533 patients who underwent aortic or mitral valve replacement, 6% of deaths were caused by arrhythmias.864 A recent report of 3726 patients undergoing transcatheter aortic valve implantation (TAVI) showed 5.6% SCD during 22 months of followup,
emphasizing the remaining
SCD
risk also after valve replacement.865
Small observational studies have shown that patients with residual
LV dysfunction after valvular surgery who undergo ICD implantation have appropriate therapy and mortality rates similar to patients with ischaemic or dilated cardiomyopathy.866–868 ICD implantation in these patients should therefore follow
DCM/HNDCM
recommendations.
In patients after TAVI, SCD has been associated with the presence of new-onset conduction disturbances (LBBB, QRS .
160 ms) and reduced LVEF ≤40%.865 SCD in these patients may be the consequence of advanced AV block, and permanent pacing indication should follow the 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.2 The role of ICD implantation for prevention of SCD after TAVI is less clear. Two recent retrospective analyses including a total of 203 patients in whom the LVEF remained ≤35% did not show survival beneﬁt from
ICD implantation, probably related to the high competing risk of death from heart failure and relevant comorbidities in this population.869,870
In patients presenting with SMVT after aortic valve replacement,
PES is indicated because of the high probability of BBR-VT as the underlying mechanism—an arrhythmia that is potentially curable with catheter ablation.871,872
SCD has been reported to occur in 0.2–0.4% of patients with MVP
per year.873,874 However, the total number of patients dying suddenly with this condition is most likely underestimated, considering that it is a common valve variant with an estimated prevalence of 2–3% in the general population.875
Using rigorous criteria for morphologic diagnosis (i.e. myxomatous mitral valve) at post-mortem, MVP has been associated with
7% of all cases of juvenile SCD in the Registry of the Veneto region of Italy.228 Recent pathological and clinical studies on SCD victims with MVP or patients with MVP and major VAs have provided insights into the potential VA substrate.130,228,876–880 In particular,
myocardial ﬁbrosis affecting both the infero-basal LV free wall and the papillary muscles has been recognized in pathological and
LGE-CMR studies.228 The scarring process has been related to mechanical stretch secondary to the excessive mobility of the mitral valve apparatus due to mitral valvular disjunction and posterior systolic curling.876 This indicates a promising role of CMR for arrhythmic risk stratiﬁcation beyond traditional electrophysiological markers.
Proposed criteria for an ‘arrhythmic MVP syndrome’ that have been associated with an increased risk for SCD include: young adults (most often women), QTc prolongation and/or negative
T-wave in inferior ECG leads, mitral annular disjunction, bi-leaﬂet involvement on echocardiography, frequent PVCs, or nonsustained PVT on Holter monitoring and/or exercise testing.130,228,876–880 Reduced LVEF and/or myocardial ﬁbrosis on
CMR may add to the risk proﬁle. These data are mainly derived from small retrospective series of SCD survivors and post-mortem studies. Therefore, identiﬁcation of the small subgroup of patients at risk of SCD remains challenging.228,874 Robust data to support recommendations for risk stratiﬁcation of SCD in patients with
MVP are not available.
Recommendation Table 36 — Recommendations for the treatment of ventricular arrhythmias in
Chagas’ cardiomyopathy
Recommendations
Classa
Levelb
Amiodarone should be considered to reduce arrhythmia burden in patients with Chagas’
cardiomyopathy who present with symptomatic
PVCs or VT.857
IIa
C
In patients with Chagas’ cardiomyopathy and recurrent, symptomatic SMVT or ICD shocks for
SMVT in whom AADs are ineffective,
contraindicated, or not tolerated, catheter ablation in specialized centres should be considered.859,860
IIa
C
In patients with Chagas’ cardiomyopathy and symptomatic VT in whom AADs (amiodarone and beta-blockers) are ineffective or not tolerated, ICD implantation may be considered.851,854–856
IIb
C
© ESC 2022
AAD, anti-arrhythmic drug; ICD, implantable cardioverter deﬁbrillator; PVCs,
premature ventricular complexes;
SMVT,
sustained monomorphic ventricular tachycardia; VT, ventricular tachycardia.
Recommendation Table 37 — Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in valvular heart disease
Recommendations
Classa
Levelb
PES with standby catheter ablation is recommended in patients with aortic valve disease and SMVT to identify and ablate BBR-VT,
especially if it occurs following a valve intervention.871,872,881
I
C
Continued


<!-- PAGE 75 -->

### Page 75

7.1.6. Congenital heart disease
Advances in surgical repair and medical treatment have improved the long-term prognosis of children born with congenital heart disease
(CHD). More than 90% now survive to adulthood,882 and consequently the prevalence of adult CHD has steadily increased.883 With fewer patients dying from peri-operative events and early heart failure, SCD has become a leading cause of death in adults with repaired CHD.884 The combination of surgical incisions, myocardial scar and residual or new anatomical abnormalities form the substrate for VAs (Figure 26).
Risk stratiﬁcation for SCD in CHD patients and no documented sustained VA remains difﬁcult due to a mixed patient population,
the absence of RCTs, and relatively small observational studies. In patients with biventricular physiology and a systemic LV, the standard criterion of an LVEF ≤35% is used for patient selection for primary prevention ICD implantation.885,886 For patients with unexplained syncope, severe arrhythmia symptoms such as palpitations or presyncope and NSVT, PES should be considered.887 In asymptomatic patients with tetralogy of Fallot (TOF) but other indicators for a
VA substrate, electrophysiological evaluation may reﬁne risk stratiﬁcation.888 The surgical era and the techniques used affect the VA substrate and occurrence of VAs and should be considered. The use of a transannular patch repair in TOF patients, for example, was found to be associated with a lower risk for VA.889 The beneﬁt of primary prevention ICD therapy in patients with single or systemic RVs is less well established and requires consideration of disease- and patientspeciﬁc factors.890,891
Sustained VA in a patient with CHD
Simple or moderate CHD and preserved biventricular function and haemodynamically tolerated VT
Catheter or surgical intervention for correctable lesions ± ICD
Pre-operative catheter mapping and ablation before or during the interventiona
(Class IIa)
N
N
Residual or new abnormalities requiring intervention
Evaluation of residual or new anatomical abnormalities
(Class I)
N
Successful ablation
Withhold of ICD
implantationa
(Class IIb)
Recurrent symptomatic
SMVT/ICD therapy despite medical treatmentb
Catheter ablation
ICD implantation
(Class I)
Catheter ablationa
(Class I)
TOF
(Class I)
Others
(Class IIa)
Y
Y
Y
Figure 26 Algorithm for the management of sustained ventricular arrhythmia in patients with congenital heart disease. CHD, congenital heart disease;
ICD, implantable cardioverter deﬁbrillator; N, No; TOF, tetralogy of Fallot; VA, ventricular arrhythmia; VT, ventricular tachycardia; Y, Yes. aData derived from patients with TOF and related lesions. bIn TOF, anti-arrhythmic drug failure is not required.
In patients with valvular heart disease and persistent LV dysfunction after surgical correction, (if possible) it is recommended that
ICD implantation for primary prevention follows
DCM/HNDCM recommendations.868
I
C
© ESC 2022
BBR-VT,
bundle branch re-entrant ventricular tachycardia;
DCM,
dilated cardiomyopathy;
HNDCM,
hypokinetic non-dilated cardiomyopathy;
ICD,
implantable cardioverter deﬁbrillator; LV, left ventricular; PES, programmed electrical stimulation; SMVT, sustained monomorphic ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4071


<!-- PAGE 76 -->

### Page 76

In CHD patients with sustained VA or CA survivors, a comprehensive evaluation of inciting factors, including cardiac imaging (particularly CMR) and haemodynamic assessment, is important
(Figure 26).892 If pre-existing or new anatomical abnormalities requiring intervention are detected, the treatment plan should consider pre- or intra-operative mapping and transection of the VT substrate,
because accessibility might be impaired post-operatively.888,893,894
Pre-operative evaluation and intervention are especially important in TOF patients undergoing surgical pulmonary re-valving. In selected patients with CHD (including those with atrial bafﬂe repair for transposition of the great arteries, Fontan operation and Ebstein anomaly), evaluation and treatment of SVT (such as intra-atrial re-entrant tachycardias or AV re-entrant tachycardias) with rapid ventricular conduction should also be considered.890,895,896
In the absence of identiﬁable reversible factors, ICD implantation for secondary prevention of SCD is recommended.349,350 While transvenous ICD systems have been most frequently used and have the advantage of anti-tachycardia and anti-bradycardia pacing,
subcutaneous ICDs may be an alternative in selected patients with limited venous access to the ventricle or with intracardiac shunts.
In CHD patients, MVT most often arises from re-entrant tachycardias using anatomical isthmuses bounded by valves, patch material, and surgical incisions. Early mapping and ablation studies,
particularly in TOF patients, identiﬁed critical anatomical isthmuses of reproducible anatomical location.897,898 Following this concept,
those anatomical isthmuses can be reconstructed and transected in sinus rhythm during catheter ablation procedures using electroanatomical mapping systems, achieving acute success rates of
80%.888,899–901 The use of conduction block across anatomical isthmuses as a procedural endpoint, in addition to non-inducibility of VT,
has further improved long-term ablation outcomes.888,899
Accordingly, catheter ablation is recommended in particular in
TOF patients with recurrent SMVT. Due to the complexity of
CHD patients as well as the VT substrate, those procedures should be performed in centres with expertise in catheter ablation of CHD
patients. Catheter ablation may be considered in lieu of ICD implantation in selected TOF patients with SMVT and preserved biventricular function, provided the combined procedural endpoint of non-inducibility and conduction block across the anatomical isthmus can be reached.888,899
Recommendation Table 38 — Recommendations for risk stratiﬁcation and primary prevention of sudden cardiac death in congenital heart disease
Recommendations
Classa
Levelb
Risk stratiﬁcation and primary prevention of SCD
All CHD patients
In adults with CHD with biventricular physiology and a left systemic ventricle presenting with symptomatic heart failure (NYHA II/III) and EF
≤35% despite ≥3 months of OMT, ICD
implantation is indicated.885,886
I
C
Continued
In patients with CHD with presumed arrhythmic syncope and with either at least moderate ventricular dysfunction or inducible SMVT on PES,
ICD implantation should be considered.887,889,902
IIa
C
In patients with advanced single ventricle or systemic RV dysfunction with additional risk factors,c ICD implantation may be considered.890,891
IIb
C
Tetralogy of Fallot
In patients after repair of TOF with arrhythmia symptoms and NSVT, electrophysiologic evaluation including PES should be considered.889,903–905
IIa
C
In patients after repair of TOF with arrhythmia symptoms and a positive PES, or a combination of other risk factorsd and a positive PES, ICD
implantation should be considered.
IIa
C
In patients after repair of TOF without arrhythmia symptoms, but with a combination of other risk factors,d electrophysiologic evaluation, including
PES, may be considered.
IIb
C
In patients with repaired TOF undergoing surgical or transcutaneous pulmonary valve replacement,
pre-operative catheter mapping and transection of VT-related anatomical isthmuses before or during the intervention may be considered.894
IIb
C
© ESC 2022
AV, atrioventricular; CHD, congenital heart disease; CMR, cardiac magnetic resonance;
EF, ejection fraction; ICD, implantable cardioverter deﬁbrillator; LV, left valve; NSVT,
non-sustained monomorphic ventricular tachycarda; NYHA, New York Heart
Association; OMT, optimal medical treatment; PES, programmed electrical stimulation;
RV, right ventricular; SCD, sudden cardiac death; SMVT, sustained monomorphic ventricular tachycarda; TOF, tetralogy of Fallot; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cData are sparse and risk factors may be lesion-speciﬁc, including non-sustained VT,
NYHA II/III, severe AV valve regurgitation, and wide QRS ≥140 ms (transposition of the great arteries).
dOther risk factors include moderate RV or LV dysfunction, extensive RV scarring on
CMR,906,907 QRS duration ≥180 ms886,908 and severe QRS fragmentation.909,910
Recommendation Table 39 — Recommendations for secondary prevention of sudden cardiac death and treatment of ventricular arrhythmia in congenital heart disease
Recommendations
Classa
Levelb
Secondary prevention of SCD and treatment of VA
All CHD patients
In patients with CHD presenting with sustained
VAs, evaluation for residual lesions or new structural abnormalities is recommended.892,893
I
B
In patients with CHD with not tolerated VT/
aborted CA due to VF, ICD implantation is indicated after exclusion of reversible causes.349,350
I
C
Continued


<!-- PAGE 77 -->

### Page 77

7.2. Primary electrical disease
7.2.1. Idiopathic ventricular ﬁbrillation
The diagnosis of idiopathic ventricular ﬁbrillation (IVF) is made in
SCA survivors, preferably with documented VF, after exclusion of structural, channelopathic, metabolic, or toxicological aetiologies.135,222,911–913 Diagnostic tests include blood chemistry, ECG (including high lead), cardiac CT/coronary angiography, telemetry/
Holter, exercise stress test, echocardiogram, sodium-channel blocker testing and CMR (see Section 5.2.3, scenario 3).135,222,911 Genetic testing for channelopathy and cardiomyopathy genes may be considered with a mutation yield of 3–17%.249,914,915 Clinical evaluation of
ﬁrst-degree family members may be considered, but the diagnostic yield is low. In particular the signiﬁcance of detected early repolarization pattern (ERP) in asymptomatic relatives is uncertain.182,916
In IVF patients, ICD implantation reduces the risk of arrhythmic death by up to
68%
compared to amiodarone352,917–921
(Figure 27). In observational studies with a mean follow-up of 5–6
years, 21.0–29.6% of IVF patients experienced an arrhythmic recurrence, corresponding to an annual ICD shock rate of 3.6–5.7%,
whereas
4.5–17.5%
experienced inappropriate shocks.919–921
Isoproterenol, verapamil, or quinidine have been employed for acute treatment of recurrent
ICD
discharges or electrical storm.912,913,918,922–926 In several small studies, quinidine was highly effective in reducing or even preventing arrhythmia inducibility during programmed stimulation.923,924,926 Moreover, a retrospective study in 46 patients showed a reduction of mean ICD shocks from
7.5 per patient over 2.9 years to 0.9 shocks per patient over 3.7
years, with a decrease in ventricular storms from 36 to 3 after quinidine initiation.922 In patients with recurrent episodes of VF triggered by a similar PVC unresponsive to medical treatment, catheter ablation has shown success (Figure 28).186,221,333,493,927–930 PVCs most commonly originate from the Purkinje system and can be eliminated with a high acute success rate of 87–100%.186,221,333,493,927–930
Detailed electroanatomic mapping may also reveal localized structural alterations (62.5% in one study).248
In patients with CHD and recurrent, symptomatic
SMVT or ICD shocks for SMVT not manageable by medical therapy or ICD reprogramming,
catheter ablation performed in specialized centres should be considered.c 899–901
IIa
C
In selected patients with CHD (including atrial bafﬂe repair for transposition of the great arteries,
Fontan operation and Ebstein anomaly)
presenting with CA, evaluation and treatment of
SVT with rapid ventricular conduction should be considered.890,895
IIa
C
Tetralogy of Fallot
In patients with repaired TOF who present with
SMVT or recurrent, symptomatic appropriate
ICD therapy for SMVT, catheter ablation performed in specialized centres is recommended.899–901
I
C
In patients with repaired TOF with SMVT who are undergoing surgical or transcutaneous pulmonary valve replacement, pre-operative catheter mapping and transection of VT-related anatomical isthmuses before or during the intervention should be considered.888,893,894
IIa
C
In patients with repaired TOF with a preserved biventricular function and symptomatic SMVT,
catheter ablation or concomitant surgical ablation performed in specialized centres may be considered as an alternative to ICD therapy.899,901
IIb
C
© ESC 2022
CA, cardiac arrest; CHD, congenital heart disease; ICD, implantable cardioverter deﬁbrillator; SCD, sudden cardiac death; SMVT, sustained monomorphic ventricular tachycardia;
SVT,
supraventricular tachycardia; TOF,
tetralogy of
Fallot;
VA,
ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cSpeciﬁc recommendations for TOF (Class I-B).
Recommendation Table 40 — Recommendations for the management of patients with idiopathic ventricular ﬁbrillation
Recommendations
Classa
Levelb
Diagnostic evaluation
It is recommended that idiopathic VF is diagnosed in a SCA survivor, preferably with documentation of VF, after exclusion of an underlying structural,
channelopathic, metabolic, or toxicological aetiology.222,911
I
B
Clinical testing (history, ECG and high precordial lead ECG, exercise test, echocardiogram) of
ﬁrst-degree family members of idiopathic VF
patients may be considered.222,278,916
IIb
B
In idiopathic VF patients, genetic testing of genes related to channelopathy and cardiomyopathy may be considered.249,278,914,915
IIb
B
Secondary prevention of SCD and treatment of VA
ICD implantation is recommended in idiopathic
VF.352,917–919
I
B
Isoproterenol infusion, verapamil, or quinidine for acute treatment of an electrical storm or recurrent ICD discharges should be considered in idiopathic VF.912,913,918,922–924,926
IIa
C
Quinidine should be considered for chronic therapy to suppress an electrical storm or recurrent ICD discharges in idiopathic VF.923,924
IIa
B
Catheter ablation by experienced electrophysiologists should be considered in idiopathic VF patients with recurrent episodes of
VF triggered by a similar PVC non-responsive to medical treatment.927–930
IIa
C
© ESC 2022
ECG, electrocardiogram; ICD, implantable cardioverter deﬁbrillator; PVC, premature ventricular complex; SCA, sudden cardiac arrest; SCD, sudden cardiac death; VA,
ventricular arrhythmia; VF, ventricular ﬁbrillation.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4073


<!-- PAGE 78 -->

### Page 78

7.2.2. Long QT syndrome (including acquired long
QT syndrome)
LQTS is characterized by a prolonged QT interval and VAs mainly triggered by adrenergic activation. The mean age at presentation is
14 years. The annual rate of SCD in asymptomatic patients with untreated LQTS has been estimated to be less than 0.5%,82 while it increases to around 5% in those with history of syncope.931
Rare variants in 17 genes932 have been associated with LQTS.
However, the causality for several of the identiﬁed genes has been questioned.166 The undisputed genes are those causing LQT1, LQT2
and LQTS3: KCNQ1, KCNH2 and SCN5A, respectively, with genespeciﬁc triggers being exercise (LQTS1), emotional stress (LQTS2)
and sleep (LQTS3). Genetic screening identiﬁes a mutation in 75% of
LQTS cases and three main genes account for 90% of positively genotyped cases.178 The subtypes of LQTS may be grouped as follows:
(1) Autosomal-dominant LQTS (prevalence: 1 in 2500) without extra-cardiac manifestation.
(2) Autosomal-dominant LQTS with extra-cardiac manifestation,
comprising:
(a) Andersen–Tawil Syndrome (LQT7), increasingly considered its own entity.933,934
(b) Timothy Syndrome (LQT8), characterized by prolonged
QT, syndactyly, cardiac malformations, autism spectrum disorder and dysmorphism.935
(3) Autosomal-recessive
LQTS
(Jervell and
Lange–Nielsen
Syndrome), combining extreme QT prolongation with congenital deafness.936
This panel of experts has conﬁrmed the diagnostic criteria proposed in the previous version of the guidelines: a QTc ≥480 ms or a LQTS risk score .3937 (Table 10) for clinical diagnosis (Figures
29 and 30). In the presence of arrhythmic syncope or CA, a QTc
≥460 ms is sufﬁcient to consider a diagnosis of LQTS. A challenge for the clinician is establishing the duration of the QT interval in patients with broad QRS complexes (e.g. in the presence of ventricular pacing or ventricular conduction defects). In this setting, a formula has been proposed that adjusts QT by QRS duration.938 While measuring the QT, the patient moving briskly from recumbent to
Patient with idiopathic ventricular fibrillation
Catheter ablation of PVC triggers
(Class IIa)
Recurrent ICD shocks
Recurrent ICD shocks
Acute treatment:
Isoproterenol
Ver
V apamil
Quinidine
(Class IIa)
Chronic treatment:
Quinidine
(Class IIa)
Genetic counselling and testing
(Class IIb)
ICD implantation
(Class I)
Figure 27 Algorithm for the management of patients with idiopathic ventricular ﬁbrillation. ICD, implantable cardioverter deﬁbrillator; PVC, premature ventricular complex.


<!-- PAGE 79 -->

### Page 79

orthostatic position may be helpful for the diagnosis of LQTS.232,939
Epinephrine challenge is not recommended as a routine diagnostic tool, as reproducibility is modest.137 Patients with a clinical diagnosis of LQTS are recommended to undergo genetic counselling and testing in specialized centres to receive genotype-speciﬁc management and permit identiﬁcation of relatives at risk. Relatives with a mutation but without QT prolongation still receive a diagnosis of LQTS, as they are at risk of experiencing VA, although less frequently than phenotype-positive patients.940
All LQTS patients receive advice on avoidance of hypokalaemia, QT-prolonging medications and genotype-speciﬁc triggers.941–943 Beta-blockers are also recommended in all LQTS
patients. Non-selective beta-blockers nadolol and propranolol have greater efﬁcacy in reducing arrhythmic risk.940,944–946
Clinical, electrocardiographic and genetic parameters should be considered for the individual risk estimation.82 Recently, risk stratiﬁcation based on QT interval duration and genotype has been integrated in a LQTS calculator (the 1-2-3 LQTS Risk calculator).947
The utility of genetic testing is exempliﬁed by the need to avoid genotype-speciﬁc risks and by the use of mexiletine as a genotypespeciﬁc treatment for LQT3, which reduces the length of QT interval and the number of arrhythmic events.948 It should be noted that different mutations in SCN5A show different responses to mexiletine.
For example, selected mutations identiﬁed in patients not responding to mexiletine showed a distinctive electrophysiological proﬁle
Telemetry tracings – short-coupled PVC inducing VF
ECG sinus rhythm – short-coupled PVCs
Figure 28 Idiopathic ventricular ﬁbrillation triggered by short-coupled premature ventricular complexes. ECG, electrocardiogram; PVC, premature ventricular complex; VF, ventricular ﬁbrillation.
ESC Guidelines
4075


<!-- PAGE 80 -->

### Page 80

when studied in vitro.949,950 Additionally, in the case of mutations that cause overlapping syndromes, mexiletine does not induce ST segment elevation, while ﬂecainide has been reported to do so.951
Given the uncertain role of beta-blockers in LQT3, there are no indications on whether mexiletine should be administered as a stand-alone therapy or in combination with beta-blockers.
Considering that some mutations may not respond to mexiletine,
it is advisable to perform oral testing to verify that the QTc shortens
40 ms before prescribing chronic treatment.948
Survivors of a CA have a high risk of recurrences, even on betablockers (14% within 5 years on therapy), supporting the use of
ICD in CA survivors.952 Moreover, ICD implantation is indicated when a patient experiences syncope and/or VA despite optimal pharmacological therapy, as syncopal events are associated with increased risk of CA.953,954 Women with LQTS, particularly
LQT2, have an increased risk of arrhythmia both during pregnancy and especially ﬁrst year post-partum.955 Silent carriers of mutations present a low, but not negligible, risk of cardiac events, and the use of beta-blockers should be considered in this group of patients.956
Left cardiac sympathetic denervation (LCSD) is recommended for symptomatic patients despite beta-blockers when ICD is contraindicated or declined, or for an ICD carrier who experiences multiple shocks while on beta-blockers. This is supported by the evidence that LCSD, especially when performed with a video-assisted technique, is safe and effective,957 well-tolerated by patients958 and does not have a negative impact on cardiovascular performance.959
However, because complications do occur and half of the patients experience breakthrough events after the procedure, LCSD is not an alternative to ICD for high-risk patients.960 Prophylactic ICD
Table 10
Modiﬁed long QT syndrome diagnostic score243
Findings
Points
ECG
QTc
≥480 ms
3.5
=460–479 ms
2
=450–459 ms (in males)
1
≥480 ms during 4th minute of recovery from exercise stress test
1
Torsade de pointes
2
T wave alternans
1
Notched T wave in 3 leads
1
Low heart rate for age
0.5
Clinical history
Syncope
With stress
2
Without stress
1
Family history
Family member(s) with deﬁnite LQTS
1
Unexplained SCD at age ,30 years in
ﬁrst-degree family
0.5
Genetic ﬁnding
Pathogenic mutation
3.5
© ESC 2022
ECG, electrocardiogram; LQTS, long QT syndrome; SCD, sudden cardiac death.
Diagnosis of LQTS with a score .3.
LQT1
LQT2
LQT3
A
B
I
II
III
aVR
aVL
aVF
V1
V4
V5
V6
V2
V3
Figure 29 Long QT syndrome electrocardiograms and torsade-de-pointes ventricular tachycardia. (A) ECG characteristics in the three major LQTS
phenotypes. (B) Example of Torsade-de-pointes in a male patient with a SCN5A (c.1238C.A, p.A413E) mutation. LQT, Long QT.


<!-- PAGE 81 -->

### Page 81

therapy in addition to OMT may be considered in asymptomatic
LQTS patients identiﬁed with high-risk according to the 1-2-3
LQTS Risk calculator.947 PES is not useful for risk stratiﬁcation in
LQTS.961
Figure 31 illustrates the algorithm for the management of patients with long QT syndrome.
Recommendation Table 41 — Recommendations for the management of patients with long QT syndrome
Recommendations
Classa
Levelb
Diagnosis
It is recommended that LQTS is diagnosed with either QTc ≥480 ms in repeated 12-lead ECGs with or without symptoms or LQTS diagnostic score .3.
I
C
In patients with clinically diagnosed LQTS, genetic testing and genetic counselling are recommended.
I
C
It is recommended that LQTS is diagnosed in the presence of a pathogenic mutation, irrespective of the QT duration.
I
C
The LQTS diagnosis should be considered in the presence of a QTc ≥460 ms and ,480 ms in repeated 12-lead ECGs in patients with an arrhythmic syncope in the absence of secondary causes for QT prolongation.952,962,963
IIa
C
Continued
Routine diagnostic testing with epinephrine challenge is not recommended in LQTS.137
III
C
General recommendations to prevent SCD
The following is recommended in LQTS:
• Avoid QT-prolonging drugs.c
• Avoid and correct electrolyte abnormalities.
• Avoid genotype-speciﬁc triggers for arrhythmias.943
I
C
Beta-blockers, ideally non-selective beta-blockers
(nadolol or propranolol), are recommended in
LQTS patients with documented QT interval prolongation, to reduce risk of arrhythmic events.940,945,946
I
B
Mexiletine is indicated in LQT3 patients with a prolonged QT interval.948
I
C
Beta-blockers should be considered in patients with a pathogenic mutation and a normal QTc interval.82
IIa
B
Risk stratiﬁcation, prevention of SCD and treatment of VA
ICD implantation in addition to beta-blockers is recommended in LQTS patients with
CA.952,953,962,963
I
B
ICD implantation is recommended in patients with LQTS who are symptomaticd while receiving beta-blockers and genotype-speciﬁc therapies.
I
C
Continued
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
T wave alternans
Brisk Standing Test
Recumbent
Standing
A
B
Figure 30 Brisk standing electrocardiogram changes and T wave alternans in Long QT syndrome patients. (A) ECG changes during brisk standing test in a male LQTS patient with KCNH2 (p.S818L) mutation, increased heart rate is associated with less adaptation of QT interval. (B) T wave alternans in a male patient with CACNA1C (p.G406R) mutation.
ESC Guidelines
4077


<!-- PAGE 82 -->

### Page 82

LCSD is indicated in patients with symptomaticd
LQTS when: (a) ICD therapy is contraindicated or declined; (b) patient is on beta-blockers and genotype-speciﬁc drugs with an ICD and experiences multiple shocks or syncope due to VA.541,957–959
I
C
Either ICD implantation or LCSD should be considered in patients with symptomaticd LQTS,
when beta-blockers and genotype-speciﬁc therapies are not tolerated or contraindicated at the therapeutic dose.
IIa
C
In LQTS, it should be considered to calculate the arrhythmic risk before initiation of therapy based on the genotype and the duration of QTc interval.940
IIa
C
Continued
ICD implantation may be considered in asymptomatic LQTS patients with high-risk proﬁle (according to the 1-2-3 LQTS Risk calculator) in addition to genotype-speciﬁc medical therapies (mexiletine in LQT3
patients).82,940,947,948
IIb
B
Invasive electrophysiologic study is not recommended in LQTS.961
III
C
© ESC 2022
CA, cardiac arrest; ECG, electrocardiogram; ICD, implantable cardioverter deﬁbrillator;
LCSD, left cardiac sympathetic denervation; LQTS, long QT syndrome; SCD, sudden cardiac death; VA, ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
chttp://www.crediblemeds.org dArrhythmic syncope or haemodynamically non-tolerated VA.
N
N
N
Y
Y
Y
Patient with long QT syndrome
General recommendationsa (Class I)
Beta-blockers k
b (Class I)
SCN5A mutation (LQT3): Mexiletine  (Class I)
:
Beta-blockers k
b (Class IIa)
Follow-up
Follow-up
Arrhythmic syncope or non-toleratedVA
V
under medical therapy p
ICD implantation
(Class IIb)
ICD implantation
(Class I)
LCSD
(Class I)
High risk featu f
res,
based on genotype and QTc
ICD contraindicated,
declined or recurrent ICD shocks
Medical therapy p
contraindicated,
or not tolerated
If LQT1, LQT2 or LQT3,
,
assess arrhythmic risk with genotype and QTc 
(1-2-3-LQTS-Risk riskcalculator)
(Class IIb)
Aborted cardiac arrest
Syncope prior to medical treatment
Asymptomatic patient with or without pathogenic mutation and
QT prolongation
Asymptomatic patient with pathogenic mutation without QT prolongation
LCSD
(Class IIa)
ICD implantation
(Class IIa)
Figure 31 Algorithm for the management of patients with long QT syndrome. ICD, implantable cardioverter deﬁbrillator; LCSD, left cardiac sympathetic denervation; LQT, long QT; N, No; VA, ventricular arrhythmia; Y, Yes. aGeneral recommendations: avoidance of QT-prolonging drugs (http://www.
crediblemeds.org), correction of electrolyte abnormalities (hypokalaemia, hypomagnesaemia, and hypocalcaemia), avoidance of genotype-speciﬁc triggers for arrhythmias (strenuous swimming in LQT1, exposure to loud noises in LQT2). bPreferred beta-blockers: nadolol and propranolol.


<!-- PAGE 83 -->

### Page 83

7.2.3. Andersen–Tawil syndrome Type 1
Andersen–Tawil syndrome Type 1, also classiﬁed as LQT7, is a rare disease (1:1 000000) characterized by three main symptoms: frequent VA
(e.g. bidirectional VT), dysmorphologies and periodic paralysis.964–967
The inward rectiﬁer current (IK1) decreased by KCNJ2 loss of function mutation968 causes an increase in U wave amplitude rather than QT
prolongation.964,967–970 Syncope or documented VT is associated with life-threatening VA, and a study found a 5-year probability of 7.9%
of life-threatening VA.967 In patients with sustained haemodynamically not-tolerated VT or CA, an ICD is recommended.964,967
Flecainide and/or beta-blockers seem to reduce VA,964,970,971
whereas amiodarone may be proarrhythmic and should only be used with an ICD.967 In patients with syncope despite medical therapy, an ICD or ILR should be discussed.967
7.2.4. Brugada syndrome
The type 1 Brugada ECG pattern is characterized by J point elevation of .2 mV with coved ST elevation and T wave inversion in at least one right precordial ECG lead, V1 or V2, positioned in the second,
third or fourth intercostal spaces (Figure 32). It may occur either spontaneously or be induced by exposure to sodium channelblocking drugs or fever.135,231,973–978 It is mandatory to exclude other conditions that may explain the type 1 pattern, so-called phenocopies.979
BrS is diagnosed in patients without other heart disease and a spontaneous type 1 pattern, regardless of symptoms, due to its rarity in the general population and association with risk.231,979,980 The type 1 pattern may also be induced by administration of a sodium channel-blocking drug as a diagnostic test in patients suspected to have concealed BrS but without a spontaneous type 1 ECG.135,136,231,387,973,978,981–985 However, provocation with drug or fever is less speciﬁc than previously thought,
with 2–4% prevalence in healthy subjects and higher prevalence in patients with AV nodal reentry tachycardia or an accessory pathway in one study.977,978,986 In the opinion of this panel of experts, an induced type 1 ECG pattern therefore requires other clinical features, such as documented PVT/VF, arrhythmic syncope, or relevant family history.
The yield of genetic testing in BrS patients is approximately 20%,
with the SCN5A gene the only gene with evidence of association for clinical testing purposes.164,980 Phenotype and genotype mismatch is seen in SCN5A families, which is explained by variable effects of mutation severity and a polygenic risk score derived from genome-wide association studies.170,979,987 Recent data also support a potential for prognostication.988,989
Psychotropic drugs, selected AADs, anaesthetic agents, cocaine,
excessive alcohol intake and fever are potential triggers to exacerbate the type 1 pattern and trigger VF.231,297 The risk of recurrent
VF among patients presenting with CA is 48% at 10 years. ICD implantation is therefore indicated in symptomatic BrS patients who are survivors of CA or have documented spontaneous sustained
VA (Figure 33).980,990–994 Approximately one-third of BrS patients present with syncope.995 The risk of arrhythmic events in BrS patients with unexplained syncope is 4 times higher than the risk in asymptomatic patients.155,990–992,994,996 Detailed patient history, including absence of prodrome or speciﬁc triggers, is essential for distinguishing arrhythmic from non-arrhythmic syncope. Nonetheless,
the aetiology of syncope is difﬁcult to determine in up to 30% of
BrS patients. In small studies, arrhythmia detected by ILR changed clinical management in 20–36% of the BrS patients with unexplained syncope.997–999
Asymptomatic patients represent a majority of newly diagnosed
BrS patients with an incidence of arrhythmic events of 0.5% per year.1000,1001 Their risk stratiﬁcation remains challenging. A spontaneous type 1 ECG pattern, as well as other ECG markers such as early repolarization pattern and QRS fragmentation, have been associated with higher risk.980,992,1002,1003 Some have been incorporated into risk scores, although their utility in intermediate-risk patients remains low.1004,1005 Electrophysiological studies remain controversial.
A
multicentre pooled analysis showed that
Recommendation Table 42 — Recommendations for management of patients with
Andersen–Tawil syndrome
Recommendations
Classa
Levelb
Diagnosis
Genetic testing is recommended in patients with suspected Andersen–Tawil syndrome.964,967
I
C
Andersen–Tawil syndrome should be considered in patients without SHD who present with at least two of the following:
• Prominent U waves with or without prolongation of the QT interval
• Bidirectional and/or polymorphic PVCs/VT
• Dysmorphic features
• Periodic paralysis
• KCNJ2 pathogenic loss of function mutation.964,965,967,968,972
IIa
C
Risk stratiﬁcation, prevention of SCD and treatment of VA
ICD implantation is recommended in patients with Andersen–Tawil syndrome after aborted CA
or not-tolerated sustained VT.964,967
I
C
Beta-blockers and/or ﬂecainide with or without acetazolamide should be considered in patients with Andersen–Tawil syndrome to treat
VA.964,970
IIa
C
An ILR should be considered in patients with
Andersen–Tawil syndrome and unexplained syncope.
IIa
C
ICD implantation may be considered in patients with Andersen–Tawil syndrome who have a history of unexplained syncope or suffer from tolerated sustained VT.967
IIb
C
© ESC 2022
CA, cardiac arrest; ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; PVCs, premature ventricular complexes; SCD, sudden cardiac death; SHD,
structural heart disease; VA, ventricular arrhythmia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4079


<!-- PAGE 84 -->

### Page 84

induction of sustained VA during electrophysiological studies was associated with a higher future risk of VA.155 Inducibility, however, was associated with a potentially clinically actionable result only in asymptomatic patients with a spontaneous type 1 Brugada pattern ECG.
In case of recurrent ICD shocks for VF, quinidine or catheter ablation have been successful in reducing shock frequency.922,1006,1007
Isoproterenol infusion can suppress electrical storm.1008 In several small studies, quinidine was effective in reducing or even preventing arrhythmia inducibility during programmed stimulation.922,1006,1007
However, adverse effects of quinidine can occur in up to 37% of patients, and quinidine is inaccessible in many countries. Cilostazol
(phosphodiesterase-3 inhibitor) can be an alternative to quinidine.1008 Electrophysiological mapping data linked to histopathological studies suggest that an abnormal ﬁbrotic arrhythmogenic substrate in the epicardial RVOT is responsible for the ST-segment elevation in the right precordial leads and VF occurrence in BrS patients.1009 Ablation of these abnormal areas can markedly suppress recurrent VF and normalize the ECG in .75% of patients.1009–1015
In patients with recurrent episodes of VF triggered by a similar
PVC non-responsive to medical treatment, catheter ablation may target the PVC, which most commonly originates from the RVOT
or Purkinje system.1013 However, data regarding the long-term follow-up after ablation are limited, with neither trial data nor evidence for ablation in asymptomatic patients.
Brugada type 1 pattern ECG
A
B
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
Early repolarization pattern ECG
II
III
Figure 32 Typical examples of (A) Brugada type 1 electrocardiogram, and (B) early repolarization pattern electrocardiogram. ECG, Electrocardiogram.
Recommendation Table 43 — Recommendations for management of patients with Brugada syndrome
Recommendations
Classa
Levelb
Diagnosis
It is recommended that BrS is diagnosed in patients with no other heart disease and a spontaneous type 1 Brugada ECG pattern.974–976
I
C
It is recommended that BrS is diagnosed in patients with no other heart disease who have survived a CA due to VF or PVT and exhibit a type
1 Brugada ECG induced by sodium channel blocker challenge or during fever.135,136,975,981,982
I
C
Genetic testing for SCN5A gene is recommended for probands with BrS.164,1016
I
C
BrS should be considered in patients with no other heart disease and induced type 1 Brugada pattern who have at least one of:
• Arrhythmic syncope or nocturnal agonal respiration
• A family history of BrS
• A family history of SD (,45 years old) with a negative autopsy and circumstance suspicious for BrS.
IIa
C
Continued


<!-- PAGE 85 -->

### Page 85

7.2.5. Early repolarization syndromes
Early repolarization syndrome (ERS) is diagnosed in a patient resuscitated from PVT or VF without any heart disease and the early repolarization pattern
(ERP);
J-point elevation
≥1 mm in ≥2 adjacent inferior and/or lateral ECG leads
(Figure 32).135,231,1017–1019 However, ERP is most often a benign
ﬁnding and the prevalence of ERP has been reported as 5.8% in adults and is more common in young males and athletes.135,231,1017–1021 Nonetheless, ERP is over-represented in relatives of SADS cases282,1022 and of CA survivors.182,916 The diagnostic yield and utility of genetic testing is low.1023–1025
High-risk ECG features have been proposed to increase likelihood of ERS: prominent J-waves ≥2 mm, dynamic changes in
J-point elevation (.0.1 mV) and J-waves associated with a horizontal or descending ST-segment (Figure 34).231,1026,1027 ERP
with a horizontal ST-segment was associated with arrhythmic risk in an elderly and IVF population.1027 Nonetheless, ERS survivors and relatives of SADS cases also exhibit a higher prevalence of the ascending/upsloping
ST
segment than controls.282,1018 At least 40% of ERS patients with VF have subsequent episodes,
with
27%
suffering multiple episodes.231,1028,1029 Isoproterenol infusion is effective in acute suppression of recurrent
ICD
discharges and electrical storm.1030–1032 AADs that block the transient outward potassium current can prevent VF.922,1030,1033 A retrospective multicentre study showed a reduction of recurrent VF after initiation of quinidine.1030 Phosphodiesterase-3 inhibitors such as cilostazol and milrinone also reduced the recurrence of VF.1032
Ablation of a PVC trigger, usually from the Purkinje system,
has an acute success rate of 87–100% and may be effective in preventing recurrence in patients with drug-refractory
VF.1010,1017 Detailed electroanatomic mapping may reveal localized structural alterations in 39% of ERS patients.1010 Ablation of these areas successfully suppressed electrical storm and may be a therapeutic option in experienced centres. Whether catheter ablation improves long-term outcomes is currently unknown.
Data for risk stratiﬁcation of patients with suspected ERS without prior CA are unavailable. In individuals with ERP and unexplained syncope, this panel has recommended that follow-up with an ILR should be considered. As the prognosis of asymptomatic subjects with ERP is good, ICD therapy is usually not indicated.1034–1036 If, however, there is a high-risk ERP and a strong family history of unexplained juvenile SD, then ICD implantation or quinidine may be considered.
BrS may be considered as a diagnosis in patients with no other heart disease who exhibit an induced type 1 Brugada
ECG.136,973,975,978,984,985
IIb
C
Sodium channel blocker test is not recommended in patients with a prior type I
Brugada pattern.
III
C
General recommendations
The following is recommended in all patients with
BrS:
(a) Avoidance of drugs that may induce
ST-segment elevation in right precordial leads (http://www.brugadadrugs.org).
(b) Avoidance of cocaine, cannabis, and excessive alcohol intake.
(c) Treatment of fever with antipyretic drugs.
I
C
Risk stratiﬁcation, prevention of SCD and treatment of VA
ICD implantation is recommended in patients with BrS who:
(a) Are survivors of an aborted CA and/or
(b) Have documented spontaneous sustained
VT.980,990–992
I
C
ICD implantation should be considered in patients with type 1 Brugada pattern and an arrhythmic syncope.990,992,996
IIa
C
Implantation of a loop recorder should be considered in BrS patients with an unexplained syncope.997,999
IIa
C
Quinidine should be considered in patients with
BrS who qualify for an ICD but have a contraindication, decline, or have recurrent ICD
shocks.922,1006,1007
IIa
C
Isoproterenol infusion should be considered in
BrS patients suffering electrical storm.1008
IIa
C
Catheter ablation of triggering PVCs and/or
RVOT epicardial substrate should be considered in BrS patients with recurrent appropriate ICD
shocks refractory to drug therapy.1010–1015
IIa
C
PES may be considered in asymptomatic patients with a spontaneous type I BrS ECG.155
IIb
B
ICD implantation may be considered in selected asymptomatic BrS patients with inducible VF
during PES using up to 2 extra stimuli.155
IIb
C
Catheter ablation in asymptomatic BrS patients is not recommended.
III
C
© ESC 2022
BrS, Brugada syndrome; CA, cardiac arrest; ECG, electrocardiogram; ICD, implantable cardioverter deﬁbrillator; PES, programmed electrical stimulation; PVCs, premature ventricular complexes; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow tract; SCD, sudden cardiac death; SD, sudden death; VA,
ventricular arrhythmia; VF, ventricular ﬁbrillation.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4081


<!-- PAGE 86 -->

### Page 86

N
N
N
Patient with ECG suspicious of Brugada Syndrome
Exclude alternative diagnosis consistent with ECGa
No documentedVA
V
Spontaneous type 1 BrS ECG
No type I BrS ECG
Discharge
Discharge
Follow-up
Follow-up
Syncope
Results
Arrhythmic syncope/
nocturnal agonical respiration
SustainedVA or
V
aborted cardiac arrest
Y
Y
Y
Y
Family history of B
f rS or SADS
ICD implantati a on
(Class IIa)
Recurrent symptomati a cVA
V
Quinidine
(Class IIa)
Recurrent symptomati a cVA
V
Cath a
eter a r blati a on
(Class IIa)
N
Arrhyth y
mic syncope
Unexplained syncope
ILR
(Class IIa)
Sodium channel blocke k r test
(Class I)
Sodium channel blocke k r test
(Class I)
General recommendationsb
(Class I)
Positive
Positive
Negative
Further evaluation according to ESC
syncope
Guidelines
Results
Negative
General recommendationsb
(Class I)
Sodium channel blocker 
k test
(Class III)
Figure 33 Part One. Algorithm for the management of patients with Brugada pattern electrocardiogram.


<!-- PAGE 87 -->

### Page 87

Exclude alternative diagnosis consistent with ECG
o a
SustainedVA or abo
V
rted cardiac arrest
N
Y
Spontaneous tyt pe 1
BrS ECG
Results
Positive
Negative
ICD implantation
(Class I)
General recommendationsb
(Class I)
Sodium channel blocker 
k test
(Class III)
ICD implantation
(Class I)
General recommendationsb
(Class I)
Sodium channel blocker 
k test
(Class I)
Recurrent sym t
ptomati a cVA
V
Quinidine
(Class IIa)
Recurrent sy t
mptomati a cVA
V
Cath a
eter ablati a on
(Class IIa)
Further evaluati a on fof r alternati a ve cause of VA/
V
CA
Recurrent sy t
mptomati a cVA
V
Figure 33 Part Two. Algorithm for the management of patients with Brugada pattern electrocardiogram. BrS, Brugada syndrome; CA, cardiac arrest;
ECG, electrocardiogram; ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; N, No; SADS, sudden arrhythmic death syndrome;
VA, ventricular arrhythmia; Y, Yes. aEcho, CMR, cardiac CT, CAG indicated according to patient clinical presentation and risk factors. bGeneral recommendations: avoidance of drugs that may induce ST-segmentation elevation in right precordial leads (http://www.brugadadrugs.org), avoidance of cocaine and excessive alcohol intake, treatment of fever with antipyretic drugs.
Recommendation Table 44 — Recommendations for the management of patients with early repolarization pattern/syndrome
Recommendations
Classa
Levelb
Diagnosis
It is recommended that the ERP is diagnosed as J-point elevation of ≥1 mm in two adjacent inferior and/or lateral ECG leads.1017,1018
I
C
It is recommended that the ERS is diagnosed in a patient resuscitated from unexplained VF/PVT in the presence of
ERP.1017,1018
I
C
In an SCD victim with a negative autopsy and medical chart review, and an ante-mortem ECG demonstrating the ERP, the diagnosis of ERS should be considered.1017,1018
IIa
C
First-degree relatives of ERS patients should be considered for clinical evaluation for ERP with additional high-risk features.c,1022,1037
IIa
B
Continued
Genetic testing in ERS patients may be considered.1023,1025
IIb
C
Clinical evaluation is not recommended routinely in asymptomatic subjects with ERP.1038,1039
III
C
Risk stratiﬁcation, prevention of SCD and treatment of VA
ICD implantation is recommended in patients with a diagnosis of ERS who have survived a CA.1017
I
B
Isoproterenol infusion should be considered for ERS
patients with electrical storm.1017,1030–1032
IIa
B
Quinidine in addition to an ICD should be considered for recurrent VF in ERS patients.922,1030,1033
IIa
B
ILR should be considered in individuals with ERP and at least one risk featured or arrhythmic syncope.1020
IIa
C
PVC ablation should be considered in ERS patients with recurrent VF episodes triggered by a similar PVC
non-responsive to medical treatment.1010
IIa
C
ICD implantation or quinidine may be considered in individuals with ERP and arrhythmic syncope and additional risk features.d,1030,1033
IIb
C
Continued
ESC Guidelines
4083


<!-- PAGE 88 -->

### Page 88

7.2.6. Catecholaminergic polymorphic ventricular tachycardia
CPVT is a heritable disorder characterized by catecholamineinduced bidirectional VT and PVT in the absence of SHD or ischaemia.
The disease has an estimated prevalence of 1 in 10000 (Figure 35).135
There are two main genetic types: a dominant disorder due to mutations in the gene encoding for the cardiac ryanodine receptor
(RYR2) and a recessive disorder caused by mutations in the cardiac calsequestrin gene
(CASQ2).135,178
Mutations in
TRDN
and
CALM1-3 have been identiﬁed in patients with atypical forms of catecholaminergic VAs.1042 At the present time, however, it is unclear whether they are distinct arrhythmic entities.1043 Patients with
KCNJ2 mutations causing Andersen–Tawil syndrome type 1 may sometimes exhibit bidirectional and PVT, but are distinguished by their syndromic associations.1044
ICD implantation or quinidine may be considered in asymptomatic individuals who demonstrate a high-risk
ERPc in the presence of a family history of unexplained juvenile SD.1030,1033
IIb
C
ICD implantation is not recommended in asymptomatic patients with an isolated ERP.1034,1035,1040
III
C
© ESC 2022
CA, cardiac arrest; ECG, electrocardiogram; ERP, early repolarization pattern; ERS,
early repolarization syndrome; ICD, implantable cardioverter deﬁbrillator; ILR,
implantable loop recorder; PVC, premature ventricular complexes; PVT, ventricular tachycardia; SCD, sudden cardiac death; SD, sudden death; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation.
aClass of recommendation.
bLevel of evidence.
cERP high-risk features: J waves .2 mm, dynamic changes in J point and ST
morphology.1020,1041
dHigh-risk ERP: family history of unexplained SD ,40 years, family history of ERS.
N
N
N
Patient with early repolarization pattern
Y
Y
Y
N
Y
Catheter ablation of PVC triggers
(Class IIa)
Quinidine
(Class IIa)
Recurrent
ICD shocks
Electrical storm
Arrhythmic syncope
Aborted cardiac arrest
ILR
(Class IIa)
ICD implantation
(Class IIb)
Quinidine
(Class IIb)
Isoproterenol
(Class IIa)
Quinidine
(Class IIa)
At least one risk factor:
ICD implantation
(Class I)
Recurrence
High risk ERPa
Family history of juvenile unexplained SD
Family history of ERS
At least one risk factor:
High risk ERPa
Family history of juvenile unexplained SD
Family history of ERS
ILR
(Class IIa)
N
Y
ILR
(Class IIa)
ICD implantation
(Class IIb)
Quinidine
(Class IIb)
ILR
(Class IIa)
No further investigation
(Class III)
High risk ERPa AND
Family history of juvenile unexplained SD
Figure 34 Management of patients with early repolarization pattern/syndrome. ERP, early repolarization pattern; ERS, early repolarization syndrome;
ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; N, No; PVC, premature ventricular complex; SD, sudden death; Y, Yes. aERP
high risk features: J waves .2 mm, dynamic changes in ST morphology.


<!-- PAGE 89 -->

### Page 89

The clinical manifestations of CPVT usually occur in the ﬁrst decade of life prompted by physical activity or emotional stress.1045 Most CPVT patients have normal ECG and echocardiogram. Nonetheless, some patients present mild ECG abnormalities, such as sinus bradycardia and prominent U waves. Exercise stress test is the most important diagnostic test, because it elicits the distinguishing bidirectional or PVT that establish the diagnosis
(Figure 36).135 A diagnosis can also be made in the presence of a mutation in genes associated with CPVT. Epinephrine or isoproterenol challenge may be considered when exercise stress testing is not feasible.1046
Diagnosis in childhood, the lack of beta-blocker therapy, and complex arrhythmias during the exercise stress test on a full dose of betablockers are independent predictors for arrhythmic events.1047
Exercise restriction and beta-blockers without intrinsic sympathomimetic activity are the ﬁrst-line therapy for CPVT patients.135
Non-selective beta-blockers such as nadolol and propranolol are preferred.1048,1049 This panel has conﬁrmed the indication to treat genetically positive family members with beta-blockers, even in the absence of documented exercise- or stress-induced VAs.1047,1050
Data suggest that ﬂecainide signiﬁcantly reduces the VA burden in
CPVT patients and should be considered in addition to beta-blockers when control of arrhythmias is incomplete.1051–1053 In selected patients who show intolerance to beta-blocker therapy, pharmacological therapy with ﬂecainide alone is an option.1054
Maximal protection with beta-blockers, ﬂecainide and ICD is indicated in survivors of a CA. An ICD should also be considered in
CPVT patients with breakthrough VA on beta-blockers and ﬂecainide.135 The ICD should, however, be programmed with long delays and high rates before deﬁbrillation, because initiating bidirectional VT
responds less effectively to deﬁbrillation than subsequent PVT/VF,
and painful shocks can trigger further and incessant arrhythmias.1055
LCSD has been proposed as an additional therapy in patients in whom pharmacological treatment is not effective or feasible.
Although LCSD reduces the recurrence of major cardiac events in previously symptomatic patients, one-third of patients still suffer recurrences of arrhythmia.1056 Therefore, LCSD has not been considered to be a replacement for ICD therapy but a complementary therapy in symptomatic patients.
A recent systematic review of 53 studies including CPVT patients with an ICD concluded that secondary prevention patients managed with OMT, LCSD and exercise restriction could reduce ICD use.1057
This observation was supported by a subsequent multicentric investigation showing that all the three SCD observed occurred in patients with an ICD.1058 At present it seems premature, on the base of this evidence, to demote ICD implant in survivors of CA with CPVT.1057
Patient with CPVT
ICD implantation (Class I)
Flecainide (Class IIa)
LCSD (Class IIa)
Flecainide (Class IIa)
General recommendationsa (Class I)
Beta-blocker k
b (Class I)
Beta-blocker k
b (Class IIa)
Arrhythmic syncope or bidirectional or polymorphicVT
Aborted cardiac arrest
Syncope or exertional PVCs orVT
Syncope or exertional PVCs orVT
Syncope or documentedVT
Syncope or documentedVT
ICD implantation (Class IIa)
LCSD (Class IIa)
Asymptomatic, no documented
,
VA
V , but pathogenic
,
mutation
Figure 35 Management of patients with catecholaminergic polymorphic ventricular tachycardia. CPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable cardioverter deﬁbrillator; LCSD, left cardiac sympathetic denervation; PVC, premature ventricular complex; VA, ventricular arrhythmia; VT, ventricular tachycardia. aGeneral recommendations: avoidance of competitive sports, avoidance of strenuous exercise, avoidance of stressful environments. bPreferred beta-blockers: nadolol, propranolol.
ESC Guidelines
4085


<!-- PAGE 90 -->

### Page 90

7.2.7. Short QT syndrome
Short QT syndrome (SQTS) is a rare genetic disorder characterised by a short QT interval, premature AF and VF in the context of a structurally normal heart.1061 It has been associated with gain of function mutations in KCNH2, KCNQ1 and loss of
Recommendation Table 45 — Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia
Recommendations
Classa
Levelb
Diagnosis
It is recommended that CPVT is diagnosed in the presence of a structurally normal heart, normal
ECG, and exercise- or emotion-induced bidirectional, or PVT.
I
C
It is recommended that CPVT is diagnosed in patients who are carriers of a mutation in disease-causing genes.
I
C
Genetic testing and genetic counselling are indicated in patients with clinical suspicion or clinical diagnosis of CPVT.
I
C
Epinephrine or isoproterenol challenge may be considered for the diagnosis of CPVT when an exercise test is not possible.
IIb
C
General recommendations
Avoidance of competitive sports, strenuous exercise, and exposure to stressful environments is recommended in all patients with CPVT.
I
C
Therapeutic interventions
Beta-blockers, ideally non-selective (nadolol or propranolol) are recommended in all patients with a clinical diagnosis of CPVT.1045,1048,1059
I
C
ICD implantation combined with beta-blockers and ﬂecainide is recommended in CPVT patients after aborted CA.1045,1047,1060
I
C
Continued
Therapy with beta-blockers should be considered for genetically positive CPVT patients without phenotype.1047,1050
IIa
C
LCSD should be considered in patients with diagnosis of CPVT when the combination of beta-blockers and ﬂecainide at therapeutic dosage are either not effective, not tolerated, or contraindicated.1056
IIa
C
ICD implantation should be considered in patients with CPVT who experience arrhythmogenic syncope and/or documented bidirectional/PVT
while on highest tolerated beta-blocker dose and on ﬂecainide.1047,1050
IIa
C
Flecainide should be considered in patients with
CPVT who experience recurrent syncope,
polymorphic/bidirectional VT, or persistent exertional PVCs, while on beta-blockers at the highest tolerated dose.1052,1053,1060
IIa
C
PES is not recommended for stratiﬁcation of SCD
risk.
III
C
© ESC 2022
CA,
cardiac arrest;
CPVT,
catecholaminergic ventricular tachycardia;
ECG,
electrocardiogram; ICD, implantable cardioverter deﬁbrillator; LCSD, left cardiac sympathetic denervation; PVT, polymorphic ventricular tachycardia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
Bidirectional PVCs during exercise
II
III
Figure 36 Exercise test of a patient with catecholaminergic polymorphic ventricular tachycardia. PVC, premature ventricular complex.


<!-- PAGE 91 -->

### Page 91

function in SLC4A.1062,1063 This panel proposed two QTc cut-off threshold for diagnosis: A QTc ≤320 ms alone, or B a
QTc ≤360 ms combined with a family history of SQTS,
aborted CA in the absence of heart disease or pathogenic mutation1064–1067 (Figure 37). The disease has high lethality in all age groups, including the ﬁrst months of life.1063,1068,1069 The probability of a ﬁrst CA by the age of 40 years is .40%.1068 While an
ICD is used for secondary prevention,1069 primary prevention remains contentious and is based upon prior symptoms and
QTc interval.1063,1068,1069 Quinidine is currently the best supported AAD, but should be monitored for excessive QT prolongation, while isoprenaline may be considered in electrical storm.1070,1071 Drugs that shorten QT interval should be avoided, e.g. nicorandil.1072 Loop recorder implantation should be considered in children and young asymptomatic SQTS
patients.
Short QT syndrome
Figure 37 Short QT syndrome.
Recommendation Table 46 — Recommendations for the management of patients with short QT syndrome
Recommendations
Classa
Levelb
Diagnosis
It is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic mutation, (b) a family history of SQTS, (c) survival from a VT/VF
episode in the absence of heart disease.1061,1068
I
C
Genetic testing is indicated in patients diagnosed with SQTS.1063
I
C
Continued
SQTS should be considered in the presence of a
QTc ≤320 ms.1064–1067,1073,1074
IIa
C
SQTS should be considered in the presence of a
QTc ≥320 ms and ≤360 ms and arrhythmic syncope.
IIa
C
SQTS may be considered in the presence of a
QTc ≥320 ms and ≤360 ms and a family history of SD at age ,40 years.
IIb
C
Risk stratiﬁcation, SCD prevention and treatment of VA
ICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA and/or (b) have documented spontaneous sustained VT.1063
I
C
ILR should be considered in young SQTS patients.
IIa
C
ICD implantation should be considered in SQTS
patients with arrhythmic syncope.
IIa
C
Quinidine may be considered in (a) SQTS patients who qualify for an ICD but present a contraindication to the ICD or refuse it, and (b)
asymptomatic SQTS patients and a family history of SCD.1069–1071
IIb
C
Isoproterenol may be considered in SQTS
patients with an electrical storm.1075
IIb
C
PES is not recommended for SCD risk stratiﬁcation in SQTS patients.
III
C
© ESC 2022
CA, cardiac arrest; ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder, SCD, sudden cardiac death; SD, sudden death; SQTS, short QT syndrome;
VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4087


<!-- PAGE 92 -->

### Page 92

### 8 Special aspects in selected populations

8.1. Pregnant patients and peri-partum cardiomyopathy
Pregnancy and the post-partum period contribute a signiﬁcant risk in women with arrhythmic heart disease and is covered in the 2018
ESC Guidelines for the management of cardiovascular diseases during pregnancy.1076–1080 New-onset VT may present during pregnancy and risk of recurrent VT is higher in patients with previous VT and SHD.1081
Peri-partum cardiomyopathy (PPCM) should be ruled out in the case of new-onset VT during the last 6 weeks of pregnancy or in the early post-partum period.1082 A genetic contribution may be present in up to 20% of patients with PPCM (in particular titin-truncating variants)1083 and future studies should reveal if genetic testing plays a role in PPCM patients with a positive family history.
8.1.1. Electrocardioversion and implantable cardioverter deﬁbrillator therapy in pregnancy
Cardioversion seems safe in all phases of pregnancy and case reports show neither compromise in fetal blood ﬂow nor initiation of preterm labour.1084 Foetal heart rate should be routinely controlled after cardioversion.1085 If an ICD is indicated, ICD implantation should be performed beyond 8 weeks of gestation with radiation protection by experienced operator teams.1086 Echocardiographic guidance or a 3D mapping system may be helpful in ICD implantation to avoid radiation.1087,1088 In pregnant patients with existing ICD,
routine ICD interrogation is recommended prior to delivery. In patients with PPCM, thresholds for early ICD implantations are higher than in other conditions because of a high rate of spontaneous recovery after delivery.1089 WCD have been suggested to temporarily prevent SCD during the ﬁrst 3–6 months after diagnosis of PPCM
with LVEF ≤35%, while awaiting recovery.1090,1091
8.1.2. Pharmacological treatment
Pharmacological treatment of arrhythmias and heart failure in pregnant women should follow treatment in non-pregnant patients with avoidance of drugs contraindicated in pregnancy, such as ACE inhibitors,
ARB inhibitors/ARNI and renin inhibitors.1080,1082,1092,1093 The ﬁrst trimester is associated with the greatest teratogenic risk. Start of pharmacological therapy is advised to begin at the latest possible point in the pregnancy and with the lowest effective dose. Drug exposure in the second and third trimestera may confer adverse effects on foetal growth and development as well as increasing the risk of pro-arrhythmia.
It is recommended to check drugs and safety data before initiation of a new drug during pregnancy, according to the 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.1080 From this list, AADs can be summarized as followed:
• Well tolerated: sotalol, oral verapamil
• Use only if potential beneﬁt outweighs potential risk: bisoprolol, carvedilol, digoxin, diltiazem (possible teratogenic effects), disopyramide (uterine contractions), ﬂecainide, lidocaine,
metoprolol, nadolol, propranolol, verapamil IV, quinidine
• Inadequate data:
Ivabradine,
mexiletine,
proprafenone,
vernakalant
• Contraindicated: amiodarone, atenolol, dronedarone.
In LQTS (LQT2 in particular), risk of cardiac events increases substantially in the post-partum period (up to one year after delivery).1094 Therefore, it is important to continue beta-blocker therapy throughout pregnancy and post-partum.955,1094,1095
Continuation of beta-blocker treatment is recommended in LQTS
and CPVT1096 and should be considered in ARVC.1097–1099 No additional risk by pregnancy is known in women with BrS1100,1101
(
ESC CardioMed chapter 53.6).1102
In patients with PPCM, use of bromocriptine as disease-speciﬁc therapy in addition to standard heart failure therapy has shown promising results in two clinical trials.1103,1104
8.1.3. Catheter ablation
In planned pregnancies, symptomatic tachyarrhythmia should be treated by catheter ablation before pregnancy. If catheter ablation is indicated in a pregnant patient, one should avoid the procedure in the ﬁrst trimester, and electroanatomical mapping-guided procedures should be preferred.1105,1106
Recommendation Table 47 — Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy
Recommendations
Classa
Levelb
Acute management of VA
During pregnancy, electrical cardioversion is recommended for sustained VT.1084
I
C
For acute conversion of haemodynamically tolerated SMVT during pregnancy, a beta-blocker,
sotalol, ﬂecainide, procainamide, or overdrive ventricular pacing should be considered.
IIa
C
Long-term management of VA
If ICD implantation is indicated during pregnancy,
implantation is recommended with optimal radiation protection.1087,1107
I
C
Continuation of beta-blockers is recommended during pregnancy and post-partum in women with
LQTS or CPVT.955,1094–1096
I
C
Continuation of beta-blockers should be considered during pregnancy in women with
ARVC.1097–1099
IIa
C
Oral metoprolol, propranolol, or verapamil should be considered for long-term management of idiopathic sustained VT during pregnancy.
IIa
C
Catheter ablation using non-ﬂuoroscopic mapping systems should be considered, preferably after the
ﬁrst trimester, in women with highly symptomatic recurrent SMVT refractory or who are intolerant to AADs.1105
IIa
C
© ESC 2022
AAD, anti-arrhythmic drug; ARVC, arrhythmogenic right ventricular cardiomyopathy;
CPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable cardioverter deﬁbrillator; LQTS, long QT syndrome; SMVT, sustained monomorphic
VT; VA, ventricular arrhythmia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 93 -->

### Page 93

8.2. Heart transplantation
Patients listed for HTX are exposed to an SCD risk and have a high incidence of VA. Data from large registries suggest a survival beneﬁt from ICDs.1108–1111 The only randomized study including patients listed for HTX was prematurely stopped because of low enrolment.1112 There are no data regarding the role of WCD in patients listed for HTX. The median expected time on the waiting list, 8–16
months, needs to be considered.1108,1110 However, this panel shares the opinion that a WCD may be an alternative for an ICD in selected patients waiting for HTX.371,1113
In post-HTX patients, SCD is responsible for around 10% of deaths.1114,1115 Transplant rejection and allograft vasculopathy are associated with SCD1114,1116,1117; therefore, ICD implantation may be appropriate in selected high-risk patients.1118
8.3. Sudden cardiac death in athletes
The incidence of SCD in athletes increases with age.4,1120 In apparently healthy athletes (.35 years), the estimated incidence of SCD
ranges from 2 to 6.3 per 100 000 participant-years. In comparison,
in young competitive athletes (≤35 years) the incidence of fatal events is signiﬁcantly lower, 0.4–3 per 100 000 participantyears.46,47,1120 Women athletes are at low risk of SCD; on average,
1 in 14 SCD in athletes occurs in women.1121
Pre-participation cardiovascular evaluation offers the potential to identify athletes at-risk for cardiovascular disease before onset of symptoms.1122–1126 The evaluation protocol needs to be adapted to the age of the athlete to account for age-speciﬁc cardiovascular disease.1125 Pre-participation evaluation, including medical history, physical examination, and ECG, appears effective in identifying cardiovascular disease in young athletes (≤35
years of age) by identiﬁcation of relevant symptoms (e.g. exertional syncope) or ECG abnormalities consistent with inheritable cardiomyopathies or channelopathies.1127–1130 Although echocardiography can increase the sensitivity of screening for SHD,
it is unfeasible as a routine test in mass screening. More cardiovascular diseases are identiﬁed by serial (annual) evaluations of adolescent athletes.1129,1131 The prevalence of false-positive results strongly depends on the criteria used to deﬁne an ECG
as ‘abnormal’.1132,1133 Additional tests, such as echocardiography, 24-hour Holter monitoring, stress testing, and CMR, are requested for athletes who had positive ﬁndings at the initial evaluation. Athletes diagnosed with clinically relevant cardiovascular disease are managed according to available
ESC
Guidelines.4,1134–1136
In middle-aged/senior athletes, the most common cause of
SCD is CAD.1125,1137 Before engaging in a vigorous physical activity, asymptomatic middle-aged/senior athletes should be evaluated using risk score systems such as the
ESC
SCORE2.4,65
Excellent rates of survival with favourable neurological outcome after CA has been reported in sports centres equipped with
AED.1137,1138 This justiﬁes the efforts for implementing emergency programs for SCD prevention, with distribution of AED in sports arenas and training of coaches and staff to perform CPR and deﬁbrillation.1139
Recommendation Table 48 — Recommendations for the prevention of sudden cardiac death before and after heart transplantation
Recommendations
Classa
Levelb
Prior to heart transplant
In patients awaiting heart transplantation, ICD
implantation for primary prevention should be considered.1108,1111,1112
IIa
C
In patients awaiting heart transplantation, WCD
may be considered.1109,1113,1119
IIb
C
Post heart transplant
In selected transplanted patients with cardiac allograft vasculopathy or treated rejection, ICD
implantation may be considered.1114,1116
IIb
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; WCD, wearable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 49 — Recommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes
Recommendations
Classa
Levelb
In athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including echocardiography and/or
CMR to conﬁrm (or exclude) an underlying disease are recommended.1123,1133,1135
I
C
It is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current guidelines for sports eligibility.
I
C
It is recommended that staff at sporting facilities are trained in CPR and in the use of AED.93,1137
I
C
Pre-participation cardiovascular evaluation of competitive athletes should be considered.46,1122,1123,1127
IIa
C
It should be considered that cardiovascular evaluation of young (,35 years) competitive athletes includes history, physical examination,
and 12-lead ECG.1123,1126,1130,1140
IIa
C
The cardiovascular risk of middle-aged and elderly individuals should be evaluated before engaging in strenuous sports through established scores such as the SCORE2 risk chart.46,1141,1142
IIa
C
© ESC 2022
AED, automated external deﬁbrillator; CMR, cardiac magnetic resonance; CPR,
cardiopulmonary resuscitation; ECG, electrocardiogram; SCD, sudden cardiac death.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4089


<!-- PAGE 94 -->

### Page 94

8.4. Wolff–Parkinson–White syndrome
In patients with Wolff–Parkinson–White (WPW) syndrome, the most common arrhythmia is AV re-entry tachycardia (AVRT;
80%), followed by AF (20–30%). SCD secondary to pre-excited AF
resulting in VF is the most feared manifestation of WPW syndrome.
The risk of CA/VF in untreated WPW patients has been estimated at
0.9–2.4 per 1000 person-year.1143,1144 The management of WPW
patients has recently been reviewed in the 2019 ESC Guidelines for the management of patients with SVT302 and updated with a particular focus on athletes in 2020.1145 In patients with ventricular pre-excitation and symptomatic AVRT, catheter ablation is recommended (class I). In asymptomatic patients with ventricular pre-excitation, both invasive (class IIa) and non-invasive (class IIb)
assessment are options for risk stratiﬁcation for SCD. While catheter ablation is recommended for asymptomatic accessory pathways with high-risk features (class I), clinical follow-up (class IIa), or catheter ablations (class IIb) are options based on informed patient choice. This decision should take into account the location of the accessory pathway, the local ablation experience and the fact that symptomatic arrhythmias will frequently develop during followup.1146 For the paediatric population, SVT due to WPW can usually be managed pharmacologically, and accessory pathways often lose antegrade conduction in the ﬁrst years of life.1147 In children with asymptomatic accessory pathways, risk stratiﬁcation is not recommend before the age of 8 years.1148
8.5. Prevention of sudden cardiac death in the elderly
Age is a strong risk factor for death. In several studies, advanced age was one of the factors associated with a reduced expected beneﬁt from ICD treatment. In patients with ischaemic cardiomyopathy enrolled in MADIT-II trial, a risk scheme composed of 5
clinical factors including age .70 years was predictive of the absence of long-term beneﬁt conferred by the ICD.1149 In a recent analysis of ICD patients enrolled in four MADIT studies, age ,75
years was a predictor of VT/VF whereas age ≥75 years was a predictor of non-arrhythmic mortality.365 Consistently, in the recent randomized DANISH trial in patients with non-ischaemic heart failure, the association between the ICD and survival decreased linearly with increasing age, while an age cut-off at ≤70 years yielded the highest survival.647 Contemporary non-randomized data corroborate these ﬁndings. In the EU-CERT-ICD prospective cohort study in patients with CAD or cardiomyopathies with indication for primary prevention ICD implantation, no
ICD beneﬁt was observed in patients aged ≥75 years.357 In contrast, there was a signiﬁcant survival beneﬁt in patients aged
,75 years. Further retrospective data are in line with this observation.1150
Biological age may vary in part according to comorbidities.
Indeed, comorbidities signiﬁcantly inﬂuence survival of ICD recipients and a high comorbidity index is associated with less survival gain in primary or secondary prevention ICD patients.1149,1151
Therefore, a simple age cut-off cannot guide the decision on ICD
implantation adequately and the ICD indication in elderly patients should be based on a personalized assessment considering the overall condition and comorbidities.
9. Key messages
9.1. General aspects
• Increased availability of public access deﬁbrillators and community training in basic life support are key elements to improve survival of out-of-hospital cardiac arrest victims.
• Risk calculators for SCD and VA implemented in clinical practice need to meet agreed high standards for the development, external validation, and reporting of prediction models.
• Patients with genetic cardiomyopathies and arrhythmia syndromes require genetic testing as a routine part of their care.
• Genetic testing and counselling require access to an expert multidisciplinary team.
• A systematic workup of cardiac arrest survivors requires a multimodal approach.
• A comprehensive autopsy is recommended in all cases of sudden death under 50 years and is desirable in all sudden death victims.
• Clinical and genetic evaluation of SADS decedents and their families leads to a diagnosis of genetic heart disease in a substantial proportion of families.
• An electrical storm refractory to drug treatment requires the availability of advanced catheter ablation techniques, mechanical circulatory support, and autonomic modulation.
• When considering ICD therapy beneﬁt, competing risk factors for non-arrhythmic death and the patient’s wishes and quality of life need to be taken into account.
9.2. Structural heart disease
• Catheter ablation is recommended in CAD patients with recurrent symptomatic SMVT despite chronic amiodarone therapy.
• Catheter ablation is the ﬁrst-line treatment for PVC-induced cardiomyopathy.
• In HNDCM/DCM patients, indication for primary prevention
ICD implantation should not be restricted to an LVEF ≤35%.
Additional risk factors (e.g. CMR and genetics) are important to consider.
• Patients with an LMNA mutation require speciﬁc risk stratiﬁcation for SCD.
• ARVC patients have a high rate of appropriate ICD interventions which may not necessarily be classiﬁed as lifesaving.
Recommendation Table 50 — Recommendations for implantable cardioverter deﬁbrillator implantation in the elderly
Recommendations
Classa
Levelb
In elderly patients in whom a beneﬁt from the deﬁbrillator is not expected due to the patient’s age and comorbidities, omission of ICD
implantation for primary prevention may be considered.647,1150,1152
IIb
B
© ESC 2022
ICD, implantable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 95 -->

### Page 95

• A validated risk calculator (HCM Risk-Kids score) is useful to assess the risk for SCD in HCM patients younger than 16 years.
• Myotonic dystrophy patients with palpitations suspected of arrhythmia, syncope or aborted sudden death need to be evaluated by invasive electrophysiological study.
• In patients with repaired tetralogy of Fallot and monomorphic VT,
catheter ablation is the preferred treatment.
9.3. Primary electrical disease
• Nadolol or propranolol are the preferred beta-blockers in LQTS
and CPVT patients.
• In asymptomatic LQTS patients the arrhythmic risk (1-2-3 Risk calculator) may be useful to calculate.
• A type 1 Brugada ECG pattern provoked by sodium channel blocker test in the absence of other ﬁndings does not diagnose the BrS.
• SCD risk stratiﬁcation in asymptomatic BrS patients with a spontaneous type 1 pattern remains controversial.
• Routine catheter ablation is not recommended in asymptomatic
BrS patients.
• The diagnosis of idiopathic VF requires exclusion of an underlying structural,
channelopathic,
or metabolic aetiology.
• ERP can be a benign ﬁnding and is distinct from ERS.
• Left cardiac denervation plays an important role in the management of CPVT and LQTS patients.
10. Gaps in evidence
10.1. General aspects
• Accurate screening tests to detect heart conditions associated with SCD in asymptomatic individuals in the general population are required.
• In patients with SHD, the optimal time interval between repeated non-invasive and invasive prognostic tests, in case of a negative test, is unknown.
• Improved assessment of genetic variants of uncertain signiﬁcance and likely pathogenic variants is needed.
• The utility of polygenic risk scores in patients at risk of SCD requires investigation.
10.2. Structural heart disease—general
• The long-term safety and efﬁcacy of S-ICDs is unknown.
• The role of primary preventive ICD therapy in patients with SHD
and mildly reduced or preserved ejection fraction has not been studied systematically.
• The optimal techniques to undertake VT substrate mapping and ablation in SHD remain to be determined.
• The role of ICD implantation in end-stage heart failure patients supported by current-generation, continuous-ﬂow LVADs is unclear.
10.3. Idiopathic premature ventricular complexes/ventricular tachycardia
• The beneﬁcial role of catheter ablation or anti-arrhythmic drug treatment in patients with asymptomatic, frequent PVCs and preserved cardiac function needs to be determined.
10.4. Coronary artery disease
• It is unknown which patients with chronic CAD and severely impaired LVEF are at low risk for SCD.
• The role of LGE-CMR for risk stratiﬁcation for SCD in chronic
CAD is unclear.
• RCTs are needed to determine the role of ICDs after successful
VT ablation in chronic CAD with mildly reduced or preserved
LVEF.
10.5. Cardiomyopathies
• It is unknown if PVC-induced cardiomyopathy is a diagnosis on its own or if an underlying predisposition is needed.
• The predictive value of LGE-CMR ﬁndings (e.g. pattern and amount of LGE) for individual risk stratiﬁcation for SCD in patients with cardiac sarcoidosis, HCM, and DCM/HNDC is unclear.
• Studies are needed to determine the role of PES in patients with cardiac sarcoidosis and DCM/HNDC who have a mildly reduced or preserved cardiac function and LGE on CMR.
• Prospective data on the association between intensity and duration of exercise and manifestation and severity of the phenotype in healthy ARVC mutation carriers are lacking.
• The beneﬁcial role of ICDs after successful ablation in ARVC patients who present with haemodynamically tolerated VT needs to be studied.
• Data on clinical outcome, predictors for arrhythmic events, and indication for treatment, including ICD therapy, in patients with biventricular and left-dominant arrhythmogenic cardiomyopathy are required.
10.6. Valvular heart disease
• There is a lack of knowledge to identify patients with MVP at risk for VA and SCD.
10.7. Congenital heart disease
• There is a lack of knowledge regarding the absolute risk for VA and
SCD in CHD that have undergone repair with contemporary surgical approaches.
10.8. Primary electrical disease
• Robust evidence is required to support the prophylactic use of the
ICD on top of medical therapy with beta-blockers and genespeciﬁc therapy in LQTS patients.
• More data are required to determine the role of LCSD and ICD in high-risk LQTS patients who do not tolerate medical therapy.
ESC Guidelines
4091


<!-- PAGE 96 -->

### Page 96

• Improved diagnostic and risk stratiﬁcation tools for asymptomatic
Brugada patients and suspected early repolarization syndrome are needed.
• The role of endo-epicardial mapping to identify localized structural alterations potentially related to IVF and targeted catheter ablation needs to be further studied.
• Long-term data are required on the efﬁcacy of the ICD vs. no ICD
in CPVT survivors of cardiac arrest.
• It is poorly understood why women are at low risk of sport-related SCD.
11. ‘What to do’ and ‘what not to do’ messages from the Guidelines
Recommendations
Classa
Levelb
Recommendations for public basic life support and access to automated external deﬁbrillator
It is recommended that public access deﬁbrillation be available at sites where cardiac arrest is more likely to occur.c
I
B
Prompt CPR by bystanders is recommended at OHCA.
I
B
It is recommended to promote community training in basic life support to increase bystander CPR rate and AED use.
I
B
Recommendations for genetic testing
Genetic testing is recommended when a condition is diagnosed in a living or deceased individual with a likely genetic basis and a risk of VA
and SCD.
I
B
When a putative causative variant is ﬁrst identiﬁed, evaluation for pathogenicity is recommended using an internationally accepted framework.
I
C
When a Class IV or Class V variant has been identiﬁed in a living or deceased individual with a condition that carries a risk of VA and SCD,
genetic testing of ﬁrst-degree and symptomatic relatives and obligate carriers is recommended.
I
C
It is recommended that genetic testing and counselling on its potential consequences should be undertaken by an expert multidisciplinary team.
I
C
It is recommended that Class III variants (of uncertain signiﬁcance) and Class IV variants should be evaluated for segregation in families where possible, and the variant re-evaluated periodically.
I
C
It is not recommended to undertake genetic testing in index patients with insufﬁcient evidence of a genetic disease.
III
C
Recommendations for evaluation of patients presenting with newly documented ventricular arrhythmia
In patients with newly documented VA (frequent PVCs, NSVT, SMVT), a baseline 12-lead ECG, recording of the VA on 12-lead ECG,
whenever possible, and an echocardiogram are recommended as ﬁrst-line evaluation.
I
C
Recommendations for evaluation of sudden cardiac arrest survivors
The investigation of a SCA survivor without obvious extra-cardiac cause is recommended to be overseen by a multidisciplinary team.
I
B
In electrically unstable patients after SCA, with suspicion of ongoing myocardial ischaemia, a coronary angiogram is indicated.
I
C
In SCA survivors, collection of blood samples at presentation is recommended for potential toxicology and genetic testing.
I
B
Retrieval of recordings from CIEDs and wearable monitors is recommended for all SCA survivors.
I
B
In SCA survivors, repeated 12-lead ECGs during stable rhythm (including high precordial lead ECG) as well as continuous cardiac monitoring are recommended.
I
B
Echocardiography is recommended for evaluation of cardiac structure and function in all SCA survivors.
I
C
Coronary imaging and CMR with LGE are recommended for evaluation of cardiac structure and function in all SCA survivors without a clear underlying cause.
I
B
Sodium channel blocker test and exercise testing is recommended in SCA survivors without a clear underlying cause.
I
B
Continued


<!-- PAGE 97 -->

### Page 97

Recommendations for evaluation of sudden death victims
Investigation of unexpected SD, especially in case of suspicion of inherited disease, should be made a public health priority.
I
B
In cases of SD, it is recommended to collect a detailed description of circumstances of death, symptoms prior to death, the family history, and to review prior medical ﬁles.
I
B
A comprehensive autopsy is recommended, ideally, in all cases of unexpected SD, and always in those under 50 years of age.
I
B
In cases of SCD, it is recommended to retain samples suitable for DNA extraction and consult a cardiac pathologist when an inherited cause is suspected or the cause of death unexplained.
I
B
Toxicology screens are recommended in SD cases with uncertain cause of death.
I
B
For SCD where the cause is known or suspected to be heritable, genetic testing targeted to the cause is recommended.
I
B
Following SADS, post-mortem genetic testing targeted to primary electrical disease is recommended when the decedent is young (,50
years of age) and/or the circumstances and/or family history support a primary electrical disease.
I
B
When an autopsy diagnoses possible heritable cardiac disease, it is recommended to refer ﬁrst-degree relatives for cardiac assessment in a specialized clinic.
I
B
In non-autopsied cases of SD where inherited cardiac disease is suspected, it is recommended to refer ﬁrst-degree relatives for cardiac assessment in a specialized clinic.
I
B
Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents
Following SADS, hypothesis-free post-mortem genetic testing using exome or genome sequencing is not recommended.
III
B
Familial evaluation of SADS decedents is recommended:
• for ﬁrst-degree relatives
• for relatives who must carry a mutation based on analysis of the family history
• for relatives with suspicious symptoms
• when the decedent’s age is ,50 years or if there are other circumstantial data or family history to suggest heritable disease.
I
B
Familial evaluation of SADS decedents is recommended to include genetic testing when post-mortem genetic testing in a SADS
decedent detects a pathogenic mutation.
I
B
Baseline familial evaluation of SADS decedents is recommended to include taking a medical history and performing physical examination,
standard- and high-precordial lead ECG, echocardiography, and exercise testing.
I
B
In SADS families without a diagnosis after clinical evaluation, follow-up is recommended for children of decedents until they reach adulthood.
I
C
In SADS families without a diagnosis after clinical evaluation, follow-up is not recommended for asymptomatic adults who can be discharged with advice to return if they develop symptoms or if the family history changes.
III
C
Recommendations for treatment of reversible conditions
Withdrawal of offending agents is recommended whenever drug-induced VA are suspected.
I
B
Investigation for reversible causes (e.g. electrolyte imbalances, ischaemia, hypoxaemia, fever)d is recommended in patients with VA.
I
C
Recommendations for the acute treatment of sustained ventricular tachycardia and electrical storm
DC cardioversion is recommended as the ﬁrst-line treatment for patients with haemodynamically not-tolerated SMVT.
I
B
DC cardioversion is recommended as the ﬁrst-line treatment for patients presenting with tolerated SMVT provided that the anaesthetic/sedation risk is low.
I
C
In patients presenting with a haemodynamically tolerated idiopathic VT, treatment with intravenous beta-blocker (RVOT VT) or verapamil (fascicular VT) is recommended.
I
C
Intravenous verapamil is not recommended in broad QRS complex tachycardia of unknown mechanism.
III
B
Mild to moderate sedation is recommended in patients with electrical storm to alleviate psychological distress and reduce sympathetic tone.
I
C
Antiarrhythmic therapy with beta-blockers (non-selective preferred) in combination with intravenous amiodarone is recommended in patients with SHD and electrical storm unless contraindicated.
I
B
Continued
ESC Guidelines
4093


<!-- PAGE 98 -->

### Page 98

Intravenous magnesium with supplementation of potassium is recommended in patients with TdP.
I
C
Isoproterenol or transvenous pacing to increase heart rate is recommended in patients with acquired LQT syndrome and recurrent
TdP despite correction of precipitating conditions and magnesium.
I
C
Catheter ablation is recommended in patients presenting with incessant VT or electrical storm due to SMVT refractory to AADs.
I
B
Recommendations for treatment with heart failure medication
Optimal medical treatment including ACE-I/ARB/ARNIs, MRAs, beta-blockers, and SGLT2 inhibitors is indicated in all heart failure patients with reduced EF.
I
A
Recommendations for implantable cardioverter deﬁbrillation implantation (general aspects)
Implantation of a cardioverter deﬁbrillator is only recommended in patients who have an expectation of good quality survival .1 year.
I
C
It is not recommended to implant an ICD in patients with incessant VAs until the VA is controlled.
III
C
Recommendations for secondary prevention of sudden cardiac death
ICD implantation is recommended in patients with documented VF or haemodynamically not-tolerated VT in the absence of reversible causes.
I
A
Recommendations for adding cardiac resynchronization therapy to implantable cardioverter deﬁbrillator
When an ICD is indicated, it is recommended to evaluate whether the patient could beneﬁt from CRT-deﬁbrillator.
I
C
Recommendations for optimization of device programming
Optimization of ICD programming is indicated to avoid inappropriate and unnecessary therapies and to reduce mortality.
I
A
In single- or dual-chamber ICD patients without bradycardia pacing indications, it is recommended to minimize ventricular pacing.
I
A
Programming of prolonged detection settings is indicated (duration criteria of at least 6–12 s or 30 intervals).
I
A
It is recommended to program the slowest tachycardia therapy zone limit ≥188 b.p.m. in primary prevention ICD patients.
I
A
In patients with SHD, programming of at least one ATP therapy is recommended in all tachyarrhythmias zones.
I
A
It is recommended to program algorithms for SVT vs. VT discrimination for tachycardias with rates up to 230 b.p.m.
I
B
It is recommended to activate lead failure alerts.
I
B
Remote monitoring is recommended to reduce the incidence of inappropriate shocks.
I
B
Programming of burst ATP as a ﬁrst attempt is recommended over ramp ATP.
I
B
For S-ICDs, a dual detection zone conﬁguration is recommended with activation of discrimination algorithm in the lower conditional shock zone
I
B
Recommendations for concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy
Catheter ablation is recommended for ICD patients with recurrent SVT resulting in inappropriate ICD therapies.
I
C
Pharmacological treatment or catheter ablation is recommended in patients with AF-related inappropriate ICD therapies despite optimal ICD programming.
I
C
Recommendation for psychosocial management after implantable cardioverter deﬁbrillator implantation
Assessment of psychological status and treatment of distress is recommended in ICD patients.
I
C
Communication between patient and physician/healthcare professional is recommended to address ICD-related concerns and to discuss quality-of-life issues before ICD implantation and during disease progression.
I
C
Continued


<!-- PAGE 99 -->

### Page 99

Recommendations for prevention of implantable cardioverter deﬁbrillator complications
Single-chamber ICD is recommended over dual-chamber ICD in primary prevention patients without current or expected indication for atrial or AV sequential pacing due to a lower risk of device-related complications.
I
A
Recommendations for end-of-life issues in implantable cardioverter deﬁbrillator carriers
Informed discussion with patient and family about ICD deactivation options and shared decision-making is indicated prior to implantation and in case of signiﬁcant health status deterioration.
I
C
Recommendations for treatment of ventricular arrhythmia in acute coronary syndrome and vasospasm
Intravenous beta-blocker treatment is indicated for patients with recurrent PVT/VF during STEMI unless contraindicated.
I
B
Prophylactic treatment with AADs (other than beta-blockers) is not recommended in ACS.
III
B
Recommendations for risk stratiﬁcation and treatment of ventricular arrhythmia early after myocardial infarction
Early (before discharge) assessment of LVEF is recommended in all patients with acute MI.
I
B
In patients with pre-discharge LVEF ≤40%, re-evaluation of LVEF 6–12 weeks after MI is recommended to assess the potential need for primary prevention ICD implantation.
I
C
Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in chronic coronary artery disease
In patients with syncope and previous STEMI, PES is indicated when syncope remains unexplained after non-invasive evaluation.
I
C
ICD therapy is recommended in patients with CAD, symptomatic heart failure (NYHA class II–III), and LVEF ≤35% despite ≥3 months of OMT.
I
A
In patients with CAD, prophylactic treatment with AADs other than beta-blockers is not recommended.
III
A
ICD implantation is recommended in patients without ongoing ischaemia with documented VF or haemodynamically not-tolerated VT
occurring later than 48 h after MI.
I
A
In patients with CAD and recurrent, symptomatic SMVT or ICD shocks for SMVT despite chronic amiodarone therapy, catheter ablation is recommended in preference to escalating AAD therapy.
I
B
Recommendations for sudden cardiac death prevention in patients with coronary anomalies
Cardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test in patients with anomalous aortic origin of a coronary artery with an interarterial course to conﬁrm/exclude myocardial ischaemia.
I
C
Cardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test after surgery in patients with anomalous aortic origin of a coronary artery with a history of aborted CA.
I
C
Surgery is recommended in patients with anomalous aortic origin of a coronary artery with CA, syncope suspected to be due to VAs or angina when other causes have been excluded.
I
C
Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia
Regular assessment of ventricular function of patients with PVC burden .10% and normal ventricular function is indicated.
I
C
Catheter ablation as ﬁrst-line treatment is recommended for symptomatic idiopathic VT/PVCs from the RVOT or the left fascicles.e
I
B
Beta-blockers or non-dihydropyridine CCB are indicated in symptomatic patients with idiopathic VT/PVCs from an origin other than the RVOT or the left fascicles.
I
C
Catheter ablation is not recommended in children ,5 years of age or ,10 kg weight except when previous medical therapy fails or when VT is not haemodynamically tolerated.
III
C
Amiodarone as a ﬁrst-line treatment is not recommended in patients with idiopathic VTs/PVCs.
III
C
Verapamil is not recommended in children ,1 year of age with PVC/VT, particularly if they have signs of heart failure or concurrent use of other AADs.
III
C
Recommendations for the management of patients with premature ventricular complex-induced or aggravated cardiomyopathy
In patients with a cardiomyopathy suspected to be caused by frequent and predominately monomorphic PVCs, catheter ablation is recommended.
I
C
Continued
ESC Guidelines
4095


<!-- PAGE 100 -->

### Page 100

Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy
Genetic testing (including at least LMNA, PLN, RBM20, and FLNC genes) is recommended in patients with DCM/HNDCM and AV
conduction delay at ,50 years, or who have a family history of DCM/HNDCM or SCD in a ﬁrst-degree relative (at age ,50 years).
I
B
Participation in high-intensity exercise including competitive sports is not recommended for individuals with DCM/HNDCM and a
LMNA mutation.
III
C
ICD implantation is recommended in patients with DCM/HNDCM, who survive SCA due to VT/VF or experience haemodynamically not-tolerated SMVT.
I
B
In a ﬁrst-degree relative of a DCM/HNDCM patient, an ECG, and an echocardiogram are recommended if:
• the index patient was diagnosed ,50 years of age or has clinical features suggestive of an inherited cause, or
• there is family history of DCM/HNDCM, or premature unexpected SD.
I
C
Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention and treatment of ventricular arrhythmia in arrhythmogenic right ventricular cardiomyopathy
In patients with suspected ARVC, CMR is recommended.
I
B
In patients with a suspected or deﬁnite diagnosis of ARVC, genetic counselling and testing are recommended.
I
B
Avoidance of high-intensity exercise is recommended in patients with a deﬁnite diagnosis of ARVC.
I
B
ICD implantation is recommended in ARVC patients with haemodynamically not-tolerated VT or VF.
I
C
In patients with ARVC and non-sustained or sustained VAs, beta-blocker therapy is recommended.
I
C
In a ﬁrst-degree relative of a patient with ARVC, ECG, and echocardiogram are recommended.
I
C
Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in hypertrophic cardiomyopathy
CMR with LGE is recommended in HCM patients for diagnostic work-up.
I
B
Genetic counselling and testing are recommended in HCM patients.
I
B
It is recommended that the 5-year risk of SCD is assessed at ﬁrst evaluation and at 1–3-year intervals or when there is a change in clinical status.
I
C
ICD implantation is recommended in HCM patients with haemodynamically not-tolerated VT or VF.
I
B
In a ﬁrst-degree relative of a patient with HCM, ECG, and echocardiogram are recommended.
I
C
Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in neuromuscular diseases
Annual follow-up with at least a 12-lead ECG is recommended in patients with muscular dystrophies, even in the concealed phase of the disease.
I
C
It is recommended that patients with neuromuscular disorders who have VAs or ventricular dysfunction are treated in the same way for arrhythmia as patients without neuromuscular disorders.
I
C
Invasive electrophysiological evaluation is recommended in patients with myotonic dystrophy and palpitations or syncope suggestive of
VA, VT, or surviving a CA.
I
C
ICD implantation is recommended in patients with myotonic dystrophy and SMVT or aborted CA not caused by BBR-VT.
I
C
In myotonic dystrophy patients, serial electrophysiological evaluation of AV conduction and arrhythmia induction is not recommended without arrhythmia suspicion or progression of ECG conduction disorders.
III
C
In symptomatic patients with BBR-VT, catheter ablation is recommended.
I
C
In patients with myotonic dystrophy undergoing ablation for BBR-VT, pacemaker/ICD implantation is recommended.
I
C
Continued


<!-- PAGE 101 -->

### Page 101

Recommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in myocarditis
In conﬁrmed or clinically suspected acute myocarditis, it is recommended that patients who present with life-threatening VA are referred to a specialized centre.
I
C
In patients with haemodynamically not-tolerated SMVT occurring in the chronic phase of myocarditis, an ICD implantation is recommended.
I
C
Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in cardiac sarcoidosis
ICD implantation is recommended in patients with cardiac sarcoidosis who have an LVEF ≤35%.
I
B
ICD implantation is recommended in patients with cardiac sarcoidosis who (a) have documented sustained VT, or (2) aborted CA.
I
B
Recommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in valvular heart disease
PES with standby catheter ablation is recommended in patients with aortic valve disease and SMVT to identify and ablate BBR-VT,
especially if it occurs following a valve intervention.
I
C
In patients with valvular heart disease and persistent LV dysfunction after surgical correction (if possible) it is recommended that ICD
implantation for primary prevention follows DCM/HNDCM recommendations.
I
C
Recommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in congenital heart disease
In adults with CHD with biventricular physiology and a left systemic ventricle presenting with symptomatic heart failure (NYHA II/III)
and EF ≤35% despite ≥3 months of OMT, ICD implantation is indicated.
I
C
In patients with CHD presenting with sustained VAs, evaluation for residual or new anatomical abnormalities is recommended.
I
B
In patients with CHD with not-tolerated VT/aborted CA due to VF, ICD implantation is indicated after exclusion of reversible causes.
I
C
In patients with repaired TOF who present with SMVT or recurrent, symptomatic appropriate ICD therapy for SMVT, catheter ablation performed in specialized centres is recommended.
I
C
Recommendations for management of patients with idiopathic ventricular ﬁbrillation
It is recommended that idiopathic VF is diagnosed in a SCA survivor, preferably with documentation of VF, after exclusion of an underlying structural, channelopathic, metabolic, or toxicological aetiology.
I
B
ICD implantation is recommended in idiopathic VF.
I
B
Recommendations for management of patients with long QT syndrome
It is recommended that LQTS is diagnosed with either QTc ≥480 ms in repeated 12-lead ECGs with or without symptoms or LQTS
diagnostic score .3.
I
C
In patients with clinically diagnosed long QT syndrome, genetic testing, and genetic counselling are recommended.
I
C
It is recommended that LQTS is diagnosed in the presence of a pathogenic mutation, irrespective of the QT duration.
I
C
Routine diagnostic testing with epinephrine challenge is not recommended in LQTS.
III
C
The following is recommended in LQTS:
• Avoid QT-prolonging drugs.f
• Avoid and correct electrolyte abnormalities.
• Avoid genotype-speciﬁc triggers for arrhythmias.
I
C
Beta-blockers, ideally non-selective beta-blockers (nadolol or propranolol), are recommended in LQTS patients with documented QT
interval prolongation, to reduce risk of arrhythmic events.
I
B
Mexiletine is indicated in LQT3 patients with a prolonged QT interval.
I
C
ICD implantation in addition to beta-blockers is recommended in LQTS patients with CA.
I
B
ICD implantation is recommended in patients with LQTS who are symptomaticg while receiving beta-blockers and genotype-speciﬁc therapies.
I
C
Continued
ESC Guidelines
4097


<!-- PAGE 102 -->

### Page 102

LCSD is indicated in patients with symptomaticg LQTS when: (a) ICD therapy is contraindicated or declined; (b) patient is on beta-blockers and genotype-speciﬁc therapies with an ICD and experiences multiple shocks or syncope due to VA.
I
C
Invasive electrophysiologic study is not recommended in LQTS.
III
C
Recommendations for management of patients with Andersen–Tawil syndrome
Genetic testing is recommended in patients with suspected Andersen–Tawil syndrome.
I
C
ICD implantation is recommended in patients with Andersen–Tawil syndrome after aborted CA not tolerated sustained VT.
I
C
Recommendations for management of patients with Brugada syndrome
It is recommended that BrS is diagnosed in patients with no other heart disease and a spontaneous type 1 Brugada ECG pattern.
I
C
It is recommended that BrS is diagnosed in patients with no other heart disease who have survived a CA due to VF or PVT and exhibit a type 1 Brugada ECG induced by sodium channel blocker challenge or during fever.
I
C
Genetic testing for SCN5A gene is recommended for probands with BrS.
I
C
Sodium channel blocker test is not recommended in patients with a prior type I Brugada pattern.
III
C
The following is recommended in all patients with BrS:
(a) Avoidance of drugs that may induce ST-segment elevation in right precordial leads (http://www.brugadadrugs.org).
(b) Avoidance of cocaine, cannabis, and excessive alcohol intake.
(c) Treatment of fever with antipyretic drugs.
I
C
ICD implantation is recommended in patients with BrS who:
(a) Are survivors of an aborted CA, and/or
(b) Have documented spontaneous sustained VT.
I
C
Catheter ablation in asymptomatic BrS patients is not recommended.
III
C
Recommendations for management of patients with early repolarizaton pattern/syndrome
It is recommended that the ERP is diagnosed as J-point elevation of ≥1 mm in two adjacent inferior and/or lateral ECG leads.
I
C
It is recommended that the ERS is diagnosed in a patient resuscitated from unexplained VF/PVT in the presence of ERP.
I
C
Clinical evaluation is not recommended routinely in asymptomatic subjects with ERP.
III
C
ICD implantation is recommended in patients with a diagnosis of ERS who have survived a CA.
I
B
ICD implantation is not recommended in asymptomatic patients with an isolated ERP.
III
C
Recommendations for management of patients with catecholaminergic polymorphic ventricular tachycardia
It is recommended that CPVT is diagnosed in the presence of a structurally normal heart, normal ECG, and exercise- or emotion-induced bidirectional or PVT.
I
C
It is recommended that CPVT is diagnosed in patients who are carriers of a mutation in disease-causing genes.
I
C
Genetic testing and genetic counselling are indicated in patients with clinical suspicion or clinical diagnosis of CPVT.
I
C
Avoidance of competitive sports, strenuous exercise, and exposure to stressful environments is recommended in all patients with
CPVT.
I
C
Beta-blockers, ideally non-selective (nadolol or propranolol), are recommended in all patients with a clinical diagnosis of CPVT.
I
C
ICD implantation combined with beta-blockers and ﬂecainide is recommended in CPVT patients after aborted CA.
I
C
PES is not recommended for stratiﬁcation of SCD risk.
III
C
Continued


<!-- PAGE 103 -->

### Page 103

### 12 Quality indicators

Quality indicators (QIs) are tools that may be used to evaluate care quality, including structural aspects, process, and outcomes of care.1153 They serve as a mechanism for enhancing adherence to guideline recommendations, through associated quality improvement initiatives and the benchmarking of care providers.1154,1155 As such, the role of QIs in improving care and outcomes is increasingly recognized by healthcare authorities, professional organizations, payers, and the public.1153
The ESC understands the need for measuring and reporting quality and outcomes of cardiovascular care, and has established methods for the development of the ESC QIs for the quantiﬁcation of care and outcomes for cardiovascular disease.1153 In parallel with the writing of this Clinical Practice Guideline document, a process has been initiated to develop QIs for patients with, or at risk of,
VA or SCD using the ESC methodology and through the collaboration with domain experts and the European Heart Rhythm
Association. These QIs, alongside their speciﬁcations and development process, will be published separately.
13. Supplementary data
Supplementary data is available at European Heart Journal online.
14. Data availability statement
No new data were generated or analysed in support of this research.
15. Author information
Author/task force Member Afﬁliations:
Marta de Riva, Cardiology, Leiden University Medical Centre,
Leiden,
Netherlands;
Bo
Gregers
Winkel,
Cardiology,
Recommendations for management of patients with short QT syndrome
It is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic mutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease.
I
C
Genetic testing is indicated in patients diagnosed with SQTS.
I
C
ICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have documented spontaneous sustained VT.
I
C
PES is not recommended for SCD risk stratiﬁcation in SQTS patients.
III
C
Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy
During pregnancy, electrical cardioversion is recommended for sustained VT.
I
C
If ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection.
I
C
Continuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT.
I
C
Recommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes
In athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including echocardiography and/or CMR to conﬁrm (or exclude) an underlying disease are recommended.
I
C
It is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current guidelines for sports eligibility.
I
C
It is recommended that staff at sporting facilities are trained in CPR and in the use of AED.
I
C
© ESC 2022
AAD, anti-arrhythmic drug; ACE-I, angiotensin-converting-enzyme inhibitor; AED, automated external deﬁbrillator; ARB, angiotensin receptor blockers; ARNIs, angiotensin receptor neprilysin inhibitor;
ARVC,
arrhythmogenic right ventricular cardiomyopathy;
ATP,
anti-tachycardia pacing;
AV,
atrioventricular;
BBR-VT,
bundle branch re-entry;
BrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CIED, cardiac implantable electronic devices; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization therapy; DC, direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome;
HCM, hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; CAD, coronary artery disease; ILR, implantable loop recorder; LCSD, left cardiac sympathetic denervation; LGE, late gadolinium enhancement; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction;
MRA, mineralocorticoid receptor antagonist; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; OMT,
optimal medical therapy; PES, programmed electrical stimulation; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow tract; SADS, sudden arrhythmic death syndrome; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SGLT2, sodium–glucose co-transporter 2; SHD,
structural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SQT, short QT syndrome; STEMI, ST-elevation myocardial infarction; SVT, supraventricular tachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cShopping malls, stadiums, public transport stations, casinos.
dList not exhaustive.
eLOE C for VT/PVCs from left fascicles.
fhttp://www.crediblemeds.org gArrhythmic syncope or haemodynamically non-tolerated VA
ESC Guidelines
4099


<!-- PAGE 104 -->

### Page 104

Rigshospitalet,
Copenhagen,
Denmark,
European
Reference
Networks for rare, low prevalence and complex diseases of the heart, ERN-GUARD HEART; Elijah R. Behr, Cardiovascular
Clinical
Academic
Group,
Cardiology
Section,
St
George’s,
University of London, London, United Kingdom, Department of
Cardiology, St George’s University Hospitals NHS Foundation
Trust, London, United Kingdom, and Cardiology, Mayo Clinic
Healthcare, London, United Kingdom; Nico A. Blom, Paediatric
Cardiology,
Leiden
University
Medical
Centre,
Leiden,
Netherlands, and Paediatric Cardiology, Amsterdam University
Medical Center, Amsterdam, Netherlands; Philippe Charron,
APHP, Centre de Référence des Maladies Cardiaques Héréditaires ou Rares, Hôpital Pitié-Salpêtrière, Paris, France, UMR_S 1166, and
ICAN Institute for Cardiometabolism, and Nutrition, Sorbonne
Université, Paris, France, and European Reference Networks for rare,
low prevalence and complex diseases of the heart,
ERN-Guard
HEART,
Paris,
France;
Domenico
Corrado,
Department of Cardiac, Thoracic and Vascular Sciences and Public
Health, University of Padova, Padova, Italy; Nikolaos Dagres,
Department of
Electrophysiology,
Heart
Center
Leipzig at
University of Leipzig, Leipzig, Germany; Christian de Chillou,
Department of Cardiology, CHRU-Nancy, Nancy, France, and
IADI, INSERM U1254, Université de Lorraine, Nancy, France; Lars
Eckardt,
Department of
Cardiology
II—Electrophysiology,
University Hospital Münster, Münster, Germany; Tim Friede,
Department of Medical Statistics, University Medical Center
Goettingen, Goettingen, Germany, and Partner Site Goettingen,
DZHK (German Center for Cardiovascular Research), Goettingen,
Germany; Kristina H. Haugaa, Department of Cardiology, Oslo
University Hospital, Rikshospitalet, Oslo, Norway, and Faculty of
Medicine, University of Oslo, Oslo, Norway; Mélèze Hocini,
Cardiology Department, Liryc Institute, Pessac, France, Hopital
Cardiologique du Haut Lévêque, Pessac, France, and Université de
Bordeaux, Bordeaux, France; Pier D. Lambiase, Institute of
Cardiovascular
Science,
University
College,
London,
United
Kingdom, Barts Heart Centre, St Bartholomews Hospital, London,
United Kingdom, and Heart, Vascular and Thoracic Institute,
Cleveland
Clinic,
London,
United
Kingdom;
Eloi
Marijon,
Cardiology Department, European Georges Pompidou Hospital,
Paris, France; Jose L. Merino, Arrhythmia and Electrophysiology
Robotic Unit, La Paz University Hospital, Universidad Autonoma,
IdiPaz, Madrid, Spain, Cardiology Department, Hospital Ruber Juan
Bravo, Madrid, Spain, and Cardiac Electrophysiology, Hospital
Viamed Santa Elena, Madrid, Spain; Petr Peichl, Cardiology
Department, IKEM, Prague, Czech Republic; Silvia G. Priori,
Molecular Medicine Department, University of Pavia, Pavia, Italy,
Molecular
Cardiology
Department,
Istituti
Clinici
Scientiﬁci
Maugeri
SpA
SB,
Pavia,
Italy,
and
Molecular
Cardiology
Department, Centro Nacional de Investigaciones Cardiovasculares
Carlos III (CNIC), Madrid, Spain, European Reference Networks for rare, low prevalence and complex diseases of the heart, ERNGUARD HEART; Tobias Reichlin, Department of Cardiology,
Inselspital—University Hospital Bern, University of Bern, Bern,
Switzerland;
Jeanette
Schulz-Menger,
Cardiology,
ECRC,
Charité—Universitätsmedizin Berlin, corporate member of Freie
Universität Berlin and Humboldt-Universität zu Berlin, Berlin,
Germany, Cardiology, Helios Clinics Berlin-Buch, Berlin, Germany,
and DZHK Partnersite Berlin, Charité, Berlin, Germany; Christian
Sticherling, Department of Cardiology, University Hospital Basel,
University of Basel, Basel, Switzerland; Stylianos Tzeis, Cardiology
Department, Mitera Hospital, Hygeia Group, Athens, Greece; Axel
Verstrael (Belgium), ESC Patient Forum, Sophia Antipolis, France;
and Maurizio Volterrani, Department of Cardiology, IRCCS San
Raffaele Roma, Rome, Italy, and Professor of Exercise Science and
Medicine, San Raffaele Telematic University of Rome, Rome.
16. Appendix
ESC Scientiﬁc Document Group
Includes Document Reviewers and ESC National Cardiac
Societies.
Document Reviewers: Maja Cikes (CPG Review Coordinator)
(Croatia), Paulus Kirchhof (CPG Review Coordinator) (Germany),
Magdy Abdelhamid (Egypt), Victor Aboyans (France), Elena Arbelo
(Spain), Fernando Arribas (Spain), Riccardo Asteggiano (Italy), Cristina
Basso (Italy), Axel Bauer (Austria), Emanuele Bertaglia (Italy), Tor
Biering-Sørensen (Denmark), Carina Blomström-Lundqvist (Sweden),
Michael A. Borger (Germany), Jelena Čelutkienė (Lithuania), Bernard
Cosyns
(Belgium),
Volkmar
Falk
(Germany),
Laurent
Fauchier
(France), Bulent Gorenek (Turkey), Sigrun Halvorsen (Norway),
Robert Hatala (Slovakia), Hein Heidbuchel (Belgium), Stefan Kaab
(Germany), Aleksandra Konradi (Russian Federation), Konstantinos
C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf
Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech
Republic), Maja-Lisa Løchen (Norway), Lars H. Lund (Sweden),
Andreas Metzner (Germany), Richard Mindham (United Kingdom),
Jens Cosedis Nielsen (Denmark), Tone M. Norekvål (Norway),
Monica Patten (Germany), Eva Prescott (Denmark), Amina Rakisheva
(Kazakhstan), Carol Ann Remme (Netherlands), Ivo Roca-Luque
(Spain), Andrea Sarkozy (Belgium), Daniel Scherr (Austria), Marta
Sitges (Spain), Rhian M. Touyz (Canada/United Kingdom), Nicolas Van
Mieghem (Netherlands), Vedran Velagic (Croatia), Sami Viskin (Israel),
and Paul G. A. Volders (Netherlands).
ESC National Cardiac Societies actively involved in the review process of the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
Algeria: Algerian Society of Cardiology, Brahim Kichou; Armenia:
Armenian Cardiologists Association, Mihran Martirosyan; Austria:
Austrian
Society of
Cardiology,
Daniel
Scherr;
Azerbaijan:
Azerbaijan Society of Cardiology, Farid Aliyev; Belgium: Belgian
Society of Cardiology, Rik Willems; Bosnia and Herzegovina:
Association of Cardiologists of Bosnia and Herzegovina, Nabil Naser;
Bulgaria: Bulgarian Society of Cardiology, Tchavdar Shalganov;
Croatia: Croatian Cardiac Society, Davor Milicic; Cyprus: Cyprus
Society of Cardiology, Theodoros Christophides; Czech Republic:
Czech Society of Cardiology, Josef Kautzner; Denmark: Danish
Society of Cardiology, Jim Hansen; Egypt: Egyptian Society of
Cardiology, Lamyaa Allam; Estonia: Estonian Society of Cardiology,
Priit Kampus; Finland: Finnish Cardiac Society, Juhani Junttila;
France:
French
Society of
Cardiology,
Christophe
Leclercq;
Georgia: Georgian Society of Cardiology, Kakhaber Etsadashvili;
Germany: German Cardiac Society, Daniel Steven; Greece:
Hellenic Society of Cardiology, Konstantinos Gatzoulis; Hungary:


<!-- PAGE 105 -->

### Page 105

Hungarian Society of Cardiology, László Gellér; Iceland: Icelandic
Society of Cardiology, David O. Arnar; Ireland: Irish Cardiac Society,
Joseph Galvin, European Reference Networks for rare, low prevalence and complex diseases of the heart, ERN-GUARD HEART; Israel: Israel
Heart Society, Moti Haim; Italy: Italian Federation of Cardiology, Carlo
Pappone; Kosovo (Republic of): Kosovo Society of Cardiology,
Shpend Elezi; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina
Kerimkulova; Latvia: Latvian Society of Cardiology, Oskars Kalejs;
Lebanon: Lebanese Society of Cardiology, Ali Rabah; Lithuania:
Lithuanian Society of Cardiology, Aras Puodziukynas; Luxembourg:
Luxembourg Society of Cardiology, Carlo Dimmer; Malta: Maltese
Cardiac Society, Mark Adrian Sammut; Moldova (Republic of):
Moldavian Society of Cardiology, Lilia David; Montenegro:
Montenegro Society of Cardiology, Aneta Boskovic; Morocco:
Moroccan
Society of
Cardiology,
Abdelhamid
Moustaghﬁr;
Netherlands: Netherlands Society of Cardiology, Alexander
H. Maass; North Macedonia: North Macedonian Society of
Cardiology,
Lidija
Poposka;
Norway:
Norwegian
Society of
Cardiology, Ole Christian Mjolstad; Poland: Polish Cardiac Society,
Przemysław Mitkowski; Portugal: Portuguese Society of Cardiology,
Leonor Parreira; Romania: Romanian Society of Cardiology, Dragos
Cozma; Russian Federation: Russian Society of Cardiology, Elena
Golukhova; San Marino: San Marino Society of Cardiology,
Roberto Bini; Serbia: Cardiology Society of Serbia, Sinisa Stojkovic;
Slovakia: Slovak Society of Cardiology, Peter Hlivak; Slovenia:
Slovenian Society of Cardiology, Andrej Pernat; Spain: Spanish
Society of Cardiology, Nicasio Perez Castellano; Sweden: Swedish
Society of Cardiology, Pyotr G. Platonov; Switzerland: Swiss
Society of Cardiology, Firat Duru; Syrian Arab Republic: Syrian
Cardiovascular Association, Ahmad Rasheed Al Saadi; Tunisia:
Tunisian Society of Cardiology and Cardio-Vascular Surgery, Sana
Ouali; Turkey: Turkish Society of Cardiology, Sabri Demircan;
Ukraine: Ukrainian Association of Cardiology, Oleg Sychov; and
United Kingdom of Great Britain and Northern Ireland:
British Cardiovascular Society, Alistair Slade.
ESC Clinical Practice Guidelines (CPG) Committee:
Colin Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid
(Egypt),
Victor
Aboyans
(France),
Sotiris
Antoniou
(United
Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas
Baumbach (United Kingdom), Michael A. Borger (Germany), Jelena
Čelutkienė (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet
(France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris
P. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung
(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian
Federation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha
(United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel),
Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Richard
Mindham (United Kingdom), Jens Cosedis Nielsen (Denmark),
Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark),
Amina Rakisheva (Kazakhstan), Marta Sitges (Spain), and Rhian
M. Touyz (Canada/United Kingdom).
17. References
1. Brignole M, Moya A, de Lange FJ, Deharo J-C, Elliott PM, Fanciulli A, et al. 2018 ESC
Guidelines for the diagnosis and management of syncope. Eur Heart J 2018;39:
1883–1948.
2. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.
Heart J 2021;42:3427–3520.
3. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the
European Society of Cardiology (ESC). Eur Heart J 2018;39:119–177.
4. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC
Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021;42:17–96.
5. Wahbi K, Babuty D, Probst V, Wissocque L, Labombarda F, Porcher R, et al.
Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. Eur
Heart J 2017;38:751–758.
6. Bucci E, Testa M, Licchelli L, Frattari A, El Halabieh NA, Gabriele E, et al. A 34-year longitudinal study on long-term cardiac outcomes in DM1 patients with normal
ECG at baseline at an Italian clinical centre. J Neurol 2018;265:885–895.
7. Chong-Nguyen C, Wahbi K, Algalarrondo V, Bécane HM, Radvanyi-Hoffman H,
Arnaud P, et al. Association between mutation size and cardiac involvement in myotonic dystrophy type 1: an analysis of the DM1-heart registry. Circ Cardiovasc
Genet 2017;10:e001526.
8. Sabovic M, Medica I, Logar N, Mandić E, Zidar J, Peterlin B. Relation of CTG expansion and clinical variables to electrocardiogram conduction abnormalities and sudden death in patients with myotonic dystrophy. Neuromuscul Disord 2003;13:
822–826.
9. Clarke
NR,
Kelion
AD,
Nixon
J,
Hilton-Jones
D,
Forfar
JC.
Does cytosine-thymine-guanine (CTG) expansion size predict cardiac events and electrocardiographic progression in myotonic dystrophy? Heart 2001;86:411–416.
10. Melacini P, Villanova C, Menegazzo E, Novelli G, Danieli G, Rizzoli G, et al.
Correlation between cardiac involvement and CTG trinucleotide repeat length in myotonic dystrophy. J Am Coll Cardiol 1995;25:239–245.
11. Lazarus A, Varin J, Ounnoughene Z, Radvanyi H, Junien C, Coste J, et al.
Relationships among electrophysiological ﬁndings and clinical status, heart function,
and extent of DNA mutation in myotonic dystrophy. Circulation 1999;99:
1041–1046.
12. Sansone VA, Brigonzi E, Schoser B, Villani S, Gaeta M, De Ambroggi G, et al. The frequency and severity of cardiac involvement in myotonic dystrophy type 2
(DM2): long-term outcomes. Int J Cardiol 2013;168:1147–1153.
13. Breton R, Mathieu J. Usefulness of clinical and electrocardiographic data for predicting adverse cardiac events in patients with myotonic dystrophy. Can J Cardiol
2009;25:e23–e27.
14. Hermans MCE, Faber CG, Bekkers SCAM, de Die-Smulders CEM, Gerrits MM,
Merkies ISJ, et al. Structural and functional cardiac changes in myotonic dystrophy type1: a cardiovascular magnetic resonance study.J Cardiovasc Magn Reson 2012;14:48.
15. Schmacht L, Traber J, Grieben U, Utz W, Dieringer MA, Kellman P, et al. Cardiac involvement in myotonic dystrophy type 2 patients with preserved ejection fraction: detection by cardiovascular magnetic resonance. Circ Cardiovasc Imaging
2016;9:e004615.
16. Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, et al.
Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008;358:2688–2697.
17. Bhakta D, Groh MR, Shen C, Pascuzzi RM, Groh WJ. Increased mortality with left ventricular systolic dysfunction and heart failure in adults with myotonic dystrophy type 1. Am Heart J 2010;160:1137–1141.
18. Petri H, Ahtarovski KA, Vejlstrup N, Vissing J, Witting N, Køber L, et al. Myocardial
ﬁbrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2014;16:59.
19. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease.
Circulation 2012;125:1043–1052.
20. Stecker EC, Reinier K, Marijon E, Narayanan K, Teodorescu C, Uy-Evanado A, et al.
Public health burden of sudden cardiac death in the United States. Circ Arrhythm
Electrophysiol 2014;7:212–217.
21. Chen LY, Sotoodehnia N, Bůžková P, Lopez FL, Yee LM, Heckbert SR, et al. Atrial
ﬁbrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med 2013;173:29–35.
22. Marijon E, Uy-Evanado A, Dumas F, Karam N, Reinier K, Teodorescu C, et al.
Warning symptoms are associated with survival from sudden cardiac arrest. Ann
Intern Med 2016;164:23–29.
23. Glinge C, Jabbari R, Risgaard B, Lynge TH, Engstrøm T, Albert CM, et al. Symptoms before sudden arrhythmic death syndrome: a nationwide study among the young in
Denmark. J Cardiovasc Electrophysiol 2015;26:761–767.
24. Ågesen FN, Lynge TH, Blanche P, Banner J, Prescott E, Jabbari R, et al. Temporal trends and sex differences in sudden cardiac death in the Copenhagen City
Heart Study. Heart 2021;107:1303–1309.
ESC Guidelines
4101


<!-- PAGE 106 -->

### Page 106

25. Winkel BG, Holst AG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL, et al.
Nationwide study of sudden cardiac death in persons aged 1–35 years. Eur Heart
J 2011;32:983–990.
26. Pilmer CM, Kirsh JA, Hildebrandt D, Krahn AD, Gow RM. Sudden cardiac death in children and adolescents between 1 and 19 years of age. Heart Rhythm 2014;11:
239–245.
27. Risgaard B, Winkel BG, Jabbari R, Behr ER, Ingemann-Hansen O, Thomsen JL, et al.
Burden of sudden cardiac death in persons aged 1 to 49 years: nationwide study in
Denmark. Circ Arrhythm Electrophysiol 2014;7:205–211.
28. Fishman GI, Chugh SS, DiMarco JP, Albert CM, Anderson ME, Bonow RO, et al.
Sudden cardiac death prediction and prevention report from a national heart,
lung, and blood institute and heart rhythm society workshop. Circulation 2010;
122:2335–2348.
29. Wong CX, Brown A, Lau DH, Chugh SS, Albert CM, Kalman JM, et al. Epidemiology of sudden cardiac death: global and regional perspectives. Heart Lung Circ 2019;28:
6–14.
30. Bougouin W, Lamhaut L, Marijon E, Jost D, Dumas F, Deye N, et al. Characteristics and prognosis of sudden cardiac death in Greater Paris: population-based approach from the Paris Sudden Death Expertise Center (Paris-SDEC). Intensive Care Med
2014;40:846–854.
31. Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death. Circulation
2012;125:620–637.
32. Gerber Y, Jacobsen SJ, Frye RL, Weston SA, Killian JM, Roger VL. Secular trends in deaths from cardiovascular diseases: a 25-year community study. Circulation 2006;
113:2285–2292.
33. Krahn AD, Connolly SJ, Roberts RS, Gent M, ATMA Investigators. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J 2004;147:837–840.
34. Becker LB, Han BH, Meyer PM, Wright FA, Rhodes KV, Smith DW, et al. Racial differences in the incidence of cardiac arrest and subsequent survival. The CPR
Chicago Project. N Engl J Med 1993;329:600–606.
35. Zhao D, Post WS, Blasco-Colmenares E, Cheng A, Zhang Y, Deo R, et al. Racial differences in sudden cardiac death. Circulation 2019;139:1688–1697.
36. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen
MJ, Houben LG, et al. Out-of-hospital cardiac arrest in the 1990’s: a populationbased study in the Maastricht area on incidence, characteristics and survival. J Am
Coll Cardiol 1997;30:1500–1505.
37. Lynge TH, Risgaard B, Banner J, Nielsen JL, Jespersen T, Stampe NK, et al.
Nationwide burden of sudden cardiac death: a study of 54,028 deaths in
Denmark. Heart Rhythm 2021;18:1657–1665.
38. Atwood C, Eisenberg MS, Herlitz J, Rea TD. Incidence of EMS-treated out-of-hospital cardiac arrest in Europe. Resuscitation 2005;67:75–80.
39. Empana J-P, Blom MT, Böttiger BW, Dagres N, Dekker JM, Gislason G, et al.
Determinants of occurrence and survival after sudden cardiac arrest—a
European perspective: The ESCAPE-NET project. Resuscitation 2018;124:7–13.
40. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the
Framingham Heart Study. Circulation 2004;110:522–527.
41. Niemeijer MN, van den Berg ME, Leening MJG, Hofman A, Franco OH, Deckers
JW, et al. Declining incidence of sudden cardiac death from 1990–2010 in a general middle-aged and elderly population: the Rotterdam Study. Heart Rhythm 2015;12:
123–129.
42. Lynge TH, Nielsen JL, Blanche P, Gislason G, Torp-Pedersen C, Winkel BG, et al.
Decline in incidence of sudden cardiac death in the young: a 10-year nationwide study of 8756 deaths in Denmark. Europace 2019;21:909–917.
43. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United
States, 1989 to 1998. Circulation 2001;104:2158–2163.
44. Dudas K, Lappas G, Stewart S, Rosengren A. Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). Circulation 2011;123:46–52.
45. Harmon KG, Asif IM, Maleszewski JJ, Owens DS, Prutkin JM, Salerno JC, et al.
Incidence, cause, and comparative frequency of sudden cardiac death in national collegiate athletic association athletes: a decade in review. Circulation 2015;132:
10–19.
46. Risgaard B, Winkel BG, Jabbari R, Glinge C, Ingemann-Hansen O, Thomsen JL, et al.
Sports-related sudden cardiac death in a competitive and a noncompetitive athlete population aged 12 to 49 years: data from an unselected nationwide study in
Denmark. Heart Rhythm 2014;11:1673–1681.
47. Holst AG, Winkel BG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL, et al.
Incidence and etiology of sports-related sudden cardiac death in Denmark—implications for preparticipation screening. Heart Rhythm 2010;7:1365–1371.
48. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006.
Circulation 2009;119:1085–1092.
49. Corrado D, Basso C, Thiene G. Sudden cardiac death in athletes: what is the role of screening? Curr Opin Cardiol 2012;27:41–48.
50. Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE.
Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J
Med 2000;343:1355–1361.
51. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med 1984;311:874–877.
52. Marijon E, Tafﬂet M, Celermajer DS, Dumas F, Perier M-C, Mustaﬁc H, et al.
Sports-related sudden death in the general population. Circulation 2011;124:
672–681.
53. Heidbuchel H, Willems R, Jordaens L, Olshansky B, Carre F, Lozano IF, et al.
Intensive recreational athletes in the prospective multinational ICD sports safety registry: results from the European cohort. Eur J Prev Cardiol 2019;26:764–775.
54. Marijon E, Bougouin W, Périer M-C, Celermajer DS, Jouven X. Incidence of sportsrelated sudden death in France by speciﬁc sports and sex. JAMA 2013;310:642–643.
55. Marijon E, Uy-Evanado A, Reinier K, Teodorescu C, Narayanan K, Jouven X, et al.
Sudden cardiac arrest during sports activity in middle age. Circulation 2015;131:
1384–1391.
56. Bagnall RD, Weintraub RG, Ingles J, Duﬂou J, Yeates L, Lam L, et al. A prospective study of sudden cardiac death among children and young adults. N Engl J Med 2016;
374:2441–2452.
57. Wisten A, Forsberg H, Krantz P, Messner T. Sudden cardiac death in 15-35-year olds in Sweden during 1992-99. J Intern Med 2002;252:529–536.
58. Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certiﬁcate-based review in a large US. community. J Am Coll Cardiol 2004;44:
1268–1275.
59. Winkel BG, Risgaard B, Sadjadieh G, Bundgaard H, Haunsø S, Tfelt-Hansen J.
Sudden cardiac death in children (1–18 years): symptoms and causes of death in a nationwide setting. Eur Heart J 2014;35:868–875.
60. Byrne R, Constant O, Smyth Y, Callagy G, Nash P, Daly K, et al. Multiple source surveillance incidence and aetiology of out-of-hospital sudden cardiac death in a rural population in the West of Ireland. Eur Heart J 2008;29:1418–1423.
61. Eckart RE, Shry EA, Burke AP, McNear JA, Appel DA, Castillo-Rojas LM, et al.
Sudden death in young adults an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol 2011;58:1254–1261.
62. Waldmann V, Karam N, Bougouin W, Sharifzadehgan A, Dumas F, Narayanan K,
et al. Burden of coronary artery disease as a cause of sudden cardiac arrest in the young. J Am Coll Cardiol 2019;73:2118–2120.
63. Waldmann V, Karam N, Rischard J, Bougouin W, Sharifzadehgan A, Dumas F, et al.
Low rates of immediate coronary angiography among young adults resuscitated from sudden cardiac arrest. Resuscitation 2020;147:34–42.
64. Lloyd-Jones DM, Wilson PWF, Larson MG, Beiser A, Leip EP, D’Agostino RB, et al.
Framingham risk score and prediction of lifetime risk for coronary heart disease.
Am J Cardiol 2004;94:20–24.
65. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021
ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J
2021;42:3227–3337.
66. Jouven X, Desnos M, Guerot C, Ducimetière P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999;99:1978–1983.
67. Dekker LRC, Bezzina CR, Henriques JPS, Tanck MW, Koch KT, Alings MW, et al.
Familial sudden death is an important risk factor for primary ventricular ﬁbrillation:
a case-control study in acute myocardial infarction patients. Circulation 2006;114:
1140–1145.
68. Kaikkonen KS, Kortelainen M-L, Linna E, Huikuri HV. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation
2006;114:1462–1467.
69. Jabbari R, Engstrøm T, Glinge C, Risgaard B, Jabbari J, Winkel BG, et al. Incidence and risk factors of ventricular ﬁbrillation before primary angioplasty in patients with ﬁrst ST-elevation myocardial infarction: a nationwide study in Denmark. J
Am Heart Assoc 2015;4:e001399.
70. Friedlander Y, Siscovick DS, Weinmann S, Austin MA, Psaty BM, Lemaitre RN, et al.
Family history as a risk factor for primary cardiac arrest. Circulation 1998;97:
155–160.
71. Deo R, Norby FL, Katz R, Sotoodehnia N, Adabag S, DeFilippi CR, et al.
Development and validation of a sudden cardiac death prediction model for the general population. Circulation 2016;134:806–816.
72. Aro AL, Reinier K, Rusinaru C, Uy-Evanado A, Darouian N, Phan D, et al. Electrical risk score beyond the left ventricular ejection fraction: prediction of sudden cardiac death in the Oregon Sudden Unexpected Death Study and the Atherosclerosis
Risk in Communities Study. Eur Heart J 2017;38:3017–3025.
73. Waks JW, Sitlani CM, Soliman EZ, Kabir M, Ghafoori E, Biggs ML, et al. Global electric heterogeneity risk score for prediction of sudden cardiac death in the general population: the Atherosclerosis Risk in Communities (ARIC) and Cardiovascular
Health (CHS) studies. Circulation 2016;133:2222–2234.


<!-- PAGE 107 -->

### Page 107

74. Yoshinaga M, Ushinohama H, Sato S, Tauchi N, Horigome H, Takahashi H, et al.
Electrocardiographic screening of 1-month-old infants for identifying prolonged
QT intervals. Circ Arrhythm Electrophysiol 2013;6:932–938.
75. Yoshinaga M, Kucho Y, Sarantuya J, Ninomiya Y, Horigome H, Ushinohama H, et al.
Genetic characteristics of children and adolescents with long-QT syndrome diagnosed by school-based electrocardiographic screening programs. Circ Arrhythm
Electrophysiol 2014;7:107–112.
76. Jørgensen T, Jacobsen RK, Toft U, Aadahl M, Glümer C, Pisinger C. Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial. BMJ 2014;348:g3617.
77. Boas R, Sappler N, von Stülpnagel L, Klemm M, Dixen U, Thune JJ, et al. Periodic repolarization dynamics identiﬁes ICD-responders in non-ischemic cardiomyopathy: a DANISH substudy. Circulation 2022;145:754–764.
78. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.
N Engl J Med 2000;342:1778–1785.
79. Barsheshet A, Goldenberg I, O-Uchi J, Moss AJ, Jons C, Shimizu W, et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events:
implications for mutation-speciﬁc response to β-blocker therapy in type 1 long-QT
syndrome. Circulation 2012;125:1988–1996.
80. Wahbi K, Ben Yaou R, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK, et al.
Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation 2019;140:293–302.
81. Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A, et al. A
new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2019;40:1850–1858.
82. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk stratiﬁcation in the long-QT syndrome. N Engl J Med 2003;348:1866–1874.
83. Miron A, Lafreniere-Roula M, Steve Fan C-P, Armstrong KR, Dragulescu A, Papaz
T, et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation 2020;142:217–229.
84. Norrish G, Ding T, Field E, Ziólkowska L, Olivotto I, Limongelli G, et al.
Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM risk-kids). JAMA Cardiol 2019;4:
918–927.
85. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014;35:2010–2020.
86. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J 2014;35:
1925–1931.
87. Collins GS, Reitsma JB, Altman DG, Moons KGM, TRIPOD Group. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis
(TRIPOD): the TRIPOD statement. Circulation 2015;131:211–219.
88. Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al.
Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA 2017;318:1377–1384.
89. Yan S, Gan Y, Jiang N, Wang R, Chen Y, Luo Z, et al. The global survival rate among adult out-of-hospital cardiac arrest patients who received cardiopulmonary resuscitation: a systematic review and meta-analysis. Crit Care 2020;24:61.
90. Hallstrom AP, Ornato JP, Weisfeldt M, Travers A, Christenson J, McBurnie MA,
et al. Public-access deﬁbrillation and survival after out-of-hospital cardiac arrest.
N Engl J Med 2004;351:637–646.
91. Nakashima T, Noguchi T, Tahara Y, Nishimura K, Yasuda S, Onozuka D, et al.
Public-access deﬁbrillation and neurological outcomes in patients with out-of-hospital cardiac arrest in Japan: a population-based cohort study. Lancet
2019;394:2255–2262.
92. Pollack RA, Brown SP, Rea T, Aufderheide T, Barbic D, Buick JE, et al. Impact of bystander automated external deﬁbrillator use on survival and functional outcomes in shockable observed public cardiac arrests. Circulation 2018;137:2104–2113.
93. Kragholm K, Wissenberg M, Mortensen RN, Hansen SM, Malta Hansen C,
Thorsteinsson K, et al. Bystander efforts and 1-year outcomes in out-of-hospital cardiac arrest. N Engl J Med 2017;376:1737–1747.
94. Kitamura T, Kiyohara K, Sakai T, Matsuyama T, Hatakeyama T, Shimamoto T, et al.
Public-access deﬁbrillation and out-of-hospital cardiac arrest in Japan. N Engl J Med
2016;375:1649–1659.
95. Hasselqvist-Ax I, Riva G, Herlitz J, Rosenqvist M, Hollenberg J, Nordberg P, et al.
Early cardiopulmonary resuscitation in out-of-hospital cardiac arrest. N Engl J
Med 2015;372:2307–2315.
96. Marijon E, Bougouin W, Celermajer DS, Perier M-C, Benameur N, Lamhaut L, et al.
Major regional disparities in outcomes after sudden cardiac arrest during sports.
Eur Heart J 2013;34:3632–3640.
97. Karam N, Narayanan K, Bougouin W, Benameur N, Beganton F, Jost D, et al. Major regional differences in Automated External Deﬁbrillator placement and Basic Life
Support training in France: further needs for coordinated implementation.
Resuscitation 2017;118:49–54.
98. Mpotos N, De Wever B, Cleymans N, Raemaekers J, Loeys T, Herregods L, et al.
Repetitive sessions of formative self-testing to refresh CPR skills: a randomised non-inferiority trial. Resuscitation 2014;85:1282–1286.
99. Gundry JW, Comess KA, DeRook FA, Jorgenson D, Bardy GH. Comparison of naive sixth-grade children with trained professionals in the use of an automated external deﬁbrillator. Circulation 1999;100:1703–1707.
100. Blewer AL, Putt ME, Becker LB, Riegel BJ, Li J, Leary M, et al. Video-only cardiopulmonary resuscitation education for high-risk families before hospital discharge: a multicenter pragmatic trial. Circ Cardiovasc Qual Outcomes 2016;9:740–748.
101. Ringh M, Rosenqvist M, Hollenberg J, Jonsson M, Fredman D, Nordberg P, et al.
Mobile-phone dispatch of laypersons for CPR in out-of-hospital cardiac arrest. N
Engl J Med 2015;372:2316–2325.
102. Stroop R, Kerner T, Strickmann B, Hensel M. Mobile phone-based alerting of
CPR-trained volunteers simultaneously with the ambulance can reduce the resuscitation-free interval and improve outcome after out-of-hospital cardiac arrest: a German, population-based cohort study. Resuscitation 2020;147:57–64.
103. Lee SY, Shin SD, Lee YJ, Song KJ, Hong KJ, Ro YS, et al. Text message alert system and resuscitation outcomes after out-of-hospital cardiac arrest: a before-and-after population-based study. Resuscitation 2019;138:198–207.
104. Fordyce CB, Hansen CM, Kragholm K, Dupre ME, Jollis JG, Roettig ML, et al.
Association of public health initiatives with outcomes for out-of-hospital cardiac arrest at home and in public locations. JAMA Cardiol 2017;2:1226–1235.
105. Andelius L, Malta Hansen C, Lippert FK, Karlsson L, Torp-Pedersen C, Kjær Ersbøll
A, et al. Smartphone activation of citizen responders to facilitate deﬁbrillation in out-of-hospital cardiac arrest. J Am Coll Cardiol 2020;76:43–53.
106. Ranthe MF, Winkel BG, Andersen EW, Risgaard B, Wohlfahrt J, Bundgaard H, et al.
Risk of cardiovascular disease in family members of young sudden cardiac death victims. Eur Heart J 2013;34:503–511.
107. Patton KK, Sotoodehnia N, DeFilippi C, Siscovick DS, Gottdiener JS, Kronmal RA.
N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study. Heart Rhythm 2011;8:228–233.
108. Everett BM, Moorthy MV, Tikkanen JT, Cook NR, Albert CM. Markers of myocardial stress, myocardial injury, and subclinical inﬂammation and the risk of sudden death. Circulation 2020;142:1148–1158.
109. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.
Circulation 2002;105:2392–2397.
110. Scott PA, Barry J, Roberts PR, Morgan JM. Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis. Eur J
Heart Fail 2009;11:958–966.
111. Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, et al. Biomarkers of myocardial stress and ﬁbrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail 2014;2:260–268.
112. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, et al.
American Heart Association/American College of Cardiology Foundation/Heart
Rhythm Society scientiﬁc statement on noninvasive risk stratiﬁcation techniques for identifying patients at risk for sudden cardiac death: a scientiﬁc statement from the
American
Heart
Association
Council on
Clinical
Cardiology
Committee on
Electrocardiography and
Arrhythmias and
Council on
Epidemiology and Prevention. Circulation 2008;118:1497–1518.
113. Varma N, Cygankiewicz I, Turakhia MP, Heidbuchel H, Hu Y-F, Chen LY, et al. 2021
ISHNE/HRS/EHRA/APHRS expert collaborative statement on mHealth in arrhythmia management: digital medical tools for heart rhythm professionals: from the international society for holter and noninvasive electrocardiology/heart rhythm society/European heart rhythm association/Asia-Paciﬁc heart rhythm society. Circ
Arrhythm Electrophysiol 2021;14:e009204.
114. Solbiati M, Casazza G, Dipaola F, Barbic F, Caldato M, Montano N, et al. The diagnostic yield of implantable loop recorders in unexplained syncope: a systematic review and meta-analysis. Int J Cardiol 2017;231:170–176.
115. Gatzoulis KA, Arsenos P, Trachanas K, Dilaveris P, Antoniou C, Tsiachris D, et al.
Signal-averaged electrocardiography: past, present, and future. J Arrhythmia 2018;
34:222–229.
116. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modiﬁcation of the task force criteria. Eur Heart J 2010;31:806–814.
117. Giudicessi JR, Ackerman MJ. Exercise testing oversights underlie missed and delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia in young sudden cardiac arrest survivors. Heart Rhythm 2019;16:1232–1239.
118. Roston TM, Kallas D, Davies B, Franciosi S, De Souza AM, Laksman ZW, et al. Burst exercise testing can unmask arrhythmias in patients with incompletely penetrant catecholaminergic polymorphic ventricular tachycardia. JACC Clin Electrophysiol
2021;7:437–441.
ESC Guidelines
4103


<!-- PAGE 108 -->

### Page 108

119. Sy RW, van der Werf C, Chattha IS, Chockalingam P, Adler A, Healey JS, et al.
Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation 2011;124:2187–2194.
120. Binder T. Transthoracic echocardiography and the standard examination of speciﬁc cardiac structures. ESC CardioMed. 3rd ed. Oxford University Press;
2022. p425–431.
121. Haugaa KH, Basso C, Badano LP, Bucciarelli-Ducci C, Cardim N, Gaemperli O, et al.
Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathy—an expert consensus document of the
European
Association of
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017;18:237–253.
122. Haugaa KH, Grenne BL, Eek CH, Ersboll M, Valeur N, Svendsen JH, et al. Strain echocardiography improves risk prediction of ventricular arrhythmias after myocardial infarction. JACC Cardiovasc Imaging 2013;6:841–850.
123. Haugaa KH, Hasselberg NE, Edvardsen T. Mechanical dispersion by strain echocardiography: a predictor of ventricular arrhythmias in subjects with lamin A/C mutations. JACC Cardiovasc Imaging 2015;8:104–106.
124. Ersboll M, Valeur N, Andersen MJ, Mogensen UM, Vinther M, Svendsen JH, et al.
Early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction. JACC Cardiovasc
Imaging 2013;6:851–860.
125. Biering-Sørensen T, Knappe D, Pouleur A-C, Claggett B, Wang PJ, Moss AJ, et al.
Regional longitudinal deformation improves prediction of ventricular tachyarrhythmias in patients with heart failure with reduced ejection fraction: a MADIT-CRT
substudy
(Multicenter
Automatic
Deﬁbrillator
Implantation
Trial-Cardiac
Resynchronization Therapy). Circ Cardiovasc Imaging 2017;10:e005096.
126. Garg R, Friedrich MG. Cardiomyopathies. ESC CardioMed. 3rd ed. Oxford
University Press; 2022, p510–515.
127. Borgquist R, Haugaa KH, Gilljam T, Bundgaard H, Hansen J, Eschen O, et al. The diagnostic performance of imaging methods in ARVC using the 2010 task force criteria. Eur Heart J Cardiovasc Imaging 2014;15:1219–1225.
128. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014
ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:
the task force for the
Diagnosis and
Management of
Hypertrophic
Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;
35:2733–2779.
129. Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. JACC Heart Fail 2017;5:
28–38.
130. Dejgaard LA, Skjølsvik ET, Lie ØH, Ribe M, Stokke MK, Hegbom F, et al. The mitral annulus disjunction arrhythmic syndrome. J Am Coll Cardiol 2018;72:1600–1609.
131. Basso C, Iliceto S, Thiene G, Perazzolo Marra M. Mitral valve prolapse, ventricular arrhythmias, and sudden death. Circulation 2019;140:952–964.
132. Achenbach S. Technology of cardiac computed tomography. ESC CardioMed. 3rd ed. Oxford University Press; 2022, p537–541.
133. Meijboom WB, van Mieghem CAG, Mollet NR, Pugliese F, Weustink AC, van Pelt
N, et al. 64-Slice computed tomography coronary angiography in patients with high,
intermediate, or low pretest probability of signiﬁcant coronary artery disease. J Am
Coll Cardiol 2007;50:1469–1475.
134. Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, et al.
Outcomes of anatomical versus functional testing for coronary artery disease. N
Engl J Med 2015;372:1291–1300.
135. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. Executive summary:
HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace 2013;15:
1389–1406.
136. Govindan M, Batchvarov VN, Raju H, Shanmugam N, Bizrah M, Bastiaenen R, et al.
Utility of high and standard right precordial leads during ajmaline testing for the diagnosis of Brugada syndrome. Heart 2010;96:1904–1908.
137. Churet M, Luttoo K, Hocini M, Haïssaguerre M, Sacher F, Duchateau J. Diagnostic reproducibility of epinephrine drug challenge interpretation in suspected long QT
syndrome. J Cardiovasc Electrophysiol 2019;30:896–901.
138. Rolf S. The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. Eur Heart J 2003;24:1104–1112.
139. Tadros R, Nannenberg EA, Lieve KV, Škorić-Milosavljević D, Lahrouchi N, Lekanne
Deprez RH, et al. Yield and pitfalls of ajmaline testing in the evaluation of unexplained cardiac arrest and sudden unexplained death: single-center experience with 482 families. JACC Clin Electrophysiol 2017;3:1400–1408.
140. Meregalli PG, Ruijter JM, Hofman N, Bezzina CR, Wilde AAM, Tan HL. Diagnostic value of ﬂecainide testing in unmasking SCN5A-related Brugada syndrome.
J Cardiovasc Electrophysiol 2006;17:857–864.
141. Krahn AD, Healey JS, Chauhan VS, Birnie DH, Champagne J, Sanatani S, et al.
Epinephrine infusion in the evaluation of unexplained cardiac arrest and familial sudden death: from the cardiac arrest survivors with preserved Ejection Fraction
Registry. Circ Arrhythm Electrophysiol 2012;5:933–940.
142. Sueda S, Kohno H, Ochi T, Uraoka T. Overview of the acetylcholine spasm provocation test. Clin Cardiol 2015;38:430–438.
143. Takagi Y, Yasuda S, Takahashi J, Tsunoda R, Ogata Y, Seki A, et al. Clinical implications of provocation tests for coronary artery spasm: safety, arrhythmic complications, and prognostic impact: multicentre registry study of the Japanese Coronary
Spasm Association. Eur Heart J 2013;34:258–267.
144. Garratt CJ, Antoniou A, Grifﬁth MJ, Ward DE, Camm AJ. Use of intravenous adenosine in sinus rhythm as a diagnostic test for latent preexcitation. Am J Cardiol
1990;65:868–873.
145. Bourke JP, Richards DA, Ross DL, Wallace EM, McGuire MA, Uther JB. Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: results,
optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol 1991;
18:780–788.
146. Gatzoulis KA, Tsiachris D, Arsenos P, Archontakis S, Dilaveris P, Vouliotis A, et al.
Prognostic value of programmed ventricular stimulation for sudden death in selected high risk patients with structural heart disease and preserved systolic function. Int J Cardiol 2014;176:1449–1451.
147. Gatzoulis KA, Vouliotis A-I, Tsiachris D, Salourou M, Archontakis S, Dilaveris P,
et al. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 2013;6:504–512.
148. Brilakis ES, Shen WK, Hammill SC, Hodge DO, Rea RF, Lexvold NY, et al. Role of programmed ventricular stimulation and implantable cardioverter deﬁbrillators in patients with idiopathic dilated cardiomyopathy and syncope. Pacing Clin
Electrophysiol 2001;24:1623–1630.
149. Brembilla-Perrot B, Suty-Selton C, Beurrier D, Houriez P, Nippert M, de la Chaise
AT, et al. Differences in mechanisms and outcomes of syncope in patients with coronary disease or idiopathic left ventricular dysfunction as assessed by electrophysiologic testing. J Am Coll Cardiol 2004;44:594–601.
150. Schmitt C, Barthel P, Ndrepepa G, Schreieck J, Plewan A, Schömig A, et al. Value of programmed ventricular stimulation for prophylactic internal cardioverterdeﬁbrillator implantation in postinfarction patients preselected by noninvasive risk stratiﬁers. J Am Coll Cardiol 2001;37:1901–1907.
151. Gatzoulis KA, Tsiachris D, Arsenos P, Antoniou C-K, Dilaveris P, Sideris S, et al.
Arrhythmic risk stratiﬁcation in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study. Eur Heart J 2019;40:2940–2949.
152. Denis A, Sacher F, Derval N, Lim HS, Cochet H, Shah AJ, et al. Diagnostic value of isoproterenol testing in arrhythmogenic right ventricular cardiomyopathy. Circ
Arrhythm Electrophysiol 2014;7:590–597.
153. Merino JL, Carmona JR, Fernández-Lozano I, Peinado R, Basterra N, Sobrino JA.
Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implications for catheter ablation. Circulation 1998;98:541–546.
154. Pezawas T, Stix G, Kastner J, Wolzt M, Mayer C, Moertl D, et al. Unexplained syncope in patients with structural heart disease and no documented ventricular arrhythmias:
value of electrophysiologically guided implantable cardioverter deﬁbrillator therapy. Europace 2003;5:305–312.
155. Sroubek J, Probst V, Mazzanti A, Delise P, Hevia JC, Ohkubo K, et al. Programmed ventricular stimulation for risk stratiﬁcation in the Brugada syndrome: a pooled analysis. Circulation 2016;133:622–630.
156. Nayyar S, Downar E, Bhaskaran AP, Massé S, Nanthakumar K. Signature signal strategy: electrogram-based ventricular tachycardia mapping. Heart Rhythm 2020;
17:2000–2009.
157. Lazarus A, Varin J, Babuty D, Anselme F, Coste J, Duboc D. Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study. J Am Coll Cardiol 2002;40:1645–1652.
158. Tandri H, Asimaki A, Abraham T, Dalal D, Tops L, Jain R, et al. Prolonged RV endocardial activation duration: a novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm 2009;6:769–775.
159. Gomes J, Finlay M, Ahmed AK, Ciaccio EJ, Asimaki A, Safﬁtz JE, et al.
Electrophysiological abnormalities precede overt structural changes in arrhythmogenic right ventricular cardiomyopathy due to mutations in desmoplakin-A combined murine and human study. Eur Heart J 2012;33:1942–1953.
160. Orini M, Graham AJ, Srinivasan NT, Campos FO, Hanson BM, Chow A, et al.
Evaluation of the reentry vulnerability index to predict ventricular tachycardia circuits using high-density contact mapping. Heart Rhythm 2020;17:576–583.
161. Jackson N, Gizurarson S, Viswanathan K, King B, Massé S, Kusha M, et al.
Decrement evoked potential mapping: basis of a mechanistic strategy for ventricular tachycardia ablation. Circ Arrhythm Electrophysiol 2015;8:1433–1442.
162. Avella A, d’Amati G, Pappalardo A, Re F, Silenzi PF, Laurenzi F, et al. Diagnostic value of endomyocardial biopsy guided by electroanatomic voltage mapping in arrhythmogenic right ventricular cardiomyopathy/dysplasia.
J
Cardiovasc
Electrophysiol 2008;19:1127–1134.
163. Wilde AAM, Behr ER. Genetic testing for inherited cardiac disease. Nat Rev Cardiol
2013;10:571–583.


<!-- PAGE 109 -->

### Page 109

164. Hosseini SM, Kim R, Udupa S, Costain G, Jobling R, Liston E, et al. Reappraisal of reported genes for sudden arrhythmic death: evidence-based evaluation of gene validity for Brugada syndrome. Circulation 2018;138:1195–1205.
165. Ingles J, Goldstein J, Thaxton C, Caleshu C, Corty EW, Crowley SB, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med
2019;12:e002460.
166. Adler A, Novelli V, Amin AS, Abiusi E, Care M, Nannenberg EA, et al. An international, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome. Circulation 2020;141:418–428.
167. Risgaard B, Jabbari R, Refsgaard L, Holst AG, Haunsø S, Sadjadieh A, et al. High prevalence of genetic variants previously associated with Brugada syndrome in new exome data. Clin Genet 2013;84:489–495.
168. James CA, Jongbloed JDH, Hershberger RE, Morales A, Judge DP, Syrris P, et al. An international evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy (ARVC) using the ClinGen framework. Circ
Genom Precis Med 2021;14:e003273.
169. Lahrouchi N, Tadros R, Crotti L, Mizusawa Y, Postema PG, Beekman L, et al.
Transethnic genome-wide association study provides insights in the genetic architecture and heritability of long QT syndrome. Circulation 2020;142:324–338.
170. Wijeyeratne YD, Tanck MW, Mizusawa Y, Batchvarov V, Barc J, Crotti L, et al.
SCN5A mutation type and a genetic risk score associate variably with Brugada syndrome phenotype in SCN5A families. Circ Genom Precis Med 2020;13:e002911.
171. Harper AR, Goel A, Grace C, Thomson KL, Petersen SE, Xu X, et al. Common genetic variants and modiﬁable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet 2021;53:135–142.
172. Tadros R, Francis C, Xu X, Vermeer AMC, Harper AR, Huurman R, et al. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat Genet 2021;53:128–134.
173. Tadros R, Tan HL, ESCAPE-NET Investigators, El Mathari S, Kors JA, Postema PG,
et al. Predicting cardiac electrical response to sodium-channel blockade and
Brugada syndrome using polygenic risk scores. Eur Heart J 2019;40:3097–3107.
174. Ware JS, Roberts AM, Cook SA. Next generation sequencing for clinical diagnostics and personalised medicine: implications for the next generation cardiologist. Heart
2012;98:276–281.
175. Ashar FN, Mitchell RN, Albert CM, Newton-Cheh C, Brody JA, Müller-Nurasyid M,
et al. A comprehensive evaluation of the genetic architecture of sudden cardiac arrest. Eur Heart J 2018;39:3961–3969.
176. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the
Association for Molecular Pathology. Genet Med 2015;17:405–424.
177. Ingles J, Lind JM, Phongsavan P, Semsarian C. Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy. Genet Med 2008;10:117–120.
178. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA
expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the
Heart Rhythm Society (HRS) and the European Heart Rhythm Association
(EHRA). Europace 2011;13:1077–1109.
179. Conte G, Wilde A, Behr ER, Scherr D, Lenarczyk R, Gandjbachkh E, et al.
Importance of dedicated units for the management of patients with inherited arrhythmia syndromes. Circ Genom Precis Med 2021;14:e003313.
180. Minier M, Probst V, Berthome P, Tixier R, Briand J, Geoffroy O, et al. Age at diagnosis of Brugada syndrome: inﬂuence on clinical characteristics and risk of arrhythmia. Heart Rhythm 2020;17:743–749.
181. Wong LCH, Roses-Noguer F, Till JA, Behr ER. Cardiac evaluation of pediatric relatives in sudden arrhythmic death syndrome: a 2-center experience. Circ
Arrhythm Electrophysiol 2014;7:800–806.
182. Mellor GJ, Blom LJ, Groeneveld SA, Winkel BG, Ensam B, Bargehr J, et al. Familial evaluation in idiopathic ventricular ﬁbrillation: diagnostic yield and signiﬁcance of J
Wave Syndromes. Circ Arrhythm Electrophysiol 2021;14:e009089.
183. Lahrouchi N, Raju H, Lodder EM, Papatheodorou E, Ware JS, Papadakis M, et al.
Utility of post-mortem genetic testing in cases of sudden arrhythmic death syndrome. J Am Coll Cardiol 2017;69:2134–2145.
184. Faber TS, Gradinger R, Treusch S, Morkel C, Brachmann J, Bode C, et al. Incidence of ventricular tachyarrhythmias during permanent pacemaker therapy in low-risk patients results from the German multicentre EVENTS study. Eur Heart J 2007;
28:2238–2242.
185. Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll
Cardiol 1993;21:110–116.
186. Noda T, Shimizu W, Taguchi A, Aiba T, Satomi K, Suyama K, et al. Malignant entity of idiopathic ventricular ﬁbrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outﬂow tract. J Am Coll Cardiol 2005;46:1288–1294.
187. Belhassen B, Viskin S. Idiopathic ventricular tachycardia and ﬁbrillation. J Cardiovasc
Electrophysiol 1993;4:356–368.
188. Zareba W, Platonov P. ECG patterns related to arrhythmias and sudden death:
channelopathies, early repolarization, and pre-excitation. ESC CardioMed. 3rd ed. Oxford University Press; 2022, p382–389.
189. Voigt J-U. Left ventricular function, heart failure, and resynchronization therapy.
ESC CardioMed. 3rd ed. Oxford University Press; 2022, p450–454.
190. Edvardsen T. Cardiomyopathies, myocarditis, and the transplanted heart. ESC
CardioMed. 3rd ed. Oxford University Press; 2022, p456–460.
191. Cygankiewicz I. Ambulatory ECG monitoring. ESC CardioMed. 3rd ed. Oxford
University Press; 2022, p393–400.
192. Gray B, Kirby A, Kabunga P, Freedman SB, Yeates L, Kanthan A, et al. Twelve-lead ambulatory electrocardiographic monitoring in Brugada syndrome: potential diagnostic and prognostic implications. Heart Rhythm 2017;14:866–874.
193. Karogiannis N, Senior R. Stress echocardiography. ESC CardioMed. 3rd ed. Oxford
University Press; 2022, p431–434.
194. Nucifora G, Muser D, Masci PG, Barison A, Rebellato L, Piccoli G, et al. Prevalence and prognostic value of concealed structural abnormalities in patients with apparently idiopathic ventricular arrhythmias of left versus right ventricular origin: a magnetic resonance imaging study. Circ Arrhythm Electrophysiol 2014;7:456–462.
195. Muser D, Nucifora G, Muser D, Nucifora G, Pieroni M, Castro SA, et al. Prognostic value of nonischemic ringlike left ventricular scar in patients with apparently idiopathic nonsustained ventricular arrhythmias. Circulation 2021;143:1359–1373.
196. Josephson ME, Callans DJ. Using the twelve-lead electrocardiogram to localize the site of origin of ventricular tachycardia. Heart Rhythm 2005;2:443–446.
197. Corrado D, Basso C, Leoni L, Tokajuk B, Bauce B, Frigo G, et al. Three-dimensional electroanatomic voltage mapping increases accuracy of diagnosing arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2005;111:3042–3050.
198. Casella M, Dello Russo A, Bergonti M, Catto V, Conte E, Sommariva E, et al.
Diagnostic yield of electroanatomic voltage mapping in guiding endomyocardial biopsies. Circulation 2020;142:1249–1260.
199. Haanschoten DM, Adiyaman A, ‘t Hart NA, Jager PL, Elvan A. Value of 3D mappingguided endomyocardial biopsy in cardiac sarcoidosis: case series and narrative review on the value of electro-anatomic mapping-guided endomyocardial biopsies.
Eur J Clin Invest 2021;51:e13497.
200. Tung R, Bauer B, Schelbert H, Lynch JP, Auerbach M, Gupta P, et al. Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: the potential role of occult inﬂammation in arrhythmogenesis. Heart Rhythm 2015;12:2488–2498.
201. Palmisano A, Vignale D, Peretto G, Busnardo E, Calcagno C, Campochiaro C, et al.
Hybrid FDG-PET/MR or FDG-PET/CT to detect disease activity in patients with persisting arrhythmias after myocarditis. JACC Cardiovasc Imaging 2021;14:
288–292.
202. Venlet J, Piers SRD, Jongbloed JDH, Androulakis AFA, Naruse Y, den Uijl DW, et al.
Isolated subepicardial right ventricular outﬂow tract scar in athletes with ventricular tachycardia. J Am Coll Cardiol 2017;69:497–507.
203. Geri G, Dumas F, Bougouin W, Varenne O, Daviaud F, Pène F, et al. Immediate percutaneous coronary intervention is associated with improved short- and long-term survival after out-of-hospital cardiac arrest. Circ Cardiovasc Interv 2015;8:e002303.
204. Vyas A, Chan PS, Cram P, Nallamothu BK, McNally B, Girotra S. Early coronary angiography and survival after out-of-hospital cardiac arrest. Circ Cardiovasc Interv
2015;8:e002321.
205. Kalarus Z, Svendsen JH, Capodanno D, Dan G-A, De Maria E, Gorenek B, et al.
Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular
Interventions (EAPCI), and European Acute Cardiovascular Care Association
(ACCA). Europace 2019;21:1603–1604.
206. Noc M, Fajadet J, Lassen JF, Kala P, MacCarthy P, Olivecrona GK, et al. Invasive coronary treatment strategies for out-of-hospital cardiac arrest: a consensus statement from the
European association for percutaneous cardiovascular interventions (EAPCI)/stent for life (SFL) groups. EuroIntervention 2014;10:31–37.
207. Verma BR, Sharma V, Shekhar S, Kaur M, Khubber S, Bansal A, et al. Coronary angiography in patients with out-of-hospital cardiac arrest without ST-segment elevation: a systematic review and meta-analysis. JACC Cardiovasc Interv 2020;13:
2193–2205.
208. Barbarawi M, Zayed Y, Kheiri B, Barbarawi O, Al-Abdouh A, Dhillon H, et al.
Optimal timing of coronary intervention in patients resuscitated from cardiac arrest without ST-segment elevation myocardial infarction (NSTEMI): a systematic review and meta-analysis. Resuscitation 2019;144:137–144.
209. Meng-Chang Y, Meng-Jun W, Xiao-Yan X, Peng KL, Peng YG, RuRong W.
Coronary angiography or not after cardiac arrest without ST segment elevation:
a systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22197.
210. Khan MS, Shah SMM, Mubashir A, Khan AR, Fatima K, Schenone AL, et al. Early coronary angiography in patients resuscitated from out of hospital cardiac arrest
ESC Guidelines
4105


<!-- PAGE 110 -->

### Page 110

without ST-segment elevation: a systematic review and meta-analysis. Resuscitation
2017;121:127–134.
211. Welsford M, Bossard M, Shortt C, Pritchard J, Natarajan MK, Belley-Côté EP. Does early coronary angiography improve survival after out-of-hospital cardiac arrest? A
systematic review with meta-analysis. Can J Cardiol 2018;34:180–194.
212. Chelly J, Mongardon N, Dumas F, Varenne O, Spaulding C, Vignaux O, et al. Beneﬁt of an early and systematic imaging procedure after cardiac arrest: insights from the
PROCAT (Parisian Region Out of Hospital Cardiac Arrest) registry. Resuscitation
2012;83:1444–1450.
213. Stiles MK, Wilde AAM, Abrams DJ, Ackerman MJ, Albert CM, Behr ER, et al. 2020
APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Heart Rhythm 2021;18:e1–e50.
214. Tseng ZH, Olgin JE, Vittinghoff E, Ursell PC, Kim AS, Sporer K, et al. Prospective countywide surveillance and autopsy characterization of sudden cardiac death:
POST SCD study. Circulation 2018;137:2689–2700.
215. Fellmann F, van El CG, Charron P, Michaud K, Howard HC, Boers SN, et al.
European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death. Eur J Hum Genet 2019;27:1763–1773.
216. Yamamoto T, Takayama M, Sato N, Yodogawa K, Iwasaki Y-K, Kato K, et al.
Inappropriate analyses of automated external deﬁbrillators used during in-hospital ventricular ﬁbrillation. Circ J 2008;72:679–681.
217. Sweeney MO, Ruetz LL, Belk P, Mullen TJ, Johnson JW, Sheldon T. Bradycardia pacing-induced short-long-short sequences at the onset of ventricular tachyarrhythmias: a possible mechanism of proarrhythmia? J Am Coll Cardiol 2007;50:
614–622.
218. Tseng ZH, Hayward RM, Clark NM, Mulvanny CG, Colburn BJ, Ursell PC, et al.
Sudden death in patients with cardiac implantable electronic devices. JAMA Intern
Med 2015;175:1342–1350.
219. Lacour P, Buschmann C, Storm C, Nee J, Parwani AS, Huemer M, et al. Cardiac implantable electronic device interrogation at forensic autopsy: an underestimated resource? Circulation 2018;137:2730–2740.
220. Curcio A, Mazzanti A, Bloise R, Monteforte N, IndolﬁC, Priori SG, et al. Clinical presentation and outcome of Brugada syndrome diagnosed with the new 2013 criteria. J Cardiovasc Electrophysiol 2016;27:937–943.
221. Haïssaguerre M, Shah DC, Jaïs P, Shoda M, Kautzner J, Arentz T, et al. Role of
Purkinje conducting system in triggering of idiopathic ventricular ﬁbrillation.
Lancet 2002;359:677–678.
222. Krahn AD, Healey JS, Chauhan V, Birnie DH, Simpson CS, Champagne J, et al.
Systematic assessment of patients with unexplained cardiac arrest: cardiac arrest survivors with preserved ejection fraction registry (CASPER). Circulation 2009;
120:278–285.
223. van der Werf C, Hofman N, Tan HL, van Dessel PF, Alders M, van der Wal AC, et al.
Diagnostic yield in sudden unexplained death and aborted cardiac arrest in the young: the experience of a tertiary referral center in The Netherlands. Heart
Rhythm 2010;7:1383–1389.
224. Eckart RE, Scoville SL, Campbell CL, Shry EA, Stajduhar KC, Potter RN, et al.
Sudden death in young adults: a 25-year review of autopsies in military recruits.
Ann Intern Med 2004;141:829–834.
225. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM, et al. An EAPCI
expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on
Coronary
Pathophysiology
&
Microcirculation
Endorsed by
Coronary
Vasomotor Disorders International Study Group. Eur Heart J 2020;41:3504–3520.
226. Rodrigues P, Joshi A, Williams H, Westwood M, Petersen SE, Zemrak F, et al.
Diagnosis and prognosis in sudden cardiac arrest survivors without coronary artery disease: utility of a clinical approach using cardiac magnetic resonance imaging. Circ
Cardiovasc Imaging 2017;10:e006709.
227. White JA, Fine NM, Gula L, Yee R, Skanes A, Klein G, et al. Utility of cardiovascular magnetic resonance in identifying substrate for malignant ventricular arrhythmias.
Circ Cardiovasc Imaging 2012;5:12–20.
228. Basso C, Perazzolo Marra M, Rizzo S, De Lazzari M, Giorgi B, Cipriani A, et al.
Arrhythmic mitral valve prolapse and sudden cardiac death. Circulation 2015;132:
556–566.
229. Obeyesekere MN, Klein GJ, Modi S, Leong-Sit P, Gula LJ, Yee R, et al. How to perform and interpret provocative testing for the diagnosis of Brugada syndrome,
long-QT syndrome, and catecholaminergic polymorphic ventricular tachycardia.
Circ Arrhythm Electrophysiol 2011;4:958–964.
230. Cheung CC, Mellor G, Deyell MW, Ensam B, Batchvarov V, Papadakis M, et al.
Comparison of ajmaline and procainamide provocation tests in the diagnosis of
Brugada syndrome. JACC Clin Electrophysiol 2019;5:504–512.
231. Antzelevitch C, Yan G-X, Ackerman MJ, Borggrefe M, Corrado D, Guo J, et al.
J-Wave syndromes expert consensus conference report: emerging concepts and gaps in knowledge. Europace 2017;19:665–694.
232. Adler A, van der Werf C, Postema PG, Rosso R, Bhuiyan ZA, Kalman JM, et al. The phenomenon of ‘QT stunning’: the abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm 2012;9:901–908.
233. Dionne A, Fournier A, Dahdah N, Abrams D, Khairy P, Abadir S. Dynamic QT
interval changes from supine to standing in healthy children. Can J Cardiol 2018;
34:66–72.
234. Foo FS, Stiles MK, Heaven D. Unmasking latent preexcitation of a right-sided accessory pathway with intravenous adenosine after unexplained sudden cardiac arrest. J
Arrhythm 2020;36:939–941.
235. Marjamaa A, Hiippala A, Arrhenius B, Lahtinen AM, Kontula K, Toivonen L, et al.
Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol 2012;23:194–199.
236. Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen W-K, Porter CJ.
Epinephrine-induced QT interval prolongation: a gene-speciﬁc paradoxical response in congenital long QT syndrome. Mayo Clin Proc 2002;77:413–421.
237. Shimizu W, Noda T, Takaki H, Nagaya N, Satomi K, Kurita T, et al. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm 2004;1:276–283.
238. Magnano AR, Talathoti N, Hallur R, Bloomﬁeld DM, Garan H. Sympathomimetic infusion and cardiac repolarization: the normative effects of epinephrine and isoproterenol in healthy subjects. J Cardiovasc Electrophysiol 2006;17:983–989.
239. Vyas H, Hejlik J, Ackerman MJ. Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response. Circulation 2006;113:1385–1392.
240. Waldmann V, Bougouin W, Karam N, Narayanan K, Sharifzadehgan A, Spaulding C,
et al. Coronary vasospasm-related sudden cardiac arrest in the community. J Am
Coll Cardiol 2018;72:814–815.
241. Etienne P, Huchet F, Gaborit N, Barc J, Thollet A, Kyndt F, et al. Mental stress test: a rapid, simple, and efﬁcient test to unmask long QT syndrome. Europace 2018;20:
2014–2020.
242. Kop WJ, Krantz DS, Nearing BD, Gottdiener JS, Quigley JF, O’Callahan M, et al.
Effects of acute mental stress and exercise on T-wave alternans in patients with implantable cardioverter deﬁbrillators and controls. Circulation 2004;109:1864–1869.
243. Schwartz PJ, Lia C. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation 2011;124:2181–2184.
244. Wang YS, Scheinman MM, Chien WW, Cohen TJ, Lesh MD, Grifﬁn JC. Patients with supraventricular tachycardia presenting with aborted sudden death: incidence,
mechanism and long-term follow-up. J Am Coll Cardiol 1991;18:1711–1719.
245. Roberts JD, Gollob MH, Young C, Connors SP, Gray C, Wilton SB, et al. Bundle branch re-entrant ventricular tachycardia: novel genetic mechanisms in a lifethreatening arrhythmia. JACC Clin Electrophysiol 2017;3:276–288.
246. Santangeli P, Hamilton-Craig C, Dello Russo A, Pieroni M, Casella M, Pelargonio G,
et al. Imaging of scar in patients with ventricular arrhythmias of right ventricular origin: cardiac magnetic resonance versus electroanatomic mapping. J Cardiovasc
Electrophysiol 2011;22:1359–1366.
247. Haïssaguerre M, Duchateau J, Dubois R, Hocini M, Cheniti G, Sacher F, et al.
Idiopathic ventricular ﬁbrillation: role of Purkinje system and microstructural myocardial abnormalities. JACC Clin Electrophysiol 2020;6:591–608.
248. Haïssaguerre M, Hocini M, Cheniti G, Duchateau J, Sacher F, Puyo S, et al. Localized structural alterations underlying a subset of unexplained sudden cardiac death. Circ
Arrhythm Electrophysiol 2018;11:e006120.
249. Mellor G, Laksman ZWM, Tadros R, Roberts JD, Gerull B, Simpson CS, et al.
Genetic testing in the evaluation of unexplained cardiac arrest: from the
CASPER (Cardiac Arrest Survivors With Preserved Ejection Fraction Registry).
Circ Cardiovasc Genet 2017;10:e001686.
250. Burns C, Bagnall RD, Lam L, Semsarian C, Ingles J. Multiple gene variants in hypertrophic cardiomyopathy in the era of next-generation sequencing. Circ Cardiovasc
Genet 2017;10:e001666.
251. Karam N, Jabre P, Narayanan K, Sharifzadehgan A, Perier M-C, Tennenbaum J, et al.
Psychological support and medical screening of ﬁrst-degree relatives of sudden cardiac arrest victims. JACC Clin Electrophysiol 2020;6:586–587.
252. Behr E, Wood DA, Wright M, Syrris P, Sheppard MN, Casey A, et al. Cardiological assessment of ﬁrst-degree relatives in sudden arrhythmic death syndrome. Lancet
2003;362:1457–1459.
253. Tan HL, Hofman N, van Langen IM, van der Wal AC, Wilde AAM. Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. Circulation 2005;112:207–213.
254. Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen
M, et al. Coronary angiography after cardiac arrest without ST-segment elevation.
N Engl J Med 2019;380:1397–1407.
255. Kern KB, Radsel P, Jentzer JC, Seder DB, Lee KS, Lotun K, et al. Randomized pilot clinical trial of early coronary angiography versus no early coronary angiography after cardiac arrest without ST-segment elevation: the PEARL study. Circulation
2020;142:2002–2012.


<!-- PAGE 111 -->

### Page 111

256. Desch S, Freund A, Akin I, Behnes M, Preusch MR, Zelniker TA, et al. Angiography after out-of-hospital cardiac arrest without ST-segment elevation. N Engl J Med
2021;385:2544–2553.
257. Arnaout M, Mongardon N, Deye N, Legriel S, Dumas F, Sauneuf B, et al.
Out-of-hospital cardiac arrest from brain cause: epidemiology, clinical features,
and outcome in a multicenter cohort. Crit Care Med 2015;43:453–460.
258. Horner JM, Horner MM, Ackerman MJ. The diagnostic utility of recovery phase
QTc during treadmill exercise stress testing in the evaluation of long QT syndrome.
Heart Rhythm 2011;8:1698–1704.
259. Perrin MJ, Angaran P, Laksman Z, Zhang H, Porepa LF, Rutberg J, et al. Exercise testing in asymptomatic gene carriers exposes a latent electrical substrate of arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2013;62:1772–1779.
260. Waldmann V, Bougouin W, Karam N, Dumas F, Sharifzadehgan A, Gandjbakhch E,
et al. Characteristics and clinical assessment of unexplained sudden cardiac arrest in the real-world setting: focus on idiopathic ventricular ﬁbrillation. Eur Heart J 2018;
39:1981–1987.
261. Nakao K, Ohgushi M, Yoshimura M, Morooka K, Okumura K, Ogawa H, et al.
Hyperventilation as a speciﬁc test for diagnosis of coronary artery spasm. Am J
Cardiol 1997;80:545–549.
262. Behr ER, Casey A, Sheppard M, Wright M, Bowker TJ, Davies MJ, et al. Sudden arrhythmic death syndrome: a national survey of sudden unexplained cardiac death.
Heart 2007;93:601–605.
263. Basso C, Aguilera B, Banner J, Cohle S, d’Amati G, de Gouveia RH, et al. Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the
Association for European Cardiovascular Pathology. Virchows Arch 2017;471:
691–705.
264. de Noronha SV, Behr ER, Papadakis M, Ohta-Ogo K, Banya W, Wells J, et al. The importance of specialist cardiac histopathological examination in the investigation of young sudden cardiac deaths. Europace 2014;16:899–907.
265. Gulino SP, Burns K, Gunther WM, MacLeod H. Improving forensic pathologic investigation of sudden death in the young. Acad Forensic Pathol 2018;8:347–391.
266. Hansen BL, Jacobsen EM, Kjerrumgaard A, Tfelt-Hansen J, Winkel BG, Bundgaard
H, et al. Diagnostic yield in victims of sudden cardiac death and their relatives.
Europace 2020;22:964–971.
267. Bjune T, Risgaard B, Kruckow L, Glinge C, Ingemann-Hansen O, Leth PM, et al.
Post-mortem toxicology in young sudden cardiac death victims: a nationwide cohort study. Europace 2018;20:614–621.
268. Allan KS, Morrison LJ, Pinter A, Tu JV, Dorian P, Rescu Epistry Investigators.
‘Presumed cardiac’ arrest in children and young adults: a misnomer? Resuscitation
2017;117:73–79.
269. Lahrouchi N, Raju H, Lodder EM, Papatheodorou S, Miles C, Ware JS, et al. The yield of postmortem genetic testing in sudden death cases with structural ﬁndings at autopsy. Eur J Hum Genet 2020;28:17–22.
270. Tester DJ, Medeiros-Domingo A, Will ML, Haglund CM, Ackerman MJ. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsynegative sudden unexplained death referred for postmortem genetic testing.
Mayo Clin Proc 2012;87:524–539.
271. Papadakis M, Raju H, Behr ER, De Noronha SV, Spath N, Kouloubinis A, et al.
Sudden cardiac death with autopsy ﬁndings of uncertain signiﬁcance: potential for erroneous interpretation. Circ Arrhythm Electrophysiol 2013;6:588–596.
272. Jacobsen EM, Hansen BL, Kjerrumgaard A, Tfelt-Hansen J, Hassager C, Kjaergaard J,
et al. Diagnostic yield and long-term outcome of nonischemic sudden cardiac arrest survivors and their relatives: results from a tertiary referral center. Heart Rhythm
2020;17:1679–1686.
273. Kjerrumgaard A, Jacobsen EM, Hansen BL, Tfelt-Hansen J, Winkel BG, Christensen
AH, et al. Diagnostic ﬁndings and follow-up outcomes in relatives to young nonautopsied sudden death victims. Int J Cardiol 2020;318:61–66.
274. Shanks GW, Tester DJ, Ackerman JP, Simpson MA, Behr ER, White SM, et al.
Importance of variant interpretation in whole-exome molecular autopsy:
population-based case series. Circulation 2018;137:2705–2715.
275. Narula N, Tester DJ, Paulmichl A, Maleszewski JJ, Ackerman MJ. Post-mortem
Whole exome sequencing with gene-speciﬁc analysis for autopsy-negative sudden unexplained death in the young: a case series. Pediatr Cardiol 2015;36:768–778.
276. Miles CJ, Behr ER. The role of genetic testing in unexplained sudden death. Transl
Res 2016;168:59–73.
277. Behr ER, Dalageorgou C, Christiansen M, Syrris P, Hughes S, Tome Esteban MT,
et al. Sudden arrhythmic death syndrome: familial evaluation identiﬁes inheritable heart disease in the majority of families. Eur Heart J 2008;29:1670–1680.
278. Kumar S, Peters S, Thompson T, Morgan N, Maccicoca I, Trainer A, et al. Familial cardiological and targeted genetic evaluation: low yield in sudden unexplained death and high yield in unexplained cardiac arrest syndromes. Heart Rhythm 2013;10:
1653–1660.
279. McGorrian C, Constant O, Harper N, O’Donnell C, Codd M, Keelan E, et al.
Family-based cardiac screening in relatives of victims of sudden arrhythmic death syndrome. Europace 2013;15:1050–1058.
280. Mellor G, Raju H, de Noronha SV, Papadakis M, Sharma S, Behr ER, et al. Clinical characteristics and circumstances of death in the sudden arrhythmic death syndrome. Circ Arrhythm Electrophysiol 2014;7:1078–1083.
281. Papadakis M, Papatheodorou E, Mellor G, Raju H, Bastiaenen R, Wijeyeratne Y,
et al. The diagnostic yield of Brugada syndrome after sudden death with normal autopsy. J Am Coll Cardiol 2018;71:1204–1214.
282. Mellor G, Nelson CP, Robb C, Raju H, Wijeyeratne Y, Hengstenberg C, et al. The prevalence and signiﬁcance of the early repolarization pattern in sudden arrhythmic death syndrome families. Circ Arrhythm Electrophysiol 2016;9:e003960.
283. Nunn LM, Lopes LR, Syrris P, Murphy C, Plagnol V, Firman E, et al. Diagnostic yield of molecular autopsy in patients with sudden arrhythmic death syndrome using targeted exome sequencing. Europace 2016;18:888–896.
284. van der Werf C, Stiekema L, Tan HL, Hofman N, Alders M, van der Wal AC, et al.
Low rate of cardiac events in ﬁrst-degree relatives of diagnosis-negative young sudden unexplained death syndrome victims during follow-up. Heart Rhythm 2014;11:
1728–1732.
285. Madhavan M, Friedman PA, Lennon RJ, Prasad A, White RD, Sriram CS, et al.
Implantable cardioverter-deﬁbrillator therapy in patients with ventricular ﬁbrillation out of hospital cardiac arrest secondary to acute coronary syndrome. J Am
Heart Assoc 2015;4:e001255.
286. Wyse DG, Friedman PL, Brodsky MA, Beckman KJ, Carlson MD, Curtis AB, et al.
Life-threatening ventricular arrhythmias due to transient or correctable causes:
high risk for death in follow-up. J Am Coll Cardiol 2001;38:1718–1724.
287. Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G, et al.
Serum potassium levels and mortality in acute myocardial infarction. JAMA 2012;
307:157–164.
288. Hoppe LK, Muhlack DC, Koenig W, Carr PR, Brenner H, Schöttker B. Association of abnormal serum potassium levels with arrhythmias and cardiovascular mortality:
a systematic review and meta-analysis of observational studies. Cardiovasc Drugs
Ther 2018;32:197–212.
289. Ravn Jacobsen M, Jabbari R, Glinge C, Kjær Stampe N, Butt JH, Blanche P, et al.
Potassium disturbances and risk of ventricular ﬁbrillation among patients with
ST-segment-elevation myocardial infarction. J Am Heart Assoc 2020;9:e014160.
290. Ahmed W, Flynn MA, Alpert MA. Cardiovascular complications of weight reduction diets. Am J Med Sci 2001;321:280–284.
291. Stephenson V. In pharmacy nursing—a dynamic new ﬁeld. Nurs RSA 1988;3:51–53.
292. Dumas F, Cariou A, Manzo-Silberman S, Grimaldi D, Vivien B, Rosencher J, et al.
Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region
Out of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv 2010;3:200–207.
293. Gibbs C, Thalamus J, Heldal K, Holla ØL, Haugaa KH, Hysing J. Predictors of mortality in high-risk patients with QT prolongation in a community hospital. Europace
2018;20:f99–f107.
294. Simpson TF, Salazar JW, Vittinghoff E, Probert J, Iwahashi A, Olgin JE, et al.
Association of QT-prolonging medications with risk of autopsy-deﬁned causes of sudden death. JAMA Intern Med 2020;180:698–706.
295. Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, Gottlieb S, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988;77:392–397.
296. Ladejobi A, Pasupula DK, Adhikari S, Javed A, Durrani AF, Patil S, et al. Implantable deﬁbrillator therapy in cardiac arrest survivors with a reversible cause. Circ Arrhythm
Electrophysiol 2018;11:e005940.
297. Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm 2009;6:1335–1341.
298. Schupp T, Behnes M, von Zworowsky M, Kim S-H, Weidner K, Rusnak J, et al.
Hypokalemia but not hyperkalemia is associated with recurrences of ventricular tachyarrhythmias in ICD recipients. Clin Lab 2020;66.
299. Gupta A, Pasupula DK, Bhonsale A, Kancharla K, Wang NC, Adelstein E, et al.
Implantable cardioverter-deﬁbrillator therapy in device recipients who survived a cardiac arrest associated with a reversible cause. J Cardiovasc Electrophysiol 2018;
29:1413–1417.
300. Marill KA, Wolfram S, Desouza IS, Nishijima DK, Kay D, Setnik GS, et al. Adenosine for wide-complex tachycardia: efﬁcacy and safety. Crit Care Med 2009;37:
2512–2518.
301. Lerman BB, Belardinelli L, West GA, Berne RM, DiMarco JP. Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity.
Circulation 1986;74:270–280.
302. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomström-Lundqvist C, et al.
655–720.
303. Ortiz M, Martín A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, et al.
Randomized comparison of intravenous procainamide vs. intravenous amiodarone
ESC Guidelines
4107


<!-- PAGE 112 -->

### Page 112

for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study.
Eur Heart J 2017;38:1329–1335.
304. Gill JS, Mehta D, Ward DE, Camm AJ. Efﬁcacy of ﬂecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality. Br Heart J 1992;68:392–397.
305. Manz M, Mletzko R, Jung W, Lüderitz B. Electrophysiological and haemodynamic effects of lidocaine and ajmaline in the management of sustained ventricular tachycardia. Eur Heart J 1992;13:1123–1128.
306. Buxton AE, Marchlinski FE, Doherty JU, Cassidy DM, Vassallo JA, Flores BT, et al.
Repetitive, monomorphic ventricular tachycardia: clinical and electrophysiologic characteristics in patients with and patients without organic heart disease. Am J
Cardiol 1984;54:997–1002.
307. Grifﬁth MJ, Garratt CJ, Rowland E, Ward DE, Camm AJ. Effects of intravenous adenosine on verapamil-sensitive ‘idiopathic’ ventricular tachycardia. Am J Cardiol
1994;73:759–764.
308. Buxton AE, Marchlinski FE, Doherty JU, Flores B, Josephson ME. Hazards of intravenous verapamil for sustained ventricular tachycardia. Am J Cardiol 1987;59:
1107–1110.
309. Rankin AC, Rae AP, Cobbe SM. Misuse of intravenous verapamil in patients with ventricular tachycardia. Lancet 1987;2:472–474.
310. Pedersen CT, Kay GN, Kalman J, Borggrefe M, Della-Bella P, Dickfeld T, et al.
EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Europace 2014;
16:1257–1283.
311. Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, et al. 2019 HRS/
EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace 2019;21:1143–1144.
312. Kowlgi GN, Cha Y-M. Management of ventricular electrical storm: a contemporary appraisal. Europace 2020;22:1768–1780.
313. Guerra F, Shkoza M, Scappini L, Flori M, Capucci A. Role of electrical storm as a mortality and morbidity risk factor and its clinical predictors: a meta-analysis.
Europace 2014;16:347–353.
314. Noda T, Kurita T, Nitta T, Chiba Y, Furushima H, Matsumoto N, et al. Signiﬁcant impact of electrical storm on mortality in patients with structural heart disease and an implantable cardiac deﬁbrillator. Int J Cardiol 2018;255:85–91.
315. Soar J, Maconochie I, Wyckoff MH, Olasveengen TM, Singletary EM, Greif R, et al.
2019 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations: summary from the basic life support; advanced life support; pediatric life support; neonatal life support; education, implementation, and teams; and ﬁrst aid task forces. Circulation
2019;140:e826–e880.
316. Eiﬂing M, Razavi M, Massumi A. The evaluation and management of electrical storm.
Tex Heart Inst J 2011;38:111–121.
317. Chatzidou S, Kontogiannis C, Tsilimigras DI, Georgiopoulos G, Kosmopoulos M,
Papadopoulou E, et al. Propranolol versus metoprolol for treatment of electrical storm in patients with implantable cardioverter-deﬁbrillator. J Am Coll Cardiol
2018;71:1897–1906.
318. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter deﬁbrillators: the OPTIC Study: a randomized trial.
JAMA 2006;295:165–171.
319. Shiga T, Ikeda T, Shimizu W, Kinugawa K, Sakamoto A, Nagai R, et al. Efﬁcacy and safety of landiolol in patients with ventricular tachyarrhythmias with or without renal impairment – subanalysis of the J-Land II study. Circ Rep 2020;2:440–445.
320. Kanamori K, Aoyagi T, Mikamo T, Tsutsui K, Kunishima T, Inaba H, et al. Successful treatment of refractory electrical storm with landiolol after more than 100 electrical deﬁbrillations. Int Heart J 2015;56:555–557.
321. Gorgels AP, van den Dool A, Hofs A, Mulleneers R, Smeets JL, Vos MA, et al.
Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol 1996;78:43–46.
322. Martí-Carvajal AJ, Simancas-Racines D, Anand V, Bangdiwala S. Prophylactic lidocaine for myocardial infarction. Cochrane Database Syst Rev 2015;2015:CD008553.
323. Viskin S, Chorin E, Viskin D, Hochstadt A, Halkin A, Tovia-Brodie O, et al.
Quinidine-responsive polymorphic ventricular tachycardia in patients with coronary heart disease. Circulation 2019;139:2304–2314.
324. Viskin S, Hochstadt A, Chorin E, Viskin D, Havakuk O, Khoury S, et al.
Quinidine-responsive out-of-hospital polymorphic ventricular tachycardia in patients with coronary heart disease. Europace 2020;22:265–273.
325. Martins RP, Urien J-M, Barbarot N, Rieul G, Sellal J-M, Borella L, et al. Effectiveness of deep sedation for patients with intractable electrical storm refractory to antiarrhythmic drugs. Circulation 2020;142:1599–1601.
326. Fudim M, Boortz-Marx R, Ganesh A, Waldron NH, Qadri YJ, Patel CB, et al. Stellate ganglion blockade for the treatment of refractory ventricular arrhythmias: a systematic review and meta-analysis. J Cardiovasc Electrophysiol 2017;28:1460–1467.
327. Do DH, Bradﬁeld J, Ajijola OA, Vaseghi M, Le J, Rahman S, et al. Thoracic epidural anesthesia can be effective for the short-term management of ventricular tachycardia storm. J Am Heart Assoc 2017;6:e007080.
328. Vaseghi M, Barwad P, Malavassi Corrales FJ, Tandri H, Mathuria N, Shah R, et al.
Cardiac sympathetic denervation for refractory ventricular arrhythmias. J Am Coll
Cardiol 2017;69:3070–3080.
329. Gatzoulis KA, Andrikopoulos GK, Apostolopoulos T, Sotiropoulos E, Zervopoulos
G, Antoniou J, et al. Electrical storm is an independent predictor of adverse longterm outcome in the era of implantable deﬁbrillator therapy. Europace 2005;7:
184–192.
330. Carbucicchio C, Santamaria M, Trevisi N, Maccabelli G, Giraldi F, Fassini G, et al.
Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-deﬁbrillators: short- and long-term outcomes in a prospective singlecenter study. Circulation 2008;117:462–469.
331. Vergara P, Tung R, Vaseghi M, Brombin C, Frankel DS, Di Biase L, et al. Successful ventricular tachycardia ablation in patients with electrical storm reduces recurrences and improves survival. Heart Rhythm 2018;15:48–55.
332. Komatsu Y, Hocini M, Nogami A, Maury P, Peichl P, Iwasaki Y, et al. Catheter ablation of refractory ventricular ﬁbrillation storm after myocardial infarction: a multicenter study. Circulation 2019;139:2315–2325.
333. Knecht S, Sacher F, Wright M, Hocini M, Nogami A, Arentz T, et al. Long-term follow-up of idiopathic ventricular ﬁbrillation ablation: a multicenter study. J Am
Coll Cardiol 2009;54:522–528.
334. Peichl P, Cihák R, Kozeluhová M, Wichterle D, Vancura V, Kautzner J. Catheter ablation of arrhythmic storm triggered by monomorphic ectopic beats in patients with coronary artery disease. J Interv Card Electrophysiol 2010;27:51–59.
335. Le Pennec-Prigent S, Flecher E, Auffret V, Leurent G, Daubert J-C, Leclercq C, et al.
Effectiveness of extracorporeal life support for patients with cardiogenic shock due to intractable arrhythmic storm. Crit Care Med 2017;45:e281–e289.
336. Mariani S, Napp LC, Lo Coco V, Delnoij TSR, Luermans JGLM, Ter Bekke RMA,
et al. Mechanical circulatory support for life-threatening arrhythmia: a systematic review. Int J Cardiol 2020;308:42–49.
337. Muser D, Liang JJ, Castro SA, Hayashi T, Enriquez A, Troutman GS, et al. Outcomes with prophylactic use of percutaneous left ventricular assist devices in high-risk patients undergoing catheter ablation of scar-related ventricular tachycardia: a propensity-score matched analysis. Heart Rhythm 2018;15:1500–1506.
338. Mathuria N, Wu G, Rojas-Delgado F, Shuraih M, Razavi M, Civitello A, et al.
Outcomes of pre-emptive and rescue use of percutaneous left ventricular assist device in patients with structural heart disease undergoing catheter ablation of ventricular tachycardia. J Interv Card Electrophysiol 2017;48:27–34.
339. Patel KK, Spertus JA, Khariton Y, Tang Y, Curtis LH, Chan PS, et al. Association between prompt deﬁbrillation and epinephrine treatment with long-term survival after in-hospital cardiac arrest. Circulation 2018;137:2041–2051.
340. Vaseghi M, Gima J, Kanaan C, Ajijola OA, Marmureanu A, Mahajan A, et al. Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: Intermediate and long-term follow-up. Heart Rhythm 2014;11:
360–366.
341. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:
the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–2200.
342. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Eur Heart J 2021;42:3599–3726.
343. AlJaroudi WA, Refaat MM, Habib RH, Al-Shaar L, Singh M, Gutmann R, et al. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac deﬁbrillator shock in patients with severe systolic heart failure
(from the GRADE Multicenter Study). Am J Cardiol 2015;115:924–931.
344. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321.
345. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med
2014;371:993–1004.
346. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.
Cardiovascular and renal outcomes with empagliﬂozin in heart failure. N Engl J
Med 2020;383:1413–1424.
347. Desai AS, McMurray JJV, Packer M, Swedberg K, Rouleau JL, Chen F, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015;36:1990–1997.
348. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.
(EACTS): The task force for the diagnosis and management of atrial ﬁbrillation of


<!-- PAGE 113 -->

### Page 113

the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;
42:373–498.
349. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable deﬁbrillator study (CIDS): a randomized trial of the implantable cardioverter deﬁbrillator against amiodarone. Circulation 2000;101:1297–1302.
350. Antiarrhythmics versus Implantable Deﬁbrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable deﬁbrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576–1583.
351. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable deﬁbrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:
748–754.
352. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al.
Meta-analysis of the implantable cardioverter deﬁbrillator secondary prevention trials.
AVID,
CASH
and
CIDS
studies.
Antiarrhythmics vs
Implantable
Deﬁbrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable
Deﬁbrillator Study. Eur Heart J 2000;21:2071–2078.
353. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted deﬁbrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933–1940.
354. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a deﬁbrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883.
355. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Haﬂey G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;
341:1882–1890.
356. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-deﬁbrillator for congestive heart failure. N Engl J Med
2005;352:225–237.
357. Zabel M, Willems R, Lubinski A, Bauer A, Brugada J, Conen D, et al. Clinical effectiveness of primary prevention implantable cardioverter-deﬁbrillators: results of the
EU-CERT-ICD controlled multicentre cohort study. Eur Heart J 2020;41:
3437–3447.
358. Schrage B, Uijl A, Benson L, Westermann D, Ståhlberg M, Stolfo D, et al.
Association between use of primary-prevention implantable cardioverterdeﬁbrillators and mortality in patients with heart failure: a prospective propensity score-matched analysis from the Swedish Heart Failure Registry. Circulation 2019;
140:1530–1539.
359. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Deﬁbrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;
375:1221–1230.
360. Jukema JW, Timal RJ, Rotmans JI, Hensen LCR, Buiten MS, de Bie MK, et al.
Prophylactic use of implantable cardioverter-deﬁbrillators in the prevention of sudden cardiac death in dialysis patients. Circulation 2019;139:2628–2638.
361. Sticherling C, Arendacka B, Svendsen JH, Wijers S, Friede T, Stockinger J, et al. Sex differences in outcomes of primary prevention implantable cardioverterdeﬁbrillator therapy: combined registry data from eleven European countries.
Europace 2018;20:963–970.
362. Junttila MJ, Pelli A, Kenttä TV, Friede T, Willems R, Bergau L, et al. Appropriate shocks and mortality in patients with versus without diabetes with prophylactic implantable cardioverter deﬁbrillators. Diabetes Care 2020;43:196–200.
363. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death without prior appropriate implantable cardioverter-deﬁbrillator therapy: a competing risk study. Circulation 2008;117:1918–1926.
364. Cleland JGF, Halliday BP, Prasad SK. Selecting patients with nonischemic dilated cardiomyopathy for ICDs: myocardial function, ﬁbrosis, and what’s attached? J Am Coll
Cardiol 2017;70:1228–1231.
365. Younis A, Goldberger JJ, Kutyifa V, Zareba W, Polonsky B, Klein H, et al. Predicted beneﬁt of an implantable cardioverter-deﬁbrillator: the MADIT-ICD beneﬁt score.
Eur Heart J 2021;42:1676–1684.
366. Knops RE, Olde Nordkamp LRA, Delnoy P-PHM, Boersma LVA, Kuschyk J,
El-Chami MF, et al. Subcutaneous or transvenous deﬁbrillator therapy. N Engl J
Med 2020;383:526–536.
367. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al.
The effect of cardiac resynchronization on morbidity and mortality in heart failure.
N Engl J Med 2005;352:1539–1549.
368. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al.
Cardiac-resynchronization therapy with or without an implantable deﬁbrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–2150.
369. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al.
Cardiac-resynchronization therapy for the prevention of heart-failure events. N
Engl J Med 2009;361:1329–1338.
370. Masri A, Altibi AM, Erqou S, Zmaili MA, Saleh A, Al-Adham R, et al. Wearable cardioverter-deﬁbrillator therapy for the prevention of sudden cardiac death: a systematic review and meta-analysis. JACC Clin Electrophysiol 2019;5:152–161.
371. Garcia R, Combes N, Defaye P, Narayanan K, Guedon-Moreau L, Boveda S, et al.
Wearable cardioverter-deﬁbrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study. Europace 2021;23:73–81.
372. Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, et al. Wearable cardioverter-deﬁbrillator after myocardial infarction. N Engl J Med 2018;379:
1205–1215.
373. Scott PA, Silberbauer J, McDonagh TA, Murgatroyd FD. Impact of prolonged implantable cardioverter-deﬁbrillator arrhythmia detection times on outcomes: a meta-analysis. Heart Rhythm 2014;11:828–835.
374. Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV. Impact of programming strategies aimed at reducing nonessential implantable cardioverter deﬁbrillator therapies on mortality: a systematic review and meta-analysis. Circ Arrhythm
Electrophysiol 2014;7:164–170.
375. Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A, et al. Programming implantable cardioverter-deﬁbrillators in patients with primary prevention indication to prolong time to ﬁrst shock: results from the PROVIDE study. J Cardiovasc
Electrophysiol 2014;25:52–59.
376. Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, et al. 2015
HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-deﬁbrillator programming and testing. Europace 2016;18:
159–183.
377. Stiles MK, Fauchier L, Morillo CA, Wilkoff BL, ESC Scientiﬁc Document Group.
2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-deﬁbrillator programming and testing.
Europace 2019;21:1442–1443.
378. Barsheshet A, Moss AJ, McNitt S, Jons C, Glikson M, Klein HU, et al. Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-deﬁbrillator. Heart Rhythm 2011;8:212–218.
379. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al.
Dual-chamber pacing or ventricular backup pacing in patients with an implantable deﬁbrillator: the Dual Chamber and VVI Implantable Deﬁbrillator (DAVID) Trial.
JAMA 2002;288:3115–3123.
380. Olshansky B, Day JD, Moore S, Gering L, Rosenbaum M, McGuire M, et al. Is dualchamber programming inferior to single-chamber programming in an implantable cardioverter-deﬁbrillator?
Results of the
INTRINSIC
RV
(Inhibition of
Unnecessary RV Pacing With AVSH in ICDs) study. Circulation 2007;115:9–16.
381. Hindricks G, Kühl M, Dagres N. The implantable cardioverter deﬁbrillator, conclusions on sudden cardiac death, and future perspective. ESC CardioMed. 3rd ed.
Oxford University Press; 2022, p2370–2376.
382. Gasparini M, Proclemer A, Klersy C, Kloppe A, Ferrer JBM, Hersi A, et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverterdeﬁbrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA 2013;309:1903–1911.
383. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al.
Reduction in inappropriate therapy and mortality through ICD programming. N
Engl J Med 2012;367:2275–2283.
384. Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM, et al. A
comparison of empiric to physician-tailored programming of implantable cardioverter-deﬁbrillators: results from the prospective randomized multicenter
EMPIRIC trial. J Am Coll Cardiol 2006;48:330–339.
385. Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, et al. Strategic programming of detection and therapy parameters in implantable cardioverterdeﬁbrillators reduces shocks in primary prevention patients: results from the
PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol
2008;52:541–550.
386. Gilliam FR, Hayes DL, Boehmer JP, Day J, Heidenreich PA, Seth M, et al. Real world evaluation of dual-zone ICD and CRT-D programming compared to single-zone programming: the ALTITUDE REDUCES study. J Cardiovasc Electrophysiol 2011;
22:1023–1029.
387. Hernandez-Ojeda J, Arbelo E, Borras R, Berne P, Tolosana JM, Gomez-Juanatey A,
et al. Patients with Brugada syndrome and implanted cardioverter-deﬁbrillators:
long-term follow-up. J Am Coll Cardiol 2017;70:1991–2002.
388. Gold MR, Weiss R, Theuns DAMJ, Smith W, Leon A, Knight BP, et al. Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-deﬁbrillator. Heart Rhythm 2014;11:1352–1358.
389. Mesquita J, Cavaco D, Ferreira A, Lopes N, Santos PG, Carvalho MS, et al.
Effectiveness of subcutaneous implantable cardioverter-deﬁbrillators and determinants of inappropriate shock delivery. Int J Cardiol 2017;232:176–180.
390. Gold MR, Lambiase PD, El-Chami MF, Knops RE, Aasbo JD, Bongiorni MG, et al.
Primary results from the understanding outcomes with the S-ICD in primary prevention patients with low ejection fraction (UNTOUCHED) trial. Circulation 2021;
143:7–17.
ESC Guidelines
4109


<!-- PAGE 114 -->

### Page 114

### 391 Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO,

et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-deﬁbrillators: Pacing Fast Ventricular Tachycardia Reduces
Shock Therapies (PainFREE Rx II) trial results. Circulation 2004;110:2591–2596.
392. Gulizia MM, Piraino L, Scherillo M, Puntrello C, Vasco C, Scianaro MC, et al. A randomized study to compare ramp versus burst antitachycardia pacing therapies to treat fast ventricular tachyarrhythmias in patients with implantable cardioverter deﬁbrillators: the PITAGORA ICD trial. Circ Arrhythm Electrophysiol 2009;2:146–153.
393. Saxon LA, Hayes DL, Gilliam FR, Heidenreich PA, Day J, Seth M, et al. Long-term outcome after ICD and CRT implantation and inﬂuence of remote device followup: the ALTITUDE survival study. Circulation 2010;122:2359–2367.
394. Varma N, Piccini JP, Snell J, Fischer A, Dalal N, Mittal S. The relationship between level of adherence to automatic wireless remote monitoring and survival in pacemaker and deﬁbrillator patients. J Am Coll Cardiol 2015;65:2601–2610.
395. Guédon-Moreau L, Kouakam C, Klug D, Marquié C, Brigadeau F, Boulé S, et al.
Decreased delivery of inappropriate shocks achieved by remote monitoring of
ICD: a substudy of the ECOST trial. J Cardiovasc Electrophysiol 2014;25:763–770.
396. Varma N, Michalski J, Epstein AE, Schweikert R. Automatic remote monitoring of implantable cardioverter-deﬁbrillator lead and generator performance: the
Lumos-T Safely RedUceS RouTine Ofﬁce Device Follow-Up (TRUST) trial. Circ
Arrhythm Electrophysiol 2010;3:428–436.
397. Ploux S, Swerdlow CD, Strik M, Welte N, Klotz N, Ritter P, et al. Towards eradication of inappropriate therapies for ICD lead failure by combining comprehensive remote monitoring and lead noise alerts. J Cardiovasc Electrophysiol 2018;29:
1125–1134.
398. Ellenbogen KA, Gunderson BD, Stromberg KD, Swerdlow CD. Performance of
Lead Integrity Alert to assist in the clinical diagnosis of implantable cardioverter deﬁbrillator lead failures: analysis of different implantable cardioverter deﬁbrillator leads. Circ Arrhythm Electrophysiol 2013;6:1169–1177.
399. Swerdlow CD, Gunderson BD, Ousdigian KT, Abeyratne A, Sachanandani H,
Ellenbogen KA. Downloadable software algorithm reduces inappropriate shocks caused by implantable cardioverter-deﬁbrillator lead fractures: a prospective study.
Circulation 2010;122:1449–1455.
400. Ruwald MH, Abu-Zeitone A, Jons C, Ruwald A-C, McNitt S, Kutyifa V, et al. Impact of carvedilol and metoprolol on inappropriate implantable cardioverterdeﬁbrillator therapy: the MADIT-CRT trial (Multicenter Automatic Deﬁbrillator
Implantation With Cardiac Resynchronization Therapy). J Am Coll Cardiol 2013;
62:1343–1350.
401. Miyazaki S, Taniguchi H, Kusa S, Komatsu Y, Ichihara N, Takagi T, et al. Catheter ablation of atrial tachyarrhythmias causing inappropriate implantable cardioverterdeﬁbrillator shocks. Europace 2015;17:289–294.
402. Mainigi SK, Almuti K, Figueredo VM, Guttenplan NA, Aouthmany A, Smukler J, et al.
Usefulness of radiofrequency ablation of supraventricular tachycardia to decrease inappropriate shocks from implantable cardioverter-deﬁbrillators. Am J Cardiol
2012;109:231–237.
403. Kosiuk J, Nedios S, Darma A, Rolf S, Richter S, Arya A, et al. Impact of single atrial
ﬁbrillation catheter ablation on implantable cardioverter deﬁbrillator therapies in patients with ischaemic and non-ischaemic cardiomyopathies. Europace 2014;16:
1322–1326.
404. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythmcontrol therapy in patients with atrial ﬁbrillation. N Engl J Med 2020;383:
1305–1316.
405. Gasparini M, Kloppe A, Lunati M, Anselme F, Landolina M, Martinez-Ferrer JB, et al.
Atrioventricular junction ablation in patients with atrial ﬁbrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-deﬁbrillator therapies and hospitalizations: atrioventricular junction ablation in CRT patients with AF. Eur J Heart Fail 2018;20:1472–1481.
406. Gasparini M, Galimberti P. Rate control: ablation and device therapy (ablate and pace). ESC CardioMed. 3rd ed. Oxford University Press; 2022, p2159–2162.
407. Kitamura T, Fukamizu S, Kawamura I, Hojo R, Aoyama Y, Komiyama K, et al.
Long-term efﬁcacy of catheter ablation for paroxysmal atrial ﬁbrillation in patients with Brugada syndrome and an implantable cardioverter-deﬁbrillator to prevent inappropriate shock therapy. Heart Rhythm 2016;13:1455–1459.
408. Magyar-Russell G, Thombs BD, Cai JX, Baveja T, Kuhl EA, Singh PP, et al. The prevalence of anxiety and depression in adults with implantable cardioverter deﬁbrillators: a systematic review. J Psychosom Res 2011;71:223–231.
409. Tzeis S, Kolb C, Baumert J, Reents T, Zrenner B, Deisenhofer I, et al. Effect of depression on mortality in implantable cardioverter deﬁbrillator recipients—ﬁndings from the prospective LICAD study. Pacing Clin Electrophysiol 2011;34:991–997.
410. Andersen CM, Theuns DAMJ, Johansen JB, Pedersen SS. Anxiety, depression, ventricular arrhythmias and mortality in patients with an implantable cardioverter deﬁbrillator: 7 years’ follow-up of the MIDAS cohort. Gen Hosp Psychiatry 2020;66:
154–160.
411. Berg SK, Thygesen LC, Svendsen JH, Christensen AV, Zwisler A-D. Anxiety predicts mortality in ICD patients: results from the cross-sectional national
CopenHeartICD survey with register follow-up. Pacing Clin Electrophysiol 2014;
37:1641–1650.
412. Thylén I, Moser DK, Strömberg A, Dekker RA, Chung ML. Concerns about implantable cardioverter-deﬁbrillator shocks mediate the relationship between actual shocks and psychological distress. Europace 2016;18:828–835.
413. Pedersen SS, van Domburg RT, Theuns DAMJ, Jordaens L, Erdman RAM. Concerns about the implantable cardioverter deﬁbrillator: a determinant of anxiety and depressive symptoms independent of experienced shocks. Am Heart J 2005;149:
664–669.
414. Frizelle DJ, Lewin B, Kaye G, Moniz-Cook ED. Development of a measure of the concerns held by people with implanted cardioverter deﬁbrillators: the ICDC. Br
J Health Psychol 2006;11:293–301.
415. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr
Scand 1983;67:361–370.
416. Frydensberg VS, Johansen JB, Möller S, Riahi S, Wehberg S, Haarbo J, et al. Anxiety and depression symptoms in Danish patients with an implantable cardioverterdeﬁbrillator: prevalence and association with indication and sex up to 2 years of follow-up (data from the national DEFIB-WOMEN study). Europace 2020;22:
1830–1840.
417. Hoogwegt MT, Kupper N, Theuns DAMJ, Zijlstra WP, Jordaens L, Pedersen SS.
Undertreatment of anxiety and depression in patients with an implantable cardioverter-deﬁbrillator: impact on health status. Health Psychol 2012;31:
745–753.
418. Lane DA, Aguinaga L, Blomström-Lundqvist C, Boriani G, Dan G-A, Hills MT, et al.
Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Paciﬁc Heart Rhythm Society
(APHRS),
and
Sociedad
Latinoamericana de
Estimulación
Cardíaca y
Electroﬁsiología (SOLEACE). Europace 2015;17:1747–1769.
419. Dunbar SB, Dougherty CM, Sears SF, Carroll DL, Goldstein NE, Mark DB, et al.
Educational and psychological interventions to improve outcomes for recipients of implantable cardioverter deﬁbrillators and their families: a scientiﬁc statement from the American Heart Association. Circulation 2012;126:2146–2172.
420. Sears SF, Sowell LDV, Kuhl EA, Kovacs AH, Serber ER, Handberg E, et al. The ICD
shock and stress management program: a randomized trial of psychosocial treatment to optimize quality of life in ICD patients. Pacing Clin Electrophysiol 2007;
30:858–864.
421. Berg SK, Rasmussen TB, Herning M, Svendsen JH, Christensen AV, Thygesen LC.
Cognitive behavioural therapy signiﬁcantly reduces anxiety in patients with implanted cardioverter deﬁbrillator compared with usual care: ﬁndings from the
Screen-ICD randomised controlled trial. Eur J Prev Cardiol 2020;27:258–268.
422. Schulz SM, Ritter O, Zniva R, Nordbeck P, Wacker C, Jack M, et al. Efﬁcacy of a web-based intervention for improving psychosocial well-being in patients with implantable cardioverter-deﬁbrillators: the randomized controlled ICD-FORUM trial.
Eur Heart J 2020;41:1203–1211.
423. van den Broek KC, Tekle FB, Habibović M, Alings M, van der Voort PH, Denollet J.
Emotional distress, positive affect, and mortality in patients with an implantable cardioverter deﬁbrillator. Int J Cardiol 2013;165:327–332.
424. Hauptman PJ, Chibnall JT, Guild C, Armbrecht ES. Patient perceptions, physician communication, and the implantable cardioverter-deﬁbrillator. JAMA Intern Med
2013;173:571–577.
425. Cikes M, Jakus N, Claggett B, Brugts JJ, Timmermans P, Pouleur A-C, et al. Cardiac implantable electronic devices with a deﬁbrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry. Eur
J Heart Fail 2019;21:1129–1141.
426. Galand V, Flécher E, Auffret V, Boulé S, Vincentelli A, Dambrin C, et al. Predictors and clinical impact of late ventricular arrhythmias in patients with continuous-ﬂow left ventricular assist devices. JACC Clin Electrophysiol 2018;4:1166–1175.
427. Nakahara S, Chien C, Gelow J, Dalouk K, Henrikson CA, Mudd J, et al. Ventricular arrhythmias after left ventricular assist device. Circ Arrhythm Electrophysiol 2013;6:
648–654.
428. Clerkin KJ, Topkara VK, Demmer RT, Dizon JM, Yuzefpolskaya M, Fried JA, et al.
Implantable cardioverter-deﬁbrillators in patients with a continuous-ﬂow left ventricular assist device: an analysis of the INTERMACS registry. JACC Heart Fail 2017;
5:916–926.
429. Oz MC, Rose EA, Slater J, Kuiper JJ, Catanese KA, Levin HR. Malignant ventricular arrhythmias are well tolerated in patients receiving long-term left ventricular assist devices. J Am Coll Cardiol 1994;24:1688–1691.
430. Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Färber G, Hannan MM,
et al. 2019 EACTS Expert Consensus on long-term mechanical circulatory support.
Eur J Cardiothorac Surg 56:230–270.


<!-- PAGE 115 -->

### Page 115

431. Makki N, Mesubi O, Steyers C, Olshansky B, Abraham WT. Meta-analysis of the relation of ventricular arrhythmias to all-cause mortality after implantation of a left ventricular assist device. Am J Cardiol 2015;116:1385–1390.
432. Yoruk A, Sherazi S, Massey HT, Kutyifa V, McNitt S, Hallinan W, et al. Predictors and clinical relevance of ventricular tachyarrhythmias in ambulatory patients with a continuous ﬂow left ventricular assist device. Heart Rhythm 2016;13:1052–1056.
433. Bedi M, Kormos R, Winowich S, McNamara DM, Mathier MA, Murali S. Ventricular arrhythmias during left ventricular assist device support. Am J Cardiol 2007;99:
1151–1153.
434. Brenyo A, Rao M, Koneru S, Hallinan W, Shah S, Massey HT, et al. Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients. J Cardiovasc Electrophysiol
2012;23:515–520.
435. Vakil K, Kazmirczak F, Sathnur N, Adabag S, Cantillon DJ, Kiehl EL, et al. Implantable cardioverter-deﬁbrillator use in patients with left ventricular assist devices: a systematic review and meta-analysis. JACC Heart Fail 2016;4:772–779.
436. Refaat MM, Tanaka T, Kormos RL, McNamara D, Teuteberg J, Winowich S, et al.
Survival beneﬁt of implantable cardioverter-deﬁbrillators in left ventricular assist device-supported heart failure patients. J Card Fail 2012;18:140–145.
437. Cantillon DJ, Tarakji KG, Kumbhani DJ, Smedira NG, Starling RC, Wilkoff BL.
Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-deﬁbrillator. Heart Rhythm 2010;7:466–471.
438. Joyce E, Starling RC. HFrEF other treatment: ventricular assist devices. ESC
CardioMed. 3rd ed. Oxford University Press; 2022, p1884–1889.
439. Younes A, Al-Kindi SG, Alajaji W, Mackall JA, Oliveira GH. Presence of implantable cardioverter-deﬁbrillators and wait-list mortality of patients supported with left ventricular assist devices as bridge to heart transplantation. Int J Cardiol 2017;
231:211–215.
440. Agrawal S, Garg L, Nanda S, Sharma A, Bhatia N, Manda Y, et al. The role of implantable cardioverter-deﬁbrillators in patients with continuous ﬂow left ventricular assist devices – a meta-analysis. Int J Cardiol 2016;222:379–384.
441. Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG,
et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Paciﬁc Heart
Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS),
International Society for Cardiovascular Infectious Diseases (ISCVID) and the
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).
Europace 2020;22:515–549.
442. Burri H, Starck C, Auricchio A, BifﬁM, Burri M, D’Avila A, et al. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-deﬁbrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Paciﬁc Heart Rhythm Society
(APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace
2021;23:983–1008.
443. Tarakji KG, Mittal S, Kennergren C, Corey R, Poole JE, Schloss E, et al. Antibacterial envelope to prevent cardiac implantable device infection. N Engl J Med 2019;380:
1895–1905.
444. Atti V, Turagam MK, Garg J, Koerber S, Angirekula A, Gopinathannair R, et al.
Subclavian and axillary vein access versus cephalic vein cutdown for cardiac implantable electronic device implantation: a meta-analysis. JACC Clin Electrophysiol 2020;6:
661–671.
445. Benz AP, Vamos M, Erath JW, Hohnloser SH. Cephalic vs. subclavian lead implantation in cardiac implantable electronic devices: a systematic review and meta-analysis. Europace 2019;21:121–129.
446. Chan N-Y, Kwong N-P, Cheong A-P. Venous access and long-term pacemaker lead failure: comparing contrast-guided axillary vein puncture with subclavian puncture and cephalic cutdown. Europace 2017;19:1193–1197.
447. Defaye P, Boveda S, Klug D, Beganton F, Piot O, Narayanan K, et al. Dual- vs. singlechamber deﬁbrillators for primary prevention of sudden cardiac death: long-term follow-up of the Déﬁbrillateur Automatique Implantable-Prévention Primaire registry. Europace 2017;19:1478–1484.
448. Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD.
Dual-chamber implantable cardioverter-deﬁbrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-deﬁbrillator registry. J Am Coll Cardiol 2011;58:1007–1013.
449. Friedman PA, Bradley D, Koestler C, Slusser J, Hodge D, Bailey K, et al. A prospective randomized trial of single- or dual-chamber implantable cardioverterdeﬁbrillators to minimize inappropriate shock risk in primary sudden cardiac death prevention. Europace 2014;16:1460–1468.
450. Chen B-W, Liu Q, Wang X, Dang A-M. Are dual-chamber implantable cardioverter-deﬁbrillators really better than single-chamber ones? A systematic review and meta-analysis. J Interv Card Electrophysiol 2014;39:273–280.
451. Epstein LM, Love CJ, Wilkoff BL, Chung MK, Hackler JW, Bongiorni MG, et al.
Superior vena cava deﬁbrillator coils make transvenous lead extraction more challenging and riskier. J Am Coll Cardiol 2013;61:987–989.
452. Larsen JM, Hjortshøj SP, Nielsen JC, Johansen JB, Petersen HH, Haarbo J, et al.
Single-coil and dual-coil deﬁbrillator leads and association with clinical outcomes in a complete Danish nationwide ICD cohort. Heart Rhythm 2016;13:706–712.
453. Kumar KR, Mandleywala SN, Madias C, Weinstock J, Rowin EJ, Maron BJ, et al.
Single coil implantable cardioverter deﬁbrillator leads in patients with hypertrophic cardiomyopathy. Am J Cardiol 2020;125:1896–1900.
454. Friedman PA, Rasmussen MJ, Grice S, Trusty J, Glikson M, Stanton MS. Deﬁbrillation thresholds are increased by right-sided implantation of totally transvenous implantable cardioverter deﬁbrillators. Pacing Clin Electrophysiol 1999;22:1186–1192.
455. Stoevelaar R, Brinkman-Stoppelenburg A, Bhagwandien RE, van Bruchem-Visser
RL, Theuns DA, van der Heide A, et al. The incidence and impact of implantable cardioverter deﬁbrillator shocks in the last phase of life: an integrated review.
Eur J Cardiovasc Nurs 2018;17:477–485.
456. Kapa S, Mueller PS, Hayes DL, Asirvatham SJ. Perspectives on withdrawing pacemaker and implantable cardioverter-deﬁbrillator therapies at end of life: results of a survey of medical and legal professionals and patients. Mayo Clin Proc 2010;
85:981–990.
457. Padeletti L, Arnar DO, Boncinelli L, Brachman J, Camm JA, Daubert JC, et al. EHRA
Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace 2010;12:1480–1489.
458. Stoevelaar R, Brinkman-Stoppelenburg A, van Driel AG, Theuns DA, Bhagwandien
RE, van Bruchem-Visser RL, et al. Trends in time in the management of the implantable cardioverter deﬁbrillator in the last phase of life: a retrospective study of medical records. Eur J Cardiovasc Nurs 2019;18:449–457.
459. Kirkpatrick JN, Gottlieb M, Sehgal P, Patel R, Verdino RJ. Deactivation of implantable cardioverter deﬁbrillators in terminal illness and end of life care. Am J Cardiol
2012;109:91–94.
460. Stevenson WG, Khan H, Sager P, Saxon LA, Middlekauff HR, Natterson PD, et al.
Identiﬁcation of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation
1993;88:1647–1670.
461. de Bakker JM, van Capelle FJ, Janse MJ, Tasseron S, Vermeulen JT, de Jonge N, et al.
Slow conduction in the infarcted human heart. “Zigzag” course of activation.
Circulation 1993;88:915–926.
462. de Chillou C, Lacroix D, Klug D, Magnin-Poull I, Marquié C, Messier M, et al. Isthmus characteristics of reentrant ventricular tachycardia after myocardial infarction.
Circulation 2002;105:726–731.
463. Hsia HH, Callans DJ, Marchlinski FE. Characterization of endocardial electrophysiological substrate in patients with nonischemic cardiomyopathy and monomorphic ventricular tachycardia. Circulation 2003;108:704–710.
464. Soejima K, Stevenson WG, Sapp JL, Selwyn AP, Couper G, Epstein LM. Endocardial and epicardial radiofrequency ablation of ventricular tachycardia associated with dilated cardiomyopathy. J Am Coll Cardiol 2004;43:1834–1842.
465. Miljoen H, State S, Dechillou C, Magninpoull I, Dotto P, Andronache M, et al.
Electroanatomic mapping characteristics of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Europace 2005;
7:516–524.
466. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al.
Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for
European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:
2793–2867.
467. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al.
2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary. J Am
Coll Cardiol 2018;72:1677–1749.
468. Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, et al.
2019 HRS expert consensus statement on evaluation, risk stratiﬁcation, and management of arrhythmogenic cardiomyopathy: executive summary. Heart Rhythm
2019;16:e373–e407.
469. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted deﬁbrillator. Circulation 2004;110:3760–3765.
470. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al.
Prognostic importance of deﬁbrillator shocks in patients with heart failure. N
Engl J Med 2008;359:1009–1017.
471. Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin J-F, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med 2016;
375:111–121.
ESC Guidelines
4111


<!-- PAGE 116 -->

### Page 116

472. Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J 2009;30:
1245–1253.
473. Palaniswamy C, Kolte D, Harikrishnan P, Khera S, Aronow WS, Mujib M, et al.
Catheter ablation of postinfarction ventricular tachycardia: ten-year trends in utilization, in-hospital complications, and in-hospital mortality in the United States.
Heart Rhythm 2014;11:2056–2063.
474. Caceres J, Jazayeri M, McKinnie J, Avitall B, Denker ST, Tchou P, et al. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation 1989;79:
256–270.
475. Blanck Z, Dhala A, Deshpande S, Sra J, Jazayeri M, Akhtar M. Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc
Electrophysiol 1993;4:253–262.
476. Chen H, Shi L, Yang B, Ju W, Zhang F, Yang G, et al. Electrophysiological characteristics of bundle branch reentry ventricular tachycardia in patients without structural heart disease. Circ Arrhythm Electrophysiol 2018;11:e006049.
477. Pathak RK, Fahed J, Santangeli P, Hyman MC, Liang JJ, Kubala M, et al. Long-term outcome of catheter ablation for treatment of bundle branch re-entrant tachycardia. JACC Clin Electrophysiol 2018;4:331–338.
478. Stevenson WG, Wilber DJ, Natale A, Jackman WM, Marchlinski FE, Talbert T, et al.
Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation 2008;118:2773–2782.
479. Della Bella P, Baratto F, Tsiachris D, Trevisi N, Vergara P, Bisceglia C, et al.
Management of ventricular tachycardia in the setting of a dedicated unit for the treatment of complex ventricular arrhythmias: long-term outcome after ablation.
Circulation 2013;127:1359–1368.
480. Maury P, Baratto F, Zeppenfeld K, Klein G, Delacretaz E, Sacher F, et al.
Radio-frequency ablation as primary management of well-tolerated sustained monomorphic ventricular tachycardia in patients with structural heart disease and left ventricular ejection fraction over 30%. Eur Heart J 2014;35:1479–1485.
481. Tung R, Vaseghi M, Frankel DS, Vergara P, Di Biase L, Nagashima K, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT
Ablation Center Collaborative Group study. Heart Rhythm 2015;12:1997–2007.
482. Santangeli P, Zado ES, Supple GE, Haqqani HM, Garcia FC, Tschabrunn CM, et al.
Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy.
Circ
Arrhythm
Electrophysiol 2015;8:1413–1421.
483. Marchlinski FE, Haffajee CI, Beshai JF, Dickfeld T-ML, Gonzalez MD, Hsia HH, et al.
Long-term success of irrigated radiofrequency catheter ablation of sustained ventricular tachycardia. J Am Coll Cardiol 2016;67:674–683.
484. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K,
et al. Prophylactic catheter ablation for the prevention of deﬁbrillator therapy. N
Engl J Med 2007;357:2657–2665.
485. Kuck K-H, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E, et al.
Catheter ablation of stable ventricular tachycardia before deﬁbrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375:31–40.
486. Anter E, Kleber AG, Rottmann M, Leshem E, Barkagan M, Tschabrunn CM, et al.
Infarct-related ventricular tachycardia. JACC Clin Electrophysiol 2018;4:1033–1048.
487. Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation 2000;101:1288–1296.
488. de Chillou C, Groben L, Magnin-Poull I, Andronache M, Abbas MM, Zhang N, et al.
Localizing the critical isthmus of postinfarct ventricular tachycardia: the value of pace-mapping during sinus rhythm. Heart Rhythm 2014;11:175–181.
489. Jaïs P, Maury P, Khairy P, Sacher F, Nault I, Komatsu Y, et al. Elimination of local abnormal ventricular activities: a new end point for substrate modiﬁcation in patients with scar-related ventricular tachycardia. Circulation 2012;125:2184–2196.
490. Berruezo A, Fernandez-Armenta J. Lines, circles, channels, and clouds: looking for the best design for substrate-guided ablation of ventricular tachycardia. Europace
2014;16:943–945.
491. Di Biase L, Burkhardt JD, Lakkireddy D, Carbucicchio C, Mohanty S, Mohanty P,
et al. Ablation of stable VTs versus substrate ablation in ischemic cardiomyopathy.
J Am Coll Cardiol 2015;66:2872–2882.
492. Berruezo A, Fernández-Armenta J, Andreu D, Penela D, Herczku C, Evertz R, et al.
Scar dechanneling: new method for scar-related left ventricular tachycardia substrate ablation. Circ Arrhythm Electrophysiol 2015;8:326–336.
493. Haïssaguerre M, Shoda M, Jaïs P, Nogami A, Shah DC, Kautzner J, et al. Mapping and ablation of idiopathic ventricular ﬁbrillation. Circulation 2002;106:962–967.
494. Shirai Y, Liang JJ, Santangeli P, Arkles JS, Schaller RD, Supple GE, et al. Comparison of the ventricular tachycardia circuit between patients with ischemic and nonischemic cardiomyopathies: detailed characterization by entrainment. Circ Arrhythm
Electrophysiol 2019;12:e007249.
495. Bhaskaran A, Tung R, Stevenson WG, Kumar S. Catheter ablation of VT in nonischaemic cardiomyopathies: endocardial, epicardial and intramural approaches.
Heart Lung Circ 2019;28:84–101.
496. Tung R, Raiman M, Liao H, Zhan X, Chung FP, Nagel R, et al. Simultaneous endocardial and epicardial delineation of 3D reentrant ventricular tachycardia. J Am Coll
Cardiol 2020;75:884–897.
497. Dinov B, Fiedler L, Schönbauer R, Bollmann A, Rolf S, Piorkowski C, et al.
Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the
Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation 2014;129:
728–736.
498. Proietti R, Essebag V, Beardsall J, Hache P, Pantano A, Wulffhart Z, et al.
Substrate-guided ablation of haemodynamically tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome. Europace 2015;17:461–467.
499. Ebert M, Richter S, Dinov B, Zeppenfeld K, Hindricks G. Evaluation and management of ventricular tachycardia in patients with dilated cardiomyopathy. Heart
Rhythm 2019;16:624–631.
500. Proietti R, Lichelli L, Lellouche N, Dhanjal T. The challenge of optimising ablation lesions in catheter ablation of ventricular tachycardia. J Arrhythmia 2021;37:
140–147.
501. Tokuda M, Sobieszczyk P, Eisenhauer AC, Kojodjojo P, Inada K, Koplan BA, et al.
Transcoronary ethanol ablation for recurrent ventricular tachycardia after failed catheter ablation: an update. Circ Arrhythm Electrophysiol 2011;4:889–896.
502. Kreidieh B, Rodríguez-Mañero M, Schurmann P, Ibarra-Cortez SH, Dave AS,
Valderrábano M. Retrograde coronary venous ethanol infusion for ablation of refractory ventricular tachycardia. Circ Arrhythm Electrophysiol 2016;9:e004352.
503. Nguyen DT, Tzou WS, Sandhu A, Gianni C, Anter E, Tung R, et al. Prospective multicenter experience with cooled radiofrequency ablation using high impedance irrigant to target deep myocardial substrate refractory to standard ablation. JACC Clin
Electrophysiol 2018;4:1176–1185.
504. Stevenson WG, Tedrow UB, Reddy V, AbdelWahab A, Dukkipati S, John RM, et al.
Infusion needle radiofrequency ablation for treatment of refractory ventricular arrhythmias. J Am Coll Cardiol 2019;73:1413–1425.
505. Igarashi M, Nogami A, Fukamizu S, Sekiguchi Y, Nitta J, Sakamoto N, et al. Acute and long-term results of bipolar radiofrequency catheter ablation of refractory ventricular arrhythmias of deep intramural origin. Heart Rhythm 2020;17:1500–1507.
506. Della Bella P, Peretto G, Paglino G, Bisceglia C, Radinovic A, Sala S, et al. Bipolar radiofrequency ablation for ventricular tachycardias originating from the interventricular septum: safety and efﬁcacy in a pilot cohort study. Heart Rhythm 2020;17:
2111–2118.
507. Cuculich PS, Schill MR, Kashani R, Mutic S, Lang A, Cooper D, et al. Noninvasive cardiac radiation for ablation of ventricular tachycardia. N Engl J Med 2017;377:
2325–2336.
508. Robinson CG, Samson PP, Moore KMS, Hugo GD, Knutson N, Mutic S, et al. Phase
I/II trial of electrophysiology-guided noninvasive cardiac radioablation for ventricular tachycardia. Circulation 2019;139:313–321.
509. Anter E, Hutchinson MD, Deo R, Haqqani HM, Callans DJ, Gerstenfeld EP, et al.
Surgical ablation of refractory ventricular tachycardia in patients with nonischemic cardiomyopathy. Circ Arrhythm Electrophysiol 2011;4:494–500.
510. Fernández-Armenta J, Berruezo A, Andreu D, Camara O, Silva E, Serra L, et al.
Three-dimensional architecture of scar and conducting channels based on high resolution ce-CMR: insights for ventricular tachycardia ablation. Circ Arrhythm
Electrophysiol 2013;6:528–537.
511. Mahida S, Sacher F, Dubois R, Sermesant M, Bogun F, Haïssaguerre M, et al. Cardiac imaging in patients with ventricular tachycardia. Circulation 2017;136:2491–2507.
512. Andreu D, Penela D, Acosta J, Fernández-Armenta J, Perea RJ, Soto-Iglesias D, et al.
Cardiac magnetic resonance–aided scar dechanneling: inﬂuence on acute and longterm outcomes. Heart Rhythm 2017;14:1121–1128.
513. Kuo L, Liang JJ, Nazarian S, Marchlinski FE. Multimodality imaging to guide ventricular tachycardia ablation in patients with non-ischaemic cardiomyopathy. Arrhythm
Electrophysiol Rev 2020;8:255–264.
514. Roca-Luque I, Van Breukelen A, Alarcon F, Garre P, Tolosana JM, Borras R, et al.
Ventricular scar channel entrances identiﬁed by new wideband cardiac magnetic resonance sequence to guide ventricular tachycardia ablation in patients with cardiac deﬁbrillators. Europace 2020;22:598–606.
515. Betensky BP, Marchlinski FE. Outcomes of catheter ablation of ventricular tachycardia in the setting of structural heart disease. Curr Cardiol Rep 2016;18:68.
516. Dukkipati SR, Koruth JS, Choudry S, Miller MA, Whang W, Reddy VY. Catheter ablation of ventricular tachycardia in structural heart disease. J Am Coll Cardiol 2017;
70:2924–2941.
517. Zeppenfeld K. Ventricular tachycardia ablation in nonischemic cardiomyopathy.
JACC Clin Electrophysiol 2018;4:1123–1140.
518. Guandalini GS, Liang JJ, Marchlinski FE. Ventricular tachycardia ablation. JACC Clin
Electrophysiol 2019;5:1363–1383.


<!-- PAGE 117 -->

### Page 117

519. Peichl P, Wichterle D, Pavlu L, Cihak R, Aldhoon B, Kautzner J. Complications of catheter ablation of ventricular tachycardia: a single-center experience. Circ
Arrhythm Electrophysiol 2014;7:684–690.
520. Katz DF, Turakhia MP, Sauer WH, Tzou WS, Heath RR, Zipse MM, et al. Safety of ventricular tachycardia ablation in clinical practice: ﬁndings from 9699 hospital discharge records. Circ Arrhythm Electrophysiol 2015;8:362–370.
521. Cheung JW, Yeo I, Ip JE, Thomas G, Liu CF, Markowitz SM, et al. Outcomes, costs,
and 30-day readmissions after catheter ablation of myocardial infarct–associated ventricular tachycardia in the real world: nationwide readmissions database 2010
to 2015. Circ Arrhythm Electrophysiol 2018;11:e006754.
522. Hendriks AA, Akca F, Dabiri Abkenari L, Khan M, Bhagwandien R, Yap S-C, et al.
Safety and clinical outcome of catheter ablation of ventricular arrhythmias using contact force sensing: consecutive case series. J Cardiovasc Electrophysiol 2015;26:
1224–1229.
523. Nogami A. Purkinje-related arrhythmias part I: monomorphic ventricular tachycardias. Pacing Clin Electrophysiol 2011;34:624–650.
524. Lerman BB. Mechanism, diagnosis, and treatment of outﬂow tract tachycardia. Nat
Rev Cardiol 2015;12:597–608.
525. Kobayashi Y. Idiopathic ventricular premature contraction and ventricular tachycardia: distribution of the origin, diagnostic algorithm, and catheter ablation. J
Nippon Med Sch 2018;85:87–94.
526. Tada H, Ito S, Naito S, Kurosaki K, Kubota S, Sugiyasu A, et al. Idiopathic ventricular arrhythmia arising from the mitral annulus: a distinct subgroup of idiopathic ventricular arrhythmias. J Am Coll Cardiol 2005;45:877–886.
527. Wasmer K, Köbe J, Dechering DG, Bittner A, Pott C, Mönnig G, et al. Ventricular arrhythmias from the mitral annulus: patient characteristics, electrophysiological
ﬁndings, ablation, and prognosis. Heart Rhythm 2013;10:783–788.
528. Tada H, Tadokoro K, Ito S, Naito S, Hashimoto T, Kaseno K, et al. Idiopathic ventricular arrhythmias originating from the tricuspid annulus: prevalence, electrocardiographic characteristics, and results of radiofrequency catheter ablation. Heart
Rhythm 2007;4:7–16.
529. Yamada T, Doppalapudi H, McElderry HT, Okada T, Murakami Y, Inden Y, et al.
Electrocardiographic and electrophysiological characteristics in idiopathic ventricular arrhythmias originating from the papillary muscles in the left ventricle: relevance for catheter ablation. Circ Arrhythm Electrophysiol 2010;3:324–331.
530. Macias C, Nakamura K, Tung R, Boyle NG, Kalyanam S, Bradﬁeld JS. Importance of delayed enhanced cardiac MRI in idiopathic RVOT-VT: differentiating mimics including early stage ARVC and cardiac sarcoidosis. J Atr Fibrillation 2014;7:1097.
531. Heeger C-H, Hayashi K, Kuck K-H, Ouyang F. Catheter ablation of idiopathic ventricular arrhythmias arising from the cardiac outﬂow tracts—recent insights and techniques for the successful treatment of common and challenging cases. Circ J
2016;80:1073–1086.
532. Pathak RK, Ariyarathna N, Garcia FC, Sanders P, Marchlinski FE. Catheter ablation of idiopathic ventricular arrhythmias. Heart Lung Circ 2019;28:102–109.
533. Yamada T, McElderry HT, Doppalapudi H, Murakami Y, Yoshida Y, Yoshida N, et al.
Idiopathic ventricular arrhythmias originating from the aortic root prevalence, electrocardiographic and electrophysiologic characteristics, and results of radiofrequency catheter ablation. J Am Coll Cardiol 2008;52:139–147.
534. Van Herendael H, Garcia F, Lin D, Riley M, Bala R, Cooper J, et al. Idiopathic right ventricular arrhythmias not arising from the outﬂow tract: prevalence, electrocardiographic characteristics, and outcome of catheter ablation. Heart Rhythm 2011;8:
511–518.
535. Latchamsetty R, Yokokawa M, Morady F, Kim HM, Mathew S, Tilz R, et al.
Multicenter outcomes for catheter ablation of idiopathic premature ventricular complexes. JACC Clin Electrophysiol 2015;1:116–123.
536. Liu Y, Fang Z, Yang B, Kojodjojo P, Chen H, Ju W, et al. Catheter ablation of fascicular ventricular tachycardia: long-term clinical outcomes and mechanisms of recurrence. Circ Arrhythm Electrophysiol 2015;8:1443–1451.
537. Hayashi T, Liang JJ, Shirai Y, Kuo L, Muser D, Kubala M, et al. Trends in successful ablation sites and outcomes of ablation for idiopathic outﬂow tract ventricular arrhythmias. JACC Clin Electrophysiol 2020;6:221–230.
538. Farré J, Wellens HJ. Philippe Coumel: a founding father of modern arrhythmology.
Europace 2004;6:464–465.
539. Neira V, Enriquez A, Simpson C, Baranchuk A. Update on long QT syndrome. J
Cardiovasc Electrophysiol 2019;30:3068–3078.
540. Winbo A, Paterson DJ. The brain-heart connection in sympathetically triggered inherited arrhythmia syndromes. Heart Lung Circ 2020;29:529–537.
541. Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004;109:1826–1833.
542. Surman TL, Stuklis RG, Chan JC. Thoracoscopic sympathectomy for long QT syndrome. Literature review and case study. Heart Lung Circ 2019;28:486–494.
543. Orvin K, Eisen A, Goldenberg I, Gottlieb S, Kornowski R, Matetzky S, et al.
Outcome of contemporary acute coronary syndrome complicated by ventricular tachyarrhythmias. Europace 2016;18:219–226.
544. Demirel F, Rasoul S, Elvan A, Ottervanger JP, Dambrink J-HE, Gosselink ATM, et al.
Impact of out-of-hospital cardiac arrest due to ventricular ﬁbrillation in patients with ST-elevation myocardial infarction admitted for primary percutaneous coronary intervention: Impact of ventricular ﬁbrillation in STEMI patients. Eur Heart J
Acute Cardiovasc Care 2015;4:16–23.
545. Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS, et al.
Incidence of and outcomes associated with ventricular tachycardia or ﬁbrillation in patients undergoing primary percutaneous coronary intervention. JAMA 2009;
301:1779–1789.
546. Demidova MM, Carlson J, Erlinge D, Platonov PG. Predictors of ventricular ﬁbrillation at reperfusion in patients with acute ST-elevation myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol 2015;115:417–422.
547. Cheng Y-J, Li Z-Y, Yao F-J, Xu X-J, Ji C-C, Chen X-M, et al. Early repolarization is associated with a signiﬁcantly increased risk of ventricular arrhythmias and sudden cardiac death in patients with structural heart diseases. Heart Rhythm 2017;14:
1157–1164.
548. Dumas F, Bougouin W, Geri G, Lamhaut L, Rosencher J, Pène F, et al. Emergency percutaneous coronary intervention in post-cardiac arrest patients without
ST-segment elevation pattern: insights from the PROCAT II registry. JACC
Cardiovasc Interv 2016;9:1011–1018.
549. Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S, et al. Early intravenous beta-blockers in patients with acute coronary syndrome–a meta-analysis of randomized trials. Int J Cardiol 2013;168:915–921.
550. Roolvink V, Ibáñez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A, et al. Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention. J Am Coll Cardiol 2016;67:
2705–2715.
551. Piccini JP, Hranitzky PM, Kilaru R, Rouleau J-L, White HD, Aylward PE, et al.
Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular ﬁbrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial
[VALIANT] Registry). Am J Cardiol 2008;102:1427–1432.
552. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy.
Circulation 2000;102:742–747.
553. Bundgaard JS, Jacobsen PK, Grand J, Lindholm MG, Hassager C, Pehrson S, et al.
Deep sedation as temporary bridge to deﬁnitive treatment of ventricular arrhythmia storm. Eur Heart J Acute Cardiovasc Care 2020;9:657–664.
554. Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, et al.
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Crit Care Med 2011;39:78–83.
555. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular ﬁbrillation. N Engl J Med
2002;346:884–890.
556. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al.
Mortality and morbidity in patients receiving encainide, ﬂecainide, or placebo.
The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781–788.
557. Baudry G, Sonneville R, Waintraub X, Lebreton G, Deguillard C, Mertens E, et al.
Extracorporeal membrane oxygenation to support life-threatening drug-refractory electrical storm. Crit Care Med 2020;48:e856–e863.
558. Demidova MM, Smith JG, Höijer C-J, Holmqvist F, Erlinge D, Platonov PG.
Prognostic impact of early ventricular ﬁbrillation in patients with ST-elevation myocardial infarction treated with primary PCI. Eur Heart J Acute Cardiovasc Care 2012;
1:302–311.
559. Podolecki T, Lenarczyk R, Kowalczyk J, Jedrzejczyk-Patej E, Chodor P, Mazurek M,
et al. Prognostic signiﬁcance of complex ventricular arrhythmias complicating
ST-segment elevation myocardial infarction. Am J Cardiol 2018;121:805–809.
560. Bougouin W, Marijon E, Puymirat E, Defaye P, Celermajer DS, Le Heuzey J-Y, et al.
Incidence of sudden cardiac death after ventricular ﬁbrillation complicating acute myocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 registry. Eur Heart J 2014;35:116–122.
561. Liang JJ, Hodge DO, Mehta RA, Russo AM, Prasad A, Cha Y-M. Outcomes in patients with sustained ventricular tachyarrhythmias occurring within 48 h of acute myocardial infarction: when is ICD appropriate? Europace 2014;16:1759–1766.
562. Ahn J-M, Lee KH, Yoo S-Y, Cho Y-R, Suh J, Shin E-S, et al. Prognosis of variant angina manifesting as aborted sudden cardiac death. J Am Coll Cardiol 2016;68:137–145.
563. Sueda S, Kohno H. Optimal medications and appropriate implantable cardioverterdeﬁbrillator shocks in aborted sudden cardiac death due to coronary spasm. Intern
Med 2018;57:1361–1369.
564. Rodríguez-Mañero M, Oloriz T, le Polain de Waroux J-B, Burri H, Kreidieh B, de
Asmundis C, et al. Long-term prognosis of patients with life-threatening ventricular arrhythmias induced by coronary artery spasm. Europace 2018;20:851–858.
565. Solomon SD, Zelenkofske S, McMurray JJV, Finn PV, Velazquez E, Ertl G, et al.
Sudden death in patients with myocardial infarction and left ventricular dysfunction,
heart failure, or both. N Engl J Med 2005;352:2581–2588.
ESC Guidelines
4113


<!-- PAGE 118 -->

### Page 118

566. Busk M, Maeng M, Kristensen SD, Thuesen L, Krusell LR, Mortensen LS, et al.
Timing, causes, and predictors of death after three years’ follow-up in the
Danish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial. Am J Cardiol 2009;104:210–215.
567. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, et al.
Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994;89:68–75.
568. Søholm H, Lønborg J, Andersen MJ, Vejlstrup N, Engstrøm T, Møller JE, et al.
Repeated echocardiography after ﬁrst ever ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention–is it necessary?
Eur Heart J Acute Cardiovasc Care 2015;4:528–536.
569. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D,
et al. Deﬁbrillator implantation early after myocardial infarction. N Engl J Med
2009;361:1427–1436.
570. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al.
Prophylactic use of an implantable cardioverter-deﬁbrillator after acute myocardial infarction. N Engl J Med 2004;351:2481–2488.
571. Exner DV, Kavanagh KM, Slawnych MP, Mitchell LB, Ramadan D, Aggarwal SG, et al.
Noninvasive risk assessment early after a myocardial infarction the REFINE study. J
Am Coll Cardiol 2007;50:2275–2284.
572. Zaman S, Narayan A, Thiagalingam A, Sivagangabalan G, Thomas S, Ross DL, et al.
Long-term arrhythmia-free survival in patients with severe left ventricular dysfunction and no inducible ventricular tachycardia after myocardial infarction. Circulation
2014;129:848–854.
573. Daubert MA, White JA, Al-Khalidi HR, Velazquez EJ, Rao SV, Crowley AL, et al.
Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era. Am Heart J 2020;223:87–97.
574. Chew DS, Heikki H, Schmidt G, Kavanagh KM, Dommasch M, Bloch Thomsen PE,
et al. Change in left ventricular ejection fraction following ﬁrst myocardial infarction and outcome. JACC Clin Electrophysiol 2018;4:672–682.
575. Bänsch D, Oyang F, Antz M, Arentz T, Weber R, Val-Mejias JE, et al. Successful catheter ablation of electrical storm after myocardial infarction. Circulation 2003;108:
3011–3016.
576. Altmann DR, Mutschelknauss M, Ehl N, Koller M, Schaer B, Jörg L, et al. Prevalence of severely impaired left ventricular ejection fraction after reperfused ST-elevation myocardial infarction. Swiss Med Wkly 2013;143:w13869.
577. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, et al. Declining risk of sudden death in heart failure. N Engl J Med 2017;377:41–51.
578. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia
Trial Investigators. Lancet 1997;349:675–682.
579. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct
Amiodarone Trial Investigators. Lancet 1997;349:667–674.
580. Clemens M, Peichl P, Wichterle D, Pavlů L, Čihák R, Aldhoon B, et al. Catheter ablation of ventricular tachycardia as the ﬁrst-line therapy in patients with coronary artery disease and preserved left ventricular systolic function: long-term results:
VT ablation in patients with preserved LV function. J Cardiovasc Electrophysiol
2015;26:1105–1110.
581. Paciﬁco A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, et al.
Prevention of implantable-deﬁbrillator shocks by treatment with sotalol.
D,
L-Sotalol Implantable Cardioverter-Deﬁbrillator Study Group. N Engl J Med 1999;
340:1855–1862.
582. Willems S, Tilz RR, Steven D, Kääb S, Wegscheider K, Gellér L, et al. Preventive or deferred ablation of ventricular tachycardia in patients with ischemic cardiomyopathy and implantable deﬁbrillator (BERLIN VT): a multicenter randomized trial.
Circulation 2020;141:1057–1067.
583. Kuck K-H, Tilz RR, Deneke T, Hoffmann BA, Ventura R, Hansen PS, et al. Impact of substrate modiﬁcation by catheter ablation on implantable cardioverter–deﬁbrillator interventions in patients with unstable ventricular arrhythmias and coronary artery disease: results from the multicenter randomized controlled SMS (substrate modiﬁcation study). Circ Arrhythm Electrophysiol 2017;10:e004422.
584. Olshansky B, Hahn EA, Hartz VL, Prater SP, Mason JW. Clinical signiﬁcance of syncope in the electrophysiologic study versus electrocardiographic monitoring
(ESVEM) trial. The ESVEM Investigators. Am Heart J 1999;137:878–886.
585. Molossi S, Agrawal H, Mery CM, Krishnamurthy R, Masand P, Sexson Tejtel SK,
et al. Outcomes in anomalous aortic origin of a coronary artery following a prospective standardized approach. Circ Cardiovasc Interv 2020;13:e008445.
586. Krasuski RA, Magyar D, Hart S, Kalahasti V, Lorber R, Hobbs R, et al. Long-term outcome and impact of surgery on adults with coronary arteries originating from the opposite coronary cusp. Circulation 2011;123:154–162.
587. Jegatheeswaran A, Devlin PJ, McCrindle BW, Williams WG, Jacobs ML, Blackstone
EH, et al. Features associated with myocardial ischemia in anomalous aortic origin of a coronary artery: a congenital heart surgeons’ society study. J Thorac Cardiovasc
Surg 2019;158:822–834.
588. Jegatheeswaran A, Devlin PJ, Williams WG, Brothers JA, Jacobs ML, DeCampli
WM, et al. Outcomes after anomalous aortic origin of a coronary artery repair:
a congenital heart surgeons’ society study. J Thorac Cardiovasc Surg 2020;160:
757–771.
589. Hoffmayer KS, Bhave PD, Marcus GM, James CA, Tichnell C, Chopra N, et al. An electrocardiographic scoring system for distinguishing right ventricular outﬂow tract arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy from idiopathic ventricular tachycardia. Heart Rhythm 2013;10:477–482.
590. Yokokawa M, Siontis KC, Kim HM, Stojanovska J, Latchamsetty R, Crawford T, et al.
Value of cardiac magnetic resonance imaging and programmed ventricular stimulation in patients with frequent premature ventricular complexes undergoing radiofrequency ablation. Heart Rhythm 2017;14:1695–1701.
591. Muser D, Santangeli P, Castro SA, Casado Arroyo R, Maeda S, Benhayon DA, et al.
Risk stratiﬁcation of patients with apparently idiopathic premature ventricular contractions: a multicenter international CMR registry. JACC Clin Electrophysiol 2020;6:
722–735.
592. Kjekshus J, Bathen J, Orning OM, Storstein L. A double-blind, crossover comparison of ﬂecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes. Am J Cardiol 1984;53:72B–78B.
593. Hamon D, Swid MA, Rajendran PS, Liu A, Boyle NG, Shivkumar K, et al. Premature ventricular contraction diurnal proﬁles predict distinct clinical characteristics and beta-blocker responses. J Cardiovasc Electrophysiol 2019;30:836–843.
594. Primeau R, Agha A, Giorgi C, Shenasa M, Nadeau R. Long term efﬁcacy and toxicity of amiodarone in the treatment of refractory cardiac arrhythmias. Can J Cardiol
1989;5:98–104.
595. Ling Z, Liu Z, Su L, Zipunnikov V, Wu J, Du H, et al. Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outﬂow tract: prospective randomized study. Circ Arrhythm
Electrophysiol 2014;7:237–243.
596. Baksiene D, Sileikiene R, Sileikis V, Kazakevicius T, Zabiela V, Zebiene M, et al.
Idiopathic ventricular tachycardia in children: curative therapy with radiofrequency ablation. Medicina (Kaunas) 2007;43:803–807.
597. Blaufox AD, Felix GL, Saul JP, Pediatric Catheter Ablation Registry. Radiofrequency catheter ablation in infants ,/=18 months old: when is it done and how do they fare?: Short-term data from the pediatric ablation registry. Circulation 2001;104:
2803–2808.
598. Lapage MJ, Bradley DJ, Dick M. Verapamil in infants: an exaggerated fear? Pediatr
Cardiol 2013;34:1532–1534.
599. Lee AKY, Andrade J, Hawkins NM, Alexander G, Bennett MT, Chakrabarti S, et al.
Outcomes of untreated frequent premature ventricular complexes with normal left ventricular function. Heart 2019;105:1408–1413.
600. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu T-Y, Alguire C, et al. Relationship between burden of premature ventricular complexes and left ventricular function.
Heart Rhythm 2010;7:865–869.
601. van Huls van Taxis CFB, Piers SRD, de Riva Silva M, Dekkers OM, Pijnappels DA,
Schalij MJ, et al. Fatigue as presenting symptom and a high burden of premature ventricular contractions are independently associated with increased ventricular wall stress in patients with normal left ventricular function.
Circ
Arrhythm
Electrophysiol 2015;8:1452–1459.
602. Sharma N, Cortez D, Imundo JR. High burden of premature ventricular contractions in structurally normal hearts: to worry or not in pediatric patients? Ann
Noninvasive Electrocardiol 2019;24:e12663.
603. Niwano S, Wakisaka Y, Niwano H, Fukaya H, Kurokawa S, Kiryu M, et al. Prognostic signiﬁcance of frequent premature ventricular contractions originating from the ventricular outﬂow tract in patients with normal left ventricular function. Heart
2009;95:1230–1237.
604. Krittayaphong R, Sriratanasathavorn C, Dumavibhat C, Pumprueg S, Boonyapisit
W, Pooranawattanakul S, et al. Electrocardiographic predictors of long-term outcomes after radiofrequency ablation in patients with right-ventricular outﬂow tract tachycardia. Europace 2006;8:601–606.
605. Komatsu Y, Nogami A, Kurosaki K, Morishima I, Masuda K, Ozawa T, et al.
Fascicular ventricular tachycardia originating from papillary muscles: Purkinje network involvement in the reentrant circuit. Circ Arrhythm Electrophysiol 2017;10:
e004549.
606. Kirk CR, Gibbs JL, Thomas R, Radley-Smith R, Qureshi SA. Cardiovascular collapse after verapamil in supraventricular tachycardia. Arch Dis Child 1987;62:1265–1266.
607. Duffee DF, Shen WK, Smith HC. Suppression of frequent premature ventricular contractions and improvement of left ventricular function in patients with presumed idiopathic dilated cardiomyopathy. Mayo Clin Proc 1998;73:430–433.


<!-- PAGE 119 -->

### Page 119

608. Chugh SS, Shen WK, Luria DM, Smith HC. First evidence of premature ventricular complex-induced cardiomyopathy: a potentially reversible cause of heart failure. J
Cardiovasc Electrophysiol 2000;11:328–329.
609. Penela D, Van Huls Van Taxis C, Van Huls Vans Taxis C, Aguinaga L,
Fernández-Armenta J, Mont L, et al. Neurohormonal, structural, and functional recovery pattern after premature ventricular complex ablation is independent of structural heart disease status in patients with depressed left ventricular ejection fraction: a prospective multicenter study. J Am Coll Cardiol 2013;62:1195–1202.
610. Penela D, Acosta J, Aguinaga L, Tercedor L, Ordoñez A, Fernández-Armenta J, et al.
Ablation of frequent PVC in patients meeting criteria for primary prevention ICD
implant: safety of withholding the implant. Heart Rhythm 2015;12:2434–2442.
611. Voskoboinik A, Hadjis A, Alhede C, Im SI, Park H, Moss J, et al. Predictors of adverse outcome in patients with frequent premature ventricular complexes: the ABC-VT
risk score. Heart Rhythm 2020;17:1066–1074.
612. Lee A, Denman R, Haqqani HM. Ventricular ectopy in the context of left ventricular systolic dysfunction: risk factors and outcomes following catheter ablation. Heart
Lung Circ 2019;28:379–388.
613. Sadron Blaye-Felice M, Hamon D, Sacher F, Pascale P, Rollin A, Duparc A, et al.
Premature ventricular contraction-induced cardiomyopathy: related clinical and electrophysiologic parameters. Heart Rhythm 2016;13:103–110.
614. Penela D, Fernández-Armenta J, Aguinaga L, Tercedor L, Ordoñez A, Bisbal F, et al.
Clinical recognition of pure premature ventricular complex-induced cardiomyopathy at presentation. Heart Rhythm 2017;14:1864–1870.
615. Aquaro GD, Pingitore A, Strata E, Di Bella G, Molinaro S, Lombardi M. Cardiac magnetic resonance predicts outcome in patients with premature ventricular complexes of left bundle branch block morphology. J Am Coll Cardiol 2010;56:
1235–1243.
616. Oebel S, Dinov B, Arya A, Hilbert S, Sommer P, Bollmann A, et al. ECG morphology of premature ventricular contractions predicts the presence of myocardial ﬁbrotic substrate on cardiac magnetic resonance imaging in patients undergoing ablation. J
Cardiovasc Electrophysiol 2017;28:1316–1323.
617. Mountantonakis SE, Frankel DS, Gerstenfeld EP, Dixit S, Lin D, Hutchinson MD,
et al. Reversal of outﬂow tract ventricular premature depolarization–induced cardiomyopathy with ablation: effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome. Heart Rhythm 2011;8:1608–1614.
618. Zang M, Zhang T, Mao J, Zhou S, He B. Beneﬁcial effects of catheter ablation of frequent premature ventricular complexes on left ventricular function. Heart 2014;
100:787–793.
619. Wijnmaalen AP, Delgado V, Schalij MJ, van Huls van Taxis CFB, Holman ER, Bax JJ,
et al. Beneﬁcial effects of catheter ablation on left ventricular and right ventricular function in patients with frequent premature ventricular contractions and preserved ejection fraction. Heart 2010;96:1275–1280.
620. Bogun F, Crawford T, Reich S, Koelling TM, Armstrong W, Good E, et al.
Radiofrequency ablation of frequent, idiopathic premature ventricular complexes:
comparison with a control group without intervention. Heart Rhythm 2007;4:
863–867.
621. Sarrazin J-F, Labounty T, Kuhne M, Crawford T, Armstrong WF, Desjardins B, et al.
Impact of radiofrequency ablation of frequent post-infarction premature ventricular complexes on left ventricular ejection fraction. Heart Rhythm 2009;6:
1543–1549.
622. El Kadri M, Yokokawa M, Labounty T, Mueller G, Crawford T, Good E, et al. Effect of ablation of frequent premature ventricular complexes on left ventricular function in patients with nonischemic cardiomyopathy. Heart Rhythm 2015;12:
706–713.
623. Lakkireddy D, Di Biase L, Ryschon K, Biria M, Swarup V, Reddy YM, et al.
Radiofrequency ablation of premature ventricular ectopy improves the efﬁcacy of cardiac resynchronization therapy in nonresponders. J Am Coll Cardiol 2012;
60:1531–1539.
624. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al.
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N
Engl J Med 1995;333:77–82.
625. Zhong L, Lee Y-H, Huang X-M, Asirvatham SJ, Shen W-K, Friedman PA, et al.
Relative efﬁcacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: a single-center retrospective study. Heart Rhythm 2014;
11:187–193.
626. Hyman MC, Mustin D, Supple G, Schaller RD, Santangeli P, Arkles J, et al. Class IC
antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy. Heart Rhythm 2018;15:159–163.
627. Laurent G, Saal S, Amarouch MY, Béziau DM, Marsman RFJ, Faivre L, et al. Multifocal ectopic Purkinje-related premature contractions: a new SCN5A-related cardiac channelopathy. J Am Coll Cardiol 2012;60:144–156.
628. Calloe K, Broendberg AK, Christensen AH, Pedersen LN, Olesen MS, de Los
Angeles Tejada M, et al. Multifocal atrial and ventricular premature contractions with an increased risk of dilated cardiomyopathy caused by a Nav1.5
gain-of-function mutation (G213D). Int J Cardiol 2018;257:160–167.
629. Mann SA, Castro ML, Ohanian M, Guo G, Zodgekar P, Sheu A, et al. R222Q
SCN5A mutation is associated with reversible ventricular ectopy and dilated cardiomyopathy. J Am Coll Cardiol 2012;60:1566–1573.
630. Beckermann TM, McLeod K, Murday V, Potet F, George AL. Novel SCN5A mutation in amiodarone-responsive multifocal ventricular ectopy-associated cardiomyopathy. Heart Rhythm 2014;11:1446–1453.
631. Doisne N, Waldmann V, Redheuil A, Waintraub X, Fressart V, Ader F, et al. A novel gain-of-function mutation in
SCN5A
responsible for multifocal ectopic
Purkinje-related premature contractions. Hum Mutat 2020;41:850–859.
632. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al.
Classiﬁcation of the cardiomyopathies: a position statement from the European
Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.
Eur Heart J 2008;29:270–276.
633. Codd MB, Sugrue DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County,
Minnesota, 1975–1984. Circulation 1989;80:564–572.
634. Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet 2017;
390:400–414.
635. Beggs SAS, Jhund PS, Jackson CE, McMurray JJV, Gardner RS. Non-ischaemic cardiomyopathy, sudden death and implantable deﬁbrillators: a review and meta-analysis. Heart 2018;104:144–150.
636. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence,
causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006;296:
1867–1876.
637. Pahl E, Sleeper LA, Canter CE, Hsu DT, Lu M, Webber SA, et al. Incidence of and risk factors for sudden cardiac death in children with dilated cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry. J Am Coll Cardiol 2012;59:
607–615.
638. Bharucha T, Lee KJ, Daubeney PEF, Nugent AW, Turner C, Sholler GF, et al.
Sudden death in childhood cardiomyopathy: results from a long-term national population-based study. J Am Coll Cardiol 2015;65:2302–2310.
639. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, et al. Proposal for a revised deﬁnition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC
working group on myocardial and pericardial diseases. Eur Heart J 2016;37:
1850–1858.
640. Asselbergs FW, Sammani A, Elliott P, Gimeno JR, Tavazzi L, Tendera M, et al.
Differences between familial and sporadic dilated cardiomyopathy: ESC EORP
Cardiomyopathy & Myocarditis registry. ESC Heart Fail 2021;8:95–105.
641. Ader F, De Groote P, Réant P, Rooryck-Thambo C, Dupin-Deguine D, Rambaud C,
et al. FLNC pathogenic variants in patients with cardiomyopathies: prevalence and genotype-phenotype correlations. Clin Genet 2019;96:317–329.
642. Kayvanpour E, Sedaghat-Hamedani F, Amr A, Lai A, Haas J, Holzer DB, et al.
Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. Clin Res Cardiol 2017;106:127–139.
643. Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent V,
et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol 2016;68:2440–2451.
644. van den Hoogenhof MMG, Beqqali A, Amin AS, van der Made I, Auﬁero S, Khan
MAF, et al. RBM20 mutations induce an arrhythmogenic dilated cardiomyopathy related to disturbed calcium handling. Circulation 2018;138:1330–1342.
645. Gigli M, Merlo M, Graw SL, Barbati G, Rowland TJ, Slavov DB, et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol
2019;74:1480–1490.
646. Heliö T, Elliott P, Koskenvuo JW, Gimeno JR, Tavazzi L, Tendera M, et al. ESC EORP
cardiomyopathy registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patients. ESC Heart Fail 2020;7:3013–3021.
647. Elming MB, Nielsen JC, Haarbo J, Videbæk L, Korup E, Signorovitch J, et al. Age and outcomes of primary prevention implantable cardioverter-deﬁbrillators in patients with nonischemic systolic heart failure. Circulation 2017;136:1772–1780.
648. Kristensen SL, Levy WC, Shadman R, Nielsen JC, Haarbo J, Videbæk L, et al. Risk models for prediction of implantable cardioverter-deﬁbrillator beneﬁt. JACC
Heart Fail 2019;7:717–724.
649. Wolff G, Lin Y, Karathanos A, Brockmeyer M, Wolters S, Nowak B, et al.
Implantable cardioverter/deﬁbrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. Clin Res Cardiol 2017;106:501–513.
650. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, et al.
Prophylactic deﬁbrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151–2158.
651. Klem I, Klein M, Khan M, Yang EY, Nabi F, Ivanov A, et al. Relationship of LVEF and myocardial scar to long-term mortality risk and mode of death in patients with nonischemic cardiomyopathy. Circulation 2021;143:1343–1358.
ESC Guidelines
4115


<!-- PAGE 120 -->

### Page 120

652. van Rijsingen IAW, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der
Kooi AJ, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol 2012;59:493–500.
653. Thuillot M, Maupain C, Gandjbakhch E, Waintraub X, Hidden-Lucet F, Isnard R,
et al. External validation of risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers. Eur J Heart Fail 2019;21:253–254.
654. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, et al. Long-term outcome and risk stratiﬁcation in dilated cardiolaminopathies. J Am Coll Cardiol
2008;52:1250–1260.
655. Skjølsvik ET, Hasselberg NE, Dejgaard LA, Lie ØH, Andersen K, Holm T, et al.
Exercise is associated with impaired left ventricular systolic function in patients with lamin A/C genotype. J Am Heart Assoc 2020;9:e012937.
656. Verstraelen TE, van Lint FHM, Bosman LP, de Brouwer R, Proost VM, Abeln BGS,
et al. Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction. Eur Heart J 2021;42:
2842–2850.
657. Knight BP, Goyal R, Pelosi F, Flemming M, Horwood L, Morady F, et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable deﬁbrillator. J Am Coll Cardiol 1999;33:1964–1970.
658. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable deﬁbrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004;292:2874–2879.
659. Merlo M, Gentile P, Artico J, Cannatà A, Paldino A, De Angelis G, et al. Arrhythmic risk stratiﬁcation in patients with dilated cardiomyopathy and intermediate left ventricular dysfunction. J Cardiovasc Med (Hagerstown) 2019;20:343–350.
660. Zecchin M, Di Lenarda A, Gregori D, Merlo M, Pivetta A, Vitrella G, et al. Are nonsustained ventricular tachycardias predictive of major arrhythmias in patients with dilated cardiomyopathy on optimal medical treatment? Pacing Clin Electro 2008;31:
290–299.
661. Link MS, Costeas XF, Grifﬁth JL, Colburn CD, Estes NA, Wang PJ. High incidence of appropriate implantable cardioverter-deﬁbrillator therapy in patients with syncope of unknown etiology and inducible ventricular arrhythmias. J Am Coll Cardiol 1997;
29:370–375.
662. Di Marco A, Brown PF, Bradley J, Nucifora G, Claver E, de Frutos F, et al. Improved risk stratiﬁcation for ventricular arrhythmias and sudden death in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 2021;77:2890–2905.
663. Kumar S, Romero J, Mehta NK, Fujii A, Kapur S, Baldinger SH, et al. Long-term outcomes after catheter ablation of ventricular tachycardia in patients with and without structural heart disease. Heart Rhythm 2016;13:1957–1963.
664. Muser D, Santangeli P, Castro SA, Pathak RK, Liang JJ, Hayashi T, et al. Long-term outcome after catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy. Circ Arrhythm Electrophysiol 2016;9:e004328.
665. Kumar S, Androulakis AFA, Sellal J-M, Maury P, Gandjbakhch E, Waintraub X, et al.
Multicenter experience with catheter ablation for ventricular tachycardia in lamin
A/C cardiomyopathy. Circ Arrhythm Electrophysiol 2016;9:e004357.
666. Oloriz T, Silberbauer J, Maccabelli G, Mizuno H, Baratto F, Kirubakaran S, et al.
Catheter ablation of ventricular arrhythmia in nonischemic cardiomyopathy: anteroseptal versus inferolateral scar sub-types. Circ Arrhythm Electrophysiol 2014;7:
414–423.
667. Francone M. Role of cardiac magnetic resonance in the evaluation of dilated cardiomyopathy: diagnostic contribution and prognostic signiﬁcance. ISRN Radiol 2014;
2014:365404.
668. Goldberger JJ, Subačius H, Patel T, Cunnane R, Kadish AH. Sudden cardiac death risk stratiﬁcation in patients with nonischemic dilated cardiomyopathy. J Am Coll
Cardiol 2014;63:1879–1889.
669. Ebert M, Wijnmaalen AP, de Riva M, Trines SA, Androulakis AFA, Glashan CA, et al.
Prevalence and prognostic impact of pathogenic variants in patients with dilated cardiomyopathy referred for ventricular tachycardia ablation.
JACC
Clin
Electrophysiol 2020;6:1103–1114.
670. Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy.
N Engl J Med 2017;376:1489–1490.
671. Quarta G, Muir A, Pantazis A, Syrris P, Gehmlich K, Garcia-Pavia P, et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation 2011;123:2701–2709.
672. Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, Jongbloed JDH, et al.
Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/
cardiomyopathy-associated mutation carriers. Eur Heart J 2015;36:847–855.
673. Rigato I, Bauce B, Rampazzo A, Zorzi A, Pilichou K, Mazzotti E, et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2013;6:533–542.
674. te Riele ASJM, James CA, Groeneweg JA, Sawant AC, Kammers K, Murray B, et al.
Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Eur Heart J 2016;37:755–763.
675. Chivulescu M, Lie ØH, Popescu BA, Skulstad H, Edvardsen T, Jurcut RO, et al. High penetrance and similar disease progression in probands and in family members with arrhythmogenic cardiomyopathy. Eur Heart J 2020;41:1401–1410.
676. Rastegar N, Te Riele ASJM, James CA, Bhonsale A, Murray B, Tichnell C, et al.
Fibrofatty changes: incidence at cardiac MR imaging in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Radiology 2016;280:405–412.
677. Aquaro GD, Barison A, Todiere G, Grigoratos C, Ait Ali L, Di Bella G, et al.
Usefulness of combined functional assessment by cardiac magnetic resonance and tissue characterization versus task force criteria for diagnosis of arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2016;118:1730–1736.
678. te Riele ASJM, Bhonsale A, James CA, Rastegar N, Murray B, Burt JR, et al.
Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratiﬁcation of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol 2013;62:1761–1769.
679. Corrado D, van Tintelen PJ, McKenna WJ, Hauer RNW, Anastastakis A, Asimaki A,
et al. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur Heart J 2020;41:1414–1429.
680. Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression.
Circulation 2007;115:1710–1720.
681. Cipriani A, Bauce B, De Lazzari M, Rigato I, Bariani R, Meneghin S, et al.
Arrhythmogenic right ventricular cardiomyopathy: characterization of left ventricular phenotype and differential diagnosis with dilated cardiomyopathy. J Am
Heart Assoc 2020;9:e014628.
682. Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari MD, et al.
Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. Int J Cardiol 2020;
319:106–114.
683. Saberniak J, Hasselberg NE, Borgquist R, Platonov PG, Sarvari SI, Smith H, et al.
Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members.
Eur J Heart Fail 2014;16:1337–1344.
684. Lie ØH, Dejgaard LA, Saberniak J, Rootwelt C, Stokke MK, Edvardsen T, et al.
Harmful effects of exercise intensity and exercise duration in patients with arrhythmogenic cardiomyopathy. JACC Clin Electrophysiol 2018;4:744–753.
685. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am
Coll Cardiol 2013;62:1290–1297.
686. Ruwald A-C, Marcus F, Estes NAM, Link M, McNitt S, Polonsky B, et al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North
American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2015;36:1735–1743.
687. Sawant AC, te Riele ASJM, Tichnell C, Murray B, Bhonsale A, Tandri H, et al. Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm 2016;13:199–207.
688. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 1988;318:129–133.
689. Finocchiaro G, Papadakis M, Robertus J-L, Dhutia H, Steriotis AK, Tome M, et al.
Etiology of sudden death in sports: insights from a United Kingdom Regional
Registry. J Am Coll Cardiol 2016;67:2108–2115.
690. Marcus GM, Glidden DV, Polonsky B, Zareba W, Smith LM, Cannom DS, et al.
Efﬁcacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol 2009;
54:609–615.
691. Hulot J-S, Jouven X, Empana J-P, Frank R, Fontaine G. Natural history and risk stratiﬁcation of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation
2004;110:1879–1884.
692. Wang W, Cadrin-Tourigny J, Bhonsale A, Tichnell C, Murray B, Monfredi O, et al.
Arrhythmic outcome of arrhythmogenic right ventricular cardiomyopathy patients without implantable deﬁbrillators. J Cardiovasc Electrophysiol 2018;29:1396–1402.
693. Pinamonti B, Dragos AM, Pyxaras SA, Merlo M, Pivetta A, Barbati G, et al.
Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. Eur Heart J 2011;32:1105–1113.
694. Brun F, Groeneweg JA, Gear K, Sinagra G, van der Heijden J, Mestroni L, et al. Risk stratiﬁcation in arrhythmic right ventricular cardiomyopathy without implantable cardioverter-deﬁbrillators. JACC Clin Electrophysiol 2016;2:558–564.
695. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, et al. Incidence and predictors of implantable cardioverter-deﬁbrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-deﬁbrillator implantation for primary prevention. J Am Coll Cardiol
2011;58:1485–1496.
696. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, et al. Prophylactic implantable deﬁbrillator in patients with arrhythmogenic right ventricular


<!-- PAGE 121 -->

### Page 121

cardiomyopathy/dysplasia and no prior ventricular ﬁbrillation or sustained ventricular tachycardia. Circulation 2010;122:1144–1152.
697. Platonov PG, Haugaa KH, Bundgaard H, Svensson A, Gilljam T, Hansen J, et al.
Primary prevention of sudden cardiac death with implantable cardioverterdeﬁbrillator therapy in patients with arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2019;123:1156–1162.
698. Link MS, Laidlaw D, Polonsky B, Zareba W, McNitt S, Gear K, et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors,
characteristics, and treatment. J Am Coll Cardiol 2014;64:119–125.
699. Schinkel AFL. Implantable cardioverter deﬁbrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications. Circ Arrhythm Electrophysiol
2013;6:562–568.
700. Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, et al. Implantable cardioverter-deﬁbrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003;
108:3084–3091.
701. Mazzanti A, Ng K, Faragli A, Maragna R, Chiodaroli E, Orphanou N, et al.
Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of arrhythmic risk. J Am Coll Cardiol 2016;68:2540–2550.
702. Cadrin-Tourigny J, Bosman LP, Wang W, Tadros R, Bhonsale A, Bourﬁss M, et al.
Sudden cardiac death prediction in arrhythmogenic right ventricular cardiomyopathy: a multinational collaboration. Circ Arrhythm Electrophysiol 2021;14:e008509.
703. Bosman LP, Sammani A, James CA, Cadrin-Tourigny J, Calkins H, van Tintelen JP,
et al. Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: a systematic review and meta-analysis. Heart Rhythm 2018;15:1097–1107.
704. Saguner AM, Vecchiati A, Baldinger SH, Rüeger S, Medeiros-Domingo A,
Mueller-Burri AS, et al. Different prognostic value of functional right ventricular parameters in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circ
Cardiovasc Imaging 2014;7:230–239.
705. Saguner AM, Medeiros-Domingo A, Schwyzer MA, On C-J, Haegeli LM, Wolber T,
et al. Usefulness of inducible ventricular tachycardia to predict long-term adverse outcomes in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol
2013;111:250–257.
706. Orgeron GM, Te Riele A, Tichnell C, Wang W, Murray B, Bhonsale A, et al.
Performance of the 2015 international task force consensus statement risk stratiﬁcation algorithm for implantable cardioverter-deﬁbrillator placement in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol
2018;11:e005593.
707. Orgeron GM, James CA, Te Riele A, Tichnell C, Murray B, Bhonsale A, et al.
Implantable cardioverter-deﬁbrillator therapy in arrhythmogenic right ventricular dysplasia/cardiomyopathy: predictors of appropriate therapy, outcomes, and complications. J Am Heart Assoc 2017;6:e006242.
708. Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G. Efﬁcacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 1992;
86:29–37.
709. Mahida S, Venlet J, Saguner AM, Kumar S, Baldinger SH, AbdelWahab A, et al.
Ablation compared with drug therapy for recurrent ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy: results from a multicenter study.
Heart Rhythm 2019;16:536–543.
710. Ermakov S, Gerstenfeld EP, Svetlichnaya Y, Scheinman MM. Use of ﬂecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2017;14:564–569.
711. Canpolat U, Kabakçi G, Aytemir K, Dural M, Şahiner L, Yorgun H, et al. Fragmented
QRS complex predicts the arrhythmic events in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia: frQRS and outcomes in ARVC/D. J
Cardiovasc Electrophysiol 2013;24:1260–1266.
712. Martin A, Crawford J, Skinner JR, Smith W. High arrhythmic burden but low mortality during long-term follow-up in arrhythmogenic right ventricular cardiomyopathy. Heart Lung Circ 2016;25:275–281.
713. Santangeli P, Dello Russo A, Pieroni M, Casella M, Di Biase L, Burkhardt JD, et al.
Fragmented and delayed electrograms within ﬁbrofatty scar predict arrhythmic events in arrhythmogenic right ventricular cardiomyopathy: Results from a prospective risk stratiﬁcation study. Heart Rhythm 2012;9:1200–1206.
714. Berruezo A, Fernández-Armenta J, Mont L, Zeljko H, Andreu D, Herczku C, et al.
Combined endocardial and epicardial catheter ablation in arrhythmogenic right ventricular dysplasia incorporating scar dechanneling technique. Circ Arrhythm
Electrophysiol 2012;5:111–121.
715. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC
guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/
American Heart Association Joint Committee on Clinical Practice Guidelines.
Circulation 2020;142:e533–e557.
716. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
Circulation 2014;130:484–495.
717. He D, Ye M, Zhang L, Jiang B. Prognostic signiﬁcance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy. Heart Lung 2018;47:122–126.
718. Weissler-Snir A, Dorian P, Rakowski H, Care M, Spears D. Primary prevention implantable cardioverter-deﬁbrillators in hypertrophic cardiomyopathy—are there predictors of appropriate therapy? Heart Rhythm 2021;18:63–70.
719. Khanna S, Wen I, Bhat A, Chen HHL, Gan GCH, Pathan F, et al. The role of multimodality imaging in the diagnosis of cardiac amyloidosis: a focused update. Front
Cardiovasc Med 2020;7:590557.
720. Pradella S, Grazzini G, De Amicis C, Letteriello M, Acquafresca M, Miele V. Cardiac magnetic resonance in hypertrophic and dilated cardiomyopathies. Radiol Med
2020;125:1056–1071.
721. Rosmini S, Biagini E, O’Mahony C, Bulluck H, Ruozi N, Lopes LR, et al. Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy. Heart 2017;103:300–306.
722. Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the
Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 2018;138:
1387–1398.
723. Kim HY, Park JE, Lee S-C, Jeon E-S, On YK, Kim SM, et al. Genotype-related clinical characteristics and myocardial ﬁbrosis and their association with prognosis in hypertrophic cardiomyopathy. J Clin Med 2020;9:1671.
724. Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm 2012;9:57–63.
725. Wang J, Wang Y, Zou Y, Sun K, Wang Z, Ding H, et al. Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy. Eur J Heart Fail 2014;16:950–957.
726. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015;65:1249–1254.
727. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RHM, et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol 2015;65:1915–1928.
728. O’Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al.
International External Validation Study of the 2014 European Society of
Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic
Cardiomyopathy (EVIDENCE-HCM). Circulation 2018;137:1015–1023.
729. Vriesendorp PA, Schinkel AFL, Liebregts M, Theuns DAMJ, van Cleemput J, ten
Cate FJ, et al. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 2015;8:829–835.
730. Lorenzini M, Anastasiou Z, O’Mahony C, Guttman OP, Gimeno JR, Monserrat L,
et al. Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population. JAMA Cardiol 2020;5:73–80.
731. Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RHM, Udelson JE, et al. Risk stratiﬁcation and outcome of patients with hypertrophic cardiomyopathy .=60 years of age. Circulation 2013;127:585–593.
732. Gimeno JR, Tomé-Esteban M, Loﬁego C, Hurtado J, Pantazis A, Mist B, et al.
Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009;30:2599–2605.
733. Pelliccia A, Lemme E, Maestrini V, Di Paolo FM, Pisicchio C, Di Gioia G, et al. Does sport participation worsen the clinical course of hypertrophic cardiomyopathy?
Clinical outcome of hypertrophic cardiomyopathy in athletes. Circulation 2018;
137:531–533.
734. Dejgaard LA, Haland TF, Lie OH, Ribe M, Bjune T, Leren IS, et al. Vigorous exercise in patients with hypertrophic cardiomyopathy. Int J Cardiol 2018;250:157–163.
735. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ.
Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;
42:873–879.
736. Rowin EJ, Maron BJ, Carrick RT, Patel PP, Koethe B, Wells S, et al. Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction. J Am Coll Cardiol 2020;75:3033–3043.
737. Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratiﬁcation and management. J Am Coll Cardiol 2017;69:761–773.
738. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ.
Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987–2991.
ESC Guidelines
4117


<!-- PAGE 122 -->

### Page 122

739. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: identiﬁcation of high risk patients. J Am Coll
Cardiol 2000;36:2212–2218.
740. Behr ER, Elliott P, McKenna WJ. Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Card Electrophysiol Rev 2002;6:
482–486.
741. Gatzoulis KA, Georgopoulos S, Antoniou C-K, Anastasakis A, Dilaveris P, Arsenos
P, et al. Programmed ventricular stimulation predicts arrhythmic events and survival in hypertrophic cardiomyopathy. Int J Cardiol 2018;254:175–181.
742. Norrish G, Qu C, Field E, Cervi E, Khraiche D, Klaassen S, et al. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. Eur J Prev Cardiol 2022;29:678–686.
743. Petryka-Mazurkiewicz J, Ziolkowska L, Kowalczyk-Domagala M, Mazurkiewicz L,
Boruc A, Spiewak M, et al. LGE for risk stratiﬁcation in primary prevention in children with HCM. JACC Cardiovasc Imaging 2020;13:2684–2686.
744. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:1596–1601.
745. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol
1989;13:1283–1288.
746. Maron BJ, Spirito P, Shen W-K, Haas TS, Formisano F, Link MS, et al. Implantable cardioverter-deﬁbrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:405–412.
747. Melacini P, Maron BJ, Bobbo F, Basso C, Tokajuk B, Zucchetto M, et al. Evidence that pharmacological strategies lack efﬁcacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart 2007;93:708–710.
748. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.
Br Heart J 1985;53:412–416.
749. Link MS, Bockstall K, Weinstock J, Alsheikh-Ali AA, Semsarian C, Estes NAM, et al.
Ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy and deﬁbrillators: triggers, treatment, and implications. J Cardiovasc Electrophysiol
2017;28:531–537.
750. Dallaglio PD, di Marco A, Moreno Weidmann Z, Perez L, Alzueta J, García-Alberola
A, et al. Antitachycardia pacing for shock prevention in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Heart Rhythm 2020;17:1084–1091.
751. Adduci C, Semprini L, Palano F, Musumeci MB, Volpe M, Autore C, et al. Safety and efﬁcacy of anti-tachycardia pacing in patients with hypertrophic cardiomyopathy implanted with an ICD. Pacing Clin Electrophysiol 2019;42:610–616.
752. Vaseghi M, Hu TY, Tung R, Vergara P, Frankel DS, Di Biase L, et al. Outcomes of catheter ablation of ventricular tachycardia based on etiology in nonischemic heart disease: an international ventricular tachycardia ablation center collaborative study.
JACC Clin Electrophysiol 2018;4:1141–1150.
753. Igarashi M, Nogami A, Kurosaki K, Hanaki Y, Komatsu Y, Fukamizu S, et al.
Radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy and apical aneurysm. JACC Clin Electrophysiol 2018;4:
339–350.
754. Dukkipati SR, d’Avila A, Soejima K, Bala R, Inada K, Singh S, et al. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol
2011;4:185–194.
755. Ross SB, Singer ES, Driscoll E, Nowak N, Yeates L, Puranik R, et al. Genetic architecture of left ventricular noncompaction in adults. Hum Genome Var 2020;7:33.
756. Weir-McCall JR, Yeap PM, Papagiorcopulo C, Fitzgerald K, Gandy SJ, Lambert M,
et al. Left ventricular noncompaction: anatomical phenotype or distinct cardiomyopathy? J Am Coll Cardiol 2016;68:2157–2165.
757. Aung N, Doimo S, Ricci F, Sanghvi MM, Pedrosa C, Woodbridge SP, et al.
Prognostic signiﬁcance of left ventricular noncompaction: systematic review and meta-analysis of observational studies. Circ Cardiovasc Imaging 2020;13:e009712.
758. Grigoratos C, Barison A, Ivanov A, Andreini D, Amzulescu M-S, Mazurkiewicz L,
et al. Meta-analysis of the prognostic role of late gadolinium enhancement and global systolic impairment in left ventricular noncompaction. JACC Cardiovasc Imaging
2019;12:2141–2151.
759. Richard P, Ader F, Roux M, Donal E, Eicher J-C, Aoutil N, et al. Targeted panel sequencing in adult patients with left ventricular non-compaction reveals a large genetic heterogeneity. Clin Genet 2019;95:356–367.
760. Seferović PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the
European Society of Cardiology. Eur J Heart Fail 2019;21:553–576.
761. Baig S, Edward NC, Kotecha D, Liu B, Nordin S, Kozor R, et al. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. Europace 2018;20:f153–f161.
762. Sperry BW, Ikram A, Hachamovitch R, Valent J, Vranian MN, Phelan D, et al. Efﬁcacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol 2016;67:2941–2948.
763. Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack F-U,
et al. Prophylactic implantation of cardioverter-deﬁbrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008;5:
235–240.
764. Merino JL, Peinado R. Arrhythmias associated with neuromuscular disorders. Card
Electrophysiol Rev 2002;6:132–135.
765. Punnoose AR, Kaltman JR, Pastor W, McCarter R, He J, Spurney CF. Cardiac disease burden and risk of mortality in hospitalized muscular dystrophy patients.
Pediatr Cardiol 2016;37:1290–1296.
766. Wahbi K, Meune C, Porcher R, Bécane HM, Lazarus A, Laforêt P, et al.
Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA 2012;307:1292–1301.
767. Lallemand B, Clementy N, Bernard-Brunet A, Pierre B, Corcia P, Fauchier L, et al.
The evolution of infrahissian conduction time in myotonic dystrophy patients: clinical implications. Heart 2012;98:291–296.
768. Nogami A. Bundle branch reentry tachycardia. ESC CardioMed. 3rd ed. Oxford
University Press; 2022, pp. 2270–2275.
769. Sanna T, Dello Russo A, Toniolo D, Vytopil M, Pelargonio G, De Martino G, et al.
Cardiac features of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutations. Eur Heart J 2003;24:2227–2236.
770. Menon SC, Etheridge SP, Liesemer KN, Williams RV, Bardsley T, Heywood MC,
et al. Predictive value of myocardial delayed enhancement in Duchenne muscular dystrophy. Pediatr Cardiol 2014;35:1279–1285.
771. Florian A, Ludwig A, Engelen M, Waltenberger J, Rösch S, Sechtem U, et al. Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients. J Cardiovasc Magn Reson 2014;16:81.
772. Prystowsky EN, Pritchett EL, Roses AD, Gallagher J. The natural history of conduction system disease in myotonic muscular dystrophy as determined by serial electrophysiologic studies. Circulation 1979;60:1360–1364.
773. Trachtenberg BH, Hare JM. Inﬂammatory cardiomyopathic syndromes. Circ Res
2017;121:803–818.
774. Hulsmans M, Clauss S, Xiao L, Aguirre AD, King KR, Hanley A, et al. Macrophages facilitate electrical conduction in the heart. Cell 2017;169:510–522.
775. Youker KA, Assad-Kottner C, Cordero-Reyes AM, Trevino AR, Flores-Arredondo
JH, Barrios R, et al. High proportion of patients with end-stage heart failure regardless of aetiology demonstrates anti-cardiac antibody deposition in failing myocardium: humoral activation, a potential contributor of disease progression. Eur
Heart J 2014;35:1061–1068.
776. Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inﬂammation in heart failure. Nat Rev Cardiol 2020;17:269–285.
777. Sagar S, Liu PP, Cooper LT. Myocarditis. Lancet 2012;379:738–747.
778. Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, et al. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis: multicenter Lombardy registry. Circulation 2018;138:1088–1099.
779. Fabre A. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart 2005;92:316–320.
780. Lynge TH, Nielsen TS, Gregers Winkel B, Tfelt-Hansen J, Banner J. Sudden cardiac death caused by myocarditis in persons aged 1–49 years: a nationwide study of 14
294 deaths in Denmark. Forensic Sci Res 2019;4:247–256.
781. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NAM, et al.
Eligibility and disqualiﬁcation recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis. J Am Coll Cardiol 2015;66:2362–2371.
782. Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on myocarditis. J Am Coll Cardiol 2012;59:779–792.
783. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al.
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology
Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:
2636–2648.
784. Singh V, Mendirichaga R, Savani GT, Rodriguez A, Blumer V, Elmariah S, et al.
Comparison of utilization trends, indications, and complications of endomyocardial biopsy in native versus donor hearts (from the Nationwide Inpatient Sample 2002
to 2014). Am J Cardiol 2018;121:356–363.
785. Aoyama N, Izumi T, Hiramori K, Isobe M, Kawana M, Hiroe M, et al. National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientiﬁc committee). Circ J 2002;66:133–144.


<!-- PAGE 123 -->

### Page 123

786. Shah Z, Mohammed M, Vuddanda V, Ansari MW, Masoomi R, Gupta K. National trends, gender, management, and outcomes of patients hospitalized for myocarditis. Am J Cardiol 2019;124:131–136.
787. Anderson BR, Silver ES, Richmond ME, Liberman L. Usefulness of arrhythmias as predictors of death and resource utilization in children with myocarditis. Am J
Cardiol 2014;114:1400–1405.
788. Kandolin R, Lehtonen J, Salmenkivi K, Räisänen-Sokolowski A, Lommi J, Kupari M.
Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 2013;6:15–22.
789. Cooper LT, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis—natural history and treatment. N Engl J Med 1997;336:1860–1866.
790. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
2012: the task force for the Diagnosis and Treatment of Acute and Chronic Heart
Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:
1787–1847.
791. Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis 2010;52:274–288.
792. JCS Joint Working Group. Guidelines for diagnosis and treatment of myocarditis
(JCS 2009): digest version. Circ J 2011;75:734–743.
793. Ali-Ahmed F, Dalgaard F, Al-Khatib SM. Sudden cardiac death in patients with myocarditis: Evaluation, risk stratiﬁcation, and management. Am Heart J 2020;220:
29–40.
794. Rosier L, Zouaghi A, Barré V, Martins R, Probst V, Marijon E, et al. High risk of sustained ventricular arrhythmia recurrence after acute myocarditis. J Clin Med 2020;9:
E848.
795. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al.
Contemporary deﬁnitions and classiﬁcation of the cardiomyopathies:
an
American Heart Association Scientiﬁc Statement from the Council on Clinical
Cardiology, Heart Failure and Transplantation Committee; Quality of Care and
Outcomes Research and Functional Genomics and Translational Biology
Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.
Circulation 2006;113:1807–1816.
796. D’Ambrosio A, Patti G, Manzoli A, Sinagra G, Di Lenarda A, Silvestri F, et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001;85:499–504.
797. Kasper EK, Agema WRP, Hutchins GM, Deckers JW, Hare JM, Baughman KL. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 1994;23:586–590.
798. Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al. Long-term follow-up of biopsy-proven viral myocarditis. J Am Coll Cardiol 2012;59:1604–1615.
799. Bennett MK, Gilotra NA, Harrington C, Rao S, Dunn JM, Freitag TB, et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000–2009. Circ Heart Fail 2013;6:676–684.
800. Schumm J, Greulich S, Wagner A, Grün S, Ong P, Bentz K, et al. Cardiovascular magnetic resonance risk stratiﬁcation in patients with clinically suspected myocarditis. J Cardiovasc Magn Reson 2014;16:14.
801. Russo AD, Casella M, Pieroni M, Pelargonio G, Bartoletti S, Santangeli P, et al.
Drug-refractory ventricular tachycardias after myocarditis: endocardial and epicardial radiofrequency catheter ablation. Circ Arrhythm Electrophysiol 2012;5:492–498.
802. Maccabelli G, Tsiachris D, Silberbauer J, Esposito A, Bisceglia C, Baratto F, et al.
Imaging and epicardial substrate ablation of ventricular tachycardia in patients late after myocarditis. Europace 2014;16:1363–1372.
803. Berte B, Sacher F, Cochet H, Mahida S, Yamashita S, Lim H, et al. Postmyocarditis ventricular tachycardia in patients with epicardial-only scar: a speciﬁc entity requiring a speciﬁc approach: epicardial-only VT ablation. J Cardiovasc Electrophysiol 2015;
26:42–50.
804. Maleszewski JJ, Orellana VM, Hodge DO, Kuhl U, Schultheiss H-P, Cooper LT.
Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis.
Am J Cardiol 2015;115:1733–1738.
805. El-Assaad I, Al-Kindi SG, Oliveira GH, Boyle GJ, Aziz PF. Implantable cardioverterdeﬁbrillator and wait-list outcomes in pediatric patients awaiting heart transplantation. Heart Rhythm 2015;12:2443–2448.
806. Ekström K, Lehtonen J, Kandolin R, Räisänen-Sokolowski A, Salmenkivi K, Kupari M.
Long-term outcome and its predictors in giant cell myocarditis: giant cell myocarditis. Eur J Heart Fail 2016;18:1452–1458.
807. Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz
EA, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001;164:2085–2091.
808. Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017;121:819–837.
809. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS
expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1304–1323.
810. Birnie DH, Kandolin R, Nery PB, Kupari M. Cardiac manifestations of sarcoidosis:
diagnosis and management. Eur Heart J 2016;38:2663–2670.
811. Trivieri MG, Spagnolo P, Birnie D, Liu P, Drake W, Kovacic JC, et al. Challenges in cardiac and pulmonary sarcoidosis: JACC state-of-the-art review. J Am Coll Cardiol
2020;76:1878–1901.
812. Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015;131:624–632.
813. Hoogendoorn JC, Sramko M, Venlet J, Siontis KC, Kumar S, Singh R, et al.
Electroanatomical voltage mapping to distinguish right-sided cardiac sarcoidosis from arrhythmogenic right ventricular cardiomyopathy. JACC Clin Electrophysiol
2020;6:696–707.
814. Banba K, Kusano KF, Nakamura K, Morita H, Ogawa A, Ohtsuka F, et al.
Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis.
Heart Rhythm 2007;4:1292–1299.
815. Takaya Y, Kusano KF, Nakamura K, Ito H. Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis. Am J Cardiol
2015;115:505–509.
816. Nordenswan H-K, Lehtonen J, Ekström K, Kandolin R, Simonen P, Mäyränpää M,
et al. Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular block. Circ Arrhythm Electrophysiol 2018;11.
817. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC
Cardiovasc Imaging 2013;6:501–511.
818. Nadel J, Lanceﬁeld T, Voskoboinik A, Taylor AJ. Late gadolinium enhancement identiﬁed with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J
Cardiovasc Imaging 2015;16:631–641.
819. Murtagh G, Lafﬁn LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV, et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratiﬁcation using cardiovascular magnetic resonance. Circ
Cardiovasc Imaging 2016;9:e003738.
820. Ekström K, Lehtonen J, Hänninen H, Kandolin R, Kivistö S, Kupari M. Magnetic resonance imaging as a predictor of survival free of life-threatening arrhythmias and transplantation in cardiac sarcoidosis. J Am Heart Assoc 2016;5:e003040.
821. Coleman GC, Shaw PW, Balfour PC, Gonzalez JA, Kramer CM, Patel AR, et al.
Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis. JACC Cardiovasc Imaging 2017;10:411–420.
822. Aizer A, Stern EH, Gomes JA, Teirstein AS, Eckart RE, Mehta D. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol 2005;96:276–282.
823. Mehta D, Mori N, Goldbarg SH, Lubitz S, Wisnivesky JP, Teirstein A. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 2011;4:43–48.
824. Okada DR, Smith J, Derakhshan A, Gowani Z, Zimmerman SL, Misra S, et al.
Electrophysiology study for risk stratiﬁcation in patients with cardiac sarcoidosis and abnormal cardiac imaging. Int J Cardiol Heart Vasc 2019;23:100342.
825. Zipse MM, Tzou WS, Schuller JL, Aleong RG, Varosy PD, Tompkins C, et al.
Electrophysiologic testing for diagnostic evaluation and risk stratiﬁcation in patients with suspected cardiac sarcoidosis with preserved left and right ventricular systolic function. J Cardiovasc Electrophysiol 2019;30:1939–1948.
826. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329–336.
827. Crawford T, Mueller G, Sarsam S, Prasitdumrong H, Chaiyen N, Gu X, et al.
Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol 2014;7:1109–1115.
828. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR, et al. Implantable cardioverter deﬁbrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc
Electrophysiol 2012;23:925–929.
829. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC,
et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-deﬁbrillators. Heart Rhythm 2012;9:884–891.
830. Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, et al. Efﬁcacy and safety of implantable cardiac deﬁbrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. EP Europace 2013;15:347–354.
831. Mohsen A, Jimenez A, Hood RE, Dickfeld T, Saliaris A, Shorofsky S, et al. Cardiac sarcoidosis: electrophysiological outcomes on long-term follow-up and the role of the implantable cardioverter-deﬁbrillator. J Cardiovasc Electrophysiol 2014;25:
171–176.
832. Azoulay L-D, Waintraub X, Haroche J, Amoura Z, Cohen Aubart F. Factors associated with implantable cardioverter deﬁbrillators appropriate therapy in cardiac sarcoidosis: a meta-analysis: implantable cardioverter deﬁbrillators in cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:17–23.
ESC Guidelines
4119


<!-- PAGE 124 -->

### Page 124

833. Smedema J-P, van Geuns R-J, Ector J, Heidbuchel H, Ainslie G, Crijns HJGM. Right ventricular involvement and the extent of left ventricular enhancement with magnetic resonance predict adverse outcome in pulmonary sarcoidosis. ESC Heart Fail
2018;5:157–171.
834. Velangi PS, Chen K-HA, Kazmirczak F, Okasha O, von Wald L, Roukoz H, et al.
Right ventricular abnormalities on cardiovascular magnetic resonance imaging in patients with sarcoidosis. JACC Cardiovasc Imaging 2020;13:1395–1405.
835. Ise T, Hasegawa T, Morita Y, Yamada N, Funada A, Takahama H, et al. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 2014;100:1165–1172.
836. Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis: effect of corticosteroid therapy. Ann Noninvasive Electrocardiol 2011;16:140–147.
837. Naruse Y, Sekiguchi Y, Nogami A, Okada H, Yamauchi Y, Machino T, et al.
Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis.
Circ Arrhythm Electrophysiol 2014;7:407–413.
838. Segawa M, Fukuda K, Nakano M, Kondo M, Satake H, Hirano M, et al. Time course and factors correlating with ventricular tachyarrhythmias after introduction of steroid therapy in cardiac sarcoidosis. Circ Arrhythm Electrophysiol 2016;9:e003353.
839. Kumar S, Barbhaiya C, Nagashima K, Choi E-K, Epstein LM, John RM, et al.
Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol 2015;8:
87–93.
840. Muser D, Santangeli P, Liang JJ, Castro SA, Magnani S, Hayashi T, et al.
Characterization of the electroanatomic substrate in cardiac sarcoidosis. JACC
Clin Electrophysiol 2018;4:291–303.
841. Jeﬁc D, Joel B, Good E, Morady F, Rosman H, Knight B, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm 2009;6:189–195.
842. Papageorgiou N, Providência R, Bronis K, Dechering DG, Srinivasan N, Eckardt L,
et al. Catheter ablation for ventricular tachycardia in patients with cardiac sarcoidosis: a systematic review. EP Europace 2018;20:682–691.
843. Siontis KC, Santangeli P, Muser D, Marchlinski FE, Zeppenfeld K, Hoogendoorn JC,
et al. Outcomes associated with catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. JAMA Cardiol 2022;7:175.
844. Hoogendoorn JC, Venlet J, Out YNJ, Man S, Kumar S, Sramko M, et al. The precordial R’ wave: a novel discriminator between cardiac sarcoidosis and arrhythmogenic right ventricular cardiomyopathy in patients presenting with ventricular tachycardia. Heart Rhythm 2021;18:1539–1547.
845. Bern C. Chagas’ disease. N Engl J Med 2015;373:456–466.
846. Bocchi EA, Bestetti RB, Scanavacca MI, Cunha Neto E, Issa VS. Chronic chagas heart disease management. J Am Coll Cardiol 2017;70:1510–1524.
847. Nunes MCP, Dones W, Morillo CA, Encina JJ, Ribeiro AL. Chagas disease. J Am Coll
Cardiol 2013;62:767–776.
848. Nunes MCP, Beaton A, Acquatella H, Bern C, Bolger AF, Echeverría LE, et al.
Chagas cardiomyopathy: an update of current clinical knowledge and management:
a scientiﬁc statement from the American heart association. Circulation 2018;138:
e169–e209.
849. Rassi A, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a risk score for predicting death in Chagas’ heart disease. N Engl J Med
2006;355:799–808.
850. Senra T, Ianni BM, Costa ACP, Mady C, Martinelli-Filho M, Kalil-Filho R, et al.
Long-term prognostic value of myocardial ﬁbrosis in patients with chagas cardiomyopathy. J Am Coll Cardiol 2018;72:2577–2587.
851. Rassi FM, Minohara L, Rassi A, Correia LCL, Marin-Neto JA, Rassi A, et al.
Systematic review and meta-analysis of clinical outcome after implantable cardioverter-deﬁbrillator therapy in patients with chagas heart disease. JACC Clin
Electrophysiol 2019;5:1213–1223.
852. Cardinalli-Neto A, Bestetti RB, Cordeiro JA, Rodrigues VC. Predictors of all-cause mortality for patients with chronic Chagas’ heart disease receiving implantable cardioverter deﬁbrillator therapy. J Cardiovasc Electrophysiol 2007;18:1236–1240.
853. Muratore CA, Batista Sa LA, Chiale PA, Eloy R, Tentori MC, Escudero J, et al.
Implantable cardioverter deﬁbrillators and chagas’ disease: results of the ICD registry Latin America. Europace 2008;11:164–168.
854. Martinelli M, de Siqueira SF, Sternick EB, Rassi A, Costa R, Ramires JAF, et al.
Long-term follow-up of implantable cardioverter-deﬁbrillator for secondary prevention in chagas’ heart disease. Am J Cardiol 2012;110:1040–1045.
855. Gali WL, Sarabanda AV, Baggio JM, Ferreira LG, Gomes GG, Marin-Neto JA, et al.
Implantable cardioverter-deﬁbrillators for treatment of sustained ventricular arrhythmias in patients with chagas’ heart disease: comparison with a control group treated with amiodarone alone. Europace 2014;16:674–680.
856. Carmo AAL, de Sousa MR, Agudelo JF, Boersma E, Rocha MOC, Ribeiro ALP, et al.
Implantable cardioverter-deﬁbrillator in chagas heart disease: a systematic review and meta-analysis of observational studies. Int J Cardiol 2018;267:88–93.
857. Stein C, Migliavaca CB, Colpani V, da Rosa PR, Sganzerla D, Giordani NE, et al.
Amiodarone for arrhythmia in patients with chagas disease: a systematic review and individual patient data meta-analysis. PLoS Negl Trop Dis 2018;12:e0006742.
858. Sosa E, Scanavacca M, D’Avila A, Piccioni J, Sanchez O, Velarde JL, et al. Endocardial and epicardial ablation guided by nonsurgical transthoracic epicardial mapping to treat recurrent ventricular tachycardia. J Cardiovasc Electrophysiol 1998;9:229–239.
859. Soto-Becerra R, Bazan V, Bautista W, Malavassi F, Altamar J, Ramirez JD, et al.
Ventricular tachycardia in the setting of chagasic cardiomyopathy: use of voltage mapping to characterize endoepicardial nonischemic scar distribution. Circ
Arrhythm Electrophysiol 2017;10:e004950.
860. Pisani CF, Romero J, Lara S, Hardy C, Chokr M, Sacilotto L, et al. Efﬁcacy and safety of combined endocardial/epicardial catheter ablation for ventricular tachycardia in chagas disease: a randomized controlled study. Heart Rhythm 2020;17:1510–1518.
861. Chizner MA, Pearle DL, deLeon AC. The natural history of aortic stenosis in adults.
Am Heart J 1980;99:419–424.
862. Delahaye JP, Gare JP, Viguier E, Delahaye F, De Gevigney G, Milon H. Natural history of severe mitral regurgitation. Eur Heart J 1991;12:5–9.
863. Groves P. Valve disease: surgery of valve disease: late results and late complications.
Heart 2001;86:715–721.
864. Blackstone EH, Kirklin JW. Death and other time-related events after valve replacement. Circulation 1985;72:753–767.
865. Urena M, Webb JG, Eltchaninoff H, Muñoz-García AJ, Bouleti C, Tamburino C, et al.
Late cardiac death in patients undergoing transcatheter aortic valve replacement:
incidence and predictors of advanced heart failure and sudden cardiac death.
J Am Coll Cardiol 2015;65:437–448.
866. Yang F, Shah B, Iwai S, Markowitz SM, Lerman BB, Stein KM. ICD implantation and arrhythmia-free survival in patients with depressed LV function following surgery for valvular heart disease. Pacing Clin Electrophysiol 2008;31:1419–1424.
867. Valles AG, Khawaja FJ, Gersh BJ, Enriquez-Sarano M, Friedman PA, Park SJ, et al.
Implantable cardioverter deﬁbrillators in patients with valvular cardiomyopathy.
J Cardiovasc Electrophysiol 2012;23:1326–1332.
868. Rodríguez-Mañero
M,
Barrio-López
MT,
Assi
EA,
Expósito-García
V,
Bertomeu-González V, Sánchez-Gómez JM, et al. Primary prevention of sudden death in patients with valvular cardiomyopathy. Rev Esp Cardiol (Engl Ed) 2016;
69:272–278.
869. Fischer-Rasokat U, Renker M, Liebetrau C, Weferling M, Rolf A, Hain A, et al.
Long-term survival in patients with or without implantable cardioverter deﬁbrillator after transcatheter aortic valve implantation. J Clin Med 2021;10:2929.
870. Nies RJ, Frerker C, Adam M, Kuhn E, Mauri V, Nettersheim FS, et al. Is there a beneﬁt of ICD treatment in patients with persistent severely reduced systolic left ventricular function after TAVI? Clin Res Cardiol 2022;111:492–501.
871. Eckart RE, Hruczkowski TW, Tedrow UB, Koplan BA, Epstein LM, Stevenson WG.
Sustained ventricular tachycardia associated with corrective valve surgery.
Circulation 2007;116:2005–2011.
872. Liang JJ, Castro SA, Muser D, Briceno DF, Shirai Y, Enriquez A, et al.
Electrophysiologic substrate, safety, procedural approaches, and outcomes of catheter ablation for ventricular tachycardia in patients after aortic valve replacement.
JACC Clin Electrophysiol 2019;5:28–38.
873. Delling FN, Vasan RS. Epidemiology and pathophysiology of mitral valve prolapse:
new insights into disease progression, genetics, and molecular basis. Circulation
2014;129:2158–2170.
874. Nalliah CJ, Mahajan R, Elliott AD, Haqqani H, Lau DH, Vohra JK, et al. Mitral valve prolapse and sudden cardiac death: a systematic review and meta-analysis. Heart
2019;105:144–151.
875. Nishimura RA, McGoon MD, Shub C, Miller FA, Ilstrup DM, Tajik AJ.
Echocardiographically documented mitral-valve prolapse. Long-term follow-up of
237 patients. N Engl J Med 1985;313:1305–1309.
876. Perazzolo Marra M, Basso C, De Lazzari M, Rizzo S, Cipriani A, Giorgi B, et al.
Morphofunctional abnormalities of mitral annulus and arrhythmic mitral valve prolapse. Circ Cardiovasc Imaging 2016;9:e005030.
877. Sriram CS, Syed FF, Ferguson ME, Johnson JN, Enriquez-Sarano M, Cetta F, et al.
Malignant bileaﬂet mitral valve prolapse syndrome in patients with otherwise idiopathic out-of-hospital cardiac arrest. J Am Coll Cardiol 2013;62:222–230.
878. Kitkungvan D, Nabi F, Kim RJ, Bonow RO, Khan MA, Xu J, et al. Myocardial ﬁbrosis in patients with primary mitral regurgitation with and without prolapse. J Am Coll
Cardiol 2018;72:823–834.
879. Nordhues BD, Siontis KC, Scott CG, Nkomo VT, Ackerman MJ, Asirvatham SJ,
et al. Bileaﬂet mitral valve prolapse and risk of ventricular dysrhythmias and death.
J Cardiovasc Electrophysiol 2016;27:463–468.
880. Essayagh B, Sabbag A, Antoine C, Benfari G, Yang L-T, Maalouf J, et al. Presentation and outcome of arrhythmic mitral valve prolapse. J Am Coll Cardiol 2020;76:
637–649.
881. Narasimhan C, Jazayeri MR, Sra J, Dhala A, Deshpande S, Biehl M, et al. Ventricular tachycardia in valvular heart disease: facilitation of sustained bundle-branch reentry by valve surgery. Circulation 1997;96:4307–4313.


<!-- PAGE 125 -->

### Page 125

882. Moons P, Bovijn L, Budts W, Belmans A, Gewillig M. Temporal trends in survival to adulthood among patients born with congenital heart disease from 1970 to 1992 in
Belgium. Circulation 2010;122:2264–2272.
883. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010.
Circulation 2014;130:749–756.
884. Koyak Z, Harris L, de Groot JR, Silversides CK, Oechslin EN, Bouma BJ, et al.
Sudden cardiac death in adult congenital heart disease. Circulation 2012;126:
1944–1954.
885. Gallego P, Gonzalez AE, Sanchez-Recalde A, Peinado R, Polo L, Gomez-Rubin C,
et al. Incidence and predictors of sudden cardiac arrest in adults with congenital heart defects repaired before adult life. Am J Cardiol 2012;110:109–117.
886. Ghai A, Silversides C, Harris L, Webb GD, Siu SC, Therrien J. Left ventricular dysfunction is a risk factor for sudden cardiac death in adults late after repair of tetralogy of Fallot. J Am Coll Cardiol 2002;40:1675–1680.
887. Khairy P, Landzberg MJ, Gatzoulis MA, Lucron H, Lambert J, Marçon F, et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation 2004;109:1994–2000.
888. Kapel GFL, Sacher F, Dekkers OM, Watanabe M, Blom NA, Thambo J-B, et al.
Arrhythmogenic anatomical isthmuses identiﬁed by electroanatomical mapping are the substrate for ventricular tachycardia in repaired tetralogy of Fallot. Eur
Heart J 2017;38:268–276.
889. Atallah J, Gonzalez Corcia MC, Walsh EP. Participating members of the pediatric and congenital electrophysiology society. Ventricular arrhythmia and lifethreatening events in patients with repaired tetralogy of Fallot. Am J Cardiol 2020;
132:126–132.
890. Kammeraad JAE, van Deurzen CHM, Sreeram N, Bink-Boelkens MTE, Ottenkamp
J, Helbing WA, et al. Predictors of sudden cardiac death after Mustard or Senning repair for transposition of the great arteries. J Am Coll Cardiol 2004;44:1095–1102.
891. Schwerzmann M, Salehian O, Harris L, Siu SC, Williams WG, Webb GD, et al.
Ventricular arrhythmias and sudden death in adults after a Mustard operation for transposition of the great arteries. Eur Heart J 2009;30:1873–1879.
892. Miyazaki A, Sakaguchi H, Ohuchi H, Matsuoka M, Komori A, Yamamoto T, et al.
Efﬁcacy of hemodynamic-based management of tachyarrhythmia after repair of tetralogy of Fallot. Circ J 2012;76:2855–2862.
893. Harrison DA, Harris L, Siu SC, MacLoghlin CJ, Connelly MS, Webb GD, et al.
Sustained ventricular tachycardia in adult patients late after repair of tetralogy of
Fallot. J Am Coll Cardiol 1997;30:1368–1373.
894. Sabate Rotes A, Connolly HM, Warnes CA, Ammash NM, Phillips SD, Dearani JA,
et al. Ventricular arrhythmia risk stratiﬁcation in patients with tetralogy of Fallot at the time of pulmonary valve replacement. Circ Arrhythm Electrophysiol 2015;8:
110–116.
895. Khairy P, Harris L, Landzberg MJ, Fernandes SM, Barlow A, Mercier L-A, et al.
Sudden death and deﬁbrillators in transposition of the great arteries with intra-atrial bafﬂes: a multicenter study. Circ Arrhythm Electrophysiol 2008;1:250–257.
896. Roca-Luque I, Rivas Gándara N, Dos Subirà L, Francisco Pascual J, Pérez-Rodon J,
Pijuan Domenech A, et al. Intra-atrial re-entrant tachycardia in patients with congenital heart disease: factors associated with disease severity. Europace 2018;20:
1343–1351.
897. Zeppenfeld K, Schalij MJ, Bartelings MM, Tedrow UB, Koplan BA, Soejima K, et al.
Catheter ablation of ventricular tachycardia after repair of congenital heart disease:
electroanatomic identiﬁcation of the critical right ventricular isthmus. Circulation
2007;116:2241–2252.
898. Kriebel T, Saul JP, Schneider H, Sigler M, Paul T. Noncontact mapping and radiofrequency catheter ablation of fast and hemodynamically unstable ventricular tachycardia after surgical repair of tetralogy of Fallot. J Am Coll Cardiol 2007;50:
2162–2168.
899. van Zyl M, Kapa S, Padmanabhan D, Chen FC, Mulpuru SK, Packer DL, et al.
Mechanism and outcomes of catheter ablation for ventricular tachycardia in adults with repaired congenital heart disease. Heart Rhythm 2016;13:1449–1454.
900. Laredo M, Frank R, Waintraub X, Gandjbakhch E, Iserin L, Hascoët S, et al. Ten-year outcomes of monomorphic ventricular tachycardia catheter ablation in repaired tetralogy of Fallot. Arch Cardiovasc Dis 2017;110:292–302.
901. Kapel GFL, Reichlin T, Wijnmaalen AP, Piers SRD, Holman ER, Tedrow UB, et al.
Re-entry using anatomically determined isthmuses: a curable ventricular tachycardia in repaired congenital heart disease. Circ Arrhythm Electrophysiol 2015;8:
102–109.
902. Bokma JP, de Wilde KC, Vliegen HW, van Dijk AP, van Melle JP, Meijboom FJ, et al.
Value of cardiovascular magnetic resonance imaging in noninvasive risk stratiﬁcation in tetralogy of Fallot. JAMA Cardiol 2017;2:678–683.
903. Koyak Z, de Groot JR, Bouma BJ, Van Gelder IC, Budts W, Zwinderman AH, et al.
Symptomatic but not asymptomatic non-sustained ventricular tachycardia is associated with appropriate implantable cardioverter therapy in tetralogy of Fallot. Int J
Cardiol 2013;167:1532–1535.
904. Khairy P, Harris L, Landzberg MJ, Viswanathan S, Barlow A, Gatzoulis MA, et al.
Implantable cardioverter-deﬁbrillators in tetralogy of Fallot. Circulation 2008;117:
363–370.
905. Koyak Z, de Groot JR, Van Gelder IC, Bouma BJ, van Dessel PFHM, Budts W, et al.
Implantable cardioverter deﬁbrillator therapy in adults with congenital heart disease: who is at risk of shocks? Circ Arrhythm Electrophysiol 2012;5:101–110.
906. Cochet H, Iriart X, Allain-Nicolaï A, Camaioni C, Sridi S, Nivet H, et al. Focal scar and diffuse myocardial ﬁbrosis are independent imaging markers in repaired tetralogy of Fallot. Eur Heart J Cardiovasc Imaging 2019;20:990–1003.
907. Babu-Narayan SV, Kilner PJ, Li W, Moon JC, Goktekin O, Davlouros PA, et al.
Ventricular ﬁbrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of fallot and its relationship to adverse markers of clinical outcome. Circulation 2006;113:405–413.
908. Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 2000;356:975–981.
909. Bokma JP, Winter MM, Vehmeijer JT, Vliegen HW, van Dijk AP, van Melle JP, et al.
QRS fragmentation is superior to QRS duration in predicting mortality in adults with tetralogy of Fallot. Heart 2017;103:666–671.
910. Egbe AC, Kothapalli S, Borlaug BA, Ammash NM, Najam M, Bajwa N, et al.
Mechanism and risk factors for death in adults with tetralogy of Fallot. Am J
Cardiol 2019;124:803–807.
911. Survivors of out-of-hospital cardiac arrest with apparently normal heart. Need for deﬁnition and standardized clinical evaluation. Consensus statement of the joint steering committees of the unexplained cardiac arrest registry of Europe and of the idiopathic ventricular ﬁbrillation registry of the United States. Circulation
1997;95:265–272.
912. Leenhardt A, Glaser E, Burguera M, Nürnberg M, Maison-Blanche P, Coumel P.
Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation 1994;89:
206–215.
913. Eisenberg SJ, Scheinman MM, Dullet NK, Finkbeiner WE, Grifﬁn JC, Eldar M, et al.
Sudden cardiac death and polymorphous ventricular tachycardia in patients with normal QT intervals and normal systolic cardiac function. Am J Cardiol 1995;75:
687–692.
914. Asatryan B, Schaller A, Seiler J, Servatius H, Noti F, Baldinger SH, et al. Usefulness of genetic testing in sudden cardiac arrest survivors with or without previous clinical evidence of heart disease. Am J Cardiol 2019;123:2031–2038.
915. Visser M, Dooijes D, van der Smagt JJ, van der Heijden JF, Doevendans PA, Loh P,
et al. Next-generation sequencing of a large gene panel in patients initially diagnosed with idiopathic ventricular ﬁbrillation. Heart Rhythm 2017;14:1035–1040.
916. Honarbakhsh S, Srinivasan N, Kirkby C, Firman E, Tobin L, Finlay M, et al.
Medium-term outcomes of idiopathic ventricular ﬁbrillation survivors and family screening: a multicentre experience. Europace 2017;19:1874–1880.
917. Meissner MD, Lehmann MH, Steinman RT, Mosteller RD, Akhtar M, Calkins H, et al.
Ventricular ﬁbrillation in patients without signiﬁcant structural heart disease: a multicenter experience with implantable cardioverter-deﬁbrillator therapy. J Am Coll
Cardiol 1993;21:1406–1412.
918. Conte G, Caputo ML, Regoli F, Marcon S, Klersy C, Adjibodou B, et al. True idiopathic ventricular ﬁbrillation in out-of-hospital cardiac arrest survivors in the Swiss
Canton Ticino: prevalence, clinical features, and long-term follow-up. Europace
2017;19:259–266.
919. Stampe NK, Jespersen CB, Glinge C, Bundgaard H, Tfelt-Hansen J, Winkel BG.
Clinical characteristics and risk factors of arrhythmia during follow-up of patients with idiopathic ventricular ﬁbrillation. J Cardiovasc Electrophysiol 2020;31:
2677–2686.
920. Conte G, Belhassen B, Lambiase P, Ciconte G, de Asmundis C, Arbelo E, et al.
Out-of-hospital cardiac arrest due to idiopathic ventricular ﬁbrillation in patients with normal electrocardiograms: results from a multicentre long-term registry.
Europace 2019;21:1670–1677.
921. Blom LJ, Visser M, Christiaans I, Scholten MF, Bootsma M, van den Berg MP, et al.
Incidence and predictors of implantable cardioverter-deﬁbrillator therapy and its complications in idiopathic ventricular ﬁbrillation patients. Europace 2019;21:
1519–1526.
922. Malhi N, Cheung CC, Deif B, Roberts JD, Gula LJ, Green MS, et al. Challenge and impact of quinidine access in sudden death syndromes: a national experience.
JACC Clin Electrophysiol 2019;5:376–382.
923. Belhassen B, Glick A, Viskin S. Excellent long-term reproducibility of the electrophysiologic efﬁcacy of quinidine in patients with idiopathic ventricular ﬁbrillation and Brugada syndrome. Pacing Clin Electrophysiol 2009;32:294–301.
924. Belhassen B, Shapira I, Shoshani D, Paredes A, Miller H, Laniado S. Idiopathic ventricular ﬁbrillation: inducibility and beneﬁcial effects of class I antiarrhythmic agents.
Circulation 1987;75:809–816.
925. Viskin S, Belhassen B. Idiopathic ventricular ﬁbrillation. Am Heart J 1990;120:
661–671.
ESC Guidelines
4121


<!-- PAGE 126 -->

### Page 126

926. Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the longterm outcome of patients with idiopathic ventricular ﬁbrillation with or without the
Brugada syndrome. J Cardiovasc Electrophysiol 1999;10:1301–1312.
927. Sadek MM, Benhayon D, Sureddi R, Chik W, Santangeli P, Supple GE, et al.
Idiopathic ventricular arrhythmias originating from the moderator band: electrocardiographic characteristics and treatment by catheter ablation. Heart Rhythm
2015;12:67–75.
928. Van Herendael H, Zado ES, Haqqani H, Tschabrunn CM, Callans DJ, Frankel DS,
et al. Catheter ablation of ventricular ﬁbrillation: importance of left ventricular outﬂow tract and papillary muscle triggers. Heart Rhythm 2014;11:566–573.
929. Santoro F, Di Biase L, Hranitzky P, Sanchez JE, Santangeli P, Perini AP, et al.
Ventricular ﬁbrillation triggered by PVCs from papillary muscles: clinical features and ablation. J Cardiovasc Electrophysiol 2014;25:1158–1164.
930. Nakamura T, Schaeffer B, Tanigawa S, Muthalaly RG, John RM, Michaud GF, et al.
Catheter ablation of polymorphic ventricular tachycardia/ﬁbrillation in patients with and without structural heart disease. Heart Rhythm 2019;16:1021–1027.
931. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation
1991;84:1136–1144.
932. Schwartz PJ, Ackerman MJ, Antzelevitch C, Bezzina CR, Borggrefe M, Cuneo BF,
et al. Inherited cardiac arrhythmias. Nat Rev Dis Primers 2020;6:58.
933. Andersen ED, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome? Acta Paediatr
Scand 1971;60:559–564.
934. Tawil R, Ptacek LJ, Pavlakis SG, DeVivo DC, Penn AS, Ozdemir C, et al. Andersen’s syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol 1994;35:326–330.
935. Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc
Natl Acad Sci U S A 2005;102:8089–8096; discussion 8086–8088.
936. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1957;54:59–68.
937. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long
QT syndrome. An update. Circulation 1993;88:782–784.
938. Rautaharju PM, Zhang Z-M, Prineas R, Heiss G. Assessment of prolonged QT and
JT intervals in ventricular conduction defects. Am J Cardiol 2004;93:1017–1021.
939. Viskin S, Postema PG, Bhuiyan ZA, Rosso R, Kalman JM, Vohra JK, et al. The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol 2010;55:1955–1961.
940. Mazzanti A, Maragna R, Vacanti G, Monteforte N, Bloise R, Marino M, et al.
Interplay between genetic substrate, QTc duration, and arrhythmia risk in patients with long QT syndrome. J Am Coll Cardiol 2018;71:1663–1671.
941. Behr ER, Roden D. Drug-induced arrhythmia: pharmacogenomic prescribing? Eur
Heart J 2013;34:89–95.
942. Weeke PE, Kellemann JS, Jespersen CB, Theilade J, Kanters JK, Hansen MS, et al.
Long-term proarrhythmic pharmacotherapy among patients with congenital long
QT syndrome and risk of arrhythmia and mortality. Eur Heart J 2019;40:
3110–3117.
943. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, et al.
Genotype-phenotype correlation in the long-QT syndrome: gene-speciﬁc triggers for life-threatening arrhythmias. Circulation 2001;103:89–95.
944. Chockalingam P, Crotti L, Girardengo G, Johnson JN, Harris KM, van der Heijden JF,
et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol
2012;60:2092–2099.
945. Ahn J, Kim HJ, Choi J-I, Lee KN, Shim J, Ahn HS, et al. Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: a meta-analysis. PLoS
One 2017;12:e0185680.
946. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, et al.
Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004;292:1341–1344.
947. Mazzanti A, Trancuccio A, Kukavica D, Pagan E, Wang M, Mohsin M, et al.
Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk). Europace 2021;24:697–698.
948. Mazzanti A, Maragna R, Faragli A, Monteforte N, Bloise R, Memmi M, et al.
Gene-speciﬁc therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol 2016;67:1053–1058.
949. Ruan Y, Liu N, Bloise R, Napolitano C, Priori SG. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.
Circulation 2007;116:1137–1144.
950. Zhu W, Mazzanti A, Voelker TL, Hou P, Moreno JD, Angsutararux P, et al.
Predicting patient response to the antiarrhythmic mexiletine based on genetic variation. Circ Res 2019;124:539–552.
951. Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L, Ronchetti E. The elusive link between LQT3 and Brugada syndrome: the role of ﬂecainide challenge.
Circulation 2000;102:945–947.
952. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, et al.
Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000;101:616–623.
953. Jons C, Moss AJ, Goldenberg I, Liu J, McNitt S, Zareba W, et al. Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol 2010;55:
783–788.
954. Liu JF, Jons C, Moss AJ, McNitt S, Peterson DR, Qi M, et al. Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. J Am Coll Cardiol 2011;57:941–950.
955. Seth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol 2007;49:1092–1098.
956. Goldenberg I, Horr S, Moss AJ, Lopes CM, Barsheshet A, McNitt S, et al. Risk for life-threatening cardiac events in patients with genotype-conﬁrmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol 2011;57:51–59.
957. Jang SY, Cho Y, Kim NK, Kim C-Y, Sohn J, Roh J-H, et al. Video-assisted thoracoscopic left cardiac sympathetic denervation in patients with hereditary ventricular arrhythmias. Pacing Clin Electrophysiol 2017;40:232–241.
958. Waddell-Smith KE, Ertresvaag KN, Li J, Chaudhuri K, Crawford JR, Hamill JK, et al.
Physical and psychological consequences of left cardiac sympathetic denervation in long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia.
Circ Arrhythm Electrophysiol 2015;8:1151–1158.
959. Anderson HN, Bos JM, Rohatgi RK, Ackerman MJ. The effect of left cardiac sympathetic denervation on exercise in patients with long QT syndrome. JACC Clin
Electrophysiol 2019;5:1084–1090.
960. Bos JM, Bos KM, Johnson JN, Moir C, Ackerman MJ. Left cardiac sympathetic denervation in long QT syndrome: analysis of therapeutic nonresponders. Circ
Arrhythm Electrophysiol 2013;6:705–711.
961. Bhandari AK, Shapiro WA, Morady F, Shen EN, Mason J, Scheinman MM.
Electrophysiologic testing in patients with the long QT syndrome. Circulation
1985;71:63–71.
962. Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M. Implantable cardioverter deﬁbrillator in high-risk long QT syndrome patients. J Cardiovasc
Electrophysiol 2003;14:337–341.
963. Schwartz PJ, Spazzolini C, Priori SG, Crotti L, Vicentini A, Landolina M, et al. Who are the long-QT syndrome patients who receive an implantable cardioverterdeﬁbrillator and what happens to them?: Data from the European long-QT syndrome implantable cardioverter-deﬁbrillator (LQTS ICD) registry. Circulation
2010;122:1272–1282.
964. Delannoy E, Sacher F, Maury P, Mabo P, Mansourati J, Magnin I, et al. Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to
KCNJ2 mutation. Europace 2013;15:1805–1811.
965. Inoue YY, Aiba T, Kawata H, Sakaguchi T, Mitsuma W, Morita H, et al. Different responses to exercise between Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia. Europace 2018;20:1675–1682.
966. Krych M, Biernacka EK, Ponińska J, Kukla P, Filipecki A, Gajda R, et al.
Andersen-Tawil syndrome: clinical presentation and predictors of symptomatic arrhythmias—possible role of polymorphisms K897T in KCNH2 and H558R in
SCN5A gene. J Cardiol 2017;70:504–510.
967. Mazzanti A, Guz D, Trancuccio A, Pagan E, Kukavica D, Chargeishvili T, et al.
Natural history and risk stratiﬁcation in Andersen-Tawil syndrome type 1. J Am
Coll Cardiol 2020;75:1772–1784.
968. Zhang L, Benson DW, Tristani-Firouzi M, Ptacek LJ, Tawil R, Schwartz PJ, et al.
Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2
mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype.
Circulation 2005;111:2720–2726.
969. Horigome H, Ishikawa Y, Kokubun N, Yoshinaga M, Sumitomo N, Lin L, et al.
Multivariate analysis of
TU
wave complex on electrocardiogram in
Andersen-Tawil syndrome with KCNJ2 mutations. Ann Noninvasive Electrocardiol
2020;25:e12721.
970. Miyamoto K, Aiba T, Kimura H, Hayashi H, Ohno S, Yasuoka C, et al. Efﬁcacy and safety of ﬂecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. Heart Rhythm 2015;12:596–603.
971. Radwański PB, Greer-Short A, Poelzing S. Inhibition of Na+ channels ameliorates arrhythmias in a drug-induced model of Andersen-Tawil syndrome. Heart Rhythm
2013;10:255–263.
972. Tristani-Firouzi M, Jensen JL, Donaldson MR, Sansone V, Meola G, Hahn A, et al.
Functional and clinical characterization of KCNJ2 mutations associated with
LQT7 (Andersen syndrome). J Clin Invest 2002;110:381–388.
973. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al.
Brugada syndrome: report of the second consensus conference: endorsed by the
Heart Rhythm Society and the European Heart Rhythm Association. Circulation
2005;111:659–670.


<!-- PAGE 127 -->

### Page 127

974. Savastano S, Rordorf R, Vicentini A, Petracci B, Taravelli E, Castelletti S, et al. A
comprehensive electrocardiographic, molecular, and echocardiographic study of
Brugada syndrome: validation of the 2013 diagnostic criteria. Heart Rhythm 2014;
11:1176–1183.
975. Richter S, Sarkozy A, Paparella G, Henkens S, Boussy T, Chierchia G-B, et al.
Number of electrocardiogram leads displaying the diagnostic coved-type pattern in Brugada syndrome: a diagnostic consensus criterion to be revised. Eur Heart J
2010;31:1357–1364.
976. Veltmann C, Papavassiliu T, Konrad T, Doesch C, Kuschyk J, Streitner F, et al.
Insights into the location of type I ECG in patients with Brugada syndrome: correlation of ECG and cardiovascular magnetic resonance imaging. Heart Rhythm 2012;
9:414–421.
977. Adler A, Rosso R, Chorin E, Havakuk O, Antzelevitch C, Viskin S. Risk stratiﬁcation in Brugada syndrome: clinical characteristics, electrocardiographic parameters, and auxiliary testing. Heart Rhythm 2016;13:299–310.
978. Hasdemir C, Payzin S, Kocabas U, Sahin H, Yildirim N, Alp A, et al. High prevalence of concealed Brugada syndrome in patients with atrioventricular nodal reentrant tachycardia. Heart Rhythm 2015;12:1584–1594.
979. Behr ER, Ben-Haim Y, Ackerman MJ, Krahn AD, Wilde AAM. Brugada syndrome and reduced right ventricular outﬂow tract conduction reserve: a ﬁnal common pathway? Eur Heart J 2021;42:1073–1081.
980. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the
FINGER Brugada syndrome registry. Circulation 2010;121:635–643.
981. Amin AS, Meregalli PG, Bardai A, Wilde AAM, Tan HL. Fever increases the risk for cardiac arrest in the Brugada syndrome. Ann Intern Med 2008;149:216–218.
982. Adler A, Topaz G, Heller K, Zeltser D, Ohayon T, Rozovski U, et al. Fever-induced
Brugada pattern: how common is it and what does it mean? Heart Rhythm 2013;10:
1375–1382.
983. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, et al.
Natural history of Brugada syndrome: insights for risk stratiﬁcation and management. Circulation 2002;105:1342–1347.
984. Rizzo A, Borio G, Sieira J, Van Dooren S, Overeinder I, Bala G, et al. Ajmaline testing and the Brugada syndrome. Am J Cardiol 2020;135:91–98.
985. Poli S, Toniolo M, Maiani M, Zanuttini D, Rebellato L, Vendramin I, et al.
Management of untreatable ventricular arrhythmias during pharmacologic challenges with sodium channel blockers for suspected Brugada syndrome. Europace
2018;20:234–242.
986. Hasdemir C, Juang JJ-M, Kose S, Kocabas U, Orman MN, Payzin S, et al. Coexistence of atrioventricular accessory pathways and drug-induced type 1 Brugada pattern.
Pacing Clin Electrophysiol 2018;41:1078–1092.
987. Probst V, Wilde AAM, Barc J, Sacher F, Babuty D, Mabo P, et al. SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome.
Circ Cardiovasc Genet 2009;2:552–557.
988. Meregalli PG, Tan HL, Probst V, Koopmann TT, Tanck MW, Bhuiyan ZA, et al. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm 2009;6:341–348.
989. Ishikawa T, Kimoto H, Mishima H, Yamagata K, Ogata S, Aizawa Y, et al. Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome. Eur Heart J 2021;42:2854–2863.
990. Gehi AK, Duong TD, Metz LD, Gomes JA, Mehta D. Risk stratiﬁcation of individuals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol
2006;17:577–583.
991. McNamara DA, Goldberger JJ, Berendsen MA, Huffman MD. Implantable deﬁbrillators versus medical therapy for cardiac channelopathies. Cochrane Database Syst
Rev 2015;2015:CD011168.
992. Priori SG, Gasparini M, Napolitano C, Della Bella P, Ottonelli AG, Sassone B, et al.
Risk stratiﬁcation in Brugada syndrome: results of the PRELUDE (PRogrammed
ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol 2012;59:37–45.
993. Dereci A, Yap S-C, Schinkel AFL. Meta-analysis of clinical outcome after implantable cardioverter-deﬁbrillator implantation in patients with Brugada syndrome. JACC
Clin Electrophysiol 2019;5:141–148.
994. Conte G, Sieira J, Ciconte G, de Asmundis C, Chierchia G-B, Baltogiannis G, et al.
Implantable cardioverter-deﬁbrillator therapy in Brugada syndrome: a 20-year single-center experience. J Am Coll Cardiol 2015;65:879–888.
995. Mascia G, Della Bona R, Ameri P, Canepa M, Porto I, Brignole M. Brugada syndrome and syncope: a systematic review. J Cardiovasc Electrophysiol 2020;31:3334–3338.
996. Subramanian M, Prabhu MA, Harikrishnan MS, Shekhar SS, Pai PG, Natarajan K. The utility of exercise testing in risk stratiﬁcation of asymptomatic patients with type 1
Brugada pattern. J Cardiovasc Electrophysiol 2017;28:677–683.
997. Kubala M, Aïssou L, Traullé S, Gugenheim A-L, Hermida J-S. Use of implantable loop recorders in patients with Brugada syndrome and suspected risk of ventricular arrhythmia. Europace 2012;14:898–902.
998. Sakhi R, Assaf A, Theuns DAMJ, Verhagen JMA, Szili-Torok T, Roos-Hesselink JW,
et al. Outcome of insertable cardiac monitors in symptomatic patients with
Brugada syndrome at low risk of sudden cardiac death. Cardiology 2020;145:
413–420.
999. Scrocco C, Ben-Haim Y, Devine B, Tome-Esteban M, Papadakis M, Sharma S, et al.
Role of subcutaneous implantable loop recorder for the diagnosis of arrhythmias in
Brugada syndrome: a United Kingdom single-center experience. Heart Rhythm
2022;19:70–78.
1000. Sieira J, Brugada P. Brugada syndrome: deﬁning the risk in asymptomatic patients.
Arrhythm Electrophysiol Rev 2016;5:164–169.
1001. Nishizaki M, Sakurada H, Yamawake N, Ueda-Tatsumoto A, Hiraoka M. Low risk for arrhythmic events in asymptomatic patients with drug-induced type 1 ECG.
Do patients with drug-induced Brugada type ECG have poor prognosis? (Con).
Circ J 2010;74:2464–2473.
1002. Conte G, de Asmundis C, Sieira J, Ciconte G, Di Giovanni G, Chierchia G-B, et al.
Prevalence and clinical impact of early repolarization pattern and
QRS-fragmentation in high-risk patients with Brugada syndrome. Circ J 2016;80:
2109–2116.
1003. Kataoka N, Mizumaki K, Nakatani Y, Sakamoto T, Yamaguchi Y, Tsujino Y, et al.
Paced QRS fragmentation is associated with spontaneous ventricular ﬁbrillation in patients with Brugada syndrome. Heart Rhythm 2016;13:1497–1503.
1004. Probst V, Goronﬂot T, Anys S, Tixier R, Briand J, Berthome P, et al. Robustness and relevance of predictive score in sudden cardiac death for patients with
Brugada syndrome. Eur Heart J 2021;42:1687–1695.
1005. Honarbakhsh S, Providencia R, Garcia-Hernandez J, Martin CA, Hunter RJ, Lim
WY, et al. A primary prevention clinical risk score model for patients with
Brugada syndrome (BRUGADA-RISK). JACC Clin Electrophysiol 2021;7:210–222.
1006. Andorin A, Gourraud J-B, Mansourati J, Fouchard S, le Marec H, Maury P, et al. The
QUIDAM study: hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk. Heart Rhythm 2017;14:1147–1154.
1007. Belhassen B, Rahkovich M, Michowitz Y, Glick A, Viskin S. Management of Brugada syndrome: thirty-three-year experience using electrophysiologically guided therapy with class 1A antiarrhythmic drugs. Circ Arrhythm Electrophysiol 2015;8:
1393–1402.
1008. Ohgo T, Okamura H, Noda T, Satomi K, Suyama K, Kurita T, et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular ﬁbrillation. Heart Rhythm 2007;4:695–700.
1009. Nademanee K, Raju H, de Noronha SV, Papadakis M, Robinson L, Rothery S, et al.
Fibrosis, connexin-43, and conduction abnormalities in the Brugada syndrome.
J Am Coll Cardiol 2015;66:1976–1986.
1010. Nademanee K, Haissaguerre M, Hocini M, Nogami A, Cheniti G, Duchateau J, et al.
Mapping and ablation of ventricular ﬁbrillation associated with early repolarization syndrome. Circulation 2019;140:1477–1490.
1011. Nademanee K, Veerakul G, Chandanamattha P, Chaothawee L, Ariyachaipanich
A, Jirasirirojanakorn K, et al. Prevention of ventricular ﬁbrillation episodes in
Brugada syndrome by catheter ablation over the anterior right ventricular outﬂow tract epicardium. Circulation 2011;123:1270–1279.
1012. Zhang P, Tung R, Zhang Z, Sheng X, Liu Q, Jiang R, et al. Characterization of the epicardial substrate for catheter ablation of Brugada syndrome. Heart Rhythm
2016;13:2151–2158.
1013. Haïssaguerre M, Extramiana F, Hocini M, Cauchemez B, Jaïs P, Cabrera JA, et al.
Mapping and ablation of ventricular ﬁbrillation associated with long-QT and
Brugada syndromes. Circulation 2003;108:925–928.
1014. Brugada J, Pappone C, Berruezo A, Vicedomini G, Manguso F, Ciconte G, et al.
Brugada syndrome phenotype elimination by epicardial substrate ablation. Circ
Arrhythm Electrophysiol 2015;8:1373–1381.
1015. Pappone C, Brugada J, Vicedomini G, Ciconte G, Manguso F, Saviano M, et al.
Electrical substrate elimination in 135 consecutive patients with Brugada syndrome. Circ Arrhythm Electrophysiol 2017;10:e005053.
1016. Yamagata K, Horie M, Aiba T, Ogawa S, Aizawa Y, Ohe T, et al.
Genotype-phenotype correlation of SCN5A mutation for the clinical and electrocardiographic characteristics of probands with Brugada syndrome: a Japanese multicenter registry. Circulation 2017;135:2255–2270.
1017. Haïssaguerre M, Derval N, Sacher F, Jesel L, Deisenhofer I, de Roy L, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med 2008;358:
2016–2023.
1018. Rosso R, Kogan E, Belhassen B, Rozovski U, Scheinman MM, Zeltser D, et al.
J-point elevation in survivors of primary ventricular ﬁbrillation and matched control subjects: incidence and clinical signiﬁcance. J Am Coll Cardiol 2008;52:
1231–1238.
1019. Macfarlane PW, Antzelevitch C, Haissaguerre M, Huikuri HV, Potse M, Rosso R,
et al. The early repolarization pattern: a consensus paper. J Am Coll Cardiol 2015;
66:470–477.
1020. Tikkanen JT, Anttonen O, Junttila MJ, Aro AL, Kerola T, Rissanen HA, et al.
Long-term outcome associated with early repolarization on electrocardiography.
N Engl J Med 2009;361:2529–2537.
ESC Guidelines
4123


<!-- PAGE 128 -->

### Page 128

1021. Sinner MF, Reinhard W, Müller M, Beckmann B-M, Martens E, Perz S, et al.
Association of early repolarization pattern on ECG with risk of cardiac and allcause mortality: a population-based prospective cohort study (MONICA/
KORA). PLoS Med 2010;7:e1000314.
1022. Nunn LM, Bhar-Amato J, Lowe MD, Macfarlane PW, Rogers P, McKenna WJ, et al.
Prevalence of J-point elevation in sudden arrhythmic death syndrome families.
J Am Coll Cardiol 2011;58:286–290.
1023. Watanabe H, Nogami A, Ohkubo K, Kawata H, Hayashi Y, Ishikawa T, et al.
Electrocardiographic characteristics and SCN5A mutations in idiopathic ventricular ﬁbrillation associated with early repolarization. Circ Arrhythm Electrophysiol
2011;4:874–881.
1024. Chauveau S, Janin A, Till M, Morel E, Chevalier P, Millat G. Early repolarization syndrome caused by de novo duplication of KCND3 detected by next-generation sequencing. HeartRhythm Case Rep 2017;3:574–578.
1025. Takayama K, Ohno S, Ding W-G, Ashihara T, Fukumoto D, Wada Y, et al. A de novo gain-of-function KCND3 mutation in early repolarization syndrome.
Heart Rhythm 2019;16:1698–1706.
1026. Rosso R, Glikson E, Belhassen B, Katz A, Halkin A, Steinvil A, et al. Distinguishing
‘benign’ from ‘malignant early repolarization’: the value of the ST-segment morphology. Heart Rhythm 2012;9:225–229.
1027. Tikkanen JT, Junttila MJ, Anttonen O, Aro AL, Luttinen S, Kerola T, et al. Early repolarization: electrocardiographic phenotypes associated with favorable longterm outcome. Circulation 2011;123:2666–2673.
1028. Nademanee K, Veerakul G, Mower M, Likittanasombat K, Krittayapong R,
Bhuripanyo K, et al. Deﬁbrillator versus beta-blockers for unexplained Death in
Thailand (DEBUT): a randomized clinical trial. Circulation 2003;107:2221–2226.
1029. Brugada J, Brugada R, Brugada P. Pharmacological and device approach to therapy of inherited cardiac diseases associated with cardiac arrhythmias and sudden death. J Electrocardiol 2000;33:41–47.
1030. Haïssaguerre M, Sacher F, Nogami A, Komiya N, Bernard A, Probst V, et al.
Characteristics of recurrent ventricular ﬁbrillation associated with inferolateral early repolarization role of drug therapy. J Am Coll Cardiol 2009;53:612–619.
1031. Aizawa Y, Chinushi M, Hasegawa K, Naiki N, Horie M, Kaneko Y, et al. Electrical storm in idiopathic ventricular ﬁbrillation is associated with early repolarization.
J Am Coll Cardiol 2013;62:1015–1019.
1032. Patocskai B, Barajas-Martinez H, Hu D, Gurabi Z, Koncz I, Antzelevitch C. Cellular and ionic mechanisms underlying the effects of cilostazol, milrinone, and isoproterenol to suppress arrhythmogenesis in an experimental model of early repolarization syndrome. Heart Rhythm 2016;13:1326–1334.
1033. Nam G-B, Kim Y-H, Antzelevitch C. Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med 2008;358:2078–2079.
1034. Rodríguez-Capitán J, Fernández-Meseguer A, García-Pinilla JM, Calvo-Bonacho E,
Jiménez-Navarro M, García-Margallo T, et al. Frequency of different electrocardiographic abnormalities in a large cohort of Spanish workers. Europace 2017;
19:1855–1863.
1035. Sun G-Z, Ye N, Chen Y-T, Zhou Y, Li Z, Sun Y-X. Early repolarization pattern in the general population: prevalence and associated factors. Int J Cardiol 2017;230:
614–618.
1036. Wu S-H, Lin X-X, Cheng Y-J, Qiang C-C, Zhang J. Early repolarization pattern and risk for arrhythmia death: a meta-analysis. J Am Coll Cardiol 2013;61:645–650.
1037. Malhi N, So PP, Cheung CC, Laksman ZWM, Healey JS, Chauhan VS, et al. Early repolarization pattern inheritance in the cardiac arrest survivors with preserved ejection fraction registry (CASPER). JACC Clin Electrophysiol 2018;4:1473–1479.
1038. Sinner
MF,
Porthan
K,
Noseworthy
PA,
Havulinna
AS,
Tikkanen
JT,
Müller-Nurasyid M, et al. A meta-analysis of genome-wide association studies of the electrocardiographic early repolarization pattern. Heart Rhythm 2012;9:
1627–1634.
1039. Adhikarla C, Boga M, Wood AD, Froelicher VF. Natural history of the electrocardiographic pattern of early repolarization in ambulatory patients. Am J Cardiol
2011;108:1831–1835.
1040. Mahida S, Derval N, Sacher F, Leenhardt A, Deisenhofer I, Babuty D, et al. Role of electrophysiological studies in predicting risk of ventricular arrhythmia in early repolarization syndrome. J Am Coll Cardiol 2015;65:151–159.
1041. Aizawa Y, Sato A, Watanabe H, Chinushi M, Furushima H, Horie M, et al.
Dynamicity of the J-wave in idiopathic ventricular ﬁbrillation with a special reference to pause-dependent augmentation of the J-wave. J Am Coll Cardiol 2012;59:
1948–1953.
1042. Priori SG, Mazzanti A, Santiago DJ, Kukavica D, Trancuccio A, Kovacic JC.
Precision medicine in catecholaminergic polymorphic ventricular tachycardia:
JACC focus seminar 5/5. J Am Coll Cardiol 2021;77:2592–2612.
1043. Bezzina CR, Lahrouchi N, Priori SG. Genetics of sudden cardiac death. Circ Res
2015;116:1919–1936.
1044. Kimura H, Zhou J, Kawamura M, Itoh H, Mizusawa Y, Ding W-G, et al. Phenotype variability in patients carrying KCNJ2 mutations. Circ Cardiovasc Genet 2012;5:
344–353.
1045. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al.
Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002;106:69–74.
1046. Krahn AD, Gollob M, Yee R, Gula LJ, Skanes AC, Walker BD, et al. Diagnosis of unexplained cardiac arrest: role of adrenaline and procainamide infusion.
Circulation 2005;112:2228–2234.
1047. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff J-M, et al.
Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009;119:2426–2434.
1048. Leren IS, Saberniak J, Majid E, Haland TF, Edvardsen T, Haugaa KH. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2016;13:433–440.
1049. Peltenburg PJ, Kallas D, Bos JM, Lieve KVV, Franciosi S, Roston TM, et al. An international multicenter cohort study on β-blockers for the treatment of symptomatic children with catecholaminergic polymorphic ventricular tachycardia.
Circulation 2022;145:333–344.
1050. van der Werf C, Nederend I, Hofman N, van Geloven N, Ebink C, Frohn-Mulder
IME, et al. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol 2012;5:748–756.
1051. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al.
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009;15:380–383.
1052. Wang G, Zhao N, Zhong S, Wang Y, Li J. Safety and efﬁcacy of ﬂecainide for patients with catecholaminergic polymorphic ventricular tachycardia: a systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e16961.
1053. van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, et al.
Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol
2011;57:2244–2254.
1054. Padﬁeld GJ, AlAhmari L, Lieve KVV, AlAhmari T, Roston TM, Wilde AA, et al.
Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade. Heart Rhythm 2016;
13:609–613.
1055. Roses-Noguer F, Jarman JWE, Clague JR, Till J. Outcomes of deﬁbrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2014;11:
58–66.
1056. De Ferrari GM, Dusi V, Spazzolini C, Bos JM, Abrams DJ, Berul CI, et al. Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. Circulation 2015;131:2185–2193.
1057. Roston TM, Jones K, Hawkins NM, Bos JM, Schwartz PJ, Perry F, et al. Implantable cardioverter-deﬁbrillator use in catecholaminergic polymorphic ventricular tachycardia: a systematic review. Heart Rhythm 2018;15:1791–1799.
1058. van der Werf C, Lieve KV, Bos JM, Lane CM, Denjoy I, Roses-Noguer F, et al.
Implantable cardioverter-deﬁbrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. Eur Heart J 2019;40:2953–2961.
1059. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients.
Circulation 1995;91:1512–1519.
1060. Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, et al. Efﬁcacy of
ﬂecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial. JAMA Cardiol 2017;2:759–766.
1061. Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol 2011;57:802–812.
1062. Thorsen K, Dam VS, Kjaer-Sorensen K, Pedersen LN, Skeberdis VA, Jurevičius J,
et al. Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger
AE3 causes short QT syndrome. Nat Commun 2017;8:1696.
1063. Mazzanti A, Kanthan A, Monteforte N, Memmi M, Bloise R, Novelli V, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol 2014;63:
1300–1308.
1064. Dhutia H, Malhotra A, Parpia S, Gabus V, Finocchiaro G, Mellor G, et al. The prevalence and signiﬁcance of a short QT interval in 18 825 low-risk individuals including athletes. Br J Sports Med 2016;50:124–129.
1065. Gallagher MM, Magliano G, Yap YG, Padula M, Morgia V, Postorino C, et al.
Distribution and prognostic signiﬁcance of QT intervals in the lowest half centile in 12,012 apparently healthy persons. Am J Cardiol 2006;98:933–935.
1066. Anttonen O, Junttila MJ, Rissanen H, Reunanen A, Viitasalo M, Huikuri HV.
Prevalence and prognostic signiﬁcance of short QT interval in a middle-aged
Finnish population. Circulation 2007;116:714–720.
1067. Kobza R, Roos M, Niggli B, Abächerli R, Lupi GA, Frey F, et al. Prevalence of long and short QT in a young population of 41,767 predominantly male Swiss conscripts. Heart Rhythm 2009;6:652–657.
1068. Giustetto C, Schimpf R, Mazzanti A, Scrocco C, Maury P, Anttonen O, et al.
Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol
2011;58:587–595.


<!-- PAGE 129 -->

### Page 129

1069. El-Battrawy I, Besler J, Liebe V, Schimpf R, Tülümen E, Rudic B, et al. Long-term follow-up of patients with short QT syndrome: clinical proﬁle and outcome. J
Am Heart Assoc 2018;7:e010073.
1070. Mazzanti A, Maragna R, Vacanti G, Kostopoulou A, Marino M, Monteforte N, et al.
Hydroquinidine prevents life-threatening arrhythmic events in patients with short
QT syndrome. J Am Coll Cardiol 2017;70:3010–3015.
1071. El-Battrawy I, Besler J, Li X, Lan H, Zhao Z, Liebe V, et al. Impact of antiarrhythmic drugs on the outcome of short QT syndrome. Front Pharmacol 2019;10:771.
1072. Malik M. Drug-induced QT/QTc interval shortening: lessons from drug-induced
QT/QTc prolongation. Drug Saf 2016;39:647–659.
1073. Giustetto C, Scrocco C, Schimpf R, Maury P, Mazzanti A, Levetto M, et al.
Usefulness of exercise test in the diagnosis of short QT syndrome. Europace
2015;17:628–634.
1074. Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B.
Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J
Electrocardiol 2007;40:228–234.
1075. Bun S-S, Maury P, Giustetto C, Deharo J-C. Electrical storm in short-QT syndrome successfully treated with Isoproterenol. J Cardiovasc Electrophysiol 2012;
23:1028–1030.
1076. Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, et al.
Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001;104:515–521.
1077. Drenthen W, Pieper PG, Roos-Hesselink JW, van Lottum WA, Voors AA, Mulder
BJM, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007;49:2303–2311.
1078. Roos-Hesselink JW, Ruys TPE, Stein JI, Thilén U, Webb GD, Niwa K, et al.
Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J 2013;34:
657–665.
1079. Linde C, Bongiorni MG, Birgersdotter-Green U, Curtis AB, Deisenhofer I,
Furokawa T, et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm
Society and Asia Paciﬁc Heart Rhythm Society. Europace 2018;20:1565–1565ao.
1080. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C,
Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165–3241.
1081. Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol 2006;97:1206–1212.
1082. Sliwa K, Mebazaa A, Hilﬁker-Kleiner D, Petrie MC, Maggioni AP, Laroche C, et al.
Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study
Group on PPCM. Eur J Heart Fail 2017;19:1131–1141.
1083. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 2016;
374:233–241.
1084. Wang Y-C, Chen C-H, Su H-Y, Yu M-H. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol 2006;126:268–269.
1085. Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG 2002;109:1406–1407.
1086. Miyoshi T, Kamiya CA, Katsuragi S, Ueda H, Kobayashi Y, Horiuchi C, et al. Safety and efﬁcacy of implantable cardioverter-deﬁbrillator during pregnancy and after delivery. Circ J 2013;77:1166–1170.
1087. Abello M, Peinado R, Merino JL, Gnoatto M, Mateos M, Silvestre J, et al.
Cardioverter deﬁbrillator implantation in a pregnant woman guided with transesophageal echocardiography. Pacing Clin Electrophysiol 2003;26:1913–1914.
1088. Hartz J, Clark BC, Ito S, Sherwin ED, Berul CI. Transvenous nonﬂuoroscopic pacemaker implantation during pregnancy guided by 3-dimensional electroanatomic mapping. HeartRhythm Case Rep 2017;3:490–492.
1089. Bauersachs J, König T, van der Meer P, Petrie MC, Hilﬁker-Kleiner D, Mbakwem A,
et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy:
a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2019;
21:827–843.
1090. Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implantable cardioverter/deﬁbrillator implantation by intensiﬁed heart failure therapy optimization supported by the wearable cardioverter/deﬁbrillator-the
PROLONG study. J Am Heart Assoc 2017;6:e004512.
1091. Duncker D, Westenfeld R, Konrad T, Pfeffer T, Correia de Freitas CA, Pﬁster R,
et al. Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clin Res
Cardiol 2017;106:582–589.
1092. Jeejeebhoy FM, Zelop CM, Lipman S, Carvalho B, Joglar J, Mhyre JM, et al. Cardiac arrest in pregnancy: a scientiﬁc statement from the American heart association.
Circulation 2015;132:1747–1773.
1093. European Society of Gynecology (ESG), Association for European Paediatric
Cardiology
(AEPC),
German
Society for
Gender
Medicine
(DGesGM),
Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the task force on the Management of Cardiovascular Diseases during Pregnancy of the European
Society of Cardiology (ESC). Eur Heart J 2011;32:3147–3197.
1094. Rashba EJ, Zareba W, Moss AJ, Hall WJ, Robinson J, Locati EH, et al. Inﬂuence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS investigators. Circulation 1998;97:451–456.
1095. Ishibashi K, Aiba T, Kamiya C, Miyazaki A, Sakaguchi H, Wada M, et al. Arrhythmia risk and β-blocker therapy in pregnant women with long QT syndrome. Heart
2017;103:1374–1379.
1096. Cheung CC, Lieve KV, Roston TM, van der Ree MH, Deyell MW, Andrade JG,
et al. Pregnancy in catecholaminergic polymorphic ventricular tachycardia. JACC
Clin Electrophysiol 2019;5:387–394.
1097. Wu L, Liang E, Fan S, Zheng L, Hu F, Liu S, et al. Effect of pregnancy in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2020;125:613–617.
1098. Bauce B, Daliento L, Frigo G, Russo G, Nava A. Pregnancy in women with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Obstet Gynecol Reprod
Biol 2006;127:186–189.
1099. Gandjbakhch E, Varlet E, Duthoit G, Fressart V, Charron P, Himbert C, et al.
Pregnancy and newborn outcomes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Int J Cardiol 2018;258:172–178.
1100. Rodríguez-Mañero M, Casado-Arroyo R, Sarkozy A, Leysen E, Sieira JA, Namdar
M, et al. The clinical signiﬁcance of pregnancy in Brugada syndrome. Rev Esp Cardiol
(Engl Ed) 2014;67:176–180.
1101. Benito B, Berruezo A. Brugada syndrome and pregnancy: delving into the role of sex hormones in ion channelopathies. Rev Esp Cardiol (Engl Ed) 2014;67:165–167.
1102. Ostrowska B, Kommata B, Malmborg H, Lundqvist CB. Arrhythmias in pregnancy.
ESC CardioMed. 3rd ed. Oxford University Press; 2022, p2868–2870.
1103. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema J-P, Becker A, et al.
Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010;121:1465–1473.
1104. Hilﬁker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A,
et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 2017;38:2671–2679.
1105. Driver K, Chisholm CA, Darby AE, Malhotra R, Dimarco JP, Ferguson JD.
Catheter ablation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol
2015;26:698–702.
1106. Wang Z, Chen YW, Jiang YH, Sun LP, Chen XJ, Tao HL, et al. Electrophysiological characteristics and therapeutic efﬁcacy of radiofrequency ablation of focal atrial tachycardia originating from the right atrial appendage during pregnancy.
Zhonghua Xin Xue Guan Bing Za Zhi 2020;48:859–865.
1107. Tuzcu V, Kilinc OU. Implantable cardioverter deﬁbrillator implantation without using ﬂuoroscopy in a pregnant patient. Pacing Clin Electrophysiol 2012;35:
e265–266.
1108. Fröhlich GM, Holzmeister J, Hübler M, Hübler S, Wolfrum M, Enseleit F, et al.
Prophylactic implantable cardioverter deﬁbrillator treatment in patients with endstage heart failure awaiting heart transplantation. Heart 2013;99:1158–1165.
1109. Sandner SE, Wieselthaler G, Zuckermann A, Taghavi S, Schmidinger H, Pacher R,
et al. Survival beneﬁt of the implantable cardioverter-deﬁbrillator in patients on the waiting list for cardiac transplantation. Circulation 2001;104:I171–176.
1110. Algalarrondo V, Perault R, Bories M-C, Narayanan K, Garcia R, Combes N, et al.
Prophylactic implantable cardioverter deﬁbrillators for primary prevention: From implantation to heart transplantation. Arch Cardiovasc Dis 2018;111:758–765.
1111. Cantero-Pérez EM, Sobrino-Márquez JM, Grande-Trillo A, Lage-Gallé E,
Rangel-Sousa D, Esteve-Ruiz IM, et al. Implantable cardioverter deﬁbrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation. Transplant Proc 2013;45:3659–3661.
1112. Pezawas T, Grimm M, Ristl R, Kivaranovic D, Moser FT, Laufer G, et al. Primary preventive cardioverter-deﬁbrillator implantation (Pro-ICD) in patients awaiting heart transplantation. A prospective, randomized, controlled 12-year follow-up study. Transpl Int 2015;28:34–41.
1113. Kao AC, Krause SW, Handa R, Karia D, Reyes G, Bianco NR, et al. Wearable deﬁbrillator use in heart failure (WIF): results of a prospective registry. BMC
Cardiovasc Disord 2012;12:123.
1114. Alba AC, Foroutan F, Hing NKVNF, Fan C-PS, Manlhiot C, Ross HJ. Incidence and predictors of sudden cardiac death after heart transplantation: a systematic review and meta-analysis. Clin Transplant 2018;32:e13206.
1115. Vakil K, Taimeh Z, Sharma A, Abidi KS, Colvin M, Luepker R, et al. Incidence, predictors, and temporal trends of sudden cardiac death after heart transplantation.
Heart Rhythm 2014;11:1684–1690.
1116. Alba AC, Fan C-PS, Manlhiot C, Dipchand AI, Stehlik J, Ross HJ. The evolving risk of sudden cardiac death after heart transplant. An analysis of the ISHLT thoracic transplant registry. Clin Transplant 2019;33:e13490.
1117. Eskander MA, Adler E, Hoffmayer KS. Arrhythmias and sudden cardiac death in post-cardiac transplant patients. Curr Opin Cardiol 2020;35:308–311.
ESC Guidelines
4125


<!-- PAGE 130 -->

### Page 130

1118. Tsai VW, Cooper J, Garan H, Natale A, Ptaszek LM, Ellinor PT, et al. The efﬁcacy of implantable cardioverter-deﬁbrillators in heart transplant recipients: results from a multicenter registry. Circ Heart Fail 2009;2:197–201.
1119. Klein HU, Meltendorf U. Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter deﬁbrillator. PACE 2010;33:
353–367.
1120. Corrado D, Zorzi A. Sudden death in athletes. Int J Cardiol 2017;237:67–70.
1121. Rajan D, Garcia R, Svane J, Tfelt-Hansen J. Risk of sports-related sudden cardiac death in women. Eur Heart J 2021;43:1198–1206.
1122. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998;339:364–369.
1123. Malhotra A, Dhutia H, Finocchiaro G, Gati S, Beasley I, Clift P, et al. Outcomes of cardiac screening in adolescent soccer players. N Engl J Med 2018;379:524–534.
1124. Corrado D, Pelliccia A, Bjørnstad HH, Vanhees L, BifﬁA, Borjesson M, et al.
Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus
Statement of the Study Group of Sport Cardiology of the Working Group of
Cardiac Rehabilitation and Exercise Physiology and the Working Group of
Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur
Heart J 2005;26:516–524.
1125. Corrado D, Schmied C, Basso C, Borjesson M, Schiavon M, Pelliccia A, et al. Risk of sports: do we need a pre-participation screening for competitive and leisure athletes? Eur Heart J 2011;32:934–944.
1126. Baggish AL, Hutter AM, Wang F, Yared K, Weiner RB, Kupperman E, et al.
Cardiovascular screening in college athletes with and without electrocardiography: a cross-sectional study. Ann Intern Med 2010;152:269–275.
1127. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA 2006;296:1593–1601.
1128. Sharma S, Estes NAM, Vetter VL, Corrado D. Clinical decisions. Cardiac screening before participation in sports. N Engl J Med 2013;369:2049–2053.
1129. Sarto P, Zorzi A, Merlo L, Vessella T, Pegoraro C, Giorgiano F, et al. Serial versus single cardiovascular screening of adolescent athletes. Circulation 2021;143:
1729–1731.
1130. Steinvil A, Chundadze T, Zeltser D, Rogowski O, Halkin A, Galily Y, et al.
Mandatory electrocardiographic screening of athletes to reduce their risk for sudden death proven fact or wishful thinking? J Am Coll Cardiol 2011;57:1291–1296.
1131. Corrado D, Pelliccia A, Heidbuchel H, Sharma S, Link M, Basso C, et al.
Recommendations for interpretation of 12-lead electrocardiogram in the athlete.
Eur Heart J 2010;31:243–259.
1132. Sharma S, Drezner JA, Baggish A, Papadakis M, Wilson MG, Prutkin JM, et al.
International recommendations for electrocardiographic interpretation in athletes. Eur Heart J 2018;39:1466–1480.
1133. Crescenzi C, Zorzi A, Vessella T, Martino A, Panattoni G, Cipriani A, et al.
Predictors of left ventricular scar using cardiac magnetic resonance in athletes with apparently idiopathic ventricular arrhythmias. J Am Heart Assoc 2021;10:
e018206.
1134. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016
European Guidelines on cardiovascular disease prevention in clinical practice:
The Sixth Joint task force of the European Society of Cardiology and Other
Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention &
Rehabilitation (EACPR). Eur Heart J 2016;37:2315–2381.
1135. Rizzo M, Spataro A, Cecchetelli C, Quaranta F, Livrieri S, Sperandii F, et al.
Structural cardiac disease diagnosed by echocardiography in asymptomatic young male soccer players: implications for pre-participation screening. Br J Sports Med
2012;46:371–373.
1136. Heidbuchel H, Arbelo E, D’Ascenzi F, Borjesson M, Boveda S, Castelletti S, et al.
Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions.
Part
2:
ventricular arrhythmias,
channelopathies,
and implantable deﬁbrillators. Europace 2021;23:147–148.
1137. Drezner JA, Peterson DF, Siebert DM, Thomas LC, Lopez-Anderson M, Suchsland
MZ, et al. Survival after exercise-related sudden cardiac arrest in young athletes:
can we do better? Sports Health 2019;11:91–98.
1138. Drezner JA, Rogers KJ, Horneff JG. Automated external deﬁbrillator use at NCAA
Division II and III universities. Br J Sports Med 2011;45:1174–1178.
1139. Borjesson M, Serratosa L, Carre F, Corrado D, Drezner J, Dugmore DL, et al.
Consensus document regarding cardiovascular safety at sports arenas: position stand from the European Association of Cardiovascular Prevention and
Rehabilitation (EACPR), section of Sports Cardiology. Eur Heart J 2011;32:
2119–2124.
1140. Drezner JA, Owens DS, Prutkin JM, Salerno JC, Harmon KG, Prosise S, et al.
Electrocardiographic Screening in National Collegiate Athletic Association
Athletes. Am J Cardiol 2016;118:754–759.
1141. Erbel R, Möhlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A, et al.
Coronary risk stratiﬁcation, discrimination, and reclassiﬁcation improvement based on quantiﬁcation of subclinical coronary atherosclerosis: the Heinz
Nixdorf Recall study. J Am Coll Cardiol 2010;56:1397–1406.
1142. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, et al.
Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012;308:788–795.
1143. Pappone C, Vicedomini G, Manguso F, Saviano M, Baldi M, Pappone A, et al.
Wolff-Parkinson-White syndrome in the era of catheter ablation: insights from a registry study of 2169 patients. Circulation 2014;130:811–819.
1144. Obeyesekere MN, Leong-Sit P, Massel D, Manlucu J, Modi S, Krahn AD, et al. Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: a meta-analysis. Circulation 2012;125:2308–2315.
1145. Heidbuchel H, Adami PE, Antz M, Braunschweig F, Delise P, Scherr D, et al.
Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions: part 1: supraventricular arrhythmias. A position statement of the Section of Sports Cardiology and Exercise from the European Association of
Preventive Cardiology (EAPC) and the European Heart Rhythm Association
(EHRA), both associations of the European Society of Cardiology. Eur J Prev
Cardiol 2020;28:1539–1551.
1146. Pappone C, Santinelli V, Manguso F, Augello G, Santinelli O, Vicedomini G, et al. A
randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med 2003;349:1803–1811.
1147. Perry JC, Garson A. Supraventricular tachycardia due to Wolff-Parkinson-White syndrome in children: early disappearance and late recurrence. J Am Coll Cardiol
1990;16:1215–1220.
1148. Pediatric and Congenital Electrophysiology Society (PACES), Heart Rhythm
Society (HRS), American College of Cardiology Foundation (ACCF), American
Heart Association (AHA), American Academy of Pediatrics (AAP), Canadian
Heart Rhythm Society (CHRS), et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a
Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital
Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS).
Endorsed by the governing bodies of PACES, HRS, the American College of
Cardiology Foundation (ACCF), the American Heart Association (AHA), the
American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm
Society (CHRS). Heart Rhythm 2012;9:1006–1024.
1149. Barsheshet A, Moss AJ, Huang DT, McNitt S, Zareba W, Goldenberg I.
Applicability of a risk score for prediction of the long-term (8-year) beneﬁt of the implantable cardioverter-deﬁbrillator. J Am Coll Cardiol 2012;59:2075–2079.
1150. Expósito
V,
Rodríguez-Mañero
M,
González-Enríquez
S,
Arias
MA,
Sánchez-Gómez JM, Andrés La Huerta A, et al. Primary prevention implantable cardioverter-deﬁbrillator and cardiac resynchronization therapy-deﬁbrillator in elderly patients: results of a Spanish multicentre study. Europace 2016;18:
1203–1210.
1151. Alhakak A, Østergaard L, Butt JH, Vinther M, Philbert BT, Jacobsen PK, et al.
Cause-speciﬁc death and risk factors of one-year mortality after implantable cardioverter-deﬁbrillator implantation: a nationwide study. Eur Heart J Qual
Care Clin Outcomes 2022;8:39–49.
1152. Poupin P, Bouleti C, Degand B, Paccalin M, Le Gal F, Bureau M-L, et al. Prognostic value of Charlson Comorbidity Index in the elderly with a cardioverter deﬁbrillator implantation. Int J Cardiol 2020;314:64–69.
1153. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, et al. European society of cardiology methodology for the development of quality indicators for the quantiﬁcation of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes
2022;8:4–13.
1154. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the
United Kingdom after removal of ﬁnancial incentives. N Engl J Med 2018;379:
948–957.
1155. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality
8 years into global payment. N Engl J Med 2019;381:252–263.
